PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Chang, JW; Choi, JY; Lee, BW; Kang, UJ; Chung, SS				Chang, JW; Choi, JY; Lee, BW; Kang, UJ; Chung, SS			Unilateral globus pallidus internus stimulation improves delayed onset post-traumatic cervical dystonia with an ipsilateral focal basal ganglia lesion	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEMIDYSTONIA; PALLIDOTOMY	Treatment with unilateral left globus pallidus internus (GPi) deep brain stimulation is reported in a patient with severe delayed onset post-traumatic cervical dystonia. He had sustained severe head trauma at the age of 17 and had developed a mile right hemiparesis. Three years after the head injury, cervical dystonia with head turning to the left side developed. Magnetic resonance imaging (MRI) showed a discrete GPi lesion on the left side. At the age of 23, he underwent unilateral left GPi deep brain stimulation. he experienced immediate but short lasting benefit form the microlesioning effect of the electrode. With activation of deep brain stimulation, there was significant improvement of the cervical dystonia, persisting for 12 months of follow up. This case underlines the importance of the globus pallidus internus in the generation and amelioration of cervical dystonia.	Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; Yonsei Univ, Coll Med, Med Res Ctr, Brain Korea 21 Project, Seoul, South Korea; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA		Chang, JW (corresponding author), Yonsei Univ, Coll Med, Dept Neurosurg, CPO Box 8044, Seoul, South Korea.		Kang, Un/AAV-2858-2020	Kang, Un/0000-0002-5970-6839; Chang, Jin Woo/0000-0002-2717-0101; Lee, Bae H./0000-0003-4719-9021			Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Berardelli A, 1998, BRAIN, V121, P1195, DOI 10.1093/brain/121.7.1195; BURTON K, 1984, NEUROLOGY, V34, P962, DOI 10.1212/WNL.34.7.962; Chang JW, 2001, BASAL GANGLIA AND THALAMUS IN HEALTH AND MOVEMENT DISORDERS, P341; Hedreen J C, 1988, Adv Neurol, V50, P123; Islekel S, 1999, STEREOT FUNCT NEUROS, V72, P248, DOI 10.1159/000029736; King RB, 2001, J NEUROSURG, V94, P309, DOI 10.3171/jns.2001.94.2.0309; Krauss JK, 1999, LANCET, V354, P837, DOI 10.1016/S0140-6736(99)80022-1; Krystkowiak P, 1998, J NEUROL NEUROSUR PS, V65, P703, DOI 10.1136/jnnp.65.5.703; Kulisevsky J, 2000, NEUROLOGY, V55, P1754, DOI 10.1212/WNL.55.11.1754; LEE MS, 1994, NEUROLOGY, V44, P1374, DOI 10.1212/WNL.44.8.1374; Loher TJ, 2000, J NEUROSURG, V92, P457, DOI 10.3171/jns.2000.92.3.0457; Lozano AM, 1997, MOVEMENT DISORD, V12, P865, DOI 10.1002/mds.870120606; MARSDEN CD, 1985, BRAIN, V108, P463, DOI 10.1093/brain/108.2.463; Munchau A, 2000, J NEUROL NEUROSUR PS, V69, P494, DOI 10.1136/jnnp.69.4.494; Obeso J A, 1988, Adv Neurol, V50, P113; Parkin S, 2001, MOVEMENT DISORD, V16, P489, DOI 10.1002/mds.1092; Tarsy D, 1998, MOVEMENT DISORD, V13, P481, DOI 10.1002/mds.870130318; Tasker RR, 1998, TXB STEREOTACTIC FUN, P1015	19	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2002	73	5					588	590		10.1136/jnnp.73.5.588			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	612UK	WOS:000179093700027	12397158	Green Published, Bronze, Green Submitted			2022-02-06	
J	Irazuzta, JE; Pretzlaff, RK; Zingarelli, B; Xue, V; Zemlan, F				Irazuzta, JE; Pretzlaff, RK; Zingarelli, B; Xue, V; Zemlan, F			Modulation of nuclear factor-kappa B activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis	CRITICAL CARE MEDICINE			English	Article						hypothermia; meningitis; brain injury; nuclear factor-kappa B; critical care; cleaved tau protein; neurobehavioral performance; long-term outcome	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; CLEAVED TAU-PROTEIN; MONOCLONAL-ANTIBODIES; WATER-CONTENT; CELL-DEATH; RAT; DAMAGE; INDUCTION; TISSUE	Objective: This study was designed to evaluate the use of moderate hypothermia in a model of meningitis-induced brain injury and its effect on the activation of nuclear factor-kappaB, biological markers of neuronal injury, and neurobehavioral performance. Design: Randomized, prospective animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: Animals underwent a basilar cistern tap receiving either sterile saline as a placebo or an equivalent volume of a group B streptococcal suspension. Sixteen hours after inoculation, animals were stratified by their clinical severity score, were randomized to either hypothermic (32-34degreesC) or normothermic (37-39degreesC) conditions, and received antibiotics. Hypothermic animals were kept under these temperature conditions for 6 hrs before rewarming. Two protocols were used. For the first protocol, changes in nuclear factor-kappaB activation and heat shock protein induction at 24 firs and 48 hrs after inoculation were evaluated. In the second protocol, serum C-tau concentrations at 5 days and neurobehavioral performances at 3 wks were assessed. Measurements and Main Results. Meningitis triggered a > 50% increase in cerebral nuclear factor-kappaB activation. The addition of a 6-hr period of hypothermia reduced nuclear factor-kappaB activation by 32% when measured at the end of the hypothermic period. At 48 hrs, this decrease in nuclear factor-kappaB activation was no longer apparent, but there was a significant decrease in the heat shock response. Serum C-tau concentrations at 5 days postinjury, a biomarker of brain injury, were reduced by 69% in hypothermic treated animals. Furthermore, hypothermia reduced the brain water content of infected animals. However, hypothermia did not improve the animals' neurobehavioral performance. Conclusion: The findings from this study suggest that hypothermia produces a transitory attenuation of nuclear factor-kappaB activation in meningitic brain injury and improvement in some biomarkers, of neuronal injury. The consequence of intermittent suppression of nuclear factor-kappaB activation by inducing specific periods of hypothermia requires further study.	Tufts Univ, New England Med Ctr, Floating Hosp Children, Div Crit Care Med, Boston, MA 02111 USA; Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA		Irazuzta, JE (corresponding author), Tufts Univ, New England Med Ctr, Floating Hosp Children, Div Crit Care Med, Boston, MA 02111 USA.		, Basilia/AAV-7582-2021				Abraham E, 2000, CRIT CARE MED, V28, pN100, DOI 10.1097/00003246-200004001-00012; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Bethea JR, 1998, J NEUROSCI, V18, P3251; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Canevari L, 1999, BRAIN RES, V817, P241, DOI 10.1016/S0006-8993(98)01278-5; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DODGE PR, 1984, NEW ENGL J MED, V311, P869, DOI 10.1056/NEJM198410043111401; Engel JA, 2000, BRAIN RES, V863, P233, DOI 10.1016/S0006-8993(00)02149-1; Gideon P, 1999, MAGN RESON IMAGING, V17, P301, DOI 10.1016/S0730-725X(98)00161-1; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hu WX, 2000, BRAIN RES, V868, P370, DOI 10.1016/S0006-8993(00)02360-X; Irazuzta JE, 2000, LIFE SCI, V67, P365, DOI 10.1016/S0024-3205(00)00637-8; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; Irazuzta JE, 2001, BRAIN RES, V913, P95, DOI 10.1016/S0006-8993(01)02764-0; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Koedel U, 2000, J INFECT DIS, V182, P1437, DOI 10.1086/315877; KONKOL RJ, 1987, ANN NEUROL, V21, P353, DOI 10.1002/ana.410210407; KOSIK KS, 1987, J NEUROSCI, V7, P3142; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCALLISTER CK, 1975, J INFECT DIS, V132, P355, DOI 10.1093/infdis/132.4.355; Meager A, 1999, CYTOKINE GROWTH F R, V10, P27, DOI 10.1016/S1359-6101(98)00024-0; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; *NIH, 1996, GUID CAR US LAB AN; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; Rossi J, 2000, DRUG CHEM TOXICOL, V23, P113, DOI 10.1081/DCT-100100106; Rowin ME, 2001, INFLAMMATION, V25, P137, DOI 10.1023/A:1011044312536; SAEZLLORENS X, 1991, J CLIN INVEST, V88, P2003, DOI 10.1172/JCI115527; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; SLOVITER RS, 1992, J NEUROSCI, V12, P3004, DOI 10.1523/JNEUROSCI.12-08-03004.1992; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TAUBER MG, 1987, J INFECT DIS, V156, P456, DOI 10.1093/infdis/156.3.456; TAUBER MG, 1992, AM J PATHOL, V141, P53; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 1999, J NEUROCHEM, V73, P437; Zingarelli B, 2001, GUT, V48, P610, DOI 10.1136/gut.48.5.610; Zysk G, 1996, J NEUROPATH EXP NEUR, V55, P722, DOI 10.1097/00005072-199606000-00006	54	40	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2002	30	11					2553	2559		10.1097/00003246-200211000-00025			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616UZ	WOS:000179322900024	12441769				2022-02-06	
J	Hinton-Bayre, AD; Geffen, G				Hinton-Bayre, AD; Geffen, G			Severity of sports-related concussion and neuropsychological test performance	NEUROLOGY			English	Article								Concussion severity grades according to the Cantu, Colorado Medical Society, and American Academy of Neurology systems were not clearly related to the presence or duration of impaired neuropsychological test performance in 21 professional rugby league athletes. The use of concussion severity guidelines and neuropsychological testing to assist return to play decisions requires further investigation.	Griffith Univ, Sch Appl Psychol, Nathan, Qld, Australia; Univ Queensland, Cognit Psychophysiol Lab, Brisbane, Qld, Australia		Hinton-Bayre, AD (corresponding author), Univ Queensland, Sch Med, CPL Edith Cavell Bldg, Herston, Qld 4006, Australia.						CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colorado Medical Society, 1990, REP SPORTS MED COMM; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Kelly JP, 1997, NEUROLOGY, V48, P581; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068	8	40	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	OCT 8	2002	59	7					1068	1070		10.1212/WNL.59.7.1068			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	601HP	WOS:000178440600019	12370464				2022-02-06	
J	Wedekind, C; Hesselmann, V; Lippert-Gruner, M; Ebel, M				Wedekind, C; Hesselmann, V; Lippert-Gruner, M; Ebel, M			Trauma to the pontomesencephalic brainstem - a major clue to the prognosis of severe traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brainstem reflexes; evoked potentials; magnetic resonance imaging; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; EVOKED-POTENTIALS; STEM LESIONS	The objective of this study was to assess the significance of an injury to the pontomesencephalic brainstem in severe traumatic brain injury [Glasgow coma score (GCS) below 8]. Forty victims of severe traumatic brain injury with and with out compounding pathologies almost equally distributed among both groups were studied. The outcome (mean follow-up, 11.3 months) was assessed by means of the Glasgow outcome score (GOS) and of the Disability rating scale (DRS). Injury of the brainstem was detected by electrophysiological investigation (evoked potentials, brainstem reflexes) and magnetic resonance imaging (MRI) carried out early after trauma. Statistical analysis (Wilcoxon signed rank test for matched pairs) revealed a significantly worse initial GCS (median 5 versus 6), GOS (median 3 versus 4), and DRS score (median 6 versus 2) for the group with brainstem lesions than for the group without such lesions. Moreover, there was a significant accumulation of lesions of the corpus callosum, the basal ganglia, and the (para-)hippocampal area detected by MRI in the brainstem lesion group. In addition, the finding of an abnormal cortical component of the median nerve evoked somatosensory potential was significantly more frequent in the patients with brainstem injury. Traumatic brainstem lesions diagnosed by MRI and/or electrophysiological investigation are associated with injury to other 'deeply' situated parts of the brain. The finding of a brainstem lesion influences to the outcome of patients after severe traumatic brain injury.	Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany; Univ Cologne, Dept Radiol, D-50924 Cologne, Germany		Wedekind, C (corresponding author), Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany.						CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; HOPF HC, 1994, MUSCLE NERVE, V17, P475, DOI 10.1002/mus.880170502; JENNETT B, 1975, LANCET, V1, P480; JORG J, 1998, EVOZIERTE POTENTIALE; Klug N, 1987, Acta Neurochir Suppl (Wien), V40, P57; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sachs, 1997, ANGEW STAT; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010	16	40	42	0	2	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2002	16	3					256	260		10.1080/02688690220148842			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	585MU	WOS:000177529200008	12201395				2022-02-06	
J	Spinella, M; Eaton, LA				Spinella, M; Eaton, LA			Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury	BRAIN INJURY			English	Article							GINKGO-BILOBA EXTRACT; ST.-JOHNS-WORT; BUSPIRONE-INDUCED MANIA; FORCED SWIMMING TEST; HYPERICUM-PERFORATUM; ANTIDEPRESSANT ACTIVITY; CLINICAL-TRIALS; VIVO REGULATION; DEPRESSION; EGB-761	The use of herbal medicines has become a very common practice. While many are safe enough to be available over-the-counter, they may pose risks due to interactions with pharmaceutical medications and effects in specific clinical populations. The case of a female patient with a history of mild traumatic brain injury and resulting depression is presented. She experienced hypomania after adding St John's wort and Ginkgo biloba to her regimen of fluoxetine and buspirone, which remitted after discontinuation of the herbal medicines. Implications for interactions between various psychopharmacologic agents, including herbal medicines and selective serotonin reuptake inhibitors (SSRIs), as well as the need for appropriate patient and health care provider education are discussed.	Richard Stockton Coll New Jersey, Div Social & Behav Sci, Pomona, NJ 08240 USA		Spinella, M (corresponding author), Richard Stockton Coll New Jersey, Div Social & Behav Sci, POB 195, Pomona, NJ 08240 USA.	marcello.s-pinella@stockton.edu					Amri H, 1997, ENDOCRINOLOGY, V138, P5415, DOI 10.1210/en.138.12.5415; Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; Artigas F, 1996, TRENDS NEUROSCI, V19, P378, DOI 10.1016/S0166-2236(96)10037-0; Barbenel DM, 2000, J PSYCHOPHARMACOL, V14, P84, DOI 10.1177/026988110001400113; Bennett DA, 1998, ANN PHARMACOTHER, V32, P1201, DOI 10.1345/aph.18026; Bersani G, 2000, PROG NEURO-PSYCHOPH, V24, P185, DOI 10.1016/S0278-5846(99)00097-4; BOLANOSJIMENEZ F, 1995, FUNDAM CLIN PHARM, V9, P169, DOI 10.1111/j.1472-8206.1995.tb00277.x; Brenner R, 2000, CLIN THER, V22, P411, DOI 10.1016/S0149-2918(00)89010-4; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Butterweck V, 2000, PLANTA MED, V66, P3, DOI 10.1055/s-2000-11119; Butterweck V, 1997, PHARMACOPSYCHIATRY, V30, P117, DOI 10.1055/s-2007-979531; Butterweck V, 1998, PLANTA MED, V64, P291, DOI 10.1055/s-2006-957437; Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024-3205(98)00299-9; Chatterjee SS, 1998, PHARMACOPSYCHIATRY, V31, P7, DOI 10.1055/s-2007-979340; Dimpfel W, 1999, Eur J Med Res, V4, P303; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fowler JS, 2000, LIFE SCI, V66, pPL141, DOI 10.1016/S0024-3205(99)00660-8; Gordon JB, 1998, AM FAM PHYSICIAN, V57, P950; Greeson JM, 2001, PSYCHOPHARMACOLOGY, V153, P402, DOI 10.1007/s002130000625; Harrer G, 1999, ARZNEIMITTEL-FORSCH, V49, P289; HARRER G, 1994, J GERIATR PSYCHIA S1, V7, P24; Hasenohrl RU, 1996, PHARMACOL BIOCHEM BE, V53, P271, DOI 10.1016/0091-3057(95)02001-2; Holsboer F, 1999, J PSYCHIATR RES, V33, P181, DOI 10.1016/S0022-3956(98)90056-5; HUGUET F, 1992, J PHARM PHARMACOL, V44, P24, DOI 10.1111/j.2042-7158.1992.tb14357.x; HUGUET F, 1994, J PHARM PHARMACOL, V46, P316, DOI 10.1111/j.2042-7158.1994.tb03802.x; Itil TM, 1998, PSYCHOPHARMACOL BULL, V34, P391; Kessler RC, 2001, AM J PSYCHIAT, V158, P289, DOI 10.1176/appi.ajp.158.2.289; Kim HL, 1999, J NERV MENT DIS, V187, P532, DOI 10.1097/00005053-199909000-00002; Labbate L A, 2000, Curr Psychiatry Rep, V2, P268, DOI 10.1007/s11920-996-0021-3; Leathem JM, 2000, J HEAD TRAUMA REHAB, V15, P1246, DOI 10.1097/00001199-200012000-00005; Leibenluft E, 1997, J CLIN PSYCHIAT, V58, P383, DOI 10.4088/JCP.v58n0902; LIEGGHIO NE, 1988, J CLIN PSYCHOPHARM, V8, P226, DOI 10.1097/00004714-198806000-00022; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 2000, COCHRANE DB SYST REV, V2; Lingaerde O, 1999, ACTA PSYCHIAT SCAND, V100, P62, DOI 10.1111/j.1600-0447.1999.tb10915.x; LOU H, 1999, CHINESE MENTAL HLTH, V13, P167; Marcilhac A, 1998, LIFE SCI, V62, P2329, DOI 10.1016/S0024-3205(98)00214-8; MCDANIEL JS, 1990, AM J PSYCHIAT, V147, P125; MCIVOR RJ, 1991, BRIT J PSYCHIAT, V158, P136, DOI 10.1192/bjp.158.1.136; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; Nathan PJ, 2001, J PSYCHOPHARMACOL, V15, P47, DOI 10.1177/026988110101500109; Nierenberg AA, 1999, BIOL PSYCHIAT, V46, P1707, DOI 10.1016/S0006-3223(99)00233-4; O'Breasail AM, 1998, CAN J PSYCHIAT, V43, P746; Peebles CT, 2000, EPILEPSY BEHAV, V1, P74, DOI 10.1006/ebeh.2000.0031; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PORSOLT RD, 1990, PHARMACOL BIOCHEM BE, V36, P963, DOI 10.1016/0091-3057(90)90107-S; Porsolt RD, 2000, ARZNEIMITTEL-FORSCH, V50, pE232; PRICE WA, 1989, J CLIN PSYCHOPHARM, V9, P150, DOI 10.1097/00004714-198904000-00025; RAPIN JR, 1994, GEN PHARMACOL-VASC S, V25, P1009, DOI 10.1016/0306-3623(94)90111-2; Schneck C, 1998, J CLIN PSYCHIAT, V59, P689, DOI 10.4088/JCP.v59n1208d; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; Schulz H, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS39, DOI 10.1177/089198879400700111; Sharpley AL, 1998, PSYCHOPHARMACOLOGY, V139, P286, DOI 10.1007/s002130050718; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Singer A, 1999, J PHARMACOL EXP THER, V290, P1363; Spinella M., 2001, PSYCHOPHARMACOLOGY H; Steer, 1993, MANUAL BECK ANXIETY; Stein DJ, 1997, S AFR MED J, V87, P763; Sussman N, 1998, J CLIN PSYCHIAT, V59, P42; TAYLOR A, 1994, PSYCHIAT RES, V54, P241, DOI 10.1016/0165-1781(94)90018-3; TeufelMayer R, 1997, PHARMACOPSYCHIATRY, V30, P113, DOI 10.1055/s-2007-979530; Volz HP, 2000, COMPR PSYCHIAT, V41, P133, DOI 10.1016/S0010-440X(00)80019-X; Winter JC, 1999, PHARMACOL BIOCHEM BE, V62, P543, DOI 10.1016/S0091-3057(98)00190-7	63	40	42	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					359	367		10.1080/02699050110103319			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700007	11953006				2022-02-06	
J	Horiuchi, T; Dietrich, HH; Hongo, K; Goto, T; Dacey, RG				Horiuchi, T; Dietrich, HH; Hongo, K; Goto, T; Dacey, RG			Role of endothelial nitric oxide and smooth muscle potassium channels in cerebral arteriolar dilation in response to acidosis	STROKE			English	Article						acid-base equilibrium; cerebral circulation; hydrogen-ion concentration; microcirculation; rats	TRAUMATIC BRAIN INJURY; BLOOD-FLOW; INTRACEREBRAL ARTERIOLES; BASILAR ARTERIES; CYCLIC-GMP; HYPERCAPNIA; SYNTHASE; RATS; PH; BICARBONATE	Background and Purpose-Potassium channels or nitric oxide or both are major mediators of acidosis-induced dilation in the cerebral circulation. However, these contributions depend on a variety or factors such as species and vessel location. The present study was designed to clarify whether potassium channels and endothelial nitric oxide are involved in acidosis-induced dilation of isolated rat cerebral arterioles. Methods-Cerebral arterioles were cannulated and monitored with an inverted microscope. Acidosis (pH 6.8 to 7.4) produced by adding hydrogen ions mediated dilation of the cerebral arterioles in a concentration-dependent manner. The role of nitric oxide and potassium channels in response to acidosis was examined with several specific inhibitors and endothelial damage. Results-The dilation was significantly inhibited by potassium chloride (30 mmol/L) and glibenclamide (3 mumol/L; ATP-sensitive potassium channel inhibitor). We found that 30 mumol/L BaCl2 (concentration-dependent potassium channel inhibitor) also affected the dilation; however, an additional treatment of 3 mumol/L glibenclamide did not produce further inhibition. Tetraethylammonium ion (1 mmol/L; calcium-activated potassium channel inhibitor) and 4-aminopyridine (100 mumol/L; voltage-dependent potassium channel inhibitor) as well as ouabain (10 mumol/L; Na-K ATPase inhibitor) and N-methylsulphonyl-6-(2-proparglytoxyphenyl) hexanamide (1 mumol/L, cytochrome P450 epoxygenase inhibitor) did not alter acidotic dilation. N-omega-Monomethyl-L-arginine (10 mumol/L) and N-omega-nitro-L-arginine (10 mumol/L) as nitric oxide synthase inhibitor blunted the dilation. Furthermore, the dilation was significantly attenuated after the endothelial impairment. Additional treatment with glibenclamide (3 mumol/L) further reduced the dilation in response to acidosis. Conclusions-Endothelial nitric oxide and smooth muscle ATP-sensitive potassium channels contribute to acidosis-induced dilation of rat cerebral arterioles. Endothelial damage caused by pathological conditions such as subarachnoid hemorrhage or traumatic brain injury may contribute to reduced blood flow despite injury-induced cerebral acidosis.	Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA; Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano 390, Japan		Dietrich, HH (corresponding author), Washington Univ, Sch Med, Dept Neurosurg, Box 8057,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R29HL057540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030555] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL57540] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30555] Funding Source: Medline		Aalkjaer C, 1996, J VASC RES, V33, P347, DOI 10.1159/000159163; Aalkjaer C, 1997, ACTA PHYSIOL SCAND, V161, P557, DOI 10.1046/j.1365-201X.1997.00263.x; ADEAGBO ASO, 1993, J CARDIOVASC PHARM, V21, P423, DOI 10.1097/00005344-199303000-00011; Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; BONNET P, 1991, PFLUG ARCH EUR J PHY, V418, P292, DOI 10.1007/BF00370529; CHARDWAJ A, 2000, AM J PHYSIOL, V279, pH1616; Chrissobolis S, 2000, AM J PHYSIOL-HEART C, V279, pH2704, DOI 10.1152/ajpheart.2000.279.6.H2704; DACEY RG, 1987, AM J PHYSIOL, V253, pH1253, DOI 10.1152/ajpheart.1987.253.5.H1253; DACEY RG, 1982, AM J PHYSIOL, V243, pH598, DOI 10.1152/ajpheart.1982.243.4.H598; DIETRICH HH, 1994, J NEUROSURG, V81, P437, DOI 10.3171/jns.1994.81.3.0437; DIETRICH HH, 1997, MICROCIRCULATION, V4, P169; DIETRICH HH, 1994, AM J PHYSIOL, V266, pH168; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hoffman WE, 2000, ANESTHESIOLOGY, V92, P442, DOI 10.1097/00000542-200002000-00026; Horiuchi T, 2001, STROKE, V32, P218, DOI 10.1161/01.STR.32.1.218; Horiuchi T, 2001, AM J PHYSIOL-HEART C, V280, pH767, DOI 10.1152/ajpheart.2001.280.2.H767; IADECOLA C, 1994, AM J PHYSIOL, V266, pR546, DOI 10.1152/ajpregu.1994.266.2.R546; IADECOLA C, 1994, J CEREB BLOOD FLOW M, V14, P1475; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; Johnson TD, 1998, AM J PHYSIOL-REG I, V274, pR541; Kajita Y, 1998, NEUROSURGERY, V42, P834, DOI 10.1097/00006123-199804000-00087; KIMURA M, 1994, STROKE, V25, P2227, DOI 10.1161/01.STR.25.11.2227; Kinoshita H, 1997, STROKE, V28, P433, DOI 10.1161/01.STR.28.2.433; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; Lindauer U, 2001, AM J PHYSIOL-HEART C, V281, pH1353, DOI 10.1152/ajpheart.2001.281.3.H1353; MIRRO R, 1993, J APPL PHYSIOL, V75, P1300, DOI 10.1152/jappl.1993.75.3.1300; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Nguyen TS, 2000, AM J PHYSIOL-HEART C, V278, pH878, DOI 10.1152/ajpheart.2000.278.3.H878; Park KW, 2001, ANESTH ANALG, V92, P990; ROSENBLUM WI, 1974, STROKE, V5, P425, DOI 10.1161/01.STR.5.4.425; SUZUKI M, 1995, AM J PHYSIOL-CELL PH, V269, pC496, DOI 10.1152/ajpcell.1995.269.2.C496; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; TODA N, 1993, AM J PHYSIOL, V265, pH929, DOI 10.1152/ajpheart.1993.265.3.H929; TODA N, 1989, AM J PHYSIOL, V257, pH141, DOI 10.1152/ajpheart.1989.257.1.H141; Toda N, 1996, J CEREBR BLOOD F MET, V16, P1068, DOI 10.1097/00004647-199609000-00032; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; Wang QO, 1998, BRAIN RES, V793, P187, DOI 10.1016/S0006-8993(98)00173-5; YOU JP, 1994, ACTA PHYSIOL SCAND, V152, P391, DOI 10.1111/j.1748-1716.1994.tb09821.x	45	40	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2002	33	3					844	849		10.1161/hs0302.104112			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	527RL	WOS:000174200600034	11872913	Green Published, Bronze			2022-02-06	
J	Wallis, G; Chatziastros, A; Bulthoff, H				Wallis, G; Chatziastros, A; Bulthoff, H			An unexpected role for visual feedback in vehicle steering control	CURRENT BIOLOGY			English	Article							INJURIES; MODELS; DRIVER	Some motor tasks can be completed, quite literally, with our eyes shut. Most people can touch their nose without looking or reach for an object after only a brief glance at its location. This distinction leads to one of the defining questions of movement control: is information gleaned prior to starting the movement sufficient to complete the task (open loop), or is feedback about the progress of the movement required (closed loop)? One task that has commanded considerable interest in the literature over the years is that of steering a vehicle, in particular lane-correction and lane-changing tasks. Recent work has suggested that this type of task can proceed in a fundamentally open loop manner [1, 2], with feedback mainly serving to correct minor, accumulating errors. This paper reevaluates the conclusions of these studies by conducting a new set of experiments in a driving simulator. We demonstrate that, in fact, drivers rely on regular visual feedback, even during the well-practiced steering task of lane changing. Without feedback, drivers fail to initiate the return phase of the maneuver, resulting in systematic errors in final heading. The results provide new insight into the control of vehicle heading, suggesting that drivers employ a simple policy of "turn and see," with only limited understanding of the relationship between steering angle and vehicle heading.	Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Univ Queensland, Sch Human Movement Studies, Percept & Motor Syst Lab, Brisbane, Qld 4072, Australia		Wallis, G (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.	gwallis@hms.uq.edu.au	Wallis, Guy/G-2342-2011; Bulthoff, Heinrich H/J-6579-2012; Bulthoff, Heinrich/AAC-8818-2019	Wallis, Guy/0000-0003-1601-1540; Bulthoff, Heinrich H/0000-0003-2568-0607; 			BOER E, 1998, P 1998 IEEE INT C IN, V1, P291; DONGES E, 1978, HUM FACTORS, V20, P691, DOI 10.1177/001872087802000607; DORF RC, 1995, MODERN CONTROL SYSTE; Duma SM, 1996, J TRAUMA, V41, P114, DOI 10.1097/00005373-199607000-00018; GODTHELP J, 1985, ERGONOMICS, V28, P1419, DOI 10.1080/00140138508963268; HARRIS CS, 1965, PSYCHOL REV, V72, P419, DOI 10.1037/h0022616; Hess R. A., 1990, IEEE Control Systems Magazine, V10, P3, DOI 10.1109/37.60415; Hildreth EC, 2000, J EXP PSYCHOL HUMAN, V26, P1106, DOI 10.1037//0096-1523.26.3.1106; Land MF, 2001, CURR BIOL, V11, P1215, DOI 10.1016/S0960-9822(01)00351-7; MCRUER D, 1969, ERGONOMICS, V12, P599, DOI 10.1080/00140136908931082; MCRUER DT, 1977, HUM FACTORS, V19, P381, DOI 10.1177/001872087701900406; *NATL HIGHW TRAFF, 1999, AIR BAG SAF FACT SHE; *NATL HIGHW TRAFF, 1999, AIR BAG VID PAG; Parkin S, 1995, ACCIDENT ANAL PREV, V27, P777, DOI 10.1016/0001-4575(95)00035-6; REID LD, 1981, ERGONOMICS, V24, P447, DOI 10.1080/00140138108924867; Salvucci DD, 2001, INT J HUM-COMPUT ST, V55, P85, DOI 10.1006/ijhc.2001.0472; Segui-Gomez M, 1998, NEW ENGL J MED, V339, P132, DOI 10.1056/NEJM199807093390219; THOMAS P, 1995, ACCIDENT ANAL PREV, V27, P561, DOI 10.1016/0001-4575(94)00085-Z	18	40	40	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	FEB 19	2002	12	4					295	299	PII S0960-9822(02)00685-1	10.1016/S0960-9822(02)00685-1			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	523RL	WOS:000173969100018	11864569				2022-02-06	
J	Bay, E; Hagerty, BM; Williams, RA; Kirsch, N; Gillespie, B				Bay, E; Hagerty, BM; Williams, RA; Kirsch, N; Gillespie, B			Chronic stress, sense of belonging, and depression among survivors of traumatic brain injury	JOURNAL OF NURSING SCHOLARSHIP			English	Article						chronic stress; sense of belonging; traumatic brain injury; depression	CLOSED-HEAD INJURY; SOCIAL SUPPORT; MAJOR DEPRESSION; DEFICITS; RECOVERY; MEMORY; MODEL; IMPAIRMENT; DISABILITY; INVENTORY	Purpose: To test whether chronic stress, interpersonal relatedness, and cognitive burden could explain depression after traumatic-brain injury (TBI). Design: A nonprobability sample of 75 mild-to-moderately injured TBI survivors and their significant others, were recruited from five TBI day-rehabilitation programs. All participants were within 2 years of the date of injury and were living in the community. Methods: During face-to-face interviews, demographic information, and estimates of brain injury severity were obtained and participants completed a cognitive battery of tests of directed attention and short-term memory, responses to the Perceived Stress Scale, Interpersonal Relatedness Inventory, Sense of Belonging Instrument, Neurobehavioral Functioning Inventory, and Center for Epidemiological Studies Depression Scale;. Findings:Chronic stress was significantly and positively related to post-TBI depression. Depression and postinjury sense of belonging were negatively related. Social support and results from the cognitive battery did not explain depression. Conclusions: Postinjury chronic stress and sense of belonging were strong predictors of postinjury depression and are variables amenable to interventions by nurses in community health, neurological centers, or rehabilitation clinics. Future studies are needed to examine bow these variables change over time during the recovery process.	Michigan State Univ, Dearborn, MI USA; Univ Michigan, Adult TBI Program, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Stat Consulting & Res, Ann Arbor, MI 48109 USA		Bay, E (corresponding author), 2106 Kratage Court, Commerce, MI 48382 USA.						*AM C REH MED, 1993, J HEAD INJURY REHABI, V8, P6; [Anonymous], 1998, REH PERS TRAUM BRAIN; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; BAUM A, 1983, J CONSULT CLIN PSYCH, V51, P565, DOI 10.1037/0022-006X.51.4.565; BAY E, 2000, J NEUROSCIENCE NURSI, V32, P169; BRAND AN, 1992, J AFFECT DISORDERS, V25, P77, DOI 10.1016/0165-0327(92)90095-N; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BRESLAU N, 1986, ARCH GEN PSYCHIAT, V43, P309; BROOKS G, 1999, THESIS U MICHIGAN AN; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Cassens G, 1990, J Neuropsychiatry Clin Neurosci, V2, P202; Channon S, 1999, J NEUROL NEUROSUR PS, V66, P162, DOI 10.1136/jnnp.66.2.162; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1995, MEASURING STRESS GUI, V1; Devins GM, 1985, TEST CRITIQUES, P144; Hagerty B M, 1992, Arch Psychiatr Nurs, V6, P172, DOI 10.1016/0883-9417(92)90028-H; Hagerty BM, 1999, NURS RES, V48, P215, DOI 10.1097/00006199-199907000-00004; Hagerty BM, 1996, ARCH PSYCHIAT NURS, V10, P235, DOI 10.1016/S0883-9417(96)80029-X; Hagerty BM, 1997, AM J ORTHOPSYCHIAT, V67, P308, DOI 10.1037/h0080234; HAGERTY BMK, 1995, NURS RES, V44, P9; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEZAK M, 1987, J HEAD INJURY REHABI, V3, P57; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TILDEN VP, 1990, NURS RES, V39, P337; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Williams RA, 2000, J PSYCHIAT RES, V34, P227, DOI 10.1016/S0022-3956(00)00012-1	48	40	41	1	11	SIGMA THETA TAU INT	INDIANAPOLIS	550 W NORTH STREET, INDIANAPOLIS, IN 46202 USA	1527-6546			J NURS SCHOLARSHIP	J. Nurs. Scholarsh.		2002	34	3					221	226		10.1111/j.1547-5069.2002.00221.x			6	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	636FX	WOS:000180444900013	12237983	Green Published			2022-02-06	
J	Thomas, SH; Orf, J; Wedel, SK; Conn, AK				Thomas, SH; Orf, J; Wedel, SK; Conn, AK			Hyperventilation in traumatic brain injury patients: Inconsistency between consensus guidelines and clinical practice	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	30th International Educational and Scientific Symposium of the Society-for-Critical-Care-Medicine	FEB 11-14, 2001	SAN FRANCISCO, CA	Soc Crit Care Med		traumatic brain injury; hyperventilation; hypocarbia	CEREBRAL-BLOOD-FLOW; TIDAL CARBON-DIOXIDE; SEVERE HEAD-INJURY; INTRAHOSPITAL TRANSPORT; HEMORRHAGIC-SHOCK; CAPNOGRAPHY; OXYGENATION; DIFFERENCE; METABOLISM; COMATOSE	Background: This study assessed patients with traumatic brain injury (TBI) to determine whether prehospital and community hospital providers employed hyperventilation therapy inconsistent with consensus recommendation against its routine use. Methods: This prospective analysis of 37 intubated TBI patients without herniation, undergoing helicopter transport to an urban Level I center, entailed flight crews' noting of assisted ventilation rate (AVR) and end-tidal carbon dioxide (ETco(2)) upon their arrival at trauma scenes or community hospitals. A priori-set levels of AVR and ETco(2) were used to assess frequency of guideline-inconsistent hyperventilation, and Fisher's exact and Kruskal-Wallis tests assessed association between guideline-inconsistent hyperventilation and manual vs. mechanical ventilation mode. Results: Inappropriately high AVR and low ETco(2) were seen in 60% and 70% of patients, respectively. Manual ventilation was associated with guideline-inconsistent hyperventilation assessed by AVR (p = 0.038) and ETco(2) (p = 0.022). Conclusion: Prehospital and community hospital hyperventilation practices are not consistent with consensus recommendations for limitation of hyperventilation therapy.	Massachusetts Gen Hosp, Dept Emergency Serv, Boston MedFlight Crit Care Transport Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA; Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA; Boston Med Ctr, Boston, MA 02118 USA		Thomas, SH (corresponding author), Massachusetts Gen Hosp, Dept Emergency Serv, Boston MedFlight Crit Care Transport Serv, MGH Clin Bldg,Room 115,55 Fruit St, Boston, MA 02114 USA.	thomas.stephen@mgh.harvard.edu		Thomas, Stephen/0000-0003-4153-3965			BHAVANISHANKAR K, 1992, CAN J ANAESTH, V8, P139; Bhende M, 1999, PEDIATR EMERG CARE, V15, P64, DOI 10.1097/00006565-199902000-00019; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Bullock R, 1995, GUIDELINES MANAGEMEN; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BURROWS FA, 1989, ANESTHESIOLOGY, V70, P219, DOI 10.1097/00000542-198902000-00007; FORTUNE JB, 1995, J TRAUMA, V39, P463; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SANTHI PB, 1994, SOLVENT EXTR ION EXC, V12, P633, DOI 10.1080/07366299408918229; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Tobias JD, 1999, PEDIATR EMERG CARE, V15, P173, DOI 10.1097/00006565-199906000-00002; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; WEINER DL, 2000, TXB PEDIAT EMERGENCY, P553; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	29	40	40	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2002	52	1					47	52		10.1097/00005373-200201000-00010			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	514PF	WOS:000173449700010	11791051				2022-02-06	
J	Grundy, PL; Harbuz, MS; Jessop, DS; Lightman, SL; Sharples, PM				Grundy, PL; Harbuz, MS; Jessop, DS; Lightman, SL; Sharples, PM			The hypothalamo-pituitary-adrenal axis response to experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; glucocorticoids; HPA axis; rat; traumatic brain injury	CORTICOTROPIN-RELEASING FACTOR; PARVOCELLULAR NEUROSECRETORY NEURONS; INSITU HYBRIDIZATION HISTOCHEMISTRY; FLUID-PERCUSSION MODEL; MESSENGER-RNA; HEAD-INJURY; PARAVENTRICULAR NUCLEUS; ARGININE-VASOPRESSIN; GLUCOCORTICOID ENDANGERMENT; PLASMA-CORTISOL	Alterations in the hypothalamo-pituitary-adrenal (HPA) axis following traumatic brain injury have not been documented in detail. We used fluid percussion injury (FPI) to evaluate the early changes in components of the HPA axis following experimental traumatic brain injury. Wistar rats were sacrificed at 2 or 4 h following sham or FRI surgery. In situ hybridization histochemistry was used to determine the expression of mRNAs of corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP) in the hypothalamus and pro-opiomelanocortin (POMC) in the pituitary. A group of animals undergoing no surgery were used as control. Repeated blood sampling from an indwelling catheter demonstrated that plasma corticosterone (CORT) levels peaked 30 min following surgery in sham and FPI animals but there was no significant difference in CORT concentration between these groups at any time. Pituitary POMC expression was increased following sham and FPI surgery (compared with control non-operated animals) but with no significant difference between the two groups undergoing surgery. Hypothalamic CRH mRNA expression was significantly higher in animals undergoing FPI compared with sham surgery. Hypothalamic AVP mRNA expression was not significantly increased when compared with control nonoperated animals. These data indicate that the anaesthesia and/or surgery associated with FPI or sham surgery induces a generalised activation of the HPA axis. The selective increase in CRH mRNA in animals undergoing FPI may be due to specific effects of traumatic brain injury rather than a general stress response and may suggest an additional neurotransmitter role for CRH following head injury. The absence of an AVP response suggests that the effects of FPI may be mediated through the CRH-alone-containing subpopulation of neurons.	Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England; Univ Bristol, Res Ctr Neuroendocrinol, Bristol, Avon, England; Univ Bristol, Div Child Hlth, Bristol, Avon, England		Grundy, PL (corresponding author), Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England.	p.l.grundy@doctors.org.uk		Lightman, Stafford/0000-0002-8546-9646			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ANTONI FA, 1986, ENDOCR REV, V7, P351, DOI 10.1210/edrv-7-4-351; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; BARTANUSZ V, 1993, ENDOCRINOLOGY, V132, P895, DOI 10.1210/en.132.2.895; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BOUZARTH WF, 1968, SURG GYNECOL OBSTETR, V126, P995; BROWNSTEIN MJ, 1986, PROG BRAIN RES, V68, P161, DOI 10.1016/S0079-6123(08)60237-X; BUCKINGHAM JC, 1994, PHARMACOL RES, V30, P35, DOI 10.1016/1043-6618(94)80085-5; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Chiolero R, 1994, New Horiz, V2, P432; CHOWDREY HS, 1995, BRIT J PHARMACOL, V116, P2417, DOI 10.1111/j.1476-5381.1995.tb15089.x; CUNNINGHAM ET, 1991, TRENDS NEUROSCI, V14, P406, DOI 10.1016/0166-2236(91)90032-P; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GOLDMAN H, 1993, ANN EMERG MED, V22, P1035, DOI 10.1016/S0196-0644(05)82747-7; GOLDMAN H, 1993, J NEUROTRAUM, V10, P385, DOI 10.1089/neu.1993.10.385; Grossman A, 1997, ANN NY ACAD SCI, V823, P225, DOI 10.1111/j.1749-6632.1997.tb48394.x; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HARBUZ MS, 1992, ENDOCRINOLOGY, V130, P1394, DOI 10.1210/en.130.3.1394; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; Ikeda Y, 1997, ACTA NEUROCHIR, V139, P1166, DOI 10.1007/BF01410978; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Kinoshita H, 2000, J NEUROENDOCRINOL, V12, P255; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Kovacs KJ, 1996, J NEUROSCI, V16, P262; LEVY A, 1988, J ENDOCRINOL, V118, P205, DOI 10.1677/joe.0.1180205; LIGHTMAN SL, 1993, ANN NY ACAD SCI, V697, P28, DOI 10.1111/j.1749-6632.1993.tb49920.x; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NAVARRA P, 1991, ENDOCRINOLOGY, V128, P37, DOI 10.1210/endo-128-1-37; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1994, ANN NY ACAD SCI, V746, P294; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; SAWCHENKO PE, 1984, P NATL ACAD SCI-BIOL, V81, P1883, DOI 10.1073/pnas.81.6.1883; SAWCHENKO PE, 1984, J NEUROSCI, V4, P1118; Sawchenko PE, 1996, PROG BRAIN RES, V107, P201; SAWCHENKO PE, 1989, CORTICOTROPIN RELEAS, P29; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; SELYE H, 1946, J ALLERGY, V17, P358, DOI 10.1210/jcem-6-2-117; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; WHITNALL MH, 1987, NEUROENDOCRINOLOGY, V45, P420, DOI 10.1159/000124768; WHITNALL MH, 1985, NATURE, V317, P248, DOI 10.1038/317248a0; WHITNALL MH, 1988, NEUROENDOCRINOLOGY, V47, P176, DOI 10.1159/000124910; WHITNALL MH, 1988, J COMP NEUROL, V275, P13, DOI 10.1002/cne.902750103; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wotjak CT, 1996, J NEUROSCI, V16, P7725; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; YOUNG WS, 1986, NEUROSCI LETT, V70, P198; YOUNG WS, 1986, BRAIN RES, V387, P231	56	40	43	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1373	1381		10.1089/08977150152725669			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000007	11780867				2022-02-06	
J	Fisher, J; Mizrahi, T; Schori, H; Yoles, E; Levkovitch-Verbin, H; Haggiag, S; Revel, M; Schwartz, M				Fisher, J; Mizrahi, T; Schori, H; Yoles, E; Levkovitch-Verbin, H; Haggiag, S; Revel, M; Schwartz, M			Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility	JOURNAL OF NEUROIMMUNOLOGY			English	Article						neuroprotection IL-6 deficiency; axonal injury; optic nerved; glutamate toxicity; inflammation	CENTRAL-NERVOUS-SYSTEM; AUTOIMMUNE T-CELLS; MYELIN BASIC-PROTEIN; SPINAL-CORD INJURY; BRAIN INJURY; MICROGLIAL ACTIVATION; CYTOKINE PRODUCTION; TRANSGENIC MICE; OPTIC-NERVE; INTERLEUKIN-6	Axonal injury initiates a process of neuronal degeneration, with resulting death of neuronal cell bodies. We show here that in C57BL/6J mice, previously shown to have a limited ability to manifest a post-traumatic protective immunity, the rate of neuronal survival is increased if IL-6 is deficient during the first 24 hours after optic nerve injury. Immunocytochemical staining preformed 7 days after the injury revealed an increased number of activated microglia in the IL-6-deficient mice compared to the wild-type mice. In addition, IL-6-deficient mice showed an increased resistance to glutamate toxicity. These findings suggest that the presence of IL-6 during the early post-traumatic phase, at least in mice that are susceptible to autoimmune disease development, has a negative effect on neuronal survival. This further substantiates the contention that whether immune-derived factors are beneficial or harmful for nerve recovery after injury depends on the phenotype of the immune cells and the timing and nature of their dialog with the damaged neural tissue. (C) 2001 Elsevier Science B.V. All rights reserved.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel		Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Haggiag, Shalom/AAL-8385-2021	Haggiag, Shalom/0000-0002-5569-4121; Fisher, Jasmin/0000-0003-4477-9047			BARRES BA, 1993, DEVELOPMENT, V118, P283; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BENNUN A, 1983, J IMMUNOL, V130, P1205; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Fiske BK, 2000, NEUROSCIENCE, V96, P807, DOI 10.1016/S0306-4522(99)00601-6; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Jensen MB, 2000, J NEUROSCI, V20, P3612, DOI 10.1523/JNEUROSCI.20-10-03612.2000; KAHN MA, 1994, GLIA, V12, P87, DOI 10.1002/glia.440120202; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LEE SC, 1993, J IMMUNOL, V150, P2659; LIU DX, 1994, J NEUROCHEM, V62, P37; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Penkowa M, 1999, GLIA, V25, P343; Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Schwartz M, 1996, J GLAUCOMA, V5, P427; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001	42	40	46	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	SEP 3	2001	119	1					1	9		10.1016/S0165-5728(01)00342-3			9	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	471VW	WOS:000170950200001	11525794				2022-02-06	
J	Firsching, R; Woischneck, D				Firsching, R; Woischneck, D			Present status of neurosurgical trauma in Germany	WORLD JOURNAL OF SURGERY			English	Article								Exact epidemiological data on head injury in Germany are limited and based on data from death certificates, the Federal Board of Statistics (Bundesamt fur Statistik), small regional cohort studies, and health insurance. With a population of 82 million people there had been 279,029 head injuries admitted to hospital in Germany in 1996. The majority had the diagnosis. "concussion," which refers to completely reversible lesions. Head injury caused the deaths of 9415 patients in 1996, which amounts to a mortality of 11.5 per 100,000 inhabitants. At the same time there were 135 independent neurosurgical units, all of which had a computerized tomography scanner available. Of all fatal cases, however, 68.4% died before they reached a hospital. The exact cost is difficult to assess, because head injury causes more costs than only the hospital stay and rehabilitation.	Otto Von Guericke Univ Magdeburg, Fak Med, Neurochirurg Klin, D-39120 Magdeburg, Germany		Firsching, R (corresponding author), Otto Von Guericke Univ Magdeburg, Fak Med, Neurochirurg Klin, Leipziger Str 44, D-39120 Magdeburg, Germany.						BOUILLION B, 1998, ZENTRALBL NEUROCHIR, V59, P4; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; *EUR STUD GROUP NI, 1994, J NEUROSURG, V80, P804; FIRSCHING R, 1998, ZENTRALBL NEUROCHIRU, V3, P195; Gesundheitsberichterstattung des Bundes, 1998, GESUNDHEITSBERICHT D; KARIMI R, 1999, ZENTRALBL NEUROCHIR, P93; Kosubek C, 1996, Rehabilitation (Stuttg), V35, P29; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; TORNER JC, 1999, TRAUMATIC BRAIN INJU, P9; INFOSYTEM VERKEHR GE; 1997, NOTFALLMEDIZIN, V10, P466; 1998, STATISCHES BUNDESAMT	12	40	43	0	4	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1221	1223					3	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	471NB	WOS:000170934500021	11571961				2022-02-06	
J	Kelly, DF; Becker, DP				Kelly, DF; Becker, DP			Advances in management of neurosurgical trauma: USA and Canada	WORLD JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; SPINAL-CORD INJURY; CEREBRAL PERFUSION-PRESSURE; SAN-DIEGO-COUNTY; COMA DATA-BANK; BRAIN INJURY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; TIRILAZAD MESYLATE; GUNSHOT WOUNDS	Traumatic brain and spinal cord injuries continue to pose serious challenges for physicians around the world. In North America, the annual number of serious head and spinal injuries has decreased over the last two decades, and of those patients who reach a hospital, the mortality and long-term morbidity have also declined. The two major reasons for this reduction in death and disability after craniospinal trauma in the United States and Canada appear to be (1) widespread implementation of prevention measures, safety legislation, and public education initiatives; and (2) further improvements in and wider availability of emergency medical systems and regional trauma centers. Improvements in neurocritical care and the implementation of evidence-based treatment guidelines for severe head injury victims may also, in part, be responsible for improved survival rates and reduced disability rates. Unfortunately, numerous clinical trials of putative neuroprotective agents conducted in North America and elsewhere during the 1990s have failed to demonstrate efficacy in head-injured patients. However, methylprednisolone does appear to confer some benefit to a select population of spinal cord injury patients. These advances in the areas of prevention, regional trauma systems, treatment guidelines, and neurocritical care that have influenced survival rates and recovery of function are discussed.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA		Kelly, DF (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Box 957039,Room 18-218 NPI, Los Angeles, CA 90095 USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AVOLIO AEC, 1992, NEUROSURGERY, V31, P557, DOI 10.1227/00006123-199209000-00019; BAKER SP, 1992, INJURY FACT BOOK, P8; BAKER SP, 1992, INJURY FACT BOOK, P149; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; *COMM TRAUM NAT RE, 1966, ACC DEATH DIS NEGL D; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Frank RG, 1992, PSYCHOL HEALTH, V6, P129; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JAGGER J, 1992, J NEUROTRAUM, V9, pS313; JENNETT B, 1978, INJURY, V10, P31; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Kraus J, 1996, NEUROTRAUMA, P13; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Kraus JF, 1993, HEAD INJURY, P1; LEVY ML, 1993, NEUROSURGERY, V33, P1018; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOBOSKY JM, 1996, NEUROTRAUMA, P1049; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MacKenzie E J, 1989, Md Med J, V38, P725; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARMAROU A, 1991, J NEUROSURG, V75, P559; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall LF, 1991, J NEUROSURG S, V75, P14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; O'Keefe GE, 1999, ANN SURG, V229, P409, DOI 10.1097/00000658-199903000-00015; Peitzman AB, 1999, ANN SURG, V230, P87, DOI 10.1097/00000658-199907000-00013; Pitts L H, 1995, New Horiz, V3, P546; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rivara FP, 1999, PEDIATRICS, V103, P883; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Seguin J, 1999, J TRAUMA, V47, pS99; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; *US DEP TRANSP, 1994, NAT HIGHW TRAFF SURG; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Wright M, 1995, Inj Prev, V1, P81, DOI 10.1136/ip.1.2.81; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	70	40	42	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1179	1185					7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	471NB	WOS:000170934500016	11571956				2022-02-06	
J	Powell, JM; Machamer, JE; Temkin, NR; Dikmen, SS				Powell, JM; Machamer, JE; Temkin, NR; Dikmen, SS			Self-report of extent of recovery and barriers to recovery after traumatic brain injury: A longitudinal study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						awareness; brain injuries; cognition; recovery of function; rehabilitation	IMPAIRED AWARENESS; HEAD-INJURY; REHABILITATION; QUALITY; ADULTS	Objective: To examine the perspective of survivors of traumatic brain injury (TBI) regarding the extent and nature of their recovery over time. Design: Inception cohort, longitudinal study. Setting: Level I trauma center. Participants: One hundred fifty-seven consecutively hospitalized individuals with TBI (mean age, 36.1 yr; 80% men) with a broad range of injury severity. Interventions: Not applicable. Main Outcome Measures: Participants reported the extent of their recovery and barriers to full recovery at 1, 6, and 12 months. Results: Participants reported a median return to normal at the 3 follow-up times of 65%, 80%, and 85%. After I month, self-reported extent of recovery correlated well with performance on the Glasgow Outcome Scale (p <.001 at 6 and 12mo) and Wechsler Adult Intelligence Scale Performance IQ (p =.001 at 12mo). The major reported barrier to recovery was physical difficulties, which constituted over half of the concerns at all time periods. Report of physic al-related concerns decreased significantly (p =.002) over time whereas cognition-related concerns increased significantly (p =.02). Conclusion: Brain injury survivors consider themselves to have greater recovery than previously reported by clinicians or family members, consider physical problems a significant factor in their recovery, and appear to become more aware of cognitive impairments over time.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Powell, JM (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; CORBET B, 1995, SPINAL CORD INJURY C, P212; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Miles M. B., 1994, QUALITATIVE DATA ANA, V2nd; Peters DE, 1996, AM J PHYS MED REHAB, V75, P144, DOI 10.1097/00002060-199603000-00016; Peters DJ, 1996, DISABIL REHABIL, V18, P593, DOI 10.3109/09638289609166320; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zar J.H., 1999, BIOSTAT ANAL, V4th; 1999, FED REG, V64, P45744	24	40	40	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2001	82	8					1025	1030		10.1053/apmr.2001.25082			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	459WT	WOS:000170275000003	11494180				2022-02-06	
J	Sihver, S; Marklund, N; Hillered, L; Langstrom, B; Watanabe, Y; Bergstrom, M				Sihver, S; Marklund, N; Hillered, L; Langstrom, B; Watanabe, Y; Bergstrom, M			Changes in mACh, NMDA and GABA(A) receptor binding after lateral fluid-percussion injury: in vitro autoradiography of rat brain frozen sections	JOURNAL OF NEUROCHEMISTRY			English	Article						binding potential; [C-11]cyano-dizocilpine; [C-11]flumazenil; lateral fluid percussion injury; 4-N-[C-11]methylpiperidylbenzilate; positron emission tomography	POSITRON-EMISSION-TOMOGRAPHY; D-ASPARTATE RECEPTOR; CORTICAL DAMAGE; AMINO-ACIDS; RELEASE; MK-801; INVIVO; SCOPOLAMINE; ANTAGONIST; TRAUMA	Adult rats were subjected to a moderate lateral fluid percussion injury (FPI), followed by survival periods of 2 and 12 h. Regional NMDA subtype glutamate, muscarinic acetylcholine and GABAA receptor binding in various brain regions was analysed by quantitative in vitro autoradiography and short-lived positron emission tomography tracers [C-11]cyanodizocilpine, 4-N-[C-11]methylpiperidylbenzilate (4-N-[C-11]MPB), and [C-11]flumazenil, respectively. The binding potential (BP, B-max/K-D) was calculated. The data with [C-11]cyano-dizocilpine showed a significant decrease in BP bilaterally for the frontoparietal cortex and hippocampus at both time points, in comparison with that of the sham-operated controls. At 12 h the decrease was significantly more prominent for the ipsilateral cortex and hippocampus than for the contralateral side. The BP of 4-N-[C-11]MPB was significantly decreased after 2 h for the trauma-side hippocampus, and after 12 h it had decreased for the trauma-site cortex and the bilateral hippocampus. The [C-11]flumazenil exhibited a significant decrease in BP for the trauma-site cortex and the underlying hippocampus by 2 h after the traumatic brain injury. After 12 h a significantly decreased BP was observed only for the trauma-site cortex. The finding of a decreased BP demonstrates the involvement of these receptor systems in the development of cellular dysfunction, which is widespread and not limited to the site of lateral FPI.	Uppsala Univ, Univ Hosp, PET Ctr, S-75185 Uppsala, Sweden; Uppsala Univ, Fac Med, Dept Neurosci, Pharmacol Unit, Uppsala, Sweden; Uppsala Univ, Fac Med, Neurosurg Unit, Uppsala, Sweden; Uppsala Univ, Fac Med, Dept Neurosci, Unit Clin Chem, Uppsala, Sweden; Osaka Biosci Inst, Dept Neurosci, Osaka, Japan; Osaka City Univ, Grad Sch Med, Dept Physiol, Osaka 558, Japan		Bergstrom, M (corresponding author), Uppsala Univ, Univ Hosp, PET Ctr, S-75185 Uppsala, Sweden.	mats.bergstrom@pet.uu.se		Marklund, Niklas/0000-0002-9797-5626			Andersson Y, 1998, J LABELLED COMPD RAD, V41, P567, DOI 10.1002/(SICI)1099-1344(199806)41:6<567::AID-JLCR96>3.3.CO;2-#; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Heiss WD, 1997, STROKE, V28, P2045, DOI 10.1161/01.STR.28.10.2045; Heiss WD, 1998, STROKE, V29, P454, DOI 10.1161/01.STR.29.2.454; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANGSTROM B, 1987, J NUCL MED, V28, P1037; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; MAZIERE M, 1984, INT J APPL RADIAT IS, V35, P973, DOI 10.1016/0020-708X(84)90215-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LG, 1988, PSYCHOPHARMACOLOGY, V96, P385, DOI 10.1007/BF00216067; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; MULHOLLAND G K, 1988, Journal of Nuclear Medicine, V29, P768; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Rudolf J, 2000, LANCET, V355, P115, DOI 10.1016/S0140-6736(99)04280-4; Sihver S, 1999, J PHARMACOL EXP THER, V290, P917; Sihver S, 1998, J NEURAL TRANSM, V105, P117; TANAKA H, 1994, ACTA NEUROCHIR, P524; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yamaki T, 1996, J NUCL MED, V37, P1166	37	40	42	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2001	78	3					417	423		10.1046/j.1471-4159.2001.00428.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	460TZ	WOS:000170325800001	11483644				2022-02-06	
J	Otto, VI; Stahel, PF; Rancan, M; Kariya, K; Shohami, E; Yatsiv, I; Eugster, HP; Kossmann, T; Trentz, O; Moreganti-Kossmann, MC				Otto, VI; Stahel, PF; Rancan, M; Kariya, K; Shohami, E; Yatsiv, I; Eugster, HP; Kossmann, T; Trentz, O; Moreganti-Kossmann, MC			Regulation of chemokines and chemokine receptors after experimental closed head injury	NEUROREPORT			English	Article						chemokines; chemokine receptors; cytokines; knockout mice; neuroinflammation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; EXPRESSION; ASTROCYTES; ALPHA; CCR5; RAT; INTERLEUKIN-8	The expression of the chemokines macrophage inflammatory protein (MIP)-2 and MIP-1 alpha and of their receptors CXCR2 and CCR5 was assessed in wild type (WT) and TNF/lymphotoxin-alpha knockout (TNF/LT-alpha-/-) mice subjected to closed head injury (CHI). At 4 h after trauma intracerebral MIP-2 and MIP-1 alpha levels were increased in both groups with MIP-2 concentrations being significantly higher in WT than in TNF/LT-alpha-/- animals (p<0.05). Thereafter, MIP-2 production declined rapidly, whereas MIP-1<alpha> remained elevated for 7 days. Expression of CXCR2 was confined to astrocytes and increased dramatically within 24 h in both mouse types. Contrarily, CCR5 expression remained constitutively low and was mainly localized to microglia. These results show that after CHI, chemokines and their receptors are regulated differentially and with independent kinetics. NeuroReport 12:2059-2064 (C) 2001 Lippincott Williams & Wilkins.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med, Clin Immunol Sect, CH-8091 Zurich, Switzerland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel		Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063; Otto, Vivianne/0000-0002-1157-0186			Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Berman JW, 1996, J IMMUNOL, V156, P3017; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cota M, 2000, J NEUROVIROL, V6, P75, DOI 10.3109/13550280009006384; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Galasso JM, 2000, EXP NEUROL, V165, P295, DOI 10.1006/exnr.2000.7466; Galasso JM, 1998, AM J PATHOL, V153, P1631, DOI 10.1016/S0002-9440(10)65752-5; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Horuk R, 1997, J IMMUNOL, V158, P2882; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; MUELLERLADNER U, 1996, J NEUROL SCI, V144, P135; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Sanders VJ, 1998, AIDS, V12, P1021, DOI 10.1097/00002030-199809000-00008; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Simpson J, 2000, J NEUROIMMUNOL, V108, P192, DOI 10.1016/S0165-5728(00)00274-5; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Xia MQ, 1997, AM J PATHOL, V150, P1267; Xiao BG, 1998, J NEUROCYTOL, V27, P575, DOI 10.1023/A:1006918110952	25	40	41	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	JUL 3	2001	12	9					2059	2064		10.1097/00001756-200107030-00053			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	446HZ	WOS:000169509000048	11435946				2022-02-06	
J	Shepard, MF; Markolf, KL; Dunbar, AM				Shepard, MF; Markolf, KL; Dunbar, AM			The effects of partial and total interosseous membrane transection on load-sharing in the cadaver forearm	JOURNAL OF ORTHOPAEDIC RESEARCH			English	Article								This study was performed to examine the effects of partial and total transection of the interosseous membrane (TOM) on load transfer in the forearm. Twenty fresh frozen forearms were instrumented with custom designed load cells placed in the proximal radius and distal ulna. Simultaneous measurements of load cell forces, radial head displacement relative to the capitellum, and local tension within the central band of the IOM were made as the wrist was loaded to 134 N with the forearm at 90 degrees of elbow flexion and in neutral pronation supination. For valgus elbow alignment (radial head contacting the capitellum), mean force carried by the distal ulna was 7.1 % of the applied wrist force and mean force transferred from radius to ulna through the IOM was 4.4%. For varus elbow alignment (mean 2.0 mm gap between the radial head and capitellum), mean distal ulna force was 28% and mean TOM force was 51%. Section of the proximal and distal one-thirds of the IOM had no significant effect upon mean distal ulnar force or mean IOM force. Total IOM section significantly increased mean distal ulnar force for varus elbow alignment in all wrist positions tested. The mean level of applied wrist force necessary to close the varus gap (89 N) decreased significantly after both partial TOM section (71 N) and total IOM section (25 N). The IOM became loaded only when the radius displaced proximally relative to the ulna, closing the gap between the radius and capitellum. As the radius displaced proximally, the wrist becomes increasingly ulnar positive, which in turn leads to direct loading of the distal ulna. This shift of force to the distal ulna could present clinically as ulnar sided wrist pain or as ulnar impaction after IOM injury. (C) 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.	Univ Calif Los Angeles, Dept Orthopaed Surg, Div Biomech, Los Angeles, CA 90095 USA		Markolf, KL (corresponding author), Univ Calif Los Angeles, Dept Orthopaed Surg, Div Biomech, Rehabil Bldg,Room 21-67,100 Vet Ave, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR043735] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR43735] Funding Source: Medline		BIRBECK DP, 1997, J HAND SURG A, V22, P975; EDWARDS GS, 1988, CLIN ORTHOP RELAT R, P61; FRIEDMAN SL, 1993, J HAND SURG-AM, V18A, P713, DOI 10.1016/0363-5023(93)90325-W; Furry KL, 1998, CLIN ORTHOP RELAT R, P40; HOPPENFELD S, 1984, SURGICAL EXPOSURES O, P109; HOTCHKISS RN, 1989, J HAND SURG-AM, V14, P256, DOI 10.1016/0363-5023(89)90017-8; HOTCHKISS RN, 1994, HAND CLIN, V10, P391; Markolf KL, 1998, J BONE JOINT SURG AM, V80A, P879, DOI 10.2106/00004623-199806000-00012; MIKIC ZD, 1983, CLIN ORTHOP RELAT R, P220; MORREY BF, 1988, J BONE JOINT SURG AM, V70A, P250, DOI 10.2106/00004623-198870020-00014; Pfaeffle HJ, 1996, J ORTHOP RES, V14, P842, DOI 10.1002/jor.1100140525; RABINOWITZ RS, 1994, J HAND SURG-AM, V19A, P385, DOI 10.1016/0363-5023(94)90050-7; SCHNEIDERMAN G, 1993, J TRAUMA, V35, P879, DOI 10.1097/00005373-199312000-00014; SELLMAN DC, 1995, J ORTHOP TRAUMA, V9, P516, DOI 10.1097/00005131-199509060-00010; Skahen JR, 1997, J HAND SURG-AM, V22A, P986, DOI 10.1016/S0363-5023(97)80037-8; Skahen JR, 1997, J HAND SURG-AM, V22A, P981, DOI 10.1016/S0363-5023(97)80036-6; SOWA DT, 1995, CLIN ORTHOP RELAT R, P106; Wallace AL, 1997, J BONE JOINT SURG BR, V79B, P422, DOI 10.1302/0301-620X.79B3.7142	18	40	41	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0736-0266			J ORTHOPAED RES	J. Orthop. Res.	JUL	2001	19	4					587	592		10.1016/S0736-0266(00)00059-0			6	Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics	461LQ	WOS:000170366100014	11518266				2022-02-06	
J	Vos, PE; Van Voskuilen, AC; Beems, T; Krabbe, PFM; Vogels, OJM				Vos, PE; Van Voskuilen, AC; Beems, T; Krabbe, PFM; Vogels, OJM			Evaluation of the traumatic coma data bank computed tomography classification for severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography scan; Glasgow Outcome Scale; outcome; prognostic factor; severe head injury; traumatic brain injury; Traumatic Coma Data Bank classification	SUBARACHNOID HEMORRHAGE; IMPAIRED CONSCIOUSNESS; BRAIN INJURY; NIMODIPINE; SCAN; HEMATOMA; TRIALS	This study determines the interrater and intrarater reliability of the Traumatic Coma Data Bank (TCDB) computed tomography (CT) scan classification for severe head injury. This classification grades the severity of the injury as follows: I = normal, II = diffuse injury, III = diffuse injury with swelling, IV = diffuse injury with shift, V = mass lesion surgically evacuated, or VI = mass lesion not operated. Patients with severe closed head injury were included. Outcome was assessed using the Glasgow Outcome Score (GOS) at 3 and 6 months. Four observers, two of them classifying the scans twice, independently evaluated CT scans. Of the initial CT scans of 63 patients (36 males, 27 females; age, 34 +/- 24 years), 6.3% were class I, 26.9% class II, 28.6% class III, 6.3% class IV, 22.2% were class V, and 9.6% class VI. The overall interrater and intrarater reliability was 0.80 and 0.85, respectively. Separate analyses resulted in higher inter- and intrarater reliabilities for the mass lesion categories (V and VI), 0.94 and 0.91, respectively, than the diffuse categories (I-IV) 0.71 and 0.67. Merging category III with IV, and V with VI resulted in inter- and intrarater reliabilities of 0.93 and 0.78, respectively. Glasgow outcome scores after 6 months were as follows: 19 dead (30%), one vegetative (2%), five severely disabled (8%), 17 moderately disabled (27%), and 21 good recovery (33%). Association measures (Sommers' D) between CT and GOS scores were statistically significant for all observers. This study shows a high intra- and interobserver agreement in the assessment of CT scan abnormalities and confirms the predictive power on outcome when the TCDB classification is used.	Univ Med Ctr Nijmegen, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Med Technol Assessment, NL-6500 HB Nijmegen, Netherlands		Vos, PE (corresponding author), Univ Med Ctr Nijmegen, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@czzoneu.azn.nl	Vos, Pieter/A-6043-2012; Krabbe, Paul/B-2563-2013; Krabbe, Paul/AAO-6590-2020	Krabbe, Paul/0000-0001-6042-1243; Krabbe, Paul/0000-0001-6042-1243			BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1977, CLIN NEUROL NEUROSUR, V80, P104; Castellan N. J, 1988, NONPARAMETRIC STAT B; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JENNETT B, 1975, LANCET, V1, P480; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; Norman, 1995, HLTH MEASUREMENT SCA; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SHAVELSON RJ, 1989, AM PSYCHOL, V44, P922, DOI 10.1037/0003-066X.44.6.922; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	25	40	41	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2001	18	7					649	655		10.1089/089771501750357591			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	457CK	WOS:000170119400001	11497091	Green Submitted			2022-02-06	
J	Penkowa, M; Giralt, M; Thomsen, PS; Carrasco, J; Hidalgo, J				Penkowa, M; Giralt, M; Thomsen, PS; Carrasco, J; Hidalgo, J			Zinc or copper deficiency-induced impaired inflammatory response to brain trauma may be caused by the concomitant metallothionein changes	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; Cu.Zn-SOD; gliosis; iNOS; MDA; MT-KO; NF-kappa B; NITT; oxidative stress; TUNEL	GROWTH-INHIBITORY FACTOR; III MESSENGER-RNA; RAT-BRAIN; OXIDATIVE STRESS; TRANSGENIC MICE; NEURODEGENERATIVE-DISORDERS; STAB WOUNDS; INDUCED HEPATOTOXICITY; REACTIVE ASTROCYTES; I-DEFICIENT	The role of zinc- and copper-deficient diets on the inflammatory response to traumatic brain injury (TBI) has been evaluated in adult rats. As expected, zinc deficiency decreased food intake and body weight gain, and the latter effect was higher than that observed in pair-fed rats. In noninjured brains, zinc deficiency only affected significantly lectin (increasing) and glial fibrillary acidic protein (GFAP) and Cu,Zn-superoxide dismutase (Cu,Zn-SOD) (decreasing) immunoreactivities (irs). In injured brains, a profound gliosis was observed in the area surrounding the lesion, along with severe damage to neurons as indicated by neuron specific enolase (NSE) ir, and the number of cells undergoing apoptosis (measured by TUNEL) was dramatically increased. Zinc deficiency significantly altered brain response to TBI, potentiating the microgliosis and reducing the astrogliosis, while increasing the number of apoptotic cells. Metallothioneins (MTs) are important zinc- and copper-binding proteins in the CNS, which could influence significantly the brain response to TBI because of their putative roles in metal homeostasis and antioxidant defenses. MT-I+II expression was dramatically increased by TBI, and this response was significantly blunted by zinc deficiency. The MT-III isoform was moderately increased by both TBI and zinc deficiency. TBI strongly increased oxidative stress levels, as demonstrated by malondialdehyde (MDA), protein tyrosine nitration (NITT), and nuclear factor kappaB (NF-kappaB) levels irs, all of which were potentiated by zinc deficiency. Further analysis revealed unbalanced expression of prooxidant and antioxidant proteins besides MT, since the levels of inducible nitric oxide synthase (iNOS) and Cu,Zn-SOD were increased and decreased, respectively, by zinc deficiency. All these effects were attributable to zinc deficiency, since pair-fed rats did not differ from normally fed rats. In general, copper deficiency caused a similar pattern of responses, albeit more moderate. Results obtained in mice with a null mutation for the MT-I+II isoforms strongly suggest that most of the effects observed in the rat brain after zinc and copper deficiencies are attributable to the concomitant changes in the MT expression.	Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Immunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark		Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Immunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain.	Juan.Hidalgo@uab.es	Hidalgo, Juan/C-9082-2011; Giralt, Mercedes/K-1626-2014; Carrasco, Javier/C-9732-2011	Hidalgo, Juan/0000-0003-0921-1122; Giralt, Mercedes/0000-0002-1806-1528; Carrasco, Javier/0000-0001-6436-0863			Acarin L, 1999, NEUROSCIENCE, V92, P827, DOI 10.1016/S0306-4522(99)00022-6; Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; ANEZAKI T, 1995, NEUROCHEM INT, V27, P89, DOI 10.1016/0197-0186(94)00170-Y; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BREMNER I, 1987, PROG FOOD NUTR SCI, V11, P1; BREMNER I, 1987, J NUTR, V117, P1595, DOI 10.1093/jn/117.9.1595; CAMPAGNE MV, 1999, J CEREB BLOOD FLOW M, V19, pS138; Carrasco J, 1998, EXP NEUROL, V153, P184, DOI 10.1006/exnr.1998.6861; Carrasco J, 1999, J NEUROTRAUM, V16, P1115, DOI 10.1089/neu.1999.16.1115; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DALTON T, 1995, NEUROCHEM INT, V27, P59, DOI 10.1016/0197-0186(94)00168-T; EBADI M, 1985, BIOL TRACE ELEM RES, V7, P129, DOI 10.1007/BF02916535; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; FREDERICKSON C, 1984, NEUROBIOLOGY ZINC A; Fu K, 1998, PANCREAS, V17, P238, DOI 10.1097/00006676-199810000-00003; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; GASULL T, 1994, AM J PHYSIOL, V266, pE760, DOI 10.1152/ajpendo.1994.266.5.E760; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.bi.55.070186.004405; Hanada K, 1998, J INVEST DERMATOL, V111, P582, DOI 10.1046/j.1523-1747.1998.00342.x; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; Hernandez J, 1997, J ENDOTOXIN RES, V4, P363, DOI 10.1177/096805199700400508; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; HIDALGO J, 1994, CHEM-BIOL INTERACT, V93, P197, DOI 10.1016/0009-2797(94)90020-5; HIDALGO J, 1997, CURR TOPICS NEUROCHE, V1, P1; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Hozumi I, 1996, BRAIN RES, V741, P197, DOI 10.1016/S0006-8993(96)00912-2; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; Inuzuka T, 1996, BRAIN RES, V709, P151, DOI 10.1016/0006-8993(95)01444-6; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Keen CL, 1998, AM J CLIN NUTR, V67, p1003S, DOI 10.1093/ajcn/67.5.1003S; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Liu J, 1998, TOXICOL APPL PHARM, V149, P24, DOI 10.1006/taap.1997.8325; Liu J, 1999, J PHARMACOL EXP THER, V289, P580; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; NALBANDYAN RM, 1983, NEUROCHEM RES, V8, P1211, DOI 10.1007/BF00963993; NARUSE S, 1994, GENE, V144, P283, DOI 10.1016/0378-1119(94)90391-3; Neal JW, 1996, NEUROPATH APPL NEURO, V22, P243; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Penkowa M, 1997, BRAIN RES, V774, P256, DOI 10.1016/S0006-8993(97)81716-7; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 1999, J NEUROSCI, V19, P2535; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITT PAES, 1992, NEUROSCI LETT, V144, P107, DOI 10.1016/0304-3940(92)90727-O; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; SUZUKI K, 1992, ACTA HISTOCHEM CYTOC, V25, P617, DOI 10.1267/ahc.25.617; Uauy R, 1998, AM J CLIN NUTR, V67, p952S, DOI 10.1093/ajcn/67.5.952S; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Yoko, 1994, Biological Signals, V3, P211; VALLEE B L, 1988, Biofactors, V1, P31; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vela JM, 1997, BRAIN RES, V767, P345, DOI 10.1016/S0006-8993(97)00628-8; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; YOUNG JK, 1991, GLIA, V4, P602, DOI 10.1002/glia.440040607; YUGUCHI T, 1995, MOL BRAIN RES, V28, P181, DOI 10.1016/0169-328X(94)00205-S; YUGUCHI T, 1995, J NEUROTRAUM, V12, P299, DOI 10.1089/neu.1995.12.299; ZHENG H, 1995, NEUROCHEM INT, V27, P43, DOI 10.1016/0197-0186(94)00167-S	74	40	47	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					447	463		10.1089/089771501750171056			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000008	11336445				2022-02-06	
J	Francois, B; Vacher, P; Roustan, J; Salle, JY; Vidal, J; Moreau, JJ; Vignon, P				Francois, B; Vacher, P; Roustan, J; Salle, JY; Vidal, J; Moreau, JJ; Vignon, P			Intrathecal baclofen after traumatic brain injury: Early treatment using a new technique to prevent spasticity	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SPINAL SPASTICITY; PROGRAMMABLE PUMP; CEREBRAL ORIGIN; EXPERIENCE; INFUSION; TETANUS	Background: In the early course of severe head trauma, the clinical value of intrathecal administration of baclofen to reduce autonomic disorders and spasticity has not been established. Methods: We studied four patients (Glasgow Coma Scale score 3 or 4) with autonomic disorders and spasticity who failed to respond to conventional treatment during the early course of head injury, Baclofen (25 mug/mL) was infused continuously through an intrathecal catheter inserted at patient bedside and subcutaneously tunneled. When this treatment was successful, the spinal catheter was removed and surgically replaced by another catheter connected to a subcutaneous pump. Clinical follow-up was obtained at 6 months after the head injury, Results: Mean delay for the initiation of intrathecal baclofen was 25 days (range, 21 to 31 days), and optimal dose was 385 +/- 185 mug/day. In all patients, the Ashworth score was consistently reduced (3.5 +/- 0.5. vs. 4.5 +/- 0.5 for upper limbs and 2 +/- 0.5 vs. 4.5 +/- 0.5 for lower limbs), as were both the frequency and intensity of autonomic disorders. The spinal catheters were used during a mean period of 9.5 +/- 1.7 days without complications. All three survivors were equipped with a programmable pump and had a lower Ashworth score at 6 months. Autonomic disorders had disappeared in two patients and remained modest in the remaining patient. Conclusion: Continuous administration of baclofen via the intrathecal route using this new technique seems to reduce autonomic disorders and spasticity during the early course of severe traumatic head injury.	Dupuytren Univ Hosp, Intens Care Unit, Limoges, France; Dupuytren Univ Hosp, Dept Rehabil, Limoges, France; Dupuytren Univ Hosp, Dept Neurosurg, Limoges, France		Francois, B (corresponding author), CHU Dupuytren, Serv Reanimat Polyvalente, 2 Ave Martin Luther King, F-87042 Limoges, France.		Vignon, Philippe/O-8886-2016; Francois, Bruno/O-8404-2016	Vignon, Philippe/0000-0003-4551-5772; Francois, Bruno/0000-0002-2531-1652			ABEL NA, 1994, ARCH PHYS MED REHAB, V75, P54; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Francois B, 1997, PRESSE MED, V26, P1045; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; MEYTHALER JM, 1994, J NEUROSURG, V57, P582; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; SILBERT PL, 1993, ANESTHESIOLOGY, V79, P199, DOI 10.1097/00000542-199307000-00049	14	40	41	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2001	50	1					158	161		10.1097/00005373-200101000-00035			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	392UQ	WOS:000166431300035	11231690				2022-02-06	
J	Dolinak, D; Smith, C; Graham, DI				Dolinak, D; Smith, C; Graham, DI			Global hypoxia per se is an unusual cause of axonal injury	ACTA NEUROPATHOLOGICA			English	Article						human global hypoxia; axonal injury; raised intracranial pressure	AMYLOID PRECURSOR PROTEIN; ISCHEMIC BRAIN-DAMAGE; MISSILE HEAD-INJURY; INTRACRANIAL-PRESSURE; DIAGNOSIS; TRAUMA; PATHOLOGY; MODEL; MILD	Irreversible hypoxic brain damage and axonal injury are present in over 90% of fatal blunt head injuries. Given the frequency each, difficulties arise as to whether or not they are due to different mechanisms and, as such, can be separately recognised and quantified. Recent literature has raised the possible role of hypoxia in the formation of axonal bulbs. The present study of 17 cases of cardio-respiratory arrest, 12 of status epilepticus, 3 of carbon monoxide poisoning and 12 controls was designed to test the relationship between hypoxia and axonal injury and to test the hypothesis whether or not the two entities can be separated into primary and secondary forms of traumatic brain injury. Axonal damage was seen in 9/17 and 7/12 of the cases with cardiac arrest and status epilepticus, respectively, in most of whom there was also evidence of raised intracranial pressure (ICP). All 3 cases of carbon monoxide poisoning had evidence of white matter damage in keeping with the classical pattern of selective vulnerability. It is concluded that the great majority of axonal damage identified in cases dying after cardiac arrest and status epilepticus can be attributed to raised ICP and the vascular complications of internal herniation. However, in some cases, axonal damage was seen in the absence of an elevated ICP, although its amount and distribution were different from diffuse axonal injury. In many cases there was an increase in expression of neuronal beta amyloid precursor protein.	Univ Glasgow, Inst Neurol Sci, Dept Neuropathol, S Glasgow Univ Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland		Graham, DI (corresponding author), Univ Glasgow, Inst Neurol Sci, Dept Neuropathol, S Glasgow Univ Hosp NHS Trust, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRIERLEY JB, 1994, GREENFIELDS NEUROPAT, P125; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1993, HEAD INJURY, P91; GRAHAM DI, 2000, IN PRESS HEAD INJURY; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; [No title captured]; [No title captured]; [No title captured]; [No title captured]	39	40	42	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2000	100	5					553	560		10.1007/s004010000218			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	352GK	WOS:000089206800014	11045678				2022-02-06	
J	Stablum, F; Umilta, C; Mogentale, C; Carlan, M; Guerrini, C				Stablum, F; Umilta, C; Mogentale, C; Carlan, M; Guerrini, C			Rehabilitation of executive deficits in closed head injury and anterior communicating artery aneurysm patients	PSYCHOLOGICAL RESEARCH-PSYCHOLOGISCHE FORSCHUNG			English	Article							RECOVERY; CONCUSSION; IMPAIRMENT; ADJUSTMENT; COGNITION; ATTENTION	This paper reports a study that was aimed to rehabilitate executive functions in closed head injury (CHI) and anterior communicating artery (ACoA) aneurysm patients. The groups tested comprised 10 CHI patients, 9 ACoA aneurysm patients and 19 controls. We employed a dual-task paradigm that is known to tap the ability to co-ordinate two actions. The treatment consisted of five experimental sessions, in which the dual-task paradigm was used. In the CHI study, the dual-task cost was measured before the treatment (assessment), immediately after the treatment (retest), and 3 months after the treatment (follow-up). In the ACoA aneurysm study, the dual-task cost was also assessed 12 months after the treatment. A significant reduction of the dual-task cost from assessment to retest was found. This reduction remained stable in the follow-up sessions. The results are discussed with reference to the absence of spontaneous recovery of this specific executive function and to the possibility that the beneficial effect of the treatment generalises to other executive functions and/or daily living activities.	Univ Padua, Dipartimento Psicol Gen, I-35131 Padua, Italy		Stablum, F (corresponding author), Univ Padua, Dipartimento Psicol Gen, Via Venezia 8, I-35131 Padua, Italy.			Stablum, Franca/0000-0003-0123-5090			Allport D. A., 1992, ATTENTION PERFORM, V14, P183; BENYISHAY Y, 1979, REHABILITATION MONOG, V61; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; DELUCA J, 1995, J CLIN EXP NEUROPSYC, V17, P100, DOI 10.1080/13803399508406586; Fuster JM., 1980, PREFRONTAL CORTEX; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LAWSON MJ, 1989, J EXPT CLIN NEUROPSY, V11, P824; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; PASHLER H, 1989, Q J EXP PSYCHOL-A, V41, P19, DOI 10.1080/14640748908402351; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prigatano GP, 1985, NEUROPSYCHOLOGICAL R; SHALLICE T, 1994, ATTENTION PERFORM, V15, P395; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; TEASDALE G, 1974, LANCET, V2, P81; TEXLER LE, 1982, COGNITIVE REHABILITA; Umilta C, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P37; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wood R L, 1987, Int Disabil Stud, V9, P149	43	40	40	0	9	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0340-0727			PSYCHOL RES-PSYCH FO	Psychol. Res.-Psychol. Forsch.	AUG	2000	63	3-4					265	278		10.1007/s004269900002			14	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	350DJ	WOS:000089085200005	11004880				2022-02-06	
J	Siren, AL; Knerlich, F; Schilling, L; Kamrowski-Kruck, H; Hahn, A; Ehrenreich, H				Siren, AL; Knerlich, F; Schilling, L; Kamrowski-Kruck, H; Hahn, A; Ehrenreich, H			Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma	NEUROCHEMICAL RESEARCH			English	Article						cryogenic cortical lesion; ET-1; ET-3; ETA-receptor; ETB-receptor; immunohistochemistry; RT PCR	CEREBROSPINAL-FLUID; CONVERTING-ENZYME; BASILAR ARTERY; B RECEPTORS; SUBARACHNOID HEMORRHAGE; GLOBAL-ISCHEMIA; PARIETAL CORTEX; MESSENGER-RNA; INJURY; IMMUNOREACTIVITY	We characterized the time-course, intensity of expression and cellular origin of components of the endothelin (ET) system in the rat brain after a standardized neurotrauma (cryogenic lesion of the parietal cortex). ET mRNAs were expressed at sham level after neurotrauma, whereas immunoreactivity for ET-1 was enhanced in glia and endothelium of the lesioned hemisphere and both hippocampi. The number of ET-3 positive mononuclear cells in the lesion perimeter increased starting at 24h after injury. At 48h after neurotrauma, ET-receptor immunoreactivity was increased in astrocytes. In basilar artery endothelium, ETB-immunoreactivity was reduced at 48h to 72h recovering at 7 days whereas ETA-receptor and ET-peptide immunoreactivities were not altered. In summary, neurotrauma leads to a multicellular stimulation of endothelins in the brain along with a delayed selective loss of vascular ETB-receptors. These changes seem to be posttranscriptional and cell type specific. They favor vasoconstriction increasing the risk of late vasospasm and ischemia.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Gottingen, Dept Psychiat, D-37075 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Univ Heidelberg Hosp, Dept Neurosurg, D-68167 Mannheim, Germany; Knoll AG, Dept Cardiovasc Res, D-6700 Ludwigshafen, Germany		Siren, AL (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.	Siren@em.mpg.de	Siren, Anna-Leena/AAE-1374-2019; Knerlich-Lukoschus, Friederike F/J-2895-2016; Knerlich-Lukoschus, Friederike/A-3233-2011	Siren, Anna-Leena/0000-0002-2217-0081; Knerlich-Lukoschus, Friederike F/0000-0002-6284-0449; Knerlich-Lukoschus, Friederike/0000-0003-4907-015X; Ehrenreich, Hannelore/0000-0001-8371-5711			Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; BERGER SL, 1989, METHOD ENZYMOL, V180, P3; Dawson DA, 1999, NEUROCHEM RES, V24, P1499, DOI 10.1023/A:1021139713026; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; EHRENREICH H, 1993, BRAIN RES, V600, P201, DOI 10.1016/0006-8993(93)91374-2; Ehrenreich H, 1999, BIOCHEM BIOPH RES CO, V261, P149, DOI 10.1006/bbrc.1999.0924; Ehrenreich H, 1999, NEUROSCIENCE, V91, P1067, DOI 10.1016/S0306-4522(98)00663-0; EHRENREICH H, 1993, J IMMUNOL, V150, P4601; EHRENREICH H, 1991, BRAIN RES, V538, P54, DOI 10.1016/0006-8993(91)90375-6; EHRENREICH H, 1995, CLEV CLIN J MED, V62, P105, DOI 10.3949/ccjm.62.2.105; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; EHRENREICH H, 1992, RES EXP MED, V192, P257, DOI 10.1007/BF02576282; FEGER GI, 1994, J CEREBR BLOOD F MET, V14, P845, DOI 10.1038/jcbfm.1994.106; FEUERSTEIN G, 1994, PEPTIDES, V15, P467, DOI 10.1016/0196-9781(94)90207-0; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; Gorlach C, 1998, J CEREBR BLOOD F MET, V18, P1357; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Hasselblatt M, 1998, BRAIN RES, V785, P253, DOI 10.1016/S0006-8993(97)01368-1; Hermann DM, 1998, NEUROREPORT, V9, P1249, DOI 10.1097/00001756-199804200-00053; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1995, J PHARMACOL EXP THER, V273, P1; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; Maeda M, 1997, ACTA NEUROPATHOL, V94, P116, DOI 10.1007/s004010050682; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; NUYTINCK HK, 1987, PROG CLIN BIOL RES, P55; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Patel TR, 1996, J CEREBR BLOOD F MET, V16, P950, DOI 10.1097/00004647-199609000-00019; Patel TR, 1996, J CEREBR BLOOD F MET, V16, P490, DOI 10.1097/00004647-199605000-00016; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; SCHILLING L, 1995, J CEREBR BLOOD F MET, V15, P699, DOI 10.1038/jcbfm.1995.86; SCHILLING L, 1994, ACTA NEUROCHIR, P79; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Spatz M, 1996, BRAIN RES, V726, P242, DOI 10.1016/0006-8993(96)00409-X; Touzani O, 1997, J CEREBR BLOOD F MET, V17, P1157, DOI 10.1097/00004647-199711000-00004; WILLETTE RN, 1993, LIFE SCI, V52, P35, DOI 10.1016/0024-3205(93)90286-C; Wu W, 1996, Chin Med Sci J, V11, P228; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YAMADA G, 1995, J CARDIOVASC PHARM, V26, pS486; Yanagisawa H, 1998, DEVELOPMENT, V125, P825	46	40	41	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUL	2000	25	7					957	969		10.1023/A:1007552408463			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	344AB	WOS:000088734500008	10959492				2022-02-06	
J	Russo, RN; O'Flaherty, S				Russo, RN; O'Flaherty, S			Bromocriptine for the management of autonomic dysfunction after severe traumatic brain injury	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						autonomic dysfunction; bromocriptine; traumatic brain injury	SEVERE HEAD-INJURY; HYPERTENSION	This case report describes a child with severe traumatic brain injury with clinical features of autonomic dysfunction in the immediate post-traumatic period. A history of severe asthma in this child contraindicated the use of beta-blockers, the first line approach, and she was managed with bromocriptine (0.05 mg/kg t.d.s) with good effect.	Royal Alexandra Hosp Children, Dept Rehabil Med, Parramatta, NSW, Australia		Russo, RN (corresponding author), Womens & Childrens Hosp, Child Dev & Rehab Dept, 72 King William Rd, N Adelaide, SA 5006, Australia.						BRINK J, 1980, J PEDIATR, V5, P721; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; HEIMER L, 1983, HUMAN BRAIN SPINAL C, P303; HORN LJ, 1996, MED REHABILITATION T, P540; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KANTER RK, 1985, CLIN PEDIATR, V24, P320, DOI 10.1177/000992288502400603; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; LABI M L C, 1990, Brain Injury, V4, P365, DOI 10.3109/02699059009026189; MCLEAN DE, 1995, J HEAD TRAUMA REHAB, V5, P1; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; OVERGAARD J, 1973, LANCET, V2, P631; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROSNER B, 1993, J PEDIATR-US, V123, P871, DOI 10.1016/S0022-3476(05)80382-8; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SHIOZAKI T, 1993, J NEUROSURG, V78, P501, DOI 10.3171/jns.1993.78.3.0501; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022	24	40	44	0	0	BLACKWELL SCIENCE ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	1034-4810			J PAEDIATR CHILD H	J. Paediatr. Child Health	JUN	2000	36	3					283	285		10.1046/j.1440-1754.2000.00485.x			3	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	317LQ	WOS:000087227200020	10849235				2022-02-06	
J	Fins, JJ				Fins, JJ			A proposed ethical framework for interventional cognitive neuroscience: A consideration of deep brain stimulation in impaired consciousness	NEUROLOGICAL RESEARCH			English	Article						neuropsychiatric research ethics; neuromodulation; traumatic brain injury; persistent vegetative state; minimally conscious state; clinical pragmatism	PATIENT; STATES	Advances in neuromodulation techniques offer the promise of new therapeutic interventions for patients with neuropsychiatric maladies. Several complex social, ethical and policy issues will attend developments in this area. In this paper an ethical framework for clinical research in interventional cognitive neuroscience is advanced. Deep brain stimulation in traumatic brain injury is considered as a paradigm case to examine ethical obligations in human subject research. These include balancing access to novel therapies versus protection of vulnerable study populations, rational evaluation of study design and research strategies, informed consent, and the importance of achieving societal consensus for this line of scientific inquiry.	Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Psychiat Med, New York, NY USA		Fins, JJ (corresponding author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, 525 E 68th St F-173, New York, NY 10021 USA.			Fins, Joseph/0000-0002-7221-0053			3National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978, DHEW PUBL; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Brody B.A, 1998, CONSENT SEEKING JUST, P32; Buchanan AE., 1990, DECIDING OTHERS ETHI; COHADON F, 1985, NEUROSTIMULATION OVE, P249; DELIAC P, 1993, NEUROCHIRURGIE, V39, P293; Dresser R, 1996, JAMA-J AM MED ASSOC, V276, P67, DOI 10.1001/jama.276.1.67; Fins JJ, 1997, KENNEDY INST ETHIC J, V7, P129, DOI 10.1353/ken.1997.0013; Fins JJ, 1999, HASTINGS CENT REP, V29, P49, DOI 10.2307/3528356; Fins JJ, 1997, ARCH GEN PSYCHIAT, V54, P415; FINS JJ, 1999, HMS BEAGLE      0223; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; HOSOBUCHI Y, 1993, ELECT MAGNETIC STIMU, P249; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Levine R., 1986, ETHICS REGULATION CL, P95; Macciocchi SN, 1997, NEUROSURG REV, V20, P161, DOI 10.1007/BF01105559; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; Miller FG, 1999, ARCH GEN PSYCHIAT, V56, P701, DOI 10.1001/archpsyc.56.8.701; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ; OSBORN CL, 1998, OVER MY HEAD; Purpura KP, 1997, NEUROSCIENTIST, V3, P8, DOI 10.1177/107385849700300110; Rinaldi P. C., 1996, Society for Neuroscience Abstracts, V22, P904; Sachs G.A., 1991, J CRIT ILLNESS, V6, P348; Schiff N. D., 1999, NEUROLOGY IMPAIRED C; Schiff ND, 2000, NEUROL RES, V22, P267; Schiff ND, 1999, P ROY SOC B-BIOL SCI, V266, P421, DOI 10.1098/rspb.1999.0654; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Thomas L, 1974, TECHNOLOGY MED, P31; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TSUBOKAWA T, 1998, TXB STEREOTACTIC FUN; Valenstein E, 1986, GREAT DESPERATE CURE; 1949, TRIALS WAR CRIMINALS, V2, P181; [No title captured]	35	40	41	0	14	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	APR	2000	22	3					273	278					6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	302VE	WOS:000086385700006	10769820				2022-02-06	
J	Crevits, L; Hanse, MC; Tummers, P; Van Maele, G				Crevits, L; Hanse, MC; Tummers, P; Van Maele, G			Antisaccades and remembered saccades in mild traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						antisaccades; remembered saccades; mild traumatic brain injury; frontal lobe	POSITRON EMISSION TOMOGRAPHY; HEAD-INJURY; CORTICAL CONTROL	The most common site of focal lesions after mild traumatic brain injury (MTBI) is the frontal lobe. This lobe, however, is difficult to examine clinically. Neuroimaging is not performed routinely and usually shows normal results in uncomplicated trauma. Antisaccades (AS) and remembered saccades (RS) are neuro-ophthalmological tests of frontal function. This study examined whether there are disturbances of latency time or error rate of; AS and RS in patients within 24 h after MTBI. Eye movements were studied with infrared-oculography. Data were obtained prospectively from 25 patients. An additional group of 6 patients with MTBI and alcohol intoxication were also examined. No statistical differences in AS or RS, either for errors or for latency time, were found between a group of age-matched controls and the patients, except in the group of alcohol-intoxicated MTBI patients. Our findings indicate that visual reflex inhibition and initiation of voluntary saccades were not disturbed in the nonintoxicated patients. It is hypothesized that the responsible frontal area was not affected. It is concluded that error rate and latency time of AS and RS are inappropriate measures for evaluating acute MTBI.	Univ Hosp Ghent, Dept Neurol, Neuroophthalmol Unit, B-9000 Ghent, Belgium; Univ Hosp Ghent, Dept Med Informat & Stat, B-9000 Ghent, Belgium		Crevits, L (corresponding author), Univ Hosp Ghent, Dept Neurol, Neuroophthalmol Unit, De Pintelaan 185, B-9000 Ghent, Belgium.						BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Gale BW, 1996, INVEST OPHTH VIS SCI, V37, P339; HADLEY DM, 1988, CLIN RADIOL, V39, P131; JANNTI V, 1983, PSYCHOPHARMACOLOGY B, V79, P251; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kronsbein H., 1994, Blutalkohol, V31, P57; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; PIERROTDESEILLIGNY C, 1995, ANN NEUROL, V37, P557, DOI 10.1002/ana.410370504; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203	12	40	40	0	12	DR DIETRICH STEINKOPFF VERLAG	DARMSTADT	PLATZ DER DEUTSCHEN EINHEIT 25, D-64293 DARMSTADT, GERMANY	0340-5354			J NEUROL	J. Neurol.	MAR	2000	247	3					179	182		10.1007/s004150050559			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	303ZC	WOS:000086457200004	10787111				2022-02-06	
J	Homayoun, P; Parkins, NE; Soblosky, J; Carey, ME; de Turco, EBR; Bazan, NG				Homayoun, P; Parkins, NE; Soblosky, J; Carey, ME; de Turco, EBR; Bazan, NG			Cortical impact injury in rats promotes a rapid and sustained increase in polyunsaturated free fatty acids and diacylglycerols	NEUROCHEMICAL RESEARCH			English	Article						arachidonic acid; diacylglycerols; docosahexaenoic acid; free fatty acids; phospholipase A(2); phospholipase C; traumatic brain injury	EXPERIMENTAL BRAIN INJURY; CYTOSOLIC PHOSPHOLIPASE A(2); INDUCED STATUS EPILEPTICUS; NERVOUS-SYSTEM; ARACHIDONIC-ACID; BOVINE BRAIN; ELECTROCONVULSIVE SHOCK; SUBCELLULAR-FRACTIONS; DOCOSAHEXAENOIC ACID; FOREBRAIN ISCHEMIA	Neurotrauma activates the release of membrane phospholipid-derived second messengers, such as free arachidonic acid (20:4n-6, AA) and diacylglycerols (DAGs). In the present study, we analyze the effect of cortical impact injury of low-grade severity applied to the rat frontal right sensory motor cortex (FRC) on the accumulation of free fatty acids (FFAs) and DAGs in eight brain areas 30 min and 24 hours after the insult. At these times, accumulation of FFAs and DAGs occurred mainly in the damaged FRC. The cerebellum was the only other brain area that displayed a significant accumulation of DAGs by day one post-injury. By 30 min, accumulation of free AA in the FRC displayed the greatest relative increase (300% over sham value), followed by foe docosahexaenoic acid (22:6n-3, DHA, 150%), while both 20:4-DAGs and 22:6-DAGs were increased 100% over sham values. At day one, free 22:6 and 22:6-DAGs showed the greatest increase (590% and 230%, respectively). These results suggest that TBI elicits the hydrolysis of phospholipids enriched in excitable membranes, targeting early on 20:4-phospholipids (by 30 min post- trauma) and followed 24 hours later by preferential hydrolysis of DHA-phospholipids. These lipid metabolic changes may contribute to the initiation and maturation of neuronal and fiber track degeneration observed following cortical impact injury.	Louisiana State Univ, Neurosci Ctr Execellence, Hlth Sci Ctr, New Orleans, LA 70112 USA; Dept Neurosurg, New Orleans, LA USA		Bazan, NG (corresponding author), Louisiana State Univ, Neurosci Ctr Execellence, Hlth Sci Ctr, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444			AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; Bazan N G, 1980, Adv Neurol, V28, P197; BAZAN NG, 1993, PROG BRAIN RES, V96, P247; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1971, ACTA PHYSIOL LAT AM, V21, P101; BAZAN NG, 1995, J NEUROTRAUM, V12, P789; BAZAN NG, 1990, LIPID MEDIATORS ISCH, P277; BENISTANT C, 1995, J LIPID RES, V36, P2311; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; Bonventre JV, 1996, J LIPID MEDIAT CELL, V14, P15, DOI 10.1016/0929-7855(96)00503-2; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COTMAN C, 1969, BIOCHEMISTRY-US, V8, P4606, DOI 10.1021/bi00839a056; DETURCO EBR, 1983, J NEUROCHEM, V40, P252, DOI 10.1111/j.1471-4159.1983.tb12679.x; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; FAROOQUI AA, 1992, ADV EXP MED BIOL, V318, P11; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; GOTO Y, 1988, STROKE, V19, P728, DOI 10.1161/01.STR.19.6.728; HAYES RL, 1991, CENTRAL NERVOUS SYST, P9; Homayoun P, 1997, J NEUROCHEM, V69, P199; HOMAYOUN P, 1988, J NEUROCHEM, V51, P45, DOI 10.1111/j.1471-4159.1988.tb04833.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Lecomte M, 1996, J NEUROCHEM, V66, P2160; MARCHESELLI VL, 1990, J NUTR BIOCHEM, V1, P382, DOI 10.1016/0955-2863(90)90009-A; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OWADA Y, 1994, MOL BRAIN RES, V25, P364, DOI 10.1016/0169-328X(94)90174-0; PETE MJ, 1994, J BIOL CHEM, V269, P19494; Pete MJ, 1996, J BIOL CHEM, V271, P18114, DOI 10.1074/jbc.271.30.18114; Pete MJ, 1996, BBA-LIPID LIPID MET, V1299, P325, DOI 10.1016/0005-2760(95)00225-1; POLITI LE, 1985, NEUROCHEM PATHOL, V3, P249; Rabin O, 1997, J NEUROCHEM, V68, P2111; Rabin O, 1998, J NEUROCHEM, V70, P325; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; REDDY TS, 1984, EUR J BIOCHEM, V145, P21, DOI 10.1111/j.1432-1033.1984.tb08517.x; REDDY TS, 1985, J NEUROSCI RES, V13, P381, DOI 10.1002/jnr.490130305; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SUN GY, 1972, BIOCHIM BIOPHYS ACTA, V280, P306, DOI 10.1016/0005-2760(72)90098-7; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VISIOLI F, 1993, J NEUROCHEM, V61, P1835, DOI 10.1111/j.1471-4159.1993.tb09824.x; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOELK H, 1973, H-S Z PHYSIOL CHEM, V354, P90, DOI 10.1515/bchm2.1973.354.1.90	59	40	42	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	FEB	2000	25	2					269	276		10.1023/A:1007583806138			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	305PW	WOS:000086550300013	10786712				2022-02-06	
J	Legros, B; Fournier, P; Chiaroni, P; Ritz, O; Fusciardi, J				Legros, B; Fournier, P; Chiaroni, P; Ritz, O; Fusciardi, J			Basal fracture of the skull and lower (IX, X, XI, XII) cranial nerves palsy: Four case reports including two fractures of the occipital condyle - A literature review	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							FATAL TRAFFIC ACCIDENTS; COLLET-SICARD SYNDROME; CLOSED-HEAD-INJURY		CHU Tours, Dept Anesthesiol & Intens Care 2, F-37044 Tours, France		Legros, B (corresponding author), CHU Tours, Dept Anesthesiol & Intens Care 2, F-37044 Tours, France.						AHLGREN P, 1962, ROFO-FORTSCHR RONTG, V97, P388; ALKER GJ, 1975, RADIOLOGY, V114, P611; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; Aubry M, 1968, Ann Otolaryngol Chir Cervicofac, V85, P338; BELL C, 1817, MIDDLESEX HOSP J, V4, P469; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; Brennan Richard J., 1993, Journal of Emergency Medicine, V11, P167, DOI 10.1016/0736-4679(93)90514-8; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; BUCHOLZ RW, 1979, J TRAUMA, V19, P768, DOI 10.1097/00005373-197910000-00009; CASTLING B, 1995, BRIT J ORAL MAX SURG, V33, P171, DOI 10.1016/0266-4356(95)90292-9; Clavier E, 1986, J Radiol, V67, P323; CLAYMAN DA, 1994, AM J NEURORADIOL, V15, P1309; Collet F., 1915, LYON MED, V124, P121; Cottalorda J, 1996, J PEDIATR ORTHOP B, V5, P61, DOI 10.1097/01202412-199605010-00013; Curri D, 1988, J Neurosurg Sci, V32, P157; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; GRUNDY DJ, 1984, SPINE, V9, P339, DOI 10.1097/00007632-198405000-00002; HARDINGSMITH J, 1981, J BONE JOINT SURG AM, V63, P1170, DOI 10.2106/00004623-198163070-00016; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; HEINZE J, 1969, MED J AUSTRALIA, V2, P1246, DOI 10.5694/j.1326-5377.1969.tb103371.x; Hollerhage H G, 1986, Zentralbl Neurochir, V47, P250; Jubier P, 1970, Rev Otoneuroophtalmol, V42, P189; LACOMBE H, 1989, ENCY MED CHIR PARIS, P20; Laine FJ, 1998, NEUROIMAG CLIN N AM, V8, P69; Lam CH, 1996, CAN J NEUROL SCI, V23, P145, DOI 10.1017/S0317167100038890; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; PALEY MD, 1995, BRIT J ORAL MAX SURG, V33, P239, DOI 10.1016/0266-4356(95)90008-X; Peeters F, 1983, Rofo, V138, P631, DOI 10.1055/s-2008-1055803; RAILA FA, 1993, SKELETAL RADIOL, V22, P269; Rebattu J, 1925, ANN MALADIES OREILE, V44, P1013; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SHLIACK H, 1965, NERVENARZT, V36, P362; Sicard J., 1917, MARSEILLE MED, V53, P385; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; STROOBANTS J, 1994, J NEUROSURG, V81, P137, DOI 10.3171/jns.1994.81.1.0137; Urculo E, 1996, J NEUROSURG, V84, P522, DOI 10.3171/jns.1996.84.3.0522; VIADAR F, 1995, ENCYCL MED CHIR, P9; WANI MA, 1991, J TRAUMA, V31, P1437, DOI 10.1097/00005373-199110000-00025; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008	41	40	42	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2000	48	2					342	348		10.1097/00005373-200002000-00031			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	284MH	WOS:000085335800036	10697104				2022-02-06	
J	Stiefel, D; Eich, G; Sacher, P				Stiefel, D; Eich, G; Sacher, P			Posttraumatic dural sinus thrombosis in children	EUROPEAN JOURNAL OF PEDIATRIC SURGERY			English	Article						dural sinus thrombosis; head injury; children	CLOSED HEAD-INJURY; SUPERIOR	Posttraumatic dural sinus thrombosis (DST) in children has rarely been described in the literature. Over a period of two years (1994-1996) we treated 131 children (n = 131) with minor or severe head-injury requiring a cranial computed tomography (CT) scan. DST was found in eight patients (6.1%), five with mild and three with severe cranial trauma. Diagnosis was suspected either because of a skull fracture crossing over a dural sinus or because of a hyperdensity at a dural sinus in the noncontrast CT scan. Enhanced CT scan was used to confirm DST. No specific symptoms related to DST were observed. DST was managed conservatively in all patients and recovery was uneventful. Recanalization of the sinus was documented to occur within three weeks to six months in six children. One patient showed a residual clot after five months and another did not have a follow-up CT scan. Based on our data we conclude that neither surgical nor medical intervention is indicated in traumatic DST in children.	Univ Zurich, Childrens Hosp, Dept Pediat Surg, Zurich, Switzerland; Univ Zurich, Childrens Hosp, Dept Radiol, Zurich, Switzerland		Stiefel, D (corresponding author), UCL, Inst Child Hlth, Neurol Dev Unit, 30 Guilford St, London WC1N 1EH, England.						CURE JK, 1995, AM J NEURORADIOL, V16, P1539; GARCIA RDJ, 1995, PEDIATR INFECT DIS J, V14, P617; HESSELBROCK R, 1985, NEUROSURGERY, V16, P825, DOI 10.1227/00006123-198506000-00017; KINAL ME, 1967, J NEUROSURG, V27, P142, DOI 10.3171/jns.1967.27.2.0142; Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7; RICH C, 1993, STROKE, V24, P603, DOI 10.1161/01.STR.24.4.603; SCHULZ U, 1994, KLIN PADIATR, V206, P342, DOI 10.1055/s-2008-1046627; STRINGER WL, 1983, NEUROSURGERY, V12, P95; Sugiura Y, 1996, NEUROL SURG TOKYO, V24, P379; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; TARRAS S, 1988, ARCH NEUROL-CHICAGO, V45, P214, DOI 10.1001/archneur.1988.00520260102029; TODOROW S, 1972, ROFO FORTSCHR RONTG, V117, P544	12	40	41	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-7248			EUR J PEDIATR SURG	Eur. J. Pediatr. Surg.	FEB	2000	10	1					41	44		10.1055/s-2008-1072321			4	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	301QL	WOS:000086321000008	10770246				2022-02-06	
J	Benrud-Larson, LM; Wegener, ST				Benrud-Larson, LM; Wegener, ST			Chronic pain in neurorehabilitation populations: Prevalence, severity and impact	NEUROREHABILITATION			English	Article						chronic pain; neurological disability; rehabilitation	SPINAL-CORD INJURY; PHANTOM LIMB PAIN; TRAUMATIC BRAIN INJURY; MULTIPLE-SCLEROSIS PATIENTS; CENTRAL POSTSTROKE PAIN; STROKE REHABILITATION; STUMP PAIN; COPING STRATEGIES; CEREBRAL-PALSY; DEPRESSION	Extensive data document the adverse impact chronic pain can have on physical and psychosocial functioning. However, only recently has chronic pain received attention as a secondary complication in neurorehabilitation populations such as spinal cord injury, multiple sclerosis, and cerebral palsy. It is not unreasonable to expect that chronic pain might exacerbate impairments already present due to a chronic, disabling condition. The current paper reviews what is known about the prevalence, severity, and psychosocial impact of chronic pain in neurorehabilitation populations. Although there is variation among different conditions, available data suggest that considerable proportions of these patient populations experience chronic pain and associated sequelae similar to that reported in the extant chronic pain literature (e.g., psychological distress). Research needs to continue investigating the impact of chronic pain in neurorehabilitation populations and work toward development of effective interventions to manage pain and disability in these patients. It is likely that effective pain management will lead to more effective rehabilitation and improved quality of life.	Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21239 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA		Wegener, ST (corresponding author), Johns Hopkins Univ, Dept Phys Med & Rehabil, Good Samaritan Prof Bldg,Suite 406,5601 Loch Rave, Baltimore, MD 21239 USA.	swegener@jhmi.edu					Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; ARCHIBALD CJ, 1994, PAIN, V58, P89, DOI 10.1016/0304-3959(94)90188-0; ARENA JG, 1990, J PSYCHOSOM RES, V34, P71, DOI 10.1016/0022-3999(90)90009-S; Banks SM, 1996, PSYCHOL BULL, V119, P95, DOI 10.1037/0033-2909.119.1.95; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERDE CB, 1999, TXB PAIN; Black-Schaffer RM, 1999, ARCH PHYS MED REHAB, V80, pS8, DOI 10.1016/S0003-9993(99)90096-5; Cairns DM, 1996, ARCH PHYS MED REHAB, V77, P329, DOI 10.1016/S0003-9993(96)90079-9; CARABELLI RA, 1985, ARCH PHYS MED REHAB, V66, P466; DAVIS RW, 1993, ARCH PHYS MED REHAB, V74, P79; Dekker JHM, 1997, AM J PHYS MED REHAB, V76, P43, DOI 10.1097/00002060-199701000-00008; DROMERICK A, 1994, STROKE, V25, P358, DOI 10.1161/01.STR.25.2.358; Dworkin RH, 1997, PAIN FORUM, V6, P127; DWORKIN RH, 1992, J ABNORM PSYCHOL, V101, P200, DOI 10.1037/0021-843X.101.1.200; Elliott TR, 1991, NEUROREHABILITATION, V1, P7; Ernst JL., 1998, SCI PSYCHOSOC PROCES, V1, P127; FENOLLOSA P, 1993, PARAPLEGIA, V31, P722, DOI 10.1038/sc.1993.114; Flick CL, 1999, ARCH PHYS MED REHAB, V80, pS21, DOI 10.1016/S0003-9993(99)90098-9; Gallagher P, 1999, BEHAV MED, V25, P117, DOI 10.1080/08964289909596741; GATCHEL RJ, 1996, PSYCHOSOCIAL FACTORS; HAYTHORNTHWAITE JA, 1991, PAIN, V46, P177, DOI 10.1016/0304-3959(91)90073-7; HILL A, 1993, PAIN, V55, P347, DOI 10.1016/0304-3959(93)90010-M; Hill A, 1999, J PAIN SYMPTOM MANAG, V17, P125, DOI 10.1016/S0885-3924(98)00136-5; HILL A, 1995, PAIN, V62, P79, DOI 10.1016/0304-3959(94)00253-B; Hillier SL, 1997, BRAIN INJURY, V11, P661; Indaco A, 1994, Acta Neurol (Napoli), V16, P97; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; JENSEN TS, 1995, PAIN, V61, P161, DOI 10.1016/0304-3959(94)00227-6; JENSEN TS, 1983, PAIN, V17, P243, DOI 10.1016/0304-3959(83)90097-0; JENSEN TS, 1985, PAIN, V21, P267, DOI 10.1016/0304-3959(85)90090-9; Jensen TS., 1994, TXB PAIN, P651; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; KEEFE FJ, 1989, PAIN, V37, P51, DOI 10.1016/0304-3959(89)90152-8; KEEFE FJ, 1986, J CONSULT CLIN PSYCH, V54, P665, DOI 10.1037/0022-006X.54.5.665; Kennedy P, 1997, SPINAL CORD, V35, P814, DOI 10.1038/sj.sc.3100569; KERNS RD, 1992, HDB PAIN ASSESSMENT, P235; KROLY P, 1987, MULTIMETHOD ASSESSME; Lahz S, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199706000-00009; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LERNER RK, 1991, ARCH PHYS MED REHAB, V72, P122; LINDESAY JEB, 1985, J ROY SOC MED, V78, P452, DOI 10.1177/014107688507800606; Loubser PG, 1996, NEUROTRAUMA, P1311; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; MARIANO AJ, 1992, CLIN J PAIN, V8, P87, DOI 10.1097/00002508-199206000-00005; MARSHALL M, 1992, CLIN J PAIN, V8, P351, DOI 10.1097/00002508-199212000-00010; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Montoya P, 1997, PAIN, V72, P87, DOI 10.1016/S0304-3959(97)00004-3; Moulin DE, 1998, NEUROL CLIN, V16, P889, DOI 10.1016/S0733-8619(05)70103-1; MOULIN DE, 1988, NEUROLOGY, V38, P1830, DOI 10.1212/WNL.38.12.1830; MURRAY TJ, 1995, NEUROL CLIN, V13, P197, DOI 10.1016/S0733-8619(18)30067-7; NEPOMUCENO C, 1979, ARCH PHYS MED REHAB, V60, P605; PARKES CM, 1973, J PSYCHOSOM RES, V17, P97, DOI 10.1016/0022-3999(73)90010-X; PARKES CM, 1984, EMOTIONAL REHABILITA; Rintala DH, 1998, ARCH PHYS MED REHAB, V79, P604, DOI 10.1016/S0003-9993(98)90032-6; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; ROY CW, 1995, CLIN REHABIL, V9, P21, DOI DOI 10.1177/026921559500900103; SANDFORD PR, 1992, ARCH PHYS MED REHAB, V73, P300; Schwartz L, 1999, ARCH PHYS MED REHAB, V80, P1243, DOI 10.1016/S0003-9993(99)90023-0; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; SHERMAN RA, 1987, PAIN, V28, P285, DOI 10.1016/0304-3959(87)90064-9; SPINHOVEN P, 1991, PAIN, V45, P29, DOI 10.1016/0304-3959(91)90161-P; STENAGER E, 1991, ACTA NEUROL SCAND, V84, P197, DOI 10.1111/j.1600-0404.1991.tb04937.x; Stormer S, 1997, SPINAL CORD, V35, P446, DOI 10.1038/sj.sc.3100411; SULLIVAN MJL, 1990, J ABNORM PSYCHOL, V99, P260, DOI 10.1037/0021-843X.99.3.260; SUMMERS JD, 1991, PAIN, V47, P183, DOI 10.1016/0304-3959(91)90203-A; Teasell R W, 1999, Phys Med Rehabil Clin N Am, V10, P237; Thompson AJ, 1998, CURR OPIN NEUROL, V11, P305, DOI 10.1097/00019052-199808000-00005; Turk DC, 1997, PROG PAIN RES MANAG, V8, P185; TURK DC, 1997, CAMBRIDGE HDB PSYCHO, P146; Turk Dennis C., 1996, P3; Turk MA, 1997, ARCH PHYS MED REHAB, V78, pS10, DOI 10.1016/S0003-9993(97)90216-1; UMLAUF RL, 1992, CLIN J PAIN, V8, P111, DOI 10.1097/00002508-199206000-00008; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VEIT CT, 1983, J CONSULT CLIN PSYCH, V51, P730, DOI 10.1037/0022-006X.51.5.730; VERMOTE R, 1986, CLIN NEUROL NEUROSUR, V88, P87, DOI 10.1016/S0303-8467(86)80002-6; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Wall P.D., 1999, TXB PAIN; Warnell P, 1991, Axone, V13, P26; Waters RL, 1998, ARCH PHYS MED REHAB, V79, P1237, DOI 10.1016/S0003-9993(98)90268-4; WEGENER ST, 1992, CLIN J PAIN, V8, P93, DOI 10.1097/00002508-199206000-00006; Weinstein SM, 1998, NEUROL CLIN, V16, P919, DOI 10.1016/S0733-8619(05)70105-5; Widerstrom-Noga EG, 1999, ARCH PHYS MED REHAB, V80, P580, DOI 10.1016/S0003-9993(99)90203-4; WOOLSEY RM, 1986, J AM PARAPLEGIA SOC, V9, P27; Zorowitz RD, 1996, AM J OCCUP THER, V50, P194, DOI 10.5014/ajot.50.3.194	87	40	40	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2000	14	3					127	137					11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	357PD	WOS:000089509300002	11455075				2022-02-06	
J	Hannay, HJ; Feldman, Z; Phan, P; Keyani, A; Panwar, N; Goodman, JC; Robertson, CS				Hannay, HJ; Feldman, Z; Phan, P; Keyani, A; Panwar, N; Goodman, JC; Robertson, CS			Validation of a controlled cortical impact model of head injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						beam balancing; behavioral outcome; controlled cortical impact; contusion; grasp strength; head injury; hippocampus; Morris water maze; motor coordination; mouse; slant board	TRAUMATIC BRAIN INJURY; COGNITIVE DEFICITS; MEMORY DEFICITS; RATS; VELOCITY; VA-045; MOTOR; MOUSE	A controlled cortical impact model of head injury was validated with mice, Mice were randomly assigned to moderate head injury, mild head injury, and sham injury groups, Beam balancing, open field activity, slant board inclination, grasp strength, and motor coordination were assessed prior to the injury and on days 1-5 postinjury, Morris water maze performance was evaluated on days 11-15 postinjury, Moderately head-injured mice took a significantly longer time to complete the motor coordination task and to find the hidden platform on the Morris water maze and had significantly fewer successful trials on bath tasks than the mildly head-injured and sham-injured mice, Mildly head-injured and sham-injured mice performed similarly on both tasks, Contusion volume at the site of impact varied with severity of injury, Moderately head-injured mice had significantly larger contusions than mice with a mild head injury, and these mice in turn had significantly larger contusions than the sham-injured mice, Both moderately and mildly head injured mice had significantly fewer surviving cells in CA1 than the sham-injured mice but did not differ from each other in this regard, Although there was a group effect, only the mildly head-injured mice had significantly fewer surviving cells in CA3.	Univ Houston, Dept Psychol, Houston, TX 77204 USA; Tel Aviv Univ, Dept Neurosurg, IL-69978 Tel Aviv, Israel; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Hannay, HJ (corresponding author), Univ Houston, Dept Psychol, 4800 Calhoun, Houston, TX 77204 USA.			Feldman, Zeev/0000-0002-9719-3894; Hannay, H. Julia/0000-0001-7023-912X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHUNG SY, 1995, J NUTR, V125, P1484; DELATORRE JC, 1995, NEUROSURGERY, V37, P273, DOI 10.1227/00006123-199508000-00012; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANNAY HJ, 1993, 11 ANN NEUR S WASH D; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; Tang YP, 1997, BEHAV BRAIN RES, V83, P195, DOI 10.1016/S0166-4328(97)86068-8; Tang YP, 1997, BRIT J PHARMACOL, V122, P257, DOI 10.1038/sj.bjp.0701385	21	40	41	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1103	1114		10.1089/neu.1999.16.1103			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500008	10595826				2022-02-06	
J	Faden, AI; Fox, GB; Fan, L; Araldi, GL; Qiao, LX; Wang, SM; Kozikowski, AP				Faden, AI; Fox, GB; Fan, L; Araldi, GL; Qiao, LX; Wang, SM; Kozikowski, AP			Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						brain trauma cell culture; neuroprotection rodent brain injury models; thyrotropin-releasing hormone analogs	THYROTROPIN-RELEASING-HORMONE; SPINAL-CORD INJURY; DOSE-RESPONSE; RAT; YM-14673; NALOXONE; DEXAMETHASONE; HYPOTENSION; CATS	Thyrotropin-releasing hormone (TRH) and certain TRH analogs show substantial neuroprotective effects in experimental brain or spinal cord trauma but also have other physiological actions (autonomic, analeptic, and endocrine) that may be undesirable for the treatment of neurotrauma in humans. We developed a novel TRH analog (2-ARA-53a), with substitutions at the NH2-terminus and imidazole ring, that preserves the neuroprotective action of TRH-like compounds while decreasing or eliminating their autonomic, analeptic, and endocrine effects. Rats administered 2-ARA-53a (1.0 mg/kg, n = 17) intravenously 30 min after lateral fluid percussion brain injury showed marked improvement in motor recovery compared with vehicle-treated controls (n = 14). Treatment of mice subjected to moderate controlled cortical impact brain injury, at the same dose and time after trauma (n = 8), improved both motor recovery and cognitive performance in a water maze place learning task compared with vehicle-treated controls (n = 8). In injured rats, no autonomic or analeptic effects were observed with this compound, and endocrine effects were significantly reduced with 2-ARA-53a, in contrast to those found with a typical NH2-terminal-substituted TRH analog (YM-14673). These findings demonstrate that the neuroprotective effects of TRH-related compounds can be dissociated from their other major physiological actions and suggest a potential role for dual-substituted TRH analogs in the treatment of clinical neurotrauma.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu		Wang, Shaomeng/0000-0002-8782-6950			AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; BASSIRI RM, 1981, J CLIN INVEST, V52, P16316; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; CEYLAN S, 1992, RES EXP MED, V192, P23, DOI 10.1007/BF02576254; CEYLAN S, 1990, RES EXP MED, V190, P111, DOI 10.1007/PL00020013; DeWitt DS, 1997, J NEUROTRAUM, V14, P931, DOI 10.1089/neu.1997.14.931; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KIEFFER JD, 1974, ACTA ENDOCRINOL-COP, V76, P495; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; OLSON GL, 1995, J MED CHEM, V38, P2866, DOI 10.1021/jm00015a009; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Povlishock JT., 1996, NEUROTRAUMA, P1325; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; RENAUD LP, 1979, SCIENCE, V205, P1275, DOI 10.1126/science.224461; TAKAMI K, 1991, JPN J PHARMACOL, V57, P405, DOI 10.1254/jjp.57.405; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; WANG GL, 1991, CHINESE MED J-PEKING, V104, P939	38	40	41	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	OCT	1999	277	4					R1196	R1204		10.1152/ajpregu.1999.277.4.R1196			9	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	259XR	WOS:000083919700034					2022-02-06	
J	Morgan, AS; Mackay, LE				Morgan, AS; Mackay, LE			Causes and complications associated with swallowing disorders in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aspiration; dysphagia; pneumonia; severe brain injury; swallowing impairment	PROLONGED INTUBATION; ASPIRATION PNEUMONIA; EARLY TRACHEOSTOMY; AIRWAY MANAGEMENT; HEAD-INJURY; DYSFUNCTION; VENTILATION; SAFE	A major complication commonly seen in persons with severe brain injury is swallowing dysfunction. The neuropathology leading to impaired swallowing is discussed. In addition, Other risk factors associated with dysfunctional swallowing, such as tracheostomy and the need for prolonged ventilatory support, are discussed. Within the intensive care environment, the consequences of impaired swallowing leading to aspiration-a major cause of pneumonia-are discussed.	St Francis Hosp & Med Ctr, Dept Surg, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Trauma Serv, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Otolaryngol Sect, Farmington, CT USA		Morgan, AS (corresponding author), St Francis Hosp & Med Ctr, Dept Surg, 114 Woodland St, Hartford, CT 06105 USA.						AASS AS, 1975, ACTA ANAESTH SCAND, V19, P127, DOI 10.1111/j.1399-6576.1975.tb05232.x; BARBA CA, 1995, SURGERY, V118, P879, DOI 10.1016/S0039-6060(05)80279-X; BLOOMFIELD EL, 1989, CRIT CARE CLIN, V5, P881; BONANNO PC, 1971, ANN SURG, V174, P29, DOI 10.1097/00000658-197107010-00005; BOYD SW, 1992, LARYNGOSCOPE, V102, P559, DOI 10.1288/00005537-199205000-00015; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; CRAVEN DE, 1982, NEW ENGL J MED, V306, P1505, DOI 10.1056/NEJM198206243062501; CRAVEN DE, 1984, AM REV RESPIR DIS, V129, P625; CUNNINGHAM ET, 1991, NORMAL ABNORMAL SWAL; DANE TEB, 1975, CHEST, V67, P398, DOI 10.1378/chest.67.4.398; DEPASO WJ, 1991, CLIN CHEST MED, V12, P269; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; FRIMAN L, 1976, ANAESTHESIA, V31, P479, DOI 10.1111/j.1365-2044.1976.tb12353.x; GARDNER AMN, 1958, Q J MED, V27, P227; Groher ME, 1992, DYSPHAGIA DIAGNOSIS; Hagen C, 1981, TOP LANG DIS, V1, P73; HOCKMAN CH, 1979, PROG NEUROBIOL, V12, P15, DOI 10.1016/0301-0082(79)90009-1; HSIEH AH, 1992, AM REV RESP, V146, P20; KHAWAJA IT, 1992, POSTGRAD MED, V92, P165; KLINGBEIL GEG, 1988, ARCH PHYS MED REHAB, V69, P493; LANZA DC, 1990, LARYNGOSCOPE, V100, P958; LAW JH, 1993, CHEST, V104, P136, DOI 10.1378/chest.104.1.136; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; LESNIK I, 1992, AM SURGEON, V58, P346; MACKAY L, 1993, DYSPHAGIA, V8, P161; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; MACKAY LE, 1997, MAXIMIZING BRAIN INJ; Martner J, 1975, Acta Physiol Scand Suppl, V425, P1; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MILLER JD, 1984, SURG NEUROL, V22, P186, DOI 10.1016/0090-3019(84)90050-8; NOWAK P, 1987, AM J OTOLARYNG, V8, P91, DOI 10.1016/S0196-0709(87)80030-3; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; REIS DJ, 1973, SCIENCE, V182, P845, DOI 10.1126/science.182.4114.845; RODRIGUEZ JL, 1990, SURGERY, V108, P655; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; STAUFFER J, 1981, AM J MED, V70, P70; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; vanHeurn LWE, 1996, CHEST, V109, P1466, DOI 10.1378/chest.109.6.1466; VEIS SL, 1985, ARCH PHYS MED REHAB, V66, P372; WHILED RE, 1984, LARYNGOSCOPE, V94, P367; WHITED RE, 1979, ANN OTO RHINOL LARYN, V88, P474, DOI 10.1177/000348947908800405; Woratyla S P, 1995, Conn Med, V59, P643	43	40	40	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					454	461		10.1097/00001199-199910000-00006			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600006	10653941				2022-02-06	
J	Kaipio, ML; Alho, K; Winkler, I; Escera, C; Surma-aho, O; Naatanen, R				Kaipio, ML; Alho, K; Winkler, I; Escera, C; Surma-aho, O; Naatanen, R			Event-related brain potentials reveal covert distractibility in closed head injuries	NEUROREPORT			English	Article						attention; audition; closed head injury; distractibility; event-related brain potential (ERP); mismatch negativity; novel sounds; P3a	INTRACEREBRAL POTENTIALS; MISMATCH NEGATIVITY; AUDITORY-CORTEX; FRONTAL-CORTEX; VISUAL-STIMULI; RARE TARGET; PERFORMANCE; ATTENTION; LESIONS	EVENT-RELATED brain potentials (ERPs) to auditory stimuli were recorded from 11 closed head injured (CHI) and 10 age-matched healthy adults. Auditory stimuli consisted of sequences of repetitive standard tones (600 Hz), occasionally replaced by deviant tones (660 Hz) or by natural novel sounds. Subjects were instructed to ignore auditory stimuli while concentrating on a demanding visuo-motor tracking task. CHI patients showed, in comparison to control subjects, significantly enhanced late P3a component in the ERPs to novel sounds. This suggests that novel stimuli cause greater distraction in CHI patients than in controls, demonstrating that ERPs provide a powerful tool to determine the physiological basis of attentional deficits in CHI patients. NeuroReport 10:2125-2129 (C) 1999 Lippincott Williams &Wilkins.	Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; Univ Barcelona, Dept Psychiat & Clin Psychobiol, Neurodynam Lab, E-08035 Barcelona, Catalonia, Spain; Hungarian Acad Sci, Inst Psychol, H-1394 Budapest, Hungary		Kaipio, ML (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 13, FIN-00014 Helsinki, Finland.		Alho, Kimmo/G-2997-2013; Winkler, Istvan/A-7659-2008; Escera, Carles/A-8658-2010	Alho, Kimmo/0000-0001-8563-2792; Winkler, Istvan/0000-0002-3344-6151; Escera, Carles/0000-0001-8203-2951			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; Alho K, 1998, PSYCHOPHYSIOLOGY, V35, P211, DOI 10.1111/1469-8986.3520211; Alho K, 1997, NEUROREPORT, V8, P3233, DOI 10.1097/00001756-199710200-00010; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; Damasio A., 1994, DESCARTES ERROR EMOT; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; ICHISE M, 1994, J NUCL MED, V35, P217; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; NAATANEN R, 1995, EAR HEARING, V16, P6; Naatanen R, 1992, ATTENTION BRAIN FUNC; Scherg M, 1989, J Cogn Neurosci, V1, P336, DOI 10.1162/jocn.1989.1.4.336; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; Schroger E, 1996, J COGNITIVE NEUROSCI, V8, P527, DOI 10.1162/jocn.1996.8.6.527; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY, P63; [No title captured]	24	40	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	JUL 13	1999	10	10					2125	2129		10.1097/00001756-199907130-00024			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	214YB	WOS:000081354200024	10424686				2022-02-06	
J	Dogan, A; Rao, AM; Baskaya, MK; Hatcher, J; Temiz, C; Rao, VLR; Dempsey, RJ				Dogan, A; Rao, AM; Baskaya, MK; Hatcher, J; Temiz, C; Rao, VLR; Dempsey, RJ			Contribution of polyamine oxidase to brain injury after trauma	JOURNAL OF NEUROSURGERY			English	Article						cerebral edema; cerebral ischemia; interconversion pathway; N-1,N-4-bis(2,3-butadienyl)-1,4-butanediamine 2HCl; polyamine oxidase; rat	CELL-DEATH; ORNITHINE DECARBOXYLASE; ISCHEMIA; BARRIER; EDEMA; RAT; FLUID	Object. The possible role of the polyamine interconversion pathway on edema. formation, traumatic injury volume, and tissue polyamine levels after traumatic brain injury (TBI) was studied using an inhibitor of the interconversion pathway enzyme, polyamine oxidase. Methods. Experimental TBI was induced in Sprague-Dawley mts by using a controlled cortical impact device at a velocity of 3 m/second, resulting in a 2-mm deformation. Immediately after TBI was induced, 100 mg/kg of N',N'-bis(2,3-butadienyl)-1,-4-butanediamine 2HCl (MDL 72527) or saline was injected intraperitoneally. Brain water content and tissue polyamine levels were measured at 24 hours after TBI. Traumatic injury volume was evaluated using 2% cresyl violet solution 7 days after TBI occurred. The MDL 72527 treatment significantly reduced brain edema (80.4 +/- 0.8% compared with 81.2 +/- 1.2%, p < 0.05) and injury volume(30.1 +/- 6.6 mm(3) compared with 42.7 +/- 13.3 mm(3), p < 0.05 compared with the saline treatment. The TBI caused a significant increase in tissue putrescine levels at the traumatized site (65.5 +/- 26.5 pmol/g in the cortex and 70.9 +/- 22.4 pmol/g in the hippocampus) compared with the nontraumatized site (7 +/- 2.4 pmol/g in the cortex and 11.4 +/- 6.4 pmol/g in the hippocampus). The increase in putrescine levels in both the traumatized and nontraumatized cortex and hippocampus was reduced by a mean of 60% with MDL 72527 treatment. Conclusions. These results demonstrate, for the first time, that the polyamine interconversion pathway has an important role in the increase of putrescine levels after TBI and that the polyamine oxidase inhibitors, blockers of the interconversion pathway, can be neuroprotective against edema formation and necrotic cavitation after TBI.	Univ Wisconsin, Ctr Clin Sci H4 338, Dept Neurol Surg, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA; Louisiana State Univ, Med Ctr, Dept Neurol Surg, Shreveport, LA USA		Dempsey, RJ (corresponding author), Univ Wisconsin, Ctr Clin Sci H4 338, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.		Dogan, Aclan/AAF-8305-2019				Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BOLKENIUS FN, 1985, BIOCHIM BIOPHYS ACTA, V838, P69, DOI 10.1016/0304-4165(85)90251-X; Cockroft Kevin M., 1995, Surgical Forum, V46, P578; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIENEL GA, 1985, J NEUROCHEM, V44, P600, DOI 10.1111/j.1471-4159.1985.tb05454.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GILAD GM, 1992, LIFE SCI, V50, pPL149, DOI 10.1016/0024-3205(92)90289-2; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; IENTILE R, 1988, J NEUROCHEM, V51, P677, DOI 10.1111/j.1471-4159.1988.tb01797.x; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KOENIG H, 1983, BIOCHEM BIOPH RES CO, V116, P1039, DOI 10.1016/S0006-291X(83)80247-2; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; RINK A, 1995, AM J PATHOL, V147, P1575; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 1995, PROG BRAIN RES, V106, P333; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; TASDEMIROGLU E, 1994, ACTA NEUROCHIR, V131, P302, DOI 10.1007/BF01808631	23	40	41	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	1999	90	6					1078	1082		10.3171/jns.1999.90.6.1078			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	198PK	WOS:000080433000014	10350255				2022-02-06	
J	Whyte, J; DiPasquale, MC; Vaccaro, M				Whyte, J; DiPasquale, MC; Vaccaro, M			Assessment of command-following in minimally conscious brain injured patients	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							VEGETATIVE STATE; COMA; SCALE	Objective: To develop a method for establishing the presence of command-following in individuals with traumatic brain injury, based on the principles of single-subject experimental design. Design: A series of single-subject experiments, individualized to the particular command-following question about a particular patient. Setting: An inpatient rehabilitation hospital with a specialized program for vegetative and minimally conscious brain injured patients. Patients: Eight individuals with serious brain injury of traumatic or nontraumatic origin, presenting in vegetative or minimally conscious states. Interventions: The frequency of performance of the behavior in question was assessed in response to commands and in relation to appropriate control conditions. Data were analyzed with chi(2) Or Fisher's exact test, as well as measures derived from signal detection theory. Main Outcome Measures: The frequency of performance of a specific behavior in the presence of a command and in relevant contrasting conditions. Results: This method identified whether a specific behavior was being performed in response to command and whether the reliability of this behavior was changing over time either spontaneously or in response to treatment. Conclusions: Quantitative assessment of command-following based on principles of single-subject experimental design can determine whether patients are capable of following commands and whether this ability changes over time or in response to treatment. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Edgington E.S., 1987, RANDOMIZATION TESTS; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; *GIV BIOM I, 1996, ASP CONS C WORKGR VE; HAGAN C, 1979, REHABILIATATION HEAD; Macmillan NA., 1991, DETECTION THEORY USE; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WHYTE J, IN PRESS REHABILITAT	15	40	40	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1999	80	6					653	660		10.1016/S0003-9993(99)90168-5			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	204LG	WOS:000080765300008	10378491				2022-02-06	
J	Muir, JK; Raghupathi, R; Saatman, KE; Wilson, CA; Lee, VMY; Trojanowski, JQ; Philips, MF; McIntosh, TK				Muir, JK; Raghupathi, R; Saatman, KE; Wilson, CA; Lee, VMY; Trojanowski, JQ; Philips, MF; McIntosh, TK			Terminally differentiated human neurons survive and integrate following transplantation into the traumatically injured rat brain	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; motor dysfunction; neuronal grafts; NT2N cells; traumatic brain injury	NERVE GROWTH-FACTOR; NEURAL PROGENITOR CELLS; FLUID-PERCUSSION MODEL; ADULT-RAT; SPINAL-CORD; STEM-CELLS; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; FACTOR INFUSION; NTERA-2 CELLS	The present study evaluated the survival and integration of human postmitotic neurons (hNT) following transplantation into the traumatically injured rodent brain. Anesthetized male Sprague-Dawley rats (n = 47) were subjected to lateral fluid percussion brain injury of moderate severity (2.4-2.6 atm). Sham animals (n = 28) were surgically prepared, but did not receive brain injury. At 24 h following injury or sham surgery, the rats were re-anesthetized and similar to 100,000 hNT cells (freshly cultured or previously frozen) or vehicle were stereotactically injected into the ipsilateral cortex. Animals were examined for neuromotor function at 48 h, 7 days, and 14 days posttransplantation using a standard battery of motor tests. Animals were sacrificed at 2 weeks postinjury and viability of hNT grafts was assessed by Nissl staining and MOC-1 immunohistochemistry, which recognizes human neural cell adhesion molecules (NCAM) expressed on hNT cells. Transplanted hNT grafts remained viable in 83% of brain-injured animals at 2 weeks following transplantation of either fresh or frozen hNT cells. Glial fibrillary acidic protein (GFAP) immunohistochemistry revealed a marked increase in the number of reactive astrocytes following brain injury in both vehicle and hNT implanted animals. These reactive astrocytes appeared not to impede grafted cells from sending projections into host tissue. Despite the survival of transplanted cells in the traumatically injured brain, hNT cells had no significant effect on posttraumatic neurologic motor function during the acute posttraumatic period. Since hNT cells are transfectable, prolonged survival of these transplanted cells in the posttraumatic milieu suggests that grafted hNT cells may be a suitable means for delivery of therapeutic, exogenous proteins into the CNS for treatment of traumatic brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 105 C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline		ANDERSON DK, 1995, BRAIN PATHOL, V5, P451, DOI 10.1111/j.1750-3639.1995.tb00624.x; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bjorklund A, 1992, Curr Opin Neurobiol, V2, P683, DOI 10.1016/0959-4388(92)90039-N; BJORKLUND A, 1993, NATURE, V362, P414, DOI 10.1038/362414a0; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH DW, 1994, J NEUROTRAUM, V13, P289; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Elsayed MH, 1996, EXP NEUROL, V137, P127, DOI 10.1006/exnr.1996.0013; Emerich DF, 1996, J NEUROSCI, V16, P5168; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; HAGG T, 1990, J NEUROSCI, V10, P3087; HANSEN JT, 1991, CRIT REV NEUROBIOL, V6, P79; HARDY M, 1994, J NEUROCHEM, V63, P482; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hodges H, 1996, NEUROSCIENCE, V72, P959, DOI 10.1016/0306-4522(96)00004-8; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; JAKEMAN LB, 1991, J COMP NEUROL, V307, P311, DOI 10.1002/cne.903070211; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; MAMPALAM TJ, 1988, J NEUROSURG, V69, P904, DOI 10.3171/jns.1988.69.6.0904; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MartinezSerrano A, 1996, CLIN NEUROSCI, V3, P301; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAJIMA Y, 1995, INT J PEDIAT HEM ONC, V2, P73; MIYAZONO M, 1996, J COMP NEUROL, V376, P1; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; NIIJIMA K, 1995, J NEUROSCI, V15, P1180; NIKKHAH G, 1994, J NEUROSCI, V14, P3449; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Powell EM, 1997, CELL TISSUE RES, V290, P385, DOI 10.1007/s004410050945; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snyder EY, 1996, CLIN NEUROSCI, V3, P310; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; Tannock GW, 1992, LACTIC ACID BACTERIA, V1, P21; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; WALICKE LR, 1986, P NATL ACAD SCI USA, V83, P9231; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	72	40	43	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					403	414		10.1089/neu.1999.16.403			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200006	10369560				2022-02-06	
J	Stover, JF; Morganti-Kossmann, MC; Lenzlinger, PM; Stocker, R; Kempski, OS; Kossmann, T				Stover, JF; Morganti-Kossmann, MC; Lenzlinger, PM; Stocker, R; Kempski, OS; Kossmann, T			Glutamate and taurine are increased in ventricular cerebrospinal fluid of severely brain-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; cell swelling; cerebrospinal fluid; contusion; glutamate; taurine; traumatic brain injury	EXCITATORY AMINO-ACIDS; CEREBRAL BLOOD-FLOW; CORTICAL EXTRACELLULAR LEVELS; RAT HIPPOCAMPAL SLICES; CONTUSION TRAUMA; HEAD-INJURY; RELEASE; LOCALIZATION; ASTROCYTES; MECHANISMS	Glutamate contributes to secondary brain damage, resulting in cell swelling and brain edema. Under in vitro conditions, increased extracellular levels of the amino acid taurine reflect glutamate-induced osmotic cell swelling. In vivo, increases in cerebrospinal fluid (CSF) taurine could, therefore, unmask glutamate-mediated cytotoxic edema formation and possibly differentiate it from vasogenic edema. To test this hypothesis, ventricular CSF glutamate and taurine levels were measured in 28 severely brain-injured patients on days 1, 5, and 14 after trauma. Posttraumatic changes in CSF amino acids were investigated in regard to extent of tissue damage and alterations in brain edema as estimated by computerized tomography. On day 1, CSF glutamate and taurine levels were significantly increased in patients with subdural or epidural hematomas (8 +/- 0.8/71 +/- 12 mu M), contusions (21 +/- 4.1/122 +/- 18 mu M), and generalized brain edema (13 +/- 3.2/80 +/- 15 mu M) compared to lumbar control CSF (1.3 +/- 0.1/12 +/- 1 mu M; P < 0.001). CSF amino acids, however, did not reflect edema formation and resolution as estimated by computerized tomography. CSF taurine correlated positively with glutamate, eventually depicting glutamate-induced cell swelling. However, parallel neuronal release of taurine with its inhibitory function cannot be excluded. Thus, the sensitivity of taurine in unmasking cytotoxic edema formation is weakened by the inability in defining its origin and function under the conditions chosen in the present study. Overall, persisting pathologic ventricular CSF glutamate and taurine levels are highly suggestive of ongoing glial and neuronal impairment in humans following severe traumatic brain injury.	Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland; Inst Neurosurg Pathophysiol, Mainz, Germany		Kossmann, T (corresponding author), Univ Zurich Hosp, Dept Trauma Surg, Ramistr 100, CH-8091 Zurich, Switzerland.	kossmann@chi.usz.ch	Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHOI DW, 1987, J NEUROSCI, V7, P357; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FURST P, 1990, J CHROMATOGR, V499, P557, DOI 10.1016/S0021-9673(00)97000-6; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HOLOPAINEN I, 1989, NEUROSCIENCE, V29, P425, DOI 10.1016/0306-4522(89)90069-9; KAMISAKI Y, 1993, BRAIN RES, V627, P181; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1992, BRAIN RES, V577, P121, DOI 10.1016/0006-8993(92)90544-J; Kempski O, 1990, Adv Neurol, V52, P219; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; MADL JE, 1993, J NEUROSCI, V13, P4429; MAGNUSSON KR, 1991, BRAIN RES, V549, P1, DOI 10.1016/0006-8993(91)90592-J; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; McIntosh TK, 1996, LAB INVEST, V74, P315; MENENDEZ N, 1989, NEUROSCI LETT, V102, P64, DOI 10.1016/0304-3940(89)90308-X; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKAMOTO K, 1983, BRAIN RES, V265, P163, DOI 10.1016/0006-8993(83)91350-1; OTTERSEN OP, 1988, ANAT EMBRYOL, V178, P407, DOI 10.1007/BF00306047; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PASANTESMORALES H, 1990, GLIA, V3, P427, DOI 10.1002/glia.440030514; SARANSAARI P, 1991, NEUROSCIENCE, V45, P451, DOI 10.1016/0306-4522(91)90240-O; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; STOCKER R, 1995, INTEGRATED APPROACH, P196; STORMMATHISEN J, 1992, MOL NEUROPHARMACOL, V2, P7; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; TABER KH, 1986, BRAIN RES, V386, P113, DOI 10.1016/0006-8993(86)90147-2; VANHARREVELD A, 1971, EXP MOL PATHOL, V15, P61, DOI 10.1016/0014-4800(71)90019-0; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WESTERGREN I, 1994, J NEUROCHEM, V62, P159; Zauner A, 1996, ACT NEUR S, V67, P40; ZUCCARELLO M, 1993, J NEUROTRAUM, V10, P397, DOI 10.1089/neu.1993.10.397	46	40	40	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1999	16	2					135	142		10.1089/neu.1999.16.135			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	173BA	WOS:000078960000003	10098958	Green Accepted			2022-02-06	
J	Cifu, DX; Kreutzer, JS; Marwitz, JH; Miller, M; Hsu, GM; Seel, RT; Englander, J; High, WM; Zafonte, R				Cifu, DX; Kreutzer, JS; Marwitz, JH; Miller, M; Hsu, GM; Seel, RT; Englander, J; High, WM; Zafonte, R			Etiology and incidence of rehospitalization after traumatic brain injury: A multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL-CORD INJURY; COMMUNITY; IMPACT; REHABILITATION; TRENDS; LENGTH; STAY	Objective: To investigate incidence and etiology of rehospitalizations at 1, 2, and 3 years after traumatic brain injury. Design: Descriptive statistics were computed in a prospective study of etiology and incidence of rehospitalization at years 1, 2, and 3 postinjury. Analysis of variance (ANOVA) and chi(2) were used to identify factors relating to rehospitalization; factors included length of stay, admission and discharge functional status, payer source, medical complications, injury severity, and demographics. Setting: Four medical centers in the federally sponsored Traumatic Brain Injury Model Systems. In each setting, the continuum of care includes emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Six hundred sixty-five rehabilitation patients admitted to acute care within 24 hours of traumatic brain injury between 1989 and 1996. Main Outcome Measures: Annual incidence and etiology of rehospitalization. Results: The annual incidence of rehospitalization ranged from 20% to 22.5%. Approximately half the rehospitalizations were for elective reasons. The most common reason for rehospitalization was for orthopedic or reconstructive surgery, followed by infectious disorders and general health maintenance. After the first year, the incidence of readmissions for seizures and psychiatric difficulties increased substantially. ANOVA and chi(2) analyses were performed on data from the first year postinjury. No statistically significant associations were noted between incidence and etiology of rehospitalization and: demographics; injury severity; payer source for rehabilitation; concurrent injuries; acute care and rehabilitation length of stays; discharge Functional Assessment Measure; and discharge residence (p > .05). Conclusions: There is a relatively stable but high rate of rehospitalization for at least 3 years after injury. The costs of rehospitalization should be considered when evaluating the long-term consequences of injury. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Thomas Jefferson Univ, AI DuPont Childrens Med Ctr, Philadelphia, PA 19107 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA		Cifu, DX (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, MCV Box 980677, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387			Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BURNS TJ, 1990, ARCH PHYS MED REHAB, V71, P138; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAVIDOFF G, 1990, ARCH PHYS MED REHAB, V71, P121; DeVivo M, 1995, SPINAL CORD INJURY C, P234; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; DINCIN J, 1993, HOSP COMMUNITY PSYCH, V44, P833; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THORNGREN M, 1990, STROKE, V21, P236, DOI 10.1161/01.STR.21.2.236; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	24	40	41	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1999	80	1					85	90		10.1016/S0003-9993(99)90312-X			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	155XZ	WOS:000077973000013	9915377				2022-02-06	
J	Fox, GB; Faden, AI				Fox, GB; Faden, AI			Traumatic brain injury causes delayed motor and cognitive impairment in a mutant mouse strain known to exhibit delayed Wallerian degeneration	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain trauma; motor and cognitive tests; Wld(s) (Ola) mutant mouse	ADULT-RAT HIPPOCAMPUS; MEDIAL TEMPORAL-LOBE; GENETIC INFLUENCES; CELLULAR REACTIONS; PERIPHERAL-NERVE; MUTATION WLD(S); MODEL; MICE; REGENERATION; EXPRESSION	Delayed Wallerian degeneration after neuronal injury is a feature of the C57BL/Wld(S) mouse mutant. In the present study, we examined the effect of unilateral controlled cortical impact (CCI) on motor and cognitive performance in C57BL/6 and C57BL/Wld(S) mice. Performance on a beam-walking task was impaired in both injured groups over the first 3 weeks; however, between 28 and 35 days post injury, C57BL/6 mice continued to improve whereas C57BL/Wld(S) mice showed increased footfaults, In a spatial learning task, C57BL/WldS animals performed consistently better than C57BL/6 mice when tested 7-10 days and 14-17 days following CCI, C57BL/WldS mice also demonstrated improved working memory performance as compared with C57BL/6 mice when trained on days 21-22 after injury; this effect was lost on days 23 and 24, and was not evident in other animals tested in the same task at 28-31 days following injury, These results indicate a marked delay in motor and cognitive impairment following CCI in C57BL/Wld(S) mice compared with injured C57BL/6 controls. This is consistent with previous work showing delayed temporal evolution of neuronal degeneration in C57BL/Wld(S) mice and suggests CCI may be a suitable model for examining the functional consequences of traumatic brain injury (TBI) in genetically altered mice, (C) 1998 Wiley-Liss, Inc.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Room EP-04, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; FOX GB, 1995, J NEUROCHEM, V65, P2796; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujiki M, 1996, J COMP NEUROL, V371, P469; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; HOFF SF, 1981, BRAIN RES, V222, P1, DOI 10.1016/0006-8993(81)90936-7; LEONARD BW, 1995, J NEUROSCI, V15, P5637; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; LYON MF, 1993, P NATL ACAD SCI USA, V90, P9717, DOI 10.1073/pnas.90.20.9717; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OConnell AW, 1997, J NEUROCHEM, V68, P2538; PERRY VH, 1990, EUR J NEUROSCI, V2, P408, DOI 10.1111/j.1460-9568.1990.tb00433.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; Povlishock JT., 1996, NEUROTRAUMA, P1325; Schauwecker PE, 1997, J COMP NEUROL, V380, P82, DOI 10.1002/(SICI)1096-9861(19970331)380:1<82::AID-CNE6>3.0.CO;2-P; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEWARD O, 1992, EXP NEUROL, V118, P340, DOI 10.1016/0014-4886(92)90192-S; Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484; Zhang ZY, 1996, J COMP NEUROL, V371, P485; Zhang ZY, 1998, EXP NEUROL, V149, P221, DOI 10.1006/exnr.1997.6717	28	40	40	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 15	1998	53	6					718	727		10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	117AF	WOS:000075757000009	9753199				2022-02-06	
J	Bombardier, CH; Rimmele, CT				Bombardier, CH; Rimmele, CT			Alcohol use and readiness to change after spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; CHANGE QUESTIONNAIRE; FUTURE-DIRECTIONS; DRINKERS; INTERVENTIONS; ISSUES; ABUSE	Objective: To describe alcohol use and motivation to change drinking among persons with recent spinal cord injury (SCI). Design: Survey Setting: Acute inpatient rehabilitation program Patients: Subjects were 58 patients with recent SCI assessed during inpatient rehabilitation. Main Outcome Measures: Short Michigan Alcoholism Screening Test (SMAST), Readiness to Change questionnaire (RTC), and alcohol use questions, Results: Subjects were on average 39 years old, 88% were male, and 86% were Caucasian. Thirty-five percent of the total sample scored in the "alcoholic" range on the SMAST, Twenty-nine (50%) of the sample were considered "at-risk" drinkers. Of these, 6 (21%) were in the precontemplation phase, 13 (45%) were in the contemplation phase, and 10 (34%) were in the action phase with respect to modifying their drinking habits. Multivariate analyses indicated that a positive history of alcoholism and higher daily consumption were associated with greater readiness to change. Conclusions: Soon after SCI, most at-risk drinkers are at least considering changes in their alcohol use. This situation may represent an underutilized window of opportunity to implement interventions designed to reduce postinjury alcohol abuse and related impairments. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Bombardier, CH (corresponding author), Harborview Med Ctr, Box 359740,325 9th Ave, Seattle, WA 98104 USA.		Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283			ANTTIPOIKA I, 1988, ALCOHOL ALCOHOLISM, V23, P115; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; CHICK J, 1985, BRIT MED J, V290, P965, DOI 10.1136/bmj.290.6473.965; DONOVAN D, 1995, RES SOC ALC JUN STEA; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLETON D, 1981, ARCH GEN PSYCHIAT, V28, P1369; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; HARBURG E, 1988, J STUD ALCOHOL, V49, P522, DOI 10.15288/jsa.1988.49.522; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; JACOBSON GR, 1989, HDB ALCOHOLISM TREAT, P54; Krause J, 1992, NEUROREHABILITATION, V2, P45; Miller WR, 1987, BRIEF DRINKER PROFIL; Miller WR, 1991, MOTIVATIONAL INTERVI; O'Donnell JJ, 1981, ALCOHOL HEALTH RES W, V6, P27; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Prochaska JO., 1992, PROGR BEHAV MODIFICA, P184; Radnitz CL, 1993, SCI PSYCHOSOC PROCES, V6, P85; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Rychtarik, 1992, PROJECT MATCH MONOGR; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769; STOVER SL, 1986, SPINAL CORD INJURY F; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	33	40	41	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1998	79	9					1110	1115		10.1016/S0003-9993(98)90180-0			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	118FX	WOS:000075828700016	9749693				2022-02-06	
J	Inoue, T; Kawaguchi, S; Kurisu, K				Inoue, T; Kawaguchi, S; Kurisu, K			Spontaneous regeneration of the pyramidal tract after transection in young rats	NEUROSCIENCE LETTERS			English	Article						brain injury; pyramidotomy; neural repair; axonal regeneration; axonal environment; gliosis; scar; aberrant projections	SPINAL-CORD; AXONS; RESTORATION; GROWTH; LIGHT	Spontaneous regeneration of the pyramidal tract after transection of the medullary pyramid was examined in young rats by the anterograde tracing method with wheat germ agglutinin-conjugated horseradish peroxidase. Care was taken to cut the tract as sharply as possible to minimize traumatic injuries. A very sharp cut produced edema-free lesions without subsequent formation of either cysts or scars, whereas a relatively blunt cut produced edema and later scars and/or cysts in the lesion. Regenerated projections in the latter cases were sparse, short, dispersed and largely aberrant as described in previous reports. By contrast, regenerated projections in the former cases were very much similar to normal in various respects: the amount, extension, path, formation of a compact bundle and termination. There was, however, a decisive difference from normal, that is, the additional aberrant projections. (C) 1998 Elsevier Science Ireland Ltd.	Kyoto Univ, Grad Sch Med, Dept Integrat Brain Sci, Kyoto 6068501, Japan; Hiroshima Univ, Sch Med, Dept Neurosurg, Hiroshima 7348551, Japan		Kawaguchi, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Integrat Brain Sci, Kyoto 6068501, Japan.						BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DEOLMOS J, 1977, NEUROSCI LETT, V6, P107, DOI 10.1016/0304-3940(77)90004-0; HOLZER W, 1921, ALLGEM Z PSYCHIAT, V77, P358; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; KALIL K, 1982, J COMP NEUROL, V211, P265, DOI 10.1002/cne.902110305; KALIL K, 1979, SCIENCE, V205, P1158, DOI 10.1126/science.472734; KAWAGUCHI S, 1986, J COMP NEUROL, V245, P258, DOI 10.1002/cne.902450208; MATTHEWS MA, 1971, J COMP NEUROL, V142, P1, DOI 10.1002/cne.901420102; MCGEER PL, 1987, MOL NEUROBIOLOGY MAM, P448; NAGASHIMA M, 1994, NEUROSCI RES, V19, P81, DOI 10.1016/0168-0102(94)90011-6; REH T, 1981, J COMP NEUROL, V200, P55, DOI 10.1002/cne.902000105; Reier P., 1983, SPINAL CORD RECONSTR, P163; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; TOLBERT DL, 1987, J COMP NEUROL, V260, P299, DOI 10.1002/cne.902600210; YING L, 1997, SCIENCE, V277, P2000	16	40	40	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 15	1998	247	2-3					151	154		10.1016/S0304-3940(98)00297-3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZP335	WOS:000073742000020	9655615				2022-02-06	
J	Max, JE; Castillo, CS; Lindgren, SD; Arndt, S				Max, JE; Castillo, CS; Lindgren, SD; Arndt, S			The neuropsychiatric rating schedule: Reliability and validity	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						assessment; children; Neuropsychiatric Rating Schedule		Objective: To evaluate reliability and validity for the Neuropsychiatric Rating Schedule (NPRS) interview designed to permit diagnosis of organic personality syndrome (OPS) or personality change due to a general medical condition (PC). Method: Subjects from prospective (n = 50) and retrospective (n = 72) studies of traumatic brain injury were aged 6 through 18 years. Parents and children were informants for the NPRS. Convergent and discriminant validity of subtypes of OPS/PC were assessed against standard scales completed by parents and teachers. Interrater reliability data (n = 20), test-retest reliability data (n = 42), as well as sensitivity-to-change data (n = 37) were collected. Results: All subtypes of OPS/PC were diagnosed, but apathy and paranoia subtypes were rare. Rating scale data supported convergent validity of OPS/PC subtypes generated With the NPRS. Affective instability, rage/aggression, and inappropriate social judgment were moderately to highly correlated, but apathy and paranoia could be discriminated from each of these subtypes. Interrater agreement for NPRS items was fair to excellent for all but one item (paranoia). Test-retest reliability was fair to good, and sensitivity to change was demonstrated. Conclusion: The NPRS generated reliable and valid diagnoses of the common subtypes of OPS/PC.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Cedar Ctr Psychiat Grp, Cedar Rapids, IA USA		Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH40856, MH31593, MHCRC43271] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH043271, R01MH040856, P30MH043271, R01MH031593, R37MH031593] Funding Source: NIH RePORTER		Achenbach, 1991, MANUAL TEACHERS REPO; Achenbach TM, 1991, MANUAL CHILD BEHAV C; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Gerson AC, 1996, PSYCHIAT RES, V65, P189, DOI 10.1016/S0165-1781(96)02851-X; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LISHMAN WA, 1987, ORGANIC PSYCHIATRY, P137; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Silver Jonathan M., 1994, P313; TEASDALE G, 1974, LANCET, V2, P81; [No title captured]	14	40	40	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAR	1998	37	3					297	304		10.1097/00004583-199803000-00015			8	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	YY719	WOS:000072177000015	9519635				2022-02-06	
J	Wildburger, R; Zarkovic, N; Tonkovic, G; Skoric, T; Frech, S; Hartleb, M; Loncaric, I; Zarkovic, K				Wildburger, R; Zarkovic, N; Tonkovic, G; Skoric, T; Frech, S; Hartleb, M; Loncaric, I; Zarkovic, K			Post-traumatic hormonal disturbances: Prolactin as a link between head injury and enhanced osteogenesis	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						severe head injury; bone fracture healing; growth regulation; hypertrophic callus formation; heterotopic ossifications; PRL; GH; PTH; ACTH; cortisol	FIBROBLAST GROWTH-FACTOR; METABOLIC RESPONSE; SPINAL-CORD; HYPERPROLACTINEMIC AMENORRHEA; MESSENGER-RNA; BRAIN INJURY; IN-VITRO; PITUITARY; TISSUE; STRESS	Traumatic brain injury (TBI) combined with fractures of long bones or large joints is often associated with enhanced osteogenesis (early fracture healing accompanied by hypertrophic callus formation and/or heterotopic ossifications). Humoral factors that cause enhanced osteogenesis in patients with TBI are not yet identified. The aim of this study was to reveal if post-traumatic change(s) of hormone levels in patients with TBI and bone fractures could be associated with the phenomenon of enhanced osteogenesis. The blood values of adrenocorticotropic hormone (ACTH), cortisol, growth hormone (GH), parathyroid hormone (PTH) and prolactin (PRL) were studied weekly over a period of three months after injury in patients with bone fractures only, those with TBI only or combined bone fractures and TBI (patients exerting enhanced osteogenesis). Stress-hormones, ACTH and cortisol, or the hormones related to the bone growth (GH and PTH) did not show any particular post-traumatic changes in the blood of patients with combined injury that could be associated with the enhanced osteogenesis. On the other hand, patients with combined bone fractures and TBI accompanied by enhanced osteogenesis had significantly elevated PRL levels in blood during the 5th week of the pest-traumatic period. Thus, the maximal PRL values were measured at the time when in this group of patients fractures were in consolidation and hypertrophic callus or heterotopic ossifications were developing (as verified by x-ray imaging). Hence, PRL does not only influence physiology of the bone metabolism but also seems to be one of the humoral factors involved in the phenomenon of enhanced osteogenesis in patients with TBI. (C) 1998, Editrice Kurtis.	Graz Univ, Clin Tramatol, A-8036 Graz, Austria; Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia; Horfervit Pharma Gmbh, Oldenburg, Germany; KBC, Fac Med, Dept Neuropathol, Zagreb, Croatia		Wildburger, R (corresponding author), Graz Univ, Clin Tramatol, Auenbruggerpl 7A, A-8036 Graz, Austria.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			ALEXANDER JW, 1993, HOST DEFENSE DYSFUNC, P995; ARNOLD J, 1993, PATHOPHYSIOLOGY SHOC, P145; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; Canalis Ernesto, 1996, P29; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; DEJERINE MME, 1918, ANN MED, V5, P497; DICARLO R, 1992, BRAIN RES, V570, P341, DOI 10.1016/0006-8993(92)90599-5; DIDUCH DR, 1993, J BONE JOINT SURG AM, V75A, P92, DOI 10.2106/00004623-199301000-00012; EMANUELE NV, 1992, MOL ENDOCRINOL, V6, P35, DOI 10.1210/me.6.1.35; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; FIORE CE, 1988, HORM METAB RES, V20, P40, DOI 10.1055/s-2007-1010744; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GREENSPAN SL, 1986, ANN INTERN MED, V104, P777, DOI 10.7326/0003-4819-104-6-777; Hermanussen M, 1995, Arctic Med Res, V54, P45; HUME DM, 1959, ANN SURG, V150, P697, DOI 10.1097/00000658-195910000-00013; JOERRING S, 1992, ARCH ORTHOP TRAUM SU, V111, P265, DOI 10.1007/BF00571521; KJAER A, 1994, EUR J ENDOCRINOL, V131, P391, DOI 10.1530/eje.0.1310391; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; KOH CY, 1993, MOL CELLUALER ENDOCR, V92, P21; KRISHNAMRA N, 1993, BONE MINER, V23, P253, DOI 10.1016/S0169-6009(08)80102-X; LARSEN PJ, 1994, PEPTIDES, V15, P783, DOI 10.1016/0196-9781(94)90030-2; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; MURAYEV OB, 1994, ANESTEZIOL REANIMAT, V5, P14; NAGY E, 1991, ENDOCRINOLOGY, V128, P2776, DOI 10.1210/endo-128-6-2776; PARROTT RF, 1994, RES VET SCI, V56, P234, DOI 10.1016/0034-5288(94)90109-0; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Renner U, 1996, EUR J ENDOCRINOL, V135, P515, DOI 10.1530/eje.0.1350515; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; SCHLECHTE J, 1992, J CLIN ENDOCR METAB, V75, P698, DOI 10.1210/jc.75.3.698; SCHLECHTE J, 1987, J CLIN ENDOCR METAB, V64, P1021, DOI 10.1210/jcem-64-5-1021; SIEGEL JH, 1991, SHOCK SEPSIS ORGAN F, P149; SOBUS KML, 1993, ARCH PHYS MED REHAB, V74, P902; THIEDE MA, 1989, MOL ENDOCRINOL, V3, P1443, DOI 10.1210/mend-3-9-1443; TORRING O, 1993, ACTA ENDOCRINOL-COP, V128, P423; TRABER DL, 1991, SHOCK SEPSIS ORGAN F, P145; WANG YH, 1992, AM J PHYS MED REHAB, V71, P328, DOI 10.1097/00002060-199212000-00004; WEISSMAN C, 1990, ANESTHESIOLOGY, V73, P308, DOI 10.1097/00000542-199008000-00020; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; WILDBURGER R, 1995, MED SCI RES, V223, P219; WILSON DM, 1992, ENDOCRINOLOGY, V131, P2488, DOI 10.1210/en.131.5.2488; WOLFE RR, 1989, DIABETES METAB REV, V5, P149, DOI 10.1002/dmr.5610050205; Zarkovic N, 1996, EUR J CLIN CHEM CLIN, V34, P23; Zellweger R, 1996, J IMMUNOL, V157, P5748	48	40	48	0	1	EDITRICE KURTIS S R L	MILAN	VIA LUIGI ZOJA 30, 20153 MILAN, ITALY	0391-4097			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	FEB	1998	21	2					78	86		10.1007/BF03350319			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	ZH579	WOS:000073125600002	9585380				2022-02-06	
J	Thakker, JC; Splaingard, M; Zhu, J; Babel, K; Bresnahan, J; Havens, PL				Thakker, JC; Splaingard, M; Zhu, J; Babel, K; Bresnahan, J; Havens, PL			Survival and functional outcome of children requiring endotracheal intubation during therapy for severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; brain injury; pediatric; outcome	SEVERE HEAD-INJURY; AGGRESSIVE TREATMENT; MANAGEMENT; MORTALITY; PROGNOSIS; SCALE; CARE; COMA	Objective: To determine the predictors of survival and functional outcome of pediatric patients with traumatic brain injury severe enough to require endotracheal intubation and mechanical ventilation. Design: Retrospective, observational cohort study. Setting: Pediatric intensive care unit (ICU) at a tertiary care children's hospital. Patients: All children (n =105) admitted over a 5-yr period with traumatic brain injury severe enough to require endotracheal intubation and mechanical ventilation, The median age was 43 months (range 1 month to 14 yrs), Of these children, 74% were male and 70% were white. Interventions: None. Measurements and Main Results: Variables studied included vital signs during the first 24 hrs of admission, Pediatric Risk of Mortality (PRISM) score, Glasgow Coma Score, duration of mechanical ventilation, and number of pediatric ICU and hospital days, Functional status was graded as normal, independent, partially dependent, or dependent in the areas of locomotion, self-care, and communication, This status was assessed at hospital discharge by chart review and at follow-up by telephone interview, The median Glasgow Coma Score was 6 (range 3 to 14) and the median PRISM score was 13 (range 1 to 51). There were 19 (18.1%) deaths, 17 in the pediatric ICU and two after hospital discharge, Of the patients who survived to hospital discharge, 39 (37.1%) patients were completely normal or independent, 42 (40%) patients were partially dependent, and seven (6.7%) patients were dependent in all three areas of function, Follow-up evaluations were available for 80 patients, with a median follow-up time of 24.5 months (range 8 to 70), Of the 78 patients who survived and were available for follow-up, the number who were functionally normal or independent increased to 69 (65.7%), At follow-up, there were eight (7.6%) patients remaining with partial dependency in at least one area of function while one (0.9%) patient continued to be dependent in all three areas of function, Mortality and dependent functional outcome were more likely in patients with younger age, lower Glasgow Coma Score, and higher PRISM score at hospital admission, Of the 27 patients with a Glasgow Coma Score of less than or equal to 5, 11 (40.7%) survived with normal or independent functional status at follow up. Of the 24 patients with PRISM scores of greater than or equal to 20, only five (20.8%) were functionally normal or independent at follow-up, The relative risk of a bad outcome for patients with a Glasgow Coma Score of less than or equal to 5 and a PRISM score of greater than or equal to 20 was ten times higher than the group of patients with a Glasgow Coma Score of less than or equal to 5 but a PRISM score of <20. Conclusions: Children with severe traumatic brain injury who survive to hospital discharge will continue to improve in their functional status over the next few years, Although low Glasgow Coma Score is strongly associated with death or poor functional outcome after therapy for traumatic brain injury, many patients with Glasgow Coma Score of less than or equal to 5 can Survive with good function. PRISM scores add to the power of Glasgow Coma Score to predict survival and functional outcome in tracheally intubated pediatric patients with Glasgow Coma Score of less than or equal to 5.	MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA; CHILDRENS HOSP WISCONSIN, MILWAUKEE, WI 53201 USA; MED COLL WISCONSIN, DEPT PHYS MED & REHABIL, MILWAUKEE, WI 53226 USA				Splaingard, Mark L/D-9206-2012; Splaingard, Mark/AAL-7356-2021	Splaingard, Mark/0000-0002-1361-4947			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOWERS SA, 1977, NEUROSURGERY, V47, P491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CASEY R, 1986, PEDIATRICS, V78, P497; Davis RJ, 1992, TXB PEDIAT INTENSIVE, P805; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUMPHREYS PR, 1984, CONCEPTS PEDIAT NEUR, V4, P230; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KUMAR R, 1991, CHILD NERV SYST, V7, P299, DOI 10.1007/BF00304824; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731	24	40	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	1997	25	8					1396	1401		10.1097/00003246-199708000-00030			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ994	WOS:A1997XQ99400030	9267956				2022-02-06	
J	Mechanick, JI; Pomerantz, F; Flanagan, S; Stein, A; Gordon, WA; Ragnarsson, KT				Mechanick, JI; Pomerantz, F; Flanagan, S; Stein, A; Gordon, WA; Ragnarsson, KT			Parathyroid hormone suppression in spinal cord injury patients is associated with the degree of neurologic impairment and not the level of injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BONE LOSS; IMMOBILIZATION; HYPERCALCEMIA; OSTEOPOROSIS; SECRETION; INVITRO; MEN	Objective: To demonstrate that after spinal cord injury (SCI) suppression of the parathyroid-vitamin D axis is associated with the degree of neurologic impairment and not the level of injury, Design: A retrospective analysis of clinical and biochemical data obtained from hospital records of patients with SCI compared to a control group of patients with traumatic brain injury (TBI). Setting: The inpatient rehabilitation unit of a tertiary care hospital. Subjects: The medical records of 82 consecutive admissions to the rehabilitation unit with a diagnosis of SCI or TBI were reviewed. Patients with SCI were classified by the American Spinal injury Association (ASIA) impairment scale and then grouped based on the completeness and level of injury. Main Outcome Measure: Comparisons of serum parathyroid hormone (PTH), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25-D) were planned. Multiple comparisons were performed for total and ionized serum calcium levels, serum phosphorus levels, and 24-hour urinary calcium excretion rates to reflect changes in mineral homeostasis. Multiple comparisons were also performed for serum albumin, prolactin, thyroid function tests, and AM cortisol levels, as well as 24-hour urinary urea nitrogen and cortisol excretion rates to reflect metabolic responses to stress. Results: Patients with SCI had significant suppression in PTH (p < .000009) and 1,25-D (p < .02) levels with elevated phosphorus (p < 0.03) and prolactin (p < .03) levels compared to patients with TBI. Also, more patients with SCI were hypoalbuminemic (p < .003) than patients with TBI. Patients with complete SCI (ASIA A) had more suppressed PTH (p < .03) and higher urinary urea nitrogen (p < .05) levels than SCI patients with incomplete injuries (ASIA B-D). Patients with complete, but not incomplete, SCI had lower albumin levels than patients with TBI (p < .05). These differences were not found between patients with tetraplegic and paraplegic SCI. ASIA motor scores did not correlate with any of the measured parameters but when used as a covariate did abolish differences in PTH and 1,25-D among the study groups by ANOVA. Conclusion: In patients with SCI, the degree of neurologic impairment. and not the level of injury, is associated with PTH suppression and markers of metabolic stress. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	CUNY MT SINAI SCH MED, DEPT REHABIL MED, NEW YORK, NY 10029 USA		Mechanick, JI (corresponding author), CUNY MT SINAI SCH MED, DIV ENDOCRINOL & METAB, NEW YORK, NY 10029 USA.			Flanagan, Steven/0000-0001-9005-5897	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [H133NS0008] Funding Source: Medline		Albright F, 1941, J CLIN ENDOCRINOL, V1, P711, DOI 10.1210/jcem-1-9-711; American Spinal Injury Association/International Medical Society of Paraplegia, 1992, INT STAND NEUR FUNCT; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CHAPPARD D, 1995, J BONE MINER RES, V10, P112; CLAUSWALKER J, 1977, J CLIN ENDOCR METAB, V44, P530, DOI 10.1210/jcem-44-3-530; FUJIYAMA K, 1995, J CLIN ENDOCR METAB, V80, P2135, DOI 10.1210/jc.80.7.2135; GARLAND DE, 1992, J ORTHOPAED RES, V10, P371, DOI 10.1002/jor.1100100309; GOWEN M, 1986, J IMMUNOL, V136, P2478; HYMAN LR, 1972, AM J DIS CHILD, V124, P723, DOI 10.1001/archpedi.1972.02110170101017; Keating J F, 1992, Disabil Rehabil, V14, P108; Kolmogoroff A, 1941, ANN MATH STAT, V12, P461, DOI 10.1214/aoms/1177731684; KRUSKAL WILLIAM H., 1952, JOUR AMER STATIST ASSOC, V47, P583, DOI 10.2307/2280779; LAWRENCE GD, 1973, J BONE JOINT SURG AM, VA 55, P87, DOI 10.2106/00004623-197355010-00008; LERMAN S, 1977, J CLIN ENDOCR METAB, V45, P425, DOI 10.1210/jcem-45-3-425; LESLIE WD, 1993, ARCH PHYS MED REHAB, V74, P960; LOGUE FC, 1990, J CLIN ENDOCR METAB, V71, P1556, DOI 10.1210/jcem-71-6-1556; MALLETTE LE, 1989, J BONE MINER RES, V4, P143; MAYNARD FM, 1977, ARCH PHYS MED REHAB, V58, P16; Mechanick JI, 1993, RES STAFF PHYS, V39, P87; NAFTCHI NE, 1980, ARCH PHYS MED REHAB, V61, P139; PIETSCHMANN P, 1992, PARAPLEGIA, V30, P204, DOI 10.1038/sc.1992.56; PILONCHERY G, 1983, CLIN ORTHOP RELAT R, P230; RAGNARSSON KT, 1981, ARCH PHYS MED REHAB, V62, P418; RODRIGUEZ GP, 1989, ARCH PHYS MED REHAB, V70, P442, DOI 10.1016/0003-9993(89)90003-8; Saltzstein R J, 1992, J Am Paraplegia Soc, V15, P232; SHETTY KR, 1993, AM J MED SCI, V305, P95, DOI 10.1097/00000441-199302000-00006; STEWART AF, 1982, NEW ENGL J MED, V306, P1136, DOI 10.1056/NEJM198205133061903; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; TORI JA, 1978, PARAPLEGIA, V16, P357; UEBELHART D, 1994, SCAND J REHABIL MED, V26, P197; VAZIRI ND, 1994, ARCH PHYS MED REHAB, V75, P766	31	40	41	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1997	78	7					692	696		10.1016/S0003-9993(97)90075-7			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	XK216	WOS:A1997XK21600003	9228870				2022-02-06	
J	Warden, CR; Brownstein, DR; DelBeccaro, MA				Warden, CR; Brownstein, DR; DelBeccaro, MA			Predictors of abnormal findings of computed tomography of the head in pediatric patients presenting with seizures	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Region IX and X of the Ambulatory-Pediatric-Association Meeting	FEB, 1996	CARMEL, CA	Ambulatory Pediat Assoc, Reg IX, Ambulatory Pediat Assoc, Reg X			RULES; RADIOGRAPHY; CHILDHOOD; DISORDERS; SELECTION; CHILDREN; INJURIES; SCANS	Study objective: To develop a preliminary clinical decision guideline, using characteristics of ED pediatric patients presenting with seizures, that successfully predicts all abnormal results of computed tomography (CT) of the head. Methods: We assembled a retrospective case series in the ED of a tertiary care children's hospital without trauma designation. The series comprised all patients who presented between January 1, 1992, and December 31, 1994, with seizures (febrile and afebrile) who underwent head CT as part of ED evaluation Results: Our inclusion criteria were met by 203 patients. Of these patients, who had a median age of 3.1 years, 53% were boys; 18% had been transferred from another facility; 25% had received anticonvulsant medication in the field, at the referring facility, or both; 32% had a history of seizures before the presenting episode; 6% had sustained a closed-head injury (CHI); 15% had a cerebrospinal fluid (CSF) shunt; 4% had an underlying malignancy or neurocutaneous disorder (NCT); and 30% had a documented fever. CT findings were abnormal in 25 patients (12%). CT showed evidence of hemorrhage in eight patients (32%), small focal abnormalities in four (16%), cerebral edema in three (12%), and shunt obstruction in two (8%). chi(2) Recursive-partitioning analysis revealed that CT scan results were always normal when the patient did not have an underlying high-risk condition (malignancy, NCT, recent CHI, or recent CSF shunt revision), was older than 6 months, had sustained a seizure of 15 minutes or less, and did not have a history of a new-onset focal neurologic deficit. Retrospective application of these criteria revealed that 41% of the CT scans could have been deferred. Conclusion: In this case series, the absence of defined high-risk factors predicted normal head CT findings. The deferral of emergency CT in this population should be considered.			Warden, CR (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,CHILDRENS HOSP,EMERGENCY SERV,SEATTLE,WA 98195, USA.						*AM COLL EM PHYS, 1993, ANN EMERG MED, V22, P875; BACHMAN DS, 1976, PEDIATRICS, V58, P828; CIAMPI A, 1988, J CLIN EPIDEMIOL, V8, P737; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Ferry P C, 1992, Pediatr Rev, V13, P248, DOI 10.1542/pir.13-7-248; Fleiss J, 1981, STAT METHODS RATES P, V2nd; FLOSNER B, 1995, FUNDAMENTALS STAT; FRIEDMAN JH, 1977, IEEE T COMPUT, V16, P404; GRANETO JW, 1993, TXB PEDIAT EMERGENCY, P464; Landfish N, 1992, J Fla Med Assoc, V79, P697; MARSHALL RJ, 1986, STAT MED, V5, P517, DOI 10.1002/sim.4780050516; MCABEE GN, 1989, PEDIATR NEUROL, V5, P102, DOI 10.1016/0887-8994(89)90034-9; MCCONNOCHIE KM, 1993, MED DECIS MAKING, V13, P30, DOI 10.1177/0272989X9301300105; MEYERS A, 1978, AM J DIS CHILD, V132, P25, DOI 10.1001/archpedi.1978.02120260027003; Reinus WR, 1996, INVEST RADIOL, V31, P101, DOI 10.1097/00004424-199602000-00007; REINUS WR, 1993, ANN EMERG MED, V22, P1298, DOI 10.1016/S0196-0644(05)80111-8; REINUS WR, 1993, RADIOLOGY, V186, P763, DOI 10.1148/radiology.186.3.8430185; RIVARA F, 1987, PEDIATRICS, V80, P579; SCHUTZMAN SA, 1993, TXB PEDIAT EMERGENCY, P268; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; Vining E P, 1986, Pediatr Rev, V8, P185, DOI 10.1542/pir.8-6-185; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; YANG PJ, 1979, NEUROLOGY, V29, P1084, DOI 10.1212/WNL.29.8.1084	25	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	APR	1997	29	4					518	523		10.1016/S0196-0644(97)70226-9			6	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	WQ539	WOS:A1997WQ53900010	9095014				2022-02-06	
J	Gennarelli, TA				Gennarelli, TA			The pathobiology of traumatic brain injury	NEUROSCIENTIST			English	Article						brain trauma; injury; calcium; axonal injury; mechanisms of cell damage	CHOLINERGIC RECEPTOR-BINDING; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; HEAD-INJURY; RAT-BRAIN; C-FOS; GENE-EXPRESSION; PROTEIN; TISSUE; INTERLEUKIN-6	The recent appreciation that traumatic brain injury is a dynamic process, initiated at the time of injury but not concluded for hours to days afterward, has resulted in the expectation that treatments can be designed to interrupt the processes that result in delayed cellular dysfunction and, thus, can decrease the amount of traumatic brain damage. Thus, for the first time, treatments specific for brain damage are envisioned. These can provide a fundamentally different approach to the treatment of the damaged brain than currently used treatments that deal with epiphenomena of traumatic injury, such as increased intracranial pressure or secondary ischemia. The processes that result in delayed cellular damage may be initiated by transient ionic fluxes induced by traumatic, temporary holes in the cell membrane lipid bilayer (mechanoporation). Resulting changes in intracellular ionic composition, if uncorrected, result in I)traumatic depolarization with resultant neurotransmitter release, postsynaptic receptor dysfunction, and excitability changes; 2) calcium-mediated activation of proteases and phospholipases, with resultant cytoskeletal protein dissolution and free radical-induced lipid peroxidation; 3) inflammatory processes that elicit tissue-damaging cytokines; and 4) immediate and delayed activation of numerous genes with a resultant production of a panoply of new proteins. The future challenge to neurotrauma investigators is to better understand these processes and to develop interventions that will halt them before permanent brain damage occurs.	ALLEGHENY UNIV HLTH SCI, CTR NEUROSCI, PHILADELPHIA, PA 19102 USA; ALLEGHENY UNIV HLTH SCI, DEPT NEUROSURG, PHILADELPHIA, PA 19102 USA								ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CHAN KH, 1993, NEUROSURGERY, V32, P247; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FERN R, 1995, NEUROSCIENTIST, V1, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1994, J NEUROSURG, V80, P409; Gennarelli TA, 1993, HEAD INJURY, P137; GENNARELLI TA, 1996, IN PRESS NEUROPATHOL; GENNARELLI TA, 1983, ACTA NEUROCHIR     S, V2, P1; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1981, MILD MODERATE HEAD I, P3; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1995, J NEUROTRAUMA, V12, P791; HAYES RL, 1981, BRAIN RES, V225, P271; HEIZER ML, 1988, FASEB J, V2, pA1519; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RINK AD, 1995, J NEUROTRAUM, V12, P137; SAATMAN KE, 1994, SOC NEUR ABSTR, V20, P115; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Soares HD, 1995, J NEUROSCI, V15, P8223; THIBAULT LE, 1992, INT RES COUNCIL BIOM, V14, P3; TSUIKI K, 1995, J NEUROCHEM, V64, P1319; WEST M, 1981, BRAIN RES, V225, P271, DOI 10.1016/0006-8993(81)90835-0; WINSTON FK, 1993, J BIOMECH ENG-T ASME, V115, P160, DOI 10.1115/1.2894116; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YAN HQ, 1992, EUR J IMMUNOL, V22, P2693; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; [No title captured]	66	40	43	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584			NEUROSCIENTIST	Neuroscientist	JAN	1997	3	1					73	81		10.1177/107385849700300117			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WC678	WOS:A1997WC67800017					2022-02-06	
J	Lannoo, E; Vingerhoets, G				Lannoo, E; Vingerhoets, G			Flemish normative data on common neuropsychological tests: Influence of age, education, and gender	PSYCHOLOGICA BELGICA			English	Article							CLOSED-HEAD-INJURY; COLOR-WORD TEST; REY-OSTERRIETH; COMPLEX FIGURE; STROOP; RECOVERY; DEFICITS	Normative data on a large, neurologically intact, nonpsychiatric sample of 200 adult Flemish subjects (male=106, female=94) are presented according to age, education, and gender. The neuropsychological test battery included the Bourdon Wiersma Dot Cancellation, the Paced Auditory Serial Addition Test (PASAT), the Stroop Color-Word Test (SCWT), the Trail Making Test (TMT), the Rey or Taylor Complex Figure Test, version A or B of the Auditory Verbal Learning Test (AVLT), version F or G of the Benton Visual Retention Test (BVRT), and the Controlled Oral Word Association Test (COWAT). Stepwise linear regression analyses reveal a significant effect of education on all measures except Dot Cancellation and an interference score of the SCWT. Age contributed significantly to performance on memory tests and timed tests. Gender only accounted for a proportion of the variance in the copy score of the Taylor Complex Figure, the delayed recall score of the Rey Complex Figure, and the results of the AVLT. The two alternate versions of the AVLT are interchangeable. The Rey and Taylor Complex Figures are not of equivalent difficulty and differentially influenced by demographic factors, as well as versions F and G of the BVRT.	STATE UNIV GHENT,B-9000 GHENT,BELGIUM								BANKEN JA, 1985, J CLIN PSYCHOL, V41, P686, DOI 10.1002/1097-4679(198509)41:5<686::AID-JCLP2270410517>3.0.CO;2-D; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1961, BENTON TEST HDB; Berry D.T.R., 1991, CLIN NEUROPSYCHOL, V5, P143, DOI [10.1080/13854049108403298, DOI 10.1080/13854049108403298]; BERRY DTR, 1992, CLIN NEUROPSYCHOL, V6, P80, DOI DOI 10.1080/13854049208404119; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; DEZEEUW J, 1981, ALGEMENE PSYCHODIAGN, V1; DULEY JF, 1993, CLIN NEUROPSYCHOL, V7, P29, DOI DOI 10.1080/13854049308401885; FISHER LM, 1990, J CLIN EXP NEUROPSYC, V12, P745, DOI 10.1080/01688639008401016; GHYS AJ, 1985, TIJDSCHRIFT KLINISCH, V15, P197; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hammes J., 1971, STROOP KLEUR WOORDTE; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; KAUFMAN AS, 1991, J CLIN PSYCHOL, V47, P548; KOSS E, 1984, INT J NEUROSCI, V24, P53, DOI 10.3109/00207458409079534; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Osterrieth PA, 1994, ARCH PSYCHOL, V30, P286; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RYAN JJ, 1984, INT J CLIN NEUROPSYC, V6, P239; Spreen O, 1991, COMPENDIUM NEUROPSYC; Strauss E, 1990, Arch Clin Neuropsychol, V5, P417, DOI 10.1016/0887-6177(90)90020-P; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAYLOR LB, 1979, FUNCTIONAL NEUROSRUG; VANZOMEREN AH, 1997, NEUROBEHAVIORAL RECO, P398; VINGERHOETS G, UNPUB REY OSTERRIETH; VONZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED	35	40	40	0	15	BELGIAN PSYCHOL SOC	LOUVAIN	TIENSESTRAAT 102, 3000 LOUVAIN, BELGIUM	0033-2879			PSYCHOL BELG	Psychol. Belg.		1997	37	3					141	155					15	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	YH623	WOS:A1997YH62300001					2022-02-06	
J	Barry, CT; Taylor, HG; Klein, S; Yeates, KO				Barry, CT; Taylor, HG; Klein, S; Yeates, KO			Validity of neurobehavioral symptoms reported in children with traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; FOLLOW-UP; FAMILY; PERFORMANCE; ADOLESCENTS; SEQUELAE	Few studies have examined the validity of neurobehavioral symptoms as correlates of the severity of traumatic brain injury (TBI) or as predictors of the neuropsychological and family consequences of injury. In the present study, 68 children with moderate to severe TBI, together with 53 children with orthopedic injuries only, were followed prospectively from the time of hospitalization. Postinjury behavior symptoms and other child and family outcomes were assessed at a baseline evaluation and again at a 6-month follow-up. The TBI group had more behavior symptoms than the orthopedic injury group at baseline and follow-up. For the TBI group, behavior symptoms at both assessments correlated with injury severity. Greater numbers of symptoms at baseline were associated with poorer neuropsychological performances and family distress at baseline, as well as more negative changes over follow-up in the child. The present findings support the utility of neurobehavioral symptoms as markers of injury severity and predictors of child and family sequelae.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PEDIAT,CLEVELAND,OH 44106; OHIO STATE UNIV,COLL MED,DEPT PEDIAT,COLUMBUS,OH 43210; COLUMBUS CHILDRENS HOSP,COLUMBUS,OH		Barry, CT (corresponding author), CASE WESTERN RESERVE UNIV,RAINBOW BABIES & CHILDRENS HOSP,DEPT PEDIAT,11100 EUCLID AVE,CLEVELAND,OH 44106, USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Klein, Susan/0000-0003-1723-8210			Achenbach, 1991, MANUAL TEACHERS REPO; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BLACK P, 1970, PHYSICAL TRAUMA ETIO, P142; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN L, 1990, TEST NONVERBAL INTEL; BROWN S, 1994, J NEUROPSYCHIATRY CL, V6, P12; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DELIS DC, 1986, CALIFORNIA VERBAL LE; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Derogatis LR, 1982, BRIEF SYMPTOM INVENT; DISIMONI F, 1978, TOKEN TEST CHILDREN; DROTAR D, 1996, UNPUB FAMILY BURDEN; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS R, 1988, LIFE STRESSORS SOCIA; MOOS RH, 1987, HLTH DAILY LIVING FO; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTTER M, 1984, DEV NEUROPSYCHIATRY, P83; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; Walker H.M., 1988, WALKER MCCONNELL SCA; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wiig E. H., 1989, TEST LANGUAGE COMPET; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; [No title captured]; [No title captured]; [No title captured]	52	40	40	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	1996	2	3					213	226		10.1080/09297049608402254			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	WM941	WOS:A1996WM94100006					2022-02-06	
J	Schwartz, AE; Stone, JG; Finck, AD; Sandhu, AA; Mongero, LB; Adams, DC; Jonassen, AE; Young, WL; Michler, RE				Schwartz, AE; Stone, JG; Finck, AD; Sandhu, AA; Mongero, LB; Adams, DC; Jonassen, AE; Young, WL; Michler, RE			Isolated cerebral hypothermia by single carotid artery perfusion of extracorporeally cooled blood in baboons	NEUROSURGERY			English	Article						brain hypothermia; cerebrovascular circulation; extracorporeal circulation	PROLONGED HYPOTHERMIA; TEMPERATURE; ISCHEMIA; ARREST; FLOW	OBJECTIVE: Hypothermia has been demonstrated to protect the brain from ischemic or traumatic injury. Previous efforts to induce cerebral hypothermia have relied on techniques requiring total body cooling that have resulted in serious cardiovascular derangements. A technique to selectively cool the brain, without systemic hypothermia, may have applications for the treatment of neurological disease. METHODS: After induction of general anesthesia in 12 baboons, the right common carotid artery and ipsilateral femoral artery were each occlusively cannulated and joined to a centrifugal pump. In a closed-circuit system, blood was continually withdrawn from the femoral artery, cooled by water bath, and infused through the common carotid artery with its external branches occluded. Pump flow was varied so that right carotid pressure approximated systemic blood pressure. In six animals, perfusate was cooled to decrease right cerebral temperature to <19 degrees C for 30 minutes. In six animals, right cerebral temperature was decreased to <25 degrees C for 3 hours. In those six animals, Xe-133 was injected into the right carotid artery before, during, and after hypothermia. Peak radioactivity and washout curves were recorded from bilateral cranial detectors. Systemic warming was accomplished by convective air and warm water blankets. Esophageal, rectal, and bilateral cerebral temperatures were continuously recorded. RESULTS: In animals cooled to <19 degrees C, right cerebral temperature decreased from 34 degrees C to 18.5 +/- 1.1 degrees C (mean +/- standard deviation), P < 0.01, in 26 +/- 13 minutes. Simultaneously, left cerebral temperature decreased to 20.7 +/- 1.6 degrees C. During 30 minutes of stable cerebral hypothermia, esophageal temperature decreased from 35.1 +/- 2.3 degrees C to 34.2 +/- 2.2 degrees C, P < 0.05. In animals cooled to <25 degrees C, right cerebral temperature decreased from 34 degrees C to 24.5 +/- 0.6 degrees C in 12.0 +/- 6.0 minutes, P < 0.01. Simultaneously, left cerebral temperature decreased to 26.3 +/- 4.8 degrees C. After 3 hours of stable cerebral hypothermia, esophageal temperature was 34.4 +/- 0.5 degrees C, P < 0.05. Right hemispheric cerebral blood flow decreased during hypothermia (26 +/- 16 ml/min/100 g) compared to values before and after hypothermia (63 +/- 29 and 51 +/- 34 ml/min/100 g, respectively; P < 0.05). Furthermore, hypothermic perfusion resulted in a proportionally increased radioactivity peak detected in the left cerebral hemisphere after right carotid artery injection of Xe-133 (0.8 +/- 0.2:1, left:right) compared to normothermia before and after hypothermia (0.3 +/- 2 and 0.3 +/- 1, respectively; P < 0.05). Normal heart rhythm, systemic arterial blood pressure, and arterial blood gas values were preserved during hypothermia in all animals. CONCLUSION: Bilateral cerebral deep or moderate hypothermia can be induced by selective perfusion of a single internal carotid artery, with minimal systemic cooling and without cardiovascular instability. This global brain hypothermia results from profoundly altered collateral cerebral circulation during artificial hypothermic perfusion. This technique may have clinical applications for neurosurgery, stroke, or traumatic brain injury.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT NEUROL SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT RADIOL,NEW YORK,NY 10032		Schwartz, AE (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANESTHESIOL,BOX 46,630 W 168TH ST,NEW YORK,NY 10032, USA.		Schwartz, Arthur/ABC-3474-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0-NS27713] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027713] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, ANN INTERN MED, V122, P622, DOI 10.7326/0003-4819-122-8-199504150-00013; ALTHAUS U, 1982, ANN SURG, V195, P492, DOI 10.1097/00000658-198204000-00018; ANGELAKOS ET, 1959, J PHARMACOL EXP THER, V127, P137; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; CHEN RYZ, 1980, J APPL PHYSIOL, V49, P178, DOI 10.1152/jappl.1980.49.2.178; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRIEPP EB, 1992, J CARDIAC SURG, V7, P134, DOI 10.1111/j.1540-8191.1992.tb00790.x; KIMOTO S, 1956, SURGERY, V39, P592; LEVY WJ, 1984, ANESTHESIOLOGY, V60, P291, DOI 10.1097/00000542-198404000-00004; MICHENFELDER JD, 1977, STROKE, V8, P87, DOI 10.1161/01.STR.8.1.87; Olesen J, 1971, STROKE, V2, P519, DOI 10.1161/01.STR.2.6.519; PARKINS WM, 1954, ANN SURG, V140, P284, DOI 10.1097/00000658-195409000-00004; PEARCY WC, 1959, ANESTHESIOLOGY, V20, P341, DOI 10.1097/00000542-195905000-00014; SCHWARTZ AE, 1994, ANESTHESIOLOGY, V81, P959, DOI 10.1097/00000542-199410000-00023; Sistino J J, 1993, J Extra Corpor Technol, V25, P15; SPETZLER RF, 1980, NEUROSURGERY, V7, P257, DOI 10.1227/00006123-198009000-00009; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; STONE JG, 1993, ANESTHESIOLOGY, V79, P36, DOI 10.1097/00000542-199307000-00008; VANDAM LD, 1959, NEW ENGL J MED, V261, P546, DOI 10.1056/NEJM195909102611106; YOUNG WL, 1990, ANESTHESIOLOGY, V73, P637, DOI 10.1097/00000542-199010000-00009; ZARINS CK, 1973, J SURG RES, V14, P97, DOI 10.1016/0022-4804(73)90015-2	22	40	40	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1996	39	3					577	581					5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VE304	WOS:A1996VE30400067	8875489				2022-02-06	
J	Sangal, RB; Sangal, JAM				Sangal, RB; Sangal, JAM			Closed head injury patients with mild cognitive complaints without neurological or psychiatric findings have abnormal visual P300 latencies	BIOLOGICAL PSYCHIATRY			English	Article						P300; closed head injury; cognitive deficits; evoked potentials; event-related potentials; brain topography			WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202		Sangal, RB (corresponding author), SLEEP DISORDERS UNIT,44199 DEQUINDRE,STE 311,TROY,MI 48098, USA.			Sangal, R/0000-0003-4031-7814			HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; SANGAL RB, 1995, CLIN ELECTROENCEPHAL, V26, P146, DOI 10.1177/155005949502600305; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	5	40	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	FEB 15	1996	39	4					305	307		10.1016/0006-3223(95)00447-5			3	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	TW730	WOS:A1996TW73000013	8645780				2022-02-06	
J	Jansen, HML; vanderNaalt, J; vanZomeren, AH; Paans, AMJ; VeenmavanderDuin, L; Hew, JM; Pruim, J; Minderhoud, JM; Korf, J				Jansen, HML; vanderNaalt, J; vanZomeren, AH; Paans, AMJ; VeenmavanderDuin, L; Hew, JM; Pruim, J; Minderhoud, JM; Korf, J			Cobalt-55 positron emission tomography in traumatic brain injury: A pilot study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; PET; cobalt-55	CLOSED-HEAD-INJURY; SPECT	Traumatic brain injury is usually assessed with the Glasgow coma scale (GCS), CT, or MRI. After such injury, the injured brain tissue is characterised by calcium mediated neuronal damage and inflammation. Positron emission tomography with the isotope cobalt-55 (Go-PET) as a calcium tracer enables imaging of affected tissue in traumatic brain injury. The aim was to determine whether additional information can be gained by Go-PET in the diagnosis of moderate traumatic brain injury and to assess any prognostic value of Co-PET. Five patients with recent moderately severe traumatic brain injury were studied. CT was performed on the day of admission, EEG within one week, and MRI and Co-PET within four weeks of injury. Clinical assessment included neurological examination, GCS, neuropsychological testing, and Glasgow outcome scale (GOS) after one year. Co-PET showed focal uptake that extended beyond the morphological abnormalities shown by MRI and CT, in brain regions that were actually diagnosed with EEG. Thus Co-PET is potentially useful for diagnostic localisation of both structural and functional abnormalities in moderate traumatic brain injury.	UNIV GRONINGEN HOSP,DEPT BIOL PSYCHIAT,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT NEUROL,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT NEUROPSYCHOL,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,NATL PET RES CTR,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT NEURORADIOL,9700 RB GRONINGEN,NETHERLANDS					van der Naalt, Joukje/0000-0001-9873-2418			APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JACOBS A, 1994, J NUCL MED, V35, P942; JANSEN HML, 1995, J NEUROL SCI, V132, P139, DOI 10.1016/0022-510X(95)00139-S; JANSEN HML, 1994, J NUCL MED, V35, P456; JENNETT B, 1975, LANCET, V3, P480; KAO CH, 1991, NUCL MED COMMUN, V12, P1007, DOI 10.1097/00006231-199112000-00002; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ROPER SN, 1991, J NUCL MED, V32, P1684; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	13	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1996	60	2					221	224		10.1136/jnnp.60.2.221			4	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	TU932	WOS:A1996TU93200024	8708661	Green Published, Bronze			2022-02-06	
J	Reinhard, DL; Whyte, J; Sandel, ME				Reinhard, DL; Whyte, J; Sandel, ME			Improved arousal and initiation following tricyclic antidepressant use in severe brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SENSORIMOTOR CORTEX INJURY; VISUAL CORTICAL PLASTICITY; NOREPINEPHRINE DEPLETION; LOCOMOTOR FUNCTION; DEPTH-PERCEPTION; VEGETATIVE STATE; HEAD-INJURY; RECOVERY; AMPHETAMINE; ABLATION	Three patients with severe traumatic brain injury demonstrated significant improvement in arousal and initiation after administration of tricyclic antidepressants. The first patient showed improved motor and speech initiation in response to amitriptyline following several months of functional plateau. The second patient was minimally responsive 2 months after injury and demonstrated improved arousal following the use of desipramine. Both patients deteriorated when the medications were discontinued and improved again when they were restarted. These two cases provide strong evidence for a medication effect, The third patient began to verbalize following desipramine administration, despite being mute for more than a year after injury. Previous case reports describe cognitive-enhancing effects, such as improved arousal, attention, memory, and initiation, of dopaminergic agents, and in the case of tricyclic antidepressants, effects on agitation. The role of norepinephrine in promoting neurological recovery after brain lesions has been demonstrated in animals. The cases presented here provide some of the first data to show similar efficacy in humans and underscore the need for contolled trials to better determine which patients will benefit. (C) 1996 by The American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV PENN,MED CTR,DEPT REHABIL MED,PHILADELPHIA,PA 19104; DRUCKER BRAIN INJURY CTR,MOSS REHABIL RES INST,PHILADELPHIA,PA; TEMPLE UNIV,PHILADELPHIA,PA 19122					Whyte, John/0000-0002-4381-1474			ASTONJONES G, 1981, J NEUROSCI, V1, P887; ASTONJONES G, 1985, PHYSIOL PSYCHOL, V13, P118; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BOYESON MG, 1994, ARCH NEUROL-CHICAGO, V51, P405, DOI 10.1001/archneur.1994.00540160107014; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, AM J PHYS MED REHABI, V72, P268; Campagnolo Denis I., 1992, Archives of Physical Medicine and Rehabilitation, V73, P975; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Dombovy Mary L., 1992, Archives of Physical Medicine and Rehabilitation, V73, P975; ECHIVERRI HC, 1988, PEDIATR NEUROL, V4, P228, DOI 10.1016/0887-8994(88)90036-7; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; GOLDSTEIN LB, 1990, STROKE, V21, P179; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GUPTA SR, 1992, ARCH PHYS MED REHAB, V73, P373, DOI 10.1016/0003-9993(92)90012-L; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HOMAN R, 1990, Society for Neuroscience Abstracts, V16, P439; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; KASAMATSU T, 1981, J NEUROPHYSIOL, V45, P254, DOI 10.1152/jn.1981.45.2.254; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; KASAMATSU T, 1982, EXP BRAIN RES, V45, P317, DOI 10.1007/BF01208591; KASAMATSU T, 1979, J COMP NEUROL, V185, P163, DOI 10.1002/cne.901850110; KATZ RT, 1995, ARCH PHYS MED REHAB, V76, P82, DOI 10.1016/S0003-9993(95)80048-4; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; MORRISON JH, 1979, SCIENCE, V205, P313, DOI 10.1126/science.451605; PETTIGREW JD, 1978, NATURE, V271, P761, DOI 10.1038/271761a0; PORCH B, 1985, Society for Neuroscience Abstracts, V11, P52; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; WALKERBATSON D, 1993, RESTOR NEUROL NEUROS, V4, P47; WATSON M, 1984, BRAIN RES, V296, P129, DOI 10.1016/0006-8993(84)90518-3; WROBLEWSKI B, 1992, J HEAD TRAUMA REHAB, V7, P109; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009	46	40	41	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1996	77	1					80	83		10.1016/S0003-9993(96)90225-7			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	TN532	WOS:A1996TN53200016	8554480				2022-02-06	
J	EDWARDS, DF; CHEN, YW; DIRINGER, MN				EDWARDS, DF; CHEN, YW; DIRINGER, MN			UNIFIED NEUROLOGICAL STROKE SCALE IS VALID IN ISCHEMIC AND HEMORRHAGIC STROKE	STROKE			English	Article						CEREBRAL ISCHEMIA; INTRACEREBRAL HEMORRHAGE; STROKE ASSESSMENT; STROKE OUTCOME; SUBARACHNOID HEMORRHAGE	ACUTE CEREBRAL-ISCHEMIA; WEIGHTED LEAST-SQUARES; RELIABILITY ASSESSMENT; TRIALS	Background and Purpose The growing interest in testing new therapeutic agents for acute brain injury has lead to increased use of stroke scales. The reliability and validity of these measures need to be examined more completely. We used structural equation modeling, a technique that merges the analytic procedures of factor analysis and multiple regression, to examine the reliability and construct validity of the Middle Cerebral Artery Neurological Scale and the Scandinavian Neurological Stroke Scale used together as the Unified Neurological Stroke Scale. We also analyzed the predictive validity, sensitivity, and specificity of the scales in predicting mortality and functional outcome. Methods We prospectively studied 84 consecutive patients admitted to a neurology/neurosurgery intensive care unit with intracerebral hemorrhage (n=30), subarachnoid hemorrhage (n=15), ischemic stroke (n=15), and traumatic brain injury (n=24). Patients were evaluated within 24 hours of admission and at 48-hour intervals until intensive care unit discharge. A total of 386 assessments were obtained. The Functional Independence Measure was administered by telephone 3 months after hospital discharge. Results High levels of reliability and construct validity were observed for the majority of the Unified Stroke Scale items. Facial palsy and eye movement items had the lowest reliability and validity. Both the Middle Cerebral Artery and Scandinavian Scales were significant predictors of outcome. Sensitivity and specificity varied by diagnosis. Predictive validity of functional outcome was best in groups with ischemic and hemorrhagic stroke rather than traumatic brain injury and subarachnoid hemorrhage. Conclusions The Unified Stroke Scale demonstrates reliability and construct and predictive validity, and its use is supported in ischemic and hemorrhagic stroke. Structural equation modeling is an appropriate technique for use with scales of this type.	WASHINGTON UNIV, SCH MED, GEORGE WARREN BROWN SCH SOCIAL WORK, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, NEUROL NEUROSURG INTENS CARE UNIT, ST LOUIS, MO 63110 USA		EDWARDS, DF (corresponding author), WASHINGTON UNIV, SCH MED, PROGRAM OCCUPAT THERAPY, BOX 8505, ST LOUIS, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537			ADAMS RJ, 1989, CLIN TRIAL METHODOLO, P54; AISH AM, 1990, QUAL QUANT, V24, P405, DOI 10.1007/BF00152013; ASPLUND K, 1985, STROKE, V16, P885; ASPLUND K, 1987, STROKE, V18, P528, DOI 10.1161/01.STR.18.2.528; Bollen KA., 1989, STRUCTURAL EQUATIONS, P179; BOYSEN G, 1993, STROKE, V25, P1885; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Candelise L, 1992, CEREBROVASC DIS, V2, P239; COTE R, 1988, CAN J NEUROL SCI, V15, P261, DOI 10.1017/S0317167100027712; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; DEHAAN R, 1993, STROKE, V24, P1178, DOI 10.1161/01.STR.24.8.1178; ECOB R, 1987, STRUCTURAL EQUATION, P10; Edward G., 1991, RELIABILITY VALIDITY; Feinstein AR, 1987, CLINIMETRICS; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; HANTSON L, 1994, STROKE, V25, P2215, DOI 10.1161/01.STR.25.11.2215; Joreskog K. G., 1993, TESTING STRUCTURAL E, P294, DOI DOI 10.1093/SF/73.3.1161; JORESKOG KG, 1990, QUAL QUANT, V24, P387, DOI 10.1007/BF00152012; Joreskog KG, 1993, LISREL 8 GUIDE PROGR; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LENZI GL, 1991, CEREBROVAS BRAIN MET, V3, P179; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; LYDEN PD, 1991, STROKE, V22, P1345, DOI 10.1161/01.STR.22.11.1345; Nunnally J., 1979, PSYCHOMETRIC THEORY; ORGOGOZO JM, 1992, STROKE, V23, P1678, DOI 10.1161/01.STR.23.11.1678; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; ORGOGOZO JM, 1986, ACUTE BRAIN ISCHEMIA, P282; PORTNOY LG, 1993, F CLIN RES APPLICATI; SHINAR D, 1985, ARCH NEUROL-CHICAGO, V42, P557, DOI 10.1001/archneur.1985.04060060059010; VANGIJN J, 1992, CEREBROVASC DIS, V2, P23, DOI 10.1159/000109059	32	40	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	1995	26	10					1852	1858		10.1161/01.STR.26.10.1852			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	RX185	WOS:A1995RX18500021	7570738				2022-02-06	
J	SACKS, GS; BROWN, RO; TEAGUE, D; DICKERSON, RN; TOLLEY, EA; KUDSK, KA				SACKS, GS; BROWN, RO; TEAGUE, D; DICKERSON, RN; TOLLEY, EA; KUDSK, KA			EARLY NUTRITION SUPPORT MODIFIES IMMUNE FUNCTION IN PATIENTS SUSTAINING SEVERE HEAD-INJURY	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article							PARENTERAL-NUTRITION; SEPTIC SHOCK; SEPSIS; HYPERALIMENTATION; SURVIVAL; CYTOKINE; TRAUMA; ORGAN; GUT	Background: Immunosuppression after severe head injury has been characterized by a depressed CD4 (T-helper/inducer)-CD8 (T-suppressor/cytotoxic) ratio and decreased T-lymphocyte responsiveness. Some investigators propose that this immunocompromized state is the result of an injury-associated hypermetabolic response and inadequate nutrient delivery during the immediate postinjury recovery phase. Previous observations from our institution demonstrated a preserved CD4-CD8 ratio in severe closed-head injury (CHI) patients receiving early parenteral nutrition (PN). It was unclear whether early PN or other aspects of patient care eliminated the characteristic depression in cellular immunity. The purpose of this study was to further investigate the effect of early PN on the immune function of CHI patients. Methods: Nine patients sustaining severe CHI were prospectively randomized to either early PN (n = 4) at day 1 or delayed PN (n = 5) at day 5. Total nutrient administration was delivered at 2 g of protein/kg per day and 40 nonprotein kcal/kg per day for at least the first 14 days of hospitalization. Analysis for T-lymphocyte expression of CD4 and CD8 cell surface antigens and interleukin-6 was performed on days 1, 3, 7, and 14 of hospitalization. T-lymphocyte activation in response to stimulation by concanavalin A (Con A), phytohemagglutinin (PHA), and pokeweed mitogens (PWM) was also assessed on these days. Results: Significant increases in total CD4 cell counts (2048 +/- 194 to 2809 +/- 129 vs 1728 +/- 347 to 1825 +/- 563, p < .05) and CD4% (42.6 +/- 4.4% to 56.2 +/- 2.6% vs 36.6 +/- 6.6% to 36.6 +/- 11.3%, p < .05) were observed at day 14 in patients receiving early vs delayed PN. An improved lymphocyte response from baseline to day 14 after Con A stimulation was demonstrated in the early PN group (3850 +/- 1596 to 16144 +/- 5024 cpm, p < .05). A significant rise in the CD4-CD8 ratio over baseline to day 14 was also noted in the early PN group (1.43 +/- 0.17 to 2.38 +/- 0.54, p < .05). Conclusions: The early aggressive nutrition support of CHI patients appears to modify immunologic function by increasing CD4 cells, CD4-CD8 ratios, and T-lymphocyte responsiveness to Con A.	UNIV TENNESSEE,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT CLIN PHARM,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT BIOSTAT,MEMPHIS,TN 38163				Dickerson, Roland N/C-5185-2008	Dickerson, Roland/0000-0002-2086-6317			ALVERDY J, 1985, ANN SURG, V202, P681, DOI 10.1097/00000658-198512000-00003; ALVERDY JC, 1988, SURGERY, V104, P185; BOOP FA, 1985, NEUROSURGERY, V16, P725; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; FORD TC, 1993, FOCUS, V15, P2; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HELLING TS, 1988, J TRAUMA, V11, P1575; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; HOYT DB, 1990, J TRAUMA, V7, P759; HUNT D, 1985, JPEN-PARENTER ENTER, V9, P121; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; KUDSK KA, 1994, ARCH SURG-CHICAGO, V129, P66; LIN C-N, 1992, Kaohsiung Journal of Medical Sciences, V8, P202; LUTZ H, 1976, TOTAL PARENTERAL ALI, P214; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; OTT L, 1991, NUTRITION CLIN PRACT, V6, P223; PAGE C, 1987, CONTEMP SURG, V32, P14; PAULSON G, 1971, CLIN CHEM, V17, P644; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; Rapp R. P., 1993, Clinical Nutrition, V12, pS70, DOI 10.1016/S0261-5614(09)90012-7; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P505; SCHLUTER B, 1991, J TRAUMA, V31, P1663, DOI 10.1097/00005373-199112000-00017; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; WILMORE DW, 1988, SURGERY, V104, P917	29	40	43	0	0	AMER SOC PARENTERAL & ENTERAL NUTRITION	SILVER SPRING	8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910	0148-6071			JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	SEP-OCT	1995	19	5					387	392		10.1177/0148607195019005387			6	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	RW055	WOS:A1995RW05500010	8577017				2022-02-06	
J	HAGGARD, P; MIALL, RC; WADE, D; FOWLER, S; RICHARDSON, A; ANSLOW, P; STEIN, J				HAGGARD, P; MIALL, RC; WADE, D; FOWLER, S; RICHARDSON, A; ANSLOW, P; STEIN, J			DAMAGE TO CEREBELLOCORTICAL PATHWAYS AFTER CLOSED-HEAD INJURY - A BEHAVIORAL AND MAGNETIC-RESONANCE-IMAGING STUDY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						MAGNETIC RESONANCE IMAGING; CEREBELLAR ATAXIA; CEREBELLAR PEDUNCLES; VISUOMOTOR TRACKING	TRACKING	The objective was to investigate the anatomical substrate of ataxia seen after severe head injury. Five patients were recruited from present and former inpatients at Rivermead Rehabilitation Centre. Ah patients had had a closed head injury and all had cerebellar type ataxia. Four normal controls were also studied. Brain MRI, clinical examination, computer based recording, and analysis of visuomotor tracking were carried out. Focal damage was found in the superior cerebellar peduncle in all five ataxic patients. The patients' tracking movements showed profound tremor, and unusual reliance on visual feedback. Ataxia seen after severe head injury can arise from damage to the superior cerebellar peduncle, which may interfere with the cerebellocortical circuits involved in coordinated movement.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND; RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND; RADCLIFFE INFIRM,DEPT NEURORADIOL,OXFORD OX2 6HE,ENGLAND				Haggard, Patrick/A-5081-2010; Miall, R. Chris/B-7449-2013	Miall, R. Chris/0000-0003-3002-1251; Haggard, Patrick/0000-0001-7798-793X; Wade, Derick/0000-0002-1188-8442; Stein, John/0000-0001-5843-8986	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Annett M., 1992, HDB NEUROPSYCHOLOGIC; BEPPU H, 1984, BRAIN, V107, P787, DOI 10.1093/brain/107.3.787; CHESTER CS, 1987, ANN NEUROL, V22, P79; Collen F M, 1991, Int Disabil Stud, V13, P50; Collen F M, 1990, Int Disabil Stud, V12, P6; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KOTSORIS HO, 1987, J NEURO REHAB, V2, P73; Krzanowski W.J., 1988, PRINCIPLES MULTIVARI; MIALL RC, 1993, J MOTOR BEHAV, V25, P53, DOI 10.1080/00222895.1993.9941639; MILLER E, BR J CLIN PSYCHOL, V23, P53; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; ORMEROD IEC, 1994, J NEUROL NEUROSUR PS, V57, P51, DOI 10.1136/jnnp.57.1.51; RICHARDSON RR, 1989, STEREOT FUNCT NEUROS, V53, P105, DOI 10.1159/000099525	15	40	40	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1995	58	4					433	438		10.1136/jnnp.58.4.433			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	QT682	WOS:A1995QT68200008	7738549	Bronze, Green Published			2022-02-06	
J	WILDBURGER, R; ZARKOVIC, N; EGGER, G; PETEK, W; ZARKOVIC, K; HOFER, HP				WILDBURGER, R; ZARKOVIC, N; EGGER, G; PETEK, W; ZARKOVIC, K; HOFER, HP			BASIC FIBROBLAST GROWTH-FACTOR (BFGF) IMMUNOREACTIVITY AS A POSSIBLE LINK BETWEEN HEAD-INJURY AND IMPAIRED BONE-FRACTURE HEALING	BONE AND MINERAL			English	Article						BASIC FIBROBLAST GROWTH FACTOR; ENHANCED OSTEOGENESIS; HETEROTOPIC OSSIFICATION; BONE FRACTURE HEALING; HEAD INJURY	AFFINITY-CHROMATOGRAPHY; HEPARIN-SEPHAROSE; FACTOR FGF; PITUITARY; TISSUES; INVITRO; CALLUS; MATRIX	Healing of fractures of long bones or large joints is often accelerated in patients with severe traumatic brain injury (TBI). However, in these patients an early fracture healing is accompanied by hypertrophic callus formation or heterotopic ossifications which might even result in an ankylosis of the affected joints. It seems that enhanced osteogenesis in patients suffering from TBI could be caused by some humoral factors, since the sera of these patients strongly promote the growth of osteoblast cells in vitro. However, humoral growth promoting factors which could perhaps induce enhanced osteogenesis are not yet identified. Hence, the aim of this study was to analyse if basic fibroblast growth factor (bFGF) could be related to the phenomenon of enhanced osteogenesis, since bFGF stimulates the growth of osteoblasts in vitro and could be found both in the brain and the bone tissue. For that purpose the values of bFGF immunoreactivity were determined in the sera of patients with TBI and bone fractures (n = 8) as well as in the sera of patients with either TBI alone (n = 10) or bone fractures alone (n = 7), during a period of three months after injury. Quantification of the bFGF immunoreactivity was done using the ELISA based on monoclonal antibodies raised against the recombinant human bFGF. The bFGF immunoreactivity values obtained were also compared with the values determined in the sera of normal, healthy persons (n = 9). In the group of patients with bone fractures alone only a transient increase of bFGF immunoreactivity (threefold above the normal values) was observed in the second week after injury. A similar increase of the values of bFGF immunoreactivity was also determined in the sera of patients with TBI only, but it lasted longer (from the Ist until the 7th to 8th week after injury). In the case of patients with TBI and bone fractures a specific pattern of post-traumatic dynamic change of the values of serum bFGF immunoreactivity was observed. Namely, the increase of bFGF immunoreactivity (up to seven-fold above the normal values) was determined even during the first week after injury. Afterwards, periods of high values of bFGF immunoreactivity observed during the 2nd, 4th and the 7-10th weeks after injury were interrupted by sudden decreases even to the normal values (during the 3rd and the 5-6th week after injury). Thus, post-traumatic increase of the serum bFGF immunoreactivity was induced both by bone fractures and TBI, while the unusual pattern of its changes could be related to the phenomenon of enhanced osteogenesis in the patients with brain injury.	RUDJER BOSKOVIC INST,ZAGREB,CROATIA; GRAZ UNIV,INST GEN & EXPTL PATHOL,GRAZ,AUSTRIA; GRAZ UNIV,SCH MED,CLIN CHEM LAB,GRAZ,AUSTRIA; UNIV ZAGREB,SCH MED,INST NEUROPATHOL,ZAGREB 41001,CROATIA		WILDBURGER, R (corresponding author), GRAZ UNIV,SCH MED,DEPT TRAUMATOL,AUENBRUGGERPLATZ 15,A-8036 GRAZ,AUSTRIA.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CANALIS E, 1988, TRIANGLE, V27, P11; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; FINKLESTEIN SP, 1990, STROKE, V21, P122; FRAUTSCHY SA, 1991, BRAIN RES, V12, P291; GAUTHIER T, 1987, BIOCHEM BIOPH RES CO, V145, P775, DOI 10.1016/0006-291X(87)91032-1; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477; LOGAN A, 1992, J NEUROSCI, V12, P3828; MAZUE G, 1992, TOXICOL LETT, V329, P64; MORMEDE P, 1985, BIOCHEM BIOPH RES CO, V128, P1108, DOI 10.1016/0006-291X(85)91054-X; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RIVA MA, 1992, MOL BRAIN RES, V15, P311, DOI 10.1016/0169-328X(92)90123-S; RODAN SB, 1992, CYTOKINES BONE METAB, P115; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518, DOI 10.1302/0301-620X.69B4.3611149; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; WILDBURGER R, 1992, ZBL CHIR, V117, P515	25	40	46	0	4	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0169-6009			BONE MINER	Bone Miner.	DEC	1994	27	3					183	192		10.1016/S0169-6009(08)80192-4			10	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	QF121	WOS:A1994QF12100002	7696886				2022-02-06	
J	ARMSTEAD, WM; KURTH, CD				ARMSTEAD, WM; KURTH, CD			THE ROLE OF OPIOIDS IN NEWBORN PIG-FLUID PERCUSSION BRAIN INJURY	BRAIN RESEARCH			English	Article						CEREBRAL CIRCULATION; FLUID PERCUSSION BRAIN INJURY; OPIOID	CEREBRAL BLOOD-FLOW; SPINAL-CORD INJURY; ENDOGENOUS OPIOIDS; HEAD-INJURY; CEREBROSPINAL-FLUID; CATS; CIRCULATION; METABOLISM; RESPONSES; NALOXONE	The present study was designed to characterize the relationship between cerebral opioid concentration, cerebral hemodynamics, and cerebral oxygenation following percussion brain injury in neonatal pigs. Previous research found that opioids represent a significant vasoactive component in the regulation of the neonatal piglet cerebral circulation. Anesthetized newborn (1-5 days old) pigs equipped with a closed cranial window were connected to a percussion device consisting of a saline-filled cylindrical reservoir with a metal pendulum. Brain injury of moderate severity (1.9-2.3 atm.) was produced by allowing the pendulum to strike a piston on the cylinder. Fluid percussion brain injury decreased pial arteriolar diameter (132 +/- 5 to 110 +/- 5 mu m within 10 min). Cerebral blood flow also fell within 10 min of injury and continued to fall progressively for 3 h, resulting in a 46 +/- 4% decrease. Within 30 s of brain injury, there was a transient increase in cerebral hemoglobin-O-2 saturation that was reversed to a progressive profound decrease in cerebral hemoglobin-O-2 saturation for the next 3 h, as measured by near infrared spectroscopy. CSF opioid concentrations were increased 10 min after brain injury; dynorphin showed the largest proportional increase (5.8 +/- 0.9 fold). The CSF concentration for other opioids continued to increase over 180 min while the dynorphin concentration progressively decreased with time. In naloxone (1 mg/kg i.v.) pretreated piglets, the brain injury induced decrease in arteriolar diameter was attenuated (129 +/- 5 to 121 +/- 5 mu m within 10 min). Similarly, the decrease in regional cerebral blood flow and cerebral hemoglobin-O-2 saturation observed following brain injury were also blunted by naloxone. These data show that CSF opioid concentrations increase following brain injury and that the time course and relative increase in CSF concentration vary from opioid to opioid. These data also indicate that in the immature animal, opioids contribute to arteriolar constriction, decreased cerebral blood flow, decreased cerebral oxygenation, and could play a role in causing ischemia after brain injury.	UNIV PENN,DEPT ANESTHESIA,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104		ARMSTEAD, WM (corresponding author), CHILDRENS HOSP PHILADELPHIA,DEPT ANESTHESIA,34TH & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.						ARMSTEAD WM, 1990, J PHARMACOL EXP THER, V255, P1083; ARMSTEAD WM, 1991, J CEREBR BLOOD F MET, V11, P380, DOI 10.1038/jcbfm.1991.78; ARMSTEAD WM, 1991, CIRC RES, V68, P922, DOI 10.1161/01.RES.68.4.922; BASKIN DS, 1985, NEUROPEPTIDES, V5, P307, DOI 10.1016/0143-4179(85)90014-9; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; KURTH CD, 1993, J CLIN MONITOR, V9, P163, DOI 10.1007/BF01617023; LAPTOOK AR, 1983, BRAIN RES, V276, P51, DOI 10.1016/0006-8993(83)90547-4; LEFFLER CW, 1985, PEDIATR RES, V19, P1160, DOI 10.1203/00006450-198511000-00009; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1988, PHARM APPROACH TREAT, P89; MCINTOSH TK, 1991, J CEREB BLOOD FLOW M, V11, pS734; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; PERRY DC, 1990, NEUR ABSTR, V16, P242; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; THURESONKLEIN A, 1989, BLOOD VESSELS, V26, P177; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1990, J NEUROSCI, V10, P3524; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; ZIMMERMAN RS, 1990, NEUROSURGERY, V26, P764, DOI 10.1227/00006123-199005000-00005	36	40	44	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 10	1994	660	1					19	26		10.1016/0006-8993(94)90834-6			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PJ969	WOS:A1994PJ96900003	7827998				2022-02-06	
J	OMMAYA, AK; THIBAULT, L; BANDAK, FA				OMMAYA, AK; THIBAULT, L; BANDAK, FA			MECHANISMS OF IMPACT HEAD-INJURY	INTERNATIONAL JOURNAL OF IMPACT ENGINEERING			English	Article							DIFFUSE AXONAL INJURY; CEREBRAL CONCUSSION; NERVE; MEMBRANE; BRAIN; CA-2+	A review of research on brain trauma mechanisms operative during head impact is presented from a clinically relevant biomechanical perspective. Emphasis is placed on microscopic mechanisms, gleaned from isolated neural tissue and cellular biomechanics research, and their relation to macro sale mechanisms observed in head injury victims and in experimental physical model experiments. Experimental and clinico-pathologic research, past and ongoing, substantiating the centripetal theory for concussive brain injury is also reviewed in the context of recent advancements in computations biomechanics of head injury brought about by the expanding availability of high speed super computers and brain imaging. A synopsis of our current computational research activities in head impact simulation is presented and some preliminary results are cited.	CTR INTERDISCIPLINARY BRAIN RES, BETHESDA, MD USA; NATL HIGHWAY TRAFF SAFETY ADM, DIV BIOMECH RES, WASHINGTON, DC USA; UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA		OMMAYA, AK (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20037 USA.						Adams JH, 1982, RECENT ADV NEUROPATH, P165; AKKAS N, 1980, J BIOMECH, V13, P737; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BANDAK FA, UNPUB EXPT COMPUTATI; BANDAK FA, UNPUB CUMULATIVE DAM; BANDAK FA, UNPUB 3 DIMENSIONAL; BANDAK FA, UNPUB ANATOMICAL FIN; BARBEE KA, 1991, THESIS U PENNSYLVANI; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; CHAN PC, UNPUB INFLUENCE SUBA; CHAN RKC, 1986, WIN ASME 86 WA NE 3; CRONWELL D, 1979, LANCET, V2, P605; DENNYBROWN D, 1941, BRAIN, P64; DIMASI F, 1991, NATIONAL HIGHWAY TRA, V1; EVANS EA, 1976, BIOPHYS J, V16, P585, DOI 10.1016/S0006-3495(76)85713-X; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; GADD CW, 1966, 10TH P STAPP CAR CRA; GALBRAITH JA, 1988, THESIS U PENNSYLVANI; GANOT G, 1981, BIOCHIM BIOPHYS ACTA, V649, P487, DOI 10.1016/0005-2736(81)90440-5; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1971, 15TH P STAPP CAR CRA; GHIBAULT IE, 1974, ACEMB, V16, P176; GOLDBERG A, 1983, INFORM PROCESS LETT, V16, P213, DOI 10.1016/0020-0190(83)90127-8; GOLDBERG RN, 1973, THERMOCHIM ACTA, V6, P1; GOLDSMITH W, 1978, J BIOMECH ENG-T ASME, V100, P25, DOI 10.1115/1.3426186; GOLDSMITH W, 1983, J BIOMECH ENG, V105, P196; GOLDSMITH W, 1984, BIOMECHANICS IMPACT; GOLDSMITH W, 1974, INT J MECH SCI, V16, P609; GOLDSMITH W, 1974, 7TH P US NAT C APPL, P160; GOLDSMITH W, 1987, J BIOMECH, V20, P487; GOLDSMITH W, 1989, OCT AAAM M NEED ANG; GOLDSMITH W, 1987, J BIOMECH, V20, P471; GOLDSMITH W, 1906, HEAD INJURY; GOLDSMITH W, 1979, J BIOMECH, V12, P211; GRAHAM DI, 1993, HEAD INJURY; GRAY JAB, 1954, J PHYSIOL-LONDON, V124, P84, DOI 10.1113/jphysiol.1954.sp005087; Gurdjian ES, 1975, IMPACT HEAD INJURY; Holbourn AHS, 1943, LANCET, V2, P438; HUMAYUN MS, 1987, P SOC NEUROSCI; HUNTER CM, 1988, EFFECTS MECHANICAL L; JANE J, 1982, SEMINARS NEUROLOGIC; JENKINS A, 1986, LANCET, V2, P445; JONES HB, 1983, J NEUROCYTOL, V12, P439, DOI 10.1007/BF01159384; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Levin HS., 1982, NEUROBEHAVIORAL CONS; LILES DR, 1978, J COMPUT PHYS, V26, P390, DOI 10.1016/0021-9991(78)90077-3; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MERRILL T, 1984, J BIOMECH, V17, P81, DOI 10.1016/0021-9290(84)90126-X; MORGAN BP, 1986, CELL CALCIUM, V7, P399, DOI 10.1016/0143-4160(86)90042-4; Newman J.A., 1986, P IRCOBI C, P121; OCHS S, 1977, NATURE, V270, P748, DOI 10.1038/270748a0; OMMAYA A, 1984, BIOMECHANICS TRAUMA; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1987, PUBLIC HEALTH REP, V102, P587; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1968, J BIOMECH; OMMAYA AK, 1966, 10TH P STAPP CAR CRA; OMMAYA AK, UNPUB TRAUMATIC UNCO; OMMAYA AK, 1973, NHTSA DOTHS0811106 C; OMMAYA AK, 1994, ASTM STP, P1229; OMMAYA AK, 1969, ACCIDENT PATHOLOGY; OMMAYA AK, 1983, DOT HS806434; OMMAYA AK, 1982, NEUROLOGICAL SURGERY, V4, P1877; ONO K, 1981, 24TH P STAPP CAR CRA; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PINCEMAILLE Y, 1989, 892439 STAPP CAR CRA; REILLY PL, 1975, LANCET, V2, P375; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1969, HDB CLIN NEUROLOGY, V3, P293; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHLIWA M, 1981, CELL BIOL, V78, P1037; SHATSKY S, 1974, 18TH P STAPP CAR CRA, P351; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; TERAKAWA S, 1982, PFLUG ARCH EUR J PHY, V395, P59, DOI 10.1007/BF00584969; THIBAULT L, 1990, 34TH P AAAM; THIBAULT LE, 1990, P INT IRCOBI C LYON; VARSACE J, 1971, 15TH P STAPP CAR CRA; VIANO D, 1989, 811708 STAPP CAR CRA; WINSTON FK, 1989, THESIS U PENNSYLVANI; WINTERS JM, 1983, J BIOMECH ENG-T ASME, V105, P63, DOI 10.1115/1.3138386; 1989, SENSORS, V6, P32; 1988, COMMITTEE REV INJURY; 1985, COMMITTEE TRAUMA RES	92	40	42	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0734-743X	1879-3509		INT J IMPACT ENG	Int. J. Impact Eng.	AUG	1994	15	4					535	560		10.1016/0734-743X(94)80033-6			26	Engineering, Mechanical; Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Mechanics	NX410	WOS:A1994NX41000015					2022-02-06	
J	HARRICK, L; KREFTING, L; JOHNSTON, J; CARLSON, P; MINNES, P				HARRICK, L; KREFTING, L; JOHNSTON, J; CARLSON, P; MINNES, P			STABILITY OF FUNCTIONAL OUTCOMES FOLLOWING TRANSITIONAL LIVING PROGRAM PARTICIPATION - 3-YEAR FOLLOW-UP	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY	The functional status and perceived problems of 21 persons with severe brain injury were reported at admission, and at 1 and 3 years post-discharge from a community-based post-acute rehabilitation programme. Functional status was measured by participation in productive activity, financial support, place of residence and level of supervision required. Improvements observed at 1-year follow-up remained stable or had improved at 3-year follow-up. Loneliness and depression, while not reported at admission, increased over time to become the two problems reported most frequently at 3-year follow-up.	QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA; KINGSTON GEN HOSP,KINGSTON K7L 2V7,ONTARIO,CANADA								BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CARLSON P, 1991, ONTARIO PSYCHOL, V23, P12; CERVELLI L, 1990, REHABILITATION ADULT, P463; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Evans R W, 1991, J Insur Med, V23, P192; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; [No title captured]	17	40	40	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1994	8	5					439	447		10.3109/02699059409150995			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	NW122	WOS:A1994NW12200005	7951206				2022-02-06	
J	LYETH, BG; JIANG, JY; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ				LYETH, BG; JIANG, JY; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ			MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN RAT-BRAIN FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						[H-3]QNB BINDING; HOMOGENATE; HIPPOCAMPUS; NEOCORTEX; BRAIN STEM; CEREBELLUM; TRAUMATIC BRAIN INJURY; FLUID PERCUSSION	DESENSITIZATION; SUPPRESSION; DEFICITS; BEHAVIOR; MOTOR	Recent evidence suggests that excessive activation of muscarinic cholinergic receptors (mAChRs) contributes significantly to the pathophysiological consequences of traumatic brain injury (TBI). To examine possible alterations in mAChRs after TBI, the affinity (K(d)) and maximum number of binding sites (B(max)) of mAChRs in hippocampus, neocortex, brain stem and cerebellum were determined by [H-3]QNB binding. Three groups of rats were examined: 1 h post-TBI (n = 21), 24 h post-TBI (n = 21) and sham-injured rats (n = 21). K(d) values were significantly higher in hippocampus and brain stem at 1 but not 24 h post-TBI compared with sham-injured controls (P < 0.05). K(d) values did not significantly differ in neocortex and cerebellum at 1 or 24 h post-TBI compared with sham-injured controls. B(max) values did not significantly differ in any brain areas at 1 or 24 h post-TBI compared with sham-injured controls. These results show that TBI significantly decreases the affinity of mAChRs in hippocampus and brain stem at an early stage post-TBI, which may contribute to desensitization of mAChRs after TBI. The findings of no change in B(max) values are consistent with a transient elevation in ACh concentrations after TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298		LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS029995, P50NS012587] Funding Source: NIH RePORTER		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; Deangelis M. M., 1992, Society for Neuroscience Abstracts, V18, P172; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELFAKAHANY EE, 1990, MEMBRANE BIOCHEM, V9, P9, DOI 10.3109/09687689009026820; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HAYES RL, 1984, SCIENCE, V20, P301; HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1984, BRAIN RES, V296, P241, DOI 10.1016/0006-8993(84)90062-3; KWARTA MM, 1987, J BIOL CHEM, V262, P16314; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEYER MR, 1982, MOL PHARMACOL, V21, P280; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SIMAN RG, 1979, P NATL ACAD SCI USA, V76, P4141, DOI 10.1073/pnas.76.8.4141; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	45	40	42	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 21	1994	640	1-2					240	245		10.1016/0006-8993(94)91879-1			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NB938	WOS:A1994NB93800030	8004451				2022-02-06	
J	MUTTAQIN, Z; UOZUMI, T; KUWABARA, S; ARITA, K; KURISU, K; OHBA, S; KOHNO, H; OGASAWARA, H; OHTANI, M; MIKAMI, T				MUTTAQIN, Z; UOZUMI, T; KUWABARA, S; ARITA, K; KURISU, K; OHBA, S; KOHNO, H; OGASAWARA, H; OHTANI, M; MIKAMI, T			HYPEREMIA PRIOR TO ACUTE CEREBRAL SWELLING IN SEVERE HEAD-INJURIES - THE ROLE OF TRANSCRANIAL DOPPLER MONITORING	ACTA NEUROCHIRURGICA			English	Article						CEREBRAL HYPEREMIA; TRANSCRANIAL DOPPLER; SEVERE HEAD INJURY; CEREBRAL EDEMA	BLOOD-FLOW; INTRACRANIAL-PRESSURE; VELOCITY-MEASUREMENTS; COMATOSE PATIENTS; BRAIN EDEMA; ULTRASOUND; METABOLISM; CHILDREN; ULTRASONOGRAPHY; VASOSPASM	Acute cerebrovascular congestion after a closed head injury is significantly related to intracranial hypertension. As an indirect method of cerebral blood flow measurement, transcranial doppler sonography (TCD) provides a rapid and noninvasive assessment of cerebral haemodynamics, including hyperaemic conditions. TCD examinations was serially performed in 35 patients with severe head injury with intact cerebral circulation; i.e. the mean flow velocity (MFV) patterns of the middle cerebral artery (MCA) did not show signs of cerebral circulatory arrest such as systolic spike, to and fro, or no flow. The results showed that the MFV of the MCAs and ipsilateral extracranial internal carotid arteries (ICAs) in 9 of these patients increased sharply and pulsatility index (PI) decreased during 48-96 hours after the injury. This was soon followed by patterns of high intracranial resistance, consistent with elevated intracranial pressure (ICP) in monitored patients and acute brain swelling on repeated computed tomographic (CT) scans. The correlation between increased MFVs, decreased PIs, and cerebral haemodynamic changes leading to acute brain swelling is discussed. The number of patients who ended with severe disability, vegetative state, or death was 66% in this group of 9 patients, compared to only 34% for the 35 patients overall with severe head injury. Though the morbidity and mortality rates largely depend on the primary injury, the presence of acute cerebral swelling aggravate the grave course in these patients. And the ability of TCD to monitor the hyperaemic state prior to oedema should lead us to adjust the therapy in order to minimize the secondary insult related to intracranial hypertension.	HIROSHIMA UNIV,SCH MED,DEPT NEUROSURG,HIROSHIMA 730,JAPAN; HIROSHIMA UNIV,SCH MED,DIV EMERGENCY MED & INTENS CARE MED,HIROSHIMA 730,JAPAN		MUTTAQIN, Z (corresponding author), DIPONEGORO UNIV,SCH MED,DEPT NEUROSURG,JL DR SUTOMO 18,SEMARANG,INDONESIA.						AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AASLID R, 1976, TRANSCRANIAL DOPPLER; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; HARDERS A, 1986, NEUROSURGICAL APPLIC; HASSLER W, 1988, J NEUROSURG, V68, P745; HENNERICI M, 1987, SURG NEUROL, V27, P439, DOI 10.1016/0090-3019(87)90251-5; KONTOS HA, 1989, STROKE, V20, P1; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MCHEDLISHVILI G, 1988, NEUROSURG REV, V11, P7, DOI 10.1007/BF01795688; MCHEDLISHVILI G, 1986, ARTERIAL BEHAVIOUR B; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; SHIGEMORI M, 1990, ACTA NEUROCHIR, V107, P5, DOI 10.1007/BF01402605; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	22	40	41	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1993	123	1-2					76	81		10.1007/BF01476289			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LR013	WOS:A1993LR01300012	8105640				2022-02-06	
J	GLANCY, KE; GLANCY, CJ; LUCKE, JF; MAHURIN, K; RHODES, M; TINKOFF, GH				GLANCY, KE; GLANCY, CJ; LUCKE, JF; MAHURIN, K; RHODES, M; TINKOFF, GH			A STUDY OF RECOVERY IN TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CLOSED HEAD-INJURY; SEVERITY SCORE; SOCIAL SUPPORT; BRAIN INJURY; DEATH SCORE; SCALE; CARE; PROBABILITY; DISABILITY; SYSTEMS	Although the majority of trauma patients are discharged home rather than to a rehabilitation facility, the timeliness of their return to function (RTF) has received little study. The present prospective study attempted to identify those factors that would predict delayed RTF. The study group consisted of patients admitted to a level I trauma center for at least 24 hours, who were of working age (18-64 years), who passed a cognitive screening examination, and who were discharged home. Demographic data and psychological profiles were collected on all participants. Patients were followed by telephone at approximately 1 1/2, 3, and 6 months after discharge. Five hundred seventy patients were entered into the study; complete follow-up data were available for 441. Statistical methods were modeled after survival analysis using a proportional hazards multiple regression to identify variables prognostic of RTF time. This type analysis is independent of time, providing a "risk" of RTF at any point in time after the injury. It also allowed the calculation a relative hazards ratio (RHR), which quantifies the impact of a prognostic variable on RTF time. Injury Severity Score (ISS) and age were found to be associated with RTF (p < 0.0001 for each). After correcting for ISS and age, five additional factors were found to be associated with RTF. Higher educational level and living in a non-family household were associated with faster RTF. Less than 100% income replacement by disability income, pre-injury hostility, and litigation related to the injury were associated with slower RTF. There were a number of other demographic, work-related, and psychosocial factors that were not related with RTF. We conclude that we have identified five factors in addition to ISS and age which may affect RTF. These data may suggest interventions directed at enhancing RTF.									BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BUZZARD F, 1928, P R MED SOC, V21, P353; CALES RH, 1985, ANN EMERG MED, V14, P853, DOI 10.1016/S0196-0644(85)80633-8; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; COX DR, 1985, ANAL SURVIVAL DATA; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; EPPERSON-SEBOUR M M, 1985, MMJ (Maryland Medical Journal), V34, P1187; FOEGE WH, 1985, INJURY AM CONTINUING; Gennarelli TA, 1985, ABBREVIATED INJURY S; GENSEMER IB, 1988, J TRAUMA, V28, P44, DOI 10.1097/00005373-198801000-00006; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; JACOBS JW, 1977, ANN INTERN MED, V86, P40, DOI 10.7326/0003-4819-86-1-40; KELLY MP, 1986, J CLIN PSYCHOL, V42, P318; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; LEE ET, 1985, STATISTICAL METHODS; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; SOMERS RL, 1983, ACCIDENT ANAL PREV, V15, P259, DOI 10.1016/0001-4575(83)90050-7; SOMERS RL, 1983, ACCIDENT ANAL PREV, V15, P247, DOI 10.1016/0001-4575(83)90049-0; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2; 1990, STATA REFERENCE MANU	39	40	42	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1992	33	4					602	609		10.1097/00005373-199210000-00017			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	JY184	WOS:A1992JY18400018	1433408				2022-02-06	
J	MARMAROU, A				MARMAROU, A			INTRACELLULAR ACIDOSIS IN HUMAN AND EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			EXPERIMENTAL HEAD-INJURY; CEREBRAL BLOOD-FLOW; CEREBROSPINAL-FLUID; IMPACT-ACCELERATION; OXYGEN-CONSUMPTION; LACTIC-ACIDOSIS; METABOLISM; RAT; TRAUMA; CAT	Brain tissue acidosis is considered to play a role in the complex sequence of events following traumatic brain injury. This report reviews the experimental and clinical research conducted at the Medical College of Virginia to help clarify the extent of metabolic derangement that occurs and to evaluate the effect of treatment. Experimental injury models in ventilated animals showed that trauma produces a mild brain tissue acidosis that recovers within hours of injury. Hypoxia combined with trauma produces a relative ischemia and exacerbates the acidosis, which eventually resolves with resuscitation. Other studies revealed that CSF lactate measurements should be interpreted with caution, particularly in patients with subarachnoid hemorrhage. The results of two randomized clinical trials testing therapeutic effects of sustained hyperventilation and treatment with tromethamine (THAM) are discussed.			MARMAROU, A (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,NEUROSURG RES LABS,BOX 508,MCV STN,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R56NS019235, P50NS012587, R01NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587, NS-19235] Funding Source: Medline		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; ANDERSEN BJ, 1989, J CEREB BLOOD FLOW M, V9, pS386; BERNTMAN L, 1978, ACTA PHYSIOL SCAND, V104, P101, DOI 10.1111/j.1748-1716.1978.tb06255.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARLSSON C, 1975, ACTA PHYSL SCAND, V95, P202; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FOLBERGROVA J, 1972, J NEUROCHEM, V19, P2507, DOI 10.1111/j.1471-4159.1972.tb01310.x; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAKANSON E, 1984, CLIN PHYSIOL, V4, P461, DOI 10.1111/j.1475-097X.1984.tb00132.x; HOVDA DA, 1990, ACT NEUR S, V51, P331; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; LEVI L, 1991, P AM ASS NEUROLOGICA, P288; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LIDDELL MJ, 1979, SURG GYNECOL OBSTET, V149, P822; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MILLEN JE, 1980, J APPL PHYSIOL, V49, P856, DOI 10.1152/jappl.1980.49.5.856; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; PETROFF OAC, 1986, ANN NEUROL, V20, P185, DOI 10.1002/ana.410200203; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSEN MJ, 1984, J NEUROSURG, V61, P76; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; ROVETTO MJ, 1975, CIRC RES, V37, P742, DOI 10.1161/01.RES.37.6.742; Siesj? BK., 1978, BRAIN ENERGY METABOL; SOOD SC, 1980, ACTA NEUROCHIR, V53, P47, DOI 10.1007/BF02074520; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	39	40	40	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S551	S562					12	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900012	1613813				2022-02-06	
J	MAZZUCCHI, A; CATTELANI, R; MISSALE, G; GUGLIOTTA, M; BRIANTI, R; PARMA, M				MAZZUCCHI, A; CATTELANI, R; MISSALE, G; GUGLIOTTA, M; BRIANTI, R; PARMA, M			HEAD-INJURED SUBJECTS AGED OVER 50 YEARS - CORRELATIONS BETWEEN VARIABLES OF TRAUMA AND NEUROPSYCHOLOGICAL FOLLOW-UP	JOURNAL OF NEUROLOGY			English	Article						AGING; HEAD INJURY; MENTAL DETERIORATION; DEMENTIA	COGNITIVE SEQUELAE; CONSECUTIVE SERIES; BRAIN INJURY; MEMORY; PROGNOSIS; RECOVERY; MODERATE; SCALE	Neuropsychological follow-up was studied in 70 consecutive head-injured subjects aged over 50 years. Diffuse deterioration (28%), moderate deterioration (25%) and dementia (21%) were the most frequent sequelae. Analysis of correlations between neuropsychological sequelae and trauma variables showed that: (1) mild trauma did not necessarily imply good prognosis and could be followed by very severe consequences; (2) duration of post-traumatic amnesia was correlated with coma duration but not with neuropsychological outcome; (3) on the whole, no prognostic predictor of the outcome was found.			MAZZUCCHI, A (corresponding author), UNIV PARMA,DEPT NEUROL,NEUROPSYCHOL UNIT,STR QUARTIERE 4,I-43100 PARMA,ITALY.		Brianti, Rodolfo/H-2152-2013; Missale, Gabriele/J-6083-2016	Brianti, Rodolfo/0000-0001-8069-3502; Missale, Gabriele/0000-0001-6691-8701			Agresti A., 1984, ANAL ORDINAL CATEGOR; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROOKS D N, 1974, Cortex, V10, P224; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DERENZI E, 1975, CORTEX, V11, P33; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Everitt B. S., 1977, ANAL CONTINGENCY TAB; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1981, MANAGEMENT HEAD INJU, P317; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Mazzucchi A, 1984, Riv Neurol, V54, P1; MEIER MJ, 1983, MAY ANN M MIDW PSYCH; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; Raven J. C., 1938, STANDARD PROGR MATRI; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Spinnler H, 1987, ITAL J NEUROL SCI S, V8; STREET RF, 1931, CONTRIBUTIONS ED, V481; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VILKKI J, 1988, J NEUROL NEUROSUR PS, V51, P1452, DOI 10.1136/jnnp.51.11.1452; Wechsler D., 1958, MEASUREMENT APPRAISA; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; WILSON R S, 1979, Journal of Clinical Neuropsychology, V1, P49, DOI 10.1080/01688637908401097; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	43	40	40	0	4	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-5354			J NEUROL	J. Neurol.	MAY	1992	239	5					256	260					5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HT306	WOS:A1992HT30600005	1607886				2022-02-06	
J	GOLDSTEIN, LH; POLKEY, CE				GOLDSTEIN, LH; POLKEY, CE			BEHAVIORAL MEMORY AFTER TEMPORAL LOBECTOMY OR AMYGDALO-HIPPOCAMPECTOMY	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							SEVERE HEAD-INJURY; EVERYDAY MEMORY; FAILURES; EPILEPSY	A total of 46 patients who had undergone surgery for the relief of temporal lobe epilepsy were tested on the Rivermead Behavioural Memory Test (RBMT) and two traditional tests of memory. The patient and a relative or close friend were also asked to complete a questionnaire about the everyday memory problems experienced by the patients. Scores on the RBMT failed to distinguish between patients who had undergone either a traditional en bloc temporal lobectomy or a more restricted resection, the amygdalo-hippocampectomy, although scores on one of the traditional memory tests did. Epilepsy-related variables did not alter the outcome of data analyses. Only relatives' questionnaire ratings of patients' memory correlated with patients' scores on the RBMT.	MAUDSLEY HOSP & INST PSYCHIAT,NEUROSURG UNIT,LONDON SE5 8AZ,ENGLAND		GOLDSTEIN, LH (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Goldstein, Laura/E-7817-2010	Goldstein, Laura/0000-0001-9387-3035			BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENNETTLEVY J, 1980, CORTEX, V18, P513; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; GOLDSTEIN LH, 1991, J ROY SOC MED, V84, P460, DOI 10.1177/014107689108400806; JONESGOTMAN M, 1987, SURGICAL TREATMENT E; LINCOLN NB, 1989, BRIT J CLIN PSYCHOL, V28, P61, DOI 10.1111/j.2044-8260.1989.tb00812.x; POLKEY CE, 1989, J NEUROL NEUROSUR PS, V52, P1050, DOI 10.1136/jnnp.52.9.1050; POLKEY CE, 1987, SURGICAL TREATMENT E; POWELL GE, 1985, BRIT J CLIN PSYCHOL, V24, P109, DOI 10.1111/j.2044-8260.1985.tb01321.x; POWELL GE, 1987, J NEUROL NEUROSUR PS, V50, P665, DOI 10.1136/jnnp.50.6.665; POWELL GE, 1979, J CLIN PSYCHOL, V35, P335, DOI 10.1002/1097-4679(197904)35:2<335::AID-JCLP2270350223>3.0.CO;2-4; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; WIESER HG, 1982, SURG NEUROL, V17, P445, DOI 10.1016/S0090-3019(82)80016-5; WILSON B, 1987, REHABILITATION MEMOR; Wilson BA., 1985, RIVERMEAD BEHAVIOURA	17	40	41	0	1	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER, LEICS, ENGLAND LE1 7DR	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	FEB	1992	31		1				75	81		10.1111/j.2044-8260.1992.tb00969.x			7	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	HE518	WOS:A1992HE51800006	1559119				2022-02-06	
J	BOUCHER, BA; KUHL, DA; FABIAN, TC; ROBERTSON, JT				BOUCHER, BA; KUHL, DA; FABIAN, TC; ROBERTSON, JT			EFFECT OF NEUROTRAUMA ON HEPATIC DRUG CLEARANCE	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							SEVERE HEAD-INJURY; INDOCYANINE GREEN; METABOLIC RESPONSE; TRAUMA PATIENTS; PLASMA-LEVELS; PHARMACOKINETICS; ANTIPYRINE; DISPOSITION; INDUCTION; LORAZEPAM	Lorazepam, antipyrine, and indocyanine green were administered to 10 patients with severe head injuries as marker substrates of hepatic glucuronidation, oxidation, and hepatic blood flow, respectively. Pharmacokinetic parameter estimates were determined at baseline (20 to 80 hours after injury) and up to three additional times thereafter (study days 4, 7, and 14). Antipyrine clearance was increased significantly from baseline (0.50 +/- 0.31 ml/min/kg) on study days 4, 7, and 14 (p < 0.0001). Increases in antipyrine clearance from baseline to the last study day were observed in all study patients ranging from 14% to 207%. A significant increase was also observed in lorazepam clearance on study day 14 relative to baseline (1.39 +/- 0.56 ml/min/kg) (p < 0.005). Increases in lorazepam clearance occurred in seven of nine patients over time ranging from 9% to 13O%. The unbound fraction of lorazepam did not change significantly over the study period. Likewise, no significant change was observed in the clearance of indocyanine green over time. Antipyrine clearance and alpha-1-acid glycoprotein (r = 0.41), and lorazepam clearance and C-reactive protein (r = -0.38) were significantly correlated (p < 0.05). Similarly, antipyrine and lorazepam clearances were significantly correlated with injury severity based on the Acute Physiologic and Chronic Health Evaluation (APACHE II) score (r = -0.43 and r = -O.37, respectively). These findings suggest that hepatic oxidative and conjugative metabolism increase significantly over time in patients after acute head injury. An awareness of the potential for pharmacokinetic alterations in similarly metabolized drugs used for patients with severe head injuries is recommended.	UNIV TENNESSEE CTR HLTH SCI,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT NEUROSURG,MEMPHIS,TN 38163; REG MED CTR,MEMPHIS,TN		BOUCHER, BA (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT CLIN PHARM,26 S DUNLAP,ROOM 202,MEMPHIS,TN 38163, USA.						ANDREASEN PB, 1974, CLIN PHARMACOL THER, V16, P1059; BACHMANN KA, IN PRESS XENOBIOTICA; BAYLIFF CD, 1985, CLIN PHARMACOL THER, V38, P457, DOI 10.1038/clpt.1985.204; BOUCHER BA, 1988, CLIN PHARMACOL THER, V44, P675, DOI 10.1038/clpt.1988.211; BURCZYNSKI FJ, 1987, AM J PHYSIOL, V252, pH953, DOI 10.1152/ajpheart.1987.252.5.H953; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CROM WR, 1987, CLIN PHARMACOL THER, V41, P645, DOI 10.1038/clpt.1987.90; DANHOF M, 1982, BRIT J CLIN PHARMACO, V13, P379, DOI 10.1111/j.1365-2125.1982.tb01389.x; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; Gibaldi M, 1982, PHARMACOKINETICS REV, V2nd, P45; GOTTLIEB ME, 1984, ARCH SURG-CHICAGO, V119, P264; HEINEMEYER G, 1986, THER DRUG MONIT, V8, P145, DOI 10.1097/00007691-198606000-00003; HERMAN RJ, 1989, CLIN PHARMACOL THER, V46, P18, DOI 10.1038/clpt.1989.101; HUANG J, 1983, J PHARM SCI, V72, P1368, DOI 10.1002/jps.2600721137; KAUFMAN HH, 1987, NEUROSURGERY, V20, P254, DOI 10.1227/00006123-198702000-00010; KHOLOUSSY AM, 1984, CRIT CARE MED, V12, P115, DOI 10.1097/00003246-198402000-00007; KIRKWOOD CF, 1986, J TRAUMA, V26, P1090, DOI 10.1097/00005373-198612000-00005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRAUS JW, 1978, CLIN PHARMACOL THER, V24, P411; LOFT S, 1987, EUR J CLIN PHARMACOL, V32, P35, DOI 10.1007/BF00609955; MARTYN J, 1987, CLIN PHARMACOL THER, V43, P250; MARTYN JAJ, 1983, ANESTH ANALG, V62, P293; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PECK CC, 1984, J PHARMACOKINET BIOP, V12, P545, DOI 10.1007/BF01060132; PERKINS MW, 1989, DICP ANN PHARMAC, V23, P316, DOI 10.1177/106002808902300408; POLLACK DS, 1979, SURG GYNECOL OBSTET, V149, P852; POWELL JR, 1986, APPLIED PHARMACOKINE, P139; REISTER EF, 1980, CLIN PHARMACOL THER, V28, P384; RELLING MV, 1987, CLIN PHARMACOL THER, V41, P651, DOI 10.1038/clpt.1987.91; SKAK C, 1987, LIVER, V7, P155; VESELL ES, 1979, CLIN PHARMACOL THER, V26, P287; WERMELING DP, 1987, DRUG INTEL CLIN PHAR, V21, P459, DOI 10.1177/106002808702100517; WILKINSON GR, 1975, CLIN PHARMACOL THER, V18, P377; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	34	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0009-9236			CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	NOV	1991	50	5	1				487	497		10.1038/clpt.1991.173			11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GT114	WOS:A1991GT11400002	1934861				2022-02-06	
J	GEFFEN, GM; ENCEL, JS; FORRESTER, GM				GEFFEN, GM; ENCEL, JS; FORRESTER, GM			STAGES OF RECOVERY DURING POSTTRAUMATIC AMNESIA AND SUBSEQUENT EVERYDAY MEMORY DEFICITS	NEUROREPORT			English	Article						PTA SCALE; BRAIN INJURY; EVERYDAY MEMORY; INDEX OF SEVERITY	HEAD-INJURY; SCALE; VALIDATION; COMA	POST-TRAUMATIC amnesia (PTA) is the period following brain trauma when patients are unable to acquire and retain information. Nineteen patients with brain injury were assessed for PTA, with a new scale, after they regained consciousness, every 24 h. Patients recovered orientation and their capacity to recognise new information, and finally their ability to recall this information. The longer the duration of PTA, the poorer was performance on an everyday memory test given one month after recovery from PTA. Patients with orthopaedic injuries and without brain injury showed minimal impairment on the PTA scale. The predictive value of the scale (multiple R = 0.88) with respect to subsequent everyday memory performance indicates its usefulness as an index of severity of brain injury.	FLINDERS UNIV,ADELAIDE,AUSTRALIA		GEFFEN, GM (corresponding author), JULIA FARR CTR,NEUROPSYCHOL RES UNIT,103 FISHER ST,ADELAIDE,SA 5063,AUSTRALIA.						ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BROOKS DN, 1983, REHABILITATION HEAD, P185; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Levin HS., 1982, NEUROBEHAVIORAL CONS; Nelson H. E, 1982, NATIONAL ADULT READI; RICHARDSON JTE, 1984, COGN NEUROPSYCHOL, V1, P217, DOI 10.1080/02643298408252023; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson BA., 1985, RIVERMEAD BEHAVIOURA	18	40	41	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	FEB	1991	2	2					105	108		10.1097/00001756-199102000-00010			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FA926	WOS:A1991FA92600010	1883986				2022-02-06	
J	JOHANSSON, E; RONNKVIST, M; FUGLMEYER, AR				JOHANSSON, E; RONNKVIST, M; FUGLMEYER, AR			TRAUMATIC BRAIN INJURY IN NORTHERN SWEDEN - INCIDENCE AND PREVALENCE OF LONG-STANDING IMPAIRMENTS AND DISABILITIES	SCANDINAVIAN JOURNAL OF REHABILITATION MEDICINE			English	Article						TRAUMATIC BRAIN INJURY; BRAIN INJURY; BRAIN CONCUSSION; INCIDENCE; IMPAIRMENT; DISABILITY		Based on a retrospective survey of hospital admissions and autopsies the incidence of traumatic brain injury (TBI) for the age range 16-60 was found to be 24.9/10 000 in the Umea district of Northern Sweden. In male youngsters aged 16-19 the incidence was remarkably high in comparison with reports from other parts of the western hemisphere. Self-reports on the prevalence of impairments and disabilities 11/2-3 years after the injury were obtained by a mailed questionnaire. Among the subjects with brain concussion 1/3 reported impairments and 1/10 disabilities, most commonly leisure-disability. By factor analysis impairments and disabilities could be logically grouped into three factors. Two of these factors clearly circumscribed combinations of impairments and disabilities, one of them being dominated by instrumental ADL, the other by basic self-care ADL. The third factor incorporated the classic post-concussion triad and memory. Taken together the findings indicate that many subjects with an early diagnosis of brain concussion, hospitalized for only one day, experienced losses in pre-injury functions and abilities. It is therefore suggested that not only radiologically and/or operatively confirmed TBIs but also subjects with brain concussion should be followed after discharge in order to minimize losses in social well-being.	UMEA UNIV HOSP,DEPT PHYS MED & REHABIL,S-90185 UMEA,SWEDEN									0	40	41	0	10	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5505			SCAND J REHABIL MED	Scand. J. Rehabil. Med.		1991	23	4					179	185					7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	GZ301	WOS:A1991GZ30100001	1838430				2022-02-06	
J	ROBINSON, SE; FOXX, SD; POSNER, MG; MARTIN, RM; DAVIS, TR; GUO, HZ; ENTERS, EK				ROBINSON, SE; FOXX, SD; POSNER, MG; MARTIN, RM; DAVIS, TR; GUO, HZ; ENTERS, EK			THE EFFECT OF M1 MUSCARINIC BLOCKADE ON BEHAVIOR AND PHYSIOLOGICAL-RESPONSES FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article											ROBINSON, SE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24413, NS07288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024413] Funding Source: NIH RePORTER		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ASHE JH, 1984, NEUROPHARMACOLOGY, V23, P1321, DOI 10.1016/0028-3908(84)90053-4; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349, DOI 10.1152/jn.1946.9.5.349; BROWN DA, 1983, TRENDS NEUROSCI, V6, P302, DOI 10.1016/0166-2236(83)90144-3; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EGLEN RM, 1986, J AUTON PHARMACOL, V5, P323; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FISHER SK, 1987, J NEUROCHEM, V48, P999, DOI 10.1111/j.1471-4159.1987.tb05618.x; GIACHETTI A, 1986, BRIT J PHARMACOL, V89, P83, DOI 10.1111/j.1476-5381.1986.tb11123.x; GIL DW, 1986, J PHARMACOL EXP THER, V237, P577; GOWER AJ, 1987, EUR J PHARMACOL, V139, P79, DOI 10.1016/0014-2999(87)90500-0; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAGAN JJ, 1988, N-S ARCH PHARMACOL, V338, P476, DOI 10.1007/BF00179317; HAYES RL, 1984, SCIENCE, V233, P301; HOSS W, 1985, INT REV NEUROBIOL, V26, P151, DOI 10.1016/S0074-7742(08)60074-4; ISHII S, 1969, LATE EFFECTS HEAD IN, P123; KEPPEL G, 1982, DESIGN ANAL RES HDB; KUNYSZ EL, 1988, BRIT J PHARMACOL, V93, P491, DOI 10.1111/j.1476-5381.1988.tb10303.x; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MCGEER E, 1985, CAN J PHARM, V64, P363; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MOCHIDA S, 1988, BRAIN RES, V455, P9, DOI 10.1016/0006-8993(88)90107-2; Newcombe F, 1980, Int Rehabil Med, V2, P133; OLNEY JW, 1983, BRAIN RES BULL, V10, P699, DOI 10.1016/0361-9230(83)90038-2; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; RASCOL O, 1988, BRAIN RES, V446, P303, DOI 10.1016/0006-8993(88)90889-X; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBINSON SE, IN PRESS BRAIN RES; ROSNER MJ, 1982, 5TH P INT S INTR PRE, P154; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUGE D, 1946, J NEUROSURG, V11, P77; RUTHERFORD WH, 1977, LANCET, V1, P1; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Toglia JU, 1969, LATE EFFECTS HEAD IN, P72; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; TURSKI WA, 1983, EXPERIENTIA, V39, P1408, DOI 10.1007/BF01990130; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEISS SJ, 1982, BIOCHEM J, P587; Winer BJ., 1971, STAT PRINCIPLES EXPT	54	40	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 12	1990	511	1					141	148		10.1016/0006-8993(90)90233-2			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CX001	WOS:A1990CX00100016	2331611				2022-02-06	
J	RICHARDS, JS; BROWN, L; HAGGLUND, K; BUA, G; REEDER, K				RICHARDS, JS; BROWN, L; HAGGLUND, K; BUA, G; REEDER, K			SPINAL-CORD INJURY AND CONCOMITANT TRAUMATIC BRAIN INJURY - RESULTS OF A LONGITUDINAL INVESTIGATION	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article									UNIV ALABAMA,DEPT REHABIL MED,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35233					Hagglund, Kristofer/0000-0001-7748-7492			BENTON A L, 1978, Archives of Neurology, V35, P364; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BOLL TJ, 1981, HDB CLIN NEUROPSYCHO; BUSCHKE J, 1974, NEUROLOGY, V11, P1019; COLOHAN RT, 1986, J HEAD TRAUMA REHABI, V1, P13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DEWOLFE AS, 1971, J CONSULT CLIN PSYCH, V36, P197, DOI 10.1037/h0030731; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; DRICKER J, 1978, NEUROPSYCHOLOGIA, V16, P683, DOI 10.1016/0028-3932(78)90003-9; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; HAMSHER KD, 1979, ARCH NEUROL-CHICAGO, V36, P837, DOI 10.1001/archneur.1979.00500490051008; HARRIS P, 1986, PARAPLEGIA, V5, P215; KEREKJARTO M, 1962, 23 K DTSCH GES PSYCH; LABATE L, 1963, J CLIN PSYCHOL, V19, P87, DOI 10.1002/1097-4679(196301)19:1<87::AID-JCLP2270190113>3.0.CO;2-N; LABATE L, 1962, J CONSULT PSYCHOL, V26, P479; LANDSDELL H, 1977, J CONSULT CLIN PSYCH, V45, P412; LARRABEE GJ, 1983, J CLIN NEUROPSYCHOL, V5, P159, DOI 10.1080/01688638308401162; LEZAK MD, 1982, 5TH EUR C INT NEUR S; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; PENDLETON MG, 1982, J CLIN PSYCHOL, V38, P392, DOI 10.1002/1097-4679(198204)38:2<392::AID-JCLP2270380232>3.0.CO;2-W; PORTER RW, 1977, 19TH P VET ADM SPIN, P188; REY A, 1964, EXAMEN CLIN PSYCHIOL; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SCHUENEMAN A, 1982, SCI DIG, V4, P35; SHAW DJ, 1966, J CLIN PSYCHOL, V22, P176, DOI 10.1002/1097-4679(196604)22:2<176::AID-JCLP2270220215>3.0.CO;2-O; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; STOVER SL, 1986, SPINAL CORD INJURY F; Talland G.A., 1965, DERANGED MEMORY; WAGNER KA, 1984, P AM SPINAL INJURY A, P96; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; Young J.S., 1982, SPINAL CORD INJURY S; ZUBRICK S, 1978, 6TH INT NEUR SOC M M	33	40	41	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	1988	67	5					211	216		10.1097/00002060-198810000-00005			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	Q9739	WOS:A1988Q973900005	3179011				2022-02-06	
J	Hall, ED; Braughler, JM; McCall, JM				Hall, Edward D.; Braughler, J. Mark; McCall, John M.			New Pharmacological Treatment of Acute Spinal Cord Trauma	JOURNAL OF NEUROTRAUMA			English	Article								Numerous experimental studies of blunt spinal cord injury have shown that while a variable degree of immediate mechanical damage occurs to spinal blood vessels and axons in proportion to the magnitude of the injury force, a considerable amount of posttraumatic tissue degeneration is due to a secondary pathophysiological process that may be modifiable by appropriate therapeutic intervention. A growing body of biochemical, physiological, and pharmacological evidence has suggested that oxygen free radical-induced lipid peroxidation, working in concert with aberrant calcium fluxes and eicosanoid generation in particular, plays a key role in progressive post-traumatic spinal cord degeneration. Of particular importance, lipid peroxidation has been linked to microvascular damage and hypoperfusion which, if severe enough, can lead to a secondary ischemie insult to the tissue. The ability of intensive dosing with the glucocorticoid steroid methylprednisolone to beneficially affect post-traumatic ischemia and to promote chronic neurologic recovery in spinal cord injured animals has been correlated not with its glucocorticoid activity, but rather with the ability to inhibit post-traumatic spinal lipid peroxidation. In view of this, a novel series of non-glucocorticoid 21-aminosteroids has been developed which lack glucocorticoid activity but are more effective inhibitors of nervous tissue lipid peroxidation than the glucocorticoid steroids. One of these, U74006F, has now been studied in some detail and appears to be a promising new agent for the acute treatment of spinal cord (and brain) trauma. The background and pre-clinical development of this compound to date is reviewed.	[Hall, Edward D.; Braughler, J. Mark; McCall, John M.] Upjohn Co, Cent Nervous Syst Dis Res Unit, Kalamazoo, MI 49001 USA		Hall, ED (corresponding author), Upjohn Co, Cent Nervous Syst Dis Res Unit, Kalamazoo, MI 49001 USA.		Hall, Edward D/F-8930-2013				ANDERSON D K, 1987, Society for Neuroscience Abstracts, V13, P1499; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1982, J NEUROSURG, V56, P106, DOI 10.3171/jns.1982.56.1.0106; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P1; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRAUGHLER JM, 1988, J PHARMACOL EXP THER, V244, P423; BRAUGHLER JM, 1983, J NEUROSURG, V58, P538; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CLARK CR, 1981, BRAIN RES, V217, P412, DOI 10.1016/0006-8993(81)90020-2; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Dimlich R. V. W., 1987, TRIENN M INT SOC STU; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; Haynes Jr RC, 1985, PHARMACOL BASIS THER, P1459; IIZUKA H, 1986, J NEUROSURG, V65, P92, DOI 10.3171/jns.1986.65.1.0092; Kontos H.A., 1987, CNS TRAUMA, V3, P257; SAMUELS HH, 1970, J MOL BIOL, V52, P57, DOI 10.1016/0022-2836(70)90177-4; Windle W.F., 1980, SPINAL CORD ITS REAC, P205; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; YOUNG W, 1985, CENTRAL NERVOUS SYST, P463	29	40	41	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	1					81	89		10.1089/neu.1988.5.81			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V22HC	WOS:000208265300007	3057217				2022-02-06	
J	Sulhan, S; Lyon, KA; Shapiro, LA; Huang, JH				Sulhan, Suraj; Lyon, Kristopher A.; Shapiro, Lee A.; Huang, Jason H.			Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article; Proceedings Paper	17th International Conference on Brain Edema and Cellular Injury	DEC 08-10, 2017	Guangzhou, PEOPLES R CHINA			Blood-brain barrier; brain edema; neuroinflammation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; MATRIX METALLOPROTEINASES; NLRP3 INFLAMMASOME; AXONAL INJURY; DOUBLE-BLIND; FUNCTIONAL RECOVERY; TRANEXAMIC ACID; CEREBRAL EDEMA; NITRIC-OXIDE; RAT MODEL	Traumatic Brain Injury (TBI) is the most frequent cause of death and disability in young adults and children in the developed world, occurring in over 1.7 million persons and resulting in 50,000 deaths in the United States alone. The Centers for Disease Control and Prevention estimate that between 3.2 and 5.3 million persons in the United States live with a TBI-related disability, including several neurocognitive disorders and functional limitations. Following the primary mechanical injury in TBI, literature suggests the presence of a delayed secondary injury involving a variety of neuroinflammatory changes. In the hours to days following a TBI, several signaling molecules and metabolic derangements result in disruption of the blood-brain barrier, leading to an extravasation of immune cells and cerebral edema. The primary, sudden injury in TBI occurs as a direct result of impact and therefore cannot be treated, but the timeline and pathophysiology of the delayed, secondary injury allows for a window of possible therapeutic options. The goal of this review is to discuss the pathophysiology of the primary and delayed injury in TBI as well as present several preclinical studies that identify molecular targets in the potential treatment of TBI. Additionally, certain recent clinical trials are briefly discussed to demonstrate the current state of TBI investigation.	[Sulhan, Suraj; Lyon, Kristopher A.; Huang, Jason H.] Baylor Scott & White Neurosci Inst, Dept Neurosurg, Temple, TX 76504 USA; [Sulhan, Suraj; Lyon, Kristopher A.; Shapiro, Lee A.; Huang, Jason H.] Texas A&M Univ, Coll Med, Temple, TX 76508 USA		Huang, JH (corresponding author), Baylor Scott & White Neurosci Inst, Dept Neurosurg, Temple, TX 76504 USA.	jason.huang@bswhealth.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168; Sulhan, Suraj/0000-0002-6462-4635	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS067435] Funding Source: Medline		Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alluri H, 2016, J BIOL CHEM, V291, P26958, DOI 10.1074/jbc.M116.735365; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Ashafaq M, 2012, NEUROCHEM RES, V37, P1747, DOI 10.1007/s11064-012-0786-1; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bai XF, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009532; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barrett EC, 2014, ADV NUTR, V5, P268, DOI 10.3945/an.113.005280; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Bralic M, 2012, COLLEGIUM ANTROPOL, V36, P1319; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fakharian E, 2018, WORLD NEUROSURG, V109, pE748, DOI 10.1016/j.wneu.2017.10.075; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hammond FM, 2015, J NEUROTRAUM, V32, P1230, DOI 10.1089/neu.2014.3803; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Hsieh HL, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-88; Hunt BJ, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12910; Jiang ZX, 2017, EXP PHYSIOL, V102, P1269, DOI 10.1113/EP086520; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kanazawa M, 2015, BRAIN, V138, P1932, DOI 10.1093/brain/awv079; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim A, 2018, J MOV DISORD, V11, P65, DOI 10.14802/jmd.18005; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li ZM, 2016, CLIN NEUROL NEUROSUR, V150, P80, DOI 10.1016/j.clineuro.2016.09.001; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YL, 2017, ACTA PHARMACOL SIN, V38, P1445, DOI 10.1038/aps.2017.103; Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070; Mandel SA, 2008, CNS NEUROSCI THER, V14, P352, DOI 10.1111/j.1755-5949.2008.00060.x; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Menzel L, 2017, GLIA, V65, P278, DOI 10.1002/glia.23091; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakase Hiroyuki, 2006, Neurosurgery, V58, pE1219, DOI 10.1227/01.NEU.0000215996.62828.76; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nikolian VC, 2018, CRIT CARE MED, V46, pE59, DOI 10.1097/CCM.0000000000002800; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Park ES, 2014, CARDIOVASC TOXICOL, V14, P1, DOI 10.1007/s12012-013-9232-0; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Samadani U., 2016, WILL CLIN TRIAL TRAU; Sangobowale MA, 2018, J NEUROTRAUM, V35, P907, DOI 10.1089/neu.2017.5348; Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com; Sorby-Adams AJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081788; Spritzer SD, 2015, NEUROLOGIST, V19, P61, DOI 10.1097/NRL.0000000000000001; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tian QY, 2014, METHODS MOL BIOL, V1155, P163, DOI 10.1007/978-1-4939-0669-7_14; Tuli HS, 2013, LIFE SCI, V93, P863, DOI 10.1016/j.lfs.2013.09.030; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang HY, 2013, MOL NEUROBIOL, V48, P452, DOI 10.1007/s12035-013-8432-8; Zhao HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23286; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	99	39	41	8	40	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN	2020	98	1					19	28		10.1002/jnr.24331			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	JM0CE	WOS:000495891200003	30259550	Green Accepted			2022-02-06	
J	Trivedi, B; Kesterke, MJ; Bhattacharjee, R; Weber, W; Mynar, K; Reddy, LV				Trivedi, Bhavin; Kesterke, Matthew J.; Bhattacharjee, Ritesh; Weber, William; Mynar, Karen; Reddy, Likith, V			Craniofacial Injuries Seen With the Introduction of Bicycle-Share Electric Scooters in an Urban Setting	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							BIKE-SHARE; USERS; ROAD	Purpose: Standing electric scooters (e-scooters) are rapidly becoming popular modes of transportation in many urban areas across the United States. However, this increase in popularity has resulted in an increase in traumatic injuries associated with these modes of expedient travel. The purpose of the present study was to determine the types of craniofacial trauma directly related to e-scooter use in a major urban center (Dallas, TX). Materials and Methods: We performed a retrospective case series and examined the medical records of the patients who had presented to the emergency department (ED) for trauma related to e-scooter use. Descriptive statistics were calculated for all variables on patient presentation, including incident notes and patient interviews, demographic information, diagnostic tests, trauma (ie, location, type, severity), treatment (ie, type, admission, outpatient referral, follow-up data), and contributing factors (ie, reported or detected alcohol use, use of protective equipment). Results: A total of 90 patients (56 males, 34 females; mean age, 31.8 years) had presented with scooter-related trauma to the ED during the first 7 months of scooters after their introduction to the metropolitan area. A total of 52 admissions (58% of all admissions) involved injuries of the head and face. The patients had presented with a myriad of craniofacial trauma, ranging from abrasions, lacerations, and concussions to intracranial hemorrhage and Le Fort II and III fractures. Of the 52 craniofacial injuries, 30 (58%) were considered severe (ie, fracture, internal hemorrhage, concussion, loss of consciousness), and 22 (42%) were considered minor (ie, lacerations, contusion, abrasion, dental). Alcohol use had been involved in 18% of all scooter-related trauma admissions, and no rider had reported wearing a helmet. Conclusions: Injuries to the head and face were commonly found with e-scooter admissions in this sample, and the high prevalence of extremity injuries suggested that patients were breaking their fall during the crash. Craniofacial trauma related to e-scooter use could be significantly reduced by the wearing of a protective helmet. Published by Elsevier Inc. on behalf of the American Association of Oral and Maxillofacial Surgeons	[Trivedi, Bhavin; Reddy, Likith, V] Texas A&M Coll Dent, Dept Oral & Maxillofacial Surg, Dallas, TX 75246 USA; [Trivedi, Bhavin] Baylor Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Waco, TX 76798 USA; [Trivedi, Bhavin] US Navy Dent Corps, Dallas, TX USA; [Kesterke, Matthew J.; Bhattacharjee, Ritesh] Texas A&M Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA; [Weber, William; Mynar, Karen] Baylor Univ, Med Ctr, Div Trauma Crit Care & Acute Care Surg, Dallas, TX USA; [Reddy, Likith, V] Texas A&M Coll Dent, Residency Program, Dallas, TX 75246 USA; [Reddy, Likith, V] Baylor Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Dallas, TX USA		Kesterke, MJ (corresponding author), Texas A&M Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA.	kesterke@tamu.edu		Bhattacharjee, Ritesh/0000-0001-5209-3331			Allem JP, 2019, PREV MED REP, V13, P62, DOI 10.1016/j.pmedr.2018.11.013; [Anonymous], 2018, BIC OTH CYCL 2016 DA; Bach T, US NEWS WORLD REPORT; Fishman E, 2016, J SAFETY RES, V56, P41, DOI 10.1016/j.jsr.2015.11.007; Friedman SM, 2016, CAN J EMERG MED, V18, P28, DOI 10.1017/cem.2015.22; Graves JM, 2014, AM J PUBLIC HEALTH, V104, pE106, DOI 10.2105/AJPH.2014.302012; Griffin R, 2008, AMBUL PEDIATR, V8, P379, DOI 10.1016/j.ambp.2008.08.002; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; Langford BC, 2015, ACCIDENT ANAL PREV, V82, P220, DOI 10.1016/j.aap.2015.05.016; Papoutsi S, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/850236; Popovich N, 2014, TRAVEL BEHAV SOC, V1, P37, DOI 10.1016/j.tbs.2013.10.006; Rogers M, DOCKLESS VEHICLES PR; Siman-Tov M, 2018, J TRANSP HEALTH, V11, P176, DOI 10.1016/j.jth.2018.10.013; Trivedi TK, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7381; Yao L, 2012, TRANSPORT RES REC, P49, DOI 10.3141/2314-07	15	39	39	5	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	NOV	2019	77	11					2292	2297		10.1016/j.joms.2019.07.014			6	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Dentistry, Oral Surgery & Medicine	JH9KD	WOS:000493086000018	31454504	Bronze			2022-02-06	
J	Li, Q; Li, QQ; Jia, JN; Sun, QY; Zhou, HH; Jin, WL; Mao, XY				Li, Qin; Li, Qiu-Qi; Jia, Ji-Ning; Sun, Qian-Yi; Zhou, Hong-Hao; Jin, Wei-Lin; Mao, Xiao-Yuan			Baicalein Exerts Neuroprotective Effects in FeCl3-Induced Posttraumatic Epileptic Seizures via Suppressing Ferroptosis	FRONTIERS IN PHARMACOLOGY			English	Article						posttraumatic epileptic seizures; baicalein; 12/15-lipoxygenase; lipid peroxidation; ferroptosis; neuroprotective	AMYLOID-BETA-PEPTIDE; OXIDATIVE STRESS; CELL-DEATH; IN-VITRO; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; MOUSE MODEL; RAT MODEL; BRAIN	Posttraumatic epilepsy (PTE) is a prevalent type of acquired epilepsy secondary to traumatic brain injury, and is characterized by repeated seizures. Traditional antiepileptic drugs have minimal response in preventing posttraumatic epileptic seizures. It is essential for the development of new therapeutic strategy. Our previous work disclosed a potent neuroprotective role of baicalein, a flavonoid extracted from Scutellaria baicalensis Georgi, against inherited epilepsy in rats. Whether baicalein has protective potential in posttraumatic epileptic seizures and the possible molecular mechanism remain elusive. Additionally, the brain is vulnerable to lipid peroxidation-induced damage due to high consumption of oxygen and abundant polyunsaturated fatty acids in neuronal membranes. Our present investigation aimed to elucidate whether baicalein exerts neuroprotective effects on posttraumatic epileptic seizures by inhibiting ferroptosis, a newly discovered lipid peroxidation-dependent cell death modality. We found that baicalein significantly reduced seizure score, number of seizures, and average seizure duration in an iron chloride (FeCl3)-induced PTE mouse model. The neuroprotective effect of baicalein was also validated in a ferric ammonium citrate (FAC)-induced HT22 hippocampal neuron damage model. Moreover, in vitro, baicalein could remarkably decrease ferroptotic indices (lipid reactive oxygen species, 4-hydroxynonenal, and prostaglandin endoperoxide synthase 2) and inhibit the expression of 12/15-lipoxygenase (12/15-LOX) in an iron-induced HT22 cell damage model. These findings were also validated in a mouse PTE model. It was concluded that baicalein exerted neuroprotective effects against posttraumatic epileptic seizures via suppressing ferroptosis and 12/15-LOX was likely to be involved in baicalein's neuroprotection.	[Li, Qin; Li, Qiu-Qi; Jia, Ji-Ning; Sun, Qian-Yi; Zhou, Hong-Hao; Mao, Xiao-Yuan] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China; [Li, Qin; Li, Qiu-Qi; Jia, Ji-Ning; Sun, Qian-Yi; Zhou, Hong-Hao; Mao, Xiao-Yuan] Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China; [Li, Qin; Li, Qiu-Qi; Jia, Ji-Ning; Sun, Qian-Yi; Zhou, Hong-Hao; Mao, Xiao-Yuan] Minist Educ, Engn Res Ctr Appl Technol Pharmacogenom, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China; [Li, Qin; Li, Qiu-Qi; Jia, Ji-Ning; Sun, Qian-Yi; Zhou, Hong-Hao; Mao, Xiao-Yuan] Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China; [Jin, Wei-Lin] Guangxi Univ Chinese Med, Ruikang Hosp, Ctr Translat Med, Nanning, Peoples R China; [Jin, Wei-Lin] Shanghai Jiao Tong Univ, Inst Nano Biomedicine & Engn, Sch Elect Informat & Elect Engn, Minist Educ,Dept Instrument Sci & Engn,Key Lab Th, Shanghai, Peoples R China; [Jin, Wei-Lin] Xian Med Univ, Shaanxi Key Lab Brain Disorders, Xian, Shaanxi, Peoples R China; [Jin, Wei-Lin] Xian Med Univ, Inst Basic & Translat Med, Xian, Shaanxi, Peoples R China		Mao, XY (corresponding author), Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.; Mao, XY (corresponding author), Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China.; Mao, XY (corresponding author), Minist Educ, Engn Res Ctr Appl Technol Pharmacogenom, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China.; Mao, XY (corresponding author), Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.; Jin, WL (corresponding author), Guangxi Univ Chinese Med, Ruikang Hosp, Ctr Translat Med, Nanning, Peoples R China.; Jin, WL (corresponding author), Shanghai Jiao Tong Univ, Inst Nano Biomedicine & Engn, Sch Elect Informat & Elect Engn, Minist Educ,Dept Instrument Sci & Engn,Key Lab Th, Shanghai, Peoples R China.; Jin, WL (corresponding author), Xian Med Univ, Shaanxi Key Lab Brain Disorders, Xian, Shaanxi, Peoples R China.; Jin, WL (corresponding author), Xian Med Univ, Inst Basic & Translat Med, Xian, Shaanxi, Peoples R China.	weilinjin@sjtu.edu.cn; xiaoyuanm@csu.edu.cn	Jin, Wei-Lin/A-8355-2013	Jin, Wei-Lin/0000-0001-8011-2405; Mao, Xiao-Yuan/0000-0002-5149-1204	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81671293, 81302750]; Natural Science Foundation of Hunan ProvinceNatural Science Foundation of Hunan Province [2017JJ3479]; Fundamental Research Funds for the Central Universities of Central South University [2018zzts900]; Hunan Provincial Department of Education Innovation Platform Open Fund Project [17K100]	This work is partially financially supported by the National Natural Science Foundation of China (nos. 81671293 and 81302750), Natural Science Foundation of Hunan Province (no. 2017JJ3479), the Fundamental Research Funds for the Central Universities of Central South University (2018zzts900), and the Hunan Provincial Department of Education Innovation Platform Open Fund Project (no. 17K100).	Acharya MM, 2008, PROG NEUROBIOL, V84, P363, DOI 10.1016/j.pneurobio.2007.10.010; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Ahn JS, 2007, ANAL BIOCHEM, V367, P259, DOI 10.1016/j.ab.2007.05.023; Andrade S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01261; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Anthonymuthu TS, 2018, FREE RADICAL BIO MED, V124, P493, DOI 10.1016/j.freeradbiomed.2018.06.031; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; Belkner J, 2005, ARTERIOSCL THROM VAS, V25, P797, DOI 10.1161/01.ATV.0000157580.26858.2d; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Carvalho AN, 2017, CURR DRUG TARGETS, V18, P705, DOI 10.2174/1389450117666160401120514; Chartrain AG, 2017, CURR PHARM DESIGN, V23, P6428, DOI 10.2174/1381612823666171031100139; Cheignon C, 2018, REDOX BIOL, V14, P450, DOI 10.1016/j.redox.2017.10.014; Chen IC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9595741; Chen ZX, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2936737; Christensen J, 2015, SEMIN NEUROL, V35, P218, DOI 10.1055/s-0035-1552923; Conrad M, 2018, GENE DEV, V32, P602, DOI 10.1101/gad.314674.118; Deng SY, 2018, BIOCHEM BIOPH RES CO, V496, P865, DOI 10.1016/j.bbrc.2018.01.136; Deschamps JD, 2006, BIOORGAN MED CHEM, V14, P4295, DOI 10.1016/j.bmc.2006.01.057; Dinda B, 2017, EUR J MED CHEM, V131, P68, DOI 10.1016/j.ejmech.2017.03.004; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Do Van B, 2016, NEUROBIOL DIS, V94, P169, DOI 10.1016/j.nbd.2016.05.011; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Gao L, 2015, PHARMACOL BIOCHEM BE, V133, P155, DOI 10.1016/j.pbb.2015.04.004; Gu XH, 2016, BEHAV BRAIN RES, V311, P309, DOI 10.1016/j.bbr.2016.05.052; HAMADA H, 1993, ARCH BIOCHEM BIOPHYS, V306, P261, DOI 10.1006/abbi.1993.1509; He C, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5216383; Islam MT, 2017, NEUROL RES, V39, P73, DOI 10.1080/01616412.2016.1251711; Kanzler Matthew A, 2018, Epilepsia Open, V3, P255, DOI 10.1002/epi4.12221; Kenny EM, 2019, CRIT CARE MED, V47, P410, DOI 10.1097/CCM.0000000000003555; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Lamar CD, 2014, J NEUROPSYCHIATRY CL, V26, piv, DOI DOI 10.1176/APPI.NEUR0PSYCH.260201; Lee DG, 2018, INT J BIOCHEM CELL B, V102, P10, DOI 10.1016/j.biocel.2018.06.005; Lee DG, 2016, TOXICOLOGY, V365, P17, DOI 10.1016/j.tox.2016.07.022; Li CR, 2011, BIOPHARM DRUG DISPOS, V32, P427, DOI 10.1002/bdd.771; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Li XJ, 2008, TRENDS MOL MED, V14, P1, DOI 10.1016/j.molmed.2007.11.002; Li YK, 2019, FREE RADICAL BIO MED, V134, P239, DOI 10.1016/j.freeradbiomed.2019.01.019; Liu AD, 2015, INT IMMUNOPHARMACOL, V24, P72, DOI 10.1016/j.intimp.2014.11.014; Liu RX, 2017, CHIN J NAT MEDICINES, V15, P152, DOI 10.1016/S1875-5364(17)30030-4; Liu YF, 2012, NEUROCHEM RES, V37, P1670, DOI 10.1007/s11064-012-0771-8; Lu SS, 2015, FUTURE MED CHEM, V7, P2005, DOI 10.4155/fmc.15.130; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Mao XY, 2018, PHARMACOL THERAPEUT, V183, P137, DOI 10.1016/j.pharmthera.2017.10.012; Mao XY, 2014, NEUROL SCI, V35, P1261, DOI 10.1007/s10072-014-1695-7; McKinnon C, 2019, ANN CLIN TRANSL NEUR, V6, P174, DOI 10.1002/acn3.682; Mendes MO, 2019, MOL CELL NEUROSCI, V96, P1, DOI 10.1016/j.mcn.2019.01.003; Pan RY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6328; Pan WD, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/789506; Pauletti A, 2017, BRAIN, V140, P1885, DOI 10.1093/brain/awx117; Pearson-Smith JN, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112365; Pi XR, 2014, SEIZURE-EUR J EPILEP, V23, P636, DOI 10.1016/j.seizure.2014.05.002; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2014, EPILEPSY BEHAV, V38, P19, DOI 10.1016/j.yebeh.2014.01.013; Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005; Probst L, 2017, BIOCHEM PHARMACOL, V140, P41, DOI 10.1016/j.bcp.2017.06.112; Qian X, 2019, BRAIN RES, V1714, P111, DOI 10.1016/j.brainres.2019.02.028; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Salim S, 2017, J PHARMACOL EXP THER, V360, P201, DOI 10.1124/jpet.116.237503; SATO M, 1990, ELECTROEN CLIN NEURO, V76, P459, DOI 10.1016/0013-4694(90)90099-6; Singh A, 2016, NEUROL CLIN, V34, P837, DOI 10.1016/j.ncl.2016.06.015; Singh NK, 2019, PROG LIPID RES, V73, P28, DOI 10.1016/j.plipres.2018.11.001; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Srivastava NK, 2019, MOL BIOL REP, V46, P1757, DOI 10.1007/s11033-019-04626-9; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Su J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071599; Szaflarski JP, 2014, NEUROPSYCH DIS TREAT, V10, P1469, DOI 10.2147/NDT.S50421; Szwajgier D, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050477; van Leyen K, 2006, STROKE, V37, P3014, DOI 10.1161/01.STR.0000249004.25444.a5; Volavka J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001148; Wang GQ, 2011, ACTA NEUROCHIR, V153, P319, DOI 10.1007/s00701-010-0750-2; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Wu TY, 2011, TAIWAN J OBSTET GYNE, V50, P131, DOI 10.1016/j.tjog.2011.04.004; Xiao XC, 2019, J CELL PHYSIOL, V234, P9130, DOI 10.1002/jcp.27590; Xie BS, 2019, CNS NEUROSCI THER, V25, P465, DOI 10.1111/cns.13069; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Xie YY, 2018, NEUROCHEM INT, V112, P179, DOI 10.1016/j.neuint.2017.07.006; Xu T, 2017, EPILEPSY BEHAV, V67, P1, DOI 10.1016/j.yebeh.2016.10.026; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Ye Q, 2019, AM J TRANSL RES, V11, P875; Zeng BY, 2017, INT REV NEUROBIOL, V135, P57, DOI 10.1016/bs.irn.2017.02.004; Zhang MR, 2020, NAT PROD RES, V34, P3335, DOI 10.1080/14786419.2019.1574786; Zhang X., 2018, CALC VAR PARTIAL DIF, V57, P1, DOI DOI 10.1016/J.PHYMED.2018.12.042; Zhang YH, 2018, REDOX BIOL, V14, P535, DOI 10.1016/j.redox.2017.11.001; Zhou L, 2016, NEUROPSYCH DIS TREAT, V12, P3145, DOI 10.2147/NDT.S117469; Zille M, 2017, STROKE, V48, P1033, DOI 10.1161/STROKEAHA.116.015609	85	39	40	0	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	JUN 7	2019	10								638	10.3389/fphar.2019.00638			13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	IC7OO	WOS:000471164800001	31231224	Green Published, gold			2022-02-06	
J	Galea, MD				Galea, Marinella DeFre			Telemedicine in Rehabilitation	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Telerehabilitation; Telehealth; Telemedicine	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; LOW-BACK-PAIN; HEART-FAILURE; HOME VISITS; TOTAL HIP; TELEREHABILITATION; CARE; TELEHEALTH; THERAPY	Telerehabilitation refers to the virtual delivery of rehabilitation services into the patient's home. This methodology has shown to be advantageous when used to enhance or replace conventional therapy to overcome geographic, physical, and cognitive barriers. The exponential growth of technology has led to the development of new applications that enable health care providers to monitor, educate, treat, and support patients in their own environment. Best practices and well-designed Telerehabilitation studies are needed to build and sustain a strong Telerehabilitation system that is integrated in the current health care structure and is cost-effective.	[Galea, Marinella DeFre] James J Peters VAMC, Multiple Sclerosis Reg Ctr, Amyotroph Lateral Sclerosis Program, Dept Spinal Cord Injury & Disorder,SCI D Unit, 130 West Kingsbridge Rd, Bronx, NY 10468 USA		Galea, MD (corresponding author), James J Peters VAMC, Multiple Sclerosis Reg Ctr, Amyotroph Lateral Sclerosis Program, Dept Spinal Cord Injury & Disorder,SCI D Unit, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.	Marinella.galea@va.gov	Galea, Marinella/Y-4010-2019	Galea, Marinella/0000-0002-4211-6170			Adamse C, 2018, J TELEMED TELECARE, V24, P511, DOI 10.1177/1357633X17716576; Bennell KL, 2017, ANN INTERN MED, V166, P453, DOI 10.7326/M16-1714; Brouwers RWM, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0477-6; Capistrant G, 2017, STATE TELEMEDICINE G; Charvet LE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177177; Conroy SS, 2018, J TELEMED TELECARE, V24, P410, DOI 10.1177/1357633X17702757; Cottrell MA, 2017, CLIN REHABIL, V31, P625, DOI 10.1177/0269215516645148; Cranen K, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5951; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; Doiron-Cadrin P, 2016, CONT CLIN TRIAL COMM, V4, P192, DOI 10.1016/j.conctc.2016.10.001; English C, 2015, INT J STROKE, V10, P465, DOI 10.1111/ijs.12474; Frederix I, 2017, ACTA CARDIOLO, V73, P222; Frederix I, 2017, EUR J PREV CARDIOL, V24, P1708, DOI 10.1177/2047487317732274; Hailey D, 2011, J TELEMED TELECARE, V17, P281, DOI 10.1258/jtt.2011.101208; Herbert MS, 2017, J PAIN, V18, P200, DOI 10.1016/j.jpain.2016.10.014; Hwang R, 2017, J PHYSIOTHER, V63, P101, DOI 10.1016/j.jphys.2017.02.017; Irgens I, 2018, SPINAL CORD, V56, P643, DOI 10.1038/s41393-017-0033-3; Jhaveri MM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017340; Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553; Khan F, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010508.pub2; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lai Byron, 2016, JMIR Rehabil Assist Technol, V3, pe8, DOI 10.2196/rehab.5524; Lichtman JH, 2013, STROKE, V44, P3429, DOI 10.1161/STROKEAHA.113.003165; Linder SM, 2015, AM J OCCUP THER, V69, DOI 10.5014/ajot.2015.015636; Martinez RN, 2017, TELEMED E-HEALTH, V23, P567, DOI 10.1089/tmj.2016.0200; Marzano G, 2017, OPEN PUBLIC HLTH J, V1, P1; Moffet H, 2017, TELEMED E-HEALTH, V23, P80, DOI 10.1089/tmj.2016.0060; Mohr DC, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1602; Nelson M, 2017, JMIR RES PROTOC, V6, P3, DOI 10.2196/resprot.7083; Nix J, 2017, INT J TELEREHABILITA, V9, P47, DOI 10.5195/ijt.2017.6218; Nouryan CN, 2018, TELEMED J E-HEALTH; Office of the National Coordinator for Health Information Technology, 2016, BREACH UNS PROT HLTH BREACH UNS PROT HLTH; Ownsworth T, 2018, J HEAD TRAUMA REHAB, V33, pE33, DOI 10.1097/HTR.0000000000000350; Pani D, 2017, J TELEMED TELECARE, V23, P292, DOI 10.1177/1357633X16632950; Pastora-Bernal Jose Manuel, 2017, J Med Internet Res, V19, pe142, DOI 10.2196/jmir.6836; Peterson C, 2014, INT J TELEREHABILITA, V6, P75, DOI [10.5195/ijt.2014.6161, 10.5195/IJT.2014.6161]; Peterson S, 2018, PHYSIOTHER THEOR PR, V34, P393, DOI 10.1080/09593985.2017.1401190; Phillips VL, 2001, PUBLIC HEALTH REP, V116, P94, DOI 10.1093/phr/116.S1.94; Piga M, 2017, SEMIN ARTHRITIS RHEU, V47, P121, DOI 10.1016/j.semarthrit.2017.03.014; Piotrowicz E, 2015, EUR J PREV CARDIOL, V22, P1368, DOI 10.1177/2047487314551537; Piotrowicz E, 2010, EUR J HEART FAIL, V12, P164, DOI 10.1093/eurjhf/hfp181; QYR Pharma & Healthcare Research Center, 2017, GLOB US TEL SYST MAR; Remy C, 2018, ANN PHYS REHABIL MED, V61, pe99; Richmond T, 2017, INT J TELEREHABILITA, V9, P63, DOI 10.5195/ijt.2017.6232; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rietdijk R, 2012, J REHABIL MED, V44, P913, DOI 10.2340/16501977-1058; Rimmer JH, 2018, CONTEMP CLIN TRIALS, V71, P186, DOI 10.1016/j.cct.2018.05.016; Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013; Schwamm LH, 2005, CIRCULATION, V111, P1078, DOI 10.1161/01.CIR.0000154252.62394.1E; Shem K, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00058; Tsavourelou A, 2016, INT J TELEREHABILITA, V8, P61, DOI 10.5195/ijt.2016.6205; Van Straaten MG, 2014, ARCH PHYS MED REHAB, V95, P1810, DOI 10.1016/j.apmr.2014.05.004; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vloothius J, 2017, BMC NEUROL, V15, P193; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Wang S, 2016, ARCH PHYS MED REHAB, V97, P1403, DOI 10.1016/j.apmr.2016.04.002; Wechsler LR, 2013, NEUROLOGY, V80, P670, DOI 10.1212/WNL.0b013e3182823361; Woo C, 2016, J SPINAL CORD MED, V39, P3, DOI 10.1179/2045772314Y.0000000202; World Federation Occupational The, 2014, INT J TELEREHABILITA, V6, P37, DOI [10.5195/IJT.2014.6153, 10.5195/ijt.2014.6153]; Wulsin L, 2012, J PSYCHOSOM RES, V72, P175, DOI 10.1016/j.jpsychores.2011.11.015	61	39	44	2	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2019	30	2					473	+		10.1016/j.pmr.2018.12.002			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	HW6VZ	WOS:000466830100014	30954160				2022-02-06	
J	Dai, WY; Wang, XG; Teng, HL; Li, C; Wang, B; Wang, J				Dai, Wangying; Wang, Xingguo; Teng, Honglin; Li, Chi; Wang, Bin; Wang, Jing			Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Celastrol; Pyroptosis; Spinal cord injury; Microglia	TRAUMATIC BRAIN; IN-VITRO; C-JUN; ACTIVATION; INFLAMMASOMES; CASPASE-1; INFECTION; PROTECTS; RECEPTOR; DISEASE	Pyroptosis pathway is closely related to inflammation. However, Celastrol effect on pyroptosis pathway after spinal cord injury (SCI) are poorly understood. We studied the anti-inflammatory and neuroprotective effects of Celastrol on acute spinal cord injury in rats, and its anti-inflammatory effects on lipopolysaccharide (LPS)/ATPinduced microgliosis. Our results show that Celastrol can improve the recovery of hindlimb motor function after SCI in Sprague-Dawley (SD) rats, and reduce the cavity area of spinal cord injury along with the neuronal loss. Celastrol simultaneously reduced the activation of microglia (especially M1 microglia) in the spinal cord, inhibited the pyroptosis-related proteins (NLRP3 ASC Caspase-1 GSDMD), reduced the release of TNF-alpha IL-1 beta and IL-18 inflammatory factors, and increased the release of IL10 cytokines. In vitro studies showed that Celastrol reduced the toxicity resulting from the administration of LPS with ATP to BV-2 cells, inhibited the pyroptosis-related proteins (NLRP3 Caspase-1 GSDMD), and inhibited the release of corresponding inflammatory factors. Finally, Celastrol can inhibit the expression of NF kappa B/p-p65 in vitro and in vivo. Our results show that Celastrol can attenuate the inflammatory response of the spinal cord after SCI, which is associated with inhibition of microglial activation and pyroptosis pathway. Further study to explore the use of Celastrol to treat SCI is warranted.	[Dai, Wangying; Wang, Xingguo; Teng, Honglin; Li, Chi; Wang, Bin; Wang, Jing] Wenzhou Med Univ, Affiliated Hosp 1, Dept Spine Surg, Wenzhou 325035, Peoples R China		Wang, J (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Spine Surg, Wenzhou 325035, Peoples R China.	wjspine@163.com			Medical and Health Technology Project of Zhejiang Province [2018KY124]	This study was supported by Medical and Health Technology Project of Zhejiang Province (2018KY124).	Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bowes AL, 2014, J NEUROTRAUM, V31, P1753, DOI 10.1089/neu.2014.3429; Cascao R, 2012, AUTOIMMUN REV, V11, P856, DOI 10.1016/j.autrev.2012.02.022; Cheng P, 2014, NEUROPHARMACOLOGY, V85, P408, DOI 10.1016/j.neuropharm.2014.06.004; Cheng S, 2018, VALPROIC ACID ATTENU, P1; DiSabato DJ, 2016, J NEUROCHEM, V139, P136, DOI 10.1111/jnc.13607; Faust K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-109; Gaudet AD, 2018, NEUROTHERAPEUTICS, V15, P554, DOI 10.1007/s13311-018-0630-7; Grabowski GA, 2017, SEMIN PEDIATR NEUROL, V24, P207, DOI 10.1016/j.spen.2017.08.005; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Jung HW, 2007, EXP MOL MED, V39, P715, DOI 10.1038/emm.2007.78; Kannaiyan R, 2011, APOPTOSIS, V16, P1028, DOI 10.1007/s10495-011-0629-6; Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200; Kim EA, 2015, NEUROTOXICOLOGY, V51, P198, DOI 10.1016/j.neuro.2015.10.013; Konieczny J, 2014, NEUROTOX RES, V26, P255, DOI 10.1007/s12640-014-9477-9; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Letellier E, 2010, IMMUNITY, V32, P240, DOI 10.1016/j.immuni.2010.01.011; Li G, 2016, BIOMATERIALS, V83, P233, DOI 10.1016/j.biomaterials.2015.11.059; Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543; Li J, 2011, SPINAL CORD, V49, P777, DOI 10.1038/sc.2011.8; Li YH, 2012, BRAIN RES, V1464, P8, DOI 10.1016/j.brainres.2012.04.054; Lin CW, 2016, NEUROSCI BULL, V32, P137, DOI 10.1007/s12264-016-0017-x; Liu JL, 2015, CELL, V161, P999, DOI 10.1016/j.cell.2015.05.011; Liu W, 2018, J DENT RES, V97, P1391, DOI 10.1177/0022034518775036; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Mortazavi MM, 2015, CLIN ANAT, V28, P27, DOI 10.1002/ca.22432; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Okada S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0026-1; Paris D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-17; Pinna GF, 2004, BIOCHEM BIOPH RES CO, V322, P778, DOI 10.1016/j.bbrc.2004.07.186; Pirhonen J, 1999, J IMMUNOL, V162, P7322; Poniatowski LA, 2017, MOL NEUROBIOL, V54, P2167, DOI 10.1007/s12035-016-9787-4; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050; Shi FS, 2013, J NEUROIMMUNOL, V260, P121, DOI 10.1016/j.jneuroim.2013.04.016; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Slowik A, 2018, J STEROID BIOCHEM, V183, P18, DOI 10.1016/j.jsbmb.2018.05.003; Vande Walle L, 2016, CURR BIOL, V26, pR568, DOI 10.1016/j.cub.2016.02.019; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang WF, 2018, J PHARM PHARMACOL, V70, P81, DOI 10.1111/jphp.12835; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Xu S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1183-8; Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009; Yang HB, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00044; You TT, 2017, ACS CHEM NEUROSCI, V8, P2381, DOI 10.1021/acschemneuro.7b00065; Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047; Yuan SY, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00683	52	39	48	6	43	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	JAN	2019	66						215	223		10.1016/j.intimp.2018.11.029			9	Immunology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pharmacology & Pharmacy	HI1SQ	WOS:000456225700024	30472522				2022-02-06	
J	Threlkeld, ZD; Bodien, YG; Rosenthal, ES; Giacino, JT; Nieto-Castanon, A; Wu, O; Whitfield-Gabrieli, S; Edlow, BL				Threlkeld, Zachary D.; Bodien, Yelena G.; Rosenthal, Eric S.; Giacino, Joseph T.; Nieto-Castanon, Alfonso; Wu, Ona; Whitfield-Gabrieli, Susan; Edlow, Brian L.			Functional networks reemerge during recovery of consciousness after acute severe traumatic brain injury	CORTEX			English	Article						Coma; Consciousness; Traumatic brain injury; Default mode network; Resting-state functional MRI	DEFAULT-MODE NETWORK; RESTING-STATE; BOLD SIGNAL; CONNECTIVITY; FMRI; DISORDERS; AWARENESS; FLUCTUATIONS; INVOLVEMENT; DIAGNOSIS	Integrity of the default mode network (DMN) is believed to be essential for human consciousness. However, the effects of acute severe traumatic brain injury (TBI) on DMN functional connectivity are poorly understood. Furthermore, the temporal dynamics of DMN reemergence during recovery of consciousness have not been studied longitudinally in patients with acute severe TBI. We performed resting-state functional magnetic resonance imaging (rs-fMRI) to measure DMN connectivity in 17 patients admitted to the intensive care unit (ICU) with acute severe TBI and in 16 healthy control subjects. Eight patients returned for follow-up rs-fMRI and behavioral assessment six months post-injury. At each time point, we analyzed DMN connectivity by measuring intra-network correlations (i.e. positive correlations between DMN nodes) and inter-network anticorrelations (i.e. negative correlations between the DMN and other resting-state networks). All patients were comatose upon arrival to the ICU and had a disorder of consciousness (DoC) at the time of acute rs-fMRI (9.2 +/- 4.6 days post-injury): 2 coma, 4 unresponsive wakefulness syndrome, 7 minimally conscious state, and 4 post-traumatic confusional state. We found that, while DMN anticorrelations were absent in patients with acute DoC, patients who recovered from coma to a minimally conscious or confusional state while in the ICU showed partially preserved DMN correlations. Patients who remained in coma or unresponsive wakefulness syndrome in the ICU showed no DMN correlations. All eight patients assessed longitudinally recovered beyond the confusional state by 6 months post-injury and showed normal DMN correlations and anticorrelations, indistinguishable from those of healthy subjects. Collectively, these findings suggest that recovery of consciousness after acute severe TBI is associated with partial preservation of DMN correlations in the ICU, followed by long-term normalization of DMN correlations and anticorrelations. Both intra-network DMN correlations and inter-network DMN anticorrelations may be necessary for full recovery of consciousness after acute severe TBI. (C) 2018 Elsevier Ltd. All rights reserved.	[Threlkeld, Zachary D.; Bodien, Yelena G.; Edlow, Brian L.] Harvard Med Sch, Ctr Neurotechnol & Neurorecovery, Massachusetts Gen Hosp, Boston, MA USA; [Threlkeld, Zachary D.; Bodien, Yelena G.; Rosenthal, Eric S.; Edlow, Brian L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA; [Bodien, Yelena G.; Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA; [Nieto-Castanon, Alfonso] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA; [Wu, Ona; Edlow, Brian L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [Whitfield-Gabrieli, Susan] MIT, McGovern Inst Brain Res, Martinos Imaging Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA		Edlow, BL (corresponding author), Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.	zthrelkeld@mgh.harvard.edu; ybodien@mgh.harvard.edu; erosenthal@mgh.harvard.edu; jgiacino@mgh.harvard.edu; alfnie@gmail.com; ona@nmr.mgh.harvard.edu; swg@mit.edu; bedlow@mgh.harvard.edu	Giacino, Joseph/AAF-1952-2021; Rosenthal, Eric Scott/A-2085-2017	Giacino, Joseph/0000-0002-7916-9698; Rosenthal, Eric Scott/0000-0003-3900-356X; Bodien, Yelena/0000-0003-4858-2903; Wu, Ona/0000-0002-5509-9461	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538]; Center for Integration of Medicine & Innovative Technology (Boston, MA, USA); American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology; National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living [90DP0039]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U48DP000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS105950, K23NS094538] Funding Source: NIH RePORTER	The authors thank the nursing staff of the Massachusetts General Hospital Neurosciences ICU, Multidisciplinary ICU, and Surgical ICU. We are grateful to the patients and families in this study for their participation and support. We acknowledge Dylan Tisdall and Andre van der Kouwe (Athinoula A. Martinos Center for Biomedical Imaging) and Himanshu Bhat (Siemens Medical Center) for the provision of WIP711D (vNav Motion-Corrected Multiecho MPRAGE) used to acquire MEMPRAGE data. This work was supported by grants from the NIH National Institute of Neurological Disorders and Stroke (K23NS094538), the Center for Integration of Medicine & Innovative Technology (Boston, MA, USA), the American Academy of Neurology/American Brain Foundation, the James S. McDonnell Foundation, the Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology, and the National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (90DP0039, Spaulding-Harvard TBI Model System). The contents of this manuscript do not necessarily represent the policy of the U.S. Department of Health and Human Services, and endorsement by the federal government should not be assumed.	Amico E, 2017, NEUROIMAGE, V148, P201, DOI 10.1016/j.neuroimage.2017.01.020; Andrews-Hanna JR, 2010, J NEUROPHYSIOL, V104, P322, DOI 10.1152/jn.00830.2009; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Birn RM, 2013, NEUROIMAGE, V83, P550, DOI 10.1016/j.neuroimage.2013.05.099; Bodien YG, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00688; Bodien YG, 2017, SEMIN NEUROL, V37, P485, DOI 10.1055/s-0037-1607310; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Braga RM, 2017, NEURON, V95, P457, DOI 10.1016/j.neuron.2017.06.038; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Crone JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026373; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Di Perri C, 2016, LANCET NEUROL, V15, P830, DOI 10.1016/S1474-4422(16)00111-3; Di X, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00493; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Golland Y, 2007, CEREB CORTEX, V17, P766, DOI 10.1093/cercor/bhk030; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; He JH, 2014, NMR BIOMED, V27, P880, DOI 10.1002/nbm.3130; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Keller CJ, 2013, J NEUROSCI, V33, P6333, DOI 10.1523/JNEUROSCI.4837-12.2013; Kirsch M, 2017, ANESTH ANALG, V124, P588, DOI 10.1213/ANE.0000000000001721; Kondziella D, 2017, NEUROCRIT CARE, V27, P401, DOI 10.1007/s12028-017-0407-6; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Muschelli J, 2014, NEUROIMAGE, V96, P22, DOI 10.1016/j.neuroimage.2014.03.028; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Qin PM, 2015, ANN NEUROL, V78, P594, DOI 10.1002/ana.24479; Raichle ME, 2011, BRAIN CONNECT, V1, P3, DOI 10.1089/brain.2011.0019; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rosazza C, 2016, ANN NEUROL, V79, P841, DOI 10.1002/ana.24634; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sair HI, 2017, RADIOLOGY, DOI [10.1148/radio1.2017162161, DOI 10.1148/RADIO1.2017162161]; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Silva S, 2015, NEUROLOGY, V85, P2036, DOI 10.1212/WNL.0000000000002196; Spadone S, 2015, P NATL ACAD SCI USA, V112, P8112, DOI 10.1073/pnas.1415439112; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Tagliazucchi E, 2014, NEURON, V82, P695, DOI 10.1016/j.neuron.2014.03.020; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wannez S, 2017, ANN NEUROL, V81, P883, DOI 10.1002/ana.24962; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Whitfield-Gabrieli S, 2011, NEUROIMAGE, V55, P225, DOI 10.1016/j.neuroimage.2010.11.048; Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058; Wu XH, 2015, J NEUROSCI, V35, P12932, DOI 10.1523/JNEUROSCI.0415-15.2015	53	39	40	0	7	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	SEP	2018	106						299	308		10.1016/j.cortex.2018.05.004			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	GV3HO	WOS:000445985200023	29871771	Green Accepted, Bronze			2022-02-06	
J	Zhao, RT; Zhou, J; Dong, XL; Bi, CW; Jiang, RC; Dong, JF; Tian, Y; Yuan, HJ; Zhang, JN				Zhao, Rui-ting; Zhou, Ju; Dong, Xin-long; Bi, Chong-wen; Jiang, Rong-cai; Dong, Jing-fei; Tian, Ye; Yuan, Heng-jie; Zhang, Jian-ning			Circular Ribonucleic Acid Expression Alteration in Exosomes from the Brain Extracellular Space after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						circular RNA; exosomes; microRNA; traumatic brain injury	RNAS; CELLS; MICRORNAS; RECOGNITION; MATURATION; REVEALS; PATHWAY; DEATH	Traumatic brain injury (TBI) has high morbidity and mortality rates. The mechanisms underlying TBI are unclear and may include the change in biological material in exosomes. Circular ribonucleic acids (circRNAs) are enriched and stable in exosomes, which can function as microRNA (miRNA) sponges to regulate gene expression levels. Therefore, we speculated that circRNAs in exosomes might play an important role in regulating gene expression after TBI and then regulate specific signaling pathways, which may protect the brain. We first isolated exosomes from the brain extracellular space in mice with TBI by digestion. We then investigated the alterations in circRNA expression in exosomes by high-throughput whole transcriptome sequencing, analyzed the data by gene ontology (GO) and pathway analysis, and constructed the circRNA-miRNA network. In this study, we identified 231 significantly and differentially expressed circRNAs, including 155 that were upregulated and 76 that were downregulated. GO analysis showed that these differentially expressed circRNAs might be related to the growth and repair of neurons, the development of the nervous system, and the transmission of nerve signals. The most highly correlated pathways that we identified were involved primarily with glutamatergic synapse and the cyclic guanosine monophosphate-protein kinase G signaling pathway. The circRNA-miRNA network predicted the potential roles of these differentially expressed circRNAs and the interaction of circRNAs with miRNAs. Our study broadens the horizon of research on gene regulation in exosomes from the brain extracellular space after TBI and provides novel targets for further research on both the molecular mechanisms of TBI and the potential intervention therapy targets.	[Zhao, Rui-ting; Zhou, Ju; Bi, Chong-wen; Yuan, Heng-jie] Tianjin Med Univ, Gen Hosp, Dept Pharm, Tianjin, Peoples R China; [Dong, Xin-long; Jiang, Rong-cai; Tian, Ye; Yuan, Heng-jie; Zhang, Jian-ning] Tianjin Med Univ, Tianjin Neurol Inst, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Dong, Jing-fei] Bloodworks Northwest, Bloodworks Res Inst, Seattle, WA USA; [Dong, Jing-fei] Univ Washington, Dept Med, Div Hematol, Sch Med, Seattle, WA 98195 USA		Tian, Y; Yuan, HJ; Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	tianye030710@163.com; hengjieyuan@163.com; jianningzhang@hotmail.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501057]; Tianjin Research Program of Application Foundation and Advanced Technology [16JCQNJC10600, 15JCQNJC11300]	This study was supported by the National Science Foundation of China (81501057) and the Tianjin Research Program of Application Foundation and Advanced Technology (grants 16JCQNJC10600 and 15JCQNJC11300).	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Cheng J, 2016, BIOINFORMATICS, V32, P1094, DOI 10.1093/bioinformatics/btv656; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Conde-Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887; Eken C, 2008, J IMMUNOL, V180, P817, DOI 10.4049/jimmunol.180.2.817; Enright AJ, 2004, GENOME BIOL, V5; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Geddes JF, 2004, FORENSIC SCI INT, V146, P83, DOI 10.1016/S0379-0738(03)00283-4; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huntley RP, 2015, NUCLEIC ACIDS RES, V43, pD1057, DOI 10.1093/nar/gku1113; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Junker K, 2016, EUR UROL, V70, P323, DOI 10.1016/j.eururo.2016.02.046; Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444; Khan S, 2011, APOPTOSIS, V16, P1, DOI 10.1007/s10495-010-0534-4; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Lin SP, 2016, BIOCHEM BIOPH RES CO, V471, P52, DOI 10.1016/j.bbrc.2016.01.183; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Michaelidis TM, 2008, CELL TISSUE RES, V331, P193, DOI 10.1007/s00441-007-0476-5; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Niedzwecki CM, 2008, J HEAD TRAUMA REHAB, V23, P209, DOI 10.1097/01.HTR.0000327253.61751.29; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pierfelice T, 2011, NEURON, V69, P840, DOI 10.1016/j.neuron.2011.02.031; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Sobrino Justin, 2013, Proc (Bayl Univ Med Cent), V26, P120; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657; Suzuki H, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl151; Talhouarne GJS, 2014, RNA, V20, P1476, DOI 10.1261/rna.045781.114; Thomas S, 2000, ACT NEUR S, V76, P397; Tojima T, 2011, NAT REV NEUROSCI, V12, P191, DOI 10.1038/nrn2996; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; Uhlen P, 2015, DEV NEUROBIOL, V75, P360, DOI 10.1002/dneu.22273; Valdmanis PN, 2013, MOL THER, V21, P1112, DOI 10.1038/mt.2013.101; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Vicens Q, 2014, CELL, V159, P13, DOI 10.1016/j.cell.2014.09.005; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Yang CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022517; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Ye SB, 2014, ONCOTARGET, V5, P5439, DOI 10.18632/oncotarget.2118; Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919	57	39	43	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2056	2066		10.1089/neu.2017.5502		MAY 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000434702400001	29409384				2022-02-06	
J	Zheng, XX; Huang, HB; Liu, JJ; Li, MH; Liu, M; Luo, T				Zheng, Xinxun; Huang, Hongbing; Liu, Jianjun; Li, Minghua; Liu, Min; Luo, Tao			Propofol Attenuates Inflammatory Response in LPS-Activated Microglia by Regulating the miR-155/SOCS1 Pathway	INFLAMMATION			English	Article						propofol; microglia; miR-155; SOCS1	PANCREATIC-CANCER CELLS; ISCHEMIA-REPERFUSION; MODEL; BRAIN; LIPOPOLYSACCHARIDE; ANESTHESIA; INHIBITION; EXPRESSION; SYSTEM; NEUROINFLAMMATION	Propofol is a widely used intravenous anesthetic agent with potential neuroprotective effect in diverse models of neuronal injury, including ischemic stroke and traumatic brain injury. However, few studies have been carried out to determine the effects and molecular mechanisms of propofol in classic microglial activation (M1 activation) related to neuronal injury. This study explored the anti-inflammatory effects of propofol in LPS-activated BV2 microglia. Propofol potently decreased the pro-inflammatory mediators, such as nitric oxide, TNF-alpha, and IL-6, at both the transcriptional and translational levels. Furthermore, propofol suppressed the expression of miR-155 in LPS-activated cells. Knockdown of miR-155 attenuated the anti-inflammatory effect of propofol in cells after LPS exposure. miR-155 was also confirmed as a negative regulator of SOCS1 expression. The inhibitory effect of propofol on LPS-induced inflammation involved the upregulation of SOCS1. Overall, these results suggest that propofol can suppress the neuroinflammatory response of microglia to LPS through the regulation of the miR-155/SOCS1 pathway.	[Zheng, Xinxun; Luo, Tao] Peking Univ, Shenzhen Hosp, Dept Anesthesiol, Shenzhen, Peoples R China; [Huang, Hongbing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Liu, Jianjun] Shenzhen Ctr Dis Control & Prevent, Key Lab Modern Toxicol Shenzhen, Shenzhen, Peoples R China; [Li, Minghua] Peking Univ, Shenzhen Hosp, Cent Lab, Shenzhen, Peoples R China; [Liu, Min] Hlth & Family Planning Capac Bldg & Continuing Ed, Shenzhen, Peoples R China		Luo, T (corresponding author), Peking Univ, Shenzhen Hosp, Dept Anesthesiol, Shenzhen, Peoples R China.	luotao_wh@yahoo.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271205]; Natural Science Foundation of Guangdong provinceNational Natural Science Foundation of Guangdong Province [2015A030313781]	This study was supported by Natural Science Foundation of China (grant no. 81271205) and Natural Science Foundation of Guangdong province (grant no. 2015A030313781).	Adachi YU, 2005, ACTA ANAESTH SCAND, V49, P331, DOI 10.1111/j.1399-6576.2005.00564.x; Adembri C, 2006, ANESTHESIOLOGY, V104, P80, DOI 10.1097/00000542-200601000-00014; Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024; Bickler PE, 2012, ANESTHESIOLOGY, V117, P280, DOI 10.1097/ALN.0b013e318260a7b9; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Chen Y, 2014, CURR MED CHEM, V21, P2146, DOI 10.2174/0929867321666131228203906; Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350; Fan K, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0268-x; Franks NP, 2015, ANESTHESIOLOGY, V122, P787, DOI 10.1097/ALN.0000000000000588; Gaudet AD, 2016, J NEUROSCI, V36, P8516, DOI 10.1523/JNEUROSCI.0735-16.2016; Goto G, 2014, MOL MED REP, V9, P1715, DOI 10.3892/mmr.2014.2038; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Guedes JR, 2014, HUM MOL GENET, V23, P6286, DOI 10.1093/hmg/ddu348; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Huang X, 2016, BRAZ J MED BIOL RES, V49, DOI [10.1590/1414-431X20165717, 10.1590/1414-431x20165717]; Ishikawa M, 2012, ANESTHESIOLOGY, V117, P1245, DOI 10.1097/ALN.0b013e3182746676; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Liu ZM, 2016, AM J TRANSL RES, V8, P4120; Luo T, 2015, INFLAMM RES, V64, P205, DOI 10.1007/s00011-015-0798-9; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Marik PE, 2005, PHARMACOTHERAPY, V25, p28S, DOI 10.1592/phco.2005.25.5_Part_2.28S; Mayer AMS, 1998, MEDICINA-BUENOS AIRE, V58, P377; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Murphy PG, 1996, BRIT J ANAESTH, V76, P536, DOI 10.1093/bja/76.4.536; Mycko MP, 2015, J NEUROSCI, V35, P16504, DOI 10.1523/JNEUROSCI.2830-15.2015; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Suk Kyoungho, 2012, Inflammopharmacology, V20, P151, DOI 10.1007/s10787-011-0108-2; Twaroski DM, 2014, ANESTHESIOLOGY, V121, P786, DOI 10.1097/ALN.0000000000000345; Velly LJ, 2003, ANESTHESIOLOGY, V99, P368, DOI 10.1097/00000542-200308000-00018; Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057; Wang DM, 2014, EUR J PHARMACOL, V728, P59, DOI 10.1016/j.ejphar.2014.01.057; Wang ZT, 2015, GENET MOL RES, V14, P7529, DOI 10.4238/2015.July.3.28; Wen Y, 2015, MOL MED, V21, P197, DOI 10.2119/molmed.2014.00199; Woodbury ME, 2015, J NEUROSCI, V35, P9764, DOI 10.1523/JNEUROSCI.4790-14.2015; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x; Zheng YY, 2008, ANESTH ANALG, V107, P2009, DOI 10.1213/ane.0b013e318187c313	38	39	44	1	24	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	FEB	2018	41	1					11	19		10.1007/s10753-017-0658-6			9	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	FS6GP	WOS:000419896200002	28875362				2022-02-06	
J	Keenan, HT; Clark, AE; Holubkov, R; Cox, CS; Ewing-Cobbs, L				Keenan, Heather T.; Clark, Amy E.; Holubkov, Richard; Cox, Charles S.; Ewing-Cobbs, Linda			Psychosocial and Executive Function Recovery Trajectories One Year after Pediatric Traumatic Brain Injury: The Influence of Age and Injury Severity	JOURNAL OF NEUROTRAUMA			English	Article						cohort; pediatrics; trauma; traumatic brain injury	BEHAVIOR PROBLEMS; SOCIAL OUTCOMES; TERM; DISORDERS; CHILDREN	Time since traumatic brain injury (TBI) and developmental stage at injury may affect the trajectory of outcomes associated with adjustment and school success. We prospectively enrolled a cohort of 519 children with either TBI or orthopedic injury (OI) age 2.5-15 years to examine children's psychosocial and executive function outcomes at 3- and 12-months post-injury. Outcome measures included the Child Behavior Checklist (CBCL), Strengths and Difficulties Questionnaire (SDQ), and Behavior Rating Inventory of Executive Function (BRIEF) ratings. Controlling for pre-injury ratings and using the OI group as the reference, children with TBI, regardless of age or injury severity, had affective, anxiety, and attention-deficit/hyperactivity disorder (ADHD) problems on the CBCL. Symptom trajectories differed both by injury severity and age at injury. Children with mild and complicated mild TBI had a decreasing anxiety trajectory, whereas children with severe TBI had increasing symptoms. Children 6-11 years of age had high ADHD and affective scores; however, the youngest children had increasing symptoms over time. On the SDQ, peer relationships and prosocial behaviors were not significantly affected by TBI but were associated with family environment. Children with severe TBI had the worst executive function scores; however, mild and complicated mild/moderate TBI groups had clinically important working memory deficits. Hispanic ethnicity and strong social capital were positively associated with multiple outcomes. Children's recovery trajectories differed by injury severity, time since injury, and developmental stage when injured. Schools need to reassess children's skills over time as new problems in behavior and learning may emerge.	[Keenan, Heather T.; Clark, Amy E.; Holubkov, Richard] Univ Utah, Dept Pediat, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA; [Cox, Charles S.] Univ Texas Houston, Med Sch Houston, Dept Pediat Surg, Houston, TX USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA		Keenan, HT (corresponding author), Univ Utah, Dept Pediat, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu			Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01/CE002188]; National Institute of Health/Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD072984]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD072984] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002188] Funding Source: NIH RePORTER	This study was supported by The Centers for Disease Control under Cooperative Agreement U01/CE002188. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. This study was supported also by the National Institute of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development K24HD072984. Neither the NICHD or the CDC played a role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Dennis M, 2014, NEUROPSYCHOL REV, V24, P389, DOI 10.1007/s11065-014-9261-x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Gallo LC, 2009, J PERS, V77, P1707, DOI 10.1111/j.1467-6494.2009.00598.x; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Gennarelli TA., 2008, ABBREVIATED INJURY S; Gioa GA, 2000, BEHAV RATING INVENTO; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Marr A., 2004, CENTRAL NERVOUS SYST; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; National Center for Injury Prevention and Control C. f. d. C. a. i. P., 2003, REP C MILD TRAUM BRA; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prasad MR, 2017, J HEAD TRAUMA REHAB, V32, pE24, DOI 10.1097/HTR.0000000000000218; Raj SP, 2014, J PEDIATR PSYCHOL, V39, P84, DOI 10.1093/jpepsy/jst075; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; Ryan NP, 2016, INT J DEV NEUROSCI, V49, P23, DOI 10.1016/j.ijdevneu.2015.12.004; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stone LL, 2010, CLIN CHILD FAM PSYCH, V13, P254, DOI 10.1007/s10567-010-0071-2; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	31	39	39	1	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					286	296		10.1089/neu.2017.5265			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000422918000009	28854841	Green Published			2022-02-06	
J	Kim, JY; Han, Y; Lee, JE; Yenari, MA				Kim, Jong Youl; Han, Yeonseung; Lee, Jong Eun; Yenari, Midori A.			The 70-kDa heat shock protein (Hsp70) as a therapeutic target for stroke	EXPERT OPINION ON THERAPEUTIC TARGETS			English	Article						70-kDa heat shock protein (Hsp70); chaperon; ischemic stroke; apoptosis; inflammation; neuroprotection	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; INTRACEREBRAL HEMORRHAGE; INDUCIBLE HEAT-SHOCK-PROTEIN-70; PHARMACOLOGICAL INDUCTION; GLUCOSE DEPRIVATION; INHIBITS APOPTOSIS; SIGNALING PATHWAY; CELL-DEATH	Introduction: The 70-kDa heat shock protein (Hsp70) is a cytosolic chaperone which facilitates protein folding, degradation, complex assembly, and translocation. Following stroke, these functions have the potential to lead to cytoprotection, and this has been demonstrated using genetic mutant models, direct gene transfer or the induction of Hsp70 via heat stress, approaches which limit its translational utility. Recently, the investigation of Hsp70-inducing pharmacological compounds, which, through their ability to inhibit Hsp90, has obvious clinical implications in terms of potential therapies to mitigate cell death and inflammation, and lead to neuroprotection from brain injury. Areas covered: In this review, we will focus on the role of Hsp70 in cell death and inflammation, and the current literature surrounding the pharmacological induction in acute ischemic stroke models with comments on potential applications at the clinical level. Expert opinion: Such neuroprotectants could be used to synergistically improve neurological outcome or to extend the time window of existing interventions, thus increasing the numbers of stroke victims eligible for treatment.	[Kim, Jong Youl; Han, Yeonseung; Lee, Jong Eun] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea; [Lee, Jong Eun] Yonsei Univ, Coll Med, Plus Project Med Sci BK21, Seoul, South Korea; [Lee, Jong Eun] Yonsei Univ, Coll Med, Brain Res Inst, Seoul, South Korea; [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, Neurology 127 VAMC 4150 Clement St, San Francisco, CA 94143 USA; [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA USA		Yenari, MA (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurology 127 VAMC 4150 Clement St, San Francisco, CA 94143 USA.; Lee, JE (corresponding author), Yonsei Univ, Coll Med, Brain Res Inst, Dept Anat,Brain Korea Plus Project Med Sci 21, 50-1 Yonsei Ro, Seoul 03722, South Korea.; Yenari, MA (corresponding author), SF VAMC, Neurology 127 VAMC 4150 Clement St, San Francisco, CA 94121 USA.	jelee@yuhs.ac; yenari@alum.mit.edu		Lee, Jong Eun/0000-0001-6203-7413; Kim, Jong Youl/0000-0002-8340-2894	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040516, R03 NS101246] Funding Source: Medline; BLRD VA [I01 BX000589] Funding Source: Medline; VAUS Department of Veterans Affairs [2I01BX000589-05A1] Funding Source: Federal RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS101246, R01NS040516] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000589] Funding Source: NIH RePORTER		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Aschkenasy G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026956; Asea Alexzander, 2008, V183, P111; Banecka-Majkutewicz Z, 2012, ACTA BIOCHIM POL, V59, P495; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Chen HW, 2003, SHOCK, V20, P274, DOI 10.1097/00024382-200309000-00013; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; de Jong PR, 2009, CELL STRESS CHAPERON, V14, P117, DOI 10.1007/s12192-008-0066-9; De Maio A, 2014, CURR PROTEIN PEPT SC, V15, P225, DOI 10.2174/1389203715666140331113057; Deane CAS, 2016, CELL STRESS CHAPERON, V21, P837, DOI 10.1007/s12192-016-0708-2; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; del Zoppo GJ, 2011, J CEREBR BLOOD F MET, V31, P1836, DOI 10.1038/jcbfm.2011.93; Ding XZ, 2001, CYTOKINE, V16, P210, DOI 10.1006/cyto.2001.0959; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Fischer N, 2010, EUR J IMMUNOL, V40, P986, DOI 10.1002/eji.200939738; Frebel K, 2006, BIOCHEM SOC T, V34, P1287, DOI 10.1042/BST0341287; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gaston JSH, 2002, CLIN EXP IMMUNOL, V127, P1, DOI 10.1046/j.1365-2249.2002.01759.x; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Heneka MT, 2000, J CEREBR BLOOD F MET, V20, P800, DOI 10.1097/00004647-200005000-00006; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Howard M, 2010, THORAX, V65, P346, DOI 10.1136/thx.2008.101139; Ivanov VN, 2006, J BIOL CHEM, V281, P1840, DOI 10.1074/jbc.M509866200; Jiang BM, 2005, CELL STRESS CHAPERON, V10, P252, DOI 10.1379/CSC-124R.1; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Jo SK, 2006, J AM SOC NEPHROL, V17, P3082, DOI 10.1681/ASN.2005101077; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Kacimi R, 2015, GLIA, V63, P1200, DOI 10.1002/glia.22811; Kelly Stephen, 2002, Curr Med Res Opin, V18 Suppl 2, ps55, DOI 10.1185/030079902125000732; Kim JY, 2015, NEUROSCIENCE, V286, P272, DOI 10.1016/j.neuroscience.2014.11.057; Kim JY, 2016, STROKE, V47, P2103, DOI 10.1161/STROKEAHA.116.012763; Kim JY, 2013, ANAT CELL BIOL, V46, P1, DOI 10.5115/acb.2013.46.1.1; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim N, 2015, NEUROSCIENCE, V284, P912, DOI 10.1016/j.neuroscience.2014.11.010; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Kriz J, 2009, ACTA NEUROPATHOL, V117, P497, DOI 10.1007/s00401-009-0496-1; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lanneau D, 2010, THESCIENTIFICWORLDJO, V10, P1543, DOI 10.1100/tsw.2010.152; Lee JE, 2004, NEUROREPORT, V15, P499, DOI 10.1097/00001756-200403010-00023; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; Manaenko A, 2010, NEUROCHEM INT, V57, P844, DOI 10.1016/j.neuint.2010.09.001; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Namura S, 1998, J NEUROSCI, V18, P3659; O'Sullivan JC, 2007, J NEUROTRAUM, V24, P532, DOI 10.1089/neu.2006.0128; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Ouyang YB, 2006, CELL STRESS CHAPERON, V11, P180, DOI 10.1379/CSC-182R.1; Ouyang YB, 2013, TRANSL STROKE RES, V4, P693, DOI 10.1007/s12975-013-0280-3; Parsons MJ, 2010, ESSAYS BIOCHEM, V47, P99, DOI [10.1042/BSE0470099, 10.1042/bse0470099]; POLLA BS, 1995, INFLAMMATION, V19, P363, DOI 10.1007/BF01534393; Porter JR, 2010, CURR OPIN CHEM BIOL, V14, P412, DOI 10.1016/j.cbpa.2010.03.019; Rabinstein Alejandro A, 2017, Continuum (Minneap Minn), V23, P62, DOI 10.1212/CON.0000000000000420; Ran RQ, 2004, CELL STRESS CHAPERON, V9, P229, DOI 10.1379/CSC-19R.1; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Sinn DI, 2007, BRAIN RES, V1135, P167, DOI 10.1016/j.brainres.2006.11.098; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/s002800050328; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Uchida S, 2006, NEUROSCI LETT, V396, P220, DOI 10.1016/j.neulet.2005.11.065; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Vogelgesang A, 2014, ACTA NEUROL SCAND, V129, P1, DOI 10.1111/ane.12165; Voloboueva LA, 2008, J CEREBR BLOOD F MET, V28, P1009, DOI 10.1038/sj.jcbfm.9600600; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yasuda H, 2005, BRAIN RES, V1032, P176, DOI 10.1016/j.brainres.2004.11.009; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhan XH, 2010, STROKE, V41, P538, DOI 10.1161/STROKEAHA.109.572537; Zhao HP, 2012, ADV PHARMACOL, V64, P1, DOI 10.1016/B978-0-12-394816-8.00001-5; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144; Zheng Z, 2004, NEUROL RES, V26, P884, DOI 10.1179/016164104X2357; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	86	39	46	2	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1472-8222	1744-7631		EXPERT OPIN THER TAR	Expert Opin. Ther. Targets		2018	22	3					191	199		10.1080/14728222.2018.1439477			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GA4KF	WOS:000428297900001	29421932	Green Accepted, Green Published			2022-02-06	
J	Kong, ZH; Chen, X; Hua, HP; Liang, L; Liu, LJ				Kong, Zhong-Hong; Chen, Xin; Hua, Hui-Po; Liang, Liang; Liu, Long-Juan			The Oral Pretreatment of Glycyrrhizin Prevents Surgery-Induced Cognitive Impairment in Aged Mice by Reducing Neuroinflammation and Alzheimer's-Related Pathology via HMGB1 Inhibition	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Postoperative cognitive dysfunction; Glycyrrhizin; High-mobility group box 1; Neuroinflammation	MOBILITY GROUP BOX-1; TRAUMATIC BRAIN-INJURY; SIGNALING PATHWAY; DYSFUNCTION; RATS; ACTIVATION; DISEASE; RAGE; INFLAMMATION; ANESTHESIA	Neuroinflammation and Alzheimer's-related pathology play essential roles in postoperative cognitive dysfunction (POCD). High-mobility group box 1 (HMGB1) is well known as a pivotal mediator in neuroinflammation, and its associations with Alzheimer's-related pathology and POCD have been also revealed. Glycyrrhizin is a nature inhibitor of HMGB1 and is reported with neuroprotective effects through oral administration. Therefore, the present study aims to test the hypothesis that the oral pretreatment of glycyrrhizin prevents POCD by inhibiting HMGB1-induced neuroinflammation and Alzheimer's-related pathology in aged mice. Aged male C57BL/6 mice were subjected to the splenectomy surgery under general anesthesia and the oral pretreatment of glycyrrhizin. The postoperative cognitive changes were evaluated by using Morris water maze (MWM) test. The protein expressions of HMGB1, TLR4, NF-kappa B, p-Tau, and pro-inflammatory cytokines were determined by Western blot assay. The hippocampal level of beta-amyloid (A beta) was assessed by ELISA assay. We found that the oral pretreatment of glycyrrhizin inhibited HMGB1 cytosolic expression, increased the PSD-95 protein expression, and attenuated the severity of postoperative memory impairment, as indicated by the shorter swimming latency and distance in MWM trials when compared with the mice subjected to the surgery alone. Additionally, the pretreatment of glycyrrhizin reduced the postoperative neuroinflammation (production of pro-inflammatory cytokines including IL-1 beta, TNF-alpha, and IL-6 as well as NF-kappa B nuclear expression) and Alzheimer's-related pathology (Tau phosphorylation at the site of AT-8 and Ser396 as well as A beta 40 and 42 concentrations) in the hippocampus of the aged mice undergoing splenectomy surgery. In conclusion, our results suggest that the oral pretreatment of glycyrrhizin can prevent the postoperative cognitive impairment by reducing neuroinflammation and Alzheimer's-related pathology in the hippocampus of aged mice via HMGB1 inhibition.	[Kong, Zhong-Hong; Hua, Hui-Po; Liang, Liang; Liu, Long-Juan] Tongchuan Min Bur, Cent Hosp, Dept Anesthesiol, Tongchuan 727000, Shaanxi, Peoples R China; [Chen, Xin] Shaanxi Prov Peoples Hosp, Dept Anesthesiol, Xian 710068, Shaanxi, Peoples R China		Liu, LJ (corresponding author), Tongchuan Min Bur, Cent Hosp, Dept Anesthesiol, Tongchuan 727000, Shaanxi, Peoples R China.	liulongjuan2015@sina.com					Arora SS, 2014, INT J NEUROSCI, V124, P236, DOI 10.3109/00207454.2013.833919; Cao XZ, 2010, PROG NEURO-PSYCHOPH, V34, P1426, DOI 10.1016/j.pnpbp.2010.07.027; Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Deiner S, 2009, Br J Anaesth, V103 Suppl 1, pi41, DOI 10.1093/bja/aep291; Fang P, 2012, MOL NEUROBIOL, V45, P499, DOI 10.1007/s12035-012-8264-y; Fodale V, 2010, ANAESTHESIA, V65, P388, DOI 10.1111/j.1365-2044.2010.06244.x; Fonken LK, 2016, J NEUROSCI, V36, P7946, DOI 10.1523/JNEUROSCI.1161-16.2016; Fujita K, 2016, SCI REP-UK, V6, DOI 10.1038/srep31895; Gravina SA, 1995, J BIOL CHEM, V270, P7013; He HJ, 2012, CNS NEUROSCI THER, V18, P994, DOI 10.1111/cns.12018; Hovens IB, 2015, NEUROBIOL LEARN MEM, V118, P74, DOI 10.1016/j.nlm.2014.11.009; Hovens IB, 2014, BRAIN BEHAV IMMUN, V38, P202, DOI 10.1016/j.bbi.2014.02.002; Hu ZH, 2010, MED HYPOTHESES, V74, P722, DOI 10.1016/j.mehy.2009.10.040; Jin WJ, 2014, NEUROREPORT, V25, P1, DOI 10.1097/WNR.0000000000000082; Kamer AR, 2012, EUR J ANAESTH, V29, P332, DOI 10.1097/EJA.0b013e3283534f56; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Li RL, 2013, J SURG RES, V185, P815, DOI 10.1016/j.jss.2013.06.043; Li YC, 2012, ACTA ANAESTH SCAND, V56, P595, DOI 10.1111/j.1399-6576.2011.02616.x; Li ZQ, 2013, BIOCHEM BIOPH RES CO, V438, P628, DOI 10.1016/j.bbrc.2013.08.003; Liu WR, 2012, NEUROL RES, V34, P3, DOI 10.1179/1743132811Y.0000000047; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Robinson AP, 2013, J AUTOIMMUN, V43, P32, DOI 10.1016/j.jaut.2013.02.005; Sanders RD, 2010, EUR J ANAESTH, V27, P3, DOI 10.1097/EJA.0b013e3283318ef9; Seymour DG, 2009, AGE AGEING, V38, P147, DOI 10.1093/ageing/afn289; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Song JH, 2013, MOLECULES, V18, P15788, DOI 10.3390/molecules181215788; Stahel PF, 2012, J TRAUMA ACUTE CARE, V73, P782, DOI 10.1097/TA.0b013e31825e898e; Tabuchi M, 2012, CELL MOL NEUROBIOL, V32, P1139, DOI 10.1007/s10571-012-9839-x; Tang JXX, 2011, ANESTHESIOLOGY, V115, P727, DOI 10.1097/ALN.0b013e31822e9306; Terrando N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00441; Tian A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141596; Tian XD, 2017, BRAIN RES, V1670, P135, DOI 10.1016/j.brainres.2017.06.001; Vacas S, 2013, BRIT MED BULL, V106, P161, DOI 10.1093/bmb/ldt006; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Wang LN, 2010, NEUROSCI LETT, V471, P152, DOI 10.1016/j.neulet.2010.01.030; Wang W, 2016, NEUROSCIENCE, V316, P328, DOI 10.1016/j.neuroscience.2015.11.001; Wang Y, 2013, MOL MED REP, V7, P1137, DOI 10.3892/mmr.2013.1322; Xie ZC, 2006, EXP GERONTOL, V41, P346, DOI 10.1016/j.exger.2006.01.014; Xu ZP, 2014, SCI REP-UK, V4, DOI 10.1038/srep03766; Yan RQ, 2014, LANCET NEUROL, V13, P319, DOI 10.1016/S1474-4422(13)70276-X; Yang GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078355; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019; Yang Qing-Wu, 2010, Front Biosci (Schol Ed), V2, P1081; Zhang JC, 2014, BRAIN RES, V1582, P176, DOI 10.1016/j.brainres.2014.07.002; Zhu YJ, 2016, BRAIN RES, V1644, P1, DOI 10.1016/j.brainres.2016.04.074	54	39	40	0	17	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2017	63	3-4					385	395		10.1007/s12031-017-0989-7			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FN4NM	WOS:000415983800013	29034441				2022-02-06	
J	Liu, YL; Xu, ZM; Yang, GY; Yang, DX; Ding, J; Chen, H; Yuan, F; Tian, HL				Liu, Ying-liang; Xu, Zhi-ming; Yang, Guo-yuan; Yang, Dian-xu; Ding, Jun; Chen, Hao; Yuan, Fang; Tian, Heng-li			Sesamin alleviates blood-brain barrier disruption in mice with experimental traumatic brain injury	ACTA PHARMACOLOGICA SINICA			English	Article						sesamin; traumatic brain injury; CCI injury; bEnd.3 cells; oxidative stress; apoptosis; BBB; tight junction proteins	OXIDATIVE STRESS; IN-VITRO; SIGNAL-TRANSDUCTION; PARKINSONS-DISEASE; CELL-DEATH; APOPTOSIS; INFLAMMATION; ACTIVATION; INHIBITION; AUTOPHAGY	Sesamin, a major lignan of sesame oil, was reported to have neuroprotective effects in several brain injury models. However, its protective action in maintaining blood-brain barrier (BBB) integrity has not been studied. In this study we investigated the effects of sesamin on the BBB in a mouse model of traumatic brain injury (TBI) and explored the underlying mechanisms. Adult male C57BL/6 mice were subjected to a controlled cortical impact (CCI) injury and then received sesamin (30 mg.kg(-1).d(-1), ip). The mice were euthanized on the 1st and 3rd days after CCI injury and samples were collected for analysis. Sesamin treatment significantly attenuated CCI-induced brain edema on the 1st and 3rd days after the injury, evidenced by the decreases in water content, tissue hemoglobin levels, Evans blue extravasation and AQP4 expression levels in the ipsilateral cortical tissue compared with the vehicle-treated group. Furthermore, sesamin treatment significantly alleviated CCI-induced loss of the tight junction proteins ZO-1 and occludin in the brain tissues. The neuroprotective mechanisms of sesamin were further explored in cultured mouse brain microvascular bEnd. 3 cells subjected to biaxial stretch injury (SI). Pretreatment with sesamin (50 mu mol/L) significantly alleviated SI-induced loss of ZO-1 in bEnd. 3 cells. Furthermore, we revealed that pretreatment with sesamin significantly attenuated SI-induced oxidative stress and early-stage apoptosis in bEnd. 3 cells by decreasing the activation of ERK, p38 and caspase-3. In conclusion, sesamin alleviates BBB disruption at least partly through its anti-oxidative and anti-apoptotic effects on endothelial cells in CCI injury. These findings suggest that sesamin may be a promising potential therapeutic intervention for preventing disruption of the BBB after TBI.	[Liu, Ying-liang; Xu, Zhi-ming; Yang, Dian-xu; Ding, Jun; Chen, Hao; Yuan, Fang; Tian, Heng-li] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Sch Med, Dept Neurosurg, Shanghai 200233, Peoples R China; [Yang, Guo-yuan] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200233, Peoples R China; [Yang, Guo-yuan] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200233, Peoples R China		Yuan, F; Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Sch Med, Dept Neurosurg, Shanghai 200233, Peoples R China.	yf021025@126.com; tianhlsh@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471245, 81671207, 81501657]; Shanghai Jiao Tong University Medicine-Engineering Research Fund [YG2016QN20]	This work was supported by grants from National Natural Science Foundation of China (No 81471245, 81671207, and 81501657), and Shanghai Jiao Tong University Medicine-Engineering Research Fund (YG2016QN20).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abu-Qare AW, 2001, J TOXICOL ENV HEAL B, V4, P313, DOI 10.1080/109374001301419737; Ahmad S, 2014, NEUROTOXICOLOGY, V45, P100, DOI 10.1016/j.neuro.2014.10.002; Ahmad S, 2013, J NEUROIMMUNOL, V264, P54, DOI 10.1016/j.jneuroim.2013.09.015; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Balazy M, 2003, AGEING RES REV, V2, P191, DOI 10.1016/S1568-1637(02)00065-X; Benga O, 2012, MOL ASPECTS MED, V33, P562, DOI 10.1016/j.mam.2012.03.008; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Cao JL, 2015, AQUAT TOXICOL, V167, P180, DOI 10.1016/j.aquatox.2015.08.004; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fujikawa T, 2005, J ETHNOPHARMACOL, V97, P375, DOI 10.1016/j.jep.2004.11.031; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hou RCW, 2004, NEUROSCI LETT, V367, P10, DOI 10.1016/j.neulet.2004.05.073; Hou RCW, 2003, J NEUROSCI RES, V74, P123, DOI 10.1002/jnr.10749; Hsieh PF, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-57; Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lee CC, 2004, J HYPERTENS, V22, P2329, DOI 10.1097/00004872-200412000-00015; Lopez-Garcia I, 2018, BRIT J PHARMACOL, V175, P284, DOI 10.1111/bph.13642; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mayr M, 2000, FASEB J, V14, P261, DOI 10.1096/fasebj.14.2.261; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathan C, 2010, CELL, V140, DOI 10.1016/j.cell.2010.03.008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Park HJ, 2015, NEUROCHEM INT, V83-84, P19, DOI 10.1016/j.neuint.2015.01.003; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804; Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1; Tian RF, 2016, BRAIN RES, V1637, P1, DOI 10.1016/j.brainres.2016.01.029; Toklu HZ, 2015, BRAIN NEUROTRAUMA MO; Warth A, 2004, ACTA NEUROPATHOL, V107, P311, DOI 10.1007/s00401-003-0812-0; Weber DJ, 2014, SCI TRANSL MED, V6, P252; Wu WH, 2010, MOL NUTR FOOD RES, V54, P1340, DOI 10.1002/mnfr.200900271; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Yang T, 2014, CELL MOL NEUROBIOL, V34, P797, DOI 10.1007/s10571-014-0070-9; Yin Q, 2015, BRIT J PHARMACOL, V172, P5573, DOI 10.1111/bph.13133; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; ZHANG J, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/4350965; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	54	39	40	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	NOV	2017	38	11					1445	1455		10.1038/aps.2017.103			11	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Pharmacology & Pharmacy	FL5CL	WOS:000414248600003	28770828	Green Published, Bronze			2022-02-06	
J	Mao, AH; Ma, XD; He, YN; Luo, J				Mao, Aihua; Ma, Xuedong; He, Yinan; Luo, Jie			Highly Portable, Sensor-Based System for Human Fall Monitoring	SENSORS			English	Article						fall detection; sensors; easy portability; body segment	ALGORITHM	Falls are a very dangerous situation especially among elderly people, because they may lead to fractures, concussion, and other injuries. Without timely rescue, falls may even endanger their lives. The existing optical sensor-based fall monitoring systems have some disadvantages, such as limited monitoring range and inconvenience to carry for users. Furthermore, the fall detection system based only on an accelerometer often mistakenly determines some activities of daily living (ADL) as falls, leading to low accuracy in fall detection. We propose a human fall monitoring system consisting of a highly portable sensor unit including a triaxis accelerometer, a triaxis gyroscope, and a triaxis magnetometer, and a mobile phone. With the data from these sensors, we obtain the acceleration and Euler angle (yaw, pitch, and roll), which represents the orientation of the user's body. Then, a proposed fall detection algorithm was used to detect falls based on the acceleration and Euler angle. With this monitoring system, we design a series of simulated falls and ADL and conduct the experiment by placing the sensors on the shoulder, waist, and foot of the subjects. Through the experiment, we re-identify the threshold of acceleration for accurate fall detection and verify the best body location to place the sensors by comparing the detection performance on different body segments. We also compared this monitoring system with other similar works and found that better fall detection accuracy and portability can be achieved by our system.	[Mao, Aihua; He, Yinan] South China Univ Technol, Sch Comp Sci & Engn, Guangzhou 510006, Guangdong, Peoples R China; [Ma, Xuedong] South China Univ Technol, Sch Elect & Informat Engn, Guangzhou 510006, Guangdong, Peoples R China; [Luo, Jie] Guangzhou Univ, Sch Fine Art & Artist Design, Guangzhou 510006, Guangdong, Peoples R China		Mao, AH (corresponding author), South China Univ Technol, Sch Comp Sci & Engn, Guangzhou 510006, Guangdong, Peoples R China.; Luo, J (corresponding author), Guangzhou Univ, Sch Fine Art & Artist Design, Guangzhou 510006, Guangdong, Peoples R China.	ahmao@scut.edu.cn; eemaxuedong@mail.scut.edu.cn; heyinanscut@outlook.com; jieluo@gzhu.edu.cn			National Natural Science Foundations of ChinaNational Natural Science Foundation of China (NSFC) [61502112]; NSF of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2016A030313499]; Science and Technology Planning Project of Guangdong Province [2015A030401030, 2015A020219014]; Guangzhou Municipal University Research Projects [1201630279]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2017ZD054]; Guangdong Province Universities and Colleges Excellent Youth Teacher Training Program; Student Research Project (SRP) of South China University of Technology	The work of this paper is financially supported by The National Natural Science Foundations of China (No. 61502112), NSF of Guangdong Province (No. 2016A030313499), The Science and Technology Planning Project of Guangdong Province (No. 2015A030401030, No. 2015A020219014), Guangzhou Municipal University Research Projects (No. 1201630279), and the Fundamental Research Funds for the Central Universities (No. 2017ZD054), The Guangdong Province Universities and Colleges Excellent Youth Teacher Training Program and the Student Research Project (SRP) of South China University of Technology.	Albert MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036556; Anderson Derek, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6388; Ando B, 2016, IEEE T INSTRUM MEAS, V65, P1960, DOI 10.1109/TIM.2016.2552678; Bian ZP, 2015, IEEE J BIOMED HEALTH, V19, P430, DOI 10.1109/JBHI.2014.2319372; Erdogan SZ, 2012, IET COMMUN, V6, P3281, DOI 10.1049/iet-com.2011.0228; Gasparrini S, 2014, SENSORS-BASEL, V14, P2756, DOI 10.3390/s140202756; He J, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17061393; Heinrich S, 2010, OSTEOPOROSIS INT, V21, P891, DOI 10.1007/s00198-009-1100-1; Hsieh CY, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17020307; Kangas M, 2007, P ANN INT IEEE EMBS, P1367, DOI 10.1109/IEMBS.2007.4352552; Kangas M, 2008, GAIT POSTURE, V28, P285, DOI 10.1016/j.gaitpost.2008.01.003; Karantonis DM, 2006, IEEE T INF TECHNOL B, V10, P156, DOI 10.1109/TITB.2005.856864; Kurniawan A, 2016, 2016 INTERNATIONAL SEMINAR ON INTELLIGENT TECHNOLOGY AND ITS APPLICATIONS (ISITIA): RECENT TRENDS IN INTELLIGENT COMPUTATIONAL TECHNOLOGIES FOR SUSTAINABLE ENERGY, P671, DOI 10.1109/ISITIA.2016.7828740; Lai CF, 2011, IEEE SENS J, V11, P763, DOI 10.1109/JSEN.2010.2062501; Lee YS, 2012, SENSORS-BASEL, V12, P573, DOI 10.3390/s120100573; Li Q, 2009, SIXTH INTERNATIONAL WORKSHOP ON WEARABLE AND IMPLANTABLE BODY SENSOR NETWORKS, PROCEEDINGS, P138, DOI [10.1109/P3644.45, 10.1109/BSN.2009.46]; Liu SH, 2012, SENSORS-BASEL, V12, P12301, DOI 10.3390/s120912301; Luque R, 2014, SENSORS-BASEL, V14, P18543, DOI 10.3390/s141018543; Munoz-Organero M, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16091464; Nari MI, 2016, 2016 INTERNATIONAL SYMPOSIUM ON ELECTRONICS AND SMART DEVICES (ISESD), P88, DOI 10.1109/ISESD.2016.7886698; Ntalampiras S., 2016, P IEEE S SER COMP IN, P1, DOI [10.1109/SSCI.2016.7850188, DOI 10.1109/SSCI.2016.7850188]; Ojetola O., 2011, 2011 7th International Conference on Intelligent Environments, P318, DOI 10.1109/IE.2011.38; Pierleoni P, 2015, IEEE SENS J, V15, P4544, DOI 10.1109/JSEN.2015.2423562; Rougier Caroline, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6384; Sorvala A., 2012, P 6 INT S MED INF CO, P1; Stone EE, 2015, IEEE J BIOMED HEALTH, V19, P290, DOI 10.1109/JBHI.2014.2312180; Tao S, 2012, SENSORS-BASEL, V12, P16920, DOI 10.3390/s121216920; Tran TH, 2017, COMPUT METH PROG BIO, V146, P151, DOI 10.1016/j.cmpb.2017.05.007; Wibisono W, 2013, CONF TECHNOL APPL, P382, DOI 10.1109/TAAI.2013.82; Yang L, 2015, SENSORS-BASEL, V15, P23004, DOI 10.3390/s150923004; Yean S., 2016, P 2016 IEEE 7 ANN IN, P1, DOI DOI 10.1109/IEMCON.2016.7746263; Yu M, 2012, IEEE T INF TECHNOL B, V16, P1274, DOI 10.1109/TITB.2012.2214786	32	39	40	4	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1424-8220		SENSORS-BASEL	Sensors	SEP	2017	17	9							2096	10.3390/s17092096			15	Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments & Instrumentation	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Engineering; Instruments & Instrumentation	FH8WD	WOS:000411484700166	28902149	Green Published, Green Submitted, gold			2022-02-06	
J	Cnossen, MC; Winkler, EA; Yue, JK; Okonkwo, DO; Valadka, AB; Steyerberg, EW; Lingsma, HF; Manley, GT				Cnossen, Maryse C.; Winkler, Ethan A.; Yue, John K.; Okonkwo, David O.; Valadka, Alex B.; Steyerberg, Ewout W.; Lingsma, Hester F.; Manley, Geoffrey T.		TRACK-TBI Investigators	Development of a Prediction Model for Post-Concussive Symptoms following Mild Traumatic Brain Injury: A TRACK-TBI Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						post-concussion symptoms; prediction model; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; COMMON DATA ELEMENTS; OUTCOME PREDICTION; RISK-FACTORS; HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; CONSTRUCT-VALIDITY; PROGNOSTIC MODELS; RECOVERY; QUESTIONNAIRE	Post-concussive symptoms occur frequently after mild traumatic brain injury (mTBI) and may be categorized as cognitive, somatic, or emotional. We aimed to: 1) assess whether patient demographics and clinical variables predict development of each of these three symptom categories, and 2) develop a prediction model for 6-month post-concussive symptoms. Patients with mTBI (Glasgow Coma Scale score 13-15) from the prospective multi-center Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot study (2010-2012) who completed the Rivermead Post Concussion Symptoms Questionnaire (RPQ) at 6 months post-injury were included. Linear regression was utilized to determine the predictive value of candidate predictors for cognitive, somatic, and emotional subscales individually, as well as the overall RPQ. The final prediction model was developed using least absolute shrinkage and selection operator shrinkage and bootstrap validation. We included 277 mTBI patients (70% male; median age 42 years). No major differences in the predictive value of our set of predictors existed for the cognitive, somatic, and emotional subscales, and therefore one prediction model for the RPQ total scale was developed. Years of education, pre-injury psychiatric disorders, and prior TBI were the strongest predictors of 6-month post-concussive symptoms. The total set of predictors explained 21% of the variance, which decreased to 14% after bootstrap validation. Demographic and clinical variables at baseline are predictive of 6-month post-concussive symptoms following mTBI; however, these variables explain less than one-fifth of the total variance in outcome. Model refinement with larger datasets, more granular variables, and objective biomarkers are needed before implementation in clinical practice.	[Cnossen, Maryse C.; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Winkler, Ethan A.; Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Yue, John K.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RC2NS069409-01, 3RC2NS069409-02S1, 5RC2NS069409-02, 1U01NS086090-01, 3U01NS086090-02S1, 3U01NS086090-02S2, 3U01NS086090-03S1, 5U01NS086090-02, 5U01NS086090-03]; U.S. DODUnited States Department of Defense [W81XWH-13-1-0441, W81XWH-14-2-0176]; European UnionEuropean Commission [602150]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	This work was supported by the following grants: NINDS 1RC2NS069409-01, 3RC2NS069409-02S1, 5RC2NS069409-02, 1U01NS086090-01, 3U01NS086090-02S1, 3U01NS086090-02S2, 3U01NS086090-03S1, 5U01NS086090-02, 5U01NS086090-03; U.S. DOD W81XWH-13-1-0441, U.S. DOD W81XWH-14-2-0176 (to G.T. Manley). The authors M.C. Cnossen, H.F. Lingsma and E.W. Steyerberg were further supported by the European Union FP 7th Framework program (grant 602150).	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cary VJ, 2016, FOREIGN; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Clay FJ, 2010, J REHABIL MED, V42, P162, DOI 10.2340/16501977-0495; Collins GS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7594; Crandall M, 2014, BRAIN INJURY, V28, P1359, DOI 10.3109/02699052.2014.919533; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M, 2010, TRAUMATIC BRAIN INJU; Goeman JJ, 2010, BIOMETRICAL J, V52, P70, DOI 10.1002/bimj.200900028; Gustavson K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-918; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hess DW, 2000, ARCH PHYS MED REHAB, V81, P359, DOI 10.1053/apmr.2000.0810359; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mueller TI, 1999, AM J PSYCHIAT, V156, P1000; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Steyerberg, 2019, CLIN PREDICTION MODE; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; The National Institute of Neurlogical Disorders and Stroke, 2015, NINDS COMM DAT EL TR; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Wolke D, 2009, BRIT J PSYCHIAT, V195, P249, DOI 10.1192/bjp.bp.108.053751; World Health Organization, 1993, ICD 10 CLASS MENT BE; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zasler ND, 2006, BRAIN INJURY MED PRI, P374; Zimmerli M, 2014, RESUSCITATION, V85, P801, DOI 10.1016/j.resuscitation.2014.02.022	58	39	39	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2017	34	16					2396	2409		10.1089/neu.2016.4819			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	FC6RI	WOS:000406968400003	28343409	Green Published			2022-02-06	
J	Thelin, EP; Nelson, DW; Vehvilainen, J; Nystrom, H; Kivisaari, R; Siironen, J; Svensson, M; Skrifvars, MB; Bellander, BM; Raj, R				Thelin, Eric Peter; Nelson, David W.; Vehvilainen, Juho; Nystrom, Harriet; Kivisaari, Riku; Siironen, Jari; Svensson, Mikael; Skrifvars, Markus B.; Bellander, Bo-Michael; Raj, Rahul			Evaluation of novel computerized tomography scoring systems in human traumatic brain injury: An observational, multicenter study	PLOS MEDICINE			English	Article							GLASGOW COMA SCALE; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CLINICAL-PRACTICE; PREDICTIVE-VALUE; IMPACT; EPIDEMIOLOGY; CLASSIFICATION; MANAGEMENT; STATEMENT	Background Traumatic brain injury (TBI) is a major contributor to morbidity and mortality. Computerized tomography (CT) scanning of the brain is essential for diagnostic screening of intracranial injuries in need of neurosurgical intervention, but may also provide information concerning patient prognosis and enable baseline risk stratification in clinical trials. Novel CT scoring systems have been developed to improve current prognostic models, including the Stockholm and Helsinki CT scores, but so far have not been extensively validated. The primary aim of this study was to evaluate the Stockholm and Helsinki CT scores for predicting functional outcome, in comparison with the Rotterdam CT score and Marshall CT classification. The secondary aims were to assess which individual components of the CT scores best predict outcome and what additional prognostic value the CT scoring systems contribute to a clinical prognostic model. Methods and findings TBI patients requiring neuro-intensive care and not included in the initial creation of the Stockholm and Helsinki CT scoring systems were retrospectively included from prospectively collected data at the Karolinska University Hospital (n = 720 from 1 January 2005 to 31 December 2014) and Helsinki University Hospital (n = 395 from 1 January 2013 to 31 December 2014), totaling 1,115 patients. The Marshall CT classification and the Rotterdam, Stockholm, and Helsinki CT scores were assessed using the admission CT scans. Known outcome predictors at admission were acquired (age, pupil responsiveness, admission Glasgow Coma Scale, glucose level, and hemoglobin level) and used in univariate, and multivariable, regression models to predict long-term functional outcome (dichotomizations of the Glasgow Outcome Scale [GOS]). In total, 478 patients (43%) had an unfavorable outcome (GOS 1-3). In the combined cohort, overall prognostic performance was more accurate for the Stockholm CT score (Nagelkerke's pseudo-R-2 range 0.24-0.28) and the Helsinki CT score (0.18-0.22) than for the Rotterdam CT score (0.13-0.15) and Marshall CT classification (0.03-0.05). Moreover, the Stockholm and Helsinki CT scores added the most independent prognostic value in the presence of other known clinical outcome predictors in TBI (6% and 4%, respectively). The aggregate traumatic subarachnoid hemorrhage (tSAH) component of the Stockholm CT score was the strongest predictor of unfavorable outcome. The main limitations were the retrospective nature of the study, missing patient information, and the varying follow-up time between the centers. Conclusions The Stockholm and Helsinki CT scores provide more information on the damage sustained, and give a more accurate outcome prediction, than earlier classification systems. The strong independent predictive value of tSAH may reflect an underrated component of TBI pathophysiology. A change to these newer CT scoring systems may be warranted.	[Thelin, Eric Peter; Nystrom, Harriet; Svensson, Mikael; Bellander, Bo-Michael] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Thelin, Eric Peter] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Biomed Campus, Cambridge, England; [Nelson, David W.] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden; [Vehvilainen, Juho; Kivisaari, Riku; Siironen, Jari; Raj, Rahul] Univ Helsinki, Dept Neurosurg, Helsinki, Finland; [Vehvilainen, Juho; Kivisaari, Riku; Siironen, Jari; Skrifvars, Markus B.; Raj, Rahul] Helsinki Univ Hosp, Helsinki, Finland; [Svensson, Mikael; Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Skrifvars, Markus B.] Univ Helsinki, Dept Anaesthesiol Intens Care & Pain Med, Helsinki, Finland; [Skrifvars, Markus B.] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia		Thelin, EP (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.; Thelin, EP (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Biomed Campus, Cambridge, England.	eric.thelin@ki.se	Thelin, Eric Peter/K-2144-2012; Raj, Rahul/K-7693-2012; Viani, Rafael/V-1196-2018; Svensson, Mikael/F-8662-2012	Thelin, Eric Peter/0000-0002-2338-4364; Raj, Rahul/0000-0003-4243-9591; Svensson, Mikael/0000-0003-1179-7003; Bellander, Bo-Michael/0000-0002-0648-2501; Nelson, David/0000-0003-2530-8207	Swedish Society of Medicine [SLS-587221]; Maire Taponen's Foundation; Medical Association Life & Health (Liv och Halsa); Swedish Medical Society in Finland; Swedish Cultural Foundation in Finland; Maud Kuistila Memorial Foundation; Eemil Aaltonen Foundation; Ella and Georg Ehrnrooth Foundation; Finnish-Norwegian Medical Foundation; Finnish Medical Foundation; Maire Taponen Foundation	EPT has received funding from the Swedish Society of Medicine (Grant no. SLS-587221, http://www.sls.se/). JV has received funding from Maire Taponen's Foundation (http://www.mairetaposensaatio.fi/). RR is funded by personal grants from the Medical Association Life & Health (Liv och Halsa, http://www.livochhalsa.fi/), the Swedish Medical Society in Finland (http://www.fls.fi/), the Swedish Cultural Foundation in Finland (http:// www.kulturfonden.fi/), the Maud Kuistila Memorial Foundation (http://www. maudkuistilanmuistosaatio.fi/), the Eemil Aaltonen Foundation (http://www.emilaaltonen.fi/ ), The Ella and Georg Ehrnrooth Foundation (http://www.ellageorg.fi/), the Finnish-Norwegian Medical Foundation (http://www.hanaholmen.fi/ en/foundations/finnish-norwegian), the Finnish Medical Foundation (http://www. laaketieteensaatio.fi/) and the Maire Taponen Foundation (http://www.mairetaposensaatio.fi/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Flynn-O'Brien KT, 2015, NEUROSURGERY, V76, P451, DOI 10.1227/NEU.0000000000000693; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hoogmartens O, 2014, PREHOSP EMERG CARE, V18, P265, DOI 10.3109/10903127.2013.856506; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Kim YJ, 2014, INT EMERG NURS, V22, P214, DOI 10.1016/j.ienj.2014.02.005; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Olivecrona M, 2016, J NEUROTRAUM, V33, pA34; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; PLOS Medicine Editors, 2014, PLOS MED, V11; R Core Team, 2016, R LANG ENV STAT COMP; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Ringdal KG, 2008, SCAND J TRAUMA RESUS, V16, DOI 10.1186/1757-7241-16-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2009, STAT BIOL HLTH; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267; [No title captured]	49	39	42	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	AUG	2017	14	8							e1002368	10.1371/journal.pmed.1002368			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF2ZW	WOS:000408766300005	28771476	Green Published, gold, Green Submitted			2022-02-06	
J	Ge, RM; Tornero, D; Hirota, M; Monni, E; Laterza, C; Lindvall, O; Kokaia, Z				Ge, Ruimin; Tornero, Daniel; Hirota, Masao; Monni, Emanuela; Laterza, Cecilia; Lindvall, Olle; Kokaia, Zaal			Choroid plexus-cerebrospinal fluid route for monocyte-derived macrophages after stroke	JOURNAL OF NEUROINFLAMMATION			English	Article						Stroke; Inflammation; Choroid plexus; Transplantation; Functional recovery	REGULATORY T-CELLS; CHEMOATTRACTANT PROTEIN-1; M2 MACROPHAGES; MOUSE MODEL; CNS; POLARIZATION; RECRUITMENT; DYNAMICS; EFFECTOR; INVASION	Background: Choroid plexus (CP) supports the entry of monocyte-derived macrophages (MDMs) to the central nervous system in animal models of traumatic brain injury, spinal cord injury, and Alzheimer's disease. Whether the CP is involved in the recruitment of MDMs to the injured brain after ischemic stroke is unknown. Methods: Adult male C57BL/6 mice were subjected to focal cortical ischemia by permanent occlusion of the distal branch of the right middle cerebral artery. Choroid plexus tissues were collected and analyzed for Vcam1, Madcam1, Cx(3)cl1, Ccl2, Nt5e, and Ifn gamma expression at different timepoints after stroke using qPCR. Changes of MDMs in CP and cerebrospinal fluid (CSF) at 1 day and 3 days after stroke were analyzed using flow cytometry. Infiltration of MDMs into CP and CSF were validated using beta-actin-GFP chimeric mice and Fgd5-CreERT2 x Lox-stop-lox-Tomato mice. CD115+ monocytes were isolated using a magnetic cell separation system from bone marrow of Cx(3)cr1-GFP or wild-type C57BL/6 donor mice. The freshly isolated monocytes or M2-like MDMs primed in vitro with IL4 and IL13 were stereotaxically injected into the lateral ventricle of stroke-affected mice to trace for their migration into ischemic hemisphere or to assess their effect on post-stroke recovery using open field, corridor, and active avoidance behavioral tests. Results: We found that CP responded to cortical stroke by upregulation of gene expression for several possible mediators of MDM trafficking and, concomitantly, MDMs increased in CP and cerebrospinal fluid (CSF). We then confirmed that MDMs infiltrated from blood into CP and CSF after the insult using beta-actinGFP chimeric mice and Fgd5-CreERT2 x Lox-stop-lox-Tomato mice. When MDMs were directly administered into CSF following stroke, they homed to the ischemic hemisphere. If they had been primed in vitro prior to their administration to become M2-like macrophages, they promoted post-stroke recovery of motor and cognitive function without influencing infarct volume. Conclusions: Our findings suggest the possibility that autologous transplantation of M2-like MDMs into CSF might be developed into a new strategy for promoting recovery also in patients with stroke.	[Ge, Ruimin; Tornero, Daniel; Hirota, Masao; Monni, Emanuela; Laterza, Cecilia; Lindvall, Olle; Kokaia, Zaal] Univ Hosp, Lund Stem Cell Ctr, Lab Stem Cells & Restorat Neurol, SE-22184 Lund, Sweden		Kokaia, Z (corresponding author), Univ Hosp, Lund Stem Cell Ctr, Lab Stem Cells & Restorat Neurol, SE-22184 Lund, Sweden.	zaal.kokaia@med.lu.se	Tornero, Daniel/N-2049-2014; Laterza, Cecilia/AAP-7932-2020; Kokaia, Zaal/AAL-6009-2020; Laterza, Cecilia/ABG-6504-2021	Tornero, Daniel/0000-0002-4812-4091; Kokaia, Zaal/0000-0003-2296-2449; 	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Union project TargetBraIn [279017]; AFA Foundation; Swedish Brain Foundation; Torsten Soderberg Foundation; Region Skane; Sparbanksstiftelsen Fars Frosta; Swedish Government Initiative for Strategic Research Areas (StemTherapy)	This work was supported by the Swedish Research Council, European Union project TargetBraIn (279017), AFA Foundation, Swedish Brain Foundation, Torsten Soderberg Foundation, Region Skane, Sparbanksstiftelsen Fars & Frosta, and Swedish Government Initiative for Strategic Research Areas (StemTherapy).	Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Baruch K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8967; Chernykh ER, 2016, CELL TRANSPLANT, V25, P1461, DOI 10.3727/096368915X690279; Desestret V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067063; Desland FA, 2014, J CENT NERV SYST DIS, V6, P7, DOI [10.4137/JCNSD.S13194, 10.4137/JCNSNSD.S13194]; Dowd E, 2005, BRAIN RES BULL, V68, P24, DOI 10.1016/j.brainresbull.2005.08.009; Gazit R, 2014, J EXP MED, V211, P1314, DOI 10.1084/jem.20130428; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gevrey JC, 2005, J IMMUNOL, V175, P3737, DOI 10.4049/jimmunol.175.6.3737; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Grealish S, 2010, EUR J NEUROSCI, V31, P2266, DOI 10.1111/j.1460-9568.2010.07265.x; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Korf-Klingebiel M, 2015, NAT MED, V21, P140, DOI 10.1038/nm.3778; Kunis G, 2015, J NEUROSCI, V35, P6381, DOI 10.1523/JNEUROSCI.3644-14.2015; Kunis G, 2013, BRAIN, V136, P3427, DOI 10.1093/brain/awt259; Liu Li, 2008, J Vis Exp, DOI 10.3791/960; Losy J, 2001, STROKE, V32, P2695, DOI 10.1161/hs1101.097380; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Miro-Mur F, 2016, BRAIN BEHAV IMMUN, V53, P18, DOI 10.1016/j.bbi.2015.08.010; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; Perez-de Puig I, 2013, J CEREBR BLOOD F MET, V33, P1955, DOI 10.1038/jcbfm.2013.155; Raposo C, 2014, J NEUROSCI, V34, P10141, DOI 10.1523/JNEUROSCI.0076-14.2014; SANSONE M, 1993, PHARMACOL BIOCHEM BE, V44, P451, DOI 10.1016/0091-3057(93)90490-K; Schlager C, 2016, NATURE, V530, P349, DOI 10.1038/nature16939; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Strazielle N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150945; Szmydynger-Chodobska J, 2012, J CEREBR BLOOD F MET, V32, P93, DOI 10.1038/jcbfm.2011.111; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; TAKEYA M, 1991, EXP MOL PATHOL, V54, P61, DOI 10.1016/0014-4800(91)90044-X; Urra X, 2009, J CEREBR BLOOD F MET, V29, P994, DOI 10.1038/jcbfm.2009.25; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016	35	39	39	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 28	2017	14								153	10.1186/s12974-017-0909-3			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	FC0LF	WOS:000406529000004	28754163	Green Published, gold			2022-02-06	
J	Shilpa, BM; Bhagya, V; Harish, G; Bharath, MMS; Rao, BSS				Shilpa, B. M.; Bhagya, V; Harish, G.; Bharath, Srinivas M. M.; Rao, Shankaranarayana B. S.			Environmental enrichment ameliorates chronic immobilisation stress-induced spatial learning deficits and restores the expression of BDNF, VEGF, GFAP and glucocorticoid receptors	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						Enriched environment; Chronic immobilisation stress; Hippocampus; Amygdalar complex; Depression; Neurotrophic factors; Glucocorticoid receptors; Structural plasticity	ENDOTHELIAL GROWTH-FACTOR; FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPAL CELL-PROLIFERATION; NEUROTROPHIC FACTOR EXPRESSION; INDUCED COGNITIVE DEFICITS; ANTERIOR CINGULATE CORTEX; DEPRESSION-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; RAT MODEL; PREFRONTAL CORTEX	Severe and prolonged stress is the main environmental factor that precipitates depression, anxiety and cognitive dysfunctions. On the other hand, exposure to environmental enrichment (EE) has been shown to induce progressive plasticity in the brain and improve learning and memory in various neurological and psychiatric disorders. It is not known whether exposure to enriched environment could ameliorate chronic immobilisation stress-induced cognitive deficits and altered molecular markers. Hence, in the present study we aimed to evaluate the effect of enriched environment on chronic immobilisation stress (CIS) associated changes in spatial learning and memory, behavioural measures of anxiety, depression and molecular markers as well as structural alterations. Male Wistar rats were subjected to chronic immobilisation stress for 2 h/day/10 days followed by 2 weeks of exposure to EE. CIS resulted in weight loss, anhedonia, increased immobility, spatial learning and memory impairment, enhanced anxiety, and reduced expression of BDNF, VEGF, GFAP and glucocorticoid receptors (GR) in discrete brain regions. Interestingly, stressed rats exposed to enrichment ameliorated behavioural depression, spatial learning and memory impairment and reduced anxiety behaviour. In addition, EE restored BDNF, VEGF, GFAP and GR expression and normalized hypotrophy of dentate gyrus and hippocampus in CIS rats. In contrast, EE did not restore hypertrophy of the amygdalar complex. Thus, EE ameliorates stress-induced cognitive deficits by modulating the neurotrophic factors, astrocytes and glucocorticoid receptors in the hippocampus, frontal cortex and amygdala. (C) 2017 Elsevier Inc. All rights reserved.	[Shilpa, B. M.; Bhagya, V; Rao, Shankaranarayana B. S.] Natl Inst Mental Hlth & Neurosci, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India; [Harish, G.; Bharath, Srinivas M. M.] Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Hosur Rd, Bengaluru 560029, India		Rao, BSS (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India.	bssrao.nimhans@gmail.com	Rao, Bhagya Venkanna/AAY-7370-2020	Rao, Bhagya Venkanna/0000-0003-0664-0335; Shankaranarayana Rao, BS/0000-0002-8323-8211			Alwis DS, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00156; Angelucci F, 2000, NEUROREPORT, V11, P1369, DOI 10.1097/00001756-200004270-00044; Anuradha H, 2008, J NEURAL TRANSM, V115, P35, DOI 10.1007/s00702-007-0821-6; Arango-Lievano M, 2015, P NATL ACAD SCI USA, V112, P15737, DOI 10.1073/pnas.1509045112; Baroncelli L, 2010, CELL DEATH DIFFER, V17, P1092, DOI 10.1038/cdd.2009.193; Baykara B, 2012, TURK NEUROSURG, V22, P604, DOI 10.5137/1019-5149.JTN.5633-11.1; Beauquis J, 2013, EXP NEUROL, V239, P28, DOI 10.1016/j.expneurol.2012.09.009; Beauquis J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013993; Benes FM, 2001, BIOL PSYCHIAT, V50, P395, DOI 10.1016/S0006-3223(01)01084-8; Bergstrom A, 2008, BRAIN RES, V1196, P41, DOI 10.1016/j.brainres.2007.12.025; Bhagya V, 2008, BEHAV BRAIN RES, V187, P190, DOI 10.1016/j.bbr.2007.08.020; Bhagya V, 2016, INDIAN J PHARMACOL, V48, P687, DOI 10.4103/0253-7613.194853; Bhagya V, 2015, J NEUROSCI RES, V93, P104, DOI 10.1002/jnr.23473; Bhagya V, 2011, PSYCHOPHARMACOLOGY, V214, P477, DOI 10.1007/s00213-010-2054-x; Bhagya VR, 2017, J NEUROSCI RES, V95, P1602, DOI 10.1002/jnr.23992; Bindu B, 2007, NEUROSCIENCE, V144, P412, DOI 10.1016/j.neuroscience.2006.09.057; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cao WY, 2014, BEHAV BRAIN RES, V265, P76, DOI 10.1016/j.bbr.2014.02.022; Chana G, 2003, BIOL PSYCHIAT, V53, P1086, DOI 10.1016/S0006-3223(03)00114-8; Chandana R, 2009, INDIAN J MED RES, V129, P189; Conrad CD, 1999, BEHAV NEUROSCI, V113, P902, DOI 10.1037/0735-7044.113.5.902; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; Dhanushkodi A, 2008, NEUROSCI BIOBEHAV R, V32, P657, DOI 10.1016/j.neubiorev.2007.10.004; Dinan TG, 2005, EUR PSYCHIAT, V20, pS326, DOI 10.1016/S0924-9338(05)80184-1; Duman Ronald S, 2009, Dialogues Clin Neurosci, V11, P239; Duman RS, 2005, NEUROBIOL AGING, V26, pS88, DOI 10.1016/j.neurobiolaging.2005.08.018; Ehninger D, 2003, CEREB CORTEX, V13, P845, DOI 10.1093/cercor/13.8.845; Elfving B, 2010, NEUROSCI LETT, V474, P13, DOI 10.1016/j.neulet.2010.02.063; Fernandez-Teruel A, 2002, PHARMACOL BIOCHEM BE, V73, P233, DOI 10.1016/S0091-3057(02)00787-6; Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022; Frodl T, 2002, BIOL PSYCHIAT, V51, P708, DOI 10.1016/S0006-3223(01)01359-2; Frodl T, 2013, NEUROBIOL DIS, V52, P24, DOI 10.1016/j.nbd.2012.03.012; Givalois L, 2004, MOL CELL NEUROSCI, V27, P280, DOI 10.1016/j.mcn.2004.07.002; Gormanns P, 2011, J PSYCHIATR RES, V45, P973, DOI 10.1016/j.jpsychires.2010.12.010; Gosselin RD, 2009, NEUROSCIENCE, V159, P915, DOI 10.1016/j.neuroscience.2008.10.018; Govindarajan A, 2006, P NATL ACAD SCI USA, V103, P13208, DOI 10.1073/pnas.0605180103; Grassi-Oliveira R, 2008, BIOL PSYCHIAT, V64, P281, DOI 10.1016/j.biopsych.2008.02.023; Harish G, 2011, BIOPRESERV BIOBANK, V9, P379, DOI 10.1089/bio.2011.0033; Hegde P, 2008, NEUROSCIENCE, V153, P20, DOI 10.1016/j.neuroscience.2008.01.042; Heine VM, 2005, EUR J NEUROSCI, V21, P1304, DOI 10.1111/j.1460-9568.2005.03951.x; Hendriksen H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011943; Huang YF, 2012, J BIOL CHEM, V287, P40938, DOI 10.1074/jbc.M112.392076; Jaeger J, 2006, PSYCHIAT RES, V145, P39, DOI 10.1016/j.psychres.2005.11.011; Jha S, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.33; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837; Kim KS, 2006, J NEUROSCI RES, V83, P497, DOI 10.1002/jnr.20754; Kiuchi T, 2012, NEUROSCIENCE, V207, P208, DOI 10.1016/j.neuroscience.2012.01.023; Koehl M, 2002, NEUROTOX RES, V4, P281, DOI 10.1080/1029842021000010866; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lakshminarasimhan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030481; Lambert WM, 2013, MOL CELL BIOL, V33, P3700, DOI 10.1128/MCB.00150-13; Li H, 2013, COMMUNITY MENT HLT J, V49, P419, DOI 10.1007/s10597-012-9567-1; Mahati K, 2016, NEUROBIOL LEARN MEM, V134, P379, DOI 10.1016/j.nlm.2016.08.017; Malik R, 2012, J NEUROPHYSIOL, V107, P1366, DOI 10.1152/jn.01009.2011; McCloskey DP, 2005, J NEUROSCI, V25, P8889, DOI 10.1523/JNEUROSCI.2577-05.2005; Miguel-Hidalgo JJ, 2000, BIOL PSYCHIAT, V48, P861, DOI 10.1016/S0006-3223(00)00999-9; Minelli A, 2011, PROG NEURO-PSYCHOPH, V35, P1322, DOI 10.1016/j.pnpbp.2011.04.013; Mitra R, 2005, P NATL ACAD SCI USA, V102, P9371, DOI 10.1073/pnas.0504011102; Mitra R, 2006, PHYSIOL BEHAV, V89, P123, DOI 10.1016/j.physbeh.2006.05.047; Morley-Fletcher S, 2003, EUR J NEUROSCI, V18, P3367, DOI 10.1111/j.1460-9568.2003.03070.x; Naert G, 2011, MOL CELL NEUROSCI, V46, P55, DOI 10.1016/j.mcn.2010.08.006; Naismith SL, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-32; Novkovic T, 2015, HIPPOCAMPUS, V25, P1, DOI 10.1002/hipo.22342; Nowacka MM, 2012, NEUROPEPTIDES, V46, P1, DOI 10.1016/j.npep.2011.05.005; Nowakowska E, 2014, PHARMACOL REP, V66, P404, DOI 10.1016/j.pharep.2013.12.008; Pang TYC, 2013, NEUROPHARMACOLOGY, V64, P515, DOI 10.1016/j.neuropharm.2012.06.029; PAPP M, 1991, PSYCHOPHARMACOLOGY, V104, P255, DOI 10.1007/BF02244188; Park HJ, 2015, ARCH PHARM RES, V38, P1204, DOI 10.1007/s12272-015-0548-0; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Pizarro JM, 2004, BRAIN RES, V1025, P10, DOI 10.1016/j.brainres.2004.06.085; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; Radecki DT, 2005, HIPPOCAMPUS, V15, P246, DOI 10.1002/hipo.20048; Ramkumar K, 2008, NEUROCHEM RES, V33, P1651, DOI 10.1007/s11064-007-9511-x; Ravenelle R, 2014, NEUROSCIENCE, V270, P76, DOI 10.1016/j.neuroscience.2014.03.060; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Richter SH, 2013, BEHAV BRAIN RES, V252, P287, DOI 10.1016/j.bbr.2013.06.021; Roceri M, 2002, MOL PSYCHIATR, V7, P609, DOI 10.1038/sj.mp.4001036; Roohafza HR, 2014, J RES MED SCI, V19, P944; Rubinow MJ, 2009, J COMP NEUROL, V512, P717, DOI 10.1002/cne.21924; Salmaso N, 2012, J NEUROSCI, V32, P8930, DOI 10.1523/JNEUROSCI.1398-12.2012; Sampedro-Piquero P, 2014, NEUROBIOL LEARN MEM, V114, P16, DOI 10.1016/j.nlm.2014.04.002; SAPOLSKY RM, 1984, ENDOCRINOLOGY, V114, P287, DOI 10.1210/endo-114-1-287; Schmidt HD, 2007, BEHAV PHARMACOL, V18, P391, DOI 10.1097/FBP.0b013e3282ee2aa8; Sheline YI, 2000, BIOL PSYCHIAT, V48, P791, DOI 10.1016/S0006-3223(00)00994-X; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Sloan SA, 2014, CURR OPIN NEUROBIOL, V27, P75, DOI 10.1016/j.conb.2014.03.005; Srikumar BN, 2007, PSYCHOPHARMACOLOGY, V193, P363, DOI 10.1007/s00213-007-0801-4; Stockmeier Craig A, 2004, Dialogues Clin Neurosci, V6, P185; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321; Suvrathan A, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0151; Taliaz D, 2010, MOL PSYCHIATR, V15, P80, DOI 10.1038/mp.2009.67; Tapia-Arancibia L, 2004, FRONT NEUROENDOCRIN, V25, P77, DOI 10.1016/j.yfrne.2004.04.001; Uysal N, 2012, NEUROSCI LETT, V514, P141, DOI 10.1016/j.neulet.2012.02.049; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Veena J, 2009, NEUROSCI LETT, V455, P178, DOI 10.1016/j.neulet.2009.03.059; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; von Gunten A, 2000, J NEUROPSYCH CLIN N, V12, P493, DOI 10.1176/appi.neuropsych.12.4.493; Vyas A, 2004, BEHAV NEUROSCI, V118, P1450, DOI 10.1037/0735-7044.118.6.1450; Vyas A, 2004, NEUROSCIENCE, V128, P667, DOI 10.1016/j.neuroscience.2004.07.013; Vyas A, 2002, J NEUROSCI, V22, P6810; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Wislowska-Stanek A, 2013, NEUROSCI LETT, V533, P17, DOI 10.1016/j.neulet.2012.11.012; Xu ZW, 2009, EUR NEUROPSYCHOPHARM, V19, P868, DOI 10.1016/j.euroneuro.2009.07.004; Yehuda R., 2012, DEPRESS RES TREAT, V2012; Yulug B, 2009, J NEUROPSYCH CLIN N, V21, P471, DOI 10.1176/appi.neuropsych.21.4.471; Zanca RM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00303; Zhang L, 2013, PHARMACOL BIOCHEM BE, V103, P693, DOI 10.1016/j.pbb.2012.12.023; Zhang L, 2011, CURR NEUROVASC RES, V8, P286, DOI 10.2174/156720211798121025	114	39	43	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	JUN 2	2017	76						88	100		10.1016/j.pnpbp.2017.02.025			13	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EY9LR	WOS:000404320600011	28288856				2022-02-06	
J	Aiolfi, A; Benjamin, E; Khor, D; Inaba, K; Lam, L; Demetriades, D				Aiolfi, Alberto; Benjamin, Elizabeth; Khor, Desmond; Inaba, Kenji; Lam, Lydia; Demetriades, Demetrios			Brain Trauma Foundation Guidelines for Intracranial Pressure Monitoring: Compliance and Effect on Outcome	WORLD JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; MORTALITY	Background Brain Trauma Foundation (BTF) guidelines recommend intracranial pressure (ICP) monitoring in patients who sustained severe traumatic brain injury (TBI). Compliance to BTF guidelines is variable, and the effect of ICP monitoring on outcomes remains a controversial issue. The purpose of this study was to assess guidelines compliance in patients who sustain a severe TBI and to analyze the effect of ICP monitoring on outcomes. Methods Trauma Quality Improvement Program database study, which included patients with isolated severe blunt head trauma (head Abbreviated Injury Scale >= 3 with Glasgow Coma Scale < 9). Patients with severe extracranial injuries excluded. Analyzed variables were demographics, comorbidities, mechanism of injuries, head injury specifics, AIS for each body area, Injury Severity Score, admission vital signs, placement of ICP catheter and craniectomy. Multivariate analysis was used to identify independent predictors for outcomes, overall and in the groups of patients with head AIS 3, 4 or 5. Results During the study period 13,188 patients with isolated severe TBI met the BTF guidelines for ICP monitoring. An ICP catheter was placed in 1519 (11.5%) patients. Stepwise logistic regression analysis identified age >= 65 years, hypotension on admission, AIS 4 and AIS 5 as independent predictors for mortality. ICP monitoring was not an independent protective variable in terms of mortality (OR 1.12; 95% CI, 0.983-1.275; p = 0.088). Overall, ICP monitor placement was independently associated with increased overall complications (OR 2.089; 95% CI, 1.85-2.358; p < 0.001), infectious complications (OR 2.282; 95% CI, 2.015-2.584; p < 0.001) and poor functional independence (OR 1.889; 95% CI, 1.575-2.264; p < 0.001). Sub analysis of the groups of patients with head AIS 3, 4, and 5 failed to show any protective effect of ICP monitors against mortality. In the group of patients with head AIS 4, ICP placement was an independent predictor of mortality (OR 2206; 95% CI, 1652-2948; p < 0.001). Conclusions Compliance with the BTF guidelines for ICP monitoring is poor. ICP monitoring does not have any survival benefit in patients with isolated severe blunt TBI and is associated with more complications and increased utilization of hospital resources.	[Aiolfi, Alberto; Benjamin, Elizabeth; Khor, Desmond; Inaba, Kenji; Lam, Lydia; Demetriades, Demetrios] Univ Southern Calif, Div Acute Care Surg, 2051 Marengo St,Inpatient Tower C,Rm C5L100, Los Angeles, CA 90033 USA		Demetriades, D (corresponding author), Univ Southern Calif, Div Acute Care Surg, 2051 Marengo St,Inpatient Tower C,Rm C5L100, Los Angeles, CA 90033 USA.	demetria@usc.edu	Aiolfi, Alberto/ABA-7242-2020; INABA, KENJI/AAC-8532-2020; Benjamin, Elizabeth/AAD-2457-2020	Aiolfi, Alberto/0000-0002-7764-6075			Agrawal D, 2016, J NEUROTRAUM, V33, P853, DOI 10.1089/neu.2015.4015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dawes AJ, 2015, JAMA SURG, V150, P965, DOI 10.1001/jamasurg.2015.1678; Dawes AJ, 2015, J TRAUMA ACUTE CARE, V78, P492, DOI 10.1097/TA.0000000000000559; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Haddad S, 2011, ANAESTH INTENS CARE, V39, P1043, DOI 10.1177/0310057X1103900610; Lane PL, 2000, CAN J SURG, V43, P442; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Mendelson AA, 2012, CAN J NEUROL SCI, V39, P571, DOI 10.1017/S0317167100015286; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; You WD, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0199-9	16	39	43	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2017	41	6					1543	1549		10.1007/s00268-017-3898-6			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	EU4AS	WOS:000400972800021	28188356				2022-02-06	
J	Welch, RD; Ellis, M; Lewis, LM; Ayaz, SI; Mika, VH; Millis, S; Papa, L				Welch, Robert D.; Ellis, Morgan; Lewis, Lawrence M.; Ayaz, Syed I.; Mika, Valerie H.; Millis, Scott; Papa, Linda			Modeling the Kinetics of Serum Glial Fibrillary Acidic Protein, Ubiquitin Carboxyl-Terminal Hydrolase-L1, and S100B Concentrations in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; glia cell response to injury; neural injury; traumatic brain injury	COMPUTED-TOMOGRAPHY FINDINGS; MILD; BIOMARKERS; MANAGEMENT; DIAGNOSIS; GFAP	Glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), and S100B have been shown to be predictive of patients with brain injury. Kinetics of these biomarkers in injured humans have not been extensively examined. This prospective multi-center study included patients with mild-to-moderate traumatic brain injury. Blood samples obtained at enrollment and every 6 h up to 24 h post-injury were assayed for GFAP, UCH-L1, and S100B. Random effects models examined changes in the biomarkers' level over time. A total of 167 patients were enrolled; mean age was 46.0 +/- 17.8, 61.1% were male, 143 (85.6%) had a Glasgow Coma Scale score of 15, and 33 (19.8%) had a positive head computed tomography (CT) scan. Baseline median biomarker concentrations for all three were higher among CT-positive patients (p < 0.0001) but GFAP was the only biomarker that significantly increased over time among CT-positive patients relative to CT-negative patients (log transformed values 0.037; 95% confidence interval 0.02, 0.05; p < 0.001), indicating a 3.7% per hour rise in GFAP concentration. There was no significant increase in either UCH-L1 or S100B in CT-positive patients (p = 0.15 and p = 0.47, respectively). GFAP concentrations increased 3.7% per hour among CT-positive patients whereas neither UCH-L1 nor S100B increased, compared with CT-negative patients. The kinetics and temporal profile of GFAP suggest it may be a more robust biomarker to detect patients with positive CT findings, particularly at later post-injury times. Further study is needed to determine if GFAP is a useful test to follow throughout a patient's clinical course.	[Welch, Robert D.; Ellis, Morgan; Ayaz, Syed I.; Mika, Valerie H.; Millis, Scott] Wayne State Univ, Sch Med, Dept Emergency Med, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA; [Welch, Robert D.] Wayne State Univ, Sch Med, Cardiovasc Res Inst, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA; [Millis, Scott] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Lewis, Lawrence M.] Washington Univ, Dept Emergency Med, Sch Med, St Louis, MO USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA		Welch, RD (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA.; Welch, RD (corresponding author), Wayne State Univ, Sch Med, Cardiovasc Res Inst, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA.	rwelch@med.wayne.edu	Mika, Valerie H./AAO-2816-2020		U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-1-0517, W81XWH-10-C-0251]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	This work is supported by the U.S. Army Medical Research and Material Command under Contract N. W81XWH-06-1-0517 and Contract N. W81XWH-10-C-0251. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. The authors would also like to acknowledge the support of Banyan Biomarkers, Inc. personnel Ronald Hayes and Art Weber.	Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2015, REP C ONTR BRAIN INJ; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Gillespie BW, 2010, EPIDEMIOLOGY, V21, pS64, DOI 10.1097/EDE.0b013e3181ce9f08; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Keizer RJ, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.131; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Lang TA, 2015, INT J NURS STUD, V52, P5, DOI 10.1016/j.ijnurstu.2014.09.006; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; McCollough CH, 2016, HEALTH PHYS, V110, P287, DOI 10.1097/HP.0000000000000391; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Succop PA, 2004, J OCCUP ENVIRON HYG, V1, P436, DOI 10.1080/15459620490462797; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Xie XH, 2012, STAT MED, V31, P2275, DOI 10.1002/sim.5371; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	30	39	40	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1957	1971		10.1089/neu.2016.4772			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500006	28031000	Green Submitted, Green Published			2022-02-06	
J	Chien, CY; Chen, YH; Han, ST; Blaney, GN; Huang, TS; Chen, KF				Chien, Chih-Ying; Chen, Yu-Hsien; Han, Shih-Tsung; Blaney, Gerald N.; Huang, Ting-Shuo; Chen, Kuan-Fu			The number of displaced rib fractures is more predictive for complications in chest trauma patients	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Rib Fractures; Displaced Rib Fractures; Complications; Chest Trauma; Prognosis; Sensitivity and Specificity; Hospitalization	ACUTE PAIN MANAGEMENT; SEVERITY SCORE; THORACIC TRAUMA; MORTALITY; MORBIDITY; INJURY	Background: Traumatic rib fractures can cause chest complications that need further treatment and hospitalization. We hypothesized that an increase in the number of displaced rib fractures will be accompanied by an increase in chest complications. Methods: We retrospectively reviewed the trauma registry between January 2013 and May 2015 in a teaching hospital in northeastern Taiwan. Patients admitted with chest trauma and rib fractures without concomitant severe brain, splenic, pelvic or liver injuries were included. The demographic data, such as gender, age, the index of coexistence disease, alcohol consumption, trauma mechanisms were analyzed as potential predictors of pulmonary complications. Pulmonary complications were defined as pneumothorax, hemothorax, flail chest, pulmonary contusion, and pneumonia. Results: In the 29 months of the study period, a total of 3151 trauma patients were admitted to our hospital. Among them, 174 patients were enrolled for final analysis. The most common trauma mechanism was road traffic accidents (58.6%), mainly motorbike accidents (n = 70, 40.2%). Three or more displaced rib fractures had higher specificity for predicting complications, compared to three or more total rib fractures (95.5% vs 59.1%). Adjusting the severity of chest trauma using TTSS and Ribscore by multivariable logistic regression analysis, we found that three or more rib fractures or any displaced rib fracture was the most significant predictor for developing pulmonary complication (aOR: 5.49 95% CI: 1.82-16.55). Furthermore, there were 18/57 (31.6%) patients with fewer than three ribs fractures developed pulmonary complications. In these 18 patients, only five patients had delayed onset complications and four of them had at least one displaced rib fracture. Discussion: In this retrospective cohort study, we found that the number of displaced or total rib fractures, bilateral rib fractures, and rib fractures in more than two areas were associated with the more chest complications. Furthermore, three or more rib fracture or any displacement were found to be the most sensitive risk factor for chest complications, independent of other risk factors or severity index. Conclusion: The number of displaced rib fractures could be a strong predictor for developing pulmonary complications. For patients with fewer than three rib fractures without rib displacement and initial lung or other organ injuries, outpatient management could be safe and efficient.	[Chien, Chih-Ying; Chen, Yu-Hsien; Blaney, Gerald N.; Huang, Ting-Shuo] Chang Gung Mem Hosp, Dept Gen Surg, Keelung, Taiwan; [Han, Shih-Tsung] Chang Gung Mem Hosp, Dept Emergency Med, Linkou, Taiwan; [Chen, Kuan-Fu] Chang Gung Mem Hosp, Dept Emergency Med, Keelung, Taiwan; [Chen, Kuan-Fu] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Chen, Kuan-Fu] Chang Gung Mem Hosp, Community Med Res Ctr, Keelung, Taiwan		Chen, KF (corresponding author), Chang Gung Mem Hosp, Dept Emergency Med, Keelung, Taiwan.; Chen, KF (corresponding author), Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan.; Chen, KF (corresponding author), Chang Gung Mem Hosp, Community Med Res Ctr, Keelung, Taiwan.	kfchen@cgmh.org.tw	Huang, Ting-Shuo/ABD-3205-2021	Huang, Ting-Shuo/0000-0002-2932-6878; Clark, Andrea/0000-0002-4269-5547	National Science Council and Chang Gung Memorial Hospital in Taiwan [100-2314-B-182A-038-MY3, CMRPG2C0201, CMRPG2B0123, CMRPG2B0273, CIRPG2E0022, CMRPG2B0373]	The study was supported by the National Science Council and Chang Gung Memorial Hospital in Taiwan (100-2314-B-182A-038-MY3, CMRPG2C0201, CMRPG2B0123, CMRPG2B0273, CIRPG2E0022 and CMRPG2B0373). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aukema TS, 2011, OPEN ACCESS EMERG M, V3, P49, DOI 10.2147/OAEM.S22802; Martinez RJA, 2013, ARCH BRONCONEUMOL, V49, P177, DOI 10.1016/j.arbres.2012.12.005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Battle CE, 2012, INJURY, V43, P8, DOI 10.1016/j.injury.2011.01.004; Ceran S, 2002, EUR J CARDIO-THORAC, V21, P57, DOI 10.1016/S1010-7940(01)01056-9; Chapman BC, 2016, J TRAUMA ACUTE CARE, V80, P95, DOI 10.1097/TA.0000000000000867; Daurat A, 2016, INJURY, V47, P147, DOI 10.1016/j.injury.2015.08.031; Dreizin D, 2012, RADIOGRAPHICS, V32, P609, DOI 10.1148/rg.323115099; Ho AMH, 2011, CURR OPIN CRIT CARE, V17, P323, DOI 10.1097/MCC.0b013e328348bf6f; JORGENSEN K, 1981, ACTA ORTHOP SCAND, V52, P273, DOI 10.3109/17453678109050103; Karmakar MK, 2003, J TRAUMA, V54, P615, DOI 10.1097/01.TA.0000053197.40145.62; Liman ST, 2003, EUR J CARDIO-THORAC, V23, P374, DOI 10.1016/S1010-7940(02)00813-8; Livingston DH, 2008, J TRAUMA, V64, P905, DOI 10.1097/TA.0b013e3181668ad7; Miskulin DC, 2001, KIDNEY INT, V60, P1498, DOI 10.1046/j.1523-1755.2001.00954.x; Pape HC, 2000, J TRAUMA, V49, P496, DOI 10.1097/00005373-200009000-00018; POOLE GV, 1981, ANN SURG, V193, P70, DOI 10.1097/00000658-198101000-00012; Simon BJ, 1998, J TRAUMA, V45, P673, DOI 10.1097/00005373-199810000-00005; Sirmali M, 2003, EUR J CARDIO-THORAC, V24, P133, DOI 10.1016/S1010-7940(03)00256-2; Subcommittee A, 2013, J TRAUMA ACUTE CARE, V74, P1363; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; WILSON RF, 1977, SURG CLIN N AM, V57, P17; ZIEGLER DW, 1994, J TRAUMA, V37, P975, DOI 10.1097/00005373-199412000-00018	22	39	44	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	FEB 28	2017	25								19	10.1186/s13049-017-0368-y			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	EM5GY	WOS:000395341200001	28241883	Green Published, gold			2022-02-06	
J	Howell, DR; Beasley, M; Vopat, L; Meehan, WP				Howell, David R.; Beasley, Michael; Vopat, Lisa; Meehan, William P., III			The Effect of Prior Concussion History on Dual-Task Gait following a Concussion	JOURNAL OF NEUROTRAUMA			English	Article						concussion; dual-task; gait; locomotion; mild traumatic brain injury	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; BALANCE CONTROL; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; MUSCULOSKELETAL INJURY; HIGH-SCHOOL; LONG-TERM; ADOLESCENTS; MANAGEMENT	Sustaining repeated concussions has been associated with worse outcomes after additional injuries. This effect has been identified using symptom inventories and neurocognitive tests; however, few investigations have examined how a prior concussion history affects gait soon after a subsequent concussion. We examined the gait characteristics of athletes with no documented concussion history (n = 31), athletes recovering from their first lifetime concussion (n = 15), and athletes recovering from their second or greater lifetime concussion (n = 22). All participants completed a single-task and dual-task gait examination, a medical history questionnaire, and a postconcussion symptom scale. Multivariate analyses of covariance (MANCOVA) models were used to evaluate mean gait differences among groups, and Spearman's q analyses were used to assess correlations between the number of lifetime concussions and gait characteristics. Patients reporting to the clinic with their second or greater lifetime concussion demonstrated smaller stride lengths than healthy control participants during dual-task walking (p = 0.01; d = 0.70). A moderate but insignificant correlation was detected between dual-task gait speed and the number of prior concussions (q = 0.41, p = 0.07). These results indicate that a cumulative effect of concussions across the lifetime may contribute to worsening dual-task dynamic motor function after concussion.	[Howell, David R.; Vopat, Lisa; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.; Beasley, Michael; Vopat, Lisa; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Howell, David R.; Beasley, Michael; Vopat, Lisa; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Beasley, Michael; Vopat, Lisa; Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA		Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu			National Hockey League Alumni Association through Corey C. Griffin Pro-Am Tournament	This study was funded by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley T. A., 2015, J SPORT HLTH SCI; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mancini M., 2011, J BIOENG BIOMED S S1, V1, P7, DOI DOI 10.4172/2155-9538.S1-007; Mancini M, 2016, GAIT POSTURE, V43, P125, DOI 10.1016/j.gaitpost.2015.08.015; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2012, GAIT POSTURE, V36, P471, DOI 10.1016/j.gaitpost.2012.04.010; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meagher J, 2015, WORLD J PSYCHIATR, V5, P305, DOI 10.5498/wjp.v5.i3.305; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Wright JM, 2014, WILD ENVIRON MED, V25, P319, DOI 10.1016/j.wem.2014.01.004; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhu WM, 2012, J SPORT HEALTH SCI, V1, P9, DOI 10.1016/j.jshs.2012.02.002; Zuckerman SL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15593	52	39	39	2	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					838	844		10.1089/neu.2016.4609			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200010	27541061				2022-02-06	
J	Zieman, G; Bridwell, A; Cardenas, JF				Zieman, Glynnis; Bridwell, Ashley; Cardenas, Javier F.			Traumatic Brain Injury in Domestic Violence Victims: A Retrospective Study at the Barrow Neurological Institute	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; head trauma; traumatic brain injury	INTIMATE PARTNER VIOLENCE; BATTERED WOMEN	Domestic violence is a national health crisis, which affects people of all ages, races, and socioeconomic classes. Traumatic brain injury is common in victims because of the high frequency of head and neck injuries inflicted through abuse. These recurrent injuries can lead to chronic symptoms with high morbidity. We conducted a retrospective chart review of 115 patients with a history of head trauma as a result of domestic violence. All patients were seen in a subspecialty traumatic brain injury clinic, at which time information regarding their histories and self-reported symptoms were recorded. In total, 109 females and 6 males were included in our study, with an age range of 4-68 years. Overall, 88% reported more than one injury and 81% reported a history of loss of consciousness associated with their injuries. Only 21% sought medical help at the time of injury. Whereas 85% had a history of abuse in adulthood, 22% had experienced abuse in both childhood and adulthood, and 60% of the patients abused as children went on to be abused as adults. Headache was the most common chief complaint, but on a self-reported symptom severity scale, behavioral symptoms were the most severe. Psychiatric disease was present in 84% of patients. Traumatic brain injury is a frequent sequela of domestic violence, from which many victims sustain multiple injuries without seeking medical care. Brain injuries are often sustained over many years and lead to lasting physical, behavioral, and cognitive consequences. Better understanding of these injuries will lead to improved care for this population.	[Zieman, Glynnis; Cardenas, Javier F.] Barrow Concuss & Brain Injury Ctr, 222 W Thomas Rd,Suite 304, Phoenix, AZ 85013 USA; [Bridwell, Ashley] Barrow Neurol Inst, Adult Neurol Program Outpatient Neurol Rehabil, Phoenix, AZ USA		Zieman, G (corresponding author), Barrow Concuss & Brain Injury Ctr, 222 W Thomas Rd,Suite 304, Phoenix, AZ 85013 USA.	Glynnis.Zieman@dignityhealth.org	Zieman, Glynnis/AAQ-3409-2020				[Anonymous], 2015, C TRAUM BRAIN INJ US; Anxiety and Depression Association of America, 2014, FACTS AND STAT; Campbel J., 2015, ED MANAG, V27, P19; Davis A, 2014, J TRAUMA NURS, V21, P300, DOI 10.1097/JTN.0000000000000086; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Monahan K, 1999, HEALTH SOC WORK, V24, P269, DOI 10.1093/hsw/24.4.269; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Murray CE, 2016, TRAUMA VIOLENCE ABUS, V17, P298, DOI 10.1177/1524838015584364; National Coalition Against Domestic Violence, 2015, DOM VIOL NAT STAT; National Coalition Against Domestic Violence, 2015, FACTS DOM VIOL PHYS; Picard M, 1991, HELPS BRAIN INJURY S; United States Department of Health & Human Services Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2016, CHILDR MALTR 2014; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Wong JYH, 2014, TRAUMA VIOLENCE ABUS, V15, P22, DOI 10.1177/1524838013496333; Wong J, 2014, CONTEMP NURSE, V46, P170, DOI 10.5172/conu.2014.46.2.170	17	39	40	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					876	880		10.1089/neu.2016.4579			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200015	27312572				2022-02-06	
J	Ma, J; Xiao, WJ; Wang, JR; Wu, J; Ren, JD; Hou, J; Gu, JW; Fan, KH; Yu, BT				Ma, Jie; Xiao, Wenjing; Wang, Junrui; Wu, Juan; Ren, Jiandong; Hou, Jun; Gu, Jianwen; Fan, Kaihua; Yu, Botao			Propofol Inhibits NLRP3 Inflammasome and Attenuates Blast-Induced Traumatic Brain Injury in Rats	INFLAMMATION			English	Article						blast-induced traumatic brain injury; propofol; NLRP3 inflammasome; inflammation; oxidative stress	NALP3 INFLAMMASOME; NEUROINFLAMMATION; CONTRIBUTES; EXPRESSION; DAMAGE	Increasing evidence has demonstrated that inflammatory response plays a crucial role in the pathogenesis of secondary injury following blast-induced traumatic brain injury (bTBI). Propofol, a lipid-soluble intravenous anesthetic, has been shown to possess therapeutic benefit during neuroinflammation on various brain injury models. Recent findings have proved that the NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome involved in the process of the inflammatory response following brain trauma, may probably be a promising target in the treatment of bTBI. Rats were randomly divided into six groups (n = 8): normal group; bTBI-12 and 24 h group; bTBI-12 h and bTBI-24 h group treated with propofol; and bTBI treated with control dimethyl sulfoxide (DMSO) group. The effect of propofol on the expression and activation of NLRP3 inflammasome and the degree of oxidative stress and inflammatory cascades, as well as the brain trauma biomarkers were evaluated in rats suffering from bTBI. The enhanced expressions and activation of NLRP3 inflammasome in the cerebral cortex of bTBI rats were substantially suppressed by the administration of propofol, which was paralleled with the decreased oxidative stress, cytokines production, and the amelioration of cerebral cortex damage. Our results have, for the first time, revealed that over-activation of NLRP3 inflammasome in the cerebral cortex may be involved in the process of neuroinflammation during the secondary injury of bTBI in rats. Propofol might relieve the inflammatory response and attenuate brain injury by inhibiting ROS and reluctant depressing NLRP3 inflammasome activation and pro-inflammatory cytokines maturation.	[Ma, Jie; Xiao, Wenjing; Wu, Juan; Ren, Jiandong; Hou, Jun; Fan, Kaihua; Yu, Botao] Chengdu Mil Gen Hosp, Dept Pharm, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China; [Wang, Junrui] Chengdu Second Peoples Hosp, Dept Orthopaed, Chengdu 610017, Sichuan, Peoples R China; [Gu, Jianwen] 306th Hosp PLA, Dept Neurosurg, 9 Anxiang Beili, Beijing 100101, Peoples R China; [Gu, Jianwen] Chengdu Mil Gen Hosp, Dept Neurosurg, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China		Gu, JW (corresponding author), 306th Hosp PLA, Dept Neurosurg, 9 Anxiang Beili, Beijing 100101, Peoples R China.; Gu, JW (corresponding author), Chengdu Mil Gen Hosp, Dept Neurosurg, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China.	gujianwen5000@sina.com; fankh2012@sina.com; botao_yu@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501658]; Chengdu Military General Hospital Project [2013YG-B033]	This study was funded by a grant from the National Natural Science Foundation of China (Grant No. 81501658) and Chengdu Military General Hospital Project (Grant No. 2013YG-B033).	Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cai JS, 2011, NEUROCHEM RES, V36, P1724, DOI 10.1007/s11064-011-0487-1; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Grasshoff C, 2005, EUR J ANAESTH, V22, P467, DOI 10.1017/S0265021505000803; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hampton T, 2011, JAMA-J AM MED ASSOC, V306, P477, DOI 10.1001/jama.2011.1092; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma Jie, 2009, Yaoxue Xuebao, V44, P344; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; Pedra JHF, 2009, CURR OPIN IMMUNOL, V21, P10, DOI 10.1016/j.coi.2009.01.006; Ren JD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930894; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Thomas S, 2000, ACT NEUR S, V76, P397; Tsuchiya M, 2002, AM J RESP CRIT CARE, V165, P54, DOI 10.1164/ajrccm.165.1.2010134; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xi HJ, 2011, BRAIN RES, V1410, P24, DOI 10.1016/j.brainres.2011.06.060; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	38	39	43	2	15	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	DEC	2016	39	6					2094	2103		10.1007/s10753-016-0446-8			10	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	EC4MX	WOS:000388106800025	27696022				2022-02-06	
J	Woods, AJ; Porges, EC; Bryant, VE; Seider, T; Gongvatana, A; Kahler, CW; de la Monte, S; Monti, PM; Cohen, RA				Woods, Adam J.; Porges, Eric C.; Bryant, Vaughn E.; Seider, Talia; Gongvatana, Assawin; Kahler, Christopher W.; de la Monte, Suzanne; Monti, Peter M.; Cohen, Ronald A.			Current Heavy Alcohol Consumption is Associated with Greater Cognitive Impairment in Older Adults	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Alcohol Consumption; Alcohol Dependence; Cognitive Aging; EtOH; Cognitive Impairment	TRAUMATIC BRAIN-INJURY; DEMENTIA; DRINKING; ETHANOL; ABUSE; AGE; ADOLESCENT; DISORDERS; DEFICITS; OUTCOMES	BackgroundThe acute consumption of excessive quantities of alcohol causes well-recognized neurophysiological and cognitive alterations. As people reach advanced age, they are more prone to cognitive decline. To date, the interaction of current heavy alcohol (ethanol [EtOH]) consumption and aging remains unclear. This study tested the hypothesis that negative consequences of current heavy alcohol consumption on neurocognitive function are worse with advanced age. Further, we evaluated the relations between lifetime history of alcohol dependence and neurocognitive function MethodsSixty-six participants underwent a comprehensive neurocognitive battery. Current heavy EtOH drinkers were classified using National Institute on Alcohol Abuse and Alcoholism criteria (EtOH heavy, n=21) based on the Timeline follow-back and a structured clinical interview and compared to nondrinkers, and moderate drinkers (EtOH low, n=45). Of the total population, 53.3% had a lifetime history of alcohol dependence. Neurocognitive data were grouped and analyzed relative to global and domain scores assessing: global cognitive function, attention/executive function, learning, memory, motor function, verbal function, and speed of processing. ResultsHeavy current EtOH consumption in older adults was associated with poorer global cognitive function, learning, memory, and motor function (ps<0.05). Furthermore, lifetime history of alcohol dependence was associated with poorer function in the same neurocognitive domains, in addition to the attention/executive domain, irrespective of age (ps<0.05). ConclusionsThese data suggest that while heavy current alcohol consumption is associated with significant impairment in a number of neurocognitive domains, history of alcohol dependence, even in the absence of heavy current alcohol use, is associated with lasting negative consequences for neurocognitive function.	[Woods, Adam J.; Porges, Eric C.; Bryant, Vaughn E.; Seider, Talia; Cohen, Ronald A.] Univ Florida, Dept Aging & Geriatr Res, Inst Aging, Ctr Cognit Aging & Memory CAM, Gainesville, FL 32610 USA; [Gongvatana, Assawin] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Kahler, Christopher W.; Monti, Peter M.] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA; Brown Univ, ARCH, Sch Publ Hlth, Providence, RI 02912 USA; [de la Monte, Suzanne] Brown Univ, Dept Pathol & Lab Med, Dept Neurosurg, Providence, RI 02912 USA		Woods, AJ (corresponding author), Univ Florida, Cognit Aging & Memory Clin Translat Res Program, Inst Aging, Dept Aging & Geriatr Res, 2004 Mowry Rd, Gainesville, FL 32610 USA.	ajwoods@ufl.edu	de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Gongvatana, Assawin/0000-0001-6102-6384; Woods, Adam/0000-0002-0786-0236	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P01AA019072, F31AA024060] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001429] Funding Source: Medline; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P01 AA019072, F31 AA024060] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG028740] Funding Source: Medline		Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton AL, 1994, MULTILINGUAL APHASIA; Brandt J., 1991, HOPKINS VERBAL LEARN; Carey CL, 2004, CLIN NEUROPSYCHOL, V18, P234, DOI 10.1080/13854040490501448; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Downer B, 2015, AM J ALZHEIMERS DIS, V30, P364, DOI 10.1177/1533317514549411; DRAKE AI, 1995, J STUD ALCOHOL, V56, P104, DOI 10.15288/jsa.1995.56.104; Draper B, 2011, AUST NZ J PSYCHIAT, V45, P985, DOI 10.3109/00048674.2011.610297; Durazzo TC, 2013, ALCOHOL CLIN EXP RES, V37, P1794, DOI 10.1111/acer.12140; Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134; Friend KB, 2005, ADDICT BEHAV, V30, P193, DOI 10.1016/j.addbeh.2004.04.020; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; Golden CJ, 1978, STROOP COLOR WORD TE; Green A, 2010, ALCOHOL CLIN EXP RES, V34, P443, DOI 10.1111/j.1530-0277.2009.01108.x; Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340; Houston RJ, 2014, ADDICT BEHAV, V39, P345, DOI 10.1016/j.addbeh.2013.09.032; Kellogg SH, 2003, DRUG ALCOHOL DEPEN, V69, P137, DOI 10.1016/S0376-8716(02)00308-3; Kist N, 2014, INT PSYCHOGERIATR, V26, P1863, DOI 10.1017/S1041610214000878; Klove H., 1963, GROOVED PEGBOARD; Marksteiner J, 2002, Wien Med Wochenschr, V152, P98, DOI 10.1046/j.1563-258x.2002.01132.x; Meyer JS, 1998, EUR NEUROL, V39, P7, DOI 10.1159/000052064; MOLINA JA, 1994, ACTA NEUROL SCAND, V89, P384; O'Dell KM, 2012, J HEAD TRAUMA REHAB, V27, P361, DOI 10.1097/HTR.0b013e318266735c; Panza F, 2009, J ALZHEIMERS DIS, V17, P7, DOI 10.3233/JAD-2009-1009; Reitan RM, 1992, TRAIL MAKING TEST; RIEGE WH, 1981, ALCOHOL CLIN EXP RES, V5, P378, DOI 10.1111/j.1530-0277.1981.tb04920.x; Schuckit MA, 2009, LANCET, V373, P492, DOI 10.1016/S0140-6736(09)60009-X; Shih CL, 2001, ALCOHOL CLIN EXP RES, V25, P612, DOI 10.1111/j.1530-0277.2001.tb02258.x; Snow WM, 2009, AGE AGEING, V38, P206, DOI 10.1093/ageing/afn284; Solfrizzi V, 2007, NEUROLOGY, V68, P1790, DOI 10.1212/01.wnl.0000262035.87304.89; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SPIRDUSO WW, 1989, PSYCHOPHARMACOLOGY, V97, P413, DOI 10.1007/BF00439461; Squeglia LM, 2014, ALCOHOL CLIN EXP RES, V38, P2509, DOI 10.1111/acer.12531; Squeglia LM, 2009, PSYCHOL ADDICT BEHAV, V23, P715, DOI 10.1037/a0016516; Sullivan EV, 2010, ALCOHOL RES HEALTH, V33, P127; Sullivan EV, 2002, NEUROPSYCHOLOGY, V16, P74, DOI 10.1037//0894-4105.16.1.74; Tyas SL, 2001, ALCOHOL RES HEALTH, V25, P299; Vinod KY, 2005, LIFE SCI, V77, P1569, DOI 10.1016/j.lfs.2005.05.041; Webb B, 1997, ALCOHOL CLIN EXP RES, V21, P1643, DOI 10.1097/00000374-199712000-00014; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilhelm CJ, 2015, BRAIN RES, V1601, P102, DOI 10.1016/j.brainres.2015.01.002; Woods AJ, 2013, J NUTR HEALTH AGING, V17, P741, DOI 10.1007/s12603-013-0398-8; Woods AJ, 2012, NEUROCASE, V18, P115, DOI 10.1080/13554794.2011.568498; Woods AJ, 2011, PM&R, V3, P426, DOI 10.1016/j.pmrj.2011.02.018	47	39	39	1	28	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	NOV	2016	40	11					2435	2444		10.1111/acer.13211			10	Substance Abuse	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse	EA8VT	WOS:000386918400023	27658235	Green Accepted			2022-02-06	
J	Nwachuku, EL; Puccio, AM; Adeboye, A; Chang, YF; Kim, J; Okonkwo, DO				Nwachuku, Enyinna L.; Puccio, Ava M.; Adeboye, Adeolu; Chang, Yue-Fang; Kim, Jinho; Okonkwo, David O.			Time course of cerebrospinal fluid inflammatory biomarkers and relationship to 6-month neurologic outcome in adult severe traumatic brain injury	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Traumatic brain injury; Biomarkers; Inflammatory cytokines; Therapeutic targets; Neurological outcome	INTERLEUKIN-6; CYTOKINES	Objective: Activation of the inflammatory cascade is a known pathophysiologic process in severe traumatic brain injury (TBI) with yet non-standardized scientific data regarding relationship to outcome. The understanding of the time course of expression of cerebrospinal fluid (CSF) biomarker levels following severe TBI is an important step toward using these biomarkers to measure injury severity and/or early response to therapeutic interventions. The objective of the current study is to report the time course and values of a battery of CSF inflammatory biomarkers following severe TBI in our reasonably sized patient cohort. Patients and methods: Our patient cohort consists of 32 consented patients, who met the study's inclusion criteria for data collection from 2000 to 2010. The time course and values of a battery of CSF biomarkers (IL-1 beta, IL-6, TNF-alpha, IFN-gamma, IL-12p70, IL-10, and IL-8) following severe TBI in this patient cohort was characterized. Additionally, the correlation of biomarker concentration with 6-month neurological outcome was assessed. Serial CSF sampling through an external ventricular drain was performed over the first five days following injury. Concentration of a panel of inflammatory biomarkers (IL-1 beta, IL-6, TNF-alpha, IFN-gamma, IL-12p70, IL-10, and IL-8) were evaluated using Meso Scale Discovery's Multi-Array technology. Glasgow Outcome Scale (GOS) score at six months following injury was dichotomized into poor outcome (GOS 1-3) and favorable outcome (GOS 4-5). Statistical analyses were performed using Kruskal-Wallis test and linear regression analysis. Results: The result shows that CSF concentrations of inflammatory biomarkers had a significant association with 6-month neurological outcome (p-values <= 0.05 for each marker), with the favorable outcome group having lower concentrations of these biomarkers on average, in comparison to the poor neurologic outcome group over the first five days after TBI. All inflammatory biomarkers decreased to normal levels by post-trauma day 5, except for IL-6 and IL-8. Upregulation and increased expression of key inflammatory markers following severe TBI were significant predictors of worse 6-month neurologic outcome. Additionally, post-trauma day 5 concentrations of IL-6 and IL-8 remained elevated over normal CSF values. Conclusion: The study shows that inflammatory biomarkers in CSF are potential biomarkers of injury severity and progression and/or recovery; they could prove beneficial in the future assessment of injury severity and response to therapy after severe TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Nwachuku, Enyinna L.; Puccio, Ava M.; Chang, Yue-Fang; Kim, Jinho; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA; [Adeboye, Adeolu] Quinnipiac Univ, Frank H Netter MD Sch Med, 300 Bassett Rd,MNH-211K, N Haven, CT 06473 USA		Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	Nwachukuel@upmc.edu; puccam@upmc.edu; Adeolu.adeboye@quinnipiac.edu; Changy@upmc.edu; Jinhokim@pitt.edu; Okonkwodo@upmc.edu			NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [2R25MH054318]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS030318]	This work was supported by an NIMH training grant (2R25MH054318) and NINDS (P01 NS030318). Authors have no conflict of interest to disclose.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Alexander GM, 2005, PAIN, V116, P213, DOI 10.1016/j.pain.2005.04.013; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Brisby H, 2002, EUR SPINE J, V11, P62, DOI 10.1007/s005860100306; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lindqvist D, 2009, BIOL PSYCHIAT, V66, P287, DOI 10.1016/j.biopsych.2009.01.030; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	20	39	40	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	OCT	2016	149						1	5		10.1016/j.clineuro.2016.06.009			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DW7JH	WOS:000383826500001	27450760				2022-02-06	
J	Balaban, C; Hoffer, ME; Szczupak, M; Snapp, H; Crawford, J; Murphy, S; Marshall, K; Pelusso, C; Knowles, S; Kiderman, A				Balaban, Carey; Hoffer, Michael E.; Szczupak, Mikhaylo; Snapp, Hillary; Crawford, James; Murphy, Sara; Marshall, Kathryn; Pelusso, Constanza; Knowles, Sean; Kiderman, Alex			Oculomotor, Vestibular, and Reaction Time Tests in Mild Traumatic Brain Injury	PLOS ONE			English	Article							ERROR SCORING SYSTEM; COGNITIVE RESERVE; BALANCE; CONCUSSION; DIZZINESS; NEURITIS; STROKE; GAIN; TBI	Objective Mild traumatic brain injury is a major public health issue and is a particular concern in sports. One of the most difficult issues with respect to mild traumatic brain injury involves the diagnosis of the disorder. Typically, diagnosis is made by a constellation of physical exam findings. However, in order to best manage mild traumatic brain injury, it is critically important to develop objective tests that substantiate the diagnosis. With objective tests the disorder can be better characterized, more accurately diagnosed, and studied more effectively. In addition, prevention and treatments can be applied where necessary. Methods Two cohorts each of fifty subjects with mild traumatic brain injury and one hundred controls were evaluated with a battery of oculomotor, vestibular and reaction time related tests applied to a population of individuals with mild traumatic brain injury as compared to controls. Results We demonstrated pattern differences between the two groups and showed how three of these tests yield an 89% sensitivity and 95% specificity for confirming a current diagnosis of mild traumatic brain injury. Interpretation These results help better characterize the oculomotor, vestibular, and reaction time differences between those the mild traumatic brain injury and non-affected individuals. This characterization will allow for the development of more effective point of care neurologic diagnostic techniques and allow for more targeted treatment which may allow for quicker return to normal activity.	[Balaban, Carey] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Hoffer, Michael E.; Szczupak, Mikhaylo; Murphy, Sara; Knowles, Sean] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA; [Hoffer, Michael E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Hoffer, Michael E.; Szczupak, Mikhaylo; Pelusso, Constanza] Univ Miami, Sports Performance & Wellness Inst, Miami, FL USA; [Crawford, James; Marshall, Kathryn] Madigan Army Med Ctr, Dept Otolaryngol, Tacoma, WA 98431 USA; [Murphy, Sara] Naval Med Ctr, San Diego, CA USA; [Kiderman, Alex] Neurokinet Inc, Pittsburgh, PA USA		Hoffer, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA.; Hoffer, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.; Hoffer, ME (corresponding author), Univ Miami, Sports Performance & Wellness Inst, Miami, FL USA.	michael.hoffer@miami.edu	Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844; Szczupak, Mikhaylo/0000-0002-2569-2184	Head Health Challenge II grant (National Football League, Underarmor, General Electric); Department of DefenseUnited States Department of Defense [W81XWH-12-C-0205]; Neuro-Kinetics, Inc.	This work was supported by Head Health Challenge II grant (National Football League, Underarmor, General Electric) and Department of Defense grant W81XWH-12-C-0205. These sponsors provided funding to conduct the study, only. The funder provided support in the form of salaries for authors (MEH, MS, CB) but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author Alex Kiderman is employed by Neuro-Kinetics, Inc. Neuro-Kinetics, Inc. provided support in the form of salaries for author AK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.; This work was supported by Head Health Challenge II grant (National Football League, Underarmor, General Electric) and Department of Defense grant W81XWH-12-C-0205. These sponsors provided funding to conduct the study, only. The funder provided support in the form of salaries for authors (MEH, MS, CB) but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author Alex Kiderman is employed by Neuro-Kinetics, Inc. Neuro-Kinetics, Inc. provided support in the form of salaries for author AK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], 2015, PREVENTION INJURY CO; Barulli D, 2013, TRENDS COGN SCI, V17, P502, DOI 10.1016/j.tics.2013.08.012; Chandrasekhar SS, 2013, NEUROREHABILITATION, V32, P445, DOI 10.3233/NRE-130867; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Chen L, 2014, NEUROLOGY, V83, P1513, DOI 10.1212/WNL.0000000000000906; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guskiewicz Kevin M, 2015, Handb Clin Neurol, V127, P157, DOI 10.1016/B978-0-444-52892-6.00010-6; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hosek J., 2011, IS DEPLOYMENT IRAQ A; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lei-Rivera L, 2013, NEUROREHABILITATION, V32, P463, DOI 10.3233/NRE-130869; Mantokoudis G, 2015, OTOL NEUROTOL, V36, P457, DOI 10.1097/MAO.0000000000000638; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Plog BA, 2015, EXPERT REV NEUROTHER, V15, P465, DOI 10.1586/14737175.2015.1031112; Poltavski DV, 2014, BRAIN INJURY, V28, P475, DOI 10.3109/02699052.2014.888771; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8	22	39	39	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2016	11	9							e0162168	10.1371/journal.pone.0162168			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DW8GK	WOS:000383892700017	27654131	gold, Green Submitted, Green Published			2022-02-06	
J	Baez, E; Echeverria, V; Cabezas, R; Avila-Rodriguez, M; Garcia-Segura, LM; Barreto, GE				Baez, Eliana; Echeverria, Valentina; Cabezas, Ricardo; Avila-Rodriguez, Marco; Miguel Garcia-Segura, Luis; Barreto, George E.			Protection by Neuroglobin expression in Brain Pathologies	FRONTIERS IN NEUROLOGY			English	Article						astrocytes; neuroglobin; mitochondria; neuroprotection; brain injury	OXYGEN-GLUCOSE DEPRIVATION; MOUSE CORTICAL-NEURONS; OXIDATIVE STRESS; PARKINSONS-DISEASE; MITOCHONDRIAL-FUNCTION; CEREBRAL MALARIA; UP-REGULATION; NITRIC-OXIDE; IN-VIVO; ASTROCYTE MITOCHONDRIA	Astrocytes play an important role in physiological, metabolic, and structural functions, and when impaired, they can be involved in various pathologies including Alzheimer, focal ischemic stroke, and traumatic brain injury. These disorders involve an imbalance in the blood flow and nutrients such as glucose and lactate, leading to biochemical and molecular changes that cause neuronal damage, which is followed by loss of cognitive and motor functions. Previous studies have shown that astrocytes are more resilient than neurons during brain insults as a consequence of their more effective antioxidant systems, transporters, and enzymes, which made them less susceptible to excitotoxicity. In addition, astrocytes synthesize and release different protective molecules for neurons, including neuroglobin, a member of the globin family of proteins. After brain injury, neuroglobin expression is induced in astrocytes. Since neuroglobin promotes neuronal survival, its increased expression in astrocytes after brain injury may represent an endogenous neuroprotective mechanism. Here, we review the role of neuroglobin in the central nervous system, its relationship with different pathologies, and the role of different factors that regulate its expression in astrocytes.	[Baez, Eliana; Cabezas, Ricardo; Avila-Rodriguez, Marco; Barreto, George E.] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, Colombia; [Echeverria, Valentina] Univ San Sebastian, Fac Ciencias Salud, Concepcion, Chile; [Miguel Garcia-Segura, Luis] CSIC, Inst Cajal, Madrid, Spain; [Barreto, George E.] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile		Barreto, GE (corresponding author), Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, Colombia.; Garcia-Segura, LM (corresponding author), CSIC, Inst Cajal, Madrid, Spain.; Barreto, GE (corresponding author), Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile.	lmgs@cajal.csic.es; gsampaio@javeriana.edu.co	Garcia-Segura, Luis M/U-3711-2017; Barreto, George E./AAD-7420-2020; Valentina Echeverria Moran, BCh/E-7765-2013; Barreto, George E./B-5747-2014	Garcia-Segura, Luis M/0000-0002-2450-2916; Barreto, George E./0000-0002-6644-1971; Valentina Echeverria Moran, BCh/0000-0003-2393-5418; Barreto, George E./0000-0002-6644-1971; Avila-Rodriguez, Marco/0000-0003-4612-3236	Pontificia Universidad Javeriana	GB's work is supported by Pontificia Universidad Javeriana.	Acaz-Fonseca E, 2016, PROG NEUROBIOL, V144, P5, DOI 10.1016/j.pneurobio.2016.06.002; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Posada-Duque RA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00231; Antao ST, 2010, ANTIOXID REDOX SIGN, V13, P769, DOI 10.1089/ars.2009.2977; Rodriguez MA, 2014, J STEROID BIOCHEM, V144, P294, DOI 10.1016/j.jsbmb.2014.07.009; Avila-Rodriguez M, 2016, MOL CELL ENDOCRINOL, V433, P35, DOI 10.1016/j.mce.2016.05.024; Avivi A, 2010, P NATL ACAD SCI USA, V107, P21570, DOI 10.1073/pnas.1015379107; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Barreto GE, 2012, INT J NEUROSCI, V122, P223, DOI 10.3109/00207454.2011.648292; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bree AJ, 2009, AM J PHYSIOL-ENDOC M, V297, pE194, DOI 10.1152/ajpendo.91041.2008; Brittain T, 2010, IUBMB LIFE, V62, P878, DOI 10.1002/iub.405; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burmester T, 2009, J EXP BIOL, V212, P1423, DOI 10.1242/jeb.000729; Cabezas R, 2016, MED CHEM, V12, P204, DOI 10.2174/1573406411666151019120444; Cabezas R, 2015, NEUROTOX RES, V27, P355, DOI 10.1007/s12640-014-9509-5; Cabezas R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00211; Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008; Jurado-Coronel JC, 2016, CURR PHARM DESIGN, V22, P1305, DOI 10.2174/138161282210160304112133; Cantinieaux D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069515; Carmody RN, 2009, J HUM EVOL, V57, P379, DOI 10.1016/j.jhevol.2009.02.011; Chen XM, 2015, NEUROSCI LETT, V606, P194, DOI 10.1016/j.neulet.2015.09.002; Chen XQ, 2005, GLIA, V50, P182, DOI 10.1002/glia.20147; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; De Marinis E, 2013, J NEUROENDOCRINOL, V25, P260, DOI 10.1111/jne.12007; De Marinis E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.30; De Marinis E, 2010, NEUROSIGNALS, V18, P223, DOI 10.1159/000323906; Dellavalle B, 2010, GLIA, V58, P1220, DOI 10.1002/glia.21002; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; Dugan LL, 2004, J BIOENERG BIOMEMBR, V36, P317, DOI 10.1023/B:JOBB.0000041761.61554.44; Duong TTH, 2009, J NEUROCHEM, V108, P1143, DOI 10.1111/j.1471-4159.2008.05846.x; Fago A, 2004, J BIOL CHEM, V279, P44417, DOI 10.1074/jbc.M407126200; Fago A, 2006, J INORG BIOCHEM, V100, P1339, DOI 10.1016/j.jinorgbio.2006.03.009; Fuchs C, 2006, CYTOGENET GENOME RES, V112, P296, DOI 10.1159/000089884; Gotting M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12284; Gorr TA, 2011, ACTA PHYSIOL, V202, P563, DOI 10.1111/j.1748-1716.2010.02205.x; Gouix E, 2014, PHARMACOL RES, V87, P8, DOI 10.1016/j.phrs.2014.06.002; Greenamyre JT, 2003, PARKINSONISM RELAT D, V9, pS59, DOI 10.1016/S1353-8020(03)00023-3; Greenberg DA, 2008, CURR OPIN PHARMACOL, V8, P20, DOI 10.1016/j.coph.2007.09.003; Guglielmotto M, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00147; Guo Y, 2015, BRAIN RES, V1600, P1, DOI 10.1016/j.brainres.2014.12.046; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hu Y, 2015, INT J MOL SCI, V16, P24895, DOI 10.3390/ijms161024895; Hundahl CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034462; Hundahl CA, 2010, BRAIN RES, V1331, P58, DOI 10.1016/j.brainres.2010.03.056; Iglesias J, 2017, MOL NEUROBIOL, V54, P2518, DOI 10.1007/s12035-016-9833-2; Jayaraman T, 2011, J BIOL CHEM, V286, P42679, DOI 10.1074/jbc.M111.271973; Jin KL, 2012, NEUROSCI LETT, V519, P47, DOI 10.1016/j.neulet.2012.05.018; Jin KL, 2011, PHARMACOLOGY, V87, P81, DOI 10.1159/000322998; Jin KL, 2010, STROKE, V41, P557, DOI 10.1161/STROKEAHA.109.567149; Jing L, 2015, INT J BIOL SCI, V11, P59, DOI 10.7150/ijbs.10174; Khan AA, 2008, FASEB J, V22, P1737, DOI 10.1096/fj.07-100784; Kubik LL, 2015, TOXICOL SCI, V144, P7, DOI 10.1093/toxsci/kfu254; Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x; Lechauve C, 2013, BBA-PROTEINS PROTEOM, V1834, P1772, DOI 10.1016/j.bbapap.2013.04.014; Lechauve C, 2009, J MOL BIOL, V388, P968, DOI 10.1016/j.jmb.2009.03.047; LeDoux SP, 2007, NEUROSCIENCE, V145, P1249, DOI 10.1016/j.neuroscience.2006.10.002; Lee MC, 2010, NEURON, V66, P859, DOI 10.1016/j.neuron.2010.05.015; Lee VY, 2002, J BIOL CHEM, V277, P16067, DOI 10.1074/jbc.M111177200; Li Y, 2016, J MOL NEUROSCI, V58, P28, DOI 10.1007/s12031-015-0645-z; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Lin Y, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-110; Liu JX, 2009, J NEUROSCI RES, V87, P164, DOI 10.1002/jnr.21826; Liu N, 2013, NEUROSCI LETT, V534, P333, DOI 10.1016/j.neulet.2012.11.025; Liu ZF, 2015, INT J CLIN EXP MED, V8, P5351; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magistretti P.J., 2002, NEUROPSYCHOPHARMACOL; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Medina-Ceja L, 2007, REV NEUROLOGIA, V45, P341, DOI 10.33588/rn.4506.2005647; Meir JU, 2009, J EXP BIOL, V212, P3330, DOI 10.1242/jeb.033761; Mohideen SS, 2013, J OCCUP HEALTH, V55, P29, DOI 10.1539/joh.12-0118-OA; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Ohsumi A, 2010, J NEUROTRAUM, V27, P1255, DOI 10.1089/neu.2009.1234; Oliveira K, 2015, METAB BRAIN DIS, V30, P1401, DOI 10.1007/s11011-015-9718-5; Patel VP, 2011, INT J CLIN EXP PATHO, V4, P215; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Picotti P, 2009, FEBS J, V276, P7027, DOI 10.1111/j.1742-4658.2009.07416.x; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Purushothuman S, 2015, BRAIN RES, V1601, P52, DOI 10.1016/j.brainres.2015.01.003; Qin HJ, 2012, BRAIN TUMOR PATHOL, V29, P10, DOI 10.1007/s10014-011-0066-9; Qiu Xin Yao, 2014, Biomol Concepts, V5, P195, DOI 10.1515/bmc-2014-0011; Quijano María Cristina, 2012, Rev. Cienc. Salud, V10, P21; Raida Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076565; Raida Zindy, 2012, Exp Transl Stroke Med, V4, P15, DOI 10.1186/2040-7378-4-15; Rappold PM, 2010, NEUROTHERAPEUTICS, V7, P413, DOI 10.1016/j.nurt.2010.07.001; Raychaudhuri S, 2008, BIOPHYS J, V95, P3559, DOI 10.1529/biophysj.108.135483; Raychaudhuri S, 2010, APOPTOSIS, V15, P401, DOI 10.1007/s10495-009-0436-5; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Reuss S, 2016, MOL NEUROBIOL, V53, P1461, DOI 10.1007/s12035-014-9082-1; Schneuer M, 2012, NEUROSCIENCE, V223, P35, DOI 10.1016/j.neuroscience.2012.07.052; Shang AJ, 2015, MOL MED REP, V12, P1693, DOI 10.3892/mmr.2015.3593; Sharlin DS, 2010, J NEUROENDOCRINOL, V22, P153, DOI 10.1111/j.1365-2826.2009.01947.x; Shelby M, 2004, REPROD TOXICOL, V18, P303, DOI 10.1016/j.reprotox.2003.10.013; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Simon R, 2013, NEUROSCI LETT, V549, P1, DOI 10.1016/j.neulet.2013.05.016; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song X, 2014, INT J CLIN EXP PATHO, V7, P2163; Steele ML, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.018; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Taylor JM, 2014, NEUROSCI LETT, V577, P125, DOI 10.1016/j.neulet.2014.03.012; Tiso M, 2011, J BIOL CHEM, V286, P18277, DOI 10.1074/jbc.M110.159541; Toro-Urrego N, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00152; Torrente D, 2014, HUM EXP TOXICOL, V33, P673, DOI 10.1177/0960327113509659; Van Leuven W, 2013, BBA-PROTEINS PROTEOM, V1834, P1764, DOI 10.1016/j.bbapap.2013.04.015; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Wang TH, 2015, CLIN TOXICOL, V53, P823, DOI 10.3109/15563650.2015.1064939; Watanabe S, 2012, J BIOL CHEM, V287, P30128, DOI 10.1074/jbc.M112.373381; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011; Woo SK, 2012, J CEREBR BLOOD F MET, V32, P525, DOI 10.1038/jcbfm.2011.159; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yu Z, 2012, NEUROSCIENCE, V218, P235, DOI 10.1016/j.neuroscience.2012.05.054; Yu Z, 2009, NEUROSCIENCE, V162, P396, DOI 10.1016/j.neuroscience.2009.04.055; Yu ZL, 2014, NEUROSCIENCE, V270, P158, DOI 10.1016/j.neuroscience.2014.04.013; Yu ZY, 2013, NEUROBIOL DIS, V56, P95, DOI 10.1016/j.nbd.2013.04.015; Yu ZY, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/756989; Yu ZY, 2012, INT J MOL SCI, V13, P6995, DOI 10.3390/ijms13066995; Yu ZY, 2009, NEUROL RES, V31, P122, DOI 10.1179/174313209X389866; Yue X, 2014, NEUROSCIENCE, V258, P385, DOI 10.1016/j.neuroscience.2013.11.038; Zhao J, 2011, SEMIN CELL DEV BIOL, V22, P705, DOI 10.1016/j.semcdb.2011.09.012; Zhao S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-67; Zhong ZX, 2013, TOXICOLOGY, V306, P16, DOI 10.1016/j.tox.2013.01.022; Zhou D, 2008, EUR J PEDIATR, V167, P1169, DOI 10.1007/s00431-007-0653-2; Zou J, 2010, NEUROCHEM INT, V56, P577, DOI 10.1016/j.neuint.2009.12.021	138	39	39	0	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	SEP 12	2016	7								146	10.3389/fneur.2016.00146			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DV6AT	WOS:000383013600002	27672379	gold, Green Published			2022-02-06	
J	Bisogno, T; Oddi, S; Piccoli, A; Fazio, D; Maccarrone, M				Bisogno, Tiziana; Oddi, Sergio; Piccoli, Alessandra; Fazio, Domenico; Maccarrone, Mauro			Type-2 cannabinoid receptors in neurodegeneration	PHARMACOLOGICAL RESEARCH			English	Article						Type-2 cannabinoid receptors; Neurodegeneration; Endocannabinoid system	IMPROVES FUNCTIONAL RECOVERY; ACID AMIDE HYDROLASE; CB2 RECEPTOR; ALZHEIMERS-DISEASE; ENDOCANNABINOID SYSTEM; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; BASAL GANGLIA; IN-VIVO; INFLAMMATORY RESPONSES	Based on its wide expression in immune cells, type-2 cannabinoid (CB2) receptors were traditionally thought to act as "peripheral receptors" with an almost exclusively immunomodulatory function. However, their recent identification in mammalian brain areas, as well as in distinct neuronal cells, has opened the way to a re-consideration of CB2 signaling in the context of brain pathophysiology, synaptic plasticity and neuroprotection. To date, accumulated evidence from several independent preclinical studies has offered new perspectives on the possible involvement of CB2 signaling in brain and spinal cord traumatic injury, as well as in the most relevant neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and Huntington's chorea. Here, we will review available information on CB2 in these disease conditions, along with data that support also its therapeutic potential to treat them. (C) 2016 Elsevier Ltd. All rights reserved.	[Bisogno, Tiziana] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Pozzuoli, Italy; [Bisogno, Tiziana; Piccoli, Alessandra; Fazio, Domenico; Maccarrone, Mauro] Campus Biomed Univ Rome, Dept Med, Via Alvaro del Portillo 21, I-00128 Rome, Italy; [Oddi, Sergio] Univ Teramo, Fac Vet Med, Via Balzarini 1, I-64100 Teramo, Italy; [Oddi, Sergio; Maccarrone, Mauro] IRCCS Santa Lucia Fdn, European Ctr Brain Res, Via Fosso di Fiorano 64, I-00143 Rome, Italy		Maccarrone, M (corresponding author), Campus Biomed Univ Rome, Dept Med, Via Alvaro del Portillo 21, I-00128 Rome, Italy.	m.maccarrone@unicampus.it	Oddi, Sergio/B-6668-2009; Maccarrone, Mauro/K-5398-2012	Oddi, Sergio/0000-0002-6217-698X; Maccarrone, Mauro/0000-0002-3990-2963; Fazio, Domenico/0000-0002-1235-9999	italian Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN)Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN) [2010BN3MXM_004]	This investigation was partly supported by the italian Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN 2010-2011 2010BN3MXM_004 project to TB and MM).	Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arevalo-Martin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049057; Arevalo-Martin A, 2010, NEUROBIOL DIS, V38, P304, DOI 10.1016/j.nbd.2010.02.002; Aso E, 2013, J ALZHEIMERS DIS, V35, P847, DOI 10.3233/JAD-130137; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Baty Darric E, 2008, Clin Neurosurg, V55, P172; Bedse G, 2015, J ALZHEIMERS DIS, V43, P1115, DOI 10.3233/JAD-141635; Benito C, 2003, J NEUROSCI, V23, P11136; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Bisogno T, 2010, CNS NEUROL DISORD-DR, V9, P564, DOI 10.2174/187152710793361568; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Bonnet AE, 2015, AGING DIS, V6, P400, DOI 10.14336/AD.2015.0617; Bouchard J, 2012, J NEUROSCI, V32, P18259, DOI 10.1523/JNEUROSCI.4008-12.2012; Brusco A, 2008, ANN NY ACAD SCI, V1139, P450, DOI 10.1196/annals.1432.037; Carrier EJ, 2004, MOL PHARMACOL, V65, P999, DOI 10.1124/mol.65.4.999; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; Chiarlone A, 2014, P NATL ACAD SCI USA, V111, P8257, DOI 10.1073/pnas.1400988111; Chiurchiu V, 2015, IMMUNOLOGY, V144, P352, DOI 10.1111/imm.12441; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; Concannon RM, 2015, EXP NEUROL, V269, P133, DOI 10.1016/j.expneurol.2015.04.007; Garcia MC, 2015, NEUROSCI LETT, V587, P1, DOI 10.1016/j.neulet.2014.12.003; den Boon FS, 2014, PFLUG ARCH EUR J PHY, V466, P2257, DOI 10.1007/s00424-014-1502-6; den Boon FS, 2012, P NATL ACAD SCI USA, V109, P3534, DOI 10.1073/pnas.1118167109; Depino AM, 2003, EUR J NEUROSCI, V18, P2731, DOI 10.1111/j.1460-9568.2003.03014.x; Di Marzo V, 2000, FASEB J, V14, P1432, DOI 10.1096/fj.14.10.1432; Dowie MJ, 2014, J CHEM NEUROANAT, V59-60, P62, DOI 10.1016/j.jchemneu.2014.06.004; Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Esposito G, 2007, J PHARMACOL EXP THER, V322, P1144, DOI 10.1124/jpet.107.121566; Fernandez-Espejo E, 2005, NEUROBIOL DIS, V18, P591, DOI 10.1016/j.nbd.2004.10.015; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Fernandez-Ruiz J, 2015, NEUROTHERAPEUTICS, V12, P793, DOI 10.1007/s13311-015-0381-7; Fernandez-Ruiz J, 2015, HANDB EXP PHARMACOL, V231, P233, DOI 10.1007/978-3-319-20825-1_8; Fernandez-Ruiz J, 2010, CNS NEUROSCI THER, V16, pe72, DOI 10.1111/j.1755-5949.2010.00144.x; Fernandez-Ruiz J, 2009, BRIT J PHARMACOL, V156, P1029, DOI 10.1111/j.1476-5381.2008.00088.x; Fezza F, 2014, MOLECULES, V19, P17078, DOI 10.3390/molecules191117078; Franklin A, 2003, J NEUROSCI, V23, P7767; Garcia C, 2011, BRIT J PHARMACOL, V163, P1495, DOI 10.1111/j.1476-5381.2011.01278.x; Garcia-Ovejero D, 2009, NEUROBIOL DIS, V33, P57, DOI 10.1016/j.nbd.2008.09.015; Giacobini E, 2013, NAT REV NEUROL, V9, P677, DOI 10.1038/nrneurol.2013.223; GLASS M, 1993, NEUROSCIENCE, V56, P523, DOI 10.1016/0306-4522(93)90352-G; Glass M, 2000, NEUROSCIENCE, V97, P505, DOI 10.1016/S0306-4522(00)00008-7; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Gomez-Galvez Y, 2016, PROG NEURO-PSYCHOPH, V64, P200, DOI 10.1016/j.pnpbp.2015.03.017; Gonzalez S, 2006, BRAIN RES, V1073, P209, DOI 10.1016/j.brainres.2005.12.014; Graham DI, 1996, ACT NEUR S, V66, P96; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Gruenblatt E, 2007, J ALZHEIMERS DIS, V12, P291; Gubellini P, 2002, J NEUROSCI, V22, P6900; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Heller Joshua E, 2009, Clin Neurosurg, V56, P84; Hoang T, 2009, FREE RADICAL BIO MED, V47, P1049, DOI 10.1016/j.freeradbiomed.2009.07.013; Hoban DB, 2013, BRAIN BEHAV IMMUN, V27, P91, DOI 10.1016/j.bbi.2012.10.001; Horti AG, 2010, BIOORGAN MED CHEM, V18, P5202, DOI 10.1016/j.bmc.2010.05.058; Howlett AC, 2005, HANDB EXP PHARMACOL, V168, P53; Iannotti FA, 2016, PROG LIPID RES, V62, P107, DOI 10.1016/j.plipres.2016.02.002; Janefjord E, 2014, CELL MOL NEUROBIOL, V34, P31, DOI 10.1007/s10571-013-9984-x; Kelsey JE, 2009, BEHAV BRAIN RES, V203, P304, DOI 10.1016/j.bbr.2009.04.035; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Koppel J, 2013, MOL MED, V19, P357, DOI 10.2119/molmed.2013.00140; Lastres-Becker I, 2001, EUR J NEUROSCI, V14, P1827, DOI 10.1046/j.0953-816x.2001.01812.x; Lastres-Becker I, 2002, NEUROTOX RES, V4, P601, DOI 10.1080/10298420290030514; Latini L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.364; Li Y, 2015, NEUROSCIENCE, V311, P253, DOI 10.1016/j.neuroscience.2015.10.041; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Moreno JLLS, 2016, J NEUROL, V263, P1390, DOI 10.1007/s00415-016-8145-9; Lu HC, 2016, BIOL PSYCHIAT, V79, P516, DOI 10.1016/j.biopsych.2015.07.028; Maccarrone M., 2015, TRENDS PHARMACOL SCI, V36; Maccarrone M, 2007, PROG NEUROBIOL, V81, P349, DOI 10.1016/j.pneurobio.2006.11.006; Maccarrone M, 2010, TRENDS BIOCHEM SCI, V35, P601, DOI 10.1016/j.tibs.2010.05.008; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Malfitano AM, 2014, SEMIN IMMUNOL, V26, P369, DOI 10.1016/j.smim.2014.04.002; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin-Moreno AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-8; Martin-Moreno AM, 2011, MOL PHARMACOL, V79, P964, DOI 10.1124/mol.111.071290; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; McIntosh TK, 1996, LAB INVEST, V74, P315; Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; Molina-Holgado F, 2002, J NEUROSCI RES, V67, P829, DOI 10.1002/jnr.10165; More SV, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0012-0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paradisi A, 2006, CURR DRUG TARGETS, V7, P1539, DOI 10.2174/1389450110607011539; Pisani A, 2005, ANN NEUROL, V57, P777, DOI 10.1002/ana.20462; Price DA, 2009, EUR J NEUROSCI, V29, P2177, DOI 10.1111/j.1460-9568.2009.06764.x; Pryce G, 2015, J NEUROIMMUNE PHARM, V10, P281, DOI 10.1007/s11481-014-9575-8; Rafii MS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0297-4; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Romero J, 2000, LIFE SCI, V66, P485, DOI 10.1016/S0024-3205(99)00618-9; Sagredo O., 2012, CNS DRUG DISCOVERY, V7, P41, DOI DOI 10.2174/157488912798842278; Sagredo O, 2007, MOL NEUROBIOL, V36, P82, DOI 10.1007/s12035-007-0004-3; Sagredo O, 2009, GLIA, V57, P1154, DOI 10.1002/glia.20838; Savonenko AV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129618; Schmole AC, 2015, NEUROBIOL AGING, V36, P710, DOI 10.1016/j.neurobiolaging.2014.09.019; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sheng WS, 2005, GLIA, V49, P211, DOI 10.1002/glia.20108; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Solas M, 2013, NEUROBIOL AGING, V34, P805, DOI 10.1016/j.neurobiolaging.2012.06.005; Tabrizi MA, 2016, CHEM REV, V116, P519, DOI 10.1021/acs.chemrev.5b00411; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Valdeolivas S, 2015, NEUROTHERAPEUTICS, V12, P185, DOI 10.1007/s13311-014-0304-z; Van der Stelt M, 2006, CELL MOL LIFE SCI, V63, P1410, DOI 10.1007/s00018-006-6037-3; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Walsh S, 2011, NEUROSCIENCE, V175, P251, DOI 10.1016/j.neuroscience.2010.12.005; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wotherspoon G, 2005, NEUROSCIENCE, V135, P235, DOI 10.1016/j.neuroscience.2005.06.009; Wu J, 2013, NEUROBIOL AGING, V34, P791, DOI 10.1016/j.neurobiolaging.2012.06.011	117	39	42	0	16	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	SEP	2016	111						721	730		10.1016/j.phrs.2016.07.021			10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DY0JV	WOS:000384784000069	27450295				2022-02-06	
J	Cnossen, MC; Polinder, S; Lingsma, HF; Maas, AIR; Menon, D; Steyerberg, EW				Cnossen, Maryse C.; Polinder, Suzanne; Lingsma, Hester F.; Maas, Andrew I. R.; Menon, David; Steyerberg, Ewout W.		CENTER-Tbi Invest Participants	Variation in Structure and Process of Care in Traumatic Brain Injury: Provider Profiles of European Neurotrauma Centers Participating in the CENTER-TBI Study	PLOS ONE			English	Article							QUESTIONNAIRE; MANAGEMENT; QUALITY; LENGTH	Introduction The strength of evidence underpinning care and treatment recommendations in traumatic brain injury (TBI) is low. Comparative effectiveness research (CER) has been proposed as a framework to provide evidence for optimal care for TBI patients. The first step in CER is to map the existing variation. The aim of current study is to quantify variation in general structural and process characteristics among centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Methods We designed a set of 11 provider profiling questionnaires with 321 questions about various aspects of TBI care, chosen based on literature and expert opinion. After pilot testing, questionnaires were disseminated to 71 centers from 20 countries participating in the CENTER-TBI study. Reliability of questionnaires was estimated by calculating a concordance rate among 5% duplicate questions. Results All 71 centers completed the questionnaires. Median concordance rate among duplicate questions was 0.85. The majority of centers were academic hospitals (n = 65, 92%), designated as a level I trauma center (n = 48, 68%) and situated in an urban location (n = 70, 99%). The availability of facilities for neuro-trauma care varied across centers; e.g. 40 (57%) had a dedicated neuro-intensive care unit (ICU), 36 (51%) had an in-hospital rehabilitation unit and the organization of the ICU was closed in 64% (n = 45) of the centers. In addition, we found wide variation in processes of care, such as the ICU admission policy and intracranial pressure monitoring policy among centers. Conclusion Even among high-volume, specialized neurotrauma centers there is substantial variation in structures and processes of TBI care. This variation provides an opportunity to study effectiveness of specific aspects of TBI care and to identify best practices with CER approaches.	[Cnossen, Maryse C.; Polinder, Suzanne; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Menon, David] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England		Lingsma, HF (corresponding author), Erasmus MC, Ctr Med Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	Badenes, Rafael/K-6628-2019; Viani, Rafael/V-1196-2018; Laureys, Steven/AAN-2097-2021; Santos, Edgar/AAV-2506-2021; Sahakian, Barbara/AAW-1198-2020; Oresic, Matej/K-7673-2016; Sahuquillo, Juan/B-3577-2008; Cooper, D. James/G-7961-2013; Castano-Leon, Ana M/ABF-6322-2020; Ercole, Ari/B-6288-2009; Gomez, Pedro/N-5051-2019; Lagares, Alfonso/B-2969-2011; Majdan, Marek/K-5017-2012; van der Jagt, Mathieu/G-1905-2017; Stocchetti, Nino/O-7444-2017	Badenes, Rafael/0000-0001-7017-0150; Laureys, Steven/0000-0002-3096-3807; Santos, Edgar/0000-0002-8976-5549; Sahakian, Barbara/0000-0001-7352-1745; Oresic, Matej/0000-0002-2856-9165; Sahuquillo, Juan/0000-0003-0713-5875; Cooper, D. James/0000-0002-5872-9051; Castano-Leon, Ana M/0000-0002-7918-5049; Ercole, Ari/0000-0001-8350-8093; Gomez, Pedro/0000-0002-4185-5238; Lagares, Alfonso/0000-0003-3996-0554; Lanyon, Linda/0000-0002-0885-1825; Feigin, Valery L./0000-0002-6372-1740; Sanchez-Porras, Renan/0000-0002-9084-8114; Esser, Patrick/0000-0002-3227-0115; Newcombe, Virginia/0000-0001-6044-9035; CAUSIN, Francesco/0000-0001-6491-7027; Te Ao, Braden/0000-0002-1050-200X; Rossi, Sandra/0000-0002-9963-8121; Smielewski, Peter/0000-0001-5096-3938; MARTIN, Didier/0000-0001-7325-4958; Wang, Kevin/0000-0002-9343-6473; Cameron, Peter/0000-0002-1443-557X; Majdan, Marek/0000-0001-8037-742X; van der Jagt, Mathieu/0000-0003-2566-8325; Synnot, Anneliese/0000-0002-4008-4208; Wade, Derick/0000-0002-1188-8442; Morganti-Kossmann, Cristina/0000-0002-0807-2063; van der Naalt, Joukje/0000-0001-9873-2418; Stocchetti, Nino/0000-0003-3250-6834; Ledig, Christian/0000-0003-4862-3138; persona, paolo/0000-0003-1584-5148; Pomposo Gaztelu, Inigo/0000-0002-3095-2649; Parizel, Paul M./0000-0002-0221-2854; Della Corte, Francesco/0000-0003-1736-2318; Bragge, Peter/0000-0003-0745-5131; Kondziella, Daniel/0000-0001-5562-9808; Ortolano, Fabrizio/0000-0003-1996-948X; Andelic, Nada/0000-0002-3719-4406	European Commission 7th Framework program [602150]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission 7th Framework program (602150). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AD HOC COMM HLTH, 1996, TDRGEN961 WHO AD HOC; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7; Cnossen MC, 2015, J NEUROTRAUMA; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; European Brain Injury Consortium, EBIC CTR SURV; European Comission, 2007, REM RES PUBL PRIV SE; Galesic M, 2009, PUBLIC OPIN QUART, V73, P349, DOI 10.1093/poq/nfp031; I. o. Medicine, 2009, IN NAT PRIOR COMP EF; Kalantar JS, 1999, J CLIN EPIDEMIOL, V52, P1117, DOI 10.1016/S0895-4356(99)00051-7; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7	15	39	40	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2016	11	8							e0161367	10.1371/journal.pone.0161367			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4DZ	WOS:000382876700016	27571205	Green Published, Green Submitted, Green Accepted, gold			2022-02-06	
J	Lorton, F; Poullaouec, C; Legallais, E; Simon-Pimmel, J; Chene, MA; Leroy, H; Roy, M; Launay, E; Gras-Le Guen, C				Lorton, F.; Poullaouec, C.; Legallais, E.; Simon-Pimmel, J.; Chene, M. A.; Leroy, H.; Roy, M.; Launay, E.; Gras-Le Guen, C.			Validation of the PECARN clinical decision rule for children with minor head trauma: a French multicenter prospective study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Minor head trauma; Children; External validation; Clinical decision rule; Cranial computed tomography	PREDICTION RULES; METHODOLOGICAL STANDARDS; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; INJURY; MANAGEMENT; RISK	Background: To date, the Pediatric Emergency Care Applied Research Network (PECARN) rule for identifying children who are at very low risk of clinically-important traumatic brain injuries after minor head trauma has not been validated prospectively in an independent population. Our goal was to evaluate the diagnostic performance of the PECARN clinical decision rule in a French pediatric population in multiple clinical settings. Methods: We conducted a multicenter, prospective, non-interventional cohort study of patients with minor head trauma who presented to three emergency departments in France. We enrolled patients younger than 16 years of age seeking a consultation within 24 h of head trauma with Glasgow Coma Scale scores of 14-15. Results: During the study period, we included 1499 children of which 421 (28 %) were under 2 years of age, and 955 (64 %) were male. A cranial computed tomography (CT) scan was performed on 76 patients (5.1 %). Of the 1499 included patients, 9 children (0.6 %) had a clinically-important traumatic brain injury, and none were classified as very low risk by the PECARN rule. In our study, the sensitivity of this clinical decision rule was 100 % (95 % CI 66.4 to 100 %), the specificity was 69.9 % (95 % CI 67.5 to 72.2 %) and the negative predictive value was 100 % (95 % CI 99.7 to 100 %). Discussion: Our study confirmed the good predictive performances of the PECARN clinical decision rule for minor head trauma in children. The PECARN rule performed similarly to our study and to its internal validation study. Conclusions: We conducted an external validation study of the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma, according to the methodological standards. The PECARN rule successfully identified all patients with clinically-important traumatic brain injuries, with a limited use of CT scans. Conducting a broad validation study with a large cohort is a prerequisite to provide sufficient statistical power before authorizing its implementation and generalization.	[Lorton, F.; Poullaouec, C.; Legallais, E.; Simon-Pimmel, J.; Roy, M.; Gras-Le Guen, C.] Univ Hosp, Dept Pediat Emergency, F-44093 Nantes 01, France; [Lorton, F.; Gras-Le Guen, C.] Univ Hosp, INSERM CIC 1413, 38 Bd Jean Monnet, F-44093 Nantes 01, France; [Chene, M. A.] Hosp St Nazaire, Dept Pediat, 11 Bd Georges Charpak, F-44606 St Nazaire, France; [Leroy, H.] Dept Hosp Vendee, Dept Emergency, F-85925 Les Oudairies 9, La Roche Sur Yo, France; [Launay, E.] Univ Hosp, Dept Pediat, F-44093 Nantes 01, France		Lorton, F (corresponding author), Univ Hosp, Dept Pediat Emergency, F-44093 Nantes 01, France.; Lorton, F (corresponding author), Univ Hosp, INSERM CIC 1413, 38 Bd Jean Monnet, F-44093 Nantes 01, France.	fleur.lorton@chu-nantes.fr		Lorton, Fleur/0000-0003-0921-4622; Launay, Elise/0000-0002-4081-4653; GRAS-LE GUEN, Christele/0000-0001-9060-2344			Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Jehle E, 2012, ANN FR MED URGENCE, V2, P199, DOI 10.1007/s13341-012-0202-4; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Lorton F, 2014, ARCH PEDIATRIE, V21, P790, DOI 10.1016/j.arcped.2014.04.015; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	21	39	39	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	AUG 4	2016	24								98	10.1186/s13049-016-0287-3			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DT4LV	WOS:000381453500001	27488722	gold, Green Published			2022-02-06	
J	Badner, A; Vawda, R; Laliberte, A; Hong, J; Mikhail, M; Jose, A; Dragas, R; Fehlings, M				Badner, Anna; Vawda, Reaz; Laliberte, Alex; Hong, James; Mikhail, Mirriam; Jose, Alejandro; Dragas, Rachel; Fehlings, Michael			Early Intravenous Delivery of Human Brain Stromal Cells Modulates Systemic Inflammation and Leads to Vasoprotection in Traumatic Spinal Cord Injury	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Mesenchymal stromal cells; Pericytes; Spinal cord injury; Vasoprotection; Interleukin-10	MESENCHYMAL STEM-CELLS; AUTOLOGOUS BONE-MARROW; MYOCARDIAL-INFARCTION; CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; BARRIER PERMEABILITY; VASCULAR DISRUPTION; HUMAN PERICYTES; IMMUNE-SYSTEM; IN-VITRO	Spinal cord injury (SCI) is a life-threatening condition withmultifaceted complications and limited treatment options. In SCI, the initial physical trauma is closely followed by a series of secondary events, including inflammation and blood spinal cord barrier (BSCB) disruption, which further exacerbate injury. This secondary pathology is partially mediated by the systemic immune response to trauma, in which cytokine production leads to the recruitment/activation of inflammatory cells. Because early intravenous delivery of mesenchymal stromal cells (MSCs) has been shown to mitigate inflammation in various models of neurologic disease, this study aimed to assess these effects in a rat model of SCI (C7-T1, 35-gram clip compression) using human brain-derived stromal cells. Quantitative polymerase chain reaction for a human-specific DNA sequence was used to assess cell biodistribution/clearance and confirmed that only a small proportion (approximately 0.001%-0.002%) of cells are delivered to the spinal cord, with the majority residing in the lung, liver, and spleen. Intriguingly, although cell populations drastically declined in all aforementioned organs, there remained a persistent population in the spleen at 7 days. Furthermore, the cell infusion significantly increased splenic and circulating levels of interleukin-10-a potent anti-inflammatory cytokine. Through this suppression of the systemic inflammatory response, the cells also reduced acute spinal cord BSCB permeability, hemorrhage, and lesion volume. These early effects further translated into enhanced functional recovery and tissue sparing 10 weeks after SCI. This work demonstrates an exciting therapeutic approach whereby a minimally invasive cell-transplantation procedure can effectively reduce secondary damage after SCI through systemic immunomodulation. SIGNIFICANCE Central nervous system pericytes (perivascular stromal cells) have recently gained significant attention within the scientific community. In addition to being recognized as major players in neurotrauma, pericytes have been discovered to share a common origin and potentially function with traditionally defined mesenchymal stromal cells (MSCs). Although there have been several in vitro comparisons, the in vivo therapeutic application of human brain-derived stromal cells has not been previously evaluated. This study demonstrates that these cells not only display a MSC phenotype in vitro but also have similar in vivo immunomodulatory effects after spinal cord injury that are more potent than those of non-central nervous system tissue-derived cells. Therefore, these cells are of great interest for therapeutic use in spinal cord injury.	[Badner, Anna; Vawda, Reaz; Laliberte, Alex; Hong, James; Mikhail, Mirriam; Jose, Alejandro; Dragas, Rachel; Fehlings, Michael] Univ Hlth Network, Toronto Western Res Inst, Div Genet & Dev, Toronto, ON, Canada; [Badner, Anna; Laliberte, Alex; Hong, James; Dragas, Rachel; Fehlings, Michael] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Fehlings, Michael] Univ Hlth Network, Toronto Western Hosp, Spinal Program, Toronto, ON, Canada		Fehlings, M (corresponding author), Univ Toronto, Inst Med Sci, Toronto Western Hosp, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca	Badner, Anna/N-8035-2019	Badner, Anna/0000-0002-5244-6165; Laliberte, Alex/0000-0002-3503-4177; Fehlings, Michael/0000-0002-5722-6364	Canadian Institutes of Health Research Training Program in Regenerative MedicineCanadian Institutes of Health Research (CIHR); Ontario Graduate ScholarshipOntario Graduate Scholarship; Halbert Chair in Neural Repair and Regeneration; Dezwirek Family Foundation	We thank Ahad Siddiqui and Madeleine O'Higgins for manuscript review and editing and Jian Wang for technical support. This work was supported by funds from the Canadian Institutes of Health Research Training Program in Regenerative Medicine (A.B.) and the Ontario Graduate Scholarship (A.B.). M.F. was supported by the Halbert Chair in Neural Repair and Regeneration and Dezwirek Family Foundation.	Acosta SA, 2015, STROKE, V46, P2616, DOI 10.1161/STROKEAHA.115.009854; Aertker BM, 2016, EXP NEUROL, V275, P411, DOI 10.1016/j.expneurol.2015.01.008; Alexanian AR, 2010, RESTOR NEUROL NEUROS, V28, P761, DOI 10.3233/RNN-2010-0547; Avolio E, 2015, CIRC RES, V116, pE81, DOI 10.1161/CIRCRESAHA.115.306146; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Birbrair A, 2015, CLIN SCI, V128, P81, DOI 10.1042/CS20140278; Blocki A, 2013, STEM CELLS DEV, V22, P2347, DOI 10.1089/scd.2012.0415; Bochev I, 2008, CELL BIOL INT, V32, P384, DOI 10.1016/j.cellbi.2007.12.007; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Brown A, 2014, J NEUROSURG-SPINE, V20, P164, DOI 10.3171/2013.10.SPINE13113; Burchfield JS, 2008, CIRC RES, V103, P203, DOI 10.1161/CIRCRESAHA.108.178475; Chen CW, 2013, STEM CELLS, V31, P305, DOI 10.1002/stem.1285; Chen M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0284-x; Choi JJ, 2008, CLIN EXP IMMUNOL, V153, P269, DOI 10.1111/j.1365-2249.2008.03683.x; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; da Silva ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932; Dayan V, 2011, BASIC RES CARDIOL, V106, P1299, DOI 10.1007/s00395-011-0221-9; De Miguel MP, 2012, CURR MOL MED, V12, P574; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Nguyen DH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-224; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Figley SA, 2014, J NEUROTRAUM, V31, P541, DOI 10.1089/neu.2013.3034; Fleming JC, 2012, J TRAUMA ACUTE CARE, V72, P1194, DOI 10.1097/TA.0b013e31824d68bd; Forgione N, 2014, J NEUROTRAUM, V31, P1776, DOI 10.1089/neu.2014.3388; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Hegyi B, 2010, INT IMMUNOL, V22, P551, DOI 10.1093/intimm/dxq039; Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004; Huston JM, 2009, J IMMUNOL, V183, P552, DOI 10.4049/jimmunol.0802684; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Ivanova-Todorova E, 2009, IMMUNOL LETT, V126, P37, DOI 10.1016/j.imlet.2009.07.010; Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681; Matsushita T, 2015, EXP NEUROL, V267, P152, DOI 10.1016/j.expneurol.2015.03.001; Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Mendel TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065691; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Min CK, 2007, BONE MARROW TRANSPL, V39, P637, DOI 10.1038/sj.bmt.1705644; MOSTAFA ME, 2001, CARDIOVASC RES, V49, P882; Oliveri RS, 2014, NEUROBIOL DIS, V62, P338, DOI 10.1016/j.nbd.2013.10.014; Rice T, 2007, J NEUROPATH EXP NEUR, V66, P184, DOI 10.1097/01.jnen.0000248552.07338.7f; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Schwartz M, 2006, J NEUROTRAUM, V23, P360, DOI 10.1089/neu.2006.23.360; Soubeyrand M, 2014, J NEUROTRAUM, V31, P1767, DOI 10.1089/neu.2013.3319; Tang GH, 2014, STEM CELLS, V32, P3150, DOI 10.1002/stem.1808; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Tsumuraya T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0252-5; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; WARNICK RE, 1995, J NEUROSCI METH, V58, P167, DOI 10.1016/0165-0270(94)00172-D; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Williams K, 2001, GLIA, V36, P156, DOI 10.1002/glia.1105; Yu DS, 2015, J MOL NEUROSCI, V56, P388, DOI 10.1007/s12031-015-0564-z; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang Y, 2013, J NEUROSCI, V33, P12970, DOI 10.1523/JNEUROSCI.1974-13.2013	64	39	39	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	AUG	2016	5	8					991	1003		10.5966/sctm.2015-0295			13	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	DY7DE	WOS:000385288800002	27245367	Green Published, gold			2022-02-06	
J	Bouzat, P; Almeras, L; Manhes, P; Sanders, L; Levrat, A; David, JS; Cinotti, R; Chabanne, R; Gloaguen, A; Bobbia, X; Thoret, S; Oujamaa, L; Bosson, JL; Payen, JF				Bouzat, Pierre; Almeras, Luc; Manhes, Pauline; Sanders, Laurence; Levrat, Albrice; David, Jean-Stephane; Cinotti, Raphael; Chabanne, Russel; Gloaguen, Aurelie; Bobbia, Xavier; Thoret, Sophie; Oujamaa, Lydia; Bosson, Jean-Luc; Payen, Jean-Francois		TBI-TCD Study Investigators	Transcranial Doppler to Predict Neurologic Outcome after Mild to Moderate Traumatic Brain Injury	ANESTHESIOLOGY			English	Article							HEAD-INJURY; INTRACRANIAL-PRESSURE; PULSATILITY INDEX; FLOW-VELOCITY; BLOOD-FLOW; DETERIORATION	Background: To assess the performance of transcranial Doppler (TCD) in predicting neurologic worsening after mild to moderate traumatic brain injury. Methods: The authors conducted a prospective observational study across 17 sites. TCD was performed upon admission in 356 patients (Glasgow Coma Score [GCS], 9 to 15) with mild lesions on cerebral computed tomography scan. Normal TCD was defined as a pulsatility index of less than 1.25 and diastolic blood flow velocity higher than 25 cm/s in the two middle cerebral arteries. The primary endpoint was secondary neurologic deterioration on day 7. Results: Twenty patients (6%) developed secondary neurologic deterioration within the first posttraumatic week. TCD thresholds had 80% sensitivity (95% CI, 56 to 94%) and 79% specificity (95% CI, 74 to 83%) to predict neurologic worsening. The negative predictive values and positive predictive values of TCD were 98% (95% CI, 96 to 100%) and 18% (95% CI, 11 to 28%), respectively. In patients with minor traumatic brain injury (GCS, 14 to 15), the sensitivity and specificity of TCD were 91% (95% CI, 59 to 100%) and 80% (95% CI, 75 to 85%), respectively. The area under the receiver operating characteristic curve of a multivariate predictive model including age and GCS was significantly improved with the adjunction of TCD. Patients with abnormal TCD on admission (n = 86 patients) showed a more altered score for the disability rating scale on day 28 compared to those with normal TCD (n = 257 patients). Conclusions: TCD measurements upon admission may provide additional information about neurologic outcome after mild to moderate traumatic brain injury. This technique could be useful for in-hospital triage in this context.	[Bouzat, Pierre; Almeras, Luc; Manhes, Pauline; Oujamaa, Lydia; Payen, Jean-Francois] CHU Grenoble Alpes, Pole Anesthesie Reanimat, Grenoble, France; [Bouzat, Pierre; Payen, Jean-Francois] INSERM, Grenoble, France; [Bouzat, Pierre; Payen, Jean-Francois] Univ Grenoble Alpes, Grenoble Inst Neurosci, Grenoble, France; [Manhes, Pauline; Thoret, Sophie; Bosson, Jean-Luc] CHU Grenoble, Ctr Invest Clin, Grenoble, France; [Sanders, Laurence] CHU Grenoble, Serv Accueil Urgences Chirurg, Grenoble, France; [Levrat, Albrice] Ctr Hosp Annecy Genevois, Serv Reanimat, Annecy, France; [David, Jean-Stephane] Hosp Civils Lyon, Dept Anesthesie Reanimat, Lyon, France; [Cinotti, Raphael] CHU Nantes, Dept Anesthesie Reanimat, Nantes, France; [Chabanne, Russel] CHU Clermont Ferrand, Dept Anesthesie Reanimat, Clermont Ferrand, France; [Gloaguen, Aurelie] CHU Dijon, Dept Med Urgence SAMU SMUR, Dijon, France; [Bobbia, Xavier] CHU Nimes, Dept Anesthesie Reanimat Urgences, Nimes, France		Bouzat, P (corresponding author), CHU Grenoble, Pole Anesthesie Reanimat, BP 217, F-38000 Grenoble, France.	pbouzat@chu-grenoble.fr	Bouzat, Pierre/L-6881-2014; Payen, Jean-Francois/L-6667-2014; bosson, jean-luc/AAP-5163-2020; David, Jean Stephane/H-9399-2019; Bouzat, Pierre/AAC-4105-2019; Chabanne, Russell/AAI-2180-2019	bosson, jean-luc/0000-0003-0967-6026; David, Jean Stephane/0000-0001-6274-7044; Bouzat, Pierre/0000-0003-4667-6738; 	Programme hospitalier de recherche Clinique interregional, Interregion Sud-est, France	Support was provided solely from institutional sources (Programme hospitalier de recherche Clinique interregional 2010, Interregion Sud-est, France).	AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Ahmad M, 2013, INTENS CARE MED, V39, P1150, DOI 10.1007/s00134-013-2885-0; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P153, DOI 10.1097/MCC.0000000000000071; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Bouzat P, 2011, NEUROSURGERY, V68, P1603, DOI 10.1227/NEU.0b013e31820cd43e; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Keller T, 2009, NEW ENGL J MED, V361, P868, DOI 10.1056/NEJMoa0903515; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Owaidah T, 2014, THROMB J, V12, DOI 10.1186/s12959-014-0028-7; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	24	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2016	125	2					346	354		10.1097/ALN.0000000000001165			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	DY3VC	WOS:000385022200014	27224640				2022-02-06	
J	Wang, KKW; Yang, ZH; Yue, JK; Zhang, ZQ; Winkler, EA; Puccio, AM; Diaz-Arrastia, R; Lingsma, HF; Yuh, EL; Mukherjee, P; Valadka, AB; Gordon, WA; Okonkwo, DO; Manley, GT; Cooper, SR; Dams-O'Connor, K; Hricik, AJ; Inoue, T; Maas, AIR; Menon, DK; Schnyer, DM; Sinha, TK; Vassar, MJ				Wang, Kevin K. W.; Yang, Zhihui; Yue, John K.; Zhang, Zhiqun; Winkler, Ethan A.; Puccio, Ava M.; Diaz-Arrastia, Ramon; Lingsma, Hester F.; Yuh, Esther L.; Mukherjee, Pratik; Valadka, Alex B.; Gordon, Wayne A.; Okonkwo, David O.; Manley, Geoffrey T.; Cooper, Shelly R.; Dams-O'Connor, Kristen; Hricik, Allison J.; Inoue, Tomoo; Maas, Andrew I. R.; Menon, David K.; Schnyer, David M.; Sinha, Tuhin K.; Vassar, Mary J.		TRACK-TBI Investigators	Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						autoantibody; autoimmunity; biomarkers; glia; traumatic brain injury	C-TERMINAL HYDROLASE-L1; COMMON DATA ELEMENTS; NEUROSURGICAL INTERVENTION; ANTIPITUITARY ANTIBODIES; INTRACRANIAL LESIONS; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; HEAD-INJURY; TRACK-TBI; BIOMARKERS	We described recently a subacute serum autoantibody response toward glial fibrillary acidic protein (GFAP) and its breakdown products 5-10 days after severe traumatic brain injury (TBI). Here, we expanded our anti-GFAP autoantibody (AutoAb[GFAP]) investigation to the multicenter observational study Transforming Research and Clinical Knowledge in TBI Pilot (TRACK-TBI Pilot) to cover the full spectrum of TBI (Glasgow Coma Scale 3-15) by using acute (<24 h) plasma samples from 196 patients with acute TBI admitted to three Level I trauma centers, and a second cohort of 21 participants with chronic TBI admitted to inpatient TBI rehabilitation. We find that acute patients self-reporting previous TBI with loss of consciousness (LOC) (n = 43) had higher day 1 AutoAb [GFAP] (mean +/- standard error: 9.11 +/- 1.42; n = 43) than healthy controls (2.90 +/- 0.92; n = 16;p = 0.032) and acute patients reporting no previous TBI (2.97 +/- 0.37; n = 106; p < 0.001), but not acute patients reporting previous TBI without LOC (8.01 +/- 1.80; n = 47; p = 0.906). These data suggest that while exposure to TBI may trigger the AutoAb[GFAP] response, circulating antibodies are elevated specifically in acute TBI patients with a history of TBI. AutoAb[GFAP] levels for participants with chronic TBI (average post-TBI time 176 days or 6.21 months) were also significantly higher (15.08 +/- 2.82; n = 21) than healthy controls (p < 0.001). These data suggest a persistent upregulation of the autoimmune response to specific brain antigen(s) in the subacute to chronic phase after TBI, as well as after repeated TBI insults. Hence, AutoAb [GFAP] may be a sensitive assay to study the dynamic interactions between post injury brain and patient-specific autoimmune responses across acute and chronic settings after TBI.	[Wang, Kevin K. W.; Yang, Zhihui; Zhang, Zhiqun] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Wang, Kevin K. W.; Yang, Zhihui; Zhang, Zhiqun] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Yue, John K.; Winkler, Ethan A.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.; Cooper, Shelly R.; Inoue, Tomoo; Vassar, Mary J.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Winkler, Ethan A.; Manley, Geoffrey T.; Cooper, Shelly R.; Inoue, Tomoo; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Puccio, Ava M.; Okonkwo, David O.; Hricik, Allison J.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Lingsma, Hester F.; Cooper, Shelly R.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Yuh, Esther L.; Mukherjee, Pratik; Sinha, Tuhin K.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Gordon, Wayne A.; Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Menon, David K.] Addenbrookes Hosp, Cambridge, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA		Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, McKnight Brain Inst, POB 100256, Gainesville, FL 32611 USA.	kwang@ufl.edu	Yue, John K/P-1348-2015; Schnyer, David/ABD-6372-2021	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Wang, Kevin/0000-0002-9343-6473; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Cooper, Shelly/0000-0003-0026-6688	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS085455] Funding Source: Medline; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085455] Funding Source: NIH RePORTER		Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Chang BG, 2009, J VIROL METHODS, V159, P15, DOI 10.1016/j.jviromet.2009.02.019; Colasanti T, 2010, AUTOIMMUN REV, V9, P807, DOI 10.1016/j.autrev.2010.07.008; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; D'Andrea MR, 2005, MED HYPOTHESES, V64, P458, DOI 10.1016/j.mehy.2004.08.024; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Derfuss T, 2012, CURR OPIN NEUROL, V25, P231, DOI 10.1097/WCO.0b013e3283533a64; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hedegaard CJ, 2009, IMMUNOLOGY, V128, pe451, DOI 10.1111/j.1365-2567.2008.02999.x; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Iseme RA, 2014, NEUROSCI BIOBEHAV R, V40, P62, DOI 10.1016/j.neubiorev.2014.01.008; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Lancaster E, 2012, NAT REV NEUROL, V8, P380, DOI 10.1038/nrneurol.2012.99; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Ponomarenko NA, 2006, IMMUNOL LETT, V103, P45, DOI 10.1016/j.imlet.2005.10.006; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Rubenstein R, 2010, J GEN VIROL, V91, P1883, DOI 10.1099/vir.0.020164-0; Saltzman J.W., 2013, CURR TRAN GERIATR GE, V1, P149; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sorokina EG, 2010, ZH NEVROL PSIKHIATR, V110, P30; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Watanabe M, 2010, CYTOKINE GROWTH F R, V21, P263, DOI 10.1016/j.cytogfr.2010.03.003; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	54	39	39	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1270	1277		10.1089/neu.2015.3881			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200393	26560343	Green Published			2022-02-06	
J	Estraneo, A; Loreto, V; Guarino, I; Boemia, V; Paone, G; Moretta, P; Trojano, L				Estraneo, Anna; Loreto, Vincenzo; Guarino, Ivan; Boemia, Virginia; Paone, Giuseppe; Moretta, Pasquale; Trojano, Luigi			Standard EEG in diagnostic process of prolonged disorders of consciousness	CLINICAL NEUROPHYSIOLOGY			English	Article						Disorders of consciousness; Vegetative state; Minimally conscious state; EEG background activity; EEG reactivity; Rehabilitation	COMA RECOVERY SCALE; ANOXIC VEGETATIVE STATE; BRAIN-INJURY; UNRESPONSIVE WAKEFULNESS; PREDICTORS; BEHAVIOR; RESPONSIVENESS; REACTIVITY; ALPHA; PAIN	Objective: This cross-sectional study assessed the ability of standard EEG in distinguishing vegetative state (VS) from minimally conscious state plus (MCS+) or MCS minus (MCS-), and to correlate EEG features with aetiology and level of responsiveness assessed by Coma Recovery Scale-Revised (CRS-R). Methods: We analyzed background EEG activity and EEG reactivity to eye opening and closing and to tactile, acoustic, nociceptive stimuli and Intermittent Photic Stimulation (IPS) in 73 inpatients (VS = 37, MC- = 11, MCS+ = 25), with traumatic (n = 21), vascular (n = 25) or anoxic (n = 27) aetiology. Results: All patients, but one, showed abnormal background activity. EEG abnormalities were more severe in VS than in MCS+ or MCS-, and in anoxic than other aetiologies. MCS+ patients with normal or Mildly Abnormal background activity showed higher scores on CRS-R than patients with moderate to severe EEG abnormalities. Reactivity to IPS, and acoustic stimuli was significantly more frequent in MCS+ and MCS- than in VS patients. Conclusions: EEG features differ between VS and MCS- or MCS+ patients and can provide evidence of relative sparing of thalamocortical connections in MCS+ patients. In anoxic patients EEG organization is more severely impaired and provides less discriminative diagnostic information. Significance: Conventional EEG can help clinicians to disentangle VS from MCS patients. (C) 2016 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Estraneo, Anna; Loreto, Vincenzo; Guarino, Ivan; Boemia, Virginia; Paone, Giuseppe; Moretta, Pasquale] Salvatore Maugeri Fdn, Sci Inst Telese Terme BN, IRCCS, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy; [Trojano, Luigi] Univ Naples 2, Dept Psychol, Neuropsychol Lab, Viale Ellittico 31, I-81100 Caserta, Italy		Estraneo, A (corresponding author), Salvatore Maugeri Fdn, IRCCS, Res Lab, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.; Estraneo, A (corresponding author), Salvatore Maugeri Fdn, IRCCS, Neurehabil Unit Disorder Consciousness, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.	anna.estraneo@fsm.it	Trojano, Luigi/F-2396-2016; Moretta, Pasquale/AAE-5162-2021	Trojano, Luigi/0000-0002-0328-9642; Moretta, Pasquale/0000-0003-2244-254X			Bekinschtein TA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00005; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2010, CLIN NEUROPHYSIOL, V121, P274, DOI 10.1016/j.clinph.2009.11.008; Bagnato S, 2015, CLIN NEUROPHYSIOL, V126, P959, DOI 10.1016/j.clinph.2014.08.005; Bagnato S, 2011, J PERIPHER NERV SYST, V16, P315, DOI 10.1111/j.1529-8027.2011.00363.x; Boccagni C, 2011, J CLIN NEUROPHYSIOL, V28, P489, DOI 10.1097/WNP.0b013e318231c8c8; Bodien YG, 2016, ARCH PHYS MED REHAB, V97, P490, DOI 10.1016/j.apmr.2015.08.422; Bruno M-A., 2012, COMA DISORDERS CONSC, P11, DOI [DOI 10.1007/978-1-4471-2440-5_2, 10.1007/978-1-4471-2440-5_2]; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Estraneo A, 2015, EUR J PHYS REHAB MED, V51, P627; Estraneo A, 2013, NEUROLOGY, V81, P1274; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Fernandez-Espejo D, 2015, JAMA NEUROL, V72, P1442, DOI 10.1001/jamaneurol.2015.2614; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirschberg R, 2011, NEUROL CLIN, V29, P773, DOI 10.1016/j.ncl.2011.07.009; Hofmeijer J, 2015, NEUROLOGY, V85, P137, DOI 10.1212/WNL.0000000000001742; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Klimesch W, 1998, NEUROSCI LETT, V244, P73, DOI 10.1016/S0304-3940(98)00122-0; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kulkarni VP, 2007, J CLIN NEUROPHYSIOL, V24, P433, DOI 10.1097/WNP.0b013e31815c2810; Latronico N, 2005, CURR OPIN CRIT CARE, V11, P126, DOI 10.1097/01.ccx.0000155357.24360.89; Logi F, 2011, BRAIN INJURY, V25, P972, DOI 10.3109/02699052.2011.589795; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Striano S, 1992, Acta Neurol (Napoli), V14, P275; Takahashi T, 2011, NIEDERMEYERS ELECTRO, P215; Trojano L, 2013, J NEUROL, V260, P306, DOI 10.1007/s00415-012-6717-x; Trojano L, 2012, J NEUROL, V259, P1888, DOI 10.1007/s00415-012-6435-4; Tsetsou S, 2015, RESUSCITATION, V97, P34, DOI 10.1016/j.resuscitation.2015.09.380; Yu T, 2013, NEUROLOGY, V80, P345, DOI 10.1212/WNL.0b013e31827f0846	41	39	42	3	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUN	2016	127	6					2379	2385		10.1016/j.clinph.2016.03.021			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DL3YH	WOS:000375569100012	27178856				2022-02-06	
J	Huber, BR; Alosco, ML; Stein, TD; Mckee, AC				Huber, Bertrand R.; Alosco, Michael L.; Stein, Thor D.; Mckee, Ann C.			Potential Long-Term Consequences of Concussive and Subconcussive Injury	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Neuropathology; Trauma; Traumatic brain injury; Chronic traumatic encephalopathy; Tau; Concussion; Subconcussion	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; AXONAL INJURY; TAU PATHOLOGY; HEAD IMPACTS; 1ST EXPOSURE; BRAIN TRAUMA; SPECTRUM; DISEASE; ACTIVATION	Repeated concussive and subconcussive trauma is associated with the later development of chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with clinical symptoms in multiple domains and a unique pattern of pathologic changes. CTE has been linked to boxing and American football; CTE has also been identified in soccer, ice hockey, baseball, rugby, and military service. To date, most large studies of CTE have come from enriched cohorts associated with brain bank donations for traumatic brain injury, although several recent studies re-examining neurodegenerative disease brain banks suggest that CTE is more common than is currently appreciated.	[Huber, Bertrand R.; Stein, Thor D.; Mckee, Ann C.] VA Boston HealthCare Syst, 150 South Huntington Ave, Boston, MA 02130 USA; [Huber, Bertrand R.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B-7800, Boston, MA 02118 USA; [Alosco, Michael L.; Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, 72 East Concord St,B-7800, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, 72 East Concord St,B-7800, Boston, MA 02118 USA; [Stein, Thor D.] Bedford Vet Affairs Med Ctr, 200 Springs Rd,Bldg 18,Room 118, Bedford, MA 01730 USA		Mckee, AC (corresponding author), Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B-7800, Boston, MA 02118 USA.	amckee@bu.edu		Stein, Thor/0000-0001-6954-4477	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG036697, P30 AG013846] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS096803, U01 NS086659] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline; RRD VA [I01 RX000991] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, F32NS096803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG036697, P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000991] Funding Source: NIH RePORTER		Arnaud L, 2006, NEURODEGENER DIS, V3, P313, DOI 10.1159/000095638; Arnaud LT, 2009, J NEUROCHEM, V110, P328, DOI 10.1111/j.1471-4159.2009.06142.x; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Buerger K, 2006, BRAIN, V129, P3035, DOI 10.1093/brain/awl269; Cajigal S., 2007, NEUROLOGY TODAY, V7, P16; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M, 1949, HOMMAGE C VINCENT; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Duong TH, 1997, BRAIN RES, V749, P152, DOI 10.1016/S0006-8993(96)01359-5; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hall GF, 2000, J CELL SCI, V113, P1373; Hall GF, 1997, P NATL ACAD SCI USA, V94, P4733, DOI 10.1073/pnas.94.9.4733; Johnson KA, 2015, ANN NEUROL; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Ke YD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007917; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling H, 2015, ACTA NEUROPATHOL; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKee AC, 2015, ACTA NEUROPATHOL; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mez J, 2016, TRAUM BRAIN INJ CLIN; Mez J, JAMA NEUROL IN PRESS; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Millspaugh JA, 1937, US NAV MED B, V35, P7; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008	55	39	39	3	56	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					503	+		10.1016/j.pmr.2015.12.007			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	DN4RU	WOS:000377055700011	27154859	Green Accepted			2022-02-06	
J	Yang, JJ; Ding, SD; Huang, WL; Hu, JN; Huang, SW; Zhang, Y; Zhuge, QC				Yang, Jianjing; Ding, Saidan; Huang, Weilong; Hu, Jiangnan; Huang, Shengwei; Zhang, Yu; Zhuge, Qichuan			Interleukin-4 Ameliorates the Functional Recovery of Intracerebral Hemorrhage Through the Alternative Activation of Microglia/Macrophage	FRONTIERS IN NEUROSCIENCE			English	Article						stroke; intracerebral hemorrhage; interleukin-4(IL-4); microglia/macrophage; recovery; M1 phenotype; M2 phenotype	TRAUMATIC BRAIN-INJURY; T-CELLS; MICROGLIA; POLARIZATION; BLOOD; INHIBITION; STROKE; RATS	Neuro-inflammation plays an important role in the recovery of brain injury after stroke. Microglia/macrophage is the major executor in the neuro-inflammation, which can be polarized into two distinct phenotypes: injurious/toxic classical activation (M1 phenotype) and protective alternative activation (M2 phenotype). Here, we investigated whether intracerebral administration of interleukin-4 (IL-4) at an early stage could affect the activation of microglia/macrophage and the corresponding outcome after intracerebral hemorrhage (ICH). The neuro-behavior was recorded between different groups in the rat ICH model. The M1 and M2 markers were then determined by qRT-PCR, western blotting, ELISA, and immunofluorescence, respectively. We observed aberrant activation of microglia/macrophage after ICH. After intracerebral injection of IL-4, M1 activation was greatly inhibited while M2 activation was enhanced, along with improving neurobehavioral recovery from deficits after ICH. Our study showed that early intracerebral injection of IL-4 potentially promotes neuro-functional recovery, probably through enhancing the alternative activation of microglia/macrophage.	[Yang, Jianjing; Ding, Saidan; Huang, Weilong; Hu, Jiangnan; Huang, Shengwei; Zhang, Yu; Zhuge, Qichuan] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China; [Zhuge, Qichuan] Wenzhou Med Univ, Zhejiang Prov Key Lab Aging & Neurol Dis, Wenzhou, Peoples R China		Zhuge, QC (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China.; Zhuge, QC (corresponding author), Wenzhou Med Univ, Zhejiang Prov Key Lab Aging & Neurol Dis, Wenzhou, Peoples R China.	qichuanzhuge@sina.com	Hu, John/AAL-6376-2021; Hu, Jiangnan/ABD-5635-2021; Hu, Jiangnan/ABB-1329-2021	Hu, Jiangnan/0000-0002-0112-7578	QZ's National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171088, 81371396]; YZ's Natural Science Foundation of Zhejiang Province [Y 2110807]	The research was supported by QZ's National Natural Science Foundation of China (No. 81171088 and 81371396) and YZ's Natural Science Foundation of Zhejiang Province (Y 2110807). We are grateful to Professor Dongming Su and Kunlin Jin (University of North Texas Health Science Center, USA) for critical suggestions on the experiments.	BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; CHAO CC, 1993, J IMMUNOL, V151, P1473; Chen M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0284-x; Chen YJ, 2015, J NEUROSCI RES, V93, P1526, DOI 10.1002/jnr.23612; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Deonarine K, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-11; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Kato T, 2000, J IMMUNOL, V164, P3554, DOI 10.4049/jimmunol.164.7.3554; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mehndiratta P, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11370; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Schallert T, 1997, ADV NEUROL, V73, P229; Tang Y, 2014, CELL DEATH DIFFER, V21, P369, DOI 10.1038/cdd.2013.159; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Wang J, 2005, NEUROCRIT CARE, V3, P77, DOI 10.1385/NCC:3:1:077; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Yang YR, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0245-4; Zhang SC, 2001, GLIA, V34, P101, DOI 10.1002/glia.1045	38	39	41	0	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAR 8	2016	10								61	10.3389/fnins.2016.00061			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DF7VR	WOS:000371566200001	27013935	gold, Green Published			2022-02-06	
J	Bodien, YG; Carlowicz, CA; Chatelle, C; Giacino, JT				Bodien, Yelena G.; Carlowicz, Cecilia A.; Chatelle, Camille; Giacino, Joseph T.			Sensitivity and Specificity of the Coma Recovery Scale-Revised Total Score in Detection of Conscious Awareness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Consciousness disorders; Rehabilitation; Sensitivity and specificity	STATE; DISORDERS	Objective: To describe the sensitivity and specificity of Coma Recovery Scale-Revised (CRS-R) total scores in detecting conscious awareness. Design: Data were retrospectively extracted from the medical records of patients enrolled in a specialized disorders of consciousness (DOC) program. Sensitivity and specificity analyses were completed using CRS-R derived diagnoses of minimally conscious state (MCS) or emerged from minimally conscious state (EMCS) as the reference standard for conscious awareness and the total CRS-R score as the test criterion. A receiver operating characteristic curve was constructed to demonstrate the optimal CRS-R total cutoff score for maximizing sensitivity and specificity. Setting: Specialized DOC program. Participants: Patients enrolled in the DOC program (N=252, 157 men; mean age, 49y; mean time from injury, 48d; traumatic etiology, n=127; nontraumatic etiology, n=125; diagnosis of coma or vegetative state, n=70; diagnosis of MCS or EMCS, n=182). Interventions: Not applicable. Main Outcome Measures: Sensitivity and specificity of CRS-R total scores in detecting conscious awareness. Results: A CRS-R total score of 10 or higher yielded a sensitivity of .78 for correct identification of patients in MCS or EMCS, and a specificity of 1.00 for correct identification of patients who did not meet criteria for either of these diagnoses (ie, were diagnosed with vegetative state or coma). The area under the curve in the receiver operating characteristic curve analysis is .98. Conclusions: A total CRS-R score of 10 or higher provides strong evidence of conscious awareness but resulted in a false-negative diagnostic error in 22% of patients who demonstrated conscious awareness based on CRS-R diagnostic criteria. A cutoff score of 8 provides the best balance between sensitivity and specificity, accurately classifying 93% of cases. The optimal total score cutoff will vary depending on the user's objective. (C) 2016 by the American Congress of Rehabilitation Medicine	[Bodien, Yelena G.; Carlowicz, Cecilia A.; Chatelle, Camille; Giacino, Joseph T.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA		Bodien, YG (corresponding author), 300 First Ave 3122, Charlestown, MA 02129 USA.	ybodien@partners.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Chatelle, Camille/0000-0002-7526-2107; Bodien, Yelena/0000-0003-4858-2903	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0039-01-00]; James S. McDonnell Foundation; Harvard Catalyst \ the Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard University; Harvard Catalyst \ the Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U48DP000039] Funding Source: NIH RePORTER	The contents of this report were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant no. 90DP0039-01-00). NIDILRR is a center within the Administration for Community Living (ACL), Department of Health and Human Services (HITS). Additional support was provided by the James S. McDonnell Foundation, Harvard Catalyst vertical bar the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award no UL1 TR001102), and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIDILRR, ACL, HI'S, National Institutes of Health, the James S. McDonnell Foundation, Harvard Catalyst, or Harvard University and its affiliated academic health care centers, and you should not assume endorsement by the Federal Government.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2015, CLIN NEUROPHYSIOL, V126, P959, DOI 10.1016/j.clinph.2014.08.005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Margetis K, 2014, NEUROMODULATION, V17, P699, DOI 10.1111/ner.12147; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35	9	39	41	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2016	97	3					490	492		10.1016/j.apmr.2015.08.422			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	DG1TJ	WOS:000371850100017	26342571	Green Accepted			2022-02-06	
J	Hanlon, LA; Huh, JW; Raghupathi, R				Hanlon, Lauren A.; Huh, Jimmy W.; Raghupathi, Ramesh			Minocycline Transiently Reduces Microglia/Macrophage Activation but Exacerbates Cognitive Deficits Following Repetitive Traumatic Brain Injury in the Neonatal Rat	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Abusive head trauma; Cognition; Inflammation; Microglia; Neurodegeneration; Pediatric	WHITE-MATTER INJURY; NONACCIDENTAL HEAD-INJURY; HYPOXIC-ISCHEMIC INJURY; LONG-TERM POTENTIATION; CYTOCHROME-C RELEASE; MICROGLIAL ACTIVATION; AXONAL INJURY; IMMATURE RAT; INTRACEREBRAL-HEMORRHAGE; RODENT MODEL	Elevated microglial/macrophage-associated biomarkers in the cerebrospinal fluid of infant victims of abusive head trauma (AHT) suggest that these cells play a role in the pathophysiology of the injury. In a model of AHT in 11-day-old rats, 3 impacts (24 hours apart) resulted in spatial learning and memory deficits and increased brain microglial/macrophage reactivity, traumatic axonal injury, neuronal degeneration, and cortical and white-matter atrophy. The antibiotic minocycline has been effective in decreasing injury-induced microglial/macrophage activation while simultaneously attenuating cellular and functional deficits in models of neonatal hypoxic ischemia, but the potential for this compound to rescue deficits after impact-based trauma to the immature brain remains unexplored. Acute minocycline administration in this model of AHT decreased microglial/macrophage reactivity in the corpus callosum of brain-injured animals at 3 days postinjury, but this effect was lost by 7 days postinjury. Additionally, minocycline treatment had no effect on traumatic axonal injury, neurodegeneration, tissue atrophy, or spatial learning deficits. Interestingly, minocycline-treated animals demonstrated exacerbated injury-induced spatial memory deficits. These results contrast with previous findings in other models of brain injury and suggest that minocycline is ineffective in reducing microglial/macrophage activation and ameliorating injury-induced deficits following repetitive neonatal traumatic brain injury.	[Hanlon, Lauren A.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19129 USA; [Huh, Jimmy W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA		Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Ramesh.raghupathi@drexelmed.edu	Raghupathi, Ramesh/AAX-5538-2021		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD069163]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD069163] Funding Source: NIH RePORTER	This study was supported by NIH grant HD069163.	Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Bishop Naomi B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P318, DOI 10.1016/j.cppeds.2006.05.004; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; Burke NN, 2014, BRAIN BEHAV IMMUN, V42, P147, DOI 10.1016/j.bbi.2014.06.015; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Z, 2006, NEUROSCIENCE, V137, P425, DOI 10.1016/j.neuroscience.2005.09.023; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Cowell RM, 2002, STROKE, V33, P795, DOI 10.1161/hs0302.103740; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; del Rey A, 2013, BRAIN BEHAV IMMUN, V33, P15, DOI 10.1016/j.bbi.2013.05.011; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Faustino JV, 2011, J NEUROSCI, V31, P12992, DOI 10.1523/JNEUROSCI.2102-11.2011; Ferrazzano P, 2013, CNS NEUROL DISORD-DR, V12, P338, DOI 10.2174/1871527311312030007; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Finnie JW, 2012, J CLIN NEUROSCI, V19, P1159, DOI 10.1016/j.jocn.2011.12.019; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Harker KT, 2002, J NEUROSCI, V22, P1155, DOI 10.1523/JNEUROSCI.22-03-01155.2002; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Ivacko JA, 1996, PEDIATR RES, V39, P39, DOI 10.1203/00006450-199601000-00006; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Lechpammer M, 2008, NEUROPATH APPL NEURO, V34, P379, DOI 10.1111/j.1365-2990.2007.00925.x; Leonardo CC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-34; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matschke J, 2009, PEDIATRICS, V124, P1587, DOI 10.1542/peds.2008-3734; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; MCRAE A, 1995, DEV BRAIN RES, V84, P245, DOI 10.1016/0165-3806(94)00177-2; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; Neumann H, 2007, J NEUROIMMUNOL, V184, P92, DOI 10.1016/j.jneuroim.2006.11.032; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Parks SE., 2012, PEDIAT ABUSIVE HEAD; PETERS A, 1976, J NEUROCYTOL, V5, P63, DOI 10.1007/BF01176183; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Pont-Lezica L, 2011, J NEUROCHEM, V119, P901, DOI 10.1111/j.1471-4159.2011.07504.x; Potts Mathew B, 2006, NeuroRx, V3, P143; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Trofimov AN, 2014, NEUROSCI BEHAV PHYSL, V44, P359, DOI DOI 10.1007/S11055-014-9918-1; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; van Groen T, 2002, BEHAV BRAIN RES, V136, P329, DOI 10.1016/S0166-4328(02)00199-7; Vann SD, 2003, BEHAV BRAIN RES, V140, P107, DOI 10.1016/S0166-4328(02)00274-7; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Wixey JA, 2011, NEUROSCIENCE, V182, P184, DOI 10.1016/j.neuroscience.2011.03.033; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	89	39	41	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2016	75	3					214	226		10.1093/jnen/nlv021			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DL7CF	WOS:000375796500002	26825312	Green Published, Bronze			2022-02-06	
J	Warne, J; Pryce, G; Hill, JM; Shi, X; Lenneras, F; Puentes, F; Kip, M; Hilditch, L; Walker, P; Simone, MI; Chan, AWE; Towers, GJ; Coker, AR; Duchen, MR; Szabadkai, G; Baker, D; Selwood, DL				Warne, Justin; Pryce, Gareth; Hill, Julia M.; Shi, Xiao; Lenneras, Felicia; Puentes, Fabiola; Kip, Maarten; Hilditch, Laura; Walker, Paul; Simone, Michela I.; Chan, A. W. Edith; Towers, Greg J.; Coker, Alun R.; Duchen, Michael R.; Szabadkai, Gyorgy; Baker, David; Selwood, David L.			Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; HUMAN CYCLOPHILIN-D; CYCLOSPORINE-A; AXONAL DEGENERATION; ATP SYNTHASE; TRIPHENYLPHOSPHONIUM CATIONS; LENTIVIRAL VECTOR; P-GLYCOPROTEIN	The mitochondrial permeability transition pore is a recognized drug target for neurodegenerative conditions such as multiple sclerosis and for ischemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, PPIF), is a positive regulator of the pore, and genetic down-regulation or knock-out improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off-target effects, immunosuppression, and toxicity. We therefore designed and synthesized a new mitochondrially targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine. X-ray analysis was used to validate the design concept, and biological evaluation revealed selective cellular inhibition of CypD and the permeability transition pore with reduced cellular toxicity compared with cyclosporine. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis, JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use.	[Warne, Justin; Pryce, Gareth; Shi, Xiao; Kip, Maarten; Simone, Michela I.; Chan, A. W. Edith; Coker, Alun R.; Selwood, David L.] UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England; [Pryce, Gareth; Lenneras, Felicia; Puentes, Fabiola; Baker, David] Queen Mary Univ London, Barts & London Sch Med & Dent, Neuroimmunol Unit, Blizard Inst, 4 Newark St, London E1 2AT, England; [Hill, Julia M.; Duchen, Michael R.; Szabadkai, Gyorgy] UCL, Dept Cell & Dev Biol, Mortimer St, London WC1E 6BT, England; [Hilditch, Laura; Towers, Greg J.] UCL, Med Res Council, Ctr Med Mol Biol, Div Infect & Immun, Mortimer St, London WC1E 6BT, England; [Walker, Paul] Cyprotex Discovery Ltd, 100 Barbirolli Sq, Manchester M2 3AB, Lancs, England; [Szabadkai, Gyorgy] Univ Padua, Dept Biomed Sci, I-35122 Padua, Italy; [Simone, Michela I.] Univ Newcastle, Sch Environm & Life Sci, Discipline Chem, Callaghan, NSW 2308, Australia		Selwood, DL (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.; Baker, D (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Neuroimmunol Unit, Blizard Inst, 4 Newark St, London E1 2AT, England.	david.baker@qmul.ac.uk; d.selwood@ucl.ac.uk	Simone, Michela I./A-6887-2011; duchen, michael/A-2116-2009; Simone, Michela/AAS-7878-2020	Simone, Michela I./0000-0002-1339-8236; duchen, michael/0000-0003-2548-4294; Simone, Michela/0000-0002-1339-8236; Walker, Paul/0000-0002-7840-9709; Selwood, David/0000-0002-6817-5064; Towers, Gregory/0000-0002-7707-0264; Coker, Alun/0000-0001-7385-0143; Szabadkai, Gyorgy/0000-0002-3006-3577	FastForward; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society; Wellcome TrustWellcome TrustEuropean Commission [090940]; Medical Research Council, a Medical Research Council Confidence in Concept AwardUK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research University College London Hospitals Biomedical Research CentreGeneral Electric; Eisai UK Ltd.Eisai Co Ltd; British Heart FoundationBritish Heart Foundation; Telethon ItalyFondazione Telethon; Italian Association for Cancer Research (AIRC)Fondazione AIRC per la ricerca sul cancro; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0801172] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0801172] Funding Source: researchfish; Wellcome TrustWellcome TrustEuropean Commission [108183/Z/15/Z] Funding Source: researchfish	This work was supported by FastForward, National Multiple Sclerosis Society, Wellcome Trust Senior Fellowship 090940 (to G. J. T.), the Medical Research Council, a Medical Research Council Confidence in Concept Award (to G. J. T. and D. S.), and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Three authors (G. S., D. B., and D. L. S.) are inventors on a patent filed by the university. Through the university revenue sharing scheme, inventors may, should the invention be commercialized and in the fullness of time, receive some financial benefit.; Supported by a studentship from Eisai UK Ltd.; Supported by the British Heart Foundation, Wellcome Trust, Telethon Italy, and the Italian Association for Cancer Research (AIRC).	Al-Izki S, 2014, BRAIN, V137, P92, DOI 10.1093/brain/awt324; Al-Izki S, 2012, MULT SCLER RELAT DIS, V1, P29, DOI 10.1016/j.msard.2011.09.001; Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111; ALLEN SJ, 1993, CELL IMMUNOL, V146, P335, DOI 10.1006/cimm.1993.1031; AMOR S, 1994, J IMMUNOL, V153, P4349; Astin R, 2013, SCI REP-UK, V3, DOI 10.1038/srep02467; Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baker D, 2011, MULT SCLER J, V17, P647, DOI 10.1177/1352458511398885; Barbarino JM, 2013, PHARMACOGENET GENOM, V23, P563, DOI 10.1097/FPC.0b013e328364db84; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Bart J, 2000, CANCER TREAT REV, V26, P449, DOI 10.1053/ctrv.2000.0194; Basso E, 2008, J BIOL CHEM, V283, P26307, DOI 10.1074/jbc.C800132200; Bonora M, 2013, CELL CYCLE, V12, P674, DOI 10.4161/cc.23599; Campbell GR, 2014, MULT SCLER J, V20, P1806, DOI 10.1177/1352458514544537; Chinopoulos C, 2011, FEBS J, V278, P1112, DOI 10.1111/j.1742-4658.2011.08026.x; Chung NS, 2004, ADV DRUG DELIVER REV, V56, P1315, DOI 10.1016/j.addr.2003.12.003; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Davis TL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000439; Du H, 2011, NEUROBIOL AGING, V32, P398, DOI 10.1016/j.neurobiolaging.2009.03.003; Dube H, 2012, BIOCHEM J, V441, P901, DOI 10.1042/BJ20111301; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Gaali S, 2010, ACS MED CHEM LETT, V1, P536, DOI 10.1021/ml1001272; Gallay PA, 2013, DRUG DES DEV THER, V7, P105, DOI 10.2147/DDDT.S30946; Gane EJ, 2010, LIVER INT, V30, P1019, DOI 10.1111/j.1478-3231.2010.02250.x; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Giorgio V, 2009, J BIOL CHEM, V284, P33982, DOI 10.1074/jbc.M109.020115; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Guo L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054914; Halestrap AP, 2015, J MOL CELL CARDIOL, V78, P129, DOI 10.1016/j.yjmcc.2014.08.018; Hampton DW, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-84; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Hazelton JL, 2009, J NEUROSCI RES, V87, P1250, DOI 10.1002/jnr.21921; Hecking M, 2008, TRANSPL INT, V21, P223, DOI 10.1111/j.1432-2277.2007.00563.x; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hoye AT, 2008, ACCOUNTS CHEM RES, V41, P87, DOI 10.1021/ar700135m; Jackson SJ, 2009, J NEUROPATH EXP NEUR, V68, P616, DOI 10.1097/NEN.0b013e3181a41d23; Jackson SJ, 2005, NEUROSCIENCE, V134, P261, DOI 10.1016/j.neuroscience.2005.02.045; Kageyama T, 2013, J NEUROL, V260, P627, DOI 10.1007/s00415-012-6692-2; Kajitani K, 2008, PROTEINS, V70, P1635, DOI 10.1002/prot.21855; Kapoor R, 2003, ANN NEUROL, V53, P174, DOI 10.1002/ana.10443; KAPPOS L, 1988, ANN NEUROL, V23, P56, DOI 10.1002/ana.410230110; Kato M, 2009, CARDIOVASC RES, V83, P335, DOI 10.1093/cvr/cvp094; Kutzelnigg A, 2014, HAND CLINIC, V122, P15, DOI 10.1016/B978-0-444-52001-2.00002-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemasters JJ, 2007, METHOD CELL BIOL, V80, P283, DOI 10.1016/S0091-679X(06)80014-2; Leo S, 2008, ANN NY ACAD SCI, V1147, P264, DOI 10.1196/annals.1427.019; Lim SY, 2011, J CELL MOL MED, V15, P2443, DOI 10.1111/j.1582-4934.2010.01235.x; Liu YY, 2006, ANAL BIOCHEM, V356, P100, DOI 10.1016/j.ab.2006.04.040; Macarron R, 2011, FUTURE MED CHEM, V3, P505, DOI [10.4155/FMC.11.19, 10.4155/fmc.11.19]; Mahad D, 2008, BRAIN, V131, P1722, DOI 10.1093/brain/awn105; MAKLER MT, 1990, Patent No. 4946849; Malouitre S, 2010, BIOCHEM J, V425, P137, DOI 10.1042/BJ20090332; Marta M, 2012, CNS NEUROL DISORD-DR, V11, P610, DOI 10.2174/187152712801661301; Martin LJ, 2014, NEUROBIOL AGING, V35, P1132, DOI 10.1016/j.neurobiolaging.2013.11.008; Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McEwan WA, 2009, J VIROL, V83, P8270, DOI 10.1128/JVI.00670-09; Millard M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013131; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nikolovska-Coleska Z, 2004, ANAL BIOCHEM, V332, P261, DOI 10.1016/j.ab.2004.05.055; Ohno N, 2014, P NATL ACAD SCI USA, V111, P9953, DOI 10.1073/pnas.1401155111; ONEILL JK, 1992, J NEUROIMMUNOL, V38, P53, DOI 10.1016/0165-5728(92)90090-8; Porteous CM, 2013, BBA-GEN SUBJECTS, V1830, P3458, DOI 10.1016/j.bbagen.2013.02.005; Pryce G, 2005, J NEUROIMMUNOL, V165, P41, DOI 10.1016/j.jneuroim.2005.04.009; Pryce G, 2014, FASEB J, V28, P117, DOI 10.1096/fj.13-239442; Quintanilla RA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-45; Raftopoulos R, 2015, MULT SCLER J, V21, P273; Rasaiyaah J, 2013, NATURE, V503, P402, DOI 10.1038/nature12769; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Reddy PH, 2012, BBA-MOL BASIS DIS, V1822, P639, DOI 10.1016/j.bbadis.2011.10.011; Reily C, 2013, REDOX BIOL, V1, P86, DOI 10.1016/j.redox.2012.11.009; Rodrigues JR, 2007, EXP PARASITOL, V115, P19, DOI 10.1016/j.exppara.2006.05.002; Ross MF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P222, DOI 10.1007/s10541-005-0104-5; Savino C, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/719407; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Schlatter D, 2005, ACTA CRYSTALLOGR D, V61, P513, DOI 10.1107/S0907444905003070; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sharma Pradeep, 2005, Farmaco (Lausanne), V60, P870, DOI 10.1016/j.farmac.2005.08.006; Smulik JA, 2002, ORG LETT, V4, P2051, DOI 10.1021/ol0258987; Starr R, 1996, J NEUROSCI RES, V44, P328; Su K, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00169; Su KG, 2012, EUR J NEUROSCI, V35, P562, DOI 10.1111/j.1460-9568.2011.07972.x; Templeton I, 2014, METHODS MOL BIOL, V1113, P471, DOI 10.1007/978-1-62703-758-7_22; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Valasani KR, 2014, ACTA CRYSTALLOGR F, V70, P717, DOI 10.1107/S2053230X14009480; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; Wu N, 2015, EUR REV MED PHARMACO, V19, P446; Ylinen LMJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001062; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	99	39	42	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	2016	291	9					4356	4373		10.1074/jbc.M115.700385			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DF8JT	WOS:000371604600009	26679998	Green Published, hybrid			2022-02-06	
J	Kota, DJ; Prabhakara, KS; van Brummen, AJ; Bedi, S; Xue, HS; DiCarlo, B; Cox, CS; Olson, SD				Kota, Daniel J.; Prabhakara, Karthik S.; van Brummen, Alexandra J.; Bedi, Supinder; Xue, Hasen; DiCarlo, Bryan; Cox, Charles S., Jr.; Olson, Scott D.			Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Traumatic brain injury; Propranolol; Mesenchymal stromal cell; beta-Blocker	CENTRAL-NERVOUS-SYSTEM; ACTIVATED MICROGLIAL/MACROPHAGE RESPONSE; ANTIINFLAMMATORY PROTEIN TSG-6; BETA-BLOCKER EXPOSURE; NEURAL STEM-CELLS; BONE-MARROW; HEAD-INJURY; IN-VIVO; INFLAMMATORY RESPONSE; SYMPATHETIC HYPERACTIVITY	More than 6.5 million patients are burdened by the physical, cognitive, and psychosocial deficits associated with traumatic brain injury (TBI) in the U.S. Despite extensive efforts to develop neuroprotective therapies for this devastating disorder, there have been no successful outcomes in human clinical trials to date. Retrospective studies have shown that beta-adrenergic receptor blockers, specifically propranolol, significantly decrease mortality of TBI through mechanisms not yet fully elucidated but are thought to counterbalance a hyperadrenergic state resulting from a TBI. Conversely, cellular therapies have been shown to improve long-term behavior following TBI, likely by reducing inflammation. Given the nonredundancy in their therapeutic mechanisms, we hypothesized that a combination of acute propranolol followed by mesenchymal stem cells (MSCs) isolated from human bone marrow would have additive effects in treating a rodent model of TBI. We have found that the treatments are well-tolerated individually and in combination with no adverse events. MSCs decrease BBB permeability at 96 hours after injury, inhibit a significant accumulation of activated microglia/ macrophage in the thalamic region of the brain both short and long term, and enhance neurogenesis short term. Propranolol decreases edema and reduces the number of fully activated microglia at 7 days and the number of semiactivated microglia at 120 days. Combinatory treatment improved cognitive and memory functions 120 days following TBI. Therefore, the results here suggest a new, efficacious sequential treatment for TBI may be achieved using the beta-blocker propranolol followed by MSC treatment.	[Kota, Daniel J.; Prabhakara, Karthik S.; van Brummen, Alexandra J.; Bedi, Supinder; Xue, Hasen; DiCarlo, Bryan; Cox, Charles S., Jr.; Olson, Scott D.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-233, Houston, TX 77030 USA		Olson, SD (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-233, Houston, TX 77030 USA.	Scott.D.Olson@uth.tmc.edu		Olson, Scott/0000-0001-8032-3755	Institute for Rehabilitation and Research (TIRR) Foundation Mission Connect Award [13-110]; Clare A. Glassell Family Pediatric Stem Cell Research Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER	This study was performed with funding support from The Institute for Rehabilitation and Research (TIRR) Foundation Mission Connect Award 13-110 and the generous support of the Clare A. Glassell Family Pediatric Stem Cell Research Fund.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081585; Bai LH, 2007, NEUROCHEM RES, V32, P353, DOI 10.1007/s11064-006-9212-x; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bauer G, 2008, MOL THER, V16, P1308, DOI 10.1038/mt.2008.93; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Calzarossa C, 2013, NEUROSCIENCE, V234, P158, DOI 10.1016/j.neuroscience.2012.12.038; Chen M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0284-x; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ern.11.113, 10.1586/ERN.11.113]; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Ker K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006686.pub2; Kotova PD, 2014, BBA-MOL CELL RES, V1843, P1899, DOI 10.1016/j.bbamcr.2014.05.002; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee H, 2013, HUM GENE THER, V24, P655, DOI 10.1089/hum.2013.001; Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; McIntosh TK, 1996, LAB INVEST, V74, P315; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062; Nicholas RS, 2001, EUR J NEUROSCI, V13, P959, DOI 10.1046/j.0953-816x.2001.01470.x; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Ribeiro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt336; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018-013-1290-8; Tran TY, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E8; Trouche E, 2010, STEM CELLS DEV, V19, P1571, DOI 10.1089/scd.2009.0353; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yoo KH, 2009, CELL IMMUNOL, V259, P150, DOI 10.1016/j.cellimm.2009.06.010; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	83	39	41	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	JAN	2016	5	1					33	44		10.5966/sctm.2015-0065			12	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	DB8FJ	WOS:000368752300010	26586775	Green Published, gold			2022-02-06	
J	Savitsky, B; Givon, A; Rozenfeld, M; Radomislensky, I; Peleg, K				Savitsky, B.; Givon, A.; Rozenfeld, M.; Radomislensky, I.; Peleg, K.			Traumatic brain injury: It is all about definition	BRAIN INJURY			English	Article						Glasgow Coma Scale (GCS); Abbreviated Injury Score (AIS); Traumatic Brain Injury (TBI); brain injury severity assessment	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; ENDOTRACHEAL INTUBATION; MORTALITY PREDICTIONS; POLYTRAUMA; AGREEMENT; TRIPLETS; IMPACT; ISS	Background: TBI may be defined by different methods. Some may be most useful for immediate clinical purposes, however less optimal for epidemiologic research. Other methods, such as the Abbreviated Injury Score (AIS), may prove more beneficial for this task, if the cut-off-points for their categories are defined correctly.Objective: To reveal the optimal cut-off-points for AIS in definition of severity of TBI in order to ensure uniformity between future studies of TBI.Results: Mortality of patients with TBI AIS 3, 4 was 1.9% and 2.9% respectively, comparing with 31.1% among TBI AIS 5+. Predictive discrimination ability of the model with cut-off-points of 5+ for TBI AIS (in comparison with other cut-off-points) was better. Patients with missing Glasgow Coma Scale (GCS) in the ED had an in-hospital mortality rate of 11.5%. In this group, 25% had critical TBI according to AIS. Normal GCS didn't indicate an absence of head injury, as, among patients with GCS 15 in the ED, 26% had serious/critical TBI injury. Moreover, 7% of patients with multiple injury and GCS 3-8 had another reason than head injury for unconsciousness.Conclusions: This study recommends the adoption of an AIS cut-off 5 as a valid definition of severe TBI in epidemiological studies, while AIS 3-4 may be defined as moderate' TBI and AIS 1-2 as mild'.	[Savitsky, B.; Givon, A.; Rozenfeld, M.; Radomislensky, I.; Peleg, K.] Israel Natl Ctr Trauma & Emergency Med Res, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Ramat Gan, Israel; [Rozenfeld, M.; Peleg, K.] Tel Aviv Univ, Sch Publ Hlth, Fac Med, Tel Aviv, Israel		Peleg, K (corresponding author), Israel Natl Ctr Trauma & Emergency Med Res, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Ramat Gan, Israel.	kobip@gertner.health.gov.il		Savitsky, Bella/0000-0001-8917-8419			Aharonson-Daniel L, 2006, J TRAUMA, V61, P711, DOI 10.1097/01.ta.0000235294.32326.e6; Bellner J, 2003, J NEUROL NEUROSUR PS, V74, P351, DOI 10.1136/jnnp.74.3.351; Butcher N, 2012, INJURY, V43, P196, DOI 10.1016/j.injury.2011.06.029; Butcher NE, 2013, J TRAUMA ACUTE CARE, V74, P884, DOI 10.1097/TA.0b013e31827e1bad; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Dinh MM, 2013, EMERG MED AUSTRALAS, V25, P457, DOI 10.1111/1742-6723.12126; Faul M, 2012, PREHOSP EMERG CARE, V16, P222, DOI 10.3109/10903127.2011.615013; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Kraus JF, NEUROLOGY; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rozenfeld M, 2014, INJURY PREV, V20, DOI 10.1136/injuryprev-2013-041042; Russell R, 2004, J TRAUMA, V56, P1321, DOI 10.1097/01.TA.0000062763.21379.D9; Sanossian N, 2014, STROKE S1, V45, pA32; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; The Association for the Advancement of Automotive Medicine (AAAM), ABBR INJ SCAL AIS; Tuma M., 2014, CRITICAL CARE RES PR, V2014, DOI DOI 10.1155/2014/105386; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Zehtabchi S, 2011, ACAD EMERG MED, V18, P637, DOI 10.1111/j.1553-2712.2011.01083.x	25	39	41	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	10					1194	1200		10.1080/02699052.2016.1187290			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DX4BR	WOS:000384324300004	27466967				2022-02-06	
J	Shan, RZ; Szmydynger-Chodobska, J; Warren, OU; Mohammad, F; Zink, BJ; Chodobski, A				Shan, Rongzi; Szmydynger-Chodobska, Joanna; Warren, Otis U.; Mohammad, Farah; Zink, Brian J.; Chodobski, Adam			A New Panel of Blood Biomarkers for the Diagnosis of Mild Traumatic Brain Injury/Concussion in Adults	JOURNAL OF NEUROTRAUMA			English	Article						blood biomarkers; concussion; diagnosis; mild traumatic brain injury	ICE HOCKEY PLAYERS; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; INJURY; SERUM; CONCUSSIONS; SEVERITY; COPEPTIN	No routine tests currently exist to objectively diagnose mild traumatic brain injury (mTBI)/concussion. Previously reported biomarkers for mTBI represented proteins released from damaged neurons or glia. However, low levels of these proteins, and/or the complexity of assays used for their detection, limits implementation of these biomarkers in routine practice. Here, we sought to identify proteins whose synthesis is altered post-mTBI and whose blood levels could be measured using standard immunoassays. Adult patients sustaining a concussion within the past 24h were enrolled. Controls were uninjured subjects and patients with orthopedic injury (OI). Four candidate biomarkers were identified: copeptin; galectin 3 (LGALS3); matrix metalloproteinase 9 (MMP9); and occludin (OCLN). A 3.4-fold decrease (p<0.0001) in plasma concentration of copeptin was found in mTBI patients within 8h after accident, compared to uninjured controls. Plasma levels of LGALS3, MMP9, and OCLN increased 3.6- to 4.5-fold (p<0.0001) within the same time frame postinjury. Levels of at least two biomarkers were altered beyond their respective cut-off values in 90% of mTBI patients, whereas in none of uninjured controls were levels of two biomarkers simultaneously changed. A positive correlation (r=0.681; p<0.001) between plasma levels of LGALS3 and OCLN was also found in mTBI patients, whereas in OI patients or uninjured subjects, these variables did not correlate. This panel of biomarkers discerns, with high accuracy, patients with isolated concussion from uninjured individuals within the first 8h after accident. These biomarkers can also aid in diagnosing concussion in the presence of OI.	[Shan, Rongzi; Szmydynger-Chodobska, Joanna; Chodobski, Adam] Brown Univ, Alpert Med Sch, Dept Emergency Med, Neurotrauma & Brain Barriers Res Lab, Providence, RI 02903 USA; [Warren, Otis U.; Zink, Brian J.] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA; [Mohammad, Farah] Henry Ford Hosp, Dept Surg, Detroit, MI 48202 USA		Chodobski, A (corresponding author), Brown Univ, Alpert Med Sch, Dept Emergency Med, Coro Ctr West, Room 112,1 Hoppin St, Providence, RI 02903 USA.	adam_chodobski@brown.edu			Department of Emergency Medicine at the Alpert Medical School of Brown University	The authors thank Branden Stearns, Darin Chheng, and Sarah Smith for their help in the recruitment of research subjects. The authors also thank Julie Sarri for her secretarial assistance. This study was supported by funds from the Department of Emergency Medicine at the Alpert Medical School of Brown University and by a fund from Diane N. Weiss.	Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chodobski A., 2014, VASCULAR MECH CNS TR, P3; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Faul M, 2010, TRAUMATIC BRAIN INJU; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Lin CC, 2010, JALA-J LAB AUTOM, V15, P253, DOI 10.1016/j.jala.2010.01.013; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Terrando N, 2011, ANN NEUROL, V70, P986, DOI 10.1002/ana.22664; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	32	39	39	1	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					49	57		10.1089/neu.2014.3811			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200006	25794137				2022-02-06	
J	Sethi, M; Heidenberg, J; Wall, SP; Ayoung-Chee, P; Slaughter, D; Levine, DA; Jacko, S; WilsonA, C; Marshall, G; Pachter, HL; Frangos, SG				Sethi, Monica; Heidenberg, Jessica; Wall, Stephen P.; Ayoung-Chee, Patricia; Slaughter, Dekeya; Levine, Deborah A.; Jacko, Sally; WilsonA, Chad; Marshall, Gary; Pachter, H. Leon; Frangos, Spiros G.			Bicycle helmets are highly protective against traumatic brain injury within a dense urban setting	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Bicycle; Bike share; Helmet; Traumatic brain injury; Trauma; Urban; Head injury	HEAD-INJURY; SAFETY HELMETS; MOTOR-VEHICLES; NEW-YORK; RISK; USERS; COLLISIONS	Background: New York City (NYC) has made significant roadway infrastructure improvements, initiated a bicycle share program, and enacted Vision Zero, an action plan to reduce traffic deaths and serious injuries. The objective of this study was to examine whether bicycle helmets offer a protective advantage against traumatic brain injury (TBI) within a contemporary dense urban setting with a commitment to road safety. Methods: A prospective observational study of injured bicyclists presenting to a Level I trauma centre was performed. All bicyclists arriving within 24 h of injury were included. Data were collected between February, 2012 and August, 2014 and included demographics, imaging studies (e.g. computed tomography (CT)), injury patterns, and outcomes including Glasgow Coma Scale (GCS) and Injury Severity Score. Results: Of 699 patients, 273 (39.1%) were wearing helmets at the time of injury. Helmeted bicyclists were more likely to have a GCS of 15 (96.3% [95% Confidence Interval (CI), 93.3-98.2] vs. 87.6 [95% CI, 84.1-90.6]) at presentation. Helmeted bicyclists underwent fewer head CTs (40.3% [95% CI, 34.4-46.4] vs. 52.8% [95% CI, 48.0-57.6]) and were less likely to sustain intracranial injury (6.3% [95% CI, 2.6-12.5] vs. 19.7% [14.7-25.6]), including skull fracture (0.9% [95% CI, 0.0-4.9] vs. 15.3% [95% CI, 10.8-20.7]) and subdural hematoma (0.0% [95% CI, 0.0-3.2] vs. 8.1% [95% CI, 4.9-12.5]). Helmeted bicyclists were significantly less likely to sustain significant TBI, i.e. Head AIS >= 3 (2.6% [95% CI: 0.7-4.5] vs. 10.6% [7.6-12.5]). Four patients underwent craniotomy while three died; all were un-helmeted. A multivariable logistic regression model showed that helmeted bicyclists were 72% less likely to sustain TBI compared with un-helmeted bicyclists (Adjusted Odds Ratio 0.28, 95% CI 0.12-0.61). Conclusions: Despite substantial road safety measures in NYC, the protective impact of simple bicycle helmets in the event of a crash remains significant. A re-assessment of helmet laws for urban bicyclists is advisable to most effectively translate Vision Zero from a political action plan to public safety reality. (C) 2015 Elsevier Ltd. All rights reserved.	[Sethi, Monica; Heidenberg, Jessica; Ayoung-Chee, Patricia; Slaughter, Dekeya; Jacko, Sally; WilsonA, Chad; Marshall, Gary; Pachter, H. Leon; Frangos, Spiros G.] NYU, Bellevue Hosp Ctr, Sch Med, Dept Surg, New York, NY 10016 USA; [Wall, Stephen P.] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA; [Levine, Deborah A.] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med & Pediat, New York, NY 10016 USA		Frangos, SG (corresponding author), NYU, Bellevue Hosp Ctr, Sch Med, Dept Surg, New York, NY 10016 USA.	Spiros.frangos@nyumc.org		Wall, Stephen/0000-0003-3965-5074; Ayoung-Chee, Patricia/0000-0003-1961-4654; Frangos, Spiros/0000-0003-2860-8969; Sethi, Monica/0000-0001-7784-0954; Marshall, Gary/0000-0003-1398-5366	Highway Safety Grant from the State of New York Governor's Traffic Safety Committee	The authors wish to acknowledge injury epidemiologist Dr. Charles DiMaggio, PhD, who advised us on the appropriateness of our statistical methods and analyses. This study was funded by a Highway Safety Grant from the State of New York Governor's Traffic Safety Committee (October, 2011-September, 2014; year 1: $48,000, year 2: $47,705, year 3: $48,206). The sponsor did not participate in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Al-Habib A, 2012, J TRAUMA ACUTE CARE, V72, P1356, DOI 10.1097/TA.0b013e318250b537; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; [Anonymous], BIC CRASH DAT 2013 C; [Anonymous], 2014, BIK SAF 2014; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Basch CH, 2014, J COMMUN HEALTH, V39, P503, DOI 10.1007/s10900-013-9785-7; Belin MA, 2012, INT J INJ CONTROL SA, V19, P171, DOI 10.1080/17457300.2011.635213; Castle SL, 2012, J SURG RES, V173, P327, DOI 10.1016/j.jss.2010.10.031; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Chapman AJ, 2014, AM J SURG, V207, P352, DOI 10.1016/j.amjsurg.2013.12.001; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Crocker P, 2012, J EMERG MED, V43, P244, DOI 10.1016/j.jemermed.2011.05.029; Davison CM, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-48; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Dultz LA, 2013, J TRAUMA ACUTE CARE, V74, P1138, DOI 10.1097/TA.0b013e31827ab722; Enserink M, 2014, SCIENCE, V345, P1261, DOI 10.1126/science.345.6202.1261; Goodman D. J., 2014, NY TIMES; Graves JM, 2014, AM J PUBLIC HEALTH, V104, pE106, DOI 10.2105/AJPH.2014.302012; Kakefuda I, 2009, ACCIDENT ANAL PREV, V41, P513, DOI 10.1016/j.aap.2009.01.014; Kaplan S, 2015, TRAFFIC INJ PREV, P1; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; Meehan WP, 2013, J PEDIATR-US, V163, P726, DOI 10.1016/j.jpeds.2013.03.073; New York City, 2014, VISION ZERO ACTION P; NYC Department of Transportation, 2010, SUST STREETS IND; NYC Department of Transportation, 2012, SUST STREETS IND; Olivier J, 2014, J AUSTRALAS COLL ROA, V25, P10; Olivier J, 2013, ACCIDENT ANAL PREV, V50, P1128, DOI 10.1016/j.aap.2012.09.003; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Povey LJ, 1999, ACCIDENT ANAL PREV, V31, P763, DOI 10.1016/S0001-4575(99)00033-0; Rivara F P, 1999, Inj Prev, V5, P194; RIVARA FP, 1994, PEDIATRICS, V93, P567; Rivara FP, 2015, INJURY PREV, V21, P47, DOI 10.1136/injprev-00002-0038rep; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC., 1999, COCHRANE DB SYST REV, V308, DOI 10.1002/14651858.CD001855; Thompson J, 2015, TRAFFIC INJ PREV, V16, P147, DOI 10.1080/15389588.2014.914626; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Tuckel P, 2014, J SAFETY RES, V51, P7, DOI 10.1016/j.jsr.2014.07.003; Webman R, 2013, J TRAUMA ACUTE CARE, V75, P877, DOI 10.1097/TA.0b013e3182a85f97; Winters M, 2010, J URBAN HEALTH, V87, P969, DOI 10.1007/s11524-010-9509-6	44	39	40	0	31	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	DEC	2015	46	12					2483	2490		10.1016/j.injury.2015.07.030			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CX9IW	WOS:000366020000030	26254573				2022-02-06	
J	Juengst, SB; Adams, LM; Bogner, JA; Arenth, PM; O'Neil-Pirozzi, TM; Dreer, LE; Hart, T; Bergquist, TF; Bombardier, CH; Dijkers, MP; Wagner, AK				Juengst, Shannon B.; Adams, Leah M.; Bogner, Jennifer A.; Arenth, Patricia M.; O'Neil-Pirozzi, Therese M.; Dreer, Laura E.; Hart, Tessa; Bergquist, Thomas F.; Bombardier, Charles H.; Dijkers, Marcel P.; Wagner, Amy K.			Trajectories of Life Satisfaction After Traumatic Brain Injury: Influence of Life Roles, Age, Cognitive Disability, and Depressive Symptoms	REHABILITATION PSYCHOLOGY			English	Article						life satisfaction; life roles; participation; depression; brain injury	QUALITY-OF-LIFE; 1ST 5 YEARS; COMMUNITY INTEGRATION; SOCIAL SUPPORT; SELF-EFFICACY; OUTCOMES; PARTICIPATION; REHABILITATION; INDIVIDUALS; RESILIENCE	Objectives: (a) Identify life satisfaction trajectories after moderate to severe traumatic brain injury (TBI); (b) establish a predictive model for these trajectories across the first 5 years postinjury; and (c) describe differences in these life satisfaction trajectory groups, focusing on age, depressive symptoms, disability, and participation in specific life roles. Research Method: Analysis of the longitudinal TBI Model Systems National Database was performed on data collected prospectively at 1-, 2-, and 5-years post-TBI. Participants (n = 3,012) had a moderate to severe TBI and were 16 years old and older. Results: Four life satisfaction trajectories were identified across the first 5 years postinjury, including: stable satisfaction, initial satisfaction declining, initial dissatisfaction improving, and stable dissatisfaction. Age, depressive symptoms, cognitive disability, and life role participation as a worker, leisure participant, and/ or religious participant at 1-year postinjury significantly predicted trajectory group membership. Life role participation and depressive symptoms were strong predictors of life satisfaction trajectories across the first 5 years post-TBI. Conclusions: The previously documented loss of life roles and prevalence of depression after a moderate to severe TBI make this a vulnerable population for whom low or declining life satisfaction is a particularly high risk. Examining individual life role participation may help to identify relevant foci for community-based rehabilitation interventions or supports.	[Juengst, Shannon B.; Arenth, Patricia M.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; [Adams, Leah M.; Bombardier, Charles H.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Cambridge, MA 02138 USA; [O'Neil-Pirozzi, Therese M.] Northwestern Univ, Dept Speech Language Pathol & Audiol, Evanston, IL 60208 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Opthalmol, Birmingham, AL USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Rochester, MI USA; [Dijkers, Marcel P.] Icahn Sch Med Mt Sinai, Dept Rehabil, New York, NY 10029 USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Juengst, SB (corresponding author), Univ Pittsburgh, Kaufmann Med Bldg,Suite 202,3471 Fifth Ave, Pittsburgh, PA 15213 USA.	sbj7@pitt.edu	Bombardier, Charles H./AAZ-3260-2021; Juengst, Shannon B/AAC-5891-2019	Bombardier, Charles H./0000-0003-4758-6283; Juengst, Shannon B/0000-0003-4709-545X	National Institute on Disability and Rehabilitation Research through Traumatic Brain Injury Model System (TBIMS) [H133A120887, H133A120084, H133A070029, H133A120037, H133A120026, H133A120096, H133A120085]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5T32AG027677]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG027677] Funding Source: NIH RePORTER	This work was supported by the National Institute on Disability and Rehabilitation Research through Traumatic Brain Injury Model System (TBIMS) Grants H133A120887, H133A120084, H133A070029, H133A120037, H133A120026, H133A120096, H133A120085, and partly supported by the National Institute on Aging (5T32AG027677).	Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Baird BM, 2010, SOC INDIC RES, V99, P183, DOI 10.1007/s11205-010-9584-9; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Biswas-Diener R., 2008, HAPPINESS UNLOCKING; Blanchflower DG, 2008, SOC SCI MED, V66, P1733, DOI 10.1016/j.socscimed.2008.01.030; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Bradshaw M., 2014, GERONTOLOGIST; Chmiel M, 2012, SOC INDIC RES, V106, P109, DOI 10.1007/s11205-011-9796-7; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2014, J HEAD TRAUMA REHABI; Corrigan JD, 2013, J HEAD TRAUMA REHAB, V28, P489, DOI 10.1097/HTR.0000000000000004; Darbonne A, 2013, J HAPPINESS STUD, V14, P951, DOI 10.1007/s10902-012-9363-1; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E., 1998, ANN REV GERONTOLOGY, V17, P304, DOI DOI 10.1891/0198-8794.17.1.304; Diener E., 2008, J POSIT PSYCHOL, V3, P137, DOI [10.1080/17439760701756946, DOI 10.1080/17439760701756946]; Diener E, 2012, AM PSYCHOL, V67, P590, DOI 10.1037/a0029541; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dorstyn D, 2014, TOP STROKE REHABIL, V21, P40, DOI 10.1310/tsr2101-40; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2014, J NEUROTRAUMA; Frijters P, 2012, J ECON BEHAV ORGAN, V82, P525, DOI 10.1016/j.jebo.2012.03.008; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Gerstorf D, 2008, DEV PSYCHOL, V44, P1148, DOI 10.1037/0012-1649.44.4.1148; Gignac MAM, 2013, SOC SCI MED, V81, P87, DOI 10.1016/j.socscimed.2012.12.013; Goverover Y., 2013, BRAIN INJURY; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Headey B, 1992, UNDERSTANDING HAPPIN; Hernandez CL, 2014, REHABIL PSYCHOL, V59, P183, DOI 10.1037/a0035887; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Juengst S, 2014, ARCH PHYS MED REHAB, V95, pE71, DOI [10.1016/j.apmr.2014.07.227, DOI 10.1016/J.APMR.2014.07.227]; Juengst S. B., 2012, SELF AWARENESS COMMU; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Krause Neal, 2003, J Gerontol B Psychol Sci Soc Sci, V58, pS160; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Mancini A. D., 2015, ASSESSMENT; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McIntosh CN, 2013, QUAL LIFE RES, V22, P2625, DOI 10.1007/s11136-013-0385-x; McLean A. M., 2013, DISABILITY REHABILIT; Mitchell E. J., 2013, DISABILITY REHABILIT; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Sander AM, 2011, J HEAD TRAUMA REHAB, V26, P158, DOI 10.1097/HTR.0b013e3181e7537e; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Walton David M, 2013, Open Orthop J, V7, P420, DOI 10.2174/1874325001307010420; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Williamson M. L. C., J HEAD INJU IN PRESS; Williamson MLC, 2013, BRAIN INJURY, V27, P992, DOI 10.3109/02699052.2013.801512	68	39	40	1	22	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2015	60	4					353	364		10.1037/rep0000056			12	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	CX4YL	WOS:000365706800006	26618215	Bronze, Green Accepted			2022-02-06	
J	Kim, JH; Ahn, SH; Cho, YW; Kim, SH; Jang, SH				Kim, Jin Hyun; Ahn, Sang Ho; Cho, Yoon Woo; Kim, Seong Ho; Jang, Sung Ho			The Relation Between Injury of the Spinothalamocortical Tract and Central Pain in Chronic Patients With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						central pain; diffusion tensor imaging; spinothalamocortical tract; traumatic brain injury	CENTRAL POSTSTROKE PAIN; SPINAL-CORD-INJURY; DIFFUSION TENSOR TRACTOGRAPHY; THALAMO-CORTICAL PATHWAY; NEUROPATHIC PAIN; CORTICORETICULAR PATHWAY; SENSORY ABNORMALITIES; MECHANISMS; MANAGEMENT; PATHOPHYSIOLOGY	Objectives: Little is known about the pathogenetic etiology of central pain in patients with traumatic brain injury (TBI). We investigated the relation between injury of the spinothalamocortical tract (STT) and chronic central pain in patients with mild TBI. Design: Retrospective survey. Participants: We recruited 40 consecutive chronic patients with mild TBI and 21 normal control subjects: 8 patients were excluded by the inclusion criteria and the remaining 32 patients were finally recruited. The patients were classified according to 2 groups based on the presence of central pain: the pain group (22 patients) and the nonpain group (10 patients). Methods: Diffusion tensor tractography for the STT was performed using the Functional Magnetic Resonance Imaging of the Brain Software Library. Values of fractional anisotropy (FA), mean diffusivity (MD), and tract volume of each STT were measured. Results: Lower FA value and tract volume were observed in the pain group than in the nonpain group and the control group (P <.05). By contrast, higher MD value was observed in the pain group than in the nonpain group and the control group (P <.05). However, no significant differences in all diffusion tensor imaging parameters were observed between the nonpain group and the control group (P >.05). Conclusions: Decreased FA and tract volume and increased MD of the STTs in the pain group appeared to indicate injury of the STT. As a result, we found that injury of the STT is related to the occurrence of central pain in patients with mild TBI. We believe that injury of the STT is a pathogenetic etiology of central pain following mild TBI.	[Kim, Jin Hyun; Ahn, Sang Ho; Cho, Yoon Woo; Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea; [Kim, Seong Ho] Yeungnam Univ, Coll Med, Dept Neurosurg, Taegu 705717, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2012R1A1A4A01001873]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A4A01001873).	Alexander AL, 2006, NEUROIMAG CLIN N AM, V16, P299, DOI 10.1016/j.nic.2006.02.006; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Barad M., 2009, CONTINUUM MINNEAP MI, V15, P30, DOI 10.1212/01.con.0000348853.20265.b7; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Deppe M, 2013, NEUROIMAGE-CLIN, V2, P258, DOI 10.1016/j.nicl.2013.01.008; Devulder J, 2002, ACTA NEUROL BELG, V102, P97; Ducreux D, 2006, BRAIN, V129, P963, DOI 10.1093/brain/awl016; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; Fillard P, 2011, NEUROIMAGE, V56, P220, DOI 10.1016/j.neuroimage.2011.01.032; Flaherty S A, 1996, AANA J, V64, P133; Goto T, 2008, PAIN, V140, P509, DOI 10.1016/j.pain.2008.10.009; Gustin SM, 2010, CEREB CORTEX, V20, P1409, DOI 10.1093/cercor/bhp205; Haines D.E., 2002, FUNDAMENTAL NEUROSCI; Hong JH, 2011, AM J NEURORADIOL, V32, P1358, DOI 10.3174/ajnr.A2497; Hong JH, 2012, EUR NEUROL, V67, P12, DOI 10.1159/000333012; Hong JH, 2010, EUR NEUROL, V64, P163, DOI 10.1159/000319040; Hong JH, 2010, NEUROSCI LETT, V468, P102, DOI 10.1016/j.neulet.2009.10.075; Jang SH, 2015, J REHABIL MED, V47, P133, DOI 10.2340/16501977-1896; Jang SH, 2013, STROKE, V44, P1099, DOI 10.1161/STROKEAHA.111.000269; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Merskey H, 1994, CLASSIFICATION CHRON; Miller M D, 1993, Fam Pract Res J, V13, P15; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Pagani E, 2008, NEUROIMAGE, V41, P657, DOI 10.1016/j.neuroimage.2008.03.021; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Seghier ML, 2005, J PAIN, V6, P208, DOI 10.1016/j.jpain.2004.11.004; Seo JP, 2014, J REHABIL MED, V46, P374, DOI 10.2340/16501977-1783; Seo JP, 2013, BRAIN INJURY, V27, P749, DOI 10.3109/02699052.2013.771794; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tenovuo O, 2007, PAIN, V131, P241, DOI 10.1016/j.pain.2007.07.003; VESTERGAARD K, 1995, PAIN, V61, P177, DOI 10.1016/0304-3959(94)00140-A; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169; Wechsler D, 1981, WECHSLER ADULT INTEL; Williams JM., 1991, MAS MEMORY ASSESSMEN; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yoon EJ, 2013, BRAIN RES, V1540, P64, DOI 10.1016/j.brainres.2013.10.007	51	39	39	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					E40	E46		10.1097/HTR.0000000000000121			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300005	25699625				2022-02-06	
J	Manskow, US; Sigurdardottir, S; Roe, C; Andelic, N; Skandsen, T; Damsgard, E; Elmstahl, S; Anke, A				Manskow, Unn Sollid; Sigurdardottir, Solrun; Roe, Cecilie; Andelic, Nada; Skandsen, Toril; Damsgard, Elin; Elmstahl, Solve; Anke, Audny			Factors Affecting Caregiver Burden 1 Year After Severe Traumatic Brain Injury: A Prospective Nationwide Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver burden; GOS-E; social network; traumatic brain injury	QUALITY-OF-LIFE; SOCIAL SUPPORT; PSYCHOSOCIAL INTERVENTION; FAMILY CAREGIVERS; DEMENTIA; SCALE; PREDICTORS; APPRAISAL; RELATIVES; DISTRESS	Objectives: To assess burden in the caregivers of patients with severe traumatic brain injury (TBI) 1 year postinjury, related to caregiver's demographic data and social network, patient's demographic data, injury severity, and functional status. Design: Prospective national multicenter study. Self-report from caregivers, patient data collected from the national cohort on patients with severe TBI. Participants: 92 caregivers. Main outcome measure: The Caregiver Burden Scale (CBS). Results: Total caregiver burden was reported high in 16% of caregivers and moderate in 34%. The mean total burden index was 2.12, indicating a moderate burden. Caregivers reported highest scores on the General strain index, followed by the Disappointment index. Poor social network, feeling loneliness, and caring for patients with severe disability were significant predictors of higher burden in univariate analyses (P <.01). Multiple linear regression analyses showed that experiencing loneliness and caring for a patient with more severe disability were independent predictors for higher caregiver burden for all CBS indices. Marital status (married) and low frequency of meeting friends were significant results in some indices. Conclusions: Lack of a social network, feeling loneliness, and patient's functional status are predictors of caregiver burden. General strain, disappointment, and isolation were identified as areas in which caregiver burden is high.	[Manskow, Unn Sollid; Anke, Audny] Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9017 Tromso, Norway; [Manskow, Unn Sollid; Damsgard, Elin] Univ Tromso, Fac Hlth Sci, Dept Hlth & Care Sci, N-9001 Tromso, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol, Fac Med, Dept Neurosci, N-7034 Trondheim, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Elmstahl, Solve] Lund Univ, Dept Hlth Sci, Div Geriatr Med, S-22100 Lund, Sweden; [Anke, Audny] Univ Tromso, Dept Clin Med, Fac Hlth Sci, N-9001 Tromso, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, N-0316 Oslo, Norway		Manskow, US (corresponding author), Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9017 Tromso, Norway.	unn.manskow@gmail.com		Andelic, Nada/0000-0002-3719-4406; Anke, Audny/0000-0002-2491-2560	North Norwegian Health Authorities [8744/SFP1108-13]	This study was conducted with grants from the North Norwegian Health Authorities (grant number 8744/SFP1108-13). The authors report no conflicts of interest.	Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andren S, 2008, J CLIN NURS, V17, P790, DOI 10.1111/j.1365-2702.2007.02066.x; Andren S, 2008, SCAND J CARING SCI, V22, P98, DOI 10.1111/j.1471-6712.2007.00498.x; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Annerstedt L, 2000, SCAND J PUBLIC HEALT, V28, P23, DOI 10.1177/140349480002800106; Arango-Lasprilla JC, 2010, NEUROREHABILITATION, V27, P83, DOI 10.3233/NRE-2010-0583; Association for the Advancement of Automotive Medicine, ABBR INJ SCAL AIS 20; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRERA M, 1986, AM J COMMUN PSYCHOL, V14, P413, DOI 10.1007/BF00922627; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Dahlrup B, 2011, CLIN INTERV AGING, V6, P9, DOI 10.2147/CIA.S14237; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; GEORGE LK, 1989, BRIT J PSYCHIAT, V154, P478, DOI 10.1192/bjp.154.4.478; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lefebvre H, 2012, BRAIN INJURY, V26, P1084, DOI 10.3109/02699052.2012.666364; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Norup A, 2012, BRAIN INJURY, V26, P1192, DOI 10.3109/02699052.2012.672790; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu CY, 2011, GEN HOSP PSYCHIAT, V33, P37, DOI 10.1016/j.genhosppsych.2010.10.006	44	39	39	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					411	423		10.1097/HTR.0000000000000085			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300013	25119652				2022-02-06	
J	Golub, VM; Brewer, J; Wu, X; Kuruba, R; Short, J; Manchi, M; Swonke, M; Younus, I; Reddy, DS				Golub, Victoria M.; Brewer, Jonathan; Wu, Xin; Kuruba, Ramkumar; Short, Jenessa; Manchi, Maunica; Swonke, Megan; Younus, Iyan; Reddy, Doodipala Samba			Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration	FRONTIERS IN AGING NEUROSCIENCE			English	Article						stereology; optical fractionator; optical disector; cavalieri estimator; neuronal injury	DESIGN-BASED STEREOLOGY; RAT HIPPOCAMPUS; TOTAL NUMBER; FRACTIONATOR; DISECTOR; CELLS; CA1; POPULATIONS; EFFICIENCY; SEIZURES	Neuronal injury and neurodegeneration are the hallmark pathologies in a variety of neurological conditions such as epilepsy, stroke, traumatic brain injury, Parkinson's disease and Alzheimer's disease. Quantification of absolute neuron and interneuron counts in various brain regions is essential to understand the impact of neurological insults or neurodegenerative disease progression in animal models. However, conventional qualitative scoring-based protocols are superficial and less reliable for use in studies of neuroprotection evaluations. Here, we describe an optimized stereology protocol for quantification of neuronal injury and neurodegeneration by unbiased counting of neurons and interneurons. Every 20th section in each series of 20 sections was processed for NeuN(+) total neuron and parvalbumin(+) interneuron immunostaining. The sections that contain the hippocampus were then delineated into five reliably predefined subregions. Each region was separately analyzed with a microscope driven by the stereology software. Regional tissue volume was determined by using the Cavalieri estimator, as well as cell density and cell number were determined by using the optical disector and optical fractionator. This protocol yielded an estimate of 1.5 million total neurons and 0.05 million PV(+) interneurons within the rat hippocarnpus. The protocol has greater predictive power for absolute counts as it is based on 3D features rather than 2D images. The total neuron counts were consistent with literature values from sophisticated systems, which are more expensive than our stereology system. This unbiased stereology protocol allows for sensitive, medium-throughput counting of total neurons in any brain region, and thus provides a quantitative tool for studies of neuronal injury and neurodegeneration in a variety of acute brain injury and chronic neurological models.	[Golub, Victoria M.; Brewer, Jonathan; Wu, Xin; Kuruba, Ramkumar; Short, Jenessa; Manchi, Maunica; Swonke, Megan; Younus, Iyan; Reddy, Doodipala Samba] Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Bryan, TX 77807 USA		Reddy, DS (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Bryan, TX 77807 USA.	reddy@medicine.tamhsc.edu		wu, xin/0000-0002-5005-6358; Reddy, Samba/0000-0003-2735-9550; Brewer, Jonathan/0000-0001-9300-3670	CounterACT Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Office of the DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD); National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 N5083460]; Texas A&M University Online Access to Knowledge (OAK) Fund; University Libraries and the Office of the Vice President for Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS083460] Funding Source: NIH RePORTER	This work was supported by the CounterACT Program, National Institutes of Health, Office of the Director and the National Institute of Neurologic Disorders and Stroke Grant U01 N5083460 (to DSR). The open access publishing fees for this article have been covered by the Texas A&M University Online Access to Knowledge (OAK) Fund, supported by the University Libraries and the Office of the Vice President for Research.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AIKA Y, 1994, EXP BRAIN RES, V99, P267; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; Boyce RW, 2010, TOXICOL PATHOL, V38, P1011, DOI 10.1177/0192623310385140; BRAENDGAARD H, 1986, J NEUROSCI METH, V18, P39, DOI 10.1016/0165-0270(86)90112-3; Bronoosh P, 2015, INT J ORAL MAX SURG, V44, P277, DOI 10.1016/j.ijom.2014.09.020; Charleston J S, 2001, Curr Protoc Toxicol, VChapter 12, DOI 10.1002/0471140856.tx1206s06; Cruz-Orive LM, 2014, J MICROSC-OXFORD, V253, P119, DOI 10.1111/jmi.12103; Cruz-Orive LM, 2004, J MICROSC-OXFORD, V213, P205, DOI 10.1111/j.1365-2818.2004.01291.x; CruzOrive LM, 1997, J MICROSC-OXFORD, V186, P93, DOI 10.1046/j.1365-2818.1997.1380695.x; CRUZORIVE LM, 1981, J MICROSC-OXFORD, V122, P235, DOI 10.1111/j.1365-2818.1981.tb01265.x; Dorph-Petersen KA, 2001, J MICROSC-OXFORD, V204, P232, DOI 10.1046/j.1365-2818.2001.00958.x; Dorph-Petersen KA, 2011, BIOL PSYCHIAT, V69, P113, DOI 10.1016/j.biopsych.2010.04.030; Floderus S, 1944, ACTA PATHOL MICROB S, V53, P1; Geuna S, 2015, CELL TISSUE RES, V360, P5, DOI 10.1007/s00441-015-2143-6; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; HARDING AJ, 1994, J NEUROSCI METH, V51, P83, DOI 10.1016/0165-0270(94)90028-0; Hattiangady B, 2011, AGING DIS, V2, P1; Jones NW, 2013, PLACENTA, V34, P1002, DOI 10.1016/j.placenta.2013.08.015; Kaplan S, 2012, NEUROQUANTOLOGY, V10, P44, DOI 10.14704/nq.2012.10.1.425; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Kuruba R., 2014, AM EPILEPSY SOC ABST; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; Mayhew TM, 2015, CELL TISSUE RES, V360, P43, DOI 10.1007/s00441-014-2038-y; Nomura T, 1997, BRAIN RES, V764, P197, DOI 10.1016/S0006-8993(97)00457-5; PAKKENBERG B, 1988, J MICROSC-OXFORD, V150, P1, DOI 10.1111/j.1365-2818.1988.tb04582.x; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Rao MS, 2006, J NEUROSCI RES, V83, P1088, DOI 10.1002/jnr.20802; ROSE RD, 1987, J COMP NEUROL, V263, P365, DOI 10.1002/cne.902630305; ROYET JP, 1991, PROG NEUROBIOL, V37, P433, DOI 10.1016/0301-0082(91)90009-P; Schettino AE, 2013, HEARING RES, V304, P153, DOI 10.1016/j.heares.2013.07.007; Selemon LD, 2007, PSYCHIAT RES, V151, P1, DOI 10.1016/j.psychres.2006.11.003; Sorensen B, 2003, J COMP NEUROL, V459, P242, DOI 10.1002/cne.10625; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Tang Y, 1997, J NEUROSCI METH, V73, P193, DOI 10.1016/S0165-0270(97)02228-0; Walker MA, 2002, AM J PSYCHIAT, V159, P821, DOI 10.1176/appi.ajp.159.5.821; Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X; West, 2012, BASIC STEREOLOGY BIO, P1; West M. J., 2012, BASIC STEREOLOGY BIO, P109; West Mark J, 2013, Cold Spring Harb Protoc, V2013, P287, DOI 10.1101/pdb.top071845; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu X., 2014, AM EPILEPSY SOC ABST	44	39	40	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	OCT 31	2015	7								196	10.5589/fnagi.2015.00196			14	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	CV3JI	WOS:000364155100001	26582988				2022-02-06	
J	Johnson, R; Harkins, K; Cary, M; Sankar, P; Karlawish, J				Johnson, Rebecca; Harkins, Kristin; Cary, Mark; Sankar, Pamela; Karlawish, Jason			The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment	SOCIAL SCIENCE & MEDICINE			English	Article						Alzheimer's; Stigma; Ethics; Disease risk; Vignette-based experiments	MENTAL-ILLNESS; ANTICIPATORY DEMENTIA; PUBLIC-ATTITUDES; BELIEFS; PEOPLE; SCALE; SCHIZOPHRENIA; INTERVENTIONS; PSYCHOPATHY; POPULATION	Background: The classification of Alzheimer's disease is undergoing a significant transformation. Researchers have created the category of "preclinical Alzheimer's," characterized by biomarker pathology rather than observable symptoms. Diagnosis and treatment at this stage could allow preventing Alzheimer's cognitive decline. While many commentators have worried that persons given a preclinical Alzheimer's label will be subject to stigma, little research exists to inform whether the stigma attached to the label of clinical Alzheimer's will extend to a preclinical disorder that has the label of "Alzheimer's" but lacks the symptoms or expected prognosis of the clinical form. Research questions: The present study sought to correct this gap by examining the foundations of stigma directed at Alzheimer's. It asked: do people form stigmatizing reactions to the label "Alzheimer's disease" itself or to the condition's observable impairments? How does the condition's prognosis modify these reactions? Methods: Data were collected through a web-based experiment with N = 789 adult members of the U.S. general population (median age = 49, interquartile range, 32-60, range = 18-90). Participants were randomized through a 3 x 3 design to read one of 9 vignettes depicting signs and symptoms of mild stage dementia that varied the disease label ("Alzheimer's" vs. "traumatic brain injury" vs. no label) and prognosis (improve vs. static vs. worsen symptoms). Four stigma outcomes were assessed: discrimination, negative cognitive attributions, negative emotions, and social distance. Results: The study found that the Alzheimer's disease label was generally not associated with more stigmatizing reactions. In contrast, expecting the symptoms to get worse, regardless of which disease label those symptoms received, resulted in higher levels of perceived structural discrimination, higher pity, and greater social distance. Conclusion: These findings suggest that stigma surrounding pre-clinical Alzheimer's categories will depend highly on the expected prognosis attached to the label. They also highlight the need for models of Alzheimer's-directed stigma that incorporate attributions about the condition's mutability. Published by Elsevier Ltd.	[Johnson, Rebecca] Princeton Univ, Dept Sociol, Princeton, NJ 08544 USA; [Harkins, Kristin; Karlawish, Jason] Univ Penn, Perelman Sch Med, Div Geriatr, Philadelphia, PA 19104 USA; [Cary, Mark] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Sankar, Pamela; Karlawish, Jason] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA		Johnson, R (corresponding author), 117 Wallace Hall, Princeton, NJ 08544 USA.	raj2@princeton.edu		Harkins, Kristin/0000-0001-5360-1043	Penn Neurodegenerative Disease Ethics and Policy Program; Marian S. Ware Alzheimers Program	The authors would like to thank the Penn Neurodegenerative Disease Ethics and Policy Program and the Marian S. Ware Alzheimers Program for funding support and the audience at the American Public Health Association Annual Meeting for feedback.	Angermeyer MC, 2003, ACTA PSYCHIAT SCAND, V108, P304, DOI 10.1034/j.1600-0447.2003.00150.x; Angermeyer MC, 1996, SOC PSYCH PSYCH EPID, V31, P316, DOI 10.1007/BF00783419; Aquilina C., 2006, DEMENTIA MIND MEANIN, P143; Arkar H., 1996, TURKISH J PSYCHIAT, V7, P191; Beard RL, 2008, SOC SCI MED, V66, P1509, DOI 10.1016/j.socscimed.2007.12.024; Beard RL, 2013, SOCIOL HEALTH ILL, V35, P130, DOI 10.1111/j.1467-9566.2012.01481.x; Behuniak SM, 2011, AGEING SOC, V31, P70, DOI 10.1017/S0144686X10000693; Blay SL, 2008, AGING MENT HEALTH, V12, P577, DOI 10.1080/13607860802343050; Blendon RJ., 2012, INT J ALZHEIMERS DIS; Carpenter BD, 2009, GERONTOLOGIST, V49, P236, DOI 10.1093/geront/gnp023; Chaufan C, 2012, SOC SCI MED, V74, P788, DOI 10.1016/j.socscimed.2011.10.033; Chen ZQ, 2014, TREE GENET GENOMES, V10, P1291, DOI 10.1007/s11295-014-0761-x; Cheng ST, 2011, INT PSYCHOGERIATR, V23, P1433, DOI 10.1017/S1041610211000834; Cohen J., 2013, STAT POWER ANAL BEHA; Corcoran C, 2005, SCHIZOPHR RES, V73, P173, DOI 10.1016/j.schres.2004.05.021; Cormack S, 1998, INT J SOC PSYCHIATR, V44, P235, DOI 10.1177/002076409804400401; Corrigan PW, 2007, SOC WORK, V52, P31, DOI 10.1093/sw/52.1.31; Corrigan PW, 2004, SCHIZOPHRENIA BULL, V30, P477, DOI 10.1093/oxfordjournals.schbul.a007095; Corrigan PW, 2000, CLIN PSYCHOL-SCI PR, V7, P48, DOI 10.1093/clipsy/7.1.48; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; Cutler SJ, 1996, GERONTOLOGIST, V36, P657, DOI 10.1093/geront/36.5.657; DiMillo J, 2015, J HEALTH PSYCHOL, V20, P393, DOI 10.1177/1359105313502566; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Edens JF, 2004, PSYCHOL CRIME LAW, V10, P393, DOI 10.1080/10683160310001629274; FOX P, 1989, MILBANK Q, V67, P58, DOI 10.2307/3350070; French SL, 2012, INT J GERIATR PSYCH, V27, P521, DOI 10.1002/gps.2747; Gauthier S, 2013, PROG NEUROBIOL, V110, P102, DOI 10.1016/j.pneurobio.2013.01.003; Greene JA, 2007, PRESCRIBING NUMBERS; Haslam N, 2002, J SOC CLIN PSYCHOL, V21, P628, DOI 10.1521/jscp.21.6.628.22793; Haslam N, 2011, PSYCHOL BULL, V137, P819, DOI 10.1037/a0022386; Haslam NO, 1998, SOC RES, V65, P291; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Jones E.E., 1984, SOCIAL STIGMA PSYCHO; Langdon SA, 2007, SOC SCI MED, V64, P989, DOI 10.1016/j.socscimed.2006.10.029; Le Couteur DG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5125; Lerman C, 2004, NAT REV CANCER, V4, P235, DOI 10.1038/nrc1301; Linden MA, 2005, BRAIN INJURY, V19, P1011, DOI 10.1080/02699050500110314; Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363; Luck T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050792; Lumley TS., 2010, COMPLEX SURVEYS GUID; Murrie DC, 2005, LAW HUMAN BEHAV, V29, P323, DOI 10.1007/s10979-005-2415-x; Phelan JC, 2005, J HEALTH SOC BEHAV, V46, P307, DOI 10.1177/002214650504600401; Rabkin J. G., 1980, ATTITUDES MENTALLY I, P15; Ralph A, 2013, BRAIN INJURY, V27, P1475, DOI 10.3109/02699052.2013.823653; Read J, 2006, ACTA PSYCHIAT SCAND, V114, P303, DOI 10.1111/j.1600-0447.2006.00824.x; Rimmer E, 2005, INT J CLIN PRACT, V59, P17, DOI 10.1111/j.1368-504X.2005.00482.x; Sabat Steven R, 2004, Am J Alzheimers Dis Other Demen, V19, P177, DOI 10.1177/153331750401900311; SARBIN TR, 1970, J CONSULT CLIN PSYCH, V35, P159, DOI 10.1037/h0030056; Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; StataCorp, 2013, STAT STAT SOFTW REL; Tinghog G, 2013, NATURE, V498, pE1, DOI 10.1038/nature12194; U. S. Department of Agriculture Economic Research Service, 2001, ERS USDA BRIEF ROOM; U. S. Department of Health and Human Services, 2014, NAT PLAN ADDR ALZH D; Van Gorp B, 2012, SOC SCI MED, V74, P1274, DOI 10.1016/j.socscimed.2011.12.045; Vodermaier A, 2010, FAM CANCER, V9, P305, DOI 10.1007/s10689-010-9325-x; von dem Knesebeck O, 2014, INT PSYCHOGERIATR, V26, P435, DOI 10.1017/S1041610213002056; Wadley VG, 2001, J GERONTOL B-PSYCHOL, V56, pP244, DOI 10.1093/geronb/56.4.P244; WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738; Werner P., 2014, STIGMA DIS DISABILIT, P223; Werner P, 2011, ALZ DIS ASSOC DIS, V25, P42, DOI 10.1097/WAD.0b013e3181f32594; Werner P, 2010, QUAL HEALTH RES, V20, P159, DOI 10.1177/1049732309358330; Wright DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031661	63	39	39	0	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	OCT	2015	143						117	127		10.1016/j.socscimed.2015.08.031			11	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Biomedical Social Sciences	CV4OE	WOS:000364245600014	26356823				2022-02-06	
J	Liu, ZH; Yip, PK; Adams, L; Davies, M; Lee, JW; Michael, GJ; Priestley, JV; Michael-Titus, AT				Liu, Zhuo-Hao; Yip, Ping K.; Adams, Louise; Davies, Meirion; Lee, Jae Won; Michael, Gregory J.; Priestley, John V.; Michael-Titus, Adina T.			A Single Bolus of Docosahexaenoic Acid Promotes Neuroplastic Changes in the Innervation of Spinal Cord Interneurons and Motor Neurons and Improves Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article						docosahexaenoic acid; neuroplasticity; omega-3 polyunsaturated fatty acids; spinal cord injury	TRAUMATIC BRAIN-INJURY; POLYUNSATURATED FATTY-ACIDS; ADULT-RAT; CORTICOSPINAL TRACT; SYNAPTIC PLASTICITY; PTEN/MTOR PATHWAY; PTEN INHIBITION; NERVOUS-SYSTEM; IN-VITRO; EXPRESSION	Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid that is essential in brain development and has structural and signaling roles. Acute DHA administration is neuroprotective and promotes functional recovery in animal models of adult spinal cord injury (SCI). However, the mechanisms underlying this recovery have not been fully characterized. Here we investigated the effects of an acute intravenous bolus of DHA delivered after SCI and characterized DHA-induced neuroplasticity within the adult injured spinal cord. We found robust sprouting of uninjured corticospinal and serotonergic fibers in a rat cervical hemisection SCI model. A mouse pyramidotomy model was used to confirm that this robust sprouting was not species or injury model specific. Furthermore, we demonstrated that corticospinal fibers sprouting to the denervated side of the cord following pyramidotomy contact V2a interneurons. We also demonstrated increased serotonin fibers and synaptophysin in direct contact with motor neurons. DHA also increased synaptophysin in rat cortical cell cultures. A reduction in phosphatase and tensin homolog (PTEN) has been shown to be involved in axonal regeneration and synaptic plasticity. We showed that DHA significantly upregulates miR-21 and downregulates PTEN in corticospinal neurons. Downregulation of PTEN and upregulation of phosphorylated AKT by DHA were also seen in primary cortical neuron cultures and were accompanied by increased neurite outgrowth. In summary, acute DHA induces anatomical and synaptic plasticity in adult injured spinal cord. This study shows that DHA has therapeutic potential in cervical SCI and provides evidence that DHA could exert its beneficial effects in SCI via enhancement of neuroplasticity.	[Liu, Zhuo-Hao; Yip, Ping K.; Adams, Louise; Davies, Meirion; Lee, Jae Won; Michael, Gregory J.; Priestley, John V.; Michael-Titus, Adina T.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England; [Liu, Zhuo-Hao] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp, Dept Neurosurg, Linkou 33305, Taiwan		Michael-Titus, AT (corresponding author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Neurosci & Trauma, 4 Newark St, London E1 2AT, England.	a.t.michael-titus@qmul.ac.uk	Liu, Zhuo-Hao/C-6758-2011	Liu, Zhuo-Hao/0000-0003-4079-8697	Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital [CMRPG3A1051-1054]; CMDRP; Barts and the London Charity; Nathalie Rose Barr PhD Studentship ISRT	This work was supported by Chang Gung Memorial Hospital, Taiwan CMRPG3A1051-1054 to Z.-H.L., CMDRP and Barts and the London Charity to P.K.Y. and A.T.M.-T., and the Nathalie Rose Barr PhD Studentship ISRT to L.A. and J.V.P. We thank Prof. F.J. Alvarez for advice on locomotor interneuron markers and Dr. L.-F. Wong for advice on qRT-PCR.	Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Al-Mosawie A, 2007, EUR J NEUROSCI, V26, P3003, DOI 10.1111/j.1460-9568.2007.05907.x; Averill S, 2004, NEUROSCIENCE, V123, P419, DOI 10.1016/j.neuroscience.2003.09.031; Azim E, 2014, NATURE, V508, P357, DOI 10.1038/nature13021; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Cafferty WBJ, 2008, J NEUROSCI, V28, P11998, DOI 10.1523/JNEUROSCI.3877-08.2008; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Cao Y, 2008, NEUROREHAB NEURAL RE, V22, P262, DOI 10.1177/1545968307308550; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; Ciranna L, 2006, CURR NEUROPHARMACOL, V4, P101, DOI 10.2174/157015906776359540; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Ding J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080429; Dougherty KJ, 2010, ANN NY ACAD SCI, V1198, P85, DOI 10.1111/j.1749-6632.2010.05502.x; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; Figueroa JD, 2013, J NEUROTRAUM, V30, P853, DOI 10.1089/neu.2012.2718; Fouad K, 2012, EXP NEUROL, V235, P91, DOI 10.1016/j.expneurol.2011.02.009; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gulino R, 2007, NEUROSCI RES, V57, P148, DOI 10.1016/j.neures.2006.10.001; Hains BC, 2002, EXP NEUROL, V175, P347, DOI 10.1006/exnr.2002.7892; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; Hawthorne AL, 2011, J NEUROSCI, V31, P5605, DOI 10.1523/JNEUROSCI.6663-10.2011; Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Jordan LM, 2008, BRAIN RES REV, V57, P183, DOI 10.1016/j.brainresrev.2007.07.019; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Kansal S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084627; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Liu G, 2012, EXP NEUROL, V233, P447, DOI 10.1016/j.expneurol.2011.11.018; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Lopez-Dolado E, 2013, J NEUROTRAUM, V30, P191, DOI 10.1089/neu.2012.2530; Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880; Macias M, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-144; Mandal CC, 2012, CARCINOGENESIS, V33, P1897, DOI 10.1093/carcin/bgs198; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Morin C, 2013, RECENT PAT ANTI-CANC, V8, P319, DOI 10.2174/1574891X113089990032; NACIMIENTO W, 1995, ACTA NEUROPATHOL, V90, P552; Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI [10.1186/1742-2094-11-6, 10.1186/s12974-014-0136-0]; Puskas LG, 2003, P NATL ACAD SCI USA, V100, P1580, DOI 10.1073/pnas.0337683100; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Ramer LM, 2004, J NEUROSCI, V24, P10796, DOI 10.1523/JNEUROSCI.3337-04.2004; Robson LG, 2010, NEUROBIOL AGING, V31, P678, DOI 10.1016/j.neurobiolaging.2008.05.027; Russell KL, 2013, PROSTAG LEUKOTR ESS, V89, P97, DOI 10.1016/j.plefa.2013.05.004; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sandhir R, 2014, NEUROCHEM INT, V78, P117, DOI 10.1016/j.neuint.2014.09.009; Saruhashi Y, 2009, ARCH ORTHOP TRAUM SU, V129, P1279, DOI 10.1007/s00402-008-0754-z; Solfrizzi V, 2006, NEUROBIOL AGING, V27, P1694, DOI 10.1016/j.neurobiolaging.2005.09.026; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Tetzlaff W, 2009, NAT NEUROSCI, V12, P1077, DOI 10.1038/nn0909-1077; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Venna VR, 2009, PSYCHONEUROENDOCRINO, V34, P199, DOI 10.1016/j.psyneuen.2008.08.025; Wang D, 2011, SPINAL CORD, V49, P486, DOI 10.1038/sc.2010.124; Ward RE, 2010, J NEUROTRAUM, V27, P1769, DOI 10.1089/neu.2010.1348; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wurtman RJ, 2006, BRAIN RES, V1088, P83, DOI 10.1016/j.brainres.2006.03.019; Yip PK, 2006, HUM MOL GENET, V15, P3107, DOI 10.1093/hmg/ddl251; Yip PK, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000399; Zhao J, 2013, NEUROSCIENCE, V238, P242, DOI 10.1016/j.neuroscience.2013.02.046	78	39	41	0	16	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 16	2015	35	37					12733	12752		10.1523/JNEUROSCI.0605-15.2015			20	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU6RC	WOS:000363659500013	26377463	Green Published, Bronze			2022-02-06	
J	Bryan, CJ; Gonzales, J; Rudd, MD; Bryan, AO; Clemans, TA; Ray-Sannerud, B; Wertenberger, E; Leeson, B; Heron, EA; Morrow, CE; Etienne, N				Bryan, Craig J.; Gonzales, Jacqueline; Rudd, M. David; Bryan, AnnaBelle O.; Clemans, Tracy A.; Ray-Sannerud, Bobbie; Wertenberger, Evelyn; Leeson, Bruce; Heron, Elizabeth A.; Morrow, Chad E.; Etienne, Neysa			DEPRESSION MEDIATES THE RELATION OF INSOMNIA SEVERITY WITH SUICIDE RISK IN THREE CLINICAL SAMPLES OF US MILITARY PERSONNEL	DEPRESSION AND ANXIETY			English	Article						suicide; military; veterans; agitation; insomnia; sleep	TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCES; PSYCHIATRIC OUTPATIENTS; MAJOR DEPRESSION; IDEATION; BEHAVIOR; DISORDERS; HEALTH; PREVALENCE; PREDICTORS	BackgroundA growing body of empirical research suggests insomnia severity is directly related to suicide ideation, attempts, and death in nonmilitary samples, even when controlling for depression and other suicide risk factors. Few studies have explored this relationship in U.S. military personnel. MethodsThe present study entailed secondary data analyses examining the associations of insomnia severity with suicide ideation and attempts in three clinical samples: Air Force psychiatric outpatients (n = 158), recently discharged Army psychiatric inpatients (n = 168), and Army psychiatric outpatients (n = 54). Participants completed the Beck Scale for Suicide Ideation, the Beck Depression Inventory-II or Patient Health Questionnaire-9, the Insomnia Severity Index, and the Posttraumatic Stress Disorder Checklist at baseline; two samples also completed these measures during follow-up. ResultsSleep disturbance was associated with concurrent ('s > 0.21; P's < 0.059) and prospective ('s > 0.39; P's < 0.001) suicide ideation in all three samples. When adjusting for age, gender, depression, and posttraumatic stress, insomnia severity was no longer directly associated with suicide ideation either concurrently ('s < 0.19; P's > 0.200) or prospectively ('s < 0.26; P's > 0.063), but depression was ('s > 0.22; P's < 0.012). Results of a latent difference score mediation model indicated that depression mediated the relation of insomnia severity with suicide ideation. ConclusionsAcross three clinical samples of military personnel, depression explained the relationship between insomnia severity and suicide risk.	[Bryan, Craig J.; Gonzales, Jacqueline; Rudd, M. David; Bryan, AnnaBelle O.; Clemans, Tracy A.; Ray-Sannerud, Bobbie] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA; [Bryan, Craig J.; Gonzales, Jacqueline; Bryan, AnnaBelle O.; Clemans, Tracy A.; Ray-Sannerud, Bobbie] Univ Utah, Salt Lake City, UT 84112 USA; [Rudd, M. David] Univ Memphis, Memphis, TN 38152 USA; [Wertenberger, Evelyn; Leeson, Bruce] Fort Carson, Colorado Springs, CO USA; [Heron, Elizabeth A.] Lackland AFB, San Antonio, TX USA; [Morrow, Chad E.] Hurlburt Field, Mary Esther, FL USA; [Etienne, Neysa] Maxwell AFB, Montgomery, AL USA		Bryan, CJ (corresponding author), Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Rudd, M. David/AAF-1359-2019	Clemans, Tracy/0000-0001-5994-1508; Bryan, Craig/0000-0002-9714-0733	Military Suicide Research Consortium [W81XWH-10-2-0181]; Department of DefenseUnited States Department of Defense [W81XWH-09-1-0569]; Department of the Air Force [09-198]	Contract grant sponsor: Military Suicide Research Consortium; Contract grant number: W81XWH-10-2-0181; Contract grant sponsor: the Department of Defense; Contract grant number: W81XWH-09-1-0569; Contract grant sponsor: the Department of the Air Force; Contract grant number: 09-198.	Agargun MY, 2007, J AFFECT DISORDERS, V98, P267, DOI 10.1016/j.jad.2006.08.005; Agargun MY, 1997, J CLIN PSYCHIAT, V58, P249; Akiskal HS, 2005, PSYCHOPATHOLOGY, V38, P273, DOI 10.1159/000088445; [Anonymous], 2010, Medical Surveillance Monthly Report, V17, P12; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P18; Armed Forces Health Surveillance Center-AFHSC, 2012, MSMR, V19, P4; BARRACLOUGH BM, 1975, PSYCHOL MED, V5, P55, DOI 10.1017/S0033291700007212; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beck AT, 1997, BEHAV RES THER, V35, P1039, DOI 10.1016/S0005-7967(97)00073-9; Benazzi F, 2003, PSYCHIAT RES, V120, P273, DOI 10.1016/S0165-1781(03)00198-7; Benazzi F, 2003, PROG NEURO-PSYCHOPH, V27, P129, DOI 10.1016/S0278-5846(02)00343-3; Bernert RA, 2005, SLEEP, V28, P1135, DOI 10.1093/sleep/28.9.1135; Bernert Rebecca A, 2007, Neuropsychiatr Dis Treat, V3, P735; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan CJ, 2008, J CLIN PSYCHOL, V64, P519, DOI 10.1002/jclp.20445; Bryan CJ, 2014, GEN HOSP PSYCHIAT, V36, P726, DOI 10.1016/j.genhosppsych.2014.09.013; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Busch KA, 2003, J CLIN PSYCHIAT, V64, P14, DOI 10.4088/JCP.v64n0105; Cole JC., 2008, BEST PRACTICES QUANT; Department of Defense, 2013, DODSER DEP DEF SUIC; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Fujino Y, 2005, SUICIDE LIFE-THREAT, V35, P227, DOI 10.1521/suli.35.2.227.62876; Hall RCW, 1999, PSYCHOSOMATICS, V40, P18, DOI 10.1016/S0033-3182(99)71267-3; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kung S, 2013, J AFFECT DISORDERS, V145, P341, DOI 10.1016/j.jad.2012.08.017; Chellappa SL, 2007, PSYCHIAT RES, V153, P131, DOI 10.1016/j.psychres.2006.05.007; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Linehan MM, 2006, PSYCHOL ASSESSMENT, V18, P303, DOI 10.1037/1040-3590.18.3.303; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; McCall WV, 2010, SLEEP MED, V11, P822, DOI 10.1016/j.sleep.2010.04.004; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; Neter J., 1989, APPL LINEAR REGRESSI; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Ribeiro JD, 2012, J AFFECT DISORDERS, V136, P743, DOI 10.1016/j.jad.2011.09.049; Rihmer Z, 2002, BIPOLAR DISORD, V4, P21, DOI 10.1034/j.1399-5618.4.s1.3.x; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Rudd MD, 2003, SUICIDE LIFE-THREAT, V33, P99, DOI 10.1521/suli.33.1.99.22790; Selig JP, 2009, RES HUM DEV, V6, P144, DOI 10.1080/15427600902911247; Sjostrom N, 2007, SLEEP, V30, P91; Taylor Daniel J, 2003, Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Trockel M, 2015, SLEEP, V38, P259, DOI 10.5665/sleep.4410; Turvey CL, 2002, AM J GERIAT PSYCHIAT, V10, P398; Weathers F.W., 1993, ANN CONV INT SOC TRA	48	39	41	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	SEP	2015	32	9					647	655		10.1002/da.22383			9	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	CQ8AD	WOS:000360827400002	26047362				2022-02-06	
J	Nelson, LD; Pfaller, AY; Rein, LE; McCrea, MA				Nelson, Lindsay D.; Pfaller, Adam Y.; Rein, Lisa E.; McCrea, Michael A.			Rates and Predictors of Invalid Baseline Test Performance in High School and Collegiate Athletes for 3 Computerized Neurocognitive Tests: ANAM, Axon Sports, and ImPACT	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline testing; computerized testing; neurocognitive testing; validity; concussion; mild traumatic brain injury; ImPACT; ANAM; Axon Sports	TEST-RETEST RELIABILITY; FALSE DISCOVERY RATE; CONCUSSION ASSESSMENT; BIOPSYCHOSOCIAL CHARACTERISTICS; COGNITIVE IMPAIRMENT; NORMATIVE DATA; BRAIN-INJURY; SENSITIVITY; SCORES; PREVALENCE	Background: Preseason baseline testing using computerized neurocognitive tests (CNTs) is increasingly performed on athletes. Adequate effort is critical to establish valid estimates of ability, but many users do not evaluate performance validity, and the conditions that affect validity are not well understood across the available CNTs. Purpose: To examine the rates and predictors of invalid baseline performance for 3 popular CNTs: Automated Neuropsychological Assessment Metrics (ANAM), Axon Sports, and Immediate Post-Concussion and Cognitive Testing (ImPACT). Study Design: Controlled laboratory study. Methods: High school and collegiate athletes (N = 2063) completed 2 of 3 CNTs each during preseason evaluations. All possible pairings were present across the sample, and the order of administration was randomized. Examiners provided 1-on-1, scripted pretest instructions, emphasizing the importance of good effort. Profile validity was determined by the manufacturers' standard criteria. Results: The overall percentage of tests flagged as of questionable validity was lowest for ImPACT (2.7%) and higher for ANAM and Axon (10.7% and 11.3%, respectively). The majority of invalid baseline profiles were flagged as such because of failure on only 1 validity criterion. Several athlete and testing factors (eg, attention deficit hyperactivity disorder [ADHD], estimated general intellectual ability, administration order) predicted validity status for 1 or more CNTs. Considering only first CNT administrations and participants without ADHD and/or a learning disability (n = 1835) brought the rates of invalid baseline performances to 2.1%, 8.8%, and 7.0% for ImPACT, ANAM, and Axon, respectively. Invalid profiles on the Medical Symptom Validity Test (MSVT) were rare (1.8% of participants) and demonstrated poor correspondence to CNT validity outcomes. Conclusion: The validity criteria for these CNTs may not identify the same causes of invalidity or be equally sensitive to effort. The validity indicators may not be equally appropriate for some athletes (eg, those with neurodevelopmental disorders). Clinical Relevance: The data suggest that athletes do not put forth widespread low effort or that some validity criteria are more sensitive to invalid performance than others. It is important for examiners to be aware of the conditions that maximize the quality of baseline assessments and to understand what sources of invalid performance are captured by the validity criteria that they obtain.	[Nelson, Lindsay D.; Pfaller, Adam Y.; Rein, Lisa E.; McCrea, Michael A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA		Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute grant [1UL1-RR031973 (-01)]; National Center for Advancing Translational Sciences (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: This work was supported by the US Army Medical Research and Materiel Command under award number W81XWH-12-1-0004. This publication was also supported by the Clinical and Translational Science Institute grant 1UL1-RR031973 (-01) and by the National Center for Advancing Translational Sciences (National Institutes of Health) grant 8UL1TR000055.	[Anonymous], 2003, GREENS MED SYMPTOM V; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; ImPACT Applications Inc, TECHN MAN ONL IMPACT; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Moriarity JM, 2012, BRIT J SPORT MED, V46, P1011, DOI 10.1136/bjsports-2011-090893; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Rahman-Filipiak AAM, 2013, NEUROPSYCHOL REV, V23, P314, DOI 10.1007/s11065-013-9241-6; Roebuck-Spencer TM, 2013, ARCH CLIN NEUROPSYCH, V28, P700, DOI 10.1093/arclin/act055; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2014, J ATHL TRAINING, V49, P659, DOI 10.4085/1062-6050-49.3.37; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Solomon GS, 2013, ARCH CLIN NEUROPSYCH, V28, P9, DOI 10.1093/arclin/acs108; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Szabo AJ, 2013, J ATHL TRAINING, V48, P851, DOI 10.4085/1062-6050-48.6.20; WechslerD, 2001, WECHSLER TEST ADULT; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	44	39	39	0	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2015	43	8					2018	2026		10.1177/0363546515587714			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	CO1DF	WOS:000358892400030	26059178	Green Accepted			2022-02-06	
J	Ilie, G; Adlaf, EM; Mann, RE; Ialomiteanu, A; Hamilton, H; Rehm, J; Asbridge, M; Cusimano, MD				Ilie, Gabriela; Adlaf, Edward M.; Mann, Robert E.; Ialomiteanu, Anca; Hamilton, Hayley; Rehm, Juergen; Asbridge, Mark; Cusimano, Michael D.			Associations between a History of Traumatic Brain Injuries and Current Cigarette Smoking, Substance Use, and Elevated Psychological Distress in a Population Sample of Canadian Adults	JOURNAL OF NEUROTRAUMA			English	Article						adults; psychological distress; substance use; traumatic brain injury	UNITED-STATES; ALCOHOL; ABUSE; WORK	This study describes the prevalence of reported history of traumatic brain injury (TBI) and its association with reports of current substance use, cigarette smoking, and psychological distress among Canadian adults in a population sample. A cross-sectional sample of 1999 Ontario adults 18-93 years of age were surveyed by telephone in 2011 as part of the Center for Addiction and Mental Health's ongoing representative survey of adult mental health and substance use in Ontario, Canada. Loss of consciousness for at least 5min or at least one overnight hospitalization resulting from symptoms associated with the TBI injury represented minimum criteria for TBI. An estimated 16.8% (95% confidence interval, 14.8, 19.0) of adults reported a TBI in their lifetime. Men had higher prevalence of TBI than women. Adults who reported a history of TBI had higher odds of reported past-year daily smoking (adjusted odds ratio [AOR]=2.15), using cannabis (AOR=2.80) and nonmedical opioids (AOR=2.90), as well as screened significantly for recent elevated psychological distress (AOR=1.97) in the past few weeks, compared to adults without a history of TBI. Co-occurrence of a history of TBI with current elevated psychological distress and substance use warrants vigilance among medical practitioners to assess the possibility of a history of TBI during reviews of the history leading to the occurrence of these conditions.	[Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Adlaf, Edward M.; Mann, Robert E.; Ialomiteanu, Anca; Hamilton, Hayley; Rehm, Juergen] Ctr Addict & Mental Hlth, Social & Epidemiol Res, Toronto, ON, Canada; [Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada; [Ilie, Gabriela; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada		Ilie, G (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	ilieg@smh.ca	Cusimano, Michael/X-4059-2019; Ilie, Gabriela/AAM-9122-2021	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [TIR103946]; Ontario Neurotrauma Foundation; AUTO21, a member of the Networks of Centers of Excellence (NCE) - Natural Sciences and Engineering Research Council (NSERC); CIHRCanadian Institutes of Health Research (CIHR); Social Sciences and Humanities Research Council (SSHRC)Social Sciences and Humanities Research Council of Canada (SSHRC); Industry Canada; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	This work was financially supported by a Team Grant (TIR103946) from Canadian Institutes of Health Research (CIHR) and by funds from the Ontario Neurotrauma Foundation. Additional funding was obtained from a grant from AUTO21, a member of the Networks of Centers of Excellence (NCE) program that is administered and funded by the Natural Sciences and Engineering Research Council (NSERC), the CIHR, and the Social Sciences and Humanities Research Council (SSHRC), in partnership with Industry Canada. R.M., H.H., and J.R. also acknowledge ongoing funding support from the Ontario Ministry of Health and Long-Term Care.	Andelic N, 2013, LANCET NEUROL, V12, P28, DOI 10.1016/S1474-4422(12)70294-6; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Billette J. M., 2013, HLTH GLANCE INJURIES; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; Cherpitel CJ, 2007, DRUG ALCOHOL REV, V26, P201, DOI 10.1080/09595230601146686; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Faul M, 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finkelstein E., 2006, INCIDENCE EC BURDEN; Frances A, 2000, DSM 4 CLASSIFICATION; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Ialomiteanu A., 2011, CAMH RES DOCUMENT SE, V35; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Institute of Medicine of the National Academies, 2013, COMM SPORTS REL CONC; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	30	39	39	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1130	1134		10.1089/neu.2014.3619			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000012	25496189	Green Accepted, Green Published			2022-02-06	
J	Chen, L; Gao, X; Zhao, S; Hu, WP; Chen, JH				Chen, Liang; Gao, Xiang; Zhao, Shu; Hu, Weipeng; Chen, Jinhui			The Small-Molecule TrkB Agonist 7, 8-Dihydroxyflavone Decreases Hippocampal Newborn Neuron Death After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						7, 8-dihydroxyflavone; Brain-derived neurotrophic factor; Cell death; Newborn neuron; Neuroprotection; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; NEUROTROPHIC FACTOR; ADULT NEUROGENESIS; DENTATE GYRUS; FLUORO-JADE; SYNAPTIC PLASTICITY; IMMATURE NEURONS; MEMORY DEFICITS; NERVOUS-SYSTEM; MESSENGER-RNAS	Previous studies in rodents have shown that after a moderate traumatic brain injury (TBI) with a controlled cortical impact (CCI) device, the adult-born immature granular neurons in the dentate gyrus are the most vulnerable cell type in the hippocampus. There is no effective approach for preventing immature neuron death after TBI. We found that tyrosine-related kinase B (TrkB), a receptor of brain-derived neurotrophic factor (BDNF), is highly expressed in adult-born immature neurons. We determined that the small molecule imitating BDNF, 7, 8-dihydroxyflavone (DHF), increased phosphorylation of TrkB in immature neurons both in vitro and in vivo. Pretreatment with DHF protected immature neurons from excitotoxicity-mediated death in vitro, and systemic administration of DHF before moderate CCI injury reduced the death of adult-born immature neurons in the hippocampus 24 hours after injury. By contrast, inhibiting BDNF signaling using the TrkB antagonist ANA12 attenuated the neuroprotective effects of DHF. These data indicate that DHF may be a promising chemical compound that promotes immature neuron survival after TBI through activation of the BDNF signaling pathway.	[Gao, Xiang; Chen, Jinhui] Indiana Univ Sch Med, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Chen, Liang; Zhao, Shu] Southern Med Univ, Guangzhou, Guangdong, Peoples R China; [Hu, Weipeng] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou, Peoples R China		Chen, JH (corresponding author), Indiana Univ Sch Med, Dept Neurol Surg, Indiana 320 W 15th St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS075733, 1R21NS072631-01A, R21 NS072631] Funding Source: Medline		Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Andero R, 2012, HIPPOCAMPUS, V22, P399, DOI 10.1002/hipo.20906; Andero R, 2011, AM J PSYCHIAT, V168, P163, DOI 10.1176/appi.ajp.2010.10030326; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Barnes AP, 2009, ANNU REV NEUROSCI, V32, P347, DOI 10.1146/annurev.neuro.31.060407.125536; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cazorla M, 2011, J CLIN INVEST, V121, P1846, DOI 10.1172/JCI43992; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G., 2000, NOVART FDN SYMP, V231, P302; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lau Anthony C., 2007, V399, P15, DOI 10.1007/978-1-59745-504-6_2; Leal G, 2015, BRAIN RES, V1621, P82, DOI 10.1016/j.brainres.2014.10.019; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Liu X, 2010, J MED CHEM, V53, P8274, DOI 10.1021/jm101206p; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Montalbano A, 2013, HIPPOCAMPUS, V23, P879, DOI 10.1002/hipo.22144; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TIMMUSK T, 1994, NEUROSCIENCE, V60, P287, DOI 10.1016/0306-4522(94)90242-9; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yan Q, 1997, J COMP NEUROL, V378, P135; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yavuz BB, 2007, INT PSYCHOGERIATR, V19, P767, DOI 10.1017/S1041610206004303; Zeng Y, 2012, J ALZHEIMERS DIS, V31, P765, DOI 10.3233/JAD-2012-120886; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	75	39	42	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUN	2015	74	6					557	567		10.1097/NEN.0000000000000199			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	CI5UH	WOS:000354824800008	25933388	Green Accepted, Green Submitted			2022-02-06	
J	Liao, KM; Ho, CH; Ko, SC; Li, CY				Liao, Kuang-Ming; Ho, Chung-Han; Ko, Shian-Chin; Li, Chung-Yi			Increased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease	MEDICINE			English	Article							MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMER-DISEASE; PARKINSONS-DISEASE; DIABETES-MELLITUS; ASSOCIATION; DECLINE	Neurodegenerative disease in patients with chronic obstructive pulmonary disease (COPD) was observed. We aim to clarify the risk of dementia in patients with COPD.The study used claims data from Taiwan's National Health Insurance Research Database. Subjects were those who received a discharge diagnosis of COPD between January 1, 2002 and December 31, 2011. Only the first hospitalization was enrolled, and the index date was the first day of admission. Patients younger than 40 years or those with a history of Alzheimer disease (AD) or Parkinson disease (PD) before the index date were excluded. The patients with COPD were then followed until receiving a diagnosis of AD or PD, death, or the end of the study. Control subjects were selected from hospitalized patients without a history of COPD, AD, or PD and were matched according to age (3 years), gender, and the year of admission at a 2:1 ratio. The comorbidities were measured from 1 year before the index date based on the ICD-9-CM codes. The study included 8640 patients with COPD and a mean age of 68.76 (+/- 10.74) years. The adjusted hazard ratio of developing dementia (AD or PD) was 1.74 (95% confidence interval=1.55-1.96) in patients with COPD compared with patients without COPD after adjusting for age, gender, and comorbidities.This nationwide cohort study demonstrates that the risk of dementia, including AD and PD, is significantly increased in patients with COPD compared with individuals in the general population.	[Liao, Kuang-Ming] Chi Mei Med Ctr, Dept Internal Med, Chiali, Taiwan; [Liao, Kuang-Ming] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan; [Ho, Chung-Han] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Ho, Chung-Han] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan; [Ko, Shian-Chin] Chi Mei Med Ctr, Dept Chest Med, Tainan, Taiwan; [Li, Chung-Yi] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 704, Taiwan; [Li, Chung-Yi] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan		Li, CY (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 138 Shengli Rd, Tainan 704, Taiwan.	cyli99@mail.ncku.edu.tw	Liao, Kuang-Ming/AAF-4994-2020; LI, CHUNG-YI/ABI-1419-2020	LI, CHUNG-YI/0000-0002-0321-8908; Ho, Chung-Han/0000-0001-5925-8477; Liao, Kuang Ming/0000-0003-4364-8248			Akomolafe A, 2006, ARCH NEUROL-CHICAGO, V63, P1551, DOI 10.1001/archneur.63.11.1551; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; Bednarek M, 2008, THORAX, V63, P402, DOI 10.1136/thx.2007.085456; Centurion VP, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-73; Chi NF, 2013, NEUROLOGY, V80, P705, DOI 10.1212/WNL.0b013e31828250af; de la Torre JC, 1999, ACTA NEUROPATHOL, V98, P1, DOI 10.1007/s004010051044; Dodd JW, 2010, EUR RESPIR J, V35, P913, DOI 10.1183/09031936.00125109; GRANT I, 1982, ARCH INTERN MED, V142, P1470, DOI 10.1001/archinte.142.8.1470; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Hnizdo Eva, 2006, COPD, V3, P95, DOI 10.1080/15412550600651552; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Li CH, 2015, QJM-INT J MED, V108, P39, DOI 10.1093/qjmed/hcu136; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Roberts RO, 2010, ALZ DIS ASSOC DIS, V24, P11, DOI 10.1097/WAD.0b013e3181a4485c; Roberts RO, 2009, ALZHEIMERS DEMENT, V5, P398, DOI 10.1016/j.jalz.2009.01.025; Rusanen M, 2013, CURR ALZHEIMER RES, V10, P549, DOI 10.2174/1567205011310050011; Schernhammer E, 2011, DIABETES CARE, V34, P1102, DOI 10.2337/dc10-1333; Singh B, 2014, JAMA NEUROL, V71, P581, DOI 10.1001/jamaneurol.2014.94; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Wysocki M, 2012, AM J GERIAT PSYCHIAT, V20, P179, DOI 10.1097/JGP.0b013e31820ee833	23	39	39	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2015	94	23							e930	10.1097/MD.0000000000000930			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ6LD	WOS:000360715000001	26061317	Green Published, gold			2022-02-06	
J	Mac Donald, CL; Adam, OR; Johnson, AM; Nelson, EC; Werner, NJ; Rivet, DJ; Brody, DL				Mac Donald, Christine L.; Adam, Octavian R.; Johnson, Ann M.; Nelson, Elliot C.; Werner, Nicole J.; Rivet, Dennis J.; Brody, David L.			Acute post-traumatic stress symptoms and age predict outcome in military blast concussion	BRAIN			English	Article						traumatic brian injury; post-traumatic stress; clinical outcome; concussion	TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL RATING-SCALE; OPERATION IRAQI FREEDOM; HEAD-INJURY; NOS-TBI; STRUCTURED INTERVIEWS; PSYCHIATRIC-DISORDERS; OEF/OIF VETERANS; NATIONAL-GUARD; MENTAL-HEALTH	High rates of adverse outcomes have been reported following blast-related concussive traumatic brain injury in US military personnel, but the extent to which such adverse outcomes can be predicted acutely after injury is unknown. We performed a prospective, observational study of US military personnel with blast-related concussive traumatic brain injury (n = 38) and controls (n = 34) enrolled between March and September 2012. Importantly all subjects returned to duty and did not require evacuation. Subjects were evaluated acutely 0-7 days after injury at two sites in Afghanistan and again 6-12 months later in the United States. Acute assessments revealed heightened post-concussive, post-traumatic stress, and depressive symptoms along with worse cognitive performance in subjects with traumatic brain injury. At 6-12 months follow-up, 63% of subjects with traumatic brain injury and 20% of controls had moderate overall disability. Subjects with traumatic brain injury showed more severe neurobehavioural, post-traumatic stress and depression symptoms along with more frequent cognitive performance deficits and more substantial headache impairment than control subjects. Logistic regression modelling using only acute measures identified that a diagnosis of traumatic brain injury, older age, and more severe post-traumatic stress symptoms provided a good prediction of later adverse global outcomes (area under the receiver-operating characteristic curve = 0.84). Thus, US military personnel with concussive blast-related traumatic brain injury in Afghanistan who returned to duty still fared quite poorly on many clinical outcome measures 6-12 months after injury. Poor global outcome seems to be largely driven by psychological health measures, age, and traumatic brain injury status. The effects of early interventions and longer term implications of these findings are unknown.	[Mac Donald, Christine L.; Johnson, Ann M.; Nelson, Elliot C.; Werner, Nicole J.; Brody, David L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Adam, Octavian R.; Rivet, Dennis J.] Naval Med Ctr Portsmouth, Portsmouth, VA 23708 USA		Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA.	cmacd@uw.edu			Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT090444]	The study was funded by the Congressionally Directed Medical Research Program (PT090444 Supplement, PI: D. Brody). The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Navy, Department of Defense, or U.S. Government. The principal investigators O. Adam, D. Brody and study director C. Mac Donald had full access to all of the data and take full responsibility for the integrity of the data and the accuracy of the analysis. The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Conaton E, 2012, DOD POLICY GUIDANCE; Conners C. K., 2000, CONNERS CONTINUOUS P; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dempsey KE, 2009, J TRAUMA NURS, V16, P10; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hamster K., 1983, MULTILINGUAL APHASIA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Maguen S, 2012, J TRAUMA STRESS, V25, P3, DOI 10.1002/jts.21669; Matthews CG., 1964, INSTRUCTION MANUAL A; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Norris JN, 2013, MIL MED, V178, P767, DOI 10.7205/MILMED-D-12-00493; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reitan RM, 1992, TRAIL MAKING TEST MA; Ruff R, 1996, ARCH CLIN NEUROPSYCH, V11, P313, DOI 10.1016/0887-6177(95)00031-3; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; SNAITH RP, 1986, BRIT J PSYCHIAT, V148, P599, DOI 10.1192/bjp.148.5.599; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Taniellian T., 2008, INVISIBLE WOUNDS WAR; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tombough T., 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WechslerD, 2001, WECHSLER TEST ADULT; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Wilde EA, 2010, J NEUROTRAUM, V27, P983, DOI 10.1089/neu.2009.1194; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	71	39	39	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY 1	2015	138		5				1314	1326		10.1093/brain/awv038			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH2DB	WOS:000353834100019	25740219	Green Published, Bronze			2022-02-06	
J	Struzyna, LA; Harris, JP; Katiyar, KS; Chen, HI; Cullen, DK				Struzyna, Laura A.; Harris, James P.; Katiyar, Kritika S.; Chen, H. Isaac; Cullen, D. Kacy			Restoring nervous system structure and function using tissue engineered living scaffolds	NEURAL REGENERATION RESEARCH			English	Article						living scaffolds; neural tissue engineering; cell transplant; biomaterials; regeneration; neurotrauma; neurodegeneration; axon pathfinding; cell migration	LONG-TERM SURVIVAL; SPINAL-CORD INJURY; NEURAL STEM-CELLS; IN-VITRO; NEUROTROPHIC FACTORS; CHONDROITINASE ABC; AXON REGENERATION; GROWTH CONES; NEURONS; RECOVERY	Neural tissue engineering is premised on the integration of engineered living tissue with the host nervous system to directly restore lost function or to augment regenerative capacity following nervous system injury or neurodegenerative disease. Disconnection of axon pathways - the long-distance fibers connecting specialized regions of the central nervous system or relaying peripheral signals - is a common feature of many neurological disorders and injury. However, functional axonal regeneration rarely occurs due to extreme distances to targets, absence of directed guidance, and the presence of inhibitory factors in the central nervous system, resulting in devastating effects on cognitive and sensorimotor function. To address this need, we are pursuing multiple strategies using tissue engineered "living scaffolds", which are preformed three-dimensional constructs consisting of living neural cells in a defined, often anisotropic architecture. Living scaffolds are designed to restore function by serving as a living labeled pathway for targeted axonal regeneration - mimicking key developmental mechanisms- or by restoring lost neural circuitry via direct replacement of neurons and axonal tracts. We are currently utilizing preformed living scaffolds consisting of neuronal clusters spanned by long axonal tracts as regenerative bridges to facilitate long-distance axonal regeneration and for targeted neurosurgical reconstruction of local circuits in the brain. Although there are formidable challenges in preclinical and clinical advancement, these living tissue engineered constructs represent a promising strategy to facilitate nervous system repair and functional recovery.	[Struzyna, Laura A.; Harris, James P.; Katiyar, Kritika S.; Chen, H. Isaac; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Struzyna, Laura A.; Harris, James P.; Chen, H. Isaac; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Ctr Neurotrauma Neurodegenerat & Restorat, Philadelphia, PA USA; [Katiyar, Kritika S.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA		Cullen, DK (corresponding author), Univ Penn, Dept Neurosurg, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.	dkacy@mail.med.upenn.edu		Harris, James/0000-0002-8458-5434	U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-13207004]; Axonia Medical, Inc.; Department of Veterans Affairs (RRD Merit Review)US Department of Veterans Affairs [B1097-I]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS T32-NS043126]; Penn Medicine Neuroscience Center; National Science FoundationNational Science Foundation (NSF) [DGE-1321851]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS090746, T32NS043126] Funding Source: NIH RePORTER	This work was made possible due to financial support provided by the U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-13207004); Axonia Medical, Inc.; Department of Veterans Affairs (RR&D Merit Review #B1097-I); National Institutes of Health (NINDS T32-NS043126); Penn Medicine Neuroscience Center; and the National Science Foundation (Graduate Research Fellowship DGE-1321851).	Apel PJ, 2010, MUSCLE NERVE, V41, P335, DOI 10.1002/mus.21485; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Borisoff JF, 2003, MOL CELL NEUROSCI, V22, P405, DOI 10.1016/S1044-7431(02)00032-5; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bryson JB, 2014, SCIENCE, V344, P94, DOI 10.1126/science.1248523; Burnett Mark G, 2004, Neurosurg Focus, V16, pE1, DOI 10.3171/foc.2004.16.5.2; Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586-008-0745-3; Colicos MA, 2006, J EXP BIOL, V209, P2312, DOI 10.1242/jeb.02163; Cristofanilli M, 2011, STEM CELLS DEV, V20, P2065, DOI 10.1089/scd.2010.0547; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Cullen DK, 2007, J NEURAL ENG, V4, P159, DOI 10.1088/1741-2560/4/2/015; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2012, TISSUE ENG PT A, V18, P2280, DOI [10.1089/ten.tea.2011.0534, 10.1089/ten.TEA.2011.0534]; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P241; Dayawansa S, 2014, NEUROL RES, V36, P1020, DOI 10.1179/1743132814Y.0000000386; Eberli D, 2006, METHOD ENZYMOL, V420, P287, DOI 10.1016/S0076-6879(06)20013-2; Faroni A, 2013, INT REV NEUROBIOL, V108, P121, DOI 10.1016/B978-0-12-410499-0.00005-8; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Fine EG, 2002, EUR J NEUROSCI, V15, P589, DOI 10.1046/j.1460-9568.2002.01892.x; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Ganguly K, 2013, NEURON, V80, P729, DOI 10.1016/j.neuron.2013.10.028; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Huang JH, 2009, TISSUE ENG PT A, V15, P1677, DOI 10.1089/ten.tea.2008.0294; Iwata A, 2006, TISSUE ENG, V12, P101, DOI 10.1089/ten.2006.12.101; JACOBS JR, 1989, J NEUROSCI, V9, P2402; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Kandel E.R., 2013, PRINCIPLES NEURAL SC, V5th; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; Korecka JA, 2007, REGEN MED, V2, P425, DOI 10.2217/17460751.2.4.425; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Madduri S, 2010, BIOMATERIALS, V31, P8402, DOI 10.1016/j.biomaterials.2010.07.052; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; Moore MJ, 2006, BIOMATERIALS, V27, P419, DOI 10.1016/j.biomaterials.2005.07.045; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pfister BJ, 2004, J NEUROSCI, V24, P7978, DOI 10.1523/JNEUROSCI.1974-04.2004; Pfister Bryan J., 2011, Critical Reviews in Biomedical Engineering, V39, P81; Pina-Crespo JC, 2012, J NEUROSCI, V32, P15837, DOI 10.1523/JNEUROSCI.3735-12.2012; RAPER JA, 1983, J NEUROSCI, V3, P31; Raper J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001933; Rosenstein JM, 2010, ORGANOGENESIS, V6, P107, DOI 10.4161/org.6.2.11687; Sepp KJ, 2001, DEV BIOL, V238, P47, DOI 10.1006/dbio.2001.0411; Shein-Idelson Mark, 2011, Front Neuroeng, V4, P10, DOI 10.3389/fneng.2011.00010; Smeal RM, 2005, ANN BIOMED ENG, V33, P376, DOI 10.1007/s10439-005-1740-z; Smith DH, 2001, TISSUE ENG, V7, P131, DOI 10.1089/107632701300062714; Smith DH, 2009, PROG NEUROBIOL, V89, P231, DOI 10.1016/j.pneurobio.2009.07.006; Struzyna LA, 2013, RESTORING BRAIN CIRC; Struzyna LA, 2014, CURR OPIN SOLID ST M, V18, P308, DOI 10.1016/j.cossms.2014.07.004; Tang XQ, 2007, J NEUROSCI, V27, P6068, DOI 10.1523/JNEUROSCI.1442-07.2007; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tornero D, 2013, BRAIN, V136, P3561, DOI 10.1093/brain/awt278; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Varier S, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001044; Wang S, 2013, CELL STEM CELL, V12, P252, DOI 10.1016/j.stem.2012.12.002; Weick JP, 2010, STEM CELLS, V28, P2008, DOI 10.1002/stem.514; Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200; Xu G, 2004, NEUROREPORT, V15, P2167, DOI 10.1097/00001756-200410050-00004; Yan QJ, 2012, BIOMED ENG ONLINE, V11, DOI 10.1186/1475-925X-11-36; Yip PK, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000399	61	39	42	2	24	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	MAY	2015	10	5					679	685		10.4103/1673-5374.156943			7	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	CK1JU	WOS:000355964400002	26109930	gold, Green Published			2022-02-06	
J	Hutchison, MG; Comper, P; Meeuwisse, WH; Echemendia, RJ				Hutchison, Michael G.; Comper, Paul; Meeuwisse, Willem H.; Echemendia, Ruben J.			A systematic video analysis of National Hockey League (NHL) concussions, part II: how concussions occur in the NHL	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Contact sports; Head injuries; Injury Prevention; Ice hockey	INJURY SURVEILLANCE SYSTEM; MENS ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY	Background Concussions in sports are a growing cause of concern, as these injuries can have debilitating short-term effects and little is known about the potential long-term consequences. This work aims to describe how concussions occur in the National Hockey League. Methods Case series of medically diagnosed concussions for regular season games over a 3.5-year period during the 2006-2010 seasons. Digital video records were coded and analysed using a standardised protocol. Results 88% (n=174/197) of concussions involved player-to-opponent contact. 16 diagnosed concussions were a result of fighting. Of the 158 concussions that involved player-to-opponent body contact, the most common mechanisms were direct contact to the head initiated by the shoulder 42% of the time (n=66/158), by the elbow 15% (n=24/158) and by gloves in 5% of cases (n=8/158). When the results of anatomical location are combined with initial contact, almost half of these events (n=74/158) were classified as direct contact to the lateral aspect of the head. Conclusions The predominant mechanism of concussion was consistently characterised by player-to-opponent contact, typically directed to the head by the shoulder, elbow or gloves. Also, several important characteristics were apparent: (1) contact was often to the lateral aspect of the head; (2) the player who suffered a concussion was often not in possession of the puck and (3) no penalty was called on the play.	[Hutchison, Michael G.; Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, Toronto, ON M5S 2W6, Canada; [Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Comper, Paul] Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Hotchkiss Brain Inst, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA		Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	Ontario Neurotrauma Foundation (ONF); Pashby Sports Safety Fund	This study received funding by Ontario Neurotrauma Foundation (ONF) and The Pashby Sports Safety Fund. The organisations that contributed funds to the research had no role in the design of the study, the collection, analysis and interpretation of the data.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Andersen TE, 2004, AM J SPORT MED, V32, p69S, DOI 10.1177/0363546503262023; [Anonymous], MAC OS X VERS 10 5 8; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hutchison M, BR J SPORTS IN PRESS; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meeuwisse WH, 2009, CLIN J SPORT MED, V19, P1, DOI 10.1097/JSM.0b013e3181979c1d; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SILVER JR, 1988, SPORTS MED, V5, P328, DOI 10.2165/00007256-198805050-00005; Tommasone BA, 2006, J ATHL TRAINING, V41, P470	20	39	40	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					552	U52		10.1136/bjsports-2013-092235			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CF4OI	WOS:000352529000013	23637116				2022-02-06	
J	Perez-Polo, JR; Rea, HC; Johnson, KM; Parsley, MA; Unabia, GC; Xu, GY; Prough, D; DeWitt, DS; Spratt, H; Hulsebosch, CE				Perez-Polo, J. R.; Rea, H. C.; Johnson, K. M.; Parsley, M. A.; Unabia, G. C.; Xu, G. -Y.; Prough, D.; DeWitt, D. S.; Spratt, H.; Hulsebosch, C. E.			A Rodent Model of Mild Traumatic Brain Blast Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						mild traumatic blast brain injury; inflammation; cytokines; phosphorylated Tau protein; memory; righting reflex response	CHEMOKINE EXPRESSION; RIGHTING REFLEX; RAT MODEL; ENCEPHALOPATHY; DEFICITS; TAU; MICROINJECTION; CONSEQUENCES; ORGANIZATION; INFLAMMATION	One of the criteria defining mild traumatic brain injury (mTBI) in humans is a loss of consciousness lasting for less than 30 min. mTBI can result in long-term impairment of cognition and behavior. In rats, the length of time it takes a rat to right itself after injury is considered to be an analog for human return to consciousness. This study characterized a rat mild brain blast injury (mBBI) model defined by a righting response reflex time (RRRT) of more than 4 min but less than 10 min. Assessments of motor coordination relying on beam-balance and foot-fault assays and reference memory showed significant impairment in animals exposed to mBBI. This study's hypothesis is that there are inflammatory outcomes to mTBI over time that cause its deleterious effects. For example, mBBI significantly increased brain levels of interleukin (IL)-1 and tumor necrosis factor- (TNF) protein. There were significant inflammatory responses in the cortex, hippocampus, thalamus, and amygdala 6 hr after mBBI, as evidenced by increased levels of the inflammatory markers associated with activation of microglia and macrophages, ionized calcium binding adaptor 1 (IBA1), impairment of the blood-brain barrier, and significant neuronal losses. There were significant increases in phosphorylated Tau (p-Tau) levels, a putative precursor to the development of neuroencephalopathy, as early as 6 hr after mBBI in the cortex and the hippocampus but not in the thalamus or the amygdala. There was an apparent correlation between RRRTs and p-Tau protein levels but not IBA1. These results suggest potential therapies for mild blast injuries via blockade of the IL-1 and TNF receptors. (c) 2014 Wiley Periodicals, Inc.	[Perez-Polo, J. R.; Rea, H. C.; Johnson, K. M.; Parsley, M. A.; Unabia, G. C.; Xu, G. -Y.; Prough, D.; DeWitt, D. S.; Spratt, H.; Hulsebosch, C. E.] Univ Texas Med Branch, Galveston, TX 77555 USA		Perez-Polo, JR (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	regino.perez-polo@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; BIGNALL KE, 1974, EXP NEUROL, V42, P566, DOI 10.1016/0014-4886(74)90079-X; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CDC, 2003, REP C MILD TRAUM BRA; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs Department of Defense, 2009, CLIN PRACT GUID MAN; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Masel BE, 2012, J NEUROTRAUM, V29, P2143, DOI 10.1089/neu.2011.2258; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mediavilla Varas Jesus, 2011, Front Neurol, V2, P58, DOI 10.3389/fneur.2011.00058; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sukhotinsky I, 2007, EUR J NEUROSCI, V25, P1417, DOI 10.1111/j.1460-9568.2007.05399.x; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	54	39	39	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2015	93	4					549	561		10.1002/jnr.23513			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4LZ	WOS:000349600500002	25410497				2022-02-06	
J	Robertson, CL; Saraswati, M				Robertson, Courtney L.; Saraswati, Manda			Progesterone protects mitochondrial function in a rat model of pediatric traumatic brain injury	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article						Mitochondrial bioenergetics; Glutathione; Neuroprotection; Pediatric brain injury; Trauma	CORTICAL CONTUSION INJURY; IMMATURE RATS; CELL-DEATH; HYPOXIA-ISCHEMIA; N-ACETYLCYSTEINE; OXIDATIVE STRESS; FEMALE RATS; CNS TRAUMA; DYSFUNCTION; RECOVERY	Progesterone has been studied extensively in preclinical models of adult traumatic brain injury (TBI), and has advanced to clinical trials in adults with TBI. However, there are very few preclinical studies in pediatric TBI models investigating progesterone for neuroprotection. Immature male and female rats (postnatal day, PND 17-21) underwent controlled cortical impact (CCI) to the left parietal cortex. Rats received either progesterone (10 mg/kg) at 1 h (i.p.) and 6 h (s.c.) after TBI or vehicle (22.5 % cyclohexdrin), and were compared to na < ve, age-matched littermates. At 24 h after CCI, brain mitochondria were isolated from the ipsilateral hemisphere. Active (State 3) and resting (State 4) mitochondrial respiration were measured, and mitochondrial respiratory control ratio (RCR, State 3/State 4) was determined. Total mitochonidral glutathione content was measured. A separate group of rats were studied for histology, and received progesterone or vehicle every 24 h (s.c.) for 7 days. In male rats, TBI reduced mitochondrial RCR, and progesterone preserved mitochondrial RCR. This improvement of RCR was predominantly through significant decreases in State 4 respiratory rates. In female rats, post-injury treatment with progesterone did not significantly improve mitochondrial RCR. Normal (uninjured) male rats had lower mitochondrial glutathione content than normal female rats. After TBI, progesterone prevented loss of mitochondrial glutathione in male rats only. Tissue loss was reduced in progesterone treated female rats at 7d after CCI. Future studies will be directed at correlation with neurologic outcome testing. These preclinical studies could provide information for planning future clinical trials of progesterone treatment in children with TBI.	[Robertson, Courtney L.; Saraswati, Manda] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Ctr, Baltimore, MD 21287 USA; [Robertson, Courtney L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA		Robertson, CL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Ctr, 1800 Orleans St,Room 6321, Baltimore, MD 21287 USA.	crober48@jhmi.edu					Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Baykara B, 2013, BIOTECH HISTOCHEM, V88, P250, DOI 10.3109/10520295.2013.769630; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Konkle ATM, 2011, ENDOCRINOLOGY, V152, P223, DOI 10.1210/en.2010-0607; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Manole MD, 2011, CURR PHARM DESIGN, V17, P3854; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Ozacmak VH, 2009, PHYSIOL RES, V58, P909, DOI 10.33549/physiolres.931647; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P43, DOI 10.1016/S0165-3806(00)00111-5; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Shimamura K, 1995, J REPROD FERTIL, V105, P253, DOI 10.1530/jrf.0.1050253; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7; Walson KH, 2011, CRIT CARE MED, V39, P335, DOI 10.1097/CCM.0b013e3181ffda0e; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	63	39	39	1	12	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	APR	2015	47	1-2					43	51		10.1007/s10863-014-9585-5			9	Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Cell Biology	CB3UO	WOS:000349554700004	25348484				2022-02-06	
J	Cuthbert, JP; Harrison-Felix, C; Corrigan, JD; Kreider, S; Bell, JM; Coronado, VG; Whiteneck, GG				Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Corrigan, John D.; Kreider, Scott; Bell, Jeneita M.; Coronado, Victor G.; Whiteneck, Gale G.			Epidemiology of Adults Receiving Acute Inpatient Rehabilitation for a Primary Diagnosis of Traumatic Brain Injury in the United States	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; outcomes; prevalence; rehabilitation; traumatic brain injury	SYSTEMS NATIONAL DATABASE; PRACTICAL SCALE; REPRESENTATIVENESS; ORIENTATION; COMA	Objective: To estimate the overall and by age-group characteristics at admission and discharge from rehabilitation between 2001 and 2010 of all late-teens and adults undergoing inpatient rehabilitation for a primary diagnosis of traumatic brain injury (TBI) in the United States. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 years and older receiving inpatient rehabilitation for a primary diagnosis of TBI between 2001 and 2010. Main Outcome Measures: Functional independence, level of disability, and living situation. Results: The incidence of TBI by age group found the largest proportion of cases to be aged 80 years and older, with a gradual decline in incidence in the age group of 30 years, at which point there was a slight increase. Injuries resulted predominantly from falls (49.8%) and motor vehicle crashes (40.8%); however, injuries to the youngest individuals were largely from motor vehicle crashes with decreasing rates as age increased, while injuries due to falls rose as age increased, with the oldest age groups most likely to incur a TBI. Preinjury alcohol misuse and substance use were found to occur in 22.9% and 12.2% of the total population, respectively; however, age distributions demonstrated high preinjury use among individuals younger than 50 years (eg, 46.4% and 30.6% for those aged 20 and 29 years, respectively) with decreasing misuse as age increased. Of the total population, 49.2% were retired, 31.1% employed, 14.1% not working, and 5.6% students. Trends by age showed that younger individuals were more likely to be students or employed (eg, 14.5% and 62.0% for those aged 20 and 29 years, respectively), with employment status peaking for those aged 30 to 39 years, and declining to 3.2% for the oldest age group (80 years and older). The trend of person(s) living alone between pre- and postrehabilitation showed the least amount of change for those aged 16 to 19 years with steadily increasing changes as age increased. Similar trends were seen for residence changes pre- and postrehabilitation, with the youngest most likely to return to living at a private residence, and a gradual decrease in return to living at a private residence as age increased. FIM instrument ("FIM") Motor and Cognitive subscale scores demonstrated that younger individuals had lower scores at admission to rehabilitation and higher scores at rehabilitation discharge. Conclusion: This study provides population estimates for all patients 16 years of age and older receiving inpatient rehabilitation for a primary diagnosis of TBI in the United States between 2001 and 2010. A recent trend shows the aging of the inpatient TBI rehabilitation population. Many characteristics important to rehabilitation outcomes are influenced by age, with older individuals trending toward being female, having less severe TBIs, incurring TBIs as a result of falls, but showing less improvement during rehabilitation, greater resulting disability, and more changes in their living situation postrehabilitation. These findings are of particular interest, as the oldest age groups considered in these analyses did not include the baby boom population.	[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Kreider, Scott; Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA		Cuthbert, JP (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@craighospital.org			US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (NIDRR); NIDRR [H133A110006]; Traumatic Brain Injury Model System Centers grant from NIDRR [H133A070029]; NIDRR	This research was supported by an intra-agency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC) and the US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (NIDRR) with supplemental funding to the NIDRR-funded Traumatic Brain Injury Model Systems National Data and Statistical Center (grant no. H133A110006). It was also supported by a Traumatic Brain Injury Model System Centers grant from NIDRR to Ohio State University (grant no. H133A070029). This article does not reflect the official policy or opinions of the CDC or the US Department of Health and Human Services and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated. The TBI Model Systems National Database is supported by NIDRR and created and maintained by the TBI Model Systems Centers Program. However, these contents do not necessarily reflect the opinions or views of the TBI Model Systems Centers, NIDRR or the US Department of Education.	American Medical Rehabilitation Providers Association, EREHABDATA 2012; [Anonymous], 1997, GUID UN DAT SET MED; Centers for Disease Control and Preve-ntion, 2011, NAT HOSP DISCH SURV; Centers for Disease Control and Prevention, AUD INS COMM BOOM 19; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan J, 2006, BRAIN INJURY MED PRI, P1105; Corrigan JD, TECHNICAL REPORT PRO; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cruise CM, 2006, CLIN GERIATR MED, V22, P257, DOI 10.1016/j.cger.2005.12.015; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Department of Veterans Affairs and Department of Defense, CLIN PRACT GUID MAN; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Faul M, 2010, TRAUMATIC BRAIN INJU; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Graham J. W., 2003, RES METHODS PSYCHOL; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kalton G., 2003, J OFF STAT, V19, P81; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Medicare Program, 2005, INP REH FAC PROS 412; National Data and Statistical Center, TRAUM BRAIN INJ MOD; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sugerman D., 2012, BRAIN INJURY MED, P45; TEASDALE G, 1974, LANCET, V2, P81; Uniform Data System, 2012, UN DAT SYST MED REH; *US DEP HHS, 2004, INT CLASS DIS 9 REV	28	39	39	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					122	135		10.1097/HTR.0000000000000012			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300015	24495917				2022-02-06	
J	Liao, GP; Harting, MT; Hetz, RA; Walker, PA; Shah, SK; Corkins, CJ; Hughes, TG; Jimenez, F; Kosmach, SC; Day, MC; Tsao, K; Lee, DA; Worth, LL; Baumgartner, JE; Cox, CS				Liao, George P.; Harting, Matthew T.; Hetz, Robert A.; Walker, Peter A.; Shah, Shinil K.; Corkins, Christopher J.; Hughes, Travis G.; Jimenez, Fernando; Kosmach, Steven C.; Day, Mary-Clare; Tsao, KuoJen; Lee, Dean A.; Worth, Laura L.; Baumgartner, James E.; Cox, Charles S., Jr.			Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cell therapy; clinical trial; intracranial pressure; pediatrics; stem cell; traumatic brain injury	MULTIPLE ORGAN DYSFUNCTION; INTRACRANIAL HYPERTENSION; PROGENITOR CELLS; PELOD SCORE; TIME-COURSE; EDEMA; TRANSPLANTATION; VALIDATION; THERAPIES; MANNITOL	Objectives: The devastating effect of traumatic brain injury is exacerbated by an acute secondary neuroinflammatory response, clinically manifest as elevated intracranial pressure due to cerebral edema. The treatment effect of cell-based therapies in the acute post-traumatic brain injury period has not been clinically studied although preclinical data demonstrate that bone marrow-derived mononuclear cell infusion down-regulates the inflammatory response. Our study evaluates whether pediatric traumatic brain injury patients receiving IV autologous bone marrow-derived mononuclear cells within 48 hours of injury experienced a reduction in therapeutic intensity directed toward managing elevated intracranial pressure relative to matched controls. Design: The study was a retrospective cohort design comparing pediatric patients in a phase I clinical trial treated with IV autologous bone marrow-derived mononuclear cells (n = 10) to a control group of age-and severity-matched children (n = 19). Setting: The study setting was at Children's Memorial Hermann Hospital, an American College of Surgeons Level 1 Pediatric Trauma Center and teaching hospital for the University of Texas Health Science Center at Houston from 2000 to 2008. Patients: Study patients were 5-14 years with postresuscitation Glasgow Coma Scale scores of 5-8. Interventions: The treatment group received 6 million autologous bone marrow-derived mononuclear cells/kg body weight IV within 48 hours of injury. The control group was treated in an identical fashion, per standard of care, guided by our traumatic brain injury management protocol, derived from American Association of Neurological Surgeons guidelines. Measurements and Main Results: The primary measure was the Pediatric Intensity Level of Therapy scale used to quantify treatment of elevated intracranial pressure. Secondary measures included the Pediatric Logistic Organ Dysfunction score and days of intracranial pressure monitoring as a surrogate for length of neurointensive care. A repeated-measure mixed model with marginal linear predictions identified a significant reduction in the Pediatric Intensity Level of Therapy score beginning at 24 hours posttreatment through week 1 (p < 0.05). This divergence was also reflected in the Pediatric Logistic Organ Dysfunction score following the first week. The duration of intracranial pressure monitoring was 8.2 +/- 1.3 days in the treated group and 15.6 +/- 3.5 days (p = 0.03) in the time-matched control group. Conclusions: IV autologous bone marrow-derived mononuclear cell therapy is associated with lower treatment intensity required to manage intracranial pressure, associated severity of organ injury, and duration of neurointensive care following severe traumatic brain injury. This may corroborate preclinical data that autologous bone marrow-derived mononuclear cell therapy attenuates the effects of inflammation in the early post-traumatic brain injury period.	[Liao, George P.; Harting, Matthew T.; Hetz, Robert A.; Walker, Peter A.; Shah, Shinil K.; Corkins, Christopher J.; Hughes, Travis G.; Jimenez, Fernando; Kosmach, Steven C.; Day, Mary-Clare; Tsao, KuoJen; Baumgartner, James E.; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Lee, Dean A.; Worth, Laura L.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Therapy, Div Pediat, Houston, TX 77030 USA		Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu	Lee, Dean Anthony/AAK-8443-2021	Lee, Dean Anthony/0000-0001-6693-5392; Harting, Matthew/0000-0002-8929-8311	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01 RR 02558, UL1 RR024148, T32 GM 0879201]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Athersys; CBR; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558, UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	Supported, in part, by grants M01 RR 02558, UL1 RR024148, and T32 GM 0879201 from the National Institutes of Health. Dr. Liao and Ms.; Day received support for article research from the National Institutes of Health (NIH). Their institutions received grant support from the NIH. Drs. Harting, Hetz, Shah, Jimenez, Tsao, Lee, and Worth received support for article research from the NIH. Dr. Kosmach received support for article research from the NIH. His institution received grant support from the NIH/National Institute of Neurological Disorders and Stroke. Dr. Cox consulted for CBR, lectured for CBR, has patents with Athersys and EMIT, and received support for article research from the NIH. Dr. Cox and his institution received grant support from the NIH, Athersys, and CBR; received royalties from EMIT; and has stock with EMIT. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS5; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS49; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS56; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS38; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cuende N, 2012, STEM CELL TRANSL MED, V1, P403, DOI 10.5966/sctm.2011-0064; Garcia PCR, 2010, INTENS CARE MED, V36, P116, DOI 10.1007/s00134-009-1489-1; Hetz RA, 2012, TRANSL STROKE RES, V3, P318, DOI 10.1007/s12975-012-0192-7; Huh Jimmy W, 2009, Anesthesiol Clin, V27, P213, DOI 10.1016/j.anclin.2009.05.006; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kamat P, 2012, PEDIATR CRIT CARE ME, V13, pE33, DOI 10.1097/PCC.0b013e31820ac08f; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Leteurtre S, 2006, LANCET, V367, P897, DOI 10.1016/S0140-6736(06)68371-2; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maltais S, 2011, EUR J CARDIO-THORAC, V39, P368, DOI 10.1016/j.ejcts.2010.04.022; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Poulsom R, 2001, J PATHOL, V195, P229, DOI 10.1002/path.976; Robertson DB, 2013, J INJ VIOLENCE RES, V5, P51, DOI [10.5249/jivr.v5i1.205, DOI 10.5249/JIVR.V5I1.205]; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Thukral A, 2007, INDIAN PEDIATR, V44, P683; Walker PA, 2010, MINERVA PEDIATR, V62, P91; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2010, REGEN MED, V5, P65, DOI 10.2217/RME.09.73; Walker PA, 2009, J TRAUMA, V67, pS120, DOI 10.1097/TA.0b013e3181ad323a; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108; Zygun DA, 2009, CRIT CARE, V13, DOI 10.1186/cc8014	53	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2015	16	3					245	255		10.1097/PCC.0000000000000324			11	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	CD1AZ	WOS:000350807300009	25581630	Green Accepted			2022-02-06	
J	Mychasiuk, R; Hehar, H; Ma, I; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene; Esser, Michael J.			Dietary intake alters behavioral recovery and gene expression profiles in the brain of juvenile rats that have experienced a concussion	Frontiers in Behavioral Neuroscience			English	Article						caloric restriction; high fat diet; mild traumatic brain injury; gRT-PCR; telomere; sex-differences	SATURATED-FAT DIET; CALORIC RESTRICTION; NEUROTROPHIC FACTOR; SEX-DIFFERENCES; ALZHEIMERS-DISEASE; TELOMERE LENGTH; SYNAPTIC PLASTICITY; NEURONAL PLASTICITY; INJURY; OBESITY	Concussion and mild traumatic brain injury (mTBI) research has made minimal progress diagnosing who will suffer from lingering symptomology or generating effective treatment strategies. Research demonstrates that dietary intake affects many biological systems including brain and neurological health. This study determined if exposure to a high fat diet (H ED) or caloric restriction (CR) altered post-concussion susceptibility or resiliency using a rodent model of pediatric concussion. Rats were maintained on HFD, CR, or standard diet (STD) throughout life (including the prenatal period and weaning). At postnatal day 30, male and female rats experienced a concussion or a sham injury which was followed by 17 days of testing. Prefrontal cortex and hippocampus tissue was collected for molecular profiling. Gene expression changes in BDNF, CREB, DNMT1, FGF-2, IGF1, LEP, PGC-1c I, SIRT1, Tau, and TERT were analyzed with respect to injury and diet. Analysis of telomere length (TL) using peripheral skin cells and brain tissue found that TL in skin significantly correlated with TL in brain tissue and TL was affected by dietary intake and injury status. With respect to mTBI outcomes, diet was correlated with recovery as animals on the HFD often displayed poorer performance than animals on the CR diet. Molecular analysis demonstrated that diet induced epigenetic changes that can be associated with differences in individual predisposition and resiliency to post-concussion syndrome.	[Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute (ACHRI); Alberta Children's Hospital Foundation; ARCHI; Markin USRP for Health and Wellness	Dr. Michael Esser reports funding from Alberta Children's Hospital Research Institute (ACHRI) and the Alberta Children's Hospital Foundation. Dr. Richelle Mychasiuk reports funding from ARCHI. Irene Ma has no financial interests to disclose. Harleeen Hehar reports funding from the Markin USRP for Health and Wellness.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barzilai N, 1999, J GERONTOL A-BIOL, V54, pB89, DOI 10.1093/gerona/54.3.B89; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Butt AM, 2005, NEUROSCI LETT, V375, P28, DOI 10.1016/j.neulet.2004.10.060; Cassidy A, 2010, AM J CLIN NUTR, V91, P1273, DOI 10.3945/ajcn.2009.28947; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dunn GA, 2011, HORM BEHAV, V59, P290, DOI 10.1016/j.yhbeh.2010.05.004; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Eisenberg DTA, 2011, AM J HUM BIOL, V23, P149, DOI 10.1002/ajhb.21127; Entringer S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003580; Ferezou-Viala J, 2007, AM J PHYSIOL-REG I, V293, pR1056, DOI 10.1152/ajpregu.00117.2007; Fusco S, 2012, P NATL ACAD SCI USA, V109, P621, DOI 10.1073/pnas.1109237109; Garrido P, 2011, AGING DIS, V2, P80; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Harris RBS, 2000, ANNU REV NUTR, V20, P45, DOI 10.1146/annurev.nutr.20.1.45; Hood MY, 2000, INT J OBESITY, V24, P1319, DOI 10.1038/sj.ijo.0801396; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kalichman L, 2007, AM J PHYS MED REHAB, V86, P650, DOI 10.1097/PHM.0b013e318115f41b; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kolb B., 2008, FUNDAMENTALS HUMAN N; Langdon KD, 2011, NEUROSCIENCE, V182, P82, DOI 10.1016/j.neuroscience.2011.03.028; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Li YY, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-98; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Mattson MP, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/neuro.24.005.2010; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; Max JE, 1998, BRAIN INJURY, V12, P41; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Molteni R, 2001, BRAIN RES REV, V37, P249, DOI 10.1016/S0165-0173(01)00128-X; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Paul L, 2011, J NUTR BIOCHEM, V22, P895, DOI 10.1016/j.jnutbio.2010.12.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Rabinovsky ED, 2004, NEUROL RES, V26, P204, DOI 10.1179/016164104225013851; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Savage JS, 2007, J LAW MED ETHICS, V35, P22, DOI 10.1111/j.1748-720X.2007.00111.x; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Vera E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053760; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Witte AV, 2009, P NATL ACAD SCI USA, V106, P1255, DOI 10.1073/pnas.0808587106; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu MV, 2009, CELL, V139, P61, DOI 10.1016/j.cell.2009.07.036; Zilles K., 1985, CORTEX RAT STEREOTAX	68	39	39	0	16	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	FEB 5	2015	9								17	10.3389/fnbeh.2015.00017			17	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	CA4CH	WOS:000348851400001	25698949	Green Published, gold			2022-02-06	
J	Duranteau, J; Asehnoune, K; Pierre, S; Ozier, Y; Leone, M; Lefrant, JY				Duranteau, Jacques; Asehnoune, Karim; Pierre, Sebastien; Ozier, Yves; Leone, Marc; Lefrant, Jean-Yves		Grp Travail Soc Francaise Anesthes; SRLF; SFMU; GEHT	Recommendations on the resuscitation of haemorrhagic shock	ANESTHESIE & REANIMATION			French	Article							TRAUMATIC BRAIN-INJURY; FLUID RESUSCITATION; HYPOTENSIVE RESUSCITATION; TRANSFUSION REQUIREMENTS; VOLUME RESUSCITATION; HYDROXYETHYL STARCH; INTRAVENOUS FLUID; LACTATE CLEARANCE; VASCULAR ACCESS; BLOOD LACTATE		[Duranteau, Jacques] Univ Paris Sud XI, Hop Paris, Hop Univ Paris Sud, Serv Anesthesie Reanimat, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France; [Asehnoune, Karim] CHU Nantes, Hotel Dieu, Serv Anesthesie Reanimat Chirurgicale, F-44035 Nantes, France		Duranteau, J (corresponding author), Univ Paris Sud XI, Hop Paris, Hop Univ Paris Sud, Serv Anesthesie Reanimat, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	jacques.duranteau@bct.aphp.fr	Leone, Marc/P-4835-2016	Leone, Marc/0000-0002-3097-758X			Agence nationale de securite du medicament et des produits de sante Haute autorite de Sante, 2012, TRANSF PLASM THER PR; Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47; Bayer O, 2013, CRIT CARE MED, V41, P2532, DOI 10.1097/CCM.0b013e3182978fb6; Bayer O, 2012, CRIT CARE MED, V40, P2543, DOI 10.1097/CCM.0b013e318258fee7; Bayer O, 2011, CRIT CARE MED, V39, P1335, DOI 10.1097/CCM.0b013e318212096a; Bhangu A, 2013, INJURY, V44, P1693, DOI 10.1016/j.injury.2012.07.193; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Bolliger D, 2009, BRIT J ANAESTH, V102, P793, DOI 10.1093/bja/aep098; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Davenport RA, 2010, BRIT J SURG, V97, P109, DOI 10.1002/bjs.6806; De Backer D, 2010, NEW ENGL J MED, V362, P779, DOI 10.1056/NEJMoa0907118; Downey DM, 2009, AM SURGEON, V75, P1100; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Fenger-Eriksen C, 2010, TRANSFUSION, V50, P2571, DOI 10.1111/j.1537-2995.2010.02752.x; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; FRITZ H, 1965, ACTA MED SCAND, V178, P403; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; Grottke O, 2010, CRIT CARE, V14, DOI 10.1186/cc8960; GUEUGNIAUD PY, 1987, LANCET, V2, P573; Hampton DA, 2013, J TRAUMA ACUTE CARE, V75, pS9, DOI 10.1097/TA.0b013e318290cd52; Hartog CS, 2011, ANESTH ANALG, V112, P156, DOI 10.1213/ANE.0b013e3181eaff91; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Haute Autorite de Sante, 2008, PRIS CHARG SURD ANT; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hess JR, 2009, TRANSFUSION, V49, P34, DOI 10.1111/j.1537-2995.2008.01944.x; Johansson PI, 2007, TRANSFUSION, V47, P593, DOI 10.1111/j.1537-2995.2007.01160.x; Leidel BA, 2012, RESUSCITATION, V83, P40, DOI 10.1016/j.resuscitation.2011.08.017; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MANIKIS P, 1995, AM J EMERG MED, V13, P619, DOI 10.1016/0735-6757(95)90043-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Meier J, 2007, CRIT CARE MED, V35, P1484, DOI 10.1097/01.CCM.0000265740.62130.1C; Moganasundram S, 2010, ANESTH ANALG, V110, P995, DOI 10.1213/ANE.0b013e3181cd6d20; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Perel P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub6; Pernod G, 2013, ANN FR ANESTH, V32, P691, DOI 10.1016/j.annfar.2013.04.016; Plurad DS, 2011, J TRAUMA, V71, P565, DOI 10.1097/TA.0b013e3182213d52; Reades R, 2011, ANN EMERG MED, V58, P509, DOI 10.1016/j.annemergmed.2011.07.020; Regnier MA, 2012, ANESTHESIOLOGY, V117, P1276, DOI 10.1097/ALN.0b013e318273349d; Ricard JD, 2013, CRIT CARE MED, V41, P2108, DOI 10.1097/CCM.0b013e31828a42c5; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; Sammour T, 2009, INJURY, V40, P104, DOI 10.1016/j.injury.2008.07.032; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Thomas-Rueddel DO, 2012, INTENS CARE MED, V38, P1134, DOI 10.1007/s00134-012-2560-x; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Vogt KN, 2012, TRANSFUSION MED, V22, P156, DOI 10.1111/j.1365-3148.2012.01150.x; Yeguiayan JM, 2011, CRIT CARE, V15, DOI 10.1186/cc9982; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	56	39	39	0	0	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	2352-5800	2352-5819		ANESTH REANIM	Anesth. Reanim.	FEB	2015	1	1					62	74		10.1016/j.anrea.2014.12.007			13	Anesthesiology	Emerging Sources Citation Index (ESCI)	Anesthesiology	V3Q7P	WOS:000218501200013					2022-02-06	
J	Post, A; Hoshizaki, TB; Gilchrist, MD; Brien, S; Cusimano, M; Marshall, S				Post, Andrew; Hoshizaki, T. B.; Gilchrist, Michael D.; Brien, Susan; Cusimano, Michael; Marshall, Shawn			Traumatic Brain Injuries: The Influence of the Direction of Impact	NEUROSURGERY			English	Article						Biomechanics; Contusion; Subarachnoid hemorrhage; Subdural hematoma; Traumatic brain injury	MULTIBODY DYNAMICS ANALYSIS; HUMAN HEAD; RECONSTRUCTION; BIOMECHANICS; ELEMENT; FALLS; ACCELERATION; MODELS; MILD	BACKGROUND: Head impact direction has been identified as an influential risk factor in the risk of traumatic brain injury (TBI) from animal and anatomic research; however, to date, there has been little investigation into this relationship in human subjects. If a susceptibility to certain types of TBI based on impact direction was found to exist in humans, it would aid in clinical diagnoses as well as prevention methods for these types of injuries. OBJECTIVE: To examine the influence of impact direction on the presence of TBI lesions, specifically, subdural hematomas, subarachnoid hemorrhage, and parenchymal contusions. METHODS: Twenty reconstructions of falls that resulted in a TBI were conducted in a laboratory based on eyewitness, interview, and medical reports. The reconstructions involved impacts to a Hybrid III anthropometric dummy and finite element modeling of the human head to evaluate the brain stresses and strains for each TBI event. RESULTS: The results showed that it is likely that increased risk of incurring a subdural hematoma exists from impacts to the frontal or occipital regions, and parenchymal contusions from impacts to the side of the head. There was no definitive link between impact direction and subarachnoid hemorrhage. In addition, the results indicate that there is a continuum of stresses and strain magnitudes between lesion types when impact location is isolated, with subdural hematoma occurring at lower magnitudes for frontal and occipital region impacts, and contusions lower for impacts to the side. CONCLUSION: This hospital data set suggests that there is an effect that impact direction has on TBI depending on the anatomy involved for each particular lesion.	[Post, Andrew; Hoshizaki, T. B.; Gilchrist, Michael D.; Brien, Susan] Univ Ottawa, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland; [Brien, Susan] Hull Hosp, Gatineau, PQ, Canada; [Cusimano, Michael] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Marshall, Shawn] Ottawa Hosp, Ottawa, ON, Canada		Post, A (corresponding author), 200 Lees Ave,Rm A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research # TIR-103946 and the Ontario Neurotrauma Foundation. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Adamec J, 2010, J FORENSIC SCI, V55, P1615, DOI 10.1111/j.1556-4029.2010.01445.x; Adams J, 1987, P 31 STAPP CAR CRASH, V96, P1355, DOI DOI 10.4271/872197; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Chalupnik JD, 1971, NIH692232 U WASH; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Doorly M.C., 2007, THESIS U COLL DUBLIN; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki TB, J NEUROL NE IN PRESS; Huang HM, 1999, J TRAUMA, V47, P538, DOI 10.1097/00005373-199909000-00019; Kang HS, 1997, P 41 STAPP CAR CRASH; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller RT, 1998, P 42 STAPP CAR CRASH; Milne G, 2014, INT J CRASHWORTHINES, V19, P323, DOI 10.1080/13588265.2013.859470; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Nahum AM, 1977, P 21 STAPP CAR CRASH; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P45; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Post A, 2013, THESIS U OTTAWA; Post A, 2014, INT J CRASHWORTHINES, V19, P301, DOI 10.1080/13588265.2014.897413; Post A, 2014, J BIOMECH, V47, P1074, DOI 10.1016/j.jbiomech.2013.12.026; Post A, 2014, J NEUROSURG, V120, P453, DOI 10.3171/2013.10.JNS131101; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Ruan J. S., 1994, THESIS WAYNE STATE U; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Schreiber DI, 1997, 41 STAPP CAR CRASH C, P277; Sosin DM, 1996, BRAIN INJURY, V10, P47; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; van Hoof Jack, 2003, Stapp Car Crash J, V47, P401; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Willinger R, 1995, P IRCOBI C; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Yoganandan N, 2011, CLIN ANAT, V24, P282, DOI 10.1002/ca.21106; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou C, 1995, 39 STAPP CAR CRASH C, P121	53	39	39	1	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2015	76	1					81	91		10.1227/NEU.0000000000000554			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AW9UC	WOS:000346602000016	25525694	Green Accepted			2022-02-06	
J	Rodriguez, RA				Rodriguez, Rudolph A.			Dialysis for Undocumented Immigrants in the United States	ADVANCES IN CHRONIC KIDNEY DISEASE			English	Article						Undocumented immigrants; ESRD; Ethics	HEALTH-CARE; EXPENDITURES; SYSTEM	The United States offers near-universal coverage for treatment of ESRD. Undocumented immigrants with ESRD are the only subset of patients not covered under a national strategy. There are 2 divergent dialysis treatment strategies offered to undocumented immigrants in the United States, emergent dialysis and chronic outpatient dialysis. Emergent dialysis, offering dialysis only when urgent indications exist, is the treatment strategy in certain states. Differing interpretations of Emergency Medicaid statute by the courts and state and federal government have resulted in the geographic disparity in treatment strategies for undocumented immigrants with ESRD. The Patient Protection and Affordable Care Act of 2010 ignored the health care of undocumented immigrants and will not provide relief to undocumented patients with catastrophic illness like ESRD, cancer, or traumatic brain injuries. The difficult patient and provider decisions are explored in this review. The Renal Physicians Association Position Statement on uncompensated renal-related care for noncitizens is an excellent starting point for a framework to address this ethical dilemma. The practice of "emergent dialysis" will hopefully be found unacceptable in the future because of the fact that it is not cost effective, ethical, or humane. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.	[Rodriguez, Rudolph A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA		Rodriguez, RA (corresponding author), Puget Sound VA Med Ctr, Nephrol & Renal Dialysis Unit, Bldg 1,Room 229,1660 South Columbian Way, Seattle, WA 98108 USA.	rudyrod@u.washington.edu					[Anonymous], 2000, CLIN NEPHROL, V54, P253; Bernstein N, 2012, NY TIMES; Campbell GA, 2010, AM J KIDNEY DIS, V55, P181, DOI 10.1053/j.ajkd.2009.06.039; Cohn D'Vera., 2009, PORTRAIT UNAUTHORIZE; Coritsidis GN, 2004, AM J KIDNEY DIS, V43, P424, DOI 10.1053/j.ajkd.2003.11.004; Davidson Adam, 2013, NY TIMES; DuBard CA, 2007, JAMA-J AM MED ASSOC, V297, P1085, DOI 10.1001/jama.297.10.1085; Garcia-Garcia G, 2005, KIDNEY INT, V68, pS58, DOI 10.1111/j.1523-1755.2005.09710.x; Goldman DP, 2006, HEALTH AFFAIR, V25, P1700, DOI 10.1377/hlthaff.25.6.1700; Gusmano M., 2012, UNDOCUMENTED IMMIGRA; Kierans C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054380; Lee P, DISCHARGE DEPORTATIO; Matthews C, 2013, TIME EC         0130; Mohanty SA, 2005, AM J PUBLIC HEALTH, V95, P1431, DOI 10.2105/AJPH.2004.044602; Nzerue C, 2011, AM J KIDNEY DIS, V58, pXXVIII, DOI 10.1053/j.ajkd.2011.08.004; Passel Jeffrey, 2013, POPULATION DECLINE U; Passel Jeffrey, 2010, UNAUTHORIZED IMMIGRA; Porter E., 2005, NY TIMES; Raghavan R, 2012, SEMIN DIALYSIS, V25, P267, DOI 10.1111/j.1525-139X.2012.01066.x; Raghavan R, 2011, NEW ENGL J MED, V364, P2183, DOI 10.1056/NEJMp1101195; Renal Physicians Association, RPA POS UNC REN REL; Sack Kevin, 2010, NY TIMES; Sheikh-Hamad D, 2007, TEXAS MED, V103, P54; Sheikh-Hamad David, 2007, Tex Med, V103, P54; Straube BM, 2009, AM J KIDNEY DIS, V53, P921, DOI 10.1053/j.ajkd.2009.04.010; Sulek JP, 2012, SAN JOSE MERCUR 1005; The Kaiser Commission on Medicaid and the Uninsured, DO MED DISPR SHAR HO; U.S. Department of Homeland Security, CLAR EXIST PRACT REL; Villarejo D, 2010, AM J IND MED, V53, P387, DOI 10.1002/ajim.20796; Wijkstrom J, 2013, AM J KIDNEY DIS, V62, P908, DOI 10.1053/j.ajkd.2013.05.019; Young MJ, 2014, NEW ENGL J MED, V370, P669, DOI 10.1056/NEJMhle1311198; Zarembo A., 2008, LOS ANGELES TIMES	32	39	39	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1548-5595	1548-5609		ADV CHRONIC KIDNEY D	Adv. Chronic Kidney Dis.	JAN	2015	22	1					60	65		10.1053/j.ackd.2014.07.003			6	Urology & Nephrology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Urology & Nephrology	AY9GA	WOS:000347856400010	25573514				2022-02-06	
J	Valko, PO; Gavrilov, YV; Yamamoto, M; Finn, K; Reddy, H; Haybaeck, J; Weis, S; Scammell, TE; Baumann, CR				Valko, Philipp O.; Gavrilov, Yury V.; Yamamoto, Mihoko; Finn, Kristen; Reddy, Hasini; Haybaeck, Johannes; Weis, Serge; Scammell, Thomas E.; Baumann, Christian R.			Damage to Histaminergic Tuberomammillary Neurons and Other Hypothalamic Neurons with Traumatic Brain Injury	ANNALS OF NEUROLOGY			English	Article							DAYTIME SLEEPINESS; NARCOLEPSY; MODAFINIL	The need for increased sleep after traumatic brain injury is a common and disabling complaint, yet its etiology is unknown. Previous studies have demonstrated diffuse damage to various hypothalamic systems, but the integrity of the histaminergic tuberomammillary nucleus, a major arousal-promoting system located in the posterior hypothalamus, has never been examined in head trauma patients. Here, we demonstrate that severe head trauma is associated with a marked loss (41%) of histaminergic neurons. Reduced histamine signaling may contribute to increased sleep need, and therapies that enhance histaminergic tone may improve arousal after head trauma or other conditions. ANN NEUROL 2015;77:177-182	[Valko, Philipp O.; Gavrilov, Yury V.; Yamamoto, Mihoko; Finn, Kristen; Scammell, Thomas E.; Baumann, Christian R.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Valko, Philipp O.; Gavrilov, Yury V.; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Gavrilov, Yury V.] Russian Acad Med Sci, Inst Expt Med, Dept Gen Pathol & Pathol Physiol, St Petersburg, Russia; [Reddy, Hasini] Beth Israel Deaconess Med Ctr, Dept Neuropathol, Boston, MA 02215 USA; [Haybaeck, Johannes] Med Univ Graz, Inst Pathol, Dept Neuropathol, Graz, Austria; [Weis, Serge] Johannes Kepler Univ Linz, Dept Neuropathol, State Neuropsychiat Hosp Wagner Jauregg, A-4040 Linz, Austria		Valko, PO (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	philipp.valko@usz.ch	Lang, Steven/AAE-8102-2021; Gavrilov, Yury/AAA-2915-2019	Lang, Steven/0000-0003-1669-9146; Baumann, Christian/0000-0003-3417-1978; Gavrilov, Yury/0000-0003-1409-7686	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32003B-125504]; Clinical Research Priority Program "Sleep and Health" of the University of Zurich	This study was supported by the Swiss National Science Foundation (grant No. 32003B-125504) and the Clinical Research Priority Program "Sleep and Health" of the University of Zurich.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Dauvilliers Y, 2013, LANCET NEUROL, V12, P1068, DOI 10.1016/S1474-4422(13)70225-4; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Jego S, 2013, NAT NEUROSCI, V16, P1637, DOI 10.1038/nn.3522; John J, 2013, ANN NEUROL, V74, P786, DOI 10.1002/ana.23968; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Ko EM, 2003, BRAIN RES, V992, P220, DOI 10.1016/j.brainres.2003.08.044; Konadhode RR, 2013, J NEUROSCI, V33, P10257, DOI 10.1523/JNEUROSCI.1225-13.2013; Luppi PH, 2013, SLEEP MED, V14, P714, DOI 10.1016/j.sleep.2013.02.004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Monti JM, 2013, SLEEP MED REV, V17, P293, DOI 10.1016/j.smrv.2012.10.002; Parmentier R, 2002, J NEUROSCI, V22, P7695; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Steininger TL, 1999, BRAIN RES, V840, P138, DOI 10.1016/S0006-8993(99)01648-0; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tabbal SD, 2012, EXP NEUROL, V237, P355, DOI 10.1016/j.expneurol.2012.07.008; Takahashi K, 2006, J NEUROSCI, V26, P10292, DOI 10.1523/JNEUROSCI.2341-06.2006; Valko PO, 2013, ANN NEUROL, V74, P794, DOI 10.1002/ana.24019	20	39	44	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2015	77	1					177	182		10.1002/ana.24298			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AZ7UN	WOS:000348423200017	25363332	Green Accepted			2022-02-06	
J	Dardiotis, E; Paterakis, K; Tsivgoulis, G; Tsintou, M; Hadjigeorgiou, GF; Dardioti, M; Grigoriadis, S; Simeonidou, C; Komnos, A; Kapsalaki, E; Fountas, K; Hadjigeorgiou, GM				Dardiotis, Efthimios; Paterakis, Konstantinos; Tsivgoulis, Georgios; Tsintou, Magdalini; Hadjigeorgiou, Georgios F.; Dardioti, Maria; Grigoriadis, Savas; Simeonidou, Constantina; Komnos, Apostolos; Kapsalaki, Eftychia; Fountas, Kostas; Hadjigeorgiou, Georgios M.			AQP4 Tag Single Nucleotide Polymorphisms in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						polymorphism; traumatic brain injury; tag SNPs; genetics; AQP4	GENETIC ASSOCIATION; AQUAPORIN-4 GENE; NERVOUS-SYSTEM; KNOCKOUT MICE; HEAD-INJURY; EDEMA; POPULATION; EVENTS	Accumulating evidence suggests that the extent of brain injury and the clinical outcome after traumatic brain injury (TBI) are modulated, to some degree, by genetic variants. Aquaporin-4 (AQP4) is the predominant water channel in the central nervous system and plays a critical role in controlling the water content of brain cells and the development of brain edema after TBI. We sought to investigate the influence of the AQP4 gene region on patient outcome after TBI by genotyping tag single nucleotide polymorphisms (SNPs) along AQP4 gene. A total of 363 patients with TBI (19.6% female) were prospectively evaluated. Data including the Glasgow Coma Scale (GCS) scores at admission, the presence of intracranial hemorrhage, and the 6-month Glasgow Outcome Scale (GOS) scores were collected. Seven tag SNPs across the AQP4 gene were identified based on the HapMap data. Using logistic regression analyses, SNPs and haplotypes were tested for associations with 6-month GOS after adjusting for age, GCS score, and sex. Significant associations with TBI outcome were detected for rs3763043 (OR [95% confidence interval (CI)]: 5.15 [1.60-16.5], p=0.006, for recessive model), rs3875089 (OR [95% CI]: 0.18 [0.07-0.50] p=0.0009, for allele difference model), and a common haplotype of AQP4 tag SNPs (OR [95% CI]: 2.94, [1.34-6.36], p=0.0065). AQP4 tag SNPs were not found to influence the initial severity of TBI or the presence of intracranial hemorrhages. In conclusion, the present study provides evidence for possible involvement of genetic variations in AQP4 gene in the functional outcome of patients with TBI.	[Dardiotis, Efthimios; Tsintou, Magdalini; Dardioti, Maria; Hadjigeorgiou, Georgios M.] Univ Thessaly, Univ Hosp Larissa, Neurogenet Lab, Dept Neurol, Larisa 41100, Greece; [Paterakis, Konstantinos; Hadjigeorgiou, Georgios F.; Fountas, Kostas] Univ Thessaly, Univ Hosp Larissa, Dept Neurosurg, Larisa 41100, Greece; [Tsivgoulis, Georgios] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Neurol 2, GR-11527 Athens, Greece; [Tsivgoulis, Georgios] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic; [Grigoriadis, Savas] Aristotle Univ Thessaloniki, Hippokrat Univ Hosp, Dept Neurosurg 2, GR-54006 Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Dept Physiol, GR-54006 Thessaloniki, Greece; [Komnos, Apostolos] Gen Hosp Larissa, Intens Care Unit, Larisa, Greece; [Kapsalaki, Eftychia] Univ Thessaly, Sch Med, Dept Radiol, Larisa 41100, Greece		Hadjigeorgiou, GM (corresponding author), Univ Thessaly, Univ Hosp Larissa, Neurogenet Lab, Dept Neurol,Biopolis, Mezourlo Hill, Larisa 41100, Greece.	gmhadji@med.uth.gr	Tsivgoulis, Georgios/AAD-5360-2020; Tsivgoulis, Georgios/AAD-7467-2019; Paterakis, Konstantinos/AAH-4554-2019	Tsivgoulis, Georgios/0000-0002-0640-3797; Dardiotis, Efthimios/0000-0003-2957-641X	European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Research Committee of the University of Thessaly, Greece [2845]	Georgios Tsivgoulis has been supported by the European Regional Development Fund - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123); The study was supported in part by a research grant of the Research Committee of the University of Thessaly, Greece (Code: 2845).	Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Ban M, 2007, J NEUROL, V254, P398, DOI 10.1007/s00415-006-0392-8; Bird TD, 2001, NEUROLOGY, V57, P1153, DOI 10.1212/WNL.57.7.1153; Carter KW, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-557; Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60; Dardiotis E, 2006, SURG NEUROL, V66, P334, DOI 10.1016/j.surneu.2006.05.042; Dardiotis E, 2012, CURR OPIN PSYCHIATR, V25, P231, DOI 10.1097/YCO.0b013e3283523c0e; Dardiotis E, 2011, PHARMACOGENET GENOM, V21, P136, DOI 10.1097/FPC.0b013e328343ab15; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Kerty E, 2013, ACTA OPHTHALMOL, V91, P88, DOI 10.1111/j.1755-3768.2011.02231.x; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li W, 2012, CNS NEUROSCI THER, V18, P558, DOI 10.1111/j.1755-5949.2012.00322.x; Li ZQ, 2009, CELL RES, V19, P519, DOI 10.1038/cr.2009.33; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Mai WH, 2013, J NEUROIMMUNOL, V255, P75, DOI 10.1016/j.jneuroim.2012.10.004; Opdal SH, 2010, PEDIATR RES, V68, P48, DOI [10.1203/PDR.0b013e3181df4e7c, 10.1203/00006450-201011001-00091]; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Park TJ, 2014, GENE, V536, P302, DOI 10.1016/j.gene.2013.12.007; Robertson CS, 2011, J NEUROTRAUM, V28, P727, DOI 10.1089/neu.2010.1476; Romeiro RR, 2007, NEUROSCI LETT, V426, P133, DOI 10.1016/j.neulet.2007.09.004; Rubino E, 2009, J HEADACHE PAIN, V10, P111, DOI 10.1007/s10194-009-0100-z; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	43	39	40	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1920	1926		10.1089/neu.2014.3347			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500004	24999750	Green Published			2022-02-06	
J	Merritt, VC; Arnett, PA				Merritt, Victoria C.; Arnett, Peter A.			Premorbid predictors of postconcussion symptoms in collegiate athletes	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Concussion; Closed head injury; Sports injuries; Postconcussion symptoms; Collegiate athletes	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; COGNITIVE RESERVE; FOOTBALL PLAYERS; HEAD-INJURY; CHILDREN	Introduction: In recent years, the sports community has been faced with the challenge of determining when it is safe to return concussed athletes to play. Given that return-to-play decisions are partially dependent upon athletes' endorsement of symptoms, better understanding what factors contribute to the presence of symptoms following concussion is crucial. The purpose of the present study was to better characterize the symptoms that athletes endorse at baseline and to determine what impact various premorbid (or preinjury) characteristics have on the presence and severity of postconcussion symptoms in the acute injury period following concussion. Method: Two groups of participants with similar ages and levels of education were examined: athletes at baseline (N = 702) and postconcussion (N = 55). Athletes were administered a comprehensive battery of neuropsychological tests, consisting of neurocognitive and neurobehavioral measures, at both time periods. The main outcome measure was the Post-Concussion Symptoms Scale (PCSS). A factor analysis was conducted on the participants' baseline PCSS data to determine the factor structure of the PCSS, and separate logistic regression analyses were conducted that examined the baseline PCSS symptom clusters (derived from the factor analysis), demographic variables, and baseline neurocognitive variables as predictors of dichotomized postconcussion PCSS total scores (i.e., low versus high symptom reporting following concussion). Results: Four distinct clusters emerged from the factor analysis measuring cognitive, physical, affective, and sleep symptoms. Logistic regression results indicated that the physical and affective symptom clusters at baseline reliably predicted athletes' postconcussion symptom group, as did sex and the neurocognitive composite score. Conclusions: These findings show that certain baseline characteristics of athletes confer risk for greater symptomatology postconcussion. Knowledge of these risk factors can assist the management and treatment of sports-related concussion.	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA		Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu	Meijer, Anna/K-5118-2016	Merritt, Victoria/0000-0001-5683-4168	Penn State Sports Medicine	The authors report no conflicts of interest, and no formal grant funding was obtained for this project. However, they would like to thank Wayne Sebastianelli and Penn State Sports Medicine for their generous support of this research.	[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; [Anonymous], 2010, IBM SPSS STAT WIND V; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bailey CM, 2009, J HEAD TRAUMA REHAB, V24, P123, DOI 10.1097/HTR.0b013e31819c1caa; Benedict, 2001, HOPKINS VERBAL LEARN; Benedict R., 1997, BRIEF VISUOSPATIAL M; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Pardini D., 2004, BR J SPORTS MED, V38, P661; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; *PSYCH CORP, 2001, WECHSL TEST AD READ; Rabinowitz AR, 2013, NEUROPSYCHOLOGY, V27, P481, DOI 10.1037/a0033023; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Smith A., 1991, SYMBOL DIGIT MODALIT; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	59	39	39	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV 26	2014	36	10					1098	1111		10.1080/13803395.2014.983463			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AX3MB	WOS:000346842300009	25493542				2022-02-06	
J	Nielson, JL; Guandique, CF; Liu, AW; Burke, DA; Lash, AT; Moseanko, R; Hawbecker, S; Strand, SC; Zdunowski, S; Irvine, KA; Brock, JH; Nout-Lomas, YS; Gensel, JC; Anderson, KD; Segal, MR; Rosenzweig, ES; Magnuson, DS; Whittemore, SR; McTigue, DM; Popovich, PG; Rabchevsky, AG; Scheff, SW; Steward, O; Courtine, G; Edgerton, VR; Tuszynski, MH; Beattie, MS; Bresnahan, JC; Ferguson, AR				Nielson, Jessica L.; Guandique, Cristian F.; Liu, Aiwen W.; Burke, Darlene A.; Lash, A. Todd; Moseanko, Rod; Hawbecker, Stephanie; Strand, Sarah C.; Zdunowski, Sharon; Irvine, Karen-Amanda; Brock, John H.; Nout-Lomas, Yvette S.; Gensel, John C.; Anderson, Kim D.; Segal, Mark R.; Rosenzweig, Ephron S.; Magnuson, David S. K.; Whittemore, Scott R.; McTigue, Dana M.; Popovich, Phillip G.; Rabchevsky, Alexander G.; Scheff, Stephen W.; Steward, Oswald; Courtine, Gregoire; Edgerton, V. Reggie; Tuszynski, Mark H.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.			Development of a Database for Translational Spinal Cord Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						monkeys; rodents; bioinformatics; translation; syndromics	TRAUMATIC BRAIN-INJURY; INDEPENDENCE MEASURE; TIME LIMITS; RECOVERY; SCALE; MULTICENTER; VALIDITY; RELIABILITY; COMPRESSION; SCIM	Efforts to understand spinal cord injury (SCI) and other complex neurotrauma disorders at the pre-clinical level have shown progress in recent years. However, successful translation of basic research into clinical practice has been slow, partly because of the large, heterogeneous data sets involved. In this sense, translational neurological research represents a "big data" problem. In an effort to expedite translation of pre-clinical knowledge into standards of patient care for SCI, we describe the development of a novel database for translational neurotrauma research known as Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION-SCI). We present demographics, descriptive statistics, and translational syndromic outcomes derived from our ongoing efforts to build a multi-center, multi-species pre-clinical database for SCI models. We leveraged archived surgical records, postoperative care logs, behavioral outcome measures, and histopathology from approximately 3000 mice, rats, and monkeys from pre-clinical SCI studies published between 1993 and 2013. The majority of animals in the database have measures collected for health monitoring, such as weight loss/gain, heart rate, blood pressure, postoperative monitoring of bladder function and drug/fluid administration, behavioral outcome measures of locomotion, and tissue sparing postmortem. Attempts to align these variables with currently accepted common data elements highlighted the need for more translational outcomes to be identified as clinical endpoints for therapeutic testing. Last, we use syndromic analysis to identify conserved biological mechanisms of recovery after cervical SCI between rats and monkeys that will allow for more-efficient testing of therapeutics that will need to be translated toward future clinical trials.	[Nielson, Jessica L.; Guandique, Cristian F.; Liu, Aiwen W.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, San Francisco, CA 94110 USA; [Burke, Darlene A.; Magnuson, David S. K.; Whittemore, Scott R.] Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; [Lash, A. Todd] Ohio State Univ, Off Res Off Responsible Res Practices, Columbus, OH 43210 USA; [Moseanko, Rod; Hawbecker, Stephanie; Strand, Sarah C.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Zdunowski, Sharon; Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA USA; [Irvine, Karen-Amanda] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA 94110 USA; [Brock, John H.; Rosenzweig, Ephron S.; Tuszynski, Mark H.] Univ Calif San Diego, Dept Neurosci, Ctr Neural Repair, La Jolla, CA 92093 USA; [Nout-Lomas, Yvette S.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA; [Gensel, John C.; Rabchevsky, Alexander G.; Scheff, Stephen W.] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Anderson, Kim D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Segal, Mark R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Ctr Bioinformat & Mol Biostat, San Francisco, CA 94110 USA; [McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Dept Neurosci, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Steward, Oswald] Univ Calif Irvine, Dept Anat & Neurobiol, Reeve Irvine Res Ctr, Irvine, CA 92717 USA; [Steward, Oswald] Univ Calif Irvine, Dept Neurobiol & Behav, Reeve Irvine Res Ctr, Irvine, CA USA; [Steward, Oswald] Univ Calif Irvine, Dept Neurosurg, Reeve Irvine Res Ctr, Irvine, CA USA; [Courtine, Gregoire] Swiss Fed Inst Technol, Ctr Neuroprosthet, CH-1015 Lausanne, Switzerland; [Courtine, Gregoire] Swiss Fed Inst Technol, Brain Mind Inst, CH-1015 Lausanne, Switzerland; [Tuszynski, Mark H.] Vet Adm Med Ctr, La Jolla, CA USA		Ferguson, AR (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	adam.ferguson@ucsf.edu	Anderson, Kim/ABA-2258-2020; Anderson, Kimberly/AAB-6460-2022; courtine, gregoire/AAJ-1694-2020; Rabchevsky, Alexander/AAQ-2451-2021; Rosenzweig, Ephron/AAI-7541-2020	Anderson, Kim/0000-0001-9252-161X; courtine, gregoire/0000-0002-5744-4142; Rabchevsky, Alexander/0000-0002-1991-0915; Ferguson, Adam/0000-0001-7102-1608; Nielson, Jessica/0000-0002-3677-3959; Magnuson, David/0000-0003-3816-3676; Steward, Oswald/0000-0001-7069-8756; Nout-Lomas, Yvette/0000-0001-6583-2308; , John/0000-0001-8980-108X; Rosenzweig, Ephron/0000-0002-0370-9643	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS067092, F32NS079030, R01NS038079, R01NS042291, R01NS031193, R01NS032000]; Craig H. Neilsen Foundation [224308]; Wings for Life [WFLUS008/12]; NYS CoRE [CO19772, R21 AG032518, R01 NS052292, P01 RR15576, P30 GM103507, R01 NS073584, R01 NS045734, R01 NS089324, R01 NS059776, P30-NS045758, P01NS010165]; Veterans AdministrationUS Department of Veterans Affairs; Kentucky Spinal Cord and Head Injury Research Trust; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Research for Cure; Roman Reed Spinal Cord Injury Research Fund of the State of California; Craig H. Neilsen Foundation; American Paralysis Association; Paralyzed Veterans of America; Christopher and Dana Reeve Foundation;  [NIH-N01-NS-3-2353];  [NIH-NO1-NS-3-2354]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, R01NS059776, F32NS079030, R01NS073584, N01NS032353, R01NS052292, R01NS067092, R01NS032000, R01NS042291, R01NS045734, R01NS073857, R01NS031193, R01NS038079, R01NS089324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG032518] Funding Source: NIH RePORTER	The authors thank, in alphabetical order, Rochelle Deibert, Crystal Forrider, Jenny Haefeli, J. Russell Huie, Amity Lin, Brandon Miller, Vladimir Muraru, Ellen Stuck, AmyTovar, Montina J. Van Meter, and Sergio Veiga for their technical assistance and fruitful discussions regarding database development. This work was supported by NIH grants R01NS067092 (to A. R. F.) and F32NS079030 (to J. L. N.); Craig H. Neilsen Foundation 224308, and Wings for Life WFLUS008/12. Primary data collection was supported by NIH grants R01NS038079, R01NS042291, R01NS031193, and R01NS032000; NYS CoRE CO19772, R21 AG032518, R01 NS052292, P01 RR15576, P30 GM103507, R01 NS073584, R01 NS045734, R01 NS089324, R01 NS059776, P30-NS045758, P01NS010165, NIH-N01-NS-3-2353, and NIH-NO1-NS-3-2354 contract (Facilities of Research Excellence in Spinal Cord Injury), the Veterans Administration, the Kentucky Spinal Cord and Head Injury Research Trust, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Research for Cure, the Roman Reed Spinal Cord Injury Research Fund of the State of California, the Craig H. Neilsen Foundation, the American Paralysis Association, Paralyzed Veterans of America, and the Christopher and Dana Reeve Foundation.	Aguilar RM, 2010, EXP NEUROL, V221, P38, DOI 10.1016/j.expneurol.2009.09.028; Anderson KD, 2011, SPINAL CORD, V49, P880, DOI 10.1038/sc.2011.20; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504; Christopher and Dana Reeve Foundation (CDRF-PRC), 2009, PAR RES CTR PAR FACT; Cook DJ, 2011, EXPERT REV CARDIOVAS, V9, P433, DOI [10.1586/erc.11.34, 10.1586/ERC.11.34]; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; Ditunno JE, 2007, NEUROREHAB NEURAL RE, V21, P539, DOI 10.1177/1545968307301880; Ditunno PL, 2001, SPINAL CORD, V39, P654, DOI 10.1038/sj.sc.3101223; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Ferguson AR, 2011, TRANSL STROKE RES, V2, P438, DOI 10.1007/s12975-011-0121-1; Fouad K, 2012, EXP NEUROL, V235, P91, DOI 10.1016/j.expneurol.2011.02.009; Irvine Karen-Amanda, 2010, J Vis Exp, DOI 10.3791/2246; Kalsi-Ryan S, 2009, TOP SPINAL CORD INJ, V14, P34, DOI DOI 10.1310/sci1404-34; Kalsi-Ryan S, 2012, J NEUROTRAUM, V29, P905, DOI 10.1089/neu.2010.1504; Lammertse DP, 2013, SPINAL CORD, V51, P2, DOI 10.1038/sc.2012.137; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Lemmon V. P., 2014, J NEUROTRAUMA; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; National Institute of Neurological Disorders and Stroke (NINDS), 2014, NINDS COMM DAT EL SP; NIF, 2014, NEUR INF FRAM DEV TO; Nout YS, 2012, NEUROREHAB NEURAL RE, V26, P556, DOI 10.1177/1545968311421934; Nout YS, 2012, NEUROTHERAPEUTICS, V9, P380, DOI 10.1007/s13311-012-0114-0; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Scargle J. D., 2000, J SCI EXPLOR, V14, P16; Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; Watzlawick R, 2014, JAMA NEUROL, V71, P91, DOI 10.1001/jamaneurol.2013.4684; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	35	39	39	1	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	21					1789	1799		10.1089/neu.2014.3399			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AR0TW	WOS:000343285300004	25077610	Green Published			2022-02-06	
J	Theadom, A; Starkey, NJ; Dowell, T; Hume, PA; Kahan, M; McPherson, K; Feigin, V				Theadom, Alice; Starkey, Nicola J.; Dowell, Tony; Hume, Patria A.; Kahan, Michael; McPherson, Kathryn; Feigin, Valery		BIONIC Res Grp	Sports-related brain injury in the general population: An epidemiological study	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain injury; Incidence; Concussion; Epidemiology; Sport and recreation; Population-based	HEAD-INJURY; RECURRENT CONCUSSION; NEW-ZEALAND; SEVERITY; OUTCOMES; TRENDS; RISK	Objectives: To determine the incidence, nature and severity of all sports-related brain injuries in the general population. Design: Population-based epidemiological incidence study. Methods: Data on all traumatic brain injury events sustained during a sports-related activity were extracted from a dataset of all new traumatic brain injury cases (both fatal and non-fatal), identified over a one-year period in the Hamilton and Waikato districts of New Zealand. Prospective and retrospective case ascertainment methods from multiple sources were used. All age groups and levels of traumatic brain injury severity were included. Details of the registering injuries and recurrent injuries sustained over the subsequent year were obtained through medical/accident records and assessment interviews with participants. Results: Of 1369 incident traumatic brain injury cases, 291 were identified as being sustained during a sports-related activity (21% of all traumatic brain injuries) equating to an incidence rate of 170 per 100,000 of the general population. Recurrent injuries occurred more frequently in adults (11%) than children (5%). Of the sports-related injuries 46% were classified as mild with a high risk of complications. Injuries were most frequently sustained during rugby, cycling and equestrian activities. It was revealed that up to 19% of traumatic brain injuries were not recorded in medical notes. Conclusions: Given the high incidence of new and recurrent traumatic brain injury and the high risk of complications following injury, further sport specific injury prevention strategies are urgently needed to reduce the impact of traumatic brain injury and facilitate safer engagement in sports activities. The high levels of 'missed' traumatic brain injuries, highlights the importance in raising awareness of traumatic brain injury during sports-related activity in the general population. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Theadom, Alice; Feigin, Valery] Auckland Univ Technol, Fac Hlth & Environm Sci, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Starkey, Nicola J.] Univ Waikato, Sch Psychol, Hamilton, New Zealand; [Dowell, Tony] Univ Otago, Wellington Sch Med & Hlth Sci, Dunedin, New Zealand; [Hume, Patria A.] Auckland Univ Technol, Fac Hlth & Environm Studies, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Kahan, Michael] Waikato Occupat Serv Ltd, Hamilton, New Zealand; [McPherson, Kathryn] Auckland Univ Technol, Fac Hlth & Environm Studies, Person Centred Res Ctr, Auckland, New Zealand		Theadom, A (corresponding author), Auckland Univ Technol, Fac Hlth & Environm Sci, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand.	alice.theadom@aut.ac.nz	Feigin, Valery/AAF-2313-2019; Hume, Patria Anne/P-1084-2017; Hume, Patria/AAN-5514-2021; Starkey, Nicola/AAJ-3795-2020	Hume, Patria Anne/0000-0003-1847-8128; Hume, Patria/0000-0003-1847-8128; Starkey, Nicola/0000-0002-4370-8186; Barber, P Alan/0000-0003-2469-9023; Feigin, Valery L./0000-0002-6372-1740; Ameratunga, Shanthi/0000-0001-8042-2251; McPherson, Kathryn/0000-0003-1240-8882; Te Ao, Braden/0000-0002-1050-200X; Theadom, Alice/0000-0003-0351-6216; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand [HRC 09/063A]	The authors declare that there are no competing interests associated with the research contained within this manuscript. The BIONIC study was funded by the Health Research Council of New Zealand (HRC 09/063A).	Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Beck AJ, 2011, BR J SPORTS MED, V45; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harris AW, 2012, J SCI MED SPORT, V15, P298, DOI 10.1016/j.jsams.2011.12.005; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; King D, 2010, NZJ SPORTS MED, V37, P56; Kolt GS, 2013, J SCI MED SPORT, V16, P87, DOI 10.1016/j.jsams.2013.01.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; Pakzad-Vaezi K, 2011, PAED CHILD HEALT-CAN, V16, P217, DOI 10.1093/pch/16.4.217; Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sport and Recreation New Zealand, 2009, SPORT RECR PART LEV; Sport New Zealand, 2012, SPORT RECR YOUNG NZ; Statistics New Zealand, 2006, NZ CENS 2006 STAT NZ; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	30	39	39	1	29	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	NOV	2014	17	6					591	596		10.1016/j.jsams.2014.02.001			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AT3PA	WOS:000344845200006	24602688	Green Accepted			2022-02-06	
J	Baral, A; Ye, HX; Jiang, PC; Yao, Y; Mao, Y				Baral, Aparajita; Ye, Hong Xing; Jiang, Pu Cha; Yao, Yu; Mao, Ying			B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients	ONCOLOGY LETTERS			English	Article						glioma; B7 family; B7-H3; B7-H1; cerebral spinal fluid; blood serum	COSTIMULATORY MOLECULE B7-H3; HUMAN PANCREATIC-CANCER; T-CELL ACTIVATION; CARCINOMA; MELANOMA; SURVIVAL; PROGNOSIS; RESPONSES; THERAPY; ANTIGEN	The B7 family consists of activating and inhibitory molecules that regulate immune responses. Recent research demonstrated the roles of soluble B7-H3 (sB7-H3) and soluble B7-H1 (sB7-H1) in the blood serum of various tumors; however, none of these studies investigated the expression of these proteins in the cerebral spinal fluid (CSF) and blood serum of patients with glioma. The aim of the present study was to investigate the expression of B7-H3 and B7-H1 in the CSF, blood serum and tissues of patients with glioma and their correlation with clinicopathological data. Between January 2012 and November 2012, samples were obtained from 78 patients with glioma, four CSF samples were obtained from patients with a moderate traumatic brain injury, four brain tissue samples were obtained from patients with a traumatic brain injury and 40 blood serum samples were obtained from healthy individuals. The expression of B7-H3 and B7-H1 in the CSF, blood serum and tumor samples of the patients with high-grade glioma was found to be higher than that in the patients with low-grade glioma. However, no significant differences in sB7-H3 and sB7-H1 expression were observed in the blood serum of the patients with glioma compared with the healthy control subjects. In addition, the expression of sB7-H3 and sB7-H1 in the CSF of the patients with glioma was higher than that in the CSF of the patients with a moderate traumatic brain injury. Furthermore, in the patients with glioma, B7-H3 and B7-H1 expression in the CSF and tumor tissue, although not in the blood serum, correlated with the glioma grade.	[Baral, Aparajita; Jiang, Pu Cha] Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan 430071, Hubei, Peoples R China; [Baral, Aparajita; Ye, Hong Xing; Yao, Yu; Mao, Ying] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China; [Mao, Ying] Fudan Univ, State Key Lab Med Neurobiol, Inst Biomed Sci, Shanghai 200032, Peoples R China		Yao, Y (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurosurg, 12 Wulumuqi Rd, Shanghai 200040, Peoples R China.	yu_yao03@126.com; yingmao168@hotmail.com		Mao, Ying/0000-0001-8055-115X	National Science Foundation for Distinguished Young Scholars of ChinaNational Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars [81272797]; Innovation Program of Shanghai Municipal Education CommissionInnovation Program of Shanghai Municipal Education Commission [13ZZ010]	The present study was supported by a grant from the National Science Foundation for Distinguished Young Scholars of China (grant no. 81272797) that was awarded to Professor Ying Mao and a grant from the Innovation Program of Shanghai Municipal Education Commission (grant no. 13ZZ010), which was awarded to Professor Yu Yao.	Boorjian SA, 2008, CLIN CANCER RES, V14, P4800, DOI 10.1158/1078-0432.CCR-08-0731; Chapoval AI, 2001, NAT IMMUNOL, V2, P269, DOI 10.1038/85339; Chen XQ, 2009, J MOL NEUROSCI, V37, P86, DOI 10.1007/s12031-008-9133-z; Chen YW, 2008, CURR CANCER DRUG TAR, V8, P404, DOI 10.2174/156800908785133141; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Frigola X, 2011, CLIN CANCER RES, V17, P1915, DOI 10.1158/1078-0432.CCR-10-0250; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Hashiguchi M, 2008, P NATL ACAD SCI USA, V105, P10495, DOI 10.1073/pnas.0802423105; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lemke D, 2012, CLIN CANCER RES, V18, P105, DOI 10.1158/1078-0432.CCR-11-0880; Loos M, 2008, CANCER LETT, V268, P98, DOI 10.1016/j.canlet.2008.03.056; Loos M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-463; Luo LQ, 2004, J IMMUNOL, V173, P5445, DOI 10.4049/jimmunol.173.9.5445; Ma LX, 2007, J HEPATOL, V46, P98, DOI 10.1016/j.jhep.2006.07.031; MERIMSKY O, 1994, TUMOR BIOL, V15, P188, DOI 10.1159/000217892; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Streit M, 2003, ONCOGENE, V22, P3172, DOI 10.1038/sj.onc.1206457; Suh WK, 2003, NAT IMMUNOL, V4, P899, DOI 10.1038/ni967; Sun J, 2010, CANCER IMMUNOL IMMUN, V59, P1163, DOI 10.1007/s00262-010-0841-1; Sun YP, 2006, LUNG CANCER-J IASLC, V53, P143, DOI 10.1016/j.lungcan.2006.05.012; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Wu CP, 2006, WORLD J GASTROENTERO, V12, P457, DOI 10.3748/wjg.v12.i3.457; Yamato I, 2009, BRIT J CANCER, V101, P1709, DOI 10.1038/sj.bjc.6605375; Yao Y, 2009, NEURO-ONCOLOGY, V11, P757, DOI 10.1215/15228517-2009-014; Zang XX, 2010, MODERN PATHOL, V23, P1104, DOI 10.1038/modpathol.2010.95; Zhang GB, 2008, IMMUNOLOGY, V123, P538, DOI 10.1111/j.1365-2567.2007.02723.x	28	39	43	1	13	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	SEP	2014	8	3					1195	1201		10.3892/ol.2014.2268			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AN8LB	WOS:000340854600046	25120686	Green Submitted, gold, Green Published			2022-02-06	
J	Morkved, N; Hartmann, K; Aarsheim, LM; Holen, D; Milde, AM; Bomyea, J; Thorp, SR				Morkved, N.; Hartmann, K.; Aarsheim, L. M.; Holen, D.; Milde, A. M.; Bomyea, J.; Thorp, S. R.			A comparison of Narrative Exposure Therapy and Prolonged Exposure therapy for PTSD	CLINICAL PSYCHOLOGY REVIEW			English	Article						Posttraumatic Stress Disorder; Trauma; Narrative Exposure Therapy; Prolonged Exposure; Review	POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; AFRICAN REFUGEE SETTLEMENT; FEMALE ASSAULT SURVIVORS; TRAUMATIC BRAIN-INJURY; DEPRESSIVE SYMPTOMS; JAPANESE PATIENTS; BOSNIAN REFUGEES; OLDER VETERANS	The purpose of this review was to compare and contrast Prolonged Exposure (PE) and Narrative Exposure Therapy (NEC). We examined the treatment manuals to describe the theoretical foundation, treatment components, and procedures, including the type, manner, and focus of exposure techniques and recording methods used. We examined extant clinical trials to investigate the range of treatment formats reported, populations studied, and clinical outcome data. Our search resulted in 32 studies on PE and 15 studies on NET. Consistent with prior reviews of PTSD treatment, it is evident that PE has a solid evidence base and its current status as a first line treatment for the populations studied to this date is warranted. We argue that NET may have advantages in treating complex traumatization seen in asylum seekers and refugees, and for this population NET should be considered a recommended treatment. NET and PE have several commonalities, and it is recommended that studies of these treatments include a broader range of populations and trauma types to expand the current knowledge on the treatment of PTSD. Published by Elsevier Ltd.	[Morkved, N.; Hartmann, K.; Aarsheim, L. M.; Holen, D.] Univ Bergen, Fac Psychol, N-5020 Bergen, Norway; [Milde, A. M.] Univ Bergen, Dept Biol & Med Psychol, N-5020 Bergen, Norway; [Milde, A. M.] Hlth Bergen, Reg Resource Ctr Violence Traumat Stress & Suicid, Bergen, Norway; [Bomyea, J.; Thorp, S. R.] SDSU UCSD Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA; [Bomyea, J.; Thorp, S. R.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Thorp, S. R.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA		Thorp, SR (corresponding author), VA San Diego Healthcare Syst, 8810 Rio San Diego Dr,Mail Code 116A4Z, San Diego, CA 92108 USA.	sthorp@ucsd.edu	Thorp, Steven/AAT-7321-2020	Morkved, Nina/0000-0003-2745-8890			Aderka IM, 2013, J CONSULT CLIN PSYCH, V81, P375, DOI 10.1037/a0031523; Aderka IM, 2011, J CONSULT CLIN PSYCH, V79, P421, DOI 10.1037/a0023318; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Asukai N, 2008, J TRAUMA STRESS, V21, P340, DOI 10.1002/jts.20337; Asukai N, 2010, J TRAUMA STRESS, V23, P744, DOI 10.1002/jts.20589; Baikie KA, 2005, ADV PSYCHIAT TREATME, V11, P338, DOI DOI 10.1192/APT.11.5.338; Bichescu D, 2007, BEHAV RES THER, V45, P2212, DOI 10.1016/j.brat.2006.12.006; Bluett EJ, 2014, J BEHAV THER EXP PSY, V45, P97, DOI 10.1016/j.jbtep.2013.09.003; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Breedlove S. M., 2007, BIOL PSYCHOL INTRO B, V5th; Breslau N, 1999, PSYCHOL MED, V29, P813, DOI 10.1017/S0033291799008612; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI 10.1177/1524838009334448; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Catani C, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-22; CIENFUEGOS AJ, 1983, AM J ORTHOPSYCHIAT, V53, P43, DOI 10.1111/j.1939-0025.1983.tb03348.x; Cloitre M, 2011, J TRAUMA STRESS, V24, P615, DOI 10.1002/jts.20697; Cloitre M, 2009, CNS SPECTRUMS, V14, P32; Courtois C. A., 2008, PSYCHOL TRAUMA-US, V1, P86, DOI DOI 10.1037/1942-9681.S.1.86; Craske MG, 2008, BEHAV RES THER, V46, P5, DOI 10.1016/j.brat.2007.10.003; Crumlish N, 2010, J NERV MENT DIS, V198, P237, DOI 10.1097/NMD.0b013e3181d61258; Cukor J, 2010, ANN NY ACAD SCI, V1208, P82, DOI 10.1111/j.1749-6632.2010.05793.x; d'Ardenne P, 2007, BEHAV COGN PSYCHOTH, V35, P293, DOI 10.1017/S1352465807003645; de Bont PAJM, 2013, BEHAV THER, V44, P717, DOI 10.1016/j.beth.2013.07.002; Eftekhari A, 2013, JAMA PSYCHIAT, V70, P949, DOI 10.1001/jamapsychiatry.2013.36; Ertl V, 2011, JAMA-J AM MED ASSOC, V306, P503, DOI 10.1001/jama.2011.1060; Feske U, 2008, J INTERPERS VIOLENCE, V23, P1027, DOI 10.1177/0886260507313967; Foa E.B., 2007, PROLONGED EXPOSURE T, V1; Foa E. B., 2011, PSYCHOL SCI PUBL INT, V14, P65; Foa EB, 2000, J TRAUMA STRESS, V13, P539, DOI 10.1023/A:1007802031411; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Foa EB, 2004, J CONSULT CLIN PSYCH, V72, P879, DOI 10.1037/0022-006X.72.5.879; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Foa EB, 2013, JAMA-J AM MED ASSOC, V310, P2650, DOI 10.1001/jama.2013.282829; Gilboa-Schechtman E, 2010, J AM ACAD CHILD PSY, V49, P1034, DOI 10.1016/j.jaac.2010.07.014; Goodson JT, 2013, J TRAUMA STRESS, V26, P419, DOI 10.1002/jts.21830; Green BL, 2000, J TRAUMA STRESS, V13, P271, DOI 10.1023/A:1007758711939; Grey N, 2001, BEHAV COGN PSYCHOTH, V29, P367, DOI 10.1017/S1352465801003095; Grissom N, 2009, NEUROBIOL LEARN MEM, V92, P215, DOI 10.1016/j.nlm.2008.07.001; GROVES P M, 1970, Psychological Review, V77, P419, DOI 10.1037/h0029810; Gwozdziewycz Nicolas, 2013, Perm J, V17, P70, DOI 10.7812/TPP/12-058; Halvorsen JO, 2010, SCAND J PSYCHOL, V51, P495, DOI 10.1111/j.1467-9450.2010.00821.x; Hembree EA, 2004, J PERS DISORD, V18, P117, DOI 10.1521/pedi.18.1.117.32767; Hensel-Dittmann D, 2011, PSYCHOTHER PSYCHOSOM, V80, P345, DOI 10.1159/000327253; Hijazi A. M., 2013, DISS ABSTR INT B, V74; Institute of Medicine, 2008, TREATM POSTTR STRESS; Ironson G, 2002, J CLIN PSYCHOL, V58, P113, DOI 10.1002/jclp.1132; Jensen S.B., 1990, J TRAUMA STRESS, V3, P115, DOI DOI 10.1002/JTS.2490030109; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Lustig Stuart L, 2004, Transcult Psychiatry, V41, P31, DOI 10.1177/1363461504041352; McDonagh A, 2005, J CONSULT CLIN PSYCH, V73, P515, DOI 10.1037/0022-006X.73.3.515; McLean CP, 2011, EXPERT REV NEUROTHER, V11, P1151, DOI [10.1586/ern.11.94, 10.1586/ERN.11.94]; McPherson J., 2011, SAGE J ONLINE, V21; Moser JS, 2010, J NERV MENT DIS, V198, P72, DOI 10.1097/NMD.0b013e3181c81fac; Nacasch N, 2011, J CLIN PSYCHIAT, V72, P1174, DOI 10.4088/JCP.09m05682blu; National Collaborating Centre for Mental Health (NCCMH), 2005, POSTTR STRESS DIS MA; Neuner F, 2004, J CONSULT CLIN PSYCH, V72, P579, DOI 10.1037/0022-006X.72.4.579; Neuner F, 2008, J CONSULT CLIN PSYCH, V76, P686, DOI 10.1037/0022-006X.76.4.686; Neuner F, 2008, CHILD ADOL PSYCH CL, V17, P641, DOI 10.1016/j.chc.2008.03.001; Neuner Frank, 2010, Cognitive Behaviour Therapy, V39, P81, DOI 10.1080/16506070903121042; Neuner F, 2002, BEHAV COGN PSYCHOTH, V30, P205, DOI 10.1017/S1352465802002072; NICE, 2005, POSTTR STREE DIS PTS, V26; Nicholl C., 2004, J MENT HEALTH, V13, P351, DOI [10.1080/09638230410001729807, DOI 10.1080/09638230410001729807]; Nickerson A, 2011, CLIN PSYCHOL REV, V31, P399, DOI 10.1016/j.cpr.2010.10.004; Onyut LP, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-7; Otto MW, 2003, BEHAV RES THER, V41, P1271, DOI 10.1016/S0005-7967(03)00032-9; Pabst A., 2014, CLIN NEUROPSYCHIATRY, V81, P61; Palic S, 2014, J NERV MENT DIS, V202, P111, DOI 10.1097/NMD.0000000000000079; Palic S, 2011, J AFFECT DISORDERS, V131, P8, DOI 10.1016/j.jad.2010.07.005; Paunovic N, 2001, BEHAV RES THER, V39, P1183, DOI 10.1016/S0005-7967(00)00093-0; Powers MB, 2010, CLIN PSYCHOL REV, V30, P635, DOI 10.1016/j.cpr.2010.04.007; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Ready DJ, 2012, PSYCHOL TRAUMA-US, V4, P84, DOI 10.1037/a0021997; Resick PA, 2003, CNS SPECTR, V8, P340, DOI 10.1017/S1092852900018605; Resick PA, 2012, J CONSULT CLIN PSYCH, V80, P201, DOI 10.1037/a0026602; Robjant K, 2010, CLIN PSYCHOL REV, V30, P1030, DOI 10.1016/j.cpr.2010.07.004; Rothbaum BO, 2005, J TRAUMA STRESS, V18, P607, DOI 10.1002/jts.20069; Rothbaum BO, 2003, ANN NY ACAD SCI, V1008, P112, DOI 10.1196/annals.1301.012; Rothbaum BO, 2000, EFFECTIVE TREATMENTS FOR PTSD, P320; Ruf M, 2010, J TRAUMA STRESS, V23, P437, DOI 10.1002/jts.20548; Schaal S, 2009, PSYCHOTHER PSYCHOSOM, V78, P298, DOI 10.1159/000229768; Schauer M., 2011, NARRATIVE EXPOSURE T; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Simon NM, 2008, J CLIN PSYCHIAT, V69, P400, DOI 10.4088/JCP.v69n0309; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Stenmark H, 2013, BEHAV RES THER, V51, P641, DOI 10.1016/j.brat.2013.07.002; Thorp SR, 2012, AM J GERIAT PSYCHIAT, V20, P276, DOI 10.1097/JGP.0b013e3182435ee9; Tuerk PW, 2013, PSYCHOL SERV, V10, P401, DOI 10.1037/a0030549; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; Van Dijk Janie A., 2003, American Journal of Psychotherapy, V57, P361; van Minnen A, 2002, BEHAV RES THER, V40, P439, DOI 10.1016/S0005-7967(01)00024-9; Vermetten E, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-013-0434-8; Weine SM, 1998, AM J PSYCHIAT, V155, P1720, DOI 10.1176/ajp.155.12.1720; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yoder M, 2012, PSYCHOL SERV, V9, P16, DOI 10.1037/a0026279; Yoder MS, 2013, INT J PSYCHIAT MED, V45, P111, DOI 10.2190/PM.45.2.b; Zang YY, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-41; Zoellner LA, 1999, BEHAV THER, V30, P581, DOI 10.1016/S0005-7894(99)80026-4	107	39	41	5	88	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	AUG	2014	34	6					453	467		10.1016/j.cpr.2014.06.005			15	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	AP7PL	WOS:000342269100001	25047447				2022-02-06	
J	Geng, YJ; Zhang, XF; Zhang, YT; Li, GL				Geng, Yanjuan; Zhang, Xiufeng; Zhang, Yuan-Ting; Li, Guanglin			A novel channel selection method for multiple motion classification using high-density electromyography	BIOMEDICAL ENGINEERING ONLINE			English	Article						Myoelectric control; Channel selection method; Multi-class common spatial pattern; High-density EMG; Pattern recognition	TARGETED MUSCLE REINNERVATION; NEURAL-MACHINE INTERFACE; PATTERN-RECOGNITION; MYOELECTRIC CONTROL; ELECTRODE CONFIGURATION; SURFACE ELECTROMYOGRAM; SIGNAL CLASSIFICATION; PROSTHESIS CONTROL; IDENTIFICATION; INFORMATION	Background: Selecting an appropriate number of surface electromyography (EMG) channels with desired classification performance and determining the optimal placement of EMG electrodes would be necessary and important in practical myoelectric control. In previous studies, several methods such as sequential forward selection (SFS) and Fisher-Markov selector (FMS) have been used to select the appropriate number of EMG channels for a control system. These exiting methods are dependent on either EMG features and/or classification algorithms, which means that when using different channel features or classification algorithm, the selected channels would be changed. In this study, a new method named multi-class common spatial pattern (MCCSP) was proposed for EMG selection in EMG pattern-recognition-based movement classification. Since MCCSP is independent on specific EMG features and classification algorithms, it would be more convenient for channel selection in developing an EMG control system than the exiting methods. Methods: The performance of the proposed MCCSP method in selecting some optimal EMG channels (designated as a subset) was assessed with high-density EMG recordings from twelve mildly-impaired traumatic brain injury (TBI) patients. With the MCCSP method, a subset of EMG channels was selected and then used for motion classification with pattern recognition technique. In order to justify the performance of the MCCSP method against different electrode configurations, features and classification algorithms, two electrode configurations (unipolar and bipolar) as well as two EMG feature sets and two types of pattern recognition classifiers were considered in the study, respectively. And the performance of the proposed MCCSP method was compared with that of two exiting channel selection methods (SFS and FMS) in EMG control system. Results: The results showed that in comparison with the previously used SFS and FMS methods, the newly proposed MCCSP method had better motion classification performance. Moreover, a fixed combination of the selected EMG channels was obtained when using MCCSP. Conclusions: The proposed MCCSP method would be a practicable means in channel selection and would facilitate the design of practical myoelectric control systems in the active rehabilitation of mildly-impaired TBI patients and in other rehabilitation applications such as the multifunctional myoelectric prostheses for limb amputees.	[Geng, Yanjuan; Li, Guanglin] Chinese Acad Sci, Shenzhen Inst Adv Technol, Key Lab Human Machine Intelligence Synerg Syst, Shenzhen, Peoples R China; [Geng, Yanjuan; Zhang, Yuan-Ting; Li, Guanglin] Chinese Acad Sci, SIAT, Key Lab Hlth Informat, Shenzhen, Peoples R China; [Zhang, Xiufeng] Natl Res Ctr Rehabil Tech Aids, Beijing, Peoples R China; [Zhang, Yuan-Ting] Chinese Univ Hong Kong, Dept Biomed Engn, Hong Kong, Hong Kong, Peoples R China; [Geng, Yanjuan; Zhang, Yuan-Ting; Li, Guanglin] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Hlth Engn, Univ Town Shenzhen, Shenzhen, Peoples R China		Li, GL (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Key Lab Human Machine Intelligence Synerg Syst, Shenzhen, Peoples R China.	gl.li@siat.ac.cn		ZHANG, Yuanting/0000-0003-4150-5470	National Key Basic Research Program of ChinaNational Basic Research Program of China [2013CB329505]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61135004, 51275101]; Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies; External Cooperation Program of the Chinese Academy of SciencesChinese Academy of Sciences [GJHZ1212]	This work was jointly supported by the National Key Basic Research Program of China (#2013CB329505), the National Natural Science Foundation of China under Grants (#61135004, #51275101), Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies, and External Cooperation Program of the Chinese Academy of Sciences (GJHZ1212). The authors would like to thank members at Center for Neural Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences for their assistance in experiment, data preprocessing and language editing. And also we would like to thank the cooperators at Guangdong Provincial Industrial Injury Rehabilitation Center for their assistance in the recruitment of subjects.	Cheng QA, 2011, IEEE T PATTERN ANAL, V33, P1217, DOI 10.1109/TPAMI.2010.195; Daley H, 2012, J ELECTROMYOGR KINES, V22, P478, DOI 10.1016/j.jelekin.2011.12.012; Dideriksen JL, 2010, PHILOS T R SOC A, V368, P2765, DOI 10.1098/rsta.2010.0094; Dipietro L, 2005, IEEE T NEUR SYS REH, V13, P325, DOI 10.1109/TNSRE.2005.850423; Doheny EP, 2010, MED ENG PHYS, V32, P468, DOI 10.1016/j.medengphy.2010.03.004; DORCAS D. S., 1966, MED BIOL ENG, V4, P367, DOI 10.1007/BF02476154; Engelhart K, 1999, MED ENG PHYS, V21, P431, DOI 10.1016/S1350-4533(99)00066-1; Farrell TR, 2008, IEEE T BIO-MED ENG, V55, P2198, DOI 10.1109/TBME.2008.923917; Geng YJ, 2012, IEEE ENG MED BIO, P2772, DOI 10.1109/EMBC.2012.6346539; Geng YJ, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-74; Geng YJ, 2013, 35 ANN INT C IEEE EM, P5918; GRAUPE D, 1975, IEEE T SYST MAN CYB, VSMC5, P252, DOI 10.1109/TSMC.1975.5408479; Hahne JM, 2012, IEEE T BIO-MED ENG, V59, P1436, DOI 10.1109/TBME.2012.2188799; Hu XL, 2009, NEUROREHAB NEURAL RE, V23, P837, DOI 10.1177/1545968309338191; Huang H, 2008, IEEE T NEUR SYS REH, V16, P37, DOI 10.1109/TNSRE.2007.910282; HUDGINS B, 1993, IEEE T BIO-MED ENG, V40, P82, DOI 10.1109/10.204774; Kawamoto H, 2003, IEEE SYS MAN CYBERN, P1648; Kendell C, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-24; Kuiken TA, 2009, JAMA-J AM MED ASSOC, V301, P619, DOI 10.1001/jama.2009.116; Kvas Gernot, 2008, 2008 6th IEEE International Conference on Industrial Informatics (INDIN), P1437, DOI 10.1109/INDIN.2008.4618330; Li GL, 2010, IEEE T NEUR SYS REH, V18, P185, DOI 10.1109/TNSRE.2009.2039619; Liu J, 2013, IEEE T NEUR SYS REH, V21, P96, DOI 10.1109/TNSRE.2012.2218832; Lock B., 2005, P 2005 MYOEL CONTR P; Nagata K, 2007, ANN INT C IEEE ENG M, P5214; Nazarpour K, 2007, IEEE T BIO-MED ENG, V54, P1762, DOI 10.1109/TBME.2007.894829; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Ramoser H, 2000, IEEE T REHABIL ENG, V8, P441, DOI 10.1109/86.895946; Rojas-Martinez M, 2013, J ELECTROMYOGR KINES, V23, P33, DOI 10.1016/j.jelekin.2012.06.009; Shibanoki T, 2013, IEEE T BIO-MED ENG, V60, P853, DOI 10.1109/TBME.2012.2205990; Tkach D, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-21; Wang YJ, 2005, P ANN INT IEEE EMBS, P5392; Wolbrecht ET, 2008, IEEE T NEUR SYS REH, V16, P286, DOI 10.1109/TNSRE.2008.918389; Young AJ, 2012, IEEE T BIO-MED ENG, V59, P645, DOI 10.1109/TBME.2011.2177662; Zhang X, 2012, IEEE T BIO-MED ENG, V59, P1649, DOI 10.1109/TBME.2012.2191551; Zhou P, 2007, J NEUROPHYSIOL, V98, P2974, DOI 10.1152/jn.00178.2007	35	39	42	1	30	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-925X			BIOMED ENG ONLINE	Biomed. Eng. Online	JUL 25	2014	13								102	10.1186/1475-925X-13-102			16	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	AM6KA	WOS:000339972300001	25060509	gold, Green Published			2022-02-06	
J	Ojo, JO; Greenberg, MB; Leary, P; Mouzon, B; Bachmeier, C; Mullan, M; Diamond, DM; Crawford, F				Ojo, Joseph O.; Greenberg, M. Banks; Leary, Paige; Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Diamond, David M.; Crawford, Fiona			Neurobehavioral, neuropathological and biochemical profiles in a novel mouse model of co-morbid post-traumatic stress disorder and mild traumatic brain injury	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						post-traumatic stress disorder; mild traumatic brain injury; mouse models; anxiety and social behavior; cognitive function; plasma and brain biomarkers	URINARY CORTISOL EXCRETION; PLASMA-CORTISOL; DEXAMETHASONE-SUPPRESSION; CEREBROSPINAL-FLUID; EMOTIONAL MEMORIES; ANIMAL-MODEL; DYSFUNCTION; DEPRESSION; INCREASE; DEFICITS	Co-morbid mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) has become the signature disorder for returning combat veterans. The clinical heterogeneity and overlapping symptomatology of mTBI and PTSD underscore the need to develop a preclinical model that will enable the characterization of unique and overlapping features and allow discrimination between both disorders. This study details the development and implementation of a novel experimental paradigm for PTSD and combined PTSD-mTBI. The PTSD paradigm involved exposure to a danger-related predator odor under repeated restraint over a 21 day period and a physical trauma (inescapable footshock). We administered this paradigm alone, or in combination with a previously established mTBI model. We report outcomes of behavioral, pathological and biochemical profiles at an acute timepoint. PTSD animals demonstrated recall of traumatic memories, anxiety and an impaired social behavior. In both mTBI and combination groups there was a pattern of disinhibitory like behavior. mTBI abrogated both contextual fear and impairments in social behavior seen in PTSD animals. No major impairment in spatial memory was observed in any group. Examination of neuroendocrine and neuroimmune responses in plasma revealed a trend toward increase in corticosterone in PTSD and combination groups, and an apparent increase in Th1 and Th17 proinflammatory cytokine(s) in the PTSD only and mTBI only groups respectively. In the brain there were no gross neuropathological changes in any groups. We observed that mTBI on a background of repeated trauma exposure resulted in an augmentation of axonal injury and inflammatory markers, neurofilament L and ICAM-1 respectively. Our observations thus far suggest that this novel stress-trauma-related paradigm may be a useful model for investigating further the overlapping and distinct spatio-temporal and behavioral/biochemical relationship between mTBI and PTSD experienced by combat veterans.	[Ojo, Joseph O.; Greenberg, M. Banks; Leary, Paige; Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA; [Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Diamond, David M.; Crawford, Fiona] James A Haley Vet Hosp, Res & Dev Serv, Tampa, FL 33612 USA; [Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] Open Univ, Dept Life Sci, Milton Keynes MK7 6AA, Bucks, England; [Diamond, David M.] Univ S Florida, Dept Psychol, Dept Mol Pharmacol & Physiol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA		Ojo, JO (corresponding author), Roskamp Inst, 2040 Whitfield Avenue, Sarasota, FL 34243 USA.	bojo@roskampinstitute.net			Roskamp Foundation	We would like to thank Ariel Gonzalez for his help in performing some of the biochemical experiments involved in this study. This study was supported by the Roskamp Foundation.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Baker DG, 2001, NEUROIMMUNOMODULAT, V9, P209, DOI 10.1159/000049028; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bluthe RM, 1999, PSYCHONEUROENDOCRINO, V24, P301, DOI 10.1016/S0306-4530(98)00077-8; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bremner JD, 2003, PSYCHONEUROENDOCRINO, V28, P733, DOI 10.1016/S0306-4530(02)00067-7; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cain DP, 1997, BEHAV BRAIN RES, V84, P179, DOI 10.1016/S0166-4328(96)00149-0; Cain DP, 1997, CURR OPIN NEUROBIOL, V7, P235, DOI 10.1016/S0959-4388(97)80012-8; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Daskalakis NP, 2013, PSYCHONEUROENDOCRINO, V38, P1895, DOI 10.1016/j.psyneuen.2013.06.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Diamond David M., 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/60803; Diamond DM, 1999, HIPPOCAMPUS, V9, P542, DOI 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.0.CO;2-N; Diamond DM, 2005, HIPPOCAMPUS, V15, P1006, DOI 10.1002/hipo.20107; Diamond DM, 2004, HIPPOCAMPUS, V14, P281, DOI 10.1002/hipo.10186; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dranovsky A, 2006, BIOL PSYCHIAT, V59, P1136, DOI 10.1016/j.biopsych.2006.03.082; Duval F, 2004, ANN NY ACAD SCI, V1032, P273, DOI 10.1196/annals.1314.036; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Goenjian AK, 1996, AM J PSYCHIAT, V153, P929; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; GRONWALL D, 1974, LANCET, V2, P605; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Joels M, 2006, TRENDS COGN SCI, V10, P152, DOI 10.1016/j.tics.2006.02.002; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KANT GJ, 1987, PHYSIOL BEHAV, V40, P775, DOI 10.1016/0031-9384(87)90282-4; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Maes M, 1998, ACTA PSYCHIAT SCAND, V98, P328, DOI 10.1111/j.1600-0447.1998.tb10092.x; MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; MCFALL ME, 1992, BIOL PSYCHIAT, V31, P1050, DOI 10.1016/0006-3223(92)90097-J; Mesquita AR, 2008, J PSYCHIATR RES, V43, P89, DOI 10.1016/j.jpsychires.2008.02.004; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ojo B, 2011, EXP NEUROL, V232, P318, DOI 10.1016/j.expneurol.2011.09.025; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Park CR, 2008, LEARN MEMORY, V15, P271, DOI 10.1101/lm.721108; PITMAN RK, 1990, BIOL PSYCHIAT, V27, P245, DOI 10.1016/0006-3223(90)90654-K; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAND CW, 1946, ARCH NEURO PSYCHIATR, V55, P79, DOI 10.1001/archneurpsyc.1946.02300130003001; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rohleder N, 2004, BIOL PSYCHIAT, V55, P745, DOI 10.1016/j.biopsych.2003.11.018; Sandi Carmen, 2007, Neural Plasticity, V2007, DOI 10.1055/2007/78970; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seedat S, 2003, PSYCHONEUROENDOCRINO, V28, P796, DOI 10.1016/S0306-4530(02)00086-0; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Spivak B, 1997, BIOL PSYCHIAT, V42, P345, DOI 10.1016/S0006-3223(96)00375-7; Stein MB, 1997, BIOL PSYCHIAT, V42, P680, DOI 10.1016/S0006-3223(96)00489-1; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; VANDERKOLK BA, 1995, J TRAUMA STRESS, V8, P505, DOI 10.1002/jts.2490080402; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; YEHUDA R, 1995, AM J PSYCHIAT, V152, P982; YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583; Young EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/archpsyc.61.4.394; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zoladz PR, 2012, PSYCHONEUROENDOCRINO, V37, P1531, DOI 10.1016/j.psyneuen.2012.02.007; Zoladz PR, 2008, STRESS, V11, P259, DOI 10.1080/10253890701768613; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI 10.1016/j.neubiorev.2013.03.024	81	39	39	1	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	JUN 23	2014	8								213	10.3389/fnbeh.2014.00213			23	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	AK1RS	WOS:000338194100001	25002839	gold, Green Published			2022-02-06	
J	Ganesh, T; Jiang, JX; Yang, MS; Dingledine, R				Ganesh, Thota; Jiang, Jianxiong; Yang, Myung-Soon; Dingledine, Ray			Lead Optimization Studies of Cinnamic Amide EP2 Antagonists	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							PROSTAGLANDIN RECEPTOR EP2; AMYOTROPHIC-LATERAL-SCLEROSIS; COLLAGEN-INDUCED ARTHRITIS; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PROSTANOID RECEPTORS; INFLAMMATORY PROCESSES; MICROGLIAL ACTIVATION; STATUS EPILEPTICUS; OXIDATIVE DAMAGE	Prostanoid receptor EP2 can play a proinflammatory role, exacerbating disease pathology in a variety of central nervous system and peripheral diseases. A highly selective EP2 antagonist could be useful as a drug to mitigate the inflammatory consequences of EP2 activation. We recently identified a cinnamic amide class of EP2 antagonists. The lead compound in this class (5d) displays anti-inflammatory and neuroprotective actions. However, this compound exhibited moderate selectivity to EP2 over the DP1 prostanoid receptor (similar to 10-fold) and low aqueous solubility. We now report compounds that display up to 180-fold selectivity against DP1 and up to 9-fold higher aqueous solubility than our previous lead. The newly developed compounds also display higher selectivity against EP4 and IP receptors and a comparable plasma pharmacokinetics. Thus, these compounds are useful for proof of concept studies in a variety of models where EP2 activation is playing a deleterious role.	[Ganesh, Thota; Jiang, Jianxiong; Yang, Myung-Soon; Dingledine, Ray] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA		Ganesh, T (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	tganesh@emory.edu	Jiang, Jianxiong/A-1987-2010	Jiang, Jianxiong/0000-0003-3955-8928; Dingledine, Ray/0000-0001-7128-4520	Alzheimer's Drug Discovery Foundation; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99/R00NS082379, U01NS058158]; NARSADNARSAD; Epilepsy Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99NS082379, U01NS058158] Funding Source: NIH RePORTER	This work was supported by Alzheimer's Drug Discovery Foundation (T.G.), NIH/NINDS Grants K99/R00NS082379 (to J.J.) and U01NS058158 (to R.D.), NARSAD Young Investigator Grant (to J.J.), and the Epilepsy Foundation (to J.J.).	Abraham NS, 2007, ALIMENT PHARM THER, V25, P913, DOI 10.1111/j.1365-2036.2007.03292.x; af Forselles KJ, 2011, BRIT J PHARMACOL, V164, P1847, DOI 10.1111/j.1476-5381.2011.01495.x; Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Akula KK, 2008, EPILEPSY RES, V78, P60, DOI 10.1016/j.eplepsyres.2007.10.008; Alavijeh Mohammad S, 2005, NeuroRx, V2, P554, DOI 10.1602/neurorx.2.4.554; Banu SK, 2009, MOL ENDOCRINOL, V23, P1291, DOI 10.1210/me.2009-0017; Baxter E. W., 2002, ORG REACT, P1, DOI DOI 10.1002/0471264180.0R059.01; Bevan CD, 2000, ANAL CHEM, V72, P1781, DOI 10.1021/ac9912247; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Breitner JC, 2011, ALZHEIMERS DEMENT, V7, P402, DOI 10.1016/j.jalz.2010.12.014; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495-200059040-00017; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dhir A, 2005, CLIN EXP PHARMACOL P, V32, P579, DOI 10.1111/j.1440-1681.2005.04233.x; Donnini S, 2007, FASEB J, V21, P2418, DOI 10.1096/fj.06-7581com; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028; Ganesh T, 2014, J MED CHEM, V57, P4454, DOI 10.1021/jm401431x; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Grosser T, 2010, ANNU REV MED, V61, P17, DOI 10.1146/annurev-med-011209-153129; Hagmann WK, 2008, J MED CHEM, V51, P4359, DOI 10.1021/jm800219f; Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017; Hirata T, 2011, CHEM REV, V111, P6209, DOI 10.1021/cr200010h; Ho L, 1999, J NEUROSCI RES, V57, P295; Holtman L, 2009, EPILEPSY RES, V84, P56, DOI 10.1016/j.eplepsyres.2008.12.006; Holtman L, 2010, EPILEPSY RES, V91, P49, DOI 10.1016/j.eplepsyres.2010.06.011; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Jiang JX, 2013, TRENDS PHARMACOL SCI, V34, P413, DOI 10.1016/j.tips.2013.05.003; Jiang JX, 2013, P NATL ACAD SCI USA, V110, P3591, DOI 10.1073/pnas.1218498110; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jiang JX, 2012, P NATL ACAD SCI USA, V109, P3149, DOI 10.1073/pnas.1120195109; Jiang JX, 2010, P NATL ACAD SCI USA, V107, P2307, DOI 10.1073/pnas.0909310107; Jin JJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-2; Jung KH, 2006, NEUROBIOL DIS, V23, P237, DOI 10.1016/j.nbd.2006.02.016; Liang XB, 2005, J NEUROSCI, V25, P10180, DOI 10.1523/JNEUROSCI.3591-05.2005; Liang XB, 2008, ANN NEUROL, V64, P304, DOI 10.1002/ana.21437; Loscher Wolfgang, 2005, NeuroRx, V2, P86, DOI 10.1602/neurorx.2.1.86; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Pardridge William M, 2005, NeuroRx, V2, P3; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Polascheck N, 2010, EXP NEUROL, V224, P219, DOI 10.1016/j.expneurol.2010.03.014; Przedborski S, 2010, MOVEMENT DISORD, V25, pS55, DOI 10.1002/mds.22638; Quan Y, 2013, J BIOL CHEM, V288, P9293, DOI 10.1074/jbc.M113.455816; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Roy S, 2006, TETRAHEDRON, V62, P7838, DOI 10.1016/j.tet.2006.05.049; Sheibanie AF, 2007, ARTHRITIS RHEUM-US, V56, P2608, DOI 10.1002/art.22794; Shie FS, 2005, AM J PATHOL, V166, P1163, DOI 10.1016/S0002-9440(10)62336-X; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sung YM, 2006, ONCOGENE, V25, P5507, DOI 10.1038/sj.onc.1209538; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178	61	39	39	0	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	MAY 22	2014	57	10					4173	4184		10.1021/jm5000672			12	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	AI0BB	WOS:000336510100019	24773616	Green Published, hybrid			2022-02-06	
J	Bondi, CO; Cheng, JP; Tennant, HM; Monaco, CM; Kline, AE				Bondi, Corina O.; Cheng, Jeffrey P.; Tennant, Heather M.; Monaco, Christina M.; Kline, Anthony E.			Old Dog, New Tricks: The Attentional Set-Shifting Test as a Novel Cognitive Behavioral Task after Controlled Cortical Impact Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; attentional set-shifting; executive function; traumatic brain injury; behavior	TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; MEDIAL PREFRONTAL CORTEX; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ENVIRONMENTAL ENRICHMENT; TEST-PERFORMANCE; EXECUTIVE FUNCTION; NEUROBEHAVIORAL BENEFIT; CHOLINERGIC MARKERS; FLUID PERCUSSION	Cognitive impairment associated with prefrontal cortical dysfunction is a major component of disability in traumatic brain injury (TBI) survivors. Specifically, deficits of cognitive flexibility and attentional set-shifting are present across all levels of injury severity. Though alterations in spatial learning have been extensively described in experimental models of TBI, studies investigating more complex cognitive deficits are relatively scarce. Hence, the aim of this preclinical study was to expand on this important issue by evaluating the effect of three injury levels on executive function and behavioral flexibility performance as assessed using an attentional set-shifting test (AST). Isoflurane-anesthetized male rats received a controlled cortical impact (CCI) injury (2.6, 2.8, and 3.0 mm cortical depth at 4 m/sec) or sham injury, whereas an additional group had no surgical manipulation (naive). Four weeks postsurgery, rats were tested on the AST, which involved a series of discriminative tasks of increasing difficulty, such as simple and compound discriminations, stimulus reversals, and intra- and extradimensional (ED) shifts. TBI produced accompanying impact depth-dependent increases in cortical lesion volumes, with the 3.0-mm cortical depth group displaying significantly larger injury volumes than the 2.6-mm group (p=0.05). Further, injury severity-induced deficits in ED set-shifting and stimulus reversals, as well as increases in total response error rates and total set loss errors, were observed. These novel findings demonstrate executive function and behavioral flexibility deficits in our animal model of CCI injury and provide the impetus to integrate the AST in the standard neurotrauma behavioral battery to further evaluate cognitive dysfunction after TBI. Ongoing experiments in our laboratory are assessing AST performance after pharmacological and rehabilitative therapies post-TBI, as well as elucidating possible mechanisms underlying the observed neuropsychological deficits.	[Bondi, Corina O.; Cheng, Jeffrey P.; Tennant, Heather M.; Monaco, Christina M.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Cheng, Jeffrey P.; Tennant, Heather M.; Monaco, Christina M.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, 3471 Fifth Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Bondi, Corina/0000-0002-5733-4912; Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD069620, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grants HD069620 and NS060005 (to A.E.K.).	Andreollo NA, 2012, ABCD-ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102-67202012000100011; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Bakker K, 2014, J NEUROTRAUM, V31, P308, DOI 10.1089/neu.2013.3045; Benge JF, 2007, BRAIN INJURY, V21, P395, DOI 10.1080/02699050701311091; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Birrell JM, 2000, J NEUROSCI, V20, P4320; Bondi CO, 2008, NEUROPSYCHOPHARMACOL, V33, P320, DOI 10.1038/sj.npp.1301410; Bondi CO, 2010, PROG NEURO-PSYCHOPH, V34, P913, DOI 10.1016/j.pnpbp.2010.04.016; Broberg BV, 2009, PSYCHOPHARMACOLOGY, V206, P631, DOI 10.1007/s00213-009-1540-5; Brooks JM, 2012, NEUROPSYCHOPHARMACOL, V37, P2476, DOI 10.1038/npp.2012.106; Cabeza R, 2004, COGNITIVE NEUROSCIEN; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Cao AH, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-10; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Chiarello C, 1996, BRAIN COGNITION, V30, P81, DOI 10.1006/brcg.1996.0006; Chudasama Y, 2006, BIOL PSYCHOL, V73, P19, DOI 10.1016/j.biopsycho.2006.01.005; Clarke HF, 2007, CEREB CORTEX, V17, P18, DOI 10.1093/cercor/bhj120; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crofts HS, 2001, CEREB CORTEX, V11, P1015, DOI 10.1093/cercor/11.11.1015; Dias R, 1996, BEHAV NEUROSCI, V110, P872, DOI 10.1037/0735-7044.110.5.872; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Finkelstein E., 2006, INCIDENCE EC BURDEN; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Godsil BP, 2013, EUR NEUROPSYCHOPHARM, V23, P1165, DOI 10.1016/j.euroneuro.2012.10.018; Goetghebeur PJD, 2010, PSYCHOPHARMACOLOGY, V212, P635, DOI 10.1007/s00213-010-1990-9; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hang Rong-Hua, 2011, Fa Yi Xue Za Zhi, V27, P346; Hashimoto K, 2008, EUR NEUROL, V59, P24, DOI 10.1159/000109257; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Ikeda K, 1995, TOHOKU J EXP MED, V177, P343, DOI 10.1620/tjem.177.343; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kobayashi M, 2009, CHEM SENSES, V34, P573, DOI 10.1093/chemse/bjp038; Kos T, 2011, PSYCHOPHARMACOLOGY, V214, P911, DOI 10.1007/s00213-010-2102-6; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Lapiz MDS, 2006, NEUROSCIENCE, V137, P1039, DOI 10.1016/j.neuroscience.2005.09.031; Li HB, 1999, BRAIN RES BULL, V48, P113, DOI 10.1016/S0361-9230(98)00157-9; Liston C, 2006, J NEUROSCI, V26, P7870, DOI 10.1523/JNEUROSCI.1184-06.2006; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Lopez-Mascaraque L, 2002, CELL DEATH DIFFER, V9, P1279, DOI 10.1038/sj.cdd.4401076; Lu XCM, 1998, NEUROSCIENCE, V84, P849, DOI 10.1016/S0306-4522(97)00520-4; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Marek GJ, 1999, EUR J PHARMACOL, V367, P197, DOI 10.1016/S0014-2999(98)00945-5; Martens KM, 2012, J NEUROTRAUM, V29, P2505, DOI 10.1089/neu.2012.2388; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McAlonan K, 2003, BEHAV BRAIN RES, V146, P97, DOI 10.1016/j.bbr.2003.09.019; McGaughy J, 2008, NEUROSCIENCE, V153, P63, DOI 10.1016/j.neuroscience.2008.01.064; Merriam EP, 1999, AM J PSYCHIAT, V156, P780; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Rajan R, 2006, SCIENCE, V311, P666, DOI 10.1126/science.1122096; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Sebastian V, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00038; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Tait DS, 2007, EUR J NEUROSCI, V25, P3719, DOI 10.1111/j.1460-9568.2007.05612.x; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tollefson GD, 1996, J CLIN PSYCHIAT, V57, P31; Tong J, 2013, J NEUROTRAUM, V30, P247, DOI 10.1089/neu.2012.2493; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Tunbridge EM, 2004, J NEUROSCI, V24, P5331, DOI 10.1523/JNEUROSCI.1124-04.2004; Vertes RP, 2004, SYNAPSE, V51, P32, DOI 10.1002/syn.10279; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033; Young JW, 2010, COGN AFFECT BEHAV NE, V10, P243, DOI 10.3758/CABN.10.2.243; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	93	39	39	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					926	937		10.1089/neu.2013.3295			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200005	24397572	Green Published			2022-02-06	
J	Calabrese, E; Du, F; Garman, RH; Johnson, GA; Riccio, C; Tong, LC; Long, JB				Calabrese, Evan; Du, Fu; Garman, Robert H.; Johnson, G. Allan; Riccio, Cory; Tong, Lawrence C.; Long, Joseph B.			Diffusion Tensor Imaging Reveals White Matter Injury in a Rat Model of Repetitive Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						voxelwise analysis; MRI; diffusion tensor imaging; blast neurotrauma; traumatic brain injury	MAGNETIC-RESONANCE HISTOLOGY; CLOSED-HEAD INJURY; AXONAL INJURY; MOUSE MODEL; INTRACRANIAL-PRESSURE; BATTLEFIELD INJURY; OPTIC-NERVE; MRI DATA; EXPOSURE; IRAQ	Blast-induced traumatic brain injury (bTBI) is one of the most common combat-related injuries seen in U.S. military personnel, yet relatively little is known about the underlying mechanisms of injury. In particular, the effects of the primary blast pressure wave are poorly understood. Animal models have proven invaluable for the study of primary bTBI, because it rarely occurs in isolation in human subjects. Even less is known about the effects of repeated primary blast wave exposure, but existing data suggest cumulative increases in brain damage with a second blast. MRI and, in particular, diffusion tensor imaging (DTI), have become important tools for assessing bTBI in both clinical and preclinical settings. Computational statistical methods such as voxelwise analysis have shown promise in localizing and quantifying bTBI throughout the brain. In this study, we use voxelwise analysis of DTI to quantify white matter injury in a rat model of repetitive primary blast exposure. Our results show a significant increase in microstructural damage with a second blast exposure, suggesting that primary bTBI may sensitize the brain to subsequent injury.	[Calabrese, Evan; Johnson, G. Allan] Duke Univ, Med Ctr, Dept Radiol, Ctr In Vivo Microscopy, Durham, NC 27710 USA; [Du, Fu] FD NeuroTechnol Inc, Ellicott City, MD USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Riccio, Cory; Tong, Lawrence C.; Long, Joseph B.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA		Long, JB (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Robert Grant Ave,Bldg 503, Silver Spring, MD 20910 USA.	joseph.long@us.army.mil			CDMRP Psychological Health and Traumatic Brain Injury Research Program [W81XWH-11-2-0127]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007171] Funding Source: NIH RePORTER	Blast exposure was performed at the Walter Reed Army Institute of Research under the support of the CDMRP Psychological Health and Traumatic Brain Injury Research Program (W81XWH-11-2-0127). Imaging work was performed at the Duke University Center for In Vivo Microscopy, an NIH/NIBIB Biomedical Technology Resource Center (P41 EB015897). We are grateful to Sally Gewalt and James Cook for assistance with the imaging pipelines. We thank Andrea Edwards, Joseph Andrist, and Donna Wilder for assistance with blast exposures, and Dr. Yi Qi, and Gary Cofer for assistance in specimen preparation and scanning.	Abe O, 2010, NEURORADIOLOGY, V52, P699, DOI 10.1007/s00234-010-0716-3; Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Anderson AW, 2001, MAGNET RESON MED, V46, P1174, DOI 10.1002/mrm.1315; Arsigny V, 2006, MAGN RESON MED, V56, P411, DOI 10.1002/mrm.20965; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Calabrese E, 2013, NEUROIMAGE, V79, P329, DOI 10.1016/j.neuroimage.2013.04.101; Cenci MA, 2002, NAT REV NEUROSCI, V3, P574, DOI 10.1038/nrn877; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodlett C, 2006, LECT NOTES COMPUT SC, V4191, P260; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnson GA, 2007, NEUROIMAGE, V37, P82, DOI 10.1016/j.neuroimage.2007.05.013; Johnson GA, 2012, NEUROIMAGE, V62, P1848, DOI 10.1016/j.neuroimage.2012.05.041; Johnson GA, 2011, TOXICOL PATHOL, V39, P85, DOI 10.1177/0192623310389622; Johnson GA, 2002, J MAGN RESON IMAGING, V16, P423, DOI 10.1002/jmri.10175; Johnson GA, 2002, RADIOLOGY, V222, P789, DOI 10.1148/radiol.2223010531; JOHNSON GA, 1993, MAGN RESON QUART, V9, P1; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lerch JP, 2012, FRONT NEUROINFORM, V6, DOI 10.3389/fninf.2012.00006; Liu CL, 2011, NEUROIMAGE, V56, P930, DOI 10.1016/j.neuroimage.2011.02.024; Long JB, 2010, IFMBE PROC, V32, P26, DOI 10.1007/978-3-642-14998-6_7; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAZURKIEWICZKWILECKI IM, 1980, PHARMACOL BIOCHEM BE, V12, P35, DOI 10.1016/0091-3057(80)90412-8; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Ni H, 2006, AM J NEURORADIOL, V27, P1776; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun SW, 2009, NEUROIMAGE, V44, P611, DOI 10.1016/j.neuroimage.2008.10.032; Sun SW, 2005, MAGN RESON MED, V53, P1447, DOI 10.1002/mrm.20488; Sylvia FR, 2001, MIL MED, V166, P918, DOI 10.1093/milmed/166.10.918; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; Yushkevich PA, 2008, NEUROIMAGE, V41, P448, DOI 10.1016/j.neuroimage.2008.01.013	69	39	39	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					938	950		10.1089/neu.2013.3144			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200006	24392843	Green Published			2022-02-06	
J	Chiaravalloti, ND; Ibarretxe-Bilbao, N; DeLuca, J; Rusu, O; Pena, J; Garcia-Gorostiaga, I; Ojeda, N				Chiaravalloti, Nancy D.; Ibarretxe-Bilbao, Naroa; DeLuca, John; Rusu, Olga; Pena, Javier; Garcia-Gorostiaga, Ines; Ojeda, Natalia			The Source of the Memory Impairment in Parkinson's Disease: Acquisition Versus Retrieval	MOVEMENT DISORDERS			English	Article						learning; memory; Parkinson's disease; cognition; Open Trial Selective Reminding Test	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; RECOGNITION MEMORY; PROCESSING-SPEED; WORKING-MEMORY; SUBCORTICAL DEMENTIA; TEST-PERFORMANCE; HIPPOCAMPAL	Memory deficits are common in persons with Parkinson's disease (PD) even without the presence of a frank dementia. These memory deficits have traditionally been attributed to inability of patients to retrieve information from long-term memory, referred to as the retrieval failure hypothesis. However, some studies additionally document problems in recognition memory, noted to be inconsistent with the retrieval failure hypothesis. Given the neuroanatomical abnormalities observed in the hippocampus of PD patients and the role of the hippocampus in learning new information, the current study was designed to specifically examine learning abilities in a nondemented PD sample through the application of a learning paradigm, the Open Trial Selective Reminding Test. We examined 27 patients with PD without dementia and 27 age-, gender-, and education-matched healthy controls (HCs) with a neuropsychological test battery designed to assess new learning and memory. Results indicated a significant difference between the groups in terms of their ability to learn a list of 10 semantically related words. However, once the groups were equated on learning abilities, no significant difference was noted between the PD and HC participants in recall or recognition of the newly learned material. The memory deficit observed in nondemented PD patients is thus largely the result of a deficit in learning new information. This finding should be used to guide treatment for memory deficits in persons with PD, and future research should seek to identify novel means of improving new learning in this population. (c) 2014 International Parkinson and Movement Disorder Society	[Chiaravalloti, Nancy D.; DeLuca, John] Kessler Fdn, W Orange, NJ USA; [Chiaravalloti, Nancy D.; DeLuca, John] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Ibarretxe-Bilbao, Naroa; Rusu, Olga; Pena, Javier; Ojeda, Natalia] Univ Deusto, Fac Psychol & Educ, Dept Methods & Expt Psychol, Neuropsychol Psychiat & Neurol Disorders Res Team, Bilbao, Spain; [DeLuca, John] Rutgers New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA; [Garcia-Gorostiaga, Ines] Galdakao Hosp, Dept Neurol, Galdakao, Spain		Ibarretxe-Bilbao, N (corresponding author), Univ Deusto, Fac Psychol & Educ, Univ 24, E-48007 Bilbao, Spain.	naroa.ibarretxe@deusto.es	Ibarretxe-Bilbao, Naroa/C-5575-2011; OJEDA, NATALIA/U-8897-2019	Ibarretxe-Bilbao, Naroa/0000-0002-2434-5252; OJEDA, NATALIA/0000-0002-0952-0649; Pena, Javier/0000-0002-0041-7020; Chiaravalloti, Nancy/0000-0003-2943-7567	Health Department of Basque GovernmentBasque Government [2011111117]; Spanish Ministry of Economy and CompetitivenessSpanish Government [PSI2012-32441]	This study was supported by the Health Department of Basque Government (2011111117; to N.I.B) and the Spanish Ministry of Economy and Competitiveness (PSI2012-32441; to N.I.B.).	Aarsland D, 2009, NEUROLOGY, V72, P1121, DOI 10.1212/01.wnl.0000338632.00552.cb; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; BEGG I, 1988, MEM COGNITION, V16, P232, DOI 10.3758/BF03197756; BELLEZZA FS, 1989, J EXP PSYCHOL LEARN, V15, P990, DOI 10.1037/0278-7393.15.5.990; Bouchard TP, 2008, NEUROBIOL AGING, V29, P1027, DOI 10.1016/j.neurobiolaging.2007.02.002; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Bronnick K, 2011, NEUROPSYCHOLOGY, V25, P114, DOI 10.1037/a0020857; Bruck A, 2004, J NEUROL NEUROSUR PS, V75, P1467, DOI 10.1136/jnnp.2003.031237; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Camicioli R, 2003, MOVEMENT DISORD, V18, P784, DOI 10.1002/mds.10444; Chiaravalloti ND, 2013, NEUROLOGY, V81, P2066, DOI 10.1212/01.wnl.0000437295.97946.a8; Chiaravalloti ND, 2013, J CLIN EXP NEUROPSYC, V35, P180, DOI 10.1080/13803395.2012.760537; Chiaravalloti N, 2009, CLIN NEUROPSYCHOL, V23, P231, DOI 10.1080/13854040802121158; Chiaravalloti ND, 2003, CLIN REHABIL, V17, P58, DOI 10.1191/0269215503cr586oa; Chiaravalloti ND, 2002, ARCH PHYS MED REHAB, V83, P1070, DOI 10.1053/apmr.2002.33729; COOPER JA, 1991, BRAIN, V114, P2095, DOI 10.1093/brain/114.5.2095; CUMMINGS JL, 1984, ARCH NEUROL-CHICAGO, V41, P874, DOI 10.1001/archneur.1984.04050190080019; Daniel S E, 1993, J Neural Transm Suppl, V39, P165; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Dubois B, 1998, COGNITIVE BEHAV ASPE; Dubois B, 2007, MOVEMENT DISORD, V22, P2314, DOI 10.1002/mds.21844; Elgh E, 2009, EUR J NEUROL, V16, P1278, DOI 10.1111/j.1468-1331.2009.02707.x; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; FLOWERS KA, 1984, J NEUROL NEUROSUR PS, V47, P1174, DOI 10.1136/jnnp.47.11.1174; Foltynie T, 2004, BRAIN, V127, P550, DOI 10.1093/brain/awh067; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Genova HM, 2013, J CLIN EXP NEUROPSYC, V35, P631, DOI 10.1080/13803395.2013.806649; Gonzalez M, 1991, CREACION VALIDACION; Goverover Y, 2009, AM J OCCUP THER, V63, P543, DOI 10.5014/ajot.63.5.543; Goverover Y, 2009, J CLIN EXP NEUROPSYC, V31, P513, DOI 10.1080/13803390802287042; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Higginson CI, 2005, J CLIN EXP NEUROPSYC, V27, P516, DOI 10.1080/13803390490515469; Ibarretxe-Bilbao N, 2011, J NEUROL SCI, V310, P70, DOI 10.1016/j.jns.2011.07.054; Ibarretxe-Bilbao N, 2009, MOVEMENT DISORD, V24, pS748, DOI 10.1002/mds.22670; Jokinen P, 2009, PARKINSONISM RELAT D, V15, P88, DOI 10.1016/j.parkreldis.2008.03.005; Junque C, 2005, MOVEMENT DISORD, V20, P540, DOI 10.1002/mds.20371; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; Lengenfelder J, 2007, REHABIL PSYCHOL, V52, P290, DOI 10.1037/0090-5550.52.3.290; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Liozidou A, 2012, J GERIATR PSYCH NEUR, V25, P215, DOI 10.1177/0891988712466456; Mahurin RK, 1993, NEUROPSYCHOLOGY ALZH; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Ojeda N, 2012, SCHIZOPHR RES, V135, P72, DOI 10.1016/j.schres.2011.12.004; Owen AM, 2004, NEUROSCIENTIST, V10, P525, DOI 10.1177/1073858404266776; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sumowski JF, 2010, NEUROPSYCHOLOGY, V24, P267, DOI 10.1037/a0017533; Tam CWC, 2005, NEUROLOGY, V64, P861, DOI 10.1212/01.WNL.0000153070.82309.D4; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TROSTER AI, 1995, BEHAV NEUROL, V8, P59, DOI 10.3233/BEN-1995-8201; van Hooren SAH, 2007, AGING NEUROPSYCHOL C, V14, P40, DOI 10.1080/138255890969483; Wechsler D., 1997, WECHSLER MEMORY SCAL; Whittington CJ, 2000, NEUROPSYCHOLOGY, V14, P233, DOI 10.1037//0894-4105.14.2.233; Williams JM, 1991, COGNITIVE BEHAV RATI; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	62	39	39	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	MAY	2014	29	6					765	771		10.1002/mds.25842			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AG4BI	WOS:000335363300011	24615718	Bronze			2022-02-06	
J	Lamberty, GJ; Nakase-Richardson, R; Farrell-Carnahan, L; McGarity, S; Bidelspach, D; Harrison-Felix, C; Cifu, DX				Lamberty, Greg J.; Nakase-Richardson, Risa; Farrell-Carnahan, Leah; McGarity, Suzanne; Bidelspach, Douglas; Harrison-Felix, Cindy; Cifu, David X.			Development of a Traumatic Brain Injury Model System Within the Department of Veterans Affairs Polytrauma System of Care	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Veterans; traumatic brain injury; NIDRR; longitudinal databases; OEF/OIF; model systems; polytrauma; VA	CONSCIOUSNESS	Background: In 2008, the Department of Veterans Affairs Polytrauma Rehabilitation Centers partnered with the National Institute on Disability and Rehabilitation Research to establish a Model Systems program of research that would closely emulate the civilian Traumatic Brain Injury (TBI) Model Systems Centers Program established in 1987. Objective: To describe the development of a TBI Model Systems program within the Department of Veterans Affairs Polytrauma System of Care. Methods: Enrollment criteria and data collection/data quality efforts for the newly established Department of Veterans Affairs sites are reviewed. Results: Significant progress has been made in the establishment of a Model Systems program for the Polytrauma System of Care. Data collection has moved forward and program-specific modifications have been implemented. Conclusion: The Veterans Affairs TBI Model System program is established and growing, with many projects underway and a strong working relationship with the civilian TBI Model System programs.	[Lamberty, Greg J.] Minneapolis VA Hlth Care Syst, Phys Med & Rehabil Serv, Minneapolis, MN USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Neuropsychol Sect MHBS, Tampa, FL 33612 USA; [McGarity, Suzanne] James A Haley Vet Hosp, Polytrauma Psychol Serv, Tampa, FL 33612 USA; [Farrell-Carnahan, Leah; Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Bidelspach, Douglas] Lebanon VAMC, Rehabil & Prosthet Serv, Lebanon, PA USA; [Harrison-Felix, Cindy] Craig Hosp, Res Dept, Englewood, CO USA		Lamberty, GJ (corresponding author), Minneapolis VA Hlth Care Syst 4K TBI, Phys Med & Rehabil Serv, One Vet Dr, Minneapolis, MN 55417 USA.	gregory.lamberty@va.gov		Cifu, David/0000-0003-1600-9387	Department of Veterans AffairsUS Department of Veterans Affairs; Department of Education, National Institute on Disability and Rehabilitation Research	The Polytrauma Rehabilitation Center Traumatic Brain Injury Model System collaboration is funded through an Interagency Agreement between the Department of Veterans Affairs and the Department of Education, National Institute on Disability and Rehabilitation Research. The views expressed in this article are those of the authors and do not necessarily reflect the policy or position of the Department of Veterans Affairs, the Department of Education, the US government, or affiliated universities.	CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Defense and Veterans Brain Injury Center, 2012, DOD WORLDWIDE NUMBER; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; McCrea M.A., 2007, MILD TRAUMATIC BRAIN; McNamee S, 2012, J HEAD TRAUMA REHAB, V27, P244, DOI 10.1097/HTR.0b013e31825e12c8; Nakase-Richardson R, ARCH PHYS M IN PRESS; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	17	39	39	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					E1	E7		10.1097/HTR.0b013e31829a64d1			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100001	23835876				2022-02-06	
J	Rosenthal, G; Furmanov, A; Itshayek, E; Shoshan, Y; Singh, V				Rosenthal, Guy; Furmanov, Alex; Itshayek, Eyal; Shoshan, Yigal; Singh, Vineeta			Assessment of a noninvasive cerebral oxygenation monitor in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain oxygenation; non-invasive monitor; jugular bulb venous monitor; severe traumatic brain injury	CALCULATING CORRELATION-COEFFICIENTS; TISSUE OXYGEN; INSPIRED OXYGEN; SWINE MODEL; BLOOD-FLOW; HYPEROXIA; TENSION; AUTOREGULATION; RESUSCITATION; METABOLISM	Object. Development of a noninvasive monitor to assess cerebral oxygenation has long been a goal in neurocritical care. The authors evaluated the feasibility and utility of a noninvasive cerebral oxygenation monitor, the CerOx 3110, which uses near-infrared spectroscopy and ultrasound to measure regional cerebral tissue oxygenation in patients with severe traumatic brain injury (TBI), and compared measurements obtained using this device to those obtained using invasive cerebral monitoring. Methods. Patients with severe TBI admitted to the intensive care unit at Hadassah-Hebrew University Hospital requiring intracranial pressure (ICP) monitoring and advanced neuromonitoring were included in this study. The authors assessed 18 patients with severe TBI using the CerOx monitor and invasive advanced cerebral monitors. Results. The mean age of the patients was 45.3 +/- 23.7 years and the median Glasgow Coma Scale score on admission was 5 (interquartile range 3-7). Eight patients underwent unilateral decompressive hemicraniectomy and 1 patient underwent craniotomy. Sixteen patients underwent insertion of a jugular bulb venous catheter, and 18 patients underwent insertion of a Licox brain tissue oxygen monitor. The authors found a strong correlation (r = 0.60, p < 0.001) between the jugular bulb venous saturation from the venous blood gas and the CerOx measure of regional cerebral tissue saturation on the side ipsilateral to the catheter. A multivariate analysis revealed that among the physiological parameters of mean arterial blood pressure, ICP, brain tissue oxygen tension, and CerOx measurements on the ipsilateral and contralateral sides, only ipsilateral CerOx measurements were significantly correlated to jugular bulb venous saturation (p < 0.001). Conclusions. Measuring regional cerebral tissue oxygenation with the CerOx monitor in a noninvasive manner is feasible in patients with severe TBI in the neurointensive care unit. The correlation between the CerOx measurements and the jugular bulb venous measurements of oxygen saturation indicate that the CerOx may be able to provide an estimation of cerebral oxygenation status in a noninvasive manner.	[Rosenthal, Guy; Furmanov, Alex; Itshayek, Eyal; Shoshan, Yigal] Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel; [Singh, Vineeta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA		Rosenthal, G (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, POB 12000, IL-91120 Jerusalem, Israel.	rosenthalg@hadassah.org.il		singh, vineeta/0000-0003-3470-3532	Ornim Medical Ltd.	This work was supported by a grant from Ornim Medical Ltd. None of the authors has any financial interest in the company or the device.	BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BLAND JM, 1995, BRIT MED J, V310, P633, DOI 10.1136/bmj.310.6980.633; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; Friess SH, 2011, NEUROSURGERY, V69, P1139, DOI 10.1227/NEU.0b013e3182284aa1; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Longhi L, 2002, ACT NEUR S, V81, P315; Marion DW, 2006, NEUROSURGERY, V58, P655; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; RACHELI N, 2012, P SPIE, V8223; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Ron A, 2013, PROC SPIE, V8583, DOI 10.1117/12.2003528; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Stocchetti N, 1991, Minerva Anestesiol, V57, P319; Teranishi K, 2012, INJURY, V43, P585, DOI 10.1016/j.injury.2010.09.042	26	39	40	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					901	907		10.3171/2013.12.JNS131089			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800015	24484228				2022-02-06	
J	Trinka, E; Brigo, F				Trinka, Eugen; Brigo, Francesco			Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward	CURRENT OPINION IN NEUROLOGY			English	Article						antiseizure drugs; biomarker; drug trial; epileptogenesis; seizure prevention	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; TEMPORAL-LOBE EPILEPSY; LONG-TERM TREATMENT; VALPROIC ACID USE; POSTTRAUMATIC EPILEPSY; EPILEPTOGENESIS; ISSUES; PREVENTION; PROPHYLAXIS	Purpose of reviewPreclinical research in epileptology has been very successful in developing antiseizure drugs (ASDs). Several preclinical proof-of-concept studies have also provided evidence for positive treatment effects of some antiepileptogenic drugs to prevent the development of epilepsy. Disappointingly, all human antiepileptogenesis trials to prevent epilepsy after brain insults have failed, because of several reasons.Recent findingsNone of the currently available ASDs have been shown to prevent epilepsy after stroke, traumatic brain injury, or in brain tumours. Retrospective series and post-hoc analyses of randomized controlled trials of patients undergoing combined radiochemotherapy for malignant glioblastoma found an increased survival of patients with valproate, thus suggesting a possible role against the symptoms related to the comorbidity of epilepsy in these patients. Target-oriented treatments such as rapamycin and everolimus are currently under clinical investigation to prevent epilepsy in patients with tuberous sclerosis.SummaryAn orchestrated effort among basic and clinical scientists is needed to develop proper antiepileptogenic drugs, powerful biomarkers, and valid clinical trial designs to bring new treatments on the market that can successfully prevent epilepsy.	[Trinka, Eugen] Paracelsus Med Univ Salzburg, Christian Doppler Med Ctr, Dept Neurol, A-5020 Salzburg, Austria; [Trinka, Eugen] Ctr Cognit Neurosci, Salzburg, Austria; [Brigo, Francesco] Univ Verona, Dept Neurol & Movement Sci, Sect Clin Neurol, I-37100 Verona, Italy; [Brigo, Francesco] Franz Tappeiner Hosp, Dept Neurol, Merano, Italy		Trinka, E (corresponding author), Paracelsus Med Univ Salzburg, Christian Doppler Med Ctr, Dept Neurol, Ignaz Harrerstr 79, A-5020 Salzburg, Austria.	e.trinka@salk.at	; Brigo, Francesco/H-6513-2013	Trinka, Eugen/0000-0002-5950-2692; Brigo, Francesco/0000-0003-0928-1577	Commission on European Affairs; Joint Task Force of the ILAE and the AES	The support of the Commission on European Affairs and the Joint Task Force of the ILAE and the AES is kindly acknowledged by the authors.	Adelow C, 2009, EPILEPSIA, V50, P1094, DOI 10.1111/j.1528-1167.2008.01726.x; Barker CA, 2013, INT J RADIAT ONCOL, V86, P504, DOI 10.1016/j.ijrobp.2013.02.012; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bialer M, 2013, EPILEPSY RES, V103, P2, DOI 10.1016/j.eplepsyres.2012.10.001; Blumenfeld H, 2008, EPILEPSIA, V49, P400, DOI 10.1111/j.1528-1167.2007.01458.x; Brooks-Kayal AR, 2013, EPILEPSIA, V54, P44, DOI 10.1111/epi.12298; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; DELATTRE JY, 1988, NEUROLOGY, V38, P194, DOI 10.1212/WNL.38.2.194; Dezsi G, 2013, EPILEPSIA, V54, P635, DOI 10.1111/epi.12118; Dichter MA, 2009, ARCH NEUROL-CHICAGO, V66, P443, DOI 10.1001/archneurol.2009.10; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea; Forsyth PA, 2003, CAN J NEUROL SCI, V30, P106, DOI 10.1017/S0317167100053361; FRANCESCHETTI S, 1990, ACTA NEUROCHIR, V103, P47, DOI 10.1007/BF01420191; French JA, 2013, EPILEPSIA, V54, P3, DOI 10.1111/epi.12294; Galanopoulou AS, 2013, EPILEPSIA, V54, P13, DOI 10.1111/epi.12295; Galanopoulou AS, 2013, EPILEPSIA, V54, P1, DOI 10.1111/epi.12293; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Glantz MJ, 1996, NEUROLOGY, V46, P985, DOI 10.1212/WNL.46.4.985; Glauser TA, 2010, NEW ENGL J MED, V362, P790, DOI 10.1056/NEJMoa0902014; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Helmstaedter C, 2013, EUR J NEUROL; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; JENNETT WB, 1969, LANCET, V1, P1023; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kerkhof M, 2013, NEURO-ONCOLOGY, V15, P961, DOI 10.1093/neuonc/not057; Koyama R, 2012, NAT MED, V18, P1271, DOI 10.1038/nm.2850; Kwan J, 2010, COCHRANE DATABASE SY, V6; LEE ST, 1989, SURG NEUROL, V31, P361, DOI 10.1016/0090-3019(89)90067-0; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; Mani R, 2011, NEUROSCI LETT, V497, P251, DOI 10.1016/j.neulet.2011.03.010; Marigold R, 2013, COCHRANE DATABASE SY, V6; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Neligan A, 2013, EPILEPSIA, V54, pe62, DOI 10.1111/epi.12148; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; O'Brien TJ, 2013, EPILEPSIA, V54, P70, DOI 10.1111/epi.12300; Okuda S, 2012, J STROKE CEREBROVASC, V21, P583, DOI 10.1016/j.jstrokecerebrovasdis.2011.01.006; PECHADRE JC, 1991, PRESSE MED, V20, P841; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; Russo E, 2011, EPILEPSIA, V52, P1341, DOI 10.1111/j.1528-1167.2011.03112.x; Russo E, 2010, EPILEPSIA, V51, P1560, DOI 10.1111/j.1528-1167.2009.02400.x; Ryther RCC, 2012, CURR NEUROL NEUROSCI, V12, P410, DOI 10.1007/s11910-012-0276-5; Schierhout G, 2001, COCHRANE DATABASE SY, V4; Schmidt D, 2012, EPILEPTIC DISORD, V14, P105, DOI 10.1684/epd.2012.0512; Simonato M, 2013, CURR OPIN NEUROL, V26, P195, DOI 10.1097/WCO.0b013e32835efe29; Sloviter RS, 2013, NEUROPHARMACOLOGY, V69, P3, DOI 10.1016/j.neuropharm.2012.01.022; Sloviter RS, 2008, EPILEPSIA, V49, P85, DOI 10.1111/j.1528-1167.2008.01931.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tremont-Lukats IW, 2008, COCHRANE DATABASE SY, V2; Tsai HC, 2012, BRIT J NEUROSURG, V26, P347, DOI 10.3109/02688697.2011.638996; Van Gompel JJ, 2012, ARCH NEUROL-CHICAGO, V69, P1476, DOI 10.1001/archneurol.2012.1200; van Luijtelaar G, 2013, NEUROBIOL DIS, V60, P126, DOI 10.1016/j.nbd.2013.08.013; van Tuijl JH, 2011, SEIZURE-EUR J EPILEP, V20, P285, DOI 10.1016/j.seizure.2010.12.012; Vecht CJ, 2006, NEUROLOGY, V67, pS10, DOI 10.1212/WNL.67.12_suppl_4.S10; Vecht CJ, 2003, SEMIN ONCOL, V30, P49, DOI 10.1053/j.seminoncol.2003.11.030; Vezzani A, 2011, EPILEPSIA, V52, P67, DOI 10.1111/j.1528-1167.2011.03242.x; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Weller M, 2011, NEUROLOGY, V77, P1156, DOI 10.1212/WNL.0b013e31822f02e1; Wilcox KS, 2013, EPILEPSIA, V54, P24, DOI 10.1111/epi.12296; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1983, CHILD BRAIN, V10, P185	72	39	40	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	APR	2014	27	2					227	235		10.1097/WCO.0000000000000067			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AD5KE	WOS:000333290500013	24556736				2022-02-06	
J	Lu, Q; Gao, L; Huang, LJ; Ruan, LH; Yang, JJ; Huang, WL; Li, ZX; Zhang, YL; Jin, KL; Zhuge, QC				Lu, Qin; Gao, Lu; Huang, Lijie; Ruan, Linhui; Yang, Jianjing; Huang, Weilong; Li, Zhenxing; Zhang, Yongliang; Jin, Kunlin; Zhuge, Qichuan			Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat	JOURNAL OF NEUROINFLAMMATION			English	Article						ICH; mTOR; Rapamycin; Outcome; Immune response	REGULATORY T-CELLS; ISCHEMIC-STROKE; GROWTH-FACTOR; MECHANISMS; PROTEIN; KINASE; INJURY; NEUROPROTECTION; ANGIOGENESIS; MICROGLIA	Background: Mammalian target of rapamycin (mTOR), a serine/threonine kinase, regulates many processes, including cell growth and the immune response. mTOR is also dysregulated in several neurological diseases, such as traumatic brain injury (TBI), stroke, and neurodegenerative disease. However, the role of mTOR in intracerebral hemorrhage (ICH) remains unexplored. The aims of our study were to determine whether inhibiting mTOR signaling could affect the outcome after ICH and to investigate the possible underlying mechanism. Methods: A rat ICH model was induced by intracerebral injection of collagenase IV into the striatum, and mTOR activation was inhibited by administration of rapamycin. mTOR signaling activation was determined by western blotting. Neurobehavioral deficit after ICH was determined by a set of modified Neurological Severity Scores (mNSS). The levels of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and cytokines were examined using flow cytometry and ELISA, respectively. Results: Our results demonstrated thatmTOR signaling was activated 30 minutes and returned to its basal level 1 day after ICH. Increased p-mTOR, which mean that mTOR signaling was activated, was predominantly located around the hematoma. Rapamycin treatment significantly improved the neurobehavioral deficit after ICH, increased the number of Tregs, increased levels of interleukin-10 and transforming growth factor-beta and reduced interferon-gamma both in peripheral blood and brain. Conclusions: Our study suggests that mTOR improves ICH outcome and modulates immune response after ICH.	[Lu, Qin; Gao, Lu; Huang, Lijie; Ruan, Linhui; Yang, Jianjing; Huang, Weilong; Li, Zhenxing; Zhang, Yongliang; Zhuge, Qichuan] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China; [Lu, Qin; Gao, Lu; Huang, Lijie; Ruan, Linhui; Yang, Jianjing; Huang, Weilong; Li, Zhenxing; Zhuge, Qichuan] Wenzhou Med Univ, Zhejiang Prov Key Lab Aging & Neurol Dis, Wenzhou, Zhejiang, Peoples R China; [Jin, Kunlin] Univ North Texas Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA		Zhuge, QC (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China.	zhugeqichuan@vip.163.com	Huang, Lijie/AAD-3489-2022; LU, QIN/AAU-1992-2021	LU, QIN/0000-0001-8211-6127	National Natural Science foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171088]	The study was supported by a grant from the National Natural Science foundation of China (No. 81171088). We are grateful to Professor Dong-Ming Su (University of North Texas Health Science Center, USA) for critical suggestions on the experiments.	An WL, 2003, AM J PATHOL, V163, P591, DOI 10.1016/S0002-9440(10)63687-5; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Castilho RM, 2009, CELL STEM CELL, V5, P279, DOI 10.1016/j.stem.2009.06.017; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Deinsberger W, 1996, NEUROL RES, V18, P475; Dello Russo C, 2009, BIOCHEM PHARMACOL, V78, P1242, DOI 10.1016/j.bcp.2009.06.097; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gliem M, 2012, ANN NEUROL, V71, P743, DOI 10.1002/ana.23529; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hartlage-Rubsamen M, 1999, J NEUROSCI RES, V57, P388, DOI 10.1002/(SICI)1097-4547(19990801)57:3<388::AID-JNR11>3.0.CO;2-2; Inagawa T, 2002, NEUROSURG REV, V25, P237, DOI 10.1007/s10143-002-0222-0; Ingall Timothy, 2004, J Insur Med, V36, P143; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Kopf H, 2007, INT IMMUNOPHARMACOL, V7, P1819, DOI 10.1016/j.intimp.2007.08.027; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Leker RR, 2009, NEUROSCIENCE, V163, P233, DOI 10.1016/j.neuroscience.2009.05.050; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Perera MN, 2006, J CLIN NEUROSCI, V13, P1, DOI 10.1016/j.jocn.2005.07.005; Popko B, 1997, MOL NEUROBIOL, V14, P19, DOI 10.1007/BF02740619; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schallert T, 1997, ADV NEUROL, V73, P229; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Suri-Payer E, 2006, SPRINGER SEMIN IMMUN, V28, P3, DOI 10.1007/s00281-006-0021-8; Wang J, 2005, NEUROCRIT CARE, V3, P77, DOI 10.1385/NCC:3:1:077; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang WG, 2012, EXP NEUROL, V233, P799, DOI 10.1016/j.expneurol.2011.11.046; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	49	39	45	1	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 6	2014	11								44	10.1186/1742-2094-11-44			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AD4ST	WOS:000333241500001	24602288	Green Published, gold			2022-02-06	
J	Arenth, PM; Russell, KC; Scanlon, JM; Kessler, LJ; Ricker, JH				Arenth, Patricia M.; Russell, Kathryn C.; Scanlon, Joelle M.; Kessler, Lauren J.; Ricker, Joseph H.			Corpus Callosum Integrity and Neuropsychological Performance After Traumatic Brain Injury: A Diffusion Tensor Imaging Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognition; corpus callosum; diffusion tensor imaging; neuropsychology; traumatic brain injury	EDITION CVLT-II; VERBAL-LEARNING TEST; AXONAL INJURY; NEUROPSYCHOMETRIC TESTS; MODERATE; MILD; MEMORY; OUTCOMES; METRICS; LESIONS	Objectives: (1) Detailed analysis of diffusion tensor imaging (DTI) parameters (fractional anisotropy and radial diffusivity) to evaluate white matter integrity in the corpus callosum (CC), and (2) examine correlations between DTI data and performance on multiple measures of cognitive functioning. Participants: Twelve individuals with a history of complicated mild, moderate, or severe traumatic brain injury (TBI) who were an average of 1.7 years postinjury and 12 control participants. Main Measures: Standardized and experimental neuropsychological tests; detailed analysis of DTI parameters. Results: The TBI group demonstrated DTI values suggesting decreased white matter integrity and correlations with severity of injury. Both groups showed correlations between DTI parameters and cognitive measures, with more significant correlations observed for the TBI group. White matter changes in the CC were evident chronically and were related to severity of injury. Conclusions: Diffusion tensor imaging parameters suggesting disruptions in white matter in the CC may be implicated in impaired performance, both in terms of cognitive tasks and reaction time, after TBI.	[Arenth, Patricia M.; Russell, Kathryn C.; Scanlon, Joelle M.; Kessler, Lauren J.; Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA USA; [Arenth, Patricia M.; Russell, Kathryn C.; Ricker, Joseph H.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA; [Russell, Kathryn C.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Ricker, JH (corresponding author), New York Univ, Sch Med, Dept Rehabil Med, Rusk Rehabil NYUMC, 240 E 38th St,Suite 15-71, New York, NY 10016 USA.	ricker@nyu.edu		Ricker, Joseph/0000-0003-3415-991X	 [NIH-NINDS R01NS048178-01];  [5T32HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048178] Funding Source: NIH RePORTER	This research was supported in part by a grant (NIH-NINDS R01NS048178-01) awarded to Dr Ricker. Dr Russell was supported by 5T32HD040686 during the preparation of this article.	Arenth PM, 2012, J CLIN EXP NEUROPSYC, V34, P333, DOI 10.1080/13803395.2011.633896; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton A., 1976, MULTILINGUAL APHASIA; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; DeJong J, 2009, ASSESSMENT, V16, P328, DOI 10.1177/1073191109336989; Delis D.C., 2000, CALIFORNIA VERBAL LE; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DEROGATIS LR, 1993, BSI BRIEF S INV ADM; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M, 2010, TRAUMATIC BRAIN INJU; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Golden CJ., 2002, STROOP COLOR WORD TE; GRANT AD, 1948, J EXP PSYCHOL, V38, P404, DOI DOI 10.1037/H0059831; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jansma JM, 2001, J COGNITIVE NEUROSCI, V13, P730, DOI 10.1162/08989290152541403; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Koch K, 2006, BRAIN RES, V1107, P140, DOI 10.1016/j.brainres.2006.06.003; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lebel C, 2012, MAGN RESON MED, V68, P474, DOI 10.1002/mrm.23254; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Nolte J., 2008, HUMAN BRAIN INTRO IT; Oh JS, 2005, NEUROREPORT, V16, P317, DOI 10.1097/00001756-200503150-00002; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Reitan R, 1985, HALSTEAD REITAN NEUR; Ricker JH, 2010, HDB REHABILITATION P, P43, DOI [10.1037/15972-003, DOI 10.1037/15972-003]; Russell KC, 2011, J CLIN EXP NEUROPSYC, V33, P538, DOI 10.1080/13803395.2010.537253; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spreen O., 1969, NEUROSENSORY CTR COM; Teasdale G, 1974, LANCET, V2, P480; Thierry AGM, 2004, AM J NEURORADIOL, V25, P370; Tisserand DJ, 2006, BRAIN COGNITION, V60, P216; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	54	39	42	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					E1	E10		10.1097/HTR.0b013e318289ede5			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600001	23558829	Green Accepted			2022-02-06	
J	Bivona, U; Riccio, A; Ciurli, P; Carlesimo, GA; Delle Donne, V; Pizzonia, E; Caltagirone, C; Formisano, R; Costa, A				Bivona, Umberto; Riccio, Angela; Ciurli, Paola; Carlesimo, Giovanni Augusto; Delle Donne, Valentina; Pizzonia, Elisa; Caltagirone, Carlo; Formisano, Rita; Costa, Alberto			Low Self-Awareness of Individuals With Severe Traumatic Brain Injury Can Lead to Reduced Ability to Take Another Person's Perspective	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						empathy; self-awareness; Theory of Mind; traumatic brain injury	COMPETENCE RATING-SCALE; FRONTOTEMPORAL DEMENTIA; NEURAL BASIS; EXECUTIVE FUNCTION; LOBE CONTRIBUTIONS; ASPERGER-SYNDROME; PEOPLE THINKING; MIND; EMPATHY; DEFICITS	Aims of this study were (i) to verify whether a deficit or a lack of self-awareness can lead to difficulties in assuming another person's perspective after a severe traumatic brain injury (TBI); (ii) to verify whether perspective-taking deficits emerge more from performance-based tasks than self-reports; and (iii) to evaluate the possible relationships between perspective-taking difficulties and some clinical, neuropsychological, neuropsychiatric, and neuroimaging variables. The Interpersonal Reactivity Index, Empathy Quotient, first-order false-belief, and faux pas written stories were administered to 28 patients with severe TBI and 28 healthy controls. The Awareness Questionnaire was also administered to TBI patients and their caregivers. Patients were split into 2 groups (impaired self-awareness vs adequate self-awareness) on the basis of the discrepancy Awareness Questionnaire score. Both TBI groups obtained lower scores than healthy controls on the Fantasy subscale of the Interpersonal Reactivity Index, the reality question of the false-belief stories, and the memory questions of the faux pas test. Only impaired self-awareness patients tended to obtain lower scores in first-order false-belief detection. Impaired self-awareness patients also performed significantly worse than both healthy controls and adequate self-awareness patients on the faux pas tasks. The analysis suggests a causal relationship between low self-awareness and perspective-taking difficulties in this population of patients.	[Bivona, Umberto; Riccio, Angela; Ciurli, Paola; Carlesimo, Giovanni Augusto; Delle Donne, Valentina; Pizzonia, Elisa; Caltagirone, Carlo; Formisano, Rita; Costa, Alberto] Santa Lucia Fdn, Rome, Italy; [Carlesimo, Giovanni Augusto; Caltagirone, Carlo] Univ Roma Tor Vergata, Rome, Italy		Bivona, U (corresponding author), IRCCS Fdn Santa Lucia, Via Ardeatina 306, I-00179 Rome, Italy.	u.bivona@hsantalucia.it	Costa, Alberto/AAA-7038-2019; Riccio, Angela/K-2745-2016; Delle Donne, Valentina/AAU-4668-2021	Riccio, Angela/0000-0002-4098-9461; COSTA, Alberto/0000-0002-4784-5524			Aboulafia-Brakha T, 2011, J NEUROPSYCHOL, V5, P39, DOI 10.1348/174866410X533660; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; Baron-Cohen S. J., 2000, UNDERSTANDING OTHER; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BROTHERS L, 1992, J COGNITIVE NEUROSCI, V4, P107, DOI 10.1162/jocn.1992.4.2.107; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Carruthers P., 1996, THEORIES THEORIES MI; Churchland PM, 1991, FUTURE FOLK PSYCHOL, P51; CICERONE KD, 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Ciurli P, 2010, J INT NEUROPSYCH SOC, V16, P360, DOI 10.1017/S135561770999141X; Cohen J., 2013, STAT POWER ANAL BEHA; Costa A, 2008, BEHAV NEUROL, V19, P71, DOI 10.1155/2008/694632; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DAVIES M, 1995, MENTAL SIMULATION; DAVIES M, 1995, FOLK PSYCHOL; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; DENNETT DC, 1978, BEHAV BRAIN SCI, V1, P568, DOI 10.1017/S0140525X00076664; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Eslinger PJ, 2012, BEHAV NEUROL, V25, P127, DOI [10.3233/BEN-2011-0351, 10.1155/2012/286427]; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Frith U, 2001, CURR DIR PSYCHOL SCI, V10, P151, DOI 10.1111/1467-8721.00137; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gallese V, 2003, PSYCHOPATHOLOGY, V36, P171, DOI 10.1159/000072786; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GALLUP GG, 1982, AM J PRIMATOL, V2, P237, DOI 10.1002/ajp.1350020302; Glodzik-Sobanska L, 2005, J NEUROL SCI, V238, P19, DOI 10.1016/j.jns.2005.06.004; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldman A. I., 1989, MIND LANG, V4, P161, DOI DOI 10.1111/J.1468-0017.1989.TB00249.X; Gordon R., 1996, THEORIES THEORY MIND, P11, DOI DOI 10.1017/CB09780511597985.003; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Gunning Dixon FM, 2003, NEUROPSYCHOLOGIA, V41, P1929; Hagen C., 1972, LEVELS COGNITIVE FUN; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 2000, FORMA COMPLETA REVIS, P1; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; JENNETT B, 1975, LANCET, V1, P480; Keenan J.P., 2003, FACE MIRROR SEARCH O; Keysers C, 2004, NEURON, V42, P335, DOI 10.1016/S0896-6273(04)00156-4; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levkovitz Y, 2011, BRAIN STIMUL, V4, P266, DOI 10.1016/j.brs.2010.12.004; Long C. J., 1992, HDB HEAD TRAUMA ACUT; McDonald S, 1999, J HEAD TRAUMA REHAB, V16, P612; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MILLER PH, 1970, CHILD DEV, V41, P613, DOI 10.2307/1127211; Morin A, 2006, CONSCIOUS COGN, V15, P358, DOI 10.1016/j.concog.2005.09.006; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Newsome MR, 2010, NEUROPSYCHOLOGY, V24, P139, DOI 10.1037/a0017432; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Orsini A., 2003, B PSICOL APPL, V239, P73; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; SELMAN RL, 1971, CHILD DEV, V42, P1721, DOI 10.1111/j.1467-8624.1971.tb03765.x; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss Donald T, 2002, PRINCIPLES FRONTAL L; Tani F., 1998, EMPATIA PROCESSI CON; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Zamboni G, 2008, NEUROLOGY, V71, P736, DOI 10.1212/01.wnl.0000324920.96835.95	102	39	40	2	37	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					157	171		10.1097/HTR.0b013e3182864f0b			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600010	23524876				2022-02-06	
J	Mychasiuk, R; Hehar, H; Farran, A; Esser, MJ				Mychasiuk, R.; Hehar, H.; Farran, A.; Esser, M. J.			Mean girls: Sex differences in the effects of mild traumatic brain injury on the social dynamics of juvenile rat play behaviour	BEHAVIOURAL BRAIN RESEARCH			English	Article						Sprague Dawley rat; Pediatric; Development; Play fighting behaviour; Concussion	CONCUSSION SYMPTOMS; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; CHILDREN; DEFENSE; NEUROSCIENCE; PLASTICITY; ATTENTION; OUTCOMES; ATTACK	Clinical studies indicate that children who experience a traumatic brain injury (TBI) are often the victim of peer rejection, have very few mutual friends, and are at risk for long-term behavioural and social impairments. Owing to the fact that peer play is critical for healthy development, it is possible that the long-term impairments are associated not only with the TBI, but also altered play during this critical period of brain development. This study was designed to determine if social dynamics and juvenile play are altered in rats that experience a mild TBI (mTBI) early in life. Play-fighting behaviours were recorded and analyzed for young male and female Sprague Dawley rats that were given either an mTBI or a sham injury. The study found that the presence of an mTBI altered the play fighting relationship, and the nature of the alterations were dependent upon the sex of the pairing and the injury status of their peers. Sham rats were significantly less likely to initiate play with an mTBI rat, and were more likely to respond to a play initiation from an mTBI rat with an avoidant strategy. This effect was significantly more pronounced in female rats, whereby it appeared that female rats with an mTBI were particularly rejected and most often excluded from play experiences. Male rats with an mTBI learned normal play strategies from their sham peers (when housed in mixed cages), whereas female rats with an mTBI show heightened impairment in these conditions. Play therapy may need to be incorporated into treatment strategies for children with TBI. (C) 2013 Elsevier B.V. All rights reserved.	[Mychasiuk, R.; Hehar, H.; Farran, A.; Esser, M. J.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg,Room 277,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Foundation; University of Calgary, Department of Paediatrics	The authors would like to thank Irene Ma for her technical assistance and the Alberta Children's Hospital Research Foundation & The University of Calgary, Department of Paediatrics for their assistance with funding.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell HC, 2010, BEHAV BRAIN RES, V207, P7, DOI 10.1016/j.bbr.2009.09.029; Bell HC, 2009, BEHAV NEUROSCI, V123, P1158, DOI 10.1037/a0017617; Biben M., 1998, ANIMAL PLAY EVOLUTIO; Bigler ED, 2013, NEUROREHABILITATION, V32, P707, DOI 10.3233/NRE-130896; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Burnett S, 2011, NEUROSCI BIOBEHAV R, V35, P1654, DOI 10.1016/j.neubiorev.2010.10.011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Darwish D, 2001, CHILD ABUSE NEGLECT, V25, P13, DOI 10.1016/S0145-2134(00)00228-3; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; GHEUSI G, 1994, BEHAV PROCESS, V33, P59, DOI 10.1016/0376-6357(94)90060-4; Himmler BT, 2013, JOVE-J VIS EXP, DOI 10.3791/4288; Hol T, 1999, BEHAV BRAIN RES, V100, P91, DOI 10.1016/S0166-4328(98)00116-8; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Joseph R, 1999, CHILD PSYCHIAT HUM D, V29, P189, DOI 10.1023/A:1022660923605; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KOLB B, 1974, J COMP PHYSIOL PSYCH, V87, P466, DOI 10.1037/h0036969; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kolb B, 2009, PAED CHILD HEALT-CAN, V14, P651, DOI 10.1093/pch/14.10.651; Kolb Teskey B, 2010, DEV PSYCHOBIOL, V54, P311; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; Mychasiuk R, 2013, J NEUROTRAUMA UNPUB; NONNEMAN AJ, 1974, BEHAV BIOL, V12, P41, DOI 10.1016/S0091-6773(74)91011-6; Pellis S. M., 1998, ANIMAL PLAY EVOLUTIO, P115, DOI [10.1017/CBO9780511608575.007, DOI 10.1017/CBO9780511608575.007]; Pellis SM, 2007, CURR DIR PSYCHOL SCI, V16, P95, DOI 10.1111/j.1467-8721.2007.00483.x; Pellis SM, 2010, AM J PLAY, V2, P278; Pellis SM, 2006, BEHAV NEUROSCI, V120, P72, DOI 10.1037/0735-7044.120.1.72; PELLIS SM, 1990, DEV PSYCHOBIOL, V23, P215, DOI 10.1002/dev.420230303; PELLIS SM, 1991, PSYCHOL REC, V41, P175, DOI 10.1007/BF03395104; PELLIS SM, 1992, BRAIN BEHAV EVOLUT, V39, P270, DOI 10.1159/000114124; Schallert T, 2002, PHARM CEREBRAL ISCHE; Smith LK, 1998, DEV PSYCHOBIOL, V33, P147, DOI 10.1002/(SICI)1098-2302(199809)33:2<147::AID-DEV5>3.3.CO;2-H; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531	45	39	41	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2014	259						284	291		10.1016/j.bbr.2013.10.048			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	AB3CA	WOS:000331667700034	24231261				2022-02-06	
J	Swick, D; Honzel, N; Larsen, J; Ashley, V				Swick, Diane; Honzel, Nikki; Larsen, Jary; Ashley, Victoria			Increased response variability as a marker of executive dysfunction in veterans with post-traumatic stress disorder	NEUROPSYCHOLOGIA			English	Article						PTSD; TBI; Go/NoGo; Cognitive control; Inhibitory control; Impulsivity	REACTION-TIME VARIABILITY; TRAUMATIC BRAIN-INJURY; DEFAULT MODE; INDIVIDUAL-DIFFERENCES; RISK-FACTORS; ADHD; MIND; PERFORMANCE; ATTENTION; DISTRIBUTIONS	The stability of cognitive control processes over time can be indexed by trial-to-trial variability in reaction time (RT). Greater RT variability has been interpreted as an indicator of executive dysfunction, inhibitory inefficiency, and excessive mental noise. Previous studies have demonstrated that combat veterans with post-traumatic stress disorder (PTSD) show substantial impairments in inhibitory control, but no studies have examined response variability in this population. In the current experiment, RT variability in the Go/NoGo response inhibition task was assessed for 45 veterans with PTSD and 34 control veterans using the intra-individual coefficient of variation (ICV) and ex-Gaussian analysis of RT distributions. Despite having mean RTs that were indistinguishable from controls, the PTSD patients had significantly greater RT variability as measured by ICV. More variable RTs were in turn associated with a greater number of false alarm errors in the patients, suggesting that less consistent performers were less successful at inhibiting inappropriate responses. RT variability was also highly correlated with self-reported symptoms of PTSD, depression, and attentional impulsiveness. Furthermore, response variability predicted diagnosis even when controlling for PTSD symptom severity. In turn, PTSD severity was correlated with self-rated attentional impulsiveness. Deficits in the top-down cognitive control processes that cause greater response variability might contribute to the maintenance of PTSD symptomology. Thus, the distractibility issues that cause more variable reaction times might also result in greater distress related to the trauma. Published by Elsevier Ltd.	[Swick, Diane; Honzel, Nikki; Larsen, Jary; Ashley, Victoria] Vet Affairs Northern Calif Hlth Care Syst, Res Serv 151, Martinez, CA 94553 USA; [Swick, Diane] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA		Swick, D (corresponding author), Vet Affairs Northern Calif Hlth Care Syst, Res Serv 151, 150 Muir Rd, Martinez, CA 94553 USA.	swicklab@gmail.com			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0086]; Clinical Science Research and Development; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000566] Funding Source: NIH RePORTER	We are grateful to Dr. Andrew Kayser for patient referrals and to all participants for taking part in the study. We thank Dr. Machelle Wilson (University of California, Davis) and Timothy Heron (VA Northern California Health Care System) for statistical advice. We also thank Dr. Catherine Fassbender for her suggestions on data analysis, and the reviewers for their comments on earlier versions of the manuscript. This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-08-2-0086 and a VA Merit Review grant from Clinical Science Research and Development. Dr. Wilson is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through grant #UL1 TR000002. The contents reported within do not represent the views of the Department of Veterans Affairs or the United States Government. The authors declare that they have no conflicts of interest.	Ashley V, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-86; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chuah YML, 2006, J NEUROSCI, V26, P7156, DOI 10.1523/JNEUROSCI.0906-06.2006; Danielmeier C, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00233; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Epstein JN, 2011, NEUROPSYCHOLOGY, V25, P427, DOI 10.1037/a0022155; Fjell AM, 2011, J NEUROSCI, V31, P18060, DOI 10.1523/JNEUROSCI.4735-11.2011; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; HEATHCOTE A, 1991, PSYCHOL BULL, V109, P340, DOI 10.1037/0033-2909.109.2.340; Heathcote A, 2004, BEHAV RES METH INS C, V36, P277, DOI 10.3758/BF03195574; Hervey AS, 2006, CHILD NEUROPSYCHOL, V12, P125, DOI 10.1080/09297040500499081; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R., 2013, DRUG ALCOHOL DEPENDE; Honzel N., COGNITIVE A IN PRESS; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kaiser S, 2008, BRAIN COGNITION, V66, P73, DOI 10.1016/j.bandc.2007.05.007; Kane MJ, 2012, CURR DIR PSYCHOL SCI, V21, P348, DOI 10.1177/0963721412454875; Larson GE, 2009, MIL MED, V174, P737, DOI 10.7205/MILMED-D-02-0308; Lee R. W., 2012, J ATTENTION DISORDER; Lew HL, 2010, NEUROREHABILITATION, V26, P271, DOI 10.3233/NRE-2010-0562; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Matzke D, 2009, PSYCHON B REV, V16, P798, DOI 10.3758/PBR.16.5.798; MCNALLY RJ, 1990, J ABNORM PSYCHOL, V99, P398, DOI 10.1037/0021-843X.99.4.398; McVay JC, 2012, J EXP PSYCHOL LEARN, V38, P525, DOI 10.1037/a0025896; McVay JC, 2009, PSYCHON B REV, V16, P857, DOI 10.3758/PBR.16.5.857; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Ode S, 2011, COGNITION EMOTION, V25, P307, DOI 10.1080/02699931.2010.494387; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Schmiedek F, 2007, J EXP PSYCHOL GEN, V136, P414, DOI 10.1037/0096-3445.136.3.414; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Simmonds DJ, 2007, NEUROPSYCHOLOGIA, V45, P2147, DOI 10.1016/j.neuropsychologia.2007.01.013; Simmons J. P., 2012, 2160588 SSRN, DOI [DOI 10.2139/SSRN.2160588, 10.2139/ssrn.2160588]; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2009, EMOTION, V9, P271, DOI 10.1037/a0014855; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suskauer SJ, 2008, J AM ACAD CHILD PSY, V47, P1141, DOI 10.1097/CHI.0b013e3181825b1f; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S13556177120000458; Tamm L, 2012, NEUROTHERAPEUTICS, V9, P500, DOI 10.1007/s13311-012-0138-5; Tarantino V, 2013, J INT NEUROPSYCH SOC, V19, P820, DOI 10.1017/S1355617713000623; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; vandenBosch RJ, 1996, SCHIZOPHRENIA BULL, V22, P643, DOI 10.1093/schbul/22.4.643; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vinogradov S, 1998, SCHIZOPHR RES, V32, P183, DOI 10.1016/S0920-9964(98)00043-7; VRANA SR, 1995, J ANXIETY DISORD, V9, P515, DOI 10.1016/0887-6185(95)00028-M; Weathers F.W., 1994, PTSD CHECKLIST MILIT; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; Whelan R, 2008, PSYCHOL REC, V58, P475, DOI 10.1007/BF03395630	63	39	39	0	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2013	51	14					3033	3040		10.1016/j.neuropsychologia.2013.10.008			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	295AH	WOS:000330088500009	24157540	Green Accepted			2022-02-06	
J	Styrke, J; Sojka, P; Bjornstig, U; Bylund, PO; Stalnacke, BM				Styrke, Johan; Sojka, Peter; Bjornstig, Ulf; Bylund, Per-Olof; Stalnacke, Britt-Marie			SEX DIFFERENCES IN SYMPTOMS, DISABILITY AND LIFE SATISFACTION THREE YEARS AFTER MILD TRAUMATIC BRAIN INJURY: A POPULATION-BASED COHORT STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; minor head injury; sex differences; post-concussion syndrome; follow-up studies; quality of life; principal component analysis; odds ratio	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; FOLLOW-UP; GENDER-DIFFERENCES; YOUNG-PEOPLE; QUESTIONNAIRE; EPIDEMIOLOGY; PREVALENCE; PREDICTORS; SEVERITY	Objective: To investigate sex differences in symptoms, structure of symptoms, disability and life satisfaction 3 years after mild traumatic brain injury. Secondary aims were to find risk factors for adverse outcome. Design: Population-based cohort study. Patients: The cohort comprised 137,000 inhabitants at risk in a defined population served by a single hospital in northern Sweden. Patients attending the emergency department following a mild traumatic brain injury in 2001 were included. Methods: Of 214 patients aged 18-64 years, 163 answered a questionnaire on symptoms, disability, and life-satisfaction 3 years post-injury. The instruments were analysed with descriptive statistics. A principal component analysis of the Rivermead Post-Concussion Symptoms Questionnaire was conducted. Risk factors were identified using logistic regression. Results: Post-concussion syndrome was found in 50% of the women and 30% of the men. Disability was found in 52% of the women and 37% of the men, and 57% of the women and 56% of the men were satisfied with their lives. For both genders, high frequency of symptoms was a risk factor for disability and low life satisfaction. Back pain was a risk factor for disability. Living alone was a risk factor for low levels of life satisfaction. The principal component analysis revealed differences between the sexes. Conclusion: There are sex differences in outcome 3 years after mild traumatic brain injury. Women and men should be analysed separately.	[Styrke, Johan; Bjornstig, Ulf] Umea Univ, Dept Surg & Perioperat Sci, Div Surg, SE-90185 Umea, Sweden; [Sojka, Peter] Mid Sweden Univ, Dept Hlth Sci, Ostersund, Sweden; [Bylund, Per-Olof] Umea Univ Hosp, Emergency & Disaster Med Ctr, S-90185 Umea, Sweden; [Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, SE-90185 Umea, Sweden		Styrke, J (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, Div Surg, SE-90185 Umea, Sweden.	johan.styrke@surgery.umu.se	Styrke, Johan/AAE-1193-2021		Swedish Association of Brain Injured and Families; Department of Research and Development, Vasternorrland County Council	The authors would like to thank Gabriel Granasen for assisting in the statistical analysis and Asta Strandberg for helping us to administer the questionnaires. This work was supported by grants from the Swedish Association of Brain Injured and Families and the Department of Research and Development, Vasternorrland County Council.	Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Covassin T, 2012, J NEUROSCI NURS, V44, P124, DOI 10.1097/JNN.0b013e318252737d; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Demakis GJ, 2010, ARCH CLIN NEUROPSYCH, V25, P191, DOI 10.1093/arclin/acq004; Edna T H, 1987, J Oslo City Hosp, V37, P41; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fayol P., 2009, Annals of Physical and Rehabilitation Medicine, V52, P497, DOI 10.1016/j.annrmp.2008.06.003; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Walker BF, 2000, J SPINAL DISORD, V13, P205, DOI 10.1097/00002517-200006000-00003; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WHO, 1992, INT STAT CLASS DIS R; Zhang SR, 2009, J REHABIL MED, V41, P1062, DOI 10.2340/16501977-0462; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	40	39	40	0	19	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					749	757		10.2340/16501977-1215			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500009	24002310	gold, Green Published, Green Submitted			2022-02-06	
J	Schaible, EV; Steinstrasser, A; Jahn-Eimermacher, A; Luh, C; Sebastiani, A; Kornes, F; Pieter, D; Schafer, MK; Engelhard, K; Thal, SC				Schaible, Eva-Verena; Steinstraesser, Arne; Jahn-Eimermacher, Antje; Luh, Clara; Sebastiani, Anne; Kornes, Frida; Pieter, Dana; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.			Single Administration of Tripeptide alpha-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice	PLOS ONE			English	Article							MELANOCYTE-STIMULATING HORMONE; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; MELANOCORTIN RECEPTORS; MICROGLIAL ACTIVATION; CEREBRAL-ISCHEMIA; TIME-COURSE; EXPRESSION; PEPTIDES; NEUROPROTECTION	Following traumatic brain injury (TBI) neuroinflammatory processes promote neuronal cell loss. Alpha-melanocyte-stimulating hormone (alpha-MSH) is a neuropeptide with immunomodulatory properties, which may offer neuroprotection. Due to short half-life and pigmentary side-effects of alpha-MSH, the C-terminal tripeptide alpha-MSH(11-13) may be an anti-inflammatory alternative. The present study investigated the mRNA concentrations of the precursor hormone proopiomelanocortin (POMC) and of melanocortin receptors 1 and 4 (MC1R/MC4R) in naive mice and 15 min, 6, 12, 24, and 48 h after controlled cortical impact (CCI). Regulation of POMC and MC4R expression did not change after trauma, while MC1R levels increased over time with a 3-fold maximum at 12 h compared to naive brain tissue. The effect of alpha-MSH(11-13) on secondary lesion volume determined in cresyl violet stained sections (intraperitoneal injection 30 min after insult of 1 mg/kg alpha-MSH(11-13) or 0.9% NaCl) showed a considerable smaller trauma in alpha-MSH(11-13) injected mice. The expression of the inflammatory markers TNF-alpha and IL-1 beta as well as the total amount of Iba-1 positive cells were not reduced. However, cell branch counting of Iba-1 positive cells revealed a reduced activation of microglia. Furthermore, tripeptide injection reduced neuronal apoptosis analyzed by cleaved caspase-3 and NeuN staining. Based on the results single alpha-MSH(11-13) administration offers a promising neuroprotective property by modulation of inflammation and prevention of apoptosis after traumatic brain injury.	[Schaible, Eva-Verena; Steinstraesser, Arne; Luh, Clara; Sebastiani, Anne; Kornes, Frida; Pieter, Dana; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany; [Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Focus Program Translat Neurosci, D-55122 Mainz, Germany; [Jahn-Eimermacher, Antje] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, D-55122 Mainz, Germany		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Aronsson AF, 2006, NEUROPEPTIDES, V40, P65, DOI 10.1016/j.npep.2005.10.006; Bhardwaj RS, 1996, J IMMUNOL, V156, P2517; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Caruso C, 2004, NEUROENDOCRINOLOGY, V79, P278, DOI 10.1159/000079321; Caruso C, 2007, ENDOCRINOLOGY, V148, P4918, DOI 10.1210/en.2007-0366; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Catania A, 2010, THESCIENTIFICWORLDJO, V10, P1840, DOI 10.1100/tsw.2010.173; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chai BX, 2006, PEPTIDES, V27, P2846, DOI 10.1016/j.peptides.2006.05.005; Charnley M, 2008, PEPTIDES, V29, P1004, DOI 10.1016/j.peptides.2008.02.004; Chen G, 2008, NEUROPEPTIDES, V42, P331, DOI 10.1016/j.npep.2008.01.004; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Dalmasso G, 2008, GASTROENTEROLOGY, V134, P166, DOI 10.1053/j.gastro.2007.10.026; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; DEANGELIS E, 1995, MICROVASC RES, V50, P25, DOI 10.1006/mvre.1995.1035; Delgado R, 1998, J LEUKOCYTE BIOL, V63, P740, DOI 10.1002/jlb.63.6.740; Dessinioti C, 2011, PHOTOCHEM PHOTOBIOL, V87, P978, DOI 10.1111/j.1751-1097.2011.00970.x; Elliott RJ, 2004, J INVEST DERMATOL, V122, P1010, DOI 10.1111/j.0022-202X.2004.22404.x; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Getting SJ, 2002, TRENDS PHARMACOL SCI, V23, P447, DOI 10.1016/S0165-6147(02)02103-X; Getting SJ, 2003, J PHARMACOL EXP THER, V306, P631, DOI 10.1124/jpet.103.051623; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Giuliani D, 2011, ACTA NEUROPATHOL, V122, P443, DOI 10.1007/s00401-011-0873-4; Haddad JJE, 2001, BIOCHEM J, V355, P29, DOI 10.1042/bj3550029; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; Huang QH, 1998, AM J PHYSIOL-REG I, V275, pR524, DOI 10.1152/ajpregu.1998.275.2.R524; Ichiyama T, 1999, BRAIN RES, V836, P31, DOI 10.1016/S0006-8993(99)01584-X; Kishi T, 2003, J COMP NEUROL, V457, P213, DOI 10.1002/cne.10454; Land Stephen C, 2012, Int J Physiol Pathophysiol Pharmacol, V4, P59; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; Manna SX, 2006, EUR J IMMUNOL, V36, P754, DOI 10.1002/eji.200535209; Mountjoy KG, 2010, ADV EXP MED BIOL, V681, P29, DOI 10.1007/978-1-4419-6354-3_3; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nahon JL, 2006, CR BIOL, V329, P623, DOI 10.1016/j.crvi.2006.03.021; Rajora N, 1997, J NEUROSCI, V17, P2181; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Savos AV, 2011, J CEREBR BLOOD F MET, V31, P606, DOI 10.1038/jcbfm.2010.130; Spaccapelo L, 2011, EUR J PHARMACOL, V670, P479, DOI 10.1016/j.ejphar.2011.09.015; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tatro JB, 1996, NEUROIMMUNOMODULAT, V3, P259, DOI 10.1159/000097281; Taylor Andrew W., 1994, Neuroimmunomodulation, V1, P188, DOI 10.1159/000097167; TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Todd SR, 2009, J TRAUMA, V66, P465, DOI 10.1097/TA.0b013e31818b1e04; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; vandeMeent HV, 1997, NEUROSURGERY, V40, P122, DOI 10.1097/00006123-199701000-00028; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WILSON JF, 1980, J ENDOCRINOL, V86, P61, DOI 10.1677/joe.0.0860061; Wong KY, 1997, NEUROIMMUNOMODULAT, V4, P37; XIA Y, 1995, NEUROREPORT, V6, P2193, DOI 10.1097/00001756-199511000-00022; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zierath D, 2011, STROKE, V42, P3415, DOI 10.1161/STROKEAHA.111.627331	66	39	42	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e71056	10.1371/journal.pone.0071056			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	WOS:000324465000173	23940690	gold, Green Published, Green Submitted			2022-02-06	
J	Burk, JM; Munkasy, BA; Joyner, AB; Buckley, TA				Burk, John M.; Munkasy, Barry A.; Joyner, A. Barry; Buckley, Thomas A.			Balance Error Scoring System Performance Changes After a Competitive Athletic Season	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; balance error scoring system; postural control	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; POSTURAL CONTROL; SOCCER; MANAGEMENT; SENSITIVITY; IMPAIRMENT; STABILITY; EXERCISE; DEFICITS	Objective: To evaluate the change in Balance Error Scoring System (BESS) performance after an athletic season. Design: A prospective longitudinal group study. Setting: University biomechanics research laboratory. Participants: A total of 58 college-aged females (23 soccer student-athletes, 16 volleyball student-athletes, and 19 recreationally active healthy college students) participated in the study. Interventions: The BESS test was administered on 2 occasions 90 days apart. For the student-athletes, the first test (PRE) was administered before the start of their athletic season and the second test (POST) was administered immediately after the season. For the recreationally active college students, the PRE test was at the beginning of the academic semester and the POST test exactly 90 days thereafter. Main Outcome Measures: Total BESS score at PRE and POST was compared with a 3 x 2 repeated measures analysis of variance. The overall change score and absolute value change score were also calculated and compared with a 1-sample t test to an expected change of zero errors. Results: There was no group by time interaction; however, there was a main effect for time. There was a significant improvement (P = 0.003) between PRE (9.00 +/- 2.97 errors) and POST (7.92 +/- 2.78 errors) BESS performance. There were significant differences for both the overall change score (1.08 errors) and the absolute value change score (2.00 errors). Conclusions: A clinically and statistically significant difference in BESS performance was identified after a 90-day intercollegiate athletic season.	[Burk, John M.] Optim Healthcare, Phys Therapy & Sports Med, Statesboro, GA USA; [Munkasy, Barry A.; Joyner, A. Barry; Buckley, Thomas A.] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA		Buckley, TA (corresponding author), Georgia So Univ, Dept Hlth & Kinesiol, POB 8076, Statesboro, GA 30460 USA.	tbuckley@georgiasouthern.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Baechle TR, 2008, ESSENTIALS STRENGTH; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Erkmen N, 2009, ISOKINET EXERC SCI, V17, P121, DOI 10.3233/IES-2009-0343; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McLeod TCV, 2009, J SPORT REHABIL, V18, P465, DOI 10.1123/jsr.18.4.465; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Onate JA, 2007, J ATHL TRAINING, V42, P446; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Valovich TC, 2003, J ATHL TRAINING, V38, P51	30	39	41	2	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2013	23	4					312	317		10.1097/JSM.0b013e318285633f			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	299AM	WOS:000330366700012	23558331				2022-02-06	
J	Rietdijk, R; Simpson, G; Togher, L; Power, E; Gillett, L				Rietdijk, Rachael; Simpson, Grahame; Togher, Leanne; Power, Emma; Gillett, Lauren			An exploratory prospective study of the association between communication skills and employment outcomes after severe traumatic brain injury	BRAIN INJURY			English	Article						Communication; language; work; employment; traumatic brain injury	QUESTIONNAIRE; ABILITIES; VALIDITY	Primary objective: The aim of this pilot study was to explore possible correlations between measures of functional communication skills in the first year post-injury and later employment outcome. Design: A preliminary observational study employing a prospective longitudinal design. Methods: Fourteen adults with traumatic brain injury completed an assessment involving two functional communication measures: an objective test of cognitive communication skills (Functional Assessment of Verbal Reasoning and Executive Strategies, FAVRES) and self-ratings of communication impairment (LaTrobe Communication Questionnaire, LCQ). Follow-up of participants' employment outcome was conducted 9-18 months after the initial assessment. Results: At follow-up, eight participants had returned to employment (working a similar number of hours to their pre-injury status), five were unemployed and one was lost to follow-up. Employment status at follow-up was strongly correlated with both FAVRES Total Accuracy scores (r=0.833) and Total Rationale scores (r=0.837), but there were no correlations with FAVRES Time and Reasoning scores or with the LCQ. Conclusions: The FAVRES shows initial promise as an assessment that may be associated with successful employment outcome following traumatic brain injury. Further research with larger samples is required to provide further information on the prognostic utility of measures such as the FAVRES and the LCQ.	[Rietdijk, Rachael; Simpson, Grahame; Gillett, Lauren] Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Rietdijk, Rachael; Togher, Leanne; Power, Emma] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Simpson, Grahame] Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Rietdijk, R (corresponding author), Univ Sydney, Fac Hlth Sci, Cumberland Campus C42,POB 170, Lidcombe, NSW 1825, Australia.	rman7827@uni.sydney.edu.au	Power, Emma/A-9263-2015; Simpson, Grahame K/W-1074-2019; Togher, Leanne/AAC-7083-2019; Rietdijk, Rachael/J-6573-2012	Power, Emma/0000-0002-2638-0406; Simpson, Grahame K/0000-0001-8156-9060; Rietdijk, Rachael/0000-0003-4343-4039; Togher, Leanne/0000-0002-4518-6748			Athanasou J. A., 2003, AUSTR J CAREER DEV, V12, P58, DOI DOI 10.1177/103841620301200108; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; Hughes J, 2007, CAN J SPEECH-LANG PA, V31, P134; Isaki E, 2000, BRAIN INJURY, V14, P441; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; MacDonald S., 2005, FUNCTIONAL ASSESSMEN; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Soo CA, 2007, BRAIN IMPAIR, V8, P101, DOI DOI 10.1375/BRIM.8.2.101; *SPSS INC, 2009, PASW STAT 18 REL VER; Struchen MA, 2003, J INT NEUROPSYCH SOC, V9, P255; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Turkstra LS, 2002, J COMMUN DISORD, V35, P467, DOI 10.1016/S0021-9924(02)00118-1; World Health Organization, 2007, INT CLASS FUNCT DIS	19	39	39	0	24	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					812	818		10.3109/02699052.2013.775491			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200007	23758261				2022-02-06	
J	Winston, GP; Stretton, J; Sidhu, MK; Symms, MR; Thompson, PJ; Duncan, JS				Winston, Gavin P.; Stretton, Jason; Sidhu, Meneka K.; Symms, Mark R.; Thompson, Pamela J.; Duncan, John S.			Structural correlates of impaired working memory in hippocampal sclerosis	EPILEPSIA			English	Article						Temporal lobe epilepsy; Hippocampal sclerosis; Working memory; Voxel-based morphometry; Diffusion tensor imaging	TEMPORAL-LOBE EPILEPSY; SUPERIOR LONGITUDINAL FASCICULUS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; PREFRONTAL CORTEX; POSTERIOR CINGULATE; MULTIPLE-SCLEROSIS; WATER DIFFUSION; PARIETAL CORTEX; PERFORMANCE	Purpose: Temporal lobe epilepsy (TLE) has been considered to impair long-term memory, whilst not affecting working memory, but recent evidence suggests that working memory is compromised. Functional MRI (fMRI) studies demonstrate that working memory involves a bilateral frontoparietal network the activation of which is disrupted in hippocampal sclerosis (HS). A specific role of the hippocampus to deactivate during working memory has been proposed with this mechanism faulty in patients with HS. Structural correlates of disrupted working memory in HS have not been explored. Methods: We studied 54 individuals with medically refractory TLE and unilateral HS (29 left) and 28 healthy controls. Subjects underwent 3T structural MRI, a visuospatial n-back fMRI paradigm and diffusion tensor imaging (DTI). Working memory capacity assessed by three span tasks (digit span backwards, gesture span, motor sequences) was combined with performance in the visuospatial paradigm to give a global working memory measure. Gray and white matter changes were investigated using voxel-based morphometry and voxel-based analysis of DTI, respectively. Key Findings: Individuals with left or right HS performed less well than healthy controls on all measures of working memory. fMRI demonstrated a bilateral frontoparietal network during the working memory task with reduced activation of the right parietal lobe in both patient groups. In left HS, gray matter loss was seen in the ipsilateral hippocampus and parietal lobe, with maintenance of the gray matter volume of the contralateral parietal lobe associated with better performance. White matter integrity within the frontoparietal network, in particular the superior longitudinal fasciculus and cingulum, and the contralateral temporal lobe, was associated with working memory performance. In right HS, gray matter loss was also seen in the ipsilateral hippocampus and parietal lobe. Working memory performance correlated with the gray matter volume of both frontal lobes and white matter integrity within the frontoparietal network and contralateral temporal lobe. Significance: Our data provide further evidence that working memory is disrupted in HS and impaired integrity of both gray and white matter is seen in functionally relevant areas. We suggest this forms the structural basis of the impairment of working memory, indicating widespread and functionally significant structural changes in patients with apparently isolated HS.	[Winston, Gavin P.; Stretton, Jason; Sidhu, Meneka K.; Symms, Mark R.; Thompson, Pamela J.; Duncan, John S.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England		Winston, GP (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, Box 29,Queen Sq, London WC1N 3BG, England.	g.winston@ucl.ac.uk	Winston, Gavin P/E-6778-2011	Winston, Gavin P/0000-0001-9395-1478; Duncan, John S/0000-0002-1373-0681	Wellcome TrustWellcome TrustEuropean Commission [083148]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802012]; Wolfson Trust; Epilepsy Society; Department of Health's NIHR Biomedical Research Centres funding schemeNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0509-10161] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802012] Funding Source: UKRI	This work was supported by the Wellcome Trust (programme grant 083148), the Medical Research Council (clinical research training fellowship G0802012 to GPW). The Epilepsy Society MRI scanner was supported by the Big Lottery Fund, Wolfson Trust and Epilepsy Society. This work was undertaken at UCLH/UCL, who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. We are grateful to the radiographers at the Epilepsy Society MRI Unit-Philippa Bartlett, Jane Burdett, and Elaine Williams-who scanned the patients and to all the patients for their kind participation.	Ahmadi ME, 2009, AM J NEURORADIOL, V30, P1740, DOI 10.3174/ajnr.A1650; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Astur R, 2005, APPL PSYCHOPHYS BIOF, V30, P307, DOI 10.1007/s10484-005-6385-z; Astur RS, 2004, BEHAV NEUROSCI, V118, P667, DOI 10.1037/0735-7044.118.4.667; Axmacher N, 2007, J NEUROSCI, V27, P7807, DOI 10.1523/JNEUROSCI.0962-07.2007; Axmacher N, 2009, EUR J NEUROSCI, V29, P1501, DOI 10.1111/j.1460-9568.2009.06676.x; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Burzynska AZ, 2011, CEREB CORTEX, V21, P2261, DOI 10.1093/cercor/bhq293; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Concha L, 2012, NEUROLOGY, V79, P455, DOI 10.1212/WNL.0b013e31826170b6; Cook PA, 2007, J MAGN RESON IMAGING, V25, P1051, DOI 10.1002/jmri.20905; CORCORAN R, 1993, CORTEX, V29, P293, DOI 10.1016/S0010-9452(13)80182-7; Cousijn H, 2012, NEUROIMAGE, V59, P1161, DOI 10.1016/j.neuroimage.2011.09.027; D'Esposito Mark, 2008, Handb Clin Neurol, V88, P237, DOI 10.1016/S0072-9752(07)88011-0; Dineen RA, 2009, BRAIN, V132, P239, DOI 10.1093/brain/awn275; Focke NK, 2008, NEUROIMAGE, V40, P728, DOI 10.1016/j.neuroimage.2007.12.031; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; HERMANN BP, 1988, J CLIN EXP NEUROPSYC, V10, P467, DOI 10.1080/01688638808408253; Hirono N, 1998, J NEUROL NEUROSUR PS, V64, P552, DOI 10.1136/jnnp.64.4.552; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Karlsgodt KH, 2008, BIOL PSYCHIAT, V63, P512, DOI 10.1016/j.biopsych.2007.06.017; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; Keller SS, 2008, EPILEPSIA, V49, P741, DOI 10.1111/j.1528-1167.2007.01485.x; Kemmotsu N, 2011, EPILEPSIA, V52, P2257, DOI 10.1111/j.1528-1167.2011.03278.x; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Koenigs M, 2009, J NEUROSCI, V29, P14980, DOI 10.1523/JNEUROSCI.3706-09.2009; Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046; Kumari V, 2003, NEUROIMAGE, V19, P1002, DOI 10.1016/S1053-8119(03)00110-1; Labate A, 2011, EPILEPSIA, V52, P712, DOI 10.1111/j.1528-1167.2011.03038.x; Liao W, 2011, HUM BRAIN MAPP, V32, P883, DOI 10.1002/hbm.21076; Mainy N, 2007, HUM BRAIN MAPP, V28, P183, DOI 10.1002/hbm.20264; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Ostby Y, 2011, NEUROPSYCHOLOGIA, V49, P3854, DOI 10.1016/j.neuropsychologia.2011.10.001; Otte WM, 2012, EPILEPSIA, V53, P659, DOI 10.1111/j.1528-1167.2012.03426.x; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Riley JD, 2010, EPILEPSIA, V51, P536, DOI 10.1111/j.1528-1167.2009.02508.x; Schon K, 2009, CEREB CORTEX, V19, P2561, DOI 10.1093/cercor/bhp006; Small DM, 2003, NEUROIMAGE, V18, P633, DOI 10.1016/S1053-8119(02)00012-5; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stretton J, 2012, NEUROIMAGE, V60, P1696, DOI 10.1016/j.neuroimage.2012.01.126; Stretton J, 2012, EPILEPSY RES, V98, P1, DOI 10.1016/j.eplepsyres.2011.10.009; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; Vestergaard M, 2011, J COGNITIVE NEUROSCI, V23, P2135, DOI 10.1162/jocn.2010.21592; Vlooswijk MCG, 2011, EPILEPSIA, V52, P1467, DOI 10.1111/j.1528-1167.2011.03108.x; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006	59	39	41	0	33	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580			EPILEPSIA	Epilepsia	JUL	2013	54	7					1143	1153		10.1111/epi.12193			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	173VP	WOS:000321110100002	23614459	Green Submitted, Green Published, hybrid			2022-02-06	
J	Johnson, EM; Traver, KL; Hoffman, SW; Harrison, CR; Herman, JP				Johnson, Erica M.; Traver, Kyle L.; Hoffman, Stuart W.; Harrison, Catherine R.; Herman, James P.			Environmental enrichment protects against functional deficits caused by traumatic brain injury	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						environmental enrichment; traumatic brain injury; morris water maze; controlled cortical impact; sensory neglect	EARLY-ONSET STIMULATION; ADULT-RAT; COGNITIVE FUNCTION; PREFRONTAL CORTEX; DENTATE GYRUS; RECOVERY; MICE; EXPRESSION; PLASTICITY; INCREASES	Environmental enrichment (EE) increases cortical weight, neuronal density, dendritic branching, and angiogenesis, all of which may be critical for functional recovery following insult. Our study was designed to determine possible benefits of pre-exposure to EE in preventing functional deficits following traumatic brain injury (TBI) to the prefrontal cortex. To examine the benefit of EE, adult male rats were placed in an enriched environment for 15 days. Enrichment was provided through social interaction, exercise, olfactory stimulation, and new objects/toys to explore. Following enrichment, experimental and age-matched controls were subjected to a moderate medial prefrontal cortex injury via controlled cortical impact (CCI). After 1 week recovery, animals were behaviorally tested to assess memory, anxiety, and sensory neglect. Lesion-induced deficits in spatial memory [Morris water maze (MWM)] were significantly attenuated in EE pre-exposed rats 18-21 days following injury. In addition, TBI-induced sensory neglect was significantly reduced in EE rats relative to non-enriched animals. No differences in anxiety-like behavior on the elevated plus maze (EPM) were detected. The behavioral data suggest that EE is neuroprotective when applied prior to TBI, resulting in improved recovery following injury.	[Johnson, Erica M.; Herman, James P.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA; [Johnson, Erica M.; Traver, Kyle L.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA; [Hoffman, Stuart W.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [Harrison, Catherine R.] FAA, Washington, DC USA		Johnson, EM (corresponding author), USAF, Res Lab, 711th Human Performance Wing,2510 5th St, Wright Patterson AFB, OH 45433 USA.	erica.johnson.7@us.af.mil	Herman, James P/D-4960-2015	Herman, James P/0000-0003-3571-2406	Air Force Research Laboratory, Wright Patterson Air Force Base; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	This research was sponsored by the Air Force Research Laboratory, Wright Patterson Air Force Base, and was funded in part by the Defense and Veterans Brain Injury Center. The authors wish to thank Mr. Chuck Goodyear for his invaluable assistance with statistical analysis, the animal research support team for their excellent assistance with enrichment housing and behavioral testing and the University of Cincinnati Neuroscience graduate program for their generous support.	Barnett V, 1994, OUTLIERS STAT DATA, V3rd; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Benaroya-Milshtein N, 2004, EUR J NEUROSCI, V20, P1341, DOI 10.1111/j.1460-9568.2004.03587.x; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; CHAMOVE AS, 1989, LAB ANIM, V23, P215, DOI 10.1258/002367789780810608; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Eslinger P. J, 1996, ATTENTION MEMORY EXE, P367; Floden D, 2008, NEUROPSYCHOLOGIA, V46, P213, DOI 10.1016/j.neuropsychologia.2007.07.020; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HENDERSO.ND, 1970, SCIENCE, V169, P768, DOI 10.1126/science.169.3947.776; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Jones TA, 1999, J NEUROSCI, V19, P10153; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Lanosa Ximena A, 2011, Neuron Glia Biol, V7, P163, DOI 10.1017/S1740925X12000099; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lippert-Gruener M, 2007, EXP NEUROL, V203, P82, DOI 10.1016/j.expneurol.2006.07.025; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; ROSENZWEIG MR, 1972, SCI AM, V226, P22, DOI 10.1038/scientificamerican0272-22; ROSENZWEIG MR, 1972, J COMP PHYSIOL PSYCH, V80, P304, DOI 10.1037/h0032978; Schrijver NCA, 2002, PHARMACOL BIOCHEM BE, V73, P209, DOI 10.1016/S0091-3057(02)00790-6; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	51	39	43	1	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	MAY 21	2013	7								44	10.3389/fnbeh.2013.00044			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	148NV	WOS:000319252700001	23734108	Green Published, gold			2022-02-06	
J	Dennis, M; Simic, N; Agostino, A; Taylor, HG; Bigler, ED; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Dennis, Maureen; Simic, Nevena; Agostino, Alba; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Irony and Empathy in Children with Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Sarcasm; Childhood head injury; Glasgow Coma Scale; Social cognition; Speech acts	HEAD-INJURY; PREDICTION; EXPERIENCE; ABILITY; MILD; MIND	Social communication involves influencing what other people think and feel about themselves. We use the term conative theory of mind (ToM) to refer to communicative interactions involving one person trying to influence the mental and emotional state of another, paradigmatic examples of which are irony and empathy. This study reports how children with traumatic brain injury (TBI) understand ironic criticism and empathic praise, on a task requiring them to identify speaker belief and intention for direct conative speech acts involving literal truth, and indirect speech acts involving either ironic criticism or empathic praise. Participants were 71 children in the chronic state of a single TBI and 57 age- and gender-matched children with orthopedic injuries (OI). Group differences emerged on indirect speech acts involving conation (i.e., irony and empathy), but not on structurally and linguistically identical direct speech acts, suggesting specific deficits in this aspect of social cognition in school-age children with TBI. Deficits in children with mild-moderate TBI were less widespread and more selective than those of children with more severe injuries. Deficits in understanding the social, conative function of indirect speech acts like irony and empathy have widespread and deep implications for social function in children with TBI. (JINS, 2013, 19, 338-348)	[Dennis, Maureen; Simic, Nevena] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Simic, Nevena] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Agostino, Alba] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Dept Pediat, Cleveland, OH 44106 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Rubin, Kenneth] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Psychiat, Cleveland, OH USA		Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	maureen.dennis@sickkids.ca	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020; Vannatta, Kathryn/E-4237-2011; Rubin, Kenneth H/M-5276-2018; Gerhardt, Cynthia/E-3109-2011	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892; Agostino, Alexandra/0000-0001-8739-0061	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1 RO1 HD 04946]	Preparation of this study was supported by National Institute of Child Health and Human Development Grant 1 RO1 HD 04946, "Social Outcomes in Pediatric Traumatic Brain Injury,'' to Keith Yeates. No conflicts of interest exist.	ACKERMAN BP, 1981, DEV PSYCHOL, V17, P472; ACKERMAN BP, 1982, CHILD DEV, V53, P1075; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Crystal D., 1997, CAMBRIDGE ENCY LANGU, P121; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; DEGROOT A, 1995, METAPHOR SYMB ACT, V10, P255, DOI 10.1207/s15327868ms1004_2; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dews Shelly, 1995, AM PSYCH ASS NEW YOR; GIBBS RW, 1995, DISCOURSE PROCESS, V20, P187, DOI 10.1080/01638539509544937; GIBBS RW, 1984, COGNITIVE SCI, V8, P275, DOI 10.1207/s15516709cog0803_4; Hancock JT, 2000, J COGN DEV, V1, P227, DOI 10.1207/S15327647JCD010204; Harris M, 2003, DISCOURSE PROCESS, V36, P147, DOI 10.1207/S15326950DP3603_1; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Hein G, 2010, NEURON, V68, P149, DOI 10.1016/j.neuron.2010.09.003; HILGARD ER, 1980, J HIST BEHAV SCI, V16, P107, DOI 10.1002/1520-6696(198004)16:2<107::AID-JHBS2300160202>3.0.CO;2-Y; Howard I, 2005, ETHNIC DIS, V15, pS51; Huang L, 2011, SOC PSYCHOL PERS SCI, V2, P351, DOI 10.1177/1948550610391677; HUTCHEON L, 1992, DIACRITICS, V22, P2, DOI 10.2307/465234; Krach S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018675; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leggitt JS, 2000, DISCOURSE PROCESS, V29, P1, DOI 10.1207/S15326950dp2901_1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Masten CL, 2011, NEUROIMAGE, V55, P381, DOI 10.1016/j.neuroimage.2010.11.060; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonald, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Mobbs D, 2009, SCIENCE, V324, P900, DOI 10.1126/science.1170539; Olsson A, 2007, SOC COGN AFFECT NEUR, V2, P3, DOI 10.1093/scan/nsm005; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Pexman PM, 2007, J NEUROLINGUIST, V20, P178, DOI 10.1016/j.jneuroling.2006.06.001; Rameson LT, 2012, J COGNITIVE NEUROSCI, V24, P235, DOI 10.1162/jocn_a_00130; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833; TEASDALE G, 1974, LANCET, V2, P81; Wilson D., 1995, RELEVANCE COMMUNICAT; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Winner E., 1997, PROBLEM MEANING BEHA; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008	48	39	40	0	29	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2013	19	3					338	348		10.1017/S1355617712001440			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	107DV	WOS:000316195900011	23331976				2022-02-06	
J	Lazaridis, C; Smielewski, P; Steiner, LA; Brady, KM; Hutchinson, P; Pickard, JD; Czosnyka, M				Lazaridis, Christos; Smielewski, Piotr; Steiner, Luzius A.; Brady, Ken M.; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek			Optimal cerebral perfusion pressure: are we ready for it?	NEUROLOGICAL RESEARCH			English	Article						Cerebral blood flow autoregulation; Pressure reactivity; Intracranial pressure; Cerebral perfusion pressure; Traumatic brain injury; Brain tissue oxygen tension	TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; BLOOD-FLOW; CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; CARDIAC-ARREST; CARDIOPULMONARY BYPASS; ENERGY-METABOLISM	Objectives: Cerebral perfusion pressure (CPP)-oriented therapy and the Lund concept lie on opposite ends of the CPP scale, in the management of head injury. Optimization of CPP by monitoring cerebral vascular pressure reactivity is an alternative approach that may reconcile these two divergent approaches, preventing both injurious hypotension and hypertension with an individualized CPP target. Methods: Indices describing cerebral vascular reactivity or cerebral blood flow autoregulation, derived from intracranial pressure, near-infrared spectroscopy, or transcranial Doppler are reviewed in this manuscript. Results: Indices of cerebrovascular reactivity and autoregulation typically converge to a U-shape curve when viewed as a function of CPP, with the best reactivity metrics indicating optimal CPP. In a retrospective study of prospectively collected data from head-injured patients, Steiner et al. demonstrated that a greater distance between averaged over total monitoring time-CPP and optimal CPP, correlated with unfavourable outcome. A recent study of 300 head-injured patients (2003-2009) showed that hypotension below optimal CPP was associated with greater mortality rate, while hypertension above optimal CPP was associated with an increase in severe disability. Discussion: Pilot studies indicating feasibility of autoregulation-oriented CPP optimization have been performed in adult and paediatric traumatic brain injury, aneurysmal subarachnoid haemorrhage, and in patients undergoing cardiothoracic surgery. It remains to be prospectively demonstrated whether optimal CPP management is able to improve outcome.	[Lazaridis, Christos; Smielewski, Piotr; Steiner, Luzius A.; Brady, Ken M.; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Lazaridis, Christos] Med Univ S Carolina, Neurosci Intens Care Unit, Charleston, SC 29425 USA; [Steiner, Luzius A.] Univ Lausanne Hosp, Dept Anesthesia, Lausanne, Switzerland; [Brady, Ken M.] Texas Childrens Hosp, Dept Anesthesiol & Pediat, Houston, TX 77030 USA		Lazaridis, C (corresponding author), Med Univ S Carolina, Dept Neurosci Neurosci Crit Care & Stroke, 96 Jonathan Lucas St,Ste 307 CSB, Charleston, SC 29425 USA.	lazaridi@musc.edu	Steiner, Luzius/J-1987-2019	Smielewski, Peter/0000-0001-5096-3938	Department of HealthEuropean Commission [NF-SI-0508-10327] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: Medline; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0600986, G9439390] Funding Source: UKRI		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Andropoulos DB, 2010, J THORAC CARDIOV SUR, V139, P543, DOI 10.1016/j.jtcvs.2009.08.022; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Barber PA, 2008, STROKE, V39, P1427, DOI 10.1161/STROKEAHA.107.502989; BARZO P, 1993, NEUROSURGERY, V32, P611; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; Bijlenga P, 2010, NEUROCRIT CARE, V13, P17, DOI 10.1007/s12028-010-9362-1; Bisschops LLA, 2012, CRIT CARE MED, V40, P1136, DOI 10.1097/CCM.0b013e3182377050; Brady KM, 2010, STROKE, V41, P1957, DOI 10.1161/STROKEAHA.109.575167; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 1997, STROKE, V41, P17; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Eide PK, 2007, NEUROL RES, V29, P798, DOI 10.1179/016164107X224132; Eide PK, 2012, J NEUROSURG, V116, P961, DOI 10.3171/2012.1.JNS111313; Frumento RJ, 2003, ANN THORAC SURG, V75, P479, DOI 10.1016/S0003-4975(02)04475-2; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grande PO, 2011, J NEUROSURG ANESTH, V23, P358, DOI 10.1097/01.ana.0000405612.20356.84; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Lamy A, 2012, NEW ENGL J MED, V366, P1489, DOI 10.1056/NEJMoa1200388; LASSEN NA, 1984, HDB PHYSL CARDIOVASC, V3, P21; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Lazaridis C, 2010, NEUROSURG CLIN N AM, V21, P353, DOI 10.1016/j.nec.2009.10.006; Lee JK, 2012, ANESTH ANALG, V114, P825, DOI 10.1213/ANE.0b013e31824762d5; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McQuillen PS, 2007, STROKE, V38, P736, DOI 10.1161/01.STR.0000247941.41234.90; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Minhas PS, 2003, NEUROSURGERY, V52, P1017, DOI 10.1227/01.NEU.0000058231.08870.1F; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Piechnik S, 1998, ACT NEUR S, V71, P269; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Rasulo FA, 2012, J NEUROSURG ANESTH, V24, P3, DOI 10.1097/ANA.0b013e318224030a; Ratsep T, 2001, J NEUROSURG, V95, P393, DOI 10.3171/jns.2001.95.3.0393; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Smielewski P, 2005, ACT NEUR S, V95, P43; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; Takasu A, 2001, RESUSCITATION, V49, P273, DOI 10.1016/S0300-9572(00)00360-9; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	71	39	39	0	20	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	MAR	2013	35	2					138	148		10.1179/1743132812Y.0000000150			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	101KL	WOS:000315773800009	23452576				2022-02-06	
J	Sanchez-Aguilar, M; Tapia-Perez, JH; Sanchez-Rodriguez, JJ; Vinas-Rios, JM; Martinez-Perez, P; de la Cruz-Mendoza, E; Sanchez-Reyna, M; Torres-Corzo, JG; Gordillo-Moscoso, A				Sanchez-Aguilar, Martin; Tapia-Perez, J. Humberto; Juan Sanchez-Rodriguez, Jose; Manuel Vinas-Rios, Juan; Martinez-Perez, Patricia; de la Cruz-Mendoza, Esperanza; Sanchez-Reyna, Martin; Gerardo Torres-Corzo, Jaime; Gordillo-Moscoso, Antonio			Effect of rosuvastatin on cytokines after traumatic head injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; rosuvastatin; cytokine; disability	BRAIN-INJURY; STATINS; SIMVASTATIN; RATS; AMNESIA; DISEASE; SCALE	Object. The favorable effect of statin treatment after traumatic brain injury (TBI) has been shown in animal studies and is probably true in humans as well. The objective of this study was to determine whether acute statin treatment following TBI could reduce inflammatory cytokines and improve functional outcomes in humans. Methods. The authors performed a double-blind randomized clinical trial in patients with moderate to severe TBI. Exclusion criteria were as follows: prior severe disability; use of modifiers of statin metabolism; multisystem trauma; prior use of mannitol, barbiturates, corticosteroids, or calcium channel blockers; isolated brainstem lesions; allergy to statins; previous hepatopathy or myopathy; previous treatment at another clinic; and pregnancy. Patients were randomly selected to receive 20 mg of rosuvastatin or placebo for 10 days. The main goal was to determine the effect of rosuvastatin on plasma levels of tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-6, and IL-10 after 72 hours of TBI. Amnesia, disorientation, and disability were assessed 3 and 6 months after TBI. Results. Thirty-six patients were analyzed according to intention-to-treat analysis; 19 patients received rosuvastatin and 17 received placebo. The best-fit mixed model showed a significant effect of rosuvastatin on the reduction of tumor necrosis factor-alpha levels (p = 0.004). Rosuvastatin treatment did not appear to affect the levels of IL-1 beta, IL-6, and IL-10. The treatment was associated with a reduction in disability scores (p = 0.03), indicating a favorable functional outcome. Life-threatening adverse effects were not observed. Conclusions. The authors' data suggest that statins may induce an antiinflammatory effect and may promote recovery after TBI. The role of statins in TBI therapy should be confirmed in larger clinical trials. Clinical trial registration no.: NCT00990028. (http://thejns.org/doi/abs/10.3171/2012.12.JNS121084)	[Sanchez-Aguilar, Martin; Juan Sanchez-Rodriguez, Jose; Manuel Vinas-Rios, Juan; Sanchez-Reyna, Martin; Gordillo-Moscoso, Antonio] Univ Autonoma San Luis Potosi, Dept Clin Epidemiol, San Luis Potosi 78210, Mexico; [de la Cruz-Mendoza, Esperanza] Univ Autonoma San Luis Potosi, Dept Nucl Med Lab, San Luis Potosi 78210, Mexico; [Juan Sanchez-Rodriguez, Jose; Manuel Vinas-Rios, Juan; Gerardo Torres-Corzo, Jaime] Hosp Cent Dr Ignacio Morones Prieto, Dept Neurosurg, San Luis Potosi, Mexico; [Martinez-Perez, Patricia] Hosp Cent Dr Ignacio Morones Prieto, Dept Neuropsychol & Rehabil, San Luis Potosi, Mexico; [Tapia-Perez, J. Humberto] Otto Von Guericke Univ, Neurochirurg Klin, Magdeburg, Germany		Sanchez-Aguilar, M (corresponding author), Univ Autonoma San Luis Potosi, Dept Clin Epidemiol, Av Venustiano Carranza 2405, San Luis Potosi 78210, Mexico.	jemarsan7@hotmail.com		TORRES-CORZO, JAIME G./0000-0002-3981-0831	Programa Integral de Fortalecimiento Institucional de la Universidad Autonoma de San Luis Potosi [C1O-PIFI-09-12.41, C1O-PIFI-03-06.06]	This study was supported by the "Programa Integral de Fortalecimiento Institucional de la Universidad Autonoma de San Luis Potosi" (C1O-PIFI-09-12.41 and C1O-PIFI-03-06.06). The medication was provided by AstraZeneca.	Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Floyd JS, 2012, JAMA-J AM MED ASSOC, V307, P1580, DOI 10.1001/jama.2012.489; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2010, ACTA NEUROCHIR, V152, P953, DOI 10.1007/s00701-009-0584-y; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt OI, 2007, ORTHOPADE, V36, P248, DOI 10.1007/s00132-007-1061-z; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Tapia-Perez JH, 2010, NEUROSURG REV, V33, P259, DOI 10.1007/s10143-010-0259-4; Turkoglu OF, 2009, SURG NEUROL, V72, P146, DOI 10.1016/j.surneu.2008.07.004; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Wood WG, 2010, ANN NY ACAD SCI, V1199, P69, DOI 10.1111/j.1749-6632.2009.05359.x	25	39	41	1	27	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2013	118	3					669	675		10.3171/2012.12.JNS121084			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	094DW	WOS:000315244200031	23289819				2022-02-06	
J	Schwarzmaier, SM; Zimmermann, R; McGarry, NB; Trabold, R; Kim, SW; Plesnila, N				Schwarzmaier, Susanne M.; Zimmermann, Ricarda; McGarry, Niamh B.; Trabold, Raimund; Kim, Seong-Woong; Plesnila, Nikolaus			In vivo temporal and spatial profile of leukocyte adhesion and migration after experimental traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Leukocytes; Inflammation; Brain trauma; Secondary brain damage; Leukocyte adhesion; Leukocyte-platelet aggregates; 2-photon microscopy; Intravital microscopy; In vivo; Mice	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; FLUID PERCUSSION INJURY; ISCHEMIC CELL-DAMAGE; P-SELECTIN; CONTUSION VOLUME; MAC-1 CD11B/CD18; EDEMA FORMATION; RATS; INFLAMMATION	Background: Leukocytes are believed to be involved in delayed cell death following traumatic brain injury (TBI). However, data demonstrating that blood-borne inflammatory cells are present in the injured brain prior to the onset of secondary brain damage have been inconclusive. We therefore investigated both the interaction between leukocytes and the cerebrovascular endothelium using in vivo imaging and the accumulation of leukocytes in the penumbra following experimentally induced TBI. Methods: Experimental TBI was induced in C57/Bl6 mice (n = 42) using the controlled cortical impact (CCI) injury model, and leukocyte-endothelium interactions (LEI) were quantified using both intravital fluorescence microscopy (IVM) of superficial vessels and 2-photon microscopy of cortical vessels for up to 14 h post-CCI. In a separate experimental group, leukocyte accumulation and secondary lesion expansion were analyzed in mice that were sacrificed 15 min, 2, 6, 12, 24, or 48 h after CCI (n = 48). Finally, leukocyte adhesion was blocked with anti-CD18 antibodies, and the effects on LEI and secondary lesion expansion were determined 16 (n = 12) and 24 h (n = 21), respectively, following TBI. Results: One hour after TBI leukocytes and leukocyte-platelet aggregates started to roll on the endothelium of pial venules, whereas no significant LEI were observed in pial arterioles or in sham-operated mice. With a delay of >4 h, leukocytes and aggregates did also firmly adhere to the venular endothelium. In deep cortical vessels (250 mu m) LEIs were much less pronounced. Transmigration of leukocytes into the brain parenchyma only became significant after the tissue became necrotic. Treatment with anti-CD18 antibodies reduced adhesion by 65%; however, this treatment had no effect on secondary lesion expansion. Conclusions: LEI occurred primarily in pial venules, whereas little or no LEI occurred in arterioles or deep cortical vessels. Inhibiting LEI did not affect secondary lesion expansion. Importantly, the majority of migrating leukocytes entered the injured brain parenchyma only after the tissue became necrotic. Our results therefore suggest that neither intravascular leukocyte adhesion nor the migration of leukocytes into cerebral tissue play a significant role in the development of secondary lesion expansion following TBI.	[Schwarzmaier, Susanne M.; Zimmermann, Ricarda; Trabold, Raimund; Kim, Seong-Woong; Plesnila, Nikolaus] Univ Munich, Med Ctr, Walter Brendel Ctr Expt Med, Inst Surg Res, D-81377 Munich, Germany; [Schwarzmaier, Susanne M.; McGarry, Niamh B.; Kim, Seong-Woong; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland; [Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res ISD, D-81377 Munich, Germany		Plesnila, N (corresponding author), Univ Munich, Med Ctr, Walter Brendel Ctr Expt Med, Inst Surg Res, Marchioninistr 15, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019				Arumugam TV, 2004, AM J PHYSIOL-HEART C, V287, pH2555, DOI 10.1152/ajpheart.00588.2004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Edens HA, 2000, ADV DRUG DELIVER REV, V41, P315, DOI 10.1016/S0169-409X(00)00049-1; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Etalamy I, 2008, THROMB RES, V121, P843, DOI 10.1016/j.thromres.2007.07.016; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HARLAN JM, 1985, BLOOD, V65, P513; Hartl R, 1997, ACT NEUR S, V70, P240; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; He PN, 2006, AM J PHYSIOL-HEART C, V291, pH591, DOI 10.1152/ajpheart.01228.2005; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ishikawa M, 2009, NEUROSURGERY, V64, P546, DOI 10.1227/01.NEU.0000337579.05110.F4; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; LEHR HA, 1994, LAB INVEST, V71, P380; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; McKeating EG, 1998, ACT NEUR S, V71, P200; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Rothlein R, 1997, NEUROLOGY, V49, pS3, DOI 10.1212/WNL.49.5_Suppl_4.S3; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Scallan J, 2010, CAPILLARY FLUID EXCH; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1999, STROKE, V30, P134, DOI 10.1161/01.STR.30.1.134; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	59	39	39	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 28	2013	10								32	10.1186/1742-2094-10-32			17	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	114OV	WOS:000316752500001	23448240	gold, Green Published, Green Accepted			2022-02-06	
J	Yang, J; Ahn, HN; Chang, M; Narasimhan, P; Chan, PH; Song, YS				Yang, Jiwon; Ahn, Hye-na; Chang, Minsun; Narasimhan, Purnima; Chan, Pak H.; Song, Yun Seon			Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						antioxidant; complement component 3; focal cerebral ischemia; oxidative stress	SUPEROXIDE DISMUTASE ACTIVITY; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; N-TERT-BUTYLNITRONE; EXPERIMENTAL STROKE; ALTERNATIVE PATHWAY; LIVER-REGENERATION; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSGENIC MICE	Oxidative stress after stroke is associated with the inflammatory system activation in the brain. The complement cascade, especially the degradation products of complement component 3, is a key inflammatory mediator of cerebral ischemia. We have shown that pro-inflammatory complement component 3 is increased by oxidative stress after ischemic stroke in mice using DNA array. In this study, we investigated whether up-regulation of complement component 3 is directly related to oxidative stress after transient focal cerebral ischemia in mice and oxygen-glucose deprivation in brain cells. Persistent up-regulation of complement component 3 expression was reduced in copper/zinc-superoxide dismutase transgenic mice, and manganese-superoxide dismutase knock-out mice showed highly increased complement component 3 levels after transient focal cerebral ischemia. Antioxidant N-tert-butyl-a-phenylnitrone treatment suppressed complement component 3 expression after transient focal cerebral ischemia. Accumulation of complement component 3 in neurons and microglia was decreased by N-tert-butyl-a-phenylnitrone, which reduced infarct volume and impaired neurological deficiency after cerebral ischemia and reperfusion in mice. Small interfering RNA specific for complement component 3 transfection showed a significant increase in brain cells viability after oxygen-glucose deprivation. Our study suggests that the neuroprotective effect of antioxidants through complement component 3 suppression is a new strategy for potential therapeutic approaches in stroke.	[Yang, Jiwon; Ahn, Hye-na; Song, Yun Seon] Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Seoul 140742, South Korea; [Chang, Minsun] Sookmyung Womens Univ, Coll Sci, Dept Med & Pharmaceut Sci, Seoul 140742, South Korea; [Narasimhan, Purnima; Chan, Pak H.; Song, Yun Seon] Stanford Univ, Dept Neurosurg, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Narasimhan, Purnima; Chan, Pak H.; Song, Yun Seon] Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA		Song, YS (corresponding author), Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Chungpa Ro 47,Gil 100, Seoul 140742, South Korea.	yssong@sookmyung.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [KRF-2008-313-E00359]; SRC program [20090063046]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [PO1 NS014543, RO1 NS025372, RO1 NS038653]; James R. Doty Endowment; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038653, P01NS014543, R01NS025372] Funding Source: NIH RePORTER	The authors declare no conflict of interest. This study was supported by National Research Foundation of Korea grant #KRF-2008-313-E00359 and SRC program # 20090063046 to Y.S.S. and by grants PO1 NS014543, RO1 NS025372, and RO1 NS038653, from the National Institutes of Health, and by the James R. Doty Endowment to P. H. C. The authors thank Cheryl Christensen for her editorial assistance and Elizabeth Hoyte for assistance with the figures.	Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801; Arumugam TV, 2009, NEUROSCIENCE, V158, P1074, DOI 10.1016/j.neuroscience.2008.07.015; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.3.CO;2-9; Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433; Chakraborti T, 2000, CELL SIGNAL, V12, P607, DOI 10.1016/S0898-6568(00)00111-X; Cojocaru Inimioara Mihaela, 2008, Rom J Intern Med, V46, P77; Cowell RM, 2003, J NEUROSCI, V23, P9459; Crehan H, 2012, INT J ALZHEIMERS DIS, V2012; Daha MR, 2010, CRIT REV IMMUNOL, V30, P47, DOI 10.1615/CritRevImmunol.v30.i1.30; Daveau M, 2004, J IMMUNOL, V173, P3418, DOI 10.4049/jimmunol.173.5.3418; del Zoppo GJ, 1999, NAT MED, V5, P995, DOI 10.1038/12431; Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664; Ducruet AF, 2009, EXP NEUROL, V219, P398, DOI 10.1016/j.expneurol.2009.07.018; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003; Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Jendrysik MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028198; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lancelot E, 1997, FREE RADICAL BIO MED, V23, P1031, DOI 10.1016/S0891-5849(97)00128-7; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Li YB, 1998, BRAIN RES, V814, P164, DOI 10.1016/S0006-8993(98)01082-8; Liu XL, 2003, ACTA ANAESTH SCAND, V47, P958, DOI 10.1034/j.1399-6576.2003.00189.x; Lockwood SF, 2005, CARDIOVASC DRUG REV, V23, P199; Maranto J, 2008, J NEUROIMMUNE PHARM, V3, P43, DOI 10.1007/s11481-007-9096-9; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; MIYAJIMA T, 1995, BIOCHEM BIOPH RES CO, V215, P114, DOI 10.1006/bbrc.1995.2440; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; Montalto MC, 2003, AM J PHYSIOL-GASTR L, V285, pG197, DOI 10.1152/ajpgi.00029.2003; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362; Papp K, 2010, RHEUMATOLOGY, V49, P2273, DOI 10.1093/rheumatology/keq278; Pavlovski D, 2012, FASEB J, V26, P3680, DOI 10.1096/fj.11-202382; Qu H, 2009, MOL IMMUNOL, V47, P185, DOI 10.1016/j.molimm.2009.08.032; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Schaefer M, 2005, J BIOL CHEM, V280, P42113, DOI 10.1074/jbc.M508146200; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Sliwa T, 2012, CURR PHARM BIOTECHNO; Song YS, 2007, J CEREBR BLOOD F MET, V27, P764, DOI 10.1038/sj.jcbfm.9600379; Stokowska A, 2011, CEREBROVASC DIS, V32, P114, DOI 10.1159/000328238; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Taskapilioglu MO, 2009, J CLIN NEUROSCI, V16, P693, DOI 10.1016/j.jocn.2008.07.077; Tsai TH, 2012, J ATHEROSCLER THROMB, V19, P523, DOI 10.5551/jat.10751; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; VAKEVA A, 1994, AM J PATHOL, V144, P1357; Vakeva A, 1998, APMIS, V106, P1149; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Vibo R, 2007, FREE RADICAL RES, V41, P282, DOI 10.1080/10715760601083235; VIK DP, 1991, BIOCHEMISTRY-US, V30, P1080, DOI 10.1021/bi00218a029; Whiteley W, 2012, STROKE, V43, P86, DOI 10.1161/STROKEAHA.111.634089; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12; Yang CM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-12; Yang JP, 2009, NEUROSCI LETT, V461, P212, DOI 10.1016/j.neulet.2009.06.060; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035; Yu SC, 2012, BIOMARKERS, V17, P319, DOI 10.3109/1354750X.2012.668712	68	39	43	1	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2013	124	4					523	535		10.1111/jnc.12111			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	079QK	WOS:000314186300010	23199288	Bronze, Green Accepted			2022-02-06	
J	Namjoshi, DR; Martin, G; Donkin, J; Wilkinson, A; Stukas, S; Fan, JJ; Carr, M; Tabarestani, S; Wuerth, K; Hancock, REW; Wellington, CL				Namjoshi, Dhananjay R.; Martin, Georgina; Donkin, James; Wilkinson, Anna; Stukas, Sophie; Fan, Jianjia; Carr, Michael; Tabarestani, Sepideh; Wuerth, Kelli; Hancock, Robert E. W.; Wellington, Cheryl L.			The Liver X Receptor Agonist GW3965 Improves Recovery from Mild Repetitive Traumatic Brain Injury in Mice Partly through Apolipoprotein E	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; AXONAL INJURY; HEAD-INJURY; AMYLOID DEPOSITION; E POLYMORPHISM; MOUSE MODEL; LIPOPROTEIN PARTICLES; APP23 MICE	Traumatic brain injury (TBI) increases Alzheimer's disease (AD) risk and leads to the deposition of neurofibrillary tangles and amyloid deposits similar to those found in AD. Agonists of Liver X receptors (LXRs), which regulate the expression of many genes involved in lipid homeostasis and inflammation, improve cognition and reduce neuropathology in AD mice. One pathway by which LXR agonists exert their beneficial effects is through ATP-binding cassette transporter A1 (ABCA1)-mediated lipid transport onto apolipoprotein E (apoE). To test the therapeutic utility of this pathway for TBI, we subjected male wild-type (WT) and apoE(-/-) mice to mild repetitive traumatic brain injury (mrTBI) followed by treatment with vehicle or the LXR agonist GW3965 at 15 mg/kg/day. GW3965 treatment restored impaired novel object recognition memory in WT but not apoE(-/-) mice. GW3965 did not significantly enhance the spontaneous recovery of motor deficits observed in all groups. Total soluble A beta(40) and A beta(42) levels were significantly elevated in WT and apoE(-/-) mice after injury, a response that was suppressed by GW3965 in both genotypes. WT mice showed mild but significant axonal damage at 2 d post-mrTBI, which was suppressed by GW3965. In contrast, apoE(-/-) mice showed severe axonal damage from 2 to 14 d after mrTBI that was unresponsive to GW3965. Because our mrTBI model does not produce significant inflammation, the beneficial effects of GW3965 we observed are unlikely to be related to reduced inflammation. Rather, our results suggest that both apoE-dependent and apoE-independent pathways contribute to the ability of GW3965 to promote recovery from mrTBI.	[Namjoshi, Dhananjay R.; Martin, Georgina; Donkin, James; Wilkinson, Anna; Stukas, Sophie; Fan, Jianjia; Carr, Michael; Tabarestani, Sepideh; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Wuerth, Kelli; Hancock, Robert E. W.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada		Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.	cheryl@cmmt.ubc.ca	Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Stukas, Sophie/0000-0001-8819-8821; Namjoshi, Dhananjay/0000-0003-1753-5581; Wuerth, Kelli/0000-0001-5260-9166	operating grant from the Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP 67088]; Alzheimer Society Research Program (ASRP, Alzheimer Society of Canada) doctoral award; ASRP post-doctoral award; CIHR Vanier studentshipCanadian Institutes of Health Research (CIHR); Child & Family Research Institute studentship	This work was supported by an operating grant (MOP 67088) to C.L.W. from the Canadian Institutes of Health Research (CIHR). D.R.N. was supported by Alzheimer Society Research Program (ASRP, Alzheimer Society of Canada) doctoral award. J.D. was supported by an ASRP post-doctoral award. S.S. was supported by a CIHR Vanier studentship. J.F. was supported by a Child & Family Research Institute studentship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeCuypere M, 2012, SURG CLIN N AM, V92, P939, DOI 10.1016/j.suc.2012.04.005; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Donkin JJ, 2010, J BIOL CHEM, V285, P34144, DOI 10.1074/jbc.M110.108100; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Faul M, 2010, TRAUMATIC BRAIN INJU; Fitz NF, 2010, J NEUROSCI, V30, P6862, DOI 10.1523/JNEUROSCI.1051-10.2010; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Groot PHE, 2005, J LIPID RES, V46, P2182, DOI 10.1194/jlr.M500116-JLR200; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iwata A, 2005, J NEUROSCI RES, V82, P103, DOI 10.1002/jnr.20607; Jamroz-Wisniewska Anna, 2007, Postepy Hig Med Dosw (Online), V61, P760; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; May S, 2011, J NEUROLOGY NEUROSCI, V2, P1; Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450-JLR200; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Petit-Turcotte C, 2007, NEUROSCIENCE, V150, P58, DOI 10.1016/j.neuroscience.2007.05.021; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Riddell DR, 2007, MOL CELL NEUROSCI, V34, P621, DOI 10.1016/j.mcn.2007.01.011; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wahrle SE, 2008, J CLIN INVEST, V118, P671, DOI 10.1172/JCI33622; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wojcicka Grazyna, 2007, Postepy Hig Med Dosw (Online), V61, P736; Zelcer N, 2007, P NATL ACAD SCI USA, V104, P10601, DOI 10.1073/pnas.0701096104; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	68	39	40	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2013	8	1							e53529	10.1371/journal.pone.0053529			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	073JI	WOS:000313738900009	23349715	Green Published, Green Submitted, gold			2022-02-06	
J	Al Nimer, F; Lindblom, R; Strom, M; Guerreiro-Cacais, AO; Parsa, R; Aeinehband, S; Mathiesen, T; Lidman, O; Piehl, F				Al Nimer, Faiez; Lindblom, Rickard; Strom, Mikael; Guerreiro-Cacais, Andre Ortlieb; Parsa, Roham; Aeinehband, Shahin; Mathiesen, Tiit; Lidman, Olle; Piehl, Fredrik			Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Inbred rat strains; Complement; Genetic; Neutrophils; Macrophages; Microglia; NK cells; CXCL1; Neurofilament light	MAJOR HISTOCOMPATIBILITY COMPLEX; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; NEUROFILAMENT LIGHT; EXPRESSION; BLOOD; SUSCEPTIBILITY; SUBSET; MHC	Increasing evidence suggests that genetic background affects outcome of traumatic brain injuries (TB!). Still, there is limited detailed knowledge on what pathways/processes are affected by genetic heterogeneity. The inbred rat strains DA and PVC differ in neuronal survival following TBI. We here carried out global expressional profiling to identify differentially regulated pathways governing the response to an experimental controlled brain contusion injury. One of the most differentially regulated molecular networks concerned immune cell trafficking. Subsequent characterization of the involved cells using flow cytometry demonstrated greater infiltration of neutrophils and monocytes, as well as a higher degree of microglia activation in DA compared to PVG rats. In addition, DA rats displayed a higher number of NK cells and a higher ratio of CD161bright compared to CD161dim NK cells. Local expression of complement pathway molecules such as Cl and C3 was higher in DA and both the key complement component C3 and membrane-attack complex (MAC) could be demonstrated on axons and nerve cells. A stronger activation of the complement system in DA was associated with higher cerebrospinal fluid levels of neurofilament-light, a biomarker for nerve/axonal injury. In summary, we demonstrate substantial differences between DA and PVC rats in activation of inflammatory pathways; in particular, immune cell influx and complement activation associated with neuronal/axonal injury after TBI. These findings suggest genetic influences acting on inflammatory activation to be of importance in TBI and motivate further efforts using experimental forward genetics to identify genes/pathways that affect outcome. (C) 2012 Elsevier Inc. All rights reserved.	[Al Nimer, Faiez] Karolinska Univ Hosp, CMM, Neuroimmunol Unit, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Mathiesen, Tiit] Karolinska Univ Hosp, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden		Al Nimer, F (corresponding author), Karolinska Univ Hosp, CMM, Neuroimmunol Unit, Dept Clin Neurosci, L8 04, S-17176 Stockholm, Sweden.	faiez.al.nimer@ki.se	Nimer, Faiez Al/ABB-9465-2020; Piehl, Fredrik/E-3451-2013; Parsa, Roham/AAV-4002-2021; mathiesen, tiit/ABC-3627-2021; Guerreiro-Cacais, Andre Ortlieb/AAE-8417-2019	Parsa, Roham/0000-0002-0864-6098; Al Nimer, Faiez/0000-0003-0937-5995; Mathiesen, Tiit/0000-0001-9463-1919; Guerreiro-Cacais, Andre Ortlieb/0000-0002-4561-2823; Lindblom, Rickard/0000-0001-7913-4981	European UnionEuropean Commission [LSHM-CT-2005-018637, LSHG-CT-2005019015, HEALTH-F4-2010-241504]; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Swedish Association of Persons with Neurological Disabilities	This study was supported by the 6th Framework Program of the European Union, NeuroproMiSe, LSHM-CT-2005-018637, EURA-Tools, LSHG-CT-2005019015, and the 7th Framework Program of the European Union, EURATrans, HEALTH-F4-2010-241504, by the Swedish Research Council, the Swedish Brain Foundation and the Swedish Association of Persons with Neurological Disabilities.	Abrams MB, 2007, EUR J NEUROSCI, V26, P1118, DOI 10.1111/j.1460-9568.2007.05725.x; Al Nimer F., 2012, ANTIOXID REDOX SIGNA; Al Nimer F, 2011, BRAIN BEHAV IMMUN, V25, P981, DOI 10.1016/j.bbi.2010.10.017; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Dominguez C.A., 2012, EUR J PAIN; Dominguez CA, 2008, PAIN, V136, P313, DOI 10.1016/j.pain.2007.07.009; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Harnesk K, 2008, J IMMUNOL, V180, P3289, DOI 10.4049/jimmunol.180.5.3289; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Inngjerdingen M, 2012, J IMMUNOL, V188, P2499, DOI 10.4049/jimmunol.1003939; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Johnson TA, 2011, J IMMUNOL, V187, P570, DOI 10.4049/jimmunol.1003823; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kheradmand T, 2008, J LEUKOCYTE BIOL, V83, P1128, DOI 10.1189/jlb.0907626; Kim EY, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2755; KORNBLUM J, 1968, J IMMUNOL, V101, P702; Kumar A., 2012, BRAIN BEHAV IMMUN; Lidman O, 2003, J NEUROSCI, V23, P9817; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marta M, 2010, GENES IMMUN, V11, P21, DOI 10.1038/gene.2009.62; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McElroy JP, 2011, NEUROL CLIN, V29, P219, DOI 10.1016/j.ncl.2010.12.002; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Norgren N, 2005, BRAIN RES BULL, V67, P264, DOI 10.1016/j.brainresbull.2005.06.031; Norimatsu Y, 2012, AM J PATHOL, V180, P1625, DOI 10.1016/j.ajpath.2011.12.012; Piehl F, 2009, NEUROSCIENCE, V158, P1143, DOI 10.1016/j.neuroscience.2008.08.031; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Salzer J, 2010, MULT SCLER J, V16, P287, DOI 10.1177/1352458509359725; Sheridan JP, 2011, MULT SCLER J, V17, P1441, DOI 10.1177/1352458511414755; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Strom M, 2012, NEUROMOL MED, V14, P15, DOI 10.1007/s12017-011-8164-8; Sun XC, 2008, CHIN J TRAUMATOL, V11, P247, DOI 10.1016/S1008-1275(08)60051-6; Swanberg M, 2005, NAT GENET, V37, P486, DOI 10.1038/ng1544; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Teunissen CE, 2005, LANCET NEUROL, V4, P32, DOI 10.1016/S1474-4422(04)00964-0; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	49	39	39	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JAN	2013	27						109	122		10.1016/j.bbi.2012.10.002			14	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	058JE	WOS:000312629100015	23044177				2022-02-06	
J	Almonte, AG; Qadri, LH; Sultan, FA; Watson, JA; Mount, DJ; Rumbaugh, G; Sweatt, JD				Almonte, Antoine G.; Qadri, Laura H.; Sultan, Faraz A.; Watson, Jennifer A.; Mount, Daniel J.; Rumbaugh, Gavin; Sweatt, J. David			Protease-activated receptor-1 modulates hippocampal memory formation and synaptic plasticity	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; hippocampus; learning; long-term potentiation (LTP); memory; protease-activated receptor-1 (PAR1)	LONG-TERM POTENTIATION; TISSUE-PLASMINOGEN ACTIVATOR; THROMBIN RECEPTOR; PATTERNED STIMULATION; POSSIBLE INVOLVEMENT; ASTROCYTE CALCIUM; NEURONAL DAMAGE; MESSENGER-RNA; MICE LACKING; MAP KINASE	Protease-activated receptor-1 (PAR1) is an unusual G-protein coupled receptor (GPCR) that is activated through proteolytic cleavage by extracellular serine proteases. Although previous work has shown that inhibiting PAR1 activation is neuroprotective in models of ischemia, traumatic injury, and neurotoxicity, surprisingly little is known about PAR1's contribution to normal brain function. Here, we used PAR1-/- mice to investigate the contribution of PAR1 function to memory formation and synaptic function. We demonstrate that PAR1-/- mice have deficits in hippocampus-dependent memory. We also show that while PAR1-/- mice have normal baseline synaptic transmission at Schaffer collateral-CA1 synapses, they exhibit severe deficits in N-methyl-d-aspartate receptor (NMDAR)-dependent long-term potentiation (LTP). Mounting evidence indicates that activation of PAR1 leads to potentiation of NMDAR-mediated responses in CA1 pyramidal cells. Taken together, this evidence and our data suggest an important role for PAR1 function in NMDAR-dependent processes subserving memory formation and synaptic plasticity.	[Almonte, Antoine G.; Qadri, Laura H.; Sultan, Faraz A.; Watson, Jennifer A.; Mount, Daniel J.; Sweatt, J. David] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; [Almonte, Antoine G.; Qadri, Laura H.; Sultan, Faraz A.; Watson, Jennifer A.; Mount, Daniel J.; Sweatt, J. David] Univ Alabama Birmingham, Evelyn F McKnight Brain Inst, Birmingham, AL 35294 USA; [Rumbaugh, Gavin] Scripps Res Inst, Dept Neurosci, Jupiter, FL USA		Sweatt, JD (corresponding author), Univ Alabama Birmingham, Dept Neurobiol, 1825 Univ Blvd,Shelby 1010, Birmingham, AL 35294 USA.	dsweatt@nrc.uab.edu		Sweatt, J. David/0000-0003-3567-485X; Almonte, Antoine/0000-0002-8778-2724	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH57014, AG031722, NS057098]; Evelyn F. McKnight Brain Research Foundation; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH057014, R01MH096847, R01MH091122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064079, P30NS057098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031722] Funding Source: NIH RePORTER	We thank Brandon Walters, Lynn Dobrunz (University of Alabama at Birmingham), Cendra Agulhon (University of North Carolina at Chapel Hill), and Stephen Traynelis (Emory University) for helpful discussions. We also thank Christopher Rex (University of California, Irvine) for help with theta-burst response analysis. We thank Kelsey Patterson and Dawn Eason (University of Alabama at Birmingham) for excellent technical assistance. This work was supported by NIH grants MH57014, AG031722, NS057098, and funds from the Evelyn F. McKnight Brain Research Foundation. The authors declare no conflicts of interest.	Agulhon C, 2008, NEURON, V59, P932, DOI 10.1016/j.neuron.2008.09.004; Agulhon C, 2010, SCIENCE, V327, P1250, DOI 10.1126/science.1184821; Almonte AG, 2007, NEUROBIOL LEARN MEM, V88, P295, DOI 10.1016/j.nlm.2007.04.004; Almonte AG, 2011, BRAIN RES, V1407, P107, DOI 10.1016/j.brainres.2011.06.042; ARAI A, 1994, HIPPOCAMPUS, V4, P1, DOI 10.1002/hipo.450040103; ARAI A, 1992, BRAIN RES, V598, P173, DOI 10.1016/0006-8993(92)90181-8; Arai AC, 2004, NEUROSCIENCE, V123, P1011, DOI 10.1016/j.neuroscience.2003.10.033; Bahr BA, 1997, J NEUROSCI, V17, P1320; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bourgognon J. M., 2008, 2008 NEUR M PLANN; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Day JJ, 2010, NAT NEUROSCI, V13, P1319, DOI 10.1038/nn.2666; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Erreger K, 2005, J PHYSIOL-LONDON, V569, P381, DOI 10.1113/jphysiol.2005.095497; Erreger K., 2007, J PHYSL, V586, P763; Fellin T, 2009, J NEUROCHEM, V108, P533, DOI 10.1111/j.1471-4159.2008.05830.x; Fiacco TA, 2009, ANNU REV PHARMACOL, V49, P151, DOI 10.1146/annurev.pharmtox.011008.145602; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gomez-Gonzalo M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000352; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Hamill CE, 2007, MOL PHARMACOL, V72, P653, DOI 10.1124/mol.107.038158; Hamill Cecily E, 2005, Clin Neurosurg, V52, P29; Hamill CE, 2009, EXP NEUROL, V217, P136, DOI 10.1016/j.expneurol.2009.01.023; Hamilton NB, 2010, NAT REV NEUROSCI, V11, P227, DOI 10.1038/nrn2803; Han KS, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-32; Hashimotodani Y, 2011, J NEUROSCI, V31, P3104, DOI 10.1523/JNEUROSCI.6000-10.2011; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Hermann GE, 2009, J NEUROSCI, V29, P9292, DOI 10.1523/JNEUROSCI.6063-08.2009; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Ito M, 2007, J NEUROCHEM, V101, P1392, DOI 10.1111/j.1471-4159.2006.04423.x; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Kreda SM, 2008, BRIT J PHARMACOL, V153, P1528, DOI 10.1038/sj.bjp.0707692; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; Lau CG, 2007, NAT REV NEUROSCI, V8, P413, DOI 10.1038/nrn2153; Lee CJ, 2007, J PHYSIOL-LONDON, V581, P1057, DOI 10.1113/jphysiol.2007.130377; Lee S, 2010, SCIENCE, V330, P790, DOI 10.1126/science.1184334; Lohman RJ, 2008, NEUROBIOL DIS, V30, P84, DOI 10.1016/j.nbd.2007.12.010; Lohman RJ, 2009, NEUROBIOL LEARN MEM, V92, P301, DOI 10.1016/j.nlm.2009.03.010; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Mannaioni G, 2008, J BIOL CHEM, V283, P20600, DOI 10.1074/jbc.M803015200; Miller CA, 2007, NEURON, V53, P857, DOI 10.1016/j.neuron.2007.02.022; Mizutani A, 1996, BRAIN RES, V739, P276, DOI 10.1016/S0006-8993(96)00834-7; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Nagai T, 2006, J NEUROSCI, V26, P12374, DOI 10.1523/JNEUROSCI.3139-06.2006; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Nicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x; Niego B, 2011, BRAIN RES, V1381, P38, DOI 10.1016/j.brainres.2011.01.016; Noorbakhsh F, 2003, NAT REV NEUROSCI, V4, P981, DOI 10.1038/nrn1255; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Olson EE, 2004, J CEREBR BLOOD F MET, V24, P964, DOI 10.1097/01.WCB.0000128266.87474.BF; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Park H, 2009, J NEUROSCI, V29, P13063, DOI 10.1523/JNEUROSCI.3193-09.2009; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P18201, DOI 10.1073/pnas.0509232102; Pawlak R, 2002, NEUROSCIENCE, V113, P995, DOI 10.1016/S0306-4522(02)00166-5; Peng Y, 2010, HIPPOCAMPUS, V20, P646, DOI 10.1002/hipo.20654; Perez-Otano I, 2005, TRENDS NEUROSCI, V28, P229, DOI 10.1016/j.tins.2005.03.004; Ramachandran R, 2008, BRIT J PHARMACOL, V153, pS263, DOI 10.1038/sj.bjp.0707507; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Shavit E, 2011, J NEUROCHEM, V119, P460, DOI 10.1111/j.1471-4159.2011.07436.x; Shigetomi E, 2008, J NEUROSCI, V28, P6659, DOI 10.1523/JNEUROSCI.1717-08.2008; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Sweatt JD, 2010, MECHANISMS OF MEMORY, 2ND EDITION, P1, DOI 10.1016/B978-0-12-374951-2.00001-9; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tongiorgi E, 2003, NEUROSCIENCE, V119, P1013, DOI 10.1016/S0306-4522(03)00196-9; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; Walker DL, 2002, PHARMACOL BIOCHEM BE, V71, P379, DOI 10.1016/S0091-3057(01)00698-0; Watt AJ, 2004, NAT NEUROSCI, V7, P518, DOI 10.1038/nn1220; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Wenker I, 2010, J NEUROPHYSIOL, V104, P1216, DOI 10.1152/jn.00429.2010; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Zhao J, 2008, J NEUROSCI, V28, P3060, DOI 10.1523/JNEUROSCI.5450-07.2008; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	85	39	39	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2013	124	1					109	122		10.1111/jnc.12075			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	051NB	WOS:000312132900012	23113835	Bronze, Green Accepted			2022-02-06	
J	Brenner, LA; Homaifar, BY; Olson-Madden, JH; Nagamoto, HT; Huggins, J; Schneider, AL; Forster, JE; Matarazzo, B; Corrigan, JD				Brenner, Lisa A.; Homaifar, Beeta Y.; Olson-Madden, Jennifer H.; Nagamoto, Herbert T.; Huggins, Joe; Schneider, Alexandra L.; Forster, Jeri E.; Matarazzo, Bridget; Corrigan, John D.			Prevalence and Screening of Traumatic Brain Injury Among Veterans Seeking Mental Health Services	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mental health; screening; sensitivity; specificity; traumatic brain injury; Veterans	IDENTIFICATION; RELIABILITY; VALIDITY; TBI; INDIVIDUALS	Objectives: To assess the prevalence of traumatic brain injury (TBI) among Veterans seeking mental health services using a 4-item tool, the Traumatic Brain Injury-4 (TBI-4), and to establish the classification accuracy of the TBI-4 using the Ohio State University TBI-Identification Method as the criterion standard. Study Design: Archival and observational data collected from individuals seeking care at a Mountain State VA Medical Center. Participants: The sample for the archival study was 1810. Three hundred sixteen Veterans completed observational study measures. Main Measures: For the archival study, TBI-4 and demographic data extracted from electronic medical records. For the observational study, the Ohio State University TBI-Identification Method and a demographic questionnaire were used. TBI-4 data were also obtained from electronic medical records. Results: The prevalence of probable TBI among those seeking VA MH treatment was 45%. Sensitivity and specificity of the TBI-4 were 0.74 and 0.56, respectively. Veterans with all levels of TBI severity sought care within this VA mental health setting. Conclusions: The prevalence of TBI in this VA mental health treatment population was higher than expected. Additional research is required to assess the clinical utility of screening for TBI among this population of Veterans.	[Brenner, Lisa A.; Homaifar, Beeta Y.; Olson-Madden, Jennifer H.; Nagamoto, Herbert T.; Huggins, Joe; Schneider, Alexandra L.; Forster, Jeri E.; Matarazzo, Bridget] VA VISN 19 Mental Illness Res Educ & Clin Ctr MIR, Denver, CO USA; [Brenner, Lisa A.; Olson-Madden, Jennifer H.; Nagamoto, Herbert T.; Matarazzo, Bridget] Univ Colorado Denver, Sch Med, Dept Psychiat, Aurora, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Neurol, Aurora, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Forster, Jeri E.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA; [Homaifar, Beeta Y.] VA Boston Healthcare Syst, Boston, MA USA; [Homaifar, Beeta Y.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA; [Nagamoto, Herbert T.] Eastern Colorado Hlth Care Syst, Vet Affairs Med Ctr, Denver, CO USA; [Forster, Jeri E.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Brenner, LA (corresponding author), VISN 19 Mental Illness Res Educ & Clin Ctr MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019	Huggins, Joe/0000-0001-8151-5062	Colorado Traumatic Brain Injury Trust Fund Program	Support for this project was provided by the Colorado Traumatic Brain Injury Trust Fund Program.	Ahmed I, 1998, Semin Clin Neuropsychiatry, V3, P23; [Anonymous], 2008, SAS COMP PROGR VERS, V9, P2; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Arciniegas DB, 2010, PSYCHIAT ANN, V40, P540, DOI 10.3928/00485713-20101022-05; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Brenner LA, 2011, 2011 DOD VA ANN SUIC; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Coetzer R, 2009, CNS SPECTRUMS, V14, P632, DOI 10.1017/S1092852900023877; Corrigan JD, 2007, OHIO STATE U TBI IDE; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Department of Veterans Affairs, VA DOD CLIN PRACT GU; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Gizlice Z., 2002, HLTH CONDITIONS BEHA; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; McFall RM, 1999, ANNU REV PSYCHOL, V50, P215, DOI 10.1146/annurev.psych.50.1.215; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Office of Applied Studies, 2005, ALC US ALC REL RISK; Olson-Madden JH, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/174579; Olson-Madden JH, 2010, J HEAD TRAUMA REHAB, V25, P470, DOI 10.1097/HTR.0b013e3181d717a7; Pepe M S, 2003, STAT EVALUATION MED; Streiner DL, 2003, J PERS ASSESS, V81, P209, DOI 10.1207/S15327752JPA8103_03; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *US DEP HHS, HEADS FACTS PHYS MIL; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P82; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50	31	39	39	2	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					21	30		10.1097/HTR.0b013e31827df0b5			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400003	23288308				2022-02-06	
J	Gurley, JM; Hujsak, BD; Kelly, JL				Gurley, James M.; Hujsak, Bryan D.; Kelly, Jennifer L.			Vestibular rehabilitation following mild traumatic brain injury	NEUROREHABILITATION			English	Article						Vestibular rehabilitation; traumatic brain injury; concussion	PAROXYSMAL POSITIONAL VERTIGO; STABILITY FOLLOWING CONCUSSION; DIZZINESS HANDICAP INVENTORY; PREDICT PROTRACTED RECOVERY; SPORTS-RELATED CONCUSSION; HEART-RATE-VARIABILITY; VESTIBULOOCULAR REFLEX; POSTURAL-CONTROL; SMOOTH-PURSUIT; FOOTBALL PLAYERS	INTRODUCTION: Vertigo, dizziness, and imbalance are a symptom complex that is commonly found following concussion. Early metabolic changes following concussion may lead to worsening of the injury and symptoms in individuals not properly managed from the outset. When symptoms do not recover spontaneously, skilled vestibular rehabilitation can be an effective modality in an attempt to normalize the individual's vestibular responses. PURPOSE: The purpose of this review is to appraise the current and accepted methods available to the skilled clinician in quantifying and treating vestibular dysfunction following concussion. Incidence and prognostic indicators will be reviewed along with common barriers to recovery. SUMMARY: Vestibular Rehabilitation following concussion utilizes similar tools and techniques employed when treating those solely with peripheral pathology. The clinician must not only have a solid understanding of when and why certain exercises are required, but also be willing to accept that less exercise may be indicated in this population. As injury to the system following mild traumatic brain injury can include both peripheral and central structures, the duration of therapy and the time to recovery may be prolonged. Co-morbidities including cognitive and behavioral issues, visual-perceptual dysfunction, metabolic dysfunction, and autonomic dysfunction may hamper the effectiveness of the traditional Vestibular Rehabilitation approach. As successful treatment does not occur in a vacuum, working closely with other disciplines well versed in treating these co-morbid issues will help the individual to obtain optimal recovery. CONCLUSION: Vestibular Rehabilitation is an effective modality for managing dizziness, vertigo, and imbalance following concussion. Careful consideration of the acuity of the injury, along with effective management of co-morbid conditions will optimize the result.	[Gurley, James M.] Mercy Coll, Phys Therapy Program, Dobbs Ferry, NY 10522 USA; [Gurley, James M.] James J Peters VAMC, Dept Otololaryngol, Bronx, NY USA; [Hujsak, Bryan D.; Kelly, Jennifer L.] New York Eye & Ear Infirm, Vestibular Rehabil Dept, New York, NY USA		Gurley, JM (corresponding author), Mercy Coll, Phys Therapy Program, 555 Broadway, Dobbs Ferry, NY 10522 USA.	jgurley@mercy.edu					Ahn S. K., 2010, TRAUMA, V20, P1; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Blatt PJ, 2000, AM J OTOL, V21, P356, DOI 10.1016/S0196-0709(00)80045-9; Brandt T, 1996, Audiol Neurootol, V1, P187; Celebisoy N, 2009, GAIT POSTURE, V29, P520, DOI 10.1016/j.gaitpost.2008.12.002; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chang WC, 2006, OTOLARYNG HEAD NECK, V135, P534, DOI 10.1016/j.otohns.2005.10.001; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; COHEN H, 1993, PHYS THER, V73, P346, DOI 10.1093/ptj/73.6.346; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Di Girolamo S, 1998, ACTA OTO-LARYNGOL, V118, P289; Donaldson CJ, 2010, OTOLARYNG HEAD NECK, V143, P820, DOI 10.1016/j.otohns.2010.09.024; Fausti S. A., 2006, JRRD, V46, P797; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Herdman S. J., 2007, VESTIBULAR REHABILIT, P314; Hillier S. L., 2007, COCHRANE DB SYST REV; Hillier SL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub3; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Lajoie Y, 2002, ARCH GERONTOL GERIAT, V35, P215, DOI 10.1016/S0167-4943(02)00027-4; Larsen AI, 2004, EUR J CARDIOV PREV R, V11, P162, DOI 10.1097/01.hjr.0000124214.21584.bb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; LISBERGER SG, 1984, J NEUROPHYSIOL, V52, P1140, DOI 10.1152/jn.1984.52.6.1140; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mahboobin A, 2005, EXP BRAIN RES, V167, P260, DOI 10.1007/s00221-005-0053-7; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; NORRE M E, 1987, Acta Oto-Rhino-Laryngologica Belgica, V41, P436; PAIGE GD, 1994, EXP BRAIN RES, V98, P355; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pavlou M, 2010, J NEUROL PHYS THER, V34, P105, DOI 10.1097/NPT.0b013e3181dde6bf; Peterson MD, 2010, J HEAD TRAUMA REHAB, V25, P193, DOI 10.1097/HTR.0b013e3181dc82fa; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Rambold H, 2002, J NEUROPHYSIOL, V87, P912, DOI 10.1152/jn.00768.2000; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; REVEL M, 1991, ARCH PHYS MED REHAB, V72, P288; REVEL M, 1994, ARCH PHYS MED REHAB, V75, P895, DOI 10.1016/0003-9993(94)90115-5; Roy JE, 2001, J NEUROSCI, V21, P2131, DOI 10.1523/JNEUROSCI.21-06-02131.2001; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Schubert MC, 2008, EXP BRAIN RES, V191, P435, DOI 10.1007/s00221-008-1537-z; SHEPARD NT, 1995, OTOLARYNG HEAD NECK, V112, P173, DOI 10.1016/S0194-5998(95)70317-9; Shepard NT, 1996, PRACTICAL MANAGEMENT; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Swait G, 2007, SPINE, V32, pE692, DOI 10.1097/BRS.0b013e31815a5a1b; Tjell C, 1998, AM J OTOL, V19, P76; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; van de Calseyde P, 1976, Acta Otorhinolaryngol Belg, V30, P569; Viirre E, 2002, LARYNGOSCOPE, V112, P500, DOI 10.1097/00005537-200203000-00017; Whitney SL, 1999, J VESTIBUL RES-EQUIL, V9, P253; Whitney SL, 2011, NEUROREHABILITATION, V29, P157, DOI 10.3233/NRE-2011-0690; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; YARDLEY L, 1992, J PSYCHOSOM RES, V36, P731, DOI 10.1016/0022-3999(92)90131-K	79	39	39	2	45	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	3					519	528		10.3233/NRE-130874			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	135DM	WOS:000318266200010	23648606				2022-02-06	
J	Khabour, OF; Alzoubi, KH; Alomari, MA; Alzubi, MA				Khabour, Omar F.; Alzoubi, Karem H.; Alomari, Mahmoud A.; Alzubi, Mohammad A.			Changes in spatial memory and BDNF expression to simultaneous dietary restriction and forced exercise	BRAIN RESEARCH BULLETIN			English	Article						Every other day fasting; Exercise; Memory; BDNF; Hippocampus	TRAUMATIC BRAIN-INJURY; HIGH-FAT DIET; CALORIC RESTRICTION; TREADMILL EXERCISE; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; PHYSICAL-EXERCISE; FOOD RESTRICTION; OXIDATIVE STRESS; COGNITIVE FUNCTION	Previous literature suggests that learning and memory formation can be influenced by diet and exercise. In the current study, we investigated the combined effects of forced swimming exercise (FSE) and every other day fasting (EODF) on spatial memory formation and on the levels of brain-derived neurotrophic factor (BDNF) in the hippocampus of Wistar male rats. The radial arm water maze (RAWM) paradigm was used to assess changes in learning and memory formation, whereas ELISA assay was used to measure BDNF protein levels. The FSE and/or EODF were simultaneously instituted for 6 weeks. Results show that FSE improved learning, short-term as well as long-term memory formation, and significantly increased BDNF protein in the hippocampus (p < 0.05). However, EODF had no effect on either spatial learning and memory formation or the levels of hippocamapal BDNF protein (p > 0.05). In addition, EODF did not modulate beneficial effect of swimming exercise on cognitive function (p > 0.05). Thus exercise enhanced, while EODF did not affect spatial learning and memory formation. (C) 2012 Elsevier Inc. All rights reserved.	[Khabour, Omar F.] Jordan Univ Sci & Technol, Dept Med Lab Sci, Irbid 22110, Jordan; [Alzoubi, Karem H.; Alzubi, Mohammad A.] Jordan Univ Sci & Technol, Dept Clin Pharm, Irbid 22110, Jordan; [Alomari, Mahmoud A.] Jordan Univ Sci & Technol, Dept Rehabil Sci, Irbid 22110, Jordan		Khabour, OF (corresponding author), Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Med Lab Sci, Irbid 22110, Jordan.	khabour@just.edu.jo	Alomari, Mahmoud A/K-3263-2014; Alzoubi, Karem/E-6285-2014	Alomari, Mahmoud A/0000-0003-3605-5946; Alzoubi, Karem/0000-0002-2808-5099	Jordan University of Science and Technology	This work has been supported from the Deanship of Research in Jordan University of Science and Technology.	Adams JM, 2008, HYPERTENSION, V52, P932, DOI 10.1161/HYPERTENSIONAHA.108.118935; Alzoubi KH, 2009, BEHAV BRAIN RES, V204, P117, DOI 10.1016/j.bbr.2009.05.025; Alzoubi KH, 2012, BEHAV BRAIN RES, V226, P205, DOI 10.1016/j.bbr.2011.09.017; Anderson RM, 2010, TRENDS ENDOCRIN MET, V21, P134, DOI 10.1016/j.tem.2009.11.005; Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Ang ET, 2006, BRAIN RES, V1113, P186, DOI 10.1016/j.brainres.2006.07.023; Arida RM, 2011, AM J PHYS MED REHAB, V90, P452, DOI 10.1097/PHM.0b013e3182063a9c; Azab M, 2009, J TOXICOL ENV HEAL A, V72, P295, DOI 10.1080/15287390802526357; Bekinschtein P, 2011, SEMIN CELL DEV BIOL, V22, P536, DOI 10.1016/j.semcdb.2011.07.002; Cechetti F, 2012, NEUROBIOL LEARN MEM, V97, P90, DOI 10.1016/j.nlm.2011.09.008; Chen Lin, 2006, Neurosci Bull, V22, P1; Collins A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004330; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Depp CA, 2010, AM J PREV MED, V39, P173, DOI 10.1016/j.amepre.2010.03.020; Diamond DM, 1999, HIPPOCAMPUS, V9, P542, DOI 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.0.CO;2-N; Drumond LE, 2012, BRAIN RES BULL, V88, P385, DOI 10.1016/j.brainresbull.2012.04.005; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Duman RS, 2005, NEUROBIOL AGING, V26, pS88, DOI 10.1016/j.neurobiolaging.2005.08.018; Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054; Fontana L, 2010, AGE, V32, P97, DOI 10.1007/s11357-009-9118-z; Fuentes T, 2012, EUR J APPL PHYSIOL, V112, P1917, DOI 10.1007/s00421-011-2164-0; Geng AL, 2007, ARCH ANIM NUTR, V61, P50, DOI 10.1080/17450390601117041; Gold SM, 2003, J NEUROIMMUNOL, V138, P99, DOI 10.1016/S0165-5728(03)00121-8; Greene WC, 2004, NAT MED, V10, P778, DOI 10.1038/nm0804-778; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Hansalik M, 2006, EXP GERONTOL, V41, P169, DOI 10.1016/j.exger.2005.11.002; Heydari AR, 2007, NUCLEIC ACIDS RES, V35, P7485, DOI 10.1093/nar/gkm860; Hoffman Martin D, 2007, Curr Pain Headache Rep, V11, P93; Hu M, 2012, ACTA HAEMATOL-BASEL, V127, P156, DOI 10.1159/000335620; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Jee YS, 2008, NEUROSCI LETT, V443, P188, DOI 10.1016/j.neulet.2008.07.078; Johnson NA, 2006, EXP PHYSIOL, V91, P693, DOI 10.1113/expphysiol.2006.033399; Kennard JA, 2012, PHYSIOL BEHAV, V106, P423, DOI 10.1016/j.physbeh.2012.02.023; Khabour OF, 2010, HIPPOCAMPUS, V20, P637, DOI 10.1002/hipo.20657; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Lojovich JM, 2010, J HEAD TRAUMA REHAB, V25, P184, DOI 10.1097/HTR.0b013e3181dc78cd; Lumini JA, 2008, SPORTS MED, V38, P735, DOI 10.2165/00007256-200838090-00003; Ma Qiang, 2008, Neurosci Bull, V24, P265, DOI 10.1007/s12264-008-0402-1; Mager DE, 2006, FASEB J, V20, P631, DOI 10.1096/fj.05-5263com; Martin LB, 2007, AM J PHYSIOL-REG I, V292, pR316, DOI 10.1152/ajpregu.00386.2006; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; MEANS LW, 1993, PHYSIOL BEHAV, V54, P503, DOI 10.1016/0031-9384(93)90243-9; Mello PB, 2008, AN ACAD BRAS CIENC, V80, P301, DOI 10.1590/S0001-37652008000200008; Mello PB, 2009, NEUROBIOL LEARN MEM, V92, P364, DOI 10.1016/j.nlm.2009.04.004; Molteni R, 2004, P NATL ACAD SCI USA, V101, P8473, DOI 10.1073/pnas.0401443101; Morgan T. E., 2007, V35, P83; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Ni H, 2011, BIOL TRACE ELEM RES, V142, P704, DOI 10.1007/s12011-010-8793-z; Nichol KE, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-13; Pan Y, 2011, NEUROSCIENCE, V197, P330, DOI 10.1016/j.neuroscience.2011.08.065; Saadipour K, 2009, Pak J Biol Sci, V12, P1206; Sim YJ, 2005, PHYSIOL BEHAV, V84, P733, DOI 10.1016/j.physbeh.2005.02.019; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Thompson D, 2012, PHYSIOL REV, V92, P157, DOI 10.1152/physrev.00012.2011; Toscano-Silva M, 2010, PHYSIOL BEHAV, V101, P302, DOI 10.1016/j.physbeh.2010.05.012; Tseng CN, 2011, J NURS RES, V19, P119, DOI 10.1097/JNR.0b013e3182198837; Varady K.A., 2008, NUTRITION; Vollert C, 2011, BEHAV BRAIN RES, V224, P233, DOI 10.1016/j.bbr.2011.05.010; Weiner RB, 2012, PROG CARDIOVASC DIS, V54, P380, DOI 10.1016/j.pcad.2012.01.006; Wu AG, 2003, NEUROSCI LETT, V339, P166, DOI 10.1016/S0304-3940(03)00008-9; Yanai S, 2004, NEUROBIOL AGING, V25, P325, DOI 10.1016/S0197-4580(03)00115-5; Zagaar M, 2012, NEUROBIOL DIS, V45, P1153, DOI 10.1016/j.nbd.2011.12.039	63	39	40	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN	2013	90						19	24		10.1016/j.brainresbull.2012.08.005			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	083ES	WOS:000314446100003	23000024				2022-02-06	
J	Tepas, JJ; Pracht, EE; Orban, BL; Flint, LM				Tepas, Joseph J., III; Pracht, Etienne E.; Orban, Barbara L.; Flint, Lewis M.			High-volume trauma centers have better outcomes treating traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	PROMMTT Symposium held at the 71st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 12-15, 2012	HI	Amer Assoc Surg Trauma		Brain injury; clinical outcome; clinical case volume; performance assessment		BACKGROUND: Survival and discharge status from severe traumatic brain injury (TBI) patients treated during the past 11 years in seven state-designated Level I trauma centers was analyzed to test for a relationship between patient volume and outcome. METHODS: Data for patients age 16 years to 64 years were aggregated by quarter for years 2000 to 2010. TBI patients were identified using DRG International Classification of Diseases-9th Rev.-Clinical Modification codes: 800 to 804 and 850.1 to 854. Severity was defined using the International Classification Injury Severity Score (ICISS) less than 0.85 (risk of death >15%). Using a random effects model controlling for sex, race, ethnicity, and insurance status, TBI volume was analyzed against quarterly inpatient mortality and functional recovery, defined as discharge to home or rehabilitation versus transfer to skilled nursing facilities. Hospitals were categorized into quarterly TBI volume quintiles, using the top quintile (highest-volume center) as control. To account for overall injury severity influence, ICISS was further categorized as less than 20%, 20% to 40%, and 40% to 60%. RESULTS: Two high-volume hospitals consistently treated more TBI patients (>40 patients per quarter). Four treated less than 40 patients per quarter, and one transitioned to high-volume midway through the study period. After controlling for severity, demographics, and insurance status, highest-volume centers demonstrated a 9% lower mortality risk (p < 0.001). Lower-volume hospitals discharged a significantly larger proportion of TBI patients to skilled nursing facilities and fewer patients to home or rehabilitation facilities (p < 0.01). CONCLUSION: High volume (>40 patients per quarter) is associated with improved severe TBI patient survival and, probably, improved quality of life. Efforts to identify best practices and implement educational interventions to improve compliance with best-practice standards will benefit patients with severe traumatic brain injury. (J Trauma Acute Care Surg. 2013;74: 143-148. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Tepas, Joseph J., III] Univ Florida, Coll Med Jacksonville, Dept Surg, Jacksonville, FL 32209 USA; [Pracht, Etienne E.; Orban, Barbara L.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA; [Flint, Lewis M.] Amer Coll Surg, Div Educ, Chicago, IL USA		Tepas, JJ (corresponding author), Univ Florida, Coll Med Jacksonville, Dept Surg, 653 W 8th St, Jacksonville, FL 32209 USA.	jjt@jax.ufl.edu					American College of Surgeons, 2007, RES OPT CAR INJ PAT; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Donabedian A, 2000, B WORLD HEALTH ORGAN, V78, P857; Donabedian A, 2001, Health Aff (Millwood), V20, P137; Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; Fantus RJ, 2006, J TRAUMA, V61, P266; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P1170, DOI 10.1001/archsurg.2011.247; LaPar DJ, ANN SURG; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Massarweh NN, 2011, J AM COLL SURGEONS, V212; Nathens A B, 2001, Adv Surg, V35, P61; Papa L, 2006, J TRAUMA, V61, P261, DOI 10.1097/01.ta.0000221789.53864.ba; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; Reinke Thomas, 2010, Manag Care, V19, P7; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089	15	39	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2013	74	1					143	147		10.1097/TA.0b013e3182788b5a			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	071VI	WOS:000313623300034	23271089				2022-02-06	
J	Arango, JI; Deibert, CP; Brown, D; Bell, M; Dvorchik, I; Adelson, PD				Arango, Jorge I.; Deibert, Christopher P.; Brown, Danielle; Bell, Michael; Dvorchik, Igor; Adelson, P. David			Posttraumatic seizures in children with severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Pediatric; Traumatic brain injury; Seizures; Anticonvulsants; Prophylaxis; Head trauma	HEAD TRAUMA; PHENYTOIN; EPILEPSY; PROPHYLAXIS; POPULATION; PREVENTION; PREDICTORS; MANAGEMENT	Traumatic brain injury (TBI) remains a leading cause of childhood death and disability worldwide. Seizures are a common complication of TBI and they are particularly common in pediatric populations. The proper management of children sustaining severe TBI is still controversial. Our study aims to share our experience contributing to build evidence for better care. Retrospective chart review was performed on individuals ages 0 to < 18 who presented to a level 1 trauma center during a 10-year period with the diagnosis of severe TBI. Data analyzed included patient's demographics, event information, clinical and radiological presentation, management, and midterm follow-up. Presence of seizures was tracked through EEG monitoring, staff witnessing, or guardian referral. The incidence of early posttraumatic seizures (EPTS) observed in our population (19 %) exceeds those previously reported. Such findings likely reflect the importance of close monitoring including EEG. An association between the presence of EPTS and the development of late posttraumatic seizures (LPTS) was evidenced (p = 0.001; 95 % CI 2.2, 16.5), while this association should not be assumed as a measure of causality, it should be considered for the management of patients presenting EPTS. Non-accidental trauma and young age were identified as independent predictors for the development of seizures. Seizures are a common complication of severe TBI among children aged 0-3 years. Given the detrimental effects that seizures produce on the injured brain, close observation and appropriate monitoring with EEG are essential for the management of children sustaining severe TBI.	[Arango, Jorge I.; Brown, Danielle; Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Neurosurg & Neurosci Res, Phoenix, AZ 85016 USA; [Deibert, Christopher P.; Bell, Michael] Childrens Hosp Pittsburgh, Dept Neurosurg & Crit Care Med, Pittsburgh, PA 15213 USA; [Deibert, Christopher P.; Bell, Michael] Univ Pittsburgh, Pittsburgh, PA USA; [Dvorchik, Igor] Nationwide Childrens Hosp, Nationwide Childrens Hosp Res Inst, Columbus, OH USA		Adelson, PD (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Neurosurg & Neurosci Res, Ambulatory Bldg B,1919 E Thomas Rd, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Adelson, David/W-2083-2019; Dvorchik, Igor/D-1749-2013				ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Black P, 1975, CIBA F S, V34, P215; Chadwick D, 2000, LANCET, V355, P334, DOI 10.1016/S0140-6736(99)00452-3; Chiaretti A, 2002, CHILD NERV SYST, V18, P109, DOI 10.1007/s00381-002-0561-8; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HENDRICK EB, 1968, J TRAUM, V8, P547; Ikonomidou C, 2010, EPILEPSY RES, V88, P11, DOI 10.1016/j.eplepsyres.2009.09.019; JENNETT B, 1975, LANCET, V1, P480; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Moshe S L, 1987, Epilepsia, V28 Suppl 1, pS3, DOI 10.1111/j.1528-1157.1987.tb05753.x; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; SATO M, 1990, ELECTROEN CLIN NEURO, V76, P459, DOI 10.1016/0013-4694(90)90099-6; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thomas K.E., 2009, STATE INJURY INDICAT; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	27	39	42	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	NOV	2012	28	11					1925	1929		10.1007/s00381-012-1863-0			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	021FY	WOS:000309871900015	22843174				2022-02-06	
J	Angeleri, R; Bosco, FM; Gabbatore, I; Bara, BG; Sacco, K				Angeleri, Romina; Bosco, Francesca M.; Gabbatore, Ilaria; Bara, Bruno G.; Sacco, Katiuscia			Assessment battery for communication (ABaCo): normative data	BEHAVIOR RESEARCH METHODS			English	Article						Normative data; Communication; Assessment; Pragmatics	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; NEUROPRAGMATICS; IMPAIRMENT; ABILITY	The Assessment Battery for Communication (ABaCo) was introduced to evaluate pragmatic abilities in patients with cerebral lesions. The battery is organized into five evaluation scales focusing on separate components of pragmatic competence. In the present study, we present normative data for individuals 15-75 years of age (N = 300). The sample was stratified by age, sex, and years of education, according to Italian National Institute of Statistics indications in order to be representative of the general national population. Since performance on the ABaCo decreases with age and lower years of education, the norms were stratified for both age and education. The ABaCo is a valuable tool in clinical practice; the normative data provided here will enable clinicians to determine different kinds and specific levels of communicative impairments more precisely.	[Angeleri, Romina; Bosco, Francesca M.; Gabbatore, Ilaria; Bara, Bruno G.; Sacco, Katiuscia] Univ Turin, Ctr Cognit Sci, Dept Psychol, I-10123 Turin, Italy; [Bosco, Francesca M.; Bara, Bruno G.; Sacco, Katiuscia] Neurosci Inst Turin, Turin, Italy; [Sacco, Katiuscia] Koelliker Hosp, CCS fMRI Neuroradiol, Turin, Italy		Angeleri, R (corresponding author), Univ Turin, Ctr Cognit Sci, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	romina.angeleri@unito.it	bosco, francesca marina/B-6746-2013; Sacco, Katiuscia/J-2133-2012; Gabbatore, Ilaria/AAC-1925-2019	bosco, francesca marina/0000-0001-6101-8587; Sacco, Katiuscia/0000-0002-9660-5236; Gabbatore, Ilaria/0000-0002-9724-8066			Adams C, 2002, J CHILD PSYCHOL PSYC, V43, P973, DOI 10.1111/1469-7610.00226; Altman D.G., 1990, PRACTICAL STAT MED R; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara Bruno, 2010, COGNITIVE PRAGMATICS; Bates E., 1976, LANGUAGE CONTEXT STU; Benton E, 1996, INT J REHABIL RES, V19, P47, DOI 10.1097/00004356-199603000-00005; Bishop DVM, 1998, J CHILD PSYCHOL PSYC, V39, P879, DOI 10.1017/S0021963098002832; Bryan K., 1995, RIGHT HEMISPHERE LAN, V2nd ed.; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Cutica I, 2006, BRAIN LANG, V98, P12, DOI 10.1016/j.bandl.2006.01.001; Dardier V, 2011, J COMMUN DISORD, V44, P359, DOI 10.1016/j.jcomdis.2011.02.001; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Ehrlich J. S, 1985, COGNITIVE REHABILITA, P32; Ferre P, 2011, REHABIL RES PRACT, V2011, DOI 10.1155/2011/131820; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; Gardner H, 1986, RIGHT HEMISPHERE COM; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Kempson R. M., 1975, PRESUPPOSITION DELIM; Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Penn C, 1985, S Afr J Commun Disord, V32, P18; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; Sacco K, 2008, J COGN SCI, V9, P111; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Zanini S, 2005, NEUROL SCI, V26, P13, DOI 10.1007/s10072-005-0377-x; Zanini S., 2003, BATTERIA LINGUAGGIO	31	39	40	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1554-351X	1554-3528		BEHAV RES METHODS	Behav. Res. Methods	SEP	2012	44	3			SI		845	861		10.3758/s13428-011-0174-9			17	Psychology, Mathematical; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	084WQ	WOS:000314571200017	22180102	Bronze, Green Submitted			2022-02-06	
J	Cope, EC; Morris, DR; Scrimgeour, AG; Levenson, CW				Cope, Elise C.; Morris, Deborah R.; Scrimgeour, Angus G.; Levenson, Cathy W.			Use of Zinc as a Treatment for Traumatic Brain Injury in the Rat: Effects on Cognitive and Behavioral Outcomes	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						TBI; zinc supplementation; anhedonia; spatial memory	HIPPOCAMPAL NEUROGENESIS; SUPPLEMENTATION; DEPRESSION; MODEL; CHELATION; DEATH	Background. While treatments for the behavioral deficits associated with traumatic brain injury (TBI) are currently limited, animal models suggest that zinc supplementation may increase resilience to TBI. Objective. This work tests the hypothesis that zinc supplementation after TBI can be used as treatment to improve behavioral outcomes such as anxiety, depression, and learning and memory. Methods. TBI was induced by controlled cortical impact to the medial frontal cortex. After TBI, rats were fed either a zinc adequate (ZA, 30 ppm) or zinc supplemented (ZS, 180 ppm) diet. Additional rats in each dietary group (ZA or ZS) were given a single intraperitoneal (ip) injection of zinc (30 mg/kg) 1 hour following injury. Results. Brain injury resulted in significant increases in anxiety-like and depression-like behaviors as well as impairments in learning and memory. None of the zinc treatments (dietary or ip zinc) improved TBI-induced anxiety. The 2-bottle saccharin preference test for anhedonia revealed that dietary ZS also did not improve depression-like behaviors. However, dietary ZS combined with an early ip zinc injection significantly reduced anhedonia (P < .001). Dietary supplementation after injury, but not zinc injection, significantly improved (P < .05) cognitive behavior as measured by the time spent finding the hidden platform in the Morris water maze test compared with injured rats fed a ZA diet. Conclusions. These data suggest that zinc supplementation may be an effective treatment option for improving behavioral deficits such as cognitive impairment and depression following TBI.	[Levenson, Cathy W.] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA; [Scrimgeour, Angus G.] USA, Environm Med Res Inst, Natick, MA 01760 USA		Levenson, CW (corresponding author), Florida State Univ, Coll Med, Tallahassee, FL 32306 USA.	cathy.levenson@med.fsu.edu		Cope, Elise/0000-0001-6239-690X; Levenson, Cathy W/0000-0003-4463-3136	US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM081382] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by the US Army Medical Research and Material Command.	Aquilani R, 2009, NUTR NEUROSCI, V12, P219, DOI 10.1179/147683009X423445; Arabi YM, 2011, AM J CLIN NUTR, V93, P569, DOI 10.3945/ajcn.110.005074; Bobilya DJ, 2008, J NUTR BIOCHEM, V19, P129, DOI 10.1016/j.jnutbio.2007.06.014; Cope EC, 2011, PHYSIOL BEHAV, V104, P942, DOI 10.1016/j.physbeh.2011.06.007; Corniola RS, 2008, BRAIN RES, V1237, P52, DOI 10.1016/j.brainres.2008.08.040; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fujimura T, 2012, BRIT J NUTR, V107, P1655, DOI 10.1017/S0007114511004867; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nowak G, 2003, POL J PHARMACOL, V55, P1143; Nowak G, 2003, BRAIN RES BULL, V61, P159, DOI 10.1016/S0361-9230(03)00104-7; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Siwek M, 2009, J AFFECT DISORDERS, V118, P187, DOI 10.1016/j.jad.2009.02.014; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Sowa-Kucma M, 2008, J NEURAL TRANSM, V115, P1621, DOI 10.1007/s00702-008-0115-7; Stork CJ, 2009, J CEREBR BLOOD F MET, V29, P1399, DOI 10.1038/jcbfm.2009.64; Tassabehji NM, 2008, PHYSIOL BEHAV, V95, P365, DOI 10.1016/j.physbeh.2008.06.017; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	25	39	40	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2012	26	7					907	913		10.1177/1545968311435337			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	981MY	WOS:000306973700011	22331212	Green Accepted			2022-02-06	
J	Nelson, NW; Hoelzle, JB; Doane, BM; McGuire, KA; Ferrier-Auerbach, AG; Charlesworth, MJ; Lamberty, GJ; Polusny, MA; Arbisi, PA; Sponheim, SR				Nelson, Nathaniel W.; Hoelzle, James B.; Doane, Bridget M.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Lamberty, Gregory J.; Polusny, Melissa A.; Arbisi, Paul A.; Sponheim, Scott R.			Neuropsychological Outcomes of US Veterans with Report of Remote Blast-Related Concussion and Current Psychopathology	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Operation Iraqi Freedom; Mild Traumatic Brain Injury; Post-traumatic Stress Disorder; Cognition	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; ADMINISTERED PTSD SCALE; OPERATION-IRAQI-FREEDOM; OEF/OIF VETERANS; TEST-SCORES; PERFORMANCE; METAANALYSIS; AFGHANISTAN	This study explored whether remote blast-related MTBI and/or current Axis I psychopathology contribute to neuropsychological outcomes among OEF/OIF veterans with varied combat histories. OEF/OIF veterans underwent structured interviews to evaluate history of blast-related MTBI and psychopathology and were assigned to MTBI (n=18), Axis I (n=24), Co-morbid MTBI/Axis I (n=34), or post-deployment control (n=28) groups. A main effect for Axis I diagnosis on overall neuropsychological performance was identified (F(3,100) = 4.81; p=.004), with large effect sizes noted for the Axis I only (d=.98) and Co-morbid MTBI/Axis I (d=.95) groups relative to the control group. The latter groups demonstrated primary limitations on measures of learning/memory and processing speed. The MTBI only group demonstrated performances that were not significantly different from the remaining three groups. These findings suggest that a remote history of blast-related MTBI does not contribute to objective cognitive impairment in the late stage of injury. Impairments, when present, are subtle and most likely attributable to PTSD and other psychological conditions. Implications for clinical neuropsychologists and future research are discussed. (JINS, 2012, 18, 845-855)	[Nelson, Nathaniel W.] Univ St Thomas, Grad Sch Profess Psychol, Minneapolis, MN 55403 USA; [Nelson, Nathaniel W.; Doane, Bridget M.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Lamberty, Gregory J.; Polusny, Melissa A.; Arbisi, Paul A.; Sponheim, Scott R.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA; [Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Lamberty, Gregory J.; Polusny, Melissa A.; Arbisi, Paul A.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Polusny, Melissa A.] Ctr Chron Dis Outcomes Res, Minneapolis, MN USA		Nelson, NW (corresponding author), Univ St Thomas, Grad Sch Profess Psychol, MOH 217,1000 LaSalle Ave, Minneapolis, MN 55403 USA.	nels0600@stthomas.edu	Polusny, Melissa Anderson/N-8112-2014; Polusny, Melissa/X-8158-2019; Sponheim, Scott/J-3857-2017	Polusny, Melissa Anderson/0000-0002-4932-305X; Polusny, Melissa/0000-0002-4932-305X; Sponheim, Scott/0000-0002-2782-0856	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI)	This study was supported by Grants funded in part by the Congressionally Directed Medical Research Programs (number PT074550, contract W81XWH-08-2-0038) to Scott R. Sponheim, PhD, and the Minnesota Veterans Research Institute (MVRI) to Nathaniel W. Nelson, PhD. The authors have no other financial or other relationships that could be interpreted as a conflict of interests affecting this manuscript.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Calhoun PS, 2008, J CLIN PSYCHIAT, V69, P1686, DOI 10.4088/JCP.v69n1103; Delis D.C., 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Erbes CR, 2009, PSYCHOL SERV, V6, P175, DOI 10.1037/a0016662; First M, 2007, STRUCTURED CLIN INTE; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Golden CJ, 1978, STROOP COLOR WORD TE; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MEYERS J, 1995, MEYERS SCORING SYSTE; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nelson N.W., NEUROPSYCHO IN PRESS; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; The Psychological Corporation, 2001, WECHSLER TEST ADULT; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wolfson, 1993, HALSTEAD REITAN NEUR; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	58	39	39	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2012	18	5					845	855		10.1017/S1355617712000616			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	999KB	WOS:000308309100007	22687547	Green Published			2022-02-06	
J	Wei, XE; Zhang, YZ; Li, YH; Li, MH; Li, WB				Wei, Xiao-Er; Zhang, Yu-Zhen; Li, Yue-Hua; Li, Ming-Hua; Li, Wen-Bin			Dynamics of Rabbit Brain Edema in Focal Lesion and Perilesion Area after Traumatic Brain Injury: A MRI Study	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; cytotoxic edema; diffusion-weighted imaging; dynamic contrast-enhanced MRI; rabbit; traumatic brain injury; vasogenic edema	BARRIER PERMEABILITY; CEREBRAL-ISCHEMIA; MODULATION; EXPRESSION; RECEPTORS; LEAKAGE; TARGET	To understand the dynamics of brain edema in different areas after traumatic brain injury (TBI) in rabbit, we used dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) to monitor blood-brain barrier (BBB) permeability and cytotoxic brain edema after weight drop-induced TBI in rabbit. The dynamics of BBB permeability and brain edema were quantified using K-trans and apparent diffusion coefficient (ADC) in the focal and perifocal lesion areas, as well as the area contralateral to the lesion. In the focal lesion area, K-trans began to increase at 3 h post-TBI, peaked at 3 days, and decreased gradually while remaining higher than sham injury animals at 7 and 30 days. ADC was more variable, increased slightly at 3 h, decreased to its lowest value at 7 days, then increased to a peak at 30 days. In the perifocal lesion area, K-trans began to increase at 1 day, peaked at 3-7 days, and returned to control level by 30 days. ADC showed a trend to increase at 1 day, followed by a continuous increase thereafter. In the contralateral area, no changes in K-trans and ADC were observed at any time-point. These data demonstrate that different types of brain edema predominate in the focal and perifocal lesion areas. Specifically cytotoxic edema was predominant in the focal lesion area while vasogenic edema predominated in the perifocal area in acute phase. Furthermore, secondary opening of the BBB after TBI may appear if secondary injury is not controlled. BBB damage may be a driving force for cytotoxic brain edema and could be a new target for TBI intervention.	[Wei, Xiao-Er; Zhang, Yu-Zhen; Li, Yue-Hua; Li, Ming-Hua; Li, Wen-Bin] Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 6, Dept Radiol, Shanghai 200233, Peoples R China		Li, WB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 6, Dept Radiol, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.	liwenbin@sh163.net			Science and Technology Commission of Shanghai Municipality, ShanghaiScience & Technology Commission of Shanghai Municipality (STCSM) [08411951200]	This study was supported in part by a grant from Science and Technology Commission of Shanghai Municipality, Shanghai (grant no. 08411951200).	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Abo-Ramadan U, 2009, EXP NEUROL, V219, P328, DOI 10.1016/j.expneurol.2009.06.002; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Cao Y, 2009, CLIN CANCER RES, V15, P1747, DOI 10.1158/1078-0432.CCR-08-1420; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Ferrier MC, 2007, NEOPLASIA, V9, P546, DOI 10.1593/neo.07289; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Haris M, 2008, J MAGN RESON IMAGING, V28, P588, DOI 10.1002/jmri.21491; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Infante-Duarte C, 2008, J MOL MED, V86, P975, DOI 10.1007/s00109-007-0292-0; Lahoud-Rahme MS, 2009, RESUSCITATION, V80, P484, DOI 10.1016/j.resuscitation.2009.01.007; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Marmarou A, 2000, ACT NEUR S, V76, P349; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Qu YZ, 2009, EUR J PHARMACOL, V606, P137, DOI 10.1016/j.ejphar.2009.01.022; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skaper SD, 2007, ANN NY ACAD SCI, V1122, P23, DOI 10.1196/annals.1403.002; Song S.K., 2010, NEUROBIOL AGING; Sourbron S, 2009, MAGN RESON MED, V62, P205, DOI 10.1002/mrm.22005; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; Turkbey B, 2010, DIAGN INTERV RADIOL, V16, P186, DOI 10.4261/1305-3825.DIR.2537-08.1; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	37	39	47	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	14					2413	2420		10.1089/neu.2010.1510			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	004SM	WOS:000308701400005	21675826	Green Published			2022-02-06	
J	McNett, M; Sarver, W; Wilczewski, P				McNett, Molly; Sarver, Wendy; Wilczewski, Patricia			The prevalence, treatment and outcomes of agitation among patients with brain injury admitted to acute care units	BRAIN INJURY			English	Article						Agitation; traumatic brain injury; intervention	PHARMACOLOGICAL MANAGEMENT; POSTTRAUMATIC AMNESIA; REALITY ORIENTATION; PHYSICAL RESTRAINT; HEAD-INJURY; REHABILITATION	Purpose: Agitation occurs in 70% of patients hospitalized with traumatic brain injury (TBI) and has adverse effects on length of stay and functional outcomes. Treatment involves pharmacological and behavioural interventions. Much research on TBI agitation has been conducted in intensive care or rehabilitation settings. This study aimed to identify agitation prevalence, treatment and outcomes among patients with TBI on acute care wards. Methods: Data abstracted from the trauma registry and medical records of adult patients with TBI admitted to an acute care ward within a Level I trauma centre over 12 months. Findings: From 219 patients, at least one agitation behaviour was present in 41% (n = 90) of patients. Clinically significant agitation was present in 8% (n = 18) of patients. Agitation behaviours included impulsiveness (30%), pulling at devices (21%) and decreased attention span (16%). Common interventions were reorientation (33%), constant supervision (32%) and benzodiazepines (30%). Agitated patients had longer length of stay (p<0.001) and were less likely to be discharged home. Physical restraints, constant supervision, redirection, reorientation and environmental modifications were associated with agitation (p<0.001). Implications: Management of agitation among patients with TBI on acute care wards can present challenges to healthcare staff. Innovative approaches are needed to promote outcomes using available resources.	[McNett, Molly] Metrohlth Med Ctr, Nursing Business Off, Cleveland, OH 44109 USA		McNett, M (corresponding author), Metrohlth Med Ctr, Nursing Business Off, 2500 Metrohlth Dr, Cleveland, OH 44109 USA.	mmcnett@metrohealth.org					Amato S, 2006, REHABIL NURS, V31, P235, DOI 10.1002/j.2048-7940.2006.tb00019.x; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Chang LY, 2008, AM J CRIT CARE, V17, P408; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Cook R, 2002, AUSTR J NEUROSCIENCE, V15, P5; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; De Guise E, 2005, BRAIN INJURY, V19, P263, DOI 10.1080/02699050400004971; Eastwood EA, 1999, NURS ECON, V17, P96; Eisenberg M.E., 2009, CRITICAL REV PHYS RE, V21, P215; Fleminger S, 2008, COCHRANE DATA BASE S, V4; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Johnson C C, 1995, Nursing, V25, P39; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; Nott MT, 2010, BRAIN INJURY, V24, P1214, DOI 10.3109/02699052.2010.506858; Rosati DL, 2002, AM J PHYS MED REHAB, V81, P90, DOI 10.1097/00002060-200202000-00003; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Thomas H, 2003, J HEAD TRAUMA REHAB, V18, P292, DOI 10.1097/00001199-200305000-00007; van der Naalt J, 2000, BRAIN INJURY, V14, P781; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; WERNER P, 1989, J AM GERIATR SOC, V37, P1122, DOI 10.1111/j.1532-5415.1989.tb06675.x; Wolf AP, 1996, BRAIN INJURY, V10, P241, DOI 10.1080/026990596124412	27	39	39	0	15	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2012	26	9					1155	1162		10.3109/02699052.2012.667587			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	971GI	WOS:000306191400013	22642404				2022-02-06	
J	Willie, JT; Lim, MM; Bennett, RE; Azarion, AA; Schwetye, KE; Brody, DL				Willie, Jon T.; Lim, Miranda M.; Bennett, Rachel E.; Azarion, Allan A.; Schwetye, Katherine E.; Brody, David L.			Controlled Cortical Impact Traumatic Brain Injury Acutely Disrupts Wakefulness and Extracellular Orexin Dynamics as Determined by Intracerebral Microdialysis in Mice	JOURNAL OF NEUROTRAUMA			English	Article						circadian rhythm; electroencephalography; electromyography; hypocretin; hypothalamus; microdialysis; orexin; sleep; traumatic brain injury	CLOSED-HEAD INJURY; HYPOCRETIN OREXIN; HUMAN NARCOLEPSY; SLEEP DISORDERS; NEURONS; RAT; DEFICIENCY; PEPTIDES; SYSTEMS; STATES	Among other deficits, traumatic brain injury (TBI) causes impaired arousal and cognitive dysfunction. Hypothalamic orexin neuropeptides (also called hypocretins) regulate levels of arousal, and cerebrospinal fluid orexin levels are reportedly low in TBI patients. We hypothesized that TBI acutely impairs the dynamics of orexin release into brain interstitial fluid, and that these extracellular orexin levels correlate with wakefulness and motor activity. To test this in mice, we combined an electromagnetic controlled cortical impact (CCI) model of experimental TBI with dual intracerebral microdialysis using one catheter in the hypothalamus and one catheter in the hippocampus, plus electroencephalography/electromyography (EEG/EMG), and motor activity monitoring. Baseline data were continuously collected in tethered but relatively freely moving mice for 2 days. Then, ipsilateral CCI or sham surgery was performed, and data collection was continued for 3 additional days. At baseline, extracellular orexin levels in the hypothalamus showed a circadian rhythm, with peak levels during the dark (wake) phase, and a nadir during the light (rest) phase. Following CCI but not sham surgery, orexin levels were depressed in both the hypothalamus and hippocampus, and diurnal fluctuation amplitudes were blunted in the hypothalamus. At baseline, correlations of orexin with wakefulness and motor activity were positive and highly significant. Following CCI but not sham surgery, the mice exhibited reduced wakefulness and motor activity, and correlations between orexin and these measures were diminished. These abnormal orexin dynamics were associated with hypothalamic astrogliosis, but not acute loss of orexin neurons, as assessed by immunohistochemistry 3 days after injury. Future studies involving experimental manipulations of the orexin system will be required to determine its contribution to neurological outcomes following injury.	[Willie, Jon T.] Emory Univ, Sch Med, Dept Neurol Surg, Atlanta, GA USA; [Lim, Miranda M.; Bennett, Rachel E.; Azarion, Allan A.; Schwetye, Katherine E.; Brody, David L.] Univ Penn, Div Sleep Med, Philadelphia, PA 19104 USA		Brody, DL (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020	Bennett, Rachel/0000-0001-9640-0575	Neurosurgery Research Education Fund; Porex Corporation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069] Funding Source: NIH RePORTER	Funding for this study was provided by a grant from the Neurosurgery Research Education Fund and Porex Corporation to J.T.W., and the National Institutes of Health R01 NS065069 to D.L.B. We thank Dr. David M. Holtzman and members of the Holtzman Laboratory for allowing us to use their controlled light/dark mouse room and electrophysiological monitoring equipment.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Cirrito JR, 2003, J NEUROSCI, V23, P8844; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Deadwyler SA, 2007, J NEUROSCI, V27, P14239, DOI 10.1523/JNEUROSCI.3878-07.2007; Fenzl T, 2009, BEHAV BRAIN RES, V203, P143, DOI 10.1016/j.bbr.2009.04.012; Franklin K.B.J., 2004, MOUSE BRAIN STEREOTA; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kiyashchenko LI, 2002, J NEUROSCI, V22, P5282; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mieda M, 2004, P NATL ACAD SCI USA, V101, P4649, DOI 10.1073/pnas.0400590101; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Mihara Y, 2011, J MOL NEUROSCI, V43, P162, DOI 10.1007/s12031-010-9438-6; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peyron C, 1998, J NEUROSCI, V18, P9996; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Renger JJ, 2004, BRAIN RES, V1010, P45, DOI 10.1016/j.brainres.2004.02.067; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Sakurai T, 1998, Cell, V92, P696; Sakurai T, 2011, TRENDS PHARMACOL SCI, V32, P451, DOI 10.1016/j.tips.2011.03.007; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Willie JT, 2008, NEUROSCIENCE, V156, P819, DOI 10.1016/j.neuroscience.2008.08.048; Willie JT, 2003, NEURON, V38, P715, DOI 10.1016/S0896-6273(03)00330-1; Willie JT, 2001, ANNU REV NEUROSCI, V24, P429, DOI 10.1146/annurev.neuro.24.1.429; Yoshida K, 2006, J COMP NEUROL, V494, P845, DOI 10.1002/cne.20859; Yoshida Y, 2001, EUR J NEUROSCI, V14, P1075, DOI 10.1046/j.0953-816x.2001.01725.x	41	39	43	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1908	1921		10.1089/neu.2012.2404			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400395	22607167	Green Published			2022-02-06	
J	Lee, HF; Lee, TS; Kou, YR				Lee, Hung-Fu; Lee, Tzong-Shyuan; Kou, Yu Ru			Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Triptolide; Traumatic brain injury; Apoptosis; Cytokines; Inflammation	CLOSED-HEAD INJURY; NF-KAPPA-B; TNF-ALPHA; TIME-COURSE; CELL-DEATH; IN-VITRO; INFLAMMATION; INHIBITION; MICE; EXPRESSION	Traumatic brain injury (TBI) is characterized by neuroinflammation, brain edema, and cerebral damage leading to impairment of neurobehavioral function. Triptolide (PG-490), a diterpenoid component from Tripterygium wilfordii Hook F., has anti-inflammatory properties. Whether triptolide has neuroprotective functions when treating TBI is unclear. To investigate this possibility, Sprague-Dawley rats were treated with triptolide immediately after TBI had been induced by a controlled cortical impact procedure or after a sham procedure. TBI produced neuroinflammation when measured on day 1 after TBI, induced cerebral damage when measured on day 1 and day 3, and impaired neurobehavioral functioning over a 28-day observation period. Triptolide suppressed TBI-induced increases in contusion volume, cell apoptosis, edema and the levels of various pro-inflammatory mediators in the brain. Thriptolide reversed the TBI-induced decrease in brain levels of anti-inflammatory cytokine interleukin-10. Importantly, triptolide improved neurobehavioral outcomes regarding motor, sensory, reflex and balance function. We conclude that triptolide confers neuroprotection against TBI, at least in part, via its anti-inflammatory activity. (c) 2012 Elsevier B.V. All rights reserved.	[Lee, Hung-Fu; Lee, Tzong-Shyuan; Kou, Yu Ru] Natl Yang Ming Univ, Inst Physiol, Sch Med, Taipei 112, Taiwan; [Lee, Hung-Fu] Cheng Hsin Gen Hosp, Dept Neurosurg, Taipei, Taiwan; [Kou, Yu Ru] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Sch Med, Taipei 112, Taiwan		Lee, TS (corresponding author), Natl Yang Ming Univ, Inst Physiol, Sch Med, Taipei 112, Taiwan.	tslee@ym.edu.tw; yrkou@ym.edu.tw	Lee, Tzong-Shyuan/AAE-5803-2020	Lee, Tzong-Shyuan/0000-0002-9593-4062; Kou, Yu Ru/0000-0002-4681-9009	Cheng Hsin General Hospital [98-15]; Yang-Ming University/Cheng Hsin Hospital Joint Research Programs [98F-117-CY12, 100F-117-CY21]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC 98-2320-B-010-016-MY3, NSC-99-2320-B-010-017-MY3]; Ministry of Education, Aim for the Top University Plan, TaiwanMinistry of Education, Taiwan	This work was supported by a grant 98-15 from the Cheng Hsin General Hospital, grants 98F-117-CY12 and 100F-117-CY21 from the Yang-Ming University/Cheng Hsin Hospital Joint Research Programs, grants NSC 98-2320-B-010-016-MY3 and NSC-99-2320-B-010-017-MY3 from the National Science Council, and a grant from Ministry of Education, Aim for the Top University Plan, Taiwan. We thank Dr. Szu-Fu Chen, Dr. Che-Feng Chang, Miss Wei-Shan Chien, Miss Jhih-Syuan Lin for their technical support and Dr. Ralph Kirby, Department of Life Sciences, National Yang-Ming University, for his help in language editing.	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fahrig T, 2005, MOL PHARMACOL, V67, P1544, DOI 10.1124/mol.104.008177; Faul JL, 2000, AM J RESP CRIT CARE, V162, P2252, DOI 10.1164/ajrccm.162.6.2002018; Gong YT, 2008, J NEUROCHEM, V107, P779, DOI 10.1111/j.1471-4159.2008.05653.x; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hoyle GW, 2010, AM J PHYSIOL-LUNG C, V298, pL830, DOI 10.1152/ajplung.00014.2010; Ikeda-Matsuo Y, 2011, J NEUROIMMUNOL, V238, P34, DOI 10.1016/j.jneuroim.2011.06.014; Jiao J, 2008, J NEUROIMMUNOL, V205, P32, DOI 10.1016/j.jneuroim.2008.08.006; Kelso ML, 2011, PROG MOL BIOL TRANSL, V98, P85, DOI 10.1016/B978-0-12-385506-0.00003-X; Kim YH, 2004, EUR J PHARMACOL, V494, P1, DOI 10.1016/j.ejphar.2004.04.040; Krakauer T, 2005, IMMUNOPHARM IMMUNOT, V27, P53, DOI [10.1081/IPH-200051294, 10.1081/IPH-51294]; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li RZ, 2004, JPN HEART J, V45, P657, DOI 10.1536/jhj.45.657; Li W, 2008, XENOBIOTICA, V38, P1551, DOI 10.1080/00498250802503359; Lin N, 2007, BIOCHEM PHARMACOL, V73, P136, DOI 10.1016/j.bcp.2006.08.027; Liu L, 2010, TOXICOLOGY, V271, P57, DOI 10.1016/j.tox.2010.03.004; Liu QY, 2006, BIOCHEM BIOPH RES CO, V345, P1122, DOI 10.1016/j.bbrc.2006.05.024; Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu Y, 2006, INVEST OPHTH VIS SCI, V47, P3796, DOI 10.1167/iovs.06-0319; Matta R, 2009, AM J TRANSL RES, V1, P267; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Qiu Daoming, 2003, Drugs R D, V4, P1, DOI 10.2165/00126839-200304010-00001; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sharma HS, 1997, ACT NEUR S, V70, P269; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stanley JL, 2005, J PSYCHOPHARMACOL, V19, P221, DOI 10.1177/0269881105051524; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Su ZD, 2010, GLIA, V58, P901, DOI 10.1002/glia.20972; Tao XL, 1998, ARTHRITIS RHEUM-US, V41, P130, DOI 10.1002/1529-0131(199801)41:1<130::AID-ART16>3.0.CO;2-4; Wu Shao-xi, 2005, Chin J Integr Med, V11, P147; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao GH, 2000, AM J PHYSIOL-LUNG C, V279, pL958, DOI 10.1152/ajplung.2000.279.5.L958; Zhou HF, 2003, NEUROREPORT, V14, P1091, DOI 10.1097/01.wnr.0000073682.00308.47; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	39	42	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048			RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	JUN 15	2012	182	1					1	8		10.1016/j.resp.2012.01.016			8	Physiology; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Physiology; Respiratory System	964UR	WOS:000305722700001	22366865				2022-02-06	
J	Shenouda, C; Hendrickson, P; Davenport, K; Barber, J; Bell, KR				Shenouda, Christian; Hendrickson, Peter; Davenport, Kathleen; Barber, Jason; Bell, Kathleen R.			The Effects of Concussion Legislation One Year Later-What Have We Learned: A Descriptive Pilot Survey of Youth Soccer Player Associates	PM&R			English	Article							HIGH-SCHOOL; FOOTBALL SOCCER; HEAD-INJURIES; SPORTS	Objective: To assess the knowledge of youth soccer athletes parents, coaches, and soccer officials regarding concussion and return-to-play guidelines contained in the Lystedt Law in Washington State. Design: Survey study. Setting: Surveys were distributed via the youth soccer association monthly electronic newsletter in September and October 2010. Links to the survey also were provided via the Washington Youth Soccer Facebook page and Twitter feed. Participants: Respondents were 18 years or older and were associated with Washington Youth Soccer. Main Outcome Measures: The percentage of correct responses to questions regarding the identification and management of concussion symptoms and return to play guidelines as outlined in the Lystedt Law. Results: A total of 391 adults responded; 63% were exclusively parents, 20% were coaches, and 17% were noncoaches (eg, club officers, referees, or volunteers). A total of 96% knew that concussions were a type of traumatic brain injury, 93% identified concussions as serious, and 93% knew that loss of consciousness is not universal. From the responses, 98% identified neurological manifestations of concussions, 90% chose to delay return to play in the presence of neurological symptoms, 85% were aware of the Lystedt Law, and only 73% knew that players must receive written clearance to return to play. A total of 88% were aware that a parent or legal guardian was not allowed to clear an athlete to return to play if a trained professional was not available. Survey respondents were less sure of soccer association guidelines for reporting medical clearance to club officials. Conclusions: These data suggest that, although general knowledge of parents, coaches, and referees in youth soccer in Washington State is high, gaps in knowledge and practice regarding the prevention of concussion in youth soccer athletes still exist. PM R 2012;4:427-435	[Shenouda, Christian; Hendrickson, Peter; Davenport, Kathleen; Barber, Jason; Bell, Kathleen R.] Univ Washington, Seattle, WA 98195 USA		Shenouda, C (corresponding author), NIH, Dept Rehabil Med, 10 Ctr Dr,Room 1-1469,MSC 1604, Bethesda, MD 20892 USA.	christianshenouda@hotmail.com		Bell, Kathleen/0000-0002-0928-2046	TBI Model Systems, NIDRR, Department of Education [H133A070032]	Funded in part by grant #H133A070032, TBI Model Systems, NIDRR, Department of Education.	Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Niedfeldt MW, 2011, CURR SPORT MED REP, V10, P324, DOI 10.1249/JSR.0b013e318237be53; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; WITHNALL C, 2005, BR J SPORTS MED S1, V39, P48	15	39	39	0	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2012	4	6					427	435		10.1016/j.pmrj.2012.02.016			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	969EO	WOS:000306038700006	22543038				2022-02-06	
J	Dhandapani, SS; Manju, D; Sharma, BS; Mahapatra, AK				Dhandapani, S. S.; Manju, D.; Sharma, B. S.; Mahapatra, A. K.			Prognostic significance of age in traumatic brain injury	JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE			English	Article						Age; brain injury; mortality; outcome; threshold		Background: Age is a strong prognostic factor following traumatic brain injury (TBI), with discrepancies defining the critical prognostic age threshold. This study was undertaken to determine the impact of various age thresholds on outcome after TBI. Materials and Methods: The ages of patients admitted with TBI were prospectively studied in relation to mode of injury, Glasgow coma score (GCS), CT category and surgical intervention. Mortality was assessed at 1 month, and neurological outcome was assessed at 6 months. Appropriate statistical analyzes (details in article) were performed. Results: Of the total 244 patients enrolled, 144 patients had severe, 38 patients had moderate and 62 patients had mild TBI, respectively. Age had significant association with grade of injury, CT category and surgical intervention (P < 0.01). Mortality at 1 month was significantly associated with increasing age with patients dead at 1 month being 15% for age < 18, 44% for age between 18 and 59 years, and 52% in the age group > 59 years respectively (P<0.001). Unfavorable outcome showed significant association with an increase in age, every decade ( P<0.001). In multivariate analysis, there was stepwise increase in the odds of unfavorable outcome across age groups centered on 40 years, independent of confounding factors. The adjusted odds ratios for unfavorable outcome with regard to age thresholds 30, 40 and 50 years were 11.3, 53.3 and 1171, respectively (P < 0.005). Moreover, there was significant association of unfavorable outcome with age > 40 years in all subgroups, based on GCS and surgical intervention (P<0.05). Conclusions: In patients with TBI, age demonstrates independent association with unfavorable outcome at 6 months, in stepwise manner centered on a threshold of 40 years.	[Dhandapani, S. S.; Sharma, B. S.; Mahapatra, A. K.] AIIMS, Dept Neurosurg, New Delhi, India; [Manju, D.] AIIMS, Neuronursing, New Delhi, India		Dhandapani, SS (corresponding author), AIIMS, Dept Neurosurg, New Delhi, India.	ssdhandu@rediffmail.com	Dhandapani, Sivashanmugam/I-2395-2013	Dhandapani, Sivashanmugam/0000-0002-3497-4255; Dhandapani, Manju/0000-0003-3351-3841			BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1982, HEAD INJURY BASIC CL, P213; Vollmer DG, 1991, NEUROSURGERY, V75, P37; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731	21	39	42	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0976-3147	0976-3155		J NEUROSCI RURAL PRA	J. Neurosci. Rural Pract.	MAY-AUG	2012	3	2					131	135		10.4103/0976-3147.98208			5	Clinical Neurology	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V3W2I	WOS:000218643500005	22865961	gold, Green Published			2022-02-06	
J	Caswell, SV; Lincoln, AE; Almquist, JL; Dunn, RE; Hinton, RY				Caswell, Shane V.; Lincoln, Andrew E.; Almquist, Jon L.; Dunn, Reginald E.; Hinton, Richard Y.			Video Incident Analysis of Head Injuries in High School Girls' Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; head injury; concussion; sports; girls' lacrosse	TRAUMATIC BRAIN-INJURY; SURVEILLANCE SYSTEM; WOMENS LACROSSE; UNITED-STATES; FOOTBALL; EPIDEMIOLOGY; MECHANISMS; SPORTS	Background: Knowledge of injury mechanisms and game situations associated with head injuries in girls' high school lacrosse is necessary to target prevention efforts. Purpose: To use video analysis and injury data to provide an objective and comprehensive visual record to identify mechanisms of injury, game characteristics, and penalties associated with head injury in girls' high school lacrosse. Study Design: Descriptive epidemiology study. Methods: In the 25 public high schools of 1 school system, 529 varsity and junior varsity girls' lacrosse games were videotaped by trained videographers during the 2008 and 2009 seasons. Video of head injury incidents was examined to identify associated mechanisms and game characteristics using a lacrosse-specific coding instrument. Results: Of the 25 head injuries (21 concussions and 4 contusions) recorded as game-related incidents by athletic trainers during the 2 seasons, 20 head injuries were captured on video, and 14 incidents had sufficient image quality for analysis. All 14 incidents of head injury (11 concussions, 3 contusions) involved varsity-level athletes. Most head injuries resulted from stick-to-head contact (n = 8), followed by body-to-head contact (n = 4). The most frequent player activities were defending a shot (n = 4) and competing for a loose ball (n = 4). Ten of the 14 head injuries occurred inside the 12-m arc and in front of the goal, and no penalty was called in 12 injury incidents. All injuries involved 2 players, and most resulted from unintentional actions. Turf versus grass did not appear to influence number of head injuries. Conclusion: Comprehensive video analysis suggests that play near the goal at the varsity high school level is associated with head injuries. Absence of penalty calls on most of these plays suggests an area for exploration, such as the extent to which current rules are enforced and the effectiveness of existing rules for the prevention of head injury.	[Caswell, Shane V.] George Mason Univ, Sports Med Assessment Res & Testing Lab, Sch Recreat Hlth & Tourism, Manassas, VA 20110 USA		Caswell, SV (corresponding author), George Mason Univ, Sports Med Assessment Res & Testing Lab, Sch Recreat Hlth & Tourism, 10900 Univ Blvd,MS 4E5, Manassas, VA 20110 USA.	scaswell@gmu.edu			National Operating Committee on Standards for Athletic Equipment; US Lacrosse Sports Science & Safety Committee	One or more of the authors has declared the following potential conflict of interest or source of funding: Funded in part by a grant from the National Operating Committee on Standards for Athletic Equipment and from the US Lacrosse Sports Science & Safety Committee. The funding organizations had no other role in the study.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Appleby B, 2002, J SCI MED SPORT, V5, P129, DOI 10.1016/S1440-2440(02)80034-2; Carter EA, 2010, INT J INJ CONTROL SA, V17, P111, DOI 10.1080/17457300903524888; DaSilva M, LACROSSE MAGAZINE; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P173; Drew K, CNYCENTRAL; Feil J, POINTS TAKEN COACHES; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; Olsen E., 1997, SCI FOOTBALL, P209; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schwarz A, 2011, NY TIMES, pB13; US Lacrosse, PART SURV US LACR; US Lacrosse, 2010, OFF RUL GIRLS WOM LA	21	39	39	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	APR	2012	40	4					756	762		10.1177/0363546512436647			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	918XO	WOS:000302285100003	22328707				2022-02-06	
J	Clarke, LA; Genat, RC; Anderson, JFI				Clarke, Lisa A.; Genat, Ross C.; Anderson, Jacqueline F. I.			Long-term cognitive complaint and post-concussive symptoms following mild traumatic brain injury: The role of cognitive and affective factors	BRAIN INJURY			English	Article						Cognition; outcome; head injury; mild brain injury; neuropsychological	POSTCONCUSSION-SYNDROME; HEAD-INJURY; DEPRESSION; ANXIETY; AGE	Primary objective: To determine whether neuropsychological test performance or affective factors predict long-term post-concussive symptoms and cognitive complaint following mild traumatic brain injury. Methods and procedures: Participants included 21 individuals with mild traumatic brain injury, 19 individuals with spinal injury but no injury to the brain and 20 neurologically-normal controls. All participants completed measures of post-concussive symptoms, cognitive complaint, depression, anxiety, and personality and were administered a variety of neuropsychological tests. Main outcomes and results: The hypothesis that depression, anxiety and neuroticism would be better predictors of post-concussive symptoms than neuropsychological test performance for all three groups was supported. Contrary to expectations, however, neuropsychological test performance was a unique predictor of cognitive complaint for the mild traumatic brain injury group. Conclusions: It was concluded that long-term post-concussive symptoms are largely representative of psychological symptoms and not brain damage, but that genuine, albeit subtle, cognitive deficits also may be present for long-term periods following mild traumatic brain injury.	[Anderson, Jacqueline F. I.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia; [Anderson, Jacqueline F. I.] The Alfred, Dept Neurosurg, Melbourne, Vic, Australia; [Anderson, Jacqueline F. I.] The Alfred, Dept Psychol, Melbourne, Vic, Australia		Anderson, JFI (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia.	jfande@unimelb.edu.au		Anderson, Jacqueline/0000-0003-4996-8189	Neurosurgery Department, The Alfred	The authors would like to thank Professor Jeffrey Rosenfeld (Director, Neurosurgery Department, The Alfred) for supporting this research project.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ashman TA, 2006, MT SINAI J MED, V73, P999; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comijs HC, 2002, J AFFECT DISORDERS, V72, P157, DOI 10.1016/S0165-0327(01)00453-0; Costa P. T., 1992, REVISED NEO PERSONAL; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lahr Denise, 2007, Cogn Neuropsychiatry, V12, P25, DOI 10.1080/13546800600714791; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; MARTIN M, 1985, PERS INDIV DIFFER, V6, P353, DOI 10.1016/0191-8869(85)90060-1; McAdams DP, 2006, PERSON NEW INTRO PER; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; O'Shea MF, 1996, COGNITIVE AFFECTIVE; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Taylor E., 1959, PSYCHOL APPRAISAL CH; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	38	39	40	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					298	307		10.3109/02699052.2012.654588			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100010	22372417				2022-02-06	
J	Oron, A; Oron, U; Streeter, J; De Taboada, L; Alexandrovich, A; Trembovler, V; Shohami, E				Oron, Amir; Oron, Uri; Streeter, Jackson; De Taboada, Luis; Alexandrovich, Alexander; Trembovler, Victoria; Shohami, Esther			Near Infrared Transcranial Laser Therapy Applied at Various Modes to Mice following Traumatic Brain Injury Significantly Reduces Long-Term Neurological Deficits	JOURNAL OF NEUROTRAUMA			English	Article						low-level laser therapy; magnetic resonance imaging; mice; motor function; pulsed laser; traumatic brain injury	CLOSED-HEAD INJURY; MYOCARDIAL-INFARCTION; EMBOLIC STROKES; LIGHT THERAPY; IRRADIATION; SAFETY; RATS; MECHANISMS; PROTEIN; MOTOR	Near-infrared transcranial laser therapy (TLT) has been found to modulate various biological processes including traumatic brain injury (TBI). Following TBI in mice, in this study we assessed the possibility of various near-infrared TLT modes (pulsed versus continuous) in producing a beneficial effect on the long-term neurobehavioral outcome and brain lesions of these mice. TBI was induced by a weight-drop device, and neurobehavioral function was assessed from 1 h to 56 days post-trauma using the Neurological Severity Score (NSS). The extent of recovery is expressed as the difference in NSS (dNSS), the difference between the initial score and that at any other later time point. An 808-nm Ga-Al-As diode laser was employed transcranially 4, 6, or 8h post-trauma to illuminate the entire cortex of the brain. Mice were divided into several groups of 6-8 mice: one control group that received a sham treatment and experimental groups that received either TLT continuous wave (CW) or pulsed wave (PW) mode transcranially. MRI was taken prior to sacrifice at 56 days post-injury. From 5-28 days post-TBI, the NSS of the laser-treated mice were significantly lower (p<0.05) than those of the non-laser-treated control mice. The percentage of surviving mice that demonstrated full recovery at 56 days post-CHI (NSS=0, as in intact mice) was the highest (63%) in the group that had received TLT in the PW mode at 100 Hz. In addition, magnetic resonance imaging (MRI) analysis demonstrated significantly smaller infarct lesion volumes in laser-treated mice compared to controls. Our data suggest that non-invasive TLT of mice post-TBI provides a significant long-term functional neurological benefit, and that the pulsed laser mode at 100 Hz is the preferred mode for such treatment.	[Oron, Amir] Kaplan Med Ctr, Dept Hand Surg, Rehovot, Israel; [Oron, Uri; Streeter, Jackson; De Taboada, Luis] PhotoThera Inc, Carlsbad, CA USA; [Alexandrovich, Alexander; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Oron, U (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Zool, IL-69978 Tel Aviv, Israel.	oronu@post.tau.ac.il		De Taboada, Luis/0000-0002-0153-6419			Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Avni D, 2005, PHOTOMED LASER SURG, V23, P273, DOI 10.1089/pho.2005.23.273; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Karu T, 2007, 10 LECT BASIC SCI LA; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; McFaddaen L., 2011, J NEUROTRAUM, V28, P2821; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Oron U, 2001, CIRCULATION, V103, P296; Oron U, 2006, PHOTOMED LASER SURG, V24, P111, DOI 10.1089/pho.2006.24.111; Shefer G, 2002, J CELL SCI, V115, P1461; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; WINSON J, 1972, BEHAV BIOL, V7, P479, DOI 10.1016/S0091-6773(72)80210-4; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Yaakobi T, 2001, J APPL PHYSIOL, V90, P2411, DOI 10.1152/jappl.2001.90.6.2411; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	33	39	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					401	407		10.1089/neu.2011.2062			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300019	22040267				2022-02-06	
J	Grant, M; Ponsford, J; Bennett, PC				Grant, Michele; Ponsford, Jennie; Bennett, Pauleen C.			The application of Goal Management Training to aspects of financial management in individuals with traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Goal Management Training; Rehabilitation; TBI; Executive functions	FRONTAL-LOBE DAMAGE; COGNITIVE REHABILITATION; PREFRONTAL CORTEX; TEST SCORE; BEHAVIOR; INTERVENTION; LESIONS	Executive functions encompass planning, problem-solving and self-monitoring abilities, abilities that are implicit in goal attainment and often compromised in individuals with traumatic brain injury (TBI). Goal Management Training (GMT) is a theoretically based rehabilitation protocol that was developed to improve goal-directed behaviour. To date, there is evidence to support the efficacy of GMT in healthy older adults and in one previously high functioning individual with acquired brain injury. However, there is no evidence that, in individuals with TBI and severe cognitive impairments, GMT leads to sustained improvement on everyday tasks requiring planning and organisation. The current study was conducted to explore the efficacy of GMT in helping individuals with TBI to improve aspects of their day-to-day financial management. Four participants with severe TBI completed a modified GMT module. Outcomes were assessed using Goal Attainment Scaling. Five control participants were also recruited as a comparison group for the Multiple Errands Task which was used to measure generalisation. The outcomes in each case were variable. Overall the results showed that the structured GMT intervention assisted some TBI individuals to improve their performance on financial management tasks, with evidence of generalisation in some cases.	[Grant, Michele; Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Clayton, Vic, Australia; [Grant, Michele; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [Bennett, Pauleen C.] La Trobe Univ, Bendigo, Vic, Australia		Grant, M (corresponding author), Monash Epworth Rehabil Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	michele.grant@monash.edu	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Becker H, 2000, NURS RES, V49, P176, DOI 10.1097/00006199-200005000-00011; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Crawford JR, 2002, NEUROPSYCHOLOGIA, V40, P1196, DOI 10.1016/S0028-3932(01)00224-X; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Cumming G, 2012, UNDERSTANDING NEW ST, P2012; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fuster, 2015, PREFRONTAL CORTEX; Goel V, 2000, COGN NEUROPSYCHOL, V17, P415, DOI 10.1080/026432900410775; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mate-Kole CC, 1999, NURS RES, V48, P220, DOI 10.1097/00006199-199907000-00005; McPherson K. M., 2009, CLIN REHABIL, V23, P269; Robertson I., 1996, GOAL MANAGEMENT TRAI; Rockwood K, 1997, J CLIN EPIDEMIOL, V50, P581, DOI 10.1016/S0895-4356(97)00014-0; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sokal RR., 1995, STAT TABLES, V3rd ed; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; van Hooren SAH, 2007, PATIENT EDUC COUNS, V65, P205, DOI 10.1016/j.pec.2006.07.010; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Zalla T, 2001, NEUROPSYCHOLOGIA, V39, P759, DOI 10.1016/S0028-3932(01)00019-7	29	39	39	1	29	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	6					852	873		10.1080/09602011.2012.693455			22	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	039EQ	WOS:000311227300003	22812612				2022-02-06	
J	Sakakima, H; Khan, M; Dhammu, TS; Shunmugavel, A; Yoshida, Y; Singh, I; Singh, AK				Sakakima, Harutoshi; Khan, Mushfiquddin; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Yoshida, Yoshihiro; Singh, Inderjit; Singh, Avtar K.			Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						GSNO; IR; motor exercise; neurorepair; neurobehavior; rehabilitation; S-nitrosylation; stroke	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NF-KAPPA-B; NITRIC-OXIDE; EXPERIMENTAL STROKE; NEUROVASCULAR UNIT; GLUTATHIONE; ACTIVATION; PATHWAY; NITROSYLATION	Purpose: Stroke disability stems from insufficient neurorepair mechanisms. Improvement of functions has been achieved through rehabilitation or therapeutic agents. Therefore, we combined exercise with a neurovascular protective agent, S-nitrosoglutathione (GSNO), to accelerate functional recovery. Methods: Stroke was induced by middle cerebral artery occlusion for 60 min followed by reperfusion in adult male rats. Animals were treated with vehicle (IR group), GSNO (0.25 mg/kg, GSNO group), rotarod exercise (EX group) and GSNO plus exercise (GSNO+EX group). The groups were studied for 14 days to determine neurorepair mechanisms and functional recovery. Results: Treated groups showed reduced infarction, decreased neuronal cell death, enhanced neurotrophic factors, and improved neurobehavioral functions. However, the GSNO+EX showed greater functional recovery (p < 0.05) than the GSNO or the EX group. A GSNO sub group, treated 24 hours after IR, still showed motor function recovery (p < 0.001). The protective effect of GSNO or exercise was blocked by the inhibition of Akt activity. Conclusions: GSNO and exercise aid functional recovery by stimulating neurorepair mechanisms. The improvements by GSNO and exercise depend mechanistically on the Akt pathway. A combination of exercise and GSNO shows greater functional recovery. Improved recovery with GSNO, even administered 24 hours post-IR, demonstrates its clinical relevance.	[Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Sakakima, Harutoshi; Khan, Mushfiquddin; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Sakakima, Harutoshi; Yoshida, Yoshihiro] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA		Singh, AK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 508 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu			Veteran Administration; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511, NS-22576, NS-37766]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511, R01NS022576, R37NS022576, R01NS037766] Funding Source: NIH RePORTER	This work was supported by grants from Veteran Administration merit awards and NIH (NS-72511, NS-22576 and NS-37766). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan for her technical help, and Ms. Chara Williams for her secretarial assistance. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript.	Aledia AS, 2002, ASAIO J, V48, P526, DOI 10.1097/00002480-200209000-00015; Chen MJ, 2005, MOL BRAIN RES, V135, P181, DOI 10.1016/j.molbrainres.2004.12.001; Cheng XW, 2010, CIRCULATION, V122, P707, DOI 10.1161/CIRCULATIONAHA.109.909218; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; CHOLLET F, 2011, OPTN SRTR ANN REP, V10, P123, DOI DOI 10.1016/S1474-4422(10)70314-8; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Clarkson AN, 2011, J NEUROSCI, V31, P3766, DOI 10.1523/JNEUROSCI.5780-10.2011; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Colagiovanni DB, 2011, INT J TOXICOL, V30, P466, DOI 10.1177/1091581811412084; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; Ding Y, 2004, NEUROSCIENCE, V123, P667, DOI 10.1016/j.neuroscience.2003.08.031; Fortenberry JD, 2001, INFLAMM RES, V50, P89; Foster MW, 2009, TRENDS MOL MED, V15, P391, DOI 10.1016/j.molmed.2009.06.007; Gladstone DJ, 2006, STROKE, V37, P179, DOI 10.1161/01.STR.0000195169.42447.78; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kaposzta Z, 2002, CIRCULATION, V106, P3057, DOI 10.1161/01.CIR.0000041251.07332.28; Ke Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016643; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim MW, 2005, BRAIN RES, V1052, P16, DOI 10.1016/j.brainres.2005.05.070; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kluge I, 1997, J NEUROCHEM, V69, P2599; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Lima B, 2009, P NATL ACAD SCI USA, V106, P6297, DOI 10.1073/pnas.0901043106; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Lo EH, 2008, BRIT J PHARMACOL, V153, pS396, DOI 10.1038/sj.bjp.0707626; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matsuda F, 2011, ACTA PHYSIOL, V201, P275, DOI [10.1111/j.1748-1716.2010.02174.x, 10.1111/j.1748-1708.2010.02174.x]; Molloy J, 1998, CIRCULATION, V98, P1372, DOI 10.1161/01.CIR.98.14.1372; Monville C, 2006, J NEUROSCI METH, V158, P219, DOI 10.1016/j.jneumeth.2006.06.001; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/ajrccm.165.7.2105032; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Wellman TL, 2003, FASEB J, V17, P379, DOI 10.1096/fj.03-0143fje; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369	46	39	40	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2012	30	5					383	396		10.3233/RNN-2012-110209			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	004UO	WOS:000308706800003	22717646	Bronze, Green Accepted			2022-02-06	
S	Xiong, Y; Mahmood, A; Meng, YL; Zhang, YL; Zhang, ZG; Morris, DC; Chopp, M		Goldstein, AL; Garaci, E		Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Zhang, Zheng Gang; Morris, Daniel C.; Chopp, Michael			Neuroprotective and neurorestorative effects of thymosin beta 4 treatment following experimental traumatic brain injury	THYMOSINS IN HEALTH AND DISEASE II	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	3rd International Symposium on Thymosins in Health and Disease	MAR 14-16, 2012	Washington, DC	George Washington Univ, Ist Superiore Sanita (ISS), Univ Rome Tor Vergata		thymosin beta 4; traumatic brain injury; rat; neuroprotection; neurorestoration	ERYTHROPOIETIN ENHANCES NEUROGENESIS; ADULT HIPPOCAMPAL NEUROGENESIS; STROMAL CELL TRANSPLANTATION; CORTICAL IMPACT INJURY; DENTATE GYRUS; CLINICAL-TRIALS; NEURONAL DEATH; SPATIAL MEMORY; NITRIC-OXIDE; CA3 REGION	Traumatic brain injury (TBI) remains a leading cause of mortality and morbidity worldwide. No effective pharmacological treatments are available for TBI because all phase II/III TBI clinical trials have failed. This highlights a compelling need to develop effective treatments for TBI. Endogenous neurorestoration occurs in the brain after TBI, including angiogenesis, neurogenesis, synaptogenesis, oligodendrogenesis, and axonal remodeling, which may be associated with spontaneous functional recovery after TBI. However, the endogenous neurorestoration following TBI is limited. Treatments amplifying these neurorestorative processes may promote functional recovery after TBI. Thymosin beta 4 (T beta 4) is the major G-actin-sequestering molecule in eukaryotic cells. In addition, T beta 4 has other properties including antiapoptosis and anti-inflammation, promotion of angiogenesis, wound healing, stem/progenitor cell differentiation, and cell migration and survival, which provide the scientific foundation for the corneal, dermal, and cardiac wound repair multicenter clinical trials. Here, we describe T beta 4 as a neuroprotective and neurorestorative candidate for treatment of TBI.	[Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Morris, Daniel C.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS62002, PO1 NS42345, PO1 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, P01NS042345, R01NS062002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG038648] Funding Source: NIH RePORTER	The authors would like to thank Susan MacPhee-Gray for editorial assistance. T beta 4 was provided by RegeneRx Biopharmaceuticals, Inc. under the Materials Transfer Agreement. This work was supported by NIH Grants RO1 NS62002 (Ye Xiong), PO1 NS42345 (Asim Mahmood, Michael Chopp), and PO1 NS023393 (Michael Chopp).	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Crockford D, 2010, ANN NY ACAD SCI, V1194, P179, DOI 10.1111/j.1749-6632.2010.05492.x; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Dettin M, 2011, CELL IMMUNOL, V271, P299, DOI 10.1016/j.cellimm.2011.07.008; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo SZ, 2009, STROKE, V40, pS4, DOI 10.1161/STROKEAHA.108.534388; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Han HS, 2005, CURR NEUROVASC RES, V2, P409, DOI 10.2174/156720205774962647; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hastings NB, 2002, J COMP NEUROL, V452, P324, DOI 10.1002/cne.10386; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; Kempermann G, 2002, DEV BRAIN RES, V134, P1, DOI 10.1016/S0165-3806(01)00224-3; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kuhn HG, 2007, CURR PHARM BIOTECHNO, V8, P127; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Markakis EA, 1999, J COMP NEUROL, V406, P449; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Paxinos G, 1997, RAT BRAIN STEREOTACT; Philp D, 2003, FASEB J, V17, P2103, DOI 10.1096/fj.03-0121fje; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Smart Nicola, 2007, Angiogenesis, V10, P229, DOI 10.1007/s10456-007-9077-x; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2006, EXP EYE RES, V83, P502, DOI 10.1016/j.exer.2006.02.001; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; Taupin P, 2007, REGEN MED, V2, P51, DOI 10.2217/17460751.2.1.51; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yamashima T, 2007, REV NEUROSCIENCE, V18, P67; Yang XT, 2011, BRAIN RES BULL, V84, P1, DOI 10.1016/j.brainresbull.2010.09.008; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao YB, 2011, J CELL PHYSIOL, V226, P2798, DOI 10.1002/jcp.22624	86	39	40	0	9	BLACKWELL SCIENCE PUBL	OXFORD	OSNEY MEAD, OXFORD OX2 0EL, ENGLAND	0077-8923		978-1-57331-910-2	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2012	1270						51	58		10.1111/j.1749-6632.2012.06683.x			8	Biochemistry & Molecular Biology; Medicine, Research & Experimental; Multidisciplinary Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Research & Experimental Medicine; Science & Technology - Other Topics	BDB63	WOS:000312489700009	23050817	Green Accepted			2022-02-06	
J	Ho, KM; Honeybul, S; Lind, CRP; Gillett, GR; Litton, E				Ho, Kwok M.; Honeybul, Stephen; Lind, Christopher R. P.; Gillett, Grant R.; Litton, Edward			Cost-Effectiveness of Decompressive Craniectomy as a Lifesaving Rescue Procedure for Patients With Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Expenditure; Resources; Cost-benefit; Outcome	PRIORITIES; COHORT	Background: Decompressive craniectomy has been traditionally used as a lifesaving rescue procedure for patients with refractory intracranial hypertension after severe traumatic brain injury (TBI), but its cost-effectiveness remains uncertain. Methods: Using data on length of stay in hospital, rehabilitation facility, procedural costs, and Glasgow Outcome Scale (GOS) up to 18 months after surgery, the average total hospital costs per life-year and quality-adjusted life-year (QALY) were calculated for patients who had decompressive craniectomy for TBI between 2004 and 2010 in Western Australia. The Corticosteroid Randomisation After Significant Head Injury prediction model was used to quantify the severity of TBI. Results: Of the 168 patients who had 18-month follow-up data available after the procedure, 70 (42%) achieved a good outcome (GOS-5), 27 (16%) had moderate disability (GOS-4), 34 (20%) had severe disability (GOS-3), 5 (3%) were in vegetative state (GOS-2), and 32 (19%) died (GOS-1). The hospital costs increased with the severity of TBI and peaked when the predicted risk of an unfavorable outcome was about 80%. The average cost per life-year gained (US$671,000 per life-year) and QALY (US$682,000 per QALY) increased substantially and became much more than the usual acceptable cost-effective limit (US$100,000 per QALY) when the predicted risk of an unfavorable outcome was >80%. Changing different underlying assumptions of the analysis did not change the results significantly. Conclusions: Severity of TBI had an important effect on cost-effectiveness of decompressive craniectomy. As a lifesaving procedure, decompressive craniectomy was not cost-effective for patients with extremely severe TBI.	[Ho, Kwok M.; Litton, Edward] Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6000, Australia; [Lind, Christopher R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Gillett, Grant R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand; [Gillett, Grant R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand		Ho, KM (corresponding author), Royal Perth Hosp, Dept Intens Care Med, Wellington St, Perth, WA 6000, Australia.	kwok.ho@health.wa.gov.au	Lind, Christopher/K-3629-2012; Ho, Kwok M./E-3546-2010; litton, edward/C-5384-2017	Lind, Christopher/0000-0001-9991-1725; Ho, Kwok M./0000-0002-6705-6004; litton, edward/0000-0002-5125-6829	Department of Intensive Care Medicine at Royal Perth Hospital	Supported by the Department of Intensive Care Medicine at Royal Perth Hospital.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AIHW, 2006, AUSTR HOSP STAT 2004; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alexander GC, 2004, ARCH INTERN MED, V164, P593, DOI 10.1001/archinte.164.6.593; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7; Cookson R, 2000, J MED ETHICS, V26, P323, DOI 10.1136/jme.26.5.323; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Daniels N, 2009, HEALTH AFFAIR, V28, pW909, DOI 10.1377/hlthaff.28.5.w909; Fuchs VR, 2010, NEW ENGL J MED, V363, P704, DOI 10.1056/NEJMp0906597; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Ho KM, 2011, BRIT J ANAESTH, V106, P528, DOI 10.1093/bja/aeq417; Ho KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003226; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Malmivaara K, 2011, EUR J NEUROL, V18, P656, DOI 10.1111/j.1468-1331.2010.03294.x; Owens DK, 2011, ANN INTERN MED, V154, P174, DOI 10.7326/0003-4819-154-3-201102010-00007; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rechner IJ, 2005, ANAESTH INTENS CARE, V33, P477, DOI 10.1177/0310057X0503300409; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39	25	39	39	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1637	1644		10.1097/TA.0b013e31823a08f1			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	869RT	WOS:000298616400035	22182872				2022-02-06	
J	Sun, YH; Dai, MC; Wang, YT; Wang, WJ; Sun, QF; Yang, GY; Bian, LG				Sun, Yuhao; Dai, Minchao; Wang, Yongting; Wang, Wenjing; Sun, Qingfang; Yang, Guo-Yuan; Bian, Liuguan			Neuroprotection and Sensorimotor Functional Improvement by Curcumin after Intracerebral Hemorrhage in Mice	JOURNAL OF NEUROTRAUMA			English	Article							BLOOD-BRAIN-BARRIER; TIGHT JUNCTION PROTEINS; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; CLINICAL-TRIAL; CELL-CULTURE; RAT-BRAIN; MATRIX; INHIBITION; MODEL	Previous studies revealed that curcumin is neuroprotective in diseases of the central nervous system such as cerebral ischemia and traumatic brain injury. However, the effect of curcumin on intracerebral hemorrhage remains unclear. We, therefore, investigated the pre-clinical effect of curcumin treatment on neurological outcomes following intracerebral hemorrhage, using a mouse model. Intracerebral hemorrhage was induced by autologous blood injection into the right basal ganglia. Curcumin (150 mg/kg) was administered 15 min after intracerebral hemorrhage. Grid walk and neurological scores were evaluated at 1, 3, 7, and 14 days post-injury. Mice were killed at 24 h or 28 days following injury, for histological examination. Evans Blue and water content in the ipsilateral and contralateral hemispheres were measured to evaluate the extent of blood-brain barrier disruption and brain edema. Zonula occludens-1 was detected by immunostaining. In situ zymography was used to measure the localization and focal enzymatic activity of matrix metalloproteinase. Our results demonstrated that curcumin reduced brain edema, measured by alleviated water content and Evans Blue leakage at 24 h (p < 0.05). Lateral ventricle measurements indicated that curcumin reduced brain tissue loss in the ipsilateral hemisphere (p < 0.05). The same dose of curcumin also significantly attenuated neurological deficits at 1 and 3 days of intracerebral hemorrhage (p < 0.05). Immunostaining showed that tight junction continuity around the hematoma was better sustained in curcumin-treated mice than in vehicle-treated mice. At 24 h, the number of matrix metalloproteinase-positive cells was significantly reduced by curcumin (p < 0.05). Our study suggests that curcumin ameliorates intracerebral hemorrhage damage by preventing matrix metalloproteinase-mediated blood-brain barrier damage and brain edema, which might provide therapeutic potential for intracerebral hemorrhage.	[Sun, Yuhao; Dai, Minchao; Wang, Wenjing; Sun, Qingfang; Yang, Guo-Yuan; Bian, Liuguan] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Ruijin Hosp, Shanghai 200025, Peoples R China; [Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Med, Dept Neurol, Ruijin Hosp, Shanghai 200025, Peoples R China; [Wang, Yongting; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Med, Neurosci & Neuroengn Res Ctr, Med Res Inst X, Shanghai 200025, Peoples R China		Bian, LG (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Ruijin Hosp, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.	bian6612@yahoo.com.cn	Wang, Yongting/C-2916-2014		Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee [09JC1409700, 10JC1410700, 10411954200, 09140902400, 10JC1408100]	This research was supported by Shanghai Committee of Science and Technology grants 09JC1409700, 10JC1410700, 10411954200 (L. G. B., Q. F. S.), 09140902400, 10JC1408100 (G.Y.Y., Y.T.W.). We thank the collaborative support of the Med-X research Institute (http//med-x.sjtu.edu.cn) and Ms. Karena Shen for assistance with manuscript preparation.	Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Baum L, 2008, J CLIN PSYCHOPHARM, V28, P110, DOI 10.1097/jcp.0b013e318160862c; Belayev L, 2003, STROKE, V34, P2221, DOI 10.1161/01.STR.0000088061.06656.1E; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Dohare P, 2008, BEHAV BRAIN RES, V193, P289, DOI 10.1016/j.bbr.2008.06.012; Ghoneim AI, 2002, PHARMACOL RES, V46, P273, DOI 10.1016/S1043-6618(02)00123-8; Grossetete M, 2008, J CEREBR BLOOD F MET, V28, P752, DOI 10.1038/sj.jcbfm.9600572; Jiang J, 2007, EUR J PHARMACOL, V561, P54, DOI 10.1016/j.ejphar.2006.12.028; Kim SY, 2005, BIOCHEM BIOPH RES CO, V337, P510, DOI 10.1016/j.bbrc.2005.09.079; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Lapchak PA, 2011, EXPERT OPIN INV DRUG, V20, P13, DOI 10.1517/13543784.2011.542410; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Rathore P, 2008, NEUROCHEM RES, V33, P1672, DOI 10.1007/s11064-007-9515-6; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1993, NEUROSCI LETT, V160, P117, DOI 10.1016/0304-3940(93)90927-D; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Wachtel M, 1999, J CELL SCI, V112, P4347; Wang HH, 2009, GLIA, V57, P24, DOI 10.1002/glia.20732; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang MS, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-57; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu CY, 2008, J NEUROCHEM, V105, P1499, DOI 10.1111/j.1471-4159.2008.05318.x; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xue MZ, 2006, J NEUROSCI, V26, P10281, DOI 10.1523/JNEUROSCI.2806-06.2006; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Zhao J, 2010, NEUROCHEM RES, V35, P374, DOI 10.1007/s11064-009-0065-y	35	39	42	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2011	28	12					2513	2521		10.1089/neu.2011.1958			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	865DS	WOS:000298291600011	21770745	Green Published			2022-02-06	
J	Bell, KR; Brockway, JA; Hart, T; Whyte, J; Sherer, M; Fraser, RT; Temkin, NR; Dikmen, SS				Bell, Kathleen R.; Brockway, Jo Ann; Hart, Tessa; Whyte, John; Sherer, Mark; Fraser, Robert T.; Temkin, Nancy R.; Dikmen, Sureyya S.			Scheduled Telephone Intervention for Traumatic Brain Injury: A Multicenter Randomized Controlled Trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation; Telephone; Treatment outcome	ROUTINE FOLLOW-UP; PARTICIPATION ASSESSMENT; FAMILY CAREGIVERS; PRIMARY-CARE; REHABILITATION; DEPRESSION; PSYCHOTHERAPY; MANAGEMENT; MODERATE; SCALE	Bell KR, Brockway JA, Hart T, Whyte J, Sherer M, Fraser RT, Temkin NR, Dikmen SS. Scheduled telephone intervention for traumatic brain injury: a multicenter randomized controlled trial. Arch Phys Med Rehabil 2011;92: 1552-60. Objective: To evaluate the effect of a Scheduled Telephone Intervention (STI) compared with usual care (UC) on function, health/emotional status, community/work activities, and well-being at 1 and 2 years after traumatic brain injury (TBI). Design: Two group, randomized controlled trial. Setting: Telephone contacts with subjects recruited in inpatient rehabilitation. Participants: Eligible subjects (N=433) with TBI (age>16y) were randomly assigned to STI plus UC (n=210) or UC (n=223) at discharge. STI subjects (n=169) completed the outcome at year 1 (118 at year 2) and 174 UC subjects at year 1 (123 at year 2). Interventions: STI subjects received calls at 2 and 4 weeks and 2, 3, 5, 7, 9, 12, 15, 18, and 21 months consisting of brief training in problem solving, education, or referral. Main Outcome Measures: A composite outcome at 1 year was the primary endpoint. Analysis on intent-to-treat basis used linear regression adjusted for site, Glasgow Coma Scale, race/ethnicity, age, FIM, sex, and Disability Rating Scale (DRS). Secondary analyses were conducted on individual and composite measures (FIM, DRS, community participation indicators, Glasgow Outcome Scale [Extended], Short Form-12 Health Survey, Brief Symptom Inventory-18, EuroQOL, and modified Perceived Quality of Life). Results: No significant differences were noted between the groups at years 1 or 2 for primary (P=.987 regression for year 1, P=.983 for year 2) or secondary analyses. Conclusions: This study failed to replicate the findings of a previous single center study of telephone-based counseling. While telephone mediated treatment has shown promise in other studies, this model of flexible counseling in problem solving and education for varied problems was not effective over and above usual care.	[Bell, Kathleen R.; Brockway, Jo Ann; Fraser, Robert T.; Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Hart, Tessa; Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA		Bell, KR (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	krbell@uw.edu		Whyte, John/0000-0002-4381-1474; Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability and Rehabilitation Research, Department of Education [H133A040004, H133A020508, H133A070040, H133A70033]	Supported by the National Institute on Disability and Rehabilitation Research, Department of Education (grant nos. H133A040004, H133A020508, H133A070040, H133A70033).	[Anonymous], 1990, HLTH POLICY, V16, P199; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Campbell C H, 1988, Rehabil Nurs, V13, P320; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Engli M, 1993, J Neurosci Nurs, V25, P78; Faul M, 2010, TRAUMATIC BRAIN INJU; Feenstra TL, 2005, VALUE HEALTH, V8, P178, DOI 10.1111/j.1524-4733.2005.04008.x; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fortney JC, 2007, J GEN INTERN MED, V22, P1086, DOI 10.1007/s11606-007-0201-9; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Johnson K, 2000, Intensive Crit Care Nurs, V16, P144, DOI 10.1054/iccn.2000.1478; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Mittag O, 2006, INT J REHABIL RES, V29, P295, DOI 10.1097/MRR.0b013e328010ba9a; Mohr DC, 2005, ARCH GEN PSYCHIAT, V62, P1007, DOI 10.1001/archpsyc.62.9.1007; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paterson B, 2001, Rehabil Nurs, V26, P48; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PONSFORD J, 2003, BRAIN INJURY, P17453; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Smith J E, 2000, Care Manag J, V2, P27; Spearman RC, 2007, BRAIN INJURY, V21, P837, DOI 10.1080/02699050701426857; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	39	40	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2011	92	10					1552	1560		10.1016/j.apmr.2011.05.018			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	833DE	WOS:000295861200004	21963122				2022-02-06	
J	Beziaud, T; Chen, XR; El Shafey, N; Frechou, M; Teng, F; Palmier, B; Beray-Berthat, V; Soustrat, M; Margaill, I; Plotkine, M; Marchand-Leroux, C; Besson, VC				Beziaud, Tiphaine; Chen, Xiao Ru; El Shafey, Nelly; Frechou, Magalie; Teng, Fei; Palmier, Bruno; Beray-Berthat, Virginie; Soustrat, Mathieu; Margaill, Isabelle; Plotkine, Michel; Marchand-Leroux, Catherine; Besson, Valerie C.			Simvastatin in traumatic brain injury: Effect on brain edema mechanisms	CRITICAL CARE MEDICINE			English	Article						blood-brain barrier; brain edema; claudin; polymorphonuclear neutrophil; simvastatin; traumatic brain injury	CADHERIN TYROSINE PHOSPHORYLATION; REDUCES NEUROLOGICAL DEFICIT; MEDIATED UP-REGULATION; VE-CADHERIN; ENDOTHELIAL-CELLS; BARRIER BREAKDOWN; TIGHT JUNCTIONS; ALPHA AGONIST; NITRIC-OXIDE; RATS	Objectives: Traumatic brain injury causes deleterious brain edema, leading to high mortality and morbidity. Brain edema exacerbates neurologic deficits and may be attributable to the breakdown of endothelial cell junction protein, leukocyte infiltration, and matrix metalloproteinase activation. These all contribute to loss of blood-brain barrier integrity. The pleiotropic effects of statins, hydroxymethylglutaryl-coenzyme A reductase inhibitors, may inhibit posttraumatic brain edema. We therefore investigated the effect of acute simvastatin on neurologic deficits, cerebral edema, and its origins. Design: Randomized laboratory animal study. Settings: University-affiliated research laboratory. Subjects: Male Sprague-Dawley rats. Interventions: Rats were subjected to lateral fluid percussion traumatic brain injury. Our preliminary dose-effect study indicated that 37.5 mg/kg simvastatin, administered orally 1 hr and 6 hrs after traumatic brain injury, has the greatest anti-edematous effect. This dose was used to study its effects on brain edema and on its mechanisms. Measurements and Main Results: We first assessed the effects of simvastatin 24 hrs after traumatic brain injury on brain edema, brain claudin-5 expression, and the vascular endothelial-cadherin pTyr731)/total vascular endothelial-cadherin ratio, matrix metalloproteinase-9 activity, intercellular adhesion molecule-1 expression, and polymorphonuclear neutrophil infiltration. We also evaluated blood-brain barrier permeability by measuring Evans blue and fluorescein sodium salt extravasation into the cerebral parenchyma. We then investigated whether simvastatin reduces neurologic deficits, edema, and blood-brain barrier permeability earlier than 24 hrs; these effects were evaluated 6 hrs after traumatic brain injury. The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Earlier, 6-hrs after traumatic brain injury, simvastatin reduced neurologic deficits, cerebral edema, and blood-brain barrier permeability. Conclusions: Simvastatin could be a new therapy for reducing posttraumatic edema by preventing damage to tight junctions and neutrophil infiltration into the parenchyma, thus preserving blood-brain barrier integrity. (Crit Care Med 2011; 39:2300-2307)	[Beziaud, Tiphaine; Chen, Xiao Ru; El Shafey, Nelly; Frechou, Magalie; Teng, Fei; Palmier, Bruno; Beray-Berthat, Virginie; Soustrat, Mathieu; Margaill, Isabelle; Plotkine, Michel; Marchand-Leroux, Catherine; Besson, Valerie C.] Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA4475, Paris, France		Besson, VC (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA4475, Paris, France.	valerie.besson@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020; Margaill, Isabelle/ABA-4362-2020; besson, valerie C/L-7388-2017; Frechou, Magalie/I-6598-2015	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380; Margaill, Isabelle/0000-0002-7941-6644; besson, valerie C/0000-0002-1491-2380; Frechou, Magalie/0000-0001-8676-1000	Fondation Des Gueules Cassees	Supported, in part, by the Fondation Des Gueules Cassees.	Allingham MJ, 2007, J IMMUNOL, V179, P4053, DOI 10.4049/jimmunol.179.6.4053; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Batteur-Parmentier S, 2000, J CEREBR BLOOD F MET, V20, P812, DOI 10.1097/00004647-200005000-00007; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Blecharz KG, 2010, MULT SCLER J, V16, P293, DOI 10.1177/1352458509358189; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; Gavard J, 2008, NAT CELL BIOL, V10, P883, DOI 10.1038/ncb0808-883; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hu JL, 2007, NAT REV DRUG DISCOV, V6, P480, DOI 10.1038/nrd2308; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Kamio K, 2010, EUR RESPIR J, V35, P637, DOI 10.1183/09031936.00134707; Kanoski SE, 2010, J ALZHEIMERS DIS, V21, P207, DOI 10.3233/JAD-2010-091414; Kim SE, 2009, EXP MOL MED, V41, P277, DOI 10.3858/emm.2009.41.4.031; Kurzepa J, 2006, FOLIA BIOL-PRAGUE, V52, P181; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Massaro M, 2010, CARDIOVASC RES, V86, P311, DOI 10.1093/cvr/cvp375; Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/0008-6363(96)00146-0; Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894; Morofuji Y, 2010, CELL MOL NEUROBIOL, V30, P727, DOI 10.1007/s10571-010-9497-9; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nagyoszi P, 2010, NEUROCHEM INT, V57, P556, DOI 10.1016/j.neuint.2010.07.002; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Soares HD, 1995, J NEUROSCI, V15, P8223; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Turkoglu OF, 2009, SURG NEUROL, V72, P146, DOI 10.1016/j.surneu.2008.07.004; Turowski P, 2005, CELL MOL NEUROBIOL, V25, P153, DOI 10.1007/s10571-004-1380-0; Turowski P, 2008, J CELL SCI, V121, P29, DOI 10.1242/jcs.022681; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360	49	39	43	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2011	39	10					2300	2307		10.1097/CCM.0b013e3182227e4a			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821EU	WOS:000294958500014	21666443				2022-02-06	
J	Kokshoorn, NE; Smit, JWA; Nieuwlaat, WA; Tiemensma, J; Bisschop, PH; Veldman, RG; Roelfsema, F; Franken, AAM; Wassenaar, MJE; Biermasz, NR; Romijn, JA; Pereira, AM				Kokshoorn, N. E.; Smit, J. W. A.; Nieuwlaat, W. A.; Tiemensma, J.; Bisschop, P. H.; Veldman, R. Groote; Roelfsema, F.; Franken, A. A. M.; Wassenaar, M. J. E.; Biermasz, N. R.; Romijn, J. A.; Pereira, A. M.			Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							ANTERIOR-PITUITARY FUNCTION; POSTTRAUMATIC HYPOPITUITARISM; LONG-TERM; DYSFUNCTION; SCALE; INSUFFICIENCY; ASSOCIATION; DEFICIENCY; FATIGUE; VALUES	Objective: Hypopituitarism after traumatic brain injury (TBI) is considered to be a prevalent condition. However, prevalence rates differ considerably among reported studies, due to differences in definitions, endocrine assessments of hypopituitarism, and confounding factors, such as timing of evaluation and the severity of the trauma. Aim: To evaluate the prevalence of hypopituitarism in a large cohort of TBI patients after long-term follow-up using a standardized endocrine evaluation. Study design: Cross-sectional study. Patients and methods: We included 112 patients with TBI, hospitalized for at least 3 days and duration of follow-up>1 year after TBI from five (neurosurgical) referral centers. Evaluation of pituitary function included fasting morning hormone measurements and insulin tolerance test (n = 90) or, when contraindicated, ACTH stimulation and/or CRH stimulation tests and a GH releasing hormone-arginine test (n = 22). Clinical evaluation included quality of life questionnaires. Results: We studied 112 patients (75 males), with median age 48 years and mean body mass index (BMI) 26.7 +/- 4.8 kg/m(2). Mean duration of hospitalization was 11 (3-105), and 33% of the patients had a severe trauma (Glasgow Coma Scale < 9) after TBI. The mean duration of follow-up was 4 (1-12) years. Hypopituitarism was diagnosed in 5.4% (6/112) of patients: severe GH deficiency (n = 3), hypogonadism (n = 1), adrenal insufficiency (n = 2). Patients diagnosed with pituitary insufficiency had significantly higher BMI (P = 0.002). Conclusion: In this study, the prevalence of hypopituitarism during long-term follow-up after TBI was low. Prospective studies are urgently needed to find reliable predictive tools for the identification of patients with a significant pre-test likelihood for hypopituitarism after TBI.	[Kokshoorn, N. E.; Smit, J. W. A.; Tiemensma, J.; Roelfsema, F.; Wassenaar, M. J. E.; Biermasz, N. R.; Romijn, J. A.; Pereira, A. M.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis C4 R, NL-2300 RC Leiden, Netherlands; [Nieuwlaat, W. A.] St Elizabeth Hosp, Dept Internal Med, Tilburg, Netherlands; [Bisschop, P. H.] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands; [Veldman, R. Groote] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands; [Franken, A. A. M.] Isala Clin, Dept Internal Med, Zwolle, Netherlands		Kokshoorn, NE (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis C4 R, POB 9600, NL-2300 RC Leiden, Netherlands.	n.e.kokshoorn@lumc.nl	Smit, J.W.A./H-8091-2014; Pereira, Alberto M./Q-7175-2017; Biermasz, Nienke/ABE-9436-2021	Smit, J.W.A./0000-0003-1052-9314; Pereira, Alberto M./0000-0002-1194-9866; Biermasz, Nienke/0000-0001-5817-3594	PfizerPfizer	This research was supported by an unrestricted grant from Pfizer.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hunt S M, 1980, Sociol Health Illn, V2, P231; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2008, PITUITARY, V11, P255, DOI 10.1007/s11102-008-0102-x; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.3275/7045, 10.1007/BF03350340]; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Ross HA, 2008, CLIN CHEM LAB MED, V46, P1334, DOI 10.1515/CCLM.2008.261; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; van Aken M O, 2005, Pituitary, V8, P183; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	39	40	0	1	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	AUG	2011	165	2					225	231		10.1530/EJE-11-0365			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	792FY	WOS:000292727400006	21646286	Bronze			2022-02-06	
J	Liu, W; Shen, Y; Plane, JM; Pleasure, DE; Deng, WB				Liu, Wei; Shen, Yan; Plane, Jennifer M.; Pleasure, David E.; Deng, Wenbin			Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia	EXPERIMENTAL NEUROLOGY			English	Article						Erythropoietin; Carbamylated erythropoietin; White matter injury; Oligodendrocyte; Microglia; PARP-1; Hypoxia-ischemia; Lipopolysaccharide; Periventricular leukomalacia	APOPTOSIS-INDUCING FACTOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; WHITE-MATTER INJURY; POLY(ADP-RIBOSE) POLYMERASE-1; CELL-DEATH; NEUROLOGICAL FUNCTION; NEONATAL STROKE	Periventricular leukomalacia (PVL) is the predominant pathology in premature infants, characterized by prominent cerebral white matter injury, and commonly caused by hypoxia-ischemia and inflammation. Activated microglia trigger white matter damage and play a major role in the development of PVL Erythropoietin (EPO) and its derivative carbamylated erythropoietin (CEPO) have been shown to be neuroprotective in several brain disease models. Here we investigated whether EPO and CEPO could provide protection in mouse models of PVL induced by hypoxia-ischemia or hypoxia-ischemia-inflammation. We administered EPO or CEPO to mice with PVL, and found that both EPO and CEPO treatments decreased microglia activation, oligodendrocyte damage and myelin depletion. We also noted improved performance in neurological function assays. Inhibited disease progression in PVL mice by EPO or CEPO treatment was associated with decreased poly-(ADP-ribose) polymerase-1 (PARP-1) activity. PARP-1 activity was increased dramatically in activated microglia in untreated mice with PVL Furthermore, we demonstrated that the neuroprotective properties of EPO and CEPO were diminished after PARP-1 gene depletion. The therapeutic doses of EPO and CEPO used in this study did not interfere with normal oligodendrocyte maturation and myelination. Together, our data demonstrate that EPO and CEPO are neuroprotective in cerebral white matter injury via a novel microglial PARP-1 dependent mechanism, and hold promise as a future treatment for PVL and other hypoxic-ischemic/inflammatory white matter diseases. (C) 2011 Elsevier Inc. All rights reserved.	[Liu, Wei; Shen, Yan; Plane, Jennifer M.; Deng, Wenbin] Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; [Pleasure, David E.] Univ Calif Davis, Sch Med, Dept Neurol, Sacramento, CA 95817 USA; [Pleasure, David E.; Deng, Wenbin] Shriners Hosp Calif, Inst Pediat Regenerat Med, Sacramento, CA 95817 USA		Deng, WB (corresponding author), UC Davis Sch Med, Dept Cell Biol & Human Anat, Inst Pediat Regenerat Med, Shriners Hosp Children, Room 653,2425 Stockton Blvd, Sacramento, CA 95817 USA.	wbdeng@ucdavis.edu	tao, li/G-7956-2011		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS059043, R01 ES015988]; Roche Foundation for Anemia Research (RoFAR); National Multiple Sclerosis SocietyNational Multiple Sclerosis Society; Feldstein Medical Foundation; Shriners Hospitals for Children; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD087566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES015988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059043] Funding Source: NIH RePORTER	We thank Warren Pharmaceuticals, Ossining, NY and H. Lundbeck A/S, Denmark for generously providing carbamylated erythropoietin. This study was supported by grants to W.D. from the NIH (R01 NS059043 and R01 ES015988), Roche Foundation for Anemia Research (RoFAR), National Multiple Sclerosis Society, Feldstein Medical Foundation, and Shriners Hospitals for Children. The authors declare no conflicts of interest.	Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; Billiards SS, 2006, J COMP NEUROL, V497, P199, DOI 10.1002/cne.20991; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Buntinx M, 2004, J NEUROSCI RES, V76, P834, DOI 10.1002/jnr.20118; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Csete M, 2004, NEUROSCI LETT, V359, P124, DOI 10.1016/j.neulet.2004.01.068; Dammann O, 2002, MENT RETARD DEV D R, V8, P46, DOI 10.1002/mrdd.10005; Deng WB, 2008, ARCH NEUROL-CHICAGO, V65, P1291, DOI 10.1001/archneur.65.10.1291; Deng WB, 2010, NAT REV NEUROL, V6, P328, DOI 10.1038/nrneurol.2010.53; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Follett PL, 2000, J NEUROSCI, V20, P9235; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Goncalves LF, 2002, MENT RETARD DEV D R, V8, P3, DOI 10.1002/mrdd.10008; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Gonzalez FF, 2009, DEV NEUROSCI-BASEL, V31, P403, DOI 10.1159/000232558; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Iwai M, 2010, STROKE, V41, P1032, DOI 10.1161/STROKEAHA.109.570325; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Li JR, 2005, P NATL ACAD SCI USA, V102, P9936, DOI 10.1073/pnas.0502552102; Li XL, 2010, J NEUROCHEM, V113, P1012, DOI 10.1111/j.1471-4159.2010.06667.x; Lykissas MG, 2007, CLIN NEUROL NEUROSUR, V109, P639, DOI 10.1016/j.clineuro.2007.05.013; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Martin JA, 2008, PEDIATRICS, V121, P788, DOI 10.1542/peds.2007-3753; McPherson RJ, 2010, CURR OPIN PEDIATR, V22, P139, DOI 10.1097/MOP.0b013e328336eb57; Milano M, 2005, J Oncol Pharm Pract, V11, P145, DOI 10.1191/1078155205jp162oa; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Nakajima H, 2004, J BIOL CHEM, V279, P42774, DOI 10.1074/jbc.M407923200; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Pang Y, 2005, J NEUROSCI RES, V80, P226, DOI 10.1002/jnr.20450; Platt MJ, 2007, LANCET, V369, P43, DOI 10.1016/S0140-6736(07)60030-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rees S, 2010, J NEUROPATH EXP NEUR, V69, P306, DOI 10.1097/NEN.0b013e3181d27138; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; Segovia KN, 2008, ANN NEUROL, V63, P520, DOI 10.1002/ana.21359; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tomimatsu T, 2002, BRAIN RES, V926, P108, DOI 10.1016/S0006-8993(01)03311-X; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; van der Kooij MA, 2008, BRAIN RES REV, V59, P22, DOI 10.1016/j.brainresrev.2008.04.007; Veto S, 2010, BRAIN, V133, P822, DOI 10.1093/brain/awp337; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Volpe JJ, 2005, PEDIATRICS, V116, P221, DOI 10.1542/peds.2005-0191; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wei L, 2006, J PHARMACOL EXP THER, V317, P109, DOI 10.1124/jpet.105.094391; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	67	39	48	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2011	230	2					227	239		10.1016/j.expneurol.2011.04.021			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	783CF	WOS:000292058400009	21596035	Green Accepted			2022-02-06	
J	Raso, GM; Esposito, E; Vitiello, S; Iacono, A; Santoro, A; D'Agostino, G; Sasso, O; Russo, R; Piazza, PV; Calignano, A; Meli, R				Raso, G. Mattace; Esposito, E.; Vitiello, S.; Iacono, A.; Santoro, A.; D'Agostino, G.; Sasso, O.; Russo, R.; Piazza, P. V.; Calignano, A.; Meli, R.			Palmitoylethanolamide Stimulation Induces Allopregnanolone Synthesis in C6 Cells and Primary Astrocytes: Involvement of Peroxisome-Proliferator Activated Receptor-alpha	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						palmitoylethanolamide; allopregnanolone; peroxisome-proliferator activated receptor-alpha; astrocyte	ACUTE REGULATORY PROTEIN; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; 5-ALPHA-REDUCED NEUROSTEROIDS; N-PALMITOYLETHANOLAMIDE; COGNITIVE DEFICITS; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS	Palmitoylethanolamide (PEA) regulates many pathophysiological processes in the central nervous system, including pain perception, convulsions and neurotoxicity, and increasing evidence points to its neuroprotective action. In the present study, we report that PEA, acting as a ligand of peroxisome-proliferator activated receptor (PPAR)-alpha, might regulate neurosteroidogenesis in astrocytes, which, similar to other glial cells and neurones, have the enzymatic machinery for neurosteroid de novo synthesis. Accordingly, we used the C6 glioma cell line and primary murine astrocytes. In the mitochondrial fraction from cells stimulated with PEA, we demonstrated an increase in steroidogenic acute regulatory protein (StAR) and cytochrome P450 enzyme (P450scc) expression, both comprising proteins considered to be involved in crucial steps of neurosteroid formation. The effects of PEA were completely blunted by GW6471, a selective PPAR-alpha antagonist, or by PPAR-alpha silencing by RNA interference. Accordingly, allopregnanolone (ALLO) levels were increased in supernatant of PEA-treated astrocytes, as revealed by gas chromatography-mass spectrometry, and this effect was inhibited by GW6471. Moreover, PEA showed a protective effect, reducing malondialdehyde formation in cells treated with L-buthionine-(S, R)sulfoximine, a glutathione depletor and, interestingly, the effect of PEA was partially inhibited by finasteride, a 5 alpha-reductase inhibitor. A similar profile of activity was demonstrated by ALLO and the lack of an additive effect with PEA suggests that the reduction of oxidative stress by PEA is mediated through ALLO synthesis. The present study provides evidence indicating the involvement of the saturated acylethanolamide PEA in ALLO synthesis through PPAR-a in astrocytes and explores the antioxidative activity of this molecule, confirming its homeostatic and protective role both under physiological and pathological conditions.	[Raso, G. Mattace; Iacono, A.; Santoro, A.; D'Agostino, G.; Sasso, O.; Russo, R.; Calignano, A.; Meli, R.] Univ Naples Federico 2, Dept Expt Pharmacol, I-80131 Naples, Italy; [Vitiello, S.; Piazza, P. V.] Univ Bordeaux, Inst F Magendie, INSERM, U862, Bordeaux, France; [Esposito, E.] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy		Meli, R (corresponding author), Univ Naples Federico 2, Dept Expt Pharmacol, Via D Montesano 49, I-80131 Naples, Italy.	meli@unina.it	russo, roberto/A-3193-2012; Calignano, Antonio/K-2542-2018; D'Agostino, Giuseppe/F-3399-2012	russo, roberto/0000-0001-5950-1617; D'Agostino, Giuseppe/0000-0002-3502-4251; Mattace Raso, Giuseppina/0000-0002-5254-139X; Santoro, Anna/0000-0002-2276-5659	Ministero dell'Universita e della Ricerca Scientifica e Tecnologica PRIN, ItalyMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)	This study was supported by a grant from the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica PRIN, Italy. The authors greatly acknowledge the excellent technical assistance of Dr. Guido Mele.	Agis-Balboa RC, 2006, P NATL ACAD SCI USA, V103, P14602, DOI 10.1073/pnas.0606544103; Akk G, 2007, PHARMACOL THERAPEUT, V116, P35, DOI 10.1016/j.pharmthera.2007.03.004; Azzolina B, 1997, J STEROID BIOCHEM, V61, P55, DOI 10.1016/S0960-0760(97)00002-2; BACHUR NR, 1965, J BIOL CHEM, V240, P1019; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; Bose HS, 2002, ENDOCR RES, V28, P295, DOI 10.1081/ERC-120016800; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Burudi EME, 1999, GLIA, V25, P44, DOI 10.1002/(SICI)1098-1136(19990101)25:1<44::AID-GLIA5>3.0.CO;2-C; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; D'Agostino G, 2007, J PHARMACOL EXP THER, V322, P1137, DOI 10.1124/jpet.107.123265; D'Agostino G, 2009, EUR J PHARMACOL, V613, P54, DOI 10.1016/j.ejphar.2009.04.022; Darmani NA, 2005, NEUROPHARMACOLOGY, V48, P1154, DOI 10.1016/j.neuropharm.2005.01.001; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50; Duval C, 2007, BBA-MOL CELL BIOL L, V1771, P961, DOI 10.1016/j.bbalip.2007.05.003; Finn DA, 2006, CNS DRUG REV, V12, P53, DOI 10.1111/j.1527-3458.2006.00053.x; Franklin A, 2003, J NEUROSCI, V23, P7767; Furukawa A, 1998, J NEUROCHEM, V71, P2231; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Higuchi Y, 1999, ARCH BIOCHEM BIOPHYS, V363, P33, DOI 10.1006/abbi.1998.1067; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; KAINU T, 1994, NEUROREPORT, V5, P2481, DOI 10.1097/00001756-199412000-00019; Karri S, 2007, J NEUROENDOCRINOL, V19, P860, DOI 10.1111/j.1365-2826.2007.01600.x; Keller AF, 2004, J NEUROSCI, V24, P907, DOI 10.1523/JNEUROSCI.4642-03.2004; Lambert DM, 2001, EPILEPSIA, V42, P321, DOI 10.1046/j.1528-1157.2001.41499.x; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; LoVerme J, 2006, J PHARMACOL EXP THER, V319, P1051, DOI 10.1124/jpet.106.111385; MARRIOT DR, 1995, NEURAL CELL CULTURE, P83; Melcangi RC, 1998, J STEROID BIOCHEM, V65, P295, DOI 10.1016/S0960-0760(98)00030-2; Mellon SH, 2002, TRENDS ENDOCRIN MET, V13, P35, DOI 10.1016/S1043-2760(01)00503-3; Mellon SH, 2007, PHARMACOL THERAPEUT, V116, P107, DOI 10.1016/j.pharmthera.2007.04.011; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Morita K, 2008, J MOL NEUROSCI, V34, P193, DOI 10.1007/s12031-007-9034-6; Ocvirk R, 2008, PAIN, V138, P402, DOI 10.1016/j.pain.2008.01.019; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; Sasso O, 2010, EUR NEUROPSYCHOPHARM, V20, P195, DOI 10.1016/j.euroneuro.2009.09.003; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Tokuda K, 2010, J NEUROSCI, V30, P16788, DOI 10.1523/JNEUROSCI.4101-10.2010; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Waters SL, 1997, AM J PHYSIOL-RENAL, V273, pF869, DOI 10.1152/ajprenal.1997.273.6.F869; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x	59	39	39	1	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0953-8194			J NEUROENDOCRINOL	J. Neuroendocrinol.	JUL	2011	23	7					591	600		10.1111/j.1365-2826.2011.02152.x			10	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	788SU	WOS:000292465500006	21554431				2022-02-06	
J	Li, GZ; Zhang, Y; Zhao, JB; Wu, GJ; Su, XF; Hang, CH				Li, Guang-Zhao; Zhang, Yang; Zhao, Jin-Bing; Wu, Guo-Jian; Su, Xing-Fen; Hang, Chun-Hua			Expression of myeloid differentiation primary response protein 88 (Myd88) in the cerebral cortex after experimental traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Myeloid differentiation primary response protein 88; NF-kappa B; Inflammatory cytokine; ICAM-1; Traumatic brain injury	TOLL-LIKE RECEPTORS; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; ISCHEMIA-REPERFUSION; CORTICAL CONTUSION; SIGNALING PATHWAY; PROINFLAMMATORY CYTOKINES; MICE; ACTIVATION	A growing body of evidence indicates that Toll-like receptors (TLRs) and Interleukin-1 (IL-1) family have been shown to be involved in the damaging inflammatory processes associated with stroke, infection, neoplasia, and other diseases in the central nervous system. Myeloid differentiation primary response protein 88 (Myd88) is a critical adaptor protein that transmits signals for TLRs and IL-1 family. Therefore, this study aimed to detect the expression of Myd88 protein and mRNA in a rat weight-dropping trauma model and to clarify the role of Myd88 after traumatic brain injury (TBI). A total of fifty-four Sprague Dawley (SD) rats were randomly divided into control group and TBI groups at hours 6, 12 and on day 1, day 2, day 3, and day 7. The TBI groups suffered experimental TBI by improved Feeney model. Myd88 expression is measured by Reverse Transcription PCR (RT-PCR), Western blot analysis and immunohistochemistry; and nuclear factor-kappaB (NF-kappa B) binding activity by electrophoretic mobility shift assay (EMSA); The levels of tumor necrosis factor-alpha (TNF-alpha) and Interleukin 1 beta (IL-1 beta) were measured by enzyme linked immunosorbent assay (ELISA) and the intercellular adhesion molecule-1 (ICAM-1) expression by immunohistochemistry. The expression of Myd88 in the injured brain was dramatically increased through 6 h and 7 days postinjury, and peaked on 3 days. NF-kappa B, TNF-alpha, IL-1 beta. and ICAM-1 also ascended significantly after TBI. Our data demonstrated that Myd88 was increasingly expressed in a parallel time course to the up-regulation of NF-kappa B, proinflammatory cytokines and ICAM-1 and there was a highly positive relationship among them. These findings might have important implications during the administration of specific Myd88 antagonists in order to prevent or reduce inflammatory response after TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Li, Guang-Zhao; Hang, Chun-Hua] So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China; [Zhang, Yang; Zhao, Jin-Bing; Wu, Guo-Jian; Su, Xing-Fen; Hang, Chun-Hua] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China		Hang, CH (corresponding author), So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	lgzh718@tom.com; hangchunhua@yahoo.cn			Natural Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]	We would like to thank Dr. Gen-bao Feng and Drs. Meng-liang Zhou for their technical assistance. This study is supported by Natural Science Foundation of Jiangsu Province, China (BK2010459).	Babcock AA, 2008, J IMMUNOL, V181, P6481, DOI 10.4049/jimmunol.181.9.6481; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen G, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93431; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Davis CN, 2006, P NATL ACAD SCI USA, V103, P2953, DOI 10.1073/pnas.0510802103; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; Feng Y, 2008, AM J PHYSIOL-HEART C, V295, pH1311, DOI 10.1152/ajpheart.00119.2008; Gao Y, 2009, BIOL PHARM BULL, V32, P1665, DOI 10.1248/bpb.32.1665; Gao Y, 2009, BIOMED PHARMACOTHER, V63, P442, DOI 10.1016/j.biopha.2008.06.028; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Hua F, 2009, BIOCHEM BIOPH RES CO, V390, P678, DOI 10.1016/j.bbrc.2009.10.027; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; Kielian T, 2007, J IMMUNOL, V178, P4528, DOI 10.4049/jimmunol.178.7.4528; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Landreth GE, 2009, CURR TOP MICROBIOL, V336, P137, DOI 10.1007/978-3-642-00549-7_8; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Loiarro M, 2007, J LEUKOCYTE BIOL, V82, P801, DOI 10.1189/jlb.1206746; Ma CX, 2009, CHINESE MED J-PEKING, V122, P1575, DOI 10.3760/cma.j.issn.0366-6999.2009.13.019; MCKEAN DJ, 1995, INT IMMUNOL, V7, P9, DOI 10.1093/intimm/7.1.9; Memet S, 2006, BIOCHEM PHARMACOL, V72, P1180, DOI 10.1016/j.bcp.2006.09.003; Mishra BB, 2009, CURR TOP MICROBIOL, V336, P83, DOI 10.1007/978-3-642-00549-7_5; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; O'Brien K, 2008, CURR MED CHEM, V15, P1105, DOI 10.2174/092986708784221458; Prendergast Catriona T., 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P315; Racke MK, 2009, CURR TOP MICROBIOL, V336, P155, DOI 10.1007/978-3-642-00549-7_9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sette Claudio, 2007, J Leukoc Biol, V82, P811; Sifringer M, 2007, NEUROBIOL DIS, V25, P614, DOI 10.1016/j.nbd.2006.11.003; Stevens SL, 2008, J CEREBR BLOOD F MET, V28, P1040, DOI 10.1038/sj.jcbfm.9600606; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276; Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018-008-8064-8; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yang CM, 2010, J CELL PHYSIOL, V224, P516, DOI 10.1002/jcp.22153; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zaheer A, 2007, BRAIN RES, V1144, P239, DOI 10.1016/j.brainres.2007.01.075	44	39	44	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 17	2011	1396						96	104		10.1016/j.brainres.2011.04.014			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	788AD	WOS:000292416900011	21530945				2022-02-06	
J	Nishijima, DK; Sena, MJ; Holmes, JF				Nishijima, Daniel K.; Sena, Matthew J.; Holmes, James F.			Identification of Low-Risk Patients With Traumatic Brain Injury and Intracranial Hemorrhage Who Do Not Need Intensive Care Unit Admission	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Intracranial hemorrhage; Traumatic; Brain injuries; Craniocerebral trauma; Triage; Intensive care	COMPUTED-TOMOGRAPHY; STATES; GUIDELINES; UTILITY	Background: Patients with traumatic brain injury (TBI) and traumatic intracranial hemorrhage are frequently admitted to the intensive care unit (ICU) but never require critical care interventions. Improved ICU triage in this patient population can improve resource utilization and decrease health care costs. We sought to identify a low-risk group of patients with TBI who do not require admission to an ICU. Methods: This is a retrospective cohort study of adult patients with TBI and traumatic intracranial hemorrhage. The need for ICU admission was defined as the presence of a critical care intervention. Patients were considered low risk if there was no critical care intervention before hospital admission. Measured outcomes included delayed critical care interventions at 48 hours and during hospitalization, mortality, and emergency surgery. Results: A total of 187 of 320 patients were considered low risk. In the low-risk group, two patients (1.1%; 95% confidence interval [CI], 0.1-3.8) had a delayed critical care intervention within 48 hours of admission and four patients (2.1%; 95% CI, 0.6-5.4) after 48 hours of admission. Two patients (1.1%; 95% CI, 0-3.8) in the low-risk group died. No patients in the low-risk group required neurosurgical intervention. Conclusion: Patients with TBI without a critical care intervention before admission are at low risk for requiring future critical care interventions. Future studies are required to validate if this low-risk criteria can serve as a safe, cost-effective triage tool for ICU admission.	[Sena, Matthew J.] UC Davis Sch Med, Dept Surg, Sacramento, CA USA; [Nishijima, Daniel K.; Holmes, James F.] UC Davis Med Ctr, Dept Emergency Med, UC Davis Sch Med, Sacramento, CA 95817 USA		Nishijima, DK (corresponding author), UC Davis Med Ctr, Dept Emergency Med, UC Davis Sch Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu			NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002] Funding Source: NIH RePORTER		af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Barker DE, 2006, AM SURGEON, V72, P1166; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Egol A, 1999, CRIT CARE MED, V27, P633; Escher M, 2004, BRIT MED J, V329, P425, DOI 10.1136/bmj.329.7463.425; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Huynh T, 2006, AM SURGEON, V72, P1162; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021	27	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2011	70	6					E101	E107		10.1097/TA.0b013e3181e88bcb			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	775QR	WOS:000291478500001	20805765	Green Accepted			2022-02-06	
J	Dagal, A; Lam, AM				Dagal, Armagan; Lam, Arthur M.			Cerebral blood flow and the injured brain: how should we monitor and manipulate it?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral blood flow; cerebral oximetry; laser Doppler flowmetry; neuromonitoring; transcranial Doppler ultrasonography	INTENSIVE-CARE-UNIT; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; TRANSCRANIAL DOPPLER; TISSUE OXYGEN; AUTOREGULATION; ISCHEMIA; REACTIVITY; MANAGEMENT; OXIMETRY	Purpose of review Cerebral ischemia plays a major role in the pathophysiology of the injured brain, including traumatic brain injury and subarachnoid hemorrhage, thus improvement in outcome may necessitate monitoring and optimization of cerebral blood flow (CBF). To interpret CBF results in a meaningful way, it may be necessary to quantify cerebral autoregulation as well as cerebral metabolism. This review addresses the recent evidence related to the changes in CBF and its monitoring/management in traumatic brain injury. Recent findings Recent evidence on the management of patients with traumatic brain injury have focused on the importance of cerebral autoregulation in maintaining perfusion, which necessitates the measurement of CBF. However, adequate CBF measurements alone would not indicate the amount of oxygen delivered to neuronal tissues. Technologic advancements in measurement devices have enabled the assessment of the metabolic state of the cerebral tissue for the purpose of guiding therapy, progress as well as prognostification. Summary Current neurocritical care management strategies are focused on the prevention and limitation of secondary brain injury where neuronal insult continues to evolve during the hours and days after the primary injury. Appropriately chosen multimodal monitoring including CBF and management measures can result in reduction in mortality and morbidity.	[Lam, Arthur M.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA 98104 USA; [Dagal, Armagan] Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA		Lam, AM (corresponding author), Swedish Med Ctr, Swedish Neurosci Inst, 500 17th St,226W, Seattle, WA 98104 USA.	Arthur.lam@swedish.org					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Artru F, 2004, J NEUROSURG ANESTH, V16, P226, DOI 10.1097/00008506-200407000-00007; Barazangi N, 2008, NEUROL INDIA, V56, P405; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Butcher K, 2010, CAN J NEUROL SCI, V37, P17, DOI 10.1017/S0317167100009604; Calderon-Arnulphi M, 2009, NEUROL RES, V31, P605, DOI 10.1179/174313209X383286; Chesnut RM, 2004, CRIT CARE CLIN, V20, P25, DOI 10.1016/S0749-0704(03)00090-3; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Daboussi A, 2009, J NEUROSURG ANESTH, V21, P339, DOI 10.1097/ANA.0b013e3181b1dbba; Dagal A, 2009, CURR OPIN ANESTHESIO, V22, P547, DOI 10.1097/ACO.0b013e32833020be; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Giustiniano E, 2010, J CARDIOVASC MED, V11, P522, DOI 10.2459/JCM.0b013e32833246e7; Highton D, 2010, CURR OPIN ANESTHESIO, V23, P576, DOI 10.1097/ACO.0b013e32833e1536; Hirsch Jennifer C, 2010, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V13, P51, DOI 10.1053/j.pcsu.2010.01.005; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hoeffner EG, 2005, J NEURO-OPHTHALMOL, V25, P313, DOI 10.1097/01.wno.0000189832.00129.2e; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kim DH, 2006, NEUROCRIT CARE, V4, P77, DOI 10.1385/NCC:4:1:077; Kincaid MS, 2008, CURR OPIN ANESTHESIO, V21, P552, DOI 10.1097/ACO.0b013e32830edc0b; Klaessens JHGM, 2003, PHYSIOL MEAS, V24, pN35, DOI 10.1088/0967-3334/24/4/N03; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lee SC, 2005, J CLIN NEUROSCI, V12, P520, DOI 10.1016/j.jocn.2004.07.016; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Littlejohns Linda R, 2003, Crit Care Nurse, V23, P17; Littlejohns LR, 2003, CRIT CARE NURSE, V23, P6; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Martin KK, 2009, AM J SURG, V197, P55, DOI 10.1016/j.amjsurg.2007.12.060; MATTA BF, 1994, ANESTH ANALG, V79, P745; Molina Carlos A, 2007, Cerebrovasc Dis, V24 Suppl 1, P1, DOI 10.1159/000107373; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Pennekamp CWA, 2009, EUR J VASC ENDOVASC, V38, P539, DOI 10.1016/j.ejvs.2009.07.008; Rigamonti A, 2008, CAN J ANAESTH, V55, P112, DOI 10.1007/BF03016323; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; SHARMA D, 2010, NEUROCRIT CARE; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Springborg JB, 2005, BRIT J ANAESTH, V94, P259, DOI 10.1093/bja/aei004; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vohra Hunaid A, 2009, Interact Cardiovasc Thorac Surg, V9, P318, DOI 10.1510/icvts.2009.206367; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; Wright WL, 2007, J NEUROL SCI, V261, P10, DOI 10.1016/j.jns.2007.04.027	52	39	44	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					131	137		10.1097/ACO.0b013e3283445898			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	732AS	WOS:000288154100003	21386665				2022-02-06	
J	Horste, GMZ; Miesbach, TA; Muller, JI; Fledrich, R; Stassart, RM; Kieseier, BC; Coleman, MP; Sereda, MW				Horste, Gerd Meyer Zu; Miesbach, Timo A.; Muller, Johanna I.; Fledrich, Robert; Stassart, Ruth M.; Kieseier, Bernd C.; Coleman, Michael P.; Sereda, Michael W.			The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration	NEUROBIOLOGY OF DISEASE			English	Article						Wallerian-degeneration-slow; Charcot-Marie-Tooth disease 1A; CMT1A; Hereditary neuropathy; Axonal degeneration; Traumatic nerve injury; Nicotinamide	HUMAN NMN ADENYLYLTRANSFERASE; FOCAL CEREBRAL-ISCHEMIA; WALLERIAN DEGENERATION; ADENINE-DINUCLEOTIDE; IN-VIVO; INHERITED NEUROPATHIES; ENZYMATIC-ACTIVITY; ANIMAL-MODELS; NAD(+) LEVELS; BRAIN-INJURY	Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy and a duplication of the peripheral myelin protein of 22 kDa (PMP22) gene causes the most frequent subform CMT1A. Clinical impairments are determined by the amount of axonal loss. Axons of the spontaneous mouse mutant Wallerian degeneration slow (Wlds) show markedly reduced degeneration following various types of injuries. Protection is conferred by a chimeric Wlds gene encoding an N-terminal part of ubiquitination factor Ube4b and full length nicotinamide mononucleotide adenylyl transferase 1 (Nmnat1). Nmnat1 enzyme generates nicotinamide adenine dinucleotide (NAD) from nicotinamide mononucleotide. Here, in a Pmp22 transgenic animal model of Charcot-Marie-Tooth disease type 1A (CMT rat), the Wlds transgene reduced axonal loss and clinical impairments without altering demyelination. Furthermore, nicotinamide - substrate precursor of the Nmnat1 enzyme - transiently delayed posttraumatic axonal degeneration in an in vivo model of acute peripheral nerve injury, but to a lower extent than Wlds. In contrast, 8 weeks of nicotinamide treatment did not influence axonal loss or clinical manifestations in the CMT rat. Therefore, nicotinamide can partially substitute for the protective Wlds effect in acute traumatic, but not in chronic secondary axonal injury. Future studies are needed to develop axon protective therapy in CMT1A which may be combined with therapeutic strategies aimed at downregulation of toxic PMP22 overexpression. (C) 2010 Elsevier Inc. All rights reserved.	[Sereda, Michael W.] Max Planck Inst Expt Med, Res Grp Mol & Translat Neurol, Dept Neurogenet, D-37075 Gottingen, Germany; [Horste, Gerd Meyer Zu; Muller, Johanna I.; Kieseier, Bernd C.] Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; [Coleman, Michael P.] Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; [Sereda, Michael W.] Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany		Sereda, MW (corresponding author), Max Planck Inst Expt Med, Res Grp Mol & Translat Neurol, Dept Neurogenet, Hermann Rein Str 3, D-37075 Gottingen, Germany.	sereda@em.mpg.de	Fledrich, Robert/AAF-1590-2020; Stassart, Ruth M/T-7093-2019; Fledrich, Robert/M-1911-2019; Horste, Gerd Meyer zu/O-9549-2016	Horste, Gerd Meyer zu/0000-0002-4341-4719	Max Planck SocietyMax Planck SocietyFoundation CELLEX; European UnionEuropean Commission; Departments of Clinical Neurophysiology and Neurology at the University of Gottingen; Del Marmol Foundation; BMBFFederal Ministry of Education & Research (BMBF) [FKZ01ES0801]; Research Commission of the Heinrich-Heine-University Dusseldorf; Fritz-Thyssen foundation	We thank Bianca Wolff and Tatjana Males for excellent technical assistance. We thank members of the Nave lab for continuous discussion and Anne K. Mausberg for critically reading the manuscript. This work was supported by the Max Planck Society and by grants of the European Union (to K.A.N.). M.W.S. was supported in part by the Departments of Clinical Neurophysiology and Neurology at the University of Gottingen, by the Del Marmol Foundation and by BMBF funding (FKZ01ES0801). G.M.z.H. was supported in part by grants from the Research Commission of the Heinrich-Heine-University Dusseldorf and from the Fritz-Thyssen foundation.	Adalbert R, 2005, EUR J NEUROSCI, V21, P271, DOI 10.1111/j.1460-9568.2004.03833.x; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Avery MA, 2009, J CELL BIOL, V184, P501, DOI 10.1083/jcb.200808042; Babetto E, 2010, J NEUROSCI, V30, P13291, DOI 10.1523/JNEUROSCI.1189-10.2010; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Conforti L, 2007, CELL DEATH DIFFER, V14, P116, DOI 10.1038/sj.cdd.4401944; Conforti L, 2009, J CELL BIOL, V184, P491, DOI 10.1083/jcb.200807175; DRAGOVIC J, 1995, RADIOTHER ONCOL, V36, P225, DOI 10.1016/0167-8140(95)01581-Z; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Feng YZ, 2006, BRAIN RES BULL, V69, P117, DOI 10.1016/j.brainresbull.2005.11.011; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Horste GMZ, 2006, CURR OPIN NEUROL, V19, P464, DOI 10.1097/01.wco.0000245369.44199.27; Kaneko S, 2006, J NEUROSCI, V26, P9794, DOI 10.1523/JNEUROSCI.2116-06.2006; KARLSSON U, 1965, J ULTRA MOL STRUCT R, V12, P160, DOI 10.1016/S0022-5320(65)80014-4; Kimura N, 2006, J NUTR SCI VITAMINOL, V52, P142, DOI 10.3177/jnsv.52.142; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; LUPSKI JR, 2005, PERIPHERAL NEUROPATH, P1659, DOI DOI 10.1016/B978-0-7216-9491-7.50073-9; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; Horste GMZ, 2007, ANN NEUROL, V61, P61, DOI 10.1002/ana.21026; Nave KA, 2007, NAT CLIN PRACT NEURO, V3, P453, DOI 10.1038/ncpneuro0583; Pareyson D, 2009, ADV EXP MED BIOL, V652, P207, DOI 10.1007/978-90-481-2813-6_14; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; Press C, 2008, J NEUROSCI, V28, P4861, DOI 10.1523/JNEUROSCI.0525-08.2008; RIBCHESTER RR, 1995, EUR J NEUROSCI, V7, P1641, DOI 10.1111/j.1460-9568.1995.tb01159.x; Sadanaga-Akiyoshi F, 2003, NEUROCHEM RES, V28, P1227, DOI 10.1023/A:1024236614015; Sahenk Z, 2005, NEUROLOGY, V65, P681, DOI 10.1212/01.WNL.0000171978.70849.c5; Sahenk Z, 1999, ANN NEUROL, V45, P16, DOI 10.1002/1531-8249(199901)45:1<16::AID-ART5>3.0.CO;2-F; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Samsam M, 2003, J NEUROSCI, V23, P2833; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Sasaki Y, 2009, J NEUROSCI, V29, P5525, DOI 10.1523/JNEUROSCI.5469-08.2009; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; Sereda MW, 2006, NEUROMOL MED, V8, P205, DOI 10.1385/NMM:8:1:205; Sereda MW, 2003, NAT MED, V9, P1533, DOI 10.1038/nm957; Shy ME, 2005, PERIPHERAL NEUROPATH, P1623; Timmerman V, 2006, NEUROMOL MED, V8, P1, DOI 10.1385/NMM:8:1:1; TSAO JW, 1994, EUR J NEUROSCI, V6, P516, DOI 10.1111/j.1460-9568.1994.tb00295.x; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wang MS, 2001, ANN NEUROL, V50, P773, DOI 10.1002/ana.10039; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Zhai RG, 2008, NATURE, V452, P887, DOI 10.1038/nature06721	54	39	39	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2011	42	1					1	8		10.1016/j.nbd.2010.12.006			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	726MS	WOS:000287727000001	21168501				2022-02-06	
J	Kaya, T; Karatepe, AG; Gunaydin, R; Koc, A; Ercan, UA				Kaya, Taciser; Karatepe, Altinay Goksel; Gunaydin, Rezzan; Koc, Aysegul; Ercan, Ulku Altundal			Inter-rater reliability of the Modified Ashworth Scale and modified Modified Ashworth Scale in assessing poststroke elbow flexor spasticity	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						hemiplegia; muscle spasticity; inter-rater variation	TRAUMATIC BRAIN-INJURY; MUSCLE SPASTICITY	The Modified Ashworth Scale (MAS) is commonly used in clinical practice for grading spasticity. However, it was modified recently by omitting grade '1 +' of the MAS and redefining grade '2'. The aim of this study was to investigate the inter-rater reliability of MAS and modified MAS (MMAS) for the assessment of poststroke elbow flexor spasticity. Sixty-four patients with poststroke hemiplegia were enrolled. The mean age and time since the stroke were 60.5 +/- 11.9 years and 15.7 +/- 10.2 weeks, respectively. The patients were tested by two raters having equal experience in applying MAS. They were not subjected to any training for administering MMAS. After performing no more than two test movements, the raters graded the resistance felt, according to the MAS and MMAS, respectively based on same stretch. The degree of agreement was analyzed using the weighted kappa (kw) statistic. Inter-rater agreements were very good for both MAS and MMAS, with weighted kappa values of 0.868 and 0.892, respectively. The highest agreements were observed for grade '0' in applying MAS and for grade '2' in applying MMAS; on the other hand, the lowest agreements were observed for grade '2' in applying MAS and for grade '3' in applying MMAS. According to our results, MAS and MMAS have very good inter-rater reliability for assessment of poststroke elbow flexor spasticity. Neither of the scales is superior to each other when using them to grade spasticity in patients with hemiplegia for this muscle group.	[Kaya, Taciser; Karatepe, Altinay Goksel; Gunaydin, Rezzan; Koc, Aysegul; Ercan, Ulku Altundal] Izmir Bozyaka Training & Res Hosp, Dept Phys Therapy & Rehabil, Izmir, Turkey		Kaya, T (corresponding author), Ilica Mah Bodur Sk 1-1, TR-35320 Narlidere Izmir, Turkey.	taciserkaya@gmail.com	Kaya, Taciser/ABH-5966-2020	Kaya, Taciser/0000-0002-8848-8420; Goksel Karatepe, Altinay/0000-0001-8086-9942			Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; Annaswamy T, 2007, AM J PHYS MED REHAB, V86, P404, DOI 10.1097/PHM.0b013e31804a7d85; Ansari Noureddin Nakhostin, 2006, Physiotherapy Theory and Practice, V22, P119, DOI 10.1080/09593980600724188; Ansari NN, 2009, NEUROREHABILITATION, V25, P235, DOI 10.3233/NRE-2009-0520; Ansari NN, 2009, NEUROREHABILITATION, V24, P225, DOI 10.3233/NRE-2009-0472; Ansari Noureddin Nakhostin, 2008, Physiotherapy Theory and Practice, V24, P205, DOI 10.1080/09593980701523802; Biering-Sorensen F, 2006, SPINAL CORD, V44, P708, DOI 10.1038/sj.sc.3101928; Blackburn M, 2002, PHYS THER, V82, P25, DOI 10.1093/ptj/82.1.25; Bohannon RW, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-30; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; Clopton Nancy, 2005, Pediatr Phys Ther, V17, P268, DOI 10.1097/01.pep.0000186509.41238.1a; Craven BC, 2010, SPINAL CORD, V48, P207, DOI 10.1038/sc.2009.107; Fleuren JFM, 2010, J NEUROL NEUROSUR PS, V81, P46, DOI 10.1136/jnnp.2009.177071; Ghotbi N, 2009, BRAIN INJURY, V23, P815, DOI 10.1080/02699050903200548; Gregson JM, 1999, ARCH PHYS MED REHAB, V80, P1013, DOI 10.1016/S0003-9993(99)90053-9; Levin MF, 2005, CLIN NEUROPHYSIOL, V116, P1754, DOI 10.1016/j.clinph.2005.03.004; Mutlu A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-44; Naghdi Soofia, 2008, Physiotherapy Theory and Practice, V24, P372, DOI 10.1080/09593980802278959; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Pierce SR, 2006, ARCH PHYS MED REHAB, V87, P697, DOI 10.1016/j.apmr.2006.01.020; Platz T, 2005, DISABIL REHABIL, V27, P7, DOI 10.1080/09638280400014634; Smith AW, 2002, AM J PHYS MED REHAB, V81, P202, DOI 10.1097/00002060-200203000-00008	23	39	43	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	2011	34	1					59	64		10.1097/MRR.0b013e32833d6cdf			6	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	733UR	WOS:000288289400008	20671560				2022-02-06	
J	Resch, JE; May, B; Tomporowski, PD; Ferrara, MS				Resch, Jacob E.; May, Bryson; Tomporowski, Phillip D.; Ferrara, Michael S.			Balance Performance With a Cognitive Task: A Continuation of the Dual-Task Testing Paradigm	JOURNAL OF ATHLETIC TRAINING			English	Article						posture; stability; executive function; response time; concussions; mild traumatic brain injuries	MILD HEAD-INJURY; POSTURAL CONTROL; STABILITY; CONCUSSION; LOAD; SWAY	Context: To ensure that concussed athletes return to play safely, we need better methods of measuring concussion severity and monitoring concussion resolution. Objective: To develop a dual-task model that assesses postural stability and cognitive processing in concussed athletes. Design: Repeated measures study. Setting: University laboratory. Patients or Other Participants: Twenty healthy, college-aged students (10 men, 10 women; age = 20 +/- 1.86 years, height = 173 +/- 4.10 cm, mass = 71.83 + 35.77 kg). Intervention(s): Participants were tested individually in 2 sessions separated by 2 days. In one session, a balance task and a cognitive task were performed separately. In the other session, the balance and cognitive tasks were performed concurrently. The balance task consisted of 6 conditions of the Sensory Organization Test performed on the NeuroCom Smart Balance Master. The cognitive task consisted of an auditory switch task (3 trials per condition, 60 seconds per trial). Main Outcome Measure(s): For the balance test, scores for each Sensory Organization Test condition; the visual, vestibular, somatosensory, and visual-conflict subscores; and the composite balance score were calculated. For the cognitive task, response time and accuracy were measured. Results: Balance improved during 2 dual-task conditions: fixed support and fixed visual reference (t(18) = -2.34, P < .05) and fixed support and sway visual reference (t(18) = -2.72, P = .014). Participants' response times were longer (F(1,18) = 67.77, P < .001, eta(2) = 0.79) and choice errors were more numerous under dual-task conditions than under single-task conditions (F(1,18) = 5.58, P = .03, eta(2) = 0.24). However, differences were observed only during category-switch trials. Conclusions: Balance was either maintained or improved under dual-task conditions. Thus, postural control took priority over cognitive processing when the tasks were performed concurrently. Furthermore, dual-task conditions can isolate specific mental processes that may be useful for evaluating concussed individuals.	[Resch, Jacob E.; Ferrara, Michael S.] St Marys Athlet Training Res & Educ Lab, Athens, GA USA; [May, Bryson; Tomporowski, Phillip D.] Univ Georgia, Cognit & Skill Acquisit Lab, Dept Kinesiol, Athens, GA 30602 USA		Resch, JE (corresponding author), Univ Texas Arlington, Dept Kinesiol, Maverick Act Ctr 113, Arlington, TX 76019 USA.	resch@uta.edu		Resch, Jacob/0000-0001-6031-3197			Andersson G, 2002, BRAIN RES BULL, V58, P135, DOI 10.1016/S0361-9230(02)00770-0; Barra J, 2006, EXP BRAIN RES, V174, P734, DOI 10.1007/s00221-006-0519-2; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; KERR B, 1985, J EXP PSYCHOL HUMAN, V11, P617, DOI 10.1037/0096-1523.11.5.617; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Martin JH, 1996, NEUROANATOMY TEXT AT, P323; MAXWELL SE, 2004, DESIGNING EXPT ANAL, P641; May B, 2009, MIL MED, V174, P1308, DOI 10.7205/MILMED-D-00-0809; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; *NEUROCOM INT INC, 2001, NEUROCOM SYST OP MAN, P1; PETERSON C, 2002, THESIS U GEORGIA ATH; Rankin JK, 2000, J GERONTOL A-BIOL, V55, pM112, DOI 10.1093/gerona/55.3.M112; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; Vuillerme N, 2004, BRAIN RES BULL, V63, P161, DOI 10.1016/j.brainresbull.2004.02.006; Vuillerme N, 2000, NEUROSCI LETT, V291, P77, DOI 10.1016/S0304-3940(00)01374-4; Vuillerme N, 2007, PSYCHOL RES-PSYCH FO, V71, P192, DOI 10.1007/s00426-005-0018-2	24	39	43	1	24	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2011	46	2					170	175		10.4085/1062-6050-46.2.170			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	737QY	WOS:000288584500009	21391802	Bronze, Green Published			2022-02-06	
J	Carlson, KB; Singh, P; Feaster, MM; Ramnarain, A; Pavlides, C; Chen, ZL; Yu, WM; Feltri, ML; Strickland, S				Carlson, Karen B.; Singh, Prabhjot; Feaster, Moses M.; Ramnarain, Anita; Pavlides, Constantine; Chen, Zu-Lin; Yu, Wei-Ming; Feltri, M. Laura; Strickland, Sidney			Mesenchymal Stem Cells Facilitate Axon Sorting, Myelination, and Functional Recovery in Paralyzed Mice Deficient in Schwann Cell-Derived Laminin	GLIA			English	Article						laminin; mesenchymal stem cell; adipose; myelin; schwann cell; sciatic nerve; CMD1A	CONGENITAL MUSCULAR-DYSTROPHY; TRAUMATIC BRAIN-INJURY; ADHESION MOLECULES L1; STROMAL CELLS; NEUROMUSCULAR SYSTEM; CARBOHYDRATE EPITOPE; BASEMENT-MEMBRANES; TRANSGENIC MICE; SCIATIC-NERVE; N-CAM	Peripheral nerve function depends on a regulated process of axon and Schwann cell development. Schwann cells interact with peripheral neurons to sort and ensheath individual axons. Ablation of laminin gamma 1 in the peripheral nervous system (PNS) arrests Schwann cell development prior to radial sorting of axons. Peripheral nerves of laminin-deficient animals are disorganized and hypomyelinated. In this study, sciatic nerves of laminin-deficient mice were treated with syngenic murine adipose-derived stem cells (ADSCs). ADSCs expressed laminin in vitro and in vivo following transplant into mutant sciatic nerves. ADSC-treatment of mutant nerves caused endogenous Schwann cells to differentiate past the point of developmental arrest to sort and myelinate axons. This was shown by (1) functional, (2) ultrastructural, and (3) immunohistochemical analysis. Treatment of laminin-deficient nerves with either soluble laminin or the immortalized laminin-expressing cell line 3T3/L1 did not overcome endogenous Schwann cell developmental arrest. In summary, these results indicate that (1) laminin-deficient Schwann cells can be rescued, (2) a cell-based approach is beneficial in comparison with soluble protein treatment, and (3) mesenchymal stem cells modify sciatic nerve function via trophic effects rather than trans-differentiation in this system. (C) 2010 Wiley-Liss, Inc.	[Carlson, Karen B.; Singh, Prabhjot; Feaster, Moses M.; Ramnarain, Anita; Chen, Zu-Lin; Yu, Wei-Ming; Strickland, Sidney] Rockefeller Univ, Lab Neurobiol & Genet, New York, NY 10065 USA; [Carlson, Karen B.] Weill Cornell New York Hosp, Div Hematol & Oncol, Dept Med, New York, NY USA; [Pavlides, Constantine] Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10065 USA; [Feltri, M. Laura] Ist Sci San Raffaele, Dept Neurol, I-20132 Milan, Italy; [Feltri, M. Laura] Ist Sci San Raffaele, Dept Biol & Technol Res DIBIT, I-20132 Milan, Italy		Strickland, S (corresponding author), Rockefeller Univ, Lab Neurobiol & Genet, 1230 York Ave, New York, NY 10065 USA.	strickland@rockefeller.edu	Feltri, Maria Laura/J-5286-2018	Strickland, Sidney/0000-0002-3072-9244; Carlson, Karen-Sue/0000-0003-0418-652X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038472]; Muscular Dystrophy AssociationMuscular Dystrophy Association [MDA4066]; Medical Scientist Training ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM07739]; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Tri-Institutional/STARR Foundation; F. M. Kirby fellowship for Sensory Neuroscience; Paul and Daisy Soros Fellowship; National Science FoundationNational Science Foundation (NSF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045630, R01NS038472] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant number: NS038472; Grant sponsor: Muscular Dystrophy Association; Grant number: MDA4066; Grant sponsor: Medical Scientist Training Program; Grant number: GM07739, Grant sponsor: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Tri-Institutional/STARR Foundation, F. M. Kirby fellowship for Sensory Neuroscience, Paul and Daisy Soros Fellowship, National Science Foundation Graduate Research Fellowship Program.	Amoh Y, 2005, P NATL ACAD SCI USA, V102, P17734, DOI 10.1073/pnas.0508440102; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Feltri ML, 2005, J PERIPHER NERV SYST, V10, P128, DOI 10.1111/j.1085-9489.2005.0010204.x; Feltri ML, 1999, ANN NY ACAD SCI, V883, P116, DOI 10.1111/j.1749-6632.1999.tb08574.x; Fujimura J, 2005, BIOCHEM BIOPH RES CO, V333, P116, DOI 10.1016/j.bbrc.2005.05.096; Gotherstrom C, 2007, TRANSPLANTATION, V84, pS35, DOI 10.1097/01.tp.0000269200.67707.c8; Haney CA, 1999, J CELL BIOL, V146, P1173, DOI 10.1083/jcb.146.5.1173; Hausman GJ, 1998, J ANIM SCI, V76, P48; Jessen KR, 1997, J ANAT, V191, P501, DOI 10.1046/j.1469-7580.1997.19140501.x; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A., 2003, NEUROSURGERY, V53, P702; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; Mercuri E, 2001, NEUROMUSCULAR DISORD, V11, P297, DOI 10.1016/S0960-8966(00)00190-5; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Mirsky R, 1996, REV NEUROL, V152, P308; Mirsky R, 2001, Prog Brain Res, V132, P3; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Patton BL, 2000, MICROSC RES TECHNIQ, V51, P247, DOI 10.1002/1097-0029(20001101)51:3<247::AID-JEMT5>3.0.CO;2-Z; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Schenke-Layland K, 2009, J SURG RES, V153, P217, DOI 10.1016/j.jss.2008.03.019; Smyth N, 1998, ANN NY ACAD SCI, V857, P283, DOI 10.1111/j.1749-6632.1998.tb10133.x; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; Sugii S, 2010, P NATL ACAD SCI USA, V107, P3558, DOI 10.1073/pnas.0910172106; Tapp H, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2473; Uziyel Y, 2000, GLIA, V32, P109, DOI 10.1002/1098-1136(200011)32:2<109::AID-GLIA10>3.0.CO;2-1; Xu YF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-21; Yang LY, 2004, CHINESE MED J-PEKING, V117, P425; Yu WM, 2009, GLIA, V57, P850, DOI 10.1002/glia.20811; Yu WM, 2009, J CELL SCI, V122, P929, DOI 10.1242/jcs.033928; Yu WM, 2005, J NEUROSCI, V25, P4463, DOI 10.1523/JNEUROSCI.5032-04.2005	42	39	41	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2011	59	2					267	277		10.1002/glia.21099			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	707MR	WOS:000286291200009	21125647	Green Accepted			2022-02-06	
J	Zurek, J; Bartlova, L; Fedora, M				Zurek, Jiri; Bartlova, Ludmila; Fedora, Michal			Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children	BRAIN INJURY			English	Article						Children; brain injury; biomarkers; outcome; hyperphosphorylated neurofilament	MILD HEAD-INJURY; PROTEIN BIOMARKERS; PRACTICAL SCALE; SERUM; DAMAGE; BLOOD	Objective: The aim of the study was to determine whether serum levels of hyperphosphorylated neurofilament NF-H correlate with severity of brain injury in children. Methods: Forty-nine patients with traumatic brain injury (TBI) were enrolled into the prospective study. Venous blood samples were taken after admission and every 24 h for a maximum of 6 consecutive days. Serum NF-H concentrations were quantified by enzyme-linked immunosorbent assay. The outcome was evaluated 6 months after TBI using Glasgow Outcome Scale (GOS) in all patients. Results: The quantitative level of pNF-H remained significantly higher in patients with poor outcome (GOS = 1) in comparison with the other patients for the 2nd-4th day (p = 0.027; p = 0.019; p = 0.01). Levels of pNF-H were significantly higher in patients with diffuse axonal injury on initial CT scan (p = 0.004). Normal levels pNF-H in the paediatric population are unknown. Objective ROC analysis was identification of optimal cut-offs of proteins for prediction of GOS = 1. Conclusions: Although further, prospective study is warranted, these findings suggest that levels of hyperphosphorylated neurofilament NF-H correlate with mortality and may be useful as predictors of outcome in children with TBI.	[Zurek, Jiri; Fedora, Michal] Univ Childrens Hosp, Dept Anesthesia & Intens Care, Brno 62500, Czech Republic; [Bartlova, Ludmila] Univ Childrens Hosp, Dept Pediat Neurol, Brno 62500, Czech Republic		Zurek, J (corresponding author), Univ Childrens Hosp, Dept Anesthesia & Intens Care, Cernopolni 9, Brno 62500, Czech Republic.	jzurek@fnbrno.cz		Zurek, Jiri/0000-0002-6409-2560			Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JENNETT B, 1975, LANCET, V1, P480; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Schwartz SM, 2001, CRIT CARE MED, V29, pS214, DOI 10.1097/00003246-200110001-00003; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; TEASDALE G, 1974, LANCET, V2, P81; ZUREK J, 2010, CESKA SLOVENSKA NEUR, V1, P37	16	39	41	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2011	25	2					221	226		10.3109/02699052.2010.541895			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800008	21219092				2022-02-06	
J	Kirkman, E; Watts, S; Cooper, G				Kirkman, E.; Watts, S.; Cooper, G.			Blast injury research models	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES			English	Article						blast; explosion; haemorrhage; trauma; resuscitation; oxygen	HYPERTONIC SALINE RESUSCITATION; VOLUME FLUID RESUSCITATION; TRAUMATIC BRAIN-INJURY; HYPOTENSIVE RESUSCITATION; BLOOD-LOSS; HEMORRHAGIC-SHOCK; BOMBING ATTACKS; RAT MODEL; SWINE; EPIDEMIOLOGY	Blast injuries are an increasing problem in both military and civilian practice. Primary blast injury to the lungs (blast lung) is found in a clinically significant proportion of casualties from explosions even in an open environment, and in a high proportion of severely injured casualties following explosions in confined spaces. Blast casualties also commonly suffer secondary and tertiary blast injuries resulting in significant blood loss. The presence of hypoxaemia owing to blast lung complicates the process of fluid resuscitation. Consequently, prolonged hypotensive resuscitation was found to be incompatible with survival after combined blast lung and haemorrhage. This article describes studies addressing new forward resuscitation strategies involving a hybrid blood pressure profile (initially hypotensive followed later by normotensive resuscitation) and the use of supplemental oxygen to increase survival and reduce physiological deterioration during prolonged resuscitation. Surprisingly, hypertonic saline dextran was found to be inferior to normal saline after combined blast injury and haemorrhage. New strategies have therefore been developed to address the needs of blast-injured casualties and are likely to be particularly useful under circumstances of enforced delayed evacuation to surgical care.									Alam HB, 2000, J SURG RES, V94, P145, DOI 10.1006/jsre.2000.6011; Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; ZUCKERMAN S., 1941, Proceedings of the Royal Society of Medicine, V31, P171; [Anonymous], 2001, J R Army Med Corps, V147, P187; [Anonymous], 2006, BATTL ADV LIF SUPP; [Anonymous], 2004, NICE TECHNOLOGY APPR, V74; Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1989, CIRC SHOCK, V28, P321; Bilski TR, 2003, J TRAUMA, V54, P814, DOI 10.1097/01.TA.0000046627.87250.1D; Bohman HR, 2005, MIL MED, V170, P297, DOI 10.7205/MILMED.170.4.297; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Cole DJ, 1999, SURGERY, V126, P510, DOI 10.1016/S0039-6060(99)70092-9; Cooper GJ, 1996, J TRAUMA, V40, pS38, DOI 10.1097/00005373-199603001-00007; DAMON EG, 1971, AEROSPACE MED, V42, P1; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; Dearden P, 2001, J R Army Med Corps, V147, P80; DRONEN SC, 1993, AM J EMERG MED, V11, P331, DOI 10.1016/0735-6757(93)90162-5; Dubick MA, 2003, J TRAUMA, V54, pS43, DOI 10.1097/01.TA.0000064514.42470.3B; Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4; Garner J, 2010, ANN SURG, V251, P1131, DOI 10.1097/SLA.0b013e3181e00fcb; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Harban FMJ, 2001, J PHYSIOL-LONDON, V533, p81P; Hodgetts TJ, 2006, EMERG MED J, V23, P745, DOI 10.1136/emj.2006.039610; Holcomb JB, 1999, J TRAUMA, V46, P49, DOI 10.1097/00005373-199901000-00009; Jeroukhimov I, 2002, J TRAUMA, V53, P1053, DOI 10.1097/00005373-200212000-00004; Kirkman E., 2006, DSTLTR19030; Klemcke HG, 2005, J TRAUMA, V59, P155, DOI 10.1097/01.TA.0000174557.89804.A2; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; Leach RM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2790; Lee CC, 2001, ANN EMERG MED, V38, P170, DOI 10.1067/mem.2001.114313; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Marti M, 2006, EMERG RADIOL, V13, P113, DOI 10.1007/s10140-006-0534-4; Martinowitz U, 2001, J TRAUMA, V50, P721, DOI 10.1097/00005373-200104000-00021; Maynard R. L., 1989, TRAUMA; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; MOORE EE, 1995, J TRAUMA, V38, P323, DOI 10.1097/00005373-199503000-00001; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Ohnishi M, 2001, EXP PHYSIOL, V86, P357, DOI 10.1113/eph8602145; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pusateri AE, 2004, J TRAUMA, V57, P555, DOI 10.1097/01.TA.0000136155.97758.CD; Rafie AD, 2004, SHOCK, V22, P262, DOI 10.1097/01.shk.0000135255.59817.8c; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sawdon M, 2002, EXP PHYSIOL, V87, P683, DOI 10.1113/eph8702432; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Sondeen JL, 2003, J TRAUMA, V54, pS110, DOI 10.1097/01.TA.0000047220.81795.3D; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; White H, 2008, EUR J ANAESTH, V25, P104, DOI 10.1017/S0265021507003420; Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019; Zakaria ER, 2006, SURGERY, V140, P579, DOI 10.1016/j.surg.2006.05.015; Zunic Gordana, 2005, Vojnosanit Pregl, V62, P273, DOI 10.2298/VSP0504273Z	62	39	44	0	9	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	0962-8436	1471-2970		PHILOS T R SOC B	Philos. Trans. R. Soc. B-Biol. Sci.	JAN 27	2011	366	1562					144	159		10.1098/rstb.2010.0240			16	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	693RA	WOS:000285241400004	21149352	Green Published			2022-02-06	
J	Youngjohn, JR; Wershba, R; Stevenson, M; Sturgeon, J; Thomas, ML				Youngjohn, James R.; Wershba, Rebecca; Stevenson, Matthew; Sturgeon, John; Thomas, Michael L.			Independent Validation of the MMPI-2-RF Somatic/Cognitive and Validity Scales in TBI Litigants Tested for Effort	CLINICAL NEUROPSYCHOLOGIST			English	Article						Minnesota Multiphasic Personality Inventory; MMPI-2-RF somatic; cognitive scales; MMPI-2-RF validity scales; Symptom validity tests; Traumatic brain injury	MALINGERED NEUROCOGNITIVE DYSFUNCTION; MULTIPHASIC PERSONALITY-INVENTORY; TRAUMATIC BRAIN-INJURY; FAKE BAD SCALE; HEAD-INJURY; BASE RATES; FORENSIC PRACTICE; METAANALYSIS; UTILITY; SYMPTOMATOLOGY	The MMPI-2 Restructured Form (MMPI-2-RF; Ben-Porath Tellegen, 2008) is replacing the MMPI-2 as the most widely used personality test in neuropsychological assessment, but additional validation studies are needed. Our study examines MMPI-2-RF Validity scales and the newly created Somatic/Cognitive scales in a recently reported sample of 82 traumatic brain injury (TBI) litigants who either passed or failed effort tests (Thomas Youngjohn, 2009). The restructured Validity scales FBS-r (restructured symptom validity), F-r (restructured infrequent responses), and the newly created Fs (infrequent somatic responses) were not significant predictors of TBI severity. FBS-r was significantly related to passing or failing effort tests, and Fs and F-r showed non-significant trends in the same direction. Elevations on the Somatic/Cognitive scales profile (MLS-malaise, GIC-gastrointestinal complaints, HPC-head pain complaints, NUC-neurological complaints, and COG-cognitive complaints) were significant predictors of effort test failure. Additionally, HPC had the anticipated paradoxical inverse relationship with head injury severity. The Somatic/Cognitive scales as a group were better predictors of effort test failure than the RF Validity scales, which was an unexpected finding. MLS arose as the single best predictor of effort test failure of all RF Validity and Somatic/Cognitive scales. Item overlap analysis revealed that all MLS items are included in the original MMPI-2 Hy scale, making MLS essentially a subscale of Hy. This study validates the MMPI-2-RF as an effective tool for use in neuropsychological assessment of TBI litigants.	[Youngjohn, James R.] Neuropsychol Clin, Scottsdale, AZ USA; [Wershba, Rebecca; Stevenson, Matthew; Sturgeon, John; Thomas, Michael L.] Arizona State Univ, Phoenix, AZ USA		Youngjohn, JR (corresponding author), 7533 E 1st St, Scottsdale, AZ 85251 USA.	drjyoungjohn@aol.com		Sturgeon, John/0000-0001-6388-0920			Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Ben-Porath YS., 2008, MMPI 2 RF MANUAL ADM; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Butcher JN, 2001, MMPI 2 MANUAL ADM SC; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; GERVAIS RO, 2007, 2007 ANN M NAT AC NE; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gervais RO, 2009, CLIN NEUROPSYCHOL, V23, P996, DOI 10.1080/13854040902748249; Gough HG, 1946, J CLIN PSYCHOL, V2, P23, DOI 10.1002/1097-4679(194601)2:1<23::AID-JCLP2270020105>3.0.CO;2-Y; Graham J.R., 1990, MMPI 2 ASSESSING PER; Green P, 1995, MANUAL ORAL WORD MEM; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Locke DEC, 2010, EPILEPSY BEHAV, V17, P252, DOI 10.1016/j.yebeh.2009.12.004; McKinley JC, 1944, J APPL PSYCHOL, V28, P153, DOI 10.1037/h0059245; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2010, CLIN NEUROPSYCHOL, V24, P701, DOI 10.1080/13854040903482863; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Nitch S. R., 2007, ASSESSMENT FEIGNED C, P78; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Sellbom M, 2008, PSYCHOL ASSESSMENT, V20, P370, DOI 10.1037/a0012952; Smart CM, 2008, J INT NEUROPSYCH SOC, V14, P842, DOI 10.1017/S1355617708081034; Tellegen A., 2008, MMPI 2 RF TECHNICAL; Thomas ML, 2010, PSYCHOL ASSESSMENT, V22, P492, DOI 10.1037/a0019229; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177; [No title captured]	38	39	39	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					463	476	PII 934589843	10.1080/13854046.2011.554444			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100009	21391149				2022-02-06	
J	Maeda, H; Zhu, BL; Ishikawa, T; Michiue, T				Maeda, Hitoshi; Zhu, Bao-li; Ishikawa, Takaki; Michiue, Tomomi			Forensic molecular pathology of violent deaths	FORENSIC SCIENCE INTERNATIONAL			English	Article						Forensic pathology; Molecular biology; Pathophysiology of death; mRNA quantification; Violent death; Molecular autopsy	ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; INTRANUCLEAR UBIQUITIN IMMUNOREACTIVITY; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TRAUMATIC BRAIN-INJURY; WOUND AGE; PULMONARY SURFACTANT; GENE-EXPRESSION; SUDDEN-DEATH; TIME-COURSE	In forensic pathology, while classical morphology remains a core procedure to investigate deaths, a spectrum of ancillary procedures has been developed and incorporated to detail the pathology. Among them, postmortem biochemistry is important to investigate the systemic pathophysiological changes involved in the dying process that cannot be detected by morphology. In addition, recent advances in molecular biology have provided a procedure to investigate genetic bases of diseases that might present with sudden death, which is called 'molecular autopsy'. Meanwhile, the practical application of RNA analyses to postmortem investigation has not been accepted due to rapid decay after death; however, recent experimental and practical studies using real-time reverse transcription-PCR have suggested that the relative quantification of mRNA transcripts can be applied in molecular pathology for postmortem investigation of deaths, which may be called 'advanced molecular autopsy'. In a broad sense, forensic molecular pathology implies applied medical sciences to investigate the genetic basis of diseases, and the pathophysiology of diseases and traumas leading to death at a biological molecular level in the context of forensic pathology. The possible applications include analyses of local pathology, including tissue injury, ischemia/hypoxia and inflammation at the site of insult or specific tissue damage from intoxication, systemic responses to violence or environmental hazards, disorders due to intoxication, and systemic pathophysiology of fatal process involving major life-support organs. A review of previous studies suggests that systematic postmortem quantitative analysis of mRNA transcripts can be established from multi-faceted aspects of molecular biology and incorporated into death investigations in forensic pathology, to support and reinforce morphological evidence. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Maeda, Hitoshi; Zhu, Bao-li; Ishikawa, Takaki; Michiue, Tomomi] Osaka City Univ, Sch Med, Dept Legal Med, Abeno Ku, Osaka 5458585, Japan; [Zhu, Bao-li] China Med Univ, Dept Forens Pathol, Sch Forens Med, Shenyang 110001, Liaoning, Peoples R China		Maeda, H (corresponding author), Osaka City Univ, Sch Med, Dept Legal Med, Abeno Ku, Asahi Machi 1-4-3, Osaka 5458585, Japan.	legalmed@med.osaka-cu.ac.jp	Ishikawa, Takaki/AAP-7005-2020				An JL, 2010, INT J LEGAL MED, V124, P99, DOI 10.1007/s00414-009-0375-2; Bacci S, 2006, INT J LEGAL MED, V120, P138, DOI 10.1007/s00414-005-0030-5; Bai RF, 2008, FORENSIC SCI INT, V175, P193, DOI 10.1016/j.forsciint.2007.07.006; Barrachina M, 2006, NEUROCHEM INT, V49, P276, DOI 10.1016/j.neuint.2006.01.018; BARTON AJL, 1993, J NEUROCHEM, V61, P1, DOI 10.1111/j.1471-4159.1993.tb03532.x; Basso C, 2008, VIRCHOWS ARCH, V452, P11, DOI 10.1007/s00428-007-0505-5; Bauer M, 2007, FORENSIC SCI INT-GEN, V1, P69, DOI 10.1016/j.fsigen.2006.11.002; Bauer Martin, 2003, Leg Med (Tokyo), V5, P220, DOI 10.1016/j.legalmed.2003.08.001; Becker J, 2004, FORENSIC SCI INT, V140, P13, DOI 10.1016/j.forsciint.2003.10.012; Chen XS, 2006, FORENSIC SCI INT, V162, P170, DOI 10.1016/j.forsciint.2006.06.044; Cina SJ, 2001, AM J FOREN MED PATH, V22, P173, DOI 10.1097/00000433-200106000-00012; COE JI, 1993, AM J FOREN MED PATH, V14, P91, DOI 10.1097/00000433-199306000-00001; Cohle SD, 2001, CARDIOVASC PATHOL, V10, P219, DOI 10.1016/S1054-8807(01)00093-X; de la Grandmaison GL, 2006, FORENSIC SCI INT, V156, P138, DOI 10.1016/j.forsciint.2004.12.024; De Paepe ME, 2002, DIAGN MOL PATHOL, V11, P170, DOI 10.1097/00019606-200209000-00008; Dettmeyer RB, 2006, FORENSIC SCI INT, V156, P51, DOI 10.1016/j.forsciint.2004.12.015; Dettmeyer R, 2008, FORENSIC SCI INT, V174, P229, DOI 10.1016/j.forsciint.2007.05.009; Dirnhofer R, 2006, RADIOGRAPHICS, V26, P1305, DOI 10.1148/rg.265065001; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Dressler J, 1998, LANCET, V352, P38, DOI 10.1016/S0140-6736(05)79520-9; Ellingsen CL, 2004, AM J FOREN MED PATH, V25, P213, DOI 10.1097/01.paf.0000127404.35694.94; Fernandez-Rodriguez A, 2006, FORENSIC SCI INT, V161, P8, DOI 10.1016/j.forsciint.2005.10.012; Ferrer-Dufol A, 2009, TOXICOL LETT, V186, P2, DOI 10.1016/j.toxlet.2008.10.025; Fineschi V, 2005, INT J LEGAL MED, V119, P94, DOI 10.1007/s00414-004-0498-4; FINGER JM, 1987, CLIN CHIM ACTA, V170, P209, DOI 10.1016/0009-8981(87)90130-6; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Grellner W, 2005, FORENSIC SCI INT, V153, P174, DOI 10.1016/j.forsciint.2004.08.021; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hausmann R, 2004, FOREN PATHOL REV, P53; HAWGOOD S, 1990, J CLIN INVEST, V86, P1, DOI 10.1172/JCI114670; Hayashi T, 2004, INT J LEGAL MED, V118, P320, DOI 10.1007/s00414-004-0468-x; Hayashi T, 2009, INT J LEGAL MED, V123, P7, DOI 10.1007/s00414-008-0235-5; He FG, 2008, FORENSIC SCI INT, V176, P152, DOI 10.1016/j.forsciint.2007.08.005; Heinrich M, 2007, INT J LEGAL MED, V121, P136, DOI 10.1007/s00414-006-0131-9; Huang WL, 2004, DRUG METAB DISPOS, V32, P1434, DOI 10.1124/dmd.104.001313; Iino M, 2003, INT J LEGAL MED, V117, P153, DOI 10.1007/s00414-003-0370-y; Ikematsu K, 2008, FORENSIC SCI INT, V179, P152, DOI 10.1016/j.forsciint.2008.05.007; Ikematsu Kazuya, 2004, Leg Med (Tokyo), V6, P97, DOI 10.1016/j.legalmed.2003.11.002; Ikematsu Kazuya, 2006, Legal Medicine, V8, P128, DOI 10.1016/j.legalmed.2005.08.012; Ikematsu Kazuya, 2003, Leg Med (Tokyo), V5, P15, DOI 10.1016/S1344-6223(02)00072-X; Ikernatsu Kazuya, 2007, Legal Medicine, V9, P265, DOI 10.1016/j.legalmed.2007.03.001; Inoue H, 2002, FORENSIC SCI INT, V130, P127, DOI 10.1016/S0379-0738(02)00352-3; Ishida K, 2000, FORENSIC SCI INT, V113, P127, DOI 10.1016/S0379-0738(00)00252-8; Ishida K, 2004, MOL TOXICOLOGY PROTO, V291, P415; Ishida Kaori, 2002, Leg Med (Tokyo), V4, P7, DOI 10.1016/S1344-6223(01)00056-6; Ishida Y, 2008, INT J LEGAL MED, V122, P409, DOI 10.1007/s00414-008-0255-1; Ishida Y, 2004, J LEUKOCYTE BIOL, V75, P59, DOI 10.1189/jlb.0403152; Ishida Yuko, 2006, Legal Medicine, V8, P102, DOI 10.1016/j.legalmed.2005.08.010; Ishikawa T, 2005, INT J LEGAL MED, V119, P231, DOI 10.1007/s00414-005-0540-1; Ishikawa T, 2008, FORENSIC SCI INT, V179, P147, DOI 10.1016/j.forsciint.2008.04.023; Ishikawa T, 2007, FORENSIC SCI INT, V171, P136, DOI 10.1016/j.forsciint.2006.10.016; Ishikawa T, 2007, INT J LEGAL MED, V121, P395, DOI 10.1007/s00414-006-0138-2; Ishikawa T, 2010, LEGAL MED-TOKYO, V12, P121, DOI 10.1016/j.legalmed.2010.01.004; JOHNSON SA, 1986, J NEUROSCI RES, V16, P267, DOI 10.1002/jnr.490160123; Kagawa Shinichiro, 2009, Legal Medicine, V11, P70, DOI 10.1016/j.legalmed.2008.09.004; Kakizaki E, 2008, FORENSIC SCI INT, V176, P236, DOI 10.1016/j.forsciint.2007.09.018; Karch Steven B, 2007, J Forensic Leg Med, V14, P389, DOI 10.1016/j.jflm.2007.04.008; Kernbach-Wighton Gerhard, 2009, Leg Med (Tokyo), V11 Suppl 1, pS31, DOI 10.1016/j.legalmed.2009.01.075; Kibayashi K, 2009, INT J LEGAL MED, V123, P371, DOI 10.1007/s00414-008-0278-7; Kitamura Osamu, 2005, Leg Med (Tokyo), V7, P340, DOI 10.1016/j.legalmed.2005.08.006; Kitamura O, 2007, INT J LEGAL MED, V121, P163, DOI 10.1007/s00414-006-0087-9; Kitamura O, 2010, LEGAL MED-TOKYO, V12, P57, DOI 10.1016/j.legalmed.2009.11.001; KONDO T, FORENSIC SC IN PRESS; Kondo Toshikazu, 2007, Legal Medicine, V9, P109, DOI 10.1016/j.legalmed.2006.11.009; Kuliwaba JS, 2005, BBA-MOL BASIS DIS, V1740, P1, DOI 10.1016/j.bbadis.2005.03.005; Landi KK, 2008, J FORENSIC SCI, V53, P213, DOI 10.1111/j.1556-4029.2007.00604.x; Li DR, 2009, HISTOL HISTOPATHOL, V24, P1113, DOI 10.14670/HH-24.1113; Li Dong-Ri, 2006, Legal Medicine, V8, P71, DOI 10.1016/j.legalmed.2005.07.004; Li Dong-Ri, 2006, Legal Medicine, V8, P78, DOI 10.1016/j.legalmed.2005.09.002; Li DR, 2010, LEGAL MED, V12, P63, DOI 10.1016/j.legalmed.2009.11.005; Liu NG, 2006, FORENSIC SCI INT, V162, P178, DOI 10.1016/j.forsciint.2006.06.040; Loddenkotter B, 2005, INT J LEGAL MED, V119, P202, DOI 10.1007/s00414-005-0531-2; Luna A, 2009, Leg Med (Tokyo), V11 Suppl 1, pS27, DOI 10.1016/j.legalmed.2009.02.040; Madea Burkhard, 2009, Leg Med (Tokyo), V11 Suppl 1, pS36, DOI 10.1016/j.legalmed.2009.01.111; Maeda Hitoshi, 2003, Leg Med (Tokyo), V5 Suppl 1, pS318, DOI 10.1016/S1344-6223(02)00160-8; Maeda Hitoshi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS46, DOI 10.1016/j.legalmed.2009.01.048; Maeda H, 2008, FORENSIC SCI MED PAT, V4, P175, DOI 10.1007/s12024-008-9029-9; Marschall S, 2006, INT J LEGAL MED, V120, P355, DOI 10.1007/s00414-006-0105-y; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Michiue T, 2008, FORENSIC SCI INT, V178, P185, DOI 10.1016/j.forsciint.2008.03.019; Michiue Tomomi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS168, DOI 10.1016/j.legalmed.2009.01.105; Michiue T, 2010, LEGAL MED, V12, P73, DOI 10.1016/j.legalmed.2009.11.007; Morling N, 2009, BIOCHEM SOC T, V37, P438, DOI 10.1042/BST0370438; Morris JA, 2006, J CLIN PATHOL, V59, P1, DOI 10.1136/jcp.2005.028183; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nakajima T, 2006, FORENSIC SCI INT, V158, P157, DOI 10.1016/j.forsciint.2005.05.028; Nogami Makoto, 2009, Legal Medicine, V11, P213, DOI 10.1016/j.legalmed.2009.05.001; Oehmichen M, 1997, EXP TOXICOL PATHOL, V49, P233, DOI 10.1016/S0940-2993(97)80017-6; Oehmichen M, 2004, FORENSIC SCI INT, V144, P221, DOI 10.1016/j.forsciint.2004.04.057; OEHMICHEN M, 1984, Z RECHTSMED, V91, P287, DOI 10.1007/BF02332322; Ohshima T, 1998, INT J LEGAL MED, V111, P251, DOI 10.1007/s004140050163; Ohshima T, 2000, FORENSIC SCI INT, V113, P153, DOI 10.1016/S0379-0738(00)00269-3; Osawa Motoki, 2008, Legal Medicine, V10, P143, DOI 10.1016/j.legalmed.2007.10.002; Pampin JB, 2006, J FORENSIC SCI, V51, P120, DOI 10.1111/j.1556-4029.2005.00014.x; PARDUE S, 1994, CELL MOL NEUROBIOL, V14, P341, DOI 10.1007/BF02088715; Paulding WR, 2000, ADV EXP MED BIOL, V475, P111; Perez-Carceles MD, 2004, FORENSIC SCI INT, V142, P1, DOI 10.1016/j.forsciint.2004.02.007; PHANG TW, 1994, J FORENSIC SCI, V39, P1275; Popivanova BK, 2003, BRAIN RES, V970, P195, DOI 10.1016/S0006-8993(03)02343-6; Preece P, 2003, MOL BRAIN RES, V118, P60, DOI 10.1016/S0169-328X(03)00337-1; Preuss J, 2008, FORENSIC SCI INT, V176, P248, DOI 10.1016/j.forsciint.2007.09.017; Quan L, 2008, INT J LEGAL MED, V122, P481, DOI 10.1007/s00414-008-0276-9; Quan L, 2001, INT J LEGAL MED, V115, P6, DOI 10.1007/s004140000200; Quan L, 2001, INT J LEGAL MED, V114, P310, DOI 10.1007/s004140000192; Quan Li, 2005, Legal Medicine, V7, P144, DOI 10.1016/j.legalmed.2004.11.002; Sato Y, 2000, INT J LEGAL MED, V113, P140, DOI 10.1007/s004140050285; SAUKKO P, 2004, KNIGHTS FORENSIC PAT, P1; Sawaguchi T, 2005, FORENSIC SCI INT, V149, P205, DOI 10.1016/j.forsciint.2004.10.015; Schneider PM, 2007, FORENSIC SCI INT, V165, P238, DOI 10.1016/j.forsciint.2006.06.067; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shimada I, 2008, INT J LEGAL MED, V122, P373, DOI 10.1007/s00414-008-0226-6; Shinone K, 2010, LEGAL MED-TOKYO, V12, P79, DOI 10.1016/j.legalmed.2010.01.001; Smolina IV, 2005, B EXP BIOL MED+, V140, P187, DOI 10.1007/s10517-005-0441-9; Sun JH, 2010, INT J LEGAL MED, V124, P27, DOI 10.1007/s00414-009-0323-1; Takahashi Hiroyuki, 2009, Legal Medicine, V11, P181, DOI 10.1016/j.legalmed.2009.03.008; Takamiya M, 2005, INT J LEGAL MED, V119, P16, DOI 10.1007/s00414-004-0453-4; Takamiya M, 2003, INT J LEGAL MED, V117, P46, DOI 10.1007/s00414-002-0354-3; Takamiya Masataka, 2006, Legal Medicine, V8, P214, DOI 10.1016/j.legalmed.2006.05.002; Takamiya M, 2008, INT J LEGAL MED, V122, P143, DOI 10.1007/s00414-007-0183-5; Takamiya Masataka, 2008, Legal Medicine, V10, P131, DOI 10.1016/j.legalmed.2007.11.003; Tanaka Jin, 2003, Leg Med (Tokyo), V5, P146, DOI 10.1016/S1344-6223(03)00076-2; Tanaka Toshiko, 2004, Leg Med (Tokyo), V6, P203, DOI 10.1016/j.legalmed.2004.05.002; Tao LY, 2006, FORENSIC SCI INT, V162, P174, DOI 10.1016/j.forsciint.2006.06.021; Tester DJ, 2006, CURR OPIN CARDIOL, V21, P166, DOI 10.1097/01.hco.0000221576.33501.83; Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013; Weis A, 2008, FORENSIC SCI INT, V175, P102, DOI 10.1016/j.forsciint.2007.05.015; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; Yasojima K, 2001, BRAIN RES PROTOC, V8, P212, DOI 10.1016/S1385-299X(01)00119-2; Yoshida C, 2011, INT J LEGAL MED, V125, P11, DOI 10.1007/s00414-009-0374-3; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1; Ishikawa Takaki, 2006, Legal Medicine, V8, P28, DOI 10.1016/j.legalmed.2006.05.004; Zhao D, 2008, FORENSIC SCI INT, V177, P176, DOI 10.1016/j.forsciint.2007.12.004; Zhao Dong, 2006, Legal Medicine, V8, P132, DOI 10.1016/j.legalmed.2005.09.001; Zhao Dong, 2009, Leg Med (Tokyo), V11 Suppl 1, pS286, DOI 10.1016/j.legalmed.2009.02.014; Zhao Dong, 2009, Leg Med (Tokyo), V11 Suppl 1, pS43, DOI 10.1016/j.legalmed.2009.01.066; Zhu B L, 2001, Leg Med (Tokyo), V3, P23, DOI 10.1016/S1344-6223(01)00006-2; Zhu B L, 2001, Leg Med (Tokyo), V3, P134, DOI 10.1016/S1344-6223(01)00020-7; Zhu Bao-Li, 2006, Legal Medicine, V8, P94, DOI 10.1016/j.legalmed.2005.10.003; Zhu Bao-Li, 2006, Legal Medicine, V8, P86, DOI 10.1016/j.legalmed.2005.10.004; Zhu BL, 2007, INT J LEGAL MED, V121, P28, DOI 10.1007/s00414-006-0102-1; Zhu Bao-Li, 2008, Legal Medicine, V10, P11, DOI 10.1016/j.legalmed.2007.06.002; Zhu Bao-Li, 2007, Legal Medicine, V9, P241, DOI 10.1016/j.legalmed.2007.01.010; Zhu Bao-Li, 2005, Legal Medicine, V7, P103, DOI 10.1016/j.legalmed.2004.08.004; Zhu BL, 2007, FORENSIC SCI INT, V173, P122, DOI 10.1016/j.forsciint.2007.02.013; Zhu Bao-Li, 2002, Leg Med (Tokyo), V4, P1, DOI 10.1016/S1344-6223(01)00051-7; Zhu Bao-Li, 2005, Legal Medicine, V7, P139, DOI 10.1016/j.legalmed.2004.10.007; Zhu BL, 2001, FORENSIC SCI INT, V117, P205, DOI 10.1016/S0379-0738(00)00410-2; Zhu BL, 2000, INT J LEGAL MED, V113, P268, DOI 10.1007/s004149900109	150	39	42	0	26	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC 15	2010	203	1-3					83	92		10.1016/j.forsciint.2010.07.024			10	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	683HJ	WOS:000284464200011	20719442				2022-02-06	
J	Kontos, AP; Elbin, RJ; Covassin, T; Larson, E				Kontos, Anthony P.; Elbin, Robert J., III; Covassin, Tracey; Larson, Elizabeth			Exploring Differences in Computerized Neurocognitive Concussion Testing Between African American and White Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Head injury; Traumatic brain injury; Cross-cultural; minority; Assessment	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; DEMOGRAPHIC-VARIABLES; WAIS-III; IMPACT; RACE; EDUCATION; RECOVERY; ACCULTURATION; CHILDREN	The purpose of the current study was to explore potential differences in pre- and post-concussion performance on a computerized neurocognitive concussion test between African American and White high-school and collegiate student-athletes. A prospective case-control design was used to compare baseline and 2- and 7-day post-concussion computerized neurocognitive performance and symptoms between 48 White and 48 African American athletes matched for age, gender, and concussion history. The Immediate Post-Concussion Assessment Cognitive Test (ImPACT) version 2.0 (NeuroHealth System, LLC, Pittsburgh, PA, USA) computer software program was used to assess neurocognitive function (i.e., verbal and visual memory, motor processing speed, and reaction time) and concussion symptoms. Regardless of race/ethnicity, there were significant decrements in computerized neurocognitive performance and increased symptoms following a concussion for the entire sample. African Americans and Whites did not differ significantly on baseline or post-concussion verbal memory, visual memory, reaction time, and total reported symptoms. However, African American participants were 2.4x more likely to have at least one clinically significant cognitive decline on ImPACT at 7 days post-concussion and scored lower at 7 days post-concussion compared with baseline on processing speed than White participants. The authors concluded that the baseline ImPACT test was culturally equivalent and construct valid for use with these two racial/ethnic groups. However, in contrast, the findings support deleterious performance for the African American athletes compared with the White athletes on the ImPACT post-concussion evaluation that is of critical clinical relevance and warrants further research.	[Kontos, Anthony P.] UPMC Ctr Sports Med, UPMC Sports Concuss Program, Pittsburgh, PA 15203 USA; [Kontos, Anthony P.; Larson, Elizabeth] Humboldt State Univ, Arcata, CA 95521 USA; [Elbin, Robert J., III] E Tennessee State Univ, Johnson City, TN 37614 USA; [Covassin, Tracey] Michigan State Univ, E Lansing, MI 48824 USA		Kontos, AP (corresponding author), UPMC Ctr Sports Med, UPMC Sports Concuss Program, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310			BAGLEY C, 1995, SOC SCI MED, V40, P1017, DOI 10.1016/0277-9536(94)00318-N; Barth JT, 1989, MILD HEAD INJURY, P257; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Feinstein L, 2003, ECONOMICA, V70, P73, DOI 10.1111/1468-0335.t01-1-00272; FERRARO F, 2005, ALZHEIMERS DIS ASS D, V19, P74; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fullilove MT, 1998, AM J PUBLIC HEALTH, V88, P1297, DOI 10.2105/AJPH.88.9.1297; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Heaton RK, 1996, NEUROPSYCHOLOGICAL A, P141; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; JENSEN AR, 1982, PERS INDIV DIFFER, V3, P423, DOI 10.1016/0191-8869(82)90007-1; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KAUFMAN AS, 1988, J CLIN PSYCHOL, V44, P231, DOI 10.1002/1097-4679(198803)44:2<231::AID-JCLP2270440224>3.0.CO;2-J; Kelly JP, 1997, NEUROLOGY, V48, P581; Kennepohl S, 2004, J INT NEUROPSYCH SOC, V10, P566, DOI 10.1017/S1355617704104128; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; LYNN R, 1990, SOC BEHAV PERSONAL, V18, P299, DOI 10.2224/sbp.1990.18.2.299; Manly JJ, 1998, J INT NEUROPSYCH SOC, V4, P291, DOI 10.1017/S1355617798002914; Manly JJ, 2005, CLIN NEUROPSYCHOL, V19, P270, DOI 10.1080/13854040590945346; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; Mayfield JW, 1997, ARCH CLIN NEUROPSYCH, V12, P111, DOI 10.1016/S0887-6177(96)00016-9; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; McKay PF, 2003, J BUS PSYCHOL, V18, P1, DOI 10.1023/A:1025062703113; Mehta KM, 2004, J AM GERIATR SOC, V52, P2120, DOI 10.1111/j.1532-5415.2004.52575.x; Nell V, 1999, S AFR J PSYCHOL, V29, P128, DOI 10.1177/008124639902900305; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; O'Bryant SE, 2004, CLIN NEUROPSYCHOL, V18, P229, DOI 10.1080/13854040490501439; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reynolds C.R., 1994, TEST MEMORY LEARNING; Sandifer H, 2005, J MED SPEECH-LANG PA, V13, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shuttleworth-Edwards AB, 2004, J CLIN EXP NEUROPSYC, V26, P903, DOI 10.1080/13803390490510824; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Shuttleworth-Edwards Ann B, 2009, Phys Sportsmed, V37, P45, DOI 10.3810/psm.2009.12.1741; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; Teng EL, 2005, ALZ DIS ASSOC DIS, V19, P267, DOI 10.1097/01.wad.0000190805.13126.8e; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3	49	39	39	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2010	25	8					734	744		10.1093/arclin/acq068			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	679KE	WOS:000284159500004	20861034	Bronze, Green Published			2022-02-06	
J	Kuo, JR; Lo, CJ; Chang, CP; Lin, HJ; Lin, MT; Chio, CC				Kuo, Jinn-Rung; Lo, Chong-Jeh; Chang, Ching-Ping; Lin, Hung-Jung; Lin, Mao-Tsun; Chio, Chung-Ching			Brain Cooling-Stimulated Angiogenesis and Neurogenesis Attenuated Traumatic Brain Injury in Rats	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Brain cooling; Angiogenesis; Neurogenesis; Gliosis	NEURAL STEM-CELLS; HUMAN HEAD-INJURY; FLUID PERCUSSION; HIPPOCAMPAL PATHOLOGY; IN-VIVO; ISCHEMIA; HYPOTHERMIA; SUPEROXIDE; MICE; PROLIFERATION	Background: Although brain cooling has been reported to be effective in improving the outcome after traumatic brain injury (TBI) in rats, the mechanisms of brain cooling-induced neuroprotective actions remain unclear. This study was to test whether angiogenesis and neurogenesis attenuating TBI could be brain cooling stimulated. Methods: Anesthetized rats, immediately after the onset of TBI, were divided into two groups and given the brain cooling (infusing 5 mL of 4 degrees C saline via the external jugular vein) or no brain cooling (infusing 5 mL of 37 degrees C saline via the external jugular vein). Results: Brain cooling without interference with the core temperature in rats significantly attenuated TBI-induced cerebral infarction (90 mm(3) vs. 250 mm(3)) and motor (61 degrees vs. 57 degrees maximal angle) and proprioceptive (14% vs. 42% maximal possible effect) function deficits, significantly reduced TBI-induced neuronal (24 vs. 62 neuronal-specific nuclear [NeuN]-TUNEL double-positive cells) and glial (5 vs. 35 GFAP-TUNEL double-positive cells) apoptosis (increased TUNEL-positive and caspase-3-positive cells), neuronal loss (102 vs. 66 NeuN-positive cells), and gliosis (40 vs. 66 GFAP-positive cells; 66 vs. 89 Iba1-positive cells), and significantly promoted angiogenesis (5-bromodeoxyuridine [BrdU]/endothelial cells vs. 1-BrdU/ endothelial cell; 58 vs. 31 vascular endothelial growth factor-positive cells), and neurogenesis (33 vs. 14 BrdU/NeuN positive cells). Conclusions: Brain cooling-stimulated angiogenesis and neurogenesis attenuated a fluid percussion TBI in rats.	[Kuo, Jinn-Rung; Lin, Hung-Jung; Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan; [Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Kuo, Jinn-Rung; Lo, Chong-Jeh] Natl Cheng Kung Univ, Sch Med, Inst Clin Med, Tainan 70101, Taiwan; [Kuo, Jinn-Rung; Chang, Ching-Ping; Lin, Hung-Jung] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Lo, Chong-Jeh] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Div Trauma & Emergency Surg, Kaohsiung, Taiwan; [Lin, Mao-Tsun] Taipei Med Univ, Inst Dis Prevent & Control, Taipei, Taiwan		Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan.	891201@mail.chi.mei.org.tw		Chang, Ching-Ping/0000-0003-0890-9414	Center of Excellence for Clinical Trial and Research in Neuroscience [NSC96-2314-B-384-006-MY3, NSC96-2314-B384-003-MY3, DOH99-TD-B-111-003]	Supported by grants NSC96-2314-B-384-006-MY3, NSC96-2314-B384-003-MY3, and DOH99-TD-B-111-003 Center of Excellence for Clinical Trial and Research in Neuroscience.	Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; DeKosky ST, 2004, J NEUROCHEM, V90, P998, DOI 10.1111/j.1471-4159.2004.02575.x; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gerner P, 2003, ANESTHESIOLOGY, V98, P1484, DOI 10.1097/00000542-200306000-00028; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234, DOI 10.1152/ajpheart.1992.263.4.H1234; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1993, STROKE, V24, P427, DOI 10.1161/01.STR.24.3.427; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Marshall L F, 2000, Clin Neurosurg, V46, P105; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sudoh Y, 2003, PAIN, V103, P49, DOI 10.1016/S0304-3959(02)00375-5; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; THALHAMMER JG, 1995, ANESTHESIOLOGY, V82, P1013, DOI 10.1097/00000542-199504000-00026; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; van Zanten ARH, 2005, CRIT CARE MED, V33, P1449, DOI 10.1097/01.CCM.0000166710.64724.34; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wang Y, 1997, J NEUROSCI, V17, P4341; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262, DOI 10.1152/ajpheart.1996.271.3.H1262	37	39	42	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2010	69	6					1467	1472		10.1097/TA.0b013e3181f31b06			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	695RT	WOS:000285391000040	21150525				2022-02-06	
J	Miotto, EC; Cinalli, FZ; Serrao, VT; Benute, GG; Lucia, MCS; Scaff, M				Miotto, Eliane Correa; Cinalli, Fernanda Zanetti; Serrao, Valeria Trunkl; Benute, Glaucia Guerra; Souza Lucia, Mara Cristina; Scaff, Milberto			Cognitive deficits in patients with mild to moderate traumatic brain injury	ARQUIVOS DE NEURO-PSIQUIATRIA			English	Article						traumatic brain injury; cognitive deficits; mild to moderate level	ATTENTION	Traumatic brain injury (TBI) is one of the most frequent causes of brain damage. Cognitive deficits reported in the literature after moderate to severe TBI include memory, language, executive functions, attention and information processing speed impairments. However, systematic studies on patients with mild TBI are scarce although neuropsychological changes are present. Objective: To investigate the cognitive functioning of patients with mild to moderate TBI. Method: We evaluated 12 patients with mild to moderate TBI using a comprehensive protocol (PN01) of neuropsychological tests. Results: There were significant deficits of episodic memory including immediate and delayed verbal memory recall, verbal recognition, immediate and delayed visual memory recall, naming, verbal fluency and information processing speed. Conclusion: These results emphasize the importance of comprehensive neuropsychological assessments even in cases of mild TBI in order to identify impaired and preserved functions providing adequate managing including rehabilitation programs for each case.	[Miotto, Eliane Correa; Serrao, Valeria Trunkl; Benute, Glaucia Guerra; Souza Lucia, Mara Cristina] Univ Sao Paulo, Sch Med, Hosp Clin, Div Psychol,IC, Sao Paulo, Brazil; [Cinalli, Fernanda Zanetti] Univ Sao Paulo, Sch Med, IC Hosp Clin, Div Psychol, Sao Paulo, Brazil; [Miotto, Eliane Correa; Souza Lucia, Mara Cristina; Scaff, Milberto] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil		Miotto, EC (corresponding author), ICHC FMUSP, Div Psychol, Av Dr Eneas de Carvalho 155, BR-05403900 Sao Paulo, Brazil.	ecmiotto@usp.br	Miotto, Eliane C/B-5380-2013; Benute, Glaucia R/P-8050-2016	Miotto, Eliane C/0000-0003-2711-1627; Benute, Glaucia R/0000-0003-4545-1887; Guerra Benute, Glaucia Rosana/0000-0003-0781-1976			Benedict, 2001, HOPKINS VERBAL LEARN; BENEDICT RHB, 1997, BRIEF VISUALSPATIAL; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; GIL R, 2005, NEUROPSICOLOGIA, P1; Gouveia PA, 2004, NEUROPSICOLOGIA HOJE, P297; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Nascimento E., 2004, ESCALA INTELIGENCIA; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; Ringe WK, 2002, ASSESSMENT, V9, P254, DOI 10.1177/1073191102009003004; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Smith A., 2002, SYMBOL DIGIT MODALIT; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Strauss E., 1998, COMPENDIUM NEUROPSYC, V2; TEASDALE G, 1974, LANCET, V2, P81; *WHO, NEUR; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	27	39	47	2	17	ASSOC ARQUIVOS NEURO- PSIQUIATRIA	SAO PAULO SP	PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL	0004-282X	1678-4227		ARQ NEURO-PSIQUIAT	Arq. Neuro-Psiquiatr.	DEC	2010	68	6					862	868		10.1590/S0004-282X2010000600006			7	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	707WA	WOS:000286319900006	21243242	gold, Green Published, Green Submitted			2022-02-06	
J	Reddy, DS; Gangisetty, O; Briyal, S				Reddy, Doodipala Samba; Gangisetty, Omkaram; Briyal, Seema			Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis	NEUROPHARMACOLOGY			English	Article						Progesterone; Epileptogenesis; Kindling; Disease-modifying; Neurosteroid; Progesterone receptor; Seizure	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; RECEPTOR KNOCKOUT MICE; GABA(A) RECEPTORS; MALE-RATS; ANTICONVULSANT ACTIVITY; ELECTRICAL-STIMULATION; CATAMENIAL EPILEPSY; STATUS EPILEPTICUS; GENDER-DIFFERENCES	Progesterone (P) is an endogenous anticonvulsant hormone. P is being evaluated as a treatment for epilepsy, traumatic brain injury, and other complex neurological conditions. Preclinical and clinical studies suggest that P appears to interrupt epileptogenic events. However, the potential disease-modifying effect of P in epileptogenic models is not widely investigated. In this study, we examined the effects of P on the development of hippocampus kindling in female mice. In addition, we determined the role of progesterone receptors (PR) in the P's effect on the kindling epileptogenesis utilizing PR knockout (PRKO) mice. P, at 25 mg/kg, did not affect seizures and did not exert sedative/motor effects in fully-kindled mice. P treatment (25 mg/kg, twice daily for 2 weeks) significantly suppressed the rate of development of behavioral kindled seizure activity evoked by daily hippocampus stimulation in wild-type (WT) mice, indicating a disease-modifying effect of P on limbic epileptogenesis. There was a significant increase in the rate of 'rebound or withdrawal' kindling during drug-free stimulation sessions following abrupt discontinuation of P treatment. A washout period after termination of P treatment prevented such acceleration in kindling. PRKO mice were kindled significantly slower than WT mice, indicating a modulatory role of PRs in seizure susceptibility. P's effects on early kindling progression was partially decreased in PRKO mice, but the overall (2-fold) delay in the rate of kindling for the induction of stage 5 seizures was unchanged in PRKO mice. Moreover, the acute anticonvulsant effect of P was undiminished in fully-kindled PRKO mice. These studies suggest that P exerts disease-modifying effects in the hippocampus kindling model at doses that do not significantly affect seizure expression and motor performance, and the kindling-retarding effects of P may occur partly through a complex PR-dependent and PR-independent mechanism. (C) 2010 Elsevier Ltd. All rights reserved.	[Reddy, Doodipala Samba; Gangisetty, Omkaram; Briyal, Seema] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, College Stn, TX 77843 USA		Reddy, DS (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, 228 Reynolds Med Bldg, College Stn, TX 77843 USA.	reddy@medicine.tamhsc.edu		Reddy, Samba/0000-0003-2735-9550	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS051398]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051398] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant NS051398 (to D.S.R.).	ALBERTSON TE, 1984, NEUROPHARMACOLOGY, V23, P1117, DOI 10.1016/0028-3908(84)90227-2; BACKSTROM T, 1984, ACTA NEUROL SCAND, V69, P240; BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; Biagini G, 2006, EXP NEUROL, V201, P519, DOI 10.1016/j.expneurol.2006.04.029; Biagini G, 2009, EPILEPSIA, V50, P53, DOI 10.1111/j.1528-1167.2008.01971.x; Brandt C, 2007, NEUROPHARMACOLOGY, V53, P207, DOI 10.1016/j.neuropharm.2007.05.001; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Christensen J, 2005, EPILEPSIA, V46, P956, DOI 10.1111/j.1528-1167.2005.51204.x; COUGHENOUR LL, 1977, PHARMACOL BIOCHEM BE, V6, P351, DOI 10.1016/0091-3057(77)90036-3; CRAIG CR, 1966, J PHARMACOL EXP THER, V153, P337; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; DeCoster MA, 2002, J NEUROSCI RES, V67, P634, DOI 10.1002/jnr.10131; DURMULLER N, 1994, EPILEPSY RES, V17, P167, DOI 10.1016/0920-1211(94)90016-7; Edwards HE, 2000, NEUROSCIENCE, V101, P895, DOI 10.1016/S0306-4522(00)00439-5; Edwards HE, 2001, BRAIN RES, V889, P260, DOI 10.1016/S0006-8993(00)03147-4; Edwards HE, 1999, BRAIN RES, V838, P136, DOI 10.1016/S0006-8993(99)01619-4; Engel J, 2007, EPILEPSY COMPREHENSI; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 2002, EPILEPSIA, V43, P14, DOI 10.1046/j.1528-1157.43.s.5.19.x; GEE KW, 1995, CRIT REV NEUROBIOL, V9, P207; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Herd MB, 2007, PHARMACOL THERAPEUT, V116, P20, DOI 10.1016/j.pharmthera.2007.03.007; HERZOG AG, 1995, NEUROLOGY, V45, P1660, DOI 10.1212/WNL.45.9.1660; Herzog AG, 1997, EPILEPSIA, V38, P1082, DOI 10.1111/j.1528-1157.1997.tb01197.x; Herzog AG, 1999, NEUROLOGY, V52, P1917, DOI 10.1212/WNL.52.9.1917-a; Herzog AG, 2008, NEUROLOGY, V70, P486, DOI 10.1212/01.wnl.0000278102.55701.d0; HOLMES GL, 1984, DEV BRAIN RES, V16, P45, DOI 10.1016/0165-3806(84)90061-0; HOLMES GL, 1984, DEV BRAIN RES, V16, P55, DOI 10.1016/0165-3806(84)90062-2; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kaminski RM, 2004, EPILEPSIA, V45, P864, DOI 10.1111/j.0013-9580.2004.04504.x; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Lonsdale D, 2003, EPILEPSIA, V44, P1494, DOI 10.1111/j.0013-9580.2003.59402.x; Lonsdale D, 2006, BRAIN RES, V1101, P110, DOI 10.1016/j.brainres.2006.05.005; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McHugh JC, 2008, INT REV NEUROBIOL, V83, P11, DOI 10.1016/S0074-7742(08)00002-0; McNamara J O, 1992, Adv Neurol, V57, P555; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Mohammad S, 1998, EPILEPSY RES, V30, P195, DOI 10.1016/S0920-1211(98)00004-7; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Nissinen J, 2004, EPILEPSY RES, V58, P119, DOI 10.1016/j.eplepsyres.2004.01.001; Patel M, 2004, FREE RADICAL BIO MED, V37, P1951, DOI 10.1016/j.freeradbiomed.2004.08.021; Pitkanen A, 2002, NEUROLOGY, V59, pS27, DOI 10.1212/WNL.59.9_suppl_5.S27; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reddy DS, 2009, EPILEPSY RES, V85, P1, DOI 10.1016/j.eplepsyres.2009.02.017; Reddy DS, 2001, EPILEPSIA, V42, P328, DOI 10.1046/j.1528-1157.2001.10100.x; Reddy DS, 2005, NEUROPHARMACOLOGY, V48, P14, DOI 10.1016/j.neuropharm.2004.09.002; Reddy DS, 2004, J PHARMACOL EXP THER, V310, P230, DOI 10.1124/jpet.104.065268; REDDY DS, 2010, SOC NEUROSCI; Rogawski MA, 2001, NEUROPHARMACOLOGY, V40, P28, DOI 10.1016/S0028-3908(00)00112-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Selye H, 1942, J LAB CLIN MED, V27, P1051; Shen H, 2010, SCIENCE, V327, P1515, DOI 10.1126/science.1184245; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Vezzani Annamaria, 2005, Epilepsy Curr, V5, P1, DOI 10.1111/j.1535-7597.2005.05101.x; WADA JA, 1978, NEUROLOGY, V28, P1026, DOI 10.1212/WNL.28.10.1026; WAHNSCHAFFE U, 1992, EPILEPSY RES, V13, P199, DOI 10.1016/0920-1211(92)90053-V; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yagami T, 2002, J NEUROCHEM, V81, P449, DOI 10.1046/j.1471-4159.2002.00800.x	74	39	39	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2010	59	7-8					573	581		10.1016/j.neuropharm.2010.08.017			9	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	682XN	WOS:000284436400002	20804775	Green Accepted			2022-02-06	
J	Echlin, PS; Tator, CH; Cusimano, MD; Cantu, RC; Taunton, JE; Upshur, REG; Czarnota, M; Hall, CR; Johnson, AM; Forwell, LA; Driediger, M; Skopelja, EN				Echlin, Paul Sean; Tator, Charles H.; Cusimano, Michael D.; Cantu, Robert C.; Taunton, Jack E.; Upshur, Ross E. G.; Czarnota, Michael; Hall, Craig R.; Johnson, Andrew M.; Forwell, Lorie A.; Driediger, Molly; Skopelja, Elaine N.			Return to play after an initial or recurrent concussion in a prospective study of physician-observed junior ice hockey concussions: implications for return to play after a concussion	NEUROSURGICAL FOCUS			English	Article						concussion; return to play; traumatic brain injury; sports injury; ice hockey	COLLEGIATE FOOTBALL PLAYERS; SPORTS CONCUSSION; COGNITIVE IMPAIRMENT; RECOVERY; RISK; STATEMENT	Object. The authors investigated return-to-play duration for initial and recurrent concussion in the same season in 2 teams of junior (16-21-year-old) ice hockey players during a regular season. Methods. The authors conducted a prospective cohort study during 1 junior regular season (2009-2010) of 67 male fourth-tier ice hockey players (mean age 18.2 +/- 1.2 years [SD], range 16-21 years) from 2 teams. Prior to the start of the season, every player underwent baseline assessments that were determined using the Sideline Concussion Assessment Tool 2 (SCAT2) and the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). The study protocol also required players who entered the study during the season to complete a baseline SCAT2 and ImPACT. If the protocol was not followed, the postinjury test results of a player without true baseline test results were compared with previously established age-and sex-matched group normative levels. Each game was directly observed by a physician and at least 1 neutral nonphysician observer. Players suspected of suffering a concussion were evaluated by the physician during the game. If a concussion was diagnosed, the player underwent clinical evaluation at the physician's office within 24 hours. The return-to-play decision was based on clinical evaluation guided by the Zurich return-to-play protocol (contained in the consensus statement of international expert opinion at the 3rd International Conference on Concussion in Sport held in Zurich, November 2008). This clinical evaluation and return-to-play protocol was augmented by the 2 tests (SCAT2 and ImPACT) also recommended by the Zurich consensus statement, for which baseline values had been obtained. Results. Seventeen players sustained a physician-observed or self-reported, physician-diagnosed concussion during a physician-observed ice hockey game. The mean clinical return-to-play duration (in 15 cases) was 12.8 +/- 7.02 days (median 10 days, range 7-29 days); the mean number of physician office visits by players who suffered a concussion (15 cases) was 2.1 +/- 1.29 (median 1.5 visits). Five of the 17 players who sustained a concussion also suffered a recurrent or second concussion. One of the 5 individuals who suffered a repeat concussion sustained his initial concussion in a regular season game that was not observed by a physician, and as a result this single case was not included in the total of 21 concussions. This initial concussion of the player was identified during baseline testing 2 days after the injury and was subsequently medically diagnosed and treated. The mean interval between the first and second concussions in these 5 players was 78.6 +/- 39.8 days (median 82 days), and the mean time between the return-to-play date of the first and second concussions was 61.8 +/- 39.7 days (median 60 days). Conclusions. The mean rates of return to play for single and recurrent concussions were higher than rates cited in recent studies involving sport concussions. The time interval between the first and second concussions was also greater than previously cited. This difference may be the result of the methodology of direct independent physician observation, diagnosis, and adherence to the Zurich return-to-play protocol. (DOI: 10.3171/2010.9.FOCUS10210)	[Echlin, Paul Sean] AIM Hlth Grp Family Med, London, ON, Canada; [Tator, Charles H.; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Taunton, Jack E.] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [Taunton, Jack E.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Family, Toronto, ON M5S 1A1, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Community Med, Toronto, ON M5S 1A1, Canada; [Czarnota, Michael] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hall, Craig R.] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Dept Physiotherapy, London, ON, Canada; [Driediger, Molly] Univ Western Ontario, Dept Kinesiol, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA		Echlin, PS (corresponding author), 320 Adelaide St, S London, ON N5Z 3L2, Canada.	p_echlinfp@hotmail.com	Cusimano, Michael/X-4059-2019; Johnson, Andrew M/B-2048-2012	Skopelja, Elaine/0000-0002-2847-8909; Johnson, Andrew M./0000-0002-7269-3016; Upshur, Ross/0000-0003-1128-0557; Cusimano, Michael/0000-0002-9989-0650	Ontario Trillium Foundation; Dr. Tom Pashby Safety Fund; Dave Irwin Foundation for Brain Injury; Canadian Institutes of Health Strategic Teams in Applied Injury ResearchCanadian Institutes of Health Research (CIHR)	This work was funded by the Ontario Trillium Foundation, the Dr. Tom Pashby Safety Fund, and the Dave Irwin Foundation for Brain Injury. The Ontario Neurotrauma Foundation is acknowledged for its administrative and facilitative contributions. Dr. Cusimano is funded by the Canadian Institutes of Health Strategic Teams in Applied Injury Research.	Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; SCHWARZ A, 2010, NY TIMES        0628; SCHWARZ A, 2010, NY TIMES        1217; Shuttleworth-Edwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P479, DOI 10.1016/j.acn.2008.07.002; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	29	39	39	0	27	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E5	10.3171/2010.9.FOCUS10210			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900006	21039139				2022-02-06	
J	Harris, NG; Mironova, YA; Hovda, DA; Sutton, RL				Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.			Chondroitinase ABC Enhances Pericontusion Axonal Sprouting But Does Not Confer Robust Improvements in Behavioral Recovery	JOURNAL OF NEUROTRAUMA			English	Article						chondroitin sulfate proteoglycans; cortex; growth-associated protein 43; immunohistochemistry; plasticity; recovery of function; sprouting; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SULFATE PROTEOGLYCANS; FUNCTIONAL RECOVERY; CORPUS-CALLOSUM; RAT-BRAIN; REGENERATION; EXPRESSION; SCAR; DEGRADATION; PLASTICITY	Traumatic brain injury (TBI) results in enduring functional deficits. Strategies aimed at promoting plasticity within the injured brain may aid in enhancing functional outcome. We have previously shown that spontaneous pericontusional axon sprouting occurs within 7-14 days after controlled cortical impact injury in the adult rat, but ultimately fails due to an increasingly growth-inhibitory environment. We therefore sought to determine whether acute infusion of chondroitinase ABC into the site of the cortical contusion, to further reduce pericontusional growth-inhibitory chondroitin sulfate proteoglycans (CSPGs), would enhance and prolong the sprouting response. We also wanted to determine if chondroitinase-enhanced sprouting would ameliorate the behavioral deficits in forelimb function that occur in this model. Acute chondroitinase infusion decreased intact CSPGs and significantly increased pericontusional cortical grey and white matter growth-associated protein 43 (GAP43)-positive axon sprouting at 7 days post-injury. A return of intact CSPGs at later time points likely contributed to the absence of persistently increased levels of axon sprouting by 14-21 days post-injury. There was no overall benefit on forelimb function during the time of maximal sprouting or at any subsequent times in three of four behavioral outcome measures. However, there was a chondroitinase-induced improvement in recovery from unskilled limb use deficits on the staircase forelimb reaching test toward sham-injured values at 28 days, which was not achieved by the vehicle-treated rats, indicating that there is some minor functional benefit of the increased sprouting induced by chondroitinase treatment. The current results, together with data from spinal cord injury models after chondroitinase intervention, suggest that a combinatorial approach with the addition of neurotrophins and rehabilitation would result in more robust axon sprouting and consequently improve behavioral outcome.	[Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu		Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055910]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	We wish to thank Ms. Jessica Harnisch and Mr. Shant Damian for technical assistance, and Dr. David McArthur for help with statistics. This work was supported by the UCLA Brain Injury Research Center, and Award Number R01 NS055910 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not represent the official views of the NINDS or the National Institutes of Health.	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Carulli D, 2010, BRAIN, V133, P2331, DOI 10.1093/brain/awq145; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Corvetti L, 2005, J NEUROSCI, V25, P7150, DOI 10.1523/JNEUROSCI.0683-05.2005; Emery DL, 2000, J COMP NEUROL, V424, P521; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris N.G., 2003, J CEREB METAB BLOOD, V21, P1318; Harris N, 2009, J NEUROTRAUM, V26, pA37; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; HORNIK K, 2008, R PROJECT STAT COMPU; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Ikegami T, 2005, EUR J NEUROSCI, V22, P3036, DOI 10.1111/j.1460-9568.2005.04492.x; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; Matsui F, 2005, J NEUROSCI RES, V81, P837, DOI 10.1002/jnr.20603; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Rasband W. S, 2008, IMAGEJ; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tom VJ, 2009, J NEUROTRAUM, V26, P2323, DOI 10.1089/neu.2009.1047; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3	38	39	41	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1971	1982		10.1089/neu.2010.1470			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500005	20809786	Green Published			2022-02-06	
J	Mirzatoni, A; Spence, RD; Naranjo, KC; Saldanha, CJ; Schlinger, BA				Mirzatoni, Anahid; Spence, Rory D.; Naranjo, Kevin C.; Saldanha, Colin J.; Schlinger, Barney A.			Injury-Induced Regulation of Steroidogenic Gene Expression in the Cerebellum	JOURNAL OF NEUROTRAUMA			English	Article						estradiol; neuroprotection; neurosteroids; songbirds	FINCH TAENIOPYGIA-GUTTATA; TRAUMATIC BRAIN-INJURY; FEMALE ZEBRA FINCHES; MESSENGER-RNA; RAT-BRAIN; AROMATASE EXPRESSION; BENZODIAZEPINE-RECEPTORS; SONGBIRD BRAIN; ESTROGEN; PROTEIN	Sex steroids assist adult neural tissue in the protection from and repair of damage resulting from neural injury; some steroids may be synthesized in the brain. Songbirds are especially useful models to explore steroidal neuroprotection and repair. First, the full suite of cholesterol transporters and steroidogenic enzymes are expressed in the zebra finch (ZF) brain. Second, estrogens promote recovery of behavioral function after damage to the adult ZF cerebellum. Third, the estrogen synthetic enzyme aromatase is rapidly upregulated in reactive glia following neural injury, including in the ZF cerebellum. We hypothesized that cerebellar injury would locally upregulate steroidogenic factors upstream of aromatase, providing the requisite substrate for neuroestrogen synthesis. We tested this hypothesis by lesioning the cerebellum of adult songbirds using both males and females that peripherally synthesize steroids in different amounts. We then used quantitative PCR to examine expression of mRNAs for the neurosteroidogenic factors TSPO, StAR, SCC, 3 beta-HSD, CYP17, and aromatase, at 2 and 8 days post-lesion. Compared to sham lesions, cerebellar lesions significantly upregulated mRNA levels of TSPO and aromatase. Sex differences in response to the lesions were detected for TSPO, StAR, and aromatase. All birds responded to experimental conditions by showing time-dependent changes in the expression of TSPO, SCC, and aromatase, suggesting that acute trauma or stress may impact neurosteroidogensis for many days. These data suggest that the cerebellum is an active site of steroid synthesis in the brain, and each steroidogenic factor likely provides neuroprotection and promotes repair.	[Mirzatoni, Anahid; Schlinger, Barney A.] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Mirzatoni, Anahid; Schlinger, Barney A.] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Spence, Rory D.] Univ Calif Los Angeles, Neuroendocrinol Lab, Brain Res Inst, Los Angeles, CA 90095 USA; [Spence, Rory D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; [Naranjo, Kevin C.; Saldanha, Colin J.] Lehigh Univ, Dept Biol Sci, Bethlehem, PA USA		Schlinger, BA (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles Young Dr S,POB 951606, Los Angeles, CA 90095 USA.	schlinge@lifesci.ucla.edu		Saldanha, Colin/0000-0003-4034-6877	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [NIMH-061944, NS-042767]; LNE [HD07228-26]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042767] Funding Source: NIH RePORTER	We thank Dr. Amnon Katz, Dr. Xuqi Chen, and Bradley Walters for their technical assistance. We thank Dr. Stephanie White for providing the surgery room. Funding was provided by National Institute of Mental Health grant NIMH-061944, NS-042767 and LNE Training Grant HD07228-26.	ADKINSREGAN E, 1990, GEN COMP ENDOCR, V78, P93, DOI 10.1016/0016-6480(90)90051-M; Arnold AP, 2004, TRENDS ENDOCRIN MET, V15, P6, DOI 10.1016/j.tem.2003.11.001; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; BALTHAZART J, 1990, J COMP NEUROL, V301, P276, DOI 10.1002/cne.903010210; Baulieu EE, 1997, MULT SCLER J, V3, P105, DOI 10.1177/135245859700300209; Chen XQ, 2005, P NATL ACAD SCI USA, V102, P7730, DOI 10.1073/pnas.0408350102; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; CORPECHOT C, 1983, BRAIN RES, V270, P119, DOI 10.1016/0006-8993(83)90797-7; Culty M, 2002, J ANDROL, V23, P439; Fester L, 2009, HIPPOCAMPUS, V19, P692, DOI 10.1002/hipo.20548; Garcia-Ovejero D, 2005, BRAIN RES REV, V48, P273, DOI 10.1016/j.brainresrev.2004.12.018; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Garcia-Segura LM, 2003, PROG NEUROBIOL, V71, P31, DOI 10.1016/j.pneurobio.2003.09.005; GARCIASEGURA LM, 2009, ADV FRONT NEUROENDOC, V30, P5; Hashimoto N, 2003, NEUROSCI LETT, V340, P45, DOI 10.1016/S0304-3940(03)00079-X; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Klein D, 1999, ELECTROPHORESIS, V20, P291, DOI 10.1002/(SICI)1522-2683(19990201)20:2<291::AID-ELPS291>3.0.CO;2-R; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; London S. E., 2003, Hormones and Behavior, V44, P62; London SE, 2007, J COMP NEUROL, V502, P507, DOI 10.1002/cne.21335; London SE, 2006, ENDOCRINOLOGY, V147, P5975, DOI 10.1210/en.2006-0154; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Pradhan DS, 2010, HORM BEHAV, V57, P381, DOI 10.1016/j.yhbeh.2010.01.008; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Remage-Healey L, 2008, NAT NEUROSCI, V11, P1327, DOI 10.1038/nn.2200; RYAN DW, 2008, GLIA, V56, P97; Saldanha CJ, 2005, GEN COMP ENDOCR, V141, P66, DOI 10.1016/j.ygcen.2004.11.013; Saldanha CJ, 2004, J COMP NEUROL, V469, P522, DOI 10.1002/cne.11035; Saldanha CJ, 2005, J NEUROBIOL, V64, P192, DOI 10.1002/neu.20147; Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016; Schlinger BA, 1997, BRAIN RES BULL, V44, P359, DOI 10.1016/S0361-9230(97)00215-3; SCHLINGER BA, 1993, ENDOCRINOLOGY, V133, P2610, DOI 10.1210/en.133.6.2610; SHEN P, 1994, MOL BRAIN RES, V24, P227, DOI 10.1016/0169-328X(94)90136-8; Sierra A, 2003, EUR J NEUROSCI, V18, P1458, DOI 10.1046/j.1460-9568.2003.02872.x; Soma KK, 2005, ENDOCRINOLOGY, V146, P4386, DOI 10.1210/en.2005-0569; Spence RD, 2009, EUR J NEUROSCI, V29, P1225, DOI 10.1111/j.1460-9568.2009.06685.x; Stocco DM, 1996, BIOCHEM PHARMACOL, V51, P197, DOI 10.1016/0006-2952(95)02093-4; Tsutsui K., 2001, P59; Tsutsui K, 2008, ENDOCRINOLOGY, V149, P2757, DOI 10.1210/en.2007-1592; VOCKEL A, 1990, J NEUROBIOL, V21, P808, DOI 10.1002/neu.480210514; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2	50	39	39	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1875	1882		10.1089/neu.2010.1330			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600011	20925573	Green Published			2022-02-06	
J	Schnuriger, B; Inaba, K; Branco, BC; Salim, A; Russell, K; Lam, L; Plurad, D; Demetriades, D				Schnuriger, Beat; Inaba, Kenji; Branco, Bernardino C.; Salim, Ali; Russell, Katie; Lam, Lydia; Plurad, David; Demetriades, Demetrios			Organ Donation: An Important Outcome after Resuscitative Thoracotomy	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							EMERGENCY-ROOM THORACOTOMY; CARDIAC-ARREST; TRAUMA; CHEST	BACKGROUND: The persistent shortage of transplantable organs remains a critical issue around the world. The purpose of this study was to investigate outcomes, including organ procurement, in trauma patients undergoing resuscitative emergency department thoracotomy (EDT). Our hypothesis was that potential organ donor rescue is one of the important outcomes after traumatic arrest and EDT. STUDY DESIGN: Retrospective study at Los Angeles County and University of Southern California Medical Center. Patients undergoing resuscitative EDT from January 1, 2006 through June 30, 2009 were analyzed. Primary outcomes measures included survival. Secondary outcomes included organ donation and the brain-dead potential organ donor. RESULTS: During the 42-month study period, a total of 263 patients underwent EDT. Return of a pulse was achieved in 85 patients (32.3%). Of those patients, 37 (43.5%) subsequently died in the operating room and 48 (56.5%) survived to the surgical intensive care unit. Overall, 5 patients (1.9%) survived to discharge and 11 patients (4.2%) became potential organ donors. Five of the 11 potential organ donors had sustained a blunt mechanism injury. Of the 11 potential organ donors, 8 did not donate: 4 families declined consent, 3 because of poor organ function, and 1 expired due to cardiopulmonary collapse. Eventually 11 organs (6 kidneys, 2 livers, 2 pancreases, and 1 small bowel) were harvested from 3 donors. Two of the 3 donors had sustained blunt injury and 1 penetrating mechanism of injury. CONCLUSIONS: Procurement of organs is one of the tangible outcomes after EDT. These organs have the potential to alter the survival and quality of life of more recipients than the number of survivors of the procedure itself. (J Am Coll Surg 2010;211:450-455. (C) 2010 by the American College of Surgeons)	[Schnuriger, Beat; Inaba, Kenji; Branco, Bernardino C.; Lam, Lydia; Plurad, David; Demetriades, Demetrios] Univ So Calif, LAC USC Med Ctr, Div Trauma Surg & Crit Care, Los Angeles, CA 90033 USA; [Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Russell, Katie] Univ Utah, Dept Surg, Salt Lake City, UT USA		Inaba, K (corresponding author), Univ So Calif, LAC USC Med Ctr, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St,Inpatient Tower C,5th Floor,Room, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu	INABA, KENJI/AAC-8532-2020				Asensio JA, 2001, J AM COLL SURGEONS, V193, P303; BRIGGS BD, 1956, JAMA-J AM MED ASSOC, V160, P1439, DOI 10.1001/jama.1956.02960520001001; DELGUERCIO LR, 1965, CIRCULATION, V31, P171; DEMETRIADES D, 1987, J TRAUMA, V27, P483, DOI 10.1097/00005373-198705000-00004; Fialka C, 2004, J TRAUMA, V57, P809, DOI 10.1097/01.TA.0000124266.39529.6E; IVATURY RR, 1991, J TRAUMA, V31, P1076, DOI 10.1097/00005373-199131080-00005; Martin SK, 2002, J TRAUMA, V53, P876, DOI 10.1097/00005373-200211000-00011; Powell DW, 2004, J AM COLL SURGEONS, V199, P211, DOI 10.1016/j.jamcollsurg.2004.04.004; Rhee PM, 2000, J AM COLL SURGEONS, V190, P288, DOI 10.1016/S1072-7515(99)00233-1; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; Sheppard FR, 2006, SURGERY, V139, P574, DOI 10.1016/j.surg.2005.12.005; TURK LN, 1954, NEW ENGL J MED, V251, P795, DOI 10.1056/NEJM195411112512001; Tuttle-Newhall JE, 2009, AM J TRANSPLANT, V9, P879, DOI 10.1111/j.1600-6143.2009.02565.x	13	39	39	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2010	211	4					450	455		10.1016/j.jamcollsurg.2010.06.012			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	663ZO	WOS:000282928900002	20729100				2022-02-06	
J	Steel, J; Youssef, M; Pfeifer, R; Ramirez, JM; Probst, C; Sellei, R; Zelle, BA; Sittaro, NA; Khalifa, F; Pape, HC				Steel, Jennifer; Youssef, Michael; Pfeifer, Roman; Ramirez, Juliana M.; Probst, Christian; Sellei, Richard; Zelle, Boris A.; Sittaro, Nicola-Alexander; Khalifa, Farah; Pape, Hans Christoph			Health-Related Quality of Life in Patients With Multiple Injuries and Traumatic Brain Injury 10+Years Postinjury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma			1ST 5 YEARS; FOLLOW-UP; HEAD-INJURY; SATISFACTION; DYSFUNCTION; DISABILITY; DEPRESSION; OUTCOMES; CANCER; MODEL	Background: The aim of this study was to examine the long-term physical and psychological consequences of multiple blunt forced trauma at >= 10-year follow-up for patients with and without traumatic brain injury (TBI). Methods: A total of 620 patients with multiple injuries were assessed with the Medical Outcomes Study-Short Form-12 and a physical reexamination at >= 10-year follow-up. Injury-related characteristics were collected from patients' medical record. Chi-square analysis, Analysis of Variance, and linear and logistic regression were performed to test differences between groups and examine predictors of physical and psychological functioning at >= 10-year follow-up. Results: Patients with multiple injuries who sustained a TBI (n = 398) were more likely to be female (p = 0.001), younger in age at the time of injury (p = 0.02), have higher Injury Severity Scores (p = 0.001), shorter ward stays (p = 0.001), and a greater number of upper extremity injuries (p = 0.02) when compared with those without TBI (n = 222). Patients with TBI reported poorer psychological functioning (p = 0.02) and more frequently reported chronic pain (p = 0.01). Patients with TBI used medical aids (p = 0.002) less frequently at follow-up when compared with patients without TBI. Significant predictors of health-related quality of life at >= 10-year follow-up included age at the time of injury (physical; p = 0.001), gender (p = 0.05), number of ventilation days (p = 0.02), satisfaction with rehabilitation (p = 0.001), disability caused by the injury (p = 0.001), and use of medical aids (physical p = 0.02). Conclusions: Prospective studies are needed with a broader range of measures that may be sensitive to the consequences of TBI. Evidence-based interventions to facilitate physical and psychological rehabilitation, designed to target at risk patients, are warranted.	[Steel, Jennifer; Youssef, Michael; Ramirez, Juliana M.; Khalifa, Farah] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Steel, Jennifer] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; [Zelle, Boris A.] Univ Pittsburgh, Sch Med, Dept Orthoped, Pittsburgh, PA 15260 USA; [Pfeifer, Roman; Pape, Hans Christoph] Univ Aachen, Dept Orthopaed & Trauma, Aachen, Germany; [Probst, Christian] Leibniz Univ Hannover, Dept Orthoped & Trauma, D-30167 Hannover, Germany; [Sittaro, Nicola-Alexander] Hannover Re Insurance, Hannover, Germany		Pape, HC (corresponding author), Univ Aachen, Dept Orthopaed & Trauma, Aachen, Germany.		/ABE-7042-2020	Pape, Hans-Christoph/0000-0002-2059-4980	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5R21CA127046-01A1, 5K07CA118576-01] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA127046, K07CA118576] Funding Source: NIH RePORTER		Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; BOUILLON B, 1989, LANGENBECKS ARCH C S, V2, P117; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P541, DOI 10.1097/00001199-200311000-00008; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Gabbe BJ, 2006, J TRAUMA, V61, P1393, DOI 10.1097/01.ta.0000225926.34180.47; Gulseren S, 2006, ARCH MED RES, V37, P133, DOI 10.1016/j.arcmed.2005.05.008; HALCOMB E, AUST CRIT CARE, V18, P17; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Lehmann U, 1999, EUR J SURG, V165, P1116, DOI 10.1080/110241599750007603; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; Martelli MF, 2008, NEUROREHABILITATION, V23, P115; Mckenzie J, 2000, BRIT MED J, V321, P632; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Narushima K, 2003, J NEUROPSYCH CLIN N, V15, P422, DOI 10.1176/appi.neuropsych.15.4.422; Neuenschwander AU, 2002, EUR J CARDIO-THORAC, V22, P287, DOI 10.1016/S1010-7940(02)00263-4; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Probst C, 2009, J TRAUMA, V66, P1212, DOI 10.1097/TA.0b013e318197b97c; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Thurston RJ, 1999, BRAIN INJURY MEMORY; Tsagarakis S, 2005, Pituitary, V8, P251, DOI 10.1007/s11102-006-6049-x	30	39	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					523	530		10.1097/TA.0b013e3181e90c24			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	649HX	WOS:000281760800007	20838121				2022-02-06	
J	Marshall, GT; James, RF; Landman, MP; O'Neill, PJ; Cotton, BA; Hansen, EN; Morris, JA; May, AK				Marshall, Gary T.; James, Robert F.; Landman, Matthew P.; O'Neill, Patrick J.; Cotton, Bryan A.; Hansen, Erik N.; Morris, John A., Jr.; May, Addison K.			Pentobarbital Coma For Refractory Intra-Cranial Hypertension After Severe Traumatic Brain Injury: Mortality Predictions and One-Year Outcomes in 55 Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	36th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 18-21, 2007	Orlando, FL	Soc Critical Care Med		Traumatic brain injury; Trauma; Intracranial hypertension; Pentobarbital coma; Hyperosmolar therapy; Barbiturate coma	HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; BARBITURATE THERAPY; MANAGEMENT; PRESSURE	Objective: To identify predictors of mortality and long-term outcomes in survivors after pentobarbital coma (PBC) in patients failing current treatment standards for severe traumatic brain injuries (TBI). This is a retrospective cohort study of severe TBI patients receiving PBC at Level I Trauma Center and tertiary university hospital. Methods: Four thousand nine hundred thirty-four patients were admitted to the trauma intensive care unit with severe TBI (head Abbreviated Injury Scale >= 3) between April 1998 and December 2004. Six hundred eleven received intracranial pressure (ICP) monitoring and 58 received PBC. Three patients underwent craniotomy for intracranial mass lesion and were excluded. The study group received standardized medical management for severe TBI including opiates, benzodiazepines, elevation of the head of bed, avoidance of hypotension and hypercapnia and hyperosmolar therapy (HOsmRx). In addition, 31 of 55 patients (56%) underwent placement of intraventricular catheters for cerebrospinal fluid drainage. If routine medical management and cerebrospinal fluid diversion failed to control ICP, then the patient was determined to have refractory intracranial hypertension (RICH) and PBC treatment was initiated. PBC was performed with pentobarbital infusion with continuous electroencephalogram monitoring to ensure adequate burst suppression. The measurements include serum sodium (Na+) and osmolality (Osm) were assessed as indicators for initiation of PBC and to estimate the 50% mortality cut-points when controlling for ICP. Follow-up functional outcomes were assessed using the Glasgow Outcome Scale and stratified according to admission Glasgow Coma Scale score and Marshall computed tomography classification. Of the 55 PBC patients, 22 (40%) survived at discharge. 19 of 22 had long-term follow-up (1 year or more) available. Of these, 13 (68%) were normal or functionally independent (Glasgow Outcome Scale score 4 or 5). Serum Na+ and Osm were associated with death (p < 0.05) when controlling for ICP. The 50% mortality cut-points were Na+ of 160 mEq/L and Osm of 330 mOsm/kg H2O. Median minimum cerebral perfusion pressure after PBC was 42 mm Hg in survivors and 34 mm Hg in nonsurvivors (p = 0.013). Conclusions: In patients with severe TBI and RICH, survival at discharge of 40% with good functional outcomes in 68% of survivors at 1 year or more can be achieved with PBC after failure of HOsmRx. Based on 50% mortality cut-points, analysis suggests the limits of HOsmRx to be Na+ of 160 mEq/L and Osm of 330 mOsm/Kg H2O. Maintenance of higher cerebral perfusion pressure after PBC is associated with survival. PBC treatment of RIH may be even more important when other treatments of RIH, such as decompressive craniectomy, are not available.	[Marshall, Gary T.] Univ Pittsburgh, Med Ctr, Dept Surg, Div Trauma & Gen Surg, Pittsburgh, PA 15213 USA; [James, Robert F.] E Carolina Univ, Div Neurosurg, Brody Sch Med, Dept Surg, Greenville, NC USA; [Landman, Matthew P.; Hansen, Erik N.; Morris, John A., Jr.; May, Addison K.] Vanderbilt Univ, Med Ctr, Dept Surg, Div Trauma & Surg Crit Care,Sect Surg Sci, Nashville, TN USA; [O'Neill, Patrick J.] Maricopa Cty Gen Hosp, Dept Surg, Div Burns Trauma & Surg Crit Care, Phoenix, AZ USA; [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX USA; [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX USA		Marshall, GT (corresponding author), Univ Pittsburgh, Med Ctr, Dept Surg, Div Trauma & Gen Surg, 200 Lothrop St,PUH F1266, Pittsburgh, PA 15213 USA.	marshallgt@upmc.edu		Marshall, Gary/0000-0003-1398-5366			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; [Anonymous], 2000, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD000033; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; COTTON BA, PRACTICE MANAGEMENT; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; LEE MW, 1994, J NEUROTRAUM, V11, P325, DOI 10.1089/neu.1994.11.325; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McKinley BA, 1998, ACT NEUR S, V71, P177; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; ROCKOFF MA, 1979, ANN NEUROL, V6, P194, DOI 10.1002/ana.410060303; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; 2005, RANDOMIZED EVALUATIO; 2004, DECRA INT MULTICENTE	29	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					275	283		10.1097/TA.0b013e3181de74c7			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	638JN	WOS:000280890800006	20699736				2022-02-06	
J	Pan, HC; Yang, DY; Ou, YC; Ho, SP; Cheng, FC; Chen, CJ				Pan, Hung-Chuan; Yang, Dar-Yu; Ou, Yen-Chuan; Ho, Shu-Peng; Cheng, Fu-Chou; Chen, Chun-Jung			Neuroprotective Effect of Atorvastatin in an Experimental Model of Nerve Crush Injury	NEUROSURGERY			English	Article						Degeneration; Neuroprotection; Regeneration; Sciatic nerve; Statin	ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL DIABETIC-NEUROPATHY; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; PERIPHERAL-NERVE; SCIATIC-NERVE; AXONAL REGENERATION; ADULT RATS; MATRIX METALLOPROTEINASES	BACKGROUND: Statins have therapeutic benefits for the management of several disorders. A short-term course of a high-dose statin pretreatment has demonstrated neuroprotective effects against neurological diseases. However, the molecular basis underlying the neuroprotective action of statins remains unclear. OBJECTIVE: We investigated whether a short-term course of high-dose atorvastatin pretreatment has beneficial effects in protecting sciatic nerve from crush injury. METHODS: Atorvastatin (5 mg/kg) or saline was given orally to Sprague-Dawley rats for 7 days before injury. The rats were subjected to crush injury in the left sciatic nerve with a vessel clamp. Biochemical, functional, electrophysiological, and morphological alterations occurring during injury-induced degeneration/regeneration were examined. RESULTS: Atorvastatin improved injury-induced neurobehavioral/electrophysiological changes and axonal loss. Damage-associated alterations, including structural disruption, oxidative stress, inflammation, and apoptosis, were attenuated by atorvastatin. After injury, regeneration-associated genes, including growth-associated protein-43, myelin basic protein, ciliary neurotrophic factor, and collagen, were upregulated by atorvastatin. The suppression of extracellular signal-regulated kinase, AKT, signal transducer and activators of transcription-1, and necrosis factor-kappa B and the elevated activation of c-Jun N-terminal kinase, Smad2/3, and activating protein-1 were associated with the neuroprotective action of atorvastatin. CONCLUSION: These findings suggest that a short-term course of high-dose atorvastatin pretreatment can protect against sciatic nerve crush injury through modifying intracellular or extracellular environments, making it favorable for regeneration.	[Cheng, Fu-Chou; Chen, Chun-Jung] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung 407, Taiwan; [Pan, Hung-Chuan] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung 407, Taiwan; [Pan, Hung-Chuan] Chung Hwa Univ Med Technol, Tainan, Taiwan; [Pan, Hung-Chuan; Cheng, Fu-Chou; Chen, Chun-Jung] Natl Chung Hsing Univ, Inst Med Technol, Taichung 40227, Taiwan; [Pan, Hung-Chuan; Ho, Shu-Peng] Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan; [Yang, Dar-Yu] Chang Bing Chwan Mem Hosp, Dept Neurosurg, Changhua, Taiwan; [Ou, Yen-Chuan] Taichung Vet Gen Hosp, Div Urol, Taichung 407, Taiwan		Chen, CJ (corresponding author), Taichung Vet Gen Hosp, Dept Educ & Res, 160 Sect 3,Taichung Kang Rd, Taichung 407, Taiwan.	cjchen@vghtc.gov.tw		Ho, Shu-Peng/0000-0003-4607-3216	Taichung Veterans General Hospital [TCVGH-HK96800]; Hungkuang University, Taichung, Taiwan	This study was supported by grant (TCVGH-HK96800) from Taichung Veterans General Hospital and Hungkuang University, Taichung, Taiwan. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Al-Majed AA, 2000, J NEUROSCI, V20, P2602; AMINOFF MJ, 1999, ELECTRODIAGNOSIS CLI, P257; ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Boyd JG, 2003, MOL NEUROBIOL, V27, P277, DOI 10.1385/MN:27:3:277; Casals-Diaz L, 2009, EXP NEUROL, V217, P84, DOI 10.1016/j.expneurol.2009.01.014; Chen CJ, 2007, EXP NEUROL, V204, P443, DOI 10.1016/j.expneurol.2006.12.004; Chen CJ, 2006, NEUROCHEM INT, V49, P62, DOI 10.1016/j.neuint.2005.12.020; Chen CJ, 2004, J VIROL, V78, P12107, DOI 10.1128/JVI.78.22.12107-12119.2004; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen YS, 2000, BIOMATERIALS, V21, P1541, DOI 10.1016/S0142-9612(00)00028-4; Chen ZY, 2001, BRAIN RES, V902, P272, DOI 10.1016/S0006-8993(01)02395-2; Cohen-Boulakia FE, 2007, DIABETES METAB, V33, P189, DOI 10.1016/j.diabet.2006.11.012; Dinh P, 2009, MICROSURG, V29, P644, DOI 10.1002/micr.20685; Dold S, 2009, BRIT J PHARMACOL, V156, P466, DOI 10.1111/j.1476-5381.2008.00043.x; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Eto M, 2008, J PERIPHER NERV SYST, V13, P242, DOI 10.1111/j.1529-8027.2008.00183.x; Gegg ME, 2005, J IMMUNOL, V174, P2327, DOI 10.4049/jimmunol.174.4.2327; Gholami MR, 2008, EUR J PHARMACOL, V590, P111, DOI 10.1016/j.ejphar.2008.05.050; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hemandez-Romero MD, 2008, J NEUROCHEM, V105, P445, DOI 10.1111/j.1471-4159.2007.05148.x; Hwang SY, 2004, BIOCHEM BIOPH RES CO, V318, P691, DOI 10.1016/j.bbrc.2004.04.082; Ii M, 2005, CIRCULATION, V112, P93, DOI 10.1161/CIRCULATIONAHA.104.511964; Kieseier BC, 1999, NEUROLOGY, V53, P20, DOI 10.1212/WNL.53.1.20; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Kirsch C, 2003, PHARMACOPSYCHIATRY, V36, pS113; Labrador RO, 1998, EXP NEUROL, V149, P243, DOI 10.1006/exnr.1997.6650; LaFleur M, 1996, J EXP MED, V184, P2311; Lee AC, 2003, EXP NEUROL, V184, P295, DOI 10.1016/S0014-4886(03)00258-9; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; Liu QH, 2008, PERITON DIALYSIS INT, V28, pS88; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Marcol W, 2003, J NEUROSCI RES, V72, P417, DOI 10.1002/jnr.10560; Moro T, 2008, LIFE SCI, V83, P531, DOI 10.1016/j.lfs.2008.07.023; Nagao H, 1996, BRAIN RES, V719, P23, DOI 10.1016/0006-8993(96)00055-8; Omura K, 2004, BRAIN RES, V1001, P13, DOI 10.1016/j.brainres.2003.10.067; Pan HC, 2007, J CLIN NEUROSCI, V14, P1089, DOI 10.1016/j.jocn.2006.08.008; Pan HC, 2006, J CLIN NEUROSCI, V13, P570, DOI 10.1016/j.jocn.2005.06.007; Pan HC, 2009, NEUROCHEM RES, V34, P518, DOI 10.1007/s11064-008-9815-5; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pedraza L, 1997, NEURON, V18, P579, DOI 10.1016/S0896-6273(00)80299-8; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Rader DJ, 2003, CLIN CARDIOL, V26, P2, DOI 10.1002/clc.4960260103; Rezaie-Majd A, 2002, ARTERIOSCL THROM VAS, V22, P1194, DOI 10.1161/01.ATV.0000022694.16328.CC; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; ROSEN JM, 1989, ANN PLAS SURG, V22, P467, DOI 10.1097/00000637-198906000-00002; Sarkey JP, 2007, J NEUROCHEM, V100, P1265, DOI 10.1111/j.1471-4159.2006.04309.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shubayev VI, 2006, MOL CELL NEUROSCI, V31, P407, DOI 10.1016/j.mcn.2005.10.011; Shubayev VI, 2002, J PERIPHER NERV SYST, V7, P28, DOI 10.1046/j.1529-8027.2002.02003.x; Siebert H, 2001, J NEUROPATH EXP NEUR, V60, P85, DOI 10.1093/jnen/60.1.85; Stein EA, 2002, AM HEART J, V144, pS43, DOI 10.1067/mhj.2002.130302; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; Valsecchi AE, 2008, J NEUROCHEM, V107, P230, DOI 10.1111/j.1471-4159.2008.05614.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang JP, 1997, BRIT J PHARMACOL, V121, P409, DOI 10.1038/sj.bjp.0701147; Wang YP, 2006, J NEUROL SCI, V247, P47, DOI 10.1016/j.jns.2006.03.011; Wang YP, 2005, ANTIOXID REDOX SIGN, V7, P1513, DOI 10.1089/ars.2005.7.1513; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; Xu QG, 2008, NEUROSCIENCE, V152, P877, DOI 10.1016/j.neuroscience.2008.01.060; Yang DY, 2007, NEUROTOXICOLOGY, V28, P1220, DOI 10.1016/j.neuro.2007.08.003; Zou T, 2006, J NEUROPATH EXP NEUR, V65, P78, DOI 10.1097/01.jnen.0000195942.25163.f5	66	39	39	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2010	67	2					376	388		10.1227/01.NEU.0000371729.47895.A0			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	628HI	WOS:000280105800034	20539249	Bronze			2022-02-06	
J	Stein, DM; Menaker, J; McQuillan, K; Handley, C; Aarabi, B; Scalea, TM				Stein, Deborah M.; Menaker, Jay; McQuillan, Karen; Handley, Christopher; Aarabi, Bizhan; Scalea, Thomas M.			Risk Factors for Organ Dysfunction and Failure in Patients with Acute Traumatic Cervical Spinal Cord Injury	NEUROCRITICAL CARE			English	Article						Organ failure; Organ dysfunction; Spinal cord injury	SOFA SCORE; RESPIRATORY COMPLICATIONS; MECHANICAL VENTILATION; MORTALITY; BRAIN; MANAGEMENT; PREDICTORS; SYSTEM; NEED	Traumatic injuries to the cervical spine cause significant disability. Much of the morbidity and mortality that occurs in patients afflicted with cervical spinal cord injury (SCI) occurs early after injury due to primary neurologic dysfunction, systemic inflammation, concomitant injuries, treatments to prevent and ameliorate secondary insults, and prolonged immobilization. This study was undertaken to determine the incidence of organ dysfunction and failure using validated measures: the Multiple Organ Dysfunction Score (MODS) and the Sequential Organ Failure Assessment (SOFA). We also sought to determine if certain patient or injury characteristics were associated with the development of organ dysfunction and failure. All patients who sustained isolated blunt cervical SCIs admitted to the R Adams Cowley Shock Trauma Center over a 15-month period were identified. American Spinal Injury Association (ASIA) motor scores, ASIA impairment scale (AIS) scores, and level of injury were recorded. Admission, first daily, worst daily, and aggregate MOD and SOFA scores were assigned for each of six organ systems. A P < 0.05 was considered significant for all statistical tests. Of 1,028 patients admitted with blunt spine injuries between January, 2007 and March, 2008, 40 patients were identified with an isolated cervical SCI that required an ICU length of stay (LOS) > 24 h. Organ failure of at least one organ system occurred in 75% of patients as calculated by MOD score and 85% of patients calculated using SOFA criteria. Multiple organ failure was found in 55% by MOD and 62.5% by SOFA scores. The most frequent system to fail was the cardiovascular system by aggregate MODS (84%), while the respiratory system was the most frequently failed system by aggregate SOFA criteria (70%). There was a strong inverse correlation between ASIA motor score and aggregate MODS and SOFA scores (r = -0.56, P = 0.0002 and r = -0.51, P = 0.0009). AIS was also found to be inversely correlated with the development of organ failure (r = -0.47, P = 0.002 and r = -0.45, P = 0.004) while anatomic level of injury was found to correlate poorly with the incidence of organ failure (r = -0.11, P = 0.5 and r = -0.10, P = 0.5). Only ASIA motor score was significantly associated with sum aggregate organ dysfunction scores when controlling for age and injury severity score (parameter estimate = -0.082, P = 0.0005 for MODS and parameter estimate = -0.057, P = 0.006 for SOFA). This study is the first to describe the incidence of organ dysfunction and failure in patients with isolated acute traumatic cervical SCI using validated organ system dysfunction scores. Respiratory, cardiovascular, neurologic, renal, hepatic, and hematologic dysfunction occurred commonly both on admission and over the ICU stay. Respiratory, cardiovascular, and neurologic failure were frequently found, while renal, hepatic, and hematologic failures were uncommon. Multiple organ failure occurred in the majority of patients. ASIA motor score and AIS were found to strongly correlate with the development of organ dysfunction and failure. Level of injury should be used with caution when describing the risk of complications and the need for medical interventions.	[Stein, Deborah M.] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Program Trauma,Div Crit Care,Sch Med, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Program Trauma,Div Crit Care,Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu; jmenaker@umm.edu; kmcquillan@umm.edu; chandley@som.umaryland.edu; baarabi@smail.umaryland.edu; tscalea@umm.edu		Stein, Deborah/0000-0003-3683-3963			American Spinal Injury Association International Medical Society of Paraplegia, 2002, INT STAND NEUR FUNCT; Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Apuzzo MLJ, 2002, NEUROSURGERY, V51, P1; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL 2005; Berlly M, 2007, J SPINAL CORD MED, V30, P309, DOI 10.1080/10790268.2007.11753946; Bilello JF, 2003, ARCH SURG-CHICAGO, V138, P1127, DOI 10.1001/archsurg.138.10.1127; Bota DP, 2002, INTENS CARE MED, V28, P1619, DOI 10.1007/s00134-002-1491-3; Brown R, 2006, RESP CARE, V51, P853; Chesnut RM, 2004, CRIT CARE CLIN, V20, P25, DOI 10.1016/S0749-0704(03)00090-3; Claxton AR, 1998, CAN J ANAESTH, V45, P144, DOI 10.1007/BF03013253; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Cook R, 2001, CRIT CARE MED, V29, P2046, DOI 10.1097/00003246-200111000-00002; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024; FISHBURN MJ, 1990, ARCH PHYS MED REHAB, V71, P197; FLETCHER DJ, 1995, SPINE, V20, P1136, DOI 10.1097/00007632-199505150-00005; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; Furlan JC, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E13; Garcia-Lopez P, 2007, SPINAL CORD, V45, P603, DOI 10.1038/sj.sc.3102001; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Grotz M, 2001, CHIRURG, V72, P723, DOI 10.1007/s001040170130; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Guly HR, 2008, RESUSCITATION, V76, P57, DOI 10.1016/j.resuscitation.2007.06.008; Hadley M, 2002, NEUROSURGERY, V50, pS58; Hassid VJ, 2008, J TRAUMA, V65, P1328, DOI 10.1097/TA.0b013e31818d07e4; Heuer M, 2009, J GASTROINTEST LIVER, V18, P197; JACKSON AB, 1994, ARCH PHYS MED REHAB, V75, P270, DOI 10.1016/0003-9993(94)90027-2; Kattail D, 2009, J TRAUMA, V67, P936, DOI 10.1097/TA.0b013e3181a8b431; Kemp CD, 2008, AM SURGEON, V74, P866; Lan MY, 2006, J FORMOS MED ASSOC, V105, P653, DOI 10.1016/S0929-6646(09)60164-9; LEMONS VR, 1994, SPINE, V19, P2315, DOI 10.1097/00007632-199410150-00011; Licina P, 2005, INJURY, V36, P2, DOI 10.1016/j.injury.2005.06.010; MacDiarmid SA, 2000, BJU INT, V85, P1014, DOI 10.1046/j.1464-410x.2000.00680.x; Maiorov DN, 1998, J NEUROTRAUM, V15, P365, DOI 10.1089/neu.1998.15.365; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marshall JC, 1997, SEPSIS, V1, P49, DOI DOI 10.1023/A:1009715402392; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; MOHLER JL, 1986, J UROLOGY, V136, P366, DOI 10.1016/S0022-5347(17)44870-1; *NAT SPIN CORD INJ, 2009, SPIN CORD INJ FACTS; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Tuli S, 2007, J SPINAL CORD MED, V30, P482, DOI 10.1080/10790268.2007.11754582; Ulvik A, 2007, CRIT CARE, V11, DOI 10.1186/cc6111; Vaidyanathan S, 2000, SPINAL CORD, V38, P197, DOI 10.1038/sj.sc.3100975; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wing PC, 2008, J SPINAL CORD MED, V31, P360, DOI 10.1080/10790268.2008.11760737; Winslow C, 2003, AM J PHYS MED REHAB, V82, P803, DOI 10.1097/01.PHM.0000078184.08835.01; Zimmer MB, 2007, J SPINAL CORD MED, V30, P319, DOI 10.1080/10790268.2007.11753947; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007; INT STANDARDS CLASSI; STANDARD NEUROLOGICA	56	39	42	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2010	13	1					29	39		10.1007/s12028-010-9359-9			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	620NF	WOS:000279505900006	20407933				2022-02-06	
J	Hakan, T; Toklu, HZ; Biber, N; Ozevren, H; Solakoglu, S; Demirturk, P; Aker, FV				Hakan, Tayfun; Toklu, Hale Z.; Biber, Necat; Ozevren, Huseyin; Solakoglu, Seyhun; Demirturk, Pelin; Aker, Fugen V.			Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability	NEUROLOGICAL RESEARCH			English	Article						Antioxidant; blood-brain barrier; brain injury; closed head trauma; edema; meloxicam	OXIDATIVE STRESS; HEAD-INJURY; RAT; CYCLOOXYGENASE-2; MODEL; INFLAMMATION; NEUROPROTECTION; METABOLISM; MODULATION; RELEASE	Objective: The overproduction of reactive oxygen species and resultant damage to cellular proteins or lipids of cell membranes and DNA by free radicals are the underlying mechanisms of many neuropathologies. Cyclooxygenase-2 (COX-2) inhibitors have been suggested to be neuroprotective by reducing prostanoid and free radical synthesis, or by directing arachidonic acid metabolism through alternate pathways. This study investigated the putative neuroprotective effect of the COX-2 inhibitor, meloxicam, in a rat model of diffuse brain injury. Methods: Sprague-Dawley rats were subjected to traumatic brain injury with a weight-drop device using 300 g 21 m weight-height impact. The groups were: control, meloxicam (2 mg/kg, i.p.), trauma and trauma z meloxicam (2 mg/kg, i.p.). Forty-eight hours after the injury, neurological examination scores were measured, the animals were decapitated and brain tissues were taken. Brain edema and blood-brain barrier (BBB) permeability were evaluated by wet-dry weight method and Evans blue (EB) extravasation respectively. In brain tissues, malonedialdehyde, glutathione, myeloperoxidase and Na/K-ATPase levels were measured. Results: The neurological examination scores mildly increased in trauma groups 48 hours after the induction of trauma. Meloxicam treatment improved the altered neurological status. The trauma caused a significant increase in brain water content that was partially reversed by meloxicam. Meloxicam also reduced the EB extravasation indicating the preservation of the BBB integrity. Meloxicam treatment also significantly reduced the increase in malondialdehyde and myeloperoxidase levels glutathione content of the brains that had been significantly increased after trauma. Conclusion: Meloxicam exerts neuroprotective effect by preserving BBB permeability and by reducing brain edema (probably by its anti-inflammatory properties) in the diffuse brain injury model.	[Hakan, Tayfun; Biber, Necat; Ozevren, Huseyin] Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, TR-34668 Istanbul, Turkey; [Toklu, Hale Z.] Marmara Univ, Sch Pharm, Dept Pharmacol, Istanbul, Turkey; [Solakoglu, Seyhun] Istanbul Univ, Istanbul Sch Med, Dept Histol & Embryol, Istanbul, Turkey; [Demirturk, Pelin; Aker, Fugen V.] Haydarpasa Numune Teaching & Res Hosp, Dept Pathol, Istanbul, Turkey		Hakan, T (corresponding author), Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, TR-34668 Istanbul, Turkey.	tayfunhakan@yahoo.com	Hakan, Tayfun/O-9979-2019; solakoglu, seyhun/AAE-5691-2020; Ozevren, Huseyin/AAC-1236-2021; solakoglu, seyhun/AAA-4412-2021; Hakan, Tayfun/P-8626-2015; Toklu, Hale/AAR-2330-2020	Hakan, Tayfun/0000-0003-1444-7076; Ozevren, Huseyin/0000-0002-5437-4003; solakoglu, seyhun/0000-0002-1389-9639; Hakan, Tayfun/0000-0003-1444-7076; Toklu, Hale/0000-0002-9797-3591			Agha AM, 1999, PHARMACOL RES, V40, P385, DOI 10.1006/phrs.1999.0522; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arafa HMM, 2007, EUR J PHARMACOL, V564, P181, DOI 10.1016/j.ejphar.2007.02.065; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; BEUGE JA, 1978, METHOD ENZYMOL, V52, P302; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; Engelhardt G, 1996, BIOCHEM PHARMACOL, V51, P29, DOI 10.1016/0006-2952(95)02110-8; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Jun-Qing Y, 2006, EUR J PHARMACOL, V547, P52, DOI 10.1016/j.ejphar.2006.07.031; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Ogino K, 1997, PHARMACOLOGY, V55, P44, DOI 10.1159/000139511; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Tegeder I, 2000, J PHARMACOL EXP THER, V292, P1161; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; [No title captured]	37	39	39	0	16	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	2010	32	6					629	635		10.1179/016164109X12464612122731			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	613SS	WOS:000279001300010	19660237				2022-02-06	
J	Brustovetsky, T; Bolshakov, A; Brustovetsky, N				Brustovetsky, Tatiana; Bolshakov, Alexey; Brustovetsky, Nickolay			Calpain Activation and Na+/Ca2+ Exchanger Degradation Occur Downstream of Calcium Deregulation in Hippocampal Neurons Exposed to Excitotoxic Glutamate	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neuron; glutamate; calcium; excitotoxicity; calpain; calpeptin	CEREBELLAR GRANULE CELLS; PERMEANT CA2+ CHELATORS; NA+-CA2+ EXCHANGER; I ACTIVATION; 3-NITROPROPIONIC ACID; NMDA EXCITOTOXICITY; CEREBRAL-ISCHEMIA; RECEPTOR CHANNELS; CORTICAL-NEURONS; RAT	Delayed calcium deregulation (DOD) plays an essential role in glutamate excitotoxicity, a major detrimental factor in stroke, traumatic brain injury, and various neurodegenerations. In the present study, we examined the role of calpain activation and Na+/Ca2+ exchanger (NCX) degradation in DOD and excitotoxic cell death in cultured hippocampal neurons. Exposure of neurons to glutamate caused DOD accompanied by secondary mitochondrial depolarization. Activation of calpain was evidenced by detecting NCX isoform 3 (NCX3) degradation products. Degradation of NCX isoform 1 (NCX1) was below the detection limit of Western blotting. Degradation of NCX3 was detected only after 1 hr of incubation with glutamate, whereas DOD occurred on average within 15 min after glutamate application. Calpeptin, an inhibitor of calpain, significantly attenuated NCX3 degradation but failed to inhibit DOD and excitotoxic neuronal death. Calpain inhibitors I, III, and VI also failed to influence DOD and glutamate-induced neuronal death. On the other hand, MK801, an inhibitor of the NMDA subtype of glutamate receptors, added shortly after the initial glutamate-induced jump in cytosolic Ca2+, completely prevented DOD and activation of calpain and strongly protected neurons against excitotoxicity. Taken together, our results suggest that, in glutamate-treated hippocampal neurons, the initial increase in cytosolic Ca2+ that precedes DOD is insufficient for sustained calpain activation, which most likely occurs downstream of DOD. (C) 2009 Wiley-Liss, Inc.	[Brustovetsky, Tatiana; Bolshakov, Alexey; Brustovetsky, Nickolay] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Brustovetsky, Nickolay] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA		Brustovetsky, N (corresponding author), Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 633 Barnhill Dr,Med Sci Bldg 547, Indianapolis, IN 46202 USA.	nbrous@iupui.edu	Bolshakov, Alexey P/K-4173-2013		NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 050131]; Indiana Spinal Cord and Brain Injury Research Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050131] Funding Source: NIH RePORTER	Contract grant sponsor: NIH/NINDS: Contract grant number: R01 NS 050131: Contract grant sponsor: Indiana Spinal Cord and Brain Injury Research Fund (to NIB.).	Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Araujo IM, 2007, CELL DEATH DIFFER, V14, P1635, DOI 10.1038/sj.cdd.4402171; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Brustovetsky T, 2004, EXP NEUROL, V189, P222, DOI 10.1016/j.expneurol.2004.03.021; Budd SL, 1996, J NEUROCHEM, V67, P2282; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; DUBINSKY JM, 1995, J NEUROSCI, V15, P7071; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KIEDROWSKI L, 1994, NEURON, V12, P295, DOI 10.1016/0896-6273(94)90272-0; Kiedrowski L, 2004, J NEUROCHEM, V90, P117, DOI 10.1111/j.1471-4159.2004.02462.x; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Li V, 2009, EXP NEUROL, V218, P171, DOI 10.1016/j.expneurol.2009.02.007; LI ZP, 1994, J BIOL CHEM, V269, P17434; MANEV H, 1991, J NEUROCHEM, V57, P1288, DOI 10.1111/j.1471-4159.1991.tb08292.x; MANEV H, 1989, MOL PHARMACOL, V36, P106; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; Minelli A, 2007, CELL CALCIUM, V41, P221, DOI 10.1016/j.ceca.2006.06.004; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Moroni F, 2008, CURR OPIN PHARMACOL, V8, P96, DOI 10.1016/j.coph.2007.10.005; Nasr P, 2003, NEUROCHEM INT, V43, P89, DOI 10.1016/S0197-0186(02)00229-2; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Sakaue M, 2000, BRAIN RES, V881, P212, DOI 10.1016/S0006-8993(00)02808-0; Secondo A, 2007, ANN NY ACAD SCI, V1099, P481, DOI 10.1196/annals.1387.052; Secondo A, 2007, CELL CALCIUM, V42, P521, DOI 10.1016/j.ceca.2007.01.006; SIMAN R, 1989, J NEUROSCI, V9, P1579; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; THAYER SA, 1990, J PHYSIOL-LONDON, V425, P85, DOI 10.1113/jphysiol.1990.sp018094; Thurneysen T, 2002, ANN NY ACAD SCI, V976, P367; Thurneysen T, 2002, MOL BRAIN RES, V107, P145, DOI 10.1016/S0169-328X(02)00461-8; TSUZUKI K, 1994, MOL BRAIN RES, V26, P37, DOI 10.1016/0169-328X(94)90071-X; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; TYMIANSKI M, 1994, J NEUROPHYSIOL, V72, P1973, DOI 10.1152/jn.1994.72.4.1973; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Vergun O, 2003, EXP NEUROL, V183, P682, DOI 10.1016/S0014-4886(03)00243-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; White RJ, 1996, J NEUROSCI, V16, P5688; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; YAMAGUCHI K, 1990, J PHYSIOL-LONDON, V420, P185, DOI 10.1113/jphysiol.1990.sp017907; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754	61	39	41	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2010	88	6					1317	1328		10.1002/jnr.22295			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	575ZK	WOS:000276112600016	19937813	Green Accepted			2022-02-06	
J	Mao, HJ; Jin, X; Zhang, LY; Yang, KH; Igarashi, T; Noble-Haeusslein, LJ; King, AI				Mao, Haojie; Jin, Xin; Zhang, Liying; Yang, King H.; Igarashi, Takuji; Noble-Haeusslein, Linda J.; King, Albert I.			Finite Element Analysis of Controlled Cortical Impact-Induced Cell Loss	JOURNAL OF NEUROTRAUMA			English	Article						brain biomechanics; controlled cortical impact; finite element models; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; CONTUSION INJURY; HIPPOCAMPAL-NEURONS; RAT; VULNERABILITY; DEFORMATION; STRAIN; MODEL	The controlled cortical impact (CCI) model has been extensively used to study region-specific patterns of neuronal injury and cell death after a focal traumatic brain injury. Although external parameters such as impact velocity and depth of penetration have been defined in this injury model, little is known about the intracranial mechanical responses within cortical and subcortical brain regions where neuronal loss is prevalent. At present, one of the best methods to determine the internal responses of the brain is finite element (FE) modeling. A previously developed and biomechanically validated detailed three-dimensional FE rat brain model, consisting of 255,700 hexahedral elements and representing all essential anatomical features of a rat brain, was used to study intracranial responses in a series of CCI experiments in which injury severity ranged from mild to severe. A linear relationship was found between the percentage of the neuronal loss observed in vivo and the FE model-predicted maximum principal strain (R-2=0.602). Interestingly, the FE model also predicted some risk of injury in the cerebellum, located remote from the point of impact, with a 25% neuronal loss for the "severe'' impact condition. More research is needed to examine other regions that do not have histological data for comparison with FE model predictions before this injury mechanism and the associated injury threshold can be fully established.	[Mao, Haojie; Jin, Xin; Zhang, Liying; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Igarashi, Takuji] Narita Red Cross Hosp, Dept Neurosurg, Chiba, Japan		Yang, KH (corresponding author), Wayne State Univ, Ctr Bioengn, 818 W Hancock, Detroit, MI 48201 USA.	king.yang@wayne.edu	Mao, Haojie/Q-7514-2018; Jin, Xin/J-6476-2015; Lang, Steven/AAE-8102-2021	Mao, Haojie/0000-0002-7563-9234; Lang, Steven/0000-0003-1669-9146	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046389, NS050159]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS065937, R01NS046389, R01NS050159] Funding Source: NIH RePORTER	This study was supported in part by grants NS046389 and NS050159 from the National Institute of Neurological Disorders and Stroke.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arbogast K., 1997, P 41 STAPP CAR CRASH; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Conti AC, 1998, J NEUROSCI, V18, P5663; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; King AI, 2003, IRCOBI C LISB PORT; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Pena A, 2005, ACT NEUR S, V95, P333; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHREIBER DI, 1997, STAPP CAR CRASH C WA; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P79; Toth Z, 1997, J NEUROSCI, V17, P8106; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; ZHOU C, 1994, 942214 SAE	35	39	39	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					877	888		10.1089/neu.2008.0616			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400010	20199194	Green Published			2022-02-06	
J	van Kessel, ME; van Nes, IJW; Brouwer, WH; Geurts, ACH; Fasotti, L				van Kessel, Marlies E.; van Nes, Ilse J. W.; Brouwer, Wiebo H.; Geurts, Alexander C. H.; Fasotti, Luciano			Visuospatial asymmetry and non-spatial attention in subacute stroke patients with and without neglect	CORTEX			English	Article						Hemi-inattention; Behavioural Inattention Task; Reaction time task; General attention	UNILATERAL SPATIAL NEGLECT; CLOSED-HEAD-INJURY; HEMISPATIAL NEGLECT; SUSTAINED ATTENTION; REACTION-TIME; DIVIDED ATTENTION; VISUAL NEGLECT; BRAIN-DAMAGE; REHABILITATION; DEFICITS	Asymmetry in performance and an association with non-lateralized attention are often mentioned as two important aspects of the clinical manifestation of visuospatial neglect. Both these aspects were investigated in 21 left (LH) and 24 right hemisphere (RH) stroke patients and in 20 healthy subjects. The letter and star cancellation subtests of the Behavioural Inattention Task (BIT) and a computerized visual reaction time task (CVRT) with stimuli presented either left, central or right in extrapersonal space were administered. In LH patients, the calculation of BIT asymmetry scores allowed a better distinction between patients with and without neglect than raw omission scores. However, in RH patients, raw and asymmetry scores led to similar classifications. In the CVRT, raw and asymmetry scores for the number of omissions also produced identical classifications. Thus, the computation of asymmetry scores for omissions did not substantially refine the diagnosis of neglect. On the other hand, more patients were classified as neglect patients by using CVRT reaction time (RT) asymmetry scores than by using BIT or CVRT omission scores. Ipsilesional RT's were chosen as a measure of general, non-lateralized attention. The ipsilesional RT's of the LH and RH patients did not differ from the healthy subjects' lateral RT's. However, within the RH group, patients with both RT asymmetries and BIT scores above cut-off level showed longer ipsilesional RT's than patients with defective RT asymmetries but normal BIT scores. This supports the idea of an interaction between lateralized and non-lateralized attentional components in neglect, in which the presence of general attentional deficits exacerbates the severity of neglect symptoms. RT tasks may contribute to the detection of asymmetries in visuospatial attention in patients with subclinical neglect symptoms, who might compensate for their lateralized deficit in paper-and-pencil tasks employing intact general attention. (C) 2009 Elsevier Srl. All rights reserved.	[van Kessel, Marlies E.; van Nes, Ilse J. W.; Geurts, Alexander C. H.; Fasotti, Luciano] Sint Maartensklin Res Dev & Educ, NL-6500 GM Nijmegen, Netherlands; [Fasotti, Luciano] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [Brouwer, Wiebo H.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Geurts, Alexander C. H.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands		van Kessel, ME (corresponding author), Sint Maartensklin Res Dev & Educ, POB 9011, NL-6500 GM Nijmegen, Netherlands.	m.vankessel@maartenskliniek.nl	Geurts, Alexander/H-8032-2014	Geurts, Alexander/0000-0001-7478-1119; van Nes, Ilse/0000-0003-3249-3789	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [14350009]	This research was supported by Research Grant 14350009 from the Netherlands Organisation for Health Research and Development.	Anderson B, 2000, NEUROPSYCHOLOGIA, V38, P785, DOI 10.1016/S0028-3932(99)00137-2; Azouvi P, 2002, J NEUROL NEUROSUR PS, V73, P160, DOI 10.1136/jnnp.73.2.160; Bartolomeo P, 1999, NEUROLOGY, V53, P2023, DOI 10.1212/WNL.53.9.2023; BARTOLOMEO P, 1994, NEUROLOGY, V44, P1710, DOI 10.1212/WNL.44.9.1710; Bartolomeo P, 2002, NEUROSCI BIOBEHAV R, V26, P217, DOI 10.1016/S0149-7634(01)00065-3; Bowen A, 1999, STROKE, V30, P1196, DOI 10.1161/01.STR.30.6.1196; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Deouell LY, 2005, J INT NEUROPSYCH SOC, V11, P697, DOI 10.1017/S13556177050824; DERME P, 1992, NEUROPSYCHOLOGIA, V30, P989, DOI 10.1016/0028-3932(92)90050-V; GAINOTTI G, 1991, J NEUROL NEUROSUR PS, V54, P1082, DOI 10.1136/jnnp.54.12.1082; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Halligan P, 1990, Int Disabil Stud, V12, P95; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1979, ANN NEUROL, V5, P166, DOI 10.1002/ana.410050210; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; KAIZER F, 1988, STROKE, V19, P335, DOI 10.1161/01.STR.19.3.335; KARNATH HO, 1988, NEUROPSYCHOLOGIA, V26, P27, DOI 10.1016/0028-3932(88)90028-0; KINSBOURNE M, 1993, BRAIN DAMAGE BEHAV C, P00063; LADAVAS E, 1990, CORTEX, V26, P307, DOI 10.1016/S0010-9452(13)80083-4; Luaute J, 2006, NEUROSCI BIOBEHAV R, V30, P961, DOI 10.1016/j.neubiorev.2006.03.001; Malhotra P, 2006, CURR OPIN NEUROL, V19, P14, DOI 10.1097/01.wco.0000198101.87670.7e; Manly T, 2002, NEUROPSYCHOL REHABIL, V12, P289, DOI 10.1080/0960201044000101; MATTINGLEY JB, 1994, J NEUROL NEUROSUR PS, V57, P597, DOI 10.1136/jnnp.57.5.597; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; PONDS RW, 1988, J GERONTOL, V436, P151; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBERTSON I, 1992, INT J NEUROSCI, V62, P45; ROBERTSON I, 2004, COGNITIVE NEURAL BAS; Robertson IH, 2001, NEUROIMAGE, V14, pS85, DOI 10.1006/nimg.2001.0838; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P1527, DOI 10.1016/S0028-3932(97)00084-5; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; ROBERTSON IH, 1989, NEUROPSYCHOLOGIA, V272, P157; Samuelsson H, 1998, J CLIN EXP NEUROPSYC, V20, P73, DOI 10.1076/jcen.20.1.73.1481; Schendel KL, 2002, J CLIN EXP NEUROPSYC, V24, P941, DOI 10.1076/jcen.24.7.941.8390; SCHMIDT IW, 1996, APPL NEUROPSYCHOL, V34, P155; Vallar G, 1998, TRENDS COGN SCI, V2, P87, DOI 10.1016/S1364-6613(98)01145-0; Vallar Giuseppe, 2003, Adv Neurol, V93, P293; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE	46	39	39	0	4	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	MAY	2010	46	5					602	612		10.1016/j.cortex.2009.06.004			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	581TN	WOS:000276547600003	19591978				2022-02-06	
J	Gwin, JT; Chu, JJ; Diamond, SG; Halstead, PD; Crisco, JJ; Greenwald, RM				Gwin, Joseph T.; Chu, Jeffery J.; Diamond, Solomon G.; Halstead, P. David; Crisco, Joseph J.; Greenwald, Richard M.			An Investigation of the NOCSAE Linear Impactor Test Method Based on In Vivo Measures of Head Impact Acceleration in American Football	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION; COLLEGIATE; PLAYERS; EPIDEMIOLOGY	The performance characteristics of football helmets are currently evaluated by simulating head impacts in the laboratory using a linear drop test method. To encourage development of helmets designed to protect against concussion, the National Operating Committee for Standards in Athletic Equipment recently proposed a new headgear testing methodology with the goal of more closely simulating in vivo head impacts. This proposed test methodology involves an impactor striking a helmeted headform, which is attached to a nonrigid neck. The purpose of the present study was to compare headform accelerations recorded according to the current (n = 30) and proposed (n = 54) laboratory test methodologies to head accelerations recorded in the field during play. In-helmet systems of six single-axis accelerometers were worn by the Dartmouth College men's football team during the 2005 and 2006 reasons (n = 20,733 impacts; 40 players). The impulse response characteristics of a subset of laboratory test impacts (n = 27) were compared with the impulse response characteristics of a matched sample of in vivo head accelerations (n = 24). Second- and third-order underdamped, conventional, continuous-time process models were developed for each impact. These models were used to characterize the linear head/headform accelerations for each impact based ore frequency domain parameters. Headform linear accelerations generated according to the proposed test method were less similar to in vivo head accelerations than headform accelerations generated by the current linear drop test method. The nonrigid neck currently utilized was not developed to simulate sport-related direct head impacts and appears to be a source of the discrepancy between frequency characteristics of in vivo and laboratory head/headform accelerations. In vivo impacts occurred 37% snore frequently on helmet regions, which are tested in the proposed standard than on helmet regions tested currently. This increase was largely due to the addition of the facemask test location. For the proposed standard, impactor velocities as high as 10.5 m/s were needed to simulate the highest energy impacts recorded in vivo. The knowledge gained from. this study may provide the basis for improving sports headgear test apparatuses with regard to mimicking in vivo linear head accelerations. Specifically, increasing the,stiffness of the neck is recommended. In addition, this study may provide a basis for selecting appropriate test impact energies for the standard performance specification to accompany the proposed standard linear impactor test method. [DOI: 10.1115/1.4000249]	[Gwin, Joseph T.; Chu, Jeffery J.; Greenwald, Richard M.] Simbex, Lebanon, NH 03766 USA; [Gwin, Joseph T.; Diamond, Solomon G.; Greenwald, Richard M.] Dartmouth, Thayer Sch Engn, Hanover, NH 03755 USA; [Gwin, Joseph T.] Univ Michigan, Div Kinesiol, Ann Arbor, MI 48109 USA; [Halstead, P. David] Univ Tennessee, Sports Biomech Impact Res Lab, Rockford, TN 37853 USA; [Crisco, Joseph J.] Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI 02903 USA		Gwin, JT (corresponding author), Simbex, Lebanon, NH 03766 USA.	jgwin@umich.edu		Diamond, Solomon/0000-0002-7589-2942; Crisco, Joseph/0000-0002-8786-0905	National Operating Committee for Standards in Athletic Equipment (NOCSAE); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048638]; NIH Small Business Innovation Research (SBIR) award [R44HD40473]; Riddell, Inc. (Chicago, IL); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	This work was funded in part by the National Operating Committee for Standards in Athletic Equipment (NOCSAE) and the National Institutes of Health (NIH) (Grant No. R01 HD048638). The HIT System was developed by Simbex (Lebanon, NH) through a NIH Small Business Innovation Research (SBIR) award (Grant No. R44HD40473). In addition, this work was supported by research and development funding from Riddell, Inc. (Chicago, IL). Analog Devices (Cambridge, MA) provided sensors and expertise in sensor integration. We appreciate and acknowledge our colleagues Tom McAllister, MD and Tina Duhaime, MD from Dartmouth Hitchcock Medical Center, Lebanon NH, Mel Cook, Southern Impact Research Center, Rockford TN, for performing laboratory helmet testing, Jeff Frechette and Scott Roy, Dartmouth College Sports Medicine, for invaluable insight and daily monitoring of the in vivo data acquisition system, and the engineering team at Simbex, including Jonathan Beckwith, Siena Calabro, Lindley Brainard, and Dan Leonard, for manufacturing and supporting the instrumented helmets. Additionally, we would like to thank the players, athletic training staff, equipment staff, and coaches from the Dartmouth College football team for their ongoing support and cooperation.	BRAZARIAN JJ, 2005, BRAIN INJURY, V19, P85; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P1; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; CRISCO JJ, 2004, ASME, V126, P849; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Foster J.K., 1977, P 21 STAPP CAR CRASH; Gadd C. W., 1966, P 10 STAPP CAR CRASH; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gwin JT, 2009, AM SOC TEST MATER, V1516, P244, DOI 10.1520/JAI101848; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR, 1970, P 14 STAPP CAR CRASH; HODGSON VR, 1982, ATHLETIC INJURIES HE, P27; King AI, 2003, INT RES COUNC BIOM I; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; *NOCSAE, 2005, 00298M05 NOCSAE; *NOCSAE, 2006, 08104M04 NOCSAE; *NOCSAE, 2007, 00106M07 NOCSAE; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosner B., 1990, FUNDAMENTALS BIOSTAT; ROWSON S, 2009, ASME, V131; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; ZERBE GO, 1982, AM J PHYSIOL, V242, pR178, DOI 10.1152/ajpregu.1982.242.3.R178	38	39	39	0	13	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JAN	2010	132	1							011006	10.1115/1.4000249			9	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	550CW	WOS:000274106900006	20524744				2022-02-06	
J	Mehta, A; Kochanek, PM; Tyler-Kabara, E; Adelson, PD; Wisniewski, SR; Berger, RP; Sidoni, MD; Bell, RL; Clark, RSB; Bell, MJ				Mehta, Amit; Kochanek, Patrick M.; Tyler-Kabara, Elizabeth; Adelson, P. David; Wisniewski, Stephen R.; Berger, Rachel P.; Sidoni, Maria D.; Bell, Rachelle L.; Clark, Robert S. B.; Bell, Michael J.			Relationship of Intracranial Pressure and Cerebral Perfusion Pressure with Outcome in Young Children after Severe Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Intracranial hypertension; Neurotrauma database; Glasgow Outcome Scale; Physiologic parameters; Childhood neurotrauma, inflicted	SEVERE HEAD-INJURY; IMPACT; NEUROPATHOLOGY; EPIDEMIOLOGY	Traumatic brain injury (TBI) is the most common cause of death for children less than 18 years of age. Current standards of care for children with severe TBI include monitoring of intracranial pressure (ICP), and goal-directed therapies to minimize ICP and optimize cerebral perfusion pressure (CPP; the mathematical difference between the mean arterial pressure and ICP). Current guidelines for ICP and CPP thresholds suggest that age-based thresholds should be adopted, but few studies have included the youngest children affected by TBI (those <2 years of age). We performed a retrospective analysis of our pediatric neurotrauma database to determine if ICP and CPP thresholds associated with favorable neurological outcome could be determined, or if the number of episodic alterations in the parameters (ICP >15 or >20 mm Hg; CPP <40 mm Hg, <45 mm Hg or <50 mm Hg) was different between children with favorable and unfavorable outcomes (based on dichotomous Glasgow Outcome Scale score at 6 months after TBI). Data from 22 children (of whom 81% had suffered from inflicted childhood neurotrauma) were analyzed in the first 7 days. Children with unfavorable outcome had more hourly readings of CPP of <45 mm Hg compared to children with favorable outcome [median (25-75%): 2 (1-31) vs. 0 (0-2); p < 0.05]. There was no difference between the number of hourly readings of ICP of >20 mm Hg between the outcome groups [median (25-75%): favorable 0 (0-1) vs. unfavorable 1 (0-4); p = 0.17]. To our knowledge, this is the first exploratory report to test if CPP and ICP thresholds can be established for this young population of children after TBI, and it suggests a CPP target threshold of 45 mm Hg. Despite good ICP control in this population, there was still a 50% incidence of unfavorable outcome, suggesting that there may be unique physiologic parameters that need to be targeted in infants with severe TBI. A prospective study is needed to fully determine what goals should be targeted for this vulnerable population. Copyright (C) 2010 S. Karger AG, Basel	[Mehta, Amit] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Tyler-Kabara, Elizabeth; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Adelson, P. David] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA		Mehta, A (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	amit.mehta@chp.edu	Tyler-Kabara, Elizabeth/H-4930-2013; Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Heron M, 2010, PEDIATRICS, V125, P4, DOI 10.1542/peds.2009-2416; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Pearl GS, 1998, CLIN LAB MED, V18, P39; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037	24	39	42	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					413	419		10.1159/000316804			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900009	20847542				2022-02-06	
J	Sawyer, RJ; Hamdallah, M; White, D; Pruzan, M; Mitchko, J; Huitric, M				Sawyer, Richard J.; Hamdallah, Myriam; White, Debbie; Pruzan, Marcia; Mitchko, Jane; Huitric, Michele			High School Coaches' Assessments, Intentions to Use, and Use of a Concussion Prevention Toolkit: Centers for Disease Control and Prevention's Heads Up: Concussion in High School Sports	HEALTH PROMOTION PRACTICE			English	Article						school coaches; concussion prevention; prevention toolkit		This study evaluated school coaches' perceptions, assessments, and use of a toolkit to prevent and manage concussions among school athletes. A computerassisted telephone survey was conducted with a stratified, random sample of high school coaches (n = 497; response rate = 39.3%; cooperation rate = 81.5%) from five states. Most reported that they had used or planned to use kit materials. Most (81%) in schools with a written plan for preventing and managing concussions indicated that the toolkit could be used to improve it and 96% of coaches in schools without a plan indicated that the kit could be used to develop one. Most assessed the kit as visually appealing, easy to use, and containing appropriate content. There were no significant differences among coaches with differing professional experience or for sports with different injury rates. Among those with other concussionprevention materials, most indicated greater satisfaction with the toolkit.	[Sawyer, Richard J.] Acad Educ Dev, Reg Educ Lab Southeast, Washington, DC 20001 USA; [Hamdallah, Myriam] Acad Educ Dev, Ctr AIDS & Community Hlth, Washington, DC 20001 USA; [White, Debbie] John Tyler Community Coll, Sociol, Chester, VA 23831 USA; [Pruzan, Marcia] Hlth Commun & Mkt Consultant, Bethesda, MD 20814 USA; [Mitchko, Jane; Huitric, Michele] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA		Sawyer, RJ (corresponding author), Acad Educ Dev, 1825 Connecticut Ave,NW, Washington, DC 20001 USA.	rsawyer@aed.org					*AM ASS PUBL OP RE, 2004, STAND DEF FIN DISP C; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Dillman DA., 2000, MAIL INTERNET SURVEY; Finkelstein E., 2006, INCIDENCE EC BURDEN; Ghiselli G, 2003, CLIN SPORT MED, V22, P445, DOI 10.1016/S0278-5919(02)00109-6; Greenberg M. T., 2005, STUDY IMPLEMENTATION; Hendrickson S G, 2000, Pediatr Nurs, V26, P159; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MACKAY M, 2001, SPORTS RECREATION IN; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mueller FO, 2001, J ATHL TRAINING, V36, P312; National Athletic Trainers Association, MIN RISK INJ HIGH SC; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rogers E., 1995, DIFFUSION INNOVATION, V4th edn.; Theye Fred, 2004, Clin Med Res, V2, P165; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watt GM, 1996, SPORTS MED, V22, P187, DOI 10.2165/00007256-199622030-00005	18	39	39	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1524-8399	1552-6372		HEALTH PROMOT PRACT	Health Promot. Pract.	JAN	2010	11	1					34	43		10.1177/1524839907309377			10	Public, Environmental & Occupational Health	Emerging Sources Citation Index (ESCI)	Public, Environmental & Occupational Health	V94YJ	WOS:000213164000008	18400880				2022-02-06	
J	Berlot, G; La Fata, C; Bacer, B; Biancardi, B; Viviani, M; Lucangelo, U; Gobbato, P; Torelli, L; Carchietti, E; Trillo, G; Daniele, M; Rinaldi, A				Berlot, Giorgio; La Fata, Cristina; Bacer, Barbara; Biancardi, Bruno; Viviani, Marino; Lucangelo, Umberto; Gobbato, Piero; Torelli, Lucio; Carchietti, Elio; Trillo, Giulio; Daniele, Massarutti; Rinaldi, Adriano			Influence of prehospital treatment on the outcome of patients with severe blunt traumatic brain injury: a single-centre study	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						ambulance; coma; helicopter; secondary brain injury; trauma	CARE	Aim, patients, and methods To compare retrospectively the outcomes of patients with severe traumatic brain injury (injury Severity Score, ISS total >= 15; the Abbreviated ISS-head, aISS(head) >= 9) admitted to our Intensive Care Unit by helicopter (helicopter emergency medical service, HEMS group=89) with those transported by ambulance (GROUND group=105) from January 2002 to December 2007. Results The groups were comparable for age, Glasgow Coma Scale, ISS total, and aISS(head). The preadmission time of the HEMS group was significantly longer as compared with the GROUND group, but the interval from admission to definitive care was significantly shorter. In the prehospital phase, HEMS patients were more aggressively treated, as indicated by a significantly greater number of procedures performed (i.e. tracheal intubation and positioning of intravenous lines) and larger volumes of fluids infused. The overall mortality was lower in the HEMS than in the GROUND patients (21 vs. 25% respectively, P<0.05). The survival with or without only minor neurological disabilities was higher in the HEMS than in the GROUND group (54 vs. 44% respectively, P<0.05); among the survivors, the rate of severe neurological disabilities was lower in the HEMS than in the GROUND group (25 vs. 31%, P<0.05). Conclusion In our experience, aggressive early treatment of patients with severe traumatic brain injury was associated with a better outcome likely because of the prevention of secondary brain injury and a shorter interval elapsing from the trauma to definitive care despite more time spent on the scene by the intervening team. European Journal of Emergency Medicine 16:312-317 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.	[Berlot, Giorgio; La Fata, Cristina; Bacer, Barbara; Biancardi, Bruno; Viviani, Marino; Lucangelo, Umberto; Gobbato, Piero; Rinaldi, Adriano] Univ Trieste, Dept Anaesthesia & Intens Care, Trieste, Italy; [Torelli, Lucio] Univ Trieste, Dept Biostat, Trieste, Italy; [Carchietti, Elio; Trillo, Giulio; Daniele, Massarutti] Friuli Venezia Giulia Helicopter Emergency Med Sy, Rome, Italy		Berlot, G (corresponding author), Cattinara Hosp, Dept Anaesthesia & Intens Care, Str Fiume 447, I-34149 Trieste, Italy.	berlot@inwind.it	Trillo, Giulio/AAC-1574-2020	BERLOT, GIORGIO/0000-0002-9231-8555			Berlot G, 2006, CRIT CARE CLIN, V22, P457, DOI 10.1016/j.ccc.2006.03.009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Frink M, 2007, UNFALLCHIRURG, V110, P334, DOI 10.1007/s00113-006-1222-2; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; Kerr W A, 1999, Prehosp Disaster Med, V14, P159; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; NARDI G, 1994, EUR J EMERG MED, V2, P69; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Sharma BR, 2005, INJURY, V36, P579, DOI 10.1016/j.injury.2004.09.009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014	18	39	42	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0969-9546	1473-5695		EUR J EMERG MED	Eur. J. Emerg. Med.	DEC	2009	16	6					312	317		10.1097/MEJ.0b013e32832d3aa1			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	528VE	WOS:000272474300005	19491690				2022-02-06	
J	Terpolilli, NA; Zweckberger, K; Trabold, R; Schilling, L; Schinzel, R; Tegtmeier, F; Plesnila, N				Terpolilli, Nicole A.; Zweckberger, Klaus; Trabold, Raimund; Schilling, Lothar; Schinzel, Reinhard; Tegtmeier, Frank; Plesnila, Nikolaus			The Novel Nitric Oxide Synthase Inhibitor 4-amino-tetrahydro-L-biopterine Prevents Brain Edema Formation and Intracranial Hypertension following Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; nitric oxide; nitric oxide synthase inhibitor; tetrahydrobiopterine (BH4); traumatic brain injury	CONTROLLED CORTICAL IMPACT; ENDOTHELIN RECEPTOR ANTAGONIST; CEREBRAL-BLOOD-FLOW; L-ARGININE; SELECTIVE-INHIBITION; HEAD-INJURY; CEREBROVASCULAR CHARACTERIZATION; SECONDARY EXPANSION; CEREBROSPINAL-FLUID; OXYGEN REDUCTION	Brain edema formation, resulting in increased intracranial pressure (ICP), is one of the most deleterious consequences of traumatic brain injury (TBI). Nitric oxide (NO) has previously been shown to be involved in the damage of the blood-brain barrier (BBB) and, thus, in the formation of post-traumatic brain edema; however, this knowledge never resulted in a clinically relevant therapeutic option because available NO synthase inhibitors have serious side effects in man. The aim of the current study was to investigate the therapeutic efficacy of VAS203, a novel tetrahydrobiopterine (BH3)-based NOS inhibitor, in experimental TBI. When added to isolated vessels rings obtained from rat basilar and middle cerebral arteries (n - 32-35) VAS203 showed the same vasoconstrictive effect as the classical NO synthase inhibitor L-(G)-nitro-arginine-methylester (L-NAME). VAS203 passed the BBB both in healthy and traumatized mouse brain (C57/BL6, n = 5 per group) and did not show any systemic side effects at therapeutic concentrations. When administered 30 min after experimental TBI (controlled cortical impact, 2.2 mg/kg/min i.v., n = 7 per group), VAS203 prevented any further increase in ICP or deterioration of cerebral blood flow. This effect was dose-dependent and long-lasting (i.e., 24 h after trauma, brain edema formation was still significantly reduced [-40%, p < 0.008; n = 7 per group] and functional improvements were present up to 7 days after TBI [p < 0.02 on post-trauma day 6; n = 8 per group]). Therefore, VAS203 may represent a promising candidate for the treatment of acute intracranial hypertension following TBI.	[Terpolilli, Nicole A.; Zweckberger, Klaus; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany; [Terpolilli, Nicole A.; Zweckberger, Klaus; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich Med Ctr Grosshadern, Inst Surg Res, Munich, Germany; [Schilling, Lothar] Heidelberg Univ, Klinikum Mannheim, Dept Neurosurg, Mannheim, Germany; [Schinzel, Reinhard; Tegtmeier, Frank] Vasopharm GmbH, Wurzburg, Germany		Plesnila, N (corresponding author), RCSI, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Terpolilli, Nicole/AAG-3598-2021; Plesnila, Nikolaus/T-7522-2019				Avontuur JAM, 1998, SHOCK, V9, P451, DOI 10.1097/00024382-199806000-00010; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Bahrami S, 2000, SHOCK, V13, P386, DOI 10.1097/00024382-200005000-00007; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Chang CP, 2004, J PHARMACOL SCI, V95, P56, DOI 10.1254/jphs.95.56; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Cosentino F, 1998, EUR HEART J, V19, pG3; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Forstermann U, 2006, BIOL CHEM, V387, P1521, DOI 10.1515/BC.2006.190; Frohlich LG, 1999, J MED CHEM, V42, P4108, DOI 10.1021/jm981129a; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gibraeil HD, 2000, BRIT J PHARMACOL, V131, P1757, DOI 10.1038/sj.bjp.0703752; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Ridger VC, 1997, BRIT J PHARMACOL, V122, P1083, DOI 10.1038/sj.bjp.0701498; Rinecker M, 2003, ACTA NEUROCHIR, V145, P977, DOI 10.1007/s00701-003-0131-1; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schmidt K, 1999, EUR J BIOCHEM, V259, P25, DOI 10.1046/j.1432-1327.1999.00003.x; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vatter H, 2005, J NEUROSURG, V102, P1101, DOI 10.3171/jns.2005.102.6.1101; Vatter H, 2005, J NEUROSURG, V102, P1108, DOI 10.3171/jns.2005.102.6.1108; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Walker G, 1997, J BIOL CHEM, V272, P16679, DOI 10.1074/jbc.272.26.16679; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Werner ER, 2003, EXP BIOL MED, V228, P1291, DOI 10.1177/153537020322801108; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	63	39	40	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1963	1975		10.1089/neu.2008.0853			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600012	19514849				2022-02-06	
J	Daboussi, A; Minville, V; Leclerc-Foucras, S; Geeraerts, T; Esquerre, JP; Payoux, P; Fourcade, O				Daboussi, Amel; Minville, Vincent; Leclerc-Foucras, Sophie; Geeraerts, Thomas; Esquerre, Jean Paul; Payoux, Pierre; Fourcade, Olivier			Cerebral Hemodynamic Changes in Severe Head Injury Patients Undergoing Decompressive Craniectomy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						intracranial pressure; decompressive craniectomy; transcranial Doppler; outcome	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; SURGICAL DECOMPRESSION; TISSUE OXYGEN; MANAGEMENT; PRESSURE; EDEMA; ICP; HEMICRANIECTOMY; PERFUSION	Objective: To assess the intracranial hemodynamic modifications induced by a decompressive craniectomy (DC) after severe traumatic brain injury (TBI), using transcranial Doppler (TCD) ultrasonography and intracranial pressure (ICP) sensor. Mortality rate and neurological outcomes were also evaluated after this procedure. Design: A prospective study was carried out on 26 TBI patients, measuring transcranial Doppler and ICP before, immediately after, and 48 hours after the DC, allowing for statistical analysis of hemodynamic changes. The mortality rate and the neurological Outcomes were assessed. Measurements and Results: After DC, ICP decreased from 37 +/- 17 to 20 +/- 13 mm Hg (P = 0.0003). The global cerebral blood flow was modified with diastolic velocities rising from 23 +/- 15 to 31 +/- 13 cm/s (P = 0.0038) and a pulsatility index decreasing from 1.70 +/- 0.66 to 1.18 +/- 0.37 (P = 0.0012). This normalization of the global cerebral hemodynamics after the DC was immediate, symmetric, and constant during the first 48 hours. Outcome was evaluated at 6 months: good recovery or moderate disability was observed in 11 patients (42%), persistent vegetative state in 7 patients (27%), and 8 patients died (31%). Conclusions: The DC results in a significant, immediate, and durable improvement of ICP associated with a normalization of cerebral blood flow velocities in most TBI patients with refractory intracranial hypertension.	[Daboussi, Amel; Esquerre, Jean Paul; Payoux, Pierre] CHU Purpan, Nucl Med Serv, F-31059 Toulouse 9, France; [Geeraerts, Thomas] Hop Bicetre, Dept Anesthesie Reanimat, Le Kremlin Bicetre, France; [Daboussi, Amel; Minville, Vincent; Leclerc-Foucras, Sophie; Fourcade, Olivier] Univ Toulouse 3, CHU Toulouse, F-31062 Toulouse, France		Fourcade, O (corresponding author), CHU Purpan, Nucl Med Serv, Pl Docteur Baylac, F-31059 Toulouse 9, France.	fourcade.o@chu-toulouse.fr	Minville, Vincent/ABE-4286-2020	Minville, Vincent/0000-0003-0516-4939; Payoux, Pierre/0000-0002-1374-1620			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; *AG NAT ACCR EV SA, 1999, ANN FR ANESTH, V18, P11; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; Heppner P, 2006, J NEUROSURG, V104, P738, DOI 10.3171/jns.2006.104.5.738; Jaeger M, 2005, ACT NEUR S, V95, P117; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; LINDEGAARD KF, 1992, TRANSCRANIAL DOPPLER, P67; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	41	39	45	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2009	21	4					339	345		10.1097/ANA.0b013e3181b1dbba			7	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	503RQ	WOS:000270557400010	19955897				2022-02-06	
J	Fingas, M; Penner, M; Silasi, G; Colbourne, F				Fingas, Matthew; Penner, Mark; Silasi, Gergely; Colbourne, Frederick			Treatment of intracerebral hemorrhage in rats with 12 h, 3 days and 6 days of selective brain hypothermia	EXPERIMENTAL NEUROLOGY			English	Article						Stroke; Intracerebral hemorrhage; Striatum; Temperature; Hypothermia; Rat; Neuroprotection	PROLONGED HYPOTHERMIA; CARDIAC-ARREST; ANIMAL-MODELS; STROKE; ISCHEMIA; INJURY; COLLAGENASE; RECOVERY; IMPROVE; LESIONS	Intracerebral hemorrhage (ICH) is a devastating stroke with no proven treatment to reduce brain injury. In this study we modeled ICH by injecting 100 mu L of autologous blood into the striatum of rats. We then tested whether hypothermia would reduce brain injury and improve recovery as has been repeatedly observed for ischemic and traumatic brain damage. Aside from reducing blood-brain barrier disruption, inflammation and edema, hypothermia has not consistently improved behavioral or histological outcome after ICH in animal studies. As this might relate to the choice of cooling method and the duration of hypothermia, we used a system that selectively cooled the injured hemisphere to similar to 32 degrees C (striatum) while the body remained normothermic. Cooling (vs. normothermia) started 1 h after ICH and lasted for 12 h, 3 days or 6 days followed by slow re-warming (similar to 1 degrees C/h). Functional impairment was evaluated from 2 to 3 weeks post-ICH at which time brain injury was determined. The ICH caused significant impairment on a neurological deficit scale and in tests of walking (horizontal ladder), skilled reaching (tray task) and spontaneous limb usage (cylinder test). Only the limb use asymmetry deficit was significantly mitigated by hypothermia, and then only by the longest treatment. Lesion volume, which averaged 16.9 mm(3), was not affected. These results, in conjunction with earlier studies, suggest that prolonged mild hypothermia will not be a profound neuroprotectant for patients with striatal ICH, but it may nonetheless improve functional recovery in addition to its use for treating cerebral edema. (C) 2009 Elsevier Inc. All rights reserved.	[Penner, Mark; Colbourne, Frederick] Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; [Fingas, Matthew; Silasi, Gergely; Colbourne, Frederick] Univ Alberta, Ctr Neurosci, Edmonton, AB T6G 2E9, Canada		Colbourne, F (corresponding author), Univ Alberta, Dept Psychol, P217 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.	fcolbour@ualberta.ca	Colbourne, Frederick/ABB-7774-2020	Colbourne, Frederick/0000-0002-9567-2082; Silasi, Gergely/0000-0003-1036-1304	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research	Research supported by a grant from the Canadian Institutes of Health Research to FC, who is supported by an Alberta Heritage Foundation for Medical Research senior medical scholar award. The authors thank N. Cumby, Lindsey Warkentin and Shannon Wowk for technical assistance and Dr. C. MacLellan for helpful comments on the manuscript.	Berger C, 2007, EXP NEUROL, V204, P131, DOI 10.1016/j.expneurol.2006.10.002; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BRODERICK J, 1994, HDB NEUROEPIDEMIOLOG, P141; Clark DL, 2008, EXP NEUROL, V212, P386, DOI 10.1016/j.expneurol.2008.04.016; Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; DeBow S, 2003, METHODS, V30, P167, DOI 10.1016/S1046-2023(03)00080-X; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Feng Honglin, 2002, Zhonghua Yi Xue Za Zhi, V82, P1622; Fingas M, 2007, EXP NEUROL, V208, P277, DOI 10.1016/j.expneurol.2007.08.018; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Kawanishi Masahiko, 2008, J Stroke Cerebrovasc Dis, V17, P187, DOI 10.1016/j.jstrokecerebrovasdis.2008.01.003; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; MacLellan CL, 2005, BRAIN RES, V1063, P40, DOI 10.1016/j.brainres.2005.09.027; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mendelow AD, 2005, LANCET, V365, P387; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nguyen AP, 2008, CURR NEUROVASC RES, V5, P171, DOI 10.2174/156720208785425710; Nguyen AP, 2008, BRAIN RES, V1193, P109, DOI 10.1016/j.brainres.2007.11.054; SACCO S, 2008, STROKE; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Ueda Y, 2004, STROKE, V35, P601, DOI 10.1161/01.STR.0000113693.56783.73; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xue Mengzhou, 2003, J Stroke Cerebrovasc Dis, V12, P152, DOI 10.1016/S1052-3057(03)00036-3; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; [No title captured]	43	39	39	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2009	219	1			SI		156	162		10.1016/j.expneurol.2009.05.007			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	489CZ	WOS:000269398600020	19445934				2022-02-06	
J	Levine, B; Svoboda, E; Turner, GR; Mandic, M; Mackey, A				Levine, Brian; Svoboda, Eva; Turner, Gary R.; Mandic, Marina; Mackey, Allison			Behavioral and functional neuroanatomical correlates of anterograde autobiographical memory in isolated retrograde amnesic patient ML	NEUROPSYCHOLOGIA			English	Article; Proceedings Paper	Meeting on Episodic Memory and the Brain	MAR, 2009	Tallinn, ESTONIA			Autonoetic consciousness; Episodic memory; fMRI; Autobiographical Interview; Case study	FRONTOTEMPORAL LOBAR DEGENERATION; MEDIAL-TEMPORAL-LOBE; EPISODIC MEMORY; RECOGNITION MEMORY; LIFE-SPAN; BRAIN; SELF; RETRIEVAL; FMRI; CONSCIOUSNESS	Patient M.L. [Levine, B., Black, S. E., Cabeza, R., Sinden, M., Mcintosh, A. R., Toth, J. P, et al. (1998). Episodic memory and the self in a case of isolated retrograde amnesia. Brain, 121, 1951-1973], lost memory for events occurring before his severe traumatic brain injury, yet his anterograde (post-injury) learning and memory appeared intact, a syndrome known as isolated or focal retrograde amnesia. Studies with M.L demonstrated a dissociation between episodic and semantic memory. His retrograde amnesia was specific to episodic autobiographical memory. Convergent behavioral and functional imaging data suggested that his anterograde memory, while appearing normal, was accomplished with reduced autonoetic awareness (awareness of the self as a continuous entity across time that is a crucial element of episodic memory). While previous research on M.L focused on anterograde memory of laboratory stimuli, in this study, M.L's autobiographical memory for post-injury events or anterograde autobiographical memory was examined using prospective collection of autobiographical events via audio diary with detailed behavioral and functional neuroanatomical analysis. Consistent with his reports of subjective disconnection from post-injury autobiographical events, M.L assigned fewer "remember" ratings to his autobiographical events than comparison subjects. His generation of event-specific details using the Autobiographical Interview [Levine, B., Svoboda, E., Hay, J., Winocur, G., & Moscovitch, M. (2002). Aging and autobiographical memory: dissociating episodic from semantic retrieval. Psychology and Aging, 17, 677-689] was low, but not significantly so, suggesting that it is possible to generate episodic-like details even when re-experiencing of those details is compromised. While listening to the autobiographical audio diary segments, M.L showed reduced activation relative to comparison subjects in midline frontal and posterior nodes previously identified as part of the autobiographical memory network. Reductions were also evident in M.L in association with personal semantic stimuli (e.g., recordings describing personal habits and routines). These data suggest an association between M.L's impoverished recollection of autobiographical material and reduced activation in midline sectors of the autobiographical memory network that support the autonoetic, first-person element of episodic memory. (C) 2009 Elsevier Ltd. All rights reserved.	[Levine, Brian; Svoboda, Eva; Turner, Gary R.; Mandic, Marina; Mackey, Allison] Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON M6A 2E1, Canada; [Levine, Brian; Svoboda, Eva; Turner, Gary R.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada		Levine, B (corresponding author), Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Mackey, Allison/0000-0002-4404-3753	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 42385-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER		Addis DR, 2007, BRAIN, V130, P2327, DOI 10.1093/brain/awm166; ADDIS DR, 2006, NEUROPSYCHOLOGIA; Aggleton JP, 2006, TRENDS COGN SCI, V10, P455, DOI 10.1016/j.tics.2006.08.003; AGGLETON JP, 2002, NEURAL SYSTEMS UNDER; Brewer W. F., 1988, REMEMBERING RECONSID, V2, p[21, ix], DOI [10.1017/CBO9780511664014.004, DOI 10.1017/CBO9780511664014.004]; Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004; Butler CR, 2008, BRAIN, V131, P2243, DOI 10.1093/brain/awn127; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; Conway MA, 1996, J EXP PSYCHOL GEN, V125, P69, DOI 10.1037/0096-3445.125.1.69; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P898, DOI 10.1076/jcen.20.6.898.1112; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; Kopelman MD, 2003, HIPPOCAMPUS, V13, P879, DOI 10.1002/hipo.10140; Kopelman MD, 2001, PHILOS T R SOC B, V356, P1409, DOI 10.1098/rstb.2001.0942; Levine B, 2004, J COGNITIVE NEUROSCI, V16, P1633, DOI 10.1162/0898929042568587; Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Linton M., 1975, EXPLORATIONS COGNITI, P376; Maguire EA, 2001, PHILOS T R SOC B, V356, P1441, DOI 10.1098/rstb.2001.0944; Maguire EA, 2003, BRAIN, V126, P1511, DOI 10.1093/brain/awg157; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; McKinnon MC, 2008, J COGNITIVE NEUROSCI, V20, P1839, DOI 10.1162/jocn.2008.20126; MCKOON G, 1986, J EXP PSYCHOL LEARN, V12, P295, DOI 10.1037/0278-7393.12.2.295; Morris R, 1999, EUR J NEUROSCI, V11, P2506, DOI 10.1046/j.1460-9568.1999.00672.x; Petrides M., 2002, PRINCIPLES FRONTAL L; Piolino P, 2005, COGN NEUROPSYCHOL, V22, P1005, DOI 10.1080/02643290442000428; Piolino P, 2003, BRAIN, V126, P2203, DOI 10.1093/brain/awg222; Piolino P, 2002, MEMORY, V10, P239, DOI 10.1080/09658210143000353; Rosenbaum RS, 2008, J COGNITIVE NEUROSCI, V20, P1490, DOI 10.1162/jocn.2008.20105; Rosenbaum RS, 2007, HIPPOCAMPUS, V17, P1241, DOI 10.1002/hipo.20354; Rosenbaum RS, 2005, NEUROPSYCHOLOGIA, V43, P989, DOI 10.1016/j.neuropsychologia.2004.10.007; Rubin DC, 1997, MEM COGNITION, V25, P859, DOI 10.3758/BF03211330; Schacter DL, 2007, NAT REV NEUROSCI, V8, P657, DOI 10.1038/nrn2213; Soderlund H, 2008, NEUROPSYCHOLOGIA, V46, P127, DOI 10.1016/j.neuropsychologia.2007.08.003; Spreng RN, 2006, MEM COGNITION, V34, P1644, DOI 10.3758/BF03195927; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; SVOBODA EM, J NEUROSCIE IN PRESS; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; Talairach J., 1988, COPLANAR STEREOTAXIC; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; Tulving E., 1972, ORG MEMORY, P381; Tulving E, 1989, EUR J COGN PSYCHOL, V1, P3, DOI [10.1080/09541448908403069, DOI 10.1080/09541448908403069]; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631	50	39	40	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	SEP	2009	47	11					2188	2196		10.1016/j.neuropsychologia.2008.12.026			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Behavioral Sciences; Neurosciences & Neurology; Psychology	468SF	WOS:000267839900006	19154750				2022-02-06	
J	Nechifor, M				Nechifor, Mihai			Magnesium in major depression	MAGNESIUM RESEARCH			English	Article	12th International Magnesium Symposium 2009	SEP 22-25, 2009	Iasi, ROMANIA			magnesium; major depression; reward system; amitriptyline; sertraline	ANXIETY-RELATED BEHAVIOR; TRAUMATIC BRAIN-INJURY; NMDA/GLUTAMATE MECHANISM; ERYTHROCYTE MAGNESIUM; DEFICIENT DIET; MICE; RATS; SUPPLEMENTATION; INVOLVEMENT; SYMPTOMS	There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs 59.1 +/- 3.2 mg/L in control group, p < 0.05) and only in patients with severe MD (Hamilton score > 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p < 0.05 vs before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl(2) 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.	Gr T Popa Univ Med & Pharmacol, Dept Pharmacol, Iasi 700115, Romania		Nechifor, M (corresponding author), Gr T Popa Univ Med & Pharmacol, Dept Pharmacol, Univ 16, Iasi 700115, Romania.	nechifor@umfiasi.ro					BANKI CM, 1985, BIOL PSYCHIAT, V20, P163, DOI 10.1016/0006-3223(85)90076-9; Barra A, 2007, MAGNESIUM RES, V20, P245; Barragan-Rodriguez L, 2008, MAGNESIUM RES, V21, P218; Chollet D, 2001, BEHAV GENET, V31, P413, DOI 10.1023/A:1012790321071; Eby GA, 2006, MED HYPOTHESES, V67, P362, DOI 10.1016/j.mehy.2006.01.047; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Hantouche EG, 1998, ENCEPHALE, V24, P469; HASEY GM, 1993, BIOL PSYCHIAT, V33, P133, DOI 10.1016/0006-3223(93)90314-4; Iezhitsa IN, 2002, MAGNESIUM RES, V15, P179; Jacka FN, 2009, AUST NZ J PSYCHIAT, V43, P45, DOI 10.1080/00048670802534408; Joffe RT, 1996, BIOL PSYCHIAT, V40, P428, DOI 10.1016/0006-3223(96)00063-7; LAWLEY SI, 1990, PHARMACOL BIOCHEM BE, V36, P539, DOI 10.1016/0091-3057(90)90253-E; Levine J, 1999, NEUROPSYCHOBIOLOGY, V39, P63, DOI 10.1159/000026562; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NAKAMURA MM, 1983, ALCOHOL CLIN EXP RES, V7, P188, DOI 10.1111/j.1530-0277.1983.tb05437.x; Nechifor M, 2004, METAL IONS BIOL MED, V8, P518; NECHIFOR M, 2002, MAGNESIUM RES PHYSL, P177; Nechifor M, 2008, MAGNESIUM RES, V21, P97; Nechifor M, 2007, NEW PERSPECTIVES IN MAGNESIUM RESEARCH: NUTRITION AND HEALTH, P369, DOI 10.1007/978-1-84628-483-0_30; Pizzagalli DA, 2008, J PSYCHIATR RES, V43, P76, DOI 10.1016/j.jpsychires.2008.03.001; Poleszak E, 2007, PHARMACOL BIOCHEM BE, V88, P158, DOI 10.1016/j.pbb.2007.07.018; Poleszak E, 2008, PHARMACOL REP, V60, P655; Singewald N, 2004, NEUROPHARMACOLOGY, V47, P1189, DOI 10.1016/j.neuropharm.2004.08.010; Spasov AA, 2008, ZH VYSSH NERV DEYAT+, V58, P476; Szewczyk B, 2008, PHARMACOL REP, V60, P588; WIDMER J, 1995, J AFFECT DISORDERS, V34, P201, DOI 10.1016/0165-0327(95)00018-I; Zieba A, 2000, HUM PSYCHOPHARM CLIN, V15, P631, DOI 10.1002/hup.231	27	39	39	2	12	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0953-1424			MAGNESIUM RES	Magnes. Res.	SEP	2009	22	3					163S	166S					4	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	491CZ	WOS:000269556100006	19780403				2022-02-06	
J	Palmio, J; Suhonen, J; Keranen, T; Hulkkonen, J; Peltola, J; Pirttila, T				Palmio, Johanna; Suhonen, Jaana; Keranen, Tapani; Hulkkonen, Janne; Peltola, Jukka; Pirttila, Tuula			Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Axonal damage; Cerebrospinal fluid; Epileptic seizure; Phosphorylated tau protein; Tau protein	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; TONIC-CLONIC SEIZURES; ALZHEIMERS-DISEASE; S-100 PROTEIN; TRANSIENT INCREASE; BIOCHEMICAL MARKER; CSF; ENOLASE; DISCRIMINATION	Purpose: Whether repeated brief seizures can cause neuronal damage is controversial. Cerebrospinal fluid (CSF) total tau (T-tau) and phosphorylated tau (P-tau) measurements have been suggested for the diagnosis of Alzheimer's disease, and T-tau may also be a marker of axonal damage and neuronal degeneration. We studied T-tau and P-tau levels and P-tau/T-tau ratio in CSF after epileptic seizures in order to determine whether they are increased after seizures. Methods: A total of 54 patients with tonic-clonic or partial secondarily generalized seizures due to various etiologies were studied and CSF obtained within 48 h after the seizure. Results: There were no statistical differences in the levels of T-tau (p = 0.09, ANOVA) or P-tau (p = 0.60) between different etiologic groups or controls. No patients with epilepsy of unknown origin had abnormal CSF T-tau whereas 11 patients with acute or remote symptomatic seizures had abnormal T-tau levels and the P-tau/T-tau ratio showed significant differences between the groups and controls (p = 0.003). Conclusions: Epileptic seizures with unknown etiology did not increase CSF tau levels. Abnormal tau levels were associated with either acute or remote symptomatic seizures with known etiology. The presence of elevated CSF tau increases the probability of symptomatic cause in a patient with a seizure. (C) 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Palmio, Johanna] Univ Tampere, Dept Neurol, FIN-33014 Tampere, Finland; [Palmio, Johanna; Keranen, Tapani; Peltola, Jukka] Tampere Univ Hosp, Dept Neurol, FIN-33521 Tampere, Finland; [Suhonen, Jaana] Jokilaakso Hosp, Dept Neurol, FIN-42120 Jamsa, Finland; [Pirttila, Tuula] Univ Kuopio, Dept Neurol, FIN-70211 Kuopio, Finland		Palmio, J (corresponding author), Univ Tampere, Dept Neurol, FIN-33014 Tampere, Finland.	johanna.palmio@uta.fi			Medical Research Fund of Tampere University Hospital	This work was supported by the Medical Research Fund of Tampere University Hospital.	Blasko I, 2006, DEMENT GERIATR COGN, V21, P9, DOI 10.1159/000089137; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Buch KBN, 1999, NEUROSCI LETT, V277, P21; Buttner T, 1999, J NEUROL, V246, P459, DOI 10.1007/s004150050383; Correale J, 1998, NEUROLOGY, V50, P1388, DOI 10.1212/WNL.50.5.1388; CULLEN KM, 1995, NEUROPATH APPL NEURO, V21, P312, DOI 10.1111/j.1365-2990.1995.tb01065.x; DELACOURTE A, 1994, BIOMED PHARMACOTHER, V48, P287, DOI 10.1016/0753-3322(94)90174-0; Engel J, 2002, PROG BRAIN RES, V135, P509; Green AJE, 2000, SEX TRANSM INFECT, V76, P443, DOI 10.1136/sti.76.6.443; Herukka SK, 2005, NEUROLOGY, V64, P1294, DOI 10.1212/01.WNL.0000156914.16988.56; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Kapaki E, 2005, INT J GERIATR PSYCH, V20, P722, DOI 10.1002/gps.1351; Kapaki EN, 2007, EUR J NEUROL, V14, P168, DOI 10.1111/j.1468-1331.2006.01593.x; Leutmezer F, 2002, EPILEPSIA, V43, P1172, DOI 10.1046/j.1528-1157.2002.50101.x; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsui T, 2007, J AM GERIATR SOC, V55, P2096, DOI 10.1111/j.1532-5415.2007.01440.x; Morikawa Y, 1999, ALCOHOL CLIN EXP RES, V23, P575, DOI 10.1097/00000374-199904001-00001; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Palmio J, 2001, J NEUROL SCI, V183, P27, DOI 10.1016/S0022-510X(00)00478-0; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Riemenschneider M, 2003, MOL PSYCHIATR, V8, P343, DOI 10.1038/sj.mp.4001220; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Shiiya N, 2004, ANN THORAC SURG, V77, P2034, DOI 10.1016/j.athoracsur.2003.12.057; Sjogren M, 2001, CLIN CHEM, V47, P1776; Steinhoff BJ, 1999, EPILEPSY RES, V36, P75, DOI 10.1016/S0920-1211(99)00026-1; Sussmuth SD, 2001, NEUROSCI LETT, V300, P95, DOI 10.1016/S0304-3940(01)01556-7; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	30	39	39	0	1	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	SEP	2009	18	7					474	477		10.1016/j.seizure.2009.04.006			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	507ID	WOS:000270844800003	19428269	Bronze			2022-02-06	
J	Stern, S; Rice, J; Philbin, N; McGwin, G; Arnaud, F; Johnson, T; Flournoy, WS; Ahlers, S; Pearce, LB; McCarron, R; Freilich, D				Stern, Susan; Rice, Jennifer; Philbin, Nora; McGwin, Gerald; Arnaud, Francoise; Johnson, Todd; Flournoy, W. Shannon; Ahlers, Stephen; Pearce, L. Bruce; McCarron, Richard; Freilich, Daniel			RESUSCITATION WITH THE HEMOGLOBIN-BASED OXYGEN CARRIER, HBOC-201, IN A SWINE MODEL OF SEVERE UNCONTROLLED HEMORRHAGE AND TRAUMATIC BRAIN INJURY	SHOCK			English	Article						Hemoglobin-based oxygen carrier; HBOC-201; hemorrhagic shock; traumatic brain injury; resuscitation	BOVINE POLYMERIZED HEMOGLOBIN; CEREBRAL-BLOOD-FLOW; HYPERTONIC SALINE DEXTRAN; LACTATED RINGERS SOLUTION; LOW-VOLUME RESUSCITATION; CROSS-LINKED HEMOGLOBIN; CLOSED-HEAD TRAUMA; INTRACRANIAL-PRESSURE; INTRAVASCULAR MACROPHAGES; HYPOTENSIVE RESUSCITATION	The purpose of this investigation was to compare the effects of initial resuscitation with HBOC-201 to that of lactated Ringer (LR) solution in the setting of uncontrolled hemorrhage and traumatic brain injury (TBI). Anesthetized immature swine underwent fluid-percussion TBI and liver laceration. During a 75-min "prehospital phase," the animals were resuscitated with HBOC-201, LR solution, or nothing (NON). Upon "hospital arrival," the animals were provided blood and 0.9% NaCl as needed, and the liver injury was repaired. Surviving animals were killed 6 h after injury. Brain tissue was processed for blood flow, and gross, light microscopic, and immunohistochemical analyses. Mean TBI force (2.6 +/- 0.6 atm) and blood loss (64.4 +/- 3.4 mL/kg) were similar between groups. Six-hour survival was significantly greater in HBOC-201 (8 of 13 [62%]) versus LR solution (1 of 11 [9%]) and NON (11 of 8 [3%]) animals (P < 0.02). Mean arterial pressures, cardiac indices, cerebral perfusion pressures, and brain tissue oxygen tension were significantly greater, and lactate and base deficit were lower in HBOC-201 as compared with LR solution animals. Blood transfusion requirements were reduced in HBOC-201 (3.6 +/- 0.6 mL/kg per survival hour) as compared to 7.1 +/- 1.2 mL/kg per survival hour. Severity of subarachnoid and intraparenchymal hemorrhages was statistically greater in LR solution-treated animals, but these differences were not likely to be clinically significant. There were no differences in glial fibrillary acidic protein and microtubule-associated protein 2. In this model of combined uncontrolled hemorrhage and TBI, initial resuscitation with HBOC-201 resulted in significant improvements in survival and systemic and cerebrovascular physiological parameters, as well as a reduction in transfusion requirements.	[Stern, Susan] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Rice, Jennifer; Philbin, Nora; Arnaud, Francoise; Johnson, Todd; Ahlers, Stephen; McCarron, Richard; Freilich, Daniel] Naval Med Res Ctr, Silver Spring, MD USA; [McGwin, Gerald] Univ Alabama Birmingham, Birmingham, AL USA; [Flournoy, W. Shannon] Walter Reed Army Inst Res, Silver Spring, MD USA; [Pearce, L. Bruce] Biopure Corp, Cambridge, MA USA		Stern, S (corresponding author), Univ Michigan, Dept Emergency Med, TC B1 354,Box 0303,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	suestern@umich.edu			US Government (Office of Naval Research)Office of Naval Research [604771N.9595.001.A0315]	The studies described herein were entirely funded by the US Government (Office of Naval Research work unit no. 604771N.9595.001.A0315). The Naval Medical Research Center and Biopure Corp. have a Cooperative Research and Development Agreement for evaluation of HBOC-201 in trauma clinical trials. No Naval Medical Research Center or other authors (with the exception of L.B.P. of Biopure Corp.) have financial or other competing interests related to this article. Hemoglobin-based oxygen carrier formulations were provided by Biopure Corp. (under Materials Transfer Agreements). There were no transfers of funds in ally of these agreements. Dr. Bruce Pearce is in employee of Biopure Corp. and has financial interest in the subject material. HBOC-201. Dr. Pearce's contribution to this article was limited to study design, protocol authorship, and editorial review.; The opinions expressed in this article are those of the authors and do not reflect the official policy of the Departments of the Navy, Army, and Defense. or the US Government.; D.F. is a military service member (or employee of the US government). This work was prepared as part of my official duties. Title 17 U.S.C 105 provides that "Copyright protection under this title is not available for any work of the United States Government." Title 17 U.S.C 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties.	Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; *AM ASS NEUR, 1995, JOINT SECT TRAUM CRI; *AM COLL SURG COT, 1997, ADV TRAUM LIF SUPP P; Arnaud F, 2006, TRANSFUSION MED, V16, P290, DOI 10.1111/j.1365-3148.2006.00678.x; Asano Y, 1998, AM J PHYSIOL-HEART C, V275, pH1313, DOI 10.1152/ajpheart.1998.275.4.H1313; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Caswell JE, 2005, AM J PHYSIOL-HEART C, V288, pH1796, DOI 10.1152/ajpheart.00905.2004; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Doucet JJ, 1999, J TRAUMA, V47, P956, DOI 10.1097/00005373-199911000-00027; Driessen B, 2003, CRIT CARE MED, V31, P1771, DOI 10.1097/01.CCM.0000063476.79749.C1; DUNHAM CM, 1991, CRIT CARE MED, V19, P231, DOI 10.1097/00003246-199102000-00020; ENZAN K, 1991, J APPL PHYSIOL, V71, P2231, DOI 10.1152/jappl.1991.71.6.2231; Feldman Z, 1997, J TRAUMA, V43, P667, DOI 10.1097/00005373-199710000-00017; Fitzpatrick MCM, 2005, J TRAUMA, V59, P273, DOI 10.1097/01.ta.0000174730.62338.88; FLAIM SF, 1991, INVEST RADIOL, V26, pS122, DOI 10.1097/00004424-199111001-00041; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; George I, 2006, AM J PHYSIOL-HEART C, V291, pH1126, DOI 10.1152/ajpheart.00076.2006; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GROSS D, 1989, J TRAUMA, V29, P79, DOI 10.1097/00005373-198901000-00016; GROSSLIGHT K, 1985, ANESTHESIOLOGY, V63, P533, DOI 10.1097/00000542-198511000-00011; Gulati A, 1996, CRIT CARE MED, V24, P137, DOI 10.1097/00003246-199601000-00023; GUNNAR W, 1988, SURGERY, V103, P398; Gurney J, 2004, J TRAUMA, V57, P726, DOI 10.1097/01.TA.0000147520.84792.B4; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnson SB, 1996, J TRAUMA, V40, P921; Kasper SM, 1996, ANESTH ANALG, V83, P921; Kaufmann CR, 2005, J TRAUMA, V59, P281; Kerby JD, 2007, SHOCK, V27, P652, DOI 10.1097/01.shk.0000248584.10400.dc; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; Lee SK, 2002, ACAD EMERG MED, V9, P969; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; Matsuoka T, 1996, J TRAUMA, V40, P915, DOI 10.1097/00005373-199606000-00009; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; McNeil JD, 2001, J TRAUMA, V50, P1063, DOI 10.1097/00005373-200106000-00015; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MIYAMOTO K, 1988, J APPL PHYSIOL, V64, P1143, DOI 10.1152/jappl.1988.64.3.1143; OLSON DA, 2004, E MED; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Pearce LB, 2003, ADV EXP MED BIOL, V530, P261; Philbin N, 2005, RESUSCITATION, V66, P367, DOI 10.1016/j.resuscitation.2005.03.019; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Rebel A, 2002, AM J PHYSIOL-HEART C, V282, pH832, DOI 10.1152/ajpheart.00880.2001; Reinhardt CP, 2001, AM J PHYSIOL-HEART C, V280, pH108, DOI 10.1152/ajpheart.2001.280.1.H108; Rice J, 2005, SHOCK, V23, P20; Rice J, 2006, J TRAUMA, V61, P1085, DOI 10.1097/01.ta.0000236640.62893.fa; Rice J, 2006, SHOCK, V26, P302, DOI 10.1097/01.shk.0000226338.48033.c2; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; SCHULTZ SC, 1993, J LAB CLIN MED, V122, P301; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 2005, J TRAUMA, V59, P560; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; SHOEMAKER WC, 1979, CRIT CARE MED, V7, P424, DOI 10.1097/00003246-197909000-00015; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Sondeen JL, 2003, J TRAUMA, V54, pS110, DOI 10.1097/01.TA.0000047220.81795.3D; SPAHN DR, 1994, ANESTH ANALG, V78, P1000; STAUB N C, 1988, Chest, V93, p84S, DOI 10.1378/chest.93.3_Supplement.84S; STERN S, 1996, ACAD EMERG MED, V3, P545; STERN SA, 1995, AM J EMERG MED, V13, P269, DOI 10.1016/0735-6757(95)90198-1; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; STERN SA, 1995, ACAD EMERG MED, V2, P89, DOI 10.1111/j.1553-2712.1995.tb03167.x; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; Talmor D, 1999, ANESTH ANALG, V89, P950, DOI 10.1097/00000539-199910000-00024; Torres LN, 2004, AM J PHYSIOL-HEART C, V286, pH1811, DOI 10.1152/ajpheart.00837.2003; Tsai AG, 2001, TRANSFUSION, V41, P1290, DOI 10.1046/j.1537-2995.2001.41101290.x; Ulatowski JA, 1998, AM J PHYSIOL-HEART C, V274, pH1933, DOI 10.1152/ajpheart.1998.274.6.H1933; VLAHAKES GJ, 1990, J THORAC CARDIOV SUR, V100, P379; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WANG Y, 1993, AM REV RESPIR DIS, V147, P927, DOI 10.1164/ajrccm/147.4.927; WINKLER GC, 1985, J LEUKOCYTE BIOL, V38, P471, DOI 10.1002/jlb.38.4.471; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F; YUAN XQ, 1991, CIRC SHOCK, V35, P231; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	87	39	41	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JAN	2009	31	1					64	79		10.1097/SHK.0b013e3181778dc3			16	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	385LO	WOS:000261815900010	18497706				2022-02-06	
J	Weichel, EA; Colyer, MH; Bautista, C; Bower, KS; French, LM				Weichel, Eric A.; Colyer, Marcus H.; Bautista, Charisma; Bower, Kraig S.; French, Louis M.			Traumatic Brain Injury Associated With Combat Ocular Trauma	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed-globe; ocular trauma; open-globe; Operation Iraqi Freedom; traumatic brain injury	UNITED-STATES; REHABILITATION; IRAQ; WAR; AFGHANISTAN; IMPAIRMENT; DEPRESSION; MANAGEMENT; OUTCOMES; SYSTEM	Purpose: To determine the impact of traumatic brain injury (TBI) on visual outcomes in combat ocular trauma (COT) and determine the association between TBI severity and types of ocular injuries. Participants: One hundred fifty-two US casualties sustained 207 globe/oculoplastic combat injuries. Methods: Retrospective, hospital-based cross-sectional study of US service members injured during Operations Iraqi Freedom and Enduring Freedom were treated by the Ophthalmology Service at Walter Reed Army Medical Center and screened for TBI by the Defense and Veterans Brain Injury Center from August 2004 to October 2006. Main Outcome Measures: The main outcome measure was best-corrected visual acuity (BCVA). Secondary outcome measures included the severity and frequency of TBI with globe, oculoplastic, and/or neuro-ophthalmic injury. Results: The frequency of COT with positive TBI screening was 101 of 152 cases (66%) in comparison with negative TBI screening, which was 51 of 152 (34%) cases. The Defense and Veterans Brain Injury Center found TBI with concomitant ocular trauma in 101 of 474 (21%) consecutive casualties. Explosive fragmentary munitions accounted for 79% of TBI-associated COT The median follow-up was 185 days. Traumatic brain injury severity did not correlate with worse final BCVA (Spearman coefficient, r = 0.12). The odds that BCVA worse than 20/200 was present with TBI was not statistically significant (OR: 1.5; 95% CI, 0.9-2.6; P =. 10). The presence of TBI in COT was not associated with worse visual outcome (Mann-Whitney U test,P = .10). Globe injuries were more common than oculoplastic or neuro-ophthalmic injury. Closed-globe injuries were more likely to have TBI than open-globe injuries (OR: 2.17; 95% CI, 1.12-4.21; P = .03). Traumatic brain injury severity associated with COT included mild TBI (31%), moderate TBI (30%), severe TBI (25%), and penetrating TBI (14%). Severe TBI is more frequently associated with COT Conclusion: Traumatic brain injury occurs in two thirds of all COT and ocular trauma is a common finding in all TBI cases. Closed-globe injuries are at highest risk for TBI while TBI does not appear to lead to poorer visual outcomes. Every patient with COT needs TBI screening. Those service members who are screened TBI positive need a referral to a TBI rehabilitation specialist.	[Weichel, Eric A.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA; [French, Louis M.] Def & Vet Brain Injury Ctr, Washington, DC USA; [Weichel, Eric A.] NEI, NIH, Bethesda, MD 20892 USA; [Bautista, Charisma; Bower, Kraig S.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Weichel, EA (corresponding author), Walter Reed Army Med Ctr, Ophthalmol Serv, 6900 Georgia Ave, Washington, DC 20307 USA.	eweichel@hotmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Andermahr J, 2006, J NEUROTRAUM, V23, P708, DOI 10.1089/neu.2006.23.708; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; *DEP DEF PERS PROC, GLOB WAR TERR OP END; *DEP DEF PERS PROC, 2003, OP IR FREED MIL WOUN; DUKEELDER S, 1972, SYSTEM OPHTHALMOLOGY, V14, P50; Elovic EP, 2008, ARCH PHYS MED REHAB, V89, pS21, DOI 10.1016/j.apmr.2007.12.012; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Flanagan SR, 2008, ARCH PHYS MED REHAB, V89, pS9, DOI 10.1016/j.apmr.2007.12.010; Frucht SJ, 2002, ADV NEUROL, V89, P85; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; *GOVTRACK US S, 1999, 110 C BILL PROV EST; GUNDERSEN T, 1947, T AM ACAD OPHTHALMOL, V52, P604; Harlan J B Jr, 2002, Ophthalmol Clin North Am, V15, P153, DOI 10.1016/S0896-1549(02)00006-8; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; HORNBLASS A, 1981, International Ophthalmology Clinics, V21, P121, DOI 10.1097/00004397-198102140-00008; Jacobs JM, 2005, AGING CLIN EXP RES, V17, P281; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn F, 2004, J FR OPHTALMOL, V27, P206, DOI 10.1016/S0181-5512(04)96122-0; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P139, DOI 10.1016/S0896-1549(02)00004-4; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P163, DOI 10.1016/S0896-1549(02)00007-X; Kwasnica C, 2008, ARCH PHYS MED REHAB, V89, pS15, DOI 10.1016/j.apmr.2007.12.006; LOWREY A, 1954, Trans Pac Coast Otoophthalmol Soc Annu Meet, V35, P39; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Naraghi FF, 1996, ORTHOPEDICS, V19, P145; Parsons J., 1941, T OPHTHAL SOC UK, V61, P157; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; STONE W, 1950, JAMA-J AM MED ASSOC, V142, P151, DOI 10.1001/jama.1950.02910210007002; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Winter CD, 2005, SURG-J R COLL SURG E, V3, P329, DOI 10.1016/S1479-666X(05)80112-X	47	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					41	50		10.1097/HTR.0b013e3181956ffd			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500007	19158595				2022-02-06	
J	Bradbury, CL; Wodchis, WP; Mikulis, DJ; Pano, EG; Hitzig, SL; McGillivray, CF; Ahmad, FN; Craven, BC; Green, RE				Bradbury, Cheryl L.; Wodchis, Walter P.; Mikulis, David J.; Pano, Ephrem G.; Hitzig, Sander L.; McGillivray, Colleen F.; Ahmad, Fahad N.; Craven, B. Catherine; Green, Robin E.			Traumatic Brain Injury in Patients With Traumatic Spinal Cord Injury: Clinical and Economic Consequences	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation; Spinal cord injuries	CLOSED HEAD-INJURY	Objective: To evaluate the clinical and economic burden of traumatic brain injury (TBI) in people with traumatic spinal cord injury (SCI). Design: Prospective, case-matched control study. Setting: Inpatient spinal cord rehabilitation program. Participants: Patients (n=10) diagnosed with traumatic SCI and concomitant TBI matched to an SCI only control group. Interventions: Not applicable. Main Outcome Measures: Inpatient rehabilitation length of stay, health care costs (patient care hours), clinician resource allocation, behavioral and critical incidents, FIM, Personality Assessment Inventory, and neuropsychological assessment findings. Results: Prolonged loss of consciousness, increased rehabilitation costs, and greater demands on clinician recourses (trend) were found in the SCI with TBI group relative to the SCI-only group. Neuropsychological test performance was significantly worse in the SCI with TBI group, while the FIM cognition score did not discriminate because of ceiling effects. Greater evidence of psychopathology was observed in the SCI with TBI group. Conclusions: The presence of TBI in SCI has a range of clinical and economic consequences. This dual diagnosis has the potential to affect SCI rehabilitation negatively, as well as quality of life and reintegration in the community. Specialized care appears to be needed to improve outcomes and to minimize clinical and economic burden, but further research is required.	[Bradbury, Cheryl L.; Wodchis, Walter P.; Pano, Ephrem G.; Hitzig, Sander L.; McGillivray, Colleen F.; Craven, B. Catherine; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON M4G 3V9, Canada; [Wodchis, Walter P.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada; [Pano, Ephrem G.; Green, Robin E.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; [Mikulis, David J.; McGillivray, Colleen F.; Craven, B. Catherine] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada; [Hitzig, Sander L.] York Univ, Dept Psychol, N York, ON M3J 1P3, Canada; [Mikulis, David J.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada		Bradbury, CL (corresponding author), Toronto Rehabil Inst, 520 Sutherland Dr, Toronto, ON M4G 3V9, Canada.	bradbury.cheryl@torontorehab.on.ca	Craven, Beverley Catharine/D-5001-2015; Mikulis, David J/H-5167-2019; Greiver, Michelle/N-8764-2015; Hitzig, Sander/AAN-2287-2020	Craven, Beverley Catharine/0000-0001-8234-6803; Greiver, Michelle/0000-0001-8957-0285; Mikulis, David/0000-0003-3956-0892; wodchis, walter/0000-0003-2494-7031; McGillivray, Colleen/0000-0002-0982-233X; Green, Robin/0000-0001-9451-3963	Ontario Neurotrauma Foundation [2005-ABI-392]	Supported by the Ontario Neurotrauma Foundation (grant no 2005-ABI-392).	Arzaga Deborah, 2003, SCI Nurs, V20, P86; COHEN J, 1994, AM PSYCHOL, V49, P997, DOI 10.1037/0003-066X.49.12.997; Cohen J., 1983, APPL MULTIPLE REGRES; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Delis D.C., 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; Granger CV, 1986, FUNCTIONAL INDEPENDE; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; Hooper HE., 1983, HOOPER VISUAL ORG TE; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KREUTZER JS, 1988, ARCH PHYS MED REHAB, V69, P764; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lin KC, 2007, CLIN REHABIL, V21, P1075, DOI 10.1177/0269215507079843; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; *MAYO CLIN STAFF, 2007, SPIN CORD INJ; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Morey, 1991, PERSONALITY ASSESSME; National Spinal Cord Injury Statistical Center, FACTS FIG GLANC; POVOLNY MA, 1993, J REHABIL, V59, P23; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; Ricker JH, 1999, TOP SPINAL CORD INJ, V5, P76; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; SABOE LA, 1991, J TRAUMA, V31, P43, DOI 10.1097/00005373-199101000-00010; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Smith A., 1982, SYMBOL DIGIT MODALIT; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sutherland J, 2006, TECHNICAL REPORT DEV; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; *US DEP HHS, 1999, TRAUM BRAIN INJ US A; WAGNER KA, 1983, ARCH PHYS MED REHAB, V64, P519; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Weschler D., 2001, WECHSLER TEST ADULT; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463	47	39	43	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S77	S84		10.1016/j.apmr.2008.07.008			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	388DB	WOS:000261999400010	19081445				2022-02-06	
J	Stewart, C; Haitsma, I; Zador, Z; Hemphill, JC; Morabito, D; Manley, G; Rosenthal, G				Stewart, Campbell; Haitsma, Iain; Zador, Zsolt; Hemphill, J. Claude, III; Morabito, Diane; Manley, Geoffrey; Rosenthal, Guy			THE NEW LICOX COMBINED BRAIN TISSUE OXYGEN AND BRAIN TEMPERATURE MONITOR: ASSESSMENT OF IN VITRO ACCURACY AND CLINICAL EXPERIENCE IN SEVERE TRAUMATIC BRAIN INJURY	NEUROSURGERY			English	Article						Brain temperature; Brain tissue oxygen tension; Clinical evaluation; In vitro accuracy; Technology assessment	SEVERE HEAD-INJURY; TENSION; PROBES	OBJECTIVE: Monitoring of brain tissue oxygen tension is increasingly being used to monitor patients after severe traumatic brain injury and to guide therapies aimed at maintaining brain tissue oxygen tension above threshold levels. The new Licox PMO combined oxygen and temperature catheter (Integra LifeSciences, Plainsboro, NJ) combines measurements of oxygen tension and temperature in a single probe inserted through a bolt mechanism. In this study, we sought to evaluate the accuracy of the new Licox PMO probe under controlled laboratory conditions and to assess the accuracy of oxygen tension and temperature measurements and the new automated card calibration system. We also describe our clinical experience with the Licox PMO probe. METHODS: Oxygen tension was measured in a 2-chambered apparatus at different oxygen tensions and temperatures. The new card calibration system was compared with a manually calibrated system. Rates of hematoma, infection, and dislodgement in Our clinical experience were recorded. RESULTS: The new Licox PMO probe accurately measures oxygen tension over a wide range of oxygen concentrations and physiological temperatures, but it does have a small tendency to underestimate oxygen tension (mean error, -3.8 +/- 3.5%) that is more pronounced between the temperatures of 33 and 39 degrees C. The thermistor of the PMO probe also has a tendency to underestimate temperature when compared with a resistance thermometer (mean error, -0.67 +/- 0.22 degrees C). The card calibration system was also found to introduce some variability in measurements of oxygen tension when compared with a manually calibrated system. Clinical experience with the new probe indicates good placement within the white matter using the improved bolt system and low rates of hematoma (2.9%), infection (0%), and dislodgement (5.9%). CONCLUSION: The new Licox PMO probe is accurate but has a small, consistent tendency to under-read oxygen tension that is more pronounced at higher temperatures. The probe tends to under-read temperature by 0.5 to 0.8 degrees C across temperatures, suggesting that caution should be used when brain temperature is measured with the Licox PMO probe and used to guide tempera tu re-directed treatment strategies. The Licox PMO probe improves upon previous models in allowing consistent and accurate placement in the white matter and obviating the need for placement of 2 separate probes to measure oxygen tension and temperature.	[Zador, Zsolt; Morabito, Diane; Manley, Geoffrey; Rosenthal, Guy] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94110 USA; [Stewart, Campbell] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94110 USA; [Haitsma, Iain] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands; [Hemphill, J. Claude, III] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands		Manley, G (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Demchuk, Andrew M/E-1103-2012; Hemphill, Claude/AAY-5630-2021	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525; zador, zsolt/0000-0003-4297-616X; Zador, Zsolt/0000-0001-9767-3372			Alessandri B, 2004, J NEUROSCI METH, V139, P161, DOI 10.1016/j.jneumeth.2004.04.021; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 1998, ACT NEUR S, V71, P162; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vath A, 2002, ACT NEUR S, V81, P307	11	39	41	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2008	63	6					1159	1164		10.1227/01.NEU.0000333265.19131.7C			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	382ZH	WOS:000261643400047	19057329				2022-02-06	
J	Case, ME				Case, Mary E.			Inflicted traumatic brain injury in infants and young children	BRAIN PATHOLOGY			English	Article						abusive injuries; head injury; retinal hemorrhages; subdural hemorrhage	DIFFUSE AXONAL INJURY; SHAKEN BABY SYNDROME; NONACCIDENTAL HEAD-INJURY; CHRONIC SUBDURAL-HEMATOMA; RETINAL HEMORRHAGE; NEUROPATHOLOGY; DEATH; MECHANISMS; MORPHOLOGY; DIAGNOSIS	This article will discuss the subject of inflicted or abusive head injury in infants and young children. Inflicted neurotrauma is a very common injury and a frequent problem in attempting to distinguish between inflicted and accidental injury. Inflicted head injury occurs usually in the home in the presence of the individual who has inflicted the injury outside the view of unbiased witnesses. Distinguishing between inflicted and accidental injury may be dependent upon the pathological findings and consideration of the circumstances surrounding the injury. The most common finding in an inflicted head injury is the presence of subdural hemorrhage. Subdural hemorrhage may occur in a variety of distributions and appearances. The natural history of subdural bleeding and the anatomy of the "subdural" will be considered. The anatomy of the dura and its attachment to the skull and to the arachnoid determines how subdural bleeding evolves into the cleaved dural border cell layer and as well as how bridging veins are torn and anatomically where bleeding will occur. Different biomechanical mechanisms result in different distributions of subdural blood and these differences will be discussed.	St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, St Louis, MO 63104 USA		Case, ME (corresponding author), St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	mcase@stlouisco.com					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bittigau P, 1998, RESTOR NEUROL NEUROS, V13, P11; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Borzone M, 1983, J Neurosurg Sci, V27, P161; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; CASE ME, 1996, ANN M NAT ASS MED EX; CASE ME, 2002, ANN M NAT ASS MED EX; CASE MES, 1993, ANN M NAT ASS MED EX; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Cuatico W, 1991, J Neurosurg Sci, V35, P139; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DIERCKX RA, 1989, ACTA NEUROL BELG, V89, P352; DIMAIO DJ, 1993, FORENSIC PATHOLOGY, P304; Dolinak D, 2006, ARCH PATHOL LAB MED, V130, P712; DOLINSKAS CA, 1978, RADIOLOGY, V126, P409, DOI 10.1148/126.2.409; DOLINSKAS CA, 1979, J TRAUMA, V19, P163, DOI 10.1097/00005373-197903000-00006; Douherty W, 1931, JAMA-J AM MED ASSOC, V97, P308; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; FRASER SG, 1995, EYE, V9, P659, DOI 10.1038/eye.1995.165; GEAN AD, 1994, HEAD TRAUMA, P367; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GOODELL CL, 1963, ARCH NEUROL-CHICAGO, V8, P429, DOI 10.1001/archneur.1963.00460040099009; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAINES DE, 1991, ANAT RECORD, V230, P3, DOI 10.1002/ar.1092300103; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HARRIS LS, 1969, AM J CLIN PATHOL, V52, P289; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; KAWAKAMI Y, 1989, NEUROSURGERY, V25, P25, DOI 10.1227/00006123-198907000-00005; Kivlin J D, 1999, Trans Am Ophthalmol Soc, V97, P545; KLEINMAN P, 1990, AM J RADIOL, V156, P703; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P285; KRAMER K, 1993, CLIN PEDIATR, V32, P366, DOI 10.1177/000992289303200610; Lee KS, 1998, BRAIN INJURY, V12, P901; Lee Kyeong-Seok, 1996, Journal of Korean Medical Science, V11, P55; LEVIN A, 1998, AM ACAD OPHTHALMOL, V16, P1; LEVIN A, 1986, PEDIATR EMERG CARE, V2, P269; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Levin AV, 1990, OPHTHALMOL CLIN N AM, V3, P249; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MATAKAS F, 1973, J NEUROL NEUROSUR PS, V36, P497, DOI 10.1136/jnnp.36.4.497; MAYFRANK L, 1993, ACTA NEUROCHIR, V120, P92, DOI 10.1007/BF02001476; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; MURATA K, 1993, NEURO MED CHIR TOKYO, V33, P391; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; PARENT AD, 1992, PEDIATR NEUROSURG, V18, P266, DOI 10.1159/000120674; PARRISH R, 1996, PED TRAUMA FORENSIC; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P391, DOI 10.1097/00000433-199812000-00019; PRIATT JH, 1995, PEDIATRICS, V96, P780; Reichard RR, 2003, J NEUROPATH EXP NEUR, V62, P237, DOI 10.1093/jnen/62.3.237; ROSENTHAL M, 1990, REHABILITATION ADULT, P521; Salehi-Had H, 2006, PEDIATRICS, V117, pE1039, DOI 10.1542/peds.2005-0811; Sargent S, 1996, J FORENSIC SCI, V41, P314; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; TOWBIN A, 1967, LANCET, V2, P940; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; WEISSGOLD DJ, 1995, SURV OPHTHALMOL, V39, P509; Wells RG, 2002, ARCH PEDIAT ADOL MED, V156, P252, DOI 10.1001/archpedi.156.3.252; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; WILBUR LS, 1992, PEDIATRICS, V89, P332; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121	87	39	41	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	OCT	2008	18	4					571	582		10.1111/j.1750-3639.2008.00204.x			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	347MW	WOS:000259146700012	18782169	Green Published			2022-02-06	
J	Case, ME				Case, Mary E.			Accidental traumatic head injury in infants and young children	BRAIN PATHOLOGY			English	Article						epidural hemorrhage; head injury; short falls; subdural hemorrhage	EXTRADURAL HEMATOMA; AXONAL INJURY; FALLS	This article will discuss accidental head injuries in infants and young children. The first category of injury is the crushing head injury. Static forces applied slowly to the head result in multiple fractures of the skull and contusions and lacerations of the brain resulting from the bone fragments striking the brain. This article will discuss the subject of short falls in young children and the resulting head injuries. Because falls are frequent events in early life, many cases have been collected and many papers written on the subject. Study of these cases is informative about the injuries likely to occur in these falls. Most often, only a minor contact injury such as scalp bruise or laceration results. In a 2 to 3% of falls, a simple linear skull fracture occurs and the majority of these are uneventful in terms of neurological deficit or intracranial bleeding. In about 1% of the fractures, an epidural or subdural hemorrhage occurs. Each of these forms of contact hemorrhages will be discussed and illustrated. While these are relatively rare injuries, it is essential that they can be identified as consistent with an accidental mechanism so that an erroneous diagnosis of inflicted injury is not made.	St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, St Louis, MO 63104 USA		Case, ME (corresponding author), St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	mcase@stlouisco.com					BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bertocci GE, 2003, ARCH PEDIAT ADOL MED, V157, P480, DOI 10.1001/archpedi.157.5.480; CASE MES, 1994, CHILD MALTREATMENT, P75; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; CHADWICK DL, 1993, J TRAUMA, V35, P968, DOI 10.1097/00005373-199312000-00031; DAWSON SL, 1980, HUM PATHOL, V11, P155, DOI 10.1016/S0046-8177(80)80136-5; Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; DUHAIME AC, 1995, NEUROSURGERY, V37, P401, DOI 10.1227/00006123-199509000-00005; FREYTAG E, 1963, ARCH PATHOL, V75, P402; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HELFER RE, 1977, PEDIATRICS, V60, P533; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; KRAVITZ H, 1969, PEDIATRICS, V44, P869; LYONS TJ, 1993, PEDIATRICS, V92, P125; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MUSEMECHE CA, 1991, J TRAUMA, V31, P1347, DOI 10.1097/00005373-199110000-00004; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Ommaya AK, 2003, BRIT J NEUROSURG, V17, P201, DOI 10.1080/0268869031000110825; Prasad MR, 1999, J CHILD NEUROL, V14, P496, DOI 10.1177/088307389901400803; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Sauvageau A, 2008, J FORENSIC SCI, V53, P479, DOI 10.1111/j.1556-4029.2008.00664.x; Servadei F, 1997, ACTA NEUROCHIR, V139, P273, DOI 10.1007/BF01808821; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; Winston, 1998, CHILD MALTREATMENT, V3, P116, DOI [DOI 10.1177/1077559598003002006, 10.1177/1077559598003002006]	26	39	42	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	OCT	2008	18	4					583	589		10.1111/j.1750-3639.2008.00203.x			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	347MW	WOS:000259146700013	18782170	Green Published			2022-02-06	
J	Numa, R; Kohen, R; Poltyrev, T; Yaka, R				Numa, R.; Kohen, R.; Poltyrev, T.; Yaka, R.			Tempol diminishes cocaine-induced oxidative damage and attenuates the development and expression of behavioral sensitization	NEUROSCIENCE			English	Article						cocaine; oxidative stress; tempol; total antioxidant capacity; behavioral sensitization; antioxidants	CLOSED-HEAD INJURY; RADICAL ABSORBENCY CAPACITY; STABLE NITROXIDE; NITRIC-OXIDE; NORCOCAINE NITROXIDE; REPERFUSION INJURY; REDOX-REGULATION; IN-UTERO; BRAIN; RAT	A variety of mechanisms has been suggested for cocaine toxicity, including the possibility that cocaine induces an increase in oxidative stress (OS) due to excessive oxidation of dopamine (e.g. dopamine quinine), or by redox cycling of cocaine oxidized metabolites. However, the association between oxidative status in the brain and cocaine induced-behavior is poorly understood. Therefore, we examined the ability of the unique antioxidant tempol to attenuate cocaine-induced oxidative damage and behavioral response. Acute cocaine treatment significantly elevated OS markers in prefrontal cortex (PFC) and nucleus accumbens (NAc) in rats, both in slices and following a single cocaine injection, which corresponded with a decrease in total antioxidant capacity JAC). Tempol, at the optimal concentration we determined that was needed to observe an antioxidant non-toxic effect in vitro (1 mM) and in vivo (200 mg/kg), completely abolished the elevation of OS markers and prevented the reduction in TAC in these areas. Importantly, tempol injections, at a dose that does not affect the basal levels of locomotor activity, attenuated both the development and expression of cocaine-induced locomotor sensitization. Finally, in cocaine-sensitized animals, tempol prevented the elevation of OS markers in both PFC and NAc. Our findings suggest that oxidation of specific sites in the brain reward system by cocaine is accompanied with behavioral changes. Tempol has a neuroprotective effect against cocaine toxicity in these regions, and it may be beneficial in the treatment of cocaine addiction. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Numa, R.; Poltyrev, T.; Yaka, R.] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Numa, R.; Kohen, R.] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmaceut, IL-91120 Jerusalem, Israel		Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il	Kohen, Ron/ABC-2281-2021	Kohen, Ron/0000-0001-7268-9845	Israel Science FoundationIsrael Science Foundation [292105]	This research was partially supported by the Israel Science Foundation (R. Y. grant No. 292105). R. Kohen and R. Yaka are affiliated with the David R. Bloom Center for Pharmacy and the Brettler Center for research in molecular pharmacology and therapeutics, School of Pharmacy, The Hebrew University of Jerusalem.	Aronovitch Y, 2007, FREE RADICAL BIO MED, V42, P1317, DOI 10.1016/j.freeradbiomed.2007.01.017; Bashkatova V, 2005, NEUROREPORT, V16, P1217, DOI 10.1097/00001756-200508010-00017; Bashkatova V, 2006, ANN NY ACAD SCI, V1074, P632, DOI 10.1196/annals.1369.061; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; BOELSTERLI UA, 1991, ARCH TOXICOL, V65, P351, DOI 10.1007/BF02284256; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO G, 1995, CLIN CHEM, V41, P1738; Dietrich JB, 2005, NEUROPHARMACOLOGY, V48, P965, DOI 10.1016/j.neuropharm.2005.01.018; Fineschi V, 2001, INT J LEGAL MED, V114, P323, DOI 10.1007/s004140000194; Fraschini C, 2000, CARBOHYD RES, V328, P585, DOI 10.1016/S0008-6215(00)00129-4; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; HAHN SM, 1995, CAN J PHYSIOL PHARM, V73, P399, DOI 10.1139/y95-051; HAHN SM, 1992, CANCER RES, V52, P1750; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Hermida-Ameijeiras A, 2004, NEUROCHEM INT, V45, P103, DOI 10.1016/j.neuint.2003.11.018; Israeli A, 2005, FREE RADICAL BIO MED, V38, P317, DOI 10.1016/j.freeradbiomed.2004.09.037; KARMELI F, 1995, GUT, V37, P386, DOI 10.1136/gut.37.3.386; KLOSS MW, 1984, BIOCHEM PHARMACOL, V33, P169, DOI 10.1016/0006-2952(84)90471-4; KLOSS MW, 1984, PSYCHOPHARMACOLOGY, V84, P221, DOI 10.1007/BF00427449; Kovacic P, 2005, MED HYPOTHESES, V64, P350, DOI 10.1016/j.mehy.2004.06.028; Kunz WS, 1999, J NEUROCHEM, V72, P1580, DOI 10.1046/j.1471-4159.1999.721580.x; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Liang QH, 2005, BIOCHEM PHARMACOL, V70, P1371, DOI 10.1016/j.bcp.2005.04.011; Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Moor E, 2001, NEUROSCI LETT, V316, P169, DOI 10.1016/S0304-3940(01)02394-1; Moritz F, 2003, J CARDIOVASC PHARM, V42, P642, DOI 10.1097/00005344-200311000-00010; Ndikum-Moffor FM, 1998, J PHARMACOL EXP THER, V284, P413; Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005; NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x; Nishiyama A, 2004, J AM SOC NEPHROL, V15, P306, DOI 10.1097/01.ASN.0000108523.02100.E0; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.3.CO;2-H; Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; Smythies J, 1998, BBA-GEN SUBJECTS, V1380, P159, DOI 10.1016/S0304-4165(97)00131-1; Soule BP, 2007, FREE RADICAL BIO MED, V42, P1632, DOI 10.1016/j.freeradbiomed.2007.02.030; Thiemermann C, 2003, CRIT CARE MED, V31, pS76, DOI 10.1097/00003246-200301001-00011; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Vetulani J, 2001, POL J PHARMACOL, V53, P303; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; Zeltcer G, 1997, FREE RADICAL RES, V27, P627, DOI 10.3109/10715769709097866	53	39	41	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	AUG 26	2008	155	3					649	658		10.1016/j.neuroscience.2008.05.058			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	344RK	WOS:000258944800010	18619523				2022-02-06	
J	Figaji, AA; Fieggen, AG; Argent, AC; LeRoux, PD; Peter, JC				Figaji, Anthony A.; Fieggen, A. Graham; Argent, Andrew C.; LeRoux, Peter D.; Peter, Jonathan C.			Does adherence to treatment targets in children with severe traumatic brain injury avoid brain hypoxia? A brain tissue oxygenation study	NEUROSURGERY			English	Article						brain hypoxia; cerebral ischemia; cerebral oxygenation; cerebral perfusion pressure; children; head injury; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; BLOOD-FLOW; INITIAL-EXPERIENCE; SUBSTRATE DELIVERY; PEDIATRIC-PATIENTS; INSPIRED OXYGEN; LOWER LIMIT; TRANSFUSION	OBJECTIVE: Most physicians rely on conventional treatment targets for intracranial pressure, cerebral perfusion pressure, systemic oxygenation, and hemoglobin to direct management of traumatic brain injury (TBI) in children. In this study, we used brain tissue oxygen tension (PbtO(2)) monitoring to examine the association between PbtO(2) values and Outcome in pediatric severe TBI and to determine the incidence of compromised PbtO(2) in patients for whom acceptable treatment targets had been achieved. METHODS: In this prospective observational study, 26 children with severe TBI and a median postresuscitation Glasgow Coma Scale score of 5 were managed with continuous PbtO(2) monitoring. The relationships between outcome and the 6-hour period of lowest PbtO(2) values and the length of time that PbtO(2) was less than 20, 15, 10, and 5 mmHg were examined. The incidence of reduced PbtO(2) for each threshold was evaluated where the following targets were met: intracranial pressure less than 20 mmHg, cerebral perfusion pressure greater than 50 mmHg, arterial oxygen tension greater than 60 mmHg (and peripheral oxygen saturation > 90%), and hemoglobin greater than 8 g/dl. RESULTS:There was a significant association between poor outcome and the 6-hour period of lowest PbtO(2) and length of time that PbtO(2) was less than 15 and 10 mmHg. Multiple logistic regression analysis showed that low PbtO(2) had an independent association with poor outcome. Despite achieving the management targets described above, 80% of patients experienced one or more episodes of compromised PbtO(2) (< 20 mmHg), and almost one-third experienced episodes of brain hypoxia (PbtO(2) < 10 mmHg). CONCLUSION: Reduced PbtO(2) is associated with poor outcome in pediatric severe TBI. In addition, many patients experience episodes of compromised PbtO(2) despite achieving acceptable treatment targets.	[Figaji, Anthony A.] Univ Cape Town, Red Cross Childrens Hosp, Div Neurosurg, Sch Child & Adolescent Hlth,Inst Child Hlth 617, ZA-7700 Rondebosch, South Africa; [Argent, Andrew C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Pediat Crit Care, ZA-7700 Rondebosch, South Africa; [LeRoux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Figaji, AA (corresponding author), Univ Cape Town, Red Cross Childrens Hosp, Div Neurosurg, Sch Child & Adolescent Hlth,Inst Child Hlth 617, Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	anthony.figaji@uct.ac.za	Argent, Andrew/J-1605-2019; Fieggen, Anthony Graham/AAT-6510-2021	Argent, Andrew/0000-0001-9333-2036; Fieggen, Anthony Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Arias Elizabeth, 2003, Natl Vital Stat Rep, V52, P1; Brain Trauma Foundation: American association of Neurological surgeons, 2007, J NEUROTRAUMA S1, V24, pS59; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; CDC National Center for Injury Prevention and Control, WEB BAS INJ STAT QUE; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Doppenberg EMR, 1997, J NEUROSURG, V87, P809, DOI 10.3171/jns.1997.87.6.0809; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Reiles E, 2007, CRIT CARE, V11, DOI 10.1186/cc5936; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Thees C, 2003, INTENS CARE MED, V29, P386, DOI 10.1007/s00134-002-1625-7; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	55	39	39	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2008	63	1					83	91		10.1227/01.NEU.0000335074.39728.00			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	341LM	WOS:000258716000019	18728572				2022-02-06	
J	Sorani, MD; Morabito, D; Rosenthal, G; Giacomini, KM; Manley, GT				Sorani, Marco D.; Morabito, Diane; Rosenthal, Guy; Giacomini, Kathleen M.; Manley, Geoffrey T.			Characterizing the dose-response relationship between mannitol and intracranial pressure in traumatic brain injury patients using a high-frequency physiological data collection system	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; brain injuries; dose-response relationship; intracranial pressure; mannitol	HYPERTONIC MANNITOL; 20-PERCENT MANNITOL; HEAD-INJURIES; HYPERTENSION; OSMOTHERAPY; MANAGEMENT; MECHANISM; OUTCOMES; SALINE; TRIAL	Despite the widespread use of mannitol to treat elevated intracranial pressure (ICP), there is no consensus regarding the optimal dosage. The objective of this study was to retrospectively characterize the dose-response relationship between mannitol and ICP using data collected with a continuous high-frequency physiological data collection system. To this end, we measured ICP continuously in 28 patients with traumatic brain injury (TBI) who were given at least one dose of mannitol. Twenty TBI patients were given a total of 85 doses of 50 g of mannitol, and 18 patients were given 50 doses of 100 g. Some patients received both amounts. Cerebral perfusion pressure was maintained above 60 mm Hg. The average ICP was 22.0 +/- 10.6 mm Hg when mannitol was administered, fell immediately after dosing, and continued falling for approximately 30 min to 15.7 +/- 8.1 mm Hg across all patients. After 30 min, ICP was equal in the 100-g group (15.6 +/- 10.9) versus the 50-g group (15.7 +/- 6.3). However, at 100 min, ICP had increased in the 50-g group to nearly its initial value but was still lower in the 100-g group (18.6 +/- 7.6 vs. 14.2 +/- 6.7 mm Hg; p = 0.001). Osmotic agents such as mannitol have been used for decades to treat cerebral edema, but there has been no definitive quantitative information regarding the dosing of mannitol. In a large, retrospective study of high-frequency ICP data, we have quantitatively shown that mannitol's effect on ICP is dose-dependent and that higher doses provide a more durable reduction in ICP.	[Morabito, Diane; Rosenthal, Guy; Manley, Geoffrey T.] San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94117 USA; [Sorani, Marco D.] Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94143 USA; [Giacomini, Kathleen M.] San Francisco Gen Hosp, Dept Biopharmaceut Sci, San Francisco, CA 94117 USA		Manley, GT (corresponding author), San Francisco Gen Hosp, Dept Neurosurg, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94117 USA.	manleyg@neurosurg.ucsf.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050173, NS049691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS049691, R01NS050173] Funding Source: NIH RePORTER		ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERECZKI D, 2001, COCHRANE DB SYST REV, V1; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Biestro A, 1997, ACTA NEUROCHIR, V139, P725, DOI 10.1007/BF01420045; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1995, New Horiz, V3, P448; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; Gondim FDA, 2005, J NEUROSURG, V103, P444; Hartl R, 1997, ACT NEUR S, V70, P40; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; Kirkpatrick PJ, 1996, NEUROSURGERY, V39, P714, DOI 10.1097/00006123-199610000-00013; Lang E W, 1995, New Horiz, V3, P400; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MCGRAW CP, 1978, SURG NEUROL, V10, P127; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Palma L, 2006, J Neurosurg Sci, V50, P63; POLLAY M, 1983, J NEUROSURG, V59, P945, DOI 10.3171/jns.1983.59.6.0945; Rapoport SI, 2000, CELL MOL NEUROBIOL, V20, P217, DOI 10.1023/A:1007049806660; REILLY MJ, 1976, POCKET CONSULT DIURE; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531	33	39	41	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					291	298		10.1089/neu.2007.0411			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600002	18373479				2022-02-06	
J	Bochicchio, GV; Lumpkins, K; O'Connor, J; Simard, M; Schaub, S; Conway, A; Bochicchio, K; Scalea, TM				Bochicchio, Grant V.; Lumpkins, Kimberly; O'Connor, James; Simard, Marc; Schaub, Stacey; Conway, Anne; Bochicchio, Kelly; Scalea, Thomas M.			Blast injury in a civilian trauma setting is associated with a delay in diagnosis of traumatic brain injury	AMERICAN SURGEON			English	Article							INDUCED NEUROTRAUMA; UNITED-STATES; OVERPRESSURE; EXPERIENCE; ISRAEL	High-pressure waves (blast) account for the majority of combat injuries and are becoming increasingly common in terrorist attacks. To our knowledge, there are no data evaluating the epidemiology of blast injury in a domestic nonterrorist setting. Data were analyzed retrospectively on patients admitted with any type of blast injury over a 10-year period at a busy urban trauma center. Injuries were classified by etiology of explosion and anatomical location. Eighty-nine cases of blast injury were identified in 57,392 patients (0.2%) treated over the study period. The majority of patients were male (78%) with a mean age of 40 +/- 17 years. The mean Injury Severity Score was 13 +/- 11 with an admission Trauma and Injury Severity Score of 0.9 +/- 0.2 and Revised Trauma Score of 7.5 +/- 0.8. The mean intensive care unit and hospital length of stay was 2 7 days and 4.6 +/- 10 days, respectively, with an overall mortality rate of 4.5 per cent. Private dwelling explosion [n = 31 (35%)] was the most common etiology followed by industrial pressure blast [n = 20 (22%)], industrial gas explosion [n = 16 (18%)], military training-related explosion [n = 15 (17%)], home explosive device [n = 8 (9%)], and fireworks explosion [n = 1 (1%)]. Maxillofacial injuries were the most common injury (n = 78) followed by upper extremity orthopedic (n = 29), head injury (n = 32), abdominal (n = 30), lower extremity orthopedic (n = 29), and thoracic (n = 19). The majority of patients with head injury [28 of 32 (88%)] presented with a Glasgow Coma Scale score of 15. CT scans on admission were initially positive for brain injury in 14 of 28 patients (50%). Seven patients (25%) who did not have a CT scan on admission had a CT performed later in their hospital course as a result of mental status change and were positive for traumatic brain injury (TBI). Three patients (11%) had a negative admission CT with a subsequently positive CT for TBI over the next 48 hours. The remaining four patients (14%) were diagnosed with skull fractures. All patients (n = 4) with an admission Glasgow Coma Scale score of less than 8 died from diffuse axonal injury. Blast injury is a complicated disease process, which may evolve over time, particularly with TBI. The missed injury rate for TBI in patients with a Glasgow Coma Scale score of 15 was 36 per cent. More studies are needed in the area of blast injury to better understand this disease process.	[Bochicchio, Grant V.; Lumpkins, Kimberly; O'Connor, James; Simard, Marc; Schaub, Stacey; Conway, Anne; Bochicchio, Kelly; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Baltimore, MD 21201 USA		Bochicchio, GV (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, 22 S Greene St, Baltimore, MD 21201 USA.	gbochicchio@umm.edu		Lumpkins, Kimberly/0000-0002-5236-9411			Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; CEBALLOS JPD, 2005, CRIT CARE MED, V33, pS107; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; *DEP JUST, 1997 REP AV BOMBM IN; Helling ER, 2004, MIL MED, V169, P872, DOI 10.7205/MILMED.169.11.872; Kapur GB, 2005, J TRAUMA, V59, P1436, DOI 10.1097/01.ta.0000197853.49084.3c; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mine Safety and Health Administration- United States Department of Labor, HIST DAT MIN DIS US; Noji EK, 2005, MIL MED, V170, P595, DOI 10.7205/MILMED.170.7.595; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906	19	39	42	0	8	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	MAR	2008	74	3					267	270					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	267OR	WOS:000253519000019	18376697				2022-02-06	
J	Lopresti, EF; Bodine, C; Lewis, C				Lopresti, Edmund F.; Bodine, Cathy; Lewis, Clayton			Assistive technology for cognition	IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-RETARDATION; IMPAIRMENTS; PEOPLE; REHABILITATION; OUTCOMES; CHILDREN; SPEECH; SYSTEM		[Lopresti, Edmund F.] AT Sci, LLC, Pittsburgh, PA 15213 USA; [Bodine, Cathy] Univ Colorado, Dept Rehabil Med, Boulder, CO 80309 USA; [Lewis, Clayton] Univ Colorado, Dept Comp Sci, Boulder, CO 80309 USA		Lopresti, EF (corresponding author), AT Sci, LLC, 160N Craig St,Suite 117, Pittsburgh, PA 15213 USA.	edlopresti@at-sciences.com					ABRAMSON R, 2000, IND STANDARD; Alzheimer's Association, 2005, BAS ALZH DIS; *AM PSYCH ASS TASK, 2000, DIAGN STAT MAN MENT, V33, P943; *AM STROKE ASS, 2006, IMP STROK; ARKELL H, 1997, INTRO DYSLEXIA DYSLE; BAECKER RM, 1995, READINGS HUMAN COMPU, P187; BANJA J, NIH CONS DEV C REH P; Bodker S., 1993, PARTICIPATORY DESIGN, P157; Bohman, 2004, COGNITIVE DISABILI 1; Braddock D., 2004, Journal of Special Education Technology, V19, P49; Carey AC, 2005, MENT RETARD, V43, P322; Carmien S., 2005, ACM Transactions on Computer-Human Interaction, V12, P233, DOI 10.1145/1067860.1067865; CARMIEN S, 2003, 2 INT WORKSH UB COMP; Cole E, 1999, NEUROREHABILITATION, V12, P39; Cole E, 1994, NeuroRehabilitation, V4, P174, DOI 10.3233/NRE-1994-4308; COLE E, 2000, P REH ENG SOC N AM R, P31; COLE E, SIGCHI B, V20, P32; *COMM CLIN RES INV, 2004, ETH COND CLIN RES IN, P43; Cushman L A, 1996, Assist Technol, V8, P103; Davies DK, 2003, RES PRACT PERS SEV D, V28, P182, DOI 10.2511/rpsd.28.4.182; Davies DK, 2002, EDUC TRAIN MENT RET, V37, P209; DAVIES DK, 2004, ABLELINK INSTRUCTION; DENNETT B, 2001, HDB ACTION RES HLTH, P116; *DEV IND WORK GROU, 2005, DEV IND ACC MULT INT; DOE T, PARTICIPATORY ACTION; EYDE LD, 2000, ETHICS RES HUMAN PAR, P61; FICKAS S, 2005, CHI 2005 WORKSH ENG; FISCHMAN MW, 2000, ETHICS RES HUMAN PAR, P35; FRANCIK E, 1999, TELECOMMUNICATIONS P; FRIEDMAN M, 1993, P REH SOC N AM RESNA, P199; Gillette Y, 2004, NEUROREHABILITATION, V19, P233; GILLETTE Y, P CSUN 2005 C; GOLINKER L, 2001, KEY QUESTIONS MEDICA; Gorman P, 2003, NEUROREHABILITATION, V18, P57; Gould JD, 1983, C HUM FACTORS COMPUT, V28, P50, DOI [10.1145/800045.801579, DOI 10.1145/800045.801579]; GRANHOLM NA, 1992, LUPUS, V1, P63, DOI 10.1177/096120339200100203; Gregor P., 2000, P 4 INT ACM C ASS TE, P85; Gronbaek K., 1997, COMPUTERS DESIGN CON, P201; Hagenmeyer V., 2004, Automatisierungstechnik, V52, P3, DOI 10.1524/auto.52.1.3.25428; Hagerman R., 1996, FRAGILE X SYNDROME D, P3; Hagerman RJ, 1999, DEV COGN NEUROSCI, P27; HAGERMAN RJ, 1999, NEURODEVELOPMENTAL D, P3173; HAGERMAN RJ, 1999, DEV PERSP PSYCHIAT, P3; Happe F, 2001, J CHILD PSYCHOL PSYC, V42, P299, DOI 10.1111/1469-7610.00723; HART M, P ASSETS 2005, P136; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Henry S.L., 2007, JUST ASK INTEGRATING; Howell JD, 2003, USEFUL BODIES: HUMANS IN THE SERVICE OF MEDICAL SCIENCE IN THE TWENTIETH CENTURY, P190; JACOBS S, WORLD BANK 2004 INT; Jinks A., 1997, Proceedings of the RESNA '97 Annual Conference. Let's Tango - Partnering People and Technology, P526; KAYE HS, 2000, 13 DIS STAT US DEP E; Keates S., 2000, ACM SIGACCESS C COMP, P129; Kime SK, 1996, BRAIN INJURY, V10, P17; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KOPPEL R, 2002, DIS COSTS US BUSINES, P1; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUTIYANAWALA A, 2006, P ACM SIGACCESS, P245; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; LOPRESTI EF, 2005, P RESNA; MA J, 2002, P INT C SPOK LANG PR, P197; Mann WC, 2002, ASSIST TECHNOL, V14, P130, DOI 10.1080/10400435.2002.10132062; Mihailidis A, 2001, ASSIST TECHNOL, V13, P23, DOI 10.1080/10400435.2001.10132031; *NAT COUNC DIS, 2004, DES INCL CREAT NEW M; NAT'L BIOETHICS ADVISORY COMM'N, 1998, RES INV PERS MENT DI; *NCDRR STAFF, 2002, NAT CTR DISSEM DIDAB, V7; Philipose M, 2004, IEEE PERVAS COMPUT, V3, P50, DOI 10.1109/MPRV.2004.7; RASKIND MH, 1995, LEARN DISABILITY Q, V18, P141, DOI 10.2307/1511201; SALES B, 1979, ETHICS RES HUMAN P B; Scharfenaker S., 2002, FRAGILE X SYNDROME D, P363; SEELMAN KD, 1998, DISABILITYS NEW PARA; SILVER LB, 2006, WHAT ARE LEARNING DI; STOCK SE, 2003, J VOCAT REHABIL, V19, P95; Stringer E.T., 1999, ACTION RES; STROCK M, 1996, ATTENTION DEFICIT HY; SVENSK A, 1997, P 4 EUR C ADV ASS TE, P432; Todis B, 2005, BRAIN INJURY, V19, P389, DOI 10.1080/02699050400003957; *US DEP COMM, 2003, TECHN ASS US ASS TEC; Wehmeyer M, 1997, EXCEPT CHILDREN, V63, P245, DOI 10.1177/001440299706300207; Wehmeyer ML, 1998, MENT RETARD, V36, P44, DOI 10.1352/0047-6765(1998)036<0044:NSOTUO>2.0.CO;2; Whyte W.F., 1943, STREET CORNER SOC; Whyte W.F., 1984, LEARNING FIELD GUIDE; WILLIAMS M, 2004, COMMUNICATION; WILLIAMS M, 2004, CAPE ARGUS      0617, P1; WILLOWS DM, 1993, VISUAL PROCESSES REA; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; WINTER R, 2001, HDB ACTION RES HLTH, P3; WONG TM, 1998, AVOIDING ETHICAL MIS, P187; 2005, SABE SUMMIT STATEMEN; [No title captured]; [No title captured]; [No title captured]; [No title captured]	96	39	39	0	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0739-5175	1937-4186		IEEE ENG MED BIOL	IEEE Eng. Med. Biol. Mag.	MAR-APR	2008	27	2					29	39		10.1109/EMB.2007.907396			11	Engineering, Biomedical; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Medical Informatics	277NT	WOS:000254220900007	18463019				2022-02-06	
J	Milman, A; Zohar, O; Maayan, R; Weizman, R; Pick, CG				Milman, A.; Zohar, O.; Maayan, R.; Weizman, R.; Pick, C. G.			DHEAS repeated treatment improves cognitive and behavioral deficits after mild traumatic brain injury	EUROPEAN NEUROPSYCHOPHARMACOLOGY			English	Article						cognitive deficits; closed head trauma model; depressive-tike behavior; mild traumatic brain injury (mTBI); dehydroepiandrosterone sulfate (DHEAS)	RIGHT PARIETAL CORTEX; DEHYDROEPIANDROSTERONE-SULFATE; HIPPOCAMPAL-NEURONS; REACTIVE ASTROGLIA; NERVOUS-SYSTEM; MICE; RAT; NEUROSTEROIDS; STEROIDS; PREGNENOLONE	Mild traumatic brain injury (mTBI) is characterized by diffused symptoms, which when combined are called "post-concussion syndrome". Dehydroepiandrosterone sulfate (DHEAS) is a neuroactive neurosteroid. Previously, we have reported that closed head mTBI causes long tasting cognitive deficits and depressive-like behavior. In the present study we describe the effects of DHEAS on the behavior of mice that suffered closed head mTBI. Following the induction of mTBI, mice were treated once a week with DHEAS (s.c. 20 mg/kg) and their performance in the passive avoidance test and the forced swimming test (FST) were evaluated 7, 30, 60 and 90 days post-injury. The most important interactions were between injury and injection (passive avoidance; p<0.001 and FST, p= 0.001), meaning that DHEAS has beneficial effects only when given to injured animals. Our results demonstrate that the tong-term cognitive and behavioral effects induced by mTBI may be improved by a repeated weekly treatment with DHEAS. (c) 2007 Elsevier B.V. and ECNP. All rights reserved.	[Milman, A.; Pick, C. G.] Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Zohar, O.] Johns Hopkins Univ, Blanchette Rockfeller Neurosci Inst, Rockville, MD 20850 USA; [Maayan, R.] Tel Aviv Univ, Lab Biol Psychiat, Felsentstein Med Res Ctr, Rabin Med Ctr, Tel Aviv, Israel; [Maayan, R.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Weizman, R.] Sackler Fac Med, Dept Psychiat, Tel Aviv, Israel; [Weizman, R.] Tel Aviv Community Mental Hlth Ctr, Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	anatmilman@gmail.com; zohar@engram.brni-jhu.org; rmayan@post.tau.ac.il; weizmana@post.tau.ac.il; pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009	Milman, Anat/0000-0002-8551-4101			Avital A, 2006, BRAIN RES BULL, V68, P419, DOI 10.1016/j.brainresbull.2005.09.015; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Juhasz-Vedres G, 2006, ENDOCRINOLOGY, V147, P683, DOI 10.1210/en.2005-0693; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Lapchak PA, 2001, INT REV NEUROBIOL, V46, P379; LeRoux PD, 1996, EXP NEUROL, V137, P49, DOI 10.1006/exnr.1996.0006; Maayan R, 2005, NEUROSCI LETT, V377, P130, DOI 10.1016/j.neulet.2004.11.086; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Prasad A, 1997, PHYSIOL BEHAV, V62, P1053, DOI 10.1016/S0031-9384(97)00239-4; Reddy DS, 1998, NEUROREPORT, V9, P3069, DOI 10.1097/00001756-199809140-00028; Reddy DS, 1998, BRAIN RES, V799, P215, DOI 10.1016/S0006-8993(98)00419-3; Reddy DS, 1998, BRAIN RES, V791, P108, DOI 10.1016/S0006-8993(98)00085-7; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schwartz AG, 2004, AGEING RES REV, V3, P171, DOI 10.1016/j.arr.2003.05.001; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	39	40	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0924-977X	1873-7862		EUR NEUROPSYCHOPHARM	Eur. Neuropsychopharmacol.	MAR	2008	18	3					181	187		10.1016/j.euroneuro.2007.05.007			7	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	265AA	WOS:000253330300003	17669633				2022-02-06	
J	Chang, PFJ; Ostir, GV; Kuo, YF; Granger, CV; Ottenbacher, KJ				Chang, Pei-Fen J.; Ostir, Glenn V.; Kuo, Yong-Fang; Granger, Carl V.; Ottenbacher, Kenneth J.			Ethnic differences in discharge destination among older patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						elderly; ethnic groups; head injuries; rehabilitation	FUNCTIONAL INDEPENDENCE MEASURE; REHABILITATION OUTCOMES; RELIABILITY; IMPACT	Objective: To estimate the association between ethnicity and discharge destination in older patients with traumatic brain injury (TBI). Design: A retrospective analysis. Setting: Nationally representative sample of older patients from the Uniform Data System for Medical Rehabilitation in 2002 and 2003. Participants: Patients (N=9240) aged 65 years or older who received inpatient rehabilitation services for TBI. Interventions: Not applicable. Main Outcome Measures: Discharge destination (home, assisted living facility, institution) and ethnicity (white, black, Hispanic). Results: Multinomial logit models showed that older Hispanics (odds ratio [OR]=2.24; 95% confidence interval [CI], 1.66-3.02) and older blacks (OR=2; 95% CI, 1.55-2.59) with TBI were significantly more likely to be discharged. home than older whites with TBI, after adjusting for relevant risk factors. Older blacks were also 78% less likely (OR=.22; 95% CI, .08-.60) to be discharged to an assisted living facility than whites after adjusting for relevant risk factors. Conclusions: Our findings indicate that older minority patients with TBI were significantly more likely to be discharged home than white patients with TBI. Studies are needed to investigate underlying factors associated with this ethnic difference.	[Chang, Pei-Fen J.; Ottenbacher, Kenneth J.] Univ Texas Galveston, Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Ostir, Glenn V.; Kuo, Yong-Fang] Univ Texas Galveston, Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA; [Ostir, Glenn V.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Granger, Carl V.] SUNY Buffalo, Dept Rehabil Med, Buffalo, NY USA		Chang, PFJ (corresponding author), Univ Texas Galveston, Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	pjchang@utmb.edu		Ottenbacher, Kenneth/0000-0001-5990-3982	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD046682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031178, K02AG019736, R01AG024806] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K02 AG019736-05, R01 AG031178, K02 AG019736, R01-AG024806, R01 AG024806-04, R01 AG031178-02, K02-AG019736, R01 AG024806] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD046682-04, K01-HD046682, K01 HD046682] Funding Source: Medline		*AM ASS RET PERS, PROTR OLD MIN; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bottemiller KL, 2006, REHABIL NURS, V31, P22, DOI 10.1002/j.2048-7940.2006.tb00006.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; CARTER GM, 1997, PROSPECTIVE PAYMENT; Centers for Disease Control and Prevention, NAT CTR INJ PREV CON; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Cruise CM, 2006, CLIN GERIATR MED, V22, P257, DOI 10.1016/j.cger.2005.12.015; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Foster M, 2000, BRAIN INJURY, V14, P1035; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lutz Barbara J, 2004, Rehabil Nurs, V29, P154; Mauthe RW, 1996, ARCH PHYS MED REHAB, V77, P10, DOI 10.1016/S0003-9993(96)90212-9; Neufeld Stewart W, 2004, Home Health Care Serv Q, V23, P29, DOI 10.1300/J027v23n04_03; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PAZ JJ, 1993, SUPPORT HISPANIC ELD, P177; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roush C V, 2000, Home Healthc Nurse, V18, P388, DOI 10.1097/00004045-200006000-00015; Swenson M M, 1998, Health Care Women Int, V19, P381; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Unsworth C, 1996, AM J OCCUP THER, V50, P207, DOI 10.5014/ajot.50.3.207; van Boxel YJ, 1996, J REHABIL SCI, V9, P11; Williams A, 2003, HEALTH ECON, V12, P65, DOI 10.1002/hec.778; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	34	39	39	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2008	89	2					231	236		10.1016/j.apmr.2007.08.143			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	260OD	WOS:000253018700005	18226645	Green Accepted			2022-02-06	
J	Osiurak, F; Aubin, G; Allain, P; Jarry, C; Richard, I; Le Gall, D				Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Richard, Isabelle; Le Gall, Didier			Object utilization and object usage: A single-case study	NEUROCASE			English	Article						tool use; apraxia; action; conceptual knowledge; object misuse	IDEOMOTOR APRAXIA; TOOL-USE; IDEATIONAL APRAXIA; SEMANTIC DEMENTIA; CORTICOBASAL DEGENERATION; SELECTIVE IMPAIRMENT; KNOWLEDGE; MEMORY; MANIPULATION; RECOGNITION	It has been suggested that both conceptual knowledge and the ability to infer function from structure can support object use. By contrast, we propose that object use requires solely the ability to reason about technical ends. Technical ends (e.g., cutting) are not purposes (e.g., eating), but the technical way to achieve them. This perspective suggests that there is no mutual relationship between technical ends and purposes since the same purpose (e.g., writing) can be achieved thanks to distinct technical ends (graving, tracing), and, inversely, the same technical end (e.g., tracing) can achieve different purposes (making up, writing). Thus, conceptual knowledge might determine which technical end is usually associated with a given purpose. To contribute to the discussion, we described the behaviour of a female patient with left temporal lobe lesions and bilateral frontal lobe lesions following a closed-head injury. Conceptual knowledge was impaired. She encountered difficulties in demonstrating the use of objects in isolation (e.g., using a screwdriver without the screw). The presence of a recipient (e.g., using a screwdriver with the screw) improved her performance. The performance was also normal when asked to perform unusual applications of objects to achieve a goal for which the usually applied object was not provided (e.g., screwing a screw with a knife). Consistent with the theoretical framework supported here, her performance profile suggests an intact ability to reason about technical ends (i.e., utilization), in the presence of a defective ability to determine the usual relationship between technical ends and purposes (i.e., usage).	[Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Le Gall, Didier] Univ Hosp Angers, Dept Neurol, Neuropsychol Unit, Angers, France; [Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Le Gall, Didier] Univ Angers, UPRES EA 2646, Psychol Lab, Angers, France; [Aubin, Ghislaine; Richard, Isabelle] Reg Ctr Rehabil Angers, Angers, France		Le Gall, D (corresponding author), Ctr Hosp Univ, Dept Neurol, Unite Neuropsychol, 4 Rue Larrey, F-49033 Angers 01, France.	DiLeGall@chu-angers.fr	Osiurak, Francois/F-1400-2011	Osiurak, Francois/0000-0003-3449-6377; ALLAIN, Philiooe/0000-0003-0668-0986			Agniel A., 1992, PROTOCOLE MONTREAL T; BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; Bartolo A, 2007, BEHAV NEUROL, V18, P143, DOI 10.1155/2007/241670; BERGEGO C, 1992, REV NEUROPSYCHOL, V2, P193; Bozeat S, 2002, COGN AFFECT BEHAV NE, V2, P236, DOI 10.3758/CABN.2.3.236; BREEDIN SD, 1994, COGNITIVE NEUROPSYCH, V11, P617, DOI 10.1080/02643299408251987; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 2001, NEUROCASE, V7, P445, DOI 10.1076/neur.7.6.445.16223; Buxbaum LJ, 2002, BRAIN LANG, V82, P179, DOI 10.1016/S0093-934X(02)00014-7; Buxbaum LJ, 2000, NEUROCASE, V6, P83, DOI 10.1093/neucas/6.2.83; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; Cubelli R, 2000, BRAIN COGNITION, V44, P144, DOI 10.1006/brcg.2000.1226; De Renzi E, 1989, HDB NEUROPSYCHOLOGY, V2, P245; Deloche G, 1997, TEST DENOMINATION OR; DERENZI E, 1994, CORTEX, V30, P3, DOI 10.1016/S0010-9452(13)80322-X; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; DESGRANGES B, 1994, ANN PSYCHOL, V94, P345; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Dumont C, 1999, NEUROCASE, V5, P447, DOI 10.1080/13554799908402739; Fukutake T, 2003, EUR NEUROL, V49, P45, DOI 10.1159/000067027; Gagnepain J., 1994, LECONS INTRO THEORIE; Gagnepain J., 1990, VOULOIR DIRE SIGNE O; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GIBB WRG, 1989, BRAIN, V112, P1171, DOI 10.1093/brain/112.5.1171; Gibson J.J, 1986, ECOLOGICAL APPROACH; Goldenberg G, 1998, NEUROPSYCHOLOGIA, V36, P581, DOI 10.1016/S0028-3932(97)00165-6; Goldenberg G, 1999, NEUROPSYCHOLOGIA, V37, P559, DOI 10.1016/S0028-3932(98)00111-0; Goldenberg G, 1997, NEUROPSYCHOLOGIA, V35, P333, DOI 10.1016/S0028-3932(96)00085-1; Hayakawa Y, 2000, EUR NEUROL, V43, P76, DOI 10.1159/000008139; Heath M, 2003, NEUROCASE, V9, P156, DOI 10.1076/neur.9.2.156.15072; HEILMAN KM, 1982, NEUROLOGY, V32, P342, DOI 10.1212/WNL.32.4.342; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; Hodges JR, 1999, P NATL ACAD SCI USA, V96, P9444, DOI 10.1073/pnas.96.16.9444; Hodges JR, 2000, BRAIN, V123, P1913, DOI 10.1093/brain/123.9.1913; Humphreys GW, 2001, BEHAV BRAIN SCI, V24, P453, DOI 10.1017/S0140525X01004150; Jeannerod M., 1997, COGNITIVE NEUROSCIEN; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; Lauro-Grotto R, 1997, CORTEX, V33, P593, DOI 10.1016/S0010-9452(08)70720-2; Le Gall D., 2000, TRAITE NEUROPSYCHOLO, P225; Le Gall D., 1998, APRAXIES ATECHNIES P; LEGALL D, 1995, REV INT PSYCHOPATHOL, V18, P229; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liepmann H., 1920, ERGEBNISSE GESAMTEN, V27, P516; Moreaud O, 1998, NEUROPSYCHOLOGIA, V36, P1295, DOI 10.1016/S0028-3932(98)00034-7; Moss HE, 1997, COGNITIVE NEUROPSYCH, V14, P901, DOI 10.1080/026432997381394; MOTOMURA N, 1994, CORTEX, V30, P167, DOI 10.1016/S0010-9452(13)80332-2; Negri GA, 2007, CORTEX, V43, P376, DOI 10.1016/S0010-9452(08)70463-5; Nespoulous J.-L., 1992, PROTOCOLE MONTREAL T; OCHIPA C, 1992, BRAIN, V115, P1061, DOI 10.1093/brain/115.4.1061; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PILGRIM E, 1991, COGNITIVE NEUROPSYCH, V8, P459, DOI 10.1080/02643299108253383; Raven JC, 1947, COLORED PROGR MATRIC; Rey A, 1959, TEST COPIE FIGURE CO; RIDDOCH MJ, 1988, COGNITIVE NEUROPSYCH, V5, P3, DOI 10.1080/02643298808252925; Rothi LJ, 1997, APRAXIA NEUROPSYCHOL, P29; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; Roy E. A., 1985, NEUROPSYCHOLOGICAL S, V23, P111, DOI [10.1016/S0166-4115(08)61139-5, DOI 10.1016/S0166-4115(08)61139-5]; Rumiati RI, 1998, J EXP PSYCHOL HUMAN, V24, P631, DOI 10.1037/0096-1523.24.2.631; SABOURAUD O, 2006, DEBAT, V140, P68; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; Signoret J.L., 1989, BATTERIE EVALUATION; SIRIGU A, 1991, BRAIN, V114, P2555, DOI 10.1093/brain/114.6.2555; Snowden JS, 1996, FRONTO TEMPORAL LOBA; Spatt J, 2002, J NEUROL, V249, P601, DOI 10.1007/s004150200070; Sunderland A, 2000, NEUROPSYCHOLOGIA, V38, P923, DOI 10.1016/S0028-3932(00)00021-X; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1975, Q J EXP PSYCHOL, V27, P635, DOI 10.1080/14640747508400525; Wilson BA, 2003, NEUROPSYCHOLOG REHAB, P1; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; ZANGWILL O L, 1960, Rev Neurol (Paris), V102, P595; [No title captured]	74	39	39	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase		2008	14	2					169	183		10.1080/13554790802108372			15	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	317QX	WOS:000257035800007	18569742				2022-02-06	
J	Schnyder, U; Wittmann, L; Friedrich-Perez, J; Hepp, U; Moergeli, H				Schnyder, Ulrich; Wittmann, Lutz; Friedrich-Perez, Josefina; Hepp, Urs; Moergeli, Hanspeter			Posttraumatic stress disorder following accidental injury: Rule or exception in Switzerland?	PSYCHOTHERAPY AND PSYCHOSOMATICS			English	Article						trauma; accidents, injury; posttraumatic stress disorder; acute stress disorder; traumatic brain injury; language proficiency; sense coherence	MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; PERITRAUMATIC DISSOCIATION; PTSD SYMPTOMS; PREDICTORS; COHERENCE; SURVIVORS; VICTIMS; ADULTS; SCALE	Background: There is still marked variability in the findings concerning psychiatric disorders associated with traumatic injury. The aim of this study was to determine the incidence of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) following accidental injuries, and to predict the PTSD symptom level at 6 months, taking into particular consideration the role of pre-existing psychiatric morbidity and insufficient command of the local language. Method: A total of 255 accident survivors who were hospitalized for at least 2 consecutive nights at a Swiss university hospital for treatment of recently acquired physical injuries were interviewed within 2 weeks of the trauma and 6 months after the accident. Patients who did not have a good command of German but were fluent in Italian, Spanish, Portuguese, Serbo-Croatian or Albanian were assessed using interpreters. The main outcome measure was the Clinician-Administered PTSD Scale. Results: Ten patients (3.9%) were diagnosed as having ASD. At 6 months, 8 patients (3.1%) had PTSD. A regression model using 12 potential predictor variables explained 40% of the variance of PTSD symptoms; mild traumatic brain injury ( p < 0.001), pain ( p < 0.05), ASD symptom level ( p < 0.001) and emotional coping ( p = 0.001) predicted higher PTSD symptom levels, while high Sense of Coherence ( p < 0.05) and perceived responsibility for the accident ( p < 0.01) were associated with lower PTSD symptom levels at follow-up. Conclusions: ASD and PTSD seem to occur less frequently following accidental injuries than previously reported in the literature. Pre-existing psychiatric morbidity and lack of proficiency in the locally spoken language do not appear to play an important role in the development of PTSD. Copyright (c) 2008 S. Karger AG, Basel.	[Schnyder, Ulrich; Wittmann, Lutz; Friedrich-Perez, Josefina; Hepp, Urs; Moergeli, Hanspeter] Univ Zurich Hosp, Dept Psychiat, CH-8091 Zurich, Switzerland		Schnyder, U (corresponding author), Univ Zurich Hosp, Dept Psychiat, Culmannstr 8, CH-8091 Zurich, Switzerland.	ulrich.schnyder@psyp.uzh.ch		Schnyder, Ulrich/0000-0003-3556-7990			ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A., 1987, UNRAVELING MYSTERY H; Asmundson GJG., 2000, BEHAV COGN PSYCHOTH, V28, P5, DOI [DOI 10.1017/S1352465800000023, 10.1017/S1352465800000023]; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake DD, 1998, CLIN ADM PTSD SCALE; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; Creamer M, 1998, AUST PSYCHOL, V33, P125, DOI 10.1080/00050069808257393; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Endler N. S., 2000, COPING HLTH INJURIES; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1999, J TRAUMA STRESS, V12, P519, DOI 10.1023/A:1024723205259; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hepp U, 2006, EUR ARCH PSY CLIN N, V256, P151, DOI 10.1007/s00406-005-0621-7; Hepp U, 2005, PSYCHOTHER PSYCHOSOM, V74, P379, DOI 10.1159/000087786; Hickling EJ, 1999, J TRAUMA STRESS, V12, P345, DOI 10.1023/A:1024784711484; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Koren D, 1999, AM J PSYCHIAT, V156, P367; Maier T, 2006, MED HYPOTHESES, V66, P103, DOI 10.1016/j.mehy.2005.07.028; Malt U F, 1992, Psychiatr Med, V10, P135; Marmar Charles R., 1997, P412; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Moore A D, 1994, Int J Rehabil Res, V17, P39, DOI 10.1097/00004356-199403000-00004; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; PEERONIGG A, 2000, ACTA PSYCHIAT SCAND, V101, P46; Schnyder U, 2000, PSYCHOTHER PSYCHOSOM, V69, P296, DOI 10.1159/000012411; Schnyder U, 1999, PSYCHOTHER PSYCHOSOM, V68, P102, DOI 10.1159/000012320; Schnyder U, 2002, J TRAUMA STRESS, V15, P487, DOI 10.1023/A:1020922023090; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sijbrandij M, 2006, BRIT J PSYCHIAT, V189, P150, DOI 10.1192/bjp.bp.105.021121; Sommer I, 2004, J PSYCHOSOM RES, V57, P329, DOI 10.1016/j.jpsychores.2004.01.010; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P1808; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Wittmann L, 2006, J TRAUMA STRESS, V19, P639, DOI 10.1002/jts.20154	47	39	42	1	14	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0033-3190			PSYCHOTHER PSYCHOSOM	Psychother. Psychosom.	JAN	2008	77	2					111	118		10.1159/000112888			8	Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry; Psychology	262EI	WOS:000253131400006	18230944	Green Accepted			2022-02-06	
J	Tamplin, J				Tamplin, Jeanette			A pilot study into the effect of vocal exercises and singing on dysarthric speech	NEUROREHABILITATION			English	Article						music therapy; singing; dysarthria; rehabilitation; TBI; stroke	INTELLIGIBILITY; INSTRUCTION; NATURALNESS; THERAPY	This pilot study aimed to investigate the effects of vocal exercises and singing on intelligibility and speech naturalness for subjects with acquired dysarthria following traumatic brain injury or stroke. A multiple case study design was used, involving pre, mid, and post-treatment assessments of intelligibility, rate, naturalness, and pause time for four subjects with dysarthria. Each subject participated in 24 individual music therapy sessions over eight weeks involving oral motor respiratory exercises, rhythmic and melodic articulation exercises, rhythmic speech cuing, vocal intonation therapy, and therapeutic singing using familiar songs. Results were measured using a standardized dysarthric speech assessment - the Sentence Intelligibility Test, waveform analysis, and ratings of speech naturalness. Statistically significant improvements in functional speech intelligibility were achieved but improvements in rate of speech were not significant. Speech naturalness improved post-treatment and a reduction in the number and length of pauses was verified via waveform analysis. Preliminary findings suggest that a program of vocal exercises and singing may facilitate more normative speech production for people with acquired dysarthria and support the need for further research in this area.	[Tamplin, Jeanette] Austin Hlth, Mus Therapy Serv, Melbourne, Vic, Australia		Tamplin, J (corresponding author), Royal Talbot Rehabil Ctr, 1 Yarra Blvd, Kew, Vic 3101, Australia.	jeanette.tamplin@austin.org.au	Tamplin, Jeanette/AAR-2855-2021	Tamplin, Jeanette/0000-0002-3623-033X			ABBS JH, 1989, DISORDERS COMMUNICAT; Baker F, 2005, BRAIN INJURY, V19, P519, DOI 10.1080/02699050400005150; BAKER F, 2004, EFFECTS SONG SINGING, P374; Baker J, 2000, J Sci Med Sport, V3, P110, DOI 10.1016/S1440-2440(00)80073-0; BANG C, 1986, MUSIC HLTH; BELLAIRE K, 1986, J COMMUN DISORD, V19, P271, DOI 10.1016/0021-9924(86)90033-X; Brown J.R., 1975, MOTOR SPEECH DISORDE; Claeys M. S., 1989, MUSIC THERAPY PERSPE, V6, P71; COHEN J, 1994, BIO-TECHNOL, V12, P8, DOI 10.1038/nbt0194-8b; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen N., 1995, MUSIC THERAPY PERSPE, V13, P69; COHEN NS, 1995, J MUSIC THER, V32, P46, DOI 10.1093/jmt/32.1.46; COHEN NS, 1988, J MUSIC THER, V25, P85, DOI 10.1093/jmt/25.2.85; COHEN NS, 1992, J MUSIC THER, V29, P87, DOI 10.1093/jmt/29.2.102; COHEN NS, 1993, J MUSIC THER, V30, P81, DOI 10.1093/jmt/30.2.81; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Duffy, 2005, MOTOR SPEECH DISORDE; HAMMEN VL, 1994, J SPEECH HEAR RES, V37, P244, DOI 10.1044/jshr.3702.244; Haneishi E, 2001, J MUSIC THER, V38, P273, DOI 10.1093/jmt/38.4.273; KENT RD, 1994, ADV ASSESSMENT TREAT; MACINTOSH GC, 1996, MUSICMEDICINE; METZ DE, 1980, SPEECH ASSESSMENT SP; Pilon MA, 1998, BRAIN INJURY, V12, P793, DOI 10.1080/026990598122188; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Sellars C, 2002, CLIN REHABIL, V16, P61, DOI 10.1191/0269215502cr468oa; STANDLEY JM, 1994, RES MUSIC THERAPY TR; Taylor D., 1997, BIOMEDICAL FDN MUSIC; THAUT M, 1991, J MUSIC THER, V28, P64, DOI 10.1093/jmt/28.2.64; Thaut M. H., 2000, SCI MODEL MUSIC THER; Thaut MH, 2001, FUNCT NEUROL, V16, P163; Thaut MH, 1996, MOVEMENT DISORD, V11, P193, DOI 10.1002/mds.870110213; Thaut MH., 2005, RHYTHM MUSIC BRAIN S; Thaut MH, 1993, J NEUROL REHABIL, V7, P9, DOI DOI 10.1177/136140969300700103; THAUT MH, 1995, INT J ARTS MED, V5, P4; THAUT MH, 1994, MUSICMEDICINE; THOMPSON B, 1995, WILDLIFE SOC B, V23, P1; Thompson EC, 1997, EUR J DISORDER COMM, V32, P397; Van der Merwe A., 1997, CLIN MANAGEMENT SENS; YORKSTON KM, 1981, J SPEECH HEAR DISORD, V46, P398, DOI 10.1044/jshd.4604.398; YORKSTON KM, 1990, J SPEECH HEAR DISORD, V55, P550, DOI 10.1044/jshd.5503.550; YORKSTON KM, 1996, SENTENCE INTELLIGIBL; [No title captured]	43	39	41	0	25	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	3					207	216					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	311IK	WOS:000256593700002	18560137				2022-02-06	
J	Bartnik, BL; Lee, SM; Hovda, DA; Sutton, RL				Bartnik, Brenda L.; Lee, Stefan M.; Hovda, David A.; Sutton, Richard L.			The fate of glucose during the period of decreased metabolism after fluid percussion injury: A C-13 NMR study	JOURNAL OF NEUROTRAUMA			English	Article						[1, 2 C-13(2)] glucose; C-13 NMR; fluid percussion injury; glutamate; glutamine; pentose phosphate pathway; rat brain	TRAUMATIC BRAIN-INJURY; ENERGY-RELATED METABOLITES; PENTOSE-PHOSPHATE PATHWAY; CEREBRAL METABOLISM; HEAD-INJURY; BLOOD-FLOW; RAT-BRAIN; NOREPINEPHRINE TURNOVER; CORTICAL CONTUSION; LIPID-PEROXIDATION	The present study determined the metabolic fate of [1, 2 C-13(2)] glucose in male control rats and in rats with moderate lateral fluid percussion injured (FPI) at 3.5 h and 24 h post-surgery. After a 3h infusion, the amount of C-13-labeled glucose increased bilaterally (26% in left/injured cerebral cortex and 45% in right cerebral cortex) at 3.5 h after FPI and in injured cortex (45%) at 24 h after injury, indicating an accumulation of unmetabolised glucose not seen in controls. No evidence of an increase in anaerobic glycolysis above control levels was found after FPI, as C-13-labeled lactate tended to decrease at both time points and was significantly reduced (33%) in the injured cortex at 24 h post- FPI. A bilateral decrease in the C-13-labeling of both glutamate and glutamine was observed in the FPI rats at 3.5 h and the glutamine pool remained significantly decreased in the injured cortex at 24 h, suggesting reduced oxidative metabolism in both neuronal and astrocyte compartments after injury. The percentage of glucose metabolism through the pentose phosphate pathway (PPP) increased in the injured (13%) and contralateral (11%) cortex at 3.5 h post- FPI and in the injured cortex (9%) at 24 h post- injury. Based upon the changes in metabolite pools, our results show an injury-induced decrease in glucose utilization and oxidation within the first 24 h after FPI. Increased metabolism through the PPP would result in increased NADPH synthesis, suggesting a need for reducing equivalents after FPI to help restore the intracellular redox state and/or in response to free radical stress.	Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA		Bartnik, BL (corresponding author), Loma Linda Univ, Dept Radiol, 234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@llu.edu		Bartnik-Olson, Brenda/0000-0002-1137-9437	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36373, NS 27544] Funding Source: Medline		Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Aureli T, 1997, BRAIN RES, V765, P218, DOI 10.1016/S0006-8993(97)00514-3; BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BAQUER NZ, 1988, CURR TOP CELL REGUL, V29, P265; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brain K, 2006, J CLIN ONCOL, V24, P95, DOI 10.1200/JCO.2006.10.064; BRAND A, 1992, BIOCHIMIE, V74, P941, DOI 10.1016/0300-9084(92)90078-S; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OPII WO, 2005, PROTEOMIC IDENTIFICA; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Preece NE, 1996, J NEUROCHEM, V67, P1718; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; SCHRADER MC, 1993, BIOCHIM BIOPHYS ACTA, V1182, P162, DOI 10.1016/0925-4439(93)90138-Q; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 2005, OXIDATIVE METABOLISM; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	65	39	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1079	1092		10.1089/neu.2006.0210			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200001	17610349				2022-02-06	
J	Sgubin, D; Aztiria, E; Perin, A; Longatti, P; Leanza, G				Sgubin, D.; Aztiria, E.; Perin, A.; Longatti, P.; Leanza, G.			Activation of endogenous neural stem cells in the adult human brain following subarachnoid hemorrhage	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain insult; cell proliferation; neural progenitor; human	RNA-BINDING PROTEIN; DELAYED CEREBRAL-ISCHEMIA; DENTATE GYRUS; PROGENITOR CELLS; SUBVENTRICULAR ZONE; ENHANCED NEUROGENESIS; PRECURSOR CELLS; PROLIFERATION; HIPPOCAMPUS; NEURONS	In the adult human brain, the presence of neural stem cells has been documented in the subgranular layer of the dentate gyrus of the hippocampus and in the sub-ventricular zone of the lateral ventricles. Neurogenesis has also been reported in rodent models of ischemic stroke, traumatic brain injury, epileptic seizures, and intracerebral or subarachnoid hemorrhage. However, only sparse information is available about the occurrence of neurogenesis in the human brain under similar pathological conditions. In the present report, we describe neural progenitor cell proliferation in the brain of patients suffering from subarachnoid hemorrhage (SAH) resulting from ruptured aneurysm. Ten cerebral samples from both SAH and control patients obtained, respectively, during aneurysm clipping and deep brain tumor removal were analyzed by reverse transcription followed by polymerase chain reaction (RT-PCR) and/or immunohistochernistry (IHC). In tissue specimens from SAH patients, RT-PCR and IHC revealed the expression of a variety of markers consistent with CNS progenitor cells, including nestin, vimentin, SOX-2, and Musashil and -2. In the same specimens, double immunohistochemistry followed by confocal analysis revealed that Musashi2 consistently colocalized with the proliferation marker Ki67. By contrast, no such gene or protein expression profiles were detected in any of the control specimens. Thus, activation of neural progenitor cell proliferation may occur in adult human brain following subarachnoid hemorrhage, possibly contributing to the promotion of spontaneous recovery, in this pathological condition. (c) 2007 Wiley-Liss, Inc.	Univ Trieste, BRAIN Ctr Neurosci, Dept Physiol & Pathol, Trieste, Italy; Treviso Hosp, Neurosurg Unit, Treviso, Italy		Leanza, G (corresponding author), Univ Trieste, BRAIN Ctr Neurosci, Dept Physiol & Pathol, Trieste, Italy.	gileanza@dfp.units.it	Perin, Alessandro/AAM-6299-2021	Perin, Alessandro/0000-0002-6697-9835			Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Calza L, 1998, P NATL ACAD SCI USA, V95, P3209, DOI 10.1073/pnas.95.6.3209; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; HIJDRA A, 1986, NEUROLOGY, V36, P329, DOI 10.1212/WNL.36.3.329; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; Hop JW, 1998, STROKE, V29, P798, DOI 10.1161/01.STR.29.4.798; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Klassen H, 2004, J NEUROSCI RES, V77, P334, DOI 10.1002/jnr.20183; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Komitova M, 2002, J CEREBR BLOOD F MET, V22, P852, DOI 10.1097/00004647-200207000-00010; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Liu JL, 1998, J NEUROSCI, V18, P7768; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mino M, 2003, NEUROL RES, V25, P839, DOI 10.1179/016164103771953934; Nakagawa E, 2000, EPILEPSIA, V41, P10, DOI 10.1111/j.1528-1157.2000.tb01498.x; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Prunell GF, 2002, NEUROREPORT, V13, P2553, DOI 10.1097/00001756-200212200-00034; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499; Sakakibara S, 2001, J NEUROSCI, V21, P8091, DOI 10.1523/JNEUROSCI.21-20-08091.2001; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; SHINGO T, 2001, EXP NEUROL, V177, P1; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Shu HJ, 2002, BIOCHEM BIOPH RES CO, V293, P150, DOI 10.1016/S0006-291X(02)00175-4; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Takizawa T, 2001, NEUROL RES, V23, P724, DOI 10.1179/016164101101199243; Tang T, 2004, CHINESE MED J-PEKING, V117, P1342; Tzeng SF, 1999, NEUROREPORT, V10, P2287, DOI 10.1097/00001756-199908020-00012; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yoshimi K, 2005, ANN NEUROL, V58, P31, DOI 10.1002/ana.20506; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	68	39	48	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2007	85	8					1647	1655		10.1002/jnr.21303			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	177UG	WOS:000247177400006	17455304				2022-02-06	
J	Zimmerman, RA; Bilaniuk, LT; Farina, L				Zimmerman, R. A.; Bilaniuk, L. T.; Farina, L.			Non-accidental brain trauma in infants: diffusion imaging, contributions to understanding the injury process	JOURNAL OF NEURORADIOLOGY			English	Article						Non-accidental trauma; imaging; child abuse; MRI; MRI diffusion imaging; traumatic	SHAKEN-BABY SYNDROME; HEAD-INJURY; SPECTROSCOPY; CHILDREN; STROKE	Analysis of MRI diffusion images from 33 infants suffering from non-accidental trauma reveals five patterns of injury. These are diffuse supratentorial hypoxic ischemic, watershed hypoxic ischemic, venous infarction, diffuse axonat injury and contusion. (c) 2007 Elsevier Masson SAS. All rights reserved.	Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA; Ist Nazl Neurol Carlo Besta, Milan, Italy		Zimmerman, RA (corresponding author), Childrens Hosp Philadelphia, Dept Radiol, Wood Room 2115,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zimmerman@email.chop.edu					Barkovich AJ, 2001, AM J NEURORADIOL, V22, P1786; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Erdem E, 2001, NEURORADIOLOGY, V43, P927, DOI 10.1007/s002340100603; Farina L, 2004, NEURORADIOLOGY, V46, P251, DOI 10.1007/s00234-003-1122-x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Jan W, 2003, NEURORADIOLOGY, V45, P393, DOI 10.1007/s00234-003-0955-7; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Wolf RL, 2001, RADIOLOGY, V218, P825, DOI 10.1148/radiology.218.3.r01fe47825; ZIMMERMAN RA, 2002, P C HELD BETH MD OCT	13	39	39	0	3	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0150-9861			J NEURORADIOLOGY	J. Neuroradiol.	MAY	2007	34	2					109	114		10.1016/j.neurad.2007.01.124			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	179CJ	WOS:000247266600005	17445894				2022-02-06	
J	Pirris, SM; Pollack, IF; Snyderman, CH; Carrau, RL; Spiro, RM; Tyler-Kabara, E; Kassam, AB				Pirris, Stephen M.; Pollack, Ian F.; Snyderman, Carl H.; Carrau, Ricardo L.; Spiro, Richard M.; Tyler-Kabara, Elizabeth; Kassam, Amin B.			Corridor surgery: the current paradigm for skull base surgery	CHILDS NERVOUS SYSTEM			English	Article						chordoma; endoscopic endonasal approach; clival tumors; pediatric skull base tumors; carotid-vertebral window	CHORDOMAS	Clival chordomas are rare tumors, especially in the pediatric population. In this report, we present the case of a 3-year-old boy who was found to have a large posterior pharyngeal, clival, and posterior fossa tumor detected on a CT scan after a closed head injury. Further questioning revealed a history of ataxia and dysphagia. Imaging confirmed severe extrinsic brain stem compression. The tumor was resected in multiple stages utilizing a minimally invasive endoscopic endonasal technique along with open transfacetal, transcondylar approach through the carotid-vertebral window. The child suffered no permanent complications as a result of our treatment and his dysphagia significantly improved. Although a complete resection was not feasible due to vascular encasement by the tumor, extensive decompression was obtained with minimal morbidity. We present this case to illustrate a new paradigm of skull base surgical approaches for large clival lesions in pediatric patients that allows aggressive resection with minimal morbidity.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA		Kassam, AB (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, 200 Lothrop St PUH B-400, Pittsburgh, PA 15213 USA.	kassamab@upmc.edu	Tyler-Kabara, Elizabeth/H-4930-2013	Tyler-Kabara, Elizabeth/0000-0003-3286-1094			Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE2; Colli B O, 2001, Neurosurg Focus, V10, pE1; GAY E, 1995, NEUROSURGERY, V36, P887, DOI 10.1227/00006123-199505000-00001; GAY E, 1995, NEUROSURGERY, V36, P896; HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S; Kassam AB, 2005, NEUROSURGERY, V57, P213, DOI 10.1227/01.NEU.0000163687.64774.E4; Kassam Amin, 2005, Neurosurg Focus, V19, pE4; Kassam Amin B, 2005, Ear Nose Throat J, V84, P312; MCMAHON PJ, 1995, HAND UPP E, V12, P1; ONEILL P, 1985, NEUROSURGERY, V16, P166, DOI 10.1227/00006123-198502000-00007	10	39	41	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2007	23	4					377	384		10.1007/s00381-006-0281-6			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	143UH	WOS:000244750900004	17226036				2022-02-06	
J	Alderman, N				Alderman, Nick			Prevalence, characteristics and causes of aggressive behaviour observed within a neurobehavioural rehabilitation service: Predictors and implications for management	BRAIN INJURY			English	Article						neurobehavioural disability; aggression; neurorehabilitation; OAS-MNR	TRAUMATIC BRAIN-INJURY; CONTINGENT RESTRAINT; PHYSICAL AGGRESSION; OVERT AGGRESSION; SETTING EVENTS; OAS-MNR; STAFF; REDUCTION; SCALE	Primary objective: To describe the characteristics and determinants of aggressive behaviour observed within a neurobehavioural unit. Research design: Statistical analysis of a database of routinely administered clinical measures, including the Overt Aggression Scale-Modified for Neurorehabilitation. Methods and procedures: Records of aggressive behaviour shown by 108 patients over 14 days were studied. Patient characteristics were also captured using 23 items from the Rehabilitation Institute of Chicago-Functional Assessment Scale. Four factors were identified: 'communication', ` cognition/ function', ` neurobehavioural disability' and ` mood & self-esteem'. Relationships between patient characteristics, external factors and their interactions with aggression were examined. Main outcomes and results: Many ( 5548) episodes of aggression were recorded. Whilst most comprised verbal aggression, 729 physical assaults were made on others. Aggressive behaviour typically followed staff prompting or no obvious antecedent. Medical intervention was rare, most aggression was managed by staff not reinforcing this behaviour. Over 80% of physical assaults were made by people rated as having severe symptoms of neurobehavioural disability and poor communication. Conclusions: Neurobehavioural units require sufficient staff resources to engage patients in purposeful activities as these were associated with the least severe aggression. Despite increased OAS-MNR usage, a standardized methodology for investigating aggression is required to ensure compatibility between datasets.	St Andreas Hosp, St Andrews Healthcare Kemsley, Consultant Clin Neuropsychol & Special Lead, Northampton NN1 5DG, England		Alderman, N (corresponding author), St Andreas Hosp, St Andrews Healthcare Kemsley, Consultant Clin Neuropsychol & Special Lead, Billing Rd, Northampton NN1 5DG, England.	alderman@standrew.co.uk		Alderman, Nick/0000-0002-8523-4142			Alderman N, 2003, STUD NEUROPSYCHOL DE, P171; Alderman N, 2001, BRAIN DAM B, P175; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1999, NEUROPSYCHOL REHABIL, V9, P385, DOI 10.1080/096020199389455; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 1990, COGNITIVE REHABILITA, P204; ALDERMAN N, 2003, NEUROLOGICAL REHABIL, P327; ALDERMAN N, 2004, RAHABILITATION NEURO, P269; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beaulieu CL, 1997, ARCH CLIN NEUROPSYCH, V12, P285, DOI 10.1093/arclin/12.4.285a; Brodaty H, 2001, INT J GERIATR PSYCH, V16, P504, DOI 10.1002/gps.382; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; Cunningham J, 2003, AGGRESSIVE BEHAV, V29, P31, DOI 10.1002/ab.10027; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Fluharty G, 2001, BRAIN INJURY, V15, P995, DOI 10.1080/02699050010025795; Freyne A, 1996, INT J GERIATR PSYCH, V11, P57, DOI 10.1002/(SICI)1099-1166(199601)11:1<57::AID-GPS290>3.0.CO;2-Z; Giles GM, 2005, BRAIN INJURY, V19, P753, DOI 10.1080/02699050500110108; GRANGER CV, 1986, GUIDE USE UNIFORM DA; GRIEVE KW, 2002, PERSONALITY INDIVIDU, V32, P639; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hoaken PNS, 2003, AGGRESSIVE BEHAV, V29, P15, DOI 10.1002/ab.10023; Howell DC., 1997, STAT METHODS PSYCHOL, V4th ed; Howes HFR, 2005, BRAIN INJURY, V19, P403, DOI 10.1080/02699050400025158; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; KAY SR, 1988, J NERV MENT DIS, V176, P547, DOI 10.1097/00005053-198809000-00008; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KINNEAR PR, 1994, SPDD WINDOWS MADE SI; Lazaro F, 2000, PSYCHIAT B, V24, P264; Manchester D, 1997, BRAIN INJURY, V11, P605, DOI 10.1080/026990597123296; McGill P, 2003, BEHAV MODIF, V27, P265, DOI 10.1177/0145445503251604; McMillan TM, 2001, BRAIN DAM B, P257; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; Novaco RW, 2004, PSYCHOL ASSESSMENT, V16, P42, DOI 10.1037/1040-3590.16.1.42; Persel CS, 1997, BRAIN INJURY, V11, P751; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; PRIGATANO GP, 1987, BNI Q, V3, P2; Pryor J, 2004, DISABIL REHABIL, V26, P974, DOI 10.1080/09638280410001702397; Pryor Julie, 2005, J Neurosci Nurs, V37, P117; *REH I CHIC, 1992, REH I CHIC FUNCT ASS; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; WAHLER RG, 1981, J APPL BEHAV ANAL, V14, P327, DOI 10.1901/jaba.1981.14-327; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Willis TJ, 2003, J HEAD TRAUMA REHAB, V18, P75, DOI 10.1097/00001199-200301000-00008; WILSON BA, 1991, HDB BEHAV THERAPY PS, P227; Winstanley S, 2004, AGGRESSIVE BEHAV, V30, P534, DOI 10.1002/ab.20052; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 2001, BRAIN DAM B, P133; Wood RL, 2001, BRAIN DAM B, P107; Wood RL, 2001, BRAIN DAM B, P3; Wood RL, 1981, APPL CONDITIONING TH, P81; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; [No title captured]	59	39	39	2	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					891	911		10.1080/02699050701543560			21	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600002	17729043				2022-02-06	
J	Chen, G; Shi, JX; Ding, YS; Yin, HX; Hang, CH				Chen, Gang; Shi, Jinxin; Ding, Yasuo; Yin, Hongxia; Hang, Chunhua			Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats	MEDIATORS OF INFLAMMATION			English	Article							ALPHA; ALLOPREGNANOLONE; INACTIVATION; INFLAMMATION; REPRESSION; MECHANISM; SUBUNIT; MUCOSA; CELLS; GUT	We have previously shown that traumatic brain injury (TBI) can induce an upregulation of nuclear factor kappa B (NF-kappa B) and proinflammatory cytokines in the gut, which play an important role in the pathogenesis of acute gut mucosal injury mediated by inflammation. In this work, we investigated whether progesterone administration modulated intestinal NF-kappa B activity and proinflammatory cytokines expression after TBI in male rats. As a result, we found that administration of progesterone following TBI could decrease NF-kappa B binding activity, NF-kappa B p65 protein expression, and concentrations of interleukin-1 beta (IL-1 beta), and tumor necrosis factor-alpha ( TNF-alpha) in the gut. TBI-induced damages of gut structure were ameliorated after progesterone injections. The results of the present study suggest that the therapeutic benefit of post-TBI progesterone injections might be due to its inhibitory effects on intestinal NF-kappa B activation and proinflammatory cytokines expression.	Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	nju_neurosurgery@163.com	Yin, Hong/AAC-5784-2020	Chen, Gang/0000-0002-0758-1907			Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Castro-Caldas M, 2003, MEDIAT INFLAMM, V12, P37, DOI 10.1080/0962935031000096953; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Claud EC, 2007, AM J PHYSIOL-GASTR L, V292, pG1411, DOI 10.1152/ajpgi.00557.2006; Davies S, 2004, GYNECOL ONCOL, V94, P463, DOI 10.1016/j.ygyno.2004.05.028; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Gotkin JL, 2006, AM J OBSTET GYNECOL, V195, P1015, DOI 10.1016/j.ajog.2006.07.002; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Homaidan FR, 2003, MEDIAT INFLAMM, V12, P277, DOI 10.1080/09629350310001619681; Horie S, 2005, FERTIL STERIL, V83, P1530, DOI 10.1016/j.fertnstert.2004.11.042; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kurachi O, 2001, J CLIN ENDOCR METAB, V86, P2275, DOI 10.1210/jc.86.5.2275; Lee JW, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93148; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pritts TA, 1998, ARCH SURG-CHICAGO, V133, P1311, DOI 10.1001/archsurg.133.12.1311; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Shields AD, 2005, AM J OBSTET GYNECOL, V193, P1144, DOI 10.1016/j.ajog.2005.05.046; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	32	39	40	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2007	2007								93431	10.1155/2007/93431			7	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	211OG	WOS:000249532500001	18274644	Green Submitted, gold, Green Published			2022-02-06	
J	Mansson, R; Hansson, MJ; Morota, S; Uchino, H; Ekdahl, CT; Elmer, E				Mansson, Roland; Hansson, Magnus J.; Morota, Saori; Uchino, Hiroyuki; Ekdahl, Christine T.; Elmer, Eskil			Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline	NEUROBIOLOGY OF DISEASE			English	Article						neurodegeneration; amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease; motor neuron disease; spinal cord injury; ischemia; apoptosis; cyclospotin; minocycline; neuroprotection; brain mitochondria	AMYOTROPHIC-LATERAL-SCLEROSIS; CYTOCHROME-C RELEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CYCLOSPORINE-A; HUNTINGTONS-DISEASE; CELL-DEATH; MICROGLIAL ACTIVATION; DOPAMINERGIC-NEURONS	Minocycline has been shown to be neuroprotective in ischemic and neurodegenerative disease models and could potentially be relevant for clinical use. We revisited the hypothesis that minocycline acts through direct inhibition of calcium-induced mitochondrial permeability transition (mPT) resulting in reduced release of cytochrome c (cyt c). Minocycline, at high dosage, was found to prevent calcium-induced mitochondrial swelling under energized conditions similarly to the mPT inhibitor cyclosporin A (CsA) in rodent mitochondria derived from the CNS. In contrast to CsA, minocycline dose-dependently reduced mitochondrial calcium retention capacity (CRC) and respiratory control ratios and was ineffective in the de-energized mPT assay. Further, minocycline did not inhibit calcium- or tBid-induced cyt c release. We conclude that the neuroprotective mechanism of minocycline is likely not related to direct inhibition of mPT and propose that the mitochondrial effects of minocycline may contribute to toxicity rather than tissue protection at high dosing in animals and humans. (c) 2006 Elsevier Inc. All rights reserved.	Lund Univ, Dept Clin Sci, Sect Restorat Neurol, Lund, Sweden; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Cellular Neurobiol, Hachioji, Tokyo, Japan; Tokyo Med Univ, Hachioji Med Ctr, Dept Anesthesiol, Hachioji, Tokyo, Japan		Mansson, R (corresponding author), Wallenberg Neurosci Ctr, Lab Expt Brain Res, BMC A13, SE-22184 Lund, Sweden.	roland.mansson@med.lu.se	Hansson, Magnus/G-4486-2014; Elmer, Eskil/F-9341-2014	Hansson, Magnus/0000-0002-0201-0638; Elmer, Eskil/0000-0001-7901-1826			Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Casarejos MJ, 2006, J NEUROCHEM, V97, P934, DOI 10.1111/j.1471-4159.2006.03777.x; Cha JH, 2004, NEUROLOGY, V63, P547; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Choi SH, 2005, J NEUROCHEM, V95, P1755, DOI 10.1111/j.1471-4159.2005.03503.x; Cornet S, 2004, EUR J PHARMACOL, V505, P111, DOI 10.1016/j.ejphar.2004.10.039; Damiano M, 2006, J NEUROCHEM, V96, P1349, DOI 10.1111/j.1471-4159.2006.03619.x; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fernandez-Gomez FJ, 2005, NEUROSCIENCE, V133, P959, DOI 10.1016/j.neuroscience.2005.03.019; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gordon PH, 2004, NEUROLOGY, V62, P1845, DOI 10.1212/01.WNL.0000125321.92112.7E; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; Karlsson J, 2004, J NEUROSURG, V101, P128, DOI 10.3171/jns.2004.101.1.0128; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Ryu JK, 2004, GLIA, V48, P85, DOI 10.1002/glia.20051; Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	47	39	43	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JAN	2007	25	1					198	205		10.1016/j.nbd.2006.09.008			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	114KN	WOS:000242665200021	17067803	Green Submitted			2022-02-06	
J	Larson, MJ; Perlstein, WM; Demery, JA; Stigge-Kaufman, DA				Larson, Michael J.; Perlstein, William M.; Demery, Jason A.; Stigge-Kaufman, David A.			Cognitive control impairments in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							ANTERIOR CINGULATE CORTEX; CLOSED-HEAD INJURY; PREFRONTAL CORTEX; WORKING-MEMORY; POSTTRAUMATIC AMNESIA; CONFLICT; DEFICITS; CONTEXT; DYSFUNCTION; SCHIZOPHRENIA	The componential nature of impaired cognitive control following traumatic brain injury (TBI) remains uncertain. We examined regulative and evaluative components of cognitive control in mild and moderate-to-severe (M/S) TBI patients and demographically-matched comparison participants using the AX-CPT task. We also examined relationships of cognitive control impairment to ratings of cognitive, behavioral, and affective symptomatology on the Dysexecutive Questionnaire (DEX). Results revealed that M/S, but not mild TBI patients showed deficits in context-processing and post-error strategic adjustments-extent of impairments correlated with TBI-related symptomatology. Thus, patients with MISS TBI evidence cognitive control dysfunction in the processing and active maintenance of context representations.	Univ Florida, Dept Clin & Hlth Psychol, HSC, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Dept McKnight Brain Inst, Gainesville, FL 32610 USA		Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC, Box 100165, Gainesville, FL 32610 USA.	wperlste@phhp.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857, R21 MH073076] Funding Source: Medline		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Barch DM, 2001, ARCH GEN PSYCHIAT, V58, P280, DOI 10.1001/archpsyc.58.3.280; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Braver TS, 2001, J EXP PSYCHOL GEN, V130, P746, DOI 10.1037//0096-3445.130.4.746; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; Burgess P, 1996, BEHAV ASSESSMENT DYS; Chapman LJ, 2001, J ABNORM PSYCHOL, V110, P31, DOI 10.1037/0021-843X.110.1.31; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Huynh H., 1976, J EDUC STAT, V1, P69, DOI [10.3102/10769986001001069, DOI 10.3102/10769986001001069, 10.2307/1164736]; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KLEVINE B, 2002, PRINCIPLES FRONTAL L, P504; LARSON MJ, 2005, IN PRESS 33 ANN M IN; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; MacDonald AW, 2003, J ABNORM PSYCHOL, V112, P689, DOI 10.1037/0021-843X.112.4.689; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; Neter J., 1985, APPL LINEAR STAT MOD; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; RABBITT PMA, 1968, Q J EXP PSYCHOL, V20, P179, DOI 10.1080/14640746808400146; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosnow RL, 1996, PSYCHOL METHODS, V1, P331, DOI 10.1037/1082-989X.1.4.331; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; ServanSchreiber D, 1996, ARCH GEN PSYCHIAT, V53, P1105; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spielberger CD., 1970, STATE TRAIT ANXIETY; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P6, DOI 10.1037//0021-843X.110.1.6; STUSS DT, 1991, SELF : INTERDISCIPLINARY APPROACHES, P255; TEASDALE G, 1974, LANCET, V2, P81; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Wechsler D, 1985, WECHSLER ADULT INTEL; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]; [No title captured]	56	39	40	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	2006	28	6					968	986		10.1080/13803390600646860			19	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	055LI	WOS:000238451800009	16822736				2022-02-06	
J	Woertgen, C; Rothoerl, RD; Schebesch, KM; Albert, R				Woertgen, Chris; Rothoerl, Ralf Dirk; Schebesch, Karl Michael; Albert, Ruth			Comparison of craniotomy and craniectomy in patients with acute subdural haematoma	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						acute subdural haematoma; craniotomy; decompressive craniectomy; outcome	DECOMPRESSIVE CRANIECTOMY; PRACTICAL SCALE; HEMICRANIECTOMY	Despite the increasing acceptance of craniectomy in patients with traumatic brain injury, the value of early decompressive craniectomy in patients with acute subdural haematoma is still under debate. In this retrospective study, we reviewed 180 patients with traumatic acute subdural haematoma, 111 of whom were treated with haematoma evacuation via craniotomy and 69 of whom were treated with early decompressive craniectomy. Due to the higher incidence of signs of herniation for patients in the craniectomy group, the mortality rate in this group was higher than that in the craniotomy group (53% vs. 32.3%). However, overall there was no significant difference in outcome between the two groups. Age and clinical signs of herniation were significantly associated with an unfavourable outcome, regardless of the type of surgery. Decompressive craniectomy did not seem to have a therapeutic advantage over craniotomy in traumatic acute subdural haernatoma. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Regensburg, Dept Neurosurg, D-93042 Regensburg, Germany		Woertgen, C (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	chris.woertgen@klinik.uni-regensburg.de					Cooper P R, 1976, Surg Neurol, V5, P25; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; JENNETT B, 1975, LANCET, V1, P480; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; TEASDALE G, 1974, LANCET, V2, P81; TOKUTOMI T, 1992, RECENT ADV NEUROTRAU, P367; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	12	39	40	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	AUG	2006	13	7					718	721		10.1016/j.jocn.2005.08.019			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099KD	WOS:000241592300002	16904897				2022-02-06	
J	King, KA; Hough, MS; Walker, MM; Rastatter, M; Holbert, D				King, Kristin A.; Hough, Monica S.; Walker, Marianna M.; Rastatter, Michael; Holbert, Don			Mild traumatic brain injury: Effects on naming in word retrieval and discourse	BRAIN INJURY			English	Article						brain injury; word retrieval; naming; discourse	CLOSED HEAD-INJURY; ADULTS	Primary objective: To investigate differences between a group with mild traumatic brain injury (MTBI) and a control group relative to standard scores and error type during word retrieval in both naming and discourse tasks. Methods and procedures: Ten participants with MTBI were age-, gender- and education-matched with 10 participants without injury. Pre-experimental tasks for the participants with MTBI included the Scales of Cognitive Ability for Traumatic Brain Injury and the Raven's Coloured Progressive Matrices and both groups received the Peabody Picture Vocabulary Test-III. Experimental tasks included the Test of Adolescent/ Adult Word Finding and the Test of Word Finding in Discourse. Main outcomes and results: Few participants (three on each experimental task) demonstrated psychometrically-based word retrieval deficits (standard score < 85); however, a significant difference in performance for the TAWF as compared to the TWFD was observed between groups. More word finding errors occurred with confrontational naming than with discourse tasks for both groups, with latency as the primary error type. Conclusions: Confrontational naming tasks may be more sensitive to subtle language difficulties occurring after MTBI. The study of adults with MTBI and their performance on semantically-based tasks offers important information for the advancement of therapeutic intervention and education.	E Carolina Univ, Dept Commun Sci & Disorders, Greenville, NC USA; E Carolina Univ, Dept Biostat, Greenville, NC USA		King, KA (corresponding author), 108 A Sunshine Lane, Winterville, NC 28590 USA.	kak1002@ecu.edu		Walker, Marianna/0000-0002-6342-9088			Adamovich B. B., 1992, SCALES COGNITIVE ABI; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barrow IM, 2003, J TRAUMA, V54, P888, DOI 10.1097/01.TA.0000057150.60668.7C; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BERNAD PG, 1991, CLIN ELECTROENCEPHAL, V22, P203, DOI 10.1177/155005949102200408; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Colohan A. R. T., 1986, J HEAD TRAUMA REHAB, V1, P13; DUNN LM, 1998, PEABODY PICTURE VOCA; EVANS RW, 1992, TRAUMATIC BRAIN INJU, V3, P427; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; German D. J., 1990, TEST ADOLESCENT ADUL; German D.J., 1991, TEST WORD FINDING DI; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; JEANETTE B, 1974, LANCET, V2, P81; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; Kaplan E, 1983, BOSTON NAMING TEST; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Raven L. C., 1956, RAVENS COLOURED PROG; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48; [No title captured]	29	39	40	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					725	732		10.1080/02699050600743824			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200007	16809205				2022-02-06	
J	Bergfeldt, U; Borg, K; Kullander, K; Julin, P				Bergfeldt, U; Borg, K; Kullander, K; Julin, P			Focal spasticity therapy with botulinum toxin: Effects on function, activities of daily living and pain in 100 adult patients	JOURNAL OF REHABILITATION MEDICINE			English	Article						botulinum toxin; spasticity; adults; cerebral palsy; stroke; traumatic injury	PLACEBO-CONTROLLED TRIAL; UPPER-LIMB SPASTICITY; UPPER EXTREMITY SPASTICITY; DOUBLE-BLIND; STROKE; MANAGEMENT; EFFICACY; SAFETY; FOOT	Objective: Analysis of the effects of a comprehensive focal spasticity program in adult patients. Design: Retrospective study of an out-patient cohort. Patients: One hundred patients were enrolled in the study (54 men and 46 women, mean age 41 years (SD 14). Cerebral palsy and stroke were equally common (80% in total). The remaining patients had miscellaneous diagnoses, including traumatic brain injury. Methods: On average 230 units (SD 101) of botulinum toxin A Botox((R)) was given for 227 principal therapy targets chosen by the patient or the caregiver. One patient could have several targets for therapy. Administration of botulinum toxin was combined with 260 additional therapeutic interventions, most of which were forms of physical therapy. The effects were assessed after 6 weeks and compared with baseline functional abilities 1 - 2 weeks prior to therapy. Results: Improvement was observed for 211 (93%) therapy targets, no change in 15 (7%), and impairment in 1, corresponding to an overall improvement in 90 patients (90%), 9 unchanged (9%) and worsening in 1. Spasticity assessment (Ashworth scale 0 - 4; 30 patients) showed a statistically significant improvement (median at baseline was 3 vs 2 after therapy, mean difference 1.2, p < 0.001). Conclusion: Improvement was observed in >= 90% of patients and in their principal therapeutic targets in a cohort receiving their first focal spasticity treatment with botulinum toxin A and additional therapy. A strict strategy for patient selection and comprehensive management was followed.	Stockholm Univ, Rehabil Med Clin, Karolinska Inst, SE-14186 Stockholm, Sweden		Bergfeldt, U (corresponding author), Stockholm Univ, Rehabil Med Clin, Karolinska Inst, SE-14186 Stockholm, Sweden.	ulla.bergfeldt@ds.se					ALBANY K, 2002, SPASTICITY ETIOLOGY, P166; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bakheit AMO, 2001, EUR J NEUROL, V8, P559, DOI 10.1046/j.1468-1331.2001.00277.x; Bhakta BB, 2000, J NEUROL NEUROSUR PS, V69, P217, DOI 10.1136/jnnp.69.2.217; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; BRIN MF, 1997, MUSCLE NERVE SPAST S, V6; BRIN MF, 1997, MUSCLE NERVE       S, V6, P208; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; CHAMBERS HG, 2002, SPASTICITY ETIOLOGY, P94; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; GARCIES JM, 2002, SPASTICITY ETIOLOGY, P44; GRACIES JM, 2002, SPASTICITY ETIOLOGY, P65; Lance J.W., 1980, SPASTICITY DISORDERE, P185; Landau WM, 2003, NEW ENGL J MED, V348, P258; LEACH J, 2002, SPASTICITY ETIOLOGY, P143; LENTNER C, 1982, GEIGY SCI TABLES, V2, P89; Mayer NH, 2002, SPASTICITY ETIOLOGY, P154; Moore AP, 2002, EUR J NEUROL, V9, P42, DOI 10.1046/j.1468-1331.2002.0090s1042.x; OBRIEN CF, 1997, MUSCLE NERVE       S, V6, P176; PIERSON S, 1997, MUSCLE NERVE       S, V6, P36; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Reichel G, 2001, J NEUROL, V248, pS25; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Richardson D, 1999, PHYSIOTHERAPY, V85, P541; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; TURNERSTOKES L, 2002, GUIDELINES USE BOTUL; Wade DT, 1992, MEASUREMENT NEUROLOG, p[15, 35]; Ward AB, 2002, EUR J NEUROL, V9, P48, DOI 10.1046/j.1468-1331.2002.0090s1048.x; Wissel J, 2000, J PAIN SYMPTOM MANAG, V20, P44, DOI 10.1016/S0885-3924(00)00146-9; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	35	39	40	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2006	38	3					166	171		10.1080/16501970500415348			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	039QS	WOS:000237321900004	16702083	gold			2022-02-06	
J	Johnston, MV; Sherer, M; Whyte, J				Johnston, MV; Sherer, M; Whyte, J			Applying evidence standards to rehabilitation research	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; ASSISTIVE TECHNOLOGY; CRITICAL-APPRAISAL; PUBLICATION BIAS; READERS GUIDE; INTERVENTIONS; CHALLENGE; OUTCOMES; COHORT	Objective: To describe evidence grading methods employed in the systematic reviews in this special series of articles. To provide an overview of results of these reviews to critique the quality of rehabilitation research. To identify issues in the application of evidence grading methods to rehabilitation. Design: Conceptual review of evidence-based practice and evidence grading methods. English-language research studies on rehabilitation of persons with spinal cord injury, traumatic brain injury, and burn for the 5-yr period of 1999-2004 were reviewed using methods of the American Academy of Neurology supplemented by Cochrane criteria and summarized. Results: Rehabilitation has a shortage of high-level studies. The number of level I treatment studies was quite limited (five in spinal cord injury, 15 in traumatic brain injury, 12 in burn rehabilitation), as was the number of level 2 studies (26, 4, and 2, respectively). Despite the large number of correlational studies published, the number of high-level (1 or 2) diagnostic and prognostic studies was surprisingly limited (34, 11, and 5, respectively). The rate of production of high-level studies is rapidly increasing. Problems were encountered in applying standard evidence criteria to complex issues encountered in some studies, suggesting limitations and issues in evidence grading methodology. Conclusions: Rehabilitation needs more high-level studies. Some improvements; in research methodology are relatively affordable (e.g., improved blinding), whereas others are expensive (e.g., large randomized controlled trials). Lower-level investigations reporting promising results need to be followed by more definitive, higher-level trials.	KMRREC, Res E, S Orange, NJ 07079 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA		Johnston, MV (corresponding author), KMRREC, Res E, 1199 Pleasant Valley Way, S Orange, NJ 07079 USA.			Whyte, John/0000-0002-4381-1474			ALDERSON P, 2004, COCHRANE REV HDB 4 2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; CAMPBELL DT, 1963, EXPT QUASI EXPERIENC; Chatfield C., 2004, ANAL TIME SERIES INT; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COOK TD, 1979, QUASI EXPT DESIGN AN; EDLUND W, 2004, AM ACAD NEUROLOGY CL; FINKEL SE, 1995, CAUSAL ANAL PANEL DA; Fuhrer MJ, 2003, DISABIL REHABIL, V25, P1243, DOI 10.1080/09638280310001596207; Gold M., 1996, COST EFFECTIVENESS H; Gray JAM, 2001, EVIDENCE BASED HEALT; HALEY SM, 1994, PHYS THER, V74, P443, DOI 10.1093/ptj/74.5.443; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Jenicek M, 2001, CLIN CASE REPORTING; Jenicek M., 2003, FDN EVIDENCE BASED M; Jensen Peter S, 2005, Ment Health Serv Res, V7, P53, DOI 10.1007/s11020-005-1965-3; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; JOHNSTON MV, 1997, ASSESSING MED REHABI, V4, P1; KEITH R, 2005, IMPROVING ASSESSMETN, P33; Kline RB., 2004, PRINCIPLES PRACTICE, V2nd; Kravitz RL, 2004, MILBANK Q, V82, P661, DOI 10.1111/j.0887-378X.2004.00327.x; Law M, 2002, EVIDENCE BASED REHAB; Little RJ, 2000, ANNU REV PUBL HEALTH, V21, P121, DOI 10.1146/annurev.publhealth.21.1.121; Luther Stephen L, 2004, SCI Nurs, V21, P206; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Mann WC, 1999, ARCH FAM MED, V8, P210, DOI 10.1001/archfami.8.3.210; Montori VM, 2000, MAYO CLIN PROC, V75, P1284, DOI 10.4065/75.12.1284; Muche R, 2002, Rehabilitation (Stuttg), V41, P311; NORCROSS JC, 2006, EVIDENCE BASED PRACT; Normand SLT, 2005, BMJ-BRIT MED J, V330, P1021, DOI 10.1136/bmj.330.7498.1021; Norris SL, 2005, ANN INTERN MED, V142, P1112, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00011; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Ottenbacher KJ, 1999, AM J OCCUP THER, V53, P181, DOI 10.5014/ajot.53.2.181; Ottenbacher KJ, 2001, AM J PHYS MED REHAB, V80, P786, DOI 10.1097/00002060-200110000-00014; *OXF CTR EV BAS ME, LEV EV GRAD REC; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; PAGLIARULO MA, 2001, INTR PHYS THERAPY; Philips Z, 2004, HEALTH TECHNOL ASSES, V8, P1; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; ROSNER B, 2005, FUNDAMENTALS BIOSTAT; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; SACIKETT DL, 2000, EVIDENCE BASED MED P; Salmon Wesley, 1997, CAUSALITY EXPLANATIO; Scherer M.J., 2001, ASSISTIVE TECHNOLOGY; SHADISH WR, 2002, EXPT QUASIEXPERIMENT; Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459; STROKE UNIT TRIALISTS' COLLABORATION, 2002, COCHRANE DATABASE SY, V1; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; *US DEP ED WWC, 2005, WWC STUD REV STAND; Vray Muriel, 2004, Therapie, V59, P273, DOI 10.2515/therapie:2004054; West S., 2002, AHRQ PUBLICATION; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; World Health Organization, 2007, INT CLASS FUNCT DIS; ZOLA IK, 1989, MILBANK Q, V67, P401, DOI 10.2307/3350151; 2001, SAMPLE POWER 2 0 COM	57	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2006	85	4					292	309		10.1097/01.phm.0000202079.58567.3b			18	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	026XI	WOS:000236376200002	16554683				2022-02-06	
J	Slobounov, S; Slobounov, E; Newell, K				Slobounov, Semyon; Slobounov, Elena; Newell, Karl			Application of virtual reality graphics in assessment of concussion	CYBERPSYCHOLOGY & BEHAVIOR			English	Article; Proceedings Paper	4th International Workshop on Virtual Rehabilitation (IWVR2005)	SEP, 2005	Los Angeles, CA				TRAUMATIC BRAIN-INJURY	Abnormal balance in individuals suffering from traumatic brain injury (TBI) has been documented in numerous recent studies. However, specific mechanisms causing balance deficits have not been systematically examined. This paper demonstrated the destabilizing effect of visual field motion, induced by virtual reality graphics in concussed individuals but not in normal controls. Fifty five student-athletes at risk for concussion participated in this study prior to injury and 10 of these subjects who suffered MTBI were tested again on day 3, day 10, and day 30 after the incident. Postural responses to visual field motion were recorded using a virtual reality (VR) environment in conjunction with balance (AMTI force plate) and motion tracking (Flock of Birds) technologies. Two experimental conditions were introduced where subjects passively viewed VR scenes or actively manipulated the visual field motion. Long-lasting destabilizing effects of visual field motion were revealed, although subjects were asymptomatic when standard balance tests were introduced. The findings demonstrate that advanced VR technology may detect residual symptoms of concussion at least 30 days post-injury.	Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA.	sms18@psu.edu					Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Jamet M, 2004, NEUROSCI LETT, V359, P61, DOI 10.1016/j.neulet.2004.02.010; Keshner E., 2000, J VESTIBUL RES-EQUIL, P1; Keshner E., 2004, INT C DIS VIRT REAL, V1; Keshner EA, 2004, ASSIST TECHNOL, V16, P54, DOI 10.1080/10400435.2004.10132074; MACH E, 1975, GRUNDLINIEN LEHRE BE; Nakamura S, 1999, PERCEPTION, V28, P893, DOI 10.1068/p2939; ROSENBERG JR, 1989, PROG BIOPHYS MOL BIO, V53, P1, DOI 10.1016/0079-6107(89)90004-7; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; WARREN R, 1976, J EXP PSYCHOL HUMAN, V2, P448, DOI 10.1037/0096-1523.2.3.448	12	39	39	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	APR	2006	9	2					188	191		10.1089/cpb.2006.9.188			4	Communication; Psychology, Applied	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Communication; Psychology	041PX	WOS:000237469200017	16640477				2022-02-06	
J	Fager, S; Hux, K; Beukelman, DR; Karantounis, R				Fager, S; Hux, K; Beukelman, DR; Karantounis, R			Augmentative and alternative communication use and acceptance by adults with traumatic brain injury	AUGMENTATIVE AND ALTERNATIVE COMMUNICATION			English	Article						traumatic brain injury; augmentative and alternative communication		The purpose of this study was to document augmentative and alternative communication (AAC) acceptance and use patterns of 25 adults with traumatic brain injuries (TBI) who used either high- or low-tech AAC devices or strategies at some point during their recovery. Specifically, the purposes were to (a) document acceptance of AAC system recommendations, (b) identify AAC use patterns by persons who accepted the recommendation and for whom AAC intervention was implemented, (c) identify AAC access patterns for message formulation and encoding, and (d) document the kind of communicative functions that different AAC strategies supported. Information was gathered via a questionnaire from speech-language pathologists who provided AAC assessments and interventions at six different sites. The speech-language pathologists provided information about individuals with TBI from their clinics for whom they had recommended AAC. Results revealed that these adults generally accepted both high- and low-tech AAC recommendations and used their AAC systems for extended periods of time. Most utilized letter-by-letter message formulation strategies. When AAC technology was abandoned, it was usually a reflection of a loss of facilitator support rather than a rejection of the technology.	Univ Nebraska, Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, Lincoln, NE 68506 USA; Rose Med Ctr, Denver, CO USA		Fager, S (corresponding author), Univ Nebraska, Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, 5401 S St, Lincoln, NE 68506 USA.	sfager@madonna.org	Hux, Karen/AAQ-2078-2020	Fager, Susan/0000-0001-8125-5977			BALL L, 2004, AUGMENT ALTERN COMM, V20, P113, DOI DOI 10.1080/0743461042000216596; Beukelman D R, 1998, AUGMENTATIVE ALTERNA; Beukelman DR, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P135; Beukelman DR, 2002, J MED SPEECH-LANG PA, V10, P237; Bruno J, 1989, AUGMENTATIVE ALTERNA, V5, P89; DeRuyter F., 1987, AUGMENTATIVE ALTERNA, V3, P18, DOI DOI 10.1080/07434618712331274209; Deruyter F, 1988, J HEAD TRAUMA REHAB, V3, P35; DeRuyter F, 1991, COMMUNICATION DISORD, P317; DERUYTER F, 1989, AUGMENTATIVE ALTERNA, V5, P49, DOI DOI 10.1080/07434618912331274966; Dongilli P, 1992, J HEAD TRAUMA REHAB, V7, P91; Doyle M, 2000, AUG ALTER COMMUN SER, P271; ENDERBY P, 1990, J DISORDERED COMMUNI, V23, P341; Fager S., 2003, AM SPEECH LANG HEAR; Fried-Oken M., 1992, J HEAD TRAUMA REHAB, V9, DOI [DOI 10.1097/00001199-199209000-00008, 10.1097/00001199-199209000-00008]; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hsieh MC, 1999, AUGMENTATIVE ALTERNA, V15, P216; Hux K, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P169; Hux K, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P93; Hux K, 2001, J MED SPEECH-LANG PA, V9, P71; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1990, Brain Injury, V4, P101, DOI 10.3109/02699059009026154; Keenan J, 1993, AUGMENTATIVE ALTERNA, V9, P184, DOI DOI 10.1080/07434619312331276591; KEETLEY A, 1994, EUROPEAN J DISORDERE, V29, P183; Ladtkow M, 1992, AUGMENTATIVE COMMUNI, P139; LAFONTAINE LM, 1987, AUGMENTATIVE ALTERNA, V3, P153; LASKER J, 1997, THEIS U NEBRASKALINC; LEVINE SP, 1992, J HEAD TRAUMA REHAB, V7, P46, DOI DOI 10.1097/00001199-199209000-00007; LIGHT J, 1990, AAC (Augmentative and Alternative Communication), V6, P184, DOI 10.1080/07434619012331275454; Light J., 1988, AUGMENTATIVE ALTERNA, V4, P2, DOI DOI 10.1080/07434618812331274557; Mathy P, 2000, AUG ALTER COMMUN SER, P183; Murphy J., 1995, AUGMENTATIVE ALTERNA, V11, P26, DOI 10.1080/07434619512331277119; SBORDONE RJ, 1988, J HEAD TRAUMA REHAB, V3, P55; Smith-Lewis M., 1987, AUGMENTATIVE ALTERNA, V3, P12; Trefler E., 1985, AUGMENTATIVE ALTERNA, V1, P151, DOI DOI 10.1080/07434618512331273651; WORKINGER M S, 1992, Brain Injury, V6, P183, DOI 10.3109/02699059209029657; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48	36	39	39	0	26	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0743-4618			AUGMENT ALTERN COMM	Augment. Altern. Commun.	MAR	2006	22	1					37	47		10.1080/07434610500243990			11	Audiology & Speech-Language Pathology; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Rehabilitation	028FC	WOS:000236471300004	17114157				2022-02-06	
J	Hynes, LM; Dickey, JP				Hynes, LM; Dickey, JP			Is there a relationship between whiplash-associated disorders and concussion in hockey? A preliminary study	BRAIN INJURY			English	Article						whiplash associated disorders; concussion; hockey; atheletic injuries; brain injuries; whiplash; return to PLA	ICE HOCKEY; CONTACT SPORTS; INJURY; HEAD; KINEMATICS	Primary objective: To examine the relationship between the occurrence of whiplash-associated disorders and concussion symptoms in hockey players. Research design: Prospective cohort observational study to examine the relationship between whiplash associated disorders and concussion in actual hockey play. Methods and procedures: Twenty hockey teams were followed prospectively for one season. Team therapists completed acute and 7-10 day follow-up evaluation questionnaires for all of the players who received either a whiplash mechanism or a concussion. Main outcomes and results: 183 players were registered for this study; 13 received either a whiplash mechanistic injury or a concussion injury. Initial injuries ranged from WAD I to WAD III and all subjects reported concussion symptoms. Only three subjects reported full resolution of both WAD and concussion symptoms at the 7-10 day follow-up evaluation. Conclusions: There is a strong association between whiplash induced neck injuries and the symptoms of concussion in hockey injuries. Both should be evaluated when dealing with athletes/patients suffering from either injury.	Univ Guelph, ANNU 334, Guelph, ON N1G 2W1, Canada		Dickey, JP (corresponding author), Univ Guelph, ANNU 334, Guelph, ON N1G 2W1, Canada.	jdickey@uoguelph.ca	Dickey, James P/K-6776-2013	Dickey, James P/0000-0002-4101-835X			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Blouin JS, 2003, EXP BRAIN RES, V150, P458, DOI 10.1007/s00221-003-1466-9; Brault JR, 2000, CLIN BIOMECH, V15, P426, DOI 10.1016/S0268-0033(99)00097-2; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2000, SEMIN NEUROL, V20, P173, DOI 10.1055/s-2000-9825; Castro WHM, 2001, INT J LEGAL MED, V114, P316, DOI 10.1007/s004140000193; Cholewicki J, 1998, ACCIDENT ANAL PREV, V30, P469, DOI 10.1016/S0001-4575(97)00103-6; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cooper MT, 2003, CLIN SPORT MED, V22, P427, DOI 10.1016/S0278-5919(02)00110-2; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Kaneoka K, 1999, SPINE, V24, P763, DOI 10.1097/00007632-199904150-00006; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kumar S, 2002, SPINE, V27, P1044, DOI 10.1097/00007632-200205150-00009; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Luan F, 2000, CLIN BIOMECH, V15, P649, DOI 10.1016/S0268-0033(00)00031-0; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McClune T, 2002, EMERG MED J, V19, P499, DOI 10.1136/emj.19.6.499; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Sim F H, 1978, Am J Sports Med, V6, P378, DOI 10.1177/036354657800600612; SPITZER WO, 1995, SPINE S8, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Young WF, 2001, POSTGRAD MED, V109, P179, DOI 10.3810/pgm.2001.03.881	28	39	39	1	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2006	20	2					179	188		10.1080/02699050500443707			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700008	16421067				2022-02-06	
J	Ahn, YH; Kim, SH; Han, BS; Kim, OL; Ahn, SH; Cho, YW; Kwon, YH; Jang, SH				Ahn, Young Hwan; Kim, Seong Ho; Han, Bong Soo; Kim, Oh Lyong; Ahn, Sang Ho; Cho, Yoon Woo; Kwon, Yong-Hyun; Jang, Sung Ho			Focal lesions of the corticospinal tract demonstrated by diffusion tensor imaging in patients with diffuse axonal injury	NEUROREHABILITATION			English	Article						motor recovery; diffusion tensor imaging; corticospinal tract; diffuse axonal injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD TRAUMA; FIBER TRACKING; FUNCTIONAL MRI; TRACTOGRAPHY; RECOVERY	Objectives: Diffusion tensor imaging (DTI) with fiber tractography (FT) could be useful for exploration of the state of the corticospinal tract (CST) at the subcortical white matter level. The purpose of this study was to demonstrate focal lesions of the CST in patients with diffuse axonal injury (DAI), using DTI with FT. Design: Two patients with DAI and six normal control subjects were recruited to this study. DTI was performed using 1.5-T with a synergy-L Sensitivity Encoding ( SENSE) head coil. Fractional anisotropy ( FA) and apparent diffusion coefficients (ADC) were measured using a region of interest (ROI) method. FTs were obtained with FA < 0.3 and an angle change > 45. as termination criteria. Results: On the DTI with FT, the focal lesions, which could not observed using routine brain MRI, were detected in the left brainstem of patient 1 and in the right pons and the left and right medulla of patient 2. The patients showed significantly decreased FA values in the focal lesions compared to normal controls. Conclusions: DTI with FT demonstrated focal lesions at the brainstem that had not been revealed by conventional brain MRI; these focal lesions explained the weaknesses of the patients. We conclude that DTI with FT may be a useful modality for use in investigating the status of CST in patients with DAI.	Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea; Ajou Univ, Sch Med, Dept Neurosurg, Suwon 441749, South Korea; Yeungnam Univ, Sch Med, Dept Neurosurg, Taegu 705717, South Korea; Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Kangwon Do, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net	Han, Bong Soo/AAL-6704-2020				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P11; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P265; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kim YH, 2004, NEUROREPORT, V15, P1899, DOI 10.1097/00001756-200408260-00013; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Ronen I, 2005, MAGN RESON MED, V54, P317, DOI 10.1002/mrm.20542; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530	20	39	39	0	0	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	3					239	243					5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	120KV	WOS:000243084500007	17167193				2022-02-06	
J	Knight, RG; Titov, N; Crawford, M				Knight, RG; Titov, N; Crawford, M			The effects of distraction on prospective remembering following traumatic brain injury assessed in a simulated naturalistic environment	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						prospective memory; virtual reality; neuropsychological assessment; logical memory; Ruff Selective Attention Test; executive functions	PROSPECTIVE MEMORY; EVENT	The aim of this investigation was to assess deficits in prospective remembering following chronic traumatic brain injuries (TBI), under conditions of high and low distraction. We constructed a virtual shopping precinct from photographs, sounds, and video Segments linked together. The street was divided into halves, a low distraction zone and a high distraction zone (with increased visual and auditory noise). Twenty persons with TBI (7 severe, 7 very severe, 6 extremely severe) and 20 matched controls completed ongoing and prospective memory tasks while "walking" along the street. In the ongoing task, participants were given ten errands to complete with a checklist accessible at any time. The prospective component required responding to three targets that appeared repeatedly. As predicted, the TBI group performed both the ongoing and the prospective components of the street task poorly compared with the controls and was more affected by distractions. The results suggest that the real-life deficits in memory skills reported by persons with TBI may become more apparent when remembering engages executive processes and that computer simulations can be used to construct sensitive measures of practical memory abilities.	Univ Otago, Dept Psychol, Dunedin, New Zealand		Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz		Titov, Nickolai/0000-0002-7268-729X			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Burgess P, 1996, BEHAV ASSESSMENT DYS; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; FARRIMOND SJ, 2006, IN PRESS APPL COGNIT, V20; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Jennett B, 1981, MANAGEMENT HEAD INJU; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDermott K, 2004, APPL COGNITIVE PSYCH, V18, P349, DOI 10.1002/acp.977; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Roediger H. L., 1996, PROSPECTIVE MEMORY T, P149; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Titov N, 2000, BRAIN INJURY, V14, P877; Titov N, 2005, BRAIN INJURY, V19, P315, DOI 10.1080/02699050400013725; Titov N, 2001, APPL COGNITIVE PSYCH, V15, P61, DOI 10.1002/1099-0720(200101/02)15:1<61::AID-ACP689>3.0.CO;2-Y; Wilson B, 1999, CASE STUDIES NEUROPS	25	39	41	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					8	16		10.1017/S1355617706060048			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800002	16433939				2022-02-06	
J	Kochanek, AR; Kline, AE; Gao, WM; Chadha, M; Lai, YC; Clark, RSB; Dixon, CE; Jenkins, LW				Kochanek, Ashley R.; Kline, Anthony E.; Gao, Wei-Min; Chadha, Mandeep; Lai, Yichen; Clark, Robert S. B.; Dixon, C. Edward; Jenkins, Larry W.			Gel-based hippocampal proteomic analysis 2 weeks following traumatic brain injury to immature rats using controlled cortical impact	DEVELOPMENTAL NEUROSCIENCE			English	Article						hippocampus; phosphorylation; pyruvate; protein oxidation; mitochondria; rat brain; pediatric traumatic brain injury	PYRUVATE-DEHYDROGENASE ACTIVITY; SYNAPTIC PLASTICITY; PHOSPHORYLATION; INHIBITION; PROTEINS; COMPLEX; STRESS	Traumatic brain injury (TBI) to postnatal day 17 rats has been shown to produce acute changes in hippocampal global protein levels and spatial learning and memory deficits. The purpose of the present study was to analyze global hippocampal protein changes 2 weeks after a moderate ipsilateral controlled cortical impact in postnatal day 17 rats using 2-dimensional difference gel electrophoresis and mass spectrometry. Paired sham and ipsilateral injured hippocampal lysates were independently labeled with different fluorescent cyanine dyes and coseparated within the same immobilized pH gradient strips and slab gel based on isoelectric point and molecular mass. Significant changes in key proteins involved in glial and neuronal stress, oxidative metabolism, calcium uptake and neurotransmitter function were found 2 weeks after injury, and their potential roles in hippocampal plasticity and cognitive dysfunction were discussed. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Texas Tech Univ, Inst Environm & Human Hlth, Dept Environm Toxicol, Lubbock, TX 79409 USA		Jenkins, LW (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	ljenkins@pitt.edu		Lai, Yi-Chen/0000-0002-9450-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042648] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T-32 HD 40686, T32 HD040686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042648-04, R01 NS042648, NS42648] Funding Source: Medline		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; BAUDRY M, 1982, NEUROSCI LETT, V31, P41, DOI 10.1016/0304-3940(82)90051-9; BROWNING M, 1981, J NEUROCHEM, V36, P1932, DOI 10.1111/j.1471-4159.1981.tb10817.x; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Herschkowitz N, 2000, BRAIN DEV-JPN, V22, P411, DOI 10.1016/S0387-7604(00)00185-6; Hertz L, 2004, J CEREBR BLOOD F MET, V24, P1241, DOI 10.1097/00004647-200411000-00008; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Lambert K G, 2000, Stress, V3, P275, DOI 10.3109/10253890009001133; Lister R, 2005, MOL MEMBR BIOL, V22, P87, DOI 10.1080/09687860500041247; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Morel N, 2003, BIOL CELL, V95, P453, DOI 10.1016/S0248-4900(03)00075-3; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; Peluffo H, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-12; Philippe JM, 2002, GLIA, V37, P365, DOI 10.1002/glia.10041; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Samikkannu T, 2003, CHEM RES TOXICOL, V16, P409, DOI 10.1021/tx025615j; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Stevenson K. L., 2000, Journal of Neurotrauma, V17, P944; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; Wu WW, 2006, J PROTEOME RES, V5, P651, DOI 10.1021/pr050405o; Yang B, 2003, NEUROSCI RES, V46, P333, DOI 10.1016/S0168-0102(03)00096-8; Yoo BC, 2001, ELECTROPHORESIS, V22, P172, DOI 10.1002/1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P	38	39	40	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					410	419		10.1159/000094167			10	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600018	16943664	Green Accepted, Bronze			2022-02-06	
J	Bilgen, M				Bilgen, M			A new device for experimental modeling of central nervous system injuries	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; spinal cord injury; animal model; injury device	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; RAT; IMMATURE	This article introduces a new device for inducing central nerve system injuries in experimental studies with animal models. The construction of the device is based on a commercially available servo-drive system incorporating the latest instrumentation technology and software developed in house to control the motion profile of the injury bit. The software, which is available upon request from the author, was designed such that the user can set the mechanical properties of the motion. For the purpose of quality control, tests were described and performed to assess the ability of the device to reproduce the prescribed motion when operated repetitively under the same set of parameters. Experiments were then conducted on animals to injure mouse brain and rat spinal cord. Following the injuries, in vivo magnetic resonance imaging was performed on the animals to depict the pathologies of the resulting injuries in the corresponding neuronal tissues. Rat spinal cords injured mildly and severely were followed longitudinally for up to 28 days postinjury. The neurobehaviors of the animals evaluated using locomotor rating scores indicated the ability of the device to produce repeatable graded injuries.	Univ Kansas, Sch Med, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA		Bilgen, M (corresponding author), Univ Kansas, Sch Med, Hoglund Brain Imaging Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	mbilgen@kumc.edu					Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSOLS GB, 1996, DOMINGUEZIA, V13, P7; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bilgen M, 2004, MAGN RESON MED, V52, P937, DOI 10.1002/mrm.20228; Bilgen M, 2005, MAGN RESON IMAGING, V23, P601, DOI 10.1016/j.mri.2005.02.003; Bilgen M, 2000, MAGN RESON MED, V43, P594; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Falconer JC, 1996, SPINE, V21, P104, DOI 10.1097/00007632-199601010-00025; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; NARAYANA PA, 2000, HDB CNS TRAUMA; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481	20	39	43	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2005	19	3					219	226		10.1177/1545968305278635			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	959LF	WOS:000231518500005	16093412				2022-02-06	
J	Othman, M; Lu, C; Klueber, K; Winstead, W; Roisen, FJ				Othman, M; Lu, C; Klueber, K; Winstead, W; Roisen, FJ			Clonal analysis of adult human olfactory neurosphere forming cells	BIOTECHNIC & HISTOCHEMISTRY			English	Article						clonal analysis; olfactory; progenitors; stem cells	EPIDERMAL-GROWTH-FACTOR; EMBRYONIC STEM-CELLS; NEURAL PROGENITORS; PRECURSOR CELLS; MOUSE BRAIN; NEURONS; IDENTIFICATION; EPITHELIUM; DIFFERENTIATION; MULTIPOTENT	Olfactory neuroepithelium (ONe) is unique because it contains progenitor cells capable of mitotic division that replace damaged or lost neurons throughout life. We isolated populations of ONe progenitors from adult cadavers and patients undergoing nasal sinus surgery that were heterogeneous and consisted of neuronal and glial progenitors. Progenitor lines have been obtained from these cultures that continue to divide and form nestin positive neurospheres. In the present study, we used clonal and population analyses to probe the self-renewal and multipotency of the neurosphere forming cells (NSFCs). NSFCs plated at the single cell level produced additional neurospheres; dissociation of these spheres resulted in mitotically active cells that continued to divide and produce spheres as long as they were subcultured. The mitotic activity of clonal NSFCs was assessed using bromodeoxyuridine (BrdU) incorporation. Lineage restriction of the clonal cultures was determined using a variety of antibodies that were characteristic of different levels of neuronal commitment: beta-tubulin isotype III, neural cell adhesion molecule (NCAM) and microtubule associated protein (MAP2), or glial restriction: astrocytes, glial fibrillary acidic protein (GFAP); and oligodendrocytes, galactocerebroside (GaIC). Furthermore, nestin expression, a marker indicative of progenitor nature, decreased in defined medium compared to serum-containing medium. Therefore, adult human ONe-derived neural progenitors retain their capacity for self-renewal, can be clonally expanded, and offer multipotent lineage restriction. Therefore, they are a unique source of progenitors for future cell replacement strategies in the treatment of neurotrauma and neurodegenerative diseases.	Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA		Roisen, FJ (corresponding author), Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.	fjrois01@louisville.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR15576] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER		Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Chang MY, 2004, DEV BRAIN RES, V153, P89, DOI 10.1016/j.devbrainres.2004.08.003; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; Engstrom CM, 2002, J NEUROSCI METH, V117, P111, DOI 10.1016/S0165-0270(02)00074-2; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; Gritti A, 1996, J NEUROSCI, V16, P1091; Huard JMT, 1998, J COMP NEUROL, V400, P469; Hulspas R, 1997, EXP NEUROL, V148, P147, DOI 10.1006/exnr.1997.6672; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Kramer PR, 2000, DEV BIOL, V227, P343, DOI 10.1006/dbio.2000.9896; Kukekov VG, 1997, GLIA, V21, P399, DOI 10.1002/(SICI)1098-1136(199712)21:4<399::AID-GLIA7>3.0.CO;2-Z; Leopold DA, 2000, LARYNGOSCOPE, V110, P417, DOI 10.1097/00005537-200003000-00016; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; Liu N, 1998, EXP NEUROL, V151, P173, DOI 10.1006/exnr.1998.6810; Liu ZP, 2003, J COMP NEUROL, V459, P368, DOI 10.1002/cne.10664; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Marshall CT, 2005, BRAIN RES, V1045, P45, DOI 10.1016/j.brainres.2005.03.041; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Meyer JR, 2000, J MED ETHICS, V26, P166, DOI 10.1136/jme.26.3.166; MORAN DT, 1982, BRAIN RES, V253, P39, DOI 10.1016/0006-8993(82)90671-0; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Mumm JS, 1996, P NATL ACAD SCI USA, V93, P11167, DOI 10.1073/pnas.93.20.11167; Murrell W, 1996, NEUROREPORT, V7, P1189, DOI 10.1097/00001756-199604260-00019; Ostenfeld T, 2004, STEM CELLS, V22, P798, DOI 10.1634/stemcells.22-5-798; Othman MM, 2003, BIOTECH HISTOCHEM, V78, P57, DOI 10.1080/10520290310001593801; Rao MS, 1999, ANAT RECORD, V257, P137; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; SATOH M, 1995, DEV BRAIN RES, V87, P111, DOI 10.1016/0165-3806(95)00057-K; Seaberg RM, 2005, DEV BIOL, V278, P71, DOI 10.1016/j.ydbio.2004.10.017; SHATOS MA, 2001, J REG MED, V2, P213; Shetty AK, 2004, HIPPOCAMPUS, V14, P595, DOI 10.1002/hipo.10206; Silani V, 1998, NEUROREPORT, V9, P1143, DOI 10.1097/00001756-199804200-00034; SOSNOWSKI JS, 1995, BRAIN RES, V702, P37, DOI 10.1016/0006-8993(95)00960-7; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Winstead W, 2005, AM J RHINOL, V19, P83, DOI 10.1177/194589240501900115; Xiao M, 2005, EXP NEUROL, V194, P12, DOI 10.1016/j.expneurol.2005.01.021; Zahir T, 2005, STEM CELLS, V23, P424, DOI 10.1634/stemcells.2004-0199; Zhang XD, 2004, EXP NEUROL, V186, P112, DOI 10.1016/j.expneurol.2003.10.022	52	39	46	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1052-0295	1473-7760		BIOTECH HISTOCHEM	Biotech. Histochem.	SEP-DEC	2005	80	5-6					189	200		10.1080/10520290500469777			12	Biotechnology & Applied Microbiology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Cell Biology	038ZS	WOS:000237269200002	16720519				2022-02-06	
J	Slomine, BS; Salorio, CF; Grados, MA; Vasa, RA; Christensen, JR; Gerring, JP				Slomine, BS; Salorio, CF; Grados, MA; Vasa, RA; Christensen, JR; Gerring, JP			Differences in attention, executive functioning, and memory in children with and without ADHD after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						attention deficit hyperactivity disorder; brain injuries; cognition; pediatrics; learning; neuropsychology	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; ADOLESCENTS; PERFORMANCE; SCALE; TESTS; COMA	Although the development of Attention Deficit Hyperactivity Disorder (ADHD) after traumatic brain injury (TBI) has been described, it is unknown whether children with TBI and ADHD have greater neuropsychological impairments than children with TBI alone. This study examines attention, executive functioning, and memory in children with TBI-only and TBI + ADHD. Caregivers of 82 children with severe TBI completed structured psychiatric interviews at enrollment to diagnose premorbid ADHD and one-year after injury to diagnose post-injury ADHD. Children underwent neuropsychological testing one year after injury. One memory measure significantly differentiated children with TBI-only from children with newly developed ADHD [secondary ADHD (S-ADHD)] and those with premorbid ADHD that persisted after injury [persisting ADHD (P-ADHD)]. Compared with the TBI-only group, children with TBI + ADHD had worse performance on measures of attention, executive functioning, and memory. Results reveal that in children with severe TBI, the behavioral diagnosis of ADHD is associated with more difficulty in attention, executive functioning, and memory. Additionally, results suggest greater deficits in memory skills in the S-ADHD group compared with the P-ADHD group. Although findings provide preliminary support for distinguishing P-ADHD from S-ADHD, further research is needed to investigate neuropsychological differences between these subgroups of children with severe TBI.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA; Kennedy Krieger Inst, Dept Psychiat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA		Slomine, BS (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA.	Slomine@Kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD 24061] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cahn DA, 1995, CHILD NEUROPSYCHOL, V1, P158, DOI 10.1080/09297049508402247; DELIS D, 1994, CALIFORNIA VERBAL LE; Dennis M, 1995, TRAUMATIC HEAD INJUR; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; Hamster K., 1983, MULTILINGUAL APHASIA; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Kaplan BJ, 1998, J CLIN EXP NEUROPSYC, V20, P518, DOI 10.1076/jcen.20.4.518.1477; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Leark R, 1996, TOVA TEST VARIABLES; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1995, TRAUMATIC HEAD INJUR; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; [No title captured]	35	39	39	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2005	11	5					645	653		10.1017/S1355617705050769			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	968TJ	WOS:000232185000016	16212692				2022-02-06	
J	Tasker, RC; Salmond, CH; Westland, AG; Pena, A; Gillard, JH; Sahakian, BJ; Pickard, JD				Tasker, RC; Salmond, CH; Westland, AG; Pena, A; Gillard, JH; Sahakian, BJ; Pickard, JD			Head circumference and brain and hippocampal volume after severe traumatic brain injury in childhood	PEDIATRIC RESEARCH			English	Article							VOXEL-BASED MORPHOMETRY; VENTRICULAR ENLARGEMENT; DIFFUSION TENSOR; CHILDREN; MRI; ATROPHY; GROWTH; ECHO; ADOLESCENTS; DEFICIENCY	Vulnerability of the hippocampus to traumatic brain injury (TBI) in adults is related to severity of injury and white matter atrophy. The objectives of this study were to determine features of anthropometry and cerebral morphometry late after TBI in childhood and to assess whether hippocampal volume is related to severity of initial ictus and changes in white matter at follow-up. Thirty-three patients underwent magnetic resonance imaging 4.9 y after severe TBI that necessitated intensive care; 23 had mechanical ventilation and intracranial pressure monitoring longer than 3 d. Magnetic resonance imaging analyses included volume of brain, hemisphere, ventricles, and hippocampal and perihippocampal regions; spatial distribution of voxel-based morphometry differences in white matter; and eigenvalues of diffusion tensor imaging diffusivity. Patients with longer intensive care ictus had smaller-than-expected occipitofrontal head circumference. Eight of these, identified by voxel-based morphometry, had periventricular white matter loss and smaller-than-expected brain volume for OFC, suggesting "atrophy"; the remainder had expected volume for a smaller OFC, suggesting "growth disturbance." Ninety-three percent of the variation in right hippocampal volume was accounted for by factors related to severity of injury and white matter atrophy. It is concluded that anthropometry and cerebral morphometric measurements late after severe TBI in childhood provides useful outcome data and indicate that, despite adequate growth in stature, effects of TBI on brain growth and hippocampal volume may extend into adulthood.	Univ Cambridge, Addenbrookes Hosp, Sch Clin, Dept Paediat, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England		Tasker, RC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin, Dept Paediat, Box 116,Hills Rd, Cambridge CB2 2QQ, England.	rct31@hermes.cam.ac.uk	Tasker, Robert C/R-5837-2019; Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Tasker, Robert/0000-0003-3647-8113	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390] Funding Source: UKRI		ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; *CHILD GROWTH FDN, 1996, GROWTH CHARTS; COULTHARD MG, 1994, ARCH DIS CHILD, V71, P281, DOI 10.1136/adc.71.3.281-a; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; DEREUCK J, 1971, EUR NEUROL, V5, P321; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Gale CR, 2004, BRAIN, V127, P321, DOI 10.1093/brain/awh034; Gale CR, 2003, BRAIN, V126, P2273, DOI 10.1093/brain/awg225; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1996, DEV BRAIN RES, V91, P274; GUZMAN AL, 1992, ACTA PAEDIATR, V81, P698, DOI 10.1111/j.1651-2227.1992.tb12337.x; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Jezzard P, 1998, MAGNET RESON MED, V39, P801, DOI 10.1002/mrm.1910390518; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; ONUMA T, 1995, J NEUROSURG, V82, P995, DOI 10.3171/jns.1995.82.6.0995; Papadakis NG, 1999, J MAGN RESON, V137, P67, DOI 10.1006/jmre.1998.1673; Papadakis NG, 2000, MAGNET RESON MED, V44, P616, DOI 10.1002/1522-2594(200010)44:4<616::AID-MRM16>3.0.CO;2-T; Salmond CH, 2002, NEUROIMAGE, V17, P1027, DOI 10.1006/nimg.2002.1153; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Tasker Robert C., 2001, Indian Journal of Pediatrics, V68, P257, DOI 10.1007/BF02723203; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Tomita H, 1990, Adv Neurol, V52, P553; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; VanPaesschen W, 1997, ANN NEUROL, V41, P41, DOI 10.1002/ana.410410109; Verger K, 2001, BRAIN INJURY, V15, P211; Xing D, 1997, MAGN RESON IMAGING, V15, P771, DOI 10.1016/S0730-725X(97)00037-4	44	39	39	0	3	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	AUG	2005	58	2					302	308		10.1203/01.PDR.0000169965.08854.25			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	952HV	WOS:000230995500022	16006434	Bronze			2022-02-06	
J	Turkstra, L; Ylvisaker, M; Coelho, C; Kennedy, M; Sohlberg, MM; Avery, J; Yorkston, K				Turkstra, L; Ylvisaker, M; Coelho, C; Kennedy, M; Sohlberg, MM; Avery, J; Yorkston, K			Practice guidelines for standardized assessment for persons with traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							AMNESIA TEST; ADOLESCENTS; ORIENTATION; DEFICITS; DAMAGE; TESTS	This article is one of a series of publications by the Academy of Neurologic Communication Disorders and Sciences (ANCDS) working groups on evidence-based clinical practice (EBP) in neurologic communication disorders. The EPB project was initiated in 1997, when ANCDS established committees of experts to develop EBP guidelines for the following areas: dysarthria, aphasia, dementia, apraxia, and cognitive-communication disorders associated with traumatic brain injury (TBI). The scope and mission of the EBP project are described in detail in previous publications (Golper et al., 2001; Kennedy et al., 2002; Sohlberg et al., 2003). This article was generated by the subcommittee on cognitive-communication disorders associated with TBI, and its purpose is to examine the evidence for the use of standardized, norm-referenced tests. Evaluation and assessment using nonstandardized tests and other approaches will be addressed in a separate publication. The full Technical Report is available at www.ancds.org.	Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA; Coll St Rose, Albany, NY USA; Univ Connecticut, New Haven, CT USA; Univ Minnesota, Minneapolis, MN USA; Univ Oregon, Eugene, OR 97403 USA; Univ Washington, Seattle, WA 98195 USA		Turkstra, L (corresponding author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			Adamovich B. B., 1992, SCALES COGNITIVE ABI; *AM PSYCH ASS, 2002, AM PSYCHOL, V57, P1060, DOI DOI 10.1037/0003-066X.57.12.1060; *AM SPEECH LANG HE, 2004, ASHA S, V24; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Benson D.F., 1986, FRONTAL LOBES; BIDDLE AK, 2002, AC NEUR COMM DIS SCI; Blosser JL, 2003, PEDIAT TRAUMATIC BRA; Carrow-Woolfolk E ., 1999, COMPREHENSIVE ASSESS; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Delis DC., 1994, CALIFORNIA VERBAL LE; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; Dunn L.M., 1997, PEABODY PICTURE VOCA, V3rd Edition; Dunn LM., 1981, PEABODY PICTURE VOCA; Ellmo W, 1997, J NEW JERSEY SPEECH, V6, P17; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Frank EM, 1996, J MED SPEECH-LANG PA, V4, P81; Frank EM, 1997, J MED SPEECH-LANG PA, V5, P97; Frattali C. M., 1995, AM SPEECH LANGUAGE H; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GARDNER MF, 1990, EXPRESSIVE 1 WORD PI; German D. J., 1990, TEST ADOLESCENT ADUL; German D.J., 1991, TEST WORD FINDING DI; GERMAN DJ, 1989, TEST WORD FINDING; GILLIS R, 1996, TRAUMATIC BRAIN INJU; Gioia GA IP, 2000, BEHAV RATING INVENTO; Golper L., 2001, EVIDENCE BASED PRACT; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Gronwall D, 1974, PSYCHOL EFFECTS CONC; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; Holland A., 1999, COMMUNICATION ACTIVI; HOTZ G, UNPUB PEDIAT TEST BR; Johnson M.B., 1989, WOODCOCK JOHNSON PSY; Kaplan E., 1988, CLIN NEUROPSYCHOLOGY, P125; Kaplan E., 2000, BOSTON NAMING TEST; Kennedy MRT, 2002, J MED SPEECH-LANG PA, V10, pIX; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; Kertesz A., 1982, W APHASIA BATTERY; LAPOINTE R, 1998, READING COMPREHENSIO; Larkins BM, 2004, BRAIN INJURY, V18, P691, DOI 10.1080/02699050310001617389; LARKINS BM, 2003, THESIS U QUEENSLAND; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; NELSON NW, 1991, COMMUNICATION DISORD, P191; Paul D.R., 2005, QUALITY COMMUNICATIO; PAULBROWN D, 2003, ASHA S, V23, P47; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Randolph C., 2001, REPEATABLE BATTERY A; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; REYNOLDS C, 1993, TEST MEMORY LEARNING; ROSSSWAIN D, 1996, ROSS INFORMATION PRO; Schuell H, 1972, MINNESOTA TEST DIFFE; Schwartz R, 1989, ASHA, V31, P91; SEMEL E, 1987, CLIN EVALUATION LANG; SEMEL W, 1995, CLIN EVALUATION LANG; SMITH K, IN PRESS CLIN PERFOR; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; SOHLBERG MM, 2001, COGNITIVE REHAVILITA; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; Towne R.L., 1993, LANG SPEECH HEAR SER, V24, P100; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 1999, LANG SPEECH HEAR SER, V30, P132, DOI 10.1044/0161-1461.3002.132; *U BUFF, 1996, FUNCT IND MEAS; Urbina S, 1997, PSYCHOL TESTING; WEBSTER JS, 1996, WEBSTERS COLL DICT; Wechsler D, 1987, MEMORY SCALE REVISED; Wiig E. H., 1989, TEST LANGUAGE COMPET; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; World Health Organization, 2007, INT CLASS FUNCT DIS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159; ZACHMAN L, 1989, WORD TEST ADOLESCENT; ZIMMERMAN IL, 1991, PRESCHOOL LANGUAGE S	81	39	39	0	15	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	JUN	2005	13	2					IX	XXXVIII					30	Audiology & Speech-Language Pathology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Neurosciences & Neurology	934LC	WOS:000229709300002					2022-02-06	
J	Elf, K; Nilsson, P; Ronne-Engstrom, E; Howells, T; Enblad, P				Elf, K; Nilsson, P; Ronne-Engstrom, E; Howells, T; Enblad, P			Cerebral perfusion pressure between 50 and 60 mm Hg may be beneficial in head-injured patients: A computerized secondary insult monitoring study	NEUROSURGERY			English	Article						head injury; multimodality monitoring; neurointensive care; outcome; secondary insults	TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; NEUROINTENSIVE CARE; NEUROSURGICAL UNIT; COMPLICATIONS; MANAGEMENT; BURDEN; AUDIT	OBJECTIVE: To describe the occurrence of secondary insults using a computerized monitoring data collecting system and to investigate their relationship to outcome when the neurointensive care was dedicated to avoiding secondary insults. METHODS: Patients 16 to 79 years old admitted to the neurointensive care unit between August 1998 and December 2002 with traumatic brain injury and 54 hours or more of valid monitoring within the first 120 hours after trauma (one value/min) were included. Monitoring of intracranial pressure (ICP), cerebral perfusion pressure (CPP), systolic blood pressure (BPS), and mean blood pressure (BPm) was required, and insult levels were defined (ICP > 25/> 35, BPS < 100/< 90/> 160/> 180, BPm < 80/< 70/> 110/> 120, and CPP < 60/< 50/> 70/> 80 mm Hg). Insults were quantified as proportion of valid monitoring time at the insult level. Logistic regression analyses were performed with admission and secondary insult variables as explanatory variables and favorable outcome as dependent variable. RESULTS: Eighty-one patients, 63 men and 18 women, with a mean age of 43.0 years, fulfilled the inclusion criteria. Seventy-two patients (89%) had Glasgow Coma Scale scores of 8 or less. Thirty-one patients (38%) had diffuse injury, and 50 (62%) had mass lesions. Mean Injury Severity Score was 26.6. After 6 months, 54% of the patients had achieved a favorable outcome. Most patients spent 5% or less of the monitoring time at the insult level except for CPP greater than 70 mm Hg. Low age, high Glasgow Coma Scale motor score, low Injury Severity Score, and CPP less than 60 mm Hg insults were significant predictors of favorable outcome in the final multiple logistic regression model. CONCLUSION: Overall, the secondary insults were rare, except for high CPP. The results suggest that patients with traumatic brain injury might benefit from a CPP slightly less than 60 mm Hg.	Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden		Enblad, P (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	Per.Enblad@neurokir.uu.se					ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Elf K, 2003, EUR J TRAUMA, V29, P74; Enblad P, 1997, J NEUROL NEUROSUR PS, V62, P512, DOI 10.1136/jnnp.62.5.512; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GENTLEMAN D, 1992, INT SURG, V77, P297; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; REILLY PL, 1975, LANCET, V2, P375; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1997, CRIT CARE MED, V25, P2048, DOI 10.1097/00003246-199712000-00024; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	39	39	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2005	56	5					962	970		10.1227/01.NEU.0000158317.00603.40			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	925LJ	WOS:000229054300032	15854244				2022-02-06	
J	Sumpter, RE; McMillan, TM				Sumpter, RE; McMillan, TM			Misdiagnosis of post-traumatic stress disorder following severe traumatic brain injury	BRITISH JOURNAL OF PSYCHIATRY			English	Article							HEAD-INJURY; SCALE; SYMPTOMS; CLINICIAN; AMNESIA	Background The incidence of posttraumatic stress disorder (PTSD) after traumatic brain injury is unclear. One issue involves the validity of diagnosis using self-report questionnaires. Aims. To compare PTSD 'caseness' arising from questionnaire self-report and structured interview. Method. Participants (n = 34) with traumatic brain injury were recruited. Screening measures and self-report questionnaires were administered, followed by the structured interview. Results. Using questionnaires, 59% fulfilled criteria for PTSD on the Posttraumatic Diagnostic Scale and 44% on the Impact of Events Scale, whereas using structured interview (Clinician-Administered PTSD Scale) only 3% were 'cases'. This discrepancy may arise from confusions between effects of PTSD and traumatic brain injury. Conclusions. After traumatic brain injury, PTSD self-report measures might be used for screening but not diagnosis. Declaration of Interest. None.	Univ Glasgow, Gartnavel Royal Hosp, Fac Med, Glasgow G12 0XH, Lanark, Scotland; Community Treatment Ctr Acquired Brain Injury, Glasgow, Lanark, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Fac Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baddeley A., 1992, SPEED CAPACITY LANGU; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Corneil W, 1999, J Occup Health Psychol, V4, P131, DOI 10.1037/1076-8998.4.2.131; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	39	40	0	5	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0007-1250	1472-1465		BRIT J PSYCHIAT	Br. J. Psychiatry	MAY	2005	186						423	426		10.1192/bjp.186.5.423			4	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	923LK	WOS:000228911200012	15863748	Bronze			2022-02-06	
J	Leclercq, PD; Murray, LS; Smith, C; Graham, DI; Nicoll, JAR; Gentleman, SM				Leclercq, PD; Murray, LS; Smith, C; Graham, DI; Nicoll, JAR; Gentleman, SM			Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; HEAD-INJURY; BETA-PROTEIN; INTRACEREBRAL HEMORRHAGE; CEREBROVASCULAR-DISEASE; A-BETA; SUBARACHNOID HEMORRHAGE; HIGH-FREQUENCY; E POLYMORPHISM	Objective: In view of the association of the apolipoprotein E (APOE) epsilon4 allele with poor outcome after traumatic brain injury we determined the frequency of cerebral amyloid angiopathy ( CAA) and the extent of haemorrhagic pathology in relation to APOE genotype in an autopsy series of 88 head injured cases. Methods: Tissue sections from the frontal and temporal lobes were immunostained for amyloid-beta peptide (Abeta) and stained for Congo red to identify vascular amyloid pathology. A semiquantitative assessment of contusions, the total contusion index, was used to estimate the severity of the haemorrhagic pathology. APOE genotypes were determined by polymerase chain reaction of genomic DNA extracted from paraffin embedded tissue sections. Results: CAA was present in 7/40 (18%) epsilon4 carriers compared with 1/48 (2%) non-epsilon4 carriers ( p = 0.021, 95% confidence interval (CI) for difference in proportions with CAA 3% to 29%) with 6/40 (4 with CAA) epsilon4 carriers being homozygotes. Thus the risk of having CAA for epsilon4 carriers was 8.4 times that for the non-epsilon4 carriers. However, there was no clear tendency for patients with CAA to have more severe or more numerous contusions (median contusion index 19 (CAA) v 14.5, p = 0.23, 95% CI for difference in medians 25 to 14). Conclusions: Presence of CAA in head injured cases was significantly associated with possession of an APOE epsilon4 allele but not with the severity of contusions.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Neurosci & Psychol Med, London W6 8RP, England; So Gen Hosp, Inst Neurol Sci, Univ Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh, Midlothian, Scotland; Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England		Gentleman, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Neurosci & Psychol Med, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.	s.gentleman@imperial.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Alonzo NC, 1998, J NEUROPATH EXP NEUR, V57, P353, DOI 10.1097/00005072-199804000-00008; BANCROFT JD, 1994, MANUAL HISTOLOGICAL, P114; Beach TG, 2000, NEUROSCI LETT, V283, P9, DOI 10.1016/S0304-3940(00)00916-2; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; Coria F, 1996, NEUROPATH APPL NEURO, V22, P216; DADA MA, 1993, AM J FOREN MED PATH, V14, P319, DOI 10.1097/00000433-199312000-00009; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Dunn LT, 2001, NEUROSURGERY, V48, P1006, DOI 10.1097/00006123-200105000-00007; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalaria RH, 2001, TRENDS NEUROSCI, V24, P392, DOI 10.1016/S0166-2236(00)01836-1; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; MASUDA J, 1988, STROKE, V19, P205, DOI 10.1161/01.STR.19.2.205; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; McCarron MO, 2000, NEUROREPORT, V11, P937, DOI 10.1097/00001756-200004070-00008; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; McCarron MO, 1999, STROKE, V30, P1643, DOI 10.1161/01.STR.30.8.1643; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; O'Donnell HC, 2000, NEW ENGL J MED, V342, P240, DOI 10.1056/NEJM200001273420403; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Premkumar DRD, 1996, AM J PATHOL, V148, P2083; Prior R, 2000, ANN NY ACAD SCI, V903, P180, DOI 10.1111/j.1749-6632.2000.tb06367.x; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Smith G, 2002, DRUG DEV IND PHARM, V28, P151, DOI 10.1081/DDC-120002448; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; VINTERS HV, 1983, STROKE, V14, P924, DOI 10.1161/01.STR.14.6.924; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WAKUI K, 1988, Neurological Surgery, V16, P1287; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097; Weller RO, 2000, ANN NY ACAD SCI, V903, P110, DOI 10.1111/j.1749-6632.2000.tb06356.x; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x	48	39	40	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2005	76	2					229	233		10.1136/jnnp.2003.025528			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	890WJ	WOS:000226541500017	15654038	Bronze, Green Published, Green Accepted			2022-02-06	
J	Hemphill, JC; Morabito, D; Farrant, M; Manley, GT				Hemphill, JC; Morabito, D; Farrant, M; Manley, GT			Brain tissue oxygen monitoring in intracerebral hemorrhage	NEUROCRITICAL CARE			English	Article						intracerebral hemorrhage; brain tissue oxygen tension; translational research; swine model	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW; BEDSIDE MICRODIALYSIS; NO EVIDENCE; TENSION; EDEMA; PO(2); AUTOREGULATION; GUIDELINES; VARIABLES	Introduction: Brain tissue oxygen (PbrO2) monitoring is an emerging technique for detection of secondary brain injury in neurocritical care. Although it has been extensively reported in traumatic brain injury and aneurysmal subarachnoid hemorrhage, its use in nontraumatic intracerebral hemorrhage (ICH) has not been well described. We report complementary preliminary studies in a large animal model and in patients that demonstrate the feasibility of PbrO2 monitoring after ICH. Methods: To assess early events after ICH, Licox Clark-type oxygen probes were inserted in the bilateral frontal white matter of four anesthetized swine that subsequently underwent right parietal hematoma formation in an experimental model of ICH. Intracranial pressure (ICP) was monitored as well. Seven patients with acute ICH, who were undergoing ICP monitoring as part of standard neurocritical care, had placement of a frontal oxygen probe, with subsequent monitoring for up to 7 days. Results: In the swine ICH model, a rise in ICP early after hematoma formation was accompanied by a decrease in ipsilateral and contralateral PbrO2. Secondary increases in hematoma volume resulted in further decreases in PbrO2 over the first hour after ICH. In patients undergoing oxygen monitoring, low PbrO2 (<15 mmHg) was common. In these patients, changes in FiO2, mean arterial pressure, and cerebral perfusion pressure (but not ICP) predicted subsequent change in PbrO2. Conclusion: Brain tissue oxygen monitoring is feasible in ICH patients, as well as in a swine model of ICH. Translational research that emphasizes complementary information derived from human and animal studies may yield additional insights not available from either alone.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; San Francisco Injury Ctr, San Francisco, CA USA		Hemphill, JC (corresponding author), San Francisco Gen Hosp, Dept Neurol, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.	jchiii@itsa.ucsf.edu	Demchuk, Andrew M/E-1103-2012; Hemphill, Claude/AAY-5630-2021	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS41420] Funding Source: Medline; ODCDC CDC HHS [R49CCR903697] Funding Source: Medline		Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; BULLOCK R, 1988, SURG NEUROL, V29, P101, DOI 10.1016/0090-3019(88)90065-1; Burbridge B, 2004, CAN ASSOC RADIOL J, V55, P326; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; De Georgia Michael A, 2004, Cleve Clin J Med, V71 Suppl 1, pS16; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hirano T, 1999, NEUROLOGY, V53, P2179, DOI 10.1212/WNL.53.9.2179; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JUVELA S, 1995, ARCH NEUROL-CHICAGO, V52, P1193, DOI 10.1001/archneur.1995.00540360071018; Kazui S, 1996, STROKE, V27, P1783, DOI 10.1161/01.STR.27.10.1783; Kett-White R, 2002, ADV TECH STAND NEUR, V27, P87; Kidwell CS, 2001, NEUROLOGY, V57, P1611, DOI 10.1212/WNL.57.9.1611; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kitaoka T, 2003, ACT NEUR S, V86, P457; Kobayashi M, 2001, STROKE, V32, P2237, DOI 10.1161/hs1001.096621; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2003, STROKE, V34, P224, DOI 10.1161/01.STR.0000046458.67968.E4; Mayer SA, 1998, STROKE, V29, P1791, DOI 10.1161/01.STR.29.9.1791; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MENDELOW AD, 1993, STROKE, V24, pI115; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2003, NEUROSURGERY, V52, P1041, DOI 10.1227/01.NEU.0000057694.96978.BC; Qureshi AI, 1999, NEUROLOGY, V52, P266, DOI 10.1212/WNL.52.2.266; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P243; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Steiner T, 2001, STROKE, V32, P2500, DOI 10.1161/hs1101.097400; Stocchetti N, 1998, ACT NEUR S, V71, P162; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Tang S, 2004, CHINESE J ORG CHEM, V24, P1133; Tuhrim S, 1999, CRIT CARE MED, V27, P617, DOI 10.1097/00003246-199903000-00045; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vath A, 2002, ACT NEUR S, V81, P307; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Xi G, 2002, ACT NEUR S, V81, P253; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	55	39	39	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	3	3					260	270		10.1385/NCC:3:3:260			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	995PG	WOS:000234115700014	16377842				2022-02-06	
S	Sharma, HS		Slikker, W; Andrews, RJ; Trembly, B		Sharma, HS			Neuroprotective effects of neurotrophins and melanocortins in spinal cord - Injury an experimental study in the rat using pharmacological and morphological approaches	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	7th International Conference on Neuroprotective Agents	NOV 14-19, 2004	Pacific Grove, CA	Cent Arkansas Chapter SIGMA XI, FDA, Natl Ctr Toxicol Res, US EPA		spinal cord injury; melanocortins; brain-derived neurotrophic factor; insulin-like growth factor-1; blood-spinal cord barrier; neuroprotection	NITRIC-OXIDE SYNTHASE; TOPICAL APPLICATION; TRAUMATIC INJURY; AXONAL INJURY; REDUCES EDEMA; UP-REGULATION; CELL CHANGES; INHIBITOR; INDOMETHACIN; REGENERATION	Spinal cord injury (SCI) induces lifetime disability, and no suitable therapy is available to treat victims or to minimze their sufferings. Recently, neurotrophins and compounds acting at melanocortin receptors have been been identified as potential neuroprotective agents. In this investigation, the neuroprotective effects of neurotrophins and melanocortins on the pathophysiology of SCI were examined in a rat model. The SCI was produced by making a longitudinal incision into the right dorsal horn of the T10-11 segments under equithesin anesthesia. In separate groups, neurotrophins [BDNF or IGF-1 (0.1-1 mu g/10 mu L in saline)] or melanocortins (ME10092, ME10354, ME10393, ME10431, and ME10501, having affinities to melanocortin receptors; 1-10 mu g in saline) were applied topically over the traumatized cord segment within 5-10 min after SCI and the rats were allowed to survive for 5 h. A, focal SCI resulted in widespread disruption of the blood-spinal cord barrier (BSCB) to Evans blue albumin (EBA), ([131])iodine, or lanthanum tracers and exhibited profound edema formation and cell or tissue destruction. Topical application of BDNF, IGF-1, or ME10501 (having high affinity to melanocortin-4 receptor, MCR-4) in high quantity markedly attenuated BSCB disruption, edema formation, and nerve cell, glial cell, and axonal injuries. On the other hand, low doses of neurotrophins or melanocortins were not effective in attenuating pathophysiology of SCI. These observations suggest that neurotrophins (BDNF and IGF-1) and melanocortins (with high affinity to MCR-4) are capable of inducing neuroprotection if applied shortly after trauma in high doses. Taken together, the results indicate that neurotrophins and melanocortins participate in the pathophysiology of spinal cord cell and tissue injury following trauma.	Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden		Sharma, HS (corresponding author), Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.	sharma@surgsci.uu.se					Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Kakulas BA, 2004, SPINAL CORD, V42, P549, DOI 10.1038/sj.sc.3101670; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; PAN W, 2004, INT J NEUROPROTEC NE, V1, P32; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P191; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P437; Sharma HS, 1997, ACT NEUR S, V70, P130; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 2003, ACT NEUR S, V86, P399; Sharma HS, 2003, ACT NEUR S, V86, P383; Sharma HS, 1997, ACT NEUR S, V70, P155; SHARMA HS, 1993, ACTA NEUROPATHOL, V86, P422; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; Sharma HS, 1998, SPINAL CORD MONITORING, P181; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SHARMA HS, 2004, INT J NEUROPROTEC NE, V1, P8; Sharma HS, 2004, BLOOD SPINAL CORD BR; SHARMA HS, 2005, ANN N Y ACAD SCI; van der Kraan M, 1999, MOL BRAIN RES, V63, P276, DOI 10.1016/S0169-328X(98)00291-5; vandeMeent HV, 1997, NEUROSURGERY, V40, P122, DOI 10.1097/00006123-199701000-00028; Vrinten DH, 2001, EUR J PHARMACOL, V429, P61, DOI 10.1016/S0014-2999(01)01306-1; Winkler T, 2003, ACTA NEUROCHIR SUPPL, V86, P425; Winkler T, 1998, SPINAL CORD MONITORING, P283; WOLTERINK G, 1990, BRAIN RES, V507, P101, DOI 10.1016/0006-8993(90)90527-I; WU W, 2000, HAND CHEM N, V17, P315	34	39	46	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-578-8	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1053						407	421		10.1196/annals.1344.036			15	Multidisciplinary Sciences; Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BDR63	WOS:000235109800042	16179548				2022-02-06	
J	Thornton, KE; Carmody, DP				Thornton, KE; Carmody, DP			Electroencephalogram biofeedback for reading disability and traumatic brain injury	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article							CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION; DEVELOPMENTAL DYSLEXIA; LEARNING-DISABILITIES; EEG BIOFEEDBACK; ACTIVATION PROFILES; WORD RECOGNITION; CHILDREN; IMPROVEMENT/REHABILITATION; REMEDIATION	The application of electroencephalogram (EEG) biofeedback with reading disability and traumatic brain injury (TBI) is relatively recent. There are many studies regarding the effectiveness (improving attention and IQ scores) of EEG biofeedback in patients with attention deficit hyperactivity disorder, who are known to have a high rate of comorbidity for learning disabilities. This suggests the possibility that EEG biofeedback specifically aimed at remediating reading disability and TBI would be effective. This article provides strong initial support for this idea and provides reason to believe that assessment and training under task conditions are likely to be fruitful. Given the significance of these problems and the absence of very effective alternatives for remediation of these conditions, efforts to complete the needed research seem warranted. Clinical use of this intervention seems to be warranted with informed consent.	Ctr Hlth Psychol, S Plainfield, NJ 07080 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Inst Study Child Dev, New Brunswick, NJ 08903 USA		Thornton, KE (corresponding author), Ctr Hlth Psychol, Suite 2A,2509 Pk Ave, S Plainfield, NJ 07080 USA.	ket@chp-neurotherapy.com	Carmody, Dennis P./AAS-7734-2020	Carmody, Dennis/0000-0002-1288-104X; thornton, kirtley/0000-0002-3303-4747			BASAREROGLU C, 1996, INT J PSYCHOPHYSIOL, V24, P110; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; BIRD BL, 1978, BIOFEEDBACK SELF-REG, V3, P1, DOI 10.1007/BF00998559; Birsh J. R., 1999, MULTISENSORY TEACHIN; Byers AP., 1995, J NEUROTHERAPY, V1, P22; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; Giannitrapani D., 1988, EEG MENTAL ACTIVITIE, P153; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOFFMAN DA, 1996, CLIN ELECTROENCEPHAL, V27, P6; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Keller I, 2001, J NEUROTHERAPY, V5, P19; Klingberg T, 2000, NEURON, V25, P493, DOI 10.1016/S0896-6273(00)80911-3; Linden M, 1996, BIOFEEDBACK SELF-REG, V21, P35, DOI 10.1007/BF02214148; Lloyd D, 2000, J INT NEUROPSYCH SOC, V6, P627, DOI 10.1017/S1355617700655121; LYON GR, 1988, J CONSULT CLIN PSYCH, V56, P830, DOI 10.1037/0022-006X.56.6.830; MARKER T, 1996, COGPACK PROGRAMMPAKE; McCandliss BD, 2003, MENT RETARD DEV D R, V9, P196, DOI 10.1002/mrdd.10080; McEvoy LK, 2000, CLIN NEUROPHYSIOL, V111, P457, DOI 10.1016/S1388-2457(99)00258-8; McKinlay W W, 1992, Brain Inj, V6, P107, DOI 10.3109/02699059209029649; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; Oakland T, 1998, J LEARN DISABIL, V31, P140, DOI 10.1177/002221949803100204; OCHS L, 1994, BERR HEAD INJ C LAS; ORLANDO PC, IN PRESS J NEUROTHER; OTHMER S, 1992, EEG BIOFEEDBACK TRAI; Othmer S., 2000, J NEUROTHERAPY, V4, P5, DOI [10.1300/J184v04n01_02, DOI 10.1300/J184v04n01_02, 10.1300/j184v04n01_02, DOI 10.1300/J184V04N01_02]; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; ROSSITER R, 2002, J NEUROTHERAPY, V6, P9; Rumsey JM, 1997, ARCH NEUROL-CHICAGO, V54, P562, DOI 10.1001/archneur.1997.00550170042013; Rumsey JM, 1997, BRAIN, V120, P739, DOI 10.1093/brain/120.5.739; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sandford J. A., 1995, INTERMEDIATE VISUAL; SANDFORD JA, 1993, CAPTAINS LOG COGNITI; SANDFORD JA, 1996, ALPHABET BINGO COMPU; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; Shaywitz BA, 2002, BIOL PSYCHIAT, V52, P101, DOI 10.1016/S0006-3223(02)01365-3; Shaywitz SE, 2003, BIOL PSYCHIAT, V54, P25, DOI 10.1016/S0006-3223(02)01836-X; Shaywitz SE, 1998, P NATL ACAD SCI USA, V95, P2636, DOI 10.1073/pnas.95.5.2636; Sheer D.E., 1984, SELF REGULATION BRAI; Sheer DE, 1976, NEUROPHYSIOLOGY LEAR; SHEER DE, 1974, LEARNING DISABLED CH; SHEER DE, 1977, BIOFEEDBACK SELF CON, P435; SIEGMUND K, 1999, NEUROSOFT INTEGRIERT; Simos PG, 2002, J CHILD NEUROL, V17, P159, DOI 10.1177/088307380201700301; Simos PG, 2001, DEV NEUROPSYCHOL, V19, P191, DOI 10.1207/S15326942DN1902_4; Simos PG, 2000, NEUROSCI LETT, V290, P61, DOI 10.1016/S0304-3940(00)01322-7; TABANO MT, 1988, ELECTROENCEPHALOGRAP, V70, P185; TANIUS TP, 2000, J NEUROTHERAPY, V4, P27; TANSEY MA, 1991, AUST J PSYCHOL, V43, P147, DOI 10.1080/00049539108260139; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Thompson L, 1998, APPL PSYCHOPHYS BIOF, V23, P243, DOI 10.1023/A:1022213731956; Thorne A, 2000, PERS SOC PSYCHOL REV, V4, P45, DOI 10.1207/S15327957PSPR0401_5; Thornton K, 2000, J HEAD TRAUMA REHAB, V15, P1285, DOI 10.1097/00001199-200012000-00008; Thornton K, 2002, ARCH CLIN NEUROPSYCH, V17, P1; Thornton K., 2000, J NEUROTHERAPY, V3, P1, DOI DOI 10.1300/J184V03N03_01; Thornton KE, 2002, NEUROREHABILITATION, V17, P69; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; Walker J. E., 2002, J NEUROTHER, V6, P31, DOI DOI 10.1300/J184v06n02_05; Watts R, 2003, MENT RETARD DEV D R, V9, P168, DOI 10.1002/mrdd.10077; Winters CA, 1997, ADOLESCENCE, V32, P451; WOOD R, 2004, TRILLION DOLLAR SHAM	72	39	40	1	16	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1056-4993			CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	JAN	2005	14	1					137	+		10.1016/j.chc.2004.07.001			27	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	883CS	WOS:000225988400009	15564056				2022-02-06	
J	Tomaiuolo, F; Worsley, KJ; Lerch, J; Di Paola, M; Carlesimo, GA; Bonanni, R; Caltagirone, C; Paus, T				Tomaiuolo, F; Worsley, KJ; Lerch, J; Di Paola, M; Carlesimo, GA; Bonanni, R; Caltagirone, C; Paus, T			Changes in white matter in long-term survivors of severe non-missile traumatic brain injury: A computational analysis of magnetic resonance images	JOURNAL OF NEUROTRAUMA			English	Article						anatomical and behavioral correlation; MRI; severe head trauma; white matter	CLOSED-HEAD-INJURY; COGNITIVE IMPAIRMENT; HIPPOCAMPAL ATROPHY; MRI; FORNIX; DAMAGE; DEGENERATION; MORPHOLOGY; MEMORY; VOLUME	The aim of this study was to investigate long-term consequences of severe non-missile traumatic brain injury (nmTBI) in patients without macroscopic focal brain lesions (>1.6 cm(3)) on regional white-matter density (WMd), and possible correlations with days of coma and memory performances. T1-weighted magnetic-resonance images (MRI) were acquired in 19 nmTBI patients, 3-113 months following the injury, and in 19 control subjects matched for age and gender. In addition, nmTBI patients underwent a battery of standardised memory tests. The MRIs were processed in a fully automatic system using voxel-by-voxel methods. Corpus callosum, fornix, anterior limb of the internal capsule, superior frontal gyrus, para-hippocampal gyrus, optic radiation and chiasma showed significant WMd reduction in nmTBI when compared to control subjects. None of the correlations between days of coma and memory performance scores with nmTBI voxels value that showed WMd reduction reached significance, with the exception of a significant negative correlation between WMd in the mid body of corpus callosum and short-story delayed recall. We detected reductions in WM density in several brain locations similar to those described in previous postmortem investigations. In addition, we observed WMd reduction in the optic chiasma and in the optic radiations; this finding may reflect transneural degeneration along the visual pathway. The weak correlations between specific anatomical sites of the reduced WMd and behavior may reflect the diffuse nature of the brain damage and/or the different time of onset between behavioral manifestations and neuropathological modifications occurring in nmTBI.	IRCCS, Fdn Santa Lucia, I-00179 Rome, Italy; McGill Univ, Dept Math & Stat, Montreal, PQ, Canada; Univ Roma Tor Vergata, Neurol Clin, Rome, Italy; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada		Tomaiuolo, F (corresponding author), IRCCS, Fdn Santa Lucia, Via Ardeatina 309, I-00179 Rome, Italy.	tomaiuoio@hsantalucia.it	Caltagirone, Carlo/B-4930-2013; Tomaiuolo, Francesco/AAC-1534-2019; Di Paola, Margherita/A-8480-2010	Tomaiuolo, Fancesco/0000-0003-1230-2770			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adams JH, 1990, HDB CLIN NEUROLOGY, P43; Adams JH, 1994, INTRO NEUROPATHOLOGY; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; BEATTY RM, 1982, J NEUROL NEUROSUR PS, V45, P143, DOI 10.1136/jnnp.45.2.143; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Capitani E, 1987, ITAL J NEUROL SCI, V8, P14; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Carlesimo G, 2002, NUOVA RIV NEUROLOGIA, V12, P1; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Kovalev VA, 2003, NEUROIMAGE, V19, P895, DOI 10.1016/S1053-8119(03)00140-X; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Rey A, 1968, REATTIVO FIGURA COMP; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spalletta G, 2003, SCHIZOPHR RES, V64, P15, DOI 10.1016/S0920-9964(03)00010-0; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; ZIJDENBOS AP, 1998, P 1 INT C MED IM COM, P439	37	39	42	0	1	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					76	82		10.1089/neu.2005.22.76			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600004	15665603				2022-02-06	
J	Wong, J; Hoe, NW; Feng, ZW; Ng, I				Wong, J; Hoe, NW; Feng, ZW; Ng, I			Apoptosis and traumatic brain injury	NEUROCRITICAL CARE			English	Article						traumatic brain injury; apoptosis; Fas; caspases; Bcl-2 family; therapeutic intervention	CEREBRAL PERFUSION-PRESSURE; DNA STRAND BREAKS; CYTOCHROME-C; TEMPORAL PROFILE; FACTOR AIF; FAS; FRAGMENTATION; EXPRESSION; RELEASE; CASPASE-3	Traumatic brain injury is a cause of high mortality and morbidity and is an area of intense research. Apoptosis plays a crucial role in the pathogenesis of head injury, and the inhibition of apoptosis can potentially reverse the deleterious effects and lead to better functional outcome. Elucidation of the apoptotic pathway and its role in traumatic brain injury will provide potential targets for therapeutic intervention. This article aims to review the current wealth of literature on apoptosis and traumatic head injury and explores the current status of therapeutic strategies available.	Natl Inst Neurosci, Dept Neurosurg, Clin Staff Off, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Natl Inst Neurosci, Dept Res, Singapore 308433, Singapore		Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Clin Staff Off, Acute Brain Injury Res Lab, Singapore 11,Jalan Tan Tock Seng,Level 3, Singapore 308433, Singapore.	ivan_ng@nni.com.sg		Wong, Hui Yin, Jill/0000-0002-7368-8593			ALBERTS B, 2002, MOL BIOL CELL, P983; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Czosnyka M, 2003, ACT NEUR S, V86, P581; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DEXTER TM, 1995, ROLE APOPTOSIS DEV T, P1; EASTMAN P, 2003, NEUROL TODAY     AUG; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Furth PA, 1997, APOPTOSIS, V2, P19, DOI 10.1023/A:1026454207398; GORCZYCA W, 1994, CYTOMETRY, V15, P169, DOI 10.1002/cyto.990150211; GORCZYCA W, 1993, CANCER RES, V53, P1945; Grodzicky T, 2002, MT SINAI J MED, V69, P208; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lallemend F, 2003, J NEUROCHEM, V87, P508, DOI 10.1046/j.1471-4159.2003.02014.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; LODISH H, 2000, MOL CELL BIOL, P1054; Maecker HL, 2000, CANCER RES, V60, P4638; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sachs LM, 1997, FASEB J, V11, P801, DOI 10.1096/fasebj.11.10.9271365; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SUVILLIAN PG, 2000, NEUROSCIENCE, V101, P289; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; SZABO I, 1991, J BIOL CHEM, V266, P3376; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zuzarte-Luis V, 2002, INT J DEV BIOL, V46, P871	58	39	41	2	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	3	2					177	182		10.1385/NCC:3:2:177			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	973UD	WOS:000232547200016	16174891				2022-02-06	
J	Donders, J; Nesbit-Greene, K				Donders, J; Nesbit-Greene, K			Predictors of neuropsychological test performance after pediatric traumatic brain injury	ASSESSMENT			English	Article						demographic variables; neuropsychological test performance	CHILDRENS CATEGORY TEST; HEAD-INJURY; CLUSTER SUBTYPES; STANDARDIZATION SAMPLE; SEX-DIFFERENCES; SHORT-TERM; INTELLIGENCE; MODERATOR; RECOVERY; VALIDITY	The influence of neurological and demographic variables on neuropsychological test performance was examined in 100 9- to 16-year-old children with traumatic brain injury (TBI). Regression analyses were conducted to determine the relative contributions of coma, neuroimaging findings, ethnicity, socioeconomic status, and gender to variance in performance on the Wechsler Intelligence Scale for Children-Third Edition (WISC-III), California Verbal Learning Test-Children's Version (CVLT-C), and the Children's Category Test. Both neurological and demographic variables contributed to performance on various WISC-III factor index scores as well as the CVLT-C. No evidence for a moderating effect of demographic variables was found, but speed of information processing mediated the effect of neurological and demographic variables on CLVT-C performance. It is concluded that demographic variables have an incremental effect on the neuropsychological test performance of children with TBI above and beyond the influence of injury severity.	Mary Free Bed Rehabil Hosp, Grand Rapids, MI USA; Mt Washington Pediat Hosp, Baltimore, MD USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Grand Rapids, MI USA.	jdonders@mfbrc.com					Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; BJORKLUND DF, 1997, DEV MEMORY CHILDHOOD, P00201; BOLL T, 1993, CHILDRENS CATEGORY T; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Coscia JM, 2001, J PEDIATR PSYCHOL, V26, P321, DOI 10.1093/jpepsy/26.6.321; Delis DC., 1994, CALIFORNIA VERBAL LE; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Donders J, 1998, CHILD NEUROPSYCHOL, V4, P178; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fox J., 1991, REGRESSION DIAGNOSTI; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; Glutting J. J., 1997, CONT INTELLECTUAL AS, P349; Harrell FE Jr, 2017, REGRESSION MODELING; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kwate N. O. A., 2001, J BLACK PSYCHOL, V27, P221, DOI DOI 10.1177/0095798401027002005; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Manly J., 2003, CLIN INTERPRETATION, P181, DOI DOI 10.1016/B978-012703570-3/50010-9; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Millis SR, 2003, CHILD NEUROPSYCHOL, V9, P221, DOI 10.1076/chin.9.3.221.16455; Moses JA, 1999, ARCH CLIN NEUROPSYCH, V14, P445, DOI 10.1016/S0887-6177(98)00030-4; Murphy KR, 2004, STAT POWER ANAL; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Nesbit-Greene K, 2002, J CLIN EXP NEUROPSYC, V24, P194, DOI 10.1076/jcen.24.2.194.996; Prifitera A., 1998, WISC 3 CLIN USE INTE, P1, DOI [10.1016/B978-012564930-8/50002-4, DOI 10.1016/B978-012564930-8/50002-4]; RAZ S, 1995, DEV PSYCHOL, V31, P958, DOI 10.1037/0012-1649.31.6.958; Reitan RM, 1995, CHILD NEUROPSYCHOL, V1, P165, DOI 10.1080/09297049508400222; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suzuki LA, 1997, AM PSYCHOL, V52, P1103, DOI 10.1037/0003-066X.52.10.1103; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	56	39	40	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2004	11	4					275	284		10.1177/1073191104268914			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	869SX	WOS:000225005600001	15486164				2022-02-06	
J	Boman, IL; Lindstedt, M; Hemmingsson, H; Bartfai, A				Boman, IL; Lindstedt, M; Hemmingsson, H; Bartfai, A			Cognitive training in home environment	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; REHABILITATION; ATTENTION; ADULTS; DEFICITS; REMEDIATION; RECOVERY; THERAPY	Primary objective: To examine the efficacy of cognitive rehabilitation in the patient's home or vocational environment. Research design: Pre-post-follow-up design. Methods and procedures: Ten outpatients with acquired attention and memory problems received cognitive training three times weekly, for 3 weeks. They received individual attention training with Attention Process Training, training for generalization for everyday activities and education in compensatory strategies for self-selected cognitive problems. Treatment effects were evaluated with neuropsychological and occupational therapy instruments before and after the training and after 3 months on impairment, activity and participation levels. Main outcomes and results: The results indicated a positive effect on some measures on impairment level, but no differences on activity or participation levels at follow-up. Conclusions: The study indicates that home-based cognitive training improves some attentional and memory functions and facilitates learning of strategies. Future controlled studies are needed to confirm the results and analyse the efficacy of different aspects of home-based training.	Danderyd Hosp, Dept Rehabil Med, S-18288 Danderyd, Sweden; Karolinska Univ Hosp, Dept Rehabil Med, Huddinge, Sweden		Boman, IL (corresponding author), Danderyd Hosp, Dept Rehabil Med, S-18288 Danderyd, Sweden.	inga-lill.boman@reh.ds.sll.se		Bartfai, Aniko/0000-0002-0815-2485; Boman, Inga-Lill/0000-0002-4533-1036			ABREU BC, 1987, AM J OCCUP THER, V41, P439, DOI 10.5014/ajot.41.7.439; Adamovich BL, 1991, COGNITIVE REHABILITA, P75; AHLSIO B, 1984, STROKE, V15, P886, DOI 10.1161/01.STR.15.5.886; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; Berg IJ, 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI DOI 10.1080/09602019108401384; Bergquist TF, 1994, J HEAD TRAUMA REHAB, V9, P50, DOI 10.1097/00001199-199412000-00007; Bernspang B., 1995, SCAND J OCCUP THER, V2, P3; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CLAESON LE, 1971, COGNITIVE TRAINING H; Davis~ AM, 1995, CLIN REHABIL, V9, P238, DOI DOI 10.1177/026921559500900310; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fisher AG, 1998, AM J OCCUP THER, V52, P509, DOI 10.5014/ajot.52.7.509; FISHER AG, 1997, ASSESSMENT MOTOR PRO; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; KAPLAN E, 1994, WAIS R NEUROPSYCHOLO; Katz Noomi, 2002, Can J Occup Ther, V69, P281; KIELHOFNER G., 1995, MODEL HUMAN OCCUPATI; Kielhofner G., 1997, CONCEPTUAL FDN OCCUP; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KOLB B, 1996, FUNDAMENTALS HUMAN N; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Lee S S, 2001, Can J Occup Ther, V68, P41; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LOFGREN H, 1989, STAT DATAANALYS; Mateer CA, 1990, COGNITIVE REHABILITA, P68; MATEER CM, 1987, J HEAD TRAUMA REHAB, V2, P79; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; NEISTADT ME, 1994, AM J OCCUP THER, V48, P421, DOI 10.5014/ajot.48.5.421; NYMAN H, 1998, CLAESONDAHL TEST; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PEPIN M, 1995, J COGNITIVE REHABILI, V13, P8; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1999, J HEAD TRAUMA REHAB, V14, P308, DOI 10.1097/00001199-199906000-00009; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; ROBERTSON IH, 1993, UNILATERAL NEGLECT C, P279; SCHWARTZ SM, 1995, AM J OCCUP THER, V49, P655, DOI 10.5014/ajot.49.7.655; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M.M., 1986, ATTENTION PROCESS TR; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THAM K, 1998, UNILATERAL NEGLECT A; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; UOMOTO JM, 1992, PHYS MED REHABILITAT, V3, P291; WECHSLER D, 1981, WAIS R MANUAL WECHLE; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; Wood R L, 1987, Int Disabil Stud, V9, P149; ZENICUS A, 1990, BRAIN INJURY, V4, P33	64	39	39	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					985	995		10.1080/02699050410001672396			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600003	15370898				2022-02-06	
J	Rancan, M; Bye, N; Otto, VI; Trentz, O; Kossmann, T; Frentzel, S; Morganti-Kossmann, MC				Rancan, M; Bye, N; Otto, VI; Trentz, O; Kossmann, T; Frentzel, S; Morganti-Kossmann, MC			The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; chemokines; cell adhesion molecules; neuroinflammation; blood-brain barrier	BARRIER DYSFUNCTION; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; MICE DEFICIENT; AXONAL INJURY; TNF-ALPHA; EXPRESSION; RECEPTOR; CX(3)CR1; CSF	The potential role of the chemokine Fractalkine (CX(3)CL1) in the pathophysiology of traumatic brain injury (TBI) was investigated in patients with head trauma and in mice after experimental cortical contusion. In control individuals, soluble (s)Fractalkine was present at low concentrations in cerebrospinal fluid (CSF) (12.6 to 57.3 pg/mL) but at much higher levels in serum (21,288 to 74,548 pg/mL). Elevation of sFractalkine in CSF of TBI patients was observed during the whole study period (means: 29.92 to 535.33 pg/mL), whereas serum levels remained within normal ranges (means: 3,100 to 59,159 pg/mL). Based on these differences, a possible passage of sFractalkine from blood to CSF was supported by the strong correlation between blood-brain barrier dysfunction (according to the CSF-/serum-albumin quotient) and sFractalkine concentrations in CSF (R = 0.706; P < 0.01). In the brain of mice subjected to closed head injury, neither Fractalkine protein nor mRNA were found to be augmented; however, Fractalkine receptor (CX(3)CR1) mRNA steadily increased peaking at 1 week postinjury (P < 0.05, one-way analysis of variance). This possibly implies the receptor to be the key factor determining the action of constitutively expressed Fractalkine. Altogether, these data suggest that the Fractalkine-CX3CRI protein system may be involved in the inflammatory response to TBI, particularly for the accumulation of leukocytes in the injured parenchyma.	Monash Univ, Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3004, Australia; Swiss Fed Inst Technol, Inst Pharmaceut Chem, Dept Chem & Appl Biosci, Zurich, Switzerland; Univ Zurich Hosp, Div Trauma Surg, Dept Surg, Zurich, Switzerland; Novartis Pharma AG, NIBR, Basel, Switzerland		Rancan, M (corresponding author), Monash Univ, Alfred Hosp, Dept Trauma Surg, Commercial Rd, Melbourne, Vic 3004, Australia.	RancanMario@hotmail.com		Morganti-Kossmann, Cristina/0000-0002-0807-2063			ANTHONY DC, 2001, PROGR BRAIN RES, P507; Balabanian K, 2002, AM J RESP CRIT CARE, V165, P1419, DOI 10.1164/rccm.2106007; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Cook DN, 2001, MOL CELL BIOL, V21, P3159, DOI 10.1128/MCB.21.9.3159-3165.2001; Fischer FR, 2000, J NEUROIMMUNOL, V110, P195, DOI 10.1016/S0165-5728(00)00351-9; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; JENNETT B, 1976, LANCET, V1, P1031; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; STOCKER R, 1995, INTEGRATED APPROACH, P196; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zujovic V, 2001, J NEUROIMMUNOL, V115, P135, DOI 10.1016/S0165-5728(01)00259-4	37	39	39	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2004	24	10					1110	1118		10.1097/01.WCB.0000133470.91843.72			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	859YP	WOS:000224304600005	15529011	Bronze			2022-02-06	
J	Jonsson, CA; Horneman, G; Emanuelson, I				Jonsson, CA; Horneman, G; Emanuelson, I			Neuropsychological progress during 14 years after severe traumatic brain injury in childhood and adolescence	BRAIN INJURY			English	Article							EXECUTIVE FUNCTION; NORMATIVE DATA; HEAD-INJURIES; CHILDREN; TERM; AGE; OUTCOMES; RECOVERY; FLUENCY; SKILLS	Objective: To investigate the impact of time since injury on neuropsychological and psychosocial outcome after serious TBI in childhood or adolescence. Methods: The subjects were eight patients with serious TBI sustained at a mean age of 14 years who had been assessed neuropsychologically at 1, 7 and 14 years after TBI. A retrospective longitudinal design was chosen to describe the development in six neuropsychological domains on the basis of the assessments. Psychosocial data were gathered from clinical knowledge and a semi-structured interview 14 years after TBI. Results: Performance of verbal IQ shows a declining trend over the three assessments, that the performance of attention and working memory is low and that verbal learning is the cognitive domain which exhibits the largest impairments. The main psychosocial result is that three of the eight subjects went from a school situation with no adjustments to adult life with early retirement. Conclusions: Time since insult is an important factor when assessing outcome after TBI in childhood and adolescence and that assessment of final outcome should not be done before adulthood.	Ostersund Hosp, Ostersund, Sweden; Univ Gothenburg, Dept Psychol, S-40020 Gothenburg, Sweden; Univ Gothenburg, Inst Hlth Women & Children, Gothenburg, Sweden		Jonsson, CA (corresponding author), Ostersund Hosp, Ostersund, Sweden.	catherine.aaro.jonsson@jll.se					Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHRISTENSEN AL, 1984, LURIAS NEUROPSYCHOLO; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Dunn LM., 1981, PEABODY PICTURE VOCA; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Enlund Mats, 1996, Upsala Journal of Medical Sciences, V101, P97; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Lehnung M, 2003, BRAIN INJURY, V17, P855, DOI 10.1080/0269905031000089369; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; *PSYK, 1996, MAN WAIS R; *PSYK AB, 1977, MAN WISC; Rydberg S., 1974, SPIQ SNABBT PERFORMA; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	34	39	39	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					921	934		10.1080/02699050410001671900			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700007	15223744				2022-02-06	
J	Nybo, T; Sainio, M; Muller, K				Nybo, T; Sainio, M; Muller, K			Stability of vocational outcome in adulthood after moderate to severe preschool brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						childhood brain injury; mid-life vocational outcome; stability of vocational status	HEAD-INJURY; TERM; CHILDREN; CHILDHOOD; TESTS; AGE	We studied how moderate to severe childhood traumatic brain injury (TBI) affects vocational outcome with time. This is the second follow-up of patients who were injured as preschoolers in traffic accidents. In the first follow-up the mean age was 23 years and in the present study the average age of the 27-patient cohort was 40 years. Twenty-two patients were assessed clinically by a neuropsychologist, neurologist and a social worker. Five patients, although not able or willing to participate in the clinical study, were contacted by telephone and interviewed on their Vocational outcome. Compared to the first follow-up, 20/27 patients in total had no change in their vocational status. Nine out of the 27 patients were working full-time, two had subsidized jobs and 16 were not working. Twenty-four of 27 patients were independent in daily living. In the neuropsychological tests of executive functions, preserved flexibility associated with full-time work status. In conclusion, (1)/(3) of the patients were still employed full-time over 30 years after the TBI. This suggests that favorable vocational Outcome, reached by young adulthood, is maintained at least until middle age.	Finnish Inst Occupat Hlth, Sect Clin Neurosci, Helsinki 00250, Finland		Nybo, T (corresponding author), Finnish Inst Occupat Hlth, Sect Clin Neurosci, Topeliuksenkatu 41AA, Helsinki 00250, Finland.	taina.nybo@occuphealth.fi		Sainio, Markku/0000-0002-3145-1301			Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Heaton R.K., 1981, WISCONSIN CARD SORTI; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Nybo T, 1999, BRAIN INJURY, V13, P759; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Verger K, 2000, BRAIN INJURY, V14, P495; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; 1999, CAMBRIDGE NEUROPSYCH; 1944, MANUAL DIRECTION SCO; 2003, FINLAND FIGURES 2003	22	39	39	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					719	723		10.1017/S1355617704105109			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700008	15327719				2022-02-06	
J	Curry, DJ; Wright, DA; Lee, RC; Kang, UJ; Frim, DM				Curry, DJ; Wright, DA; Lee, RC; Kang, UJ; Frim, DM			Surfactant poloxamer 188-related decreases in inflammation and tissue damage after experimental brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						surfactant; poloxamer; traumatic brain injury; chemotaxis; membrane fluidity; cytokine; pediatric neurosurgery	NEUTROPHIL ACTIVATION; EXCITOTOXIC LESIONS; CYTOKINE PRODUCTION; RHEOTHRX INJECTION; BLOCK POLYMER; MEMBRANE; CELLS; INTERLEUKIN-1; AGGREGATION; FIBROBLASTS	Object. The surfactant, poloxamer 188 (P-188), has been found to protect against tissue injury in various experimental models. Its protective mechanism may involve the effects of the surfactant against oxidative stress and inflammation. The authors investigated the role of P-188 in the reduction of tissue injury and macrophage response in a model of excitotoxic brain injury in the rat striatum. Methods. Fifteen Sprague-Dawley rats underwent stereotactic injection of 120 nmol of quinolinic acid into the striatum and received intracisternal injection of vehicle or P-188 (40 mg/kg) at 10 minutes and 4 hours postinjury. Rats were killed after 1 week, and the histological score was determined based on the degree of overall tissue injury (Grades 1-4) at the lesion site. The number of macrophages within the lesioned striatum was compared with that found within the striatum on the nonoperated contralateral side. The scores related to tissue damage and the macrophage ratios of each group were then compared using t-tests. Striatal injection of the toxin produced a lesion characterized by necrosis and inflammation surrounding the injection site in all six control animals. In rats in which intracisternal P-188 was administered, significantly less tissue injury was demonstrated (mean score 2.45 +/- 0.74) than in controls (mean score 3.14 +/- 0.75) (p = 0.045). The rats that received intracisternal surfactant also had significantly less macrophage infiltrate (mean ratio 1.06 +/- 0.18) than control animals (mean ratio 2.00 +/- 0.48) (p = 0.004). Conclusions. The surfactant P-188 reduces tissue loss and macrophage infiltrate after excitotoxic brain injury in the rat. Possible mechanisms of this effect may include direct surfactant modulation of inflammatory cell membrane fluidity.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA		Frim, DM (corresponding author), Univ Chicago, Childrens Hosp, Sect Pediat Neurosurg, MC-40661klkl,5841 S Maryland Ave, Chicago, IL 60637 USA.	dfrim@peds.bsd.uchicago.edu	Wright, David/K-7898-2012; Kang, Un/AAV-2858-2020	Wright, David/0000-0002-2785-0254; Kang, Un/0000-0002-5970-6839; Lee, Raphael C./0000-0002-6628-1867			AdamsGraves P, 1997, BLOOD, V90, P2041, DOI 10.1182/blood.V90.5.2041; ARMSTRONG JK, 1995, THROMB RES, V79, P437, DOI 10.1016/0049-3848(95)00134-D; BAJAJ AK, 1989, CIRCULATION, V79, P645, DOI 10.1161/01.CIR.79.3.645; Bastiaanse EML, 1997, CARDIOVASC RES, V33, P272, DOI 10.1016/S0008-6363(96)00193-9; Batrakova E, 1999, PHARM RES-DORDR, V16, P1373, DOI 10.1023/A:1018942823676; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; Clarke MSF, 1999, LEARN MEMORY, V6, P634, DOI 10.1101/lm.6.6.634; COLBASSANI HJ, 1989, STROKE, V20, P1241, DOI 10.1161/01.STR.20.9.1241; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAHLGREN C, 1980, CELL BIOPHYS, V2, P253, DOI 10.1007/BF02790453; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1993, NEUROREPORT, V4, P655, DOI 10.1097/00001756-199306000-00013; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GIULIAN D, 1989, J NEUROSCI, V9, P4416; HUNTER R, 1981, J IMMUNOL, V127, P1244; Jackson JK, 2000, BIOMATERIALS, V21, P1483, DOI 10.1016/S0142-9612(00)00034-X; Jagannath C, 1999, ANTIMICROB AGENTS CH, V43, P2898, DOI 10.1128/AAC.43.12.2898; Jewell RC, 1997, J PHARM SCI, V86, P808, DOI 10.1021/js960491e; KNIZE DM, 1969, SURG GYNECOL OBSTETR, V129, P1019; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; MAY LE, 1958, J AM GERIATR SOC, V6, P814, DOI 10.1111/j.1532-5415.1958.tb00788.x; MCINTOSH TK, 1999, SECONDARY BRAIN INJU; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; MEZROW CK, 1992, J THORAC CARDIOV SUR, V103, P1143; MIYANCHI Y, 1966, CIRCULATION S, V33, P171; Moghimi SM, 1996, J NATL CANCER I, V88, P766, DOI 10.1093/jnci/88.11.766; Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OWEN E, 1978, J CELL SCI, V32, P363; Parnaud G, 2001, BRIT J CANCER, V84, P90, DOI 10.1054/bjoc.2000.1540; PATON B, 1968, USE NONIONIC DETERGE; PERSKIN MH, 1992, MECH AGEING DEV, V64, P303, DOI 10.1016/0047-6374(92)90086-S; PINKERTON PH, 1978, J CLIN PATHOL, V31, P300, DOI 10.1136/jcp.31.4.300; RODEHEAVER GT, 1980, ANN EMERG MED, V9, P572, DOI 10.1016/S0196-0644(80)80228-9; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scholer N, 2000, J MICROENCAPSUL, V17, P639; SPIKA S, 1996, CLIN IMMUNOL IMMUNOP, V79, P224; Tan J, 1999, J BIOMED MATER RES, V46, P465, DOI 10.1002/(SICI)1097-4636(19990915)46:4<465::AID-JBM4>3.0.CO;2-N; Toth K, 1997, CLIN HEMORHEOL MICRO, V17, P117; UHLER TA, 1994, NEUROSURGERY, V34, P122; WADDELL W, 1957, METABOLISM, V9, P572; WANG M, 2000, JOINT SECT PED NEURO, P48; WEATHERL.RC, 1969, SURGERY, V66, P208; WELLS R, 1968, CIRCULATION       S2, V37, P168; WOLACH B, 1992, J LEUKOCYTE BIOL, V51, P324, DOI 10.1002/jlb.51.4.324; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	50	39	40	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	1		S			91	96		10.3171/ped.2004.101.2.0091			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	843QS	WOS:000223100100015	16206978				2022-02-06	
J	Shimamura, M; Garcia, JM; Prough, DS; Hellmich, HL				Shimamura, M; Garcia, JM; Prough, DS; Hellmich, HL			Laser capture microdissection and analysis of amplified antisense RNA from distinct cell populations of the young and aged rat brain: effect of traumatic brain injury on hippocampal gene expression	MOLECULAR BRAIN RESEARCH			English	Article						traumatic brain injury; laser capture microdissection; hippocampal gene expression; RNA amplification; aging	MEMORY DYSFUNCTION; CEREBRAL-ISCHEMIA; CDNA SYNTHESIS; IN-SITU; RT-PCR; QUANTIFICATION; TRANSCRIPTION; SENESCENCE; DEFICITS; CYCLE	To explore the molecular mechanisms underlying the increased vulnerability of the aged brain to traumatic brain injury (TBI), we compared the expression of several age-related genes in the CA1, CA3 and dentate gyrus subfields of the young and aged rat hippocampus before and after lateral fluid percussion TBI. Using laser capture microdissection (LCM), we obtained hippocampal neurons and glia from the neuropil adjacent to the pyramidal and granule cell layers. Subsequently, we linearly amplified and analyzed the antisense mRNA using Northern blot and ribonuclease protection assays (RPA). Our procedures, which have not been previously applied to quantitative analysis of LCM mRNA from neural tissue, included a modified reverse transcription step to enhance full-length cDNA synthesis, thus enhancing the yield of larger components of in vitro-transcribed mRNA for downstream analysis. Northern analysis showed greater expression of two aging-associated genes, p21 and brain-derived neurotrophic factor (BDNF) in the aged hippocampus. The age-related differences in p21 and BDNF expression were particularly prominent after TBI. By quantitative RPA analysis, we found that the expression of p21, known to be induced in senescent cells, was significantly greater in the CA3 region of aged rats, an area that is selectively vulnerable to TBI. However, expression of genes associated with regenerative and repair functions was significantly decreased in aged hippocampus. Our RPA results indicate that substantial age-dependent differences in the transcriptional profile of distinct regions of the hippocampal formation may account, in part, for their differential susceptibility to brain injury. (C) 2003 Elsevier B.V All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Yokohama City Univ, Sch Med, Dept Neurol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; AMARAL DG, 1990, PROG BRAIN RES, V83, P1; Ambesi-Impiombato A, 2003, BRAIN RES PROTOC, V11, P189, DOI 10.1016/S1385-299X(03)00056-4; Antropova YG, 2002, B EXP BIOL MED+, V134, P81, DOI 10.1023/A:1020677209755; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bimonte HA, 2003, NEUROBIOL AGING, V24, P37, DOI 10.1016/S0197-4580(02)00015-5; Bonaventure P, 2002, BRAIN RES, V943, P38, DOI 10.1016/S0006-8993(02)02504-0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Busser J, 1998, J NEUROSCI, V18, P2801; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Donehower LA, 2002, J CELL PHYSIOL, V192, P23, DOI 10.1002/jcp.10104; Drosopoulos WC, 1998, J MOL MED-JMM, V76, P604, DOI 10.1007/s001090050257; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Feldman AL, 2002, BIOTECHNIQUES, V33, P906, DOI 10.2144/02334mt04; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hawkins PR, 2003, BIOTECHNIQUES, V34, P768, DOI 10.2144/03344st06; Hayashi M, 2001, BRAIN RES, V918, P191, DOI 10.1016/S0006-8993(01)03002-5; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoyer S, 2002, J NEURAL TRANSM, V109, P991, DOI 10.1007/s007020200082; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Kamme F, 2003, J NEUROSCI, V23, P3607; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Kramer DL, 2001, CANCER RES, V61, P7754; Luzzi V, 2001, AM J PATHOL, V158, P2005, DOI 10.1016/S0002-9440(10)64672-X; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McShea A, 1999, MED HYPOTHESES, V52, P525, DOI 10.1054/mehy.1997.0680; Meiners S, 2003, MOL NEUROBIOL, V27, P177, DOI 10.1385/MN:27:2:177; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Paccaud F, 2002, AGING CLIN EXP RES, V14, P314; Parlato R, 2002, ANAL BIOCHEM, V300, P139, DOI 10.1006/abio.2001.5463; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; Poldrack RA, 2003, NEUROPSYCHOLOGIA, V41, P245, DOI 10.1016/S0028-3932(02)00157-4; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Santos-Eggimann B, 2002, AGING CLIN EXP RES, V14, P287; Smith MA, 1996, BEHAV BRAIN RES, V78, P25, DOI 10.1016/0166-4328(95)00220-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Sykova E, 2002, HIPPOCAMPUS, V12, P269, DOI 10.1002/hipo.1101; Sykova E, 2001, Prog Brain Res, V132, P339; Tomasevic G, 1999, MOL BRAIN RES, V70, P304, DOI 10.1016/S0169-328X(99)00146-1; Tomasevic G, 1999, NEUROSCIENCE, V90, P781, DOI 10.1016/S0306-4522(98)00484-9; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wehrle-Haller B, 2003, J PATHOL, V200, P481, DOI 10.1002/path.1399; Wilkinson D. C., 1999, IN SITU HYBRIDIZATIO; Wittenberg GM, 2002, TRENDS NEUROSCI, V25, P501, DOI 10.1016/S0166-2236(02)02231-2; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5; Zhang JL, 1999, BIOCHEM J, V337, P231, DOI 10.1042/0264-6021:3370231; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406	63	39	41	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAR 17	2004	122	1					47	61		10.1016/j.molbrainres.2003.11.015			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	804BD	WOS:000220273300006	14992815				2022-02-06	
J	Esquenazi, A				Esquenazi, A			Evaluation and management of spastic gait in patients with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						gait; spasticity; traumatic brain injury; upper motoneuron syndrome		Damage to the corticospinal system after brain injury interferes with activities of daily living, mobility, and communication. The chief cause of this interference has to do with impairment to produce and regulate voluntary movement accompanied by the presence of spasticity. This review advocates that the evaluation of "spasticity" should focus on 3 issues: (1) identifying the clinical pattern Of motor dysfunction and its source; (2) identifying the patient's ability to control muscles involved in the clinical pattern; and (3) the differential role of muscle stiffness and contracture as it relates to the functional problem. We have identified and described 6 clinical patterns of motor dysfunction affecting the lower limbs during gait, found in patients with traumatic brain injury and residual from upper motor neuron lesions. We have presented the use of dynamic electromyography to identify the voluntary and spastic characteristics of individual muscles in gait and the use of anesthetic nerve blocks to identify properties of stiffness and contracture in particular muscle groups. Treatment algorithms for these problems include identification of the muscles that contribute to the deformity across a joint; the stage of patient recovery; and most important, the clinical goals applicable to the patient. The treatment strategies based on the algorithm included in this article were focused on the use of chemodenervation of targeted muscles, neuro-orthopedic surgery, and other therapeutic strategies.	Albert Einstein Med Ctr, Dept Phys Med & Rehabil, Philadelphia, PA 19141 USA		Esquenazi, A (corresponding author), Albert Einstein Med Ctr, Dept Phys Med & Rehabil, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	aesquena@einstein.edu					ASHWORTH B, 1964, PRACTITIONER, V192, P540; Brin M F, 1997, Muscle Nerve Suppl, V6, pS208; CAMPBELL SK, 1991, CONT MANAGEMENT MOTO, P146; ESQUENAZI A, 1993, DELISAS REHABILITATI; Esquenazi A, 1995, GAIT ANAL THEORY APP, P412; FARMER SF, 1993, J PHYSIOL-LONDON, V463, P83, DOI 10.1113/jphysiol.1993.sp019585; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; JANKOVIC J, 1991, ARCH NEUROL-CHICAGO, V48, P1253, DOI 10.1001/archneur.1991.00530240057020; KOMAN LA, 1990, NIH CONSENSUS DEV C; Lance JW, 1980, SPASTICITY DISORDERE; Mayer N, 1996, MED REHABILITATION T, P411; Mayer NH, 2004, J HEAD TRAUMA REHAB, V19, P119, DOI 10.1097/00001199-200403000-00005; Mayer NH, 2001, ADV NEUROL, V87, P311; Mayer NH, 1997, MUSCLE NERVE, pS21	14	39	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2004	19	2					109	118		10.1097/00001199-200403000-00004			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	809NR	WOS:000220643900004	15247822				2022-02-06	
J	Wang, YT; Kent, RD; Duffy, JR; Thomas, JE; Weismer, G				Wang, YT; Kent, RD; Duffy, JR; Thomas, JE; Weismer, G			Alternating motion rate as an index of speech motor disorder in traumatic brain injury	CLINICAL LINGUISTICS & PHONETICS			English	Article						speech motor disorder; traumatic brain injury; alternating motion rate	CLOSED-HEAD-INJURY; VOICE ONSET TIME; DYSARTHRIC SPEAKERS; ELECTROMAGNETIC ARTICULOGRAPHY; KINEMATIC ANALYSIS; VERBAL IMPAIRMENT; SPEAKING RATE; FEATURES; CHILDREN	The task of syllable alternating motion rate (AMR) (also called diadochokinesis) is suitable for examining speech disorders of varying degrees of severity and in individuals with varying levels of linguistic and cognitive ability. However, very limited information on this task has been published for subjects with traumatic brain injury (TBI). This study is a quantitative and qualitative acoustic analysis of AMR in seven subjects with TBI. The primary goal was to use acoustic analyses to assess speech motor control disturbances for the group as a whole and for individual patients. Quantitative analyses included measures of syllable rate, syllable and intersyllable gap durations, energy maxima, and voice onset time (VOT). Qualitative analyses included classification of features evident in spectrograms and waveforms to provide a more detailed description. The TBI group had (1) a slowed syllable rate due mostly to lengthened syllables and, to a lesser degree, lengthened intersyllable gaps, (2) highly correlated syllable rates between AMR and conversation, (3) temporal and energy maxima irregularities within repetition sequences, (4) normal median VOT values but with large variation, and (5) a number of speech production abnormalities revealed by qualitative analysis, including explosive speech quality, breathy voice quality, phonatory instability, multiple or missing stop bursts, continuous voicing, and spirantization. The relationships between these findings and TBI speakers' neurological status and dysarthria types are also discussed. It was concluded that acoustic analyses of the AMR task provides specific information on motor speech limitations in individuals with TBI.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA		Kent, RD (corresponding author), Univ Wisconsin, Waisman Ctr, Rm 435,1500 Highland Ave, Madison, WI 53705 USA.	kent@waisman.wisc.edu	Kent, Raymond D/AAI-1928-2020		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC00319] Funding Source: Medline		ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; Auzou P, 2000, CLIN LINGUIST PHONET, V14, P131; BLUMBERGER J, 1995, BRAIN INJURY, V9, P797, DOI 10.3109/02699059509008235; Brown J.R., 1975, MOTOR SPEECH DISORDE; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; DAVIS K, 1995, J CHILD LANG, V22, P275, DOI 10.1017/S030500090000979X; Dembowski J., 1993, ANN B RES I LOGOPEDI, V27, P13; Duffy JR., 2020, MOTOR SPEECH DISORDE; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Goozee JV, 1999, J MED SPEECH-LANG PA, V7, P209; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; Kent R.D., 2002, ACOUSTIC ANAL SPEECH, V2nd ed.; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; Kent RD, 1999, J MED SPEECH-LANG PA, V7, P83; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; Kent RD, 1997, FOLIA PHONIATR LOGO, V49, P63, DOI 10.1159/000266440; KENT RD, 1980, J PHONETICS, V8, P157, DOI 10.1016/S0095-4470(19)31460-3; KENT RD, 1982, BRAIN LANG, V15, P259, DOI 10.1016/0093-934X(82)90060-8; KREUL EJ, 1972, J SPEECH HEAR RES, V15, P72, DOI 10.1044/jshr.1501.72; Kuehn D. P., 1976, J PHONETICS, V4, P303, DOI 10.1016/S0095-4470(19)31257-4; LEFKOWITZ D, 1994, J MED SPEECH-LANG PA, V2, P1; McHenry M, 2000, LARYNGOSCOPE, V110, P1157, DOI 10.1097/00005537-200007000-00017; MCHENRY MA, 1994, J SPEECH HEAR RES, V37, P1271, DOI 10.1044/jshr.3706.1271; McHenry MA, 1998, ARCH PHYS MED REHAB, V79, P545, DOI 10.1016/S0003-9993(98)90071-5; McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; McHenry MA, 2001, BRAIN INJURY, V15, P741, DOI 10.1080/02699050010013932; McHenry MA, 1996, DISORDERS MOTOR SPEE, P229; MILENKOVIC P, 2000, TIME FREQUENCY ANAL; Nishio M, 2001, CLIN LINGUIST PHONET, V15, P309; Ozsancak C, 2001, FOLIA PHONIATR LOGO, V53, P48, DOI 10.1159/000052653; PORTNOY RA, 1982, J SPEECH HEAR DISORD, V47, P324, DOI 10.1044/jshd.4703.324; PTACEK PH, 1966, J SPEECH HEAR RES, V9, P353, DOI 10.1044/jshr.0903.353; RIETVELD ACM, 1987, J PHONETICS, V15, P273, DOI 10.1016/S0095-4470(19)30571-6; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; Weismer, 1998, J MED SPEECH-LANG PA, V6, P165; WILSON J T L, 1990, Brain Injury, V4, P349; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215; [No title captured]	48	39	41	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	JAN-FEB	2004	18	1					57	84		10.1080/02699200310001596160			28	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	773JA	WOS:000188894800004	15053268				2022-02-06	
J	Bain, AC; Shreiber, DI; Meaney, DF				Bain, AC; Shreiber, DI; Meaney, DF			Modeling of microstructural kinematics during simple elongation of central nervous system tissue	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							AXONAL INJURY; STRETCH; HEAD	Damage to axons and glial cells in the central nervous system (CNS) white matter is a nearly universal feature of traumatic brain injury, yet it is not clear how the tissue mechanical deformations are transferred to the cellular components of the CNS. Defining how cellular deformations relate to the applied tissue deformation field can both highlight cellular populations at risk for mechanical injury, and define the fraction of cells in a specific population that will exhibit damage. In this investigation, microstructurally based models of CNS white matter were developed and tested against measured transformations of the CNS tissue microstructure under simple elongation. Results show that axons in the unstretched optic nerves were significantly wavy or undulated, where the measured axonal path length was greater than the end-to-end distance of the axon. The average undulation parameter-defined as the true axonal length divided by the end-to-end length-was 1.13. In stretched nerves, mean axonal undulations decreased with increasing applied stretch ratio (lambda)-the mean undulation values decreased to 1.06 at lambda = 1.06, 1.04 at lambda =1.12, and 1.02 at lambda =1.25. A model describing the gradual coupling, or tethering, of the axons to the surrounding glial cells best fit the experimental data. These modeling efforts indicate the fraction of the axonal and glial populations experiencing deformation increases with applied elongation, consistent with the observation that both axonal and glial cell injury increases at higher levels of white matter injury. Ultimately, these results can be used in conjunction with computational simulations of traumatic brain injury to aid in establishing the relative risk of cellular structures in the CNS white matter to mechanical injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 120 Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Shreiber, David/ABE-8254-2021	Meaney, David/0000-0002-0954-4122; Shreiber, David/0000-0001-8248-419X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD41699] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 N535712] Funding Source: Medline		Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BANDAK FA, 1996, AGARD HEAD INJ SPEC; Billiar KL, 1997, J BIOMECH, V30, P753, DOI 10.1016/S0021-9290(97)00019-5; BREIG A, 1960, BIOMECHANICS CENTRAL, P183; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; LANIR Y, 1979, J BIOMECH, V12, P423, DOI 10.1016/0021-9290(79)90027-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RIGBY BJ, 1959, J GEN PHYSIOL, V43, P265, DOI 10.1085/jgp.43.2.265; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Smith DH, 1999, J NEUROSCI, V19, P4263; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; VIIDIK A, 1968, Journal of Biomechanics, V1, P3, DOI 10.1016/0021-9290(68)90032-8; WAXMAN SG, 1995, AXON STRUCTURE FUNCT, P682; Zar J.H., 1999, BIOSTAT ANAL, V4; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	19	39	39	0	3	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	DEC	2003	125	6					798	804		10.1115/1.1632627			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	767XR	WOS:000188499600006	14986404				2022-02-06	
J	Ruff, RM				Ruff, RM			A friendly critique of neuropsychology: facing the challenges of our future	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	21st Annual Conference of the National-Academy-of-Neuropsychology	OCT 31-NOV 03, 2001	SAN FRANCISCO, CA	Natl Acad Neuropsychol		neuropsychological testing; history of neuropsychology; cognitive treatment	TRAUMATIC BRAIN-INJURY; UNIFIED DEFINITION; SEARCH	Neuropsychology emerged as a discipline in the 1940s when prior to performing a craniotomy, neurosurgeons based their localization on EEGs, X-rays and neuropsychological test results. This practice ended in the mid 1970s when computerized tomography became available. As the neuropsychologists' role in localizing has become miniscule, the referral questions have shifted to obtaining quantitative descriptions of the patient's cognitive status. The current paper explores future directions for neuropsychology on the basis of asking the following question: Are we meeting the needs of the patients? The answer is clear: Patients' needs are not met by merely diagnosing cognitive deficits. There is a growing need to advance services that maintain cognitive health, since modem societies place increasing value on highly educated and skilled work forces. Thus, the time has come for neuropsychologists to identify as caretakers for cognitive health. Just as we expect from the disciplines responsible for physical and emotional health, we must provide a combination of diagnostic and treatment services for cognitive health. (C) 2003 National Academy of Neuropsychology. Published. by Elsevier Ltd. All rights reserved.	St Marys Hosp, San Francisco, CA 94117 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Stanford, CA 94305 USA		Ruff, RM (corresponding author), St Marys Hosp, 450 Stanyan St, San Francisco, CA 94117 USA.	ronuff@mindpring.com					[Anonymous], 1996, Neurology, V47, P592; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Baldo Juliana V, 2002, Appl Neuropsychol, V9, P193, DOI 10.1207/S15324826AN0904_1; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Broca P., 1865, B SOC ANTHROPOL PAR, V1865, P337; Friston KJ, 1997, TRENDS COGN SCI, V1, P21, DOI 10.1016/S1364-6613(97)01001-2; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; GRANT I, 1996, NEUROPSYCHOLOGICAL A; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Levin H.S., 1989, MILD HEAD INJURY; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Pribram K. H., 1971, LANGUAGES BRAIN; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P99; Ruff RM, 1999, BRAIN INJURY, V13, P943; Squire LR., 1987, MEMORY BRAIN; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; SWEET J, 2001, INITIAL RESULTS D40; TARTER RE, 1988, MED NEUROPSYCHOLOGY; Teuber HL, 1955, ANNU REV PSYCHOL, V6, P267, DOI 10.1146/annurev.ps.06.020155.001411; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Weiskrantz L., 1991, PERSPECTIVES COGNITI; WERNICKE C, 1874, APHASISCHE SYMPTOMKO; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; World Health Organization, 1980, INT CLASS IMP DIS HA; [No title captured]	27	39	39	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2003	18	8					847	864		10.1016/j.acn.2003.07.002			18	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	747WZ	WOS:000186830200003	14609580	Bronze			2022-02-06	
J	Lotocki, G; Alonso, OF; Frydel, T; Dietrich, WD; Keane, RW				Lotocki, G; Alonso, OF; Frydel, T; Dietrich, WD; Keane, RW			Monoubiquitination and cellular distribution of XIAP in neurons after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						inhibitors of apoptosis; XIAP; ubiquitin; traumatic brain injury	UBIQUITIN-PROTEIN LIGASE; APOPTOSIS PROTEIN; LINKED INHIBITOR; IN-VITRO; DEGRADATION; ACTIVATION; CASPASE-3; CLEAVAGE; DEATH; RATS	XIAP is a member of the inhibitor of apoptosis (IAP) gene family that, in addition to suppressing cell death by inhibition and polyubiquitination of caspases, is involved in an increasing number of signaling cascades. Moreover, the function and regulation of XIAP in the central nervous system (CNS) is poorly understood. In this study, the authors investigated the cell-type expression, the subcellular distribution, ubiquitination of XIAP, and levels of Smac/DIABLO in the normal adult rat brain and in brains subjected to moderate traumatic brain injury (TBI). In the normal brain, XIAP was predominantly expressed in the perinuclear region of neurons. Traumatized brains showed dramatic alterations in cellular and regional expression of XIAP early after injury. Stereologic analyses of the number of XIAP-positive cells within the hippocampus of both hemispheres showed a biphasic response. Immunoprecipitation and immunoblots of extracts derived from different brain regions demonstrated that a single ubiquitin modifies XIAP. Normal cortex contained significantly higher levels of monoubiquitinated XIAP than hippocampus. TBI induced alterations in levels of monoubiquitinated XIAP that correlated with changes in XIAP distribution and immunoreactivity, suggesting that monoubiquitination of XIAP may be a regulator of XIAP location or activity. Similar levels of Smac/DIABLO were present in lysates of normal and traumatized brains. These data demonstrate for the first time a region-specific regulation of XIAP monoubiquitination in the normal adult rat brain, and after TBI, that may be a key event in the regulation of XIAP function contributing to the pathogenesis following injury.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Miami Project Cure Paralysis, Miami, FL USA		Keane, RW (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30921-10] Funding Source: Medline		BIRKEYREFFEY A, 2001, J BIOL CHEM, V276, P26542; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Conti AC, 1998, J NEUROSCI, V18, P5663; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang HK, 2000, J BIOL CHEM, V275, P26661; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Korhonen L, 2001, MOL CELL NEUROSCI, V17, P364, DOI 10.1006/mcne.2000.0935; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Lotocki G, 2002, IUBMB LIFE, V54, P231, DOI 10.1080/15216540215675; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4845; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shibata M, 2002, NEUROREPORT, V13, P1985, DOI 10.1097/00001756-200210280-00031; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	28	39	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2003	23	10					1129	1136		10.1097/01.WCB.0000086938.68719.E0			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	729DD	WOS:000185755500003	14526223	Bronze			2022-02-06	
J	Poggi, G; Liscio, M; Adduci, A; Galbiati, S; Sommovigo, M; Degrate, A; Strazzer, S; Castelli, E				Poggi, G; Liscio, M; Adduci, A; Galbiati, S; Sommovigo, M; Degrate, A; Strazzer, S; Castelli, E			Neuropsychiatric sequelae in TBI: a comparison across different age groups	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; CHILDREN; CONSEQUENCES; INDIVIDUALS; ADJUSTMENT; DEPRESSION; DISORDERS; ISSUES; DAMAGE	Objective: Traumatic brain injury (TBI) is the leading cause of death and permanent disability in developmental age. Neurobehavioural symptoms are not uncommon in these patients. The aim of this study was to identify the main neuropsychiatric sequelae of TBI at different ages and study the possible correlations with clinical features in the acute phase and outcome in order to better plan rehabilitative treatment and re-entry into society. Method: Ninety-six post-traumatic patients, ranging from 0 - 18 years, underwent a complete psychological evaluation protocol at 1 year from trauma. Patients were divided into three different age groups ( 0 - 6 years; 7 - 13 years; 14 - 18 years) and received a protocol made up of age-appropriate scales. Results: Different psychological problems were found across the three groups; more frequently younger patients show internalizing problems such as withdrawal and closure, while, with age, behaviour problems become more frequent, characterized by hyperactivity and aggressiveness. Factors that were most predictive of psychological, behaviour and adjustment problems include GOS scores, the degree of impairment on the neurological examination and male gender. Conclusions: Psychological and behavioural problems differ across the three age groups and determine a different outcome, rehabilitation plan and re-entry into society. These problems should, thus, be investigated and treated specifically according to age.	IRCCS Eugenio Medea, I-23842 Bosisio Parini, LC, Italy		Poggi, G (corresponding author), IRCCS Eugenio Medea, Via Don Luigi Monza 20, I-23842 Bosisio Parini, LC, Italy.	gpoggi@bp.lnf.it	Galbiati, Susanna/AAH-6883-2019; Strazzer, Sandra/AAH-5712-2019; Castelli, Enrico/J-1887-2012; Poggi, Geraldina/K-4490-2016	Galbiati, Susanna/0000-0001-7209-4251; Strazzer, Sandra/0000-0001-8414-6565; Poggi, Geraldina/0000-0003-0589-6347			Achenbach T. M., 1983, CHILD BEHAV CHECKLIS; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Bowen A, 1999, BRAIN INJURY, V13, P547; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Deb S, 1999, AM J PSYCHIAT, V156, P374; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Franulic A, 2000, BRAIN INJURY, V14, P431; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Gualtieri CT, 1999, NEUROREHABILITATION, V13, P103; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; JENNETT B, 1975, LANCET, V1, P480; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NEWCOMER P, 1997, TEST ANSIA DEPRESSIO; Nybo T, 1999, BRAIN INJURY, V13, P759; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; ROBIN AH, 1999, ARCH PHYS MED REHAB, V80, P991; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SANAVIO E, 1996, CBA 2 0 COGNITIVE BE; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sherwin ED, 2000, BRAIN INJURY, V14, P267; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Thurber C A, 1998, Pediatr Rehabil, V2, P149; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	42	39	39	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2003	17	10					835	846		10.1080/0269905031000088612			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	719CR	WOS:000185186500002	12963550				2022-02-06	
J	Whyte, J				Whyte, J			Clinical trials in rehabilitation - What are the obstacles?	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Clinical Trials in Medical Rehabilitation Conference	NOV 01-02, 2002	PARSIPPANY, NEW JERSEY			rehabilitation; randomized clinical trials; rehabilitation research	TRAUMATIC BRAIN INJURY; OUTCOMES	Across rehabilitation, there is a shortage of treatments that have demonstrated efficacy and effectiveness through rigorously controlled clinical trials. Although rehabilitation efficacy and effectiveness research present many of the obstacles that are found in research on other biomedical domains, they also present a number of obstacles that are specific to the conceptual framework underlying rehabilitation practice. In this article, I review the specific challenges presented by the need to rigorously define the research participants, the treatment under investigation, and the outcomes by which treatment response will be measured. I also suggest research that will be necessary to surmount some of these obstacles.	Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER		BORKOVEC TD, 1996, NIMH PSYCHOTHERAPY R, V5, P14; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Clifton GL, 2001, J NEUROSURG, V95, P733; Ebenbichler GR, 1998, BRIT MED J, V316, P731, DOI 10.1136/bmj.316.7133.731; Jull G, 2002, SPINE, V27, P1835, DOI 10.1097/00007632-200209010-00004; Robinson K. M., 1990, PRACTICAL MANAGEMENT, P201; Saunders, 1995, CLIN REHABIL, V9, P126, DOI DOI 10.1177/026921559500900207; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Whyte J, 2001, AM J PHYS MED REHAB, V80, P865, DOI 10.1097/00002060-200111000-00012; WHYTE J, 1997, ASSESSING MED REHABI, P43; [No title captured]	12	39	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2003	82	10		S			S16	S21		10.1097/01.PHM.0000086992.95121.C2			6	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	724YP	WOS:000185516100004	14502034				2022-02-06	
J	Gaur, A; Sinclair, M; Caruso, E; Peretti, G; Zaleske, D				Gaur, A; Sinclair, M; Caruso, E; Peretti, G; Zaleske, D			Heterotopic ossification around the elbow following burns in children: Results after excision	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							BONE-FORMATION; INJURY	Background: Major burn injuries close to joints alter the function of the musculoskeletal system through tissue loss and limitation of joint motion. In children with involvement of the hand, wrist, and forearm, restriction of elbow motion secondary to heterotopic ossification following a burn injury severely limits the function of the upper extremity. The purpose of this study was to review elbow function following excision of heterotopic ossification around the elbow in children. Methods: Eight children (ten elbows) from a population of 3245 consecutive patients who were admitted to our pediatric burn center were found to have severe heterotopic ossification of the elbow, leading to an inability to reach the mouth for feeding and the head and the perineum for self-care. Excision of the heterotopic ossification was undertaken if the patient had this limitation of function and if movement was restricted to a total arc of motion of <50degrees. Pain was not an indication for the operation. The procedure was performed at an average of 17.3 months following the injury. Results: Seven children (nine elbows) were available for follow-up at an average of fifty-six months after surgery. All nine elbows had an improved arc of motion (an average increase of 57degrees). Following excision, heterotopic ossification did not recur. All children were able to reach the face and the perineum following the operation. Conclusions: Excision of heterotopic ossification around the elbow following a burn injury in children can improve the arc of motion and improve the function of the extremity. A relatively simple operative and postoperative regimen can achieve satisfactory results. Level of Evidence: Therapeutic study, Level IV (case series [no, or historical, control group]). See Instructions to Authors for a complete description of levels of evidence.	Med Coll Penn & Hahnemann Univ, Dept Orthoped Surg, Philadelphia, PA 19102 USA; Altona Childrens Hosp, D-22763 Hamburg, Germany; Luigi Sacco Univ Hosp, Dept Orthopaed, Milan, Italy; Hosp San Raffaele, Dept Orthopaed, I-20132 Milan, Italy; Childrens Natl Med Ctr, Pediat Orthopaed Dept, Washington, DC 20010 USA; Massachusetts Gen Hosp, Boston, MA USA; Boston Shriners Hosp, Boston, MA USA		Gaur, A (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Orthoped Surg, Philadelphia, PA 19102 USA.		; Peretti, Giuseppe/K-6358-2016	caruso, enzo massimo/0000-0002-3118-2412; Peretti, Giuseppe/0000-0001-9341-7187			Beingessner DM, 2000, J HAND SURG-AM, V25A, P483, DOI 10.1053/jhsu.2000.6922; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Crawford C M, 1986, J Burn Care Rehabil, V7, P323, DOI 10.1097/00004630-198607000-00005; ELLEDGE ES, 1988, J TRAUMA, V28, P684, DOI 10.1097/00005373-198805000-00023; EVANS BE, 1959, J BONE JOINT SURG AM, V41, P785; EVANS EB, 1966, J BONE JOINT SURG AM, VA 48, P643, DOI 10.2106/00004623-196648040-00002; EVANS EB, 1991, CLIN ORTHOP RELAT R, P94; HOFFER MM, 1978, J TRAUMA, V18, P667, DOI 10.1097/00005373-197809000-00009; JAY MS, 1981, CLIN PEDIATR, V20, P734, DOI 10.1177/000992288102001108; Kluger G, 2000, J CHILD NEUROL, V15, P406, DOI 10.1177/088307380001500610; KOCH BM, 1992, ARCH PHYS MED REHAB, V73, P1104; Kolar J, 1971, Acta Chir Plast, V13, P133; KOLAR J, 1959, J BONE JOINT SURG AM, V41, P103, DOI 10.2106/00004623-195941010-00011; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; MUNSTER AM, 1972, J TRAUMA, V12, P1071, DOI 10.1097/00005373-197212000-00008; Pape HC, 2001, J ORTHOP TRAUMA, V15, P229, DOI 10.1097/00005131-200105000-00001; PETERSON SL, 1989, J TRAUMA, V29, P365, DOI 10.1097/00005373-198903000-00015; Pruitt B A Jr, 1974, Clin Plast Surg, V1, P667; PUZAS JE, 1989, CLIN ORTHOP RELAT R, P269; SCHIELE JP, 1972, RADIOLOGY, V104, P13; Shafritz AB, 1998, CLIN ORTHOP RELAT R, P46; Viola RW, 1999, J HAND SURG-AM, V24A, P370; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7	24	39	40	0	0	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG	2003	85A	8					1538	1543		10.2106/00004623-200308000-00016			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	708DP	WOS:000184552100016	12925635				2022-02-06	
J	Goldstein, LB				Goldstein, LB			Neuropharmacology of TBI-induced plasticity	BRAIN INJURY			English	Article							LONG-TERM POTENTIATION; SENSORIMOTOR CORTEX INJURY; HIPPOCAMPAL DENTATE GYRUS; TRAUMATIC BRAIN INJURY; CLOSED HEAD-INJURY; MOTOR RECOVERY; DOUBLE-BLIND; LASTING POTENTIATION; VISUAL-CORTEX; BEAM-WALKING	Primary objective: The purpose of this report is to review both fundamental studies in laboratory animals and preliminary clinical data suggesting that certain drugs may affect behavioural recovery after brain injury. Main outcomes and results: Laboratory studies show that systemically-administered drugs that affect specific central neurotransmitters including norepinephrine and GABA influence recovery in a predictable manner. Although some drugs such as d-amphetamine have the potential to enhance recovery, others such as neuroleptics and other central dopamine receptor antagonists, benzodiazepines and the anti-convulsants phenytoin and phenobarbital may be detrimental. In one study, 72% of patients with traumatic brain injury received one or a combination of the drugs that may impair recovery based on both animal experiments and studies in recovering stroke patients. Conclusions: Until the true impact of these classes of drugs are better understood, care should be exercised in the use of medications that may interfere with the recovery process in patients with traumatic brain injury. Additional research needs to be completed before the clinical efficacy of drugs that may enhance recovery can be established.	Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis,Dept Med Neurol, Head Stroke Policy Program,Ctr Clin Hlth Policy R, Durham, NC 27710 USA; Durham Dept Vet Affairs Med Ctr, Durham, NC USA		Goldstein, LB (corresponding author), Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis,Dept Med Neurol, Head Stroke Policy Program,Ctr Clin Hlth Policy R, Box 3651, Durham, NC 27710 USA.						ALTMAN HJ, 1983, BEHAV BRAIN RES, V7, P51, DOI 10.1016/0166-4328(83)90004-9; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; ARTOLA A, 1989, NMDA RECEPTOR, P153; BENVENGA MJ, 1988, PHARMACOL BIOCHEM BE, V30, P205, DOI 10.1016/0091-3057(88)90445-5; BLISS TVP, 1982, TRENDS NEUROSCI, V5, P289, DOI 10.1016/0166-2236(82)90181-3; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; CORBETT D, 1980, BRAIN RES BULL, V5, P637, DOI 10.1016/0361-9230(80)90198-7; CORWIN JV, 1986, EXP NEUROL, V94, P683, DOI 10.1016/0014-4886(86)90247-5; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; CROW TJ, 1968, NATURE, V219, P736, DOI 10.1038/219736a0; DAHL D, 1990, BRAIN RES, V526, P347, DOI 10.1016/0006-8993(90)91245-C; DAHL D, 1989, P NATL ACAD SCI USA, V86, P4776, DOI 10.1073/pnas.86.12.4776; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; DIETRICH WD, 1990, STROKE, V21, P147; DOUGLAS RM, 1983, J COMP NEUROL, V219, P285, DOI 10.1002/cne.902190304; DOUGLAS RM, 1982, BRAIN RES, V240, P259, DOI 10.1016/0006-8993(82)90221-9; DUNBAR G L, 1989, Society for Neuroscience Abstracts, V15, P132; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVERITT BJ, 1983, NEUROSCIENCE, V10, P397, DOI 10.1016/0306-4522(83)90142-2; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; Goldstein LB, 2000, NEUROPHARMACOLOGY, V39, P852, DOI 10.1016/S0028-3908(99)00249-X; GOLDSTEIN LB, 1992, BRAIN RES, V580, P129, DOI 10.1016/0006-8993(92)90936-4; Goldstein LB, 1999, REV NEUROL-FRANCE, V155, P731; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; GOLDSTEIN LB, 1990, STROKE, V21, P139; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; GOLDSTEIN LB, 1990, J NEURO REHAB, V4, P137; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HERNANDEZ TD, 1994, BRAIN RES, V635, P300, DOI 10.1016/0006-8993(94)91451-6; HOPKINS WF, 1984, SCIENCE, V226, P350, DOI 10.1126/science.6091272; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HOVDA DA, 1983, FED PROC, V42, P1157; INNES IR, 1985, PHARMACOL BASIS THER, P477; ITO T, 1988, CAN J PHYSIOL PHARM, V66, P1010, DOI 10.1139/y88-165; KASAMATSU T, 1979, J COMP NEUROL, V185, P163, DOI 10.1002/cne.901850110; KELLER A, 1990, J COMP NEUROL, V300, P47, DOI 10.1002/cne.903000105; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Larsson M, 1988, Compr Gerontol A, V2, P53; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIPSEY JR, 1984, LANCET, V1, P297; Marshall L. F., 1985, CENTRAL NERVOUS SYST, P45; MATHEW RJ, 1985, PSYCHOPHARMACOLOGY, V87, P298, DOI 10.1007/BF00432711; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; MOSKOWITZ MA, 1975, P NATL ACAD SCI USA, V72, P834, DOI 10.1073/pnas.72.3.834; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; PEROUTKA SJ, 1977, NEUROPHARMACOLOGY, V16, P549, DOI 10.1016/0028-3908(77)90023-5; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; REDING MJ, 1995, NEUROLOGY, V45, pA222; REDING MJ, NEUROLOGY S4, V45, P95; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHALLERT T, 1992, PHYS MED REHABIL, V6, P375; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; STANTON PK, 1985, BRAIN RES, V361, P276, DOI 10.1016/0006-8993(85)91299-5; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; SWANSON LW, 1982, NEUROSCI RES PROG B, V20, P612; VANHASSELT P, 1973, NEUROPHARMACOLOGY, V12, P245, DOI 10.1016/0028-3908(73)90109-3; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; VARGO JM, 1989, BEHAV NEUROSCI, V103, P1017, DOI 10.1037/0735-7044.103.5.1017; Walker-Batson D, 2001, STROKE, V32, P2093, DOI 10.1161/hs0901.095720; WALKERBATSON D, 1992, RESTOR NEUROL NEUROS, V4, P47, DOI 10.3233/RNN-1992-4106; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WILLIAMS S, 1988, SCIENCE, V242, P84, DOI 10.1126/science.2845578	86	39	43	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					685	694		10.1080/0269905031000107179			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500006	12850953				2022-02-06	
J	Kroppenstedt, SN; Thomale, UW; Griebenow, M; Sakowitz, OW; Schaser, KD; Mayr, PS; Unterberg, AW; Stover, JF				Kroppenstedt, SN; Thomale, UW; Griebenow, M; Sakowitz, OW; Schaser, KD; Mayr, PS; Unterberg, AW; Stover, JF			Effects of early and late intravenous norepinephrine infusion on cerebral perfusion, microcirculation, brain-tissue oxygenation, and edema formation in brain-injured rats	CRITICAL CARE MEDICINE			English	Article						blood pressure elevation; brain edema; catecholamines; cerebral perfusion; intravital microscopy; laser Doppler flowmetry; orthogonal spectral polarization imaging; traumatic brain injury	CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID GLUTAMATE; BLOOD-FLOW; DOWN-REGULATION; BARRIER; NORADRENALINE; HYPOXANTHINE; METABOLISM; HYPEREMIA; DOPAMINE	Objectives: Reduction of cerebral perfusion during the early phase after traumatic brain injury is followed by a later phase of normal to increased perfusion. Thus, pharmacologically elevating mean arterial blood pressure with the aim of improving cerebral perfusion may exert different time-dependent effects on cortical perfusion, microcirculation, tissue oxygenation and brain edema formation after traumatic brain injury. Design: Randomized, placebo-controlled trial. Setting: Experimental laboratory at a university hospital. Subjects: A total of 37 male Sprague-Dawley rats subjected to a focal cortical contusion. Interventions: At 4 or 24 hrs after focal traumatic brain injury, mean arterial blood pressure was increased to 120 mm Hg for 90 mins by infusing norepinephrine. In rats receiving physiologic saline, mean arterial blood pressure remained unchanged. In the first series, pericontusional cortical perfusion was measured using the laser Doppler flowmetry scanning technique before injury and before, during, and after the infusion period. In a second series, intracranial and cerebral perfusion pressure and intraparenchymal perfusion and tissue oxygen measured within the contused and pericontusional cortex were recorded continuously before, during, and after norepinephrine infusion. Changes in cortical microcirculation were investigated by orthogonal polarization spectral imaging. At the end of each experiment, hemispheric swelling and water content were determined gravimetrically. Measurements and Main Results., At 4 and 24 hrs after traumatic brain injury, intravenous norepinephrine significantly increased pericontusional cortical perfusion, which was also reflected by an increase in diameters and flow velocities of pericontusional arterioles and venules. Cerebral perfusion pressure and intraparenchymal perfusion and tissue oxygen were significantly increased during norepinephrine infusion at 4 and 24 hrs. Hemispheric swelling and water content showed no difference between the groups. Conclusions: After cortical impact injury, early and late intravenous norepinephrine infusion pressure-dependently increased cerebral perfusion and tissue oxygenation without aggravating or reducing brain edema formation. Future studies are warranted to determine long-term changes of short and prolonged norepinephrine-induced increases in mean arterial blood pressure and cerebral perfusion pressure.	Humboldt Univ, Dept Neurosurg, Berlin, Germany; Humboldt Univ, Virchow Med Ctr, Charite, Dept Traumatol & Reconstruct Surg, Berlin, Germany; Oxford Optron, Oxford, England		Stover, JF (corresponding author), Humboldt Univ, Dept Neurosurg, Berlin, Germany.			Sakowitz, Oliver/0000-0003-3248-6335; Misch, Martin/0000-0001-5283-5753			ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Burger R, 1999, J NEUROTRAUM, V16, P1149, DOI 10.1089/neu.1999.16.1149; BUSIJA DW, 1987, J CEREBR BLOOD F MET, V7, P184, DOI 10.1038/jcbfm.1987.42; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; CHIUEH CC, 1978, BRAIN RES, V145, P291, DOI 10.1016/0006-8993(78)90863-6; Dings J, 1998, NEUROL RES, V20, pS71; Dong E, 1999, EUR J PHARMACOL, V384, P17, DOI 10.1016/S0014-2999(99)00652-4; EDVINSSON L, 1978, J PHYSIOL-LONDON, V274, P149, DOI 10.1113/jphysiol.1978.sp012140; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Groner W, 1999, NAT MED, V5, P1209, DOI 10.1038/13529; HARDEBO JE, 1977, ACTA PHYSIOL SCAND, V101, P342, DOI 10.1111/j.1748-1716.1977.tb06016.x; Heck DA, 1997, J PHARMACOL EXP THER, V282, P1219; HEMPELMANN RG, 1993, BRIT J PHARMACOL, V110, P1321, DOI 10.1111/j.1476-5381.1993.tb13963.x; HU ZW, 1992, J CARDIOVASC PHARM, V20, P982, DOI 10.1097/00005344-199212000-00020; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIRKEBY OJ, 1995, J APPL PHYSIOL, V79, P1479, DOI 10.1152/jappl.1995.79.5.1479; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU J, 1993, ARCH BIOCHEM BIOPHYS, V302, P118, DOI 10.1006/abbi.1993.1189; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489, DOI 10.1152/ajplegacy.1976.231.2.489; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MCCALDEN TA, 1977, AM J PHYSIOL, V233, pH458, DOI 10.1152/ajpheart.1977.233.4.H458; Noh JS, 1999, EXP NEUROL, V159, P217, DOI 10.1006/exnr.1999.7144; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; SAVAKI HE, 1982, BRAIN RES, V234, P65, DOI 10.1016/0006-8993(82)90473-5; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Thomale UW, 2001, J NEUROSCI METH, V108, P85, DOI 10.1016/S0165-0270(01)00375-2; Tirone TA, 2001, WORLD J SURG, V25, P461, DOI 10.1007/s002680020338; Unterberg AW, 1997, ACT NEUR S, V70, P106; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287, DOI 10.1152/ajpendo.1988.254.3.E287	48	39	40	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2003	31	8					2211	2221		10.1097/01.CCM.0000080482.06856.62			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712KV	WOS:000184797600020	12973182				2022-02-06	
J	Schoenberg, MR; Duff, K; Scott, JG; Adams, RL				Schoenberg, MR; Duff, K; Scott, JG; Adams, RL			An evaluation of the clinical utility of the OPIE-3 as an estimate of premorbid WAIS-III FSIQ	CLINICAL NEUROPSYCHOLOGIST			English	Article							DEMOGRAPHIC-VARIABLES; COMBINED PERFORMANCE; INTELLIGENCE; SCORES; DEPRESSION; SEVERITY; DECLINE; AGE	The clinical utility of the Oklahoma Premorbid Intelligence Estimate-3 (OPIE-3; Schoenberg, Scott, Duff, & Adams, 2002) in estimating premorbid FSIQ was investigated with the WAIS-III standardization sample. The OPIE-3 algorithms combine Vocabulary, Information, Matrix Reasoning, and Picture Completion subtest raw scores with demographic variables to predict FSIQ. Estimated WAIS-III FSIQ scores are presented for patients' diagnosed with dementia, traumatic brain injury, Huntington's disease, Korsakoff's disease, chronic alcohol use, temporal lobectomy, and schizophrenia. A group of patients with depression was employed as a clinical control group. The OPIE-3V and OPIE-3MR algorithms performed well, with the average predicted FSIQ of the combined clinical sample approximating the mean FSIQ of healthy adults. The OPIE-3(Best), which is a procedure that employs either the OPIE-3V, OPIE-3MR, or OPIE-3(2ST) algorithms in a best performance method, is presented. Recommendations in the application of the OPIE-3 are made and future research is proposed.	Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland, Dept Neurol, Cleveland, OH 44106 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; INTEGRIS Jim Thorpe Rehabil Ctr, Oklahoma City, OK USA; Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA		Schoenberg, MR (corresponding author), Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland, Dept Neurol, 11100 E Euclid Ave, Cleveland, OH 44106 USA.		Schultz, Susan K./M-3516-2019; Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			ALEKOUMBIDES A, 1987, INT J CLIN NEUROPSYC, V9, P11; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 1999, ARCH CLIN NEUROPSYCH, V14, P341, DOI 10.1016/S0887-6177(98)00028-6; BAADE LE, IN PRESS ARCH CLIN N; BOONE KB, 1995, NEUROPSYCHOLOGY, V9, P390, DOI 10.1037/0894-4105.9.3.390; Cockburn J, 2000, J CLIN EXP NEUROPSYC, V22, P508, DOI 10.1076/1380-3395(200008)22:4;1-0;FT508; Cohen J., 2013, STAT POWER ANAL BEHA; COLLINS LF, 2000, THESIS U MEMPHIS, V60, P4210; CORRELL RE, 1985, PSYCHOL REP, V57, P295, DOI 10.2466/pr0.1985.57.1.295; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Franzen MD, 1997, ARCH CLIN NEUROPSYCH, V12, P711, DOI 10.1016/S0887-6177(97)00046-2; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LYNCH JK, 1997, PRACTICE NEUROPSYCHO, P91; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; MURREY GJ, 2000, FORENSIC EVALUATION; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Psychological Corporation, 2001, MAN WECHSL TEST AD R; RUSSELL EW, 1972, J CONSULT CLIN PSYCH, V39, P133, DOI 10.1037/h0033212; SCHINKA JA, 2000, CLIN GUIDE NEUROPSYC; Schoenberg MR, 2002, CLIN NEUROPSYCHOL, V16, P426, DOI 10.1076/clin.16.4.426.13913; Schopp LH, 2001, REHABIL PSYCHOL, V46, P279, DOI 10.1037/0090-5550.46.3.279; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; Silverstein M L, 1990, Arch Clin Neuropsychol, V5, P317, DOI 10.1016/0887-6177(90)90030-S; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	33	39	39	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2003	17	3					308	321		10.1076/clin.17.3.308.18088			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	748DP	WOS:000186847100003	14704882				2022-02-06	
J	Blaha, M; Lazar, D; Winn, RH; Ghatan, S				Blaha, M; Lazar, D; Winn, RH; Ghatan, S			Hemorrhagic complications of intracranial pressure monitors in children	PEDIATRIC NEUROSURGERY			English	Article						intracranial pressure monitoring; complications; children; head injury	TRAUMATIC BRAIN INJURY; CLINICAL-PRACTICE; HEAD TRAUMA; EXPERIENCE; DEVICE; TRIAL; RISK	Intracranial pressure (ICP) monitoring plays a valuable role in the management of head injuries and other causes of raised ICP in the pediatric population. The purpose of this study was to investigate the incidence of hemorrhage after ICP monitor insertion, and to classify these complications in a clinically relevant manner. Hospital charts of 431 children (ages 0-16 years) admitted to a level 1 trauma center over a 2-year period were reviewed and 112 patients (134 insertions) who underwent intraparenchymal ICP monitoring were identified. The authors reviewed postoperative neuroradiological studies. One hundred and nineteen procedures were carried out without any hemorrhage (grade 0). After 10 insertions, a small punctate hemorrhage or localized subarachnoid hemorrhage occurred (grade 1). Three patients sustained an intracerebral hemorrhage that did not require evacuation or manifest as a new neurological deficit (grade 2). There were no hemorrhagic complications that necessitated evacuation or resulted in a noticeable change in the patient's clinical condition (grade 3). We propose a new grading system for hemorrhage after ICP monitor insertion. We found a complication rate close to 10% in our pediatric patients. Fortunately, these hemorrhages were clinically silent and no neurosurgical intervention was necessary. However, grade 1 and grade 2 hemorrhages may manifest with a false reading of high ICP, and the long-term consequences of these complications are not known. Of note, only 23% of these complications were reflected in the patients charts, which may explain the low complication rates reported in other studies that did not analyze postoperative neuroradiological studies.	Childrens Hosp & Med Ctr, Dept Neurol Surg, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA		Ghatan, S (corresponding author), Childrens Hosp & Med Ctr, Dept Neurol Surg, Seattle, WA 98105 USA.	ghatan@u.washington.edu		Blaha, Martin/0000-0002-9611-498X			Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; BLAHA M, 2000, ANEST NEODKL PECE, V2, P54; Bochicchio M, 1996, INTENS CARE MED, V22, P1070, DOI 10.1007/BF01699230; BULLCOK R, 2001, NEUROTRAUMA CRIT FAL; Campisi M, 1989, Minerva Anestesiol, V55, P205; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DEAN JM, 1981, NEUROSURGERY, V9, P627; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Filippi R, 2000, NEUROSURG REV, V23, P94; Guyot LL, 1998, ACT NEUR S, V71, P47; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Lane PL, 2000, CAN J SURG, V43, P442; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Schurer L, 1997, ACT NEUR S, V70, P296; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Spitzfaden AC, 1999, PEDIATR NEUROSURG, V31, P194, DOI 10.1159/000028861; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Winkelman C, 2000, Am J Crit Care, V9, P373; WINN HR, 1977, SURG NEUROL, V8, P41; WOSTER PS, 1990, CLIN PHARMACY, V9, P762; YABLON JS, 1993, J CLIN MONITOR, V9, P171, DOI 10.1007/BF01617024	27	39	40	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	JUL	2003	39	1					27	31		10.1159/000070877			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	690CH	WOS:000183529400008	12784075				2022-02-06	
J	Chua, K; Chuo, A; Kong, KH				Chua, K; Chuo, A; Kong, KH			Urinary incontinence after traumatic brain injury: incidence, outcomes and correlates	BRAIN INJURY			English	Article							STROKE; REHABILITATION	Objectives: To document the incidence and outcome of urinary incontinence (UI) and urinary retention (UR) during acute traumatic brain injury (TBI) rehabilitation and determine associated clinical variables. Methods: Retrospective case series. Results: Eighty-four patients (mean age 44.7+/-17.9 years; 66 males, 18 females) with first-ever TBI within 6 weeks of injury. On admission, UI was present in 52 (62%). UR defined as post-void residual urine volumes of >100 mls was present in eight (9.5%). Forty-six (54.8%) needed external collecting devices and six (7.1%) used indwelling catheters. Bilateral lesions, diabetes mellitus and faecal impaction were present in 70.2, 10.7 and 6.0%, respectively. UI was associated with poorer functional status (measured by the modified Barthel index) and presence of bilateral lesions (p<0.01). UR was associated with diabetes mellitus and faecal impaction (p<0.01). On discharge, 31 (36.9%) remained incontinent. Conclusion: UI is common after acute TBI and is associated with poorer functional outcome.	Tan Tock Seng Hosp, Dept Rehabil Med, Singapore 569766, Singapore; Changi Gen Hosp, Dept Geriatr Med, Singapore, Singapore		Chua, K (corresponding author), Tan Tock Seng Hosp, Dept Rehabil Med, 17,Ang Mo Kio Ave 9, Singapore 569766, Singapore.						ABRAMS P, 1999, CONSENSUS REPORT THE; BENBOW S, 1991, LANCET, V338, P1602, DOI 10.1016/0140-6736(91)92439-9; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; BROCKLEHURST JC, 1985, J AM GERIATR SOC, V33, P540, DOI 10.1111/j.1532-5415.1985.tb04618.x; GARCIA J G, 1990, Brain Injury, V4, P203, DOI 10.3109/02699059009026167; GELBER DA, 1993, STROKE, V24, P378, DOI 10.1161/01.STR.24.3.378; Gross JC, 2000, ARCH PHYS MED REHAB, V81, P22, DOI 10.1016/S0003-9993(00)90216-8; JONGBLOED L, 1986, STROKE, V17, P65; KHAN Z, 1990, UROLOGY, V35, P265, DOI 10.1016/0090-4295(90)80048-R; KHAN Z, 1981, J UROLOGY, V126, P86, DOI 10.1016/S0022-5347(17)54392-X; Kong K. H., 1994, Annals Academy of Medicine Singapore, V23, P319; Kong KH, 2000, ARCH PHYS MED REHAB, V81, P1464, DOI 10.1053/apmr.2000.9630; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; OOSTRA K, 1995, BRAIN INJURY, V10, P459; Owen D C, 1995, Rehabil Nurs, V20, P197; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; WADE D, 1995, ARCH PHYS MED REHAB, V64, P24; WADE DT, 1985, Q J MED, V56, P601; Ween JE, 1996, NEUROLOGY, V47, P659, DOI 10.1212/WNL.47.3.659; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956	22	39	40	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2003	17	6					469	478		10.1080/02699050210154268			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400002	12745703				2022-02-06	
J	Ernest, D; French, C				Ernest, D; French, C			Propofol infusion syndrome - Report of an adult fatality	ANAESTHESIA AND INTENSIVE CARE			English	Article						propofol : cardiac failure; metabolic acidosis; rhabdomyolysis		This report describes a fatal case of the propofol infusion syndrome in an adult patient being sedated for a closed head injury using high doses' of propofol. The features of circulatory collapse, metabolic acidosis, mild rhabdomyolysis and renal impairment are consistent with the syndrome and not readily attributable to alternative aetiologies. Potential mechanisms for the syndrome may relate to antagonism of beta-receptors, impaired myocardial oxygen utilization and a specific disruption to fatty-acid oxidation. This is the first published Australian case of the propofol infusion syndrome in an adult and should serve as an additional case report to the existing literature highlighting this potentially fatal syndrome in adults.	Box Hill Hosp, Intens Care Unit, Box Hill, Vic 3128, Australia; Western Hosp, Melbourne, Vic, Australia		Ernest, D (corresponding author), Box Hill Hosp, Intens Care Unit, Nelson Rd, Box Hill, Vic 3128, Australia.		Ernest, David/I-1699-2013; French, Craig/ABF-5087-2020	French, Craig/0000-0003-1363-9711; /0000-0002-4157-5148			Badr AE, 2001, ANESTHESIOLOGY, V94, P536, DOI 10.1097/00000542-200103000-00030; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; BRUSSEL T, 1989, ANESTH ANALG, V69, P35; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; DIPRIVAN, 2002, 2002 MIMS ANN, P16; Kelly DF, 2001, J NEUROSURG, V95, P925, DOI 10.3171/jns.2001.95.6.0925; Murray M., 2001, ANESTHESIOLOGY, V95, pA378; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	13	39	39	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	2003	31	3					316	319					4	Anesthesiology; Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; General & Internal Medicine	696EQ	WOS:000183873900014	12879680				2022-02-06	
J	Kipnis, J; Nevo, U; Panikashvili, D; Alexandrovich, A; Yoles, E; Akselrod, S; Shohami, E; Schwartz, M				Kipnis, J; Nevo, U; Panikashvili, D; Alexandrovich, A; Yoles, E; Akselrod, S; Shohami, E; Schwartz, M			Therapeutic vaccination for closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; autoimmune neuroprotection; strain differences; CNS inflammation; EAE-susceptibility; Cop-1 (Glatiramer acetate)	SPINAL-CORD INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; T-CELL LINES; RETINAL GANGLION-CELLS; MULTIPLE-SCLEROSIS; COPOLYMER 1; OPTIC-NERVE; PROTECTIVE AUTOIMMUNITY	Closed head injury often has a devastating outcome, partly because the insult, like other injuries to the central nervous system (CNS), triggers self-destructive processes. During studies of the response to other CNS insults, it was unexpectedly discovered that the immune system, if well controlled, provides protection against self-destructive activities. Here we show that in mice with closed head injury, the immune system plays a key role in the spontaneous recovery. Strain-related differences were observed in the ability to harness a T cell-dependent protective mechanism against the effects of the injury. We further show that the trauma-induced deficit could be reduced, both functionally and anatomically, by post-traumatic vaccination with Cop-1, a synthetic copolymer used to treat patients with multiple sclerosis and found (using a different treatment protocol) to effectively counteract the loss of neurons caused by axonal injury or glutamate-induced toxicity. We suggest that a compound such as Cop-1 can be safely developed as a therapeutic vaccine to boost the body's immune repair mechanisms, thereby providing multifactorial protection against the consequences of brain trauma.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sch Phys & Astron, Dept Med Phys, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.						Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; Aharoni R, 2002, J NEUROIMMUNOL, V126, P58, DOI 10.1016/S0165-5728(02)00053-X; Antel JP, 1999, J NEUROIMMUNOL, V100, P181, DOI 10.1016/S0165-5728(99)00186-1; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bar-Or A, 1999, J NEUROIMMUNOL, V100, P252, DOI 10.1016/S0165-5728(99)00193-9; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BENNUN A, 1982, J IMMUNOL, V129, P303; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; Benton RL, 2001, BRAIN RES, V893, P292, DOI 10.1016/S0006-8993(00)02995-4; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dal Canto MC, 2000, J NEUROIMMUNOL, V104, P79, DOI 10.1016/S0165-5728(99)00230-1; Farina C, 2001, BRAIN, V124, P705, DOI 10.1093/brain/124.4.705; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI200112837; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Kipnis J, 2002, TRENDS MOL MED, V8, P319, DOI 10.1016/S1471-4914(02)02373-0; Kipnis J, 2002, J NEUROIMMUNOL, V130, P78, DOI 10.1016/S0165-5728(02)00219-9; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KIPNIS J, 2002, P NATL ACAD SCI USA, V12, P12; Lundberg C, 2001, J COMP NEUROL, V431, P75; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; Mizrahi T, 2002, J IMMUNOL, V169, P5971, DOI 10.4049/jimmunol.169.10.5971; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Neumann H, 2000, J NEURAL TRANSM-SUPP, P59; Nevo U, 2003, TRENDS MOL MED, V9, P88, DOI 10.1016/S1471-4914(03)00024-8; O'Connor KC, 2001, J CLIN IMMUNOL, V21, P81, DOI 10.1023/A:1011064007686; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Schori H, 2001, J NEUROIMMUNOL, V119, P199, DOI 10.1016/S0165-5728(01)00358-7; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schwartz M, 2000, INVEST OPHTH VIS SCI, V41, P349; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Schwartz M, 2001, SURV OPHTHALMOL, V45, pS256, DOI 10.1016/S0039-6257(01)00208-9; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; Schwartz M, 2001, J MOL MED-JMM, V78, P594, DOI 10.1007/s001090000172; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Schwartz M, 1999, MOL MED TODAY, V5, P470, DOI 10.1016/S1357-4310(99)01592-0; Sela M, 1999, Int Rev Immunol, V18, P201, DOI 10.3109/08830189909043025; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Solberg Y, 1999, SURV OPHTHALMOL, V44, pS85, DOI 10.1016/S0039-6257(99)00093-4; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Streilein JW, 2000, ANN NY ACAD SCI, V917, P297; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Teitelbaum D, 1999, P NATL ACAD SCI USA, V96, P3842, DOI 10.1073/pnas.96.7.3842; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Weiner HL, 1999, P NATL ACAD SCI USA, V96, P3333, DOI 10.1073/pnas.96.7.3333; Wekerle H, 1996, IMMUNOL REV, V149, P231, DOI 10.1111/j.1600-065X.1996.tb00907.x; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROTRAUM, V18, P339, DOI 10.1089/08977150151071017; Yoon DH, 1999, YONSEI MED J, V40, P313, DOI 10.3349/ymj.1999.40.4.313	67	39	43	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					559	569		10.1089/089771503767168483			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900004	12906740				2022-02-06	
J	Konrad, K; Gauggel, S; Schurek, J				Konrad, K; Gauggel, S; Schurek, J			Catecholamine functioning in children with traumatic brain injuries and children with attention-deficit/hyperactivity disorder	COGNITIVE BRAIN RESEARCH			English	Article						attention-deficit/hyperactivity disorder; traumatic brain injury; urinary catecholamines; eyeblink rate	DEFICIT-HYPERACTIVITY DISORDER; CORTICAL COGNITIVE FUNCTION; INHIBITORY CONTROL; HEAD-INJURY; ADHD; EPINEPHRINE; MECHANISMS	Recent studies suggest that children with attention-deficit/hyperactivity disorder (ADHD) and children with traumatic brain injuries (TBI) show changes in similar neuronal networks, including the dopaminergic (DA) and norepinephrinergic (NA) systems. Therefore, indirect measures of catecholamine activity were assessed. Twenty-six children with TBI, 31 children with ADHD, and 26 normal controls, 8 to 12 years of age, were investigated with a 90-min cognitive test battery. Before and after the tests, urine samples were collected to measure catecholamine activity in response to cognitive stress. Spontaneous eyeblinking as an indirect measure of DA activity was counted. Children with TBI and ADHD excreted significantly more normetanephrine in resting situations and less epinephrine (EPI) after cognitive stress, and showed a decreased blink rate compared to normal controls. Children with TBI also showed a higher excretion of metanephrine in the resting situation in comparison to children with ADHD and controls. Whereas children with ADHD showed a higher tonic activity of the NA system and a less adaptive EPI excretion in response to cognitive stress, children with TBI seem to be additionally impaired in their tonic EPI excretion. Our study provides further support for similar but also different neurobiochemical characteristics in both groups. (C) 2003 Elsevier Science B.V. All rights reserved.	Rhein Westfal TH Aachen, Dept Child & Adolescent Psychiat, D-52074 Aachen, Germany; Univ Technol Chemnitz, Dept Psychol, Chemnitz, Germany; Univ Marburg, Dept Clin Chem, Marburg, Germany		Konrad, K (corresponding author), Rhein Westfal TH Aachen, Dept Child & Adolescent Psychiat, Neuenhofer Weg 21, D-52074 Aachen, Germany.	kerstin.konrad@kjp.rwth-anchen.de	Konrad, Kerstin/H-7747-2013	Konrad, Kerstin/0000-0001-9039-2615; Gauggel, Siegfried/0000-0002-2742-4917			Anderson GM, 2000, J AM ACAD CHILD PSY, V39, P635, DOI 10.1097/00004583-200005000-00018; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; Arnsten AFT, 1996, ARCH GEN PSYCHIAT, V53, P448; Caplan R, 1996, BIOL PSYCHIAT, V39, P1032, DOI 10.1016/0006-3223(95)00315-0; Cyr M, 1998, DRUGS, V56, P215, DOI 10.2165/00003495-199856020-00005; DAUGHERTY TK, 1993, J GENET PSYCHOL, V154, P177, DOI 10.1080/00221325.1993.9914731; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Dopfner M., 1998, DIAGNOSTIK SYSTEM PS; ELIA J, 1990, CLIN PHARMACOL THER, V48, P57, DOI 10.1038/clpt.1990.118; ELWOOD SW, 1986, J HUM STRESS, V12, P154, DOI 10.1080/0097840X.1986.9936782; GLOWINSKI J, 1984, CIBA F SYMP, V107, P150; Halperin JM, 1997, J AM ACAD CHILD PSY, V36, P1688, DOI 10.1097/00004583-199712000-00017; Hanna GL, 1996, BIOL PSYCHIAT, V40, P553, DOI 10.1016/0006-3223(96)00103-5; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; KARSON CN, 1983, BRAIN, V106, P643, DOI 10.1093/brain/106.3.643; KHAN AU, 1981, AM J PSYCHIAT, V138, P108; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; MAAS JW, 1983, MHPG BASIC MECHANISM, P33; Pliszka SR, 1996, J AM ACAD CHILD PSY, V35, P264, DOI 10.1097/00004583-199603000-00006; PLISZKA SR, 1994, J AM ACAD CHILD PSY, V33, P1165, DOI 10.1097/00004583-199410000-00012; PYCOCK CJ, 1980, NATURE, V286, P74, DOI 10.1038/286074a0; RANDOLPH C, 1992, BRAIN INJURY, V12, P383; Roozendaal B, 1996, P NATL ACAD SCI USA, V93, P1429, DOI 10.1073/pnas.93.4.1429; SCHACHAR R, 1989, UNPUB PARENT INTERVI; Solanto MV, 2000, NEUROSCI BIOBEHAV R, V24, P27, DOI 10.1016/S0149-7634(99)00061-5; Swanson JM, 1998, MOL PSYCHIATR, V3, P38, DOI 10.1038/sj.mp.4000354; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TUCHMAN M, 1985, PEDIATRICS, V75, P324; UNNEWEHR S, 1995, DIAGNOSTISCHES INTER; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Williams SM, 1998, CEREB CORTEX, V8, P321, DOI 10.1093/cercor/8.4.321; ZAMETKIN AJ, 1979, ANN NEUROL, V5, P453, DOI 10.1002/ana.410050509	35	39	39	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0926-6410			COGNITIVE BRAIN RES	Cognit. Brain Res.	MAY	2003	16	3					425	433		10.1016/S0926-6410(03)00057-0			9	Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science; Neurosciences & Neurology	677MW	WOS:000182813000011	12706222				2022-02-06	
J	Regard, M; Knoch, D; Gutling, E; Landis, T				Regard, Marianne; Knoch, Daria; Guetling, Eva; Landis, Theodor			Brain Damage and Addictive Behavior: A Neuropsychological and Electroencephalogram Investigation With Pathologic Gamblers	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						Cerebral dysfunction; Impulse control disorder; Pathologic gambling		Background: Gambling is a form of nonsubstance addiction classified as an impulse control disorder. Pathologic gamblers are considered healthy with respect to their cognitive status. Lesions of the frontolimbic systems, mostly of the right hemisphere, are associated with addictive behavior. Because gamblers are not regarded as "brain-lesioned" and gambling is nontoxic, gambling is a model to test whether addicted "healthy" people are relatively impaired in frontolimbic neuropsychological functions. Methods: Twenty-one nonsubstance dependent gamblers and nineteen healthy subjects underwent a behavioral neurologic interview centered on incidence, origin, and symptoms of possible brain damage, a neuropsychological examination, and an electroencephalogram. Results: Seventeen gamblers (81%) had a positive medical history for brain damage (mainly traumatic head injury, pre- or perinatal complications). The gamblers, compared with the controls, were significantly more impaired in concentration, memory, and executive functions, and evidenced a higher prevalence of non-right-handedness (43%) and, non-left-hemisphere language dominance (52%). Electroencephalogram (EEG) revealed dysfunctional activity in 65% of the gamblers, compared with 26% of controls. Conclusions: This study shows that the "healthy" gamblers are indeed brain-damaged. Compared with a matched control population, pathologic gamblers evidenced more brain injuries, more fronto-temporo-limbic neuropsychological dysfunctions and more EEG abnormalities. The authors thus conjecture that addictive gambling may be a consequence of brain damage, especially of the frontolimbic systems, a finding that may well have medicolegal consequences.	[Regard, Marianne] Univ Zurich Hosp, Dept Neurol, Neuropsychol Unit, CH-8091 Zurich, Switzerland; Univ Hosp, Dept Neurol, Geneva, Switzerland		Regard, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Neuropsychol Unit, CH-8091 Zurich, Switzerland.	mregard@npsy.unizh.ch	Knoch, Daria/H-7324-2012		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32.40682.94]	The authors thank Drs. Maria Stegmann and Mario Gmur and Gambler's Anonymous, Zurich, Switzerland, for their help in assessing and recruiting subjects. This study was supported in part by the Swiss National Science Foundation grant No. 32.40682.94.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI 10.1016/S0028-3932(02)00016-7; Brickenkamp R., 1981, TEST D2 AUFMERKSAMKE, V7th ed.; CARLTON PL, 1992, NEUROPSYCHOBIOLOGY, V25, P44, DOI 10.1159/000118808; CARLTON PL, 1987, J CLIN PSYCHIAT, V48, P487; Cavedini P, 2002, BIOL PSYCHIAT, V51, P334, DOI 10.1016/S0006-3223(01)01227-6; CHAPMAN LJ, 1987, BRAIN COGNITION, V6, P175, DOI 10.1016/0278-2626(87)90118-7; Crockford DN, 1998, CAN J PSYCHIAT, V43, P43, DOI 10.1177/070674379804300104; Cummings JL, 1997, BRAIN LANG, V57, P22, DOI 10.1006/brln.1997.1832; De Marchi N, 1998, ACTA PSYCHIAT SCAND, V97, P62; GESCHWIND N, 1982, P NATL ACAD SCI-BIOL, V79, P5097, DOI 10.1073/pnas.79.16.5097; Glosser G, 2000, J NEUROL NEUROSUR PS, V68, P53, DOI 10.1136/jnnp.68.1.53; GOLDENBERG G, 1989, BEHAV NEUROL, V2, P79; GOLDSTEIN L, 1985, BIOL PSYCHIAT, V20, P1232, DOI 10.1016/0006-3223(85)90180-5; Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980; Knecht T, 1993, Arch Kriminol, V191, P65; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; Nyffeler T, 2001, NEUROPSY NEUROPSY BE, V14, P73; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Potenza M N, 2001, Semin Clin Neuropsychiatry, V6, P217, DOI 10.1053/scnp.2001.22929; Potenza MN, 2001, JAMA-J AM MED ASSOC, V286, P141, DOI 10.1001/jama.286.2.141; Rahman S, 1999, BRAIN, V122, P1469, DOI 10.1093/brain/122.8.1469; Regard M, 1997, NEUROLOGY, V48, P1185, DOI 10.1212/WNL.48.5.1185; REGARD M, 1994, NEUROPSY NEUROPSY BE, V7, P303; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; REGARD M, 1985, NEUROPSYCHOLOGIA, V23, P431, DOI 10.1016/0028-3932(85)90031-4; Regard M, 1983, THESIS, V43, P2714; Rosenberg DR, 1997, J PSYCHIATR NEUROSCI, V22, P29; Rosenthal R J, 1997, Psychoanal Rev, V84, P593; RUGLE L, 1993, J NERV MENT DIS, V181, P107, DOI 10.1097/00005053-199302000-00006; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Soutullo CA, 1998, PSYCHIAT ANN, V28, P592, DOI 10.3928/0048-5713-19981001-10; Specker S M, 1995, Ann Clin Psychiatry, V7, P175, DOI 10.3109/10401239509149623; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Trimble MR, 1997, J NEUROPSYCH CLIN N, V9, P429	40	39	42	2	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1543-3633			COGN BEHAV NEUROL	Cogn. Behav. Neurol.	MAR	2003	16	1					47	53		10.1097/00146965-200303000-00006			7	Behavioral Sciences; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	V21VM	WOS:000208235100006	14765001				2022-02-06	
J	Bounds, TA; Schopp, L; Johnstone, B; Unger, C; Goldman, H				Bounds, TA; Schopp, L; Johnstone, B; Unger, C; Goldman, H			Gender differences in a sample of vocational rehabilitation clients with TBI	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; INDIVIDUALS; WOMEN	Because traumatic brain injury affects between 1.5 and 2 mil lion individuals per year and results in long term vocational and financial difficulties, there is growing interest in determining those factors that predict successful outcomes for specific groups of individuals with TBI. An NIH consensus panel on TBI has suggested that women are one group that needs more attention, particularly given the studies indicating that men and women experience different cognitive [ 141, emotional [ 19], and vocational outcomes following TBI [5]. The current study evaluated differences in injury severity, demographics, neuropsychological abilities, and vocational and financial outcomes for 78 persons with TBI (55 male, 23 female) who received services from a state Vocational Rehabilitation Division (DVR). Despite similar injury severity, neuropsychological and demographic characteristics, more men (43.6%) received Maintenance services from MO-DVR than women (21.7%). Of note, only 4.4% of the women were successfully employed through DVR, compared to 23.6% of the men. In addition, 73.9% of the women had services terminated after being accepted by DVR but before services were initiated, compared to 56.4% of the men. The significance of these results is discussed, as are the limitations of the current project.	Univ Missouri, Sch Med, Dept Hlth Psychol, Columbia, MO 65212 USA; Missouri Dept Elementary & Secondary Educ, Div Vocat Rehabil, Jefferson City, MO 65102 USA		Bounds, TA (corresponding author), Univ Missouri, Sch Med, Dept Hlth Psychol, DC046-46,1 Hosp Dr, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			BROOKS N, 1987, BRAIN INJURY, V10, P5; CHANSKY NM, 1966, VOCAT GUID QUART, V15, P71, DOI 10.1002/j.2164-585X.1966.tb01162.x; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FINE M, 1988, WOMEN DISABILITIES; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HARRISON DK, 1985, J APPL REHABILITATIO, V17, P14; HOLVEY JM, 1986, J APPL REHABILITATIO, V17, P51; HURT GD, 2000, NEUROPSYCHOLOGICAL M; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; KIMURA D, 1992, SCI AM, V267, P119; KLVE H, 1963, MED CLIN N AM; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; *NIH, 1999, REH PERS TRAUM BRAIN; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Reitan RM, 1992, TRAIL MAKING TEST MA; Reitan RM, 1985, HALSTEADREITAN NEURO; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *TRAUM BRAIN INJ M, 2000, TBI FACTS FIGURES, V6; TREIMAN DJ, 1975, AM SOCIOL REV, V40, P174, DOI 10.2307/2094344; TURKHEIMER E, 1992, PSYCHOLOGICAL ASSESS, V4, P8; WECHSLER D, 1997, WMS, V3; Wechsler D, 1997, WAIS, VIII; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; [No title captured]	27	39	39	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2003	18	3					189	196					8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	733ZZ	WOS:000186031900002	14530583				2022-02-06	
J	Oehmichen, M; Walter, T; Meissner, C; Friedrich, HJ				Oehmichen, M; Walter, T; Meissner, C; Friedrich, HJ			Time course of cortical hemorrhages after closed traumatic brain injury: Statistical analysis of posttraumatic histomorphological alterations	JOURNAL OF NEUROTRAUMA			English	Article						cortical hemorrhage; histomorphological criteria; statistical evaluation; time course; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; SPINAL-CORD-INJURY; HEAD-INJURY; NEURONAL DEGENERATION; AXONAL INJURY; ADULT-RAT; CONTUSIONS; ACCUMULATION; ASTROCYTES; EXPRESSION	We examined 305 autopsied brains for histomorphological alterations to determine the time course of reactions in cortical hemorrhages following traumatic closed brain injury. Eighteen morphological criteria were considered: red blood cells (RBCs), polymorphonuclear leukocytes (PMNs), macrophages (Ms), RBC-containing Ms, hemosiderin, hematoidin, lipid-containing Ms, fibroblasts, endothelial cells, collagenous fibres, gemistocytic astrocytes, fibrillary gliosis, hemosiderin-containing astrocytes, neuronal damage, neuronophagy, axonal swelling (beta-amyloid precursor protein: beta-APP), axonal bulbs (van Gieson stairi), and mineralisation of neurons. The interval between the time of brain injury and death ranged from 1 min to 58 years. Following routine staining and immunohistochemical staining of microglia (CD68), astrocytes (GFAP) and injured axons (beta-APP), paraffin sections were examined by light microscopy for the presence of the selected histomorphological features. For each cytomorphological phenomenon, the time at which it could be demonstrated for the first time and for the last time (observation period) was determined. The relative frequency of each criterion was established for each observation period. The limits of confidence for the respective relative frequencies were estimated with a reliability of 95% according to Clopper and Pearson. An apparent correlation was found between the frequency of a given histomorphological phenomenon and the length of the posttraumatic interval. To check for accuracy of prediction, half of the cases (group 1; n = 153) were used to develop a multistage evaluation model; half (group 2; n = 152) were used to evaluate the validity of the data of group 1. Applying this model, 117 of the 152 control group cases (76.97%) could be correctly classified and further 26 cases (17.11%) being assigned to an interval close to the correct interval. Thus, this model allows classification of the correct posttraumatic interval or an interval close to the correct posttraumatic interval in about 95% of cases. We developed a software program that allows the estimation of survival time of TBI based on the relative frequency of the 18 morphological features. Applying this software will help to estimate the posttraumatic interval of cortical hemorrhages following TBI of unknown survival time (till.walter@t-online.de).	Med Univ Lubeck, Inst Legal Med, D-23562 Lubeck, Germany; Univ Kiel, Inst Legal Med, Kiel, Germany; Med Univ Lubeck, Inst Med Biometry & Stat, D-23538 Lubeck, Germany		Oehmichen, M (corresponding author), Med Univ Lubeck, Inst Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.	oehmich@rmed.mu-luebeck.de					ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Adams RD, 1968, INTRO NEUROPATHOLOGY; Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Baldwin SA, 1998, J NEUROTRAUM, V15, P1015, DOI 10.1089/neu.1998.15.1015; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BAZZAZ AA, 1995, NEUROPATHOL APPL NEU, V21, P447; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cizkova D, 2000, CELL MOL NEUROBIOL, V20, P367, DOI 10.1023/A:1007018327133; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; COLMANT GW, 1963, ZEREBRALE HYPOXIE; COOPER CJ, 1934, BIOMETRIKA, V26, P404; COURVILLE CB, 1964, FORENSIC NEUROPATHOL; EISENMENGER W, 1977, THESIS MUNCHEN; ENG LF, 1983, PROG NEUROPATH, V5, P19; Engel S, 1996, ACT NEUR S, V66, P87; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; HALBHUBER KJ, 1995, WOUND HEALING PROCES, P203; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOWARTH F., 1955, ACTA ANAT, V25, P112; JACOB H, 1961, Dtsch Z Gesamte Gerichtl Med, V51, P352, DOI 10.1007/BF00575848; KENNADY JC, 1967, PAC MED SURG, V75, P163; Kimelberg HK, 1997, RES LEG MED, V17, P295; Kleinbaum D. G., 1998, LOGISTIC REGRESSION; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Krauland W, 1973, Beitr Gerichtl Med, V30, P226; LAIHO K, 1995, WOUND HEALING PROCES, P229; Lassmann H, 1997, RES LEG MED, V17, P253; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; LOBERG EM, 1992, ACTA NEUROPATHOL, V84, P234; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Meyermann R, 1997, RES LEG MED, V17, P261; MOSSAKOWSKI M J, 1972, Neuropatologia Polska, V10, P317; Muller G, 1930, Z GESAMTE NEUROL PSY, V124, P1, DOI 10.1007/BF02865091; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; Oehmichen M, 1997, RES LEG MED, V17, P203; Oehmichen M, 1981, Beitr Gerichtl Med, V39, P57; OEHMICHEN M, 1986, FORENSIC SCI INT, V30, P281, DOI 10.1016/0379-0738(86)90136-2; OEHMICHEN M, 1990, WUNDHEILUNG; OEHMICHEN M, 1995, WOUND HEALING PROCES, P15; OEHMICHEN M, 1978, MONONUCLEAR PHAGOCYT; PETERS G, 1955, HDB SPEZIELLEN PATHO, V13, P363; Povlishock John T., 1995, P504; Povlishock JT, 1997, RES LEG MED, V17, P175; RUBINSTEIN LJ, 1962, J NEUROPATH EXP NEUR, V21, P116, DOI 10.1097/00005072-196201000-00010; RYAN GA, 1994, J TRAUMA, V36, P469; SACHS L, 1994, STAT STAT METHODEN I; SAMPEDRO MN, 1998, SCIENCE, V240, P1784; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHRODER R, 1998, CHRONOMORPHOLOGIE ZE; SELLIER K, 1963, HEFTE UNFALLHEILKUND, V76; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Soares HD, 1995, J NEUROSCI, V15, P8223; Spielmeyer W, 1922, HISTOPATHOLOGIE NERV; STRASSMANN G, 1949, ARCH PATHOL, V47, P205; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Van Gieson J., 1889, NEW YORK MED J, V50, P57; [No title captured]	60	39	41	1	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2003	20	1					87	103		10.1089/08977150360517218			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	641BB	WOS:000180723200008	12614591				2022-02-06	
J	Pong, K; Zaleska, MM				Pong, Kevin; Zaleska, Margaret M.			Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; cerebral ischemia; immunophilin ligands; Parkinson's disease; neurodegeneration; spinal cord injury; traumatic brain injury		There is a significant unmet need for therapeutic agents in the treatment of neurodegenerative diseases. Given their clinical importance, prototypical molecules that clearly exhibit both neuroprotective and neuroregenerative activities have been highly sought after. The journey led to the exploitation of neurotrophins, a family of proteins that had extraordinary therapeutic properties in pre-clinical models of neurodegeneration. Although experimentally promising, clinical development of neurotrophins for various neurological indications, such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Parkinson's Disease was met with severe obstacles and setbacks, such as the inability to deliver these large proteins to target population of neurons, instability of the proteins, and non-specific activity. Immunophilins are proteins that act as receptors for immunosuppresant drugs, i.e. FK506 (tacrolimus), cyclosporin A, and rapamycin (sirolimus, Rapamune). Studies indicate immunophilins are expressed 10-100 fold higher in CNS and PNS tissue than in immune tissue. Subsequent studies revealed potent neuroprotective and neuroregenerative properties of immunophilin ligands in both culture and animal models. In contrast to neurotrophins, most immunophilin ligands are highly stable, small molecules that can readily cross the blood-brain barrier and are orally bioavailable. Taken together, these data prompted the development of nonimmunosuppressive immunophilin ligands with potent therapeutic activities, although the potency of select compounds has come into question in more recent studies. This review will examine the experimental evidence supporting the use of immunophilin ligands for the treatment of neurodegenerative diseases and the current progression of these molecules in clinical trials.	[Pong, Kevin; Zaleska, Margaret M.] Wyeth Res, Dept Neurosci, CN 8000, Princeton, NJ 84543 USA		Pong, K (corresponding author), Wyeth Res, Dept Neurosci, CN 8000, Princeton, NJ 84543 USA.	pongk@wyeth.com					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Anneser JMH, 2001, NEUROREPORT, V12, P2663, DOI 10.1097/00001756-200108280-00015; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Becker DB, 2000, J RECONSTR MICROSURG, V16, P613, DOI 10.1055/s-2000-9379; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; Bocquet A, 2001, EUR J PHARMACOL, V415, P173, DOI 10.1016/S0014-2999(01)00850-0; Butcher SP, 1997, J NEUROSCI, V17, P6939; Carreau A, 1997, NEUROPHARMACOLOGY, V36, P1755, DOI 10.1016/S0028-3908(97)00160-3; Castilho RF, 2000, EXP NEUROL, V164, P94, DOI 10.1006/exnr.2000.7405; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 2000, NEUROSCIENCE, V100, P515, DOI 10.1016/S0306-4522(00)00312-2; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; Costantini LC, 2001, EUR J NEUROSCI, V13, P1085, DOI 10.1046/j.0953-816x.2001.01473.x; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Eberling JL, 2002, EXP NEUROL, V178, P236, DOI 10.1006/exnr.2002.8023; Emborg ME, 2001, EXP NEUROL, V168, P171, DOI 10.1006/exnr.2000.7592; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo X, 2001, ANN NEUROL, V50, P6, DOI 10.1002/ana.1030; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; Hamilton GS, 2002, J MED CHEM, V45, P3549, DOI 10.1021/jm010556c; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Harper S, 1999, NEUROSCIENCE, V88, P257, DOI 10.1016/S0306-4522(98)00221-8; Herr I, 1999, BRAIN RES, V826, P210, DOI 10.1016/S0006-8993(99)01288-3; Iwasaki Y, 2002, NEUROL RES, V24, P573, DOI 10.1179/016164102101200555; Kealey J.T, 2003, FRONT BIOSCI C, V8, P1; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Keswani SC, 2003, ANN NEUROL, V53, P57, DOI 10.1002/ana.10401; Khan Z, 2002, NEUROSCIENCE, V114, P601, DOI 10.1016/S0306-4522(02)00314-7; KITAMURA Y, 1994, J NEUROIMMUNOL, V50, P221; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Lench NJ, 1997, HUM GENET, V99, P547, DOI 10.1007/s004390050404; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Li PA, 2001, BRAIN RES, V890, P306, DOI 10.1016/S0006-8993(00)03179-6; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; LYONS WE, 1995, J NEUROSCI, V15, P2985; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Nakai A, 1997, NEUROBIOL DIS, V4, P288, DOI 10.1006/nbdi.1997.0146; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Parker EM, 2000, NEUROPHARMACOLOGY, V39, P1913, DOI 10.1016/S0028-3908(00)00028-9; Pong K, 2003, EXPERT OPIN BIOL TH, V3, P127; Revill WP, 2002, J PHARMACOL EXP THER, V302, P1278, DOI 10.1124/jpet.102.034264; Ross DT, 2001, NEUROSCI LETT, V297, P113, DOI 10.1016/S0304-3940(00)01683-9; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sauer H, 1999, BRAIN RES, V842, P109, DOI 10.1016/S0006-8993(99)01851-X; Sezen SF, 2001, NAT MED, V7, P1073, DOI 10.1038/nm1001-1073; Sharkey J, 1996, STROKE, V27, P2282, DOI 10.1161/01.STR.27.12.2282; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shefner JM, 2001, NEUROLOGY, V57, P1857, DOI 10.1212/WNL.57.10.1857; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Shiraishi S, 2001, J PHARMACOL EXP THER, V297, P657; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Small SL, 1996, ANN NEUROL, V40, P575, DOI 10.1002/ana.410400406; Springer JE, 2000, J NEUROSCI, V20, P7246; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Sugawara T, 1999, NEUROREPORT, V10, P3949, DOI 10.1097/00001756-199912160-00041; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TALUKDER G, 1995, J NEUROPHYSIOL, V73, P73, DOI 10.1152/jn.1995.73.1.73; Tanaka K, 2002, NEUROSCI LETT, V321, P45, DOI 10.1016/S0304-3940(01)02547-2; Tanaka K, 2002, NEUROSCI LETT, V330, P147, DOI 10.1016/S0304-3940(02)00755-3; Tanaka K, 2001, BRAIN RES, V889, P225, DOI 10.1016/S0006-8993(00)02851-1; Tanaka K, 2000, ACTA MED OKAYAMA, V54, P275; Tanaka KI, 2002, SYNAPSE, V43, P219, DOI 10.1002/syn.10031; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Terashima A, 1998, BRAIN RES, V786, P255, DOI 10.1016/S0006-8993(97)01435-2; Terashima A, 2000, NEUROPHARMACOLOGY, V39, P1920, DOI 10.1016/S0028-3908(00)00015-0; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang M S, 1999, J Spinal Cord Med, V22, P287; Wu YQ, 2002, J MED CHEM, V45, P3558, DOI 10.1021/jm0200456; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Zhang CY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0002.2001; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998	91	39	41	0	0	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2003	2	6					349	356		10.2174/1568007033482652			8	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5WX	WOS:000497811900001	14683462				2022-02-06	
J	Servadei, F; Verlicchi, A; Soldano, F; Zanotti, B; Piffer, S				Servadei, F; Verlicchi, A; Soldano, F; Zanotti, B; Piffer, S			Descriptive epidemiology of head injury in Romagna and Trentino	NEUROEPIDEMIOLOGY			English	Article						head injury; epidemiology; hospital registry; prevention; bicycles; road accidents; Italy	TRAUMATIC BRAIN INJURY; UNITED-STATES; POPULATION; TRENDS; FEATURES; COUNTY	We studied the occurrence of head injury in two different Italian regions: Romagna and Trentino. Both geographical areas attract large numbers of seasonal tourists. The study was carried out over 1 year (January 1, 1998 to December 31, 1998), prospectively in Romagna and retrospectively in Trentino because of their different head injury management protocols. The study was based on all admissions to hospital extracted by medical staff from the case records, and all cases were identified by the ICD-9 codes (ranges: 800.0-800.3, 801.0-801.3, 803.0-803.3, 850, 851.0-851.1, 852.0-852.1, 853.0-853.1, 854.0-854.1). The annual incidence of hospitalization for head injury was 314/100,000, 297 for Romagna and 332 for Trentino. The causes of head trauma and the type of injuries were similar to those reported in the international literature, and so were the characteristics of the population at risk. Romagna recorded a higher incidence of head injury among the elderly, probably due to the widespread use of bicycles without safety helmets. In Romagna, where neurosurgery departments exist, hospital mortality was low (8/100,000/year). Based on similar international literature findings, different prevention measures are suggested to reduce the occurrence and severity of head injury. Copyright (C) 2002 S. Karger AG, Basel.	Maurizio Bufalini Hosp, Div Neurotraumatol, I-47023 Cesena, Italy; Santa Chiara Hosp, Div Neurol, Trento, Italy; Azienda Provinciale Serv Sanitari, Observ Epidemiol, Trent, Italy; Univ Udine, Fac Med, Dept Med Stat, I-33100 Udine, Italy; Santa Maria Misericordia Hosp, Div Neurosurg, Udine, Italy; Borgo Trento City Hosp, Dept Neurosurg, Verona, Italy		Servadei, F (corresponding author), Maurizio Bufalini Hosp, Div Neurotraumatol, I-47023 Cesena, Italy.			Servadei, Franco/0000-0002-3595-3464			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; BAKER SP, 1984, INJURY FACT BOOK, P27; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GRAHAM D, 1986, SERIES, V13; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hillier SL, 1997, BRAIN INJURY, V11, P649; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; MacKenzie E J, 1989, Md Med J, V38, P725; MCSWAIN NE, 1984, J TRAUMA, V24, P233, DOI 10.1097/00005373-198403000-00009; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; Servadei F, 1985, J Neurosurg Sci, V29, P297; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; SERVADEI F, 1993, PROF SANIT PUBBLICA, V2, P50; SERVADEI F, 1993, TRAUMI RICERCA PREVE, P39; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1997, INCIDENTALITA STRADA; 1990, CONSUMER REP, V55, P348	35	39	40	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350			NEUROEPIDEMIOLOGY	Neuroepidemiology	NOV-DEC	2002	21	6					297	304		10.1159/000065523			8	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Neurosciences & Neurology	616DX	WOS:000179287400006	12411733				2022-02-06	
J	Kinoshita, K; Chatzipanteli, K; Alonso, OF; Howard, M; Dietrich, WD				Kinoshita, K; Chatzipanteli, K; Alonso, OF; Howard, M; Dietrich, WD			The effect of brain temperature on hemoglobin extravasation after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						hemoglobin; traumatic brain injury; hypothermia; hyperthermia; secondary injury; rat	CORTICAL IMPACT INJURY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; PERMEABILITY CHANGES; BARRIER DISRUPTION	Object. Although the benefits of posttraumatic hypothermia have been reported in experimental studies, the potential for therapeutic hypothermia to increase intracerebral hemorrhage remains a clinical concern. The purpose of this study was to quantify the amount of extravasated hemoglobin after traumatic brain injury (TBI) and to assess the charges in intracerebral hemoglobin concentrations under posttraumatic hypothermic and hyperthermic conditions. Methods. Intubated and anesthetized rats were subjected to fluid-percussion injury (FPI). In the first experiment, rats were divided into moderate (1.8-2.2 atm) and severe (2.4-2.7 arm) TBI groups. In the second experiment, the effects of 3 hours of posttraumatic hypothermia (33 or 30degreesC), hyperthermia (39degreesC), or normothermia (37degreesC) on hemoglobin levels following moderate trauma were assessed. The rats were pet-fused with saline at 24 hours postinjury, and then the traumatized and contralateral hemispheres, including the cerebellum, were dissected from whole brain. The hemoglobin level in each brain was quantified using a spectrophotometric hemoglobin assay. The results of these assays indicate that moderate and severe FPI induce increased levels of hemoglobin in the ipsilateral hemisphere (p < 0.0001). After severe TBI, the hemoglobin concentration was also significantly increased in the contralateral hemisphere (p < 0.05) and cerebellum (p < 0.005). Posttraumatic hypothermia (30degreesC) attenuated hemoglobin levels (p < 0.005) in the ipsilateral hemisphere, %vhcreas hyperthermia had a marked adverse effect on the hemoglobin concentration in the contralateral hemisphere (p < 0.05) and cerebellum (p < 0.005). Conclusions. Injury severity is an important determinant of the degree of hemoglobin extravasation after TBI. Posttraumatic hypothermia reduced hemoglobin extravasation, whereas hyperthermia increased hemoglobin levels compared with normothermia. These findings are consistent with previous data reporting that posttraumatic temperature manipulations alter the cerebrovascular and inflammatory consequences of TBI.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; ELSABBAN F, 1995, INT J BIOMETEOROL, V38, P92, DOI 10.1007/BF01270666; FAHIM MA, 1995, ANAT REC, V242, P77, DOI 10.1002/ar.1092420110; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; JENKINS A, 1989, NEUROPATH APPL NEURO, V15, P477, DOI 10.1111/j.1365-2990.1989.tb01247.x; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kazui S, 1997, STROKE, V28, P2370, DOI 10.1161/01.STR.28.12.2370; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Klatzo I, 1969, Clin Neurosurg, V16, P472; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Krause KR, 2000, AM SURGEON, V66, P348; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MURRAY J, 1999, TRAUMA SCI BASIC CAR, P122; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PATT A, 1988, SURG CLIN N AM, V68, P775; Peng ZC, 1997, BRAIN RES BULL, V42, P119, DOI 10.1016/S0361-9230(96)00206-7; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; REED RL, 1990, CIRC SHOCK, V32, P141; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sagher O, 1997, J NEUROSURG, V87, P431, DOI 10.3171/jns.1997.87.3.0431; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SOKRAB TEO, 1988, ACTA NEUROPATHOL, V75, P557, DOI 10.1007/BF00686200; SPEZIALI G, 1994, J SURG RES, V57, P80, DOI 10.1006/jsre.1994.1114; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zilles K., 1985, CORTEX RAT STEREOTAX	77	39	40	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2002	97	4					945	953		10.3171/jns.2002.97.4.0945			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	604MY	WOS:000178626400035	12405386				2022-02-06	
J	Marciano, PG; Eberwine, JH; Ragupathi, R; Saatman, KE; Meaney, DF; McIntosh, TK				Marciano, PG; Eberwine, JH; Ragupathi, R; Saatman, KE; Meaney, DF; McIntosh, TK			Expression profiling following traumatic brain injury: A review	NEUROCHEMICAL RESEARCH			English	Article						traumatic brain injury; microarray; immediate early genes; cytokines; neurotrophic factors; gene expression	NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; HEAT-SHOCK-PROTEIN; FOS MESSENGER-RNA; C-FOS; GENE-EXPRESSION; CELL-DEATH; RAT-BRAIN; NEUROTROPHIC FACTOR; DIFFERENTIAL EXPRESSION	Traumatic brain injury (TBI) elicits a complex sequence of putative autodestructive and neuroprotective cellular cascades. It is hypothesized that the genomic responses of cells in the injured brain serve as the basis for these cascades. Traditional methods for analyzing differential gene expression following brain trauma demonstrate that immediate early genes, cytokines, transcription factors, and neurotrophic factors can all participate in the brain's active and directed response to injury, and may do so concurrently. It is this complexity and multiplicity of interrelated molecular mechanisms that has demanded new methods for comprehensive and parallel evaluation of putative as well as novel gene targets. Recent advances in DNA microarray technology have enabled the simultaneous evaluation of thousands of genes and the subsequent generation of massive amounts of biological data relevant to CNS injury. This emerging technology can serve to further current knowledge regarding recognized molecular cascades as well as to identify novel molecular mechanisms that occur throughout the post-traumatic period. The elucidation of the complex alterations in gene expression underlying the pathological sequelae following TBI is of central importance in the design of future therapeutic agents.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Eberwine, James/B-2247-2010	Meaney, David/0000-0002-0954-4122			ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENVENISTE EN, 1992, CHEM IMMUNOL, V52, P106; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; D'MELLO SR, 1991, J NEUROCHEM, V57, P1570, DOI 10.1111/j.1471-4159.1991.tb06353.x; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; Eberwine J, 1996, BIOTECHNIQUES, V20, P584; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GIULIAN D, 1995, J NEUROSCI, V15, P7712; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HANSEN JN, 1974, NUCLEIC ACIDS RES, V1, P787, DOI 10.1093/nar/1.6.787; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lobenhofer EK, 2001, ENVIRON HEALTH PERSP, V109, P881, DOI 10.2307/3454988; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Noordewier MO, 2001, TRENDS BIOTECHNOL, V19, P412, DOI 10.1016/S0167-7799(01)01735-8; NORRIS JG, 1994, J IMMUNOL, V152, P841; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; O'Dell DM, 1998, BIOTECHNIQUES, V25, P566, DOI 10.2144/98254bm04; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Oyesiku NM, 1996, J COMP NEUROL, V364, P68, DOI 10.1002/(SICI)1096-9861(19960101)364:1<68::AID-CNE6>3.0.CO;2-Q; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Porchet N, 2000, METH MOL B, V125, P305; Prediger EA, 2000, METH MOL B, V160, P495; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; RUZDIJIC S, 1993, BRAIN RES, V601, P230, DOI 10.1016/0006-8993(93)91715-5; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SHARP FR, 1994, NEUROTOXICOLOGY, V15, P51; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THERY C, 1993, NEUROSCI LETT, V150, P195, DOI 10.1016/0304-3940(93)90534-R; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YOUNG B, 1992, J NEUROTRAUM, V9, pS375	91	39	44	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	OCT	2002	27	10					1147	1155		10.1023/A:1020973308941			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	611VE	WOS:000179037800018	12462413				2022-02-06	
J	Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH				Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH			Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury	BRAIN RESEARCH			English	Article						brain microdialysis; glucose; glutamate; traumatic brain injury	TRAUMATIC BRAIN INJURY; HUMAN HEAD-INJURY; GLUTAMATE RELEASE; RAT; BW619C89; DAMAGE; ANTAGONISTS; LAMOTRIGINE; ASPARTATE; MECHANISM	Increases in brain interstitial excitatory amino acid (EAA(1)) concentrations after ischemia are ameliorated by use-dependent Na+ channel antagonists and by supplementing interstitial glucose, but the regulation of EAA(1) after traumatic brain injury (TBI) is unknown. We studied the regulation of EAA(1), after TBI using the controlled cortical impact model in rats. To monitor changes in EAA(1), microdialysis probes were placed in the cortex adjacent to the contusion and in the ipsilateral hippocampus. Significant increases in dialysate EAA, after TBI were found compared to levels measured in sham controls. Treatment with the use-dependent Na+ channel antagonist 619C89 (30 mg/kg i.v.) did not significantly decrease dialysate glutamate compared to vehicle controls in hippocampus (10.4 +/- 2.4 vs. 11.9 +/- 1.6 muM), but there was significant decrease in dialysate glutamate in cortex after 619C89 treatment (19.3 +/- 3 vs. 12.6 +/- 1.1 muM, P<0.05). Addition of 30 mM glucose to the dialysate, a treatment that decreases EAA(1) after ischemia, had no significant effect upon dialysate glutamate after TBI in cortex (20.0 +/- 4.9 vs. 11.7 +/- 3.4 mu M) or in hippocampus (10.9 +/- 2.0 vs. 8.9 +/- 2.4 mu M). These results suggest that neither increased release of EAAs due to Na+ channel-mediated depolarization nor failure of glutamate reuptake due to glucose deprivation can explain the majority of the increase in EAA(1) following TBI. Published by Elsevier Science B.V.	Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Vernalis Ltd, Wokingham, England; Vet Affairs Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA		Graham, SH (corresponding author), Univ Pittsburgh, Dept Neurol, 526 S BST, Pittsburgh, PA 15213 USA.	sgra@pitt.edu	Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318] Funding Source: Medline		Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHOI DW, 1987, J NEUROSCI, V7, P357; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; EDWARDS MD, 1994, ANESTHESIOLOGY, V81, pA857; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; SWANSON RA, 1994, BRAIN RES, V664, P94, DOI 10.1016/0006-8993(94)91958-5; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zauner A, 1996, ACT NEUR S, V67, P40	27	39	47	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 5	2002	943	1					15	22	PII S0006-8993(02)02471-X	10.1016/S0006-8993(02)02471-X			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576TK	WOS:000177021000003	12088834	Green Submitted			2022-02-06	
J	Ciccone, AM; Stewart, KC; Meyers, BF; Guthrie, TJ; Battafarano, RJ; Trulock, EP; Cooper, JD; Patterson, GA				Ciccone, AM; Stewart, KC; Meyers, BF; Guthrie, TJ; Battafarano, RJ; Trulock, EP; Cooper, JD; Patterson, GA			Does donor cause of death affect the outcome of lung transplantation?	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Article; Proceedings Paper	81st Annual Meeting of the American-Association-for-Thoracic-Surgery	MAY 06-09, 2001	SAN DIEGO, CALIFORNIA	Amer Assoc Thorac Surg			BRAIN-DEATH; SURVIVAL; BRONCHIOLITIS; DYSFUNCTION; ALLOGRAFTS; REJECTION; EMBOLI; RAT	Background: Accumulating evidence suggests that the donor's cause of death may influence posttransplantation allograft function. We conducted a retrospective analysis of our adult lung transplant experience to investigate the influence of donor traumatic brain injury versus nontraumatic brain injury on posttransplantation outcome. Methods: We retrospectively reviewed donor records and recipient medical charts for 500 consecutive lung transplants performed between July 1988 and December 1999. Recipient follow-up was complete, with a minimum follow-up of 1 year of survival. Results: There were 295 and 205 donors in the traumatic and nontraumatic brain injury groups, respectively. Young male donors predominated in the traumatic brain injury group. Recipients receiving donor lungs from the traumatic and nontraumatic brain injury groups did not differ by age, sex, diagnosis, type of transplant (single-lung versus double-lung) or requirement for pretransplantation mechanical ventilatory assistance. Recipients did not differ in immediate or 24-hour PaO2/inspired oxygen ratio, ventilation time, hospital stay, hospital mortality, or overall survival. Recipients of organs from donors who died of traumatic brain injury showed a higher severity and frequency of rejection episodes during the first year after transplantation. Freedoms from bronchiolitis obliterans syndrome at 5 years were 34.5% and 50.8% for recipients of organs from donors who died of traumatic and nontraumatic brain injury, respectively (P =.002). Conclusions: The cause of donor brain death does not appear to influence early results of lung transplantation. Traumatic brain injury, or some phenomenon associated with it, may predispose a transplanted lung and its recipient toward more severe early rejection episodes and subsequent development of bronchiolitis obliterans syndrome.	Washington Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Pulm Med, St Louis, MO 63110 USA		Patterson, GA (corresponding author), 1 Barnes Jewish Plaza,3108 Queeny Tower, St Louis, MO 63110 USA.						BANDO K, 1995, J THORAC CARDIOV SUR, V110, P4, DOI 10.1016/S0022-5223(05)80003-0; BUSSON M, 1995, TRANSPLANT P, V27, P1662; COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P713; Meyers B F, 1998, Semin Thorac Cardiovasc Surg, V10, P213; Meyers BF, 1999, ANN SURG, V230, P362, DOI 10.1097/00000658-199909000-00009; Meyers BF, 1999, J THORAC CARDIOV SUR, V117, P358, DOI 10.1016/S0022-5223(99)70434-4; Novick RJ, 1999, J HEART LUNG TRANSPL, V18, P425, DOI 10.1016/S1053-2498(98)00057-6; NOVITSKY D, 1984, HEART TRANSPLANT, V4, P63; Novitzky D, 1997, TRANSPLANT P, V29, P3770, DOI 10.1016/S0041-1345(97)01149-4; Pratschke J, 1999, TRANSPLANT P, V31, P874, DOI 10.1016/S0041-1345(98)01813-2; ROSENDALE BE, 1992, J HEART LUNG TRANSPL, V11, P72; SHANLIN RJ, 1988, J AM COLL CARDIOL, V12, P727, DOI 10.1016/S0735-1097(88)80065-2; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Simonetti VA, 1998, CLIN TRANSPLANT, V12, P504; Smith MA, 1998, J THORAC CARDIOV SUR, V116, P812, DOI 10.1016/S0022-5223(98)00444-9; SUNDARESAN S, 1995, J THORAC CARDIOV SUR, V109, P1075, DOI 10.1016/S0022-5223(95)70190-7; SUNDARESAN S, 1993, ANN THORAC SURG, V56, P1409, DOI 10.1016/0003-4975(93)90699-I; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001; Varela A, 1997, J THORAC CARDIOV SUR, V114, P1119, DOI 10.1016/S0022-5223(97)70029-1; WALLER DA, 1995, J HEART LUNG TRANSPL, V14, P318; Yousem SA, 1996, J HEART LUNG TRANSPL, V15, P1	24	39	39	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0022-5223			J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	MAR	2002	123	3					429	436		10.1067/mtc.2002.120732			8	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery	531TV	WOS:000174434100007	11882812	Bronze			2022-02-06	
J	Worrall, L; McCooey, R; Davidson, B; Larkins, B; Hickson, L				Worrall, L; McCooey, R; Davidson, B; Larkins, B; Hickson, L			The validity of functional assessments of communication and the Activity/Participation components of the ICIDH-2: do they reflect what really happens in real-life?	JOURNAL OF COMMUNICATION DISORDERS			English	Article						functional communication; ICIDH-2; functional assessment; functional treatment of aphasia	APHASIA; PERSPECTIVE	This paper aims to provide a better understanding of the nature of functional communication activities so that assessment and treatment efforts are based on a theoretical framework and empirical data, Three sources of information are discussed. The first is the Activity/Participation dimensions of the World Health Organization's International Classification of Functioning, Disability, and Health. The second source is existing assessments of functional communication. The final source is data obtained from observational studies conducted in our research unit. The studies have observed the everyday communication of people with aphasia, people with Traumatic Brain Injury (TBI), and patients in hospital. The simplification of real-life communication in the WHO classification scheme, the variability of item sampling in existing assessments, and the complexity of communication observed in real-life settings has led to the conclusion that there are three levels of functional communication assessment: generic, population-specific, and individualized. Clinicians may choose which level suits their purpose. When clinicians routinely choose from a range of sophisticated functional assessments to inform their therapy, the seed that Martha Taylor Sarno planted and nourished for the past 30 years or more will truly flourish throughout the world of speech-language pathology. Learning outcomes: As a result of this activity, participants will (1) understand the theoretical framework and data base that motivates assessment and treatment of functional communication activities, (2) be able to discuss the World Health Organization's Classification of Functioning, Disability and Health and (3) gain information about functional assessment and observational sampling of real world communication activities across three levels. (C) 2002 Elsevier Science Inc. All rights reserved.	Univ Queensland, Dept Speech Pathol & Audiol, Commun Disabil Ageing Res Unit, Brisbane, Qld 4072, Australia		Worrall, L (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Commun Disabil Ageing Res Unit, Brisbane, Qld 4072, Australia.		Davidson, Bronwyn/F-8741-2010; Worrall, Linda/D-2579-2010; Hickson, Louise MH/F-8748-2010	Worrall, Linda/0000-0002-3283-7038; Hickson, Louise MH/0000-0001-6832-4173; O'Halloran, Robyn/0000-0002-2772-2164			*AM SPEECH LANG HE, 2001, SCOP PRACT SPEECH LA; BAKERR, 2000, NEUROGENIC COMMUNICA, P81; CAREY R, 1990, ADV CLIN REHABILITAT, V3, P217; DAVIDSON B, 1998, 8 INT APH REH C KWA; Davidson B, 2000, NEUROGENIC COMMUNICA, P19; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; Enderby P. M., 2000, NEUROGENIC COMMUNICA, P247; Frattali C M, 1993, Disabil Rehabil, V15, P1; Frattali C. M., 1995, AM SPEECH LANGUAGE H; Frattali C. M., 1998, MEASURING OUTCOMES S; FRATTALI CM, 1992, APHASIOLOGY, V6, P63, DOI 10.1080/02687039208248577; FRATTALI CM, 2000, NEUROGENIC COMMUNICA, P67; Holland A., 1998, COMMUNICATION ACTIVI; Holland A., 1980, COMMUNICATIVE ABILIT; Holmes J., 1992, INTRO SOCIOLINGUISTI; Hustad Katherine C., 1998, Seminars in Speech and Language, V19, P291, DOI 10.1055/s-2008-1064051; JORDAN L, 1996, ASPHASIA SOCIAL APPR; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Larkins B., 2000, NEUROGENIC COMMUNICA, P206; LEDORZE G, 1995, APHASIOLOGY, V9, P239; LOMAS J, 1989, J SPEECH HEAR DISORD, V54, P113, DOI 10.1044/jshd.5401.113; McDowell I., 1996, MEASURING HLTH GUIDE; Parr S., 2000, NEUROGENIC COMMUNICA, P55; Pye D. J., 2000, NEUROGENIC COMMUNICA, P312; Rogers M A, 1999, Phys Med Rehabil Clin N Am, V10, P907; Sarno M. T., 1969, FUNCTIONAL COMMUNICA; SimmonsMackie NN, 1996, DISABIL REHABIL, V18, P540, DOI 10.3109/09638289609166315; Spradley J.P., 2016, PARTICIPANT OBSERVAT; TOFFOLO D, 1995, AUSTR ASS SPEECH HEA; WHO, 2000, INT CLASS FUNCT DIS; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 1997, ICIDH 2 INT CLASS IM; World Health Organization, 2007, INT CLASS FUNCT DIS; WORRALL L, 1992, APHASIOLOGY, V6, P105, DOI 10.1080/02687039208248581; Worrall L., 1995, TREATMENT APHASIA, P47; Worrall L, 2000, NEUROGENIC COMMUNICA; WORRALL L, 1999, 2000 EMBRACING CHANG, P5; Worrall L., 1999, FUNCTIONAL COMMUNICA	38	39	43	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	MAR-APR	2002	35	2					107	137	PII S0021-9924(02)00060-6	10.1016/S0021-9924(02)00060-6			31	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	553BE	WOS:000175655000003	12036147				2022-02-06	
J	Deutsch, A; Fiedler, RC; Granger, CV; Russell, CF				Deutsch, A; Fiedler, RC; Granger, CV; Russell, CF			The Uniform Data System for Medical Rehabilitation report of patients discharged from comprehensive medical rehabilitation programs in 1999	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						activities of daily living; functional assessment; disability evaluation; rehabilitation	FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN INJURY; FIRST ADMISSIONS; ASSESSMENT SCALES; 1ST ADMISSIONS; RELIABILITY; STROKE; VALIDITY; FIM	This is the 10th annual report describing patients discharged from comprehensive medical rehabilitation programs in the United States that subscribe to the Uniform Data System for Medical Rehabilitation. The analysis included 298,973 complete records of first admission cases discharged alive from 676 facilities in 1999. The data show that patients receiving care in comprehensive rehabilitation programs show measurable functional improvement and that a high percentage of patients are discharged to community-based settings.	SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, Buffalo, NY 14214 USA		Deutsch, A (corresponding author), SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, 232 Parker Hall,3435 Main St, Buffalo, NY 14214 USA.		Deutsch, Anne/B-7530-2017	Deutsch, Anne/0000-0003-2290-7757			*CARF REH ACCR COM, 1999, 1999 MED REH STAND M; CARTER GM, 2000, WORK PLAN INPATIENT; CARTER GM, 1997, PATIENT CLASSIFICATI; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Deutsch A, 1996, CRITICAL REV PHYS ME, V8, P267; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fiedler RC, 1997, AM J PHYS MED REHAB, V76, P76, DOI 10.1097/00002060-199701000-00017; Fiedler RC, 1996, AM J PHYS MED REHAB, V75, P125, DOI 10.1097/00002060-199603000-00010; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P69, DOI 10.1097/00002060-199801000-00013; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1992, STROKE, V23, P978, DOI 10.1161/01.STR.23.7.978; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P62, DOI 10.1097/00002060-199501000-00011; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P52, DOI 10.1016/S0003-9993(98)90208-8; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; Hamilton BB, 1999, ARCH PHYS MED REHAB, V80, P385, DOI 10.1016/S0003-9993(99)90274-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; *HLTH CARE FIN ADM, 2000, 1999 HCFA STAT; Iwanenko W, 2001, AM J PHYS MED REHAB, V80, P56, DOI 10.1097/00002060-200101000-00014; Iwanenko W, 1999, AM J PHYS MED REHAB, V78, P384, DOI 10.1097/00002060-199907000-00020; *JOINT COMM ACCR H, 2001, LIST PERF MEAS SYST; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; Stineman MG, 1997, ARCH PHYS MED REHAB, V78, P980, DOI 10.1016/S0003-9993(97)90061-7; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; *SUNY BUFF, 1996, GUID UN DAT SET MED; *SUNY BUFF, 1996, GETT START UN DAT SY; Turpin RS, 1997, AM J PHYS MED REHAB, V76, P138, DOI 10.1097/00002060-199703000-00010; [No title captured], DOI DOI 10.1177/026921559000400405	37	39	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2002	81	2					133	142		10.1097/00002060-200202000-00010			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	515GJ	WOS:000173486800009	11807350				2022-02-06	
J	Vasa, RA; Gerring, JP; Grados, M; Slomine, B; Christensen, JR; Rising, W; Denckla, MB; Riddle, MA				Vasa, RA; Gerring, JP; Grados, M; Slomine, B; Christensen, JR; Rising, W; Denckla, MB; Riddle, MA			Anxiety after severe pediatric closed head injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						closed head injury; anxiety	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ATTENTION-DEFICIT; CHILDREN; ADOLESCENTS; COMA	Objective: To assess the frequency of anxiety symptoms and disorders 1 year after severe pediatric closed head injury (CHI) and to determine the risk factors associated with these postinjury outcomes. Method: Ninety-seven subjects were prospectively followed for 1 year after severe CHI (Glasgow Coma Scale Score = 3-8). Assessments of preinjury and 1 year postinjury psychiatric status and psychosocial adversity were conducted. Frequency of anxiety symptoms and disorders 1 year after injury were the outcome measures. Data collection occurred between 1992 and 1996. Results: There was a significant increase in the total number of anxiety symptoms after injury compared with before injury. The most frequent symptoms were overanxious symptoms, followed by obsessive-compulsive symptoms, separation anxiety symptoms, and simple phobia symptoms. There was a trend toward an increase in the frequency of overanxious disorder after injury. Preinjury anxiety symptoms correlated positively with postinjury anxiety symptoms and disorders, Younger age at injury correlated positively with postinjury anxiety symptoms. Conclusions: One year after severe CHI, children are at risk for a variety of anxiety symptoms and, possibly, overanxious disorder. Preinjury anxiety and younger age at injury are risk factors for these disturbances.	Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA		Vasa, RA (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	vasa@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO-RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		Blacker D., 2000, HDB PSYCHIAT MEASURE, P7; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Costello E. Jane, 1995, P109; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P1569, DOI 10.1097/00004583-199912000-00019; Last CG, 1996, J AM ACAD CHILD PSY, V35, P1502, DOI 10.1097/00004583-199611000-00019; LAST CG, 1987, AM J PSYCHIAT, V144, P1580; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; REEVES JC, 1987, J AM ACAD CHILD PSY, V26, P144, DOI 10.1097/00004583-198703000-00004; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; TEASDALE G, 1974, LANCET, V2, P81; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	24	39	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	FEB	2002	41	2					148	156		10.1097/00004583-200202000-00008			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	514PZ	WOS:000173451400008	11837404				2022-02-06	
S	Morrison, RS; Kinoshita, Y; Johnson, MD; Ghatan, S; Ho, JT; Garden, G		Alzheimer, C		Morrison, RS; Kinoshita, Y; Johnson, MD; Ghatan, S; Ho, JT; Garden, G			Neuronal survival and cell death signaling pathways	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; TRAIL-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CYCLIN-DEPENDENT KINASES; TRANSGENIC MOUSE MODEL; N-TERMINAL KINASE; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; BCL-X-L	Neuronal viability is maintained through a complex interacting network of signaling pathways that can be perturbed in response to a multitude of cellular stresses. A shift in the balance of signaling pathways after stress or in response to pathology can have drastic consequences for the function or the fate of a neuron. There is significant evidence that acutely injured and degenerating neurons may die by an active mechanism of cell death. This process involves the activation of discrete signaling pathways that ultimately compromise mitochondrial structure, energy metabolism and nuclear integrity. In this review we examine recent evidence pertaining to the presence and activation of anti- and pro-cell death regulatory pathways in nervous system injury and degeneration.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA		Morrison, RS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.			Garden, Gwenn/0000-0002-8753-6515			Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Anderson CNG, 1999, J NEUROSCI, V19, P664; Araki T, 1998, BRAIN RES, V794, P239, DOI 10.1016/S0006-8993(98)00231-5; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Attardi LD, 2000, GENE DEV, V14, P704; Ay I, 2001, MOL BRAIN RES, V87, P71, DOI 10.1016/S0169-328X(00)00285-0; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Balass M, 1997, P NATL ACAD SCI USA, V94, P6054, DOI 10.1073/pnas.94.12.6054; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Busser J, 1998, J NEUROSCI, V18, P2801; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chakravarthy BR, 1999, J NEUROCHEM, V72, P933, DOI 10.1046/j.1471-4159.1999.0720933.x; Chechlacz M, 2001, J NEUROCHEM, V78, P141, DOI 10.1046/j.1471-4159.2001.00380.x; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chen RW, 1999, J NEUROSCI, V19, P9654; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Coovert DD, 2000, J MED GENET, V37, P536, DOI 10.1136/jmg.37.7.536; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cregan SP, 1999, J NEUROSCI, V19, P7860; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2001, MOL BRAIN RES, V87, P257, DOI 10.1016/S0169-328X(01)00008-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; D'Mello SR, 2000, J NEUROSCI RES, V59, P24, DOI 10.1002/(SICI)1097-4547(20000101)59:1<24::AID-JNR4>3.0.CO;2-8; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295; de la Monte SM, 1998, LAB INVEST, V78, P401; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Ding XL, 2000, AM J PATHOL, V157, P1983, DOI 10.1016/S0002-9440(10)64837-7; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Droin N, 2000, CANCER RES, V60, P7039; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Elovaara I, 1999, ACTA NEUROPATHOL, V98, P355, DOI 10.1007/s004010051094; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Enokido Y, 1996, NEUROSCI LETT, V203, P1, DOI 10.1016/0304-3940(95)12247-8; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Faddis BT, 1997, J NEUROSCI, V17, P951; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 1997, NEUROREPORT, V8, P2483, DOI 10.1097/00001756-199707280-00014; Ferri CC, 1998, J NEUROBIOL, V34, P1; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Frade JM, 1999, DEVELOPMENT, V126, P683; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Frank S, 1999, BIOCHEM BIOPH RES CO, V257, P454, DOI 10.1006/bbrc.1999.0493; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Harris CA, 2001, J BIOL CHEM, V276, P37754; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Hirata H, 1997, J NEUROCHEM, V69, P780; Hisahara S, 2001, J EXP MED, V193, P111, DOI 10.1084/jem.193.1.111; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jin KL, 2001, J NEUROCHEM, V77, P1508, DOI 10.1046/j.1471-4159.2001.00361.x; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROSCI, V17, P1397; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kowaltowski AJ, 2000, AM J PHYSIOL-CELL PH, V279, pC852, DOI 10.1152/ajpcell.2000.279.3.C852; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kuechle MK, 2001, CELL DEATH DIFFER, V8, P868, DOI 10.1038/sj.cdd.4400897; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Kuntz C, 2000, EXP NEUROL, V165, P184, DOI 10.1006/exnr.2000.7464; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; LaFerla FM, 1996, J CLIN INVEST, V98, P1626, DOI 10.1172/JCI118957; Lakkaraju A, 2001, J BIOL CHEM, V276, P32000, DOI 10.1074/jbc.M100138200; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Leonard JR, 2001, DEV BRAIN RES, V128, P187, DOI 10.1016/S0165-3806(01)00174-2; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1033.2001.02024.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Martinou I, 1998, NEUROREPORT, V9, P15, DOI 10.1097/00001756-199801050-00004; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2001, TRENDS NEUROSCI, V24, P255, DOI 10.1016/S0166-2236(00)01838-5; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; McGinnis KM, 1999, J NEUROCHEM, V72, P1899, DOI 10.1046/j.1471-4159.1999.0721899.x; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; McShea A, 1997, AM J PATHOL, V150, P1933; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIYASHITA T, 1994, CANCER RES, V54, P3131; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Morrison RS, 1996, J NEUROSCI, V16, P1337; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Namura S, 1998, J NEUROSCI, V18, P3659; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Nath R, 2001, CELL MOL BIOL LETT, V6, P173; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Prudlo J, 2000, BRAIN RES, V879, P183, DOI 10.1016/S0006-8993(00)02745-1; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Qin ZH, 1999, J NEUROSCI, V19, P4023; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Reimann-Philipp U, 2001, J NEUROSCI RES, V64, P654, DOI 10.1002/jnr.1119; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sadoul R, 1998, CELL DEATH DIFFER, V5, P805, DOI 10.1038/sj.cdd.4400438; SAEIPPER CD, 2001, DEVELOPMENT, V128, P137; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sakhi S, 1996, NEUROREPORT, V8, P233, DOI 10.1097/00001756-199612200-00047; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sawa A, 1999, J NEURAL TRANSM-SUPP, P87; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sedel F, 1999, EUR J NEUROSCI, V11, P3904, DOI 10.1046/j.1460-9568.1999.00814.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Seidl R, 1999, NEUROSCI LETT, V260, P9, DOI 10.1016/S0304-3940(98)00945-8; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shibata M, 2000, J CLIN INVEST, V106, P643, DOI 10.1172/JCI10203; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; Smith CD, 2002, PROTEIN SCI, V11, P625, DOI 10.1110/ps.37802; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Sun YF, 2001, J BIOL CHEM, V276, P16240, DOI 10.1074/jbc.M010419200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tamami M, 1996, J BIOL CHEM, V271, P24551, DOI 10.1074/jbc.271.40.24551; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Tong X, 2000, INT J RADIAT BIOL, V76, P1387; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.t01-1-00218.x; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Uberti D, 1998, EUR J NEUROSCI, V10, P246, DOI 10.1046/j.1460-9568.1998.00042.x; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Vemuri MC, 2001, CELL DEATH DIFFER, V8, P245, DOI 10.1038/sj.cdd.4400806; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Vincent I, 2001, NEUROSCIENCE, V105, P639, DOI 10.1016/S0306-4522(01)00219-6; Vincent I, 1997, J NEUROSCI, V17, P3588; Vogel KS, 1998, MOL CELL NEUROSCI, V11, P19, DOI 10.1006/mcne.1998.0670; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang Y, 1999, NEUROSCIENCE, V94, P1153, DOI 10.1016/S0306-4522(99)00264-X; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Whalen MJ, 2000, ACT NEUR S, V76, P61; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wiese S, 1999, EUR J NEUROSCI, V11, P1668, DOI 10.1046/j.1460-9568.1999.00585.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOOD KA, 1995, J NEUROSCI, V15, P5851; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 1998, J NEUROSCI, V18, P1363; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamagishi S, 2001, J BIOL CHEM, V276, P5129, DOI 10.1074/jbc.M007258200; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeung MC, 1998, AIDS, V12, P349, DOI 10.1097/00002030-199804000-00002; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	394	39	41	0	3	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						41	86					46	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	BW92A	WOS:000183600500002	12575817				2022-02-06	
J	Prabhu, VC; Bailes, JE				Prabhu, VC; Bailes, JE			Chronic subdural hematoma complicating arachnoid cyst secondary to soccer-related head injury: Case report	NEUROSURGERY			English	Article						arachnoid cyst; head injury; "heading," soccer; subdural hematoma	INTRACYSTIC HEMORRHAGE; BRAIN INJURY; PLAYERS; FOOTBALL; RUPTURE	OBJECTIVE AND IMPORTANCE: Soccer has become a popular sport, with more than 200 million Federation International Football Association-registered soccer players worldwide and 16 million participants in the United States. The risk of sustaining a significant head injury from a strike to a soccer ball with the head is unknown, but it may be increased with the presence of an underlying congenital arachnoid cyst. CLINICAL PRESENTATION: We describe the case of a 16-year-old female patient who sustained a large chronic and subacute subdural hematoma without a loss of consciousness from being struck on the head by a soccer ball. Because of the large size of the hematoma and her contralateral symptoms, surgery was performed. INTERVENTION: A temporal craniotomy for evacuation of a large chronic and subacute subdural hematoma with removal and fenestration of the arachnoid cyst resulted in resolution of her symptoms. Rigid craniotomy fixation of this small operative flap should allow the patient to return to soccer participation in the future. CONCLUSION: Although many may not consider soccer a contact sport, recent epidemiological data suggest that it is a common cause of sports-related concussion. In addition, as our case report demonstrates, there is a risk of significant intracranial injury and hematoma formation subsequent to a strike on the head by a soccer ball, and arachnoid cysts may contribute an additional risk of head injury.	W Virginia Univ, Sch Med, Hlth Sci Ctr 3610, Dept Neurosurg, Morgantown, WV 26506 USA		Bailes, JE (corresponding author), W Virginia Univ, Sch Med, Hlth Sci Ctr 3610, Dept Neurosurg, POB 9183, Morgantown, WV 26506 USA.						Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Choi JU, 1998, PEDIATR NEUROSURG, V29, P260, DOI 10.1159/000028733; Huang D, 1999, AM J NEURORADIOL, V20, P1284; ILDAN F, 1994, NEUROSURG REV, V17, P229, DOI 10.1007/BF00418441; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kadiogly H H, 1994, Zentralbl Neurochir, V55, P172; Kawanishi A, 1999, NEUROL MED-CHIR, V39, P231, DOI 10.2176/nmc.39.231; Lipinski CA, 1997, PEDIATR EMERG CARE, V13, P27, DOI 10.1097/00006565-199702000-00009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Ochi M, 1996, EUR RADIOL, V6, P640; Oka Yoshihisa, 1994, Neurologia Medico-Chirurgica, V34, P95, DOI 10.2176/nmc.34.95; Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P341; Tucker AM, 1997, SPORTS MED, V23, P21, DOI 10.2165/00007256-199723010-00003; Vigil DV, 1998, CLIN J SPORT MED, V8, P234, DOI 10.1097/00042752-199807000-00013; Youmans IR, 1996, NEUROLOGICAL SURG, P967	21	39	42	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2002	50	1					195	197					3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	506AC	WOS:000172946900046	11844251				2022-02-06	
J	Mori, T; Wang, XY; Kline, AE; Siao, CJ; Dixon, CE; Tsirka, SE; Lo, EH				Mori, T; Wang, XY; Kline, AE; Siao, CJ; Dixon, CE; Tsirka, SE; Lo, EH			Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma	NEUROREPORT			English	Article						blood-brain barrier; brain edema; extracellular matrix; neuroprotection; proteolysis	FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; NEURONAL DEATH; GENE; MATRIX-METALLOPROTEINASE-9; HIPPOCAMPUS; APOPTOSIS; SEIZURE; DAMAGE; STROKE	Tissue plasminogen activator (tPA) may play a deleterious role after brain injury. Here, we compared the response to traumatic brain injury in tPA knockout (KO) and wildtype (WT) mice after controlled cortical impact. At 6 h after trauma, blood-brain barrier permeability was equally increased in all mice. However, by 24 h specific gravity measurements of brain edema were significantly worse in WT mice than in KO mice. At 1 and 2 days post-trauma, mice showed deficits in rotarod performance, but by day 7 all mice recovered motor function and there were no differences between WT and KO mice. At 7 days, cortical lesion volumes were significantly reduced in KO mice compared with WT mice. However, there were no significant differences: in CA3 hippocampal neuron survival. These data suggest that tPA amplifies cortical brain damage and edema in this mouse model of traumatic brain injury. NeuroReport 12:4117-4120 (C) 2001 Lippincott Williams & Wilkins.	Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Charlestown, MA 02129 USA; Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA		Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, MGH E 149-2322, Charlestown, MA 02129 USA.		Tsirka, Stella/AAD-4018-2019				Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CUZNER ML, 2001, NEUROPROTECTION; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; Gary DS, 2001, J NEUROCHEM, V76, P1485, DOI 10.1046/j.1471-4159.2001.00173.x; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hacke W, 1999, NEUROLOGY, V53, pS3; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rogove AD, 1999, J CELL SCI, V112, P4007; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang XY, 1999, NEUROSCI LETT, V274, P79, DOI 10.1016/S0304-3940(99)00682-5; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228	28	39	40	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	DEC 21	2001	12	18					4117	4120		10.1097/00001756-200112210-00051			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	502LT	WOS:000172745600062	11742249				2022-02-06	
J	Dennis, M; Barnes, MA				Dennis, M; Barnes, MA			Comparison of literal, inferential, and intentional text comprehension in children with mild or severe closed head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed-head injury; inferential language; language of mental states and intentions; literal language; text comprehension deficit	ELABORATIVE INFERENCES; PRETENSE THEORY; DISCOURSE; ADOLESCENTS; MEMORY; CONSTRAINTS; NARRATIVES; CHILDHOOD; DECEPTION; DEFICITS	Background: Children with head injury have impairments in pragmatic language at the level of both single words and texts. Text comprehension deficits are likely to be the more consequential for everyday and academic function, yet the relative magnitudes of literal and nonliteral text comprehension deficits have not been measured. Design: We compared the magnitude of the impairment in three forms of text comprehension for children with mild or severe head injury relative with controls: literal language (understanding literal text information), inferential language (making pragmatic inferences, textual coherence inferences, or enriching inferences), and the language of mental states and intentions (eg, producing speech acts, appreciating irony, and understanding deception). Measures: Effect sizes were used to measure the magnitude of the difference between children with head injury and age-matched controls, Results: Children with severe closed-head injury were significantly impaired on tasks of literal text understanding, inferencing, and intentionality. Children with mild head injury were impaired on some inferencing and all intentionality tasks, although they had no literal text comprehension deficits. Conclusions: For both groups, the greatest deficits (ie, the largest effect sizes) were on tasks requiring understanding of the language of mental states and intentions. The data bear on the long-term effects of childhood closed-head injury on text- and discourse-level language and also on the nature and timing of language rehabilitation in children with head injury.	Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Hosp Sick Children, Dept Psychol, Brain & Behav Program, Toronto, ON M5G 1X8, Canada		Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mdennis@sickkids.on.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2RO1NS 21889-16] Funding Source: Medline		Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARA BG, 1998, COGNITION CONTEXT; Bara Bruno G., 1995, COGNITIVE SCI DEV AP; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BARNES MA, 2001, BRAIN LANG, P76; BJORKLUND DF, 1986, J EXP CHILD PSYCHOL, V41, P367, DOI 10.1016/0022-0965(86)90045-7; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Carlson SM, 1998, CHILD DEV, V69, P672, DOI 10.2307/1132197; CASTEEL MA, 1993, DEV PSYCHOL, V29, P346, DOI 10.1037/0012-1649.29.2.346; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1999, BRAIN DAM B, P235; CLARK HH, 1984, J EXP PSYCHOL GEN, V113, P121, DOI 10.1037/0096-3445.113.1.121; Cohen J, 1977, STAT POWER ANAL BEHA; DEMOREST A, 1984, CHILD DEV, V55, P1527, DOI 10.2307/1130022; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dews S, 1999, J PRAGMATICS, V31, P1579, DOI 10.1016/S0378-2166(99)00005-3; DEWS S, 1995, AM PSYCHOL ASS NEW Y; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL; Fillmore C.J., 1968, UNIVERSALS LINGUISTI, P1; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Giora R, 1997, COGN LINGUIST, V8, P183, DOI 10.1515/cogl.1997.8.3.183; HALL WS, 1987, J PSYCHOLINGUIST RES, V16, P289, DOI 10.1007/BF01069284; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; Johnson-Laird Philip Nicholas, 1983, MENTAL MODELS COGNIT; JORDAN F M, 1990, Brain Injury, V4, P27; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORGENSEN J, 1984, J EXP PSYCHOL GEN, V113, P112, DOI 10.1037/0096-3445.113.1.112; KAUFER DS, 1981, J PRAGMATICS, V5, P495, DOI 10.1016/0378-2166(81)90015-1; KINTSCH W, 1994, AM PSYCHOL, V49, P294, DOI 10.1037/0003-066X.49.4.294; KREUZ RJ, 1989, J EXP PSYCHOL GEN, V118, P374, DOI 10.1037/0096-3445.118.4.374; KREUZ RJ, 1993, METAPHOR SYMB ACT, V8, P97, DOI 10.1207/s15327868ms0802_2; KUMONNAKAMURA S, 1995, J EXP PSYCHOL GEN, V124, P3, DOI 10.1037/0096-3445.124.1.3; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LONG DL, 1988, DISCOURSE PROCESS, V11, P35, DOI 10.1080/01638538809544690; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S., 2000, ADV UNDERSTANDING CO; MCKOON G, 1992, PSYCHOL REV, V99, P440, DOI 10.1037/0033-295X.99.3.440; MORROW DG, 1990, INFERENCES TEXT COMP; Muecke Douglas C., 1969, COMPASS IRONY; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.2307/1131728; PESKIN J, 1989, UNPUB CONCEALING 1 I; Pexman PM, 2000, DISCOURSE PROCESS, V29, P201, DOI 10.1207/S15326950dp2903_2; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCHOLNICK EK, 1991, PERSPECTIVES LANGUAG; Schwoebel John, 2000, METAPHOR SYMBOL, V15, P47, DOI [10.1080/10926488.2000.9678864, DOI 10.1080/10926488.2000.9678864]; SODIAN B, 1994, CHILDRENS EARLY UNDE; Sperber D., 1981, RADICAL PRAGMATICS; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WHITNEY P, 1991, DISCOURSE PROCESS, V14, P133, DOI 10.1080/01638539109544779; WHITNEY P, 1987, READ RES QUART, V22, P299, DOI 10.2307/747970; Wiig EH, 1985, TEST LANGUAGE COMPET; Wilson D., 1986, RELEVANCE COMMUNICAT; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Winner E., 1997, PROBLEM MEANING BEHA; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	69	39	39	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2001	16	5					456	468		10.1097/00001199-200110000-00005			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	483JF	WOS:000171631700005	11574041				2022-02-06	
J	Turnbull, SJ; Campbell, EA; Swann, IJ				Turnbull, SJ; Campbell, EA; Swann, IJ			Post-traumatic stress disorder symptoms following a head injury: does amnesia for the event influence the development of symptoms?	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; BRAIN INJURY; VICTIMS; SCALE; POPULATION; COMMUNITY; PTSD	Background: There is controversy as to whether PTSD can develop following a brain injury with a loss of consciousness. However, no studies have specifically examined the influence of the memories that the individuals may or may not have on the development of symptoms. Aims: To consider how amnesia for the traumatic event effects the development and profile of traumatic stress symptoms. Method: Fifteen hundred case records from an Accident and Emergency Unit were screened to identify 371 individuals with traumatic brain injury who were sent questionnaires by post. The 53 subsequent valid responses yielded three groups: those with no memory (n = 14), untraumatic memories (n = 14), and traumatic memories (n = 26) of the index event. The IES-R was used as a screening measure followed by a structured interview (CAPS-DX) to determine caseness and provide details of symptom profile. Results: Groups with no memories or traumatic memories of the index event reported higher levels of psychological distress than the group with untraumatic memories. Ratings of PTSD symptoms were less severe in the no memory groups compared to those with traumatic memories. Conclusions: Psychological distress was associated with having traumatic or no memories of an index event. Amnesia for the event did not protect against PTSD; however, it does appear to protect against the severity and presence of specific intrusive symptoms.	Astley Ainslie Hosp, Lothian Primary Care NHS Trust, Dept Psychol, Edinburgh EH9 2HL, Midlothian, Scotland; Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland; Glasgow Royal Infirm, Accid & Emergency Unit, Glasgow G4 0SF, Lanark, Scotland		Turnbull, SJ (corresponding author), Astley Ainslie Hosp, Lothian Primary Care NHS Trust, Dept Psychol, 133 Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.						American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Blake D.D., 1996, CLIN ADM PTSD SCALE; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Koren D, 1999, AM J PSYCHIAT, V156, P367; KOSS MP, 1989, PSYCHOL WOMEN QUART, V13, P27, DOI 10.1111/j.1471-6402.1989.tb00983.x; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Middelboe T., 1992, European Psychiatry, V7, P183; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	39	40	0	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					775	785		10.1080/02699050110034334			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400003	11516346				2022-02-06	
J	Zhao, YD; Wang, WH				Zhao, YD; Wang, WH			Neurosurgical trauma in People's Republic of China	WORLD JOURNAL OF SURGERY			English	Article								An epidemiological investigation for neurological disorders was conducted in the People's Republic of China in 1983 and 1985. The incidence of traumatic neurological injury was 55.4 patients per 100,000 population in the six big cities and 64.1 patients in the 21 rural areas. The mortality rates were 6.3 per 100,000 population (male:female = 1.7:1.0) in the six cities and 9.7 (m:f = 2.5:1) in the rural areas. In the cities, the causes of brain injury were vehicle accidents (31.7%), followed by assaults (23.8%), falls (21.8%), stumbles (15.4%), and others. Brain concussion was 68.4%, contusion was 26.0%, and intracranial hematoma was 5.6%. The incidence of spinal cord injury was 0.67 per 100,000 population in Beijing and 1.37 in Shanghai. Male versus female ratio was 7 to 1 and the peak incidence was found in ages from 20 to 30 years old. In the past decade, vehicle accidents increased along with the increasing, number of cars and motor bicycles. As a result of a series of administrative measures, such as improvement of traffic control and safe-driving education, mean mortality decreased from 33.4 per 10,000 motor vehicles in 1990 to 22.0 in 1995. It has been estimated that approximately 50,000 to 60,000 people die from vehicle accidents per year. Among these cases, brain injury accounts for 39% to 57% and spinal cord injury about 10%. Since vehicle accidents are the most common cause for neurotraumatic death, an effort is needed to prevent and to decrease the incidence of these accidental traumatic injuries.	Beijing Neurosurg Inst, Dept Neurosurg, Beijing 100050, Peoples R China; Beijing Neurosurg Inst, Dept Neuroepidemiol, Beijing 100050, Peoples R China		Zhao, YD (corresponding author), Beijing Neurosurg Inst, Dept Neurosurg, 6 Tiantan Xili, Beijing 100050, Peoples R China.						FENG QN, 1993, CHIN J SPINE SPINAL, V6, P266; SHI YQ, 1994, PRACTICAL NEUROLOGY, P319; WANG ZG, 1995, J TRAFFIC MED, V23, P71; WANG ZG, 1996, CHIN J TRAUMATOL, V12, P141; YANG JH, 1996, CHINESE BIOCH J, V12, P143; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23; Zhu GL, 1989, CHIN J NEUROSURG S, V5, P44	7	39	45	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1202	1204					3	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	471NB	WOS:000170934500018	11571958				2022-02-06	
J	Schultheis, MT; Mourant, RR				Schultheis, MT; Mourant, RR			Virtual reality and driving: Tthe road to better assessment for cognitively impaired populations	PRESENCE-TELEOPERATORS AND VIRTUAL ENVIRONMENTS			English	Article							TRAUMATIC BRAIN INJURY; CEREBRAL-DAMAGE; PERFORMANCE; ENVIRONMENTS; PREDICTION	Individuals with cognitive impairments can be faced with difficulties that may challenge their ability to drive an automobile, and this impairment is often very disruptive to vocational, social, and domestic activities. Rehabilitation specialists are often given the task of determining capacity to drive. However, traditional assessment methods are fraught with various limitations, including dependence on subjective interpretation of behaviors, nonstandardized procedures, and few ecologically valid measures. A virtual reality-based driving-assessment system (VR-DAS) offers the opportunity to overcome many of the limitations of current methodologies. Specifically, a VR-DAS permits the development of relevant driving scenarios that can provide objective and quantifiable measures of driving behaviors, allowing for increasing standardization and consistency of protocols. VR-DAS also allows for the creation of realistic and interactive driving scenarios at varying levels of challenge and complexity. When coupled with the immersive features offered through a head-mounted display (HMD), the VR-DAS may allow drivers to experience the sense of real-life driving, resulting in behavior and responsiveness that may be more predictive of actual driving ability. To examine these potential benefits and the validity of a VR-DAS, a collaborative study is presently being conducted, comparing VR-DAS performance and actual behind-the-wheel performance in adults with acquired brain injury (such as traumatic brain injury and stroke).	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosic Lab, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Northeastern Univ, Dept Mech Ind & Mfg Engn, Boston, MA 02115 USA		Schultheis, MT (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosic Lab, W Orange, NJ USA.	mschultheis@kmrrec.org		Schultheis, Maria/0000-0002-6558-548X			BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brown D. J., 1998, P 2 EUR C DIS VIRT R, P11; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GIANUTSOS R, 1994, BEHAV RES METH INSTR, V26, P183, DOI 10.3758/BF03204615; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Haikonen S, 1998, Appl Neuropsychol, V5, P24, DOI 10.1207/s15324826an0501_3; HIRSEKORN L, 1998, CYBERPSYCHOLOGY BEHA, V1, P385; Hoffman HG, 2000, PAIN, V85, P305, DOI 10.1016/S0304-3959(99)00275-4; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER; KEWMAN DG, 1985, REHABIL PSYCHOL, V30, P11; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; LEVINE O, 1998, P HUM FACT ERG SOC 4, P1136; LINGS S, 1991, APPL ERGON, V22, P75, DOI 10.1016/0003-6870(91)90305-2; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Michon J.A., 1985, HUMAN BEHAV TRAFFIC; Mourant R. R., 1999, P 41 ANN M HUM FACT, P1268; Nash EB, 2000, INT J HUM-COMPUT INT, V12, P1, DOI 10.1207/S15327590IJHC1201_1; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; Rizzo A., 1994, P 2 INT C VIRT REAL, P135; RIZZO AA, 1997, PSYCHONEUROPHYSIOLOG, P123; Rosenthal M, 1999, REHABILITATION ADULT; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1996, P MED MEETS VIRT REA, P100; SCHIFF W, 1994, BEHAV RES METH INSTR, V26, P192, DOI 10.3758/BF03204617; Schultheis MT, 1999, ARCH CLIN NEUROPSYCH, V14, P794; WACHTEL J, 2000, P 8 ANN MED MEETS VI, P100; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; WESTWOOD JD, 2000, MED MEETS VIRTUAL RE, P207; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5	37	39	39	1	15	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	1054-7460	1531-3263		PRESENCE-TELEOP VIRT	Presence-Teleoper. Virtual Env.	AUG	2001	10	4					431	439		10.1162/1054746011470271			9	Computer Science, Cybernetics; Computer Science, Software Engineering	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science	492AT	WOS:000172143800008					2022-02-06	
J	Henshall, DC; Skradski, SL; Bonislawski, DP; Lan, JQ; Simon, RP				Henshall, DC; Skradski, SL; Bonislawski, DP; Lan, JQ; Simon, RP			Caspase-2 activation is redundant during seizure-induced neuronal death	JOURNAL OF NEUROCHEMISTRY			English	Article						brain; epilepsy; kainic acid; programmed cell death; rat; TNF	TRAUMATIC BRAIN INJURY; EVOKED LIMBIC SEIZURES; CELL-DEATH; DNA FRAGMENTATION; KAINIC ACID; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; SIGNALING COMPLEX; ADAPTER MOLECULE; RAT-BRAIN	Seizure-induced neuronal death may be under the control of the caspase family of cell death proteases. We examined the role of caspase-2 in a model of focally evoked limbic seizures with continuous EEG recording. Seizures were elicited by microinjection of kainic acid into the amygdala of the rat and terminated after 40 min by diazepam. Caspase-2 was constitutively present in brain, mostly within neurons, and was detected in both cytoplasm and nucleus. Cleaved caspase-2 (12 kDa) was detected immediately following seizure termination within injured ipsilateral hippocampus, contiguous with increased Val-Asp-Val-Ala-Asp (VDVADase) activity, a putative measure of activated caspase-2. Expression of receptor interacting protein (RIP)-associated Ich-l-homologous protein with death domain (RAIDD) was increased following seizures, whereas expression of RIP and tumor necrosis factor receptor associated protein with death domain (TRADD), other components thought to be linked to the caspase-2 activation and signaling mechanism, were unchanged. Intracerebroventricular administration of z-VDVAD-fluoromethyl ketone blocked seizure-induced caspase-2 activity but did not alter caspase-8 activity and failed to affect DNA fragmentation or neuronal death. These data support activation of caspase-2 following seizures but suggest that parallel caspase pathways may circumvent deficits in caspase-2 function to complete the cell death process.	Legacy Clin Res & Technol Ltd, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA		Henshall, DC (corresponding author), Legacy Clin Res & Technol Ltd, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	dhenshall@DowNeurobiology.org	Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039016] Funding Source: NIH RePORTER		Ahmad M, 1997, CANCER RES, V57, P615; Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen J, 1998, J NEUROSCI, V18, P4914; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 2000, ACTA NEUROPATHOL, V99, P245, DOI 10.1007/PL00007434; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2000, BRAIN RES, V858, P290, DOI 10.1016/S0006-8993(99)02452-X; Henshall DC, 1999, J NEUROCHEM, V73, P1573, DOI 10.1046/j.1471-4159.1999.0731573.x; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kinoshita M, 1997, J CEREBR BLOOD F MET, V17, P507, DOI 10.1097/00004647-199705000-00004; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Paxinos P., 1997, RAT BRAIN STEREOTAXI; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; POLLARD H, 1994, NEUROREPORT, V5, P1053, DOI 10.1097/00001756-199405000-00009; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TANAKA S, 1988, BRAIN RES, V463, P163, DOI 10.1016/0006-8993(88)90541-0; Troy CM, 2000, J NEUROSCI, V20, P1386; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WASTERLAIN CG, 1994, BRAIN DEV-JPN, V16, P279, DOI 10.1016/0387-7604(94)90025-6; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	45	39	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2001	77	3					886	895		10.1046/j.1471-4159.2001.00291.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	429WX	WOS:000168541900018	11331417	Bronze			2022-02-06	
J	Feinstein, A; Ouchterlony, D; Somerville, J; Jardine, A				Feinstein, A; Ouchterlony, D; Somerville, J; Jardine, A			The effects of litigation on symptom expression: a prospective study following mild traumatic brain injury	MEDICINE SCIENCE AND THE LAW			English	Article							MINOR HEAD-INJURY; QUESTIONNAIRE; RECOVERY; SCALE	Objective: To prospectively assess the association between litigation and neurobehavioural symptoms following mild Traumatic Brain Injury (TBI). Design: a prospective study with the inception cohort assessed on average 42.2(17.2) days after injury. Setting: an outpatient clinic within a large general hospital. Patients: a consecutive sample of 100 clinic attenders with mild TBI. Outcome measures: A cognitive screen (Mini-Mental State Examination (MMSE), Galveston Orientation and Amnesia Test (GOAT), a measure of psychological distress (the 28 item General Health Questionnaire (GHQ)) and two head injury outcome measures, the Glasgow Outcome Scale (GOS) and the Rivermead Head Injury Follow-up Questionnaire (RHFUQ). Results: Demographic characteristics, TBI severity ratings and premorbid risk factors for poor outcome did not differ between litigants (27.8 per cent of the sample) and non-litigants. However, litigants were significantly more anxious (p <0.0001), depressed (p <0.01), had greater social dysfunction (p <0.0001) and had poorer outcome on the GOS (p <0.002) and RHFUQ (p <0.002). There were no cognitive differences between the groups. Conclusions: the data demonstrate an association between litigation and increased psychological distress at the outset of the litigation process. While association is not synonymous with causality, the absence of demographic, premorbid and TBI related differences between litigants and non-litigants suggests that the pursuit of compensation may influence the subjective expression of symptoms following mild traumatic brain injury.	Sunnybrook Hosp, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada		Feinstein, A (corresponding author), Sunnybrook Hosp, Room FG38,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Jardine, Alan/L-5770-2019				Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Cartlidge N E, 1981, HEAD INJURY; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; KAY DWK, 1971, LANCET, V2, P1052; Kay Thomas E., 1992, Archives of Physical Medicine and Rehabilitation, V73, P955; KELLY R, 1981, J ROY SOC MED, V74, P275, DOI 10.1177/014107688107400407; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P160; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V	21	39	40	0	1	CHILTERN PUBLISHING	BEACONSFIELD	34 AYLESBURY END, BEACONSFIELD, BUCKS, ENGLAND HP9 1LW	0025-8024			MED SCI LAW	Med. Sci. Law	APR	2001	41	2					116	121		10.1177/002580240104100206			6	Law; Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Government & Law; Legal Medicine; Pathology	431EA	WOS:000168617800006	11368391				2022-02-06	
J	Pillai, S; Praharaj, SS; Mohanty, A; Kolluri, VRS				Pillai, S; Praharaj, SS; Mohanty, A; Kolluri, VRS			Prognostic factors in children with severe diffuse brain injuries: A study of 74 patients	PEDIATRIC NEUROSURGERY			English	Article						head trauma; prognostic factors; diffuse brain injury	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; GLASGOW COMA SCALE; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; OUTCOME PREDICTION; DATA-BANK; AGE; ADOLESCENTS; MANAGEMENT	Severe diffuse brain injury in children has a devastating influence on their physical and psychological development. This retrospective study was undertaken to analyse the factors that influence outcome in children with such injuries. The short-term outcomes (Glasgow outcome score) of 74 children (age less than or equal to 15 years) with severe diffuse brain injury and no focal operable mass lesions on CT scan, admitted between 1992 and 1998 at the National Institute of Mental Health and Neurosciences were analysed. The prognostic factors analysed were age, gender, time after injury to admission, nature of injury, highest post-resuscitation Glasgow coma score (GCS), pupillary reaction, horizontal oculocephalic reflex and CT scan findings. The following factors were found to be independent predictors of poor outcome: GCS 3-5 (p < 0.003), absent verbal response (p < 0.001), motor response score of 1-3 (p < 0.001), absent pupillary reaction (p < 0.001), absent oculocephalic reflex (p < 0.001) and presence of traumatic subarachnoid haemorrhage on CT scan (p < 0.002). These independent variables were then subjected to a stepwise logistic regression analysis, and the most important variables for predicting outcome were oculocephalic reflex and GCS, which together correctly predicted unfavourable outcome with a sensitivity of 79% and a specificity of 65%, An early CT scan or a single CT scan did not have any prognostic significance. Copyright (C) 2001 S. Karger AG,Basel.	Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India		Praharaj, SS (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Hosur Rd, Bangalore 560029, Karnataka, India.	sspraharaj@hotmail.com					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CARDIA E, 1990, CHILD NERV SYST, V6, P23, DOI 10.1007/BF00262261; COURVILLE CB, 1965, ARCH SURG-CHICAGO, V90, P157; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FACCO E, 1986, CHILD NERV SYST, V2, P67; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Fleischer A S, 1976, Surg Neurol, V6, P31; FRANCEL PC, 1996, NEUROL SURG, V4, P1730; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUMPHREYS RP, 1983, CONCEPTS PEDIAT NEUR, P230; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Paret Gideon, 1999, Harefuah, V136, P677; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; Prpic I, 1993, Lijec Vjesn, V115, P224; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Sganzerla E P, 1989, Minerva Anestesiol, V55, P177; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 1996, ACTA NEUROCHIR, V138, P543, DOI 10.1007/BF01411174; VAPALAHTI M, 1986, ANN CLIN RES, V18, P37; Woischneck D, 1998, ACT NEUR S, V71, P138; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P405; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	43	39	40	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	FEB	2001	34	2					98	103		10.1159/000056002			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	420EH	WOS:000167991100007	11287810				2022-02-06	
J	Green, P; Iverson, GL				Green, P; Iverson, GL			Effects of injury severity and cognitive exaggeration on olfactory deficits in head injury compensation claims	NEUROREHABILITATION			English	Article						olfaction; neuropsychological assessment; brain injury; anosmia	IMPAIRMENT	The purpose of this study was to examine the relationship between exaggeration and scores on a test of olfactory discrimination in patients being assessed in connection with a claim for financial benefits. Participants were 448 patients referred to a private practice in Edmonton, Alberta, Canada for psychological or neuropsychological assessment, related to evaluation of impairment and disability resulting from a work-related or non-work related accident. All patients were involved in some form of compensation claim at the time of their evaluation. All patients completed two tests designed to detect exaggerated cognitive deficits, the Computerized Assessment of Response Bias (CARB) and the Word Memory Test (WMT) as part of their evaluation, The diagnostic groups included 322 head injury cases, varying from very minor to very severe. Normative data for the smell test were derived from 126 patients with orthopedic injuries who passed both the CARB and the WMT Patients with more severe traumatic brain injuries were 10-12 times more likely to have olfactory deficits than persons with trivial to mild head injuries, In a subgroup of patients who failed either the CARB or the WMT, there was no relationship between injury severity and total scores on the smell test. Therefore, the dose-response relationship between brain injury severity and olfactory deficits is severely attenuated when patients who are probably exaggerating their cognitive deficits are included in the analyses, Those patients with trivial to mild head injuries who demonstrated adequate effort on both the CARB and the WMT were no more likely to show olfactory deficits than the non-head-injured orthopedic control subjects. Therefore, anosmia following mild traumatic brain injury should not be concluded from self-reports or from tests of smell unless tests of effort have been passed. Effort should also be controlled in group studies of olfaction.	Univ British Columbia, Vancouver, BC V5Z 1M9, Canada		Green, P (corresponding author), Neurobiohav Associates, Suite 201,17107-107 Ave, Edmonton, AB T5S 1G3, Canada.			Iverson, Grant/0000-0001-7348-9570			ALLEN LM, 1999, S CARB WMT MANUALS; CONDOR R, 1992, COMPUTERIZED ASSESSM; Costanzo R. M., 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; Cox, 1997, MANUAL COMPUTERIZED; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P55; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Green P, 1998, ARCH CLIN NEUROPSYCH, V13, P138; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 1999, S CARB WMT MANUALS; GREEN P, 1997, NATL ACAD NEUROPSYCH; GREEN P, IN PRESS CLIN NEUROP; Green P., 1996, WORD MEMORY TEST USE; Iverson G., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V0005, P00213, DOI DOI 10.1037/0894-4105.5.3.213; POURMAND R, 1999, PRACTICING NEUROLOGY; Reynolds CR, 1998, CRIT ISS NE, P261; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P839; ROHLING ML, IN PRESS ARCH CLIN N; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; van der Werf SP, 2000, NEUROPSY NEUROPSY BE, V13, P199; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745	25	39	41	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2001	16	4					237	243					7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	521VC	WOS:000173861200008	11790910				2022-02-06	
J	Yan, HQ; Yu, JY; Kline, AE; Letart, P; Jenkins, LW; Marion, DW; Dixon, CE				Yan, HQ; Yu, JY; Kline, AE; Letart, P; Jenkins, LW; Marion, DW; Dixon, CE			Evaluation of combined fibroblast growth factor-2 and moderate hypothermia therapy in traumatically brain injured rats	BRAIN RESEARCH			English	Article						controlled cortical impact; neurotrophin; MWM	SPINAL-CORD INJURY; CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC HYPOTHERMIA; CDP-CHOLINE; BEHAVIORAL DEFICITS; HIPPOCAMPAL-NEURONS; FUNCTIONAL RECOVERY; UP-REGULATION; LONG-TERM; CELL LOSS	Both the exogenous administration of fibroblast growth factor-2 (FGF-2) or the induction of moderate hypothermia have been shown to attenuate histopathology and improve functional outcome after traumatic brain injury (TBI). Since combined therapeutic strategies may be more beneficial than single therapies, we examined the potential synergistic effect of FGF-2 combined with moderate hypothermia treatment induced 10 min after TBI on functional and histological outcome following controlled cortical impact (CCI) injury. Fifty male Sprague-Dawley rats were randomized to one sham and four CCI treatment groups: Sham+vehicle (VEH); FGF-2 (45 mug/kg/h for 3 h i.v.)+Normothermia (37 +/- 0.5 degreesC); FGF-2+Hypothermia (32 +/- 0.5 degreesC for 3 h); VEH+Norm; VEH+Hypo. Vestibulomotor performance on the beam balance and beam-walk (BW) tasks on post-operative days 1-5 and spatial memory acquisition in the Morris water maze (MWM) on days 14-18 were assessed. After 4 weeks survival, histological evaluations (CA(1) and CA(3) cell counts and lesion volume) were performed. MWM performance improved in all treatment groups, but combined treatment was not more efficacious than either alone. The FGF-2+Hypo group performed significantly better than the other injured treatment groups in the BW task. Lastly, no significant group differences in beam balance or histological outcome were observed. These data suggest a suboptimal and incomplete synergy of combined FGF-2 and hypothermia treatment. These data may indicate that either our dose of FGF-2 or combination therapy was not optimized in our model. (C) 2000 Elsevier Science BN. All rights reserved.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Loyola Univ Chicago, Dept Neurosurg, Maywood, IL 60153 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, R01NS033150, P50NS030318, R01NS040125] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40125, NS33150, NS30318] Funding Source: Medline		BAFFOUR R, 1995, J NEUROSURG, V83, P105, DOI 10.3171/jns.1995.83.1.0105; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Bethel A, 1997, STROKE, V28, P609, DOI 10.1161/01.STR.28.3.609; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUKI A, 1999, NEUROL RES, V21, P585; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cuevas P, 1998, SURG NEUROL, V49, P77, DOI 10.1016/S0090-3019(97)00193-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DORMAN RV, 1983, J NEUROCHEM, V40, P276, DOI 10.1111/j.1471-4159.1983.tb12682.x; Fitzsimonds RM, 1998, PHYSIOL REV, V78, P143, DOI 10.1152/physrev.1998.78.1.143; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; JONES SB, 1984, J APPL PHYSIOL, V57, P808, DOI 10.1152/jappl.1984.57.3.808; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kusumoto M, 1997, METAB BRAIN DIS, V12, P113, DOI 10.1023/B:MEBR.0000007106.51802.37; Lee TT, 1999, J NEUROTRAUM, V16, P347, DOI 10.1089/neu.1999.16.347; LIU Z, 1993, BRAIN RES, V626, P335, DOI 10.1016/0006-8993(93)90598-H; LOUIS JC, 1993, EUR J NEUROSCI, V5, P1610, DOI 10.1111/j.1460-9568.1993.tb00230.x; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1996, CRIT CARE MED, V24, pS81; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Ramirez JJ, 1999, NEUROREPORT, V10, P1201, DOI 10.1097/00001756-199904260-00008; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; Valouskova V, 1999, NEUROBIOL LEARN MEM, V71, P132, DOI 10.1006/nlme.1998.3877; YING Z, 1993, J CEREBR BLOOD F MET, V13, P378, DOI 10.1038/jcbfm.1993.51	52	39	39	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 22	2000	887	1					134	143		10.1016/S0006-8993(00)03002-X			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	387HH	WOS:000166116800016	11134598				2022-02-06	
J	Ginis, I; Hallenbeck, JM; Liu, J; Spatz, M; Jaiswal, R; Shohami, E				Ginis, I; Hallenbeck, JM; Liu, J; Spatz, M; Jaiswal, R; Shohami, E			Tumor necrosis factor and reactive oxygen species cooperative cytotoxicity is mediated via inhibition of NF-kappa B	MOLECULAR MEDICINE			English	Article							CLOSED-HEAD INJURY; DNA-BINDING ACTIVITY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; BETA-PEPTIDE TOXICITY; FACTOR-ALPHA; TNF-ALPHA; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS	Background: Tumor necrosis factor alpha (TNF alpha) plays a key role in pathogenesis of brain injury. However, TNF alpha exhibits no cytotoxicity in primary cultures of brain cells. This discrepancy suggests that other pathogenic stimuli that exist in the setting of brain injury precipitate TNF alpha cytotoxicity. The hypothesis was tested that reactive oxygen species (ROS), that are released early after brain injury, act synergistically with TNF alpha in causing cell death. Materials and Methods: Cultured human and rat brain capillary endothelial cells (RBEC), and cortical astrocytes were treated with TNF alpha alone or together with different doses of H2O2, and apoptotic cell death and DNA fragmentation were measured by means of 3'-OH-terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and Hoechst fluorescence assay, respectively. The effect of H2O2 on TNF alpha -induced activation of nuclear factor kappa B (NF-kappaB) was measured by Western blots of cytoplasmic and nuclear extracts of RBEC using anti-inhibitor of NF-kappaB (I kappaB) and anti-p65 subunit of NF-kappaB antibodies. Nuclear translocation of NF-kappaB was investigated by immunofluorescent staining of RBEC with anti-p65 antibodies. Results: TNF alpha alone had no cytotoxic effect in brain endothelial cells and astrocytes at concentrations up to 100 ng/ml. Go-treatment with 5-10 muM of H2O2 caused a two-fold increase in the number of apoptotic cells 24 hr later. Similar doses (1-3 muM) of H2O2 initiated early DNA fragmentation. H2O2 inhibited TNF alpha -induced accumulation of p69 in the nucleus, although it had no effect on degradation of the I kappaB in cytoplasm. Immunostaining confirmed that H2O2 inhibited p65 transport to the nucleus. Conclusions: Reactive oxygen species could act synergistically with TNF alpha in causing cytotoxicity via inhibition of a cytoprotective branch of TNF alpha signaling pathways, which starts with NF-kappaB activation.	NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel			ginisi@ninds.nih.gov					Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BARGER SW, 1998, NEUROPROTECTIVE SIGN, P163; Baronet AM, 1999, CLIN PSYCHOL REV, V19, P819, DOI 10.1016/S0272-7358(98)00076-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; Carroll JE, 1998, MOL BRAIN RES, V56, P186, DOI 10.1016/S0169-328X(98)00045-X; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Furukawa K, 1998, J NEUROCHEM, V70, P1876; Ginis I, 1997, AM J PHYSIOL-CELL PH, V272, pC295, DOI 10.1152/ajpcell.1997.272.1.C295; GINIS I, 1995, J IMMUNOL, V155, P802; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171, DOI 10.1152/ajpcell.1999.276.5.C1171; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Hallenbeck JM, 1997, NEUROLOGY, V49, pS5, DOI 10.1212/WNL.49.5_Suppl_4.S5; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; ISRAEL N, 1992, J IMMUNOL, V149, P3386; ITO A, 1995, J NEUROCHEM, V65, P463; Jornot L, 1997, FEBS LETT, V416, P381, DOI 10.1016/S0014-5793(97)01244-1; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144, DOI 10.1152/ajpcell.2000.278.1.C144; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Love S, 1999, BRAIN PATHOL, V9, P119; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MEIRSTRELL ME, 1997, SHOCK, V8, P341; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; OHARA Y, IN PRESS ACTA NEUROC; Piette J, 1997, BIOL CHEM, V378, P1237; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; Rahman A, 1998, AM J PHYSIOL-LUNG C, V275, pL533, DOI 10.1152/ajplung.1998.275.3.L533; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Spatz M, 1997, AM J PHYSIOL-CELL PH, V272, pC231, DOI 10.1152/ajpcell.1997.272.1.C231; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tenneti L, 1998, J NEUROCHEM, V71, P946; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YAMASAKI T, 1992, J NEUROSURG, V77, P279, DOI 10.3171/jns.1992.77.2.0279; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	83	39	39	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	DEC	2000	6	12					1028	1041		10.1007/BF03402054			14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	392MT	WOS:000166415800004	11474119	Green Published, gold			2022-02-06	
J	Sallis, RE; Jones, K				Sallis, RE; Jones, K			Prevalence of headaches in football players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						athletic injuries; brain concussion; football; head injuries	CEREBRAL CONCUSSION; HEAD-INJURIES; 2ND IMPACT; SPORTS; MANAGEMENT; PREVENTION; TRAUMA; SCHOOL	Background: Football coaches and team physicians rely heavily on players' reports of symptoms in deciding whether a player may return to the game after sustaining head trauma. The decision is made difficult by the wide variety of associated symptoms, some of which (e.g., headache is among the most common) may or may not be associated with serious head injury. More information is needed about the clinical significance of football-related headache. Methods: To assess the frequency of headache associated with playing football, we analyzed responses to our questionnaire asking about incidence, frequency, and outcome of football-related headache from 443 football players (320 from college, 123 from high school). Results: Eighty-five percent of respondents reported previous headache related to hitting in football. Asked specifically about their most recent game, 21% of respondents reported having had headache during that game. Of players who had headache, only 19% informed the team physician, trainer, or coach, and only 6% were removed from the game. Twenty-seven percent of respondents reported previous diagnosis of cerebral concussion by medical personnel. Defensive backs (25%), defensive linemen (19%), and offensive linemen (18%) were most likely to have headache, related to hitting. Conclusions: Our data confirm that posttraumatic headache is commonly associated with football participation and often goes unreported. Given that the most serious complications of head injuries (e.g., second-impact syndrome) occur infrequently, headache aa an isolated symptom lacks specificity in predicting such complications in football players. Therefore, unless it persists or is accompanied by additional symptoms, headache alone may not reliably suggest the need to remove players from the game.	Kaiser Permanente Med Ctr, Dept Family Med, Fontana, CA USA; Pomona Coll, Dept Phys Educ, Claremont, CA 91711 USA		Sallis, RE (corresponding author), Kaiser Permanente Med Off, Dept Family Med Sports Med, 10850 Arrow Rt, Rancho Cucamonga, CA 91730 USA.	robert.e.sallis@kp.org					CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P31; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Sallis R. E., 1998, Medicine and Science in Sports and Exercise, V30, pS157; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider RC., 1973, HEAD NECK INJURIES F; SCHNEIDER RC, 1985, SPORTS INJURIES MECH, P877; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; *SPORTS MED COMM C, 1991, GUID MAN CONC SPORTS, P4; *UCLA SCH MED, 1995, SPORTS MED, V17, P1; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	24	39	40	2	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	NOV	2000	32	11					1820	1824		10.1097/00005768-200011000-00002			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	372ED	WOS:000165220600002	11079509				2022-02-06	
J	Whalen, MJ; Carlos, TM; Wisniewski, SR; Clark, RSB; Melick, JA; Marion, DW; Kochanek, PM				Whalen, MJ; Carlos, TM; Wisniewski, SR; Clark, RSB; Melick, JA; Marion, DW; Kochanek, PM			Effect of neutropenia and granulocyte colony stimulating factor-induced neutrophilia on blood-brain barrier permeability and brain edema after traumatic brain injury in rats	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; rats; granulocyte colony stimulating factor; blood-brain barrier; edema; controlled cortical impact; neutrophils	NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; ADHESION MOLECULES; CEREBROSPINAL-FLUID; REPERFUSION INJURY; ACUTE-INFLAMMATION; SMOOTH-MUSCLE; IN-VIVO	Objective: Granulocyte colony stimulating factor (GCSF) has been used to increase systemic absolute neutrophil count (ANC) in patients with severe traumatic brain injury to reduce nosocomial infection risk. However, the effect of increasing systemic ANC on the pathogenesis of experimental traumatic brain injury has not been studied. Thus, we evaluated the effect of systemic ANC on blood-brain barrier (BBB) damage and brain edema after traumatic brain injury in rats. Design: Experimental study. Setting: Research laboratory at the University of Pittsburgh, PA. Subjects: Forty-three adult male Sprague-Dawley rats. Interventions: Protocol I: rats were randomized to receive either vinblastine sulfate to reduce ANC, GCSF to increase ANC, or saline before controlled cortical impact (CCI) of moderate overall severity. Evans blue was used to assess BBB damage at 4-24 hrs after CGI. Protocol II: rats received GCSF or saline before CCI. Brain edema was estimated at 24 hrs using (wet - dry) / wet weight method. Protocol III: rats received GCSF or saline before CCI. Brain neutrophil accumulation was estimated at 24 hrs using a myeloperoxidase assay. Measurements and Main Results: Physiologic variables were controlled before CCI was maintained at normal in all animals before traumatic brain injury. No rats were anemic, hypoglycemic, or hypotensive before CCI. Protocol I: compared with control, systemic ANC decreased in vinblastine-treated rats and increased in GCSF-treated rats. BBB damage correlated with systemic ANC. Protocol II: mean systemic ANC before traumatic brain injury Increased 15-fold in rats given GCSF vs. control; however no difference in brain edema was observed at 24 hrs after injury between groups. Protocol III: median systemic ANC at the time of CCI was increased ten-fold in rats given GCSF vs. control. No difference in brain myeloperoxidase activity 24 hrs after CCI was observed in rats treated with GCSF vs. control. Conclusions: Systemic ANC influences BBB damage after traumatic brain injury produced by CGI. Because BBB damage and brain edema are discordant, mechanisms other than BBB damage likely predominate in the pathogenesis of brain edema after contusion. The implications of increased BBB permeability with the administration of GCSF in our model remains to be determined. Increasing systemic ANG before CCI with GCSF administration does not increase posttraumatic brain neutrophil accumulation or brain edema after CCI in rats. The finding that neutrophil infiltration is not enhanced by systemic neutrophilia suggests that the ability of GCSF-stimulated neutrophils to migrate into injured tissue may be impaired, Further studies are needed to evaluate the effects of GCSF administration on secondary injury and functional outcome in experimental models of traumatic brain injury.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Brain Trauma Res Ctr, Pittsburgh, PA USA		Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 4th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		Adamson P, 1999, J IMMUNOL, V162, P2964; Adelson PD, 1998, ACT NEUR S, V71, P104; Azzara A, 1996, BRIT J HAEMATOL, V92, P161, DOI 10.1046/j.1365-2141.1996.00295.x; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Deetjen C, 1999, IMMUNOPHARMACOLOGY, V43, P23, DOI 10.1016/S0162-3109(99)00036-3; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Goldman S, 1998, CLIN PERINATOL, V25, P699, DOI 10.1016/S0095-5108(18)30106-4; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Katayama Y, 1998, ACT NEUR S, V71, P289; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDSBERG PJ, 1995, J NEUROSURG, V82, P269, DOI 10.3171/jns.1995.82.2.0269; Matsumoto T, 1997, LAB INVEST, V77, P119; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; Pajkrt D, 1997, BLOOD, V90, P1415, DOI 10.1182/blood.V90.4.1415.1415_1415_1424; Peter FW, 1998, MICROSURG, V18, P290, DOI 10.1002/(SICI)1098-2752(1998)18:4<290::AID-MICR15>3.3.CO;2-U; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Rosenbloom AJ, 1999, J LEUKOCYTE BIOL, V66, P83, DOI 10.1002/jlb.66.1.83; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96, DOI 10.1002/jlb.46.2.96; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Soares HD, 1995, J NEUROSCI, V15, P8223; Squadrito F, 1997, BRIT J PHARMACOL, V120, P333, DOI 10.1038/sj.bjp.0700904; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; TERASHIMA T, 1995, AM J RESP CELL MOL, V13, P69, DOI 10.1165/ajrcmb.13.1.7541223; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yakovlev A., 1994, Society for Neuroscience Abstracts, V20, P423; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; YOUNG AB, 1985, NEUROSURGERY, V16, P725	67	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2000	28	11					3710	3717		10.1097/00003246-200011000-00029			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376AQ	WOS:000165436000022	11098978				2022-02-06	
J	Hrbac, J; Kohen, R				Hrbac, J; Kohen, R			Biological redox activity: Its importance, methods for its quantification and implication for health and disease	DRUG DEVELOPMENT RESEARCH			English	Article						redox potential; biological redox state; cyclic voltammetry; antioxidants; reactive oxygen species	CLOSED-HEAD INJURY; OXIDATIVE STRESS; ANTIOXIDANT CAPACITY; CYCLIC VOLTAMMETRY; IN-VIVO; REDUCTION; TISSUES	Cellular redox phenomena are involved in numerous biochemical pathways and play a key role in many pathological events and clinical situations. The overall oxidation/reduction (redox) state present in biological compartments is a major target for possible pharmaceutical intervention and, consequently, the processes associated with its change have attracted increased attention in recent years. This overview describes the methods for evaluating the concentrations of redox active compounds and their redox activity and the methods for evaluating the overall biological fluids and tissues redox capacity, with a focus on the redox potential parameter, its modulation, its measurement, and its importance for diagnosis and treatment. Examples of voltammetric measurement of reducing power profiles of biological tissues and fluids in healthy and disease states are discussed. (C) 2000 Wiley-Liss, Inc.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel		Kohen, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, POB 12065, IL-91120 Jerusalem, Israel.	ronko@cc.huji.ac.il	Hrbac, Jan/A-1007-2009				Alexander R W, 1998, Trans Am Clin Climatol Assoc, V109, P129; Berry EM, 1999, MED HYPOTHESES, V53, P397, DOI 10.1054/mehy.1998.0786; Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272; BLAU S, 2000, IN PRESS DIGEST DIS; Cao GH, 1999, METHOD ENZYMOL, V299, P50; CLARK WM, 1965, OXIDATION REDUCTION; Dolan ME, 1998, ANTI-CANCER DRUG, V9, P437, DOI 10.1097/00001813-199806000-00011; Elangovan V, 2000, FREE RADICAL RES, V32, P125, DOI 10.1080/10715760000300131; Engelhardt JF, 1999, ANTIOXID REDOX SIGN, V1, P5, DOI 10.1089/ars.1999.1.1-5; Halliwell B., 1989, FREE RADICAL BIO MED, P160; HAWKRIDGE FM, 1973, ANAL CHEM, V45, P1021, DOI 10.1021/ac60329a038; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kohen R, 1999, BIOMED PHARMACOTHER, V53, P181, DOI 10.1016/S0753-3322(99)80087-0; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kohen R, 2000, FREE RADICAL BIO MED, V28, P871, DOI 10.1016/S0891-5849(00)00191-X; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KOHEN R, 2000, IN PRESS TOXICOLOGY; KOHEN R, 1993, 100 ILSI; Kuhn DM, 1998, J NEUROSCI, V18, P7111; LOXTON GE, 1953, NATURE, V171, P524, DOI 10.1038/171524a0; NOEL M, 1990, CYCLIC VOLTAMMETRY F, P62; O'Neill RD, 1998, CRIT REV NEUROBIOL, V12, P69, DOI 10.1615/CritRevNeurobiol.v12.i1-2.40; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.3.CO;2-H; Prieto-Alamo MJ, 1999, CARCINOGENESIS, V20, P415, DOI 10.1093/carcin/20.3.415; RIGO A, 1977, FEBS LETT, V80, P130, DOI 10.1016/0014-5793(77)80422-5; ROSSITER BW, 1986, PHYSICAL METHODS CHE, V2; ROUILLON JD, 1987, J PHARMACOL METHOD, V17, P179, DOI 10.1016/0160-5402(87)90029-5; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAPIRO HM, 1972, J SURG RES, V13, P138, DOI 10.1016/0022-4804(72)90057-1; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Torimura M, 1998, ANAL CHEM, V70, P4690, DOI 10.1021/ac980621z; Wang S, 1998, P SOC EXP BIOL MED, V217, P197, DOI 10.3181/00379727-217-44223; WEISSENBERGER A, 1971, PHYSICAL METHODS CHE, V1; YANNAI EB, 1997, J CEREB BLOOD FLOW M, V17, P273; ZHANG C, 1998, INT SER ON ADVANC FR, V2, P1	41	39	39	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0272-4391	1098-2299		DRUG DEVELOP RES	Drug Dev. Res.	JUL-AUG	2000	50	3-4					516	527		10.1002/1098-2299(200007/08)50:3/4<516::AID-DDR35>3.0.CO;2-B			12	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	359TK	WOS:000089628000035					2022-02-06	
J	Meeuwisse, WH; Hagel, BE; Mohtadi, NGH; Butterwick, DJ; Fick, GH				Meeuwisse, WH; Hagel, BE; Mohtadi, NGH; Butterwick, DJ; Fick, GH			The distribution of injuries in men's Canada west university football - A 5-year analysis	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							HIGH-SCHOOL FOOTBALL; HEAD; CONCUSSION; SPORTS; FATALITIES; REGISTRY	We conducted a prospective cohort study from 1993 to 1997 to determine the frequency and severity of injury in men's Canada West university football. The Canadian Intercollegiate Sport Injury Registry was used to document baseline preseason data, daily athlete participation, and subsequent injury from five varsity football teams. An injury was defined as "any injury resulting in one or more complete or partial sessions of time loss" or "any concussion or transient neck neurologic injury." The annual proportion of injured athletes ranged from 53.5% to 60.4%, with a 5-year total of 1811 injuries. Regression analysis indicated that the rate of nonconcussion, nonneck neurologic injuries increased. Concussion (N = 110), hamstring strain (N = 88), and brachial plexus (N = 84) injuries were the most common, specific injury diagnoses. Knee injuries resulted in the highest rate of severe (greater than or equal to 7 sessions of time loss) injury and resulted in the most time loss (3350.5 sessions). Ligament sprains and muscle strains and spasms accounted for approximately half of all injury diagnoses. A total of 1173 injuries (65%) were related to contact between players or between players and other obstacles. Future studies should be conducted to identify risk factors for the ultimate purpose of implementing injury prevention strategies.	Univ Calgary, Ctr Sports Med, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada		Meeuwisse, WH (corresponding author), Univ Calgary, Ctr Sports Med, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.		Hagel, Brent/AAK-3319-2020				ADKISON JW, 1974, CLIN ORTHOP RELAT R, P131; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ALLEY RH, 1964, JAMA-J AM MED ASSOC, V188, P418; Blyth Carl S, 1974, Phys Sportsmed, V2, P45, DOI 10.1080/00913847.1974.11948096; BLYTH CS, 1974, PHYSICIAN SPORTSMED, V2, P49; BLYTH CS, 1974, PHYSICIAN SPORTSMED, V2, P71; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cahill B R, 1979, Am J Sports Med, V7, P183, DOI 10.1177/036354657900700309; CANALE ST, 1981, AM J SPORT MED, V9, P384, DOI 10.1177/036354658100900608; CANTU RC, 1992, CLIN J SPORT MED, V2, P180; DAGLAU RF, 1980, AM J SPORTS MED, V8, P257; DEHAVEN KE, 1986, AM J SPORT MED, V14, P218, DOI 10.1177/036354658601400307; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V12, P122; GRONWALL D, 1975, LANCET, V2, P995; KARPAKKA J, 1993, BRIT J SPORT MED, V27, P135, DOI 10.1136/bjsm.27.2.135; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, AM SOC TEST MATER, V1305, P35, DOI 10.1520/STP11770S; LINDER MM, 1995, CLIN J SPORT MED, V5, P167, DOI 10.1097/00042752-199507000-00006; MEEUWISSE WH, 1988, CAN J SPORT SCI, V13, P35; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Meeuwisse WH, 1999, J INFORMATICS PRIM C, P2; MEEUWISSE WH, 1994, THESIS U CALGARY CAL; Mueller F O, 1974, J Sports Med, V2, P1; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; MUELLER FO, 1984, ATHLETIC TRAINING, V19, P189; Murphy R J, 1978, Phys Sportsmed, V6, P94, DOI 10.1080/00913847.1978.11710760; *NAT COLL ATHL ASS, 1998, INJ SURV SYST; *NAT COLL ATHL ASS, 1996, INJ SURV SYST; Olson O C, 1979, Phys Sportsmed, V7, P75, DOI 10.1080/00913847.1979.11710899; POWELL J, 1987, Athletic Training, V22, P19; Powell J W, 1988, Am J Sports Med, V16 Suppl 1, pS134; POWELL JW, 1992, AM J SPORT MED, V20, P686, DOI 10.1177/036354659202000609; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; PRITCHETT JW, 1980, AM J SPORT MED, V8, P197, DOI 10.1177/036354658000800310; PRITCHETT JW, 1982, J BONE JOINT SURG AM, V64, P240, DOI 10.2106/00004623-198264020-00015; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; VERESCHAGIN KS, 1991, PHYSICIAN SPORTSMED, V19, P96; Whitley RI, 1985, HERPESVIRUSES, V3, P1; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	44	39	40	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JUL-AUG	2000	28	4					516	523		10.1177/03635465000280041201			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	337PK	WOS:000088370700012	10921643				2022-02-06	
J	Greenspan, AI; Mackenzie, EJ				Greenspan, AI; Mackenzie, EJ			Use and need for post-acute services following paediatric head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CHILDREN; REHABILITATION	This paper aims to document the types of inpatient and outpatient post-acute services children receive after discharge from an acute care hospital for head injury and to better understand the extent to which children fail to receive services and the reasons for not receiving needed services. A follow-up was conducted on 95 children (aged 5-15) 1 year after they were hospitalized for head injury. Parents were interviewed by phone concerning their child's use of and need for medical, rehabilitation, and social services since the injury. Questions were also asked regarding the child's current health status and behaviour. Inpatient records were reviewed to obtain information on the characteristics of the injury. Overall use of outpatient rehabilitation and social services was low during the year following injury, ranging from 0-18%, of the study sample. Although need for and use of services was positively correlated with head injury severity, it appears that unmet need was highest for children with the least severe head injuries. Finally, need for physical or occupational therapy and mental health services was unrecognized for one third of children with physical limitations and 40% of children with at least 14 identified behaviour problems. These findings underscore the need for physicians and other health care professionals to thoroughly evaluate children during follow-up visits as well as during the initial hospitalization for head injury-related deficits. Identification of functional deficits or behavioural problems should be followed-up by evaluation and treatment by qualified rehabilitation professionals.	Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21218 USA		Greenspan, AI (corresponding author), Emory Univ, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.						ADAY LA, 1980, HLTH CARE US EQUITAB; ADAY LA, 1984, ACCESS MED CARE US H; ANDERSEN R, 1978, MED CARE, V16, P533, DOI 10.1097/00005650-197807000-00001; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; *COMM TRAUM RES CO, 1985, INJ AM CONT HLTH PRO; EISEN M, 1980, R2313HEW; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; GREENSPAN AI, 1989, MARYLAND MED J, V28, P239; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hulka B S, 1978, J Community Health, V4, P140, DOI 10.1007/BF01318950; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; JAFFE KM, 1992, PEDIATR ANN, V21, P443; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; SOLOMON E, 1988, THESIS J HOPKINS U B; STONNINGTON HH, 1991, VIRGINIA MED Q, V18, P159; TEASDALE G, 1974, LANCET, V2, P81; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Zill N., 1985, BEHAV PROBLEM SCALES; ZILL N, 1985, BEHAV PROBLEMS INDEX	24	39	39	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2000	14	5					417	429					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	316MQ	WOS:000087171500003	10834337				2022-02-06	
J	Jones, SJ; Pato, MV; Sprague, L; Stokes, M; Munday, R; Haque, N				Jones, SJ; Pato, MV; Sprague, L; Stokes, M; Munday, R; Haque, N			Auditory evoked potentials to spectro-temporal modulation of complex tones in normal subjects and patients with severe brain injury	BRAIN			English	Article						auditory evoked potentials; auditory cortex; brain injury; coma; mismatch negativity	EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY; TRAUMATIC COMA; HEAD-INJURY; CORTEX; TOOL; REPRESENTATION; NEUROSCIENCE; RESPONSES; PARADIGM	In order to assess higher auditory processing capabilities, long-latency auditory evoked potentials (AEPs) were recorded to synthesized musical instrument tones in 22 post-comatose patients with severe brain injury causing variably attenuated behavioural responsiveness. On the basis of normative studies, three different types of spectre-temporal modulation were employed. When a continuous 'clarinet) tone changes pitch once every few seconds, N1/P2 potentials are evoked at latencies of similar to 90 and 180 ms, respectively. Their distribution in the fronto-central region is consistent with generators in the supratemporal cortex of both hemispheres. When the pitch is modulated at a much faster rate (similar to 16 changes/s), responses to each change are virtually abolished but potentials with similar distribution are still elicited by changing the timbre (e.g. 'clarinet' to 'oboe') every few seconds. These responses appear to represent the cortical processes concerned with spectral pattern analysis and the grouping of frequency components to form sound 'objects'. Following a period of 16/s oscillation between two pitches, a more anteriorly distributed negativity is evoked on resumption of a steady pitch. Various lines of evidence suggest that this is probably equivalent to the 'mismatch negativity' (MMN), reflecting a pre-perceptual, memory-based process for detection of change in spectrotemporal sound patterns. This method requires no offline subtraction of AEPs evoked by the onset of a tone, and the MMN is produced rapidly and robustly with considerably larger amplitude (usually >5 mu V) than that to discontinuous pure tones. In the brain-injured patients, the presence of AEPs to two or more complex tone stimuli (in the combined assessment of two authors who mere 'blind! to the clinical and behavioural data) was significantly associated with the demonstrable possession of discriminative hearing (the ability to respond differentially to verbal commands, in the assessment of a further author who was blind to the AEP findings). Behavioural and electrophysiological findings were in accordance in 18/22 patients, but no AEPs could be recorded in two patients who had clear behavioural evidence of discriminative hearing. The absence of long-latency AEPs should not, therefore, be considered indicative of complete functional deafness. Conversely, AEPs mere substantially preserved in two patients without behavioural evidence of discriminative hearing. Although not necessarily indicative of conscious 'awareness', such AEP preservation might help to identify sentient patients who are prevented by severe motor disability from communicating their perception.	UCL Natl Hosp Neurol & Neurosurg, Dept Clin Neurophysiol, London WC1N 3BG, England; Royal Hosp Neurodisabil, Res Dept, London, England; Royal Hosp Neurodisabil, Occupat Therapy Dept, London, England		Jones, SJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Clin Neurophysiol, Queen Sq, London WC1N 3BG, England.	sjjones@ion.ucl.ac.uk	da Assuncao AMC Vaz Patto, Maria/A-1091-2017; Stokes, Maria/G-2288-2011	da Assuncao AMC Vaz Patto, Maria/0000-0002-0653-3428; Stokes, Maria/0000-0002-4204-0890			ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; Bregman A.S., 1990, AUDITORY SCENE ANAL; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; COWAN N, 1984, PSYCHOL BULL, V96, P341, DOI 10.1037/0033-2909.96.2.341; EGGERMONT JJ, 1995, NEUROREPORT, V6, P1645, DOI 10.1097/00001756-199508000-00014; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GUERIT JM, 1999, ELECTROEN CLIN NEURO, V110, P1260; Halliday A.M, 1993, EVOKED POTENTIALS CL; Jones SJ, 1998, EVOKED POTENTIAL, V108, P355, DOI 10.1016/S0168-5597(98)00009-4; Jones SJ, 1998, EVOKED POTENTIAL, V108, P131, DOI 10.1016/S0168-5597(97)00077-4; Jones SJ, 1999, EEG CL N SU, P41; JONES SJ, 2000, P 4 INT S MEM AW AN, V4, P269; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; NAATANEN R, 1995, EAR HEARING, V16, P6; Pato MV, 1999, COGNITIVE BRAIN RES, V7, P295; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Rappaport M, 1990, J Neuropsychiatry Clin Neurosci, V2, P399; RITTER W, 1995, EAR HEARING, V16, P52, DOI 10.1097/00003446-199502000-00005; RUIJS MBM, 1993, NEUROPEDIATRICS, V24, P307, DOI 10.1055/s-2008-1071562; SAMSON S, 1994, NEUROPSYCHOLOGIA, V32, P231, DOI 10.1016/0028-3932(94)90008-6; Schreiner CE, 1998, AUDIOL NEURO-OTOL, V3, P104, DOI 10.1159/000013785; SHIN DY, 1989, ARCH PHYS MED REHAB, V70, P189; Signorino M, 1997, J PSYCHOPHYSIOL, V11, P59; STEINSCHNEIDER M, 1995, BRAIN RES, V674, P147, DOI 10.1016/0006-8993(95)00008-E; Versnel H, 1998, J ACOUST SOC AM, V103, P2502, DOI 10.1121/1.422771; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685; Yabe H, 1998, PSYCHOPHYSIOLOGY, V35, P615, DOI 10.1017/S0048577298000183	33	39	42	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2000	123		5				1007	1016		10.1093/brain/123.5.1007			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	323TK	WOS:000087580900014	10775545	Bronze			2022-02-06	
J	Nell, V; Yates, DW; Kruger, J				Nell, V; Yates, DW; Kruger, J			An extended Glasgow Coma Scale (GCS-E) with enhanced sensitivity to mild brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Aspen Neurobehavioral Conference	APR, 1998	ASPEN, COLORADO			Glasgow Coma Scale; mild traumatic brain injury; posttraumatic amnesia; developing countries; rehabilitation	HEAD-INJURY	Objective: The Glasgow Coma Scale-Extended (GCS-E) was developed to flag mild cases of concussion (corresponding to Grades I and II concussion as defined by the American Academy of Neurology) at the time of first contact with the health care system. Subjects and Setting: The GCS-E was applied to 561 consecutive admissions with GCS scores of 13 to 15 at two hospitals in South Africa and two in the United Kingdom (UK). Results: The amnesia scale was readily learned and reliably applied by emergency department staff without affecting the standard scoring of the GCS itself. Among patients with an admitting GCS of 15, 27% in the UK and 31% in South Africa reported amnesia of some duration. Conclusions: Wide use of the GCS-E would hold mild traumatic brain injury cases in the treatment loop, improve access to counselling, rehabilitation services, and personal injury compensation, and reduce the "cognitive dissonance" between victims of mild traumatic brain injury and treating professionals.	Univ S Africa, Inst Social & Hlth Sci, ZA-0001 Pretoria, South Africa; Univ S Africa, Dept Psychol, ZA-0001 Pretoria, South Africa; Univ Manchester, Dept Surg, Manchester, Lancs, England		Nell, V (corresponding author), Univ S Africa, Inst Social & Hlth Sci, POB 392, ZA-0001 Pretoria, South Africa.						Benton A. L, 1989, MILD HEAD INJURY, P3; BLAKELY TA, 1993, MED SCI LAW, V33, P231, DOI 10.1177/002580249303300309; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Jennett B, 1989, MILD HEAD INJURY, P23; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marshall LF, 1989, MILD HEAD INJURY, P276; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; NELL V, 1997, 972 U S AFR HLTH PSY; NORUSIS MJ, 1993, SPSS WINDOWS BASE SY; Romer CJ, 1995, PREVENTION CRITICAL; TEASDALE G, 1974, LANCET, V2, P81; THURMAN DJ, 1995, WHO STANDARDS SURVEI; Wilson BA., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [DOI 10.1080/09602019208401410, 10.1080/09602019208401410]; [No title captured]	16	39	42	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2000	81	5					614	617		10.1053/mr.2000.3877			4	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	311CT	WOS:000086867800013	10807101				2022-02-06	
J	Sahjpaul, R; Girotti, M				Sahjpaul, R; Girotti, M			Intracranial pressure monitoring in severe traumatic brain injury - Results of a Canadian survey	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTENSIVE-CARE; UNITED-KINGDOM; MANAGEMENT; METABOLISM; HYPOTHERMIA; MORTALITY	Objective: The purpose of this study was to obtain information from Canadian neurosurgeons regarding their opinions on, and utilization of, intracranial pressure (ICP) monitoring for severe traumatic brain injury (TBT). Methods: A brief survey was sent to practicing Canadian neurosurgeons questioning them about their utilization of, and confidence in, intracranial pressure monitoring in the management of patients with severe TBI. Results: One hundred and ninety-six surveys were mailed. There were 103 responses for a response rate of 52.6%. The vast majority of responding neurosurgeons (98.1%) utilized ICP monitoring in the management of patients with severe TB I, with most (63.4%) using it in more than 75% of their patients, 14.9% using it in 50-75% of patients, 14.9% in 25-50% of patients, and 6.9% using it in less than 25% of patients. The level of confidence that routine monitoring improves outcome from severe TBI ranged from 23.3% having a low level of confidence, 56,3% having an intermediate level of confidence, to 20.4% having a high level of confidence. Most respondents (78.6%) felt that some form of prospective trial evaluating the role of ICP monitoring in improving outcome from severe TBI was warranted; 17.4% felt such a trial was not warranted and 3.9% were uncertain. Conclusions: While ICP monitoring has gained almost universal acceptance among responding Canadian neurosurgeons, their level of confidence that routine monitoring improves outcome from severe TBI was quite variable, with only 20.4% of respondents having a high level of confidence. Over 75% of respondents felt that some form of prospective trial evaluating the utility of ICP monitoring is warranted. This information is being used in consideration of a prospective trial addressing this issue.	London Hlth Sci Ctr, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada		Sahjpaul, R (corresponding author), London Hlth Sci Ctr, Dept Clin Neurol Sci, Univ Campus,339 Windermere Rd, London, ON N6A 5A5, Canada.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Chesnut RM, 1998, SURG NEUROL, V50, P187, DOI 10.1016/S0090-3019(98)00075-5; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1997, AM ASS NEUROLOGI SUM, P2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schneck MJ, 1998, CRIT CARE MED, V26, P1787, DOI 10.1097/00003246-199811000-00012; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601	33	39	46	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2000	27	2					143	147					5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	313DY	WOS:000086986100010	10830348				2022-02-06	
J	Lang, EW; Chesnut, RM				Lang, EW; Chesnut, RM			A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic brain injury patients	BRITISH JOURNAL OF NEUROSURGERY			English	Article						autoregulation; blood pressure; cerebral perfusion pressure; cerebrovascular circulation; data acquisition; individual therapy; intracranial pressure; monitoring; traumatic brain injury	SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; AUTO-REGULATION; PLATEAU WAVES; VOLUME; HYPERTENSION; METABOLISM; MANAGEMENT	To avoid ischaemic secondary insults after severe head injury (SHI) it would be helpful to know the relationship between cerebral perfusion pressure (CPP) and intracranial pressure (ICP). Static cerebrovascular autoregulation (AR) was tested in 14 patients after SHI. Mean arterial pressure (MAP) was varied to detect changes in intracranial pressure (ICP) indicative of intact AR. Three types of responses were observed: (1) MAP elevation causes an increase in ICP; (2) MAP elevation has no or very little effect on ICP; (3) MAP elevation lowers ICP; Changes between types 1/2 and type 3 suggests AR breakpoints. Varying response types and breakpoints were observed between and within patients. Lower AR breakpoints were seen from 60 to 80 mmHg CPP, upper breakpoints were as high as 112. CPP monitoring achieves a twofold utility in targeted therapy: (1) defining the range of intact AR; and (2) lower AR breakpoint assessment to avoid secondary insults. Although the precise relationship between pAR breakpoints and the adequacy of cerebral perfusion to meet metabolic needs remains unclear, a technique such as described here is simple and has much to offer in targeting therapy toward specific pathophysiological processes in traumatic brain injury.	Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA; San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94110 USA		Lang, EW (corresponding author), Dept Neurosurg, Weimarer Str 8, D-24106 Kiel, Germany.	lange@nch.uni-kiel.de		Chesnut, Randall/0000-0001-6377-3666			BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1996, GUIDELINES MANAGEMEN; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; CZOSNYKA M, 1994, ACTA NEUROCHIR, V126, P113, DOI 10.1007/BF01476419; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; DeWitt D S, 1995, New Horiz, V3, P376; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; Halliday A, 1996, CRIT CARE MED, V24, P1273, DOI 10.1097/00003246-199607000-00039; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; JONES KC, 1994, J HOME HLTH CARE PRA, V6, P1; KONTOS HA, 1985, ANN BIOMED ENG, V13, P329, DOI 10.1007/BF02584251; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Magi E, 1996, CRIT CARE MED, V24, P1275, DOI 10.1097/00003246-199607000-00041; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NAU R, 1992, CLIN NEUROL NEUROSUR, V94, P143, DOI 10.1016/0303-8467(92)90071-A; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROSNER MJ, 1994, INTRACRANIAL PRESSUR, V9, P222; ROSNER MJ, 1993, NEUROSURGICAL INTENS, V30, P57; Schneck MJ, 1998, CRIT CARE MED, V26, P1787, DOI 10.1097/00003246-199811000-00012; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; TEASDALE G, 1974, LANCET, V2, P81; TSUTSUME H, 1986, INTRACRANIAL PRESSUR, V5, P661; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459	48	39	41	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	APR	2000	14	2					117	126					10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	316NC	WOS:000087172700006	10889883				2022-02-06	
J	Elangovan, V; Shohami, E; Gati, I; Kohen, R				Elangovan, V; Shohami, E; Gati, I; Kohen, R			Increased hepatic lipid soluble antioxidant capacity as compared to other organs of streptozotocin-induced diabetic rats: A cyclic voltammetry study	FREE RADICAL RESEARCH			English	Article						low molecular weight antioxidant capacity; cyclic voltammetry; oxidative stress; reducing equivalents; vitamin C; alpha-tocopherol; liver	CLOSED-HEAD INJURY; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; MELLITUS; DAMAGE; LIVER	It has been suggested that oxidative stress plays an important role in the chronic complications of diabetes. The experimental findings regarding the changes in tissue antioxidant enzymes and lipid peroxidation of diabetic tissues have been inconsistent. Previous studies in our laboratory demonstrated that the reducing power of a specific tissue correlates with its low molecular weight antioxidant (LMWA) capacity. In the present study, the overall LMWA capacity (reducing equivalents) of plasma and tissues of streptozotocin (STZ)-induced diabetic rats (1-4 weeks) and insulin treated diabetic rats were measured by cyclic voltammetry. Levels of water and lipid soluble LMWA capacity progressively decreased in the diabetic plasma, kidney, heart and brain, while the diabetic liver, at 2, 3 and 4 weeks after STZ injection, showed a significant increase in the overall lipid soluble LMWA capacity (p < 0.001). Subsequently, analysis of specific components by high pressure liquid chromatography (electrochemical detection) showed decreased levels of ascorbic acid in plasma, kidney, heart and brain of diabetic animals. The alpha-tocopherol level dropped in all tissues, except for the liver in which there was a significant increase (p < 0.01 and p < 0.001 at 2-4 weeks). Lipid peroxidation was assessed by conjugated diene levels, which increased significantly in all diabetic tissues except the liver. Insulin treatment that was started after 3 weeks of diabetes and continued for 3 weeks showed no change in the conjugated dienes and in the overall LMWA capacity in all organs. Our results suggest a unique behavior of the liver in the STZ-induced diabetic rats to the stress and indicate its higher capacity to cope with oxidative stress as compared to other organs.	Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel		Kohen, R (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	ronko@cc.huji.ac.il	Kohen, Ron/ABC-2281-2021	Kohen, Ron/0000-0001-7268-9845			Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Buege J A, 1978, Methods Enzymol, V52, P302; Ceriello A, 1997, DIABETES CARE, V20, P194, DOI 10.2337/diacare.20.2.194; GODIN DV, 1988, MOL CELL BIOCHEM, V84, P223, DOI 10.1007/BF00421057; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; LOW PA, 1991, DIABETES, V40, P873, DOI 10.2337/diabetes.40.7.873; Mak DHF, 1996, MOL CELL BIOCHEM, V162, P153; Maxwell SRJ, 1997, EUR J CLIN INVEST, V27, P484, DOI 10.1046/j.1365-2362.1997.1390687.x; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; PARINANDI NL, 1990, BIOCHIM BIOPHYS ACTA, V1047, P63, DOI 10.1016/0005-2760(90)90261-U; Sano T, 1998, DIABETOLOGIA, V41, P1355, DOI 10.1007/s001250051076; SAXENA AK, 1993, BIOCHEM PHARMACOL, V45, P539, DOI 10.1016/0006-2952(93)90124-F; Sechi LA, 1997, DIABETOLOGIA, V40, P23, DOI 10.1007/s001250050638; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; SUKALSKI KA, 1993, FREE RADICAL BIO MED, V14, P57, DOI 10.1016/0891-5849(93)90509-S; Sundaram RK, 1996, CLIN SCI, V90, P255, DOI 10.1042/cs0900255; WOHAIEB SA, 1987, DIABETES, V36, P1014, DOI 10.2337/diabetes.36.9.1014; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YOUNG IS, 1992, FREE RADICAL BIO MED, V13, P41, DOI 10.1016/0891-5849(92)90164-C	29	39	40	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.		2000	32	2					125	134		10.1080/10715760000300131			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	276HG	WOS:000084871500003	10653483				2022-02-06	
J	Thatcher, RW				Thatcher, RW			EEG operant conditioning (biofeedback) and traumatic brain injury	CLINICAL ELECTROENCEPHALOGRAPHY			English	Article						discriminant functions; EEG biofeedback; normative databases; quantitative EEG; traumatic brain injury	CLOSED-HEAD INJURY; QUANTITATIVE EEG; FOLLOW-UP; REHABILITATION; NEUROFEEDBACK; ATTENTION		Univ S Florida, Vet Adm Med Ctr, Coll Med, Tampa, FL 33620 USA; Def & Vet Head Injury Program, Washington, DC USA		Thatcher, RW (corresponding author), Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33504 USA.						ALLEN JB, 1996, PSYCHOLPHYSIOLOGY S, V33, pSU7; AYERS ME, 1987, NATL HEAD INJURY SYL, P380; Baehr E, 1998, INT J PSYCHOPHYSIOL, V31, P89, DOI 10.1016/S0167-8760(98)00041-5; Baehr E, 1998, J NEUROTHER, V2, P12; BARTH J, 1983, NEUROSURGERY, V13, P520; BERNAD PG, 1988, CLIN ELECTROENCEPHAL, V19, P174; Byers AP., 1995, J NEUROTHERAPY, V1, P22; CAVENESS W, 1977, TRAUMA, V18, P61; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen M. J., 1975, 8 ANN WINT C BRAIN R, P1; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FOX SS, 1968, SCIENCE, V162, P1299, DOI 10.1126/science.162.3859.1299; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Ham LP, 1996, BIOFEEDBACK SELF-REG, V21, P93, DOI 10.1007/BF02284689; HETZLER BE, 1977, PHYSIOL BEHAV, V19, P527, DOI 10.1016/0031-9384(77)90229-3; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOFFMAN DA, 1996, CLIN ELECTROENCEPHAL, V27, P6; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JOHN ER, 1977, SCIENCE, V196, P1393, DOI 10.1126/science.867036; JONES CL, 1992, HDB HEAD TRAUMA; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; Lubar JF, 1997, APPL PSYCHOPHYS BIOF, V22, P111, DOI 10.1023/A:1026276228832; LUBAR JF, 1981, ARCH NEUROL-CHICAGO, V38, P700, DOI 10.1001/archneur.1981.00510110060009; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; LUBAR JF, 1991, BIOFEEDBACK SELF-REG, V16, P210; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; NEHAM A, 1998, QUANTITATIVE MULTIVA; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 1996, BRAIN TOPOGR, V8, P201, DOI 10.1007/BF01184770; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; Peniston EG., 1993, ADV MED PSYCHOTHER, V6, P37; Rattok Jack, 1994, P703; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENFELD JP, 1971, PHYSIOL BEHAV, V7, P489, DOI 10.1016/0031-9384(71)90099-0; ROSENFELD JP, 1969, SCIENCE, V165, P821, DOI 10.1126/science.165.3895.821; ROSENFELD JP, 1990, BIOFEEDBACK SELF-REG, V15, P99, DOI 10.1007/BF00999142; ROSENFELD JP, 1995, BIOFEEDBACK SELF-REG, V20, P241, DOI 10.1007/BF01474516; SALAZAR AM, 1998, EFFICACY TRAUMATIC B; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; STERMAN MB, 1974, EPILEPSIA, V15, P395, DOI 10.1111/j.1528-1157.1974.tb04016.x; Sterman MB, 1996, BIOFEEDBACK SELF-REG, V21, P3, DOI 10.1007/BF02214147; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher R.W, 1998, J NEUROTHERAPY, V24, P8; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; THATCHER RW, 1999, INTRO QUANTITATIVE E; TINIUS T, 1996, 4 ANN SSNR C MARC IS; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; WILDER CS, 1976, HLTH INTERVIEW SURVE; [No title captured]	64	39	43	0	16	CLINICAL EEG	PEWAUKEEE	N27 W23957 PAUL RD, STE 202, PEWAUKEEE, WI 53072 USA	0009-9155			CLIN ELECTROENCEPHAL	Clin. Electroencephalogr.	JAN	2000	31	1					38	44		10.1177/155005940003100110			7	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Neurosciences & Neurology	269NY	WOS:000084485500008	10638351				2022-02-06	
J	Schootman, M; Fuortes, L				Schootman, M; Fuortes, L			Functional status following traumatic brain injuries: population-based rural-urban differences	BRAIN INJURY			English	Article							HEAD-INJURY; OUTCOMES; REHABILITATION; DISABILITY	Many studies have described functional outcomes following traumatic brain injury (TBI), but few have attempted to contrast differences in functional status and receipt of services of persons residing in rural and urban counties. Persons hospitalized with TBI completed a self-administered survey 1-1.5 years after their injury. Survivors of TBI in rural areas were more likely to be functionally dependent and reported a lower health status than their urban counterparts. Additionally, those who did not receive any TBI-related services but perceived an additional service need were more likely to be functionally dependent than those who received services and did not perceive any additional need. Perceived service needs of those functionally dependent are described. Further investigations into this rural-urban difference are warranted to maximize functional status following TBI for all individuals.	Bur Injury & Disabil Prevent, Des Moines, IA USA; Univ Iowa, Iowa City, IA USA		Schootman, M (corresponding author), Washington Univ, Div Hlth Behav Res, Campus Box 8504,4444 Forest Pk Ave,Suite 6700, St Louis, MO 63108 USA.	mschootm@im.wustl.edu	Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824	FDA HHS [CFDA 93.234A] Funding Source: Medline		DIRMEN S, 1993, BRAIN INJURY, V7, P113; GOLDSTEIN MS, 1984, AM J PUBLIC HEALTH, V74, P611, DOI 10.2105/AJPH.74.6.611; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; IDLER EL, 1991, J GERONTOL, V46, pS55, DOI 10.1093/geronj/46.2.S55; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; KILGORE KM, 1995, ARCH PHYS MED REHAB, V76, pSC21; LOLLAR DJ, 1994, P REC S 17 19 FEBR C; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schootman M, 1998, BIOM HLTH R, V21, P73; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Torner James C., 1996, P19; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	16	39	39	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1999	13	12					995	1004					10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600005	10628504				2022-02-06	
J	Karlovits, T; McColl, MA				Karlovits, T; McColl, MA			Coping with community reintegration after severe brain injury: a description of stresses and coping strategies	BRAIN INJURY			English	Article							DISEASE-RELATED STRESSORS; CLOSED HEAD-INJURY; MENTAL-ILLNESS; INTEGRATION; INDIVIDUALS; ADJUSTMENT; ADULTS	A basic qualitative approach was used to describe the stresses and coping strategies of 11 adults with severe brain injury during a critical period of reintegrating into a new community. Subjects identified nine problems as stressful. The: stresses conform to a theoretical model of community integration, consisting of four factors. social support, independent living, occupation, and a general integration faster. These stresses identified by subjects may be used in the development of a new measure of stress for persons with brain injury. Subjects used eight coping strategies to deal with these stresses. The coping strategies represent a sampling of three major types of coping: problem-focused, perception-focused, and emotion-focused. The findings show that subjects made more use of problem-focused coping strategies than any other type of coping, suggesting that persons with brain injury have awareness of the problems they face and the ability to assert some control over eliminating or managing these problems. The stresses and coping strategies are consistent with existing studies involving persons with brain injury. However, significant differences in some coping strategies reported in this study change how some forms of coping are thought about. The findings delineate the need for professionals to assist persons with brain injury develop more positive, adaptive coping strategies.	N Bay Psychiat Hosp, Minist Hlth, N Bay, ON P1B 8L1, Canada; Queens Univ, Kingston, ON K7L 3N6, Canada		Karlovits, T (corresponding author), N Bay Psychiat Hosp, Minist Hlth, Box 3010,HWY 11N, N Bay, ON P1B 8L1, Canada.						ALBRECHT TL, 1982, SOC WORK, V6, P201; BOWLBY J, 1960, ATTACHMENT LOSS ATTA, V1; CARLING PJ, 1990, AM PSYCHOL, V45, P969, DOI 10.1037/0003-066X.45.8.969; CARLSON P, 1991, ONTARIO PSYCHOL, V23, P12; CERVELLI L, 1990, REHABILITATION ADULT; COGSWELL B, 1977, SOCIAL PSYCHOL ASPEC, P123; CUTLER DL, 1983, EFFECTIVE AFTERCARE; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Field PA, 1985, NURSING RES APPL QUA; FOLDMAN S, 1986, J PERS SOC PSYCHOL, V50, P571; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1984, STRESS; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; GOVE WR, 1973, AM J SOCIOL, V78, P812, DOI 10.1086/225404; HOLAHAN CJ, 1986, J PERS SOC PSYCHOL, V51, P389, DOI 10.1037/0022-3514.51.2.389; HOLMES T, 1989, LIFE CHANGING LIFE E; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOLOHAN CJ, 1985, J PERS SOC PSYCHOL, V49, P739; ITTENBACH RF, 1993, RES DEV DISABIL, V14, P275, DOI 10.1016/0891-4222(93)90022-C; Jean VM, 1997, MULT SCLER J, V3, P191, DOI 10.1177/135245859700300304; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; KASL SV, 1970, PSYCHOSOM MED, V32, P19, DOI 10.1097/00006842-197001000-00002; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LAZARUS RS, 1974, COPING ADAPTATION, P207; Lazarus RS, 1977, HUMAN BEHAV ENV CURR; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCHAFFIE HE, 1992, J ADV NURS, V17, P933, DOI 10.1111/j.1365-2648.1992.tb02021.x; MCNETT S, 1997, NURS RES, V36, P98; MECHANIC D, 1962, STUDENTS STRESS; Merriam, 2009, QUALITATIVE RES CASE; MILLER SM, 1988, J PERS SOC PSYCHOL, V54, P142, DOI 10.1037/0022-3514.54.1.142; Monat A., 1985, STRESS COPING ANTHOL, V2nd ed.; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Moos RH., 1982, HDB STRESS, P212; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nieves C C, 1991, Rehabil Nurs, V16, P129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; *ONT BRAIN INJ ASS, 1996, STAT CANADA; Parkes CM., 1972, BEREAVEMENT STUDIES; PEARLIN LI, 1978, J HLTH SOCIAL BEHAV, V19, P1; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; RAHE RH, 1964, J PSYCHOSOM RES, V8, P35, DOI 10.1016/0022-3999(64)90020-0; SPIRITO A, 1995, J AM ACAD CHILD PSY, V34, P283, DOI 10.1097/00004583-199503000-00011; Strauss A, 1990, BASIS QUALITATIVE RE; THOITS PA, 1986, J CONSULT CLIN PSYCH, V54, P416, DOI 10.1037/0022-006X.54.4.416; THOMPSON BE, 1984, EXP FLUIDS, V2, P47; WEISS JP, 1976, J APPL PHOTOGR ENG, V2, P7; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	58	39	39	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1999	13	11					845	861					17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253FZ	WOS:000083547000002	10579657				2022-02-06	
J	Sanders, MJ; Dietrich, WD; Green, EJ				Sanders, MJ; Dietrich, WD; Green, EJ			Cognitive function following traumatic brain injury: Effects of injury severity and recovery period in a parasagittal fluid-percussive injury model	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; fluid percussion; Morris water maze; recovery; severity	MORRIS WATER MAZE; CLOSED HEAD-INJURY; SPATIAL NAVIGATION; RATS; MEMORY; LESIONS; DEFICITS; IMPAIRMENT; DAMAGE; HYPOTHERMIA	Previous work in this laboratory has demonstrated that rats show substantial deficits on the cued and hidden versions of the Morris water maze, as well as an apparent time-dependent recovery over a period of months, following moderate parasagittal fluid-percussion (FP) injury. However, the longitudinal nature of those studies precluded definitive statements regarding recovery because of the possible confound of practice-dependent improvements in performance. The present experiments were undertaken to address this issue and to investigate more closely the relationship between impact severity and posttraumatic learning/memory deficits, which have not been examined thoroughly in this model, Separate groups of rats were subjected to mild (1.1 to 1.4 atm), moderate (1.8 to 2.1 atm), or severe (2.2 to 2.7 atm) FP injury (or sham surgery) and tested on several water maze tasks at either 5 days or 8 weeks after injury, Moderately and severely injured animals showed impairment in acquisition of the hidden platform task at both time points, Cued platform task performance was impaired significantly in severely injured animals 8 weeks after insult. Mildly injured animals exhibited no significant deficits on either task at either time point. The results indicate that deficits on the hidden platform task are more robust than those on the cued platform task, and that performance on both tasks is dependent on injury severity. They also indicate that the learning/memory deficits in this model are relatively enduring, suggesting that the model is a reasonable one for assessing potential treatment regimens.	Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA; Univ Miami, Program Neurosci, Coral Gables, FL 33124 USA		Green, EJ (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL036588] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL36588] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [3029] Funding Source: Medline		Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Cain DP, 1996, REV NEUROSCIENCE, V7, P215; DEBRUIN JPC, 1994, BRAIN RES, V652, P323, DOI 10.1016/0006-8993(94)90243-7; DEKKER AJ, 1994, NEUROSCIENCE, V60, P299, DOI 10.1016/0306-4522(94)90244-5; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; SANDERS MJ, 1998, J NEUROTRAUM, V15, P894; Savage LM, 1997, BEHAV BRAIN RES, V82, P133, DOI 10.1016/S0166-4328(97)80983-7; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6	31	39	41	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					915	925		10.1089/neu.1999.16.915			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900006	10547100				2022-02-06	
J	Nakamura, M; Saatman, KE; Galvin, JE; Scherbel, U; Raghupathi, R; Trojanowski, JQ; McIntosh, TK				Nakamura, M; Saatman, KE; Galvin, JE; Scherbel, U; Raghupathi, R; Trojanowski, JQ; McIntosh, TK			Increased vulnerability of NFH-LacZ transgenic mouse to traumatic brain injury-induced behavioral deficits and cortical damage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						neurofilament; inclusion body; Lewy body; neuromotor function; neurodegeneration	FIBROBLAST GROWTH-FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; FOCAL CEREBRAL-ISCHEMIA; LEWY BODY DEMENTIAS; NEUROFILAMENT SUBUNIT; ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; HEAT-SHOCK; MESSENGER-RNA	The authors evaluated the neurobehavioral and neuropathologic sequelae after traumatic brain injury (TBI) in transgenic (TG) mice expressing truncated high molecular weight neurofilament (NF) protein fused to beta-galactosidase (NFH-LacZ), which develop Lewy body-like NF-rich inclusions throughout the CNS. TG mice and their wild-type (WT) littermates were subjected to controlled cortical impact brain injury (TG, n = 19; WT, n = 17) or served as uninjured controls (TG, n = 11; WT, n = 11). During a 3-week period, mice were evaluated with an array of neuromotor function tests including neuroscore, beam balance, and both fast and slow acceleration rotarod. Brain-injured WT and TG mice showed significant motor dysfunction until 15 days and 21 days postinjury, respectively (P < .025). Compared with brain-injured WT mice, brain-injured TG mice had significantly greater motor dysfunction as assessed by neuroscore (P < .01) up to and including 15 days post-injury. Similarly, brain-injured TG mice performed significantly worse than brain-injured WT mice on slow acceleration rotarod at 2, 8, and 15 days post-injury (P < .05), and beam balance over 2 weeks post-injury (P < .01). Histopathologic analysis showed significantly greater tissue loss in the injured hemisphere in TG mice at 4 weeks postinjury (P < .01). Together these data show that NFH-LacZ TG mice are more behaviorally and histologically vulnerable to TBI than WT mice, suggesting that the presence of NF-rich inclusions may exacerbate neuromotor dysfunction and cell death after TBI.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Dept Neurol, Philadelphia, PA 19102 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		Galvin, James/AAM-7492-2021; Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline		Clark RSB, 1997, J NEUROSCI, V17, P9172; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; Conner JM, 1997, J NEUROSCI, V17, P2295; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIXON CE, 1991, J NEUROSCI METH, V39, P353; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GALVIN JE, IN PRESS ADV NEUROL; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GONZALEZ AM, 1994, BRAIN RES, V665, P285, DOI 10.1016/0006-8993(94)91349-8; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; ITOH T, 1992, ACTA NEUROPATHOL, V83, P240, DOI 10.1007/BF00296785; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LANDMESSER L, 1992, NEURON, V8, P291, DOI 10.1016/0896-6273(92)90296-P; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Liberini P, 1996, TRENDS PHARMACOL SCI, V17, P155, DOI 10.1016/0165-6147(96)81592-6; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock John T., 1993, P185; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; SINSON G, 1995, J NEUROCHEM, V65, P2209; TOKUTAKE S, 1990, INT J BIOCHEM, V22, P1; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; TROJANOWSKI JQ, 1994, ANN NY ACAD SCI, V747, P92; TU PH, 1995, J CELL BIOL, V129, P1629, DOI 10.1083/jcb.129.6.1629; Tu PH, 1997, LAB INVEST, V76, P441; Tu PH, 1997, J NEUROSCI, V17, P1064; VICKERS JC, 1994, J NEUROSCI, V14, P5603; WILLARD M, 1981, J CELL BIOL, V89, P198, DOI 10.1083/jcb.89.2.198; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMASAKI H, 1992, LAB INVEST, V66, P734	55	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	1999	19	7					762	770		10.1097/00004647-199907000-00006			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	277TC	WOS:000084948800006	10413031	Bronze			2022-02-06	
J	Makatura, TJ; Lam, CS; Leahy, BJ; Castillo, MT; Kalpakjian, CZ				Makatura, TJ; Lam, CS; Leahy, BJ; Castillo, MT; Kalpakjian, CZ			Standardized memory tests and the appraisal of everyday memory	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PERFORMANCE	Although ecological validity of traditional tests of memory has been questioned, use of these tests remains the standard in clinical practice. More recently, however, standardized measures with more emphasis on ecological relevance have been developed. One hundred and nineteen adults with diagnosed brain injuries completed traditional instruments of memory assessment, the Luria Nebraska Neuropsychological Battery Memory Scale (LNNB-M) and the Wechsler Memory Scale-Revised (WMS-R). Subjects also completed the Rivermead Behavioural Memory Test (RBMT), an instrument designed to measure everyday memory. Additionally, clinicians rated subjects' day-to-day memory functioning at the rehabilitation facility. Results suggest that RBMT is most accurate in classifying severity of memory impairment as rated by clinicians. The LNNB-M and WMS-R were relatively accurate at classifying severely impaired and unimpaired subjects, but were much less accurate at classifying subjects in the mild and moderate impairment ranges. Implications for interpretation and use of these instruments in rehabilitation settings are discussed.	IIT, Inst Psychol, Chicago, IL 60616 USA		Lam, CS (corresponding author), IIT, Inst Psychol, 3101 S Dearborn, Chicago, IL 60616 USA.			Kalpakjian, Claire/0000-0001-6652-1245			BACH P J, 1981, Clinical Neuropsychology, V3, P19; BEHRICK HP, 1984, EVERYDAY MEMORY ACTI, P19; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bornstein R A, 1989, Arch Clin Neuropsychol, V4, P15, DOI 10.1016/0887-6177(89)90003-6; Brooks D N, 1979, Int Rehabil Med, V1, P166; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; BUTTERS N, 1975, HIPPOCAMPUS, V2, P377; Cermak L. S., 1982, HUMAN MEMORY AMNESIA; CONKEY RC, 1938, ARCH PSYCHOL, V232, P1; CRONHOLM B, 1957, Acta Chir Scand, V113, P263; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; ELWOOD RW, 1991, CLIN NEUROPSYCHOL, V5, P329; ERICKSON RC, 1977, PSYCHOL BULL, V84, P1130, DOI 10.1037/0033-2909.84.6.1130; Faust D, 1988, Arch Clin Neuropsychol, V3, P145, DOI 10.1016/0887-6177(88)90060-1; FILSKOV S, 1981, HDB CLIN NEUROPSYCHO; GOLDEN CJ, 1978, J CONSULT CLIN PSYCH, V46, P1258, DOI 10.1037/0022-006X.46.6.1258; GOLDEN CJ, 1981, J CONSULT CLIN PSYCH, V49, P304, DOI 10.1037/0022-006X.49.2.304; GOLDEN CJ, 1982, J CONSULT CLIN PSYCH, V50, P452, DOI 10.1037/0022-006X.50.3.452; Golden CJ, 1985, LURIA NEBRASKA NEURO; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; HERMANN D, 1978, PRACTICAL ASPECTS ME, P35; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P239, DOI 10.1080/01688638508401257; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lishman W. A., 1987, ORGANIC PSYCHIAT; MAKATURA TJ, 1993, DISS ABSTR INT, V54, P1078; Mayes A., 1992, HDB NEUROPSYCHOLOGIC, P73; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; STRUBB RL, 1977, MENTAL STATUS EXAMIN; SUNDERLAND A, 1986, J GERONTOL, V41, P376, DOI 10.1093/geronj/41.3.376; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Wechsler D, 1987, MEMORY SCALE REVISED; Wedding D, 1989, Arch Clin Neuropsychol, V4, P233, DOI 10.1016/0887-6177(89)90016-4; WILKINS AJ, 1978, PRACTICAL ASPECTS ME, P27; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; WILSON B, 1987, REHABILITATION MEMOR; WILSON BA, 1985, REVERMEAD BEHAV MEMO; [No title captured]	45	39	41	0	25	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1999	13	5					355	367					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	200LE	WOS:000080541100004	10367146				2022-02-06	
J	Park, NW; Proulx, GB; Towers, WM				Park, NW; Proulx, GB; Towers, WM			Evaluation of the attention process training programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED HEAD-INJURY; RECOVERY; MEMORY	This study evaluated the effectiveness of attention process training (APT), a training programme that provides practice in a variety of tasks requiring several different types of attention. The APT programme was administered to 23 traumatically brain-injured (TBI) participants. Training lasted about 40 hours, and typically consisted of 2-hour sessions spread out over 7 months. Results show that performance of the TBI participants improved after training on the primary outcome measures, but did not improve significantly more than the performance of a control group, given the outcome measures twice, but no training. We conclude that direct training does not improve the integrity of damaged attention functions, but does result in learning of specific skills.	Baycrest Ctr Geriatr Care, Kunin Lunenfeld Clin Res Unit, N York, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Dept Psychol, N York, ON M6A 2E1, Canada								Barlow DH, 1984, SINGLE CASE EXPT DES; Beck AT, 1987, BECK DEPRESSION INVE; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DOBBS AR, 1989, PSYCHOL AGING, V4, P500, DOI 10.1037/0882-7974.4.4.500; GORDON WA, 1991, COGNITIVE REHABILITA, P13; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heaton PDRK., 1993, WISCONSIN CARD SORTI; KAZNIAK AW, 1985, DEPRESSION ELDERLY I; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; KOLERS PA, 1984, J VERB LEARN VERB BE, V23, P425, DOI 10.1016/S0022-5371(84)90282-2; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LURIA AR, 1996, HUMAN BRAIN PSYCHOL; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; MATEER CA, 1990, DEV CLIN NEUROPSYCHO, P68; MORRIS CD, 1977, J VERB LEARN VERB BE, V16, P519, DOI 10.1016/S0022-5371(77)80016-9; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; PONSFORD J, 1990, COGNITIVE REHABILITA, P48; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; ROEDIGER HL, 1989, VARIATIONS MEMORY CO, P00003; ROTHI LJ, 1983, J CLIN NEUROPSYCHOL, V5, P73, DOI 10.1080/01688638308401152; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spreen O, 1991, COMPENDIUM NEUROPSYC; STURM W, 1977, NEUROPSYCHOLOGICAL R, V7, P81; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1988, CLIN NEUROPSYCHOL, V2, P246, DOI [DOI 10.1080/13854048808520107, 10.1080/13854048808520107]; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VONZOMEREN AH, 1981, REACTION TIME ATTENT; Wood R L, 1987, Int Disabil Stud, V9, P149; Zangwill OL, 1947, B J PSYCHOL-GEN SECT, V37, P60, DOI 10.1111/j.2044-8295.1947.tb01121.x	40	39	40	0	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR	1999	9	2					135	154		10.1080/713755595			20	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	185ZJ	WOS:000079701300002					2022-02-06	
J	Karli, DC; Burke, DT; Kim, HJ; Calvanio, R; Fitzpatrick, M; Temple, D; MacNeil, M; Pesez, K; Lepak, P				Karli, DC; Burke, DT; Kim, HJ; Calvanio, R; Fitzpatrick, M; Temple, D; MacNeil, M; Pesez, K; Lepak, P			Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation	BRAIN INJURY			English	Article							AMANTADINE TREATMENT; SYMPTOMS; PATIENT	Traumatic brain injury poses significant and diverse challenges to rehabilitation efforts. Neurobehavioural deficits represent a particularly difficult barrier to rehabilitative progress and societal reintegration. Early studies have identified dopaminergic drugs such as amantadine, bromocriptine and sinemet as potentially assistive in countering these deficits. To date, side effect profiles have been relatively benign, noted most frequently in small-scale case trials. The case of a 40-year-old patient with bilateral frontal traumatic brain injuries, and previous arteriovenous malformation (AVM) bleed with significant ataxia, dysarthria and neurobehavioural deficits is presented. This ions range study demonstrates, through multiple varied dosing schedules, a trade off between the benefits and side effects of dopaminergic therapy, with implications for a larger brain injury population.	Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; Spaulding Rehabil Hosp, Dept Neuropsychol, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Nursing, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Phys Therapy, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Occupat Therapy, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Speech Therapy, Boston, MA 02114 USA		Burke, DT (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.						Chandler M C, 1988, Brain Inj, V2, P309; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; HORVATH TB, 1974, J NEUROL NEUROSUR PS, V37, P416, DOI 10.1136/jnnp.37.4.416; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WOLF AP, 1995, BRAIN INJURY, V9, P487, DOI 10.3109/02699059509008208	14	39	40	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1999	13	1					63	68		10.1080/026990599121908			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	158TA	WOS:000078131200009	9972445				2022-02-06	
J	Gordon, WR; Brown, M; Sliwinski, M; Hibbard, MR; Patti, N; Weiss, MJ; Kalinsky, R; Sheerer, M				Gordon, WR; Brown, M; Sliwinski, M; Hibbard, MR; Patti, N; Weiss, MJ; Kalinsky, R; Sheerer, M			The enigma of "hidden" traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MILD HEAD-INJURY; SEQUELAE	Objective: To examine individuals with "hidden" traumatic brain injury (TBI), defined in this study as those who sustained a blow to the head, with altered mental status, and experienced a substantial number of the cognitive, behavioral, and emotional sequelae typically associated with brain injury but did not make the causal connection between the injury and its consequences. Design: Comparison of four groups of individuals matched for age, gender, years of education, and duration of loss of consciousness. Setting: This study of hidden TBI followed the identification of 143 individuals who, within a larger study of people with TBI who live in the community, identified themselves as "nondisabled" (they were to be part of the comparison sample) but who had experienced a blow to the head that left them at minimum dazed and confused. Participants: 21 of these 143 individuals also reported large numbers of Symptoms (eg, headaches, memory problems) associated with TBI. This group (Hidden TBI-High Symptoms group) was compared to three other matched samples: one with known TBI (Known Mild TBI group) and one with no disability (No Disability group) (both of which were drawn from the larger study), and one group of individuals who identified themselves as having no disability but who had experienced a blow to the head that resulted in a few symptoms (Head Trauma-Low Symptoms group). Main Outcome Measures: All study participants were administered an interview that incorporated several existing instruments documenting levels of reported symptoms, emotional well-being/distress, and vocational/social handicaps. Results: The Hidden TBI-High Symptoms group was found to be similar to the Known Mild TBI group in terms of the number and types of symptoms experienced, whereas the Head Trauma-Low Symptoms group was similar in this respect to the No Disability group. The two former groups also evidenced high levels of emotional distress, whereas the two latter groups did not. However, on measures of handicap, the Hidden TBI-High Symptoms and Head Trauma-Low Symptoms groups were similar to the No Disability group and dissimilar from the Known Mild TBI group in that the last group experienced vocational handicap, in particular, whereas the other groups did not. Conclusions: We conclude that hidden TBI occurs at a nontrivial level (7% of our nondisabled sample). Also, individuals with hidden TBI (with persistent symptoms), unlike those with known mild TBI, are likely to experience emotional distress but not vocational handicap following injury.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA		Gordon, WR (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.						Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Beck AT, 1987, BECK DEPRESSION INVE; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Ommaya, 1997, Semin Clin Neuropsychiatry, V2, P163; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; *SAS I INC, 1992, SAS STAT SOFTW REL 6; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SYMONDS C, 1962, LANCET, V1, P1; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; World Health Organization, 1980, INT CLASS IMP DIS HA	31	39	39	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					39	56		10.1097/00001199-199812000-00006			18	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300006	9885317				2022-02-06	
J	Bombardier, CH; Thurber, CA				Bombardier, CH; Thurber, CA			Blood alcohol level and early cognitive status after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; STROKE PATIENTS; ABUSE; REHABILITATION; INTOXICATION; POPULATION	Statement of Purpose: This archival study sought to clarify the relationship between admission blood alcohol level (BAL) after traumatic brain injury (TBI) and subsequent neuropsychological functioning. It was hypothesized that BAL would be positively correlated with impairment on basic neuropsychological tests and that this relation would weaken as time since TBI increased. Methods: Fifty-eight patients were tested within 60 days of their TBI. Correlational analyses were used to test the relation between neuropsychological performance and admission BAL. Results: As expected, BAL was unrelated to demographic variables or lag time bt tween TBI and time of testing. Bivariate correlations showed that higher BAL predicted poorer performance on a broad range of neuropsychological tests. Patients tested less than 30 days after their TBI showed the strongest effects. Conclusions: Neuropsychological impairments detected 1-2 months after TBI may be affected by BAL at the time of hospital admission. The influence of BAL seems greatest during the first month postinjury, but may persist beyond 30 days in some areas of cognitive function. Blood alcohol at the time of injury may have a direct effect on cognitive functioning or may be a proxy for the effects of chronic alcohol use or abuse. Clinical implications are discussed.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA		Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359740, Seattle, WA 98104 USA.		Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U48/CCU009654, R49/CCR011714-01, R49/CCR002570] Funding Source: Medline		ABRAHAM E, 1995, AM PSYCH ASS CONV TO; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; FEIN G, 1990, WESTERN J MED, V152, P531; FREEDLAND E, 1993, EMERGENCY MED CLIN N, V11, P255; GALSKI T, 1993, STROKE, V24, P1794, DOI 10.1161/01.STR.24.12.1794; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; LAMARRE CJ, 1994, J PSYCHIATR NEUROSCI, V19, P103; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MITRUSHINA M, 1994, J PSYCHIATR RES, V28, P85, DOI 10.1016/0022-3956(94)90037-X; OSMON DC, 1992, ARCH PHYS MED REHAB, V73, P414; Rey A., 1964, EXAMEN CLIN PSYCHOL; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Spreen O, 1991, COMPENDIUM NEUROPSYC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296; [No title captured]	31	39	40	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					725	734		10.1080/026990598122124			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500001	9755364				2022-02-06	
J	Hicks, RR; Boggs, A; Leider, D; Kraemer, P; Brown, R; Scheff, SW; Seroogy, KB				Hicks, RR; Boggs, A; Leider, D; Kraemer, P; Brown, R; Scheff, SW; Seroogy, KB			Effects of exercise following lateral fluid percussion brain injury in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain-derived neurotrophic factor; cognition; traumatic brain injury	NEUROTROPHIN-3 MESSENGER-RNAS; LONG-TERM POTENTIATION; DOPAMINERGIC-NEURONS; INCREASED EXPRESSION; CEREBRAL INFARCTION; FOREBRAIN ISCHEMIA; PHYSICAL-ACTIVITY; DYNAMIC EXERCISE; BLOOD-FLOW; HIPPOCAMPUS	Previous studies have suggested that brain-derived neurotrophic factor (BDNF) is involved in memory and learning, and may be neuroprotective following various brain insults. Exercise has been found to increase BDNF mRNA levels in various brain regions, including specific subpopulations of hippocampal neurons. In the present study, we were interested in whether following traumatic brain injury, exercise could increase BDNF mRNA expression, attenuate neuropathology, and improve cognitive and neuromotor performance. We subjected adult male Sprague-Dawley rats to a fluid percussion brain injury, followed by either 18 days of treadmill exercise or handling. Spatial memory was evaluated in a Morris Water Maze (MWM) and motor function was evaluated with a battery of neuromotor tests. Neuropathology was evaluated by measuring the cortical lesion volume and the extent of neuronal loss in the hippocampus, Expression of BDNF mRNA in the hippocampus was assessed with in situ hybridization and densitometry. Hybridization signal for BDNF mRNA was significantly increased bilaterally in the exercise group in hippocampal regions CA1 and CA3 (p < 0.05), but not in the granule cell layer of the dentate gyrus, No significant differences were observed between the groups in neuropathology, spatial memory, or motor performance. This study suggests that after traumatic brain injury, exercise elevates BDNF mRNA in specific regions of the hippocampus.	Univ Kentucky, Dept Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Dept Psychol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hicks, RR (corresponding author), Univ Kentucky, Dept Phys Therapy, CAHP Bldg,Rm 213, Lexington, KY 40536 USA.						Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEBRUIN LA, 1990, AM J PHYSIOL, V259, pR773, DOI 10.1152/ajpregu.1990.259.4.R773; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Dishman RK, 1997, MED SCI SPORT EXER, V29, P63, DOI 10.1097/00005768-199701000-00010; Dragunow M, 1997, MOL BRAIN RES, V46, P274, DOI 10.1016/S0169-328X(97)00021-1; Dustman R. E., 1994, Journal of Aging and Physical Activity, V2, P143; ETNIER JL, 1995, SPORTS MED, V19, P81, DOI 10.2165/00007256-199519020-00001; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; JORGENSEN LG, 1992, J APPL PHYSIOL, V73, P1825, DOI 10.1152/jappl.1992.73.5.1825; JURASKA JM, 1989, BRAIN RES, V479, P115, DOI 10.1016/0006-8993(89)91341-3; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KRAEMER PJ, 1995, PSYCHOBIOLOGY, V23, P144; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LINDSAY RM, 1993, NEUROTROPHIC FACTORS, P257; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOHAMMED AH, 1993, BEHAV BRAIN RES, V57, P183, DOI 10.1016/0166-4328(93)90134-C; Montkowski A, 1997, NEUROREPORT, V8, P779, DOI 10.1097/00001756-199702100-00040; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Paxinos G, 1997, RAT BRAIN STEREOTAXI; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rocamora N, 1996, J NEUROSCI, V16, P4411; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Somani SM, 1996, BIOCHEM MOL BIOL INT, V38, P587; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744, DOI 10.1152/jappl.1989.67.2.744; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Ueyama T, 1997, NEUROSCI RES, V28, P103, DOI 10.1016/S0168-0102(97)00030-8; WhiteWelkley JE, 1996, J APPL PHYSIOL, V80, P931, DOI 10.1152/jappl.1996.80.3.931; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	51	39	40	0	6	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	MAY	1998	12	1					41	47					7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	150NT	WOS:000077671800004	12671319				2022-02-06	
J	Kroppenstedt, SN; Schneider, GH; Thomale, UW; Unterberg, AW				Kroppenstedt, SN; Schneider, GH; Thomale, UW; Unterberg, AW			Protective effects of aptiganel HCl (Cerestat (R)) following controlled cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						aptiganel HCl; brain edema; contusion volume; excitatory amino acids; intracranial pressure; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL STROKE; GLUTAMATE; MODEL; ISCHEMIA; CALCIUM; EDEMA; ANTAGONIST; MECHANISMS	Recent studies have demonstrated a neuroprotective effect of the noncompetitive N-methyl-D-aspartate receptor antagonist aptiganel HCl (Cerestat (R)) in focal cerebral ischemia. In the present study, we investigated the protective ability of aptiganel HCl after controlled cortical impact injury (impact depth = 2 mm; impactor velocity = 7 mm/sec) of the left temporoparietal cortex in rats. Intravenous aptiganel HCl (2 mg/kg) or a respective volume of vehicle was injected 15 min after trauma. Animals were sacrificed 24 h after trauma. Contusion volume was measured planimetrically from hematoxylin-eosin-stained coronal slices. Hemispheric swelling and water content were determined gravimetrically. Thirty minutes before sacrifice, a Codman intracranial pressure (ICP) probe was placed in the right hemisphere, and ICP as well as mean arterial blood pressure (MABP) and cerebral perfusion pressure (CPP) were monitored. Aptiganel HCl reduced contusion volume by 13.6% in treated rats (p < 0.05). Hemispheric swelling was also significantly diminished by 31.5% in accordance to a decrease in hemispheric water content (controls, 82.78 +/- 0.12%, vs. aptiganel HCl, 82.30 +/- 0.18%, p < 0.05). Posttraumatic ICP was not significantly lower in the aptiganel HCl treated animals (25.5 +/- 2.4 mm Hg vs. 32.0 +/- 2.7 mm Hg, p = 0.096). MABP was found to be higher in the treatment group 24 h after injury (107.8 +/- 3.6 mm Hg vs. 89.9 +/- 2.4 mm Hg, p < 0.001), resulting in a higher CPP (82.6 +/- 4.2 mm Hg vs. 57.2 +/- 4.6 mm Hg, p < 0.05). Taken together, aptiganel HCl exerts various beneficial effects following experimental traumatic brain injury. It decreases contusion volume and hemispheric swelling as well as water content. Thus, this drug appears promising for further clinical trials in brain trauma.	Humboldt Univ, Rudolf Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany		Kroppenstedt, SN (corresponding author), Humboldt Univ, Rudolf Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.						ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ARONOWSKI J, 1994, STROKE, V25, P2235, DOI 10.1161/01.STR.25.11.2235; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1996, NEUROTRAUMA, P375; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FIELDS RD, 1991, J NEUROSCI, V11, P134; KATAYAMA Y, 1990, ACT NEUR S, V51, P183; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1994, INTRACRANAL PRESSURE, V11, P331; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1993, STROKE, V24, P2074, DOI 10.1161/01.STR.24.12.2074; Muir KW, 1995, ANN NY ACAD SCI, V765, P279, DOI 10.1111/j.1749-6632.1995.tb16585.x; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PARK CK, 1994, ACTA NEUROCHIR, P279; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; TORREGROSA G, 1994, J VASC RES, V31, P221, DOI 10.1159/000159047; UNTERBERG AW, 1996, ACTA NEUROCHIR WIE S, V70, P106; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	41	39	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					191	197		10.1089/neu.1998.15.191			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500004	9528919				2022-02-06	
J	Mukhin, AG; Ivanova, SA; Faden, AI				Mukhin, AG; Ivanova, SA; Faden, AI			mGluR modulation of post-traumatic neuronal death: role of NMDA receptors	NEUROREPORT			English	Article						in vitro model; metabotropic glutamate receptor; neuronal death; neuroprotection; NMDA receptor	METABOTROPIC GLUTAMATE RECEPTORS; SPINAL-CORD INJURY; SIGNAL TRANSDUCTION; BRAIN INJURY; AMINO-ACIDS; ANTAGONIST; CELLS; NEUROTOXICITY; AGONIST; CALCIUM	THE potential interaction between group I metabotropic glutamate receptors (mGluR) and NMDA receptors in mediating of post-traumatic neuronal death was studied using an in vitro trauma model. Treatment with group I mGluR antagonists provided significant neuroprotection either in the presence or absence of an NMDA receptor antagonist. In contrast, treatment with a group I mGluR agonist alone significantly exacerbated injury; this exacerbation was significantly, but incompletely, reduced in the presence of an NMDA receptor antagonist. These findings are consistent with the conclusion that the effects of group I mGluR activation on posttraumatic cell death are mediated only in part through NMDA receptor modulation and suggest that group I mGluR antagonists may have important therapeutic potential.	GEORGETOWN UNIV, MED CTR, INST COGNIT & COMPUTAT SCI, WASHINGTON, DC 20007 USA						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		ABE T, 1992, J BIOL CHEM, V267, P13361; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1987, J NEUROSCI, V7, P369; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Mukhin A, 1996, J NEUROSCI, V16, P6012; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WONG EHF, 1986, BRIT J PHARMACOL, V89, P536; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	25	39	39	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JUL 28	1997	8	11					2561	2566		10.1097/00001756-199707280-00028			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XP313	WOS:A1997XP31300031	9261827				2022-02-06	
J	Onifer, SM; Cannon, AB; Whittemore, SR				Onifer, SM; Cannon, AB; Whittemore, SR			Altered differentiation of CNS neural progenitor cells after transplantation into the injured adult rat spinal cord	CELL TRANSPLANTATION			English	Article; Proceedings Paper	3rd Annual Conference of the American-Society-for-Neural-Transplantation	APR 25-27, 1996	CLEARWATER BEACH, FL	Amer Soc Neural Transplantat		neural progenitor cells; neuronal differentiation; CNS transplantation; spinal cord injury	RECEPTOR MESSENGER-RNA; EMBRYONIC BRAIN-STEM; LOCUS COERULEUS; RAPHE NEURONS; GROWTH; GRAFTS; LINE; IMMUNOREACTIVITY; TISSUE; REINNERVATION	Denervation of CNS neurons and peripheral organs is a consequence of traumatic SCI, Intraspinal transplantation of embryonic CNS neurons is a potential strategy for reinnervating these targets, Neural progenitor cell lines are being investigated as alternates to embryonic CNS neurons, RN33B is an immortalized neural progenitor cell line derived from embryonic rat raphe nuclei following infection with a retrovirus encoding the temperature-sensitive mutant of SV40 large T-antigen, Transplantation studies have shown that local epigenetic signals in intact or partially neuron-depleted adult rat hippocampal formation or striatum direct RN33B cell differentiation to complex multipolar morphologies resembling endogenous neurons, After transplantation into neuron-depleted regions of the hippocampal formation or striatum, RN33B cells were relatively undifferentiated or differentiated with bipolar morphologies, The present study examines RN33B cell differentiation after transplantation into normal spinal cord and under different lesion conditions, Adult rats underwent either unilateral lesion of lumbar spinal neurons by intraspinal injection of kainic acid or complete transection at the T10 spinal segment, Neonatal rats underwent either unilateral lesion of lumbar motoneurons by sciatic nerve crush or complete transection at the T10 segment, At 2 or 6-7 wk postinjury, lacZ-labeled RN33B cells were transplanted into the lumbar enlargement of injured and age-matched normal rats, At 2 wk posttransplantation, bipolar and some multipolar RN33B cells were found throughout normal rat gray matter, In contrast, only bipolar RN33B cells were seen in gray matter of kainic acid lesioned, sciatic nerve crush, or transection rats, These observations suggest that RN33B cell multipolar morphological differentiation in normal adult spinal cord is mediated by direct cell-cell interaction through surface molecules on endogenous neurons and may be suppressed by molecules released after SCI, They also indicate that the fate of immortalized neural progenitor cell lines in injured CNS must be stringently characterized. (C) 1997 Elsevier Science Inc.	MIAMI PROJECT CURE PARALYSIS, DEPT NEUROL SURG, MIAMI, FL 33136 USA; MIAMI PROJECT CURE PARALYSIS, DEPT PHYSIOL & BIOPHYS, MIAMI, FL 33136 USA		Onifer, SM (corresponding author), UNIV MIAMI, SCH MED, MIAMI PROJECT CURE PARALYSIS, 1600 NW 10TH AVE R-48, MIAMI, FL 33136 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026887, R55NS026887] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26887] Funding Source: Medline		Adams FS, 1996, NEUROCHEM RES, V21, P619, DOI 10.1007/BF02527762; BAKHIT C, 1991, BRAIN RES, V554, P264, DOI 10.1016/0006-8993(91)90199-6; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BENVENISTE EN, 1997, IMMUNOLOGY NERVOUS S, P419; BJORKLUND A, 1986, NEUROSCIENCE, V18, P685, DOI 10.1016/0306-4522(86)90063-1; Bregman B. S., 1994, FUNCTIONAL NEURAL TR, P489; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; Brundin P, 1987, PROG BRAIN RES <D>, V71, P293; BRUNELLO N, 1990, NEUROSCI LETT, V118, P238, DOI 10.1016/0304-3940(90)90636-N; BUCHANAN JT, 1986, BRAIN RES, V381, P225, DOI 10.1016/0006-8993(86)90071-5; BUNGE R, 1983, SPINAL CORD RECONSTR, P341; BUNGE RP, 1993, ADV NEUROL, V59, P75; CATTANEO E, 1994, DEV BRAIN RES, V83, P197, DOI 10.1016/0165-3806(94)00137-5; DAS GD, 1983, J NEUROL SCI, V62, P191, DOI 10.1016/0022-510X(83)90199-5; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; FAROOQUE M, 1995, J NEUROTRAUM, V12, P41, DOI 10.1089/neu.1995.12.41; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; FOSTER GA, 1990, PROG BRAIN RES, V82, P247; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FRISEN J, 1994, EXP NEUROL, V129, P183, DOI 10.1006/exnr.1994.1160; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Giordano M, 1996, CELL TRANSPLANT, V5, P563, DOI 10.1016/0963-6897(96)00027-9; HOFFER BJ, 1991, TRENDS NEUROSCI, V14, P384, DOI 10.1016/0166-2236(91)90168-T; HORVAT JC, 1991, RESTOR NEUROL NEUROS, V2, P289, DOI 10.3233/RNN-1991-245618; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; MOORMAN SJ, 1990, BRAIN RES, V508, P194, DOI 10.1016/0006-8993(90)90396-S; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; NOTHIAS F, 1990, J COMP NEUROL, V301, P520, DOI 10.1002/cne.903010404; NYGREN LG, 1977, BRAIN RES, V129, P227, DOI 10.1016/0006-8993(77)90003-8; ONIFER SM, 1993, CELL TRANSPLANT, V2, P131, DOI 10.1177/096368979300200207; ONIFER SM, 1993, EXP NEUROL, V122, P130, DOI 10.1006/exnr.1993.1114; PRIVAT A, 1990, PROGR BRAIN RES, V78, P155; RAJAOFETRA N, 1992, BRAIN RES, V572, P329, DOI 10.1016/0006-8993(92)90495-U; REIER PJ, 1992, EXP NEUROL, V115, P177, DOI 10.1016/0014-4886(92)90245-L; REYNOLDS ME, 1991, BRAIN RES, V559, P149, DOI 10.1016/0006-8993(91)90298-A; RISLING M, 1992, J NEUROCYTOL, V21, P79, DOI 10.1007/BF01189007; ROMANES GJ, 1946, J ANAT, V80, P117; ROUDET C, 1995, BRAIN RES, V677, P1, DOI 10.1016/0006-8993(95)00068-2; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SEIGER A, 1985, NEURAL GRAFTING MAMM, P71; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Shihabuddin LS, 1996, J NEUROCYTOL, V25, P101, DOI 10.1007/BF02284789; SHIMOHAMA S, 1989, MOL BRAIN RES, V5, P271, DOI 10.1016/0169-328X(89)90061-2; SIERADZAN K, 1989, NEUROSCIENCE, V31, P115, DOI 10.1016/0306-4522(89)90034-1; Sugar O, 1940, J NEUROPHYSIOL, V3, P1; TAGO H, 1989, BRAIN RES, V495, P271, DOI 10.1016/0006-8993(89)90221-7; TESSLER A, 1988, J COMP NEUROL, V270, P537, DOI 10.1002/cne.902700407; White LA, 1997, J NEUROSCI RES, V47, P242, DOI 10.1002/(SICI)1097-4547(19970201)47:3<242::AID-JNR2>3.0.CO;2-I; WHITE LA, 1992, J CHEM NEUROANAT, V5, P327, DOI 10.1016/0891-0618(92)90020-Q; WHITE LA, 1994, J NEUROIMMUNOL, V49, P135, DOI 10.1016/0165-5728(94)90189-9; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; WICTORIN K, 1992, NEUROREPORT, V3, P1045, DOI 10.1097/00001756-199212000-00003; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0; YAKOVLEFF A, 1995, EXP BRAIN RES, V106, P69; [No title captured]	62	39	47	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.	MAY-JUN	1997	6	3					327	338		10.1016/S0963-6897(97)00037-7			12	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cell Biology; Research & Experimental Medicine; Transplantation	XA193	WOS:A1997XA19300014	9171165				2022-02-06	
J	PohlmannEden, B; Bruckmeir, J				PohlmannEden, B; Bruckmeir, J			Predictors and dynamics of posttraumatic epilepsy	ACTA NEUROLOGICA SCANDINAVICA			English	Article						severe head trauma; posttraumatic epilepsy; predictors	POST-TRAUMATIC EPILEPSY; SEIZURES	Objectives - The goal of our study was to identify clinical, neurophysiological and neuroradiological variables in severe head trauma (SHT) with predictive value for posttraumatic epilepsy (PTE) and to evaluate the influence of each risk factor for the dynamics of epilepsy. Material and methods - We systematically compared 57 PTE patients with 50 age and sex-matched control patients with SHT and no PTE. Mean follow-up was a years. Results - Of all PTE-patients 68.5% had their first seizure within 2 years after the trauma. Significant risk factors for PTE were focal signs in the first examination (P<0.01), missile injuries (P<0.01), frontal lesions (P<0.01), intracerebral hemorrhage (P<0.01), diffuse contusion (P<0.01), prolonged posttraumatic amnesia (P<0.001), depression fracture (P<0.01) and cortical-subcortical lesions (P<0.001). The combination of the last 3 variables conferred a particularly high risk for PTE (logistic regression analysis). Combined seizure pattern, high seizure frequency, AED-noncompliance and alcohol abuse predicted poor seizure control. Conclusion The risk for PTE is clearly determined by those variables which correlate with the severity, the extent of tissue loss and the penetrating nature of the brain trauma.			PohlmannEden, B (corresponding author), UNIV HEIDELBERG,DEPT NEUROL,MANNHEIM HOSP,D-68135 MANNHEIM,GERMANY.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; DASILVA AM, 1990, ACT NEUR S, V50, P48; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HAUSER WA, 1990, NEW ENGL J MED, V325, P540; JANZ D, 1982, NERVENARZT, V53, P238; JENNETT WB, 1975, EPILEPSY NONMISSILE; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MIZUKAWA K, 1991, JPN J PSYCHIAT NEUR, V45, P285; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WILMORE LJ, 1992, NEUROL CLIN, V4, P869	15	39	41	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	MAY	1997	95	5					257	262		10.1111/j.1600-0404.1997.tb00206.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WZ792	WOS:A1997WZ79200001	9188898				2022-02-06	
J	Glang, A; Todis, B; Cooley, E; Wells, J; Voss, J				Glang, A; Todis, B; Cooley, E; Wells, J; Voss, J			Building social networks for children and adolescents with traumatic brain injury: A school-based intervention	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						education; pediatrics; social support; traumatic brain injury	SEVERE DISABILITIES; GENERAL-EDUCATION; HEAD-INJURY; FOLLOW-UP; STUDENTS; PEERS; SUPPORT; REHABILITATION; CLASSROOM; MODERATE	Objective: Three boys, ages 8, 11, and 13, who experienced social isolation as a result of traumatic brain injury, were studied to investigate the effectiveness of a school-based, educator-mediated intervention aimed at increasing the social networks of students with traumatic brain injury. ii four-phase problem-solving process was instituted in which a student-centered school team identified goals and strategies for increasing the student's social opportunities and then met frequently to review progress toward the goals. Main Outcome Measures: Frequency of students' social contacts with nondisabled peers, parent and educator social validation ratings, and participant observations, Results: The number of social contacts for each strident increased over baseline levels and was maintained over the course of the study. Parents, teachers, and students were generally satisfied with the process and with the concomitant increases in students' degree of social integration. Anecdotal follow-up reports indicated that these results were not maintained over time. Conclusions: The study's findings raise important questions about the varying perspectives on the importance of social integration, the degree to which educators can serve as change agents in students' social experiences, and the type of follow-up support required to maintain increases in students' social interactions.	W ED FAR W LAB,SPECIAL EDUC PROJECTS,SAN FRANCISCO,CA; OREGON CTR APPL SCI,EUGENE,OR		Glang, A (corresponding author), WESTERN OREGON STATE COLL,99 W 10TH,SUITE 370,EUGENE,OR 97401, USA.						BADMAN LJ, 1992, HLTH ED Q, V19, P9; Begali V., 1987, HEAD INJURY CHILDREN; BELLE D, 1984, M AM PSYCHOL ASS TOR; BLOSSER J, 1995, J HEAD TRAUMA REHAB, V10, P46, DOI 10.1097/00001199-199504000-00006; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; COOLEY E, STUDENTS ACQUIRED BR; COWEN EL, 1988, AM J COMMUN PSYCHOL, V16, P591, DOI 10.1007/BF00922773; DEATON AV, 1994, ED DIMENSIONS ACQUIR; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; EVANS IM, 1994, J ASSOC PERS SEVERE, V19, P326, DOI 10.1177/154079699401900408; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GERSTEN R, 1995, EXCEPT CHILDREN, V62, P52, DOI 10.1177/001440299506200105; GOETHE KE, 1984, PSYCHIAT ANN, V14, P540, DOI 10.3928/0048-5713-19840701-11; GRENOTSCHEYER M, 1994, J ASSOC PERS SEVERE, V19, P253, DOI 10.1177/154079699401900402; HALL LJ, 1994, J ASSOC PERS SEVERE, V19, P302, DOI 10.1177/154079699401900406; HELMSTETTER E, 1994, J ASSOC PERS SEVERE, V19, P263, DOI 10.1177/154079699401900403; Hux K, 1996, INTERV SCH CLIN, V31, P158, DOI 10.1177/105345129603100305; JENKINS JR, 1992, EXCEPT CHILDREN, V58, P555, DOI 10.1177/001440299205800610; KAMPS DM, 1994, J APPL BEHAV ANAL, V27, P49, DOI 10.1901/jaba.1994.27-49; KENNEDY CH, 1994, J ASSOC PERS SEVERE, V19, P1; KEPLER KL, 1996, CHILDREN ACQUIRED BR; KISHI GS, 1994, J ASSOC PERS SEVERE, V19, P277, DOI 10.1177/154079699401900404; KLONOFF H, 1974, CLIN NEUROPSYCHOLOGY; LEAHEM J, 1996, BRAIN INJURY, V10, P27; LEHR E, 1990, PSYCHOL MANAGEMENT T, P155; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LUCYSHYN JM, 1996, CHILDREN ACQUIRED BR; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; OSWALD H, 1994, SOCIAL NETWORKS SOCI; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RUTTER M, 1983, DEV NEUROPSYCHIATRY; SALISBURY CL, 1995, EXCEPT CHILDREN, V62, P125, DOI 10.1177/001440299506200203; SANDLER IN, 1989, MARSHALING SOCIAL SU; Savage R. C., 1994, ED DIMENSIONS ACQUIR; SAVAGE RC, 1996, CHILDREN ACQUIRED BR; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; SINGER GHS, 1996, CHILDREN ACQUIRED BR; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; SOWERS JA, 1996, ROAD AUTONOMY PROMOT; STAINBACK S, 1984, EXCEPT CHILDREN, V50, P400, DOI 10.1177/001440298405000502; STAUB D, 1994, J ASSOC PERS SEVERE, V19, P314, DOI 10.1177/154079699401900407; TODIS B, 1993, FAMILIES DISABILITY; Vieth AZ, 1996, BRAIN INJURY, V10, P465, DOI 10.1080/026990596124322; Wechsler D., 1974, WECHSLER ADULT INTEL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLER B, 1990, CAN J REHABIL, V2, P167; WILLIAMS J, 1991, HEAD INJURY FAMILY M; WOLCHIK S, 1989, CHILDRENS SOCIAL NET; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	54	39	39	0	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1997	12	2					32	47		10.1097/00001199-199704000-00005			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	WT782	WOS:A1997WT78200006					2022-02-06	
J	Bohnert, AM; Parker, JG; Warschausky, SA				Bohnert, AM; Parker, JG; Warschausky, SA			Friendship and social adjustment of children following a traumatic brain injury: An exploratory investigation	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; BEHAVIOR	Despite evidence that suggests that children who survive traumatic brain injuries (TBIs) experience disruptions in their peer relationships, the peer experiences of children with TBIs have rarely been studied empirically to date. Data were gathered on measures of peer adjustment for a sample of 22 children with TBIs and were compared with children from a matched control group. Children with TBIs were found to be less socially and athletically competent than children who had not experienced a TBI. Among boys, TBI was also related to lower academic competence. Children with more severe injuries had greater difficulty managing conflict, coordinating play, and developing intimacy in their closest friendships. Girls were more likely than boys to have friendships that predated the injury. Results are discussed in terms of the significance of the social disruption that apparently occurs surrounding injury.	UNIV MICHIGAN,ANN ARBOR,MI 48109		Bohnert, AM (corresponding author), PENN STATE UNIV,DEPT PSYCHOL,314 MOORE BLDG,UNIVERSITY PK,PA 16802, USA.			Bohnert, Amy/0000-0002-0864-2900			ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARTER S, 1986, MANUAL SELFPERCEPTIO; Lehr E, 1990, PSYCHOL MANAGEMENT T; OKUN A, 1994, DEV PSYCHOPATHOL, V6, P77, DOI 10.1017/S0954579400005897; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Parker JG, 1996, DEV PSYCHOL, V32, P1025, DOI 10.1037/0012-1649.32.6.1025; PARKER JG, 1993, DEV PSYCHOL, V29, P611, DOI 10.1037/0012-1649.29.4.611; PARKER JG, 1995, DEV PSYCHOPATHOLOGY, V0002, P00096; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Thurstone LL, 1927, AM J PSYCHOL, V38, P368, DOI 10.2307/1415006; WARSCHAUSKY S, 1995, M SOC RES CHILD DEV	15	39	39	0	5	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		1997	13	4					477	486		10.1080/87565649709540688			10	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	YH782	WOS:A1997YH78200001					2022-02-06	
J	Urculo, E; Arrazola, M; Arrazola, M; Riu, I; Moyua, A				Urculo, E; Arrazola, M; Arrazola, M; Riu, I; Moyua, A			Delayed glossopharyngeal and vagus nerve paralysis following occipital condyle fracture - Case report	JOURNAL OF NEUROSURGERY			English	Article						glossopharyngeal nerve; vagus nerve; head injury; occipital condyle fracture	ANATOMY	This report describes a case of delayed glossopharyngeal and vagus nerve paralysis following a closed head injury. A depressed fracture of the occipital condyle was diagnosed using high-resolution computerized tomography (CT) scanning and three-dimensional CT images. Magnetic resonance imaging complemented the study. The anatomical features, mechanisms, diagnosis, and treatment of this unusual lesion are discussed.	POLICLIN GUIPUZCOA, SERV RADIOL NEURORADIOL, E-20011 SAN SEBASTIAN, SPAIN		Urculo, E (corresponding author), POLICLIN GUIPUZCOA, NEUROSURG SERV, PARQUE MIRAMON S-N, E-20011 SAN SEBASTIAN, SPAIN.						ALKER GJ, 1975, RADIOLOGY, V114, P611; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; DEOLIVEIRA E, 1985, SURG NEUROL, V24, P293, DOI 10.1016/0090-3019(85)90042-4; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; DICHIRO GD, 1964, J NEUROSURG, V21, P447, DOI 10.3171/jns.1964.21.6.0447; DICKMAN CA, 1991, J NEUROSURG, V75, P221, DOI 10.3171/jns.1991.75.2.0221; DIETERMANN JL, 1983, TRAUMATOLOGY SKULL B; DOLAN KD, 1979, CRC CR REV DIAGN IM, V12, P101; ELGAMMAL T, 1990, RADIOLOGY DIAGNOSIS, V3; GOLDSTEIN SJ, 1982, SURG NEUROL, V17, P350, DOI 10.1016/0090-3019(82)90308-1; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; Hollerhage H G, 1986, Zentralbl Neurochir, V47, P250; KRETSCHMANN HJ, 1992, CRANIAL NEUROIMAGING; Lang J, 1991, CLIN ANATOMY POSTERI; MARIANI PJ, 1990, ANN EMERG MED, V19, P1447, DOI 10.1016/S0196-0644(05)82618-6; MENZEL J, 1981, CRANIAL NERVES ANATO; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; RHOTON AL, 1975, J NEUROSURG, V42, P541, DOI 10.3171/jns.1975.42.5.0541; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008	24	39	39	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1996	84	3					522	525		10.3171/jns.1996.84.3.0522			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TW713	WOS:A1996TW71300024	8609569				2022-02-06	
J	KAITARO, T; KOSKINEN, S; KAIPIO, ML				KAITARO, T; KOSKINEN, S; KAIPIO, ML			NEUROPSYCHOLOGICAL PROBLEMS IN EVERYDAY LIFE - A 5-YEAR FOLLOW-UP-STUDY OF YOUNG SEVERELY CLOSED-HEAD-INJURED PATIENTS	BRAIN INJURY			English	Article								The aim of this follow-up study was to examine the long-term disabilities and handicaps caused by severe head injuries and their effects on the everyday life of patients and their relatives. The group studied consisted of 19 subjects who had suffered a severe closed-head injury during 1984 and had been rehabilitated in the Kapyla Rehabilitation Center. In 1989 a thorough functional assessment of these patients was carried out. In addition, information concerning the quality of life, activities of daily living (ADL) and social situation was gathered by means of questionnaires filled in by the patient and, if possible, by a close relative. The results indicated the importance of changes in cognitive functions, personality and emotional reactions. Changes in personality and emotional reactions were especially emphasized by the relatives. We also correlated the patients' and their relatives' estimates of the occurrence of memory problems in everyday life with the results of objective memory tests. We found that verbal memory tests reached significant correlations with the estimates of everyday memory problem, whereas tests of visual memory, though able to discriminate the brain-injured from normal subjects, did not correlate on a statistically significant level with the estimates of patients and relatives. The implications of the results for methods of assessment and the planning of rehabilitation programmes are discussed.	KAPYLA REHABIL CTR, SF-00160 HELSINKI, FINLAND								BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1988, SCAND J REHABIL MED, P41; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GOODGOLD J, 1988, REHABILITATION MED; KAITARO T, 1992, ML114 SOC INS I PUBL; MAHONEY F I, 1965, Md State Med J, V14, P61; MOSKOWITZ E, 1957, J Chronic Dis, V5, P342, DOI 10.1016/0021-9681(57)90092-9; NIEMI ML, 1988, STROKE, V19, P1101, DOI 10.1161/01.STR.19.9.1101; NOTT PN, 1975, BRIT J SOC CLIN PSYC, V14, P199, DOI 10.1111/j.2044-8260.1975.tb00170.x; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PIETILA ML, 1992, ML114 SOC INS I PUBL, P35; RANKIN J, 1957, Scott Med J, V2, P200; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; VIITANEN M, 1987, UMEA U MED DISSERTAT, V201; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; 1986, HDB FINNISH VERSION	19	39	39	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	1995	9	7					713	727		10.3109/02699059509008227			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	RZ814	WOS:A1995RZ81400004	8680398				2022-02-06	
J	TENNANT, A; MACDERMOTT, N; NEARY, D				TENNANT, A; MACDERMOTT, N; NEARY, D			THE LONG-TERM OUTCOME OF HEAD-INJURY - IMPLICATIONS FOR SERVICE PLANNING	BRAIN INJURY			English	Article								As most of those experiencing traumatic brain injury tend to be young, disabled survivors will be gradually accruing in each locality as each year passes. How many need continuing care a decade after injury? How many need day care, or need help with finding work, or continuing support for carers? 190 patients who had been admitted to two UK regional neurosurgical units on average some 7 years earlier were followed up. With an average age of 29 years these patients stayed in hospital for an average 33 days. At follow-up 23% were classified as having moderate disability or worse on the Glasgow Outcome Scale, including 7.4% who had died subsequent to discharge. Survivors were given a neuropsychological assessment and a socioeconomic interview. Of the survivors, 17% had failed to make a good recovery, but 36% were failing to occupy their time in a meaningful way. Age over 30 at time of injury, not occupied before injury, and above-average length of stay were some of the predictors for failing to occupy time. Quality of life was severely curtailed for those who could not occupy their time, as was the case for their carers. Appropriate counselling, Vocational evaluation and family support in the early years following injury may help to improve quality of life for both the head-injured person and their carers.	MANCHESTER ROYAL INFIRM,DEPT NEUROL,MANCHESTER M13 9WL,LANCS,ENGLAND		TENNANT, A (corresponding author), UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND.						[Anonymous], 1980, INT CLASSIFICATION I; COADY MSE, 1991, RESOURCE IMPLICATION; COCKBURN JM, 1988, CLIN REHABIL, V2, P315; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; EDWARDS FC, 1990, HLTH SERVICES ADULTS; FAHY TJ, 1967, LANCET, V2, P475; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; Hunt SM, 1986, MEASURING HLTH STATU; JENNETT B, 1975, LANCET, V1, P480; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; Kinsella G, 1989, Int Disabil Stud, V11, P9; KREUTZER JS, 1988, INT DISABILITY STUDI, V13, P162; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LONDON PS, 1989, BRIT J OCCUPATIONAL, V52, P101; MURPHY L D, 1990, Brain Injury, V4, P95, DOI 10.3109/02699059009026153; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; WILKINSON SM, 1989, CLIN REHABIL, V3, P317; 1990, LANCET, V335, P886; 1989, CARING PEOPLE; 1988, MANAGEMENT TRAUMATIC	21	39	40	0	1	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1995	9	6					595	605		10.3109/02699059509008218			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	RU016	WOS:A1995RU01600006	7581355				2022-02-06	
J	BIASCA, N; SIMMEN, HP; BARTOLOZZI, AR; TRENTZ, O				BIASCA, N; SIMMEN, HP; BARTOLOZZI, AR; TRENTZ, O			REVIEW OF TYPICAL ICE-HOCKEY INJURIES - SURVEY OF THE NORTH-AMERICAN NHL AND HOCKEY-CANADA VERSUS EUROPEAN LEAGUES	UNFALLCHIRURG			English	Article								Ice hockey is considerd to be one of the fastest and roughest of all sports. Prospective injury reports of the North American National Hockey League, the Canadian Amateur Hockey Association and of several European teams (UdSSR, CSSR, Sweden and Switzerland) are reviewed to evaluate the patterns, anatomic locations, circumstances and sequelae of ice hockey-related injuries. Although different injury reporting systems are used in North America and Europe, knee injuries (sprains of the collateral ligaments) accounted for the majority of games missed (40%), followed by injuries to the shoulder (dislocation, acromio-clavicular joint separation, rotator cuff strain and tears, 20%), the groin (15%), and the back (10%). Mandatory helmets and face masks reduced the number of facial and eye injuries to a quarter from 1972 to 1983. The frequency of only concussion but also cervical spine lesions is increasing. The prevention of head, face, eye and neck injuries should mainly be accomplished by enforcement of current rules (mandatory helmets with face masks) and institution of new rules. Improvement in protective equipment would also have the effect of decreasing the frequency of injuries.			BIASCA, N (corresponding author), UNIV ZURICH HOSP,DEPT SURG,CH-8091 ZURICH,SWITZERLAND.							0	39	39	0	18	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0177-5537			UNFALLCHIRURG	Unfallchirurg	MAY	1995	98	5					283	288					6	Emergency Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Surgery	RB436	WOS:A1995RB43600006	7610390				2022-02-06	
J	YONEDA, Y; OGITA, K				YONEDA, Y; OGITA, K			RAPID AND SELECTIVE ENHANCEMENT OF DNA-BINDING ACTIVITY OF THE TRANSCRIPTION FACTOR AP1 BY SYSTEMIC ADMINISTRATION OF N-METHYL-D-ASPARTATE IN MURINE HIPPOCAMPUS	NEUROCHEMISTRY INTERNATIONAL			English	Article							CEREBELLAR GRANULE CELLS; MESSENGER-RNA EXPRESSION; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; C-FOS PROTEIN(S); PRIMARY CULTURES; JUN; STIMULATION; ACTIVATION; RECEPTORS	Brain nuclear extracts of ddY mice contained 3 different transcription factors with leucine-zipper domains, including activator protein-1 (AP1), cyclic AMP responsive element binding protein (CREB) and Myc. An intraperitoneal injection of N-methyl-D-aspartate (NMDA) was effective in selectively inducing 6-fold enhancement of DNA binding activity of AP1 in the hippocampus 2 h after the administration. Furthermore, NMDA induced less than 2-fold potentiation of the AP1 binding in the striatum, hypothalamus, medulla-pons and cerebral cortex in a rank order of decreasing magnitude. However, the AP1 binding was not significantly affected by the systemic injection of NMDA in the midbrain and cerebellum In contrast, NMDA virtually did not alter DNA binding activities of both CREB and Myc in discrete structures of murine brain under similar experimental conditions. These results suggest that the systemic administration of NMDA may induce rapid and selective enhancement of DNA binding activity of AP1 in murine hippocampus.			YONEDA, Y (corresponding author), SETSUNAN UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL,45-1 NAGAOTOGE CHO,HIRAKATA,OSAKA 57301,JAPAN.		Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X			BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVAL JL, 1989, J NEUROCHEM, V52, P1954, DOI 10.1111/j.1471-4159.1989.tb07285.x; DESSI F, 1993, J NEUROCHEM, V60, P1953, DOI 10.1111/j.1471-4159.1993.tb13427.x; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; LIU F, 1993, J BIOL CHEM, V268, P6714; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OGITA K, 1994, IN PRESS J NEUROCHEM; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SHIN C, 1990, J NEUROCHEM, V55, P1050, DOI 10.1111/j.1471-4159.1990.tb04595.x; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; YONEDA Y, 1989, ANAL BIOCHEM, V177, P250, DOI 10.1016/0003-2697(89)90047-X; YONEDA Y, 1993, NEUROSCI LETT, V161, P161, DOI 10.1016/0304-3940(93)90284-R; YONEDA Y, 1993, J NEUROCHEM, V61, pS256	30	39	39	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0197-0186			NEUROCHEM INT	Neurochem. Int.	SEP	1994	25	3					263	271		10.1016/0197-0186(94)90070-1			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH035	WOS:A1994PH03500007	7833794				2022-02-06	
J	CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR				CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR			INFANT WALKER-RELATED INJURIES - A PROSPECTIVE-STUDY OF SEVERITY AND INCIDENCE	PEDIATRICS			English	Article						INFANT WALKERS; INJURY CONTROL; HEAD INJURIES	CONTINUING PROBLEM; BABY WALKERS	Objective. To determine the incidence and significance of walker-related injuries in infants. Methods. During a 3-year, 8-month period, all infants who were brought to the University of Virginia Pediatric Emergency Department with a walker-related injury were prospectively studied. During the emergency department visit, demographic and epidemiologic information were recorded. The annual incidence of walker-related injuries occurring in infants <1 year of age that resulted in a hospital emergency department visit was calculated from the home zip codes of the injured patients and from the population of infants <1 year of age living in Charlottesville and in Albemarle County. Results. Sixty-five patients were enrolled in the study. The age distribution ranged from 3 months to 17 months, with 95% younger <1 year old. Mechanisms associated with walker-related injuries included stairway falls in 46 infants (71%), tip-overs in 14 infants (21%), falls from a porch in 2 infants (3%), and burns in 3 infants (5%). These injuries predominantly involved the head and neck region (97%), with few injuries to the extremities (6%) and trunk (3%). Although the majority of injuries were minor, significant injuries occurred in 19 infants (29%). These injuries included skull fracture, concussion, intracranial hemorrhage, full-thickness burns, c-spine fracture, and death. After excluding the burned patients, all the serious injuries resulted from falls down stairs. The annual incidence of injuries occurring in infants <1 year of age, related to the use of walkers, and resulting in an emergency department visit was 8.9/1000, and for serious injuries was 1.7/1000. Conclusions. The incidence and significance of infant walker-related injuries in infants are unacceptably high.			CHIAVIELLO, CT (corresponding author), UNIV VIRGINIA,DEPT PEDIAT,DIV EMERGENCY MED,BOX 523-21,CHARLOTTESVILLE,VA 22908, USA.						BIRCHALL MA, 1988, BURNS, V14, P244, DOI 10.1016/0305-4179(88)90049-6; COATS TJ, 1991, ARCH EMERG MED, V8, P52; COURY DL, 1992, AJDC, V146, pA507; CROUCHMAN M, 1986, DEV MED CHILD NEUROL, V28, P757; DIMARIO FJ, 1990, CLIN PEDIATR, V29, P405, DOI 10.1177/000992289002900709; FAZEN LE, 1982, PEDIATRICS, V70, P106; GAUDREAULT P, 1986, ANN EMERG MED, V15, P808, DOI 10.1016/S0196-0644(86)80378-X; GLEADHILL DNS, 1987, ARCH DIS CHILD, V62, P491, DOI 10.1136/adc.62.5.491; HOLM VA, 1983, AM J DIS CHILD, V137, P1189, DOI 10.1001/archpedi.1983.02140380049016; JOHNSON C F, 1990, Pediatric Emergency Care, V6, P58, DOI 10.1097/00006565-199003000-00017; KAUFFMAN IB, 1977, PERCEPT MOTOR SKILL, V45, P1323, DOI 10.2466/pms.1977.45.3f.1323; KAVANAGH CA, 1982, AM J DIS CHILD, V136, P205, DOI 10.1001/archpedi.1982.03970390019005; MEYER M, 1988, BURNS, V14, P145, DOI 10.1016/0305-4179(88)90222-7; MILLAR R, 1975, INJURY, V7, P8, DOI 10.1016/0020-1383(75)90051-0; PARTINGTON MD, 1991, ANN EMERG MED, V20, P652, DOI 10.1016/S0196-0644(05)82386-8; RIDENOUR MV, 1982, PERCEPT MOTOR SKILL, V55, P1201, DOI 10.2466/pms.1982.55.3f.1201; RIEDER MJ, 1986, PEDIATRICS, V78, P488; SILVERSTEIN MK, 1984, CLIN PEDIATR, V23, P330; STOFFMAN JM, 1984, CAN MED ASSOC J, V131, P573; 1980, INT CLASSIFICATION D, V1	20	39	42	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	JUN	1994	93	6					974	976					3	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	NP678	WOS:A1994NP67800018	8190586				2022-02-06	
J	AISEN, ML; ARNOLD, A; BAIGES, I; MAXWELL, S; ROSEN, M				AISEN, ML; ARNOLD, A; BAIGES, I; MAXWELL, S; ROSEN, M			THE EFFECT OF MECHANICAL DAMPING LOADS ON DISABLING ACTION TREMOR	NEUROLOGY			English	Article								Patients with severe action tremor have uncontrollable, relatively rapid oscillatory motion superimposed on otherwise useable slower voluntary motor activity. Because a mechanical damper produces an opposing force proportional to velocity, applying damping loads to tremorous limbs should attenuate the (high-velocity) tremor component of movement while permitting the slower purposeful portion to proceed relatively unopposed. In this study, the effect of upper extremity damping in three degrees of freedom was examined in 10 patients with cerebellar action tremor due to multiple sclerosis or traumatic brain injury. Variable amounts of damping were applied by prototype energy-dissipating orthoses which generated resistive viscous loads by means of computer-controlled magnetic particle brakes. All patients experienced statistically and functionally significant tremor reduction with the application of damping.	MIT,CAMBRIDGE,MA 02139; UNIV PUERTO RICO,RIO PIEDRAS,PR 00931; UNIV PUERTO RICO,PUERTO,NY		AISEN, ML (corresponding author), CORNELL UNIV,BURKE REHAB HOSP,COLL MED,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.						AISEN M, 1991, ARCH NEUROL-CHICAGO, V49, P513; ARNOLD A, 1992, THESIS MIT; HEWER LR, 1972, BRAIN, V95, P579; HOMBERG V, 1987, J NEUROL NEUROSUR PS, V50, P568, DOI 10.1136/jnnp.50.5.568; MAXWELL S, THESIS MIT; MORRICE B L, 1987, Society for Neuroscience Abstracts, V13, P1700; ROSEN M, IN PRESS J REHABIL R; SANES JN, 1988, J NEUROL NEUROSUR PS, V51, P934, DOI 10.1136/jnnp.51.7.934	8	39	39	0	7	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology	JUL	1993	43	7					1346	1350		10.1212/WNL.43.7.1346			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LM104	WOS:A1993LM10400015	8327136				2022-02-06	
J	LAZARUS, JAC				LAZARUS, JAC			ASSOCIATED MOVEMENT IN HEMIPLEGIA - THE EFFECTS OF FORCE EXERTED, LIMB USAGE AND INHIBITORY TRAINING	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						HEMIPLEGIA; INHIBITION; TRAUMATIC BRAIN INJURY	COORDINATION	The intensity of associated movement or motor overflow in the contralateral limb during a unimanual task was evaluated in postacute traumatic brain injured (TBI) young adults with left side hemiplegia and age-matched controls. Both groups demonstrated increased overflow with increasing active limb force, although the trend was for greater overflow to occur in the TBI group, particularly when the spastic limb was active. Following three successive days of inhibitory training with electromyographic feedback, TBI subjects were able to significantly reduce the amount of overflow in the contralateral limb, greater inhibition occurring in the noninvolved limb during spastic limb movement. The results are discussed in terms of a dual model of inhibitory control and the role of such processes in uncoupling the limbs for independent limb usage.			LAZARUS, JAC (corresponding author), UNIV WISCONSIN,DEPT PHYS EDUC & DANCE,2000 OBSERV DR,MADISON,WI 53706, USA.						BRODAL A, 1973, BRAIN, V96, P675, DOI 10.1093/brain/96.4.675; Burke D, 1988, Adv Neurol, V47, P401; BURKE D, 1970, J NEUROL NEUROSUR PS, V33, P216, DOI 10.1136/jnnp.33.2.216; CAMBIER J, 1977, NEUROLOGY, V27, P646, DOI 10.1212/WNL.27.7.646; CERNACEK J, 1961, ARCH NEUROL-CHICAGO, V4, P165, DOI 10.1001/archneur.1961.00450080047005; COHEN HJ, 1967, J PEDIATR-US, V71, P39, DOI 10.1016/S0022-3476(67)80228-2; DENNIS M, 1976, NEUROPSYCHOLOGIA, V14, P455, DOI 10.1016/0028-3932(76)90074-9; Fog E., 1963, CLIN DEV MED, V10, P52; JEBSON RH, 1971, ARCH PHYS MED REHAB, V51, P170; KELSO JAS, 1979, J EXP PSYCHOL HUMAN, V5, P229, DOI 10.1037/0096-1523.5.2.229; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; LANCE JW, 1974, ARCH PHYS MED REHAB, V55, P332; LAZARUS JAC, 1991, DEV MED CHILD NEUROL, V33, P32; LAZARUS JAC, 1987, DEV MED CHILD NEUROL, V29, P726; MARTENIUK RG, 1980, TUTORIALS MOTOR BEHA; MOORE J, 1980, RECOVERY FUNCTION TH, P9; MORASSO P, 1983, HUM MOVEMENT SCI, V2, P197, DOI 10.1016/0167-9457(83)90017-9; MULLEY G, 1982, SCAND J REHABIL MED, V14, P117; SEMMES J, 1968, NEUROPSYCHOLOGIA, V6, P11, DOI 10.1016/0028-3932(68)90035-3; STERN JA, 1976, MENTAL HLTH CHILDREN, V2, P113; TODOR JI, 1986, DEV MED CHILD NEUROL, V28, P205; TODOR JI, 1986, PSYCHOL MOTOR BEHAV, P239; WALTER CB, 1990, J MOTOR BEHAV, V22, P451; Winer BJ., 1971, STAT PRINCIPLES EXPT; YENSEN R, 1965, PERCEPT MOTOR SKILL, V20, P967, DOI 10.2466/pms.1965.20.3.967; Zulch K. J., 1969, HDB CLIN NEUROLOGY, P404; Zulch KJ, 1975, CEREBRAL LOCALIZATIO, P32	27	39	44	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1992	73	11					1044	1049					6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	JX141	WOS:A1992JX14100004	1444770				2022-02-06	
J	DURE, LS; YOUNG, AB; PENNEY, JB				DURE, LS; YOUNG, AB; PENNEY, JB			COMPARTMENTALIZATION OF EXCITATORY AMINO-ACID RECEPTORS IN HUMAN STRIATUM	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							GLUTAMATE-BINDING-SITES; TRAUMATIC BRAIN INJURY; CENTRAL NERVOUS-SYSTEM; DOPAMINE UPTAKE SITES; BASAL GANGLIA; HUNTINGTONS-DISEASE; SUBSTANCE-P; CAUDATE-NUCLEUS; PROJECTION NEURONS; NMDA RECEPTOR	Division of the mammalian neostriatum into two intermingled compartments called striosomes and matrix has been established by analysis of enzyme activity, neuropeptide distribution, nucleic acid hybridization, and neurotransmitter receptor binding. Striosomes and matrix are distinct with respect to afferent and efferent connections, and these regions provide the potential for modulation and integration of information flow within basal ganglia circuitry. The primary neurotransmitters of corticostriatal afferents are excitatory amino acids, but to date no correlation of excitatory amino acid receptors and striatal compartments has been described. We examined binding to the three pharmacologically distinct ion-otropic excitatory amino acid receptors, N-methyl-D-aspartate, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, and kainate, in human striatum using in vitro receptor autoradiography and compared the binding to striosomes and matrix histochemically defined by acetylcholinesterase activity. Our findings reveal increased binding to N-methyl-D-aspartate receptors and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in matrix relative to striosomes and increased kainate receptor binding in striosomes relative to matrix. These results suggest that afferent input to the two striatal compartments may be mediated by pharmacologically distinct excitatory amino acid receptor subtypes.			DURE, LS (corresponding author), UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109, USA.		Dure, Leon/B-3243-2008; Young, Anne/AAF-4283-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS019613, P01NS015655, P50NS015655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 08671] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19613, NS 15655] Funding Source: Medline		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; AUER R, 1985, ACTA NEUROPATHOL, V67, P279, DOI 10.1007/BF00687813; BESSON MJ, 1988, NEUROSCIENCE, V26, P101, DOI 10.1016/0306-4522(88)90130-3; BESSON MJ, 1990, NEUROSCIENCE, V39, P33, DOI 10.1016/0306-4522(90)90220-X; BOLAM JP, 1990, BRAIN RES, V529, P57, DOI 10.1016/0006-8993(90)90811-O; BOLAM JP, 1988, NEUROSCIENCE, V24, P853, DOI 10.1016/0306-4522(88)90073-5; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; CHAPMAN AG, 1989, NEUROSCI LETT, V107, P256, DOI 10.1016/0304-3940(89)90827-6; CHESSELET MF, 1986, NEUROSCIENCE, V17, P547, DOI 10.1016/0306-4522(86)90030-8; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; DONNAN GA, 1991, J COMP NEUROL, V304, P419, DOI 10.1002/cne.903040307; DURE LS, 1991, ANN NEUROL, V30, P785, DOI 10.1002/ana.410300607; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAULL RLM, 1986, BRAIN RES, V381, P153, DOI 10.1016/0006-8993(86)90704-3; FAULL RLM, 1989, BRAIN RES, V488, P381, DOI 10.1016/0006-8993(89)90735-X; FERRANTE RJ, 1987, BRAIN RES, V416, P141, DOI 10.1016/0006-8993(87)91506-X; GENESERJENSEN FA, 1971, Z ZELLFORSCH MIK ANA, V114, P460, DOI 10.1007/BF00325634; GERFEN CR, 1985, J COMP NEUROL, V236, P454, DOI 10.1002/cne.902360404; GERFEN CR, 1987, J NEUROSCI, V7, P3935; GERFEN CR, 1985, P NATL ACAD SCI USA, V82, P8780, DOI 10.1073/pnas.82.24.8780; GERFEN CR, 1984, NATURE, V311, P461, DOI 10.1038/311461a0; GERFEN CR, 1989, SCIENCE, V246, P385, DOI 10.1126/science.2799392; GERFEN CR, 1988, BRAIN RES, V460, P161, DOI 10.1016/0006-8993(88)91217-6; GIMENEZAMAYA JM, 1991, J NEUROSCI, V11, P779; GIMENEZAMAYA JM, 1990, NEUROSCIENCE, V34, P111, DOI 10.1016/0306-4522(90)90306-O; GOTO S, 1989, ANN NEUROL, V25, P298, DOI 10.1002/ana.410250315; GOTO S, 1990, ACTA NEUROPATHOL, V80, P88, DOI 10.1007/BF00294227; GRAYBIEL AM, 1978, P NATL ACAD SCI USA, V75, P5723, DOI 10.1073/pnas.75.11.5723; GRAYBIEL AM, 1984, NEUROSCIENCE, V13, P1157, DOI 10.1016/0306-4522(84)90293-8; GRAYBIEL AM, 1980, P NATL ACAD SCI-BIOL, V77, P1214, DOI 10.1073/pnas.77.2.1214; GRAYBIEL AM, 1981, NEUROSCIENCE, V6, P377, DOI 10.1016/0306-4522(81)90131-7; GRAYBIEL AM, 1981, P NATL ACAD SCI-BIOL, V78, P5871, DOI 10.1073/pnas.78.9.5871; GRAYBIEL AM, 1989, P NATL ACAD SCI USA, V86, P9020, DOI 10.1073/pnas.86.22.9020; GRAYBIEL AM, 1983, CHEM NEUROANATOMY, P427; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; GREENAMYRE JT, 1985, J PHARMACOL EXP THER, V233, P254; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GREENAMYRE JT, 1984, J NEUROSCI, V4, P2133; GROVES PM, 1988, J NEUROSCI, V8, P892; HABER SN, 1986, HUM NEUROBIOL, V5, P159; HEDREEN J C, 1990, Society for Neuroscience Abstracts, V16, P1119; HERKENHAM M, 1981, NATURE, V291, P415, DOI 10.1038/291415a0; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; JANSEN KLR, 1990, BRAIN RES, V532, P351, DOI 10.1016/0006-8993(90)91783-D; JIMENEZCASTELLANOS J, 1989, NEUROSCIENCE, V32, P297, DOI 10.1016/0306-4522(89)90080-8; JOHNSTON JG, 1990, DEV BRAIN RES, V57, P93, DOI 10.1016/0165-3806(90)90189-6; KAWAGUCHI Y, 1990, J NEUROSCI, V10, P3421; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; LANGER LF, 1989, BRAIN RES, V498, P344, DOI 10.1016/0006-8993(89)91114-1; LONDON ED, 1979, MOL PHARMACOL, V15, P492; LOOPUIJT LD, 1989, BRAIN RES BULL, V22, P805, DOI 10.1016/0361-9230(89)90023-3; LOWENSTEIN PR, 1989, J COMP NEUROL, V288, P428, DOI 10.1002/cne.902880306; LOWENSTEIN PR, 1990, BRAIN RES, V510, P122, DOI 10.1016/0006-8993(90)90736-U; MALACH R, 1986, J NEUROSCI, V6, P3436; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURRIN LC, 1989, BRAIN RES, V480, P170; NIELSEN EO, 1990, J NEUROCHEM, V54, P686, DOI 10.1111/j.1471-4159.1990.tb01925.x; PALACIOS JM, 1981, NEUROSCI LETT, V25, P101, DOI 10.1016/0304-3940(81)90315-3; PENNY GR, 1988, J COMP NEUROL, V269, P275, DOI 10.1002/cne.902690211; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PETIT F, 1986, NEUROPHARMACOLOGY, V25, P1015, DOI 10.1016/0028-3908(86)90196-6; PLAITAKIS A, 1990, ANN NEUROL, V28, P3, DOI 10.1002/ana.410280103; QUIRION R, 1985, BRAIN RES, V331, P358, DOI 10.1016/0006-8993(85)91563-X; RAGSDALE CW, 1990, P NATL ACAD SCI USA, V87, P6196, DOI 10.1073/pnas.87.16.6196; RAGSDALE CW, 1981, BRAIN RES, V208, P259, DOI 10.1016/0006-8993(81)90556-4; RAINBOW TC, 1984, BRAIN RES, V309, P173, DOI 10.1016/0006-8993(84)91025-4; REID M, 1988, EUR J PHARMACOL, V147, P411, DOI 10.1016/0014-2999(88)90176-8; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; REINER A, 1990, BRAIN RES REV, V15, P251, DOI 10.1016/0165-0173(90)90003-7; RICHFIELD EK, 1987, J COMP NEUROL, V262, P446, DOI 10.1002/cne.902620308; SAKURAI SY, 1991, NEUROSCIENCE, V40, P533, DOI 10.1016/0306-4522(91)90139-F; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIMASKO SM, 1984, EUR J PHARMACOL, V106, P653, DOI 10.1016/0014-2999(84)90074-8; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SUGIMOTO T, 1987, J COMP NEUROL, V263, P607, DOI 10.1002/cne.902630411; TURNER BH, 1988, BRAIN RES, V473, P60, DOI 10.1016/0006-8993(88)90315-0; TURSKI L, 1990, BRAIN RES, V512, P125, DOI 10.1016/0006-8993(90)91180-O; VANDERKOOY D, 1984, DEV BRAIN RES, V14, P300, DOI 10.1016/0165-3806(84)90318-3; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WIELOCH T, 1985, NEUROSCI LETT, V58, P25, DOI 10.1016/0304-3940(85)90323-4; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; Young AB, 1986, QUANTITATIVE RECEPTO, P79; ZAHM DS, 1990, J COMP NEUROL, V296, P403, DOI 10.1002/cne.902960306	91	39	39	0	0	NATL ACAD PRESS	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 15	1992	89	16					7688	7692		10.1073/pnas.89.16.7688			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ321	WOS:A1992JJ32100083	1380163	Green Published, Bronze			2022-02-06	
J	BUCKLEY, WE				BUCKLEY, WE			CONCUSSIONS IN COLLEGE FOOTBALL - A MULTIVARIATE-ANALYSIS	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article											BUCKLEY, WE (corresponding author), PENN STATE UNIV,HLTH ASPECTS SPORTS,DEPT HLTH EDUC,19D WHITE BLDG,UNIVERSITY PK,PA 16802, USA.							0	39	40	0	9	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1988	16	1					51	56		10.1177/036354658801600109			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	P9831	WOS:A1988P983100009	3344880				2022-02-06	
J	GOLDSTEIN, FC; LEVIN, HS				GOLDSTEIN, FC; LEVIN, HS			EPIDEMIOLOGY OF PEDIATRIC CLOSED HEAD-INJURY - INCIDENCE, CLINICAL CHARACTERISTICS, AND RISK-FACTORS	JOURNAL OF LEARNING DISABILITIES			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Choux M., 1986, HEAD INJURIES NEWBOR, P163; COOPER PR, 1982, HEAD INJURY, P1; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; CRAFT AW, 1972, HDB CLIN NEUROLOGY, V23, P445; DECKER MD, 1984, JAMA-J AM MED ASSOC, V252, P2571, DOI 10.1001/jama.252.18.2571; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FLETCHER JM, 1985, INJURED CHILD, P30; FRANKOWSKI RF, 1985, INJURED CHILD, P20; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOETHE KE, 1986, ADV CLIN NEUROPSYCHO, V3, P213; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; JAMISON DL, 1974, ARCH DIS CHILD, V49, P376, DOI 10.1136/adc.49.5.376; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1981, MANAGEMENT HEAD INJU; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KLAUBER MR, 1986, PREV MED, V15, P139, DOI 10.1016/0091-7435(86)90084-8; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1980, J NEUROSURG S, V53, P35; Kraus JF, 1987, HEAD INJURY, V2, P1; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H. S., 1984, AGING RECOVERY FUNCT, P169; Levin HS., 1982, NEUROBEHAVIORAL CONS; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MOYES CD, 1980, CHILD CARE HLTH DEV, V6, P1, DOI 10.1111/j.1365-2214.1980.tb00791.x; OKA H, 1977, BRAIN, V100, P287, DOI 10.1093/brain/100.2.287; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1981, AM J PSYCHIAT, V138, P1535; SCHERZ RG, 1981, PEDIATRICS, V68, P572; SMITH MD, 1975, J TRAUMA, V15, P987, DOI 10.1097/00005373-197511000-00008; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TAKAHASHI H, 1980, CHILD BRAIN, V7, P124; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Velardi F., 1986, HEAD INJURIES NEWBOR, P125; WILLIAMS AF, 1981, PEDIATRICS, V68, P576; [No title captured]	49	39	41	0	0	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1987	20	9					518	525		10.1177/002221948702000903			8	Education, Special; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Rehabilitation	K8155	WOS:A1987K815500006	3320241				2022-02-06	
J	KOBRINE, AI; TIMMINS, E; RAJJOUB, RK; RIZZOLI, HV; DAVIS, DO				KOBRINE, AI; TIMMINS, E; RAJJOUB, RK; RIZZOLI, HV; DAVIS, DO			DEMONSTRATION OF MASSIVE TRAUMATIC BRAIN-SWELLING WITHIN 20 MINUTES AFTER INJURY - CASE-REPORT	JOURNAL OF NEUROSURGERY			English	Article									GEORGE WASHINGTON UNIV,MED CTR,DEPT NEUROL SURG,WASHINGTON,DC 20006; GEORGE WASHINGTON UNIV,MED CTR,DEPT RADIOL,WASHINGTON,DC 20006								Kobrine A I, 1973, Surg Neurol, V1, P34	1	39	40	1	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1977	46	2					256	258		10.3171/jns.1977.46.2.0256			3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CT438	WOS:A1977CT43800017	833645				2022-02-06	
J	MARTIN, JP				MARTIN, JP			SIGNS OF OBSTRUCTION OF THE SUPERIOR LONGITUDINAL SINUS FOLLOWING CLOSED HEAD INJURIES (TRAUMATIC HYDROCEPHALUS)	BRITISH MEDICAL JOURNAL			English	Article																	COLLIER W, 1891, BRIT MED J, V1, P521; GARCIN R, 1949, THROMBO PHLEBITES CE; Holmes G, 1915, Br Med J, V2, P493; MARTIN IP, 1941, BRIT MEDICAL J, V2, P537; MARTIN IP, 1941, BRIT MEDICAL J, V1, P349; McAlpine D, 1937, BRAIN, V60, P180, DOI 10.1093/brain/60.2.180; Symonds C P, 1940, Br Med J, V2, P348; SYMONDS CP, 1944, P ROY SOC MED, V37, P386; TURNER AL, 1931, INTRACRANIAL PYOGENI	9	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.		1955	2	AUG20					467	470		10.1136/bmj.2.4937.467			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB459	WOS:A1955WB45900007	13240151	Green Published			2022-02-06	
J	Turner, JWA				Turner, JWA			Facial palsy in closed head injuries - The prognosis	LANCET			English	Article																	Davies DO, 1943, BRIT J SURG, V30, P237, DOI 10.1002/bjs.18003011909; Howe HA, 1937, ARCH NEURO PSYCHIATR, V38, P1190, DOI 10.1001/archneurpsyc.1937.02260240070005; KEIPER GF, 1923, ANN OTOL ST LOUIS, V32, P236; Leigh AD, 1943, LANCET, V1, P38; Symonds CP, 1943, LANCET, V1, P7; Turner JWA, 1943, BRAIN, V66, P140; Weddell G, 1943, LANCET, V1, P236	7	39	39	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1944	1						756	757					2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V9626	WOS:000188752300495					2022-02-06	
J	Bhaskar, S; Bradley, S; Chattu, VK; Adisesh, A; Nurtazina, A; Kyrykbayeva, S; Sakhamuri, S; Moguilner, S; Pandya, S; Schroeder, S; Banach, M; Ray, D				Bhaskar, Sonu; Bradley, Sian; Chattu, Vijay Kumar; Adisesh, Anil; Nurtazina, Alma; Kyrykbayeva, Saltanat; Sakhamuri, Sateesh; Moguilner, Sebastian; Pandya, Shawna; Schroeder, Starr; Banach, Maciej; Ray, Daniel			Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2)	FRONTIERS IN PUBLIC HEALTH			English	Article						coronavirus disease 2019; COVID-19; telemedicine; telerehabilitation; telepsychiatry; teleneurology	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; PATIENT SATISFACTION; CHRONIC DISEASES; TELE-MEDICINE; TELEHEALTH; CARE; TELEPSYCHIATRY; IMPROVE; INTERVENTIONS	Technology has acted as a great enabler of patient continuity through remote consultation, ongoing monitoring, and patient education using telephone and videoconferencing in the coronavirus disease 2019 (COVID-19) era. The devastating impact of COVID-19 is bound to prevail beyond its current reign. The vulnerable sections of our community, including the elderly, those from lower socioeconomic backgrounds, those with multiple comorbidities, and immunocompromised patients, endure a relatively higher burden of a pandemic such as COVID-19. The rapid adoption of different technologies across countries, driven by the need to provide continued medical care in the era of social distancing, has catalyzed the penetration of telemedicine. Limiting the exposure of patients, healthcare workers, and systems is critical in controlling the viral spread. Telemedicine offers an opportunity to improve health systems delivery, access, and efficiency. This article critically examines the current telemedicine landscape and challenges in its adoption, toward remote/tele-delivery of care, across various medical specialties. The current consortium provides a roadmap and/or framework, along with recommendations, for telemedicine uptake and implementation in clinical practice during and beyond COVID-19.	[Bhaskar, Sonu; Bradley, Sian; Chattu, Vijay Kumar; Adisesh, Anil; Nurtazina, Alma; Kyrykbayeva, Saltanat; Sakhamuri, Sateesh; Moguilner, Sebastian; Pandya, Shawna; Schroeder, Starr; Banach, Maciej; Ray, Daniel] REPROGRAM Telemed Subcommittee, Pandem Hlth Syst REsilience PROGRAM REPROGRAM Con, Sydney, NSW, Australia; [Bhaskar, Sonu] Liverpool Hosp, Dept Neurol, Sydney, NSW, Australia; [Bhaskar, Sonu] South Western Sydney Local Hlth Dist, Sydney, NSW, Australia; [Bhaskar, Sonu] Ingham Inst Appl Med Res, Neurovasc Imaging Lab, Sydney, NSW, Australia; [Bhaskar, Sonu] Ingham Inst Appl Med Res, NSW Brain Clot Bank, Sydney, NSW, Australia; [Bhaskar, Sonu] Univ New South Wales, South Western Sydney Clin Sch, UNSW Med, Sydney, NSW, Australia; [Bradley, Sian] Univ New South Wales UNSW Med Sydney, South West Sydney Clin Sch, Sydney, NSW, Australia; [Chattu, Vijay Kumar; Adisesh, Anil] Univ Toronto, Dept Med, Toronto, ON, Canada; [Chattu, Vijay Kumar; Adisesh, Anil] St Michaels Hosp, Toronto, ON, Canada; [Nurtazina, Alma; Kyrykbayeva, Saltanat] Semey Med Univ, Dept Epidemiol & Biostat, Semey, Kazakhstan; [Sakhamuri, Sateesh] Univ West Indies, Dept Clin Med Sci, St Augustine, Trinidad Tobago; [Moguilner, Sebastian] Trinity Coll Dublin, Global Brain Hlth Inst, Dublin, Ireland; [Pandya, Shawna] Univ Alberta, Alberta Hlth Serv, Edmonton, AB, Canada; [Pandya, Shawna] Univ Alberta, Project PoSSUM, Edmonton, AB, Canada; [Schroeder, Starr] Penn Med Lancaster Gen Hosp, Lancaster, PA USA; [Schroeder, Starr] Project PoSSUM, Lancaster, PA USA; [Banach, Maciej] Polish Mothers Mem Hosp Res Inst PMMHRI, Lodz, Poland; [Banach, Maciej] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland; [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland; [Ray, Daniel] Univ Coll London UCL, Farr Inst Hlth Informat, Birmingham, W Midlands, England; [Ray, Daniel] NHS Fdn Trust, Birmingham, W Midlands, England		Bhaskar, S (corresponding author), REPROGRAM Telemed Subcommittee, Pandem Hlth Syst REsilience PROGRAM REPROGRAM Con, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Liverpool Hosp, Dept Neurol, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), South Western Sydney Local Hlth Dist, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Ingham Inst Appl Med Res, Neurovasc Imaging Lab, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Ingham Inst Appl Med Res, NSW Brain Clot Bank, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Univ New South Wales, South Western Sydney Clin Sch, UNSW Med, Sydney, NSW, Australia.	sonu.bhaskar@health.nsw.gov.au	Chattu, Vijay Kumar/C-2778-2014; sakhamuri, sateesh/AAV-4834-2021; Nurtazina, Alma/AAZ-1614-2020; Banach, Maciej/A-1271-2009; Kyrykbayeva, Saltanat/AAP-2979-2021; Bhaskar, Sonu M. M./AAU-1402-2020	Chattu, Vijay Kumar/0000-0001-9840-8335; sakhamuri, sateesh/0000-0002-6383-4999; Banach, Maciej/0000-0001-6690-6874; Kyrykbayeva, Saltanat/0000-0001-6151-6025; Bhaskar, Sonu M. M./0000-0002-9783-3628; Adisesh, Anil/0000-0002-4973-8474			Achey M, 2014, MOVEMENT DISORD, V29, P871, DOI 10.1002/mds.25903; Ambrosino N, 2017, EXPERT REV RESP MED, V11, P893, DOI 10.1080/17476348.2017.1383898; Ambrosino N, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0090-7; Ambrosino N, 2016, BREATHE, V12, P351, DOI 10.1183/20734735.014616; Ambrosino N, 2016, EUR RESPIR J, V48, P648, DOI 10.1183/13993003.01721-2015; American Academy of Neurology (AAn), NTR; [Anonymous], **NON-TRADITIONAL**; Ateriya N, 2018, NATL MED J INDIA, V31, P215, DOI 10.4103/0970-258X.258220; Banach M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104891; Barker-Davies RM, 2020, BRIT J SPORT MED, V54, P949, DOI 10.1136/bjsports-2020-102596; Basiri Keivan, 2015, Adv Biomed Res, V4, P58, DOI 10.4103/2277-9175.151874; Bhaskar S, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00664; Bhaskar S, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00112; Bhatt A, NTR; Blakey JD, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01147-2018; Blanco C, 2020, J GEN INTERN MED, V35, P2757, DOI 10.1007/s11606-020-05955-3; Block VAJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154335; Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105; Booth R, NTR; Brennan JA, 1999, J TELEMED TELECARE, V5, P18, DOI 10.1258/1357633991932342; Brunetti ND, 2020, OPEN HEART, V7, DOI 10.1136/openhrt-2019-001157; Bruyneel M, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0093-2018; Calderon VJ, 2018, INTERV NEUROL, V7, P347, DOI 10.1159/000487334; Capozzo R, 2020, AMYOTROPH LAT SCL FR, V21, P542, DOI 10.1080/21678421.2020.1773502; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Chaffin Hally M, 2019, Hawaii J Health Soc Welf, V78, P280; Chahin N, 2008, NEUROLOGY, V70, P1967, DOI 10.1212/01.wnl.0000312510.49768.eb; CHAN S, 2017, CURR PSYCHIAT REP, V0019; Chan S, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0630-9; Chee Ru-Ik, 2018, Curr Ophthalmol Rep, V6, P36, DOI 10.1007/s40135-018-0161-8; Chen Y, 2020, TOP STROKE REHABIL, V27, P81, DOI 10.1080/10749357.2019.1683792; Cheshire WP, 2021, J TELEMED TELECARE, V27, P572, DOI 10.1177/1357633X19899237; Chipps J, 2012, AFR J PSYCHIATRY, V15, P235, DOI [http://dx.doi.org/10.4314/ajpsy.v15i4.30, 10.4314/ajpsy.v15i4.30]; Chuchu N, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013193; Dams-O'Connor K, 2018, J NEUROTRAUM, V35, P1138, DOI 10.1089/neu.2017.5347; de Bustos EM, 2018, TELEMED E-HEALTH, V24, P155, DOI 10.1089/tmj.2017.0035; DeJong SM, 2018, ACAD PSYCHIATR, V42, P800, DOI 10.1007/s40596-018-0947-x; Dharmar M, 2013, CRIT CARE MED, V41, P2388, DOI 10.1097/CCM.0b013e31828e9824; Dharmasaroja PA, 2010, NEUROCRIT CARE, V13, P62, DOI 10.1007/s12028-010-9360-3; Donate-Martinez A, 2016, ARCH GERONTOL GERIAT, V62, P169, DOI 10.1016/j.archger.2015.09.008; Donelan K, 2019, AM J MANAG CARE, V25, P40; Ertelt TW, 2011, INT J EAT DISORDER, V44, P687, DOI 10.1002/eat.20874; European Commission. Joint Research Centre Data Catalogue, NTR; Fisher E, 2017, POPUL HEALTH MANAG, V20, P342, DOI 10.1089/pop.2016.0087; Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2; Freir V, 1999, J TELEMED TELECARE, V5, P157, DOI 10.1258/1357633991933567; Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164; Gabriel KMA, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01676-6; Gandapur Y, 2016, EUR HEART J-QUAL CAR, V2, P237, DOI 10.1093/ehjqcco/qcw018; Gordon HS, 2020, J GEN INTERN MED, V35, P1751, DOI 10.1007/s11606-020-05673-w; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Gurbeta L, 2018, J AM MED INFORM ASSN, V25, P1213, DOI 10.1093/jamia/ocy055; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Harerimana B, 2019, INT J MENT HEALTH NU, V28, P657, DOI 10.1111/inm.12571; HASSAN A, 2019, CUREUS, V0011; Helleman J, 2020, AMYOTROPH LAT SCL FR, V21, P183, DOI 10.1080/21678421.2020.1718712; Helleman J, 2020, AMYOTROPH LAT SCL FR, V21, P167, DOI 10.1080/21678421.2019.1706581; Hernandez C, 2014, BREATHE, V10, P198, DOI 10.1183/20734735.008314; Hobson E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028526; Huo XQ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018302; Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096; Inglis SC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub3; Jaeger B, 2016, J INHERIT METAB DIS, V39, P559, DOI 10.1007/s10545-016-9924-2; Karunanithi M., 2014, INTERV CARDIOL, V6, P227, DOI [DOI 10.2217/ica.14.4, 10.2217/ica.14.4]; Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503; Katz M, 2020, ANN PALLIAT MED, V9, pS75, DOI 10.21037/apm.2019.11.12; Khader YS, 2014, INT J TELEMED APPL, V2014, DOI 10.1155/2014/819837; Klein BC, 2020, NEUROLOGY, V94, P903, DOI 10.1212/WNL.0000000000009494; Klompas M, 2020, ANN INTERN MED, V172, P619, DOI 10.7326/M20-0751; Kovacevic P, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2494-6; Kuehn BM, 2016, CIRCULATION, V134, P1189, DOI 10.1161/CIRCULATIONAHA.116.025282; Kuipers E, 2019, J MED INTERNET RES, V21, DOI 10.2196/13551; Kuntz JG, 2020, J PAIN SYMPTOM MANAG, V60, pE28, DOI 10.1016/j.jpainsymman.2020.06.001; Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Linschoten M, 2020, EUR HEART J, V41, P1795, DOI 10.1093/eurheartj/ehaa280; Lyerly MJ, 2016, J TELEMED TELECARE, V22, P114, DOI 10.1177/1357633X15589534; Macaraig M, 2018, J PUBLIC HEALTH MAN, V24, P567, DOI 10.1097/PHH.0000000000000627; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; MAJUMDER S, 2019, SENSORS BASEL, V0019; Martin-Lesende I, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-118; Martinez RN, 2017, PM&R, V9, P231, DOI 10.1016/j.pmrj.2016.07.002; Mbuagbaw L, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0654-6; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; Mehraeen E, 2018, STUD HEALTH TECHNOL, V248, P172, DOI 10.3233/978-1-61499-858-7-172; Michaud TL, 2018, INT J TECHNOL ASSESS, V34, P410, DOI 10.1017/S0266462318000454; Molinari G, 2002, J TELEMED TELECARE, V8, P97, DOI 10.1258/1357633021937541; MOUSTAFA H, 2019, J TELEMED TELEC 0807; Munafo D, 2016, SLEEP BREATH, V20, P777, DOI 10.1007/s11325-015-1298-4; Napi NM, 2019, HEALTH TECHNOL-GER, V9, P679, DOI 10.1007/s12553-019-00357-w; Nemecek R, 2019, WIEN KLIN WOCHENSCHR, V131, P620, DOI 10.1007/s00508-019-01562-3; Ohta Y, 2018, J CLIN NEUROSCI, V56, P74, DOI 10.1016/j.jocn.2018.07.006; Orozco-Beltran D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7677; Paganoni S, 2019, MUSCLE NERVE, V60, P147, DOI 10.1002/mus.26606; Palmieri V, 2011, G ITAL CARDIOL, V12, P829, DOI 10.1714/996.10828; Park LG, 2014, J ADV NURS, V70, P1932, DOI 10.1111/jan.12400; Pepin JL, 2017, RESPIROLOGY, V22, P1508, DOI 10.1111/resp.13183; Pinto A, 2010, J NEUROL NEUROSUR PS, V81, P1238, DOI 10.1136/jnnp.2010.206680; Piotrowicz E, 2020, JAMA CARDIOL, V5, P300, DOI 10.1001/jamacardio.2019.5006; Piotrowicz E, 2019, AM HEART J, V217, P148, DOI 10.1016/j.ahj.2019.08.015; Porritt A, NTR; Rawstorn JC, 2016, HEART, V102, P1183, DOI 10.1136/heartjnl-2015-308966; Reilly RO, 2007, PSYCHIAT SERV, V58, P836; Ruskin PE, 2004, AM J PSYCHIAT, V161, P1471, DOI 10.1176/appi.ajp.161.8.1471; Sable CA, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e3; Salisbury C, 2016, LANCET PSYCHIAT, V3, P515, DOI 10.1016/S2215-0366(16)00083-3; Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013; Satou GM, 2017, CIRCULATION, V135, pE648, DOI 10.1161/CIR.0000000000000478; Sayani S, 2019, THER ADV CHRONIC DIS, V10, DOI 10.1177/2040622319891587; Scalvini S, 2001, Ital Heart J Suppl, V2, P1091; Schwab S, 2007, NEUROLOGY, V69, P898, DOI 10.1212/01.wnl.0000269671.08423.14; Selzler AM, 2018, CHRON RESP DIS, V15, P41, DOI 10.1177/1479972317724570; Serpen G, 2018, PROCEDIA COMPUT SCI, V140, P238, DOI 10.1016/j.procs.2018.10.324; Sharma R, 2017, INT J EMERG MED, V10, DOI 10.1186/s12245-017-0146-7; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141; Siwicki B., HLTHCARE IT NEWS; Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567; Subbaraman R, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-001018; Subramanian S, 2020, CRIT CARE MED, V48, P553, DOI 10.1097/CCM.0000000000004190; Swanson MB, 2021, J TELEMED TELECARE, V27, P343, DOI 10.1177/1357633X19877746; Szperka CL, 2020, HEADACHE, V60, P833, DOI 10.1111/head.13810; Tande AJ, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa003; Truelove S, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003144; Turino C, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01128-2016; van Houwelingen CTM, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8407; Vatankhah B, 2008, CEREBROVASC DIS, V25, P332, DOI 10.1159/000118378; Vitacca M, 2018, THER ADV RESPIR DIS, V12, DOI 10.1177/1753465818754778; Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607; White C, 2019, BMJ SUPPORT PALLIAT, V9, P202, DOI 10.1136/bmjspcare-2015-000935; Wilcox ME, 2012, CRIT CARE, V16, DOI 10.1186/cc11429; Williams TL, 2001, TELEMED J E-HEALTH, V7, P293, DOI 10.1089/15305620152814700; World Health Organization (WHO), 2018, ART INT GOOD GLOB SU; World Health Organization (WHO) WHO, NTR; Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9; Yang CP, 2017, PEDIATR EMERG CARE, V33, P474, DOI 10.1097/PEC.0000000000000653; Yeoh CB, 2020, ANESTH ANALG, V131, P16, DOI 10.1213/ANE.0000000000004884; Yue JK, 2020, J NEUROSCI RURAL PRA, V11, P23, DOI 10.1055/s-0039-3402581; Zheng X, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.005616; Zimetbaum P, 2010, CIRCULATION, V122, P1629, DOI 10.1161/CIRCULATIONAHA.109.925610	140	38	38	17	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		2296-2565		FRONT PUBLIC HEALTH	Front. Public Health	SEP 7	2020	8								410	10.3389/fpubh.2020.00410			16	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	NW5MT	WOS:000575056700001	33014958	gold, Green Published	Y	N	2022-02-06	
J	Hornby, TG; Reisman, DS; Ward, IG; Scheets, PL; Miller, A; Haddad, D; Fox, EJ; Fritz, NE; Hawkins, K; Henderson, CE; Hendron, KL; Holleran, CL; Lynskey, JE; Walter, A				Hornby, T. George; Reisman, Darcy S.; Ward, Irene G.; Scheets, Patricia L.; Miller, Allison; Haddad, David; Fox, Emily J.; Fritz, Nora E.; Hawkins, Kelly; Henderson, Christopher E.; Hendron, Kathryn L.; Holleran, Carey L.; Lynskey, James E.; Walter, Amber		Locomotor CPG Appraisal Team	Clinical Practice Guideline to Improve Locomotor Function Following Chronic Stroke, Incomplete Spinal Cord Injury, and Brain Injury	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						clinical practice guidelines; locomotor function; rehabilitation	BODY-WEIGHT SUPPORT; ANKLE-FOOT ORTHOSIS; QUALITY-OF-LIFE; RHYTHMIC AUDITORY-STIMULATION; PRESERVED EJECTION FRACTION; RANDOMIZED CONTROLLED-TRIAL; CHRONIC HEMIPARETIC STROKE; WALKING TRAINING-PROGRAM; VIRTUAL-REALITY GAMES; TRAUMATIC BRAIN	Background: Individuals with acute-onset central nervous system (CNS) injury, including stroke, motor incomplete spinal cord injury, or traumatic brain injury, often experience lasting locomotor deficits, as quantified by decreases in gait speed and distance walked over a specific duration (timed distance). The goal of the present clinical practice guideline was to delineate the relative efficacy of various interventions to improve walking speed and timed distance in ambulatory individuals greater than 6 months following these specific diagnoses. Methods: A systematic review of the literature published between 1995 and 2016 was performed in 4 databases for randomized controlled clinical trials focused on these specific patient populations, at least 6 months postinjury and with specific outcomes of walking speed and timed distance. For all studies, specific parameters of training interventions including frequency, intensity, time, and type were detailed as possible. Recommendations were determined on the basis of the strength of the evidence and the potential harm, risks, or costs of providing a specific training paradigm, particularly when another intervention may be available and can provide greater benefit. Results: Strong evidence indicates that clinicians should offer walking training at moderate to high intensities or virtual reality-based training to ambulatory individuals greater than 6 months following acute-onset CNS injury to improve walking speed or distance. In contrast, weak evidence suggests that strength training, circuit (ie, combined) training or cycling training at moderate to high intensities, and virtual reality-based balance training may improve walking speed and distance in these patient groups. Finally, strong evidence suggests that body weight-supported treadmill training, robotic-assisted training, or sitting/standing balance training without virtual reality should not be performed to improve walking speed or distance in ambulatory individuals greater than 6 months following acute-onset CNS injury to improve walking speed or distance. Discussion: The collective findings suggest that large amounts of task-specific (ie, locomotor) practice may be critical for improvements in walking function, although only at higher cardiovascular intensities or with augmented feedback to increase patient's engagement. Lower-intensity walking interventions or impairment-based training strategies demonstrated equivocal or limited efficacy. Limitations: As walking speed and distance were primary outcomes, the research participants included in the studies walked without substantial physical assistance. This guideline may not apply to patients with limited ambulatory function, where provision of walking training may require substantial physical assistance. The guideline suggests that task-specific walking training should be performed to improve walking speed and distance in those with acute-onset CNS injury although only at higher intensities or with augmented feedback. Future studies should clarify the potential utility of specific training parameters that lead to improved walking speed and distance in these populations in both chronic and subacute stages following injury. Disclaimer: These recommendations are intended as a guide for clinicians to optimize rehabilitation outcomes for persons with chronic stroke, incomplete spinal cord injury, and traumatic brain injury to improve walking speed and distance.	[Hornby, T. George; Henderson, Christopher E.] Indiana Univ, Dept Phys Med & Rehabil, Indianapolis, IN 46204 USA; [Hornby, T. George] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Reisman, Darcy S.; Miller, Allison] Univ Delaware, Dept Phys Therapy, Newark, DE USA; [Ward, Irene G.; Miller, Allison; Haddad, David] Kessler Inst Rehabil, W Orange, NJ USA; [Ward, Irene G.] Univ Med & Dent New Jersey, Newark, NJ USA; [Scheets, Patricia L.] Infin Rehab, Wilsonville, OR USA; [Fox, Emily J.; Hendron, Kathryn L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA; [Fox, Emily J.; Hawkins, Kelly] Brooks Rehabil Ctr, Jacksonville, FL USA; [Fritz, Nora E.] Wayne State Univ, Dept Phys Therapy, Detroit, MI USA; [Hendron, Kathryn L.] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; [Holleran, Carey L.] Washington Univ, Program Phys Therapy, St Louis, MO 63110 USA; [Lynskey, James E.] AT Still Univ, Dept Phys Therapy, Mesa, AZ 85206 USA; [Walter, Amber] Sheltering Arms Hosp, Mechanicsville, VA USA		Hornby, TG (corresponding author), Rehabil Hosp Indiana, Locomotor Recovery Lab, 4141 Shore Dr, Indianapolis, IN 46254 USA.	tghornby@iu.edu	Hornby, Thomas/AAS-1131-2020; Fritz, Nora/ABG-6696-2020		American Physical Therapy Association (APTA) Practice Division; Academy of Neurologic Physical Therapy (ANPT)	The American Physical Therapy Association (APTA) Practice Division and the Academy of Neurologic Physical Therapy (ANPT) provided funding to support the development and preparation of this document. Neither association influenced the recommendations put forth by this guideline.	About the CMS Innovation Center, CMS INN CTR CTR MED; Ada L, 2003, ARCH PHYS MED REHAB, V84, P1486, DOI 10.1016/S0003-9993(03)00349-6; Ada L, 2010, STROKE, V41, P1237, DOI 10.1161/STROKEAHA.109.569483; Alexeeva N, 2011, J SPINAL CORD MED, V34, P362, DOI 10.1179/2045772311Y.0000000018; [Anonymous], 2018, SPINAL CORD INJURY S; Aruin AS, 2012, TOP STROKE REHABIL, V19, P556, DOI 10.1310/tsr1906-556; Awad LN, 2016, NEUROREHAB NEURAL RE, V30, P661, DOI 10.1177/1545968315619696; Awad LN, 2015, NEUROREHAB NEURAL RE, V29, P499, DOI 10.1177/1545968314554625; Balasubramanian CK, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/591013; Bang Dae-Hyouk, 2016, J Phys Ther Sci, V28, P2381, DOI 10.1589/jpts.28.2381; Bang DH, 2016, NEUROREHABILITATION, V38, P343, DOI 10.3233/NRE-161325; Bang DH, 2014, J PHYS THER SCI, V26, P1689, DOI 10.1589/jpts.26.1689; Bang DH, 2013, CLIN REHABIL, V27, P1118, DOI 10.1177/0269215513501528; BARBEAU H, 1987, MED BIOL ENG COMPUT, V25, P341, DOI 10.1007/BF02447435; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Bayouk JF, 2006, INT J REHABIL RES, V29, P51, DOI 10.1097/01.mrr.0000192100.67425.84; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Bethoux F, 2014, NEUROREHAB NEURAL RE, V28, P688, DOI 10.1177/1545968314521007; Biering-Sorensen B, 2009, MUSCLE NERVE, V40, P499, DOI 10.1002/mus.21391; Billinger SA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0519-8; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Bobath B., 1990, ADULT HEMIPLEGIA EVA; Bochkezanian V, 2015, SPINAL CORD, V53, P418, DOI 10.1038/sc.2015.48; Bonan IV, 2004, ARCH PHYS MED REHAB, V85, P274, DOI 10.1016/j.apmr.2003.06.016; Bourbonnais D, 2002, AM J PHYS MED REHAB, V81, P890, DOI 10.1097/00002060-200212000-00002; Bowden MG, 2006, STROKE, V37, P872, DOI 10.1161/01.STR.0000204063.75779.8d; Boyne P, 2016, PHYS THER, V96, P1533, DOI 10.2522/ptj.20150277; Brogardh C, 2012, ARCH PHYS MED REHAB, V93, P253, DOI 10.1016/j.apmr.2011.09.005; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Buesing C, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0062-0; Center for Medicare and Medicaid Innovation, BUNDL PAYM CAR IMPR; Cha J, 2007, J NEUROTRAUM, V24, P1000, DOI 10.1089/neu.2006.0233; Cha Y, 2014, NEUROREHABILITATION, V35, P681, DOI 10.3233/NRE-141182; Chen IH, 2014, NEUROREHAB NEURAL RE, V28, P45, DOI 10.1177/1545968313497102; Cho KH, 2015, TOHOKU J EXP MED, V236, P273, DOI 10.1620/tjem.236.273; Cho KH, 2014, GAIT POSTURE, V39, P523, DOI 10.1016/j.gaitpost.2013.09.003; Cho KH, 2013, AM J PHYS MED REHAB, V92, P371, DOI 10.1097/PHM.0b013e31828cd5d3; Chun JY, 2016, ANN REHABIL MED-ARM, V40, P972, DOI 10.5535/arm.2016.40.6.972; Chung E, 2014, RESTOR NEUROL NEUROS, V32, P313, DOI 10.3233/RNN-130353; Clark DJ, 2013, NEUROREHAB NEURAL RE, V27, P335, DOI 10.1177/1545968312469833; CMS Takes Action to Modernize Medicare Home Health, 2019, CMS TAK ACT MOD MED; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Combs SA, 2013, DISABIL REHABIL, V35, P860, DOI 10.3109/09638288.2012.717575; Combs-Miller SA, 2014, CLIN REHABIL, V28, P873, DOI 10.1177/0269215514520773; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Cramer SC, 2011, BRAIN, V134, P1591, DOI 10.1093/brain/awr039; CROZIER KS, 1992, PARAPLEGIA, V30, P762, DOI 10.1038/sc.1992.147; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Danks KA, 2016, J NEUROL PHYS THER, V40, P232, DOI 10.1097/NPT.0000000000000143; Danks KA, 2016, ARCH PHYS MED REHAB, V97, pS185, DOI 10.1016/j.apmr.2016.01.039; Darekar A, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0035-3; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; Dean CM, 2010, J PHYSIOTHER, V56, P97, DOI 10.1016/S1836-9553(10)70039-4; Dean CM, 2000, ARCH PHYS MED REHAB, V81, P409, DOI 10.1053/mr.2000.3839; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Dhamoon MS, 2007, STROKE, V38, P1752, DOI 10.1161/STROKEAHA.106.480988; Dietz V, 2014, BRAIN, V137, P654, DOI 10.1093/brain/awt262; Diong J, 2013, AM J PHYS MED REHAB, V92, P565, DOI 10.1097/PHM.0b013e318274605a; Diong JHL, 2012, MUSCLE NERVE, V46, P237, DOI 10.1002/mus.23356; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Druzbicki M, 2015, J REHABIL MED, V47, P419, DOI 10.2340/16501977-1949; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-39; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Duncan PW, 2000, NEUROPHARMACOLOGY, V39, P835, DOI 10.1016/S0028-3908(00)00003-4; Duncan PW, 2011, AM PHYS THER ASS COM; Esquenazi A, 2013, PM&R, V5, P280, DOI 10.1016/j.pmrj.2012.10.009; Everaert DG, 2013, NEUROREHAB NEURAL RE, V27, P579, DOI 10.1177/1545968313481278; Field-Fote EC, 2011, PHYS THER, V91, P48, DOI 10.2522/ptj.20090359; FINCH L, 1991, PHYS THER, V71, P842, DOI 10.1093/ptj/71.11.842; Flansbjer UB, 2008, J REHABIL MED, V40, P42, DOI 10.2340/16501977-0129; Forrester LW, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0158-1; Freivogel S, 2008, BRAIN INJURY, V22, P625, DOI 10.1080/02699050801941771; Fritz SL, 2013, TOP STROKE REHABIL, V20, P218, DOI 10.1310/tsr2003-218; Gama GL, 2015, AM J PHYS MED REHAB, V94, P718, DOI 10.1097/PHM.0000000000000240; Geidl W, 2018, NEUROL INT, V10, P13, DOI 10.4081/ni.2018.6993; Gil-Gomez JA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-30; Globas C, 2012, NEUROREHAB NEURAL RE, V26, P85, DOI 10.1177/1545968311418675; Goodman RN, 2014, J REHABIL RES DEV, V51, P213, DOI 10.1682/JRRD.2013.02.0050; Gordon CD, 2013, STROKE, V44, P1179, DOI 10.1161/STROKEAHA.111.000642; Gottschall JS, 2005, J APPL PHYSIOL, V99, P23, DOI 10.1152/japplphysiol.01190.2004; Gottschall JS, 2003, J APPL PHYSIOL, V94, P1766, DOI 10.1152/japplphysiol.00670.2002; Gracies JM, 2017, NEUROLOGY, V89, P2245, DOI 10.1212/WNL.0000000000004687; Gracies JM, 2015, LANCET NEUROL, V14, P992, DOI 10.1016/S1474-4422(15)00216-1; Hafer-Macko CE, 2008, J REHABIL RES DEV, V45, P261, DOI 10.1682/JRRD.2007.02.0040; Hesse S, 2013, NEUROREHABILITATION, V33, P77, DOI 10.3233/NRE-130930; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Hesse S, 1999, BIOMED TECH, V44, P194, DOI 10.1515/bmte.1999.44.7-8.194; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Holleran CL, 2018, J NEUROL PHYS THER, V42, P94, DOI 10.1097/NPT.0000000000000217; Holleran CL, 2015, J NEUROL PHYS THER, V39, P95, DOI 10.1097/NPT.0000000000000077; Holleran CL, 2014, NEUROREHAB NEURAL RE, V28, P643, DOI 10.1177/1545968314521001; Holleran CL, 2016, COMMUNITY MOBILITY M; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Hornby TG, 2016, NEUROREHAB NEURAL RE, V30, P440, DOI 10.1177/1545968315604396; Hornby TG, 2012, PHYS THER, V92, P1278, DOI 10.2522/ptj.20110310; Hornby TG, 2011, TOP STROKE REHABIL, V18, P293, DOI 10.1310/tsr1804-293; Howlett OA, 2015, ARCH PHYS MED REHAB, V96, P934, DOI 10.1016/j.apmr.2015.01.013; Hui-Chan Christina W Y, 2009, Hong Kong Med J, V15, P42; In T, 2016, MED SCI MONITOR, V22, P4046, DOI 10.12659/MSM.898157; Israel JF, 2006, PHYS THER, V86, P1466, DOI 10.2522/ptj.20050266; Ivey FM, 2015, J STROKE CEREBROVASC, V24, P2539, DOI 10.1016/j.jstrokecerebrovasdis.2015.07.002; Jacobs PL, 2004, SPORTS MED, V34, P727, DOI 10.2165/00007256-200434110-00003; Jaffe DL, 2004, J REHABIL RES DEV, V41, P283, DOI 10.1682/JRRD.2004.03.0283; Jayaraman A, 2013, J NEUROL PHYS THER, V37, P112, DOI 10.1097/NPT.0b013e31828390a1; Jeong YG, 2016, TOP STROKE REHABIL, V23, P406, DOI 10.1080/10749357.2016.1168592; Jin H, 2013, NEUROREHABILITATION, V32, P327, DOI 10.3233/NRE-130852; Jin H, 2012, DISABIL REHABIL, V34, P1665, DOI 10.3109/09638288.2012.658952; Johannsen L, 2010, NEUROREHAB NEURAL RE, V24, P243, DOI 10.1177/1545968309347679; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kang HK, 2012, CLIN REHABIL, V26, P246, DOI 10.1177/0269215511419383; Kang TW, 2016, J STROKE CEREBROVASC, V25, P848, DOI 10.1016/j.jstrokecerebrovasdis.2015.11.037; Katch VL, 2011, ESSENTIALS EXERCISE; Kendrick D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009848.pub2; Kilinc M, 2016, TOP STROKE REHABIL, V23, P17, DOI 10.1179/1945511915Y.0000000011; Kim C M, 2001, J Stroke Cerebrovasc Dis, V10, P265, DOI 10.1053/jscd.2001.123775; Kim H, 2015, INT J REHABIL RES, V38, P156, DOI 10.1097/MRR.0000000000000103; Kim JH, 2009, AM J PHYS MED REHAB, V88, P693, DOI 10.1097/PHM.0b013e3181b33350; Kim JH, 2013, NEUROREHABILITATION, V33, P565, DOI 10.3233/NRE-130991; Kim N., 2016, J EXP STROKE TRANSL, V9, P1, DOI [DOI 10.3343/ALM.2016.36.1.67, DOI 10.4172/1939-067X.1000145]; Kim N, 2015, J PHYS THER SCI, V27, P655, DOI 10.1589/jpts.27.655; Kim Sung-Jin, 2016, J Phys Ther Sci, V28, P2596; Kimberley TJ, 2010, J REHABIL RES DEV, V47, P851, DOI 10.1682/JRRD.2010.02.0019; Kitzman DW, 2010, CIRC-HEART FAIL, V3, P659, DOI 10.1161/CIRCHEARTFAILURE.110.958785; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kluding PM, 2013, STROKE, V44, P1660, DOI 10.1161/STROKEAHA.111.000334; Knarr BA, 2013, MUSCLE NERVE, V48, P971, DOI 10.1002/mus.23835; Krishnan S, 2018, DISABIL REHABIL, V40, P1401, DOI 10.1080/09638288.2017.1297855; Kuys S, 2006, PHYSIOTHER RES INT, V11, P219, DOI 10.1002/pri.344; Labruyere R, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-4; Lam T, 2015, J REHABIL RES DEV, V52, P113, DOI 10.1682/JRRD.2014.03.0090; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; Lau RWK, 2012, MED SCI SPORT EXER, V44, P1409, DOI 10.1249/MSS.0b013e31824e4f8c; Laver K, 2013, AUST OCCUP THER J, V60, P93, DOI [10.1111/1440-1630.12018, 10.1111/1440-1630.12087]; Laver K, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-64; Laver K, 2011, J REHABIL MED, V43, P354, DOI 10.2340/16501977-0678; Lee CH, 2014, HONG KONG PHYSIOTHER, V32, P51, DOI 10.1016/j.hkpj.2014.04.002; Lee SSM, 2015, CLIN BIOMECH, V30, P269, DOI 10.1016/j.clinbiomech.2015.01.004; Lee SW, 2013, CLIN REHABIL, V27, P921, DOI 10.1177/0269215513485100; Lee YH, 2015, AM J PHYS MED REHAB, V94, P687, DOI 10.1097/PHM.0000000000000233; Levin MF, 2015, PHYS THER, V95, P415, DOI 10.2522/ptj.20130579; Lewis GN, 2012, DISABIL REHABIL, V34, P1880, DOI 10.3109/09638288.2012.670036; Liao LR, 2016, MED SCI SPORT EXER, V48, P1227, DOI 10.1249/MSS.0000000000000909; Llorens R, 2015, CLIN REHABIL, V29, P261, DOI 10.1177/0269215514543333; Lohse KR, 2018, ARCH PHYS MED REHAB, V99, P1424, DOI 10.1016/j.apmr.2017.12.024; Lucareli PR, 2011, SPINAL CORD, V49, P1001, DOI 10.1038/sc.2011.37; Luft AR, 2008, STROKE, V39, P3341, DOI 10.1161/STROKEAHA.108.527531; Macko R F, 2005, Top Stroke Rehabil, V12, P45; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Madhavan S, 2011, CLIN NEUROPHYSIOL, V122, P1588, DOI 10.1016/j.clinph.2011.01.011; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002840.pub3; Mehrholz J, 2013, STROKE, V44, pE127, DOI 10.1161/STROKEAHA.113.003061; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub3; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; Middleton A, 2015, J AGING PHYS ACTIV, V23, P314, DOI 10.1123/japa.2013-0236; Middleton A, 2014, TOP STROKE REHABIL, V21, P462, DOI 10.1310/tsr2106-462; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Moore JL, 2018, J NEUROL PHYS THER, V42, P174, DOI 10.1097/NPT.0000000000000229; Moore JL, 2010, STROKE, V41, P129, DOI 10.1161/STROKEAHA.109.563247; Moore SA, 2016, ARCH PHYS MED REHAB, V97, P596, DOI 10.1016/j.apmr.2015.12.018; Mudge S, 2009, ARCH PHYS MED REHAB, V90, P1989, DOI 10.1016/j.apmr.2009.07.015; Munari D, 2016, EUR J PHYS REHAB MED, V54, P408; Nadeau S, 1999, CLIN BIOMECH, V14, P125, DOI 10.1016/S0268-0033(98)00062-X; Nadeau S, 2011, PROG BRAIN RES, V192, P161, DOI 10.1016/B978-0-444-53355-5.00011-7; Newham DJ, 2001, DISABIL REHABIL, V23, P379; OLNEY SJ, 1994, PHYS THER, V74, P872, DOI 10.1093/ptj/74.9.872; Ouellette MM, 2004, STROKE, V35, P1404, DOI 10.1161/01.STR.0000127785.73065.34; Pak S, 2008, TOP STROKE REHABIL, V15, P177, DOI 10.1310/tsr1503-177; Pandey A, 2015, CIRC-HEART FAIL, V8, P33, DOI 10.1161/CIRCHEARTFAILURE.114.001615; Pang MYC, 2005, J AM GERIATR SOC, V53, P1667, DOI 10.1111/j.1532-5415.2005.53521.x; Paoloni M, 2010, NEUROREHAB NEURAL RE, V24, P254, DOI 10.1177/1545968309349940; Park HJ, 2011, CLIN REHABIL, V25, P451, DOI 10.1177/0269215510389200; Park IM, 2013, J PHYS THER SCI, V25, P379, DOI 10.1589/jpts.25.379; Park J, 2015, NEUROREHABILITATION, V37, P193, DOI 10.3233/NRE-151252; Park YH, 2013, J EXERC REHABIL, V9, P489, DOI 10.12965/jer.130066; Patten C, 2004, J REHABIL RES DEV, V41, P293, DOI 10.1682/JRRD.2004.03.0293; Patterson SL, 2007, ARCH PHYS MED REHAB, V88, P115, DOI 10.1016/j.apmr.2006.10.025; Peurala SH, 2005, ARCH PHYS MED REHAB, V86, P1557, DOI 10.1016/j.apmr.2005.02.005; Plummer P, 2007, NEUROREHAB NEURAL RE, V21, P137, DOI 10.1177/1545968306295559; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; Pollock A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub2; Prajapati SK, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/612458; Resnick B, 2008, TOP STROKE REHABIL, V15, P494, DOI 10.1310/tsr1505-494; Ribeiro T, 2013, EUR J PHYS REHAB MED, V49, P451; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Rose D, 2011, NEUROREHAB NEURAL RE, V25, P140, DOI 10.1177/1545968310384270; Rycroft-Malone J, 2008, J NURS MANAGE, V16, P404, DOI 10.1111/j.1365-2834.2008.00859.x; Rydwik E, 2006, CLIN REHABIL, V20, P645, DOI 10.1191/0269215506cre986oa; Saraf P, 2010, PHYS THER, V90, P224, DOI 10.2522/ptj.20090064; Schmidt R. A., 1999, MOTOR CONTROL LEARNI; Scrivener K, 2012, J REHABIL MED, V44, P824, DOI 10.2340/16501977-1028; Severinsen K, 2014, AM J PHYS MED REHAB, V93, P29, DOI 10.1097/PHM.0b013e3182a518e1; Sharp KG, 2014, ARCH PHYS MED REHAB, V95, P615, DOI 10.1016/j.apmr.2013.11.016; Sheikh M, 2016, CLIN REHABIL, V30, P1088, DOI 10.1177/0269215515611467; Shields RK, 2002, J ORTHOP SPORT PHYS, V32, P65, DOI 10.2519/jospt.2002.32.2.65; Shiffman RN, 2012, J AM MED INFORM ASSN, V19, P94, DOI 10.1136/amiajnl-2011-000172; Shumway-Cook A, 2003, J AM GERIATR SOC, V51, P393, DOI 10.1046/j.1532-5415.2003.51114.x; Shumway-Cook A, 2002, PHYS THER, V82, P670, DOI 10.1093/ptj/82.7.670; SNF PPS Payment Model Research, 2019, SNF PPS PAYM MOD RES; Song GB, 2015, J PHYS THER SCI, V27, P2057, DOI 10.1589/jpts.27.2057; Song HS, 2015, J PHYS THER SCI, V27, P187, DOI 10.1589/jpts.27.187; States RA, 2009, J NEUROL PHYS THER, V33, P179, DOI 10.1097/NPT.0b013e3181c29a8c; States RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006075.pub2; Stein J, 2014, AM J PHYS MED REHAB, V93, P987, DOI 10.1097/PHM.0000000000000119; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, pS107; Takao T, 2015, J PHYS THER SCI, V27, P159, DOI 10.1589/jpts.27.159; Tang A, 2016, J REHABIL MED, V48, P841, DOI 10.2340/16501977-2163; Tang A, 2014, INT J STROKE, V9, P883, DOI 10.1111/ijs.12156; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Teixeira-Salmela LF, 1999, ARCH PHYS MED REHAB, V80, P1211, DOI 10.1016/S0003-9993(99)90018-7; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Ucar DE, 2014, NEUROREHABILITATION, V34, P447, DOI 10.3233/NRE-141054; Vahlberg B, 2017, DISABIL REHABIL, V39, P1615, DOI 10.1080/09638288.2016.1206631; van de Port IGL, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-43; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; VISINTIN M, 1989, CAN J NEUROL SCI, V16, P315, DOI 10.1017/S0317167100029152; Werner C, 2002, STROKE, V33, P2895, DOI 10.1161/01.STR.0000035734.61539.f6; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; Winding KM, 2018, DIABETES OBES METAB, V20, P1131, DOI 10.1111/dom.13198; WINSTEIN CJ, 1989, ARCH PHYS MED REHAB, V70, P755; Won SH, 2015, J PHYS THER SCI, V27, P2581, DOI 10.1589/jpts.27.2581; Wu M, 2016, AM J PHYS MED REHAB, V95, P911, DOI 10.1097/PHM.0000000000000517; Wu M, 2014, ARCH PHYS MED REHAB, V95, P799, DOI 10.1016/j.apmr.2013.12.021; Wu M, 2012, ARCH PHYS MED REHAB, V93, P782, DOI 10.1016/j.apmr.2011.12.018; Xu TM, 2018, ARCH PHYS MED REHAB, V99, P563, DOI 10.1016/j.apmr.2017.06.032; Yagura H, 2006, ARCH PHYS MED REHAB, V87, P529, DOI 10.1016/j.apmr.2005.11.035; Yang C. H, 2016, J EXP STROKE TRANSL, V9, P1; Yang JF, 2014, NEUROREHAB NEURAL RE, V28, P314, DOI 10.1177/1545968313508473; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Yang YR, 2007, GAIT POSTURE, V25, P185, DOI 10.1016/j.gaitpost.2006.03.007; Yang YR, 2006, CLIN REHABIL, V20, P860, DOI 10.1177/0269215506070701; Yavuzer G, 2006, CLIN REHABIL, V20, P960, DOI 10.1177/0269215506070315; Yen CL, 2008, NEUROREHAB NEURAL RE, V22, P22, DOI 10.1177/1545968307301875; Yom C, 2015, J PHYS THER SCI, V27, P845, DOI 10.1589/jpts.27.845; You YY, 2012, J PHYS THER SCI, V24, P571, DOI 10.1589/jpts.24.571; Zbogar D, 2017, SPINAL CORD, V55, P172, DOI 10.1038/sc.2016.129; Zbogar D, 2017, ARCH PHYS MED REHAB, V98, P2449, DOI 10.1016/j.apmr.2017.05.009; Zorner B, 2010, J NEUROTRAUM, V27, P241, DOI 10.1089/neu.2009.0901	249	38	39	20	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JAN	2020	44	1					49	100		10.1097/NPT.0000000000000303			52	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	KL0WC	WOS:000513152300008	31834165				2022-02-06	
J	Zwirner, J; Scholze, M; Waddell, JN; Ondruschka, B; Hammer, N				Zwirner, Johann; Scholze, Mario; Waddell, John Neil; Ondruschka, Benjamin; Hammer, Niels			Mechanical Properties of Human Dura Mater in Tension - An Analysis at an Age Range of 2 to 94 Years	SCIENTIFIC REPORTS			English	Article							SKULL-BRAIN MODEL; HUMAN HEAD; IMPACT; BLAST; INJURIES; FRACTURE; GUNSHOT; EPIDEMIOLOGY; POSTMORTEM; THICKNESS	Realistic human head models are of great interest in traumatic brain injury research and in the forensic pathology courtroom and teaching. Due to a lack of biomechanical data, the human dura mater is underrepresented in head models. This study provides tensile data of 73 fresh human cranial dura mater samples retrieved from an area between the anterior middle and the posterior middle meningeal artery. Tissues were adapted to their native water content using the osmotic stress technique. Tensile tests were conducted under quasi-static uniaxial testing conditions with simultaneous digital image correlation. Human temporal dura mater is mechanically highly variable with regards to its elastic modulus of 70 +/- 44 MPa, tensile strength of 7 +/- 4 MPa, and maximum strain of 11 +/- 3 percent. Mechanical properties of the dura mater did not vary significantly between side nor sex and decreased with the age of the cadaver. Both elastic modulus and tensile strength appear to have constant mechanical parameters within the first 139 hours post mortem. The mechanical properties provided by this study can help to improve computational and physical human head models. These properties under quasi-static conditions do not require adjustments for side nor sex, whereas adjustments of tensile properties accompanied with normal aging may be of interest.	[Zwirner, Johann; Hammer, Niels] Univ Otago, Dept Anat, Dunedin, New Zealand; [Scholze, Mario] Tech Univ Chemnitz, Inst Mat Sci & Engn, Chemnitz, Germany; [Waddell, John Neil] Univ Otago, Sir John Walsh Res Inst, Fac Dent, Dunedin, New Zealand; [Ondruschka, Benjamin] Univ Leipzig, Inst Legal Med, Leipzig, Germany; [Hammer, Niels] Univ Leipzig, Dept Orthoped & Trauma Surg, Leipzig, Germany; [Hammer, Niels] Fraunhofer IWU, Dresden, Germany; [Hammer, Niels] Med Univ Graz, Dept Anat, Graz, Austria		Zwirner, J; Hammer, N (corresponding author), Univ Otago, Dept Anat, Dunedin, New Zealand.; Hammer, N (corresponding author), Univ Leipzig, Dept Orthoped & Trauma Surg, Leipzig, Germany.; Hammer, N (corresponding author), Fraunhofer IWU, Dresden, Germany.; Hammer, N (corresponding author), Med Univ Graz, Dept Anat, Graz, Austria.	medijo@gmx.de; niels.hammer@medunigraz.at		Scholze, Mario/0000-0002-0120-2478	German Research Foundation (DFG)German Research Foundation (DFG); University of Leipzig	The authors would like to thank Marlene Black for her help with plastination for "Figure 1" and Miss Joanna Tomlinson for proofreading the paper as a native speaker. We acknowledge support from the German Research Foundation (DFG) and the University of Leipzig within the program of Open Access Publishing.	Asgharpour Z, 2014, J MECH BEHAV BIOMED, V33, P16, DOI 10.1016/j.jmbbm.2013.02.010; BANDAK FA, 1995, J NEUROTRAUM, V12, P679, DOI 10.1089/neu.1995.12.679; Carr D, 2015, INT J LEGAL MED, V129, P505, DOI 10.1007/s00414-014-1073-2; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chauvet D, 2010, NEUROSURG REV, V33, P287, DOI 10.1007/s10143-010-0261-x; De Kegel D, 2018, J MECH BEHAV BIOMED, V79, P122, DOI 10.1016/j.jmbbm.2017.12.023; Fam MD, 2018, J NEUROL SURG PART B, V79, P614, DOI 10.1055/s-0038-1651501; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gu LX, 2012, COMPOS PART B-ENG, V43, P3160, DOI 10.1016/j.compositesb.2012.04.014; Haimann MCJ, 1998, J ANAT, V192, P99; Hammer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105037; Hong JY, 2011, SPINE J, V11, P1121, DOI 10.1016/j.spinee.2011.11.001; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Keene DD, 2016, J ROY ARMY MED CORPS, V162, P355, DOI 10.1136/jramc-2015-000490; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kozerska Magdalena, 2015, Folia Med Cracov, V55, P33; Li ZG, 2011, ANN BIOMED ENG, V39, P2984, DOI 10.1007/s10439-011-0409-z; Liang ZY, 2015, APPL BIONICS BIOMECH, V2015, P1, DOI 10.1155/2015/837585; MacManus DB, 2017, ACTA BIOMATER, V57, P384, DOI 10.1016/j.actbio.2017.05.022; Mahoney PF, 2017, INT J LEGAL MED, V131, P1043, DOI 10.1007/s00414-017-1557-y; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Maxeiner H, 2009, RECHTSMEDIZIN, V19, P111, DOI 10.1007/s00194-008-0585-9; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Ondruschka B, 2018, J NEUROTRAUM, V35, P2044, DOI 10.1089/neu.2017.5441; PATIN DJ, 1993, ANESTH ANALG, V76, P535; Protasoni M, 2011, J NEUROSURG, V114, P1723, DOI 10.3171/2010.12.JNS101732; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Scholze M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29583-4; Schyma C, 2012, INT J LEGAL MED, V126, P607, DOI 10.1007/s00414-012-0704-8; Shetye SS, 2014, J MECH BEHAV BIOMED, V34, P146, DOI 10.1016/j.jmbbm.2014.02.014; Tan LB, 2014, INT J NUMER METH BIO, V30, P1476, DOI 10.1002/cnm.2668; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thali MJ, 2002, AM J FOREN MED PATH, V23, P223, DOI 10.1097/00000433-200209000-00003; Thali MJ, 2002, FORENSIC SCI INT, V125, P195, DOI 10.1016/S0379-0738(01)00639-9; Thali MJ, 2002, FORENSIC SCI INT, V125, P178, DOI 10.1016/S0379-0738(01)00637-5; Thali MJ, 2002, FORENSIC SCI INT, V127, P168, DOI 10.1016/S0379-0738(02)00117-2; van Noort R, 1981, Clin Phys Physiol Meas, V2, P197, DOI 10.1088/0143-0815/2/3/003; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wolpers C., 1944, KLIN WOCHENSCHR, V23, P169, DOI 10.1007/BF01773402; Yue X., 2010, FINITE ELEMENT ANAL; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zwirner J, 2017, INT J LEGAL MED, V131, P1581, DOI 10.1007/s00414-017-1580-z	47	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 13	2019	9								16655	10.1038/s41598-019-52836-9			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM3PD	WOS:000496129600004	31723169	gold, Green Published			2022-02-06	
J	Jahns, FP; Miroz, JP; Messerer, M; Daniel, RT; Taccone, FS; Eckert, P; Oddo, M				Jahns, Fritz-Patrick; Miroz, John Paul; Messerer, Mahmoud; Daniel, Roy T.; Taccone, Fabio Silvio; Eckert, Philippe; Oddo, Mauro			Quantitative pupillometry for the monitoring of intracranial hypertension in patients with severe traumatic brain injury	CRITICAL CARE			English	Article						Traumatic brain injury; Pupillometry; Pupillary reactivity; Neurological Pupil index; Intracranial pressure; Intracranial hypertension; Outcome; Prognosis	PORTABLE INFRARED PUPILLOMETRY; MODELS; INDEX	Background: Elevated intracranial pressure (ICP) is frequent after traumatic brain injury (TBI) and may cause abnormal pupillary reactivity, which in turn is associated with a worse prognosis. Using automated infrared pupillometry, we examined the relationship between the Neurological Pupil index (NPi) and invasive ICP in patients with severe TBI. Methods: This was an observational cohort of consecutive subjects with severe TBI (Glasgow Coma Scale [GCS] <9 with abnormal lesions on head CT) who underwent parenchymal ICP monitoring and repeated NPi assessment with the NPi-200 (R) pupillometer. We examined NPi trends over time (four consecutive measurements over intervals of 6h) prior to sustained elevated ICP >20mmHg. We further analyzed the relationship of cumulative abnormal NPi burden (%NPi values <3 during total ICP monitoring time) with intracranial hypertension (ICHT)categorized as refractory (ICHT-r; requiring surgical decompression) vs. non-refractory (ICHT-nr; responsive to medical therapy)and with the 6-month Glasgow Outcome Score (GOS). Results: A total of 54 patients were studied (mean age 54 +/- 21years, 74% with focal injuries on CT), of whom 32 (59%) had ICHT. Among subjects with ICHT, episodes of sustained elevated ICP (n=43, 172 matched ICP-NPi samples; baseline ICP [T-6h] 14 +/- 5mmHg vs. ICPmax [T-0h] 30 +/- 9mmHg) were associated with a concomitant decrease of the NPi (baseline 4.2 +/- 0.5 vs. 2.8 +/- 1.6, p<0.0001 ANOVA for repeated measures). Abnormal NPi values were more frequent in patients with ICHT-r (n=17; 38 [3-96]% of monitored time vs. 1 [0-9]% in patients with ICHT-nr [n=15] and 0.5 [0-10]% in those without ICHT [n=22]; p=0.007) and were associated with an unfavorable 6-month outcome (15 [1-80]% in GOS 1-3 vs. 0 [0-7]% in GOS 4-5 patients; p=0.002). Conclusions: In a selected cohort of severe TBI patients with abnormal head CT lesions and predominantly focal cerebral injury, elevated ICP episodes correlated with a concomitant decrease of NPi. Sustained abnormal NPi was in turn associated with a more complicated ICP course and worse outcome.	[Jahns, Fritz-Patrick; Eckert, Philippe; Oddo, Mauro] Univ Lausanne, CHUV, Dept Intens Care Med, Fac Biol & Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland; [Miroz, John Paul; Oddo, Mauro] Univ Lausanne, CHUV, Crit Care Clin Res Unit, Fac Biol & Med, CH-1011 Lausanne, Switzerland; [Messerer, Mahmoud; Daniel, Roy T.] Lausanne Univ Hosp, CHUV, Fac Biol & Med, Dept Clin Neurosci,Neurosurg Serv, CH-1011 Lausanne, Switzerland; [Taccone, Fabio Silvio] Erasme Univ Hosp, Dept Intens Care Med, Brussels, Belgium		Oddo, M (corresponding author), Univ Lausanne, CHUV, Dept Intens Care Med, Fac Biol & Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.; Oddo, M (corresponding author), Univ Lausanne, CHUV, Crit Care Clin Res Unit, Fac Biol & Med, CH-1011 Lausanne, Switzerland.	Mauro.Oddo@chuv.ch	MIROZ, John-Paul/AAR-7445-2020; Messerer, Mahmoud/AAZ-3527-2020		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission	Mauro Oddo is supported by research grants from the Swiss National Science Foundation.	Alali AS, 2019, J NEUROSURG, V9, P1; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen JW, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-548; Chesnut RM, 2018, J NEUROTRAUM, V35, P54, DOI 10.1089/neu.2016.4472; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Couret D, 2019, NEUROCRIT CARE, V30, P492, DOI 10.1007/s12028-018-0664-z; Couret D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1239-z; Delfino AE, 2009, BRIT J ANAESTH, V103, P255, DOI 10.1093/bja/aep138; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Hall CA, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8010019; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Hoshi Takuo, 2017, Masui, V66, P174; Kesmarky K, 2017, J NEUROTRAUM, V34, P2235, DOI 10.1089/neu.2016.4606; Larson MD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1349-7; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Larson MD, 2012, ANESTHESIOLOGY, V116, P980, DOI 10.1097/ALN.0b013e318251d21b; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Olson DM, 2016, NEUROCRIT CARE, V24, P251, DOI 10.1007/s12028-015-0182-1; Ong C, 2019, NEUROCRIT CARE, V30, P307, DOI 10.1007/s12028-018-0620-y; Ong C, 2019, NEUROCRIT CARE, V30, P316, DOI 10.1007/s12028-018-0607-8; Robba C, 2018, INTENS CARE MED, V44, P1284, DOI 10.1007/s00134-018-5305-7; Rollins MD, 2014, ANESTHESIOLOGY, V121, P1037, DOI 10.1097/ALN.0000000000000384; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Sharshar T, 2014, INTENS CARE MED, V40, P484, DOI 10.1007/s00134-014-3214-y; Shirozu K, 2017, J CLIN MONIT COMPUT, V31, P291, DOI 10.1007/s10877-016-9839-3; Shoyombo I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25477-7; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Volpi PC, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0197-y	32	38	39	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	MAY 2	2019	23								155	10.1186/s13054-019-2436-3			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW9LB	WOS:000467011200001	31046817	gold, Green Published			2022-02-06	
J	Yuan, XC; Wu, QB; Wang, P; Jing, YL; Yao, HJ; Tang, YS; Li, ZG; Zhang, HG; Xiu, RJ				Yuan, Xiaochen; Wu, Qingbin; Wang, Peng; Jing, Yingli; Yao, Haijiang; Tang, Yinshan; Li, Zhigang; Zhang, Honggang; Xiu, Ruijuan			Exosomes Derived From Pericytes Improve Microcirculation and Protect Blood-Spinal Cord Barrier After Spinal Cord Injury in Mice	FRONTIERS IN NEUROSCIENCE			English	Article						pericytes; exosomes; spinal cord injury; microcirculation; microvascular	MESENCHYMAL STROMAL CELLS; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; STEM-CELLS; MATRIX METALLOPROTEINASES; MICROVASCULAR PERICYTES; RAT; AQUAPORIN-4; MODEL; TRANSPLANTATION	Spinal cord injury (SCI) often leads to severe and permanent paralysis and places a heavy burden on individuals, families, and society. Until now, the therapy of SCI is still a big challenge for the researchers. Transplantation of mesenchymal stem cells (MSCs) is a hot spot for the treatment of SCI, but many problems and risks have not been resolved. Some studies have reported that the therapeutic effect of MSCs on SCI is related to the paracrine secretion of cells. The exosomes secreted by MSCs have therapeutic potential for many diseases. There are abundant pericytes which possess the characteristics of stem cells in the neurovascular unit. Due to the close relationship between pericytes and endothelial cells, the exosomes of pericytes can be taken up by endothelial cells more easily. There are fewer studies about the therapeutic potential of the exosomes derived from pericytes on SCI now. In this study, exosomes of pericytes were transplanted into the mice with SCI to study the restoration of motor function and explore the underlying mechanism. We found that the exosomes derived from pericytes could reduce pathological changes, improve the motor function, the blood flow and oxygen deficiency after SCI. In addition, the exosomes could improve the endothelial ability to regulate blood flow, protect the blood-spinal cord barrier, reduce edema, decrease the expression of HIF-1 alpha, Bax, Aquaporin-4, and MMP2, increase the expression of Claudin-5, bcl-2 and inhibit apoptosis. The experiments in vitro proved that exosomes derived from pericytes could protect the barrier of spinal cord microvascular endothelial cells under hypoxia condition, which was related to PTEN/AKT pathway. In summary, our study showed that exosomes of pericytes had therapeutic prospects for SCI.	[Yuan, Xiaochen; Wu, Qingbin; Zhang, Honggang; Xiu, Ruijuan] Chinese Acad Med Sci, Inst Microcirculat, Key Lab Microcirculat, Minist Hlth, Beijing, Peoples R China; [Yuan, Xiaochen; Wu, Qingbin; Zhang, Honggang; Xiu, Ruijuan] Peking Union Med Coll, Beijing, Peoples R China; [Wang, Peng] Hebei Prov Hosp Tradit Chinese Med, Orthoped Dept, Shijiazhuang, Hebei, Peoples R China; [Jing, Yingli] Beijing Inst Brain Disorders, Ctr Neural Injury & Repair, China Rehabilltat Sci Inst, China Rehabil Res Ctr,Beijing Key Lab Neural Inju, Beijing, Peoples R China; [Yao, Haijiang] Capital Med Univ, Beijing Boai Hosp, Treatment Ctr TCM, Sch Rehabil,China Rehabil Res Ctr, Beijing, Peoples R China; [Tang, Yinshan] Zhejiang Univ, Dept Rehabil Tradit Chinese Med, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China; [Li, Zhigang] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China		Wu, QB; Zhang, HG (corresponding author), Chinese Acad Med Sci, Inst Microcirculat, Key Lab Microcirculat, Minist Hlth, Beijing, Peoples R China.; Wu, QB; Zhang, HG (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.; Li, ZG (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.	wuqingbin@imc.pumc.edu.cn; lizhigang620620@163.com; zhang1966126@163.com	Yao, Haijiang/ABG-3886-2021	Xiu, Ruijuan/0000-0002-1446-2711	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81603678]; Chinese Academy of Medical Sciences & Peking Union Medical College [3332014006, 3332015123]; Special Fund for Basic Scientific Research of the Central Public Research Institutes [2016CZ-1, 2018CZ-8]; CAMS Initiative for Innovative Medicine (CAMS-I2M) [2016-I2M-3-006]	This study was supported by the National Natural Science Foundation of China (No. 81603678), the innovation fund of the Chinese Academy of Medical Sciences & Peking Union Medical College (Nos. 3332014006 and 3332015123), the Special Fund for Basic Scientific Research of the Central Public Research Institutes (Nos. 2016CZ-1 and 2018CZ-8), and the CAMS Initiative for Innovative Medicine (CAMS-I2M) (No. 2016-I2M-3-006).	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alilain WJ, 2011, NATURE, V475, P196, DOI 10.1038/nature10199; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Breakefield XO, 2011, MOL THER, V19, P1574, DOI 10.1038/mt.2011.169; Bsibsi M, 2006, GLIA, V53, P688, DOI 10.1002/glia.20328; Camussi G, 2013, BIOCHEM SOC T, V41, P283, DOI 10.1042/BST20120192; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Cavallucci V, 2011, CURR PHARM DESIGN, V17, P215, DOI 10.2174/138161211795049705; Chaput N, 2011, SEMIN IMMUNOPATHOL, V33, P419, DOI 10.1007/s00281-010-0233-9; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cizkova D, 2011, J NEUROTRAUM, V28, P1951, DOI 10.1089/neu.2010.1413; De Luca C, 2017, PROG MOL BIOL TRANSL, V148, P167, DOI 10.1016/bs.pmbts.2017.04.002; Dore-Duffy P, 2011, METHODS MOL BIOL, V686, P49, DOI 10.1007/978-1-60761-938-3_2; Fan ZK, 2013, J NEUROTRAUM, V30, P473, DOI 10.1089/neu.2012.2574; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Feron F, 2005, BRAIN, V128, P2951, DOI 10.1093/brain/awh657; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ho AD, 2008, CYTOTHERAPY, V10, P320, DOI 10.1080/14653240802217011; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Huang JH, 2017, J NEUROTRAUM, V34, P3388, DOI 10.1089/neu.2017.5063; Hubbard JA, 2016, EXP NEUROL, V283, P85, DOI 10.1016/j.expneurol.2016.05.003; Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848; Katsuda T, 2013, PROTEOMICS, V13, P1637, DOI 10.1002/pmic.201200373; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Lai RC, 2011, REGEN MED, V6, P481, DOI [10.2217/RME.11.35, 10.2217/rme.11.35]; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Li TF, 2013, STEM CELLS DEV, V22, P845, DOI 10.1089/scd.2012.0395; Li ZY, 2007, IN VIVO, V21, P61; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Liebner S, 2011, INT J DEV BIOL, V55, P467, DOI 10.1387/ijdb.103224sl; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Neganova AY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173805; Neirinckx V, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0202-2; Nielsen S, 1997, J NEUROSCI, V17, P171; Noble LJ, 2002, J NEUROSCI, V22, P7526; Nohda K, 2007, SPINE, V32, P1060, DOI 10.1097/01.brs.0000261560.53428.90; Orekhov AN, 2014, CARDIOVASC RES, V103, P438, DOI 10.1093/cvr/cvu168; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; Oudega M, 2012, CELL TISSUE RES, V349, P269, DOI 10.1007/s00441-012-1440-6; Pavlov AN, 2014, PHYSIOL MEAS, V35, P1983, DOI 10.1088/0967-3334/35/10/1983; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Ratajczak MZ, 2014, POL ARCH MED WEWN, V124, P417, DOI 10.20452/pamw.2355; Record M, 2011, BIOCHEM PHARMACOL, V81, P1171, DOI 10.1016/j.bcp.2011.02.011; Rendell MS, 1999, COMP BIOCHEM PHYS A, V122, P399, DOI 10.1016/S1095-6433(99)00022-7; Rodriguez R, 2012, CELL RES, V22, P62, DOI 10.1038/cr.2011.157; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Seki T, 2003, NEUROSURGERY, V53, P192, DOI 10.1227/01.NEU.0000068988.28788.2C; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Simonavicius N, 2012, BLOOD, V120, P1516, DOI 10.1182/blood-2011-01-332338; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Strazielle N, 2013, MOL PHARMACEUT, V10, P1473, DOI 10.1021/mp300518e; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Varma AK, 2013, NEUROCHEM RES, V38, P895, DOI 10.1007/s11064-013-0991-6; Villarroya-Beltri Carolina, 2013, Methods Mol Biol, V1024, P41, DOI 10.1007/978-1-62703-453-1_4; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Wu QB, 2015, CLIN HEMORHEOL MICRO, V60, P231, DOI 10.3233/CH-141856; Wyatt LA, 2012, PROG BRAIN RES, V201, P233, DOI 10.1016/B978-0-444-59544-7.00012-3; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yuan XC, 2017, ANDROLOGIA, V49, DOI 10.1111/and.12692; Yuan XC, 2018, AM J TRANSL RES, V10, P2372; Yuan XC, 2011, J PINEAL RES, V51, P220, DOI 10.1111/j.1600-079X.2011.00882.x; Zhang JL, 2015, INT J BIOCHEM CELL B, V60, P43, DOI 10.1016/j.biocel.2014.12.020; Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339	79	38	40	1	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	APR 16	2019	13								319	10.3389/fnins.2019.00319			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HU2AV	WOS:000465074000001	31040762	Green Published, gold			2022-02-06	
J	Kochanek, PM; Tasker, RC; Carney, N; Totten, AM; Adelson, PD; Selden, NR; Davis-O'Reilly, C; Hart, EL; Bell, MJ; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Vavilala, MS; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Carney, Nancy; Totten, Annette M.; Adelson, P. David; Selden, Nathan R.; Davis-O'Reilly, Cynthia; Hart, Erica L.; Bell, Michael J.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Vavilala, Monica S.; Wainwright, Mark S.			Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critical care; evidence-based medicine; guidelines; pediatrics; systematic review; traumatic brain injury	EARLY DECOMPRESSIVE CRANIECTOMY; COMMON DATA ELEMENTS; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL PERFUSION-PRESSURE; THERAPEUTIC HYPOTHERMIA; HYPERTONIC SALINE; HEAD-INJURY; SINGLE-CENTER; CHILDREN; OUTCOMES	Objectives: The purpose of this work is to identify and synthesize research produced since the second edition of these Guidelines was published and incorporate new results into revised evidence-based recommendations for the treatment of severe traumatic brain injury in pediatric patients. Methods and Main Results: This document provides an overview of our process, lists the new research added, and includes the revised recommendations. Recommendations are only provided when there is supporting evidence. This update includes 22 recommendations, nine are new or revised from previous editions. New recommendations on neuroimaging, hyperosmolar therapy, analgesics and sedatives, seizure prophylaxis, temperature control/hypothermia, and nutrition are provided. None are level I, three are level II, and 19 are level III. The Clinical Investigators responsible for these Guidelines also created a companion algorithm that supplements the recommendations with expert consensus where evidence is not available and organizes possible interventions into first and second tier utilization. The purpose of publishing the algorithm as a separate document is to provide guidance for clinicians while maintaining a clear distinction between what is evidence based and what is consensus based. This approach allows, and is intended to encourage, continued creativity in treatment and research where evidence is lacking. Additionally, it allows for the use of the evidence-based recommendations as the foundation for other pathways, protocols, or algorithms specific to different organizations or environments. The complete guideline document and supplemental appendices are available electronically from this journal. These documents contain summaries and evaluations of all the studies considered, including those from prior editions, and more detailed information on our methodology. Conclusions: New level II and level III evidence-based recommendations and an algorithm provide additional guidance for the development of local protocols to treat pediatric patients with severe traumatic brain injury. Our intention is to identify and institute a sustainable process to update these Guidelines as new evidence becomes available.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Anesthesiol Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA; [Carney, Nancy; Totten, Annette M.; Davis-O'Reilly, Cynthia; Hart, Erica L.] Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosci, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosurg, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Bell, Michael J.] Childrens Natl Med Ctr, Crit Care Med, Washington, DC 20010 USA; [Bratton, Susan L.] Univ Utah, Pediat, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Kissoon, Niranjan] Univ British Columbia, Child & Family Res Inst, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Dept Pediat, Div Pediat Crit Care Med, Sch Nursing,Sch Med, Durham, NC 27706 USA; [Vavilala, Monica S.] Univ Washington, Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, HIPRC, Seattle, WA 98195 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Anesthesiol Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Tasker, Robert C/R-5837-2019; Totten, Annette/P-7909-2019; Kissoon, Niranjan/AAC-6140-2021; Adelson, David/W-2083-2019	Totten, Annette/0000-0002-9100-8678; Kissoon, Niranjan/0000-0001-8847-9973; Reuter-Rice, Karin/0000-0003-1501-8994	U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911 QY-14-C-0086]; Brain Trauma Foundation	Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to Stanford University (W911 QY-14-C-0086) and a subcontract awarded to Oregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Bata SC, 2014, ANZ J SURG, V84, P438, DOI 10.1111/ans.12582; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bell MJ, 2017, CHILD NERV SYST, V33, P1663, DOI 10.1007/s00381-017-3530-y; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Crompton E, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002565; Crompton EM, 2017, CRIT CARE MED, V45, P575, DOI 10.1097/CCM.0000000000002205; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; de Andrade AF, 2011, ARQ NEURO-PSIQUIAT, V69, P79, DOI 10.1590/S0004-282X2011000100016; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kurz JE, 2016, PEDIATR CRIT CARE ME, V17, P649, DOI 10.1097/PCC.0000000000000765; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG PEDIAT, V16, P1; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; Prasad GL, 2015, BRAIN INJURY, V29, P1; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taha AA, 2011, J NEUROSCI NURS, V43, P291, DOI 10.1097/JNN.0b013e318234e9b2; Tasker RC, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002526; Tasker RC, 2017, PEDIATR CRIT CARE ME, V18, P355, DOI 10.1097/PCC.0000000000001098; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558	63	38	41	3	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2019	20	3					280	289		10.1097/PCC.0000000000001736			10	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	HN4QS	WOS:000460169200017	30830016				2022-02-06	
J	Zhou, JY; Deng, YY; Li, F; Yin, CX; Shi, JS; Gong, QH				Zhou, Jiayin; Deng, Yuanyuan; Li, Fei; Yin, Caixia; Shi, Jingshan; Gong, Qihai			Icariside II attenuates lipopolysaccharide-induced neuroinflammation through inhibiting TLR4/MyD88/NF-kappa B pathway in rats	BIOMEDICINE & PHARMACOTHERAPY			English	Article						Icariside II; Lipopolysaccharide; Neuroinflammation; Toll-like 4; Brain	LPS-INDUCED NEUROINFLAMMATION; EPIMEDIUM-BREVICORNUM; COGNITIVE DEFICITS; MAJOR CONSTITUENT; INDUCED APOPTOSIS; INFLAMMATION; ACTIVATION; ICARIIN; MICE	Inflammation in central nervous system (CNS) plays a vital role in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia (DLB), HIV-related dementia and traumatic brain injury. Icariside II (ICS II), an active flavonoid compound derived from a Chinese herbal medicine Epimedium brevicornum Maxim, has been shown to possess a neuroprotective effect on AD model. However, whether ICS II has a directly protective effect on acute neuroinflammation remains still unclear. Therefore, the current study was designed to investigate the possible protective effect of ICS II on acute neuroinflammation induced by intracerebroventricular (ICV) injection of lipopolysaccharide (LPS), and further to explore its possible mechanism. After ICS II was prophylactically administered for 7 days before LPS injection, the rats were randomly divided into five groups as follows: sham group (n = 9), sham + ICS II-H (10 mg/kg) (n = 9), LPS (n = 14), LPS + ICS II-L (3 mg/kg) (n = 14), LPS + ICS II-H (10 mg/kg) (n = 14) groups, respectively. As expected, LPS injection exhibited neuronal morphological damage, and ionized calcium binding adapter molecule 1 (IBA-1) of microglia and glial fibrillary acidic protein (GFAP) of astrocyte were activated. However, pre-treatment with ICS II not only inhibited the activation of microglia and astrocyte, but also significantly reversed the expressions of inflammatory factors such as interleukin-1 beta (IL-1 beta), tumor necrosis factor (TNF-alpha), cyclooxygenase-2 (COX-2), as well as the expressions of Toll-Like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88) and TNF receptor associated factor 6 (TRAF6). Furthermore, ICS II inhibited the degradation of I kappa B and the following activation of NF-kappa B. Hence it is concluded that ICS II attenuates LPS-induced neuroinflammation through inhibiting TLR4/MyD88/NF-kappa B pathway in rats, and it has potential value as a new therapeutic agent to treat neuroinflammation-related diseases, such as AD.	[Zhou, Jiayin; Deng, Yuanyuan; Li, Fei; Yin, Caixia; Shi, Jingshan; Gong, Qihai] Zunyi Med Univ, Minist Educ, Key Lab Basic Pharmacol, Zunyi 563000, Guizhou, Peoples R China; [Zhou, Jiayin; Deng, Yuanyuan; Li, Fei; Shi, Jingshan; Gong, Qihai] Zunyi Med Univ, Minist Educ, Joint Int Res Lab Ethnomed, Zunyi 563003, Guizhou, Peoples R China		Gong, QH (corresponding author), Zunyi Med Univ, 6 Xuefu West Rd, Zunyi 563000, Guizhou, Peoples R China.	gqh@zmc.edu.cn	shan, Shi Jing/AAX-7736-2020; Qihai, Gong/AAM-9343-2021	shan, Shi Jing/0000-0002-2537-1751; Deng, Yuanyuan/0000-0003-3366-165X	Program for excellent young talents of Zunyi Medical Uiverstity [15zy-002]; Science and Technology Innovation Talent Team of Guizhou Province [20154023]; "hundred" level of high-level innovative talents in Guizhou Province [QKHRCPT 20165684]; Program for Changjiang Scholars and Innovative Research Team in University, ChinaProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT_17R113]	This work was supported by the Program for excellent young talents of Zunyi Medical Uiverstity (Grant No. 15zy-002), the Science and Technology Innovation Talent Team of Guizhou Province (Grant No. 20154023), the "hundred" level of high-level innovative talents in Guizhou Province (Grant No. QKHRCPT 20165684), and Program for Changjiang Scholars and Innovative Research Team in University, China (Grant No. IRT_17R113).	Azam F., 2017, J BIOMOL STRUCT DYN, P1; Badshah H, 2016, SCI REP-UK, V6, DOI 10.1038/srep24493; Buttner-Ennever J., 1997, J ANAT, V191, P315, DOI DOI 10.1017/S0021878297232310; Chang X, 2015, EXP CELL RES, V334, P136, DOI 10.1016/j.yexcr.2015.04.004; Cheng T, 2015, MOLECULES, V20, P21274, DOI 10.3390/molecules201219763; Chu SH, 2014, INT IMMUNOPHARMACOL, V19, P317, DOI 10.1016/j.intimp.2014.01.018; Deng YY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00039; Dhull DK, 2012, J CHEM NEUROANAT, V43, P48, DOI 10.1016/j.jchemneu.2011.10.001; Fu SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094604; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Kempuraj D., 2016, J NEUROL NEUROSURG S, V1; Lee KS, 2009, CANCER LETT, V280, P93, DOI 10.1016/j.canlet.2009.02.024; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Li WX, 2015, PHARMACOL BIOCHEM BE, V138, P40, DOI 10.1016/j.pbb.2015.09.001; Lin ST, 2008, MOL CELL BIOCHEM, V315, P41, DOI 10.1007/s11010-008-9787-4; Liu LP, 2013, ACTA PHARMACOL SIN, V34, P455, DOI 10.1038/aps.2013.11; Ma J, 2017, ONCOTARGET, V8, P27676, DOI 10.18632/oncotarget.15398; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Nasrallah FA, 2016, NEUROIMAGE, V127, P196, DOI 10.1016/j.neuroimage.2015.08.013; Niranjan R, 2013, MOL NEUROBIOL, V48, P412, DOI 10.1007/s12035-013-8428-4; QUAN N, 1994, J NEUROIMMUNOL, V49, P125, DOI 10.1016/0165-5728(94)90188-0; Ryan SM, 2016, AGEING RES REV, V27, P77, DOI 10.1016/j.arr.2016.03.007; Song J, 2017, MOL CARCINOGEN, V56, P36, DOI 10.1002/mc.22471; Song J, 2012, CHEM-BIOL INTERACT, V199, P9, DOI 10.1016/j.cbi.2012.05.005; Tweedie D, 2009, J NEUROSCI METH, V183, P182, DOI 10.1016/j.jneumeth.2009.06.034; Tyagi E, 2008, J NEUROIMMUNOL, V205, P51, DOI 10.1016/j.jneuroim.2008.08.015; Venezia S, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0195-7; Vullhorst D, 2017, J NEUROSCI, V37, P5232, DOI 10.1523/JNEUROSCI.2630-16.2017; Walter S, 2007, CELL PHYSIOL BIOCHEM, V20, P947, DOI 10.1159/000110455; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; Woodling NS, 2016, ACS CHEM NEUROSCI, V7, P454, DOI 10.1021/acschemneuro.6b00016; Xia Y, 2006, BRAIN RES, V1095, P85, DOI 10.1016/j.brainres.2006.03.112; Yan BY, 2014, BRAIN RES, V1573, P63, DOI 10.1016/j.brainres.2014.05.023; Yan LL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00106; Yin CX, 2016, NEUROSCIENCE, V328, P69, DOI 10.1016/j.neuroscience.2016.04.022; Yong VW, 2010, NEUROSCIENTIST, V16, P408, DOI 10.1177/1073858410371379; Yu Q, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8470381; Zhang Guo-Xia, 2013, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V29, P42; Zong N, 2016, BEHAV BRAIN RES, V313, P111, DOI 10.1016/j.bbr.2016.06.055	40	38	40	7	18	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0753-3322	1950-6007		BIOMED PHARMACOTHER	Biomed. Pharmacother.	MAR	2019	111						315	324		10.1016/j.biopha.2018.10.201			10	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	HL5AK	WOS:000458737800034	30590319	gold			2022-02-06	
J	Peruzzaro, ST; Andrews, MMM; Al-Gharaibeh, A; Pupiec, O; Resk, M; Story, D; Maiti, P; Rossignol, J; Dunbar, GL				Peruzzaro, S. T.; Andrews, M. M. M.; Al-Gharaibeh, A.; Pupiec, O.; Resk, M.; Story, D.; Maiti, P.; Rossignol, J.; Dunbar, G. L.			Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Interleukin-10; Mesenchymal stem cells; Neuroinflammation; CD163	FUNCTIONAL RECOVERY; EXPRESSION; NEUROPROTECTION; POLARIZATION; MICROGLIA; ATTENUATE; NEURONS; CORTEX; CD163	BackgroundTraumatic brain injury (TBI) is a major cause for long-term disability, yet the treatments available that improve outcomes after TBI limited. Neuroinflammatory responses are key contributors to determining patient outcomes after TBI. Transplantation of mesenchymal stem cells (MSCs), which release trophic and pro-repair cytokines, represents an effective strategy to reduce inflammation after TBI. One such pro-repair cytokine is interleukin-10 (IL-10), which reduces pro-inflammatory markers and trigger alternative inflammatory markers, such as CD163. In this study, we tested the therapeutic effects of MSCs that were engineered to overexpress IL-10 when transplanted into rats following TBI in the medial frontal cortex.MethodsThirty-six hours following TBI, rats were transplanted with MSCs and then assessed for 3weeks on a battery of behavioral tests that measured motor and cognitive abilities. Histological evaluation was then done to measure the activation of the inflammatory response. Additionally, immunomodulatory effects were evaluated by immunohistochemistry and Western blot analyses.ResultsA significant improvement in fine motor function was observed in rats that received transplants of MSCs engineered to overexpress IL-10 (MSCs + IL-10) or MSCs alone compared to TBI + vehicle-treated rats. Although tissue spared was unchanged, anti-inflammatory effects were revealed by a reduction in the number of glial fibrillary acidic protein cells and CD86 cells in both TBI + MSCs + IL-10 and TBI + MSC groups compared to TBI + vehicle rats. Microglial activation was significantly increased in the TBI + MSC group when compared to the sham + vehicle group. Western blot data suggested a reduction in tumor necrosis factor-alpha in the TBI + MSCs + IL-10 group compared to TBI + MSC group. Immunomodulatory effects were demonstrated by a shift from classical inflammation expression (CD86) to an alternative inflammation state (CD163) in both treatments with MSCs and MSCs + IL-10. Furthermore, co-labeling of both CD86 and CD163 was detected in the same cells, suggesting a temporal change in macrophage expression.ConclusionsOverall, our findings suggest that transplantation of MSCs that were engineered to overexpress IL-10 can improve functional outcomes by providing a beneficial perilesion environment. This improvement may be explained by the shifting of macrophage expression to a more pro-repair state, thereby providing a possible new therapy for treating TBI.	[Peruzzaro, S. T.; Andrews, M. M. M.; Al-Gharaibeh, A.; Pupiec, O.; Resk, M.; Story, D.; Maiti, P.; Rossignol, J.; Dunbar, G. L.] Cent Michigan Univ, Field Neurosci Inst, Lab Restorat Neurol, Mt Pleasant, MI 48859 USA; [Peruzzaro, S. T.; Andrews, M. M. M.; Al-Gharaibeh, A.; Pupiec, O.; Resk, M.; Story, D.; Maiti, P.; Rossignol, J.; Dunbar, G. L.] Cent Michigan Univ, Program Neurosci, Mt Pleasant, MI 48859 USA; [Story, D.; Maiti, P.; Dunbar, G. L.] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI 48859 USA; [Maiti, P.; Dunbar, G. L.] St Marys Michigan, Field Neurosci Inst, Saginaw, MI 48604 USA; [Maiti, P.] Saginaw Valley State Univ, Dept Biol, Saginaw, MI 48610 USA; [Maiti, P.; Dunbar, G. L.] Saginaw Valley State Univ, Brain Res Lab, Saginaw, MI 48610 USA; [Rossignol, J.] Cent Michigan Univ, Coll Med, Mt Pleasant, MI 48859 USA		Rossignol, J; Dunbar, GL (corresponding author), Cent Michigan Univ, Field Neurosci Inst, Lab Restorat Neurol, Mt Pleasant, MI 48859 USA.	rossi1j@cmich.edu; dunba1g@cmich.edu	Rossignol, Julien/I-1013-2019	Rossignol, Julien/0000-0002-8662-0547; Story, Darren/0000-0002-0902-5728; Dunbar, Gary/0000-0003-4730-9323; Gharaibeh, Abeer/0000-0003-3549-1826	Office of Research and Sponsored Programs at Central Michigan University; College of Medicine at Central Michigan University; College of Humanities and Social and Behavioral Sciences at Central Michigan University; John G. Kulhavi Professorship; Field Neurosciences Institute	This work was supported by the Office of Research and Sponsored Programs at Central Michigan University, the College of Medicine at Central Michigan University, the College of Humanities and Social and Behavioral Sciences at Central Michigan University, the Field Neurosciences Institute, and the John G. Kulhavi Professorship.	Balasingam V, 1996, J NEUROSCI, V16, P2945; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135; Choi JJ, 2008, CLIN EXP IMMUNOL, V153, P269, DOI 10.1111/j.1365-2249.2008.03683.x; Colburn RW, 1997, J NEUROIMMUNOL, V79, P163, DOI 10.1016/S0165-5728(97)00119-7; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Evans HG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4199; Garcia JM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00244; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hasan A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00028; Holladay C, 2011, MOL THER, V19, P969, DOI 10.1038/mt.2010.311; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kowal K, 2011, FOLIA HISTOCHEM CYTO, V49, P365, DOI 10.5603/FHC.2011.0052; Liao WB, 2016, BIOMATERIALS, V77, P87, DOI 10.1016/j.biomaterials.2015.11.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Manning E, 2010, HUM GENE THER, V21, P713, DOI 10.1089/hum.2009.147; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Mastro-Martinez I, 2015, BRAIN INJURY, V29, P1497, DOI 10.3109/02699052.2015.1053525; Metz Gerlinde A, 2009, J Vis Exp, DOI 10.3791/1204; Min CK, 2007, BONE MARROW TRANSPL, V39, P637, DOI 10.1038/sj.bmt.1705644; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nakajima M, 2017, MOL THER-METH CLIN D, V6, P102, DOI 10.1016/j.omtm.2017.06.005; Njoroge JM, 2001, CYTOMETRY, V44, P38, DOI 10.1002/1097-0320(20010501)44:1<38::AID-CYTO1080>3.0.CO;2-T; Peruzzaro ST, 2013, RESTOR NEUROL NEUROS, V31, P431, DOI 10.3233/RNN-120299; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; Quan FS, 2016, EXP THER MED, V12, P1671, DOI 10.3892/etm.2016.3527; Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhang B, 2015, EXP NEUROL, V273, P83, DOI 10.1016/j.expneurol.2015.08.001; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	42	38	38	2	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 5	2019	16								2	10.1186/s12974-018-1383-2			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	HG3WF	WOS:000454905000001	30611291	gold, Green Published			2022-02-06	
J	Alosco, ML; Tripodis, Y; Fritts, NG; Heslegrave, A; Baugh, CM; Conneely, S; Mariani, M; Martin, BM; Frank, S; Mez, J; Stein, TD; Cantu, RC; Mckee, AC; Shaw, LM; Trojanowski, JQ; Blennow, K; Zetterberg, H; Stern, RA				Alosco, Michael L.; Tripodis, Yorghos; Fritts, Nathan G.; Heslegrave, Amanda; Baugh, Christine M.; Conneely, Shannon; Mariani, Megan; Martin, Brett M.; Frank, Samuel; Mez, Jesse; Stein, Thor D.; Cantu, Robert C.; Mckee, Ann C.; Shaw, Leslie M.; Trojanowski, John Q.; Blennow, Kaj; Zetterberg, Henrik; Stern, Robert A.			Cerebrospinal fluid tau, A beta, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration	ALZHEIMERS & DEMENTIA			English	Article						Cerebrospinal fluid; A beta; sTREM2; Chronic traumatic encephalopathy; Microglial activation; Alzheimer's disease; Repetitive head impacts; Concussion; Subconcussive	CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMERS-DISEASE; BRAIN-INJURY; SOLUBLE TREM2; COGNITIVE IMPAIRMENT; POTENTIAL BIOMARKER; MULTIPLE-SCLEROSIS; PHOSPHORYLATED TAU; AMYLOID-BETA; MOUSE MODEL	Introduction: Cerebrospinal fluid (CSF) protein analysis may facilitate detection and elucidate mechanisms of neurological consequences from repetitive head impacts (RHI), such as chronic traumatic encephalopathy. We examined CSF concentrations of total tau (t-tau), phosphorylated tau, and amyloid beta(1-42) and their association with RHI in former National Football League (NFL) players. The role of microglial activation (using sTREM2) was examined as a pathogenic mechanism of chronic traumatic encephalopathy. Methods: Sixty-eight former NFL players and 21 controls underwent lumbar puncture to quantify t-tau, p-tau(181), amyloid beta(1-)(42), and sTREM2 in the CSF using immunoassays. The cumulative head impact index estimated RHI. Results: No between-group differences for CSF analytes emerged. In the former NFL players, the cumulative head impact index predicted higher t-tau concentrations (P = .041), and higher sTREM2 levels were associated with higher t-tau concentrations (P = .009). Discussion: In this sample of former NFL players, greater RHI and increased microglial activation were associated with higher CSF t-tau concentrations. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Alosco, Michael L.; Tripodis, Yorghos; Fritts, Nathan G.; Conneely, Shannon; Mariani, Megan; Martin, Brett M.; Mez, Jesse; Stein, Thor D.; Cantu, Robert C.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Alosco, Michael L.; Tripodis, Yorghos; Fritts, Nathan G.; Conneely, Shannon; Mariani, Megan; Martin, Brett M.; Mez, Jesse; Stein, Thor D.; Cantu, Robert C.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Alosco, Michael L.; Mez, Jesse; Cantu, Robert C.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA; [Heslegrave, Amanda; Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Heslegrave, Amanda; Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Martin, Brett M.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02215 USA; [Frank, Samuel] Harvard Med Sch, Dept Neurol, Boston, MA USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Jamaica Plain, MA USA; [Stein, Thor D.; Mckee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Cantu, Robert C.] Concuss Legacy Fdn, Boston, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA		Stern, RA (corresponding author), Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.	bobstern@bu.edu	Lang, Steven/AAE-8102-2021; , Bob/ABA-8507-2020; Baugh, Christine/AAG-2324-2020	Lang, Steven/0000-0003-1669-9146; Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608; Heslegrave, Amanda/0000-0002-7290-6405	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG13846, R01 NS078337, R56 9500304025, U01 NS093334, U01NS086659-01, 1F32NS096803-01, K23AG046377, RF1AG05416, RF1AG054156-01, P30AG10124]; Department of Veterans AffairsUS Department of Veterans Affairs [I01-CX001038]; National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI [1UL1TR001430]; Royal Swedish Academy of Sciences; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [UKDRI-1003] Funding Source: UKRI; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659, R01NS078337, R56NS078337, K23NS102399, U01NS093334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, P30AG010124, RF1AG054156, K23AG046377] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by grants from the NIH (P30 AG13846; R01 NS078337; R56 9500304025; U01 NS093334, U01NS086659-01; 1F32NS096803-01; K23AG046377; RF1AG05416; RF1AG054156-01; P30AG10124) and Department of Veterans Affairs (I01-CX001038). This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant Number 1UL1TR001430. KB holds the Torsten Soderberg professorship at the Royal Swedish Academy of Sciences. The sTREM2 measurements were supported by the Leonard Wolfson Experimental Neurology Centre at UCL. The content is solely the responsibility of the authors. There is no sponsor.	Alosco Michael L, 2018, Alzheimers Dement (Amst), V10, P56, DOI 10.1016/j.dadm.2017.10.003; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cherry JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185541; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Deters KD, 2017, J ALZHEIMERS DIS, V58, P1245, DOI 10.3233/JAD-161114; Gispert JD, 2016, ALZHEIMERS DEMENT, V12, P1259, DOI 10.1016/j.jalz.2016.06.005; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grossman M, 2014, JAMA NEUROL, V71, P442, DOI 10.1001/jamaneurol.2013.6064; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Hampel H, 2004, ARCH GEN PSYCHIAT, V61, P95, DOI 10.1001/archpsyc.61.1.95; Henjum K, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0182-1; Heslegrave A, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0071-x; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Houck Z, 2018, J INT NEUROPSYCH SOC, V24, P1, DOI 10.1017/S1355617717000716; Hu WT, 2013, NEUROLOGY, V81, P1945, DOI 10.1212/01.wnl.0000436625.63650.27; Intriligator, 1983, HDB ECONOMETRICS, V1, P391, DOI DOI 10.1016/S1573-4412(83)01011-9; Jack CR, 2016, NEUROLOGY, V87, P539, DOI 10.1212/WNL.0000000000002923; Jay TR, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0197-5; Jin SC, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0016-9; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kang JH, 2015, ALZHEIMERS DEMENT, V11, P772, DOI 10.1016/j.jalz.2015.05.003; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lee CYD, 2018, NEURON, V97, P1032, DOI 10.1016/j.neuron.2018.02.002; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Li YK, 2003, J NEUROSCI, V23, P1605; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Metcalfe MJ, 2010, MT SINAI J MED, V77, P50, DOI 10.1002/msj.20163; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ohrfelt A, 2016, MULT SCLER J, V22, P1587, DOI 10.1177/1352458515624558; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/s1474-4422(16)00070-3, 10.1016/S1474-4422(16)00070-3]; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Piccio L, 2008, BRAIN, V131, P3081, DOI 10.1093/brain/awn217; Piccio L, 2016, ACTA NEUROPATHOL, V131, P925, DOI 10.1007/s00401-016-1533-5; Piccio L, 2016, MULT SCLER J, V22, P54; Rosso SM, 2003, ARCH NEUROL-CHICAGO, V60, P1209, DOI 10.1001/archneur.60.9.1209; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Spiegel J, 2016, J ALZHEIMERS DIS, V49, P93, DOI 10.3233/JAD-150167; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Suarez-Calvet M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1767; Suarez-Calvet M, 2016, EMBO MOL MED, V8, P466, DOI 10.15252/emmm.201506123; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Teunissen CE, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0359-x; Udeochu J, 2018, NEURON, V97, P991, DOI 10.1016/j.neuron.2018.02.018; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhao Y., 2018, NEURON, V97	68	38	38	3	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	SEP	2018	14	9					1159	1170		10.1016/j.jalz.2018.05.004			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GS9AZ	WOS:000444008800007	30049650	Green Accepted			2022-02-06	
J	Kuo, C; Wu, L; Loza, J; Senif, D; Anderson, SC; Camarillo, DB				Kuo, Calvin; Wu, Lyndia; Loza, Jesus; Senif, Daniel; Anderson, Scott C.; Camarillo, David B.			Comparison of video-based and sensor-based head impact exposure	PLOS ONE			English	Article							SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; IN-VIVO; MOUTHGUARD; MANAGEMENT; KINEMATICS; DEVICE; SYSTEM	Previous research has sought to quantify head impact exposure using wearable kinematic sensors. However, many sensors suffer from poor accuracy in estimating impact kinematics and count, motivating the need for additional independent impact exposure quantification for comparison. Here, we equipped seven collegiate American football players with instrumented mouthguards, and video recorded practices and games to compare video-based and sensor-based exposure rates and impact location distributions. Over 50 player-hours, we identified 271 helmet contact periods in video, while the instrumented mouthguard sensor recorded 2,032 discrete head impacts. Matching video and mouthguard real-time stamps yielded 193 video-identified helmet contact periods and 217 sensor-recorded impacts. To compare impact locations, we binned matched impacts into frontal, rear, side, oblique, and top locations based on video observations and sensor kinematics. While both video-based and sensor-based methods found similar location distributions, our best method utilizing integrated linear and angular position only correctly predicted 81 of 217 impacts. Finally, based on the activity timeline from video assessment, we also developed a new exposure metric unique to American football quantifying number of cross-verified sensor impacts per player-play. We found significantly higher exposure during games (0.35, 95% CI: 0.29 - 0.42) than practices (0.20, 95% CI: 0.17 - 0.23) (p<0.05). In the traditional impacts per player-hour metric, we observed higher exposure during practices (4.7) than games (3.7) due to increased player activity in practices. Thus, our exposure metric accounts for variability in on-field participation. While both video-based and sensor-based exposure datasets have limitations, they can complement one another to provide more confidence in exposure statistics.	[Kuo, Calvin; Loza, Jesus; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Wu, Lyndia; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Senif, Daniel; Anderson, Scott C.] Stanford Univ, Stanford Sports Med, Stanford, CA 94305 USA		Kuo, C (corresponding author), Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA.	calvink@stanford.edu	Wu, Lyndia/AAQ-1106-2020; Kuo, Calvin/AAH-1933-2019	Wu, Lyndia/0000-0002-8236-032X; Kuo, Calvin/0000-0001-8401-9136	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; Stanford Child Health Research Institute Transdisciplinary Initiatives Program; Stanford Bio-X Graduate Research Fellowship Program	This study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, the Stanford Child Health Research Institute Transdisciplinary Initiatives Program, and the Stanford Bio-X Graduate Research Fellowship Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barris S, 2008, SPORTS MED, V38, P1025, DOI 10.2165/00007256-200838120-00006; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Group BD and TCW, 2018, TRAUM BRAIN INJ COMM; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Kindschi K, 2015, CLIN J SPORT MED, V25, P201; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Kuo C, 2016, J BIOMECH; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Li BX, 2001, IEEE WORKSHOP ON CONTENT-BASED ACCESS OF IMAGE AND VIDEO LIBRARIES, PROCEEDINGS, P132, DOI 10.1109/IVL.2001.990867; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2014, AM SOC TEST MATER, V1552, P41, DOI 10.1520/STP155220120108; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; SAE (Society of Automotive Engineers), 1995, J2111 SAE; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wu LC, 2018, SCI REP, V8, P1, DOI [10.1038/s41598-017-17765-5, DOI 10.1038/S41598-017-17765-5]; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; Xing JL, 2011, IEEE T IMAGE PROCESS, V20, P1652, DOI 10.1109/TIP.2010.2102045	44	38	38	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2018	13	6							e0199238	10.1371/journal.pone.0199238			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ7CA	WOS:000435541300028	29920559	Green Published, gold, Green Submitted			2022-02-06	
J	Boris, JR; Bernadzikowski, T				Boris, Jeffrey R.; Bernadzikowski, Thomas			Demographics of a large paediatric Postural Orthostatic Tachycardia Syndrome Program	CARDIOLOGY IN THE YOUNG			English	Article						Ehlers-Danlos; joint hypermobility; concussion; dysautonomia; autoimmune	JOINT HYPERMOBILITY; MANAGEMENT	Objective: The aim of this study was to identify and evaluate demographic and clinical features of paediatric patients with postural orthostatic tachycardia syndrome in a tertiary hospital speciality clinic. Method: This is a retrospective review of clinical data obtained during initial outpatient evaluation. Results: A total of 708 patients met the evaluation criteria. Female patients outnumbered males, 3.45:1. Caucasians were over-represented at 94.1% of patients. Median age at diagnosis was 15.7 years. Joint hypermobility occurred in 57.3% of patients; 22.4% had hypermobile Ehlers-Danlos syndrome; and 34.9% had hypermobility spectrum disorder. Median age of onset of symptoms was 12.6 years in patients with hypermobility versus 13.7 years in those without (p = 0.0001). Median duration of symptoms was 3.3 years with hypermobility versus 1.5 years without (p < 0.00001). Putative triggers included infection in 23.6% of patients, concussion in 11.4%, and surgery/trauma in 2.8%. Concurrent inflammatory disorders were noted in 5.2% of patients. Six symptoms comprised 80% of initial patient complaints. Overall, 66% of patients subsequently had at least 10 symptoms, 50% had at least 14 symptoms, and 30% reported at least 26 symptoms. Symptoms were largely cardiovascular, gastrointestinal, and neurological. Paediatric patients with postural orthostatic tachycardia syndrome seen in a large speciality clinic are predominantly female, are mostly Caucasian, have onset of symptoms in early adolescence, and have symptoms for over two years before diagnosis. Over half of patients have joint hypermobility. More than one-third of patients have a possible autoimmune or inflammatory trigger, including infection, concussion, or surgery/trauma. Patients experience symptoms that are highly variable and multi-system in origin over the course of illness.	[Boris, Jeffrey R.; Bernadzikowski, Thomas] Childrens Hosp Philadelphia, Div Cardiol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Boris, Jeffrey R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA		Boris, JR (corresponding author), Childrens Hosp Philadelphia, Div Cardiol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	borisj@email.chop.edu	Boris, Jeffrey/AAC-9942-2021; Boris, Jeffrey/L-5204-2019	Boris, Jeffrey/0000-0002-0428-7681	Division of Cardiology at the Children's Hospital of Philadelphia; Dysautonomia International	Students received financial support for their database work from the Division of Cardiology at the Children's Hospital of Philadelphia and from Dysautonomia International.	Burkhardt BEU, 2011, J PEDIATR-US, V158, P28, DOI 10.1016/j.jpeds.2010.07.020; Castori M, 2017, AM J MED GENET C, V175, P148, DOI 10.1002/ajmg.c.31539; Dida BC, 2002, E AFR MED J, V79, P80; Dysautonomia International, 2012, FIND DOCT EXP AUT DI; Fedorowski A, 2017, EUROPACE, V19, P1211, DOI 10.1093/europace/euw154; Friedman AW, 2003, LUPUS, V12, P274, DOI 10.1191/0961203303lu330oa; Gazit Y, 2003, AM J MED, V115, P33, DOI 10.1016/S0002-9343(03)00235-3; George SA, 2016, HEART RHYTHM, V13, P943, DOI 10.1016/j.hrthm.2015.12.012; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Henderson FC, 2017, AM J MED GENET C, V175, P195, DOI 10.1002/ajmg.c.31549; Hoeldtke RD, 2006, CLIN AUTON RES, V16, P390, DOI 10.1007/s10286-006-0373-0; Kanjwal K, 2011, CARDIOL J, V18, P527, DOI 10.5603/CJ.2011.0008; Kanjwal Khalil, 2010, Indian Pacing Electrophysiol J, V10, P173; Kovacic K, 2014, J PEDIATR-US, V164, P1104, DOI 10.1016/j.jpeds.2014.01.046; Li JW, 2014, CHINESE MED J-PEKING, V127, P3684, DOI 10.3760/cma.j.issn.0366-6999.20140244; Mar PL, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00220; Medes J., 1871, AM J MED SCI, P18; O'Sullivan BP, 2009, LANCET, V373, P1891, DOI 10.1016/S0140-6736(09)60327-5; Pianosi PT, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12122; Plash WB, 2013, CLIN SCI, V124, P109, DOI 10.1042/CS20120276; Raj Satish R, 2006, Indian Pacing Electrophysiol J, V6, P84; Raj SR, 2005, CIRCULATION, V111, P2734, DOI 10.1161/CIRCULATIONAHA.104.497594; Robertson D, 1999, AM J MED SCI, V317, P75, DOI 10.1097/00000441-199902000-00001; Rowe PC, 1999, J PEDIATR-US, V135, P494, DOI 10.1016/S0022-3476(99)70173-3; SCHONDORF R, 1993, CLIN AUTONOMIC DISOR, P641; Sheldon RS, 2015, HEART RHYTHM, V12, pE41, DOI 10.1016/j.hrthm.2015.03.029; Venkatesan T, 2014, EXP BRAIN RES, V232, P2563, DOI 10.1007/s00221-014-3967-0; Vernino S, 2000, NEW ENGL J MED, V343, P847, DOI 10.1056/NEJM200009213431204; Wallace DC, 2015, CELL, V163, P33, DOI 10.1016/j.cell.2015.08.067	29	38	38	1	6	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1047-9511	1467-1107		CARDIOL YOUNG	Cardiol. Young	MAY	2018	28	5					668	674		10.1017/S1047951117002888			7	Cardiac & Cardiovascular Systems; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Pediatrics	GH6GN	WOS:000433542200007	29357955				2022-02-06	
J	Patricios, JS; Ardern, CL; Hislop, MD; Aubry, M; Bloomfield, P; Broderick, C; Clifton, P; Echemendia, RJ; Ellenbogen, RG; Falvey, EC; Fuller, GW; Grand, J; Hack, D; Harcourt, PR; Hughes, D; McGuirk, N; Meeuwisse, W; Miller, J; Parsons, JT; Richiger, S; Sills, A; Moran, KB; Shute, J; Raftery, M				Patricios, Jon S.; Ardern, Clare L.; Hislop, Michael David; Aubry, Mark; Bloomfield, Paul; Broderick, Carolyn; Clifton, Patrick; Echemendia, Ruben J.; Ellenbogen, Richard G.; Falvey, Eanna Cian; Fuller, Gordon Ward; Grand, Julie; Hack, Dallas; Harcourt, Peter Rex; Hughes, David; McGuirk, Nathan; Meeuwisse, Willem; Miller, Jeffrey; Parsons, John T.; Richiger, Simona; Sills, Allen; Moran, Kevin B.; Shute, Jenny; Raftery, Martin			Implementation of the 2017 Berlin Concussion in Sport Group Consensus Statement in contact and collision sports: a joint position statement from 11 national and international sports organisations	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article								The 2017 Berlin Concussion in Sport Group Consensus Statement provides a global summary of best practice in concussion prevention, diagnosis and management, underpinned by systematic reviews and expert consensus. Due to their different settings and rules, individual sports need to adapt concussion guidelines according to their specific regulatory environment. At the same time, consistent application of the Berlin Consensus Statement's themes across sporting codes is likely to facilitate superior and uniform diagnosis and management, improve concussion education and highlight collaborative research opportunities. This document summarises the approaches discussed by medical representatives from the governing bodies of 10 different contact and collision sports in Dublin, Ireland in July 2017. Those sports are: American football, Australian football, basketball, cricket, equestrian sports, football/soccer, ice hockey, rugby league, rugby union and skiing. This document had been endorsed by 11 sport governing bodies/national federations at the time of being published.	[Patricios, Jon S.] Univ Pretoria, Sect Sports Med, Fac Hlth Sci, Johannesburg, South Africa; [Patricios, Jon S.] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Ardern, Clare L.] Linkoping Univ, Dept Physiotherapy, Linkoping, Sweden; [Ardern, Clare L.] La Trobe Univ, Sch Allied Hlth, Melbourne, Vic, Australia; [Hislop, Michael David; Raftery, Martin] World Rugby, Dublin, Ireland; [Aubry, Mark; Richiger, Simona] Int Ice Hockey Federat, Zurich, Switzerland; [Bloomfield, Paul; Broderick, Carolyn; McGuirk, Nathan] Natl Rugby League, Sydney, NSW, Australia; [Clifton, Patrick; Harcourt, Peter Rex; Hughes, David] Australian Football League, Melbourne, Vic, Australia; [Clifton, Patrick; Hughes, David] Australian Inst Sport, Canberra, ACT, Australia; [Echemendia, Ruben J.; Grand, Julie; Meeuwisse, Willem] Natl Hockey League, New York, NY USA; [Echemendia, Ruben J.] Univ Orthoped Ctr, Concuss Care Clin, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Ellenbogen, Richard G.; Miller, Jeffrey; Sills, Allen] Natl Football League, New York, NY USA; [Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Falvey, Eanna Cian] Irish Rugby Football Union, Dublin, Ireland; [Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Ctr Urgent & Emergency Care Res, Sheffield, S Yorkshire, England; [Hack, Dallas; Parsons, John T.] Natl Coll Athlet Assoc, Indianapolis, IN USA; [Sills, Allen] Federat Equestre Int, Lausanne, Switzerland; [Moran, Kevin B.] Gael Athlet Assoc, Dublin, Ireland; [Shute, Jenny] Federat Int Ski, Oberhofen, Switzerland; [Shute, Jenny] Federat Int Ski, Thunersee, Switzerland		Patricios, JS (corresponding author), Univ Pretoria, Fac Hlth Sci, Sect Sports Med, ZA-2121 Pretoria, South Africa.	jpat@mweb.co.za	Hislop, Michael David/I-2339-2019; Echemendia, Ruben/R-6939-2019	Broderick, Carolyn/0000-0003-0096-796X; Hughes, David/0000-0002-4194-2147; Fuller, Gordon Ward/0000-0001-8532-3500	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bruce JM, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2016-097091; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Echemendia RJ, 2017, BRIT J SPORT MED, V51; Echemendia RJ., 2017, BR J SPORTS MED; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P870, DOI 10.1136/bjsports-2017-097508; Emery CA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097452; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2016, BRIT J SPORT MED, V2017, P838, DOI DOI 10.1136/BJSP0RTS-2017-097699; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; Patricios J, 2017, BRIT J SPORT MED, V51; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475	22	38	38	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2018	52	10					635	641		10.1136/bjsports-2018-099079			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	GE7FP	WOS:000431399000011	29500252	hybrid, Green Published, Green Accepted			2022-02-06	
J	Scharfen, J; Peters, JM; Holling, H				Scharfen, Jana; Peters, Judith Marie; Holling, Heinz			Retest effects in cognitive ability tests: A meta-analysis	INTELLIGENCE			English	Article						Meta-analysis; Cognitive ability; Intelligence; Retest effect	MILLER ANALOGIES TEST; LONG-TERM RETENTION; WORKING-MEMORY; OLDER-ADULTS; EFFECT SIZE; CONCUSSION ASSESSMENT; SPATIAL ORIENTATION; SELECTION SETTINGS; STRUCTURAL-CHANGES; INHIBITORY CONTROL	Retest effects are referred to as the increase in test scores due to the repeated administration of cognitive ability tests. This meta-analysis attempts to update and extend previous meta-analyses by examining the size of retest effects and its determinants in a high number of cognitive ability tests for up to four test administrations. Strict inclusion and exclusion criteria were applied regarding study design, participant age and health status, and cognitive ability tests. An extensive literature search detected 174 samples from 122 studies, which resulted in 786 test outcomes and an overall sample size of 153,185. A comprehensive longitudinal multilevel meta-analysis revealed significant retest effects and no further score gains after the third test administration. Moderator analyses for multiple retests indicated that cognitive ability operation and content, equivalence of test forms, retest interval and participant age have a significant influence on the size of the retest effect. Implications for future research and retesting practice are discussed.	[Scharfen, Jana; Peters, Judith Marie; Holling, Heinz] Westfalische Wilhelms Univ Munster, Inst Psychol, Fliednerstr 21, D-48149 Munster, Germany		Scharfen, J (corresponding author), Westfalische Wilhelms Univ Munster, Inst Psychol, Fliednerstr 21, D-48149 Munster, Germany.	jana.scharfen@uni-muenster.de; holling@uni-muenster.de	; Holling, Heinz/K-3728-2017	Scharfen, Jana/0000-0003-1285-6319; Holling, Heinz/0000-0002-0311-3970	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [HO 1286/6-4]	This work was supported by the Deutsche Forschungsgemeinschaft [HO 1286/6-4].	ACKERMAN PL, 1987, PSYCHOL BULL, V102, P3, DOI 10.1037/0033-2909.102.1.3; Albers F, 2009, DIAGNOSTICA, V55, P71, DOI 10.1026/0012-1924.55.2.71; Allalouf A, 1998, J EDUC MEAS, V35, P31, DOI 10.1111/j.1745-3984.1998.tb00526.x; ANASTASI A, 1981, AM PSYCHOL, V36, P1086, DOI 10.1037/0003-066X.36.10.1086; Arendasy ME, 2017, INTELLIGENCE, V62, P89, DOI 10.1016/j.intell.2017.03.003; Arendasy ME, 2013, INTELLIGENCE, V41, P181, DOI 10.1016/j.intell.2013.02.004; Arthur W, 2010, INT J SELECT ASSESS, V18, P1, DOI 10.1111/j.1468-2389.2010.00476.x; Au J, 2015, PSYCHON B REV, V22, P366, DOI 10.3758/s13423-014-0699-x; BADDELEY AD, 1968, PSYCHON SCI, V10, P341; Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19; Bartels C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-118; BECKER BJ, 1990, REV EDUC RES, V60, P373, DOI 10.2307/1170759; BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bennett GK, 1990, DIFFERENTIAL APTITUD; Benton A., 1976, MULTILINGUAL APHASIA; BORS DA, 1993, CAN J EXP PSYCHOL, V47, P763, DOI 10.1037/h0084956; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; Broglio SP, 2007, J ATHL TRAINING, V42, P509; BRYK AS, 1988, AM J EDUC, V97, P65, DOI 10.1086/443913; Buehner M, 2005, INTELLIGENCE, V33, P251, DOI 10.1016/j.intell.2005.01.002; Buschkuhl M, 2007, THESIS; Calamia M, 2013, CLIN NEUROPSYCHOL, V27, P1077, DOI 10.1080/13854046.2013.809795; Calamia M, 2012, CLIN NEUROPSYCHOL, V26, P543, DOI 10.1080/13854046.2012.680913; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; Carroll J.B., 1993, HUMAN COGNITIVE ABIL, DOI DOI 10.1017/CBO9780511571312; Cattell R. B., 1987, INTELLIGENCE ITS STR; Childers TL, 2000, J BUS RES, V47, P109, DOI 10.1016/S0148-2963(98)00055-1; Colom R, 2012, INTELLIGENCE, V40, P479, DOI 10.1016/j.intell.2012.05.004; Cook TD., 1979, QUASIEXPERIMENTATION; COOPER H. M., 2009, HDB RES SYNTHESIS ME, V2nd; Cooper HM, 2017, RES SYNTHESIS METAAN; Cowan N, 2005, COGNITIVE PSYCHOL, V51, P42, DOI 10.1016/j.cogpsych.2004.12.001; Coyle TR, 2006, INTELLIGENCE, V34, P15, DOI 10.1016/j.intell.2005.04.001; Crone EA, 2009, DEVELOPMENTAL SCI, V12, P55, DOI 10.1111/j.1467-7687.2008.00743.x; Dahlin E, 2008, PSYCHOL AGING, V23, P720, DOI 10.1037/a0014296; de Oliveira RS, 2014, EINSTEIN-SAO PAULO, V12, P149, DOI 10.1590/S1679-45082014AO2954; DERSIMONIAN R, 1983, HARVARD EDUC REV, V53, P1; Do B.-R., 2011, THESIS; Donner Y, 2015, PSYCHON B REV, V22, P1308, DOI 10.3758/s13423-015-0811-x; Dunlop PD, 2011, INT J SELECT ASSESS, V19, P217, DOI 10.1111/j.1468-2389.2011.00549.x; Ekstrom RB., 1976, MANUAL KIT FACTOR RE; Enge S, 2014, J EXP PSYCHOL LEARN, V40, P987, DOI 10.1037/a0036165; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; Flanagan J. C., 1962, DESIGN STUDY AM YOUT; French J. W., 1963, KIF REFERENCE TESTS; Freund PA, 2011, INTELLIGENCE, V39, P233, DOI 10.1016/j.intell.2011.02.009; GIBBONS RD, 1993, J EDUC STAT, V18, P271, DOI 10.3102/10769986018003271; Gil-Gouveia R., 2015, ACTA NEUROLOGICA SCA; Grissom N, 2009, NEUROBIOL LEARN MEM, V92, P215, DOI 10.1016/j.nlm.2008.07.001; Guthke J., 2001, PERSPEKTIVEN INTELLI; Halford GS, 2007, TRENDS COGN SCI, V11, P236, DOI 10.1016/j.tics.2007.04.001; Hasegawa H, 1997, JPN J PSYCHOL, V68, P417, DOI 10.4992/jjpsy.68.417; Hausknecht JP, 2007, J APPL PSYCHOL, V92, P373, DOI 10.1037/0021-9010.92.2.373; Hausknecht JP, 2002, J APPL PSYCHOL, V87, P243, DOI 10.1037//0021-9010.87.2.243; Hayes TR, 2015, INTELLIGENCE, V48, P1, DOI 10.1016/j.intell.2014.10.005; Hedges LV, 2010, RES SYNTH METHODS, V1, P39, DOI 10.1002/jrsm.5; HOLLAND BS, 1988, PSYCHOL BULL, V104, P145, DOI 10.1037/0033-2909.104.1.145; HOLLING H, 2004, INTELLIGENZDIAGNOSTI; HOLM S, 1979, SCAND J STAT, V6, P65; HUBER O, 1980, ACTA PSYCHOL, V45, P187, DOI 10.1016/0001-6918(80)90031-1; Hulsheger UR, 2007, INT J SELECT ASSESS, V15, P3, DOI 10.1111/j.1468-2389.2007.00363.x; Hunter J.E., 2004, METHODS META ANAL CO, V2nd ed.; Ishak KJ, 2007, CLIN TRIALS, V4, P525, DOI 10.1177/1740774507083567; Iuliano E, 2015, EXP GERONTOL, V70, P105, DOI 10.1016/j.exger.2015.07.008; Jaber MY, 2013, COMPUT IND ENG, V64, P866, DOI 10.1016/j.cie.2012.12.005; Jager A, 1982, DIAGNOSTICA, V28, P195; Karch D, 2013, DTSCH ARZTEBL INT, V110, P643, DOI 10.3238/arztebl.2013.0643; Kelly ME, 2014, AGEING RES REV, V15, P28, DOI 10.1016/j.arr.2014.02.004; Klauer KJ, 2008, REV EDUC RES, V78, P85, DOI 10.3102/0034654307313402; Klauer KJ, 2014, Z PADAGOG PSYCHOL, V28, P5, DOI 10.1024/1010-0652/a000123; Konstantopoulos S., 2011, RES SYNTH METHODS, V17, P279; Kozhevnikov M, 2001, MEM COGNITION, V29, P745, DOI 10.3758/BF03200477; KUBINGER KD, 2003, SCHLUSSELBEGRIFFE PS; KULIK JA, 1984, AM EDUC RES J, V21, P435, DOI 10.2307/1162453; KYLLONEN PC, 1990, INTELLIGENCE, V14, P389, DOI 10.1016/S0160-2896(05)80012-1; LADER MH, 1964, J NEUROL NEUROSUR PS, V27, P210, DOI 10.1136/jnnp.27.3.210; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; LANE RG, 1966, J APPL PSYCHOL, V50, P409, DOI 10.1037/h0023817; Langenecker SA, 2007, J CLIN EXP NEUROPSYC, V29, P842, DOI 10.1080/13803390601147611; Lievens F, 2005, PERS PSYCHOL, V58, P981, DOI 10.1111/j.1744-6570.2005.00713.x; Lievens F, 2007, J APPL PSYCHOL, V92, P1672, DOI 10.1037/0021-9010.92.6.1672; Lo AHY, 2012, J NEUROPSYCHOL, V6, P212, DOI 10.1111/j.1748-6653.2011.02023.x; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Lyall S. M., 2016, PLOS ONE, V11; Maerlender AC, 2016, J CLIN EXP NEUROPSYC, V38, P869, DOI 10.1080/13803395.2016.1168781; Matton N, 2009, INTELLIGENCE, V37, P412, DOI 10.1016/j.intell.2009.03.011; Mehlsen M, 2009, PSYCHO-ONCOL, V18, P248, DOI 10.1002/pon.1398; Meneghetti C, 2016, PSYCHOL RES-PSYCH FO, V80, P113, DOI 10.1007/s00426-014-0644-7; MESSICK S, 1981, PSYCHOL BULL, V89, P191, DOI 10.1037/0033-2909.89.2.191; MILLMAN J, 1965, EDUC PSYCHOL MEAS, V25, P707, DOI 10.1177/001316446502500304; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Musekiwa A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164898; NEVO B, 1976, MEAS EVAL GUID, V9, P16, DOI 10.1080/00256307.1976.12022706; Newell A., 1981, COGN SKILLS ACQUISIT, V1, P1; Ng E, 2015, LEARN INDIVID DIFFER, V40, P141, DOI 10.1016/j.lindif.2015.04.007; Nguyen HT, 2015, J OCCUP ENVIRON MED, V57, P676, DOI 10.1097/JOM.0000000000000424; Nijenhuis J., 2007, INTELLIGENCE, V35, P238; Oelhafen S, 2013, NEUROPSYCHOLOGIA, V51, P2781, DOI 10.1016/j.neuropsychologia.2013.08.012; Olenick J, 2016, INT J SELECT ASSESS, V24, P324, DOI 10.1111/ijsa.12151; Ones DenizS., 2005, BLACKWELL HDB PERSON, P331; Pereira DR, 2015, ARCH CLIN NEUROPSYCH, V30, P424, DOI 10.1093/arclin/acv028; PETERS M, 1995, BRAIN COGNITION, V28, P39, DOI 10.1006/brcg.1995.1032; Powers KL, 2013, PSYCHON B REV, V20, P1055, DOI 10.3758/s13423-013-0418-z; Puddey IB, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-48; R Core Team, 2018, R LANGUAGE ENV STAT; Randall JG, 2017, HUM RESOUR MANAGE R, V27, P536, DOI 10.1016/j.hrmr.2016.10.002; Randall JG, 2016, J PERS PSYCHOL, V15, P45, DOI 10.1027/1866-5888/a000149; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Raven J, 1962, COLOURED PROGR MATRI; Raven J. C, 1936, STANDARD PROGR MATRI; Raven J. C., 1962, ADV PROGR MATRICES S; Reeve CL, 2009, INTELLIGENCE, V37, P34, DOI 10.1016/j.intell.2008.05.003; Reeve CL, 2005, INTELLIGENCE, V33, P535, DOI 10.1016/j.intell.2005.05.003; Robinson SJ, 2013, AVIAT SPACE ENVIR MD, V84, P592, DOI 10.3357/ASEM.3391.2013; Roediger HL, 2011, TRENDS COGN SCI, V15, P20, DOI 10.1016/j.tics.2010.09.003; Roediger HL, 2006, PSYCHOL SCI, V17, P249, DOI 10.1111/j.1467-9280.2006.01693.x; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Salminen T, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00166; Salthouse TA, 2004, DEV PSYCHOL, V40, P813, DOI 10.1037/0012-1649.40.5.813; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Salthouse TA, 2008, NEUROPSYCHOLOGY, V22, P800, DOI 10.1037/a0013091; Sandberg P, 2014, AGING NEUROPSYCHOL C, V21, P577, DOI 10.1080/13825585.2013.839777; SARASON IG, 1960, J EXP PSYCHOL, V59, P185, DOI 10.1037/h0047062; Schellig D., 1997, BLOCK TAPPING TEST; Schleicher DJ, 2010, J APPL PSYCHOL, V95, P603, DOI 10.1037/a0018920; SCHUERGER JM, 1989, J CLIN PSYCHOL, V45, P294, DOI 10.1002/1097-4679(198903)45:2<294::AID-JCLP2270450218>3.0.CO;2-N; Scott G, 2004, CREATIVITY RES J, V16, P361, DOI 10.1207/s15326934crj1604_1; Shaffer D. D. R., 2010, DEV PSYCHOL CHILDHOO; Sharma VK, 2014, J CLIN DIAGN RES, V8, P10, DOI [10.7860/JCDR/2014/7256.3668, 10.7660/JCDP/201477256.3668]; SHEPARD RN, 1976, SCIENCE, V191, P952, DOI 10.1126/science.1251207; Soveri A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081693; SPIELBERGER CD, 1959, J APPL PSYCHOL, V43, P259, DOI 10.1037/h0042419; Sun JZ, 2016, HUM BRAIN MAPP, V37, P3375, DOI 10.1002/hbm.23246; Suss HM, 2002, INTELLIGENCE, V30, P261, DOI 10.1016/S0160-2896(01)00100-3; Thurstone L. L., 1959, TEST ADM MANUAL SPAC; Thurstone L.L., 1938, PRIMARY MENTAL ABILI; Thurstone T. G., 1958, MANUAL SRA PRIMARY M; Thurstone T. G., 1963, PRIMARY MENTAL ABILI; Toril P, 2014, PSYCHOL AGING, V29, P706, DOI 10.1037/a0037507; Trikalinos TA, 2012, CLIN TRIALS, V9, P610, DOI 10.1177/1740774512453218; Uttal DH, 2013, PSYCHOL BULL, V139, P352, DOI 10.1037/a0028446; van Eersel M. E. A., 2015, PLOS ONE, V10, P1; Van Iddekinge CH, 2011, J APPL PSYCHOL, V96, P941, DOI 10.1037/a0023562; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; VENKATESAN M, 1986, J PUBLIC POLICY MARK, V5, P29, DOI 10.1177/074391568600500102; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Villado AJ, 2016, J BUS PSYCHOL, V31, P233, DOI 10.1007/s10869-015-9408-7; Wang P, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00720; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1958, MEASUREMENT APPRAISA; Woehlke A. B., 1963, PERS PSYCHOL, P198; Zachary R. A., 1986, SHIPLEY I LIVING SCA; Zehnder F, 2009, RESTOR NEUROL NEUROS, V27, P507, DOI 10.3233/RNN-2009-0491	157	38	38	4	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0160-2896	1873-7935		INTELLIGENCE	Intelligence	MAR-APR	2018	67						44	66		10.1016/j.intell.2018.01.003			23	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	FY1AM	WOS:000426544000006					2022-02-06	
J	Levitch, CF; Zimmerman, ME; Lubin, N; Kim, N; Lipton, RB; Stewart, WF; Kim, M; Lipton, ML				Levitch, Cara F.; Zimmerman, Molly E.; Lubin, Naomi; Kim, Namhee; Lipton, Richard B.; Stewart, Walter F.; Kim, Mimi; Lipton, Michael L.			Recent and Long-Term Soccer Heading Exposure Is Differentially Associated With Neuropsychological Function in Amateur Players	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injury; Sport; Cognitive impairment; Soccer; Heading; Repetitive head trauma	TRAUMATIC BRAIN-INJURY; FOOTBALL SOCCER; COGNITIVE IMPAIRMENT; CONSEQUENCE; CONCUSSIONS; FREQUENCY; SPORTS; IMPACT	Objectives: The present study examined the relative contribution of recent or long-term heading to neuropsychological function in amateur adult soccer players. Participants and Methods: Soccer players completed a baseline questionnaire (HeadCount-12m) to ascertain heading during the prior 12 months (long-term heading, LTH) and an online questionnaire (HeadCount-2w) every 3 months to ascertain heading during the prior 2 weeks (recent heading, RH). Cogstate, a battery of six neuropsychological tests, was administered to assess neuropsychological function. Generalized estimating equations were used to test if LTH or RH was associated with neuropsychological function while accounting for the role of recognized concussion. Results: A total of 311 soccer players completed 630 HeadCount-2w. Participants had an average age of 26 years. Participants headed the ball a median of 611 times/year (mean = 1,384.03) and 9.50 times/2 weeks (mean = 34.17). High levels of RH were significantly associated with reduced performance on a task of psychomotor speed (p = .02), while high levels of LTH were significantly associated with poorer performance on tasks of verbal learning (p = .03) and verbal memory (p = .04). Significantly better attention (p = .02) was detectable at moderately high levels of RH, but not at the highest level of RH. One hundred and seven (34.4%) participants reported a lifetime history of concussion, but this was not related to neuropsychological function and did not modify the association of RH or LTH with neuropsychological function. Conclusion: High levels of both RH and LTH were associated with poorer neuropsychological function, but on different domains. The clinical manifestations following repetitive exposure to heading could change with chronicity of exposure.	[Levitch, Cara F.; Zimmerman, Molly E.] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA; [Zimmerman, Molly E.; Lubin, Naomi; Kim, Namhee; Lipton, Richard B.; Kim, Mimi; Lipton, Michael L.] Albert Einstein Coll Med, Bronx, NY 10461 USA; [Zimmerman, Molly E.; Lubin, Naomi; Kim, Namhee; Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, 111 E 210th St, Bronx, NY 10467 USA; [Lubin, Naomi; Kim, Namhee; Lipton, Michael L.] Montefiore Med Ctr, Gruss Magnet Resonance Res Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Lipton, Richard B.] Montefiore Med Ctr, Dept Neurol, 111 E 210th St, Bronx, NY 10467 USA; [Lipton, Richard B.; Kim, Mimi] Montefiore Med Ctr, Dept Epidemiol & Populat Hlth, 111 E 210th St, Bronx, NY 10467 USA; [Stewart, Walter F.] Sutter Hlth Res, Walnut Creek, CA USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Psychiat & Behav Sci, 111 E 210th St, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Lipton, Michael L.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA		Lipton, ML (corresponding author), Albert Einstein Coll Med, MRRC, 1300 Morris Pk Ave,Room 219C, Bronx, NY 10461 USA.	Michael.lipton@einstein.yu.edu	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082432]; Dana Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grant R01NS082432; Principal Investigator: M.L.L) and The Dana Foundation. The authors report no disclosures relevant to the manuscript.	Adams J, 2007, CLIN J SPORT MED, V17, P304, DOI 10.1097/JSM.0b013e31803202c8; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Catenaccio E, 2016, RES SPORTS MED, V24, P416, DOI 10.1080/15438627.2016.1234472; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Davidson PSR, 2006, J INT NEUROPSYCH SOC, V12, P210, DOI 10.1017/S1355617706060334; Di Virgilio TG, 2016, EBIOMEDICINE, V13, P66, DOI 10.1016/j.ebiom.2016.10.029; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; FIFA, 2007, FIFA BIG COUNT 2006 FIFA BIG COUNT 2006; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hardin J.W., 2005, GEN ESTIMATING EQUAT; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lingsma H, 2017, NEUROLOGY, V88, P822, DOI 10.1212/WNL.0000000000003679; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Orme DR, 2004, REHABIL PSYCHOL, V49, P250, DOI 10.1037/0090-5550.49.3.250; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Rodrigues AC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00038; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Stewart WF, 2017, NEUROLOGY, V88, P901, DOI 10.1212/WNL.0000000000003657; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	40	38	38	1	17	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	FEB	2018	24	2					147	155		10.1017/S1355617717000790			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	FT3XL	WOS:000423081900004	28829004	Green Accepted			2022-02-06	
J	Theadom, A; Starkey, N; Barker-Collo, S; Jones, K; Ameratunga, S; Feigin, V				Theadom, Alice; Starkey, Nicola; Barker-Collo, Suzanne; Jones, Kelly; Ameratunga, Shanthi; Feigin, Valery		BIONIC4you Res Grp	Population-based cohort study of the impacts of mild traumatic brain injury in adults four years post-injury	PLOS ONE			English	Article							POST-CONCUSSION SYMPTOMS; HEAD-INJURY; HOSPITAL ANXIETY; NEW-ZEALAND; PARTICIPATION; MODERATE; QUESTIONNAIRE; PREDICTORS; DEPRESSION; VALIDITY	There is increasing evidence that some people can experience persistent symptoms for up to a year following mild TBI. However, few longitudinal studies of mild TBI exist and the longer-term impact remains unclear. The purpose of this study is to determine if there are long-term effects of mild traumatic brain injury (TBI) four-years later. Adults (aged >= 16 years) identified as part of a TBI incidence study who experienced a mild-TBI four-years ago (N = 232) were compared to age-sex matched controls (N = 232). Sociodemographic variables, prior TBI and symptoms were assessed at the time of injury. Four years post-injury participants completed the Rivermead Post-Concussion Symptom Questionnaire, Hospital Anxiety and Depression Scale, Pittsburgh Sleep Quality Index and the Participation Assessment with Recombined Tools. Analysis of covariance was used to compare differences between TBI cases four years post-injury and controls, controlling for prior TBI and depression. A multiple regression model was used to identify the predictors of increased symptoms and reduced participation. The mild-TBI sample experienced significantly increased self-reported cognitive symptoms (F = 19.90, p = < 0.01) four years post-injury than controls. There were no differences between the groups for somatic (F = 0.02, p = 0.89) or emotional symptoms (F = 0.31, p = 0.58). Additionally, the mild-TBI group reported significantly poorer community participation across all three domains: productivity (F = 199.07, p = < 0.00), social relations (F = 13.93, p = < 0.00) and getting out and about (F = 364.69, p = < 0.00) compared to controls. A regression model accounting for 41% of the variance in cognitive symptoms in TBI cases revealed a history of TBI, receiving acute medical attention and baseline cognitive symptoms, sleep quality, anxiety and depression were predictive of outcome. The results indicate that whilst somatic and emotional symptoms resolve over time, cognitive symptoms can become persistent and that mild TBI can impact longer-term community participation. Early intervention is needed to reduce the longer-term impact of cognitive symptoms and facilitate participation.	[Theadom, Alice; Jones, Kelly; Feigin, Valery] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Dept Psychol, Knighton Rd, Waikato, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Dept Psychol, Auckland, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand		Theadom, A (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand.	alice.theadom@aut.ac.nz	Jones, Kelly/I-5199-2019; Feigin, Valery/AAF-2313-2019; Starkey, Nicola/AAJ-3795-2020	Starkey, Nicola/0000-0002-4370-8186; Feigin, Valery L./0000-0002-6372-1740; Theadom, Alice/0000-0003-0351-6216	Health Research Council of New ZealandHealth Research Council of New Zealand [13/408]	This work was supported by Health Research Council of New Zealand 13/408 to VF.	Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Hopkins WG, 2002, SCALE MAGNITUDES EFF; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Matuseviciene G, 2016, J REHABIL MED, V48, P19, DOI 10.2340/16501977-2025; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sveen U, 2016, DISABIL REHABIL, V38, P2296, DOI 10.3109/09638288.2015.1129445; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Theadom A, 2017, ARCH PHYS MED REHAB, V98, P1560, DOI 10.1016/j.apmr.2017.01.010; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	38	39	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2018	13	1							e0191655	10.1371/journal.pone.0191655			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU2GT	WOS:000423668400052	29385179	Green Published, Green Submitted, gold			2022-02-06	
J	Fang, J; Wang, HD; Zhou, J; Dail, W; Zhu, YH; Zhou, Y; Wang, XL; Zhou, ML				Fang, Jiang; Wang, Handong; Zhou, Jian; Dail, Wei; Zhu, Yihao; Zhou, Yuan; Wang, Xiaoliang; Zhou, Mengliang			Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						Baicalin; traumatic brain injury; Akt; nuclear factor erythroid 2-related factor 2; apoptosis; oxidative stress	NRF2-ARE SIGNALING PATHWAY; FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; POTENTIAL MECHANISM; SYNAPTIC PROTEINS; RAT MODEL; PI3K/AKT; ACTIVATION; PROTECTS; NEUROTOXICITY	Background: The neuroprotective effects of Baicalin liave been confirmed in several central nervous system (CNS) diseases. However, its possible effect on traumatic brain injury (TBI) model is still not clear. The present study is aimed to investigate the role and the underling mechanisms of 7-D-glucuronic acid-5,6-diliydroxyflavone (Baicalin) on TBI model. Methods: The weight-drop model of TBI in Institute of Cancer Research mice was treated with Baicalin intrapcritoncally at 30 minutes after TBI. LY294002 (LY) (a commonly used PI3K/ Akt pathway inhibitor) was injected into the left ventricle at 30 minutes before TBI. All mice were euthanized at 24 hours after TBI to collect the brain tissue for a series of tests except for neurological function, which was measured at 2 hours and 1 and 3 days post-TBI. Results: Baicalin administration significantly improved neurobehavioral function, alleviated brain edema, and reduced apoptosis-positive cells by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay accompanied with the upregulation of B-cell lymphoma 2 (Bcl-2) and downregulation of Bcl-2-associated X protein (Bax) and cleaved-caspase 3 by Western blot. Besides, TBI-induced oxidant stress status was also restored in the Baicalin group by measuring malondialdehyde (MDA) content, glutathione peroxidase (GPx), and superoxide dismutase (SOD) levels in the injured brain cortex. Furthermore, translocation of Nrf2 to the nucleus was dramatically enhanced by Baicalin verified by immunofluorescence and Western blot analyses. Accordingly, its downstream antioxidative enzymes nicotinamide adenine dinuclcotide phosphate:quinine oxidoreductase 1 (NQO-1) and heme oxygenase 1 (HO-1) were also activated by Baicalin confirmed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot. I lowever, cotreutment with Baicalin and LY could partly abolish Baicalin-induced activation of Nrf2 and its neuroprotective effects in TBI. Conclusion: This study demonstrates that Baicalin provides a neuroprotective effect in TBI mice model via activating the Akt/Nrf2 pathway.	[Fang, Jiang; Wang, Handong] Southeast Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhou, Jian; Dail, Wei; Zhou, Yuan] Nanjing Med Univ, Jinling Hosp, Jinling Clin Med Coll, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhu, Yihao; Wang, Xiaoliang; Zhou, Mengliang] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81571162, 81401026]; Military Medical Youth Training Program [16QNP042]; Project of Hospital Management of Nanjing General Hospital of Nanjing Military Region [2017013]	This study was grant supported by the National Natural Science Foundation of China (nos 81672503, 81571162, and 81401026), Military Medical Youth Training Program (no 16QNP042), and the Project of Hospital Management of Nanjing General Hospital of Nanjing Military Region (no 2017013).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Ali T, 2018, MOL NEUROBIOL, V55, P6076, DOI 10.1007/s12035-017-0798-6; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; Cao Y, 2010, BRAIN RES, V1357, P115, DOI 10.1016/j.brainres.2010.07.108; Cao YG, 2011, BRAIN RES BULL, V85, P396, DOI 10.1016/j.brainresbull.2011.05.002; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding HT, 2015, CELL MOL NEUROBIOL, V35, P623, DOI 10.1007/s10571-015-0156-z; Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Du G., 2016, NEUROL RES, P1; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frebel K, 2006, BIOCHEM SOC T, V34, P1287, DOI 10.1042/BST0341287; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; He P, 2017, OXID MED CELL LONGEV, V2017, P1, DOI 10.1155/2017/4820414; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kojima T, 2015, INVEST OPHTH VIS SCI, V56, P8382, DOI 10.1167/iovs.15-18295; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Li LR, 2014, CHEM-BIOL INTERACT, V209, P56, DOI 10.1016/j.cbi.2013.12.005; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Li X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164237; Liu ZW, 2017, NEUROCHEM RES, V42, P1375, DOI 10.1007/s11064-017-2186-z; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Shi XQ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1401790; Tang GM, 2017, ONCOTARGET, V8, P97977, DOI 10.18632/oncotarget.20105; Tarrago T, 2008, BIOORGAN MED CHEM, V16, P7516, DOI 10.1016/j.bmc.2008.04.067; Tu XK, 2011, NEUROCHEM RES, V36, P2022, DOI 10.1007/s11064-011-0526-y; Tu XK, 2009, NEUROCHEM RES, V34, P1626, DOI 10.1007/s11064-009-9953-4; Wang HC, 2016, WORLD NEUROSURG, V87, P463, DOI 10.1016/j.wneu.2015.10.010; Xi YL, 2016, CHIN J NAT MEDICINES, V14, P48, DOI 10.3724/SP.J.1009.2016.00048; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Zhang Q, 2016, ONCOTARGET, V7, P80872, DOI 10.18632/oncotarget.12645; Zhang ZJ, 2012, J AGR FOOD CHEM, V60, P8171, DOI 10.1021/jf301511m; Zheng WX, 2014, BRAIN INJURY, V28, P227, DOI 10.3109/02699052.2013.860469; Zhou ZQ, 2017, NEURAL REGEN RES, V12, P1625, DOI 10.4103/1673-5374.217335; Zuo DY, 2016, NEUROTOX RES, V30, P159, DOI 10.1007/s12640-016-9611-y	49	38	40	2	6	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2018	12						2497	2508		10.2147/DDDT.S163951			12	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GP8QN	WOS:000441177000003	30127597	Green Published, gold, Green Submitted			2022-02-06	
J	Gill, J; Mustapic, M; Diaz-Arrastia, R; Lange, R; Gulyani, S; Diehl, T; Motamedi, V; Osier, N; Stern, RA; Kapogiannis, D				Gill, Jessica; Mustapic, Maja; Diaz-Arrastia, Ramon; Lange, Rael; Gulyani, Seema; Diehl, Tom; Motamedi, Vida; Osier, Nicole; Stern, Robert A.; Kapogiannis, Dimitrios			Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel	BRAIN INJURY			English	Article						Exosomes; post-traumatic stress disorder; tau; traumatic brain injury (TBI); inflammation	TRAUMATIC BRAIN-INJURY; PRECLINICAL ALZHEIMERS-DISEASE; POSTTRAUMATIC-STRESS-DISORDER; EXTRACELLULAR VESICLES; BLOOD EXOSOMES; IN-VIVO; ENCEPHALOPATHY; PTSD; PROTEINS; INVENTORY	Objective: Identify biomarkers in peripheral blood that relate to chronic post-concussive and behavioural symptoms following traumatic brain injuries (TBIs) to ultimately improve clinical management.Research design: We compared military personnel with mild TBIs (mTBIs) (n=42) to those without TBIs (n=22) in concentrations of tau, amyloid-beta (A42) and cytokines (tumour necrosis factor alpha (TNF, interleukin (IL)-6 and -10) in neuronal-derived exosomes from the peripheral blood. We utilized nanosight technology coupled with ultra-sensitivity immunoassay methods. We also examined the impact of post-concussive and behavioural symptoms including depression and post-traumatic stress disorder (PTSD) on these neuronal-derived markers.Results: We report that concentrations of exosomal tau (F-1,F-62=10.50), A42 (F-1,F-61=5.32) and IL-10 (F-1,F-59=4.32) were elevated in the mTBI group compared to the controls. Within the mTBI group, regression models show that post-concussive symptoms were most related to exosomal tau elevations, whereas exosomal IL-10 levels were related to PTSD symptoms.Conclusions: These findings suggest that chronic post-concussive symptoms following an mTBI relate to altered exosomal activity, and that greater tau pathology may underlie chronic post-concussive symptoms that develop following mTBIs. It also suggests that central inflammatory activity contributes to PTSD symptoms following an mTBI, providing necessary insights into the role of inflammation in chronic PTSD symptoms.	[Gill, Jessica; Motamedi, Vida; Osier, Nicole] NINR, Tissue Injury Branch, NIH, Bethesda, MD 20892 USA; [Mustapic, Maja; Gulyani, Seema; Diehl, Tom; Kapogiannis, Dimitrios] NIA, Aging, NIH, Baltimore, MD 21224 USA; [Diaz-Arrastia, Ramon] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Lange, Rael] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Stern, Robert A.] Boston Univ, Alzheimers Dis & CTE Ctr, Neurosurg & Anat & Neurobiol, Boston, MA 02215 USA		Gill, J (corresponding author), NIH, Intramural Res Program, Bldg 10, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017; Kapogiannis, Dimitrios/AAW-4934-2020; Osier, Nicole/Q-7913-2017; , Bob/ABA-8507-2020; Mustapic, Maja/AAV-3212-2020	Kapogiannis, Dimitrios/0000-0003-2181-3118; Osier, Nicole/0000-0002-2903-6774; 	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institute of Nursing Research, Intramural Research Program; National Institute on Aging, Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000975] Funding Source: NIH RePORTER	This work was supported by the The Center for Neuroscience and Regenerative Medicine; National Institute of Nursing Research, Intramural Research Program; and National Institute on Aging, Intramural Research Program.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Armstrong RA, 2016, NEUROPATHOL APPL NEU, V2, P185; Baker S, 2016, J ALZHEIMERS DIS, V54, P1207, DOI 10.3233/JAD-160371; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bersani FS, 2016, BRAIN BEHAV IMMUN, V52, P153, DOI 10.1016/j.bbi.2015.10.015; Bogoslovsky T, 2016, J NEUROTRAUM, V5, P70; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Devoto C, 2017, CELL TRANSPLANT, V26, P1169, DOI 10.1177/0963689717714098; Dinkins MB, 2014, NEUROBIOL AGING, V35, P1792, DOI 10.1016/j.neurobiolaging.2014.02.012; Ebenezer PJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160923; Falker C, 2016, J NEUROCHEM, V137, P88, DOI 10.1111/jnc.13514; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gatson JW, 2016, J NEUROSURG, V124, P1646, DOI 10.3171/2015.6.JNS15639; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Hamlett ED, 2018, FREE RADICAL BIO MED, V114, P110, DOI 10.1016/j.freeradbiomed.2017.08.028; Hoge EA, 2009, DEPRESS ANXIETY, V26, P447, DOI 10.1002/da.20564; Jin Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2783-2; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Korkut C, 2009, CELL, V139, P393, DOI 10.1016/j.cell.2009.07.051; Lai CPK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00228; Lejbman N, 2016, BRAIN INJURY, V30, P1436, DOI 10.1080/02699052.2016.1219054; Lindqvist D, 2014, BRAIN BEHAV IMMUN, V42, P81, DOI 10.1016/j.bbi.2014.06.003; Mac Donald CL, 2016, J NEUROTRAUM, V22, P23; Mac Donald CL, 2016, J NEUROTRAUM, V4, P12; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mittelbrunn M, 2012, NAT REV MOL CELL BIO, V13, P328, DOI 10.1038/nrm3335; Nie H, 2014, PROG NEURO-PSYCHOPH, V51, P16, DOI 10.1016/j.pnpbp.2014.01.002; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rajendrana L, 2007, NEURODEGENER DIS, V4, P164, DOI 10.1159/000101841; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Saenz-Cuesta M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00050; Saman S, 2014, J ALZHEIMERS DIS, V40, pS47, DOI 10.3233/JAD-132135; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sokolova V, 2011, COLLOID SURFACE B, V87, P146, DOI 10.1016/j.colsurfb.2011.05.013; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Tucker Phebe, 2010, Am J Disaster Med, V5, P113; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Yuyama K, 2012, J BIOL CHEM, V287, P10977, DOI 10.1074/jbc.M111.324616; Zhou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092828	60	38	39	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	10			SI		1277	1284		10.1080/02699052.2018.1471738			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	GS6YO	WOS:000443846200014	29913077	Green Accepted			2022-02-06	
J	He, HF; Liu, WF; Zhou, YY; Liu, YB; Weng, PQ; Li, YS; Fu, HG				He, Hefan; Liu, Weifeng; Zhou, Yingying; Liu, Yibin; Weng, Peiqing; Li, Yasong; Fu, Huangde			Sevoflurane post-conditioning attenuates traumatic brain injury-induced neuronal apoptosis by promoting autophagy via the PI3K/AKT signaling pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						traumatic brain injury; sevoflurane post-conditioning; cell apoptosis; autophagy; PI3K/AKT signaling pathway	PROVIDES NEUROPROTECTION; HYPOXIA-ISCHEMIA; MODEL; AKT; ACTIVATION; EXPRESSION; INHIBITOR; STRESS; RATS	Background: Sevoflurane post-conditioning exerts nerve-protective effects through inhibiting caspase-dependent neuronal apoptosis after a traumatic brain injury (TBI). Autophagy that is induced by the endoplasmic reticulum stress plays an important role in the secondary neurological dysfunction after a TBI. However, the relationship between autophagy and caspase-dependent apoptosis as well as the underlying nerve protection mechanism that occurs with sevoflurane post-conditioning following a TBI remains unclear. Methods: The Feeney TBI model was used to induce brain injury in rats. Evaluation of the modified neurological severity scores, measurement of brain water content, Nissl staining, and terminal deoxynucleotidyl transferase dUTP nick end labeling assay were used to determine the neuroprotective effects of the sevoflurane post-conditioning. Both immunofluorescence and Western blot analyses were used to detect the expression of autophagy-related proteins microtubule-associated protein 1 light chain 3-II and Beclin-1, pro-apoptotic factors, as well as the activation of the phosphatidylinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway within the lesioned cortex. Results: Autophagy and neuronal apoptosis were activated in the lesioned cortex following the TBI. Sevoflurane post-conditioning enhanced early autophagy, suppressed neuronal apoptosis, and alleviated brain edema, which improved nerve function after a TBI (all P<0.05). Sevoflurane post-conditioning induced the activation of PI3K/AKT signaling after the TBI (P<0.05). The neuroprotective effects of sevoflurane post-conditioning were reversed through the autophagy inhibitor 3-methyladenine treatment. Conclusion: Neuronal apoptosis and the activation of autophagy were involved in the secondary neurological injury following a TBI. Sevoflurane post-conditioning weakened the TBI-induced neuronal apoptosis by regulating autophagy via PI3K/AKT signaling.	[He, Hefan; Liu, Weifeng; Zhou, Yingying; Liu, Yibin; Weng, Peiqing] Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesia, 34 Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China; [Li, Yasong] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou, Fujian, Peoples R China; [Fu, Huangde] Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China		Liu, WF (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesia, 34 Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China.; Fu, HG (corresponding author), Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China.	rong281@126.com; xiangrong_chen281@126.com			Fujian Province Natural Science FoundationNatural Science Foundation of Fujian Province [2016J01520]	This work was supported by grants from the Fujian Province Natural Science Foundation (no 2016J01520 for Professor Hefan He).	Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V59, P190, DOI 10.1016/j.bbi.2016.09.002; Chen XR, 2017, J NEUROINFLAMM, V14, DOI [10.1186/s12974-017-0917-3, 10.1186/s12974-018-1151-3]; Chen Y, 2015, BRIT J ANAESTH, V114, P327, DOI 10.1093/bja/aeu271; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4; Delbary-Gossart S, 2016, BRAIN, V139, P1762, DOI 10.1093/brain/aww074; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Du GL, 2016, NEUROL RES, V38, P1012, DOI 10.1080/01616412.2016.1240393; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; He RN, 2015, AUTOPHAGY, V11, P740, DOI 10.1080/15548627.2015.1034404; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kim HC, 2017, J NEUROSURG ANESTH, V29, P37, DOI 10.1097/ANA.0000000000000331; Lai ZM, 2016, BRAIN RES, V1630, P25, DOI 10.1016/j.brainres.2015.10.050; Lee H, 2015, BRIT J ANAESTH, V114, P307, DOI 10.1093/bja/aeu268; Li L, 2017, ONCOTARGET, V8, P28544, DOI 10.18632/oncotarget.15325; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Miao JY, 2016, NEUROCHEM RES, V41, P2300, DOI 10.1007/s11064-016-1944-7; Ren XY, 2014, NEUROL SCI, V35, P1401, DOI 10.1007/s10072-014-1726-4; Ryter Stefan W, 2013, J Biochem Pharmacol Res, V1, P176; Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x; Sun DD, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00193; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Wang HL, 2016, ACTA NEUROCHIR SUPPL, V121, P55, DOI 10.1007/978-3-319-18497-5_10; Yang ZC, 2014, MOL MED REP, V9, P843, DOI 10.3892/mmr.2014.1912; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zhu YM, 2017, NEUROSCIENCE, V356, P125, DOI 10.1016/j.neuroscience.2017.05.004	30	38	43	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2018	12						629	638		10.2147/DDDT.S158313			10	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GB1HG	WOS:000428801300001	29606856	Green Published, Green Submitted, gold			2022-02-06	
J	Kenney, K; Iacono, D; Edlow, BL; Katz, DI; Diaz-Arrastia, R; Dams-O'Connor, K; Daneshvar, DH; Stevens, A; Moreau, AL; Tirrell, LS; Varjabedian, A; Yendiki, A; van der Kouwe, A; Mareyam, A; McNab, JA; Gordon, WA; Fischl, B; McKee, AC; Perl, DP				Kenney, Kimbra; Iacono, Diego; Edlow, Brian L.; Katz, Douglas I.; Diaz-Arrastia, Ramon; Dams-O'Connor, Kristen; Daneshvar, Daniel H.; Stevens, Allison; Moreau, Allison L.; Tirrell, Lee S.; Varjabedian, Ani; Yendiki, Anastasia; van der Kouwe, Andre; Mareyam, Azma; McNab, Jennifer A.; Gordon, Wayne A.; Fischl, Bruce; McKee, Ann C.; Perl, Daniel P.			Dementia After Moderate-Severe Traumatic Brain Injury: Coexistence of Multiple Proteinopathies	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						alpha-Synuclein; beta-Amyloid; Hyperphosphorylated tau; Neurodegeneration; Neurofibrillary tangle; Proteinopathy; Traumatic brain injury	AMYOTROPHIC-LATERAL-SCLEROSIS; ONSET ALZHEIMERS-DISEASE; HEAD-INJURY; RISK; ENCEPHALOPATHY; PATHOLOGY; TDP-43; DEGENERATION; INDIVIDUALS; PERSIST	We report the clinical, neuroimaging, and neuropathologic characteristics of 2 patients who developed early onset dementia after a moderate-severe traumatic brain injury (TBI). Neuropathological evaluation revealed abundant beta-amyloid neuritic and cored plaques, diffuse beta-amyloid plaques, and frequent hyperphosphorylated-tau neurofibrillary tangles (NFT) involving much of the cortex, including insula and mammillary bodies in both cases. Case 1 additionally showed NFTs in both the superficial and deep cortical layers, occasional perivascular and depth-of-sulci NFTs, and parietal white matter rarefaction, which corresponded with decreased parietal fiber tracts observed on ex vivo MRI. Case 2 additionally showed NFT predominance in the superficial layers of the cortex, hypothalamus and brainstem, diffuse Lewy bodies in the cortex, amygdala and brainstem, and intraneuronal TDP-43 inclusions. The neuropathologic diagnoses were atypical Alzheimer disease (AD) with features of chronic traumatic encephalopathy and white matter loss (Case 1), and atypical AD, dementia with Lewy bodies and coexistent TDP-43 pathology (Case 2). These findings support an epidemiological association between TBI and dementia and further characterize the variety of misfolded proteins that may accumulate after TBI. Analyses with comprehensive clinical, imaging, genetic, and neuropathological data are required to characterize the full clinicopathological spectrum associated with dementias occurring aftermoderate-severe TBI.	[Kenney, Kimbra; Iacono, Diego] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bldg 51,Room 2306,4860 South Palmer Rd, Bethesda, MD 20889 USA; [Iacono, Diego; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, Bethesda, MD 20814 USA; [Iacono, Diego; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, CNRM, Bethesda, MD 20814 USA; [Iacono, Diego] Henry M Jackson Fdn Adv Mil Res HJF, Boston, MA USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Ctr Neurotechnol & Neurorecovery, Boston, MA 02114 USA; [Edlow, Brian L.; Stevens, Allison; Moreau, Allison L.; Tirrell, Lee S.; Varjabedian, Ani; Yendiki, Anastasia; van der Kouwe, Andre; Mareyam, Azma; Fischl, Bruce] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [Edlow, Brian L.; Stevens, Allison; Moreau, Allison L.; Tirrell, Lee S.; Varjabedian, Ani; Yendiki, Anastasia; van der Kouwe, Andre; Mareyam, Azma; Fischl, Bruce] Harvard Med Sch, Charlestown, MA USA; [Katz, Douglas I.; Daneshvar, Daniel H.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Katz, Douglas I.; Daneshvar, Daniel H.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Katz, Douglas I.; Daneshvar, Daniel H.] Boston Univ, Sch Med, CTE Program, Boston, MA 02118 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [McNab, Jennifer A.] Stanford Univ, Dept Radiol, Radiol Sci Lab, Stanford, CA 94305 USA; [Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Boston, MA USA; [McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA		Kenney, K (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, Bldg 51,Room 2306,4860 South Palmer Rd, Bethesda, MD 20889 USA.	kimbra.kenney@usuhs.edu	Iacono, Diego/K-8203-2016; McNab, Jennifer/ABG-2746-2021; Moreau, Allison L./T-2625-2019	Iacono, Diego/0000-0001-5511-0950; Moreau, Allison L./0000-0002-8758-8622; MICHAUD, ANI/0000-0001-9039-3212; McNab, Jennifer/0000-0002-1763-0792; Daneshvar, Daniel/0000-0003-3691-9513	Chronic Effects of Neurotrauma Consortium (DoD VA) [W81XWH-13-2-0095]; Brain Tissue Repository (BTR) and Neuropathology Core, CNRM, USUHS [308049-4.01-60855]; Boston University Alzheimer's disease Center [NIA P30 AG13846, 0572063345-5]; Department of Veterans AffairsUS Department of Veterans Affairs; Worldwide Wrestling Foundation; Andlinger Foundation; American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075, U24 RR021382]; National Institute for Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896, R01EB006758, R01EB019956, R21EB018907]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG022381, 5R01AG008122, R01 AG016495]; National Center for Alternative Medicine [RC1 AT005728-01]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052585-01, 1R21NS072652-01, 1R01NS070963, R01NS083534, 5U01NS086625, U01NS086625, K23NS094538]; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD074651-01A1]; Shared Instrumentation Grants [1S10RR023401, 1S10RR019307, 1S10RR023043]; NIH Blueprint for Neuroscience ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5U01-MH093765]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR023401, 1S10RR019307, 1S10RR023043]; VA award [IO1RX 002170]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538, U01NS086659] Funding Source: NIH RePORTER	Supported by Chronic Effects of Neurotrauma Consortium (DoD & VA), Award Number W81XWH-13-2-0095 and VA award IO1RX 002170; The Brain Tissue Repository (BTR) and Neuropathology Core, CNRM, USUHS, CNRM Award Number 308049-4.01-60855; Boston University Alzheimer's disease Center NIA P30 AG13846, supplement 0572063345-5; Department of Veterans Affairs; Worldwide Wrestling Foundation and the Andlinger Foundation; American Academy of Neurology/American Brain Foundation; the James S. McDonnell Foundation; the National Center for Research Resources (P41RR014075, U24 RR021382); the National Institute for Biomedical Imaging and Bioengineering (P41EB015896, R01EB006758, R21EB018907, R01EB019956, R21EB018907); the National Institute on Aging (AG022381, 5R01AG008122, R01 AG016495); the National Center for Alternative Medicine (RC1 AT005728-01); the National Institute of Neurological Disorders and Stroke (R01NS052585-01, 1R21NS072652-01, 1R01NS070963, R01NS083534, 5U01NS086625, U01NS086625, K23NS094538); National Institute of Child Health and Development (K01 HD074651-01A1) and was made possible by the resources provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. NIH Blueprint for Neuroscience Research (5U01-MH093765), part of the multiinstitutional Human Connectome Project also provided support. This research also utilized resources provided by National Institutes of Health shared instrumentation grants 1S10RR023401, 1S10RR019307, and 1S10RR023043.	Augustinack JC, 2005, ANN NEUROL, V57, P489, DOI 10.1002/ana.20426; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, NEUROREHABILITATION, V32, P199, DOI 10.3233/NRE-130838; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Daneshvar DH, 2013, 2014 ALZH ASS INT C; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Elobeid A, 2016, J NEUROPATH EXP NEUR, V75, P316, DOI 10.1093/jnen/nlw002; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Josephs KA, 2015, ANN NEUROL, V78, P697, DOI 10.1002/ana.24493; Katzman R, 1996, NEUROLOGY, V46, P889; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kenney K, 2014, 2014 ALZH ASS INT C; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; Management of Major Depressive Disorder Working Group, 2016, VA DOD CLIN PRACT GU; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2010, J NEUROPATH EXP NEUR, V92, P608; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Mortimer JA, 1991, INT J EPIDEMIOL; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Tateno A, 2015, GEN HOSP PSYCHIAT, V37, DOI 10.1016/j.genhosppsych.2014.09.016; Tolppanen A-M, 2017, ALZHEIMERS DEMENT; Tsolaki M, 1997, Int Psychogeriatr, V9, P327, DOI 10.1017/S104161029700447X; Tsuang D, 2013, JAMA NEUROL, V70, P223, DOI 10.1001/jamaneurol.2013.600; Vossel KA, 2013, NEUROCASE, V19, P295, DOI 10.1080/13554794.2012.667124; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015	54	38	39	1	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JAN	2018	77	1					50	63		10.1093/jnen/nlx101			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	GB3IB	WOS:000428948900004	29155947	hybrid, Green Published			2022-02-06	
J	Kovacs, ZI; Tu, TW; Sundby, M; Qureshi, F; Lewis, BK; Jikaria, N; Burks, SR; Frank, JA				Kovacs, Zsofia I.; Tu, Tsang-Wei; Sundby, Maggie; Qureshi, Farhan; Lewis, Bobbi K.; Jikaria, Neekita; Burks, Scott R.; Frank, Joseph A.			MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain	THERANOSTICS			English	Article						pulsed focused ultrasound; microbubbles; sterile inflammation; blood-brain barrier; hyperphosphorylated Tau	CHRONIC TRAUMATIC ENCEPHALOPATHY; TUMOR BARRIER DISRUPTION; RAT GLIOMA MODEL; ALZHEIMERS-DISEASE; DRUG-DELIVERY; LIPOSOMAL DOXORUBICIN; BLOOD-TUMOR; IN-VIVO; STERILE INFLAMMATION; ANTIBODY DELIVERY	Magnetic resonance imaging (MRI)-guided pulsed focused ultrasound (pFUS) combined with microbubbles (MB) contrast agent infusion has been shown to transiently disrupt the blood-brain barrier (BBBD), increasing the delivery of neurotherapeutics to treat central nervous system (CNS) diseases. pFUS interaction with the intravascular MB results in acoustic cavitation forces passing through the neurovascular unit (NVU), inducing BBBD detected on contrast-enhanced MRI. Multiple pFUS+MB exposures in Alzheimer's disease (AD) models are being investigated as a method to clear amyloid plaques by activated microglia or infiltrating immune cells. Since it has been reported that pFUS+MB can induce a sterile inflammatory response (SIR) [1-5] in the rat, the goal of this study was to investigate the potential long-term effects of SIR in the brain following single and six weekly sonications by serial high-resolution MRI and pathology. Methods: Female Sprague Dawley rats weighing 217 +/- 16.6 g prior to sonication received bromo-deoxyuridine (BrdU) to tag proliferating cells in the brain. pFUS was performed at 548 kHz, ultrasound burst 10 ms and initial peak negative pressure of 0.3 MPa (in water) for 120 s coupled with a slow infusion of similar to 460 mu L/kg (5-8x10(7) MB) that started 30 s before and 30 s during sonication. Nine 2 mm focal regions in the left cortex and four regions over the right hippocampus were treated with pFUS+MB. Serial high-resolution brain MRIs at 3 T and 9.4 T were obtained following a single or during the course of six weekly pFUS+MB resulting in BBBD in the left cortex and the right hippocampus. Animals were monitored over 7 to 13 weeks and imaging results were compared to histology. Results: Fewer than half of the rats receiving a single pFUS+MB exposure displayed hypointense voxels on T2*-weighted (w) MRI at week 7 or 13 in the cortex or hippocampus without differences compared to the contralateral side on histograms of T2* maps. Single sonicated rats had evidence of limited microglia activation on pathology compared to the contralateral hemisphere. Six weekly pFUS+MB treatments resulted in pathological changes on T2* w images with multiple hypointense regions, cortical atrophy, along with 50% of rats having persistent BBBD and astrogliosis by MRI. Pathologic analysis of the multiple sonicated animals demonstrated the presence of metallophagocytic Prussian blue-positive cells in the parenchyma with significantly (p<0.05) increased areas of activated astrocytes and microglia, and high numbers of systemic infiltrating CD68(+) macrophages along with BrdU(+) cells compared to contralateral brain. In addition, multiple treatments caused an increase in the number of hyperphosphorylated Tau (pTau)-positive neurons containing neurofibrillary tangles (NFT) in the sonicated cortex but not in the hippocampus when compared to contralateral brain, which was confirmed by Western blot (WB) (p<0.04). Conclusions: The repeated SIR following multiple pFUS+MB treatments could contribute to changes on MR imaging including persistent BBBD, cortical atrophy, and hypointense voxels on T2w and T2*w images consistent with pathological injury. Moreover, areas of astrogliosis, activated microglia, along with higher numbers of CD68(+) infiltrating macrophages and BrdU(+) cells were detected in multiple sonicated areas of the cortex and hippocampus. Elevations in pTau and NFT were detected in neurons of the multiple sonicated cortex. Minimal changes on MRI and histology were observed in single pFUS+MB-treated rats at 7 and 13 weeks post sonication. In comparison, animals that received 6 weekly sonications demonstrated evidence on MRI and histology of vascular damage, inflammation and neurodegeneration associated with the NVU commonly observed in trauma. Further investigation is recommended of the long-term effects of multiple pFUS+MB in clinical trials.	[Kovacs, Zsofia I.; Tu, Tsang-Wei; Sundby, Maggie; Qureshi, Farhan; Lewis, Bobbi K.; Jikaria, Neekita; Burks, Scott R.; Frank, Joseph A.] NIH, Frank Lab, Clin Ctr, Radiol & Imaging Sci, Bldg 10, Bethesda, MD 20892 USA; [Tu, Tsang-Wei] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Tu, Tsang-Wei] Howard Univ, Dept Radiol, Mol Imaging Lab, Washington, DC 20059 USA; [Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA		Kovacs, ZI; Frank, JA (corresponding author), Frank Lab, Bldg 10,Room B1N256,10 Ctr Dr,MSC 1074, Bethesda, MD 20854 USA.	zsofia.kovacs@nih.gov; jf5z@nih.gov	Frank, Joseph/W-2021-2019; frank, joseph/AAJ-6680-2020	Qureshi, Farhan/0000-0001-5541-1518; Burks, Scott/0000-0003-2030-3845	Intramural Research Program of the Clinical Center; Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health; Department of Defense through the Center for Neuroscience and Regenerative Medicine (Henry M. Jackson Foundation Award) [308049-10.01-60855, CNRM-89-3899]; CLINICAL CENTER [ZIACL040014] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Programs of the Clinical Center and of the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health. Dr. Tsang-Wei Tu was funded by the Department of Defense through the Center for Neuroscience and Regenerative Medicine (Henry M. Jackson Foundation Award #308049-10.01-60855, USU Site No. CNRM-89-3899).	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alecou T, 2017, J ULTRAS MED, V36, P2257, DOI 10.1002/jum.14256; Alkins RD, 2013, NEURO-ONCOLOGY, V15, P1225, DOI 10.1093/neuonc/not052; Alonso A, 2010, NEUROSCIENCE, V169, P116, DOI 10.1016/j.neuroscience.2010.04.001; Alzheimer's Association, 2016, Alzheimers Dement, V12, P459; Amantea D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00147; Anderson SA, 2005, BLOOD, V105, P420, DOI 10.1182/blood-2004-06-2222; Aryal M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0166061; Aryal M, 2015, J CONTROL RELEASE, V204, P60, DOI 10.1016/j.jconrel.2015.02.033; Aryal M, 2015, PHYS MED BIOL, V60, P2511, DOI 10.1088/0031-9155/60/6/2511; Aryal M, 2013, J CONTROL RELEASE, V169, P103, DOI 10.1016/j.jconrel.2013.04.007; Aslund AKO, 2015, J CONTROL RELEASE, V220, P287, DOI 10.1016/j.jconrel.2015.10.047; Banks WA, 2016, NAT REV DRUG DISCOV, V15, P275, DOI 10.1038/nrd.2015.21; Baseri B, 2012, PHYS MED BIOL, V57, pN65, DOI 10.1088/0031-9155/57/7/N65; Bellucci A, 2011, NEURODEGENER DIS, V8, P221, DOI 10.1159/000322228; Burgess A, 2013, P SPIE, V8588; Burgess A, 2014, RADIOLOGY, V273, P736, DOI 10.1148/radiol.14140245; Burgess A, 2012, J CONTROL RELEASE, V163, P125, DOI 10.1016/j.jconrel.2012.08.012; Burgess A, 2011, THER DELIV, V2, P281, DOI 10.4155/TDE.11.5; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Caselli RJ, 2017, MAYO CLIN PROC, V92, P978, DOI 10.1016/j.mayocp.2017.02.011; Chai WY, 2014, J CONTROL RELEASE, V192, P1, DOI 10.1016/j.jconrel.2014.06.023; Chapman CD, 2013, PHARM RES-DORDR, V30, P2475, DOI 10.1007/s11095-012-0915-1; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen PY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0451-y; Cho H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31201; Chu PC, 2016, SCI REP-UK, V6, DOI 10.1038/srep33264; Chu PC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15477; Chu PC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/627496; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Downs ME, 2015, SCI REP-UK, V5, DOI 10.1038/srep15076; Downs ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125911; Fix SM, 2018, ULTRASOUND MED BIOL, V44, P1266, DOI 10.1016/j.ultrasmedbio.2018.02.006; Fuger P, 2017, NAT NEUROSCI, V20, P1371, DOI 10.1038/nn.4631; Fung LK., 2017, SCI TRANSL MED, V9; Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Goertz DE, 2015, INT J HYPERTHER, V31, P134, DOI 10.3109/02656736.2015.1009179; Gomez Diana, 2012, Front Biosci (Schol Ed), V4, P74; Gurlek A, 1998, J RECONSTR MICROSURG, V14, P337, DOI 10.1055/s-2007-1000187; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Head E, 2012, J ALZHEIMERS DIS, V32, P1029, DOI 10.3233/JAD-2012-120937; Hefendehl JK, 2014, AGING CELL, V13, P60, DOI 10.1111/acel.12149; Hernandez F, 2013, J ALZHEIMERS DIS, V33, pS141, DOI 10.3233/JAD-2012-129025; Hong J.T., 2017, CNS NEUROL DISORD DR; Horodyckid C, 2017, J NEUROSURG, V126, P1351, DOI 10.3171/2016.3.JNS151635; Hynynen K, 2003, ACT NEUR S, V86, P555; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Iqbal K, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.225; Itani M, 2012, MOL IMAGING BIOL, V14, P40, DOI 10.1007/s11307-011-0475-5; Jalali S, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-114; Jordao JF, 2013, EXP NEUROL, V248, P16, DOI 10.1016/j.expneurol.2013.05.008; Jordao JF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010549; Kobus T, 2016, J CONTROL RELEASE, V238, P281, DOI 10.1016/j.jconrel.2016.08.001; Kobus T, 2016, ULTRASOUND MED BIOL, V42, P481, DOI 10.1016/j.ultrasmedbio.2015.10.009; Kohler C, 2013, NEUROBIOL AGING, V34, P1369, DOI 10.1016/j.neurobiolaging.2012.11.010; Kovacs ZI, 2017, P NATL ACAD SCI USA; Kovacs Z, 2014, J CONTROL RELEASE, V187, P74, DOI 10.1016/j.jconrel.2014.05.033; Kovacs ZI, 2018, THERANOSTICS, V8, P2245, DOI 10.7150/thno.24181; Kovacs ZI, 2017, P NATL ACAD SCI USA, V114, pE75, DOI 10.1073/pnas.1614777114; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Lee DE, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0390-9; Leinenga G, 2016, NAT REV NEUROL, V12, P161, DOI 10.1038/nrneurol.2016.13; Leinenga G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2512; Liu HL, 2008, ULTRASOUND MED BIOL, V34, P598, DOI 10.1016/j.ultrasmedbio.2008.01.011; Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; McConnell HL, 2017, J BIOL CHEM, V292, P762, DOI 10.1074/jbc.R116.760215; Mcdannold N, 2008, ULTRASOUND MED BIOL, V34, P930, DOI 10.1016/j.ultrasmedbio.2007.11.009; McDannold N, 2017, ULTRASOUND MED BIOL, V43, P469, DOI 10.1016/j.ultrasmedbio.2016.09.019; McDannold N, 2016, J NEUROSURG, V125, P1539, DOI 10.3171/2015.10.JNS151525; McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMahon D, 2018, THERANOSTICS, V8, P2249, DOI 10.7150/thno.25468; McMahon D, 2017, THERANOSTICS, V7, P3989, DOI 10.7150/thno.21630; McMahon D, 2017, SCI REP-UK, V7, DOI 10.1038/srep45657; Mead BP, 2016, J CONTROL RELEASE, V223, P109, DOI 10.1016/j.jconrel.2015.12.034; Meng Y, 2017, ANN NEUROL, V81, P611, DOI 10.1002/ana.24933; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; Morgan D, 2011, J INTERN MED, V269, P54, DOI 10.1111/j.1365-2796.2010.02315.x; Mulik RS, 2016, BIOMATERIALS, V83, P257, DOI 10.1016/j.biomaterials.2016.01.021; Mullin L, 2011, CONTRAST MEDIA MOL I, V6, P126, DOI 10.1002/cmmi.414; Nance E, 2014, J CONTROL RELEASE, V189, P123, DOI 10.1016/j.jconrel.2014.06.031; National Research Council (US) Committee, 2011, COMM UPD GUID CAR US, V8th; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Nisbet RM, 2017, BRAIN, V140, P1220, DOI 10.1093/brain/awx052; Noble W, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00083; O'Reilly MA, 2017, J ULTRAS MED, V36, P475, DOI 10.7863/ultra.16.02005; O'Reilly MA, 2012, RADIOLOGY, V263, P96, DOI 10.1148/radiol.11111417; O'Reilly MA, 2010, PHYS MED BIOL, V55, P5251, DOI 10.1088/0031-9155/55/18/001; O'Reilly MA, 2017, THERANOSTICS, V7, P3573, DOI 10.7150/thno.20621; Olumolade OO, 2016, ULTRASOUND MED BIOL, V42, P2270, DOI 10.1016/j.ultrasmedbio.2016.05.004; Park EJ, 2012, J CONTROL RELEASE, V163, P277, DOI 10.1016/j.jconrel.2012.09.007; Park J, 2017, J CONTROL RELEASE, V250, P77, DOI 10.1016/j.jconrel.2016.10.011; Park J, 2012, J CONTROL RELEASE, V162, P134, DOI 10.1016/j.jconrel.2012.06.012; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Raymond SB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002175; Reher P, 1999, CYTOKINE, V11, P416, DOI 10.1006/cyto.1998.0444; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Russo MV, 2015, TRENDS IMMUNOL, V36, P637, DOI 10.1016/j.it.2015.08.002; Ruthirakuhan M, 2016, EXPERT OPIN PHARMACO, V17, P2417, DOI 10.1080/14656566.2016.1258060; Samiotaki G, 2013, IEEE T ULTRASON FERR, V60, P2257, DOI 10.1109/TUFFC.2013.6644731; Scarcelli T, 2014, BRAIN STIMUL, V7, P304, DOI 10.1016/j.brs.2013.12.012; Shadfar S, 2015, ARCH PHARM RES, V38, P2106, DOI 10.1007/s12272-015-0648-x; Sierra C, 2017, J CEREBR BLOOD F MET, V37, P1236, DOI 10.1177/0271678X16652630; Silburt J, 2017, P NATL ACAD SCI USA; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Song KH, 2017, THERANOSTICS, V7, P144, DOI 10.7150/thno.15987; Stamatovic SM, 2008, CURR NEUROPHARMACOL, V6, P179, DOI 10.2174/157015908785777210; Stumm RK, 2002, J NEUROSCI, V22, P5865; Su WS, 2015, ONCOTARGET, V6, P42290, DOI 10.18632/oncotarget.5978; Sun P, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7020021; Sun T, 2017, P NATL ACAD SCI USA, V114, pE10281, DOI 10.1073/pnas.1713328114; Suzuki Y, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00002; Nhan T, 2013, J CONTROL RELEASE, V172, P274, DOI 10.1016/j.jconrel.2013.08.029; Treat LH, 2007, INT J CANCER, V121, P901, DOI 10.1002/ijc.22732; Treat LH, 2012, ULTRASOUND MED BIOL, V38, P1716, DOI 10.1016/j.ultrasmedbio.2012.04.015; Tu TW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19094-z; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Tu TW, 2014, J NEUROPATH EXP NEUR, V73, P1152, DOI 10.1097/NEN.0000000000000140; Tufail Y, 2010, NEURON, V66, P681, DOI 10.1016/j.neuron.2010.05.008; Turner RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00222; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Wang YP, 2016, NAT REV NEUROSCI, V17, P5, DOI 10.1038/nrn.2015.1; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Wei KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058995; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Wu SK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46689; Wu SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090107; Yulug B, 2017, BRAIN RES BULL, V131, P199, DOI 10.1016/j.brainresbull.2017.04.015; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	135	38	39	1	10	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2018	8	17					4837	4855		10.7150/thno.24512			19	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	GT0FX	WOS:000444107300019	30279741	Green Submitted, gold, Green Published			2022-02-06	
J	Rose, CR; Ziemens, D; Untiet, V; Fahlke, C				Rose, Christine R.; Ziemens, Daniel; Untiet, Verena; Fahlke, Christoph			Molecular and cellular physiology of sodium-dependent glutamate transporters	BRAIN RESEARCH BULLETIN			English	Article						EAAT; GLAST; GLT-1; Anion conductance; Astrocyte; Tripartite synapse	AMINO-ACID TRANSPORTER; BERGMANN GLIAL-CELLS; SYNAPTICALLY RELEASED GLUTAMATE; CEREBELLAR PURKINJE-CELLS; AMYOTROPHIC-LATERAL-SCLEROSIS; RAT HIPPOCAMPAL ASTROCYTES; PLASMA-MEMBRANE VESICLES; NMDA RECEPTOR ACTIVATION; TRAUMATIC BRAIN-INJURY; GATED CHLORIDE CHANNEL	Glutamate is the major excitatory transmitter in the vertebrate brain. After its release from presynaptic nerve terminals, it is rapidly taken up by high-affinity sodium-dependent plasma membrane transporters. While both neurons and glial cells express these excitatory amino acid transporters (EAATs), the majority of glutamate uptake is accomplished by astrocytes, which convert synaptically-released glutamate to glutamine or feed it into their own metabolism. Glutamate uptake by astrocytes not only shapes synaptic transmission by regulating the availability of glutamate to postsynaptic neuronal receptors, but also protects neurons from hyper-excitability and subsequent excitotoxic damage. In the present review, we provide an overview of the molecular and cellular characteristics of sodium-dependent glutamate transporters and their associated anion permeation pathways, with a focus on astrocytic glutamate transport. We summarize their functional properties and roles within tripartite synapses under physiological and pathophysiological conditions, exemplifying the intricate interactions and interrelationships between neurons and glial cells in the brain. (C) 2016 Elsevier Inc. All rights reserved.	[Rose, Christine R.; Ziemens, Daniel] Heinrich Heine Univ Dusseldorf, Fac Math & Nat Sci, Inst Neurobiol, Univ Str 1, D-40225 Dusseldorf, Germany; [Untiet, Verena; Fahlke, Christoph] Forschungszentrum Julich, Inst Complex Syst, Zellullare Biophys ICS 4, Julich, Germany		Rose, CR (corresponding author), Heinrich Heine Univ Dusseldorf, Fac Math & Nat Sci, Inst Neurobiol, Univ Str 1, D-40225 Dusseldorf, Germany.	rose@uni-duesseldorf.de	Untiet, Verena/AAZ-4783-2020; Fahlke, Christoph/G-3635-2013	Untiet, Verena/0000-0002-1888-6378; Fahlke, Christoph/0000-0001-8602-9952	German Research FoundationGerman Research Foundation (DFG) [Ro2327/8-1]	We thank Lisa Felix, Institute of Neurobiology, for critical comments on the manuscript and Dr. Jan-Philipp Machtens, Institute of Complex Systems, for helpful discussion and providing figures 2 and 3. This work was supported by the German Research Foundation (Ro2327/8-1).	Abrahamsen B, 2013, J NEUROSCI, V33, P1068, DOI 10.1523/JNEUROSCI.3396-12.2013; Adamczyk A, 2011, PSYCHIAT GENET, V21, P90, DOI 10.1097/YPG.0b013e328341a307; Al Awabdh S, 2016, GLIA, V64, P1252, DOI 10.1002/glia.22997; Albrecht J, 2010, BIOCHEM PHARMACOL, V80, P1303, DOI 10.1016/j.bcp.2010.07.024; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; AMATO A, 1994, J NEUROPHYSIOL, V72, P1686, DOI 10.1152/jn.1994.72.4.1686; Anderson CM, 2000, GLIA, V32, P1; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Arnth-Jensen N, 2002, NAT NEUROSCI, V5, P325, DOI 10.1038/nn825; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Asztely F, 1997, NEURON, V18, P281, DOI 10.1016/S0896-6273(00)80268-8; Azarias G, 2011, J NEUROSCI, V31, P3550, DOI 10.1523/JNEUROSCI.4378-10.2011; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Bellamy TC, 2005, GLIA, V52, P325, DOI 10.1002/glia.20248; Ben-Ari Y, 2001, TRENDS NEUROSCI, V24, P353, DOI 10.1016/S0166-2236(00)01813-0; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Benediktsson AM, 2012, GLIA, V60, P175, DOI 10.1002/glia.21249; Bennay M, 2008, GLIA, V56, P1138, DOI 10.1002/glia.20685; Bergles DE, 2002, J NEUROSCI, V22, P10153; Bergles DE, 1999, CURR OPIN NEUROBIOL, V9, P293, DOI 10.1016/S0959-4388(99)80043-9; Bergles DE, 1997, P NATL ACAD SCI USA, V94, P14821, DOI 10.1073/pnas.94.26.14821; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bernardinelli Y, 2004, P NATL ACAD SCI USA, V101, P14937, DOI 10.1073/pnas.0405315101; Billups D, 2013, J NEUROSCI, V33, P17429, DOI 10.1523/JNEUROSCI.1466-13.2013; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Bordey A, 2003, J NEUROPHYSIOL, V89, P979, DOI 10.1152/jn.00904.2002; Bordey A, 1997, J NEUROPHYSIOL, V78, P461, DOI 10.1152/jn.1997.78.1.461; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; BOWMAN CL, 1984, NATURE, V311, P656, DOI 10.1038/311656a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Broer A, 2002, J PHYSIOL-LONDON, V539, P3, DOI 10.1013/jphysiol.2001.013303; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Carmona MA, 2009, P NATL ACAD SCI USA, V106, P12524, DOI 10.1073/pnas.0903328106; Cater RJ, 2016, J GEN PHYSIOL, V148, P13, DOI 10.1085/jgp.201511556; Cauli O, 2009, METAB BRAIN DIS, V24, P69, DOI 10.1007/s11011-008-9115-4; Chan H, 2003, NEUROCHEM INT, V43, P525, DOI 10.1016/S0197-0186(03)00043-3; Chatton JY, 2016, GLIA, V64, P1667, DOI 10.1002/glia.22971; Chatton JY, 2000, EUR J NEUROSCI, V12, P3843, DOI 10.1046/j.1460-9568.2000.00269.x; Chatton JY, 2001, BRAIN RES, V893, P46, DOI 10.1016/S0006-8993(00)03286-8; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Chen JC, 2005, NEUROPHARMACOLOGY, V49, P703, DOI 10.1016/j.neuropharm.2005.05.002; Chen S, 2002, J NEUROSCI, V22, P2165, DOI 10.1523/JNEUROSCI.22-06-02165.2002; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Cholet N, 2002, CEREB CORTEX, V12, P515, DOI 10.1093/cercor/12.5.515; Clark BA, 2002, J NEUROSCI, V22, P4428, DOI 10.1523/JNEUROSCI.22-11-04428.2002; COOPER AJL, 1987, NEUROCHEM PATHOL, V6, P67, DOI 10.1007/BF02833601; COOPER AJL, 1979, J BIOL CHEM, V254, P4982; Crisman TJ, 2009, P NATL ACAD SCI USA, V106, P20752, DOI 10.1073/pnas.0908570106; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Deitmer JW, 2010, BRAIN RES REV, V63, P113, DOI 10.1016/j.brainresrev.2009.10.006; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dvorzhak A, 2016, J NEUROSCI, V36, P4959, DOI 10.1523/JNEUROSCI.0316-16.2016; Escartin C, 2006, J NEUROSCI, V26, P5978, DOI 10.1523/JNEUROSCI.0302-06.2006; Ewers D, 2013, P NATL ACAD SCI USA, V110, P12486, DOI 10.1073/pnas.1300772110; Fahlke C, 2016, PFLUG ARCH EUR J PHY, V468, P491, DOI 10.1007/s00424-015-1768-3; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Fontana ACK, 2015, J NEUROCHEM, V134, P982, DOI 10.1111/jnc.13200; Foran E, 2014, GLIA, V62, P1241, DOI 10.1002/glia.22677; Furness DN, 1997, EUR J NEUROSCI, V9, P1961, DOI 10.1111/j.1460-9568.1997.tb00763.x; Furuta A, 1997, J NEUROSCI, V17, P8363; Gameiro A, 2011, BIOPHYS J, V100, P2623, DOI 10.1016/j.bpj.2011.04.034; Garaschuk O, 1998, J PHYSIOL-LONDON, V507, P219, DOI 10.1111/j.1469-7793.1998.219bu.x; Gegelashvili G, 2001, Prog Brain Res, V132, P267; Gegelashvili G, 2014, J NEUROCHEM, V131, P712, DOI 10.1111/jnc.12957; Genda EN, 2011, J NEUROSCI, V31, P18275, DOI 10.1523/JNEUROSCI.3305-11.2011; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; Genoud C, 2006, PLOS BIOL, V4, P2057, DOI 10.1371/journal.pbio.0040343; Giaume C, 2010, NAT REV NEUROSCI, V11, P87, DOI 10.1038/nrn2757; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Glowatzki E, 2006, J NEUROSCI, V26, P7659, DOI 10.1523/JNEUROSCI.1545-06.2006; Gonzalez-Gonzalez IM, 2009, J NEUROCHEM, V110, P264, DOI 10.1111/j.1471-4159.2009.06125.x; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grewer C, 2005, BIOCHEMISTRY-US, V44, P11913, DOI 10.1021/bi050987n; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; Grewer C, 2012, J BIOL CHEM, V287, P26921, DOI 10.1074/jbc.M112.364059; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Hanelt I, 2015, J BIOL CHEM, V290, P15962, DOI 10.1074/jbc.M115.656876; Hanson E, 2015, GLIA, V63, P1784, DOI 10.1002/glia.22844; Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962; Hasegawa J, 2006, NEURON, V50, P63, DOI 10.1016/j.neuron.2006.02.022; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Herman MA, 2007, J NEUROSCI, V27, P9736, DOI 10.1523/JNEUROSCI.3009-07.2007; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.0.CO;2-N; Holmseth S, 2012, J NEUROSCI, V32, P6000, DOI 10.1523/JNEUROSCI.5347-11.2012; Huang H, 2004, J NEUROSCI, V24, P5659, DOI 10.1523/JNEUROSCI.1338-04.2004; Huang YHH, 2004, CURR OPIN NEUROBIOL, V14, P346, DOI 10.1016/j.conb.2004.05.007; Huang YHH, 2004, J NEUROSCI, V24, P103, DOI 10.1523/JNEUROSCI.4473-03.2004; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jen JC, 2005, NEUROLOGY, V65, P529, DOI 10.1212/01.WNL.0000172638.58172.5a; Jensen AA, 2015, CURR OPIN PHARMACOL, V20, P116, DOI 10.1016/j.coph.2014.10.008; Jensen AA, 2009, J MED CHEM, V52, P912, DOI 10.1021/jm8013458; Jensen S, 2013, NAT STRUCT MOL BIOL, V20, P1224, DOI 10.1038/nsmb.2663; Kafitz KW, 2008, J NEUROSCI METH, V169, P84, DOI 10.1016/j.jneumeth.2007.11.022; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P3143, DOI 10.1021/bi00256a017; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Karus C, 2015, GLIA, V63, P936, DOI 10.1002/glia.22793; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Kelly T, 2010, J NEUROCHEM, V115, P1123, DOI 10.1111/j.1471-4159.2010.07009.x; Kelly T, 2009, GLIA, V57, P921, DOI 10.1002/glia.20817; KETTENMANN H, 1984, NEUROSCI LETT, V52, P25, DOI 10.1016/0304-3940(84)90345-8; Kirischuk S, 2007, PFLUG ARCH EUR J PHY, V454, P245, DOI 10.1007/s00424-007-0207-5; Kirischuk S, 2016, GLIA, V64, P1655, DOI 10.1002/glia.22943; Koch HP, 2007, J NEUROSCI, V27, P2943, DOI 10.1523/JNEUROSCI.0118-07.2007; Kovermann P, 2010, J BIOL CHEM, V285, P23676, DOI 10.1074/jbc.M110.126557; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; Kugler P, 2004, HIPPOCAMPUS, V14, P975, DOI 10.1002/hipo.20015; Langer J, 2017, GLIA, V65, P293, DOI 10.1002/glia.23092; Langer J, 2009, J PHYSIOL-LONDON, V587, P5859, DOI 10.1113/jphysiol.2009.182279; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; Leary GP, 2007, J NEUROSCI, V27, P2938, DOI 10.1523/JNEUROSCI.4851-06.2007; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1997, BRAIN RES, V744, P129, DOI 10.1016/S0006-8993(96)01022-0; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Linden DJ, 1997, NEURON, V18, P983, DOI 10.1016/S0896-6273(00)80337-2; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Machtens JP, 2015, CELL, V160, P542, DOI 10.1016/j.cell.2014.12.035; MACVICAR BA, 1989, J NEUROSCI, V9, P3577; Magistretti PJ, 2005, J NEURAL TRANSM, V112, P77, DOI 10.1007/s00702-004-0171-6; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Marcaggi P, 2004, GLIA, V47, P217, DOI 10.1002/glia.20027; Marcaggi P, 2003, J PHYSIOL-LONDON, V552, P89, DOI 10.1113/jphysiol.2003.044263; Marcaggi P, 2001, PROG NEUROBIOL, V64, P157, DOI 10.1016/S0301-0082(00)00043-5; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Matsugami TR, 2006, P NATL ACAD SCI USA, V103, P12161, DOI 10.1073/pnas.0509144103; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Meier SD, 2008, GLIA, V56, P1127, DOI 10.1002/glia.20684; Melzer N, 2005, P NATL ACAD SCI USA, V102, P19214, DOI 10.1073/pnas.0508837103; Melzer N, 2003, J BIOL CHEM, V278, P50112, DOI 10.1074/jbc.M307990200; Mennerick S, 1998, J NEUROSCI, V18, P4490; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mim C, 2005, J GEN PHYSIOL, V126, P571, DOI 10.1085/jgp.200509365; Mim C, 2007, BIOCHEMISTRY-US, V46, P9007, DOI 10.1021/bi7005465; Minelli A, 2001, NEUROSCIENCE, V108, P51, DOI 10.1016/S0306-4522(01)00375-X; Mongin A. A., 2015, PFLUGERS ARCH, V468, P421; Morel L, 2014, J NEUROSCI, V34, P10950, DOI 10.1523/JNEUROSCI.1167-14.2014; Moretto MB, 2005, EXP NEUROL, V195, P400, DOI 10.1016/j.expneurol.2005.06.005; MULLER T, 1994, J NEUROSCI, V14, P2503; Munch C, 2002, J NEUROCHEM, V82, P594, DOI 10.1046/j.1471-4159.2002.01012.x; Murphy-Royal C, 2015, NAT NEUROSCI, V18, P219, DOI 10.1038/nn.3901; Nakagawa T, 2008, EUR J NEUROSCI, V28, P1719, DOI 10.1111/j.1460-9568.2008.06494.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Nothmann D, 2011, J BIOL CHEM, V286, P3935, DOI 10.1074/jbc.M110.187492; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Otis TS, 2000, J NEUROSCI, V20, P2749; Overstreet LS, 1999, J NEUROSCI, V19, P9663; Owe SG, 2006, J PHYSIOL-LONDON, V577, P591, DOI 10.1113/jphysiol.2006.116830; Pannasch U, 2014, NAT NEUROSCI, V17, P549, DOI 10.1038/nn.3662; Parinejad N, 2016, J NEUROSCI, V36, P7640, DOI 10.1523/JNEUROSCI.0197-16.2016; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Pellerin L, 1997, J NEUROCHEM, V69, P2132; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Petr GT, 2015, J NEUROSCI, V35, P5187, DOI 10.1523/JNEUROSCI.4255-14.2015; Phillis JW, 1996, BRAIN RES, V730, P150; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Pow DV, 2000, NEUROSCI LETT, V280, P21, DOI 10.1016/S0304-3940(99)00988-X; Rao KVR, 2012, NEUROCHEM INT, V61, P575, DOI 10.1016/j.neuint.2012.01.012; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Raponi E, 2007, GLIA, V55, P165, DOI 10.1002/glia.20445; Rauen T, 2004, NEUROCHEM INT, V45, P1095, DOI 10.1016/j.neuint.2004.04.006; Rauen T, 2000, AMINO ACIDS, V19, P53, DOI 10.1007/s007260070033; Reyes N, 2009, NATURE, V462, P880, DOI 10.1038/nature08616; Rimmele TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109243; Rivera C, 2005, J PHYSIOL-LONDON, V562, P27, DOI 10.1113/jphysiol.2004.077495; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Rose CR, 2016, GLIA, V64, P1611, DOI 10.1002/glia.22964; Rose CR, 1996, J NEUROSCI, V16, P5393; Rose EM, 2009, J NEUROSCI, V29, P8143, DOI 10.1523/JNEUROSCI.1081-09.2009; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rusakov DA, 1998, J NEUROSCI, V18, P3158; Ryan RM, 2010, J NEUROCHEM, V114, P565, DOI 10.1111/j.1471-4159.2010.06796.x; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Schneider N, 2014, J BIOL CHEM, V289, P1815, DOI 10.1074/jbc.M113.517177; Schousboe A, 2003, NEUROCHEM RES, V28, P347, DOI 10.1023/A:1022397704922; Schousboe A, 2004, NEUROCHEM INT, V45, P521, DOI 10.1016/j.neuint.2003.11.001; Schousboe A, 2014, ADV NEUROBIOL, V11, P13, DOI 10.1007/978-3-319-08894-5_2; Schreiner A. E., 2013, ISRN NEUROL; Schreiner AE, 2014, J COMP NEUROL, V522, P204, DOI 10.1002/cne.23450; Shibata T, 1997, J NEUROSCI, V17, P9212; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Soni N, 2014, PHARMACOL BIOCHEM BE, V127, P70, DOI 10.1016/j.pbb.2014.10.001; SONNEWALD U, 1993, J NEUROCHEM, V61, P1179, DOI 10.1111/j.1471-4159.1993.tb03641.x; Sonnewald U, 2014, J NEUROCHEM, V131, P399, DOI 10.1111/jnc.12812; Stephan J, 2012, GLIA, V60, P965, DOI 10.1002/glia.22328; Stolzenberg S, 2012, J PHYS CHEM B, V116, P5372, DOI 10.1021/jp301726s; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sullivan R, 2004, GLIA, V45, P155, DOI 10.1002/glia.10317; Swanson RA, 1997, J NEUROSCI, V17, P932; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; Takasaki C, 2008, J NEUROSCI, V28, P4995, DOI 10.1523/JNEUROSCI.0861-08.2008; Takayasu Y, 2005, J NEUROSCI, V25, P8788, DOI 10.1523/JNEUROSCI.1020-05.2005; Takayasu Y, 2009, ACTA PHYSIOL, V197, P1, DOI 10.1111/j.1748-1716.2009.02019.x; Takumi Y, 1997, NEUROSCIENCE, V79, P1137, DOI 10.1016/S0306-4522(97)00025-0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Torres-Salazar D, 2007, J BIOL CHEM, V282, P34719, DOI 10.1074/jbc.M704118200; Tzingounis AV, 2007, NAT REV NEUROSCI, V8, P935, DOI 10.1038/nrn2274; Ullensvang K, 1997, EUR J NEUROSCI, V9, P1646, DOI 10.1111/j.1460-9568.1997.tb01522.x; Ullian EM, 2004, GLIA, V47, P209, DOI 10.1002/glia.20082; Untiet V, 2017, GLIA, V65, P388, DOI 10.1002/glia.23098; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Uwechue NM, 2012, J PHYSIOL-LONDON, V590, P2317, DOI 10.1113/jphysiol.2011.226605; Vallejo-Illarramendi A, 2005, J NEUROCHEM, V95, P341, DOI 10.1111/j.1471-4159.2005.03370.x; van Amen-Hellebrekers C. J., 2016, EUR J MED GENET; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Vandenberg RJ, 2013, PHYSIOL REV, V93, P1621, DOI 10.1152/physrev.00007.2013; Venkatesan S, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004551; Verbich D, 2012, GLIA, V60, P1067, DOI 10.1002/glia.22335; Verdon G, 2014, ELIFE, V3, DOI 10.7554/eLife.02283; Verdon G, 2012, NAT STRUCT MOL BIOL, V19, P355, DOI 10.1038/nsmb.2233; Vermeiren C, 2005, J NEUROCHEM, V94, P405, DOI 10.1111/j.1471-4159.2005.03216.x; Veruki ML, 2006, NAT NEUROSCI, V9, P1388, DOI 10.1038/nn1793; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Watzke N, 2000, J GEN PHYSIOL, V116, P609, DOI 10.1085/jgp.116.5.609; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Wersinger E, 2006, J PHYSIOL-LONDON, V577, P221, DOI 10.1113/jphysiol.2006.118281; Winter N, 2012, BRAIN, V135, P3416, DOI 10.1093/brain/aws255; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; Yang YJ, 2009, NEURON, V61, P880, DOI 10.1016/j.neuron.2009.02.010; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; ZHANG YM, 1994, J BIOL CHEM, V269, P19573; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751; Zhang Z, 2007, P NATL ACAD SCI USA, V104, P18025, DOI 10.1073/pnas.0704570104; Zheng KY, 2008, BIOPHYS J, V95, P4584, DOI 10.1529/biophysj.108.129874; Zhou JZ, 2004, J NEUROSCI, V24, P6301, DOI 10.1523/JNEUROSCI.1404-04.2004; Zhou M, 2006, J NEUROPHYSIOL, V95, P134, DOI 10.1152/jn.00570.2005; Zhou Y, 2014, J NEUROSCI, V34, P13472, DOI 10.1523/JNEUROSCI.2282-14.2014; Zomot E, 2007, NATURE, V449, P726, DOI 10.1038/nature06133	264	38	38	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN	2018	136				SI		3	16		10.1016/j.brainresbull.2016.12.013			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FU2AX	WOS:000423651700002	28040508				2022-02-06	
J	Hill, RL; Singh, IN; Wang, JA; Hall, ED				Hill, Rachel L.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Time courses of post-injury mitochondrial oxidative damage and respiratory dysfunction and neuronal cytoskeletal degradation in a rat model of focal traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Mitochondria; Peroxynitrite 4-hydroxynonenal; Acrolein; Calpain	CONTROLLED CORTICAL IMPACT; LATERAL FLUID PERCUSSION; CYCLOSPORINE-A ANALOG; LIPID-PEROXIDATION; NITRIC-OXIDE; CELL-DEATH; ANTIOXIDANT THERAPIES; HIPPOCAMPAL-NEURONS; MOUSE MODEL; CALPAIN-I	Traumatic brain injury (TBI) results in rapid reactive oxygen species (ROS) production and oxidative damage to essential brain cellular components leading to neuronal dysfunction and cell death. It is increasingly appreciated that a major player in TBI-induced oxidative damage is the reactive nitrogen species (RNS) peroxynitrite (PN) which is produced in large part in injured brain mitochondria. Once formed, PN decomposes into highly reactive free radicals that trigger membrane lipid peroxidation (LP) of polyunsaturated fatty acids (e.g. arachidonic acid) and protein nitration (3-nitrotyrosine, 3-NT) in mitochondria and other cellular membranes causing various functional impairments to mitochondrial oxidative phosphorylation and calcium (Ca2+) buffering capacity. The LP also results in the formation of neurotoxic reactive aldehyde byproducts including 4-hydroxynonenal (4-HNE) and propenal (acrolein) which exacerbates ROS/RNS production and oxidative protein damage in the injured brain. Ultimately, this results in intracellular Ca2+ overload that activates proteolytic degradation of alpha-spectrin, a neuronal cytoskeletal protein. Therefore, the aim of this study was to establish the temporal evolution of mitochondrial dysfunction, oxidative damage and cytoskeletal degradation in the brain following a severe controlled cortical impact (CCI) TBI in young male adult rats. In mitochondria isolated from an 8 mm diameter cortical punch including the 5 mm wide impact site and their respiratory function studied ex vivo, we observed an initial decrease in complex I and II mitochondrial bioenergetics within 3 h (h). For complex I bioenergetics, this partially recovered by 12-16 h, whereas for complex II respiration the recovery was complete by 12 h. During the first 24 h, there was no evidence of an injury-induced increase in LP or protein nitration in mitochondrial or cellular homogenates. However, beginning at 24 h, there was a gradual secondary decline in complex I and II respiration that peaked at 72 h. post-TBI that coincided with progressive peroxidation of mitochondrial and cellular lipids, protein nitration and protein modification by 4-HNE and acrolein. The oxidative damage and respiratory failure paralleled an increase in Ca2+-induced proteolytic degradation of the neuronal cytoskeletal protein alpha-spectrin indicating a failure of intracellular Ca2+ homeostasis. These findings of a surprisingly delayed peak in secondary injury, suggest that the therapeutic window and needed treatment duration for certain antioxidant treatment strategies following CCI-TBI in rodents may be longer than previously believed. (C) 2017 Elsevier Ltd. All rights reserved.	[Hill, Rachel L.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, 741 S Limestone St, Lexington, KY 40536 USA; [Singh, Indrapal N.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Neurosci, 741 S Limestone St, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr SCoBIRC, 741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01 NS083405, 5R01 NS084857, 5P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS077889, P30NS051220, R01NS083405, R01NS084857] Funding Source: NIH RePORTER	This work was supported by the following grants from the National Institute of Neurological Disorders and Stroke: 5R01 NS083405, 5R01 NS084857 and 5P30 NS051220.	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Facecchia K., 2011, J TOXICOL, V2011, P1; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Glancy B, 2012, BIOCHEMISTRY-US, V51, P2959, DOI 10.1021/bi2018909; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B., 2008, FREE RADICALS BIOL M; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kuznetsov AV, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00082; Lai J C, 1979, Methods Enzymol, V55, P51; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Llorente-Folch I, 2013, J NEUROSCI, V33, P13957, DOI 10.1523/JNEUROSCI.0929-13.2013; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nobre HV, 2009, OXID MED CELL LONGEV, V2, P130, DOI 10.4161/oxim.2.3.8488; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Ucal M, 2017, J NEUROTRAUM, V34, P475, DOI 10.1089/neu.2016.4411; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yan XX, 2012, CURR GERIATR REP, V1, P85, DOI 10.1007/s13670-012-0009-2; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	64	38	39	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		45	56		10.1016/j.neuint.2017.03.015			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600006	28342966	Green Accepted			2022-02-06	
J	Madden, LK; Hill, M; May, TL; Human, T; Guanci, MM; Jacobi, J; Moreda, MV; Badjatia, N				Madden, Lori Kennedy; Hill, Michelle; May, Teresa L.; Human, Theresa; Guanci, Mary McKenna; Jacobi, Judith; Moreda, Melissa V.; Badjatia, Neeraj			The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society	NEUROCRITICAL CARE			English	Article						Targeted temperature management; Hypothermia; Normothermia; Controlled normothermia; Fever treatment; Therapeutic hypothermia; Guideline; GRADE methodology; Implementation guideline; Shivering; Metabolism; Patient management; Systematic review; Complications	HOSPITAL CARDIAC-ARREST; MILD THERAPEUTIC HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; SHIVERING THRESHOLD; INTENSIVE-CARE; COMATOSE SURVIVORS; CARDIOPULMONARY-RESUSCITATION; MODERATE HYPOTHERMIA	Targeted temperature management (TTM) is often used in neurocritical care to minimize secondary neurologic injury and improve outcomes. TTM encompasses therapeutic hypothermia, controlled normothermia, and treatment of fever. TTM is best supported by evidence from neonatal hypoxic-ischemic encephalopathy and out-of-hospital cardiac arrest, although it has also been explored in ischemic stroke, traumatic brain injury, and intracranial hemorrhage patients. Critical care clinicians using TTM must select appropriate cooling techniques, provide a reasonable rate of cooling, manage shivering, and ensure adequate patient monitoring among other challenges. The Neurocritical Care Society recruited experts in neurocritical care, nursing, and pharmacotherapy to form a writing Committee in 2015. The group generated a set of 16 clinical questions relevant to TTM using the PICO format. With the assistance of a research librarian, the Committee undertook a comprehensive literature search with no back date through November 2016 with additional references up to March 2017. The Committee utilized GRADE methodology to adjudicate the quality of evidence as high, moderate, low, or very low based on their confidence that the estimate of effect approximated the true effect. They generated recommendations regarding the implementation of TTM based on this systematic review only after considering the quality of evidence, relative risks and benefits, patient values and preferences, and resource allocation. This guideline is intended for neurocritical care clinicians who have chosen to use TTM in patient care; it is not meant to provide guidance regarding the clinical indications for TTM itself. While there are areas of TTM practice where clear evidence guides strong recommendations, many of the recommendations are conditional, and must be contextualized to individual patient and system needs.	[Madden, Lori Kennedy] Univ Calif Davis, Sacramento, CA 95817 USA; [Hill, Michelle] Riverside Methodist Hosp, Columbus, OH 43214 USA; [May, Teresa L.] Maine Med Ctr, Portland, ME 04102 USA; [Human, Theresa] Washington Univ, Barnes Jewish Hosp, St Louis, MO USA; [Guanci, Mary McKenna] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Jacobi, Judith] Indiana Univ, Hlth Methodist Hosp, Indianapolis, IN 46204 USA; [Moreda, Melissa V.] Duke Raleigh Hosp, Raleigh, NC USA; [Badjatia, Neeraj] Univ Maryland, Baltimore, MD 21201 USA		Madden, LK (corresponding author), Univ Calif Davis, Sacramento, CA 95817 USA.	lkmadden@ucdavis.edu	Badjatia, Neeraj/AAS-4855-2021; Jacobi, Judith/ABE-2757-2020; Madden, Lori K/K-3749-2012	Jacobi, Judith/0000-0003-2421-0734; Madden, Lori K/0000-0001-9179-4202; Badjatia, Neeraj/0000-0003-1509-9034			Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Akula VP, 2015, J PEDIATR-US, V166, P856, DOI 10.1016/j.jpeds.2014.12.061; Alfonsi P, 2014, ANESTH ANALG, V119, P58, DOI 10.1213/ANE.0000000000000193; Alfonsi P, 2009, ANESTHESIOLOGY, V111, P102, DOI 10.1097/ALN.0b013e3181a979c1; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Argibay-Lago A, 2014, ENFERM CLIN, V24, P323, DOI 10.1016/j.enfcli.2014.07.004; Arulkumaran N, 2012, RESUSCITATION, V83, P151, DOI 10.1016/j.resuscitation.2011.10.002; Avery KR, 2015, CRIT CARE NURSE, V35, P29, DOI 10.4037/ccn2015937; Badjatia N, 2006, NEUROLOGY, V66, P1739, DOI 10.1212/01.wnl.0000218166.54150.0a; Badjatia N, 2007, NEUROCRIT CARE, V6, P186, DOI 10.1007/s12028-007-0011-2; Badjatia N, 2010, NEUROSURGERY, V66, P696, DOI 10.1227/01.NEU.0000367618.42794.AA; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bagna FC, 2013, OPEN CRIT CARE MED J, V6, P31; Bardutzky J, 2004, INTENS CARE MED, V30, P151, DOI 10.1007/s00134-003-1988-4; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; BEAUFORT AM, 1995, EUR J ANAESTH, V12, P95; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bednar F, 2016, J THROMB THROMBOLYS, V41, P549, DOI 10.1007/s11239-015-1274-7; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 2016, CIRCULATION, V134, P797, DOI 10.1161/CIRCULATIONAHA.116.021989; Bjelland TW, 2014, ACTA ANAESTH SCAND, V58, P709, DOI 10.1111/aas.12300; Bjelland TW, 2013, DRUG METAB DISPOS, V41, P214, DOI 10.1124/dmd.112.045567; Boulant JA, 2006, J APPL PHYSIOL, V100, P1347, DOI 10.1152/japplphysiol.01064.2005; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Broessner G, 2009, STROKE, V40, pE657, DOI 10.1161/STROKEAHA.109.557652; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Callaway CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129709; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; Chih-Hung W, 2015, MEDICINE, V94, P1; Chmayssani M, 2015, NEUROCRIT CARE, V22, P265, DOI 10.1007/s12028-014-0076-7; Choi HA, 2011, NEUROCRIT CARE, V14, P389, DOI 10.1007/s12028-010-9474-7; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Cueni-Villoz N, 2011, CRIT CARE MED, V39, P2225, DOI 10.1097/CCM.0b013e31822572c9; Cumming TB, 2011, STROKE, V42, P153, DOI 10.1161/STROKEAHA.110.594598; Curtis J, 2014, CRIT CARE MED, V42, pA1421; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; de Waard MC, 2015, EMERG MED J, V32, P775, DOI 10.1136/emermed-2014-203811; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; DELAUNAY L, 1993, ANESTHESIOLOGY, V79, P470, DOI 10.1097/00000542-199309000-00009; deWitte J, 1997, ACTA ANAESTH SCAND, V41, P506, DOI 10.1111/j.1399-6576.1997.tb04732.x; Deye N, 2015, CIRCULATION, V132, P182, DOI 10.1161/CIRCULATIONAHA.114.012805; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Dobak S, 2016, NEUROLOGY, P86; Donnino MW, 2015, CIRCULATION, V132, P2448, DOI 10.1161/CIR.0000000000000313; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Earp J K, 1992, Am J Crit Care, V1, P43; Eastwood GM, 2015, J CRIT CARE, V30, P138, DOI 10.1016/j.jcrc.2014.09.022; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Ettleson MD, 2014, J CLIN ENDOCR METAB, V99, pE2010, DOI 10.1210/jc.2014-1449; Fevold RT, 2015, J CRIT CARE, V30, P574, DOI 10.1016/j.jcrc.2015.01.016; Fink EL, 2012, PEDIATR CRIT CARE ME, V13, P80, DOI 10.1097/PCC.0b013e3181fe27c7; Flint AC, 2007, NEUROCRIT CARE, V7, P109, DOI 10.1007/s12028-007-0068-y; Fox M, 2012, CRIT CARE MED, V40, P235; Frank SM, 1997, AM J PHYSIOL-REG I, V272, pR557, DOI 10.1152/ajpregu.1997.272.2.R557; Fries M, 2009, J CRIT CARE, V24, P453, DOI 10.1016/j.jcrc.2008.10.012; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Gajarski RJ, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1199-9; Geocadin RG, 2017, NEUROLOGY, V88, P2141, DOI 10.1212/WNL.0000000000003966; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Greif R, 2001, ANESTH ANALG, V93, P620, DOI 10.1097/00000539-200109000-00018; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Hammer L, 2009, AM J EMERG MED, V27, P570, DOI 10.1016/j.ajem.2008.04.028; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hasper D, 2011, EMERG MED J, V28, P483, DOI 10.1136/emj.2009.090464; Hata JS, 2008, NEUROCRIT CARE, V9, P37, DOI 10.1007/s12028-007-9015-1; Haugk M, 2010, CRIT CARE MED, V38, P1569, DOI 10.1097/CCM.0b013e3181e47a20; Heard KJ, 2010, RESUSCITATION, V81, P9, DOI 10.1016/j.resuscitation.2009.09.015; Heier T, 2002, ANESTHESIOLOGY, V97, P90, DOI 10.1097/00000542-200207000-00013; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hodgson CL, 2013, CRIT CARE, V17, DOI 10.1186/cc11820; Hoedemaekers CW, 2007, CRIT CARE, V11, DOI 10.1186/cc6104; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzinger U, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0856-2; Hoque N, 2010, PEDIATRICS, V126, pE124, DOI 10.1542/peds.2009-2995; Hostler D, 2009, APPL PHYSIOL NUTR ME, V34, P582, DOI 10.1139/H09-011; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jacob M, 2015, RESUSCITATION, V96, P260, DOI 10.1016/j.resuscitation.2015.08.018; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Jacobshagen C, 2009, RESUSCITATION, V80, P1223, DOI 10.1016/j.resuscitation.2009.06.032; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jarrah S, 2011, NEUROCRIT CARE, V14, P382, DOI 10.1007/s12028-011-9506-y; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jeppesen AN, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1302-9; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Joffre J, 2014, RESUSCITATION, V85, P769, DOI 10.1016/j.resuscitation.2014.02.013; Jurado LV, 2011, PHARMACOTHERAPY, V31, P1250, DOI 10.1592/phco.31.12.1250; Kaufmann J, 2016, RESUSCITATION, V102, P63, DOI 10.1016/j.resuscitation.2016.02.012; Keegan SP, 2011, NEUROCRIT CARE, V15, pS219; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Knapik P, 2012, RESUSCITATION, V83, P208, DOI 10.1016/j.resuscitation.2011.09.001; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHT A, 1983, INTENS CARE MED, V9, P275, DOI 10.1007/BF01691254; Komatsu R, 2006, BRIT J ANAESTH, V96, P732, DOI 10.1093/bja/ael101; Krawczyk P, 2013, KARDIOL POL, V71, P270, DOI 10.5603/KP.2013.0040; Krizanac D, 2013, RESUSCITATION, V84, P805, DOI 10.1016/j.resuscitation.2012.11.022; Kurz A, 1997, ANESTHESIOLOGY, V86, P1046, DOI 10.1097/00000542-199705000-00007; Laish-Farkash A, 2007, ISR MED ASSOC J, V9, P252; Laptook AR, 2014, THER HYPOTHERMIA TEM, V4, P193, DOI 10.1089/ther.2014.0009; Lascarrou JB, 2014, RESUSCITATION, V85, P1257, DOI 10.1016/j.resuscitation.2014.05.017; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Leary M, 2014, RESUSCITATION, V85, P244, DOI 10.1016/j.resuscitation.2013.10.027; Lenhardt R, 2009, ANESTHESIOLOGY, V111, P110, DOI 10.1097/ALN.0b013e3181a979a3; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Logan A, 2011, CRIT CARE NURSE, V31, pE18, DOI 10.4037/ccn2011618; Lord AS, 2014, NEUROCRIT CARE, V21, P200, DOI 10.1007/s12028-013-9948-5; Lyden P, 2016, STROKE, V47, P2888, DOI 10.1161/STROKEAHA.116.014200; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Mahmood MA, 2007, J NEUROL SCI, V261, P47, DOI 10.1016/j.jns.2007.04.038; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markota A, 2015, J EMERG MED, V49, P98, DOI 10.1016/j.jemermed.2014.12.059; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; May T, 2011, NEUROCRIT CARE, V15, pS212; May T, 2011, RESUSCITATION, V82, P1100, DOI 10.1016/j.resuscitation.2011.03.037; Mayer KA, 2014, ACAD EMERG MED, V21, pS98; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Merchant RM, 2009, CIRC-CARDIOVASC QUAL, V2, P421, DOI 10.1161/CIRCOUTCOMES.108.839605; Milne SE, 2002, J CARDIOTHOR VASC AN, V16, P32, DOI 10.1053/jcan.2002.29657; Mirzoyev SA, 2010, RESUSCITATION, V81, P1632, DOI 10.1016/j.resuscitation.2010.08.007; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Moler FW, 2017, NEW ENGL J MED, V376, P318, DOI 10.1056/NEJMoa1610493; Mort TC, 1996, J CLIN ANESTH, V8, P361, DOI 10.1016/0952-8180(96)00081-5; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; Nakajima Y, 2002, ANESTH ANALG, V94, P1646, DOI 10.1097/00000539-200206000-00053; Nakamura T, 1998, ACT NEUR S, V71, P85; Nakamura T, 2008, ACTA NEUROCHIR SUPPL, V102, P203, DOI 10.1007/978-3-211-85578-2_40; Nicolaou G, 1997, CAN J ANAESTH, V44, P636, DOI 10.1007/BF03015448; Nielsen N, 2011, CIRCULATION, V124; Nihara Y, 2013, EUR J ANESTH S, V30, P189; O'Grady NP, 2008, CRIT CARE MED, V36, P1330, DOI 10.1097/CCM.0b013e318169eda9; Oddo M, 2010, NEUROCRIT CARE, V12, P10, DOI 10.1007/s12028-009-9280-2; Olson DM, 2013, AM J CRIT CARE, V22, P70, DOI 10.4037/ajcc2013907; Olson DaiWai M, 2008, Nurs Crit Care, V13, P305, DOI 10.1111/j.1478-5153.2008.00298.x; Oshima T, 2015, RESUSCITATION, V88, P81, DOI 10.1016/j.resuscitation.2014.12.025; Osuka A, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.05.012; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Park B, 2015, CRIT CARE MED, V43, P1757, DOI 10.1097/CCM.0000000000001014; Park SM, 2012, CRIT CARE MED, V40, P3070, DOI 10.1097/CCM.0b013e31825b931e; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Perrone S, 2010, PEDIATR NEUROL, V43, P236, DOI 10.1016/j.pediatrneurol.2010.05.009; Piironen K, 2014, STROKE, V45, P486, DOI 10.1161/STROKEAHA.113.003180; Pittl U, 2013, CLIN RES CARDIOL, V102, P607, DOI 10.1007/s00392-013-0572-3; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; POLI S, 2014, CRIT CARE, V18; Presciutti M, 2012, CRIT CARE NURSE, V32, P33, DOI 10.4037/ccn2012189; Puccio AM, 2009, NEUROCRIT CARE, V11, P82, DOI 10.1007/s12028-009-9213-0; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Rana M, 2011, INT J CARDIOL, V152, P321, DOI 10.1016/j.ijcard.2010.07.026; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Riker RR, 2015, BEST PRACT RES-CLIN, V29, P435, DOI 10.1016/j.bpa.2015.09.006; Salciccioli JD, 2013, RESUSCITATION, V84, P1728, DOI 10.1016/j.resuscitation.2013.06.008; Sanuth B, 2015, CRIT CARE MED, V43, P54; Seder DB, 2009, CRIT CARE MED, V37, pS211, DOI 10.1097/CCM.0b013e3181aa5bad; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; Seule M, 2012, CRIT CARE, V16, pA16, DOI [DOI 10.1186/CC11274, 10.1186/cc11274]; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Shinozaki K, 2012, AM J EMERG MED, V30, P1838, DOI 10.1016/j.ajem.2012.03.024; SLADEN RN, 1995, J CARDIOTHOR VASC AN, V9, P147, DOI 10.1016/S1053-0770(05)80185-5; Snider J, 2012, CRIT CARE MED, V40, pU159; Souckova L, 2013, EUR J CLIN PHARMACOL, V69, P309, DOI 10.1007/s00228-012-1360-0; Staykov D, 2013, NEUROCRIT CARE, V18, P178, DOI 10.1007/s12028-012-9762-5; Steblovnik K, 2016, CIRCULATION, V134, P2128, DOI 10.1161/CIRCULATIONAHA.116.024872; Stelfox HT, 2010, BMC ANESTHESIOL, V10, DOI 10.1186/1471-2253-10-13; Stiller K, 2013, CHEST, V144, P825, DOI 10.1378/chest.12-2930; Stockmann H, 2014, RESUSCITATION, V85, P1494, DOI 10.1016/j.resuscitation.2014.07.018; Sund-Levander M, 2000, J CLIN NURS, V9, P55, DOI 10.1046/j.1365-2702.2000.00352.x; Sunjic KM, 2015, CRIT CARE MED, V43, P2228, DOI 10.1097/CCM.0000000000001223; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Tanaka H, 2014, CRIT CARE, V18, pS181; Taniguchi Y, 2011, ANESTH ANALG, V113, P540, DOI 10.1213/ANE.0b013e3182273b19; Taniguchi Y, 2010, ANESTH ANALG, V111, P409, DOI 10.1213/ANE.0b013e3181e332bb; Taylor BE, 2016, CRIT CARE MED, V44, P390, DOI [10.1097/CCM.0000000000001525, 10.1177/0148607115621863]; Tiainen M, 2009, CRIT CARE MED, V37, P403, DOI 10.1097/CCM.0b013e31819572c4; Tilemann LM, 2016, CLIN RES CARDIOL, V105, P332, DOI 10.1007/s00392-015-0925-1; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Toma A, 2010, CRIT CARE MED, V38, P504, DOI 10.1097/CCM.0b013e3181cb0a02; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Trauma Quality Improvement Program (TQIP), 2015, BEST PRACT MAN TRAUM; Vaga A, 2008, RESUSCITATION, V76, P25, DOI 10.1016/j.resuscitation.2007.07.008; Varon J, 2008, RESUSCITATION, V78, P248, DOI 10.1016/j.resuscitation.2008.03.223; Wadhwa A, 2005, BRIT J ANAESTH, V94, P756, DOI 10.1093/bja/aei105; Wahby KA, 2014, RESUSCITATION, V85, P533, DOI 10.1016/j.resuscitation.2013.12.014; Williams ML, 2014, RESUSCITATION, V85, P1469, DOI 10.1016/j.resuscitation.2014.08.018; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Zeiner A, 2004, RESUSCITATION, V60, P253, DOI 10.1016/j.resuscitation.2003.11.006; Zeiner A, 2010, RESUSCITATION, V81, P861, DOI 10.1016/j.resuscitation.2010.03.018; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zweifler RM, 2004, STROKE, V35, P2331, DOI 10.1161/01.STR.0000141161.63181.f1	205	38	48	1	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2017	27	3					468	487		10.1007/s12028-017-0469-5			20	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FN7DT	WOS:000416179300020	29038971	Bronze			2022-02-06	
J	Nikolian, VC; Georgoff, PE; Pai, MP; Dennahy, IS; Chtraklin, K; Eidy, H; Ghandour, MH; Han, YY; Srinivasan, A; Li, YQ; Alam, HB				Nikolian, Vahagn C.; Georgoff, Patrick E.; Pai, Manjunath P.; Dennahy, Isabel S.; Chtraklin, Kiril; Eidy, Hassan; Ghandour, Mohamed H.; Han, Yanyan; Srinivasan, Ashok; Li, Yongqing; Alam, Hasan B.			Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	47th Annual Meeting of the Western-Trauma-Association (WTA)	MAR 05-10, 2017	Snowbird, UT	Western Trauma Assoc		Valproic acid; traumatic brain injury; polytrauma; neurologic recovery; swine	HISTONE DEACETYLASE INHIBITION; TRANS-RETINOIC ACID; FRESH-FROZEN PLASMA; RODENT MODEL; PHARMACOLOGICAL RESUSCITATION; PROSURVIVAL PHENOTYPE; PORCINE MODEL; DIFFERENTIATION; ACETYLATION; HYPOTHERMIA	BACKGROUND We have previously shown that treatment with valproic acid (VPA) decreases brain lesion size in swine models of traumatic brain injury (TBI) and controlled hemorrhage. To translate this treatment into clinical practice, validation of drug efficacy and evaluation of pharmacologic properties in clinically realistic models of injury are necessary. In this study, we evaluate neurologic outcomes and perform pharmacokinetic analysis of a single dose of VPA in swine subjected to TBI, hemorrhagic shock, and visceral hemorrhage. METHODS Yorkshire swine (n = 5/cohort) were subjected to TBI, hemorrhagic shock, and polytrauma (liver and spleen injury, rib fracture, and rectus abdominis crush). Animals remained in hypovolemic shock for 2 hours before resuscitation with isotonic sodium chloride solution (ISCS; volume = 3x hemorrhage) or ISCS + VPA (150 mg/kg). Neurologic severity scores were assessed daily for 30 days, and brain lesion size was measured via magnetic resonance imaging on postinjury days (PID) 3 and 10. Serum samples were collected for pharmacokinetic analysis. RESULTS Shock severity and response to resuscitation were similar in both groups. Valproic acid-treated animals demonstrated significantly less neurologic impairment between PID 1 to 5 and smaller brain lesions on PID 3 (mean lesion size SEM, mm(3): ISCS = 4,956 1,511 versus ISCS + VPA = 828 +/- 279; p = 0.047). No significant difference in lesion size was identified between groups at PID 10 and all animals recovered to baseline neurologic function during the 30-day observation period. Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean +/- SD: ISCS = 6.2 +/- 1.6 vs ISCS + VPA = 3.6 +/- 1.5; p = 0.002; days to task mastery: ISCS = 7.0 +/- 1.0 vs ISCS + VPA = 4.8 +/- 0.5; p = 0.03). The mean +/- SD maximum VPA concentrations, area under the curve, and half-life were 145 +/- 38.2 mg/L, 616 +/- 150 hour<bold>mg</bold>/L, and 1.70 +/- 0.12 hours. CONCLUSIONS In swine subjected to TBI, hemorrhagic shock, and polytrauma, VPA treatment is safe, decreases brain lesion size, and reduces neurologic injury compared to resuscitation with ISCS alone. These benefits are achieved at clinically translatable serum concentrations of VPA. LEVEL OF EVIDENCE Therapeutic (preclinical study).	[Nikolian, Vahagn C.; Georgoff, Patrick E.; Dennahy, Isabel S.; Chtraklin, Kiril; Eidy, Hassan; Ghandour, Mohamed H.; Han, Yanyan; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Pai, Manjunath P.] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Han, Yanyan] Univ Michigan, Dept Pharmaceut Sci, Coll Pharm, Ann Arbor, MI 48109 USA; [Srinivasan, Ashok] Univ Michigan, Dept Radiol, Neuroradiol Sect, Ann Arbor, MI 48109 USA		Alam, HB (corresponding author), Univ Michigan Hosp, Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.; Alam, HB (corresponding author), Univ Michigan Hosp, Gen Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Dennahy, Isabel/0000-0002-4778-8910	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-1-0520]; Frederick A. Coller Surgical Society Research Fellowship Award	This work was supported by a grant from the US Army Medical Research and Materiel Command, Contract W81XWH-09-1-0520 (PI: Hasan B. Alam). In addition, components of this project were funded by grants award from the Frederick A. Coller Surgical Society Research Fellowship Award (Awardee: Vahagn C. Nikolian).	Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; Bambakidis T, 2016, J NEUROTRAUM, V33, P1514, DOI 10.1089/neu.2015.4163; Causey MW, 2013, J SURG RES, V184, P533, DOI 10.1016/j.jss.2013.03.087; Cimino G, 2006, CANCER RES, V66, P8903, DOI 10.1158/0008-5472.CAN-05-2726; Das C, 2005, IUBMB LIFE, V57, P137, DOI 10.1080/15216540500090629; de Vries HM, 2014, J TRAUMA ACUTE CARE, V77, P183, DOI 10.1097/TA.0000000000000252; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Findlay LJ, 2015, THER CLIN RISK MANAG, V11, P75, DOI 10.2147/TCRM.S57695; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Georgoff PE, 2016, J AM COLL SURGEONS, V223, pS160, DOI 10.1016/j.jamcollsurg.2016.06.347; Georgoff PE, 2016, J TRAUMA ACUTE CARE, V81, P1020, DOI 10.1097/TA.0000000000001249; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Halaweish I, 2015, SHOCK, V44, P6, DOI 10.1097/SHK.0000000000000319; Halaweish I, 2015, J AM COLL SURGEONS, V220, P809, DOI 10.1016/j.jamcollsurg.2015.01.057; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hwabejire JO, 2014, J SURG RES, V186, P363, DOI 10.1016/j.jss.2013.09.016; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jepsen CH, 2014, J TRAUMA ACUTE CARE, V77, P292, DOI 10.1097/TA.0000000000000333; Jin G, 2014, SURGERY, V156, P221, DOI 10.1016/j.surg.2014.03.038; Jin G, 2011, SURGERY, V150, P429, DOI 10.1016/j.surg.2011.07.001; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; Kotwal RS, 2016, JAMA SURG, V151, P15, DOI 10.1001/jamasurg.2015.3104; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; Lennartsson A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0043-3; Li YQ, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/523481; Lin T, 2007, SURGERY, V141, P784, DOI 10.1016/j.surg.2007.01.014; Liu ZC, 2014, SHOCK, V41, P104, DOI 10.1097/SHK.0000000000000074; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Nanau RM, 2013, CLIN BIOCHEM, V46, P1323, DOI 10.1016/j.clinbiochem.2013.06.012; Pataskar A, 2016, EMBO J, V35, P24, DOI 10.15252/embj.201591206; Rasmussen Todd E, 2015, J Trauma Acute Care Surg, V79, pS61, DOI 10.1097/TA.0000000000000795; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; Wanczyk M, 2011, FRONT BIOSCI-LANDMRK, V16, P340, DOI 10.2741/3691	40	38	39	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2017	83	6					1066	1073		10.1097/TA.0000000000001612			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	FO4RL	WOS:000416832700010	28697014				2022-02-06	
J	Zhao, YY; Lee, JH; Chen, DD; Gu, XH; Caslin, A; Li, JM; Yu, SP; Wei, L				Zhao, Yingying; Lee, Jin Hwan; Chen, Dongdong; Gu, Xiaohuan; Caslin, Asha; Li, Jimei; Yu, Shan Ping; Wei, Ling			DL-3-n-butylphthalide induced neuroprotection, regenerative repair, functional recovery and psychological benefits following traumatic brain injury in mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						NBP; Traumatic brain injury; Regeneration; Inflammation; Depression	FOCAL CEREBRAL-ISCHEMIA; PHARMACOLOGICALLY INDUCED HYPOTHERMIA; ADULT-RAT HIPPOCAMPUS; NEURAL STEM; CHIRAL 3-N-BUTYLPHTHALIDE; PARKINSONS-DISEASE; PROGENITOR CELLS; DENTATE GYRUS; NITRIC-OXIDE; HEAD-INJURY	Previous investigations suggest that DL-3-n-butylphthalide (NBP) is a promising multifaceted drug for the treatment of stroke. It is not clear whether NBP can treat traumatic brain injury (TBI) and what could be the mechanisms of therapeutic benefits. To address these issues, TBI was induced by a controlled cortical impact in adult male mice. NBP (100 mg/kg) or saline was intraperitoneally administered within 5 min after TBI. One day after TBI, apoptotic events including caspase-3/9 activation, cytochrome c release from the mitochondria, and apoptosis-inducing factor (AIF) translocation into the nucleus in the pericontusion region were attenuated in NBP-treated mice compared to TBI-saline controls. In the assessment of the nuclear factor kappa-light-chain-enhancer of activated B (NF-kappa B) pathway, NBP ameliorated the p65 expression and the p-I kappa B-alpha/I kappa B-alpha ratio, indicating reduced NF-kappa B activation. Consistently, NBP reduced the upregulation of proinflammatory cytokines such as tumor necrotizing factor-alpha (TNF-alpha) and interleukin-1beta (IL-1 beta) after TBI. In sub-acute treatment experiments, NBP was intranasally delivered once daily for 3 days. At 3 days after TBI, this repeated NBP treatment significantly reduced the contusion volume and cell death in the pericontusion region. In chronic experiments up to 21 days after TBI, continues daily intranasal NBP treatment increased neurogenesis, angiogenesis, and arteriogenesis in the post-TBI brain, accompanied with up regulations of regenerative genes including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), endothelial-derived nitric oxide synthase (eNOS), and matrix metallopeptidase 9 (MMP-9). The NBP treatment significantly improved sensorimotor functional recovery and reduced post-TBP depressive behavior. These new findings demonstrate that NBP shows multiple therapeutic benefits after TBI. (C) 2017 Elsevier Ltd. All rights reserved.	[Zhao, Yingying; Li, Jimei; Yu, Shan Ping] Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Lab Stem Cell Biol & Neural Regenerat & Funct Reco, Beijing 100050, Peoples R China; [Zhao, Yingying; Lee, Jin Hwan; Chen, Dongdong; Gu, Xiaohuan; Caslin, Asha; Yu, Shan Ping; Wei, Ling] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Dept Neurol, Sch Med, Atlanta, GA 30322 USA; [Lee, Jin Hwan; Chen, Dongdong; Gu, Xiaohuan; Yu, Shan Ping] VA Med Ctr, Ctr Visual & Neurocognit Rehabil Atlanta, Decatur, GA 30033 USA		Wei, L (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,Woodruff Mem Res Bldg, Atlanta, GA 30322 USA.; Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle, Atlanta, GA 30322 USA.	lwei7@emory.edu		Yu, Shan Ping/0000-0003-1335-1398	VA Merit grant [RX000666]; AHA Postdoctoral FellowshipAmerican Heart Association [15POST25680013];  [NS075338];  [NS085568];  [NS091585]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS085568, R01NS091585, R21NS075338] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This study was supported by NS075338 (LW), NS085568 (LW/SPY), NS091585 (LW), AHA Postdoctoral Fellowship 15POST25680013 (JHL), and a VA Merit grant RX000666 (SPY).	Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Ben-Hur T, 2003, MOL CELL NEUROSCI, V24, P623, DOI 10.1016/S1044-7431(03)00218-5; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009; Chang Q, 2003, ACTA PHARMACOL SIN, V24, P796; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Chong ZZ, 2000, CHINESE MED J-PEKING, V113, P613; Chong ZZ, 1999, ACTA PHARMACOL SIN, V20, P696; Christoforidis GA, 2005, AM J NEURORADIOL, V26, P1789; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Collen A, 2003, BLOOD, V101, P1810, DOI 10.1182/blood-2002-05-1593; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cryan JF, 2005, PSYCHOPHARMACOLOGY, V182, P335, DOI 10.1007/s00213-005-0093-5; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; Deng W, 1997, Chin Med Sci J, V12, P102; Djupesland P. G., THER DEILY, V5, P709; Dong Gao-xiang, 2002, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V24, P93; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Erdo Franciska, 2007, Orv Hetil, V148, P633, DOI 10.1556/OH.2007.27916; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Feng Y. P., 1995, Yaoxue Xuebao, V30, P741; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gertz K, 2006, CIRC RES, V99, P1132, DOI 10.1161/01.RES.0000250175.14861.77; Greenberg DA, 2013, CELL MOL LIFE SCI, V70, P1753, DOI 10.1007/s00018-013-1282-8; Guo WX, 2012, NAT PROTOC, V7, P2005, DOI 10.1038/nprot.2012.123; Huang JZ, 2010, NEUROSCI LETT, V475, P89, DOI 10.1016/j.neulet.2010.03.053; Jakubs K, 2008, J NEUROSCI, V28, P12477, DOI 10.1523/JNEUROSCI.3240-08.2008; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; Lee JH, 2016, BRAIN STRUCT FUNCT, V221, P3259, DOI 10.1007/s00429-015-1099-3; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Li JM, 2010, BRAIN RES, V1359, P216, DOI 10.1016/j.brainres.2010.08.061; Liao SJ, 2009, BRAIN RES, V1289, P69, DOI 10.1016/j.brainres.2009.06.018; Lin J. F., 1996, Yaoxue Xuebao, V31, P166; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu X. G., 1995, Yaoxue Xuebao, V30, P896; Liu XB, 2008, CNS NEUROL DISORD-DR, V7, P227, DOI 10.2174/187152708784936617; Contreras DL, 2006, PHARMACOL THERAPEUT, V112, P553, DOI 10.1016/j.pharmthera.2006.05.003; Ma SP, 2009, N-S ARCH PHARMACOL, V379, P565, DOI 10.1007/s00210-009-0398-8; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Mohamad O, 2013, J PHYSIOL-LONDON, V591, P149, DOI 10.1113/jphysiol.2012.239251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; NIBUYA M, 1995, J NEUROSCI, V15, P7539; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Peng Y, 2007, J PHARMACOL EXP THER, V321, P902, DOI 10.1124/jpet.106.118760; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Rolfe A, 2015, BRAIN NEUROTRAUMA MO; Rosenberg H, 2015, NEUROPSYCHOLOGY, V29, P509, DOI 10.1037/neu0000171; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Semenza GL, 2007, J CELL BIOCHEM, V102, P840, DOI 10.1002/jcb.21523; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tobin MK, 2014, J CEREBR BLOOD F MET, V34, P1573, DOI 10.1038/jcbfm.2014.130; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; Xiong NA, 2012, NEUROBIOL AGING, V33, P1777, DOI 10.1016/j.neurobiolaging.2011.03.007; Xu HL, 2000, ACTA PHARMACOL SIN, V21, P433; Yan CH, 1998, ACTA PHARMACOL SIN, V19, P117; Yokota T, 2006, STEM CELLS, V24, P13, DOI 10.1634/stemcells.2004-0346; Zhang L. Y., 1996, Yaoxue Xuebao, V31, P18; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhao YN, 2013, NEURAL REGEN RES, V8, P2615, DOI 10.3969/j.issn.1673-5374.2013.28.003	69	38	41	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		82	92		10.1016/j.neuint.2017.03.017			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600009	28359729	Green Accepted			2022-02-06	
J	Lynall, RC; Mauntel, TC; Pohlig, RT; Kerr, ZY; Dompier, TP; Hall, EE; Buckley, TA				Lynall, Robert C.; Mauntel, Timothy C.; Pohlig, Ryan T.; Kerr, Zachary Y.; Dompier, Thomas P.; Hall, Eric E.; Buckley, Thomas A.			Lower Extremity Musculoskeletal Injury Risk After Concussion Recovery in High School Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; adolescents; functional movement; dynamic balance	GENERALIZED ESTIMATING EQUATIONS; LONGITUDINAL DATA-ANALYSIS; GAIT BALANCE CONTROL; FOOTBALL PLAYERS; CONTROL DEFICITS; COLLEGIATE; ASSOCIATION; ADOLESCENTS; INCREASES; STATEMENT	Context: Although an association between concussion and musculoskeletal injury has been described in collegiate and professional athletes, no researchers have investigated an association in younger athletes. Objective: To determine if concussion in high school athletes increased the risk for lower extremity musculoskeletal injury after return to activity. Design: Observational cohort study. Setting: One hundred ninety-six high schools across 26 states. Patients or Other Participants: We used data from the National Athletic Treatment, Injury and Outcomes Network surveillance system. Athletic trainers provided information about sport-related concussions and musculoskeletal injuries in athletes in 27 sports, along with missed activity time due to these injuries. Main Outcome Measure(s): Three general estimating equations were modeled to predict the odds of sustaining (1) any lower extremity injury, (2) a time-loss lower extremity injury, or (3) a non-time-loss lower extremity injury after concussion. Predictors were the total number of previous injuries, number of previous concussions, number of previous lower extremity injuries, number of previous upper extremity injuries, and sport contact classification. Results: The initial dataset contained data from 18 216 athletes (females = 39%, n = 6887) and 46 217 injuries. Lower extremity injuries accounted for most injuries (56.3%), and concussions for 4.3% of total injuries. For every previous concussion, the odds of sustaining a subsequent time-loss lower extremity injury increased 34% (odds ratio [OR] = 1.34; 95% confidence interval [CI] = 1.13, 1.60). The number of previous concussions had no effect on the odds of sustaining any subsequent lower extremity injury (OR = 0.97; 95% CI = 0.89, 1.05) or a non-time-loss injury (OR = 1.01; 95% CI = 0.92, 1.10). Conclusions: Among high school athletes, concussion increased the odds of sustaining subsequent time-loss lower extremity injuries but not non-time-loss injuries. By definition, time-loss injuries may be considered more severe than non-time-loss injuries. The exact mechanism underlying the increased risk of lower extremity injury after concussion remains elusive and should be further explored in future research.	[Lynall, Robert C.] Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA; [Mauntel, Timothy C.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed, Bethesda, MD USA; [Pohlig, Ryan T.] Univ Delaware, Biostat Core Facil, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE 19716 USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN USA; [Hall, Eric E.] Elon Univ, Dept Exercise Sci, Elon, NC USA		Lynall, RC (corresponding author), Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA.	rlynall@uga.edu	Lynall, Robert/M-2888-2014; Buckley, Thomas A/B-7525-2016	Lynall, Robert/0000-0002-0785-6640; Buckley, Thomas A/0000-0002-0515-0150	National Athletic Trainers' Association Research & Education Foundation; Bio Crossroads in partnership; Central Indiana Corporate Partnership Foundation	Funding for this study was provided by the National Athletic Trainers' Association Research & Education Foundation and BioCrossroads in partnership with the Central Indiana Corporate Partnership Foundation. The funding organizations had no role in the design and conduct of this study; the collection, management, analysis, or data interpretation; the preparation, review, or manuscript approval; or the decision to submit the manuscript for publication. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the study sponsors. We thank the many athletic trainers who have volunteered their time and efforts to submit data to the NATION. Their efforts are greatly appreciated and have had a tremendously positive effect on the safety of high school student- athletes.	[Anonymous], 1988, PEDIATRICS, V81, P737; Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Dubose DF, 2017, MED SCI SPORT EXER, V49, P167, DOI 10.1249/MSS.0000000000001067; Ghisletta P, 2004, J EDUC BEHAV STAT, V29, P421, DOI 10.3102/10769986029004421; Gilbert FC, 2016, SPORTS HEALTH, V8, P661, DOI 10.1177/1941738116666509; Grier TL, 2011, MIL MED, V176, P1292, DOI 10.7205/MILMED-D-11-00215; Hauret KG, 2010, AM J PREV MED, V38, pS61, DOI 10.1016/j.amepre.2009.10.021; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kucera KL, 2016, MED SCI SPORT EXER, V48, P1053, DOI 10.1249/MSS.0000000000000872; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lynall RC, 2016, BRIT J SPORT MED, V50, P1211, DOI 10.1136/bjsports-2015-095360; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Federation of State High School Associations, 2015, PART STAT; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Oldham JR, 2017, SPORTS HEALTH, V9, P305, DOI 10.1177/1941738116680999; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Talarico MK, 2017, J SPORT SCI, V35, P1118, DOI 10.1080/02640414.2016.1211307; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	31	38	38	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV	2017	52	11					1028	1034		10.4085/1062-6050-52.11.22			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FR0MQ	WOS:000418756400005	29140128	Green Published, Bronze			2022-02-06	
J	Erdodi, LA; Tyson, BT; Shahein, AG; Lichtenstein, JD; Abeare, CA; Pelletier, CL; Zuccato, BG; Kucharski, B; Roth, RM				Erdodi, Laszlo A.; Tyson, Bradley T.; Shahein, Ayman G.; Lichtenstein, Jonathan D.; Abeare, Christopher A.; Pelletier, Chantalle L.; Zuccato, Brandon G.; Kucharski, Brittany; Roth, Robert M.			The power of timing: Adding a time-to-completion cutoff to the Word Choice Test and Recognition Memory Test improves classification accuracy	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Embedded validity indicators; Performance validity assessment; Recognition Memory Test; Time-to-completion cutoffs; Word Choice Test	TRAUMATIC BRAIN-INJURY; PERFORMANCE TEST-II; CARD SORTING TEST; LEARNING TEST-II; RESPONSE BIAS; FIGURE TEST; DIGIT SPAN; NEUROPSYCHOLOGICAL TESTS; INVALID PERFORMANCE; INCOMPLETE EFFORT	Introduction: The Recognition Memory Test (RMT) and Word Choice Test (WCT) are structurally similar, but psychometrically different. Previous research demonstrated that adding a time-to-completion cutoff improved the classification accuracy of the RMT. However, the contribution of WCT time-cutoffs to improve the detection of invalid responding has not been investigated. The present study was designed to evaluate the classification accuracy of time-to-completion on the WCT compared to the accuracy score and the RMT. Method: Both tests were administered to 202 adults (M-age=45.3 years, SD=16.8; 54.5% female) clinically referred for neuropsychological assessment in counterbalanced order as part of a larger battery of cognitive tests. Results: Participants obtained lower and more variable scores on the RMT (M=44.1, SD=7.6) than on the WCT (M=46.9, SD=5.7). Similarly, they took longer to complete the recognition trial on the RMT (M=157.2s,SD=71.8) than the WCT (M=137.2s, SD=75.7). The optimal cutoff on the RMT (43) produced .60 sensitivity at .87 specificity. The optimal cutoff on the WCT (47) produced .57 sensitivity at .87 specificity. Time-cutoffs produced comparable classification accuracies for both RMT (192s; .48 sensitivity at .88 specificity) and WCT (171s; .49 sensitivity at .91 specificity). They also identified an additional 6-10% of the invalid profiles missed by accuracy score cutoffs, while maintaining good specificity (.93-.95). Functional equivalence was reached at accuracy scores 43 (RMT) and 47 (WCT) or time-to-completion 192s (RMT) and 171s (WCT). Conclusions: Time-to-completion cutoffs are valuable additions to both tests. They can function as independent validity indicators or enhance the sensitivity of accuracy scores without requiring additional measures or extending standard administration time.	[Erdodi, Laszlo A.; Abeare, Christopher A.; Zuccato, Brandon G.; Kucharski, Brittany] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Erdodi, Laszlo A.; Tyson, Bradley T.; Lichtenstein, Jonathan D.; Pelletier, Chantalle L.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Serv, Lebanon, NH USA; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA; [Shahein, Ayman G.] Western Univ, Schulich Sch Med, London, ON, Canada		Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Conners, 2004, CONNERS CONTINUOUS P; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Delis D.C., 2000, CALIFORNIA VERBAL LE; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, FORENSIC NEUROPSYCHO, P2; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Meyers J. E., 1995, CLIN NEUROPSYCHOL, V9, P63, DOI [10.1080/13854049508402059, DOI 10.1080/13854049508402059]; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOLUTIONS W; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Rey, 1964, EXAMEN CLINIQUE PSYC; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	55	38	38	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2017	39	4					369	383		10.1080/13803395.2016.1230181			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EQ6HT	WOS:000398183100006	28285575				2022-02-06	
J	Zarcone, D; Corbetta, S				Zarcone, Davide; Corbetta, Simona			Shared mechanisms of epilepsy, migraine and affective disorders	NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	International Multidisciplinary Seminar (STRESA HEADACHE)	MAY 25-27, 2017	Stresa, ITALY			Epilepsy; Migraine; Affective disorders; Common mechanisms	HEADACHES	Since the nineteenth century several clinical features have been observed in common between migraine and epilepsy (such as episodic attacks, triggering factors, presence of aura, frequent familiarity), but only in recent years researchers have really engaged in finding a common pathogenic mechanism. From studies of disease incidence, we understand how either migraine among patients with epilepsy or epilepsy among migraine patients are more frequent than in the general population. This association may result from a direct causality, by the same environmental risk factors and/or by a common genetic susceptibility. Ischemic events are the most frequent direct causes, especially among women and elderly people: migraine can lead to silent or clinically considerable strokes, and these ones could explain the increased risk of developing epilepsy in people with a history of migraine. Head injuries can lead headache, often with migraine characteristics, and seizures. But there are also many idiopathic cases. The comorbidity migraine-epilepsy might be explained in these cases by a neuronal hyperexcitability, which increases the risk of both diseases: a higher concentration of extracellular glutamate, the main excitatory neurotransmitter, leads in fact as a result a Cortical Spreading Depression (the pathophysiological mechanism at the base of aura) and convulsions; antiepileptic drugs such as topiramate are, therefore, used also in migraine prophylaxis. A genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures. The channelopathies, especially engaging sodium and potassium ions, can be the common pathogenic mechanism of migraine and epilepsy. Both migraine and epilepsy also have, compared to the general population, a higher prevalence and incidence of affective disorders such as anxiety, depression and suicidal ideation. Anxiety and depression can be part of symptoms that accompany migraine or seizures. Female patients with a long history of illness and frequent attacks are the most at risk. The impact of these diseases on the quality of life is the most obvious cause of these disorders, furthermore some antiepileptic drugs can have depressive effects on mood; the anxious-depressive disorders often result from the interaction between iatrogenic and psychosocial factor with common neurobiological pathogenesis. A chronic lowering of 5-HT (serotonin) levels has been demonstrated both in migraineurs and in depressed patients; amitriptyline and venlafaxine are the most indicated drugs in the treatment of migraine with comorbid depression currently. Likewise imbalance in dopamine levels has been also demonstrated: a D2 receptor genotype has been directly related to comorbidity migraine-depression. In women, hormonal fluctuations are also crucial, especially in the post-partum and late luteal phase, when the estrogenic reduction, associated with up-regulation of SNPs and down-regulation of serotonergic and GABAergic systems, increases the risk of migraine and depression. Furthermore, central sensitization phenomena have been highlighted in both diseases, and result in a progressive increase in the frequency of attacks up to chronicity and the consequent development of drug resistance and overuse. Further studies will be necessary to deepen the close relationship between these three diseases.	[Zarcone, Davide; Corbetta, Simona] Gallarate Hosp, UO Neurol & Stroke Unit, ASST Valle Olona, Gallarate, Italy		Zarcone, D (corresponding author), Gallarate Hosp, UO Neurol & Stroke Unit, ASST Valle Olona, Gallarate, Italy.	davide.zarcone@asst-valleolona.it					Bussone G, 2013, NEUROL SCI, V34, pS29, DOI 10.1007/s10072-013-1362-4; Castelnuovo G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00468; Hesdorffer DC, 2016, CNS SPECTRUMS, V21, P230, DOI 10.1017/S1092852915000929; Kramer DR, 2017, STEREOT FUNCT NEUROS, V95, P1, DOI 10.1159/000452841; Lampl C, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0649-2; Nye BL, 2015, HEADACHE, V55, P359, DOI 10.1111/head.12536; Seo JH, 2016, EPILEPSY BEHAV, V60, P204, DOI 10.1016/j.yebeh.2016.03.028; Winawer MR, 2013, EPILEPSIA, V54, P288, DOI 10.1111/epi.12072	8	38	40	2	20	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2017	38			1			S73	S76		10.1007/s10072-017-2902-0			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	EV6FJ	WOS:000401865000015	28527083				2022-02-06	
J	Dobson, JL; Yarbrough, MB; Perez, J; Evans, K; Buckley, T				Dobson, John L.; Yarbrough, Mary Beth; Perez, Jose; Evans, Kelsey; Buckley, Thomas			Sport-related concussion induces transient cardiovascular autonomic dysfunction	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						concussion; brain injury; cardiovascular; autonomic	TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; PROFESSIONAL FOOTBALL PLAYERS; MANAGEMENT PRACTICE PATTERNS; LOW-FREQUENCY POWER; POSTCONCUSSION SYNDROME; RECURRENT CONCUSSION; ATHLETIC TRAINERS; EXERCISE; ASSOCIATION	Recent evidence suggests that concussions may disrupt autonomic cardiovascular control. This study investigated the initial effects of concussion on cardiovascular function using three autonomic reflex tests. Twenty-three recreational athletes (12 women, 11 men) were divided into concussed (n = 12) and control (n = 11) groups. Concussed participants performed forced breathing, standing, and Valsalva autonomic tests four times: 1) within 48 h of injury; 2) 24 h later; 3) 1 wk after injury; and 4) 2 wk after injury. The controls performed the same tests on the same schedule. Differences in heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) responses to the tests were continuously measured using finger photoplethysmography and were analyzed using repeated-measures multivariate ANOVAs and ANOVAs. Within 48 h of injury, the concussed group had significantly greater resting SBP (t(21) = 2.44, P = 0.02, d = 1.03), HR (t(21) = 2.33, P = 0.03, d = 1.01), and SBP responses to standing (t(21) = 2.98, P = 0.01, d = 1.24), and 90% SBP normalization times (t(21) = 2.64, P = 0.02, d = 1.10) after the Valsalva, but those group differences subsided 24 h later. There was also a significant interaction with the HR responses to forced breathing (F-3,F-60 = 4.13, P = 0.01, eta p(2) = 0.17), indicating the concussed responses declined relative to the control's over time. The results demonstrate that concussion disrupted autonomic cardiovascular control, and that autonomic reflex tests are practical means by which to evaluate that dysfunction.	[Dobson, John L.; Yarbrough, Mary Beth; Perez, Jose; Evans, Kelsey] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA; [Buckley, Thomas] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Buckley, Thomas] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA		Dobson, JL (corresponding author), POB 8076, Statesboro, GA 30458 USA.	jdobson@georgiasouthern.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Aminoff M, 1996, NEUROLOGY, V46, P873; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blake TA, 2016, BRAIN INJURY, V30, P132, DOI 10.3109/02699052.2015.1093659; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Cap?-Aponte JE., 2013, SPINE, V4, P1; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Goldstein DS, 2011, EXP PHYSIOL, V96, P1255, DOI 10.1113/expphysiol.2010.056259; Goodman B, 2013, NEUROLOGY, V80, P265; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heyer GL, 2016, CLIN J SPORT MED, V26, P40, DOI 10.1097/JSM.0000000000000183; Hilz MJ, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0584-5; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Kanjwal K, 2010, CARDIOL J, V17, P482; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; King ML, 1997, BRAIN INJURY, V11, P445; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; La Fountaine MF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00013; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Low PA, 2008, CLIN AUTONOMIC DISOR; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moak JP, 2007, HEART RHYTHM, V4, P1523, DOI 10.1016/j.hrthm.2007.07.019; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Papaioannou BP, 2006, COMPUT CARDIOL, V33, P853; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Parashar R, 2016, J CLIN DIAGN RES, V10, pCC11, DOI 10.7860/JCDR/2016/16889.7497; Rahman F, 2011, CLIN AUTON RES, V21, P133, DOI 10.1007/s10286-010-0098-y; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sung CW, 2016, CLIN NEUROPHYSIOL, V127, P1629, DOI 10.1016/j.clinph.2015.08.006; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; Wieling W., 2013, AUTONOMIC FAILURE TX, P290	56	38	38	1	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	APR	2017	312	4					R575	R584		10.1152/ajpregu.00499.2016			10	Physiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Physiology	HB1XG	WOS:000450822100004	28148495	Bronze			2022-02-06	
J	Iverson, KM; Dardis, CM; Pogoda, TK				Iverson, Katherine M.; Dardis, Christina M.; Pogoda, Terri K.			Traumatic brain injury and PTSD symptoms as a consequence of intimate partner violence	COMPREHENSIVE PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; WOMEN VETERANS; RISK-FACTOR; INTERPERSONAL VIOLENCE; MENTAL-HEALTH; PRIMARY-CARE; STRANGULATION; HOMICIDE; STATE; IRAQ	Objective: To effectively diagnose and treat women who have experienced intimate partner violence (IPV), it is important to identify the full range of physical and mental health consequences, including hidden wounds such as traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD). We aimed to identify the occurrence of IPV-related TBI and associated PTSD symptoms among women veterans who experienced IPV. Methods: A web-based survey was administered in 2014 to a national sample of U.S. women veterans. Among 411 respondents (75% participation rate), 55% reported IPV during their lives. These participants (N = 224) completed screening measures of IPV-related TBI, PTSD, and past-year IPV and comprised the current sample. Results: A total of 28.1% (n = 63) met criteria for IPV-related TBI history, and 12.5% (n = 28) met criteria for IPV-related TBI with current symptoms. When adjusting for race, income, and past-year IPV, women with IPV-related TBI with current symptoms were 5.9 times more likely to have probable IPV-related PTSD than those with no IPV-related TBI history. Despite symptom overlap between TBI and PTSD, women with IPV-related TBI with current symptoms were significantly more likely to meet criteria for all four DSM-5 PTSD symptom clusters compared to women with an IPV-related TBI history without current symptoms (Cramer's V's =.34.42). Conclusion: Findings suggest there may be clinical utility in screening women who experience lifetime IPV for both TBI and PTSD symptoms in order to help clinicians better target their examinations, treatment, and referrals. Published by Elsevier Inc.	[Iverson, Katherine M.; Dardis, Christina M.] Womens Hlth Sci Div, Natl Ctr PTSD, VA Boston Hlthcare Syst, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA; [Iverson, Katherine M.; Dardis, Christina M.] Boston Univ, Sch Med, Dept Psychiat, 72 East Concord St, Boston, MA 02118 USA; [Pogoda, Terri K.] Ctr Hlthcare Org & Implement Res, VA Boston Hlthcare Syst, 150 S Huntington Ave Bldg 9, Boston, MA 02130 USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, 715 Albany St, Boston, MA 02118 USA		Iverson, KM (corresponding author), Womens Hlth Sci Div, Natl Ctr PTSD, VA Boston Hlthcare Syst, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.	katherine.iverson@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780	Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development (HSRD); Dr. Iverson's HSR&D Career Development Award [CDA 10-029]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5R25MH08091607]; VA HSRD Services; Quality Enhancement Research Initiative; VA HSR&D Investigator Initiated Research [11-078, 11-358]; Presidential Early Career Award for Scientists and EngineersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [USA 14-275]	This work was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development (HSR&D) Services as part of Dr. Iverson's HSR&D Career Development Award (CDA 10-029) and her Presidential Early Career Award for Scientists and Engineers (USA 14-275). Dr. Iverson is an investigator with the Implementation Research Institute, at the George Warren Brown School of Social Work, Washington University in St. Louis; through an award from the National Institute of Mental Health (5R25MH08091607) and the VA HSR&D Services, Quality Enhancement Research Initiative. This material is also based upon work supported in part by VA HSR&D Investigator Initiated Research Award #11-078 and #11-358. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or United States government. The authors have no conflicts of interest to report.	Amoroso T., J NERVOUS M IN PRESS; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Association A.P, 2013, DIAGN STAT MAN MENT; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Bovin M.J, 2015, PSYCHOL ASSESS, V27; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Campbell JC, 2007, TRAUMA VIOLENCE ABUS, V8, P246, DOI 10.1177/1524838007303505; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Department of Veterans Affairs, 2016, DOD CLIN PRACT GUID; Dichter ME, PAST YEAR I IN PRESS; Dichter ME, 2015, MIL MED, V180, P1124, DOI 10.7205/MILMED-D-14-00582; Dichter ME, 2011, WOMEN HEALTH ISS, V21, pS190, DOI 10.1016/j.whi.2011.04.008; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Dutton MA, 2009, TRAUMA VIOLENCE ABUS, V10, P211, DOI 10.1177/1524838009334451; Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gerber MR, 2014, J WOMENS HEALTH, V23, P302, DOI 10.1089/jwh.2013.4513; Glass N, 2008, J EMERG MED, V35, P329, DOI 10.1016/j.jemermed.2007.02.065; Goldin Y, 2016, SCREENING HIST TRAUM; Golding JM, 1999, J FAM VIOLENCE, V14, P99, DOI 10.1023/A:1022079418229; GRISSO JA, 1991, AM J EPIDEMIOL, V134, P59, DOI 10.1093/oxfordjournals.aje.a115993; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IBM, 2013, INV IBM SPSS STAT WI; Institute of Medicine, 2011, CLIN PREV SERV WOM C; Iverson KM, 2016, GEN HOSP PSYCHIAT, V40, P33, DOI 10.1016/j.genhosppsych.2016.03.001; Iverson KM, 2015, MED CARE, V53, pS112, DOI 10.1097/MLR.0000000000000263; Iverson KM, 2013, J TRAUMA STRESS, V26, P767, DOI 10.1002/jts.21867; Iverson KM, 2013, PSYCHOL VIOLENCE, V3, P273, DOI 10.1037/a0030956; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Iverson KM, 2011, J CONSULT CLIN PSYCH, V79, P193, DOI 10.1037/a0022512; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Johnson DM, 2011, J CONSULT CLIN PSYCH, V79, P542, DOI 10.1037/a0023822; Kimerling R, 2016, J GEN INTERN MED, V31, P888, DOI 10.1007/s11606-016-3701-7; Kimerling R, 2015, MED CARE, V53, pS97, DOI 10.1097/MLR.0000000000000272; Kochanek PM, 2016, LANCET NEUROL, V15, P13, DOI 10.1016/S1474-4422(15)00339-7; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; National Center for Veterans Analysis and Statistics, 2014, VET POP LIV VET AG G; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Smith DJ, 2001, J EMERG MED, V21, P323, DOI 10.1016/S0736-4679(01)00402-4; Sohal H, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-49; St Ivany A, 2016, FAM COMMUNITY HEALTH, V39, P129, DOI 10.1097/FCH.0000000000000094; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sweeney AC, 2013, WOMEN HEALTH ISS, V23, pE73, DOI 10.1016/j.whi.2012.12.004; Tjaden P., 1998, PREVALENCE INCIDENCE; U.S. Preventive Services Task Force, 2013, SCREEN INT PARTN VIO; Veterans Health Administration Domestic Violence Task Force, 2013, PLAN IMPL DOM VIOL I; Warshaw C., 2013, SYSTEMATIC REV TRAUM; Weathers F.W., 2013, PTSD CHECKLIST DSM 5; World Health Organization DoRHaR, 2013, GLOB REG EST VIOL WO	51	38	38	2	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0010-440X	1532-8384		COMPR PSYCHIAT	Compr. Psychiat.	APR	2017	74						80	87		10.1016/j.comppsych.2017.01.007			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	EP9MI	WOS:000397697300012	28126481				2022-02-06	
J	Stacey, A; Lucas, S; Dikmen, S; Temkin, N; Bell, KR; Brown, A; Brunner, R; Diaz-Arrastia, R; Watanabe, TK; Weintraub, A; Hoffman, JM				Stacey, Arthur; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.; Brown, Allen; Brunner, Robert; Diaz-Arrastia, Ramon; Watanabe, Thomas K.; Weintraub, Alan; Hoffman, Jeanne M.			Natural History of Headache Five Years after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						headache; post-traumatic headache; secondary headache; TBI	CHRONIC POSTTRAUMATIC HEADACHE; MILITARY PERSONNEL; CHRONIC PAIN; PREVALENCE; IMPACT; VETERANS; PERSIST; SLEEP; RATES; IRAQ	Headache is one of the most frequently reported symptoms following traumatic brain injury (TBI). Little is known about how these headaches change over time. We describe the natural history of headache in individuals with moderate to severe TBI over 5 years after injury. A total of 316 patients were prospectively enrolled and followed at 3, 6, 12, and 60 months after injury. Individuals were 72% male, 73% white, and 55% injured in motor vehicle crashes, with an average age of 42. Pre-injury headache was reported in 17% of individuals. New or worse headache prevalence remained consistent with at least 33% at all time points. Incidence was > 17% at all time points with first report of new or worse headache in 20% of participants at 60 months. Disability related to headache was high, with average headache pain (on 0-10 scale) ranging from 5.5 at baseline to 5.7 at 60 months post-injury, and reports of substantial impact on daily life across all time points. More than half of classifiable headaches matched the profile of migraine or probable migraine. Headache is a substantial problem after TBI. Results suggest that ongoing assessment and treatment of headache after TBI is needed, as this symptom may be a problem up to 5 years post-injury.	[Stacey, Arthur; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Hoffman, Jeanne M.] Univ Washington, Med Ctr, Dept Rehabil Med, Seattle, WA 98195 USA; [Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bell, Kathleen R.] UT Southwestern, Dept Phys Med & Rehabil, Dallas, TX USA; [Brown, Allen] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Brunner, Robert] Univ Alabama Birmingham, UAB Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Watanabe, Thomas K.] Einstein Med Ctr, MossRehab Elkins Pk, Elkins Pk, PA USA; [Weintraub, Alan] Craig Hosp, CNS Med Grp, Englewood, CO USA		Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	jeanneh@uw.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594; Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services	Arthur Stacey has nothing to disclose. Sylvia Lucas has received a grant from the National Institute of Disability, Independent Living, and Rehabilitation Research during the conduct of the study; grants from Amgen and Allergan; and consultation fee from Lilly, outside the submitted work. Sureyya Dikmen received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Nancy Temkin received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study; and personal fees from Novartis, Celgene, Sage, TauRx, and other drug companies for participation on DSMBs outside the submitted work. Kathleen R. Bell received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Allen Brown received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Robert Brunner received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Ramon Diaz-Arrastia has nothing to disclose. Thomas K. Watanabe received a grant from National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Alan Weintraub received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Jeanne M. Hoffman received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study.	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bekkelund SI, 2003, HEADACHE, V43, P59, DOI 10.1046/j.1526-4610.2003.03010.x; Bettucci D, 1998, ITAL J NEUROL SCI, V19, P20, DOI 10.1007/BF03028807; Brown AW, 2015, PM&R, V7, P3, DOI 10.1016/j.pmrj.2014.06.016; Couch JR, 2016, HEADACHE, V56, P1004, DOI 10.1111/head.12837; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Finkel AG, 2012, HEADACHE, V52, P957, DOI 10.1111/j.1526-4610.2012.02167.x; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Smitherman TA, 2013, HEADACHE, V53, P427, DOI 10.1111/head.12074; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042	29	38	39	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1558	1564		10.1089/neu.2016.4721			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500007	27927072				2022-02-06	
J	Stewart, WF; Kim, N; Ifrah, CS; Lipton, RB; Bachrach, TA; Zimmerman, ME; Kim, M; Lipton, ML				Stewart, Walter F.; Kim, Namhee; Ifrah, Chloe S.; Lipton, Richard B.; Bachrach, Tamar A.; Zimmerman, Molly E.; Kim, Mimi; Lipton, Michael L.			Symptoms from repeated intentional and unintentional head impact in soccer players	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL IMPAIRMENT; UNITED-STATES; YOUTH SOCCER; ENCEPHALOPATHY; POLYMORPHISM; ASSOCIATION; CONCUSSIONS; SPORTS	Objective: To determine the rate and differential contribution of heading vs unintentional head impacts (e.g., head to head, goal post) to CNS symptoms in adult amateur soccer players. Methods: Amateur soccer players completed baseline and serial on-line 2-week recall questionnaires (HeadCount) and reported (1) soccer practice and games, (2) heading and unintentional soccer head trauma, and (3) frequency and severity (mild to very severe) of CNS symptoms. For analysis, CNS symptoms were affirmed if one or more moderate, severe, or very severe episodes were reported in a 2-week period. Repeated measures logistic regression was used to assess if 2-week heading exposure (i.e., 4 quartiles) or unintentional head impacts (i.e., 0, 1, 21) were associated with CNS symptoms. Results: A total of 222 soccer players (79% male) completed 470 HeadCount questionnaires. Mean (median) heading/2 weeks was 44 (18) for men and 27 (9.5) for women. One or more unintentional head impacts were reported by 37% of men and 43% of women. Heading-related symptoms were reported in 20% (93 out of 470) of the HeadCounts. Heading in the highest quartile was significantly associated with CNS symptoms (odds ratio [OR] 3.17, 95% confidence interval [CI] 1.57-6.37) when controlling for unintentional exposure. Those with 21 unintentional exposures were at increased risk for CNS symptoms (OR 6.09, 95% CI 3.33-11.17) as were those with a single exposure (OR 2.98, 95% CI 1.69-5.26) when controlling for heading. Conclusions: Intentional (i.e., heading) and unintentional head impacts are each independently associated with moderate to very severe CNS symptoms.	[Stewart, Walter F.] Sutter Hlth Res, Walnut Creek, CA USA; [Kim, Namhee; Ifrah, Chloe S.; Bachrach, Tamar A.; Lipton, Michael L.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10467 USA; [Kim, Namhee; Ifrah, Chloe S.; Bachrach, Tamar A.; Lipton, Michael L.] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA; [Lipton, Richard B.; Zimmerman, Molly E.] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; [Lipton, Richard B.; Kim, Mimi] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA; Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Zimmerman, Molly E.] Fordham Univ, Bronx, NY 10458 USA		Lipton, ML (corresponding author), Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA.	Michael.Lipton@einstein.yu.edu	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS082432]; Dana Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432] Funding Source: NIH RePORTER	Study funded by NIH (R01 NS082432) and Dana Foundation.	Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Dart J, GUARDIAN; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Faul M, 2010, TRAUMATIC BRAIN INJU; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KAHNEMAN D, 1993, PSYCHOL SCI, V4, P401, DOI 10.1111/j.1467-9280.1993.tb00589.x; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Koutures CG, 2010, PEDIATRICS, V125, P410, DOI 10.1542/peds.2009-3009; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Robinson MD, 2002, J PERS SOC PSYCHOL, V83, P198, DOI 10.1037//0022-3514.83.1.198; Rodrigues AC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00038; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	38	38	38	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 28	2017	88	9					901	908		10.1212/WNL.0000000000003657			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EP4HH	WOS:000397341100021	28148633	Green Published			2022-02-06	
J	Xu, ZM; Yuan, F; Liu, YL; Ding, J; Tian, HL				Xu, Zhi-ming; Yuan, Fang; Liu, Ying-liang; Ding, Jun; Tian, Heng-li			Glibenclamide Attenuates Blood-Brain Barrier Disruption in Adult Mice after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; apoptosis; BBB; TBI	SPINAL-CORD-INJURY; SUBARACHNOID HEMORRHAGE; ISCHEMIC-STROKE; CEREBRAL EDEMA; RAT MODEL; APOPTOSIS; ATP; INHIBITION; CHANNEL; SULFONYLUREAS	Glibenclamide is a hypoglycemic drug that is widely used for the treatment of diabetes mellitus type 2 (DM II), but it also plays a protective role following injury to the central nervous system (CNS). However, the precise mechanisms underlying its neuroprotective actions remain to be elucidated. Therefore, the present study evaluated the effects of glibenclamide on the blood-brain barrier (BBB) in a mouse model of traumatic brain injury (TBI). In the present study, 86 adult male C57BL/6 mice were exposed to a controlled cortical impact (CCI) injury and then received glibenclamide (10 lg) for 3 days. Tight junction (TJ) protein levels, BBB permeability, and tissue hemoglobin levels were evaluated following the CCI injury. Additionally, a biaxial stretch injury was applied to cell cultures of bEnd. 3 cells using the Cell Injury Controller II system to explore the mechanisms by which glibenclamide inhibits apoptosis-signaling pathways. Compared with the control group, glibenclamide-treated mice exhibited decreases in brain water content (p < 0.05), tissue hemoglobin levels (p < 0.05), and Evans Blue extravasation (p < 0.01) after the CCI injury. Glibenclamide primarily attenuated apoptosis via the JNK/c-jun signaling pathway and resulted in an elevation of stretch injury-induced ZO-1 expression in bEnd. 3 cells (p < 0.01). Glibenclamide downregulated the activity of the JNK/c-jun apoptosis-signaling pathway which, in turn, decreased apoptosis in endothelial cells (ECs). This may have prevented the disruption of the BBB in a mouse model of TBI.	[Xu, Zhi-ming; Yuan, Fang; Liu, Ying-liang; Ding, Jun; Tian, Heng-li] Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 6, Dept Neurosurg, Shanghai, Peoples R China		Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, 600 YiShan Rd, Shanghai 200030, Peoples R China.	tianhlsh@126.com			National Nature and Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271383, 81471245, 81501048]; Shanghai Science and Technique Committee [13411951401]	This work was supported by grants from National Nature and Science Foundation of China (no. 81271383,81471245, 81501048) and the Shanghai Science and Technique Committee (no.13411951401).	Abu-Qare AW, 2001, J TOXICOL ENV HEAL B, V4, P313, DOI 10.1080/109374001301419737; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Anuradha C. V., 2001, Indian Journal of Physiology and Pharmacology, V45, P408; Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; Chen LQ, 2016, ANN HEMATOL, V95, P365, DOI 10.1007/s00277-015-2567-9; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; FELDMAN JM, 1985, AM J MED, V79, P102, DOI 10.1016/S0002-9343(85)80015-2; Jayakumar AR, 2014, TRANSL STROKE RES, V5, P28, DOI 10.1007/s12975-014-0328-z; KRAMER W, 1995, DIABETES RES CLIN PR, V28, pS67, DOI 10.1016/0168-8227(95)01076-P; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kurland DB, 2013, PHARMACEUTICALS, V6, P1287, DOI 10.3390/ph6101287; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li Y, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-014-2826-z; MARBLE A, 1971, DRUGS, V1, P109, DOI 10.2165/00003495-197101020-00001; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Panten U, 1996, EXP CLIN ENDOCR DIAB, V104, P1, DOI 10.1055/s-0029-1211414; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pompermayer K, 2007, EUR J PHARMACOL, V556, P215, DOI 10.1016/j.ejphar.2006.10.065; Riddle MC, 2003, J CLIN ENDOCR METAB, V88, P528, DOI 10.1210/jc.2002-021971; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, TRANSL STROKE RES, V3, P286, DOI 10.1007/s12975-012-0149-x; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204-013-1034-4; Song JS, 2002, ENVIRON TOXICOL PHAR, V11, P85, DOI 10.1016/S1382-6689(01)00108-9; Stark RJ, 2016, CLIN SCI, V130, P451, DOI 10.1042/CS20150592; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thompson EM, 2013, NEOPLASIA, V15, P535, DOI 10.1593/neo.13164; Tien YC, 2011, INT J MOL SCI, V12, P4053, DOI 10.3390/ijms12064053; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Tosun C, 2013, BRAIN SCI, V3, P215, DOI 10.3390/brainsci3010215; Wali B, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/460909; Webster Gregory D, 2008, Biomed Sci Instrum, V44, P483; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	47	38	38	2	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					925	933		10.1089/neu.2016.4491			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200020	27297934				2022-02-06	
J	Maneshi, MM; Maki, B; Gnanasambandam, R; Belin, S; Popescu, GK; Sachs, F; Hua, SZ				Maneshi, Mohammad Mehdi; Maki, Bruce; Gnanasambandam, Radhakrishnan; Belin, Sophie; Popescu, Gabriela K.; Sachs, Frederick; Hua, Susan Z.			Mechanical stress activates NMDA receptors in the absence of agonists	SCIENTIFIC REPORTS			English	Article							D-ASPARTATE RECEPTOR; MECHANOSENSITIVE ION CHANNELS; MOUSE CENTRAL NEURONS; FORCE/TENSION SENSORS; CORTICAL ASTROCYTES; ENDOTHELIAL-CELLS; GLIAL-CELLS; LIVE CELLS; CALCIUM; GLUTAMATE	While studying the physiological response of primary rat astrocytes to fluid shear stress in a model of traumatic brain injury (TBI), we found that shear stress induced Ca2+ entry. The influx was inhibited by MK-801, a specific pore blocker of N-Methyl-D-aspartic acid receptor (NMDAR) channels, and this occurred in the absence of agonists. Other NMDA open channel blockers ketamine and memantine showed a similar effect. The competitive glutamate antagonists AP5 and GluN2B-selective inhibitor ifenprodil reduced NMDA-activated currents, but had no effect on the mechanically induced Ca2+ influx. Extracellular Mg2+ at 2 mM did not significantly affect the shear induced Ca2+ influx, but at 10 mM it produced significant inhibition. Patch clamp experiments showed mechanical activation of NMDAR and inhibition by MK-801. The mechanical sensitivity of NMDARs may play a role in the normal physiology of fluid flow in the glymphatic system and it has obvious relevance to TBI.	[Maneshi, Mohammad Mehdi; Gnanasambandam, Radhakrishnan; Sachs, Frederick; Hua, Susan Z.] Univ Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA; [Maneshi, Mohammad Mehdi; Hua, Susan Z.] Univ Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY 14260 USA; [Maki, Bruce; Belin, Sophie; Popescu, Gabriela K.] Univ Buffalo, Dept Biochem, Buffalo, NY 14260 USA		Hua, SZ (corresponding author), Univ Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA.; Hua, SZ (corresponding author), Univ Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY 14260 USA.	zhua@buffalo.edu	Belin, Sophie/AAJ-7962-2020; popescu, gabriela k/AAB-6155-2022	popescu, gabriela k/0000-0003-4658-2002; Maki, Bruce/0000-0002-6760-375X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS085517, NS098385, NS097016, HL054887]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL054887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085517, R21NS098385, R01NS097016] Funding Source: NIH RePORTER	This work was supported by National Institute of Health grant NS085517 (S.Z.H.), grants NS098385 and NS097016 (G.K.P.), and grant HL054887 (F.S.).	Akinlaja J, 1998, BIOPHYS J, V75, P247, DOI 10.1016/S0006-3495(98)77511-3; Bae C, 2013, P NATL ACAD SCI USA, V110, pE1162, DOI 10.1073/pnas.1219777110; Bae C, 2011, BIOCHEMISTRY-US, V50, P6295, DOI 10.1021/bi200770q; Besch SR, 2002, PFLUG ARCH EUR J PHY, V445, P161, DOI 10.1007/s00424-002-0903-0; Bowman CL, 2007, TOXICON, V49, P249, DOI 10.1016/j.toxicon.2006.09.030; Bresink I, 1996, BRIT J PHARMACOL, V119, P195, DOI 10.1111/j.1476-5381.1996.tb15971.x; BRODE HL, 1959, PHYS FLUIDS, V2, P217, DOI 10.1063/1.1705911; Combes M, 2015, J NEUROSCI RES, V93, P633, DOI 10.1002/jnr.23524; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812; Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270; Cox C. D., 2016, NATURE COMMUNICATION, V7; Dai JW, 1996, MOL BIOL CELL, V7, P2614; Drew LJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000515; Dzamba D, 2013, CURR NEUROPHARMACOL, V11, P250, DOI 10.2174/1570159X11311030002; Emnett CM, 2013, MOL PHARMACOL, V84, P935, DOI 10.1124/mol.113.089334; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Gnanasambandam R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125503; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Guo J, 2014, ANTIOXID REDOX SIGN, V20, P986, DOI 10.1089/ars.2013.5708; Haidekker MA, 2000, AM J PHYSIOL-HEART C, V278, pH1401, DOI 10.1152/ajpheart.2000.278.4.H1401; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Heureaux J, 2014, CELL MOL BIOENG, V7, P307, DOI 10.1007/s12195-014-0337-8; Hua X, 2004, J NEUROSCI RES, V76, P86, DOI 10.1002/jnr.20061; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Innocenti B, 2000, J NEUROSCI, V20, P1800; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kloda A, 2007, P NATL ACAD SCI USA, V104, P1540, DOI 10.1073/pnas.0609649104; Lalo U, 2006, J NEUROSCI, V26, P2673, DOI 10.1523/JNEUROSCI.4689-05.2006; Lee MC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014123; MACVICAR BA, 1984, SCIENCE, V226, P1345, DOI 10.1126/science.6095454; Malomouzh AI, 2011, MUSCLE NERVE, V44, P987, DOI 10.1002/mus.22250; Maneshi MM, 2015, J NEUROTRAUM, V32, P1020, DOI 10.1089/neu.2014.3677; Markin V S, 2015, Open J Biophys, V5, P80; Martinac B, 2014, ANTIOXID REDOX SIGN, V20, P952, DOI 10.1089/ars.2013.5471; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Palygin O, 2010, CELL CALCIUM, V48, P225, DOI 10.1016/j.ceca.2010.09.004; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PASTI L, 1995, J BIOL CHEM, V270, P15203, DOI 10.1074/jbc.270.25.15203; Rahimzadeh J, 2011, AM J PHYSIOL-CELL PH, V301, pC646, DOI 10.1152/ajpcell.00099.2011; Sachs Frederick, 2015, World J Neurol, V5, P74, DOI 10.5316/wjn.v5.i3.74; Schipke CG, 2001, FASEB J, V15, P1270, DOI 10.1096/fj.00-0439fje; Singh P, 2012, J BIOL CHEM, V287, P4348, DOI 10.1074/jbc.M111.253740; Slavchov RI, 2014, J PHYS CHEM B, V118, P12660, DOI 10.1021/jp506965v; Suchyna TM, 2009, BIOPHYS J, V97, P738, DOI 10.1016/j.bpj.2009.05.018; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Suchyna TM, 2000, BIOPHYS J, V78, p173A; Thrane AS, 2012, P NATL ACAD SCI USA, V109, P18974, DOI 10.1073/pnas.1209448109; Uchino S, 2001, FEBS LETT, V506, P117, DOI 10.1016/S0014-5793(01)02899-X; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yang C, 2015, BBA-MOL CELL RES, V1853, P1889, DOI 10.1016/j.bbamcr.2015.05.001; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	55	38	38	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 3	2017	7								39610	10.1038/srep39610			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG6IB	WOS:000391147000001	28045032	Green Published, gold			2022-02-06	
J	Gallaway, M; Scheiman, M; Mitchell, GL				Gallaway, Michael; Scheiman, Mitchell; Mitchell, G. Lynn			Vision Therapy for Post-Concussion Vision Disorders	OPTOMETRY AND VISION SCIENCE			English	Article						vision therapy; vision rehabilitation; concussion; convergence insufficiency; accommodative insufficiency; near point of convergence	TRAUMATIC BRAIN-INJURY; RANDOMIZED CLINICAL-TRIAL; INSUFFICIENCY SYMPTOM SURVEY; CONVERGENCE INSUFFICIENCY; OCULOMOTOR REHABILITATION; VISUAL FUNCTION; DYSFUNCTIONS; CHILDREN; RESPONSIVITY; STATEMENT	Purpose. To determine the frequency and types of vision disorders associated with concussion, and to determine the success rate of vision therapy for these conditions in two private practice settings. Methods. All records over an 18-month period of patients referred for post-concussion vision problems were reviewed from two private practices. Diagnoses of vergence, accommodative, or eye movement disorders were based on pre-established, clinical criteria. Vision therapy was recommended based on clinical findings and symptoms. Results. Two hundred eighteen patient records were found with a diagnosis of concussion. Fifty-six percent of the concussions were related to sports, 20% to automobile accidents, and 24% to school, work, or home-related incidents. The mean age was 20.5 years and 58% were female. Eighty-two percent of the patients had a diagnosis of an oculomotor problem [binocular problems (62%), accommodative problems (54%), eye movement problems (21%)]. The most prevalent diagnoses were convergence insufficiency (CI, 47%) and accommodative insufficiency (AI, 42%). Vision therapy was recommended for 80% of the patients. Forty-six per cent (80/175) either did not pursue treatment or did not complete treatment. Of the 54% (95/175) who completed therapy, 85% of patients with CI were successful and 15% were improved, and with AI, 33% were successful and 67% improved. Clinically and statistically significant changes were measured in symptoms, near point of convergence, positive fusional vergence, and accommodative amplitude. Conclusions. In this case series, post-concussion vision problems were prevalent and CI and AI were the most common diagnoses. Vision therapy had a successful or improved outcome in the vast majority of cases that completed treatment. Evaluation of patients with a history of concussion should include testing of vergence, accommodative, and eye movement function. Prospective clinical trials are necessary to assess the natural history of concussion-related vision disorders and treatment effectiveness.	[Gallaway, Michael; Scheiman, Mitchell] Salus Univ, Penn Coll Optometry, 1200 W Godfrey Ave, Philadelphia, PA 19141 USA; [Mitchell, G. Lynn] Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA		Gallaway, M (corresponding author), Salus Univ, Penn Coll Optometry, 1200 W Godfrey Ave, Philadelphia, PA 19141 USA.	mgallaway@salus.edu	Mitchell, Gladys/E-7973-2012	Scheiman, Mitchell/0000-0002-9274-5696			Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Borsting EJ, 2003, OPTOMETRY VISION SCI, V80, P832, DOI 10.1097/00006324-200312000-00014; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Faul M, 2010, TRAUMATIC BRAIN INJU; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hunt AW, 2016, J HEAD TRAUMA REHAB, V31, P252, DOI 10.1097/HTR.0000000000000174; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P357, DOI 10.1097/OPX.0b013e3181989252; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 1996, J Am Optom Assoc, V67, P193; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Scheiman M., 2014, CLIN MANAGEMENT BINO; Scheiman M., 2011, COCHRANE DB SYST REV, V16; Scheiman M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1336, DOI 10.1001/archopht.126.10.1336; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Tannen B, 2015, VIS DEV REHAB, V1, P206; Thiagarajan P, 2014, OPTOM VIS PERF, V2, P539; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Youngstrom EA, 2014, J PEDIATR PSYCHOL, V39, P204, DOI 10.1093/jpepsy/jst062	34	38	38	4	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					68	73		10.1097/OPX.0000000000000935			6	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	EM5ZZ	WOS:000395393900010	27505624				2022-02-06	
J	Gao, YY; Zhuang, Z; Gao, ST; Li, X; Zhang, ZH; Ye, ZN; Li, LW; Tang, C; Zhou, ML; Han, X; Li, J				Gao, Yongyue; Zhuang, Zong; Gao, Shanting; Li, Xiang; Zhang, Zihuan; Ye, Zhennan; Li, Liwen; Tang, Chao; Zhou, Mengliang; Han, Xiao; Li, Jie			Tetrahydrocurcumin reduces oxidative stress-induced apoptosis via the mitochondrial apoptotic pathway by modulating autophagy in rats after traumatic brain injury	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Traumatic brain injury; tetrahydrocurcumin; oxidative stress; autophagy; mitochondrial apoptosis pathway	RAPAMYCIN PROTECTS; CEREBRAL-ISCHEMIA; HYPOXIA-ISCHEMIA; CELL-DEATH; IN-VITRO; NEUROPROTECTION; INHIBITION; CURCUMIN; DISEASE; MODELS	Tetrahydrocurcumin (THC) has been identified as a multi-functional neuroprotective agent in numerous neurological disorders. Oxidative stress as a result of injury may induce neuronal apoptosis after traumatic brain injury (TBI). Treatment with THC may improve neurological function following TBI by attenuating oxidative stress and apoptosis and by enhancing autophagy. The purpose of this study was to investigate the mechanism of neuroprotection by THC against oxidative stress-induced neuronal apoptosis after TBI. We hypothesized that neuroprotection by THC may involve modulation of autophagy and the mitochondria apoptotic pathway. We used western blot analysis to evaluate the effect of THC on proteins involved in mitochondrial autophagy and apoptosis after TBI. The terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay and immunofluorescence staining were used to confirm the role of THC in apoptosis and autophagy, respectively. THC-induced neuroprotection was assessed by neurological severity scoring (NSS) and by measuring the brain water content. We demonstrated that treatment with THC increased expression of autophagy-associated proteins LC3-II and Beclin-1 at 24 h post-TBI. Treatment with THC also reduced expression of malondialdehyde (MDA) and increased glutathione peroxidase (GPx) activity. Further, treatment with THC attenuated apoptosis by modulating mitochondrial apoptosis and reducing oxidative stress. Treatment with 3-methyladenine (3-MA) mitigated autophagy activation and reversed the inhibitory effect of THC on the translocation of Bax to the mitochondrial membrane. Moreover, treatment with THC improved neurological function and reduced the brain water content in rats after TBI. We concluded that the neuroprotective effects of THC are mediated by enhancing autophagy activation and by attenuation of oxidative stress and apoptosis after TBI, probably by modulating the mitochondrial apoptotic pathway. We suggest that THC may be an effective therapeutic agent to treat TBI.	[Gao, Yongyue; Zhuang, Zong; Li, Xiang; Ye, Zhennan; Li, Liwen; Tang, Chao; Zhou, Mengliang; Li, Jie] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Gao, Shanting] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China; [Han, Xiao] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Dept Biochem & Mol Biol, Nanjing 210002, Jiangsu, Peoples R China; [Zhang, Zihuan] Zhongdu Hosp, Dept Neurosurg, Bengbu 233015, Anhui, Peoples R China		Li, J (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njLi-jiepro@126.com		Zhou, Meng-liang/0000-0002-1165-5489	Jinling Hospital of Nanjing, School of Medicine, Nanjing University [2010 M023]; Major Innovative Project of Medical Science and Technology of Nanjing Military Command [14ZX16]; Project of Nanjing Science and Technology Development [201605078]; National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81400980]	This work was supported by grants from Jinling Hospital of Nanjing, School of Medicine, Nanjing University (No. 2010 M023) and the Major Innovative Project of Medical Science and Technology of Nanjing Military Command (No. 14ZX16) and the Project of Nanjing Science and Technology Development (No. 201605078) and the National Natural Science Foundation, China (No. 81400980).	Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Chen J, 2015, AM J TRANSL RES, V7, P1510; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheng KK, 2013, AAPS J, V15, P324, DOI 10.1208/s12248-012-9444-4; Clark RS, 2014, AUTOPHAGY, V4, P88; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Grivennikova VG, 2010, BBA-BIOENERGETICS, V1797, P939, DOI 10.1016/j.bbabio.2010.02.013; Hagberg H, 2014, LANCET NEUROL, V13, P217, DOI 10.1016/S1474-4422(13)70261-8; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Liu F, 2016, NEUROPEPTIDES, V58, P1, DOI 10.1016/j.npep.2016.03.004; Ma J, 2016, AM J TRANSL RES, V8, P1895; Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377; Mishra S, 2011, NEUROREPORT, V22, P23, DOI 10.1097/WNR.0b013e328341e141; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Song KI, 2015, PLANTA MED, V81, P286, DOI 10.1055/s-0035-1545696; Tyagi N, 2012, J MOL NEUROSCI, V47, P128, DOI 10.1007/s12031-011-9695-z; Ulbrich F, 2016, J NEUROCHEM, V138, P859, DOI 10.1111/jnc.13662; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zhang QC, 2016, AM J TRANSL RES, V8, P1197; Zhen YL, 2016, AM J TRANSL RES, V8, P911	36	38	41	0	11	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2017	9	3					887	899					13	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	ER7XK	WOS:000399028800005	28386319				2022-02-06	
J	Hwang, S; Ma, L; Kawata, K; Tierney, R; Jeka, JJ				Hwang, Sungjae; Ma, Lei; Kawata, Keisuke; Tierney, Ryan; Jeka, John J.			Vestibular Dysfunction after Subconcussive Head Impact	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; head trauma; human studies; outcome measures; sensory function	POSTURAL CONTROL; SOCCER; CONCUSSION; BALANCE; STABILITY; COLLEGIATE; INJURY; FOOTBALL; POSITION; UPRIGHT	Current thinking views mild head impact (i.e., subconcussion) as an underrecognized phenomenon that has the ability to cause significant current and future detrimental neurological effects. Repeated mild impacts to the head, however, often display no observable behavioral deficits based on standard clinical tests, which may lack sensitivity. The current study investigates the effects of subconcussive impacts from soccer heading with innovative measures of vestibular function and walking stability in a pre-0-2 h, post-24 h post-heading repeated measures design. The heading group (n = 10) executed 10 headers with soccer balls projected at a velocity of 25 mph (11.2 m/sec) over 10 min. Subjects were evaluated 24 h before, immediately after, and 24 h after soccer heading with: the modified Balance Error Scoring System (mBESS); a walking stability task with visual feedback of trunk movement; and galvanic vestibular stimulation (GVS) while standing with eyes closed on foam. A control group (n = 10) followed the same protocol with no heading. The results showed significant decrease in trunk angle, leg angle gain, and center of mass gain relative to GVS for the heading group compared with controls. Medial-lateral trunk orientation displacement and velocity during treadmill walking increased immediately after mild head impact for the heading group compared with controls. Controls showed an improvement in mBESS scores over time, indicating a learning effect, which was not observed with the heading group. These results suggest that mild head impact leads to a transient dysfunction in vestibular processing, which deters walking stability during task performance.	[Hwang, Sungjae; Ma, Lei; Kawata, Keisuke; Tierney, Ryan; Jeka, John J.] Temple Univ, Dept Kinesiol, 1800 N Broad St, Philadelphia, PA 19122 USA		Hwang, S (corresponding author), Temple Univ, Dept Kinesiol, 1800 N Broad St, Philadelphia, PA 19122 USA.	sungjae.hwang@temple.edu		Ma, Lei/0000-0002-0050-6461; Jeka, John/0000-0001-5942-3209	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG041714-01A1]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG041714] Funding Source: NIH RePORTER	This study was partially supported by NIH grant R21 AG041714-01A1, J. Jeka, PI. The authors thank Eric Anson, PhD and Peter Agada, MS for their input and assistance.	[Anonymous], 1995, GAIT POSTURE; Anson E, 2014, EXP BRAIN RES, V232, P1941, DOI 10.1007/s00221-014-3885-1; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Bouguet J-Y, 2013, CAMERA CALIBRATION T; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Clark D, 2012, NEUROLOGY, V78, pE140, DOI 10.1212/WNL.0b013e31825bc685; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Day BL, 2010, J PHYSIOL-LONDON, V588, P671, DOI 10.1113/jphysiol.2009.181768; Donelan JM, 2004, J BIOMECH, V37, P827, DOI 10.1016/j.jbiomech.2003.06.002; Franke LM, 2012, J REHABIL RES DEV, V49, P985, DOI 10.1682/JRRD.2011.12.0250; Gard SA, 2004, HUM MOVEMENT SCI, V22, P597, DOI 10.1016/j.humov.2003.11.002; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hurt CP, 2010, GAIT POSTURE, V31, P461, DOI 10.1016/j.gaitpost.2010.02.001; Hwang S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088132; Ijmker T, 2013, J BIOMECH, V46, P2109, DOI 10.1016/j.jbiomech.2013.07.005; Jeka J, 2004, J NEUROPHYSIOL, V92, P2368, DOI 10.1152/jn.00983.2003; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Logan D, 2010, EXP BRAIN RES, V206, P337, DOI 10.1007/s00221-010-2414-0; MACKINNON CD, 1993, J BIOMECH, V26, P633, DOI 10.1016/0021-9290(93)90027-C; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; O'Connor SM, 2009, J NEUROPHYSIOL, V102, P1411, DOI 10.1152/jn.00131.2009; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterka RJ, 2004, J NEUROPHYSIOL, V91, P410, DOI 10.1152/jn.00516.2003; PETERKA RJ, 1995, EXP BRAIN RES, V105, P101; Piersol, 2000, RANDOM DATA ANAL MEA; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schmid-Priscoveanu A, 2000, EXP BRAIN RES, V134, P212; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Winter D. A., 2009, BIOMECHANICS MOTOR C, DOI 10.1002/9780470549148	42	38	38	0	53	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					8	15		10.1089/neu.2015.4238			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100002	26885560	Green Published			2022-02-06	
J	Storzbach, D; Twamley, EW; Roost, MS; Golshan, S; Williams, RM; O'Neil, M; Jak, AJ; Turner, AP; Kowalski, HM; Pagulayan, KF; Huckans, M				Storzbach, Daniel; Twamley, Elizabeth W.; Roost, Mai S.; Golshan, Shahrokh; Williams, Rhonda M.; O'Neil, Maya; Jak, Amy J.; Turner, Aaron P.; Kowalski, Halina M.; Pagulayan, Kathleen F.; Huckans, Marilyn			Compensatory Cognitive Training for Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive training; mild traumatic brain injury; OEF/OIF/OND Veterans	POSTTRAUMATIC-STRESS-DISORDER; MEMORY QUESTIONNAIRE PRMQ; OF-THE-LITERATURE; NEUROPSYCHOLOGICAL OUTCOMES; RETROSPECTIVE MEMORY; MILITARY PERSONNEL; LATENT STRUCTURE; NORMATIVE DATA; US VETERANS; REHABILITATION	Objective: The purpose of the study was to evaluate the efficacy of group-based compensatory cognitive training (CCT) for Operation Enduring Freedom (OEF)/Operation Iraqi Freedom(OIF)/Operation New Dawn (OND) Veterans with a history of mild traumatic brain injury. Method: One hundred nineteen OEF/OIF/OND Veterans with history of mild traumatic brain injury participated at 3 sites, and 50 of the Veterans were randomized to CCT group, while 69 Veterans were randomized to the usual care control group. The CCT group participated in 10 weeks of CCT. Both CCT and usual care groups were assessed at baseline, 5 weeks (midway through CCT), 10 weeks (immediately following CCT), and 15 weeks (5-week follow-up) on measures of subjective cognitive complaints, use of cognitive strategies, psychological functioning, and objective cognitive performance. Results: Veterans who participated in CCT reported significantly fewer cognitive and memory difficulties and greater use of cognitive strategies. They also demonstrated significant improvements on neurocognitive tests of attention, learning, and executive functioning, which were 3 of the cognitive domains targeted in CCT. Conclusions: Findings indicate that training in compensatory cognitive strategies facilitates behavioral change (ie, use of cognitive strategies) as well as both subjective and objective improvements in targeted cognitive domains.	[Storzbach, Daniel; Roost, Mai S.; O'Neil, Maya; Kowalski, Halina M.; Huckans, Marilyn] VA Portland Healthcare Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Storzbach, Daniel; O'Neil, Maya; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Storzbach, Daniel] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Twamley, Elizabeth W.; Jak, Amy J.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Twamley, Elizabeth W.; Golshan, Shahrokh; Jak, Amy J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Williams, Rhonda M.; Turner, Aaron P.; Pagulayan, Kathleen F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA; [Williams, Rhonda M.; Turner, Aaron P.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Pagulayan, Kathleen F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Storzbach, D (corresponding author), VA Portland Healthcare Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	daniel.storzbach@va.gov	Pagulayan, Kati/AAR-9225-2020; Turner, Aaron/A-7902-2009	Turner, Aaron/0000-0001-6897-8003	VA Merit Review AwardUS Department of Veterans Affairs [D7217-R]; Veterans Affairs Health Services Research and Development Center of Innovation grant; Center to Improve Veteran Involvement in Care [CIN 13-404]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1 K12 HS019456 01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS022981] Funding Source: NIH RePORTER	This work was supported by VA Merit Review Award #D7217-R to Daniel Storzbach and Elizabeth Twamley from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development. Author Maya O'Neil is currently receiving funding from a Veterans Affairs Health Services Research and Development Center of Innovation grant, Center to Improve Veteran Involvement in Care, Award #CIN 13-404, and an Agency for Healthcare Research and Quality-funded PCOR K12 award to MEO (#1 K12 HS019456 01). For the remaining authors, none were declared. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Medical Centers in Portland, Oregon, San Diego, California, and Seattle, Washington.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Beck A., 1996, MANUAL BDI 2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict RHB, 2003, MULT SCLER J, V9, P95, DOI 10.1191/1352458503ms861oa; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cappa SF, 2005, EUR J NEUROL, V12, P665; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; Crawford JR, 2006, BRIT J CLIN PSYCHOL, V45, P83, DOI 10.1348/014466505X28748; de Frias CM, 2005, PSYCHOL ASSESSMENT, V17, P168, DOI 10.1037/1040-3590.17.2.168; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Delis DC., 2001, DELIS KAPLAN EXECUTI; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dixon RA, 2001, J CLIN EXP NEUROPSYC, V23, P650, DOI 10.1076/jcen.23.5.650.1242; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huckans M, 2013, NEUROPSYCHOL REV, V23, P63, DOI 10.1007/s11065-013-9230-9; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Mausbach BT, 2007, SCHIZOPHRENIA BULL, V33, P1364, DOI 10.1093/schbul/sbm014; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Stroupe KT, 2013, J REHABIL RES DEV, V50, P1047, DOI 10.1682/JRRD.2012.06.0107; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Twamley EW, 2015, J HEAD TRAUMA REHAB, V30, P391, DOI 10.1097/HTR.0000000000000076; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; WEATHERS FW, 1994, 9 ANN M INT SOC TRAU; Wechsler D., 2008, WECHSLER ADULT INTEL; Wilkinson G.S., 2006, WRAT 4 WIDE RANGE AC; Wykes T, 2011, SCHIZOPHRENIA BULL, V37, pS80, DOI 10.1093/schbul/sbr064	49	38	38	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2017	32	1					16	24		10.1097/HTR.0000000000000228			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EI2GH	WOS:000392304400002	27022961				2022-02-06	
J	Westermann, RW; Kerr, ZY; Wehr, P; Amendola, A				Westermann, Robert W.; Kerr, Zachary Y.; Wehr, Peter; Amendola, Annuziato			Increasing Lower Extremity Injury Rates Across the 2009-2010 to 2014-2015 Seasons of National Collegiate Athletic Association Football: An Unintended Consequence of the "Targeting" Rule Used to Prevent Concussions?	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; knee; ankle injury; football; rule change	SURVEILLANCE SYSTEM; SPORTS; EPIDEMIOLOGY; STATEMENT; PLAYERS	Background: Sports-related concussions (SRCs) have gained increased societal interest in the past decade. The National Collegiate Athletic Association (NCAA) has implemented legislation and rule changes to decrease the incidence and risk of head injury impacts. The targeting rule forbids initiating contact with the crown of a helmet and targeting defenseless players in the head and neck area; however, there are concerns that this rule change has unintentionally led to an increased incidence of lower extremity injuries. Purpose/Hypothesis: The purpose of this study was to evaluate the change in lower extremity injury rates in NCAA football during the 2009-2010 to 2014-2015 seasons. We hypothesized that the lower extremity injury rate has increased across the time period. Study Design: Descriptive epidemiology study. Methods: Sixty-eight NCAA football programs provided 153 team-seasons of data to the NCAA Injury Surveillance Program. Lower extremity injuries (ie, hip/groin, upper leg/thigh, knee, lower leg/Achilles, foot/toes) and SRCs sustained during NCAA football games were examined. We calculated injury rates per 1000 athlete-exposures (AEs) for lower extremity injuries and SRCs. Rate ratios (RRs) compared injury rates between the 2009-2010 to 2011-2012 and 2012-2013 to 2014-2015 seasons. Results: Overall, 2400 lower extremity injuries were reported during the 2009-2010 to 2014-2015 seasons; most were to the knee (33.6%) and ankle (28.5%) and caused by player contact (59.2%). The lower extremity injury rate increased in 2012-2013 to 2014-2015 compared with 2009-2010 to 2011-2012 (23.55 vs 20.45/1000 AEs, respectively; RR, 1.15; 95% CI, 1.06-1.25). This finding was retained when restricted to injuries due to player contact (RR, 1.19; 95% CI, 1.07-1.32) but not for injuries due to noncontact/overuse (RR, 0.96; 95% CI, 0.80-1.14). When examining player contact injury rates by anatomic site, only ankle injuries had an increase (RR, 1.36; 95% CI, 1.13-1.64). The SRC rate also increased in 2012-2013 to 2014-2015 compared with 2009-2010 to 2011-2012 (3.52 vs 2.63/1000 AEs, respectively; RR, 1.34; 95% CI, 1.08-1.66). Conclusion: The lower extremity injury rate has increased in NCAA football athletes. Similarly, SRC rates have increased, although this may be caused by concurrent policies related to better education, identification, and management. Targeting rule changes may be contributing to increased rates of player contact-related ankle injuries. Alongside continued surveillance research to examine longitudinal time trends, more in-depth individual-level examinations of how targeting rule changes influence coaching and player behaviors are warranted.	[Westermann, Robert W.; Kerr, Zachary Y.; Wehr, Peter; Amendola, Annuziato] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; [Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA; [Amendola, Annuziato] Duke Univ, Durham, NC USA		Westermann, RW (corresponding author), Univ Iowa Hosp & Clin, Dept Orthopaed Surg, 200 Hawkins Dr,01008 JPP, Iowa City, IA 52242 USA.	robert-westermann@uiowa.edu		Kerr, Zachary/0000-0003-1423-1259; Westermann, Robert/0000-0002-5289-4689	NCAA; Arthrex Inc.	One or more of the authors has declared the following potential conflict of interest or source of funding: The National Collegiate Athletic Association (NCAA) Injury Surveillance Program data were provided by the Datalys Center for Sports Injury Research and Prevention. The Injury Surveillance Program was funded by the NCAA. The content of this report is solely the responsibility of the authors and does not necessarily reflect the views of the NCAA. Dr Amendola receives intellectual property royalties from Arthrex Inc, Arthrosurface, and Smith & Nephew; has stock or stock options in First Ray Inc; and is a paid consultant for Arthrex Inc.	[Anonymous], 1905, WASHINGTON POST; Barzilai P, 2014, US TODAY SPORTS 0127; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick R, 2007, J ATHL TRAINING, V42, P221; Dragoo JL, 2013, KNEE, V20, P191, DOI 10.1016/j.knee.2012.07.006; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Golightly YM, 2009, J PHYS ACT HEALTH, V6, P638, DOI 10.1123/jpah.6.5.638; Gorse K, 1997, J ATHL TRAINING, V32, P304; Guido Paul, 2007, 50 YEARS COLL FOOTBA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Heck JF, 2004, J ATHL TRAINING, V39, P101; Hershman EB, 2012, AM J SPORT MED, V40, P2200, DOI 10.1177/0363546512458888; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Larsen E, 1999, SCAND J MED SCI SPOR, V9, P285; LEWIS GM, 1969, RES QUART, V40, P717, DOI 10.1080/10671188.1969.10614909; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Parsons J, 2014, 2014 15 NCAA SPORTS; Redding R, 2013, NCAA FOOTBALL 2013 2; Redding R, 2008, NCAA FOOTBALL 2008 R; Shealy JE, 2000, AM SOC TEST MATER, V1397, P132, DOI 10.1520/STP12871S; Smith MD., 2015, NBC SPORTS      1130; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Weir DR., 2009, NATL FOOTBALL LEAGUE; Wright JM, 2010, CURR SPORT MED REP, V9, P129, DOI 10.1249/JSR.0b013e3181df1179; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	30	38	38	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2016	44	12					3230	3236		10.1177/0363546516659290			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EE8VS	WOS:000389905400027	27511792				2022-02-06	
J	Bu, W; Ren, HL; Deng, YP; Del Mar, N; Guley, NM; Moore, BM; Honig, MG; Reiner, A				Bu, Wei; Ren, Huiling; Deng, Yunping; Del Mar, Nobel; Guley, Natalie M.; Moore, Bob M.; Honig, Marcia G.; Reiner, Anton			Mild Traumatic Brain Injury Produces Neuron Loss That Can Be Rescued by Modulating Microglial Activation Using a CB2 Receptor Inverse Agonist	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; neuron loss; neuron rescue; cerebral cortex; striatum; basolateral amygdala; cannabinoid type-2 receptor inverse agonist	RAT BASOLATERAL AMYGDALA; CONDITIONED FEAR; BASAL GANGLIA; AXONAL INJURY; CELL-DEATH; CONTAINING INTERNEURONS; GABAERGIC INTERNEURONS; INHIBITORY CIRCUITS; GLUTAMATE-RECEPTOR; CORPUS-CALLOSUM	We have previously reported that mild TBI created by focal left-side cranial blast in mice produces widespread axonal injury, microglial activation, and a variety of functional deficits. We have also shown that these functional deficits are reduced by targeting microglia through their cannabinoid type-2 (CB2) receptors using 2-week daily administration of the CB2 inverse agonist SMM-189. CB2 inverse agonists stabilize the G-protein coupled CB2 receptor in an inactive conformation, leading to increased phosphorylation and nuclear translocation of the cAMP response element binding protein (CREB), and thus bias activated microglia from a pro-inflammatory M1 to a pro-healing M2 state. In the present study, we showed that SMM-189 boosts nuclear pCREB levels in microglia in several brain regions by 3 days after TBI, by using pCREB/CD68 double immunofluorescent labeling. Next, to better understand the basis of motor deficits and increased fearfulness after TBI, we used unbiased stereological methods to characterize neuronal loss in cortex, striatum, and basolateral amygdala (BLA) and assessed how neuronal loss was affected by SMM-189 treatment. Our stereological neuron counts revealed a 20% reduction in cortical and 30% reduction in striatal neurons bilaterally at 2-3 months post blast, with SMM-189 yielding about 50% rescue. Loss of BLA neurons was restricted to the blast side, with 33% of Thy1+ fear-suppressing pyramidal neurons and 47% of fear-suppressing parvalbuminergic (PARV) interneurons lost, and Thy1-negative fear-promoting pyramidal neurons not significantly affected. SMM-189 yielded 50-60% rescue of Thy1+ and PARV neuron loss in BLA. Thus, fearfulness after mild TBI may result from the loss of fear-suppressing neuron types in BLA, and SMM-189 may reduce fearfulness by their rescue. Overall, our findings indicate that SMM-189 rescues damaged neurons and thereby alleviates functional deficits resulting from TBI, apparently by selectively modulating microglia to the beneficial M2 state. CB2 inverse agonists thus represent a promising therapeutic approach for mitigating neuroinflammation and neurodegeneration.	[Bu, Wei; Ren, Huiling; Deng, Yunping; Del Mar, Nobel; Guley, Natalie M.; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Moore, Bob M.] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA		Reiner, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.; Reiner, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	Neuroscience Institute at UTHSC; Methodist Hospitals Endowed Professorship in Neuroscience; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-081370]; College of Pharmacy at UTHSC; Office of the Dean of the College of Medicine at UTHSC	Supported by the Neuroscience Institute and the Office of the Dean of the College of Medicine, both at UTHSC, The Methodist Hospitals Endowed Professorship in Neuroscience (AR), NIH grant NS-081370 (AR), and the College of Pharmacy at UTHSC (BM).	Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Atwood BK, 2012, PROG NEURO-PSYCHOPH, V38, P16, DOI 10.1016/j.pnpbp.2011.12.001; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Baek JH, 2013, J NEUROSCI METH, V216, P87, DOI 10.1016/j.jneumeth.2013.03.021; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bales JW, 2011, EXP NEUROL, V229, P300, DOI 10.1016/j.expneurol.2011.02.013; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bartolini G, 2013, NEURON, V79, P849, DOI 10.1016/j.neuron.2013.08.014; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Benito C, 2003, J NEUROSCI, V23, P11136; Brown GC, 2015, BRAIN RES, V1628, P288, DOI 10.1016/j.brainres.2015.08.031; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Ciocchi S, 2010, NATURE, V468, P277, DOI 10.1038/nature09559; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DeFelipe J, 2013, NAT REV NEUROSCI, V14, P202, DOI 10.1038/nrn3444; Deng YP, 2007, J CHEM NEUROANAT, V33, P167, DOI 10.1016/j.jchemneu.2007.02.008; Deng YP, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00198; Deng YP, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00051; Donat CK, 2014, ACTA NEUROBIOL EXP, V74, P197; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Faul M, 2010, TRAUMATIC BRAIN INJU; Firsching R, 2012, J NEUROL SURG PART A, V73, P204, DOI 10.1055/s-0032-1304815; Fujinaga M, 2010, BIOORG MED CHEM LETT, V20, P1565, DOI 10.1016/j.bmcl.2010.01.074; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Godavarthi SK, 2014, J NEUROCHEM, V130, P444, DOI 10.1111/jnc.12726; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Gorski JA, 2002, J NEUROSCI, V22, P6309; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hattox AM, 2007, J NEUROPHYSIOL, V98, P3330, DOI 10.1152/jn.00397.2007; Haubensak W, 2010, NATURE, V468, P270, DOI 10.1038/nature09553; Heck D. H., 2015, SOC NEUR ABST, V589, P13; Heldt SA, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.101; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Herry C, 2014, NAT NEUROSCI, V17, P1644, DOI 10.1038/nn.3869; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Janak PH, 2015, NATURE, V517, P284, DOI 10.1038/nature14188; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Jayakumar AR, 2016, NEUROCHEM RES, V41, P307, DOI 10.1007/s11064-015-1801-0; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kallakuri S, 2012, BRAIN RES, V1452, P29, DOI 10.1016/j.brainres.2012.02.065; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kordower JH, 2001, ANN NEUROL, V49, P202, DOI 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.3.CO;2-V; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laksari K, 2014, J MECH BEHAV BIOMED, V32, P132, DOI 10.1016/j.jmbbm.2013.12.021; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Liu Y., 2016, SOC NEUR ABST, V607, P14; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luthi A, 2014, NAT NEUROSCI, V17, P1635, DOI 10.1038/nn.3849; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Lunn CA, 2006, J PHARMACOL EXP THER, V316, P780, DOI 10.1124/JPET.105.093500; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mascagni F, 2003, BRAIN RES, V976, P171, DOI 10.1016/S0006-8993(03)02625-8; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Morozov A, 2011, J NEUROSCI, V31, P339, DOI 10.1523/JNEUROSCI.5537-10.2011; Muller JF, 2007, J COMP NEUROL, V500, P513, DOI 10.1002/cne.21185; Muller JF, 2003, J COMP NEUROL, V456, P217, DOI 10.1002/cne.10435; Muller JF, 2006, J COMP NEUROL, V494, P635, DOI 10.1002/cne.20832; Myers KM, 2006, LEARN MEMORY, V13, P216, DOI 10.1101/lm.119806; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Neervannan S, 2006, EXPERT OPIN DRUG MET, V2, P715, DOI 10.1517/17425255.2.5.715; Ozdinler PH, 2011, J NEUROSCI, V31, P4166, DOI 10.1523/JNEUROSCI.4184-10.2011; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; PETERS A, 1985, J COMP NEUROL, V238, P263, DOI 10.1002/cne.902380303; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rainnie DG, 2006, J COMP NEUROL, V498, P142, DOI 10.1002/cne.21049; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Reiner A, 1998, BRAIN RES REV, V28, P235, DOI 10.1016/S0165-0173(98)00016-2; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rosenkranz JA, 2001, J NEUROSCI, V21, P4090, DOI 10.1523/JNEUROSCI.21-11-04090.2001; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Shi L, 2004, J COMP NEUROL, V478, P282, DOI 10.1002/cne.20303; Shitaka Y., 2001, J NEUROPATHOL EXP NE, V70, P551, DOI DOI 10.1097/NEN.0B013E31821F891F; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Tam WY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07279; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tovar-y-Romo LB, 2016, J NEUROCHEM, V136, P13, DOI 10.1111/jnc.13362; Truitt WA, 2009, NEUROSCIENCE, V160, P284, DOI 10.1016/j.neuroscience.2009.01.083; Tsuda S, 2016, NEUROREPORT, V27, P724, DOI 10.1097/WNR.0000000000000598; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wolff SBE, 2014, NATURE, V509, P453, DOI 10.1038/nature13258; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yttri EA, 2016, NATURE, V533, P402, DOI 10.1038/nature17639; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046; Zhang L, 2015, INT J MED SCI, V12, P288, DOI 10.7150/ijms.10527	116	38	39	1	13	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 6	2016	10								449	10.3389/fnins.2016.00449			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DY7FI	WOS:000385294600001	27766068	Green Published, gold			2022-02-06	
J	Hinzman, JM; Wilson, JA; Mazzeo, AT; Bullock, MR; Hartings, JA				Hinzman, Jason M.; Wilson, J. Adam; Mazzeo, Anna Teresa; Bullock, M. Ross; Hartings, Jed A.			Excitotoxicity and Metabolic Crisis Are Associated with Spreading Depolarizations in Severe Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						electrocorticography; multi-modal monitoring; spreading depression	HUMAN CEREBRAL-CORTEX; HUMAN HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; AMINO-ACID RELEASE; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; GLUTAMATE RELEASE; BLOOD-FLOW; PERIINFARCT DEPOLARIZATIONS; ONLINE MICRODIALYSIS	Cerebral microdialysis has enabled the clinical characterization of excitotoxicity (glutamate > 10 mu M) and non-ischemic metabolic crisis (lactate/pyruvate ratio [LPR] > 40) as important components of secondary damage in severe traumatic brain injury (TBI). Spreading depolarizations (SD) are pathological waves that occur in many patients in the days following TBI and, in animal models, cause elevations in extracellular glutamate, increased anaerobic metabolism, and energy substrate depletion. Here, we examined the association of SD with changes in cerebral neurochemistry by placing a microdialysis probe alongside a subdural electrode strip in peri-lesional cortex of 16 TBI patients requiring neurosurgery. In 107 h (median; range: 76-117 h) of monitoring, 135 SDs were recorded in six patients. Glutamate (50 mu mol/L) and lactate (3.7 mmol/L) were significantly elevated on day 0 in patients with SD compared with subsequent days and with patients without SD, whereas pyruvate was decreased in the latter group on days 0 and 1 (two-way analysis of variance [ANOVA], p values < 0.05). In patients with SD, both glutamate and LPR increased in a dose-dependent manner with the number of SDs in the microdialysis sampling period (0, 1, >= 2 SD) [glutamate: 2.1 -> 7.0 -> 52.3 mu mol/L; LPR: 27.8 -> 29.9 -> 45.0, p values < 0.05]. In these patients, there was a 10% probability of SD occurring when glutamate and LPR were in normal ranges, but a 60% probability when both variables were abnormal (> 10 mu mol/L and > 40 mu mol/L, respectively). Taken together with previous studies, these preliminary clinical results suggest SDs are a key pathophysiological process of secondary brain injury associated with non-ischemic glutamate excitotoxicity and severe metabolic crisis in severe TBI patients.	[Hinzman, Jason M.; Wilson, J. Adam; Hartings, Jed A.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [Hartings, Jed A.] Univ Cincinnati, Inst Neurosci, Neurotrauma Ctr, Cincinnati, OH USA; [Mazzeo, Anna Teresa; Bullock, M. Ross] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA; [Mazzeo, Anna Teresa] Univ Turin, Dept Anesthesia & Intens Care, Turin, Italy; [Bullock, M. Ross] Univ Miami, Dept Neurosurg, Miami, FL USA; [Hartings, Jed A.] Mayfield Clin, Cincinnati, OH USA		Hinzman, JM (corresponding author), Univ Cincinnati, 231 Albert Sabin Way,ML0517, Cincinnati, OH 45267 USA.	jmhinz2@gmail.com		Hartings, Jed/0000-0001-8583-3471; Mazzeo, Anna Teresa/0000-0002-8454-7243			Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cruz NF, 1999, J CEREBR BLOOD F MET, V19, P380, DOI 10.1097/00004647-199904000-00004; De Fazio M, 2011, NEUROCRIT CARE, V14, P91, DOI 10.1007/s12028-010-9494-3; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2008, NEUROL RES, V30, P876, DOI 10.1179/174313208X309739; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2014, J NEUROSURG, V120, P434, DOI 10.3171/2013.9.JNS13581; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2012, LANCET NEUROL, V11, P389, DOI 10.1016/S1474-4422(12)70085-6; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Krajewski KL, 2011, ACTA NEUROCHIR SUPPL, V110, P125, DOI 10.1007/978-3-7091-0353-1_22; Landolt H, 1998, J CLIN NEUROSCI, V5, P193, DOI 10.1016/S0967-5868(98)90037-6; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; McGinn Melissa J., 2016, NEUROSURG CLIN N AM, V27, P397; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Somjen GG, 2004, IONS BRAIN NORMAL FU; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; TAYLOR DL, 1994, J NEUROCHEM, V62, P2368; Timofeev I, 2008, ACTA NEUROCHIR SUPPL, V102, P99, DOI 10.1007/978-3-211-85578-2_20; Timofeev I, 2013, J CEREBR BLOOD F MET, V33, P422, DOI 10.1038/jcbfm.2012.186; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; Zauner A, 1996, ACT NEUR S, V67, P40; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113	70	38	38	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1775	+		10.1089/neu.2015.4226			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100006	26586606	Green Published			2022-02-06	
J	Jorge, RE; Acion, L; Burin, DI; Robinson, RG				Jorge, Ricardo E.; Acion, Laura; Burin, Debora I.; Robinson, Robert G.			Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury A Randomized Clinical Trial	JAMA PSYCHIATRY			English	Article							MAJOR DEPRESSIVE DISORDER; BLUNT HEAD-INJURY; PSYCHIATRIC-DISORDERS; AXIS-I; ASSOCIATION; ILLNESS; RISK; ESCITALOPRAM; RELATIVES; ONSET	IMPORTANCE Prevention is more effective than treatment to decrease the burden of significant medical conditions such as depressive disorders, a major cause of disability worldwide. Traumatic brain injury (TBI) is a candidate for selective strategies to prevent depression given the incidence, prevalence, and functional effect of depression that occurs after TBI. OBJECTIVE To assess the efficacy of sertraline treatment in preventing depressive disorders following TBI. DESIGN, SETTING, AND PARTICIPANTS A double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted at a university hospital from July 3, 2008, to September 17, 2012, with 24 weeks of follow-up. A consecutive sample of 534 patients aged 18 to 85 years, hospitalized for mild, moderate, or severe TBI, was eligible for the study. Ninety-four patients consented to participate and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84%) completed the study. Intention-to-treat data analysis was conducted from July 1, 2014, to December 31, 2015. INTERVENTIONS Placebo or sertraline, 100 mg/d, for 24 weeks or until development of a mood disorder. MAIN OUTCOMES AND MEASURES Time to onset of depressive disorders, as defined by the DSM-IV, associated with TBI. RESULTS Of the 94 patients in the study (38 female and 56 male; 92 white), the number needed to treat to prevent depression after TBI at 24 weeks was 5.9 (95% CI, 3.1-71.1; chi(2) = 4.6; P = .03) for sertraline treatment vs placebo. The influence of sertraline in the course of neuropsychological variables was not detected. The intervention was well tolerated, and adverse effects were mild in both the sertraline and placebo groups. CONCLUSIONS AND RELEVANCE Sertraline appears to be efficacious to prevent the onset of depressive disorders following TBI. Future studies should replicate these findings in a large sample of patients with TBI and depict their long-term physical, cognitive, behavioral, and functional outcomes.	[Jorge, Ricardo E.; Acion, Laura] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, One Baylor Plaza, Houston, TX 77030 USA; [Acion, Laura] Univ Iowa, Iowa Consortium Subst Abuse Res & Evaluat, Iowa City, IA USA; [Acion, Laura] Univ Buenos Aires, CONICET, Fac Ciencias Exactas & Nat, Inst Calculo, Buenos Aires, DF, Argentina; [Burin, Debora I.] Univ Buenos Aires, CONICET, Fac Psicol, Buenos Aires, DF, Argentina; [Robinson, Robert G.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA		Jorge, RE (corresponding author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, One Baylor Plaza, Houston, TX 77030 USA.	ricardo.jorge@bcm.edu		Burin, D. I./0000-0002-2515-719X; Acion, Laura/0000-0001-5213-6012	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS055827]	This study was funded by grant R01 NS055827 from the National Institutes of Health.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Beekman ATF, 2010, CURR OPIN PSYCHIATR, V23, P8, DOI 10.1097/YCO.0b013e328333e17f; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Finkelstein E., 2006, INCIDENCE EC BURDEN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hertz L, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00025; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Jorge R, 2002, NEUROREHABILITATION, V17, P311; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Jorge RE, 2010, ARCH GEN PSYCHIAT, V67, P187, DOI 10.1001/archgenpsychiatry.2009.185; Karpova NN, 2012, SCIENCE, V335; Karpova NN, 2011, SCIENCE, V334, P1731, DOI 10.1126/science.1214592; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; McGahuey CA, 2000, J SEX MARITAL THER, V26, P25, DOI 10.1080/009262300278623; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reynolds CF, 2007, ARCH GEN PSYCHIAT, V64, P884, DOI 10.1001/archpsyc.64.8.884; Robinson RG, 2008, JAMA-J AM MED ASSOC, V299, P2391, DOI 10.1001/jama.299.20.2391; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; van Zoonen K, 2014, INT J EPIDEMIOL, V43, P318, DOI 10.1093/ije/dyt175; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	42	38	41	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	OCT	2016	73	10					1041	1047		10.1001/jamapsychiatry.2016.2189			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	DZ5QG	WOS:000385916000009	27626622				2022-02-06	
J	Mychasiuk, R; Hehar, H; Ma, I; Candy, S; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene; Candy, Sydney; Esser, Michael J.			Reducing the time interval between concussion and voluntary exercise restores motor impairment, short-term memory, and alterations to gene expression	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						hippocampus; mild traumatic brain injury; prefrontal cortex; rodent models; telomere length	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; COGNITIVE DYSFUNCTION; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; SPORTS CONCUSSION; FAT DIET; MODEL; PLASTICITY; RECOVERY	Despite the most common form of brain injury, there has been little progress in the prognosis and treatment of concussion/mild traumatic brain injury (mTBI). Current return-to-play' guidelines are conservative, deterring the initiation of physical and social activity until patients are asymptomatic; but the effects of post-injury exercise have not been adequately investigated. Therefore, this study examined the effects of voluntary exercise on concussion recovery. Using a translational rodent model of concussion, we examined the influence of exercise on injury-associated behaviours that comprise post-concussive syndrome (PCS) and gene expression changes (bdnf, dnmt1, Igf-1, pgc1-a, Tert) in prefrontal cortex and hippocampus. In addition, as we have previously demonstrated telomere length (TL) to be a reliable predictor of mTBI prognosis, TL was also examined. The results suggest that exercise initiated within 1-3days post-concussion significantly improved motor and cognitive functioning, but had limited efficacy treating emotional impairments. What is more, when deprived of social interaction and exercise, a combination similar to clinical recommendations for rest until symptom resolution, animals did not recover and exhibited impairments similar to typical mTBI animals. Exercise aided in restoration of mTBI-induced modifications to gene expression in both brain regions. An inverse relationship between the exercise return interval and TL was identified, indicating greater recovery with acute exercise reinstatement. Although additional strategies may need to be employed for emotional functioning, these findings support re-evaluation of return-to-play' guidelines, suggesting that exercise is valuable for the treatment of concussion.	[Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene] Univ Calgary, Dept Psychol, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada; [Candy, Sydney; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Dept Psychol, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute (ACHRI); Alberta Children's Hospital Foundation (ACHF); Canadian Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	The authors thank Dr C Teskey, K. Yu and R. Tobias for their technical assistance. They also thank the Alberta Children's Hospital Research Institute (ACHRI), the Alberta Children's Hospital Foundation (ACHF) and the Canadian Institute for Health Research (CIHR) for their financial support.	Baek S, 2004, NEUROSCI LETT, V363, P94, DOI 10.1016/j.neulet.2004.03.059; Baker LD, 2010, ARCH NEUROL-CHICAGO, V67, P71, DOI 10.1001/archneurol.2009.307; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bell HC, 2010, BEHAV BRAIN RES, V207, P7, DOI 10.1016/j.bbr.2009.09.029; Bernardo TC, 2016, BRAIN PATHOL, V26, P648, DOI 10.1111/bpa.12403; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Cotman CW, 2002, EXERC SPORT SCI REV, V30, P75, DOI 10.1097/00003677-200204000-00006; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Golshani Peyman, 2005, Thalamus & Related Systems, V3, P227, DOI 10.1017/S1472928807000222; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2013, J NEUROTRAUM, V30, P281, DOI 10.1089/neu.2012.2616; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hamilton M, 2016, BRAIN INJURY, V30, P819, DOI 10.3109/02699052.2016.1146962; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Ji LL, 2010, DOSE-RESPONSE, V8, P73, DOI 10.2203/dose-response.09-048.Ji; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Mangiola A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/736104; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McCrory P, 2008, S AFR J SPORTS MED, V21, P36; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; MONDON CE, 1985, J APPL PHYSIOL, V58, P1553, DOI 10.1152/jappl.1985.58.5.1553; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Ozdemir D, 2012, NEUROSCI LETT, V507, P84, DOI 10.1016/j.neulet.2011.11.059; Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X; PELLIS SM, 1992, BEHAV BRAIN RES, V50, P135, DOI 10.1016/S0166-4328(05)80295-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shi H, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-83; Smidt N, 2005, AUST J PHYSIOTHER, V51, P71, DOI 10.1016/S0004-9514(05)70036-2; Solomon GS, 2016, PHYSICIAN SPORTSMED, V44, P14, DOI 10.1080/00913847.2016.1121091; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x	59	38	39	0	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2016	44	7					2407	2417		10.1111/ejn.13360			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DY8QE	WOS:000385394100002	27521273				2022-02-06	
J	Kellermann, I; Kleindienst, A; Hore, N; Buchfelder, M; Brandner, S				Kellermann, Isabel; Kleindienst, Andrea; Hore, Nirjhar; Buchfelder, Michael; Brandner, Sebastian			Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Biomarker; S100B; Neurotrauma; Neuroproteins; Cerebrospinal fluid	CEREBROSPINAL-FLUID; S-100 PROTEIN; BIOMARKERS	Objectives: S100B has been proposed as a putative biochemical marker in determining the extent of brain injury and corresponding prognosis in neurotrauma. The aim of this study was to evaluate the prognostic value of S100B early concentrations in serum and cerebrospinal fluid (CSF) in traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH), to determine prognostically relevant threshold values and to evaluate fluctuation following EVD placement. Patients and methods: In 102 patients (45 SAH and 57 TBI) under intensive care unit (ICU) treated between January 2011 and December 2012 with external ventricular drain (EVD) S100B measurements were performed simultaneously in serum and CSF during the first 5 days and before and after EVD exchange. Glasgow coma scale (GCS) was assessed on admission and Glasgow outcome scale (GOS) 6 months later. Results: Peak S100B levels in CSF and serum were measured on the first day after admission and concentrations decreased during the ensuing days post injury gradually. CSF and serum S100B concentrations in TBI patients were significantly higher than in SAH (p < 0.005). Both in TBI and SAH patients S100B concentrations in CSF and serum were significantly higher in patients with an unfavorable outcome (GOS 1-3) in comparison to patients with a good outcome (GOS 4-5). Correlation of S100B concentrations in serum and GOS score at 6 months was significant both in TBI and SAH (p<0.05). Serum S100B concentrations >0.7 mu g/l correlated with 100% mortality. Correlation between S100B in CSF and GOS was significant in SAH (p < 0.05), whereas it was not significant in TBI. After EVD exchange (n = 53) we found a significant increase of S100B concentration in CSF (p < 0.005). Conclusion: Initial S100B levels have a limited prognostic value in neurotrauma with CSF concentrations being highly sensitive to smallest influences like EVD placement. However, high initial S100B levels of >0.7 mu g/dl in serum are associated with 100% mortality, which might help to guide therapy strategies in severe neurotrauma. (C) 2016 Elsevier B.V. All rights reserved.	[Kellermann, Isabel; Kleindienst, Andrea; Hore, Nirjhar; Buchfelder, Michael; Brandner, Sebastian] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany		Brandner, S (corresponding author), Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany.	isabel.kellermann@web.de; andrea.kleindienst@uk-erlangen.de; nirjhar.hore@uk-erlangen.de; michael.buchfelder@uk-erlangen.de; sebastian.brandner@uk-erlangen.de	Kleindienst, Andrea/F-1674-2014; Brandner, Sebastian/AAU-2615-2021	Kleindienst, Andrea/0000-0003-4758-0324; Brandner, Sebastian/0000-0002-8635-7195			Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Brandner S, 2012, Acta Neurochir Suppl, V114, P217, DOI 10.1007/978-3-7091-0956-4_42; Brandner S, 2013, J NEUROTRAUM, V30, P1205, DOI 10.1089/neu.2012.2621; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Egea-Guerrero JJ, 2013, J NEUROTRAUM, V30, P1762, DOI 10.1089/neu.2012.2606; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Rohlwink UK, 2014, CLIN CHEM, V60, P823, DOI 10.1373/clinchem.2013.212472; TAKAYASU M, 1985, J NEUROSURG, V63, P417, DOI 10.3171/jns.1985.63.3.0417; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75	16	38	40	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2016	145						79	83		10.1016/j.clineuro.2016.04.005			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DP0KZ	WOS:000378180000015	27101088				2022-02-06	
J	Nolin, P; Stipanicic, A; Henry, M; Lachapelle, Y; Lussier-Desrochers, D; Rizzo, A; Allain, P				Nolin, Pierre; Stipanicic, Annie; Henry, Mylene; Lachapelle, Yves; Lussier-Desrochers, Dany; Rizzo, Albert Skip; Allain, Philippe			ClinicaVR: Classroom-CPT: A virtual reality tool for assessing attention and inhibition in children and adolescents	COMPUTERS IN HUMAN BEHAVIOR			English	Article						ClinicaVR; Classroom-CPT; Inhibition; Validity; Reliability; Children; Virtual reality; Virtual classroom	CONTINUOUS PERFORMANCE-TEST; TRAUMATIC BRAIN-INJURY; DEFICIT HYPERACTIVITY DISORDER; ECOLOGICAL VALIDITY; REHABILITATION; ENVIRONMENT; TASK; ADHD; SCENARIO	Having garnered interest both in clinic and research areas, the Virtual Classroom (Rizzo et al., 2000) assesses children's attention in a virtual context. The Digital MediaWorks team (www.dmw.ca) has evolved the original basic classroom concept over a number of iterations to form the ClinicaVR Suite containing the Classroom-CPT as one of its components. The present study has three aims: investigate certain validity and reliability aspects of the tool; examine the relationship between performance in the virtual test and the attendant sense of presence and cybersickness experienced by participants; assess potential effects of gender and age on performance in the test. The study was conducted with 102 children and adolescents from Grade 2 to Grade 10. All participants were enrolled in a regular school program. Results support both concurrent and construct validity as well as temporal stability of ClinicaVR: Classroom-Continuous Performance Test (CPT). Gender exerted no effect on performance, while age did. The test did not cause much cybersickness. We recommend ClinicaVR: Classroom-CPT as an assessment tool for selective and sustained attention, and inhibition, in clinic and research domains. (C) 2016 Elsevier Ltd. All rights reserved.	[Nolin, Pierre; Stipanicic, Annie; Henry, Mylene; Lachapelle, Yves; Lussier-Desrochers, Dany] Univ Quebec Trois Rivieres, Lab Rech Interdisciplinaire Real Virtuelle LARI R, Quebec City, PQ, Canada; [Nolin, Pierre; Stipanicic, Annie; Henry, Mylene; Lachapelle, Yves; Lussier-Desrochers, Dany] Univ Quebec Trois Rivieres, Chaire Rech Technol Soutien Autodeterminat, Chaire TSA, Quebec City, PQ, Canada; [Rizzo, Albert Skip] Univ So Calif, Dept Psychiat, Inst Creat Technol, Playa Vista, CA USA; [Rizzo, Albert Skip] Univ So Calif, Sch Gerontol, Playa Vista, CA USA; [Allain, Philippe] Univ Angers, LUNAM, Lab Psychol Pays de la Loire, EA 4638, Angers, France		Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Dept Psychoeduc, Lab Rech Interdisciplinaire Real Virtuelle, CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	pierre.nolin@uqtr.ca			Canada Foundation for Innovation (FCI)Canada Foundation for InnovationFonds der Chemischen Industrie [1842]; Ministere de l'Economie, de l'Innovation et des Exportations du Quebec (MDEIE); Fond de Developpement Academique du Roseau de l'Universite du Quebec (FODAR); Fonds Institutionnel de Recherche (FIR) de l'Universite du Quebec a Trois-Rivieres (UQTR)	This research was supported by Canada Foundation for Innovation (FCI, No. 1842), The Ministere de l'Economie, de l'Innovation et des Exportations du Quebec (MDEIE), the Fond de Developpement Academique du Roseau de l'Universite du Quebec (FODAR), and Fonds Institutionnel de Recherche (FIR) de l'Universite du Quebec a Trois-Rivieres (UQTR). The authors would like to thank Roman Mitura and Dean Klimchuk from the Digital MediaWorks company for allowing them to use the Virtual Classroom and ClinicaVR: Classroom. The authors would also like to thank the following people for their valuable contributions to this research project: the staff of the Academie les Estacades de Trois-Rivieres, particularly Mrs. Rosemarie Boucher, Mrs. Luce Mongrain and Mr. Michel Boutin; Dr. David Fecteau of the Centre Hospitalier Regional de Trois-Rivieres; Mr. Fernand Bouchard of the St. Maurice Physiotherapy Clinic; Mrs Nancy Mignault, directrice du Conseil du Loisir Scientifique - Trois-Rivieres, and all research assistants from our laboratory.	Adams R, 2009, CHILD NEUROPSYCHOL, V15, P120, DOI 10.1080/09297040802169077; Albani G, 2010, ANN REV CYBERTHERAPY, V8, P73; Allain P., 2011, J CYBERTHERAPY REHAB, V4, P278; Aymerich-Franch L, 2010, CYBERPSYCH BEH SOC N, V13, P649, DOI 10.1089/cyber.2009.0412; Baumgartner T, 2006, CYBERPSYCHOL BEHAV, V9, P30, DOI 10.1089/cpb.2006.9.30; Betts J, 2006, CHILD NEUROPSYCHOL, V12, P205, DOI 10.1080/09297040500488522; Bouchard S, 2007, ANN REV CYBERTHERAPY, V5, P128; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Cegalis JA, 1991, VIGIL SOFTWARE TESTI; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Egeland J, 2010, J ATTEN DISORD, V13, P339, DOI 10.1177/1087054708323019; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Gutierrez-Maldonado J, 2009, ANU PSICOL, V40, P211; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P207, DOI 10.1080/09084282.2011.643956; Kennedy RS, 1993, INT J AVIAT PSYCHOL, V3, P203, DOI [10.1207/s15327108ijap0303_3, DOI 10.1207/S15327108IJAP0303_3]; Klinger E, 2009, ANN REV CYBERTHERAPY, V7, P248; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; Larson EB, 2011, BRAIN INJURY, V25, P274, DOI 10.3109/02699052.2010.551648; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Marcotte T. D., 2010, NEUROPSYCHOLOGY EVER; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Moreau G, 2006, ANN REV CYBERTHERAPY, V4, P59; Nolin P, 2009, ANN REV CYBERTHERAPY, V7, P240; Parsons T., 2015, VIRTUAL REALITY TECH, P177; Parsons TD, 2005, AGING NEUROPSYCHOL C, V12, P78, DOI 10.1080/13825580590925125; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Parsons TD, 2009, DEV NEUROREHABIL, V12, P224, DOI 10.1080/17518420902991719; Parsons TD, 2008, ANN REV CYBERTHERAPY, V6, P23; Penn PR, 2009, DEV NEUROREHABIL, V12, P32, DOI 10.1080/17518420902739365; Pollak Y, 2010, CNS SPECTRUMS, V15, P125, DOI 10.1017/S109285290002736X; Pollak Y, 2009, J DEV BEHAV PEDIATR, V30, P2, DOI 10.1097/DBP.0b013e3181969b22; Pugnetti L., 1998, CYBERPSYCHOLOGY BEHA, V1, P151, DOI DOI 10.1089/CPB.1998.1.151; Raspelli S., 2009, J CYBER THER REHABIL, V2, P299; Riva G, 2007, CYBERPSYCHOL BEHAV, V10, P45, DOI 10.1089/cpb.2006.9993; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 2002, HUM FAC ER, P1027; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Robillard G, 2002, 25 C SOC QUEB RECH P; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Sbordone R.J., 2008, NEUROPSYCHOLOGY HDB, P367; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Sheridan, 1992, PRESENCE-TELEOP VIRT, V1, P120, DOI [10.1162/pres.1992.1.1.120, DOI 10.1162/PRES.1992.1.1.120]; Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948; Trepagnier CG, 1999, NEUROREHABILITATION, V12, P63; van der Linden WJ, 2008, Z PSYCHOL, V216, P3, DOI 10.1027/0044-3409.216.1.3; van der Linden WJ, 2008, Z PSYCHOL, V216, P1, DOI 10.1027/0044-3409.216.1.1; Wang M, 2011, NEUROEPIDEMIOLOGY, V36, P2, DOI 10.1159/000320847; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Yen HL, 2007, ANN ACAD MED SINGAP, V36, P62	52	38	42	0	48	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0747-5632	1873-7692		COMPUT HUM BEHAV	Comput. Hum. Behav.	JUN	2016	59						327	333		10.1016/j.chb.2016.02.023			7	Psychology, Multidisciplinary; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	DI8KB	WOS:000373748800035					2022-02-06	
J	Srinivasan, A; Aggarwal, A; Gaudihalli, S; Mohanty, M; Dhandapani, M; Singh, H; Mukherjee, KK; Dhandapani, S				Srinivasan, Anirudh; Aggarwal, Ashish; Gaudihalli, Sachin; Mohanty, Manju; Dhandapani, Manju; Singh, Harminder; Mukherjee, Kanchan K.; Dhandapani, Sivashanmugam			Impact of Early Leukocytosis and Elevated High-Sensitivity C-Reactive Protein on Delayed Cerebral Ischemia and Neurologic Outcome After Subarachnoid Hemorrhage	WORLD NEUROSURGERY			English	Article						DCI; Early inflammatory response; GOS; hs-CRP; Ictus; New infarct; Outcome; TLC	INTERCELLULAR-ADHESION MOLECULE-1; TRAUMATIC BRAIN INJURY; HEAD-INJURY; VASOSPASM; SERUM; DEFICITS; DAMAGE; COUNT	BACKGROUND: The role of inflammatory response in the pathophysiology of subarachnoid hemorrhage (SAH) is being increasingly recognized. This study analyzed the impact of cellular and biochemical markers of early inflammatory response to ictus on outcome after SAH. METHODS: Patients with SAH were prospectively studied for markers of early cellular, biochemical, and cytotoxic inflammatory response, including total leukocyte count (TLC), high-sensitivity C-reactive protein (hs-CRP), and lactate dehydrogenase. The relationship of these markers to delayed cerebral ischemia (DCI), new infarct, and Glasgow Outcome Scale (GOS) score at 3 months was studied. RESULTS: The study comprised 246 patients. Of patients, 94 who developed DCI had a significantly higher TLC [+/- SD] (11.2 3 10(3)/mm(3) [+/- 4.0] vs. 9.4 x 10(3)/mm(3) [+/- 2.9], P = 0.001) and 62 with new infarct had significantly higher TLC (11.0 X 10(3)/mm(3) [+/- 3.6] vs. 9.8 X 10(3)/mm(3) [+/- 3.4], P = 0.05). GOS score had a significant inverse relationship to TLC at admission. The mean TLC [+/- SD] was 12.7 x 10(3)/mm(3) [+/- 4.2], 11.7 x 10(3)/mm(3) [+/- 3.1], 10.2 x 10(3)/mm(3) [+/- 3.4], and 9.3 x 10(3)/mm(3) [+/- 2.8] among patients with GOS scores of 1, 3, 4, and 5 (P < 0.001). hs-CRP showed a trend of an inverse relationship to GOS score in univariate analysis. Lactate dehydrogenase had no relationship with any outcome parameter. In multivariate analysis, higher admission TLC had a significant association with DCI (P = 0.01) and poorer GOS score (P < 0.001), and higher hs-CRP had a significant association with poorer GOS score (P = 0.05). CONCLUSIONS: A leukocytosis response to ictus seems to have a significant independent association with both DCI and poor GOS score, and hs-CRP level had a significant independent association with poor GOS score, indicating preeminence of early cellular response in SAH pathophysiology.	[Srinivasan, Anirudh; Aggarwal, Ashish; Gaudihalli, Sachin; Mohanty, Manju; Mukherjee, Kanchan K.; Dhandapani, Sivashanmugam] Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India; [Dhandapani, Manju] Post Grad Inst Med Educ & Res, Natl Inst Nursing Educ, Chandigarh, India; [Singh, Harminder] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA		Dhandapani, S (corresponding author), Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.	ssdhandapani.neurosurg@gmail.com	Dhandapani, Sivashanmugam/I-2395-2013	Dhandapani, Sivashanmugam/0000-0002-3497-4255; Dhandapani, Manju/0000-0003-3351-3841			Aggarwal A, 2013, J NEUROSCI RURAL PRA, V4, P257, DOI 10.4103/0976-3147.118762; Badjatia N, 2011, STROKE, V42, P2436, DOI 10.1161/STROKEAHA.111.614685; Dhandapani M, 2014, J CLIN NURS, V23, P1114, DOI 10.1111/jocn.12396; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Dhandapani S S, 2012, Asian J Neurosurg, V7, P17, DOI 10.4103/1793-5482.95690; Dhandapani SS, 2007, INDIAN J NEUROTRAUM, V4, P35, DOI 10.1016/S0973-0508(07)80009-8; Dhandapani Sivashanmugam, 2015, Surg Neurol Int, V6, pS543, DOI 10.4103/2152-7806.168067; Dhandapani S, 2015, WORLD NEUROSURG, V84, P1244, DOI 10.1016/j.wneu.2015.05.058; Dhandapani S, 2015, NEUROL INDIA, V63, P531, DOI 10.4103/0028-3886.162026; Dhandapani S, 2015, ACTA NEUROCHIR, V157, P399, DOI 10.1007/s00701-014-2297-0; Dhandapani S, 2014, J CLIN NEUROSCI, V21, P745, DOI 10.1016/j.jocn.2013.07.038; Dhandapani S, 2013, NEUROL INDIA, V61, P406, DOI 10.4103/0028-3886.117616; Dhandapani S, 2013, ACTA NEUROCHIR, V155, P237, DOI 10.1007/s00701-012-1571-2; Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311; Hadjivassiliou M, 2001, NEUROLOGY, V56, P1672, DOI 10.1212/WNL.56.12.1672; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hong CM, 2014, BIOMARKERS, V19, P95, DOI 10.3109/1354750X.2014.881418; Hutter BO, 1999, ACT NEUR S, V72, P157; Hwang SH, 2013, J KOREAN NEUROSURG S, V54, P289, DOI 10.3340/jkns.2013.54.4.289; Jeon YT, 2012, J NEUROSURG ANESTH, V24, P317, DOI 10.1097/ANA.0b013e31826047a2; Juvela S, 2012, ACTA NEUROCHIR, V154, P397, DOI 10.1007/s00701-011-1243-7; Kaynar MY, 2004, J NEUROSURG, V101, P1030, DOI 10.3171/jns.2004.101.6.1030; Kratz A., 2012, HARRISONS PRINCIPLES, V18th ed, P3585; Kubo Y, 2008, SURG NEUROL, V69, P592, DOI 10.1016/j.surneu.2008.02.014; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; Mack WJ, 2002, J NEUROSURG, V96, P71, DOI 10.3171/jns.2002.96.1.0071; Maiuri F, 1987, J Neurosurg Sci, V31, P45; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; Muroi C, 2013, NEUROSURGERY, V72, P367, DOI 10.1227/NEU.0b013e31828048ce; NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79; Nissen JJ, 2000, ACT NEUR S, V76, P55; Nordestgaard BG, 2009, NUTR METAB CARDIOVAS, V19, P521, DOI 10.1016/j.numecd.2009.07.005; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; Provencio JJ, 2010, NEUROCRIT CARE, V12, P244, DOI 10.1007/s12028-009-9308-7; Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Tewari M, 2015, ANN NEUROSCI, V22, P78, DOI 10.5214/ans.0972.7531.220205; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275	38	38	41	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2016	90						91	95		10.1016/j.wneu.2016.02.049			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DS1MS	WOS:000380360500013	26898490				2022-02-06	
J	Tsukamoto, H; Suga, T; Takenaka, S; Tanaka, D; Takeuchi, T; Hamaoka, T; Isaka, T; Ogoh, S; Hashimoto, T				Tsukamoto, Hayato; Suga, Tadashi; Takenaka, Saki; Tanaka, Daichi; Takeuchi, Tatsuya; Hamaoka, Takafumi; Isaka, Tadao; Ogoh, Shigehiko; Hashimoto, Takeshi			Repeated high-intensity interval exercise shortens the positive effect on executive function during post-exercise recovery in healthy young males	PHYSIOLOGY & BEHAVIOR			English	Article						Brain; Cognitive function; Glycogen depletion; Neuronal activation; Psychological arousal	TRAUMATIC BRAIN-INJURY; LACTATE OXIDATION COMPLEX; COGNITIVE PERFORMANCE; MODERATE EXERCISE; GLUCOSE; METABOLISM; STROOP; INTERFERENCE; CONSUMPTION; ACTIVATION	A single bout of aerobic exercise improves executive function (EF), but only for a short period. Compared with a single bout of aerobic exercise, we recently found that high-intensity interval exercise (HIIE) could maintain a longer improvement in EF. However, the mechanism underlying the effect of different exercise modes on the modifications of EF remains unclear. The purpose of the current investigation was to test our hypothesis that the amount of exercise-induced lactate production and its accumulation affects human brain function during and after exercise, thereby affecting post-exercise EF: Ten healthy male subjects performed cycle ergometer exercise. The HIIE protocol consisted of four 4-min bouts at 90% peak VO2 with a 3-min active recovery period at 60% peak VO2. The amount of lactate produced during exercise was manipulated by repeating the HIIE twice with a resting period of 60 min between the 1st HIIE and 2nd HIIE. To evaluate EF, a color-word Stroop task was performed, and reverse-Stroop interference scores were obtained. EF immediately after the 1st HIIE was significantly improved compared to that before exercise, and the improved EF was sustained during 40 min of the post-exercise recovery. However, for the 2nd HIIE, the improved EF was sustained for only 10 min of the post-exercise recovery period, despite the performance of the same exercise. In addition, during and following HIIE, the glucose and lactate accumulation induced by the 2nd HIIE was significantly lower than that induced by the 1st HIIE. Furthermore, there was an inverse relationship between lactate and EF by plotting the changes in lactate levels against changes in EF from pre-exercise during the late phase of post-exercise recovery. These findings suggested the possibility that repeated bouts of HIIE, which decreases lactate accumulation, may dampen the positive effect of exercise on EF during the post-exercise recovery. (C) 2016 The Authors. Published by Elsevier Inc.	[Tsukamoto, Hayato; Suga, Tadashi; Takenaka, Saki; Tanaka, Daichi; Takeuchi, Tatsuya; Hamaoka, Takafumi; Isaka, Tadao; Hashimoto, Takeshi] Ritsumeikan Univ, Grad Sch Sport & Hlth Sci, Kyoto, Shiga, Japan; [Tsukamoto, Hayato] Japan Soc Promot Sci, Tokyo, Japan; [Hamaoka, Takafumi] Tokyo Med Univ, Sch Med, Tokyo 1608402, Japan; [Ogoh, Shigehiko] Toyo Univ, Grad Sch Engn, Saitama, Japan		Hashimoto, T (corresponding author), Ritsumeikan Univ, Grad Sch Sport & Hlth Sci, Kyoto, Shiga, Japan.	thashimo@fc.ritsumei.ac.jp	Tsukamoto, Hayato/AAE-9348-2019; Meijer, Anna/K-5118-2016	Tsukamoto, Hayato/0000-0001-5512-0497; Ogoh, Shigehiko/0000-0001-5297-6468	Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [26702029, 25560344]	We thank all of the subjects who participated in the study. This work was supported by the Ministry of Education, Culture, Sports, Science and Technology - Grant-in-Aid for Young Scientists (A) for TH (no. 26702029); Grant-in-Aid for Exploratory Research for TH (no. 25560344).	Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Ando S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063630; Angadi SS, 2015, J APPL PHYSIOL, V119, P753, DOI 10.1152/japplphysiol.00518.2014; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Byun KH, 2014, NEUROIMAGE, V98, P336, DOI 10.1016/j.neuroimage.2014.04.067; Casanova F, 2013, MED SCI SPORT EXER, V45, P1610, DOI 10.1249/MSS.0b013e31828b2ce9; Chang YK, 2012, BRAIN RES, V1453, P87, DOI 10.1016/j.brainres.2012.02.068; Dalsgaard MK, 2004, AM J PHYSIOL-REG I, V287, pR534, DOI 10.1152/ajpregu.00256.2004; Dalsgaard MK, 2003, EXP PHYSIOL, V88, P297, DOI 10.1113/eph8802469; Dalsgaard MK, 2002, J PHYSIOL-LONDON, V540, P681, DOI 10.1113/jphysiol.2001.013062; Febbraio MA, 1999, J APPL PHYSIOL, V87, P2341, DOI 10.1152/jappl.1999.87.6.2341; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Glenn TC, 2015, J NEUROTRAUM, V32, P811, DOI 10.1089/neu.2014.3482; Grego F, 2005, INT J SPORTS MED, V26, P27, DOI 10.1055/s-2004-817915; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Hashimoto T, 2008, MED SCI SPORT EXER, V40, P486, DOI [10.1249/mss.0b013e31815fcb04, 10.1249/MSS.0b013e31815fcb04]; Hillman CH, 2003, INT J PSYCHOPHYSIOL, V48, P307, DOI 10.1016/S0167-8760(03)00080-1; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; Ide K, 2000, PROG NEUROBIOL, V61, P397, DOI 10.1016/S0301-0082(99)00057-X; Ikeda Y, 2010, PERCEPT MOTOR SKILL, V110, P654, DOI 10.2466/PMS.110.2.654-660; Kamijo K, 2007, INT J PSYCHOPHYSIOL, V65, P114, DOI 10.1016/j.ijpsycho.2007.04.001; Kemppainen J, 2005, J PHYSIOL-LONDON, V568, P323, DOI 10.1113/jphysiol.2005.091355; Little JP, 2011, J APPL PHYSIOL, V111, P1554, DOI 10.1152/japplphysiol.00921.2011; Lucas S.J., 2015, J CEREB BLOOD FLOW M; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Newington Jordan T, 2013, J Neurodegener Dis, V2013, P234572, DOI 10.1155/2013/234572; Nybo L, 2004, PROG NEUROBIOL, V72, P223, DOI 10.1016/j.pneurobio.2004.03.005; Nybo L, 2003, J APPL PHYSIOL, V95, P1125, DOI 10.1152/japplphysiol.00241.2003; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; Ogoh S, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12163; Puhan MA, 2006, ANN INTERN MED, V145, P816, DOI 10.7326/0003-4819-145-11-200612050-00006; Rasmussen P, 2011, FASEB J, V25, P2865, DOI 10.1096/fj.11-183822; Rognmo O, 2012, CIRCULATION, V126, P1436, DOI 10.1161/CIRCULATIONAHA.112.123117; Schurr A, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00170; SEGAL SS, 1979, J APPL PHYSIOL, V47, P514, DOI 10.1152/jappl.1979.47.3.514; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; SVEBAK S, 1985, J PERS SOC PSYCHOL, V48, P107, DOI 10.1037/0022-3514.48.1.107; Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8; Thompson C, 2015, EUR J APPL PHYSIOL, V115, P1825, DOI 10.1007/s00421-015-3166-0; Tjonna AE, 2008, CIRCULATION, V118, P346, DOI 10.1161/CIRCULATIONAHA.108.772822; Tsukamoto H, 2016, PHYSIOL BEHAV, V155, P224, DOI 10.1016/j.physbeh.2015.12.021; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Wisloff U, 2007, CIRCULATION, V115, P3086, DOI 10.1161/CIRCULATIONAHA.106.675041; Wyss MT, 2011, J NEUROSCI, V31, P7477, DOI 10.1523/JNEUROSCI.0415-11.2011; Yanagisawa H, 2010, NEUROIMAGE, V50, P1702, DOI 10.1016/j.neuroimage.2009.12.023	52	38	39	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	JUN 1	2016	160						26	34		10.1016/j.physbeh.2016.03.029			9	Psychology, Biological; Behavioral Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Behavioral Sciences	DM7ME	WOS:000376543900005	27060507	hybrid			2022-02-06	
J	Yan, CX; Gao, N; Sun, HJ; Yin, J; Lee, P; Zhou, L; Fan, XQ; Yu, FS				Yan, Chenxi; Gao, Nan; Sun, Haijing; Yin, Jia; Lee, Patrick; Zhou, Li; Fan, Xianqun; Yu, Fu-Shin			Targeting Imbalance between IL-1 beta and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse Corneas	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INFLAMMATORY CELL INFILTRATION; TRAUMATIC BRAIN-INJURY; HUMAN MONOCYTES; INTERLEUKIN-1; EXPRESSION; RATS; NEUTRALIZATION; MELLITUS; IMPROVES; PROMOTES	Patients with diabetes mellitus often develop corneal complications and delayed wound healing. How diabetes might alter acute inflammatory responses to tissue injury, leading to delayed wound healing, remains mostly elusive. Using a streptozotocin-induced type I diabetes mellitus mice and corneal epithelium-debridement wound model, we discovered that although wounding induced marked expression of IL-1 beta and the secreted form of IL-1 receptor antagonist (sIL-1Ra), diabetes suppressed the expressions of sIL-1Ra but not IL-1 beta in healing epithelia and both in whole cornea. In normoglycemic mice, IL-1 beta or sIL-1Ra blockade delayed wound healing and influenced each other's expression. In diabetic mice, in addition to delayed reepithelization, diabetes weakened phosphatidylinositol 3-kinase-Akt signaling, caused cell apoptosis, diminished cell proliferation, suppressed neutrophil and natural killer cell infiltrations, and impaired sensory nerve reinnervation in heating mouse corneas. Local administration of recombinant IL-1Ra partially, but significantly, reversed these pathological changes in the diabetic corneas. CXCL10 was a downstream chemokine of IL-1 beta-IL-1Ra, and exogenous CXCL10 alleviated delayed wound healing in the diabetic, but attenuated it in the normal corneas. In conclusion, the suppressed early innate/inflammatory responses instigated by the imbalance between IL-1 beta and IL-1Ra is an underlying cause for delayed wound healing in the diabetic corneas. Local application of IL-1Ra accelerates reepithelialization and may be used to treat chronic corneal and potential skin wounds of diabetic patients.	[Yan, Chenxi; Fan, Xianqun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol,Grad Program, Shanghai 200011, Peoples R China; [Yan, Chenxi; Gao, Nan; Sun, Haijing; Yin, Jia; Lee, Patrick; Yu, Fu-Shin] Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; [Yan, Chenxi; Gao, Nan; Sun, Haijing; Yin, Jia; Lee, Patrick; Yu, Fu-Shin] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Zhou, Li] Henry Ford Hlth Syst, Henry Ford Immunol Program, Dept Dermatol, Detroit, MI USA		Yu, FS (corresponding author), Wayne State Univ, Dept Ophthalmol, Sch Med, 4717 St Antoine,Room K417, Detroit, MI 48201 USA.; Fan, XQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.	fanxq@sh163.net; fyu@med.wayne.edu		Yan, Chenxi/0000-0002-1637-0597; Fan, Xianqun/0000-0002-9394-3969	NIH/National Eye Institute (NEI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY10869, EY17960, p30 EY04078]; Research to Prevent Blindness unrestricted grant; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY017960, R01EY010869, P30EY004068] Funding Source: NIH RePORTER	Supported by NIH/National Eye Institute (NEI) grants R01EY10869, EY17960 (F.-S.Y.), and p30 EY04078 (NEI core to Wayne State University; F.-S.Y.) and Research to Prevent Blindness unrestricted grant (to Kresge Eye Institute; F.-S.Y.).	Amin A, 2012, J PATHOL, V227, P165, DOI 10.1002/path.3960; Amparo F, 2013, JAMA OPHTHALMOL, V131, P715, DOI 10.1001/jamaophthalmol.2013.195; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Banda NK, 2005, J IMMUNOL, V174, P3608, DOI 10.4049/jimmunol.174.6.3608; Banerjee M, 2012, CLIN CHIM ACTA, V413, P1163, DOI 10.1016/j.cca.2012.03.021; Bettahi I, 2014, DIABETES, V63, P715, DOI 10.2337/db13-1260; Bikbova G, 2012, CURR DIABETES REV, V8, P294, DOI 10.2174/157339912800840479; Carpintero R, 2010, P NATL ACAD SCI USA, V107, P17692, DOI 10.1073/pnas.1009443107; Cavalli G, 2015, RHEUMATOLOGY, V54, P2134, DOI 10.1093/rheumatology/kev269; Chavey C, 2009, AGING-US, V1, P674, DOI 10.18632/aging.100064; Chikama T, 2007, CORNEA, V26, pS75, DOI 10.1097/ICO.0b013e31812f6d8e; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; Dinarello CA, 2010, CURR OPIN ENDOCRINOL, V17, P314, DOI 10.1097/MED.0b013e32833bf6dc; Donath MY, 2013, DIABETES OBES METAB, V15, P193, DOI 10.1111/dom.12172; Donath MY, 2013, CELL METAB, V17, P860, DOI 10.1016/j.cmet.2013.05.001; Doz E, 2008, J IMMUNOL, V180, P1169, DOI 10.4049/jimmunol.180.2.1169; Ebaid H, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-235; Esser N, 2014, DIABETES RES CLIN PR, V105, P141, DOI 10.1016/j.diabres.2014.04.006; Evans I, 2006, CYTOKINE, V33, P274, DOI 10.1016/j.cyto.2006.02.003; Gabay C, 1999, CYTOKINE, V11, P561, DOI 10.1006/cyto.1998.0451; Gagen D, 2010, EXP EYE RES, V91, P676, DOI 10.1016/j.exer.2010.08.007; Gao D, 2014, AM J PHYSIOL-ENDOC M, V307, pE289, DOI 10.1152/ajpendo.00430.2013; Gao N, 2015, INFECT IMMUN, V83, P4154, DOI 10.1128/IAI.00980-15; Garcia C, 2010, DIABETES METAB, V36, P327, DOI 10.1016/j.diabet.2010.07.001; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Goldbach-Mansky R, 2012, CLIN EXP IMMUNOL, V167, P391, DOI 10.1111/j.1365-2249.2011.04533.x; Goncalves NP, 2015, J NEUROPATH EXP NEUR, V74, P203, DOI 10.1097/NEN.0000000000000164; Harikumar KB, 2014, NAT IMMUNOL, V15, P231, DOI 10.1038/ni.2810; Hasegawa M, 2013, J DERMATOL SCI, V70, P34, DOI 10.1016/j.jdermsci.2013.01.007; Hedberg-Buenz A, 2016, EXP EYE RES, V146, P386, DOI 10.1016/j.exer.2015.07.020; HELQVIST S, 1994, DAN MED BULL, V41, P151; Hong JW, 2001, INVEST OPHTH VIS SCI, V42, P2795; Huang HY, 2001, J CLIN ENDOCR METAB, V86, P1387, DOI 10.1210/jc.86.3.1387; Hwang MW, 2001, J AM COLL CARDIOL, V38, P1546, DOI 10.1016/S0735-1097(01)01591-1; Ishida Y, 2006, J IMMUNOL, V176, P5598, DOI 10.4049/jimmunol.176.9.5598; Ishida Y, 2012, J CLIN INVEST, V122, P711, DOI 10.1172/JCI43027; Kaji Y, 2005, BRIT J OPHTHALMOL, V89, P254, DOI 10.1136/bjo.2004.055541; Kandhare AD, 2014, CHEM-BIOL INTERACT, V219, P101, DOI 10.1016/j.cbi.2014.05.012; Li GL, 2013, BRAIN RES BULL, V90, P79, DOI 10.1016/j.brainresbull.2012.10.002; Lin M, 2013, KIDNEY INT, V83, P887, DOI 10.1038/ki.2013.11; Liu Q, 2012, AM J PATHOL, V181, P452, DOI 10.1016/j.ajpath.2012.04.010; Ljubimov AV, 2015, PROG RETIN EYE RES, V49, P17, DOI 10.1016/j.preteyeres.2015.07.002; MANDRUPPOULSEN T, 1993, CYTOKINE, V5, P185, DOI 10.1016/1043-4666(93)90003-N; Merhi-Soussi F, 2005, CYTOKINE, V32, P163, DOI 10.1016/j.cyto.2005.09.004; Molnarfi N, 2007, J IMMUNOL, V178, P446, DOI 10.4049/jimmunol.178.1.446; Palmer G, 2007, J INVEST DERMATOL, V127, P1938, DOI 10.1038/sj.jid.5700803; Pflugfelder SC, 2006, AM J OPHTHALMOL, V142, P316, DOI 10.1016/j.ajo.2006.05.002; Saha B, 2010, CYTOKINE, V50, P1, DOI 10.1016/j.cyto.2009.11.021; Schmidt MI, 1999, LANCET, V353, P1649, DOI 10.1016/S0140-6736(99)01046-6; Schwartzman ML, 2010, DIABETES, V59, P1780, DOI 10.2337/db10-0110; Shi LQ, 2012, J NEUROSCI RES, V90, P816, DOI 10.1002/jnr.22798; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Stapleton WM, 2008, EXP EYE RES, V86, P753, DOI 10.1016/j.exer.2008.02.001; Sun HJ, 2015, INVEST OPHTH VIS SCI, V56, P3383, DOI 10.1167/iovs.15-16606; Thomay AA, 2009, AM J PATHOL, V174, P2129, DOI 10.2353/ajpath.2009.080765; Wang F, 2012, AM J PATHOL, V181, P2058, DOI 10.1016/j.ajpath.2012.08.029; WEBER A, 2010, SCI SIGNAL, V3; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Xu KP, 2011, INVEST OPHTH VIS SCI, V52, P3301, DOI 10.1167/iovs.10-5670; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yin J, 2011, INVEST OPHTH VIS SCI, V52, P6589, DOI 10.1167/iovs.11-7709	64	38	41	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2016	186	6					1466	1480		10.1016/j.ajpath.2016.01.019			15	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	DN7DZ	WOS:000377236800007	27109611	Bronze, Green Published			2022-02-06	
J	Kawata, K; Tierney, R; Phillips, J; Jeka, JJ				Kawata, K.; Tierney, R.; Phillips, J.; Jeka, J. J.			Effect of Repetitive Sub-concussive Head Impacts on Ocular Near Point of Convergence	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						convergence insufficiency; head impact kinematics; sports concussion; eye	ACCOMMODATION; IMPAIRMENT; SYMPTOMS; VERGENCE; INJURY	This study intended to examine effects of repetitive sub-concussive head impacts on ocular near point of convergence (NPC). 20 healthy young adult soccer players were assigned to either a heading or control group. Heading subjects completed 10 headers of soccer balls projected at a speed of 11.2 m/s. Control subjects did not perform heading. Linear head acceleration was measured with a triaxial accelerometer. The NPC assessment was performed at pre-, 0h post-, and 24h post-heading. During the NPC assessment participants were seated and a visual target was moved towards the eyes at 1cm/sec. The participant signaled when he/she experienced diplopia or deviation of the eye was observed, and the distance was recorded. The assessment was repeated twice and average NPC scores were used for further analysis. Soccer heading induced mean group head accelerations of 14.49 +/- 5.4 g. Mild head impacts led to an increased NPC distance, which was supported by a significant Group x Time interaction. In the heading group, 0h post- and 24h post-heading NPC scores were significantly receded compared to baseline. Conversely, NPC scores for the control group showed no difference over time. Our findings indicate that mild frontal head impacts affekt NPC for a minimum of 24h-post heading, suggesting that oculomotor processes are disrupted, at least transiently, by repetitive mild head impact.	[Kawata, K.; Tierney, R.; Phillips, J.; Jeka, J. J.] Temple Univ, Kinesiol, 1800 N Broad st, Philadelphia, PA 19122 USA		Kawata, K (corresponding author), Temple Univ, Kinesiol, 1800 N Broad st, Philadelphia, PA 19122 USA.	tud46150@temple.edu			College of Public Health at Temple University; Pennsylvania Athletic Trainers' Society	This research was supported in part by internal funds from the College of Public Health at Temple University to Dr. Jeka and by the Pennsylvania Athletic Trainers' Society doctoral grant to K. Kawata.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abraham Neethu G, 2015, Oman J Ophthalmol, V8, P14, DOI 10.4103/0974-620X.149856; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen Y, 2002, PROG BRAIN RES, V140, P255; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; DAUM KM, 1984, AM J OPTOM PHYS OPT, V61, P16; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hamed MM, 2013, INDIAN J OPHTHALMOL, V61, P325, DOI 10.4103/0301-4738.97553; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; HUNG GK, 1980, IEEE T BIO-MED ENG, V27, P439, DOI 10.1109/TBME.1980.326752; HUNG GK, 1986, DOC OPHTHALMOL, V62, P165, DOI 10.1007/BF00229128; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Linthorne NP, 2006, SPORT BIOMECH, V5, P243, DOI 10.1080/14763140608522877; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Phillips J, 2015, J EYE MOVEMENT RES, V8; Pochon JB, 2001, CEREB CORTEX, V11, P260, DOI 10.1093/cercor/11.3.260; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Red S, 2014, J VIS, V14, P298; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Von Noorden GK, 2002, BINOCULAR VISION OCU, V6th; Xu L, 2014, EXP NEUROL	41	38	38	0	12	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAY	2016	37	5					405	410		10.1055/s-0035-1569290			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DL4KZ	WOS:000375606000012	26859643				2022-02-06	
J	El Idrissi, NB; Bosch, S; Ramaglia, V; Aronica, E; Baas, F; Troost, D				El Idrissi, Nawal Bahia; Bosch, Sanne; Ramaglia, Valeria; Aronica, Eleonora; Baas, Frank; Troost, Dirk			Complement activation at the motor end-plates in amyotrophic lateral sclerosis	JOURNAL OF NEUROINFLAMMATION			English	Article						Amyotrophic lateral sclerosis; Motor end-plates; Complement; C1q; MAC; CD55; CD59	TRAUMATIC BRAIN-INJURY; G93A MOUSE MODEL; NEUROMUSCULAR-JUNCTION; TRANSMITTER RELEASE; PATHWAY ACTIVATION; ANIMAL-MODELS; ALS; DISEASE; SYSTEM; NERVE	Background: Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease with no available therapy. Components of the innate immune system are activated in the spinal cord and central nervous system of ALS patients. Studies in the SOD1(G93A) mouse show deposition of C1q and C3/C3b at the motor end-plate before neurological symptoms are apparent, suggesting that complement activation precedes neurodegeneration in this model. To obtain a better understanding of the role of complement at the motor end-plates in human ALS pathology, we analyzed post-mortem tissue of ALS donors for complement activation and its regulators. Methods: Post-mortem intercostal muscle biopsies were collected at autopsy from ALS (n = 11) and control (n = 6) donors. The samples were analyzed for C1q, membrane attack complex (MAC), CD55, and CD59 on the motor end-plates, using immunofluorescence or immunohistochemistry. Results: Here, we show that complement activation products and regulators are deposited on the motor end-plates of ALS patients. C1q co-localized with neurofilament in the intercostal muscle of ALS donors and was absent in controls (P = 0.001). In addition, C1q was found deposited on the motor end-plates in the intercostal muscle. MAC was also found deposited on motor end-plates that were innervated by nerves in the intercostal muscle of ALS donors but not in controls (P = 0.001). High levels of the regulators CD55 and CD59 were detected at the motor end-plates of ALS donors but not in controls, suggesting an attempt to counteract complement activation and prevent MAC deposition on the end-plates before they are lost. Conclusions: This study provides evidence that complement activation products are deposited on innervated motor end-plates in the intercostal muscle of ALS donors, indicating that complement activation may precede end-plate denervation in human ALS. This study adds to the understanding of ALS pathology in man and identifies complement as a potential modifier of the disease process.	[El Idrissi, Nawal Bahia; Bosch, Sanne; Ramaglia, Valeria; Baas, Frank] Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Aronica, Eleonora; Troost, Dirk] Univ Amsterdam, Acad Med Ctr, Dept Neuropathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands		Baas, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	f.baas@amc.nl	Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428; Aronica, Eleonora/0000-0002-3542-3770			Anderson AJ, 2004, J NEUROTRAUM, V21, P1831, DOI 10.1089/0897715042664894; APPEL SH, 1991, ADV NEUROL, V56, P405; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cozzolino M, 2008, ANTIOXID REDOX SIGN, V10, P405, DOI 10.1089/ars.2007.1760; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Dupuis L, 2009, CURR OPIN PHARMACOL, V9, P341, DOI 10.1016/j.coph.2009.03.007; Dupuis L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005390; Eisen A, 2001, MUSCLE NERVE, V24, P564, DOI 10.1002/mus.1042; El Idrissi NB, 2015, ACTA NEUROPATHOL, V129, P653, DOI 10.1007/s00401-015-1404-5; Ferraiuolo L, 2007, J NEUROSCI, V27, P9201, DOI 10.1523/JNEUROSCI.1470-07.2007; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Heurich B, 2011, J NEUROIMMUNOL, V235, P104, DOI 10.1016/j.jneuroim.2011.03.011; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Humayun S, 2009, J NEUROIMMUNOL, V210, P52, DOI 10.1016/j.jneuroim.2009.01.028; Karlsborg M, 2004, AMYOTROPH LATERAL SC, V5, P136, DOI 10.1080/14660820410018982; Lee JD, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-119; LEHRER GM, 1959, J BIOPHYS BIOCHEM CY, V6, P399, DOI 10.1083/jcb.6.3.399; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leslie M, 2012, SCIENCE, V337, P1034, DOI 10.1126/science.337.6098.1034; Lin F, 2001, IMMUNOLOGY, V104, P215, DOI 10.1046/j.1365-2567.2001.01287.x; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Lobsiger CS, 2007, P NATL ACAD SCI USA, V104, P7319, DOI 10.1073/pnas.0702230104; Lobsiger CS, 2014, P NATL ACAD SCI USA, V111, pE5, DOI 10.1073/pnas.1321606111; Lobsiger CS, 2013, P NATL ACAD SCI USA, V110, pE4385, DOI 10.1073/pnas.1318309110; Mantovani S, 2014, J NEUROIMMUNOL, V276, P213, DOI 10.1016/j.jneuroim.2014.09.005; Mitchell JD, 2007, LANCET, V369, P2031, DOI 10.1016/S0140-6736(07)60944-1; Mohamed HA, 2002, J NEUROSCI RES, V69, P110, DOI 10.1002/jnr.10271; Muchnik S, 2002, CLIN NEUROPHYSIOL, V113, P1066, DOI 10.1016/S1388-2457(02)00108-6; O'Shaughnessy TJ, 1998, MUSCLE NERVE, V21, P81, DOI 10.1002/(SICI)1097-4598(199801)21:1<81::AID-MUS11>3.0.CO;2-3; Pagani MR, 2006, J NEUROSCI, V26, P2661, DOI 10.1523/JNEUROSCI.4394-05.2006; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Ramaglia V, 2008, AM J PATHOL, V172, P1043, DOI 10.2353/ajpath.2008.070660; Ramaglia V, 2009, MOL IMMUNOL, V47, P302, DOI 10.1016/j.molimm.2009.09.019; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021; Soltys J, 2012, J NEUROIMMUNOL, V244, P63, DOI 10.1016/j.jneuroim.2012.01.003; Sta M, 2011, NEUROBIOL DIS, V42, P211, DOI 10.1016/j.nbd.2011.01.002; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; UCHITEL OD, 1988, P NATL ACAD SCI USA, V85, P7371, DOI 10.1073/pnas.85.19.7371; UCHITEL OD, 1992, NEUROLOGY, V42, P2175, DOI 10.1212/WNL.42.11.2175; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Woodruff TM, 2014, P NATL ACAD SCI USA, V111, pE3, DOI 10.1073/pnas.1321248111; Woodruff TM, 2008, J IMMUNOL, V181, P8727, DOI 10.4049/jimmunol.181.12.8727; Woodruff TM, 2008, ADV EXP MED BIOL, V632, P143, DOI 10.1007/978-0-387-78952-1_11	50	38	38	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 7	2016	13								72	10.1186/s12974-016-0538-2			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DI6EQ	WOS:000373592400001	27056040	gold, Green Published			2022-02-06	
J	Antonakakis, M; Dimitriadis, SI; Zervakis, M; Micheloyannis, S; Rezaie, R; Babajani-Feremi, A; Zouridakis, G; Papanicolaou, AC				Antonakakis, Marios; Dimitriadis, Stavros I.; Zervakis, Michalis; Micheloyannis, Sifis; Rezaie, Roozbeh; Babajani-Feremi, Abbas; Zouridakis, George; Papanicolaou, Andrew C.			Altered cross-frequency coupling in resting-state MEG after mild traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Magnetoencephalography (MEG); Mild traumatic brain injury; Cross-frequency coupling; Tensors; Biomarkers	FUNCTIONAL CONNECTIVITY; NEURONAL OSCILLATIONS; WORKING-MEMORY; AXONAL INJURY; DYNAMICS; EEG; MAGNETOENCEPHALOGRAPHY; SYNCHRONIZATION; REORGANIZATION; CORTEX	Cross-frequency coupling (CFC) is thought to represent a basic mechanism of functional integration of neural networks across distant brain regions. In this study, we analyzed CFC profiles from resting state Magnetoencephalographic (MEG) recordings obtained from 30 mild traumatic brain injury (mTBI) patients and 50 controls. We used mutual information (MI) to quantify the phase-to-amplitude coupling (PAC) of activity among the recording sensors in six nonoverlapping frequency bands. After forming the CFC-based functional connectivity graphs, we employed a tensor representation and tensor subspace analysis to identify the optimal set of features for subject classification as mTBI or control. Our results showed that controls formed a dense network of stronger local and global connections indicating higher functional integration compared to mTBI patients. Furthermore, mTBI patients could be separated from controls with more than 90% classification accuracy. These findings indicate that analysis of brain networks computed from resting-state MEG with PAC and tensorial representation of connectivity profiles may provide a valuable biomarker for the diagnosis of mTBI. (C) 2016 Elsevier B.V. All rights reserved.	[Antonakakis, Marios; Zervakis, Michalis] Tech Univ Crete, Sch Elect & Comp Engn, Digital Image & Signal Proc Lab, Khania 73100, Greece; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Med, Inst Psychol Med & Clin Neurosci, Cardiff CF10 3AX, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, CUBRIC, Cardiff CF10 3AX, S Glam, Wales; [Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, Dept Informat, Artificial Intelligence & Informat Anal Lab, Thessaloniki 54124, Greece; [Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, Dept Informat, Neuroinformat Grp, Thessaloniki 54124, Greece; [Micheloyannis, Sifis] Univ Crete, Sch Med, L Widen Lab, Iraklion, Greece; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Clin Neurosci, Memphis, TN 38163 USA; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Le Bonheur Childrens Hosp, Neurosci Inst, Memphis, TN USA; [Zouridakis, George] Basque Ctr Cognit Brain & Language BCBL, Paseo Mikeletegi 69, Donostia San Sebastian 20009, Spain; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Engn Technol, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Comp Sci, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Biomed Engn, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Elect & Comp Engn, Houston, TX 77204 USA; [Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Zouridakis, George] Univ Houston, Houston, TX 77204 USA		Antonakakis, M (corresponding author), Tech Univ Crete, Sch Elect & Comp Engn, Digital Image & Signal Proc Lab, Khania 73100, Greece.	mantonakakis@isc.tuc.gr	Antonakakis, Marios/ABD-8218-2020; DIMITRIADIS, STAVROS I/AAN-8992-2020; Zouridakis, George/R-8876-2019	Antonakakis, Marios/0000-0003-1173-7895; DIMITRIADIS, STAVROS I/0000-0002-0000-5392; Zouridakis, George/0000-0002-7770-9857; Rezaie, Roozbeh/0000-0002-7494-339X; Basque Center on Cognition, Brain and Language, BCBL./0000-0002-8345-6892	Department of Defense Congressionally Directed Medical Research ProgramUnited States Department of Defense; THALES project (CYBERSENSORS - High Frequency Monitoring System for Integrated Water Resources Management of Rivers) - NSRF of the Greek Ministry of DevelopmentThales Group; "YPERTHEN" project under the Interreg	The project reported here is part of a larger study, the Integrated Clinical Protocol, conducted by the investigators and staff of the Mission Connect Mild Traumatic Brain Injury Translational Research Consortium and supported by the Department of Defense Congressionally Directed Medical Research Program. The graph representation and analysis is supported by a THALES project (CYBERSENSORS - High Frequency Monitoring System for Integrated Water Resources Management of Rivers) funded by the NSRF2007-13 of the Greek Ministry of Development. The analysis methodology was partly supported by the "YPERTHEN" project under the Interreg framework of Greek-Cyprus Co-operation 2007-2013.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; ACRM, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI 10.1097/00001199-199309000-00010; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Antonakakis M, 2015, IEEE ENG MED BIO, P7426, DOI 10.1109/EMBC.2015.7320108; Antonakakis M, 2013, IEEE INT C BIOINF BI; Assistant Secretary D. O. D, 2007, TRAUM BRAIN INJ DEF; Axmacher N, 2010, NEURON, V65, P541, DOI 10.1016/j.neuron.2010.02.006; Axmacher N, 2010, P NATL ACAD SCI USA, V107, P3228, DOI 10.1073/pnas.0911531107; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Canolty RT, 2010, TRENDS COGN SCI, V14, P506, DOI 10.1016/j.tics.2010.09.001; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cohen MX, 2009, J COGNITIVE NEUROSCI, V21, P875, DOI 10.1162/jocn.2009.21062; Cohen MX, 2009, J COGNITIVE NEUROSCI, V21, P390, DOI 10.1162/jocn.2008.21020; Colgin LL, 2009, NATURE, V462, P353, DOI 10.1038/nature08573; Conover W.J., 1998, PRACTICAL NONPARAMET; Contreras D, 1997, NEUROSCIENCE, V76, P11; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Dimitriadis SI, 2015, COGN NEURODYNAMICS, V9, P371, DOI 10.1007/s11571-015-9330-8; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dimitriadis SI, 2013, IEEE ENG MED BIO, P2940, DOI 10.1109/EMBC.2013.6610156; Dimitriadis SI, 2012, IEEE T BIO-MED ENG, V59, P1302, DOI 10.1109/TBME.2012.2186568; Dimitriadis S. I., 2013, QUANTIZATION TIME VA, V3, P397; Dimitriadis S. I., 2016, IEEE T NEUR IN PRESS; Dimitriadis SI, 2015, NEUROIMAGE-CLIN, V9, P519, DOI 10.1016/j.nicl.2015.09.011; Dimitriadis SI, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00350; Dimitriadis SI, 2015, ANN BIOMED ENG, V43, P977, DOI 10.1007/s10439-014-1143-0; Dimitriadis SI, 2012, BRAIN COGNITION, V80, P45, DOI 10.1016/j.bandc.2012.04.001; Dimitriadis SI, 2012, NONLIN DYNAM PSYCHOL, V16, P5; Dimitriadis SI, 2010, J NEUROSCI METH, V193, P145, DOI 10.1016/j.jneumeth.2010.08.027; Dimitriadis SI, 2010, NEUROSCI LETT, V483, P11, DOI 10.1016/j.neulet.2010.07.034; Dimitriadis SI, 2009, BRAIN TOPOGR, V22, P119, DOI 10.1007/s10548-008-0071-4; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Escudero J, 2011, ANN BIOMED ENG, V39, P2274, DOI 10.1007/s10439-011-0312-7; Florin E, 2015, NEUROIMAGE, V111, P26, DOI 10.1016/j.neuroimage.2015.01.054; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gibbons J. D., 2011, NONPARAMETRIC STAT I; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; He X, 2005, ADV NEURAL INFORM PR, V18; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; HORN RA, 1990, SIAM J MATRIX ANAL A, V11, P481, DOI 10.1137/0611034; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jensen O, 2007, TRENDS COGN SCI, V11, P267, DOI 10.1016/j.tics.2007.05.003; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jirsa V, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00078; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; Levin H. S., 2009, MISSION CONNECT MILD, DOI 10.21236/ADA550012; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Li LY, 2015, IEEE ENG MED BIO, P6963, DOI 10.1109/EMBC.2015.7319994; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Osipova D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003990; Palva JM, 2011, PROG BRAIN RES, V193, P335, DOI 10.1016/B978-0-444-53839-0.00022-3; Palva JM, 2005, J NEUROSCI, V25, P3962, DOI 10.1523/JNEUROSCI.4250-04.2005; Pinal D, 2015, NEUROBIOL AGING, V36, P1611, DOI 10.1016/j.neurobiolaging.2015.01.009; Pollonini L, 2010, IEEE ENG MED BIO, P1730, DOI 10.1109/IEMBS.2010.5626702; Raskin S. A., 2000, NEUROPSYCHOLOGICAL M, P93; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Richiardi J, 2011, NEUROIMAGE, V56, P616, DOI 10.1016/j.neuroimage.2010.05.081; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Ruff R. M., 1989, MILD HEAD INJURY, P176; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sireci SG, 2003, J EDUC MEAS, V40, P277, DOI 10.1111/j.1745-3984.2003.tb01108.x; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Stam CJ, 2010, INT J PSYCHOPHYSIOL, V77, P186, DOI 10.1016/j.ijpsycho.2010.06.024; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 1996, J NEUROSCI, V16, P2788; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; TEASDALE G, 1974, LANCET, V2, P81; Tognoli E, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00122; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; Tort ABL, 2010, J NEUROPHYSIOL, V104, P1195, DOI 10.1152/jn.00106.2010; Tort ABL, 2009, P NATL ACAD SCI USA, V106, P20942, DOI 10.1073/pnas.0911331106; Tort ABL, 2008, P NATL ACAD SCI USA, V105, P20517, DOI 10.1073/pnas.0810524105; Tsiaras V, 2011, COMPUT BIOL MED, V41, P1166, DOI 10.1016/j.compbiomed.2011.04.004; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Voytek B, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00191; Zouridakis G, 2012, J MECH MED BIOL, V12, DOI 10.1142/S0219519412400064	108	38	39	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	APR	2016	102						1	11		10.1016/j.ijpsycho.2016.02.002			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	DM9QY	WOS:000376702000002	26910049	Bronze, Green Submitted, Green Accepted			2022-02-06	
J	Gelonch, O; Garolera, M; Valls, J; Rossello, L; Pifarre, J				Gelonch, Olga; Garolera, Maite; Valls, Joan; Rossello, Lluis; Pifarre, Josep			Executive function in fibromyalgia: Comparing subjective and objective measures	COMPREHENSIVE PSYCHIATRY			English	Article							BEHAVIOR RATING INVENTORY; SELF-REPORTED DIFFERENCES; TRAUMATIC BRAIN-INJURY; ECOLOGICAL VALIDITY; WORKING-MEMORY; MAJOR DEPRESSION; HEALTHY CONTROLS; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE COMPLAINTS; DECISION-MAKING	Background: There is evidence to suggest the existence of an executive dysfunction in people diagnosed with fibromyalgia, although there are certain inconsistencies between studies. Here, we aim to compare executive performance between patients with fibromyalgia and a control group by using subjective and objective cognitive tests, analyzing the influence of patient mood on the results obtained, and studying associations between the two measures. Method: 82 patients diagnosed with fibromyalgia and 42 healthy controls, matched by age and years of education, were assessed using the Behavioral Rating Inventory of Executive Function Adult Version (BRIEF-A) as a subjective measure of executive functioning. A selection of objective cognitive tests were also used to measure a series of executive functions and to identify symptoms of depression and anxiety. Results: Patients with fibromyalgia perceived greater difficulties than the control group on all of the BRIEF-A scales. However, after adjustments were made for depression and anxiety the only differences that remained were those associated with the working memory scale and the Metacognition and Global Executive Composite index. In the case of the objective cognitive tests, a significantly worse overall performance was evidenced for the fibromyalgia patients. However, this also disappeared when adjustments were made for depression and anxiety. After this adjustment, fibromyalgia patients only performed significantly worse for the interference effect in the Stroop Test. Although there were no significant associations between most of the objective cognitive tests and the BRIEF-A scales, depression and anxiety exhibited strong associations with almost all of the BRIEF-A scales and with several of the objective cognitive tests. Conclusions: Patients with fibromyalgia showed executive dysfunction in subjective and objective measures, although most of this impairment was associated with mood disturbances. Exceptions to this general rule were observed in the impairment of working memory evidenced on the BRIEF-A scale and the inhibition impairment exhibited by the interference effect from the Stroop Test. The two types of measurement provide different yet complementary information. (C) 2016 Elsevier Inc. All rights reserved.	[Gelonch, Olga; Garolera, Maite] Consorci Sanitari Terrassa, Clin Res Grp Brain Cognit & Behav, Terrassa, Spain; [Gelonch, Olga; Pifarre, Josep] Univ Lleida, C Montserrat Roig 2, Lleida 25008, Spain; [Garolera, Maite] Hosp Terrassa, Consorci Sanitari Terrassa, Neuropsychol Unit, Terrassa, Spain; [Valls, Joan; Pifarre, Josep] IRB Lleida, Inst Biomed Res Lleida, Lleida, Spain; [Rossello, Lluis] Hosp Univ Santa Maria, Fibromyalgia & Chron Fatigue Syndrome Unit, Rheumatol Sect, Lleida, Spain		Pifarre, J (corresponding author), Univ Lleida, C Montserrat Roig 2, Lleida 25008, Spain.	pifarre1@comll.cat	Garolera, Maite/A-3109-2015; GELONCH, OLGA/P-6406-2018; Garolera, Maite/D-7811-2012; Pifarre, Josep/B-5884-2009	Garolera, Maite/0000-0001-7443-8249; GELONCH, OLGA/0000-0002-0788-2486; Garolera, Maite/0000-0001-7443-8249; Rossello, Lluis/0000-0001-6752-4851; Pifarre, Josep/0000-0001-6284-4709; Valls, Joan/0000-0002-4806-7568			Amutio A, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01572; Arnold LM, 2008, PATIENT EDUC COUNS, V73, P114, DOI 10.1016/j.pec.2008.06.005; Artiola L., 1999, MANUAL NORMAS PROCED; Balash Y, 2013, ACTA NEUROL SCAND, V127, P344, DOI 10.1111/ane.12038; Barkley RA, 2011, DEV NEUROPSYCHOL, V36, P137, DOI 10.1080/87565641.2010.549877; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Berryman C, 2014, CLIN PSYCHOL REV, V34, P563, DOI 10.1016/j.cpr.2014.08.003; Bombin-Gonzalez I, 2014, REV NEUROLOGIA, V59, P77, DOI 10.33588/rn.5902.2013578; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Cherry BJ, 2014, J GERONTOL B-PSYCHOL, V69, P199, DOI 10.1093/geronb/gbs122; Ciszewski S, 2014, EAT BEHAV, V15, P175, DOI 10.1016/j.eatbeh.2014.01.004; Moreno MIC, 2012, PSICOTHEMA, V24, P668; Crombez G, 2005, PAIN, V116, P4, DOI 10.1016/j.pain.2005.03.035; Fietta Pierluigi, 2007, Acta Biomed, V78, P88; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ganguli M, 2009, INT J GERIATR PSYCH, V24, P1277, DOI 10.1002/gps.2257; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Gioia GA, 2005, PSYCHOL ASSESS RESOU; Glass JM, 2011, J PAIN, V12, P1219, DOI 10.1016/j.jpain.2011.06.007; Glass JM, 2009, RHEUM DIS CLIN N AM, V35, P299, DOI 10.1016/j.rdc.2009.06.002; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Golden C, STROOP COLOR WORD TE; Gracely RH, 2002, ARTHRITIS RHEUM-US, V46, P1333, DOI 10.1002/art.10225; Greve KW, 2001, CLIN NEUROPSYCHOL, V15, P228, DOI 10.1076/clin.15.2.228.1901; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hadjiefthyvoulou F, 2012, COGN BEHAV NEUROL, V25, P128, DOI 10.1097/WNN.0b013e318261459c; Hanssen KT, 2014, ACTA NEUROL SCAND, V129, P234, DOI 10.1111/ane.12177; Harvey PO, 2005, NEUROIMAGE, V26, P860, DOI 10.1016/j.neuroimage.2005.02.048; Heaton R.K., 1981, WISCONSIN CARD SORTI; Landro NI, 1997, J PSYCHOSOM RES, V42, P297, DOI 10.1016/S0022-3999(96)00301-7; Leeuw M, 2007, J BEHAV MED, V30, P77, DOI 10.1007/s10865-006-9085-0; Lewis MW, 2011, NEUROPSYCHOL REHABIL, V21, P145, DOI 10.1080/09602011.2010.543867; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Li Y, 2013, SCAND J PSYCHOL, V54, P485, DOI 10.1111/sjop.12083; Liik M, 2009, EPILEPSY RES, V84, P194, DOI 10.1016/j.eplepsyres.2009.02.006; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; Luerding R, 2008, BRAIN, V131, P3222, DOI 10.1093/brain/awn229; Magan I, 2008, SPAN J PSYCHOL, V11, P626, DOI 10.1017/S1138741600004637; Martyr A, 2012, DEMENT GERIATR COGN, V33, P189, DOI 10.1159/000338233; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Mercado F, 2013, INT J PSYCHOPHYSIOL, V88, P182, DOI 10.1016/j.ijpsycho.2013.03.017; Miro E, 2011, PSYCHOL HEALTH, V26, P765, DOI 10.1080/08870446.2010.493611; Moore DJ, 2007, J PSYCHIATR RES, V41, P97, DOI 10.1016/j.jpsychires.2005.10.008; Munguia-Izquierdo D, 2008, PSICOTHEMA, V20, P427; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Park DC, 2001, ARTHRITIS RHEUM, V44, P2125, DOI 10.1002/1529-0131(200109)44:9<2125::AID-ART365>3.0.CO;2-1; Peters AT, 2014, J PSYCHIATR RES, V53, P87, DOI 10.1016/j.jpsychires.2014.02.018; Power BD, 2012, J NEUROPSYCH CLIN N, V24, P215, DOI 10.1176/appi.neuropsych.11060145; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Reid RC, 2012, INT J NEUROSCI, V122, P500, DOI 10.3109/00207454.2012.673516; Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roth RM, 2004, PSYCHIAT CLIN N AM, V27, P83, DOI 10.1016/S0193-953X(03)00112-6; Schmidt-Wilcke T, 2010, SCHMERZ, V24, P46, DOI 10.1007/s00482-009-0872-8; Seo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037808; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shmygalev S., 2014, PAIN THER; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; Spielberger C. D., 2008, CUESTIONARIO ANSIEDA; Spielberger CD., 1970, STATE TRAIT ANXIETY; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Tesio V, 2014, ARTHRITIS CARE RES H; Torta R, 2014, REUMATISMO, V66, P92, DOI 10.4081/reumatismo.2014.769; van Beilen M, 2005, J PSYCHIATR RES, V39, P585, DOI 10.1016/j.jpsychires.2005.02.001; Verdejo-Garcia A, 2009, ARCH CLIN NEUROPSYCH, V24, P113, DOI 10.1093/arclin/acp014; Vogel A, 2011, LUPUS, V20, P35, DOI 10.1177/0961203310382430; Walitt B, 2008, RHEUMATOL INT, V28, P561, DOI 10.1007/s00296-007-0487-2; Wechsler D, 1999, WAIS 3 WCALA INTELIG; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140; Zimmer HD, 2008, NEUROSCI BIOBEHAV R, V32, P1373, DOI 10.1016/j.neubiorev.2008.05.016	72	38	38	0	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0010-440X	1532-8384		COMPR PSYCHIAT	Compr. Psychiat.	APR	2016	66						113	122		10.1016/j.comppsych.2016.01.002			10	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	DH4ML	WOS:000372760000016	26995244	Green Accepted			2022-02-06	
J	Riedy, G; Senseney, JS; Liu, W; Ollinger, J; Sham, E; Krapiva, P; Patel, JB; Smith, A; Yeh, PH; Graner, J; Nathan, D; Caban, J; French, LM; Harper, J; Eskay, V; Morissette, J; Oakes, TR				Riedy, Gerard; Senseney, Justin S.; Liu, Wei; Ollinger, John; Sham, Elyssa; Krapiva, Pavel; Patel, Jigar B.; Smith, Alice; Yeh, Ping-Hong; Graner, John; Nathan, Dominic; Caban, Jesus; French, Louis M.; Harper, Jamie; Eskay, Victoria; Morissette, John; Oakes, Terrence R.			Findings from Structural MR Imaging in Military Traumatic Brain Injury	RADIOLOGY			English	Article							WHITE-MATTER LESIONS; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSE AXONAL INJURY; COMMON DATA ELEMENTS; MILD HEAD-INJURY; SERVICE MEMBERS; BLAST; SYMPTOMS; TBI; HYPERINTENSITIES	Purpose: To describe the initial neuroradiology findings in a cohort of military service members with primarily chronic mild traumatic brain injury (TBI) from blast by using an integrated magnetic resonance (MR) imaging protocol. Materials and Methods: This study was approved by the Walter Reed National Military Medical Center institutional review board and is compliant with HIPAA guidelines. All participants were military service members or dependents recruited between August 2009 and August 2014. There were 834 participants with a history of TBI and 42 participants in a control group without TBI (not explicitly age-and sex-matched). MR examinations were performed at 3 T primarily with three-dimensional volume imaging at smaller than 1 mm(3) voxels for the structural portion of the examination. The structural portion of this examination, including T1-weighted, T2-weighted, before and after contrast agent administrtion T2 fluid attenuation inversion recovery, and susceptibility-weighted images, was evaluated by neuroradiologists by using a modified version of the neuroradiology TBI common data elements (CDEs). Incident odds ratios (ORs) between the TBI participants and a comparison group without TBI were calculated. Results: The 834 participants were diagnosed with predominantly chronic (mean, 1381 days; median, 888 days after injury) and mild (92% [768 of 834]) TBI. Of these participants, 84.2% (688 of 817) reported one or more blast-related incident and 63.0% (515 of 817) reported loss of consciousness at the time of injury. The presence of white matter T2-weighted hyperintense areas was the most common pathologic finding, observed in 51.8% (432 of 834; OR, 1.75) of TBI participants. Cerebral microhemorrhages were observed in a small percentage of participants (7.2% [60 of 834]; OR, 6.64) and showed increased incidence with TBI severity (P < .001, moderate and severe vs mild). T2-weighted hyperintense areas and microhemorrhages did not collocate by visual inspection. Pituitary abnormalities were identified in a large proportion (29.0% [242 of 834]; OR, 16.8) of TBI participants. Conclusion: Blast-related injury and loss of consciousness is common in military TBI. Structural MR imaging demonstrates a high incidence of white matter T2-weighted hyperintense areas and pituitary abnormalities, with a low incidence of microhemorrhage in the chronic phase. (C) RSNA, 2015	[Riedy, Gerard; Senseney, Justin S.; Liu, Wei; Ollinger, John; Sham, Elyssa; Yeh, Ping-Hong; Graner, John; Nathan, Dominic; Caban, Jesus; Harper, Jamie; Eskay, Victoria; Morissette, John; Oakes, Terrence R.] NCNC, Bethesda, MD USA; [Riedy, Gerard; Senseney, Justin S.; Liu, Wei; Ollinger, John; Sham, Elyssa; Yeh, Ping-Hong; Graner, John; Nathan, Dominic; Caban, Jesus; French, Louis M.; Eskay, Victoria; Morissette, John; Oakes, Terrence R.] NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA; [Riedy, Gerard; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Riedy, Gerard; Smith, Alice; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Yeh, Ping-Hong] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Krapiva, Pavel; French, Louis M.] WRNMMC, Bethesda, MD USA; [Patel, Jigar B.] VAMHCS, Baltimore, MD USA		Riedy, G (corresponding author), NCNC, Bethesda, MD USA.; Riedy, G (corresponding author), NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA.; Riedy, G (corresponding author), Ctr Neurosci & Regenerat Med, Bethesda, MD USA.; Riedy, G (corresponding author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.	griedy1@gmail.com	french, louis/AAB-2083-2020	Patel, Jigar/0000-0002-2343-9142; french, louis/0000-0002-9451-0604	Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT074437, 13129004]; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300606]	Supported by the Congressionally Directed Medical Research Program (grants PT074437 and 13129004) and Center for Neuroscience and Regenerative Medicine (grant 300606).	Agresti A., 2007, INTRO CATEGORICAL DA, P21; Aradi M, 2013, HEADACHE, V53, P752, DOI 10.1111/head.12013; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Assareh A, 2011, CNS NEUROSCI THER, V17, P525, DOI 10.1111/j.1755-5949.2010.00181.x; Barkhof F, 2002, CEREBROVASC DIS, V13, P21, DOI 10.1159/000049146; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; Deeks J, 2010, STAT METHODS GROUP C, P1; Defense and Veterans Brain Injury Center, 2015, DOD WORLDW NUMB TBI; Department of Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Erten-Lyons D, 2013, NEUROLOGY, V81, P977, DOI 10.1212/WNL.0b013e3182a43e45; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Galluzzi S, 2008, J NEUROL SCI, V273, P3, DOI 10.1016/j.jns.2008.06.023; Guerrero AF, 2010, MIL MED, V175, P574, DOI 10.7205/MILMED-D-09-00189; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kim SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102229; Kochunov P, 2008, HUM BRAIN MAPP, V29, P36, DOI 10.1002/hbm.20369; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Pagano M, 2000, PRINCIPLES BIOSTATIS, P151; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Sahraian MA, 2010, CLIN NEUROL NEUROSUR, V112, P609, DOI 10.1016/j.clineuro.2010.03.022; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilkinson C. W., 2012, FRONT NEUROL, V3, P11, DOI DOI 10.3389/FNEUR.2012.00011; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	44	38	38	0	11	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	2016	279	1					207	215		10.1148/radiol.2015150438			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	DP7WK	WOS:000378709700020	26669604	Bronze			2022-02-06	
J	Zuckerman, SL; Yengo-Kahn, AM; Buckley, TA; Solomon, GS; Sills, AK; Kerr, ZY				Zuckerman, Scott L.; Yengo-Kahn, Aaron M.; Buckley, Thomas A.; Solomon, Gary S.; Sills, Allen K.; Kerr, Zachary Y.			Predictors of postconcussion syndrome in collegiate student-athletes	NEUROSURGICAL FOCUS			English	Article						sport-related concussion; traumatic brain injury; collegiate athletics; NCAA; postconcussion syndrome	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; HIGH-SCHOOL; PROLONGED RECOVERY; RISK-FACTORS; SYNDROME PCS; SYMPTOMS; EPIDEMIOLOGY; MANAGEMENT	OBJECTIVE Sport-related concussion (SRC) has emerged as a public health problem, especially among studentathletes. Whereas most concussions resolve by 2 weeks, a minority of patients experience postconcussion syndrome (PCS), in which symptoms persist for months. The objective of this study was to elucidate factors predictive of PCS among a sample of National Collegiate Athletic Association (NCAA) student-athletes in the academic years 2009-2010 to 2014-2015. METHODS The SRC data originated from the NCAA Injury Surveillance Program (ISP) in the 2009-2010 to 2014-2015 academic seasons. The NCAA ISP is a prospective database made up of a convenience sample of schools across all divisions. All SRCs are reported by certified athletic trainers. The PCS group consisted of concussed student-athletes with concussion-related symptoms that lasted >= 4 weeks. The non-PCS group consisted of concussed student-athletes with symptom resolution in <= 2 weeks. Those with symptoms that resolved in the intermediate area of 2-4 weeks were excluded. Odds ratios (ORs) were estimated using logistic regression. RESULTS During the 2009-2010 to 2014-2015 seasons, 1507 NCAA student-athletes sustained an SRC, 112 (7.4%) of whom developed PCS (i.e., concussion-related symptoms that lasted >= 4 weeks). Men's ice hockey contributed the largest proportion of concussions to the PCS group (28.6%), whereas men's football contributed the largest proportion of concussions in the non-PCS group (38.6%). In multivariate analysis, recurrent concussion was associated with increased odds of PCS (OR 2.08, 95% CI 1.28-3.36). Concussion symptoms that were also associated with increased odds of PCS included retrograde amnesia (OR 2.75, 95% CI 1.34-5.64), difficulty concentrating (OR 2.35, 95% CI 1.23-4.50), sensitivity to light (OR 1.97, 95% CI 1.09-3.57), and insomnia (OR 2.19, 95% CI 1.30-3.68). Contact level, sex, and loss of consciousness were not associated with PCS. CONCLUSIONS Postconcussion syndrome represents one of the most impactful sequelae of SRC. In this study of exclusively collegiate student-athletes, the authors found that recurrent concussions and various concussion-related symptoms were associated with PCS. The identification of initial risk factors for the development of PCS may assist sports medicine clinicians in providing timely interventions and treatments to prevent morbidity and shorten recovery time after SRC.	[Zuckerman, Scott L.; Yengo-Kahn, Aaron M.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37232 USA; [Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA		Zuckerman, SL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Med Ctr North T4224, 1211 Med Ctr Dr, Nashville, TN 37232 USA.	scott.zuckerman@vanderbilt.edu	Buckley, Thomas A/B-7525-2016; Solomon, Gary/K-9011-2019; Yengo-Kahn, Aaron/AAV-7647-2020	Buckley, Thomas A/0000-0002-0515-0150; Yengo-Kahn, Aaron/0000-0002-5989-3064; Kerr, Zachary/0000-0003-1423-1259			Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; [Anonymous], 2013, 2013 14 NCAA SPORTS; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Franke LM, 2015, J HEAD TRAUMA REHAB, V30, pE34, DOI 10.1097/HTR.0000000000000042; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Luoto TM, 2015, BRAIN INJURY, V29, P565, DOI 10.3109/02699052.2014.1002421; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Morgan CD, 2015, CHILD NERV SYST, V31, P2305, DOI 10.1007/s00381-015-2916-y; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Olympia RP, 2015, CLIN J SPORT MED; Ouellet J, 2008, BEHAV NEUROL, V20, P27, DOI [10.1155/2008/520328, 10.3233/BEN-2008-0213]; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Reuben A, 2014, EMERG MED J, V31, P72, DOI 10.1136/emermed-2012-201667; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rose SC, 2015, BRAIN INJURY, V29, P798, DOI 10.3109/02699052.2015.1004756; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Solomon Gary S, 2013, J Surg Orthop Adv, V22, P193; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Wing R, 2016, CLIN PEDIATR, V55, P228, DOI 10.1177/0009922815592879; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zuckerman SL, 2015, INT J SPORTS MED, V36, P419, DOI 10.1055/s-0034-1395587; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	53	38	38	0	20	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E13	10.3171/2016.1.FOCUS15593			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500002	27032916	gold			2022-02-06	
J	Nordin, LE; Moller, MC; Julin, P; Bartfai, A; Hashim, F; Li, TQ				Nordin, Love Engstrom; Moller, Marika Christina; Julin, Per; Bartfai, Aniko; Hashim, Farouk; Li, Tie-Qiang			Post mTBI fatigue is associated with abnormal brain functional connectivity	SCIENTIFIC REPORTS			English	Article							ANTERIOR CINGULATE CORTEX; DEFAULT-MODE NETWORK; RESTING-STATE; INJURY; MRI; CONCUSSION; DISRUPTION; ATTENTION; SELECTION; RECOVERY	This study set out to investigate the behavioral correlates of changes in resting-state functional connectivity before and after performing a 20 minute continuous psychomotor vigilance task (PVT) for patients with chronic post-concussion syndrome. Ten patients in chronic phase after mild traumatic brain injury (mTBI) with persisting symptoms of fatigue and ten matched healthy controls participated in the study. We assessed the participants' fatigue levels and conducted resting-state fMRI before and after a sustained PVT. We evaluated the changes in brain functional connectivity indices in relation to the subject's fatigue behavior using a quantitative data-driven analysis approach. We found that the PVT invoked significant mental fatigue and specific functional connectivity changes in mTBI patients. Furthermore, we found a significant linear correlation between self-reported fatigue and functional connectivity in the thalamus and middle frontal cortex. Our findings indicate that resting-state fMRI measurements may be a useful indicator of performance potential and a marker of fatigue level in the neural attentional system.	[Nordin, Love Engstrom; Li, Tie-Qiang] Karolinska Univ Hosp Huddinge, Dept Diagnost Med Phys, Stockholm, Sweden; [Nordin, Love Engstrom; Hashim, Farouk; Li, Tie-Qiang] Karolinska Inst, Div Med Imaging & Technol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Moller, Marika Christina; Julin, Per; Bartfai, Aniko] Karolinska Inst, KIDS, Danderyd Hosp, Dept Clin Sci, Solnavagen 1, S-17177 Solna, Sweden; [Moller, Marika Christina] Uppsala Univ, Ctr Clin Res, Sormland, Uppsala, Sweden; [Julin, Per] Stora Skondal Fdn, Neurol Rehabil Clin, Stockholm, Sweden; [Hashim, Farouk] Karolinska Univ Hosp, Dept Radiol, Stockholm, Sweden		Nordin, LE (corresponding author), Karolinska Univ Hosp Huddinge, Dept Diagnost Med Phys, Stockholm, Sweden.; Nordin, LE (corresponding author), Karolinska Inst, Div Med Imaging & Technol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.	love.engstrom-nordin@karolinska.se	MAller, Marika C/N-8782-2016; Moller, Marika/S-5427-2019	MAller, Marika C/0000-0001-8700-5186; Moller, Marika/0000-0001-8700-5186; Li, Tie-Qiang/0000-0002-4866-5904; Hashim, Farouk/0000-0003-1656-4217	Swedish Research CouncilSwedish Research CouncilEuropean Commission; ALF Medicine in Stockholm; Centre for Clinical Research Sormland and Promobilia; Karolinska InstituteKarolinska Institutet; Karolinska University HospitalKarolinska Institutet	This study was supported by research grants from the Swedish Research Council, ALF Medicine in Stockholm, Centre for Clinical Research Sormland and Promobilia. The authors also would like to acknowledge the support from Karolinska Institute and Karolinska University Hospital.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brzezicka A, 2013, BEHAV BRAIN SCI, V36, P682, DOI 10.1017/S0140525X13000940; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Dobryakova E., 2013, J INT NEUROPSYCH SOC, V19, P1; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gronwall D, 1989, MILD HEAD INJURY, P153; Hetherington H, 2015, Handb Clin Neurol, V127, P309, DOI 10.1016/B978-0-444-52892-6.00020-9; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Leung HC, 2002, J COGNITIVE NEUROSCI, V14, P659, DOI 10.1162/08989290260045882; Li T. Q., 2015, P ISMRM, P1256; Lim J, 2010, NEUROIMAGE, V49, P3426, DOI 10.1016/j.neuroimage.2009.11.020; Mastropasqua C, 2015, BRAIN TOPOGR, V28, P548, DOI 10.1007/s10548-014-0422-2; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Moller MC, 2014, J CLIN EXP NEUROPSYC, V36, P716, DOI 10.1080/13803395.2014.933779; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Park HJ, 2013, SCIENCE, V342, P579, DOI 10.1126/science.1238411; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shin SS, 2014, PROG NEUROL SURG, V28, P86, DOI 10.1159/000358767; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van der Linden D, 2003, ACTA PSYCHOL, V113, P45, DOI 10.1016/S0001-6918(02)00150-6; Wang YL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00259; Wang YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076315; Yuan R, 2016, BRAIN STRUCT FUNCT, V221, P1971, DOI 10.1007/s00429-015-1018-7; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	51	38	38	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 16	2016	6								21183	10.1038/srep21183			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD8KV	WOS:000370176300003	26878885	Green Published, gold, Green Submitted			2022-02-06	
J	Alsalaheen, BA; Whitney, SL; Marchetti, GF; Furman, JM; Kontos, AP; Collins, MW; Sparto, PJ				Alsalaheen, Bara A.; Whitney, Susan L.; Marchetti, Gregory F.; Furman, Joseph M.; Kontos, Anthony P.; Collins, Michael W.; Sparto, Patrick J.			Relationship Between Cognitive Assessment and Balance Measures in Adolescents Referred for Vestibular Physical Therapy After Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild traumatic brain injury; vestibular rehabilitation; dizziness	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; MINIMAL DETECTABLE CHANGE; DYNAMIC GAIT INDEX; HIGH-SCHOOL; POSTURAL STABILITY; FOOTBALL PLAYERS; NEUROCOGNITIVE FUNCTION; FUNCTIONAL GAIT; SYMPTOMS	Objective:To examine the relationship between cognitive and balance performance in adolescents with concussion.Design:Retrospective case series.Setting:Tertiary.Patients:Sixty patients.Interventions:Correlation analyses were performed to describe the relationship between symptoms, cognitive measure, and balance measure at the time of initiation of vestibular physical therapy.Main Outcome Measures:Cognitive performance was assessed using the Immediate Post-concussion Assessment and Cognitive Testing (ImPACT). The dizziness and balance function measures included dizziness severity rating, Activities-specific Balance Confidence scale (ABC), Dizziness Handicap Inventory (DHI), Functional Gait Assessment, gait speed, Timed UP and GO, Five Times Sit to Stand, and Sensory Organization Test (SOT). To account for multiple comparisons, the False Discovery Rate method was used.Results:Performance measures of balance were significantly correlated with cognitive measures. Greater total symptom scores were related to greater impairment in the ABC and DHI (r = 0.35-0.39, P 0.008) and worse performance in condition 2 of the SOT (r = -0.48, P = 0.004). Among the ImPACT composite scores, lower memory scores were correlated with impaired balance performance measures (r = 0.37-0.59, P 0.012). Lower visual memory was also correlated with worse ABC scores.Conclusions:The significant relationships reported between the cognitive performance scores and balance measures may reflect that similar levels of functioning exist across domains in individuals with protracted recovery who receive vestibular physical therapy.	[Alsalaheen, Bara A.] Univ Michigan Flint, Dept Phys Therapy, Flint, MI 48502 USA; [Whitney, Susan L.; Furman, Joseph M.; Sparto, Patrick J.] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA USA; [Whitney, Susan L.; Furman, Joseph M.; Sparto, Patrick J.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Whitney, Susan L.] King Saud Univ, Dept Rehabil Sci, Riyadh, Saudi Arabia; [Marchetti, Gregory F.] Duquesne Univ, Dept Phys Therapy, Pittsburgh, PA 15219 USA; [Kontos, Anthony P.; Collins, Michael W.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA		Alsalaheen, BA (corresponding author), Univ Michigan Flint, Dept Phys Therapy, 2157 William S White Bldg,303 E Kearsley St, Flint, MI 48502 USA.	alsalahe@umflint.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310; Sparto, Patrick/0000-0002-8351-3789	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG024827] Funding Source: Medline; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30 DC005205, K01 DC012332] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332, P30DC005205] Funding Source: NIH RePORTER		Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2014, PEDIATR PHYS THER, V26, P191, DOI 10.1097/PEP.0000000000000037; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berthoz A, 1996, COGNITIVE BRAIN RES, V3, P101, DOI 10.1016/0926-6410(95)00035-6; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanes DA, 2006, J VESTIBUL RES-EQUIL, V16, P75; Harris LR, 2000, EXP BRAIN RES, V135, P12, DOI 10.1007/s002210000504; ISRAEL I, 1993, EXP BRAIN RES, V96, P335; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lord SR, 2002, J GERONTOL A-BIOL, V57, pM539, DOI 10.1093/gerona/57.8.M539; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Marchetti GF, 2014, J NEUROL PHYS THER, V38, P119, DOI 10.1097/NPT.0000000000000015; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; NAKAMURA T, 1995, BRAIN, V118, P1157, DOI 10.1093/brain/118.5.1157; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Risey J, 1990, J Vestib Res, V1, P31; Salbach NM, 2006, ARCH PHYS MED REHAB, V87, P1597, DOI 10.1016/j.apmr.2006.08.336; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schautzer F, 2003, ANN NY ACAD SCI, V1004, P316, DOI 10.1196/annals.1303.029; Smith PF, 2005, J VESTIBUL RES-EQUIL, V15, P1; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Vitte E, 1996, EXP BRAIN RES, V112, P523; Whitney S. L., 2007, VESTIBULAR REHABILIT, P272; Wrisley DM, 2003, ARCH PHYS MED REHAB, V84, P1528, DOI 10.1016/S0003-9993(03)00274-0	67	38	38	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2016	26	1					46	52		10.1097/JSM.0000000000000185			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	DA2JB	WOS:000367620000007	25706663	Green Accepted			2022-02-06	
J	Lant, ND; Gonzalez-Lara, LE; Owen, AM; Fernandez-Espejo, D				Lant, Nicholas D.; Gonzalez-Lara, Laura E.; Owen, Andrian M.; Fernandez-Espejo, Davinia			Relationship between the anterior forebrain mesocircuit and the default mode network in the structural bases of disorders of consciousness	NEUROIMAGE-CLINICAL			English	Article						Disorders of consciousness; Default mode network; Thalamus; Basal ganglia; Anterior forebrain mesocircuit; Precuneus; DTI; Tractography; White matter; Traumatic brain injury; Hypoxic-ischemic brain injury; Vegetative state; Minimally conscious state	DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN-INJURY; BLUNT HEAD-INJURY; MACAQUE MONKEY; PARAHIPPOCAMPAL CORTICES; FUNCTIONAL CONNECTIVITY; VEGETATIVE STATE; DAMAGED PATIENTS; THALAMIC NUCLEI; MULTIMODAL MRI	The specific neural bases of disorders of consciousness (DOC) are still not well understood. Some studies have suggested that functional and structural impairments in the default mode network may play a role in explaining these disorders. In contrast, others have proposed that dysfunctions in the anterior forebrain mesocircuit involving striatum, globus pallidus, and thalamus may be the main underlying mechanism. Here, we provide the first report of structural integrity of fiber tracts connecting the nodes of the mesocircuit and the default mode network in 8 patients with DOC. We found evidence of significant damage to subcortico-cortical and cortico-cortical fibers, which were more severe in vegetative state patients and correlated with clinical severity as determined by Coma Recovery Scale-Revised (CRS-R) scores. In contrast, fiber tracts interconnecting subcortical nodes were not significantly impaired. Lastly, we found significant damage in all fiber tracts connecting the precuneus with cortical and subcortical areas. Our results suggest a strong relationship between the default mode network and most importantly the precuneus - and the anterior forebrain mesocircuit in the neural basis of the DOC. (C) 2015 The Authors. Published by Elsevier Inc.	[Lant, Nicholas D.; Gonzalez-Lara, Laura E.; Owen, Andrian M.; Fernandez-Espejo, Davinia] Univ Western Ontario, Brain & Mind Inst, London, ON N6A 5B7, Canada; [Fernandez-Espejo, Davinia] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England		Fernandez-Espejo, D (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.		Gonzalez-Lara, Laura/S-2209-2018; Fernandez-Espejo, Davinia/AAT-5481-2021	Gonzalez-Lara, Laura/0000-0002-2688-2721; Fernandez-Espejo, Davinia/0000-0001-5941-7546	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [0000032597]; James S. McDonnell Foundation; Schulich Research Opportunities Program; Canada Excellence Research Chairs ProgramCanada Research Chairs [0000025914]	This research was supported by generous funding from the Canadian Institutes of Health Research (Post-doctoral fellowship: D.F-E.; Operating Grant 0000032597: A.M.O.), James S. McDonnell Foundation (A.M.O.), Schulich Research Opportunities Program (N.D.L.), and the Canada Excellence Research Chairs Program (0000025914; A.M.O., D.F-E.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Natalie Osborne for assistance in healthy participant data collection.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cherubini A, 2007, NEUROIMAGE, V34, P1331, DOI 10.1016/j.neuroimage.2006.11.024; Cieslik EC, 2013, CEREB CORTEX, V23, P2677, DOI 10.1093/cercor/bhs256; Crone JS, 2015, NEUROIMAGE, V110, P101, DOI 10.1016/j.neuroimage.2015.01.037; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Cruse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049933; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fernandez-Espejo D, 2015, JAMA NEUROL, P1, DOI [10.1001/jamaneurol.2015.2614, DOI 10.1001/JAMANEUROL.2015.2614]; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Frazier JA, 2005, AM J PSYCHIAT, V162, P1256, DOI 10.1176/appi.ajp.162.7.1256; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; GENTRY LR, 1994, RADIOLOGY, V191, P1; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Gibson RM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00950; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guillery RW, 2002, NEURON, V33, P163, DOI 10.1016/S0896-6273(01)00582-7; Hannawi Y, 2015, NEUROLOGY, V84, P1272, DOI 10.1212/WNL.0000000000001404; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Klein JC, 2010, NEUROIMAGE, V51, P555, DOI 10.1016/j.neuroimage.2010.02.062; Kobayashi Y, 2003, J COMP NEUROL, V466, P48, DOI 10.1002/cne.10883; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Lavenex P, 2002, J COMP NEUROL, V447, P394, DOI 10.1002/cne.10243; Leh SE, 2007, NEUROSCI LETT, V419, P113, DOI 10.1016/j.neulet.2007.04.049; Lutkenhoff ES, 2015, ANN NEUROL, V78, P68, DOI 10.1002/ana.24423; Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Mars RB, 2012, CEREB CORTEX, V22, P1894, DOI 10.1093/cercor/bhr268; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Menzler K, 2011, NEUROIMAGE, V54, P2557, DOI 10.1016/j.neuroimage.2010.11.029; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morel A., 2007, STEREOTACTIC ATLAS H; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Morris R, 1999, EUR J NEUROSCI, V11, P2506, DOI 10.1046/j.1460-9568.1999.00672.x; Naci L., 2013, JAMA NEUROL, DOI 10.1001/jamaneurol/2013.3686; Naci L, 2014, P NATL ACAD SCI USA, V111, P14277, DOI 10.1073/pnas.1407007111; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Saab AS, 2013, CURR OPIN NEUROBIOL, V23, P1065, DOI 10.1016/j.conb.2013.09.008; Sala-Llonch R, 2010, J ALZHEIMERS DIS, V22, P523, DOI 10.3233/JAD-2010-101038; Sallet J, 2013, J NEUROSCI, V33, P12255, DOI 10.1523/JNEUROSCI.5108-12.2013; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; SELEMON LD, 1985, J NEUROSCI, V5, P776; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Utevsky AV, 2014, J NEUROSCI, V34, P932, DOI 10.1523/JNEUROSCI.4227-13.2014; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055	78	38	42	2	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2016	10						27	35		10.1016/j.nicl.2015.11.004			9	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI0LX	WOS:000373189000003	26693399	Green Published, gold			2022-02-06	
J	Lawrence, T; Helmy, A; Bouamra, O; Woodford, M; Lecky, F; Hutchinson, PJ				Lawrence, T.; Helmy, A.; Bouamra, O.; Woodford, M.; Lecky, F.; Hutchinson, P. J.			Traumatic brain injury in England and Wales: prospective audit of epidemiology, complications and standardised mortality	BMJ OPEN			English	Article							GLASGOW COMA SCALE; HEAD-INJURY; IMPACT; PERFORMANCE; MANAGEMENT; COHORT; CARE	Objectives: To provide a comprehensive assessment of the management of traumatic brain injury (TBI) relating to epidemiology, complications and standardised mortality across specialist units. Design: The Trauma Audit and Research Network collects data prospectively on patients suffering trauma across England and Wales. We analysed all data collected on patients with TBI between April 2014 and June 2015. Setting: Data were collected on patients presenting to emergency departments across 187 hospitals including 26 with specialist neurosurgical services, incorporating factors previously identified in the Ps14 multivariate logistic regression (Ps14(n)) model multivariate TBI outcome prediction model. The frequency and timing of secondary transfer to neurosurgical centres was assessed. Results: We identified 15 820 patients with TBI presenting to neurosurgical centres directly (6258), transferred from a district hospital to a neurosurgical centre (3682) and remaining in a district general hospital (5880). The commonest mechanisms of injury were falls in the elderly and road traffic collisions in the young, which were more likely to present in coma. In severe TBI (Glasgow Coma Score (GCS) <= 8), the median time from admission to imaging with CT scan is 0.5 hours. Median time to craniotomy from admission is 2.6 hours and median time to intracranial pressure monitoring is 3 hours. The most frequently documented complication of severe TBI is bronchopneumonia in 5% of patients. Risk-adjusted W scores derived from the Ps14(n) model indicate that no neurosurgical unit fell outside the 3 SD limits on a funnel plot. Conclusions: We provide the first comprehensive report of the management of TBI in England and Wales, including data from all neurosurgical units. These data provide transparency and suggests equity of access to high-quality TBI management provided in England and Wales.	[Lawrence, T.; Bouamra, O.; Woodford, M.] Univ Manchester, Salford Royal Hosp, Manchester Med Acad Hlth Sci Ctr, Trauma Audit & Res Network,Inst Populat Hlth, Salford, Lancs, England; [Helmy, A.; Hutchinson, P. J.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Helmy, A.; Hutchinson, P. J.] Addenbrookes Hosp, Dept Neurosurg, Cambridge, England; [Lecky, F.] Univ Sheffield, Sch Hlth & Related Res ScHARR, Hlth Serv Res Sect, Ctr Urgent & Emergency Care Res CURE, Sheffield, S Yorkshire, England		Helmy, A (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge, England.; Helmy, A (corresponding author), Addenbrookes Hosp, Dept Neurosurg, Cambridge, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; bouamra, omar/0000-0002-3155-4634; Lawrence, Thomas/0000-0003-3648-7634	University of Cambridge, UKUniversity of Cambridge; Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship [G0802251]; National Institute for Health Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1002277, G0802251] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004, 12/35/57, 13/15/02, NIHR-RP-R3-12-013] Funding Source: researchfish	AH is supported by the University of Cambridge, UK and Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (grant number G0802251). PJH is supported by National Institute for Health Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and the National Institute for Health Research Biomedical Research Centre, Cambridge.	[Anonymous], 2007, GUIDELINES MANAGEMEN; Bouamra O, 2015, EMERG MED J, V32, P933, DOI 10.1136/emermed-2015-205176; Brasel KJ, 2013, J TRAUMA ACUTE CARE, V74, P1363, DOI 10.1097/TA.0b013e31828b82f5; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Fuller G, 2015, EUR J EMERG MED, V22, P42, DOI 10.1097/MEJ.0000000000000117; HOLLIS S, 1995, J TRAUMA, V38, P763, DOI 10.1097/00005373-199505000-00015; Kirkman MA, 2013, J NEUROTRAUM, V30, P1385, DOI 10.1089/neu.2013.2881; Lecky F, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20010; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; National Institute for Health and Clinical Excellence, 2014, HEAD INJ TRIAG ASS I; NICE, 2014, TRIAG ASS INV EARL M; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Reith FCM, 2016, INTENS CARE MED, V42, P3, DOI 10.1007/s00134-015-4124-3; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Walder B, 2013, J NEUROTRAUM, V30, P1934, DOI 10.1089/neu.2013.2955	20	38	38	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2016	6	11							e012197	10.1136/bmjopen-2016-012197			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG8JQ	WOS:000391303400109	27884843	Green Accepted, Green Published, gold			2022-02-06	
J	Lobue, C; Denney, D; Hynan, LS; Rossetti, HC; Lacritz, LH; Hart, J; Womack, KB; Woon, FL; Cullum, CM				LoBue, Christian; Denney, David; Hynan, Linda S.; Rossetti, Heidi C.; Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.; Woon, Fu L.; Cullum, C. Munro			Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Age of onset; mild cognitive impairment; risk factors; traumatic brain injury	HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; DEMENTIA; DEPRESSION; PREVALENCE; PATHOLOGY; ONSET	This study examined whether history of traumatic brain injury (TBI) is associated with increased risk and earlier onset of mild cognitive impairment (MCI). Subjects with MCI (n = 3,187) and normal cognition (n = 3,244) were obtained from the National Alzheimer's Coordinating Center database. TBI was categorized based on lifetime reported TBI with loss of consciousness (LOC) without chronic deficit. Logistic regression was used to examine TBI history as a predictor of MCI, adjusted for demographics, apolipoprotein E-epsilon 4 (ApoE4), a composite vascular risk score, and history of psychiatric factors. ANCOVA was used to examine whether age at MCI diagnosis and estimated age of onset differed between those with (TBI+) and without (TBI-) a history of TBI. TBI history was a significant predictor (p < 0.01) and associated with increased odds of MCI diagnosis in unadjusted (OR = 1.25; 95% CI = 1.05-1.49) and adjusted models, accounting for age, education, ApoE4, and a composite vascular score (OR = 1.32; 95% CI = 1.10-1.58). This association, however, was largely attenuated (OR = 1.14; 95% CI = 0.94-1.37; p = 0.18) after adjustment for reported history of depression. MCI was diagnosed a mean of 2.3 years earlier (p < 0.001) in the TBI+ group, and although TBI+ subjects had an estimated mean of decline 1.7 years earlier, clinician-estimated age of onset failed to differ (p = 0.13) when gender and psychiatric factors were controlled. This is the first report of a possible role for TBI as a risk factor in MCI, but its association may be related to other factors such as gender and depression and requires further investigation.	[LoBue, Christian; Denney, David; Hynan, Linda S.; Rossetti, Heidi C.; Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.; Woon, Fu L.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA		Lobue, C (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75208 USA.	christian.lobue@utsouthwestern.edu	Womack, Kyle/O-5422-2018; Hynan, Linda S/P-6473-2016; Cullum, C. Munro/AAC-2496-2019	Womack, Kyle/0000-0002-6060-9075; Cullum, C. Munro/0000-0001-9706-5465; Hynan, Linda/0000-0002-4642-7769	NIH/NIA Alzheimer's Disease Center Grant [P3012300-19]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P30 AG010129];  [P50 AG016573];  [P50 AG016570];  [P50 AG005131];  [P50AG023501];  [P30 AG035982];  [P30AG028383];  [P30 AG010124];  [P50 AG005136];  [P50 AG033514];  [P50 AG005681];  [U01 AG032984]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG035982, P50AG005146, P30AG028383, P50AG016570, P01AG003991, P30AG013846, P50AG005142, P30AG010124, P50AG005681, P30AG013854, P50AG005131, P30AG019610, P30AG008017, P50AG016574, P50AG016573, U01AG016976, P30AG010133, P30AG010161, P50AG005136, U01AG032984, P30AG008051, P50AG005138, P50AG005133, P30AG012300, P50AG025688, P30AG010129, P50AG033514, P50AG008702, P50AG005134, P50AG023501] Funding Source: NIH RePORTER	Funding for this study was provided in part by the NIH/NIA P3012300-19 Alzheimer's Disease Center Grant. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30AG028383 (PI LindaVan Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD). The Alzheimer's Disease Genetic Consortium (ADGC) is funded by NIA Grant U01 AG032984.	Abisambra JF, 2014, J ALZHEIMERS DIS, V40, P495, DOI 10.3233/JAD-131019; Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Byers AL, 2011, NAT REV NEUROL, V7, P323, DOI 10.1038/nrneurol.2011.60; DeRight J, 2015, ANN BEHAV MED, V49, P344, DOI 10.1007/s12160-014-9681-0; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Faul M, 2010, TRAUMATIC BRAIN INJU, V2, P1; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geda YE, 2008, ARCH GEN PSYCHIAT, V65, P1193, DOI 10.1001/archpsyc.65.10.1193; Gilbert M, 2014, INT PSYCHOGERIATR, V26, P1593, DOI 10.1017/S1041610214000842; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Luchsinger JA, 2005, NEUROLOGY, V65, P545, DOI 10.1212/01.wnl.0000172914.08967.dc; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Tabachnick B.G., 2001, USING MULTIVARIATE S; US National Institutes of Health, 1998, NIH CONS STAT, P26	39	38	39	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	51	3					727	736		10.3233/JAD-150895			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DJ5IL	WOS:000374240200009	26890760	Green Accepted			2022-02-06	
J	Pugh, MJ; Finley, EP; Wang, CP; Copeland, LA; Jaramillo, CA; Swan, AA; Elnitsky, CA; Leykum, LK; Mortensen, EM; Eapen, BA; Noel, PH; Pugh, JA				Pugh, Mary Jo; Finley, Erin P.; Wang, Chen-Pin; Copeland, Laurel A.; Jaramillo, Carlos A.; Swan, Alicia A.; Elnitsky, Christine A.; Leykum, Luci K.; Mortensen, Eric M.; Eapen, Blessen A.; Noel, Polly H.; Pugh, Jacqueline A.		TRACC Res Team	A retrospective cohort study of comorbidity trajectories associated with traumatic brain injury in veterans of the Iraq and Afghanistan wars	BRAIN INJURY			English	Article						Comorbidity; Trajectories; Iraq and Afghanistan wars; veteran; healthcare; brain injury	POLYTRAUMA-CLINICAL-TRIAD; SUBSTANCE USE DISORDERS; MENTAL-HEALTH; GENDER-DIFFERENCES; COMBAT DEPLOYMENT; OEF/OIF VETERANS; ALCOHOL-USE; CARE; PREVALENCE; SYMPTOMS	Objectives: To identify and validate trajectories of comorbidity associated with traumatic brain injury in male and female Iraq and Afghanistan war Veterans (IAV).Methods: Derivation and validation cohorts were compiled of IAV who entered the Department of Veterans Affairs (VA) care and received 3 years of VA care between 2002-2011. Chronic disease and comorbidities associated with deployment including TBI were identified using diagnosis codes. A latent class analysis (LCA) of longitudinal comorbidity data was used to identify trajectories of comorbidity.Results: LCA revealed five trajectories that were similar for women and men: (1) Healthy, (2) Chronic Disease, (3) Mental Health, (4) Pain and (5) Polytrauma Clinical Triad (PCT: pain, mental health and TBI). Two additional classes found in men were 6) Minor Chronic and 7) PCT with chronic disease. Among these gender-stratified trajectories, it was found that women were more likely to experience headache (Pain trajectory) and depression (Mental Health trajectory), while men were more likely to experience lower back pain (Pain trajectory) and substance use disorder (Mental Health trajectory). The probability of TBI was highest in the PCT-related trajectories, with significantly lower probabilities in other trajectories.Conclusions: It was found that TBI was most common in PCT-related trajectories, indicating that TBI is commonly comorbid with pain and mental health conditions for both men and women. The relatively young age of this cohort raises important questions regarding how disease burden, including the possibility of neurodegenerative sequelae, will accrue alongside normal age-related decline in individuals with TBI. Additional big data' methods and a longer observation period may allow the development of predictive models to identify individuals with TBI that are at-risk for adverse outcomes.	[Pugh, Mary Jo; Finley, Erin P.; Jaramillo, Carlos A.; Swan, Alicia A.; Leykum, Luci K.; Eapen, Blessen A.; Noel, Polly H.; Pugh, Jacqueline A.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA; [Pugh, Mary Jo; Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Finley, Erin P.; Swan, Alicia A.; Leykum, Luci K.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA; [Copeland, Laurel A.] Cent Texas Vet Hlth Baylor Scott & White, Ctr Appl Hlth Res, Temple, TX USA; [Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Dept Med, Bryan, TX USA; [Elnitsky, Christine A.; TRACC Res Team] Univ N Carolina, Sch Nursing, Coll Hlth & Human Serv, Charlotte, NC USA; [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA; [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr Dallas, Div Gen Internal Med, Dallas, TX USA; [Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA		Pugh, MJ (corresponding author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	pughm@uthscsa.edu	Pugh, Mary Jo/K-5336-2019; Mortensen, Eric/AAF-2713-2020; Copeland, Laurel A/C-3763-2017; Swan, Alicia A/O-3536-2018; Pugh, Jacqueline/I-6199-2013	Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel A/0000-0002-9478-0209; Swan, Alicia A/0000-0003-2412-0499; Pugh, Jacqueline/0000-0003-4933-141X; Noel, Polly/0000-0002-1519-7489; Finley, Erin/0000-0003-4497-7721; Mortensen, Eric/0000-0002-3880-5563	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Healthcare System/Audie L. Murphy Division; Edith Nourse Rogers VA Memorial Hospital; VA Research and Development	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). The funding agency had no role in data collection, analysis or manuscript development. The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the Edith Nourse Rogers VA Memorial Hospital. We also acknowledge assistance with manuscript preparation by Natalie Rohde, Margaret Wells, Barbara Elizondo and Kathleen Franklin. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Drs. Pugh, Finley, Copeland, Jaramillo, Leykum, Mortensen, Eapen and Pugh are VA employees; this study was funded by VA Research and Development.	Abrams TE, 2013, PSYCHIAT SERV, V64, P142, DOI 10.1176/appi.ps.201200217; Bandeen-Roche K, 1997, J AM STAT ASSOC, V92, P1375, DOI 10.2307/2965407; Bean-Mayberry B, 2010, VA EVIDENCE BASED SY; Besterman-Dahan K, 2012, J HEALTH CARE CHAPL, V18, P151, DOI 10.1080/08854726.2012.723538; Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295; Carle A, 2015, CLIN ENDOCRINOL, V83, P717, DOI 10.1111/cen.12787; Chapman PL, 2012, MIL MED, V177, P270, DOI 10.7205/MILMED-D-11-00305; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cifu D.X., 2015, TRAUMATIC BRAIN INJU, P6; Cornell JE, 2009, APP MULTIVARIATE RES, V12, P163; Cutler JA, 2008, HYPERTENSION, V52, P818, DOI 10.1161/HYPERTENSIONAHA.108.113357; Defense Manpower Data Center, 2012, CONT TRACK SYST PROF; Elnitsky CA, 2013, MIL MED, V178, P775, DOI 10.7205/MILMED-D-13-00012; Falvo MJ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1124; Fryar Cheryl D, 2012, NCHS Data Brief, P1; Haskell SG, 2012, CLIN J PAIN, V28, P163, DOI 10.1097/AJP.0b013e318223d951; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Kelsall HL, 2015, EPIDEMIOL REV, V37, P38, DOI 10.1093/epirev/mxu014; Kitahara CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034979; Kline A, 2010, AM J PUBLIC HEALTH, V100, P276, DOI 10.2105/AJPH.2009.162925; Krishnan LL, 2005, DEMENT GERIATR COGN, V20, P245, DOI 10.1159/000087345; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Maguen S, 2012, MIL MED, V177, P797, DOI 10.7205/MILMED-D-11-00412; McAndrew LM, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-73; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; National Center for PTSD, 2010, REP VA CONS C PRACT; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Olives C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060308; Patten E, 2011, WOMEN US MILITARY GR; Pietrzak E, 2012, J MIL VETERANS HEALT, V20, P24; Poblador-Plou B, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-84; Prados-Torres A, 2014, J CLIN EPIDEMIOL, V67, P254, DOI 10.1016/j.jclinepi.2013.09.021; Pugh MJ, 2015, EPILEPSIA, V56, P321, DOI 10.1111/epi.12873; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; PUGH MJV, 2015, THE JOURNAL OF HEAD, V30, P29; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Shepperd S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000086; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Street AE, 2013, J GEN INTERN MED, V28, pS556, DOI 10.1007/s11606-013-2333-4; Thomsen CJ, 2011, J PSYCHIATR RES, V45, P1321, DOI 10.1016/j.jpsychires.2011.04.003; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; U.S. Department of Health and Human Services, 2010, MULT CHRON COND STRA; Vanderpump MPJ, 2011, BRIT MED BULL, V99, P39, DOI 10.1093/bmb/ldr030; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1; Vogt D, 2013, MILITARY PSYCHOL DES, P148; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432	53	38	38	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	12					1481	1490		10.1080/02699052.2016.1219055			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ED1IO	WOS:000388599100010	27834535				2022-02-06	
J	Tichy, J; Spechtmeyer, S; Mittelbronn, M; Hattingen, E; Rieger, J; Senft, C; Foerch, C				Tichy, Julia; Spechtmeyer, Sabrina; Mittelbronn, Michel; Hattingen, Elke; Rieger, Johannes; Senft, Christian; Foerch, Christian			Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma	JOURNAL OF NEURO-ONCOLOGY			English	Article						Glioblastoma; GFAP; Serum; Diagnostic marker; Biomarker	MGMT PROMOTER METHYLATION; TRAUMATIC BRAIN-INJURY; PROGNOSTIC VALUE; PLASMA-LEVELS; TUMOR VOLUME; TEMOZOLOMIDE; EXPRESSION; BIOMARKER	Glioblastoma (GBM) is the most common malignant primary brain tumor. Although clinical presentation and brain imaging might be suggestive, histopathological evaluation by means of a brain biopsy is routinely performed to establish the diagnosis. A serum marker indicative of GBM may simplify the diagnostic work-up of patients suspected to having a brain tumor. We prospectively examined 113 patients with newly diagnosed single supratentorial or infratentorial space-occupying brain lesions. Glial fibrillary acidic protein (GFAP) levels were determined from venous blood samples via a prototype ELISA assay prior to any invasive procedures. Serum levels of GFAP were correlated with histopathological findings and MRI parameters. GFAP values were significantly higher in GBM patients (n = 33) compared to all other tumors (p < 0.001). A GFAP serum concentration of a parts per thousand yen0.01 A mu g/L revealed a sensitivity of 85 % and a specificity of 70 % for differentiating GBM from other entities. By applying a GFAP cut-off point of 0.20 A mu g/L, specificity was maximized (99 %), but sensitivity dropped to 27 %. In GBM patients, serum GFAP values were significantly correlated with tumor volume. GBM patients with high GFAP levels showed more in vivo GFAP expression as well as more necrosis and perilesional edema compared to GBM patients having low or non-detectable GFAP levels. GFAP serum concentrations differentiated between patients with GBM and patients with cerebral mass lesions of other entities with a moderate diagnostic accuracy. Serum GFAP levels in GBM patients were positively correlated with tumor volume and histopathological tumor characteristics.	[Tichy, Julia; Spechtmeyer, Sabrina; Foerch, Christian] Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany; [Tichy, Julia; Rieger, Johannes] Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, D-60054 Frankfurt, Germany; [Tichy, Julia; Mittelbronn, Michel] Goethe Univ Frankfurt, Neurol Inst, Edinger Inst, D-60054 Frankfurt, Germany; [Mittelbronn, Michel] German Canc Consortium DKTK, Heidelberg, Germany; [Mittelbronn, Michel] German Canc Res Ctr, Heidelberg, Germany; [Hattingen, Elke] Goethe Univ Frankfurt, Inst Neuroradiol, D-60054 Frankfurt, Germany; [Senft, Christian] Goethe Univ Frankfurt, Dept Neurosurg, D-60054 Frankfurt, Germany; [Tichy, Julia] Goethe Univ Hosp Frankfurt, Dr Senckenberg Inst Neurooncol, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany		Tichy, J (corresponding author), Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany.; Tichy, J (corresponding author), Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, D-60054 Frankfurt, Germany.; Tichy, J (corresponding author), Goethe Univ Frankfurt, Neurol Inst, Edinger Inst, D-60054 Frankfurt, Germany.; Tichy, J (corresponding author), Goethe Univ Hosp Frankfurt, Dr Senckenberg Inst Neurooncol, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	julia.tichy@kgu.de	Hattingen, Elke/D-7880-2015; Senft, Christian/F-4252-2010	Senft, Christian/0000-0003-1288-6913; Hattingen, Elke/0000-0002-8392-9004; Mittelbronn, Michel/0000-0002-2998-052X			Brommeland T, 2007, ACTA NEUROL SCAND, V116, P380, DOI 10.1111/j.1600-0404.2007.00889.x; Brunkhorst R, 2010, TRANSL STROKE RES, V1, P246, DOI 10.1007/s12975-010-0040-6; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676; Perez-Larraya JG, 2014, CANCER-AM CANCER SOC, V120, P3972, DOI 10.1002/cncr.28949; Harter PN, 2010, NEUROPATH APPL NEURO, V36, P623, DOI 10.1111/j.1365-2990.2010.01100.x; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Jung CS, 2011, HISTOL HISTOPATHOL, V26, P1327, DOI 10.14670/HH-26.1327; Kiviniemi A, 2015, J NEURO-ONCOL, V124, P237, DOI 10.1007/s11060-015-1829-7; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Larsson IM, 2014, RESUSCITATION, V85, P1654, DOI 10.1016/j.resuscitation.2014.09.007; Lyubimova NV, 2011, B EXP BIOL MED+, V150, P732, DOI 10.1007/s10517-011-1236-9; Lyubimova NV, 2013, KLIN LAB DIAGN, V71-72, P40; Mayer CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062101; Nduom EK, 2013, J NEUROSURG, V119, P427, DOI 10.3171/2013.3.JNS122226; Noreen F, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju161; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Okonogi N, 2015, ANTICANCER RES, V35, P1229; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Petzold A, 2015, BRAIN RES, V1600, P17, DOI 10.1016/j.brainres.2014.12.027; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Wang K, 2014, ASIAN PAC J CANCER P, V15, P10893, DOI 10.7314/APJCP.2014.15.24.10893; Weise LM, 2014, STEREOT FUNCT NEUROS, V92, P129, DOI 10.1159/000360582; Weller M, 2015, CLIN CANCER RES, V21, P2057, DOI 10.1158/1078-0432.CCR-14-2737; Wilhelmsson U, 2003, ONCOGENE, V22, P3407, DOI 10.1038/sj.onc.1206372; YUNG WKA, 1985, J NEURO-ONCOL, V3, P35	29	38	40	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	JAN	2016	126	2					361	369		10.1007/s11060-015-1978-8			9	Oncology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Neurosciences & Neurology	DB7WS	WOS:000368728300017	26518540				2022-02-06	
J	Zhao, MF; Liang, F; Xu, HD; Yan, W; Zhang, JM				Zhao, Mingfei; Liang, Feng; Xu, Hangdi; Yan, Wei; Zhang, Jianmin			Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation	MOLECULAR MEDICINE REPORTS			English	Article						methylene blue; traumatic brain injury; autophagy; microglia	IMPROVES FUNCTIONAL RECOVERY; EDEMA; MECHANISMS	Traumatic brain injury (TBI) leads to permanent neurological impairment, and methylene blue (MB) exerts central nervous system neuroprotective effects. However, only one previous study has investigated the effectiveness of MB in a controlled cortical impact injury model of TBI. In addition, the specific mechanisms underlying the effect of MB against TBI remain to be elucidated. Therefore, the present study investigated the neuroprotective effect of MB on TBI and the possible mechanisms involved. In a mouse model of TBI, the animals were randomly divided into sham, vehicle (normal saline) or MB groups. The treatment time-points were 24 and 72 h (acute phase of TBI), and 14 days (chronic phase of TBI) post-TBI. The brain water content (BWC), and levels of neuronal death, and autophagy were determined during the acute phase, and neurological deficit, injury volume and microglial activation were assessed at all time-points. The injured hemisphere BWC was significantly increased 24 h post-TBI, and this was attenuated following treatment with MB. There was a significantly higher number of surviving neurons in the MB group, compared with the Vehicle group at 24 and 72 h post-TBI. In the acute phase, the MB-treated animals exhibited significantly upregulated expression of Beclin 1 and increased LC3-II to LC3-I ratios, compared with the vehicle group, indicating an increased rate of autophagy. Neurological functional deficits, measured using the modified neurological severity score, were significantly lower in the acute phase in the MB-treated animals and cerebral lesion volumes in the MB-treated animals were significantly lower, compared with the other groups at all time-points. Microglia were activated 24 h after TBI, peaked at 72 h and persisted until 14 days after TBI. Although the number of Iba-1-positive cells in the vehicle and MB groups 24 h post-TBI were not significantly different, marked microglial inhibition was observed in the MB group 72 h and 14 days after -TBI. These results indicated that MB exerts a neuroprotective effect by increasing autophagy, decreasing brain edema and inhibiting microglial activation.	[Zhao, Mingfei; Liang, Feng; Yan, Wei; Zhang, Jianmin] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China; [Xu, Hangdi] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Resp Med, Hangzhou 310016, Zhejiang, Peoples R China		Yan, W (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	ywisyw@163.com; zjm135@vip.sina.com		Yan, Wei/0000-0002-1123-0835	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81200956]	This study was supported by a grant from the National Natural Science Foundation of China (grant. no. 81200956). This manuscript was copyedited by an English speaking professional with a science background at Elixigen Corporation (Huntington Beach, CA, USA).	[Anonymous], 2011, GUID CAR US LAB AN; Auchter A, 2014, J ALZHEIMERS DIS, V42, pS525, DOI 10.3233/JAD-141527; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Callaway NL, 2004, PHARMACOL BIOCHEM BE, V77, P175, DOI 10.1016/j.pbb.2003.10.007; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Congdon EE, 2012, AUTOPHAGY, V8, P609, DOI 10.4161/auto.19048; Dibaj P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043963; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Duan YL, 2003, J NEUROBIOL, V57, P183, DOI 10.1002/neu.10262; Dvela-Levitt M, 2014, J NEUROTRAUM, V31, P1942, DOI 10.1089/neu.2014.3544; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Eroglu B, 2014, J NEUROCHEM, V130, P626, DOI 10.1111/jnc.12781; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fenn AM, 2014, J NEUROTRAUM, V31, pA100; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Han ZL, 2013, NEUROL MED-CHIR, V53, P630; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kwok Edmund S H, 2006, J Intensive Care Med, V21, P359, DOI 10.1177/0885066606290671; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lu J, 2005, ACT NEUR S, V95, P281; Maslow AD, 2006, ANESTH ANALG, V103, P2, DOI 10.1213/01.ane.0000221261.25310.fe; Paciullo CA, 2010, PHARMACOTHERAPY, V30, P702, DOI 10.1592/phco.30.7.702; Parekkadan B, 2008, NEUROSCI LETT, V438, P190, DOI 10.1016/j.neulet.2008.03.094; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Wang AM, 2010, J BIOL CHEM, V285, P15714, DOI 10.1074/jbc.M109.098806; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873	40	38	46	0	12	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JAN	2016	13	1	A				13	20		10.3892/mmr.2015.4551			8	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	DA5UG	WOS:000367867500003	26572258	Green Published, hybrid, Green Submitted			2022-02-06	
J	Guo, N; Xu, CS; Guo, W; Du, YP; Feng, JC				Guo, Ning; Xu, Changsheng; Guo, Wei; Du, Yongpeng; Feng, Jicai			Characterization of spatter in underwater wet welding by X-ray transmission method	MATERIALS & DESIGN			English	Article						Welding spatter; Underwater wet welding; X-ray imaging system; FCAW	METAL TRANSFER; FUME FORMATION	The spatter forming mechanism of underwater flux-cored wire wet welding is characterized by using a self-developed X-ray transmission system. Three representative spatter modes, droplet repelled spatter, explosive spatter and molten pool shock spatter, forming during underwater wet welding have been observed. The generation of droplet repelled spatter is due to the excessive repulsive forces for metal transfer. The diameter of this type of spatter is largest relatively, which can reach about 4.5 mm. In addition, explosive spatter, with size about 2.5 mm, is changed from the droplet with high horizontal speed caused by a slight explosion occurs at the touching location of the droplet and molten surface. Moreover, the dimension of molten pool shock spatter is smallest potentially among the spatter types during underwater wet welding, and it is only about 0.8 mm. It is generated from ridgy liquid column on [he molten pool surface because of the relatively severe concussion of the molten pool. The size, macroscopic pattern as well as chemical composition of these three types of spatters are different. (C) 2015 Elsevier Ltd. All rights reserved	[Guo, Ning; Feng, Jicai] Harbin Inst Technol, State Key Lab Adv Welding & Joining, Harbin 150000, Peoples R China; [Guo, Ning; Xu, Changsheng; Guo, Wei; Du, Yongpeng; Feng, Jicai] Harbin Inst Technol Weihai, Shandong Prov Key Lab Special Welding Technol, Weihai 264200, Peoples R China		Guo, N (corresponding author), 2Wenhuaxi Rd, Weihai 264209, Peoples R China.	gn21c@126.com			State Key Development Program for Basic Research of ChinaState Key Development Program for Basic Research of China [2013CB035502]; State Key Lab of Advanced Welding & Joining, Harbin Institute of TechnologyHarbin Institute of Technology [AWJ-M13-12]; Shandong Provincial Science and Technology Development Project [2014GGX103033]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014 M561343]	We are grateful for the financial support to this study from the State Key Development Program for Basic Research of China (2013CB035502), the State Key Lab of Advanced Welding & Joining, Harbin Institute of Technology (AWJ-M13-12), Shandong Provincial Science and Technology Development Project (2014GGX103033), and China Postdoctoral Science Foundation (2014 M561343).	Baune E, 2001, SCI TECHNOL WELD JOI, V6, P139, DOI 10.1179/136217101101538677; Chen JH, 1996, WELD J, V75, pS311; Ersoy U, 2008, WELD J, V87, P51; Farson D, 1998, WELD J, V77, p315S; Guo N, 2015, MATER LETT, V144, P90, DOI 10.1016/j.matlet.2015.01.033; Haidar J, 1996, J PHYS D APPL PHYS, V29, P2951, DOI 10.1088/0022-3727/29/12/003; Han GM, 2003, MATER DESIGN, V24, P699, DOI 10.1016/S0261-3069(03)00092-X; Heider A, 2013, PHYSCS PROC, V41, P112, DOI 10.1016/j.phpro.2013.03.058; Jenkins NT, 2005, SCI TECHNOL WELD JOI, V10, P537, DOI 10.1179/174329305X48310; Kang MJ, 2003, WELD J, V82, p238S; Labanowski Jerzy, 2011, Welding International, V25, P933, DOI 10.1080/09507116.2010.540847; Li K, 2014, INT J ADV MANUF TECH, V74, P693, DOI 10.1007/s00170-014-5990-5; Liao MT, 1999, INT J ADV MANUF TECH, V15, P49, DOI 10.1007/s001700050038; Liu SY, 2013, INT J HEAT MASS TRAN, V62, P604, DOI 10.1016/j.ijheatmasstransfer.2013.03.051; Molleda F, 2007, MATER CHARACT, V58, P936, DOI 10.1016/j.matchar.2006.09.011; Pires I, 2007, MATER DESIGN, V28, P1623, DOI 10.1016/j.matdes.2006.02.012; Rowe M, 2001, SCI TECHNOL WELD JOI, V6, P387, DOI 10.1179/stw.2001.6.6.387; Shijun Liao, 1999, Communications in Nonlinear Science & Numerical Simulation, V4, P104; Teran G, 2014, MAT SCI ENG A-STRUCT, V599, P105, DOI 10.1016/j.msea.2014.01.078; Wang Yan, 2013, Electric Welding Machine, V43, P96, DOI 10.7512/j.issn.1001-2303.2013.04.23	20	38	42	2	38	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-1275	1873-4197		MATER DESIGN	Mater. Des.	NOV 15	2015	85						156	161		10.1016/j.matdes.2015.06.152			6	Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	CV9CN	WOS:000364585000020					2022-02-06	
J	Rao, W; Zhang, L; Peng, C; Hui, H; Wang, K; Su, N; Wang, L; Dai, SH; Yang, YF; Chen, T; Luo, P; Fei, Z				Rao, Wei; Zhang, Lei; Peng, Cheng; Hui, Hao; Wang, Kai; Su, Ning; Wang, Li; Dai, Shu-hui; Yang, Yue-fan; Chen, Tao; Luo, Peng; Fei, Zhou			Downregulation of STIM2 improves neuronal survival after traumatic brain injury by alleviating calcium overload and mitochondrial dysfunction	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Traumatic brain injury; Neurons; SOCE; Mitochondria dysfunction; Calcium homeostasis	CA2+ ENTRY; INDUCED APOPTOSIS; GENE-EXPRESSION; ER STRESS; HOMER 1A; IN-VITRO; PROTEINS; CHANNELS; DISEASE; NEUROPROTECTION	Although store-operated calcium entry (SOCE) has been implicated in several neurological disorders, the exact mechanism for its role in traumatic brain injury (TBI) has not been elucidated. In this study, we found that TBI upregulated the expression of a calcium sensor protein called stromal interactive molecule 2 (STIM2); however, the levels of its homologue, STIM1, were unaffected. Both STIM1 and STIM2 are crucial components of SOCE, both in vivo and in vitro. Using shRNA, we discovered that downregulation of STIM2, but not STIM1, significantly improved neuronal survival in both an in vitro and in vivo model of TBI, decreasing neuronal apoptosis, and preserving neurological function. This neuroprotection was associated with alleviating TBI-induced calcium overload and preserving mitochondrial function. Additionally, downregulation of STIM2 not only inhibited Ca2+ release from the endoplasmic reticulum (ER), but also reduced SOCE-mediated Ca2+ influx, decreased mitochondrial Ca2+, restored mitochondrial morphology and improved mitochondrial function, including MMP maintenance, ROS production and ATP synthesis. These results indicate that inhibition of STIM2 can protect neurons from TEI by inhibiting calcium overload and preserving mitochondrial function. This suggests that STIM2 might be an effective interventional target for TBI. (C) 2015 Elsevier B.V. All rights reserved.	[Rao, Wei; Zhang, Lei; Peng, Cheng; Hui, Hao; Wang, Kai; Su, Ning; Wang, Li; Dai, Shu-hui; Yang, Yue-fan; Chen, Tao; Luo, Peng; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China		Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China.	feizhou@fmmu.edu.cn	Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81430043]; National Science and Technology Major Project of China [2013ZX 09113109-02C]; National Science and Technology Pillar Program of China [2012BAI11B02]; Program for Changjiang Scholars and Innovative Research Team in UniversityProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT-14208]; Key Project of the Twelfth Five-year Plan of Scientific Research of China [AWS11J008]; Science and Technology Project of Shaanxi [2013KTCQ03-01]	We are indebted to the members of our laboratories at the Department of Neurosurgery, Xijing Hospital of the Fourth Military Medical University. The work was funded by the National Natural Science Foundation of China (No. 81430043), the National Science and Technology Major Project of China (2013ZX 09J13109-02C), the National Science and Technology Pillar Program of China (No. 2012BAI11B02), the Program for Changjiang Scholars and Innovative Research Team in University (No. IRT-14208), the Key Project of the Twelfth Five-year Plan of Scientific Research of China (AWS11J008) and the Science and Technology Project of Shaanxi (No. 2013KTCQ03-01).	Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Baba A, 2003, J NEUROSCI, V23, P7737; Bakowski D, 2012, PFLUG ARCH EUR J PHY, V464, P27, DOI 10.1007/s00424-012-1095-x; Berna-Erro A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000522; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Bojarski L, 2009, BBA-MOL CELL RES, V1793, P1050, DOI 10.1016/j.bbamcr.2008.11.008; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Cetin A, 2006, NAT PROTOC, V1, P3166, DOI 10.1038/nprot.2006.450; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Fei F, 2014, NEUROSCIENCE, V267, P187, DOI 10.1016/j.neuroscience.2014.02.037; Gemes G, 2011, J NEUROSCI, V31, P3536, DOI 10.1523/JNEUROSCI.5053-10.2011; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gruszczynska-Biegala J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019285; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hartmann J, 2014, NEURON, V82, P635, DOI 10.1016/j.neuron.2014.03.027; Johnstone LS, 2010, J CELL MOL MED, V14, P1890, DOI 10.1111/j.1582-4934.2010.01097.x; Kawamata H, 2014, J NEUROSCI, V34, P2331, DOI 10.1523/JNEUROSCI.2689-13.2014; Korkotian E, 2014, J NEUROSCI, V34, P11641, DOI 10.1523/JNEUROSCI.0381-14.2014; Laker RC, 2014, J BIOL CHEM, V289, P12005, DOI 10.1074/jbc.M113.530527; Lalonde J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005242; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Li B, 2014, FREE RADICAL RES, V48, P758, DOI 10.3109/10715762.2014.905687; Li Y, 2013, BRAIN RES, V1495, P95, DOI 10.1016/j.brainres.2012.12.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4; Lowery R.L., 2014, JOVE-J VIS EXP, V17, P1; Luo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.116; Luo P, 2012, APOPTOSIS, V17, P975, DOI 10.1007/s10495-012-0736-z; Majewski L, 2015, BBA-MOL CELL RES, V1853, P1940, DOI 10.1016/j.bbamcr.2015.01.019; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mitchell CB, 2012, J NEUROCHEM, V122, P1155, DOI 10.1111/j.1471-4159.2012.07840.x; Moccia F, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00153; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Muller MS, 2014, GLIA, V62, P526, DOI 10.1002/glia.22623; Novgorodov SA, 2014, J BIOL CHEM, V289, P13142, DOI 10.1074/jbc.M113.530311; Quintana A, 2012, CELL CALCIUM, V52, P57, DOI 10.1016/j.ceca.2012.02.005; Rao W, 2013, BIOCHEM BIOPH RES CO, V441, P351, DOI 10.1016/j.bbrc.2013.10.054; Selvaraj S, 2012, J CLIN INVEST, V122, P1354, DOI 10.1172/JCI61332; Singaravelu K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174029; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Skibinska-Kijek A, 2009, ACTA NEUROBIOL EXP, V69, P413; Soboloff J, 2012, NAT REV MOL CELL BIO, V13, P549, DOI 10.1038/nrm3414; Somasundaram A, 2014, J NEUROSCI, V34, P9107, DOI 10.1523/JNEUROSCI.0263-14.2014; Spaethling J, 2012, NEUROBIOL DIS, V46, P646, DOI 10.1016/j.nbd.2012.03.003; Stathopulos PB, 2009, J BIOL CHEM, V284, P728, DOI 10.1074/jbc.C800178200; Steinbeck JA, 2011, EXP NEUROL, V232, P185, DOI 10.1016/j.expneurol.2011.08.022; Sun SY, 2014, NEURON, V82, P79, DOI 10.1016/j.neuron.2014.02.019; Suzuki J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5153; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wang WZ, 2015, J BIOL CHEM, V290, P168, DOI 10.1074/jbc.M114.617167; Wu J, 2011, CHEM BIOL, V18, P777, DOI 10.1016/j.chembiol.2011.04.012; Xia JS, 2014, J PHYSIOL-LONDON, V592, P3443, DOI 10.1113/jphysiol.2014.275065; Zeiger W, 2013, J BIOL CHEM, V288, P26955, DOI 10.1074/jbc.M113.473355; Zhang M, 2014, NEUROREPORT, V25, P507, DOI 10.1097/WNR.0000000000000127; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	59	38	39	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0925-4439	1879-260X		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	NOV	2015	1852	11					2402	2413		10.1016/j.bbadis.2015.08.014			12	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CS5QJ	WOS:000362132700007	26300487	Bronze			2022-02-06	
J	Graves, JM; Rivara, FP; Vavilala, MS				Graves, Janessa M.; Rivara, Frederick P.; Vavilala, Monica S.			Health Care Costs 1 Year After Pediatric Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							ABUSIVE HEAD TRAUMA; UNITED-STATES; OUTCOMES; CHILDREN; ADOLESCENTS; DISABILITY; MORTALITY; MODELS	Objectives. This study sought to estimate total health care costs for mild, moderate, and severe pediatric traumatic brain injury (TBI) and to compare individual- and population-level costs across levels of TBI severity. Methods. Using 2007 to 2010 MarketScan Commercial Claims and Encounters data, we estimated total quarterly health care costs 1 year after TBI among enrollees (aged < 18 years). We compared costs across levels of TBI severity using generalized linear models. Results. Mild TBI accounted for 96.6% of the 319 103 enrollees with TBI; moderate and severe TBI accounted for 1.7% and 1.6%, respectively. Adjusted individual health care costs for moderate and severe TBI were significantly higher than mild TBI in the year after injury (P < .01). At the population level, moderate and severe TBI costs were 88% and 75% less than mild TBI, respectively. Conclusions. Individually, moderate and severe TBI initially generated costs that were markedly higher than those of mild TBI. At the population level, costs following mild TBI far exceeded those of more severe cases, a result of the extremely high population burden of mild TBI.	[Graves, Janessa M.; Rivara, Frederick P.; Vavilala, Monica S.] Harborview Injury & Res Ctr HIPRC, Seattle, WA USA; [Graves, Janessa M.] Washington State Univ Spokane, Coll Nursing, Spokane, WA 99210 USA; [Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA		Graves, JM (corresponding author), Washington State Univ Spokane, Coll Nursing, POB 1495, Spokane, WA 99210 USA.	janessa.graves@wsu.edu	Graves, Janessa M./J-2596-2019	Graves, Janessa M./0000-0002-7659-2634	National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072308-03]; HIPRC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	The study was supported by funding from the National Institute of Neurologic Disorders and Stroke (grant R01 NS072308-03 to M. S. V.) and the HIPRC.	Blough DK, 1999, J HEALTH ECON, V18, P153, DOI 10.1016/S0167-6296(98)00032-0; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; Clark DE., ICDPIC STATA MODULE; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Faul M, 2010, TRAUMATIC BRAIN INJU; Greene NH, 2015, INJ PREV; Hansen LG, HLTH RES DATA REAL W; Hu JH, 2013, J NEUROTRAUM, V30, P1755, DOI 10.1089/neu.2013.2857; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller TR, 2014, PEDIATRICS, V134, pE1545, DOI 10.1542/peds.2014-1385; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Peterson C, 2014, PEDIATRICS, V134, P91, DOI 10.1542/peds.2014-0117; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Sanchez AI, 2012, J HEAD TRAUMA REHAB, V27, P159, DOI 10.1097/HTR.0b013e3182074c41; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Truven Health Analytics, MARKETSCAN STUD ABBR; US Department of Labor, 2011, CONS PRIC IND INFL C	30	38	39	0	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	OCT	2015	105	10					E35	E41		10.2105/AJPH.2015.302744			7	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	CZ9UC	WOS:000367441500013	26270293	Green Published, Green Submitted			2022-02-06	
J	Dean, PJA; Sato, JR; Vieira, G; McNamara, A; Sterr, A				Dean, Philip J. A.; Sato, Joao Ricardo; Vieira, Gilson; McNamara, Adam; Sterr, Annette			Long-term structural changes after mTBI and their relation to post-concussion symptoms	BRAIN INJURY			English	Article						Magnetic resonance imaging; diffusion tensor imaging; cortical thickness; mild traumatic brain injury; persistent post-concussion syndrome	TRAUMATIC BRAIN-INJURY; WHITE-MATTER ABNORMALITIES; VOXEL-BASED MORPHOMETRY; SURFACE-BASED ANALYSIS; DIFFUSE AXONAL INJURY; HUMAN CEREBRAL-CORTEX; HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; UNITED-STATES; MILD	Primary objective: To investigate sustained structural changes in the long-term (>1 year) after mild traumatic brain injury (mTBI) and their relationship to ongoing post-concussion syndrome (PCS). Research design: Morphological and structural connectivity magnetic resonance imaging (MRI) data were acquired from 16 participants with mTBI and nine participants without previous head injury. Main outcomes and results: Participants with mTBI had less prefrontal grey matter and lower fractional anisotropy (FA) in the anterior corona radiata and internal capsule. Furthermore, PCS severity was associated with less parietal lobe grey matter and lower FA in the corpus callosum. Conclusions: There is evidence for both white and grey matter damage in participants with mTBI over 1 year after injury. Furthermore, these structural changes are greater in those that report more PCS symptoms, suggesting a neurophysiological basis for these persistent symptoms.	[Dean, Philip J. A.; McNamara, Adam; Sterr, Annette] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England; [Sato, Joao Ricardo] Univ Fed ABC, Ctr Math Computat & Cognit, Sao Paulo, Brazil; [Sato, Joao Ricardo; Vieira, Gilson] Univ Sao Paulo, Fac Med, Dept Radiol, NIF LIM44, Sao Paulo, Brazil		Dean, PJA (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	p.dean@surrey.ac.uk		Sterr, Annette/0000-0003-4490-985X; Dean, Philip/0000-0002-2362-513X; Sato, Joao Ricardo/0000-0002-7503-9781	Wingate Foundation Scholarship, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200128] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0200128] Funding Source: UKRI	This research was supported by a Wingate Foundation Scholarship, UK.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dean PJA, 2013, NEUROREPORT, V24, P677, DOI 10.1097/WNR.0b013e3283637aa4; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gonzalez PG, 2011, PM&R, V3, pS413, DOI 10.1016/j.pmrj.2011.08.536; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; NCIPC, 2003, REP C MILD TRAUM BRA; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Shen S, 2013, J MAGN RESON IMAGING, V37, P1468, DOI 10.1002/jmri.23927; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Weiss D. S, 2007, CROSS CULTURAL ASSES, P218; World Health Organization, 2004, ICD 10 INT STAT CLAS; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	65	38	39	1	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2015	29	10					1211	1218		10.3109/02699052.2015.1035334			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CR3UK	WOS:000361258400010	26067623				2022-02-06	
J	Gabbatore, I; Sacco, K; Angeleri, R; Zettin, M; Bara, BG; Bosco, FM				Gabbatore, Ilaria; Sacco, Katiuscia; Angeleri, Romina; Zettin, Marina; Bara, Bruno G.; Bosco, Francesca M.			Cognitive Pragmatic Treatment: A Rehabilitative Program for Traumatic Brain Injury Individuals	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive; communication; pragmatics; training; traumatic brain injury	CLOSED-HEAD-INJURY; COMMUNICATION PARTNERS; NARRATIVE LANGUAGE; ADULTS; IMPAIRMENTS; SKILLS; MIND; COMPREHENSION; RECOGNITION; DISCOURSE	Objective: To verify the efficacy of Cognitive Pragmatic Treatment (CPT), a new rehabilitation training program for improving communicative-pragmatic abilities. Design: The CPT program consists of 24 group sessions, concerned with improving several communication modalities, theory of mind (ToM), and cognitive components that can affect pragmatic performance, such as awareness and executive functions. Participants: A sample of 15 adults with severe traumatic brain injury. Main Measures: Improvements were evaluated before and after training, using the equivalent forms of the Assessment Battery for Communication (ABaCo), a tool for evaluating comprehension and production of a wide range of pragmatic phenomena. A neuropsychological and ToM assessment was also conducted. Results: The patients' performance improved after training, in terms of both comprehension and production, in all the communication modalities assessed by the ABaCo, that is, linguistic, extralinguistic, paralinguistic, and social appropriateness abilities. The follow-up showed that the improvement of patients persists after 3 months from the end of the training. Conclusions: The results suggest that the CPT program is efficacious in improving communicative-pragmatic abilities in individuals with TBI, and that improvements at this level are still detectable even in chronic patients years after the injury.	[Gabbatore, Ilaria; Sacco, Katiuscia; Angeleri, Romina; Bara, Bruno G.; Bosco, Francesca M.] Univ & Polytech Turin, Ctr Cognit Sci, Dept Psychol, Via Po 14, I-10123 Turin, Italy; [Sacco, Katiuscia] Koelliker Hosp, Brain Imaging Grp, Turin, Italy; [Bara, Bruno G.; Bosco, Francesca M.] Neurosci Inst Turin, Turin, Italy; [Zettin, Marina] Ctr Puzzle, Turin, Italy; [Angeleri, Romina] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Bosco, FM (corresponding author), Univ & Polytech Turin, Ctr Cognit Sci, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	francesca.bosco@unito.it	Gabbatore, Ilaria/AAC-1925-2019; bosco, francesca marina/B-6746-2013	Gabbatore, Ilaria/0000-0002-9724-8066; bosco, francesca marina/0000-0001-6101-8587	Cassa di Risparmio di Torino, CRT, Vivomeglio Project	This research has been supported by Cassa di Risparmio di Torino, CRT, Vivomeglio Project.	Altman D.G., 1990, PRACTICAL STAT MED R; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; ATEN JL, 1982, J SPEECH HEAR DISORD, V47, P93, DOI 10.1044/jshd.4701.93; Bara B. G., 1998, COGNITION CONTEXT, P317; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara Bruno, 2010, COGNITIVE PRAGMATICS; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM., 2010, PRAGMATICS ENCY, P391; Bosco FM, INT J HLTH IN PRESS; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brownell H, 2013, J HEAD TRAUMA REHAB, V28, P446, DOI 10.1097/HTR.0b013e31825b5e85; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cattelani R., 2006, NEUROPSICOLOGIA SIND; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Cummings L., 2014, PRAGMATIC DISORDERS; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dollaghan CA, 2004, J COMMUN DISORD, V37, P391, DOI 10.1016/j.jcomdis.2004.04.002; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; Ehrlich J. S, 1985, COGNITIVE REHABILITA, P32; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; Evans K, 2011, BRAIN INJURY, V25, P767, DOI 10.3109/02699052.2011.576307; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Galetto V, 2013, J NEUROLINGUIST, V26, P649, DOI 10.1016/j.jneuroling.2013.05.004; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gaudreau G, 2013, NEUROPSYCHOLOGY, V27, P702, DOI 10.1037/a0034655; Gindri Gigiane, 2014, Dement. neuropsychol., V8, P58, DOI 10.1590/S1980-57642014DN81000009; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Holland AL, 1991, J NEUROLINGUISTICS, V6, P197, DOI DOI 10.1016/0911-6044(91)90007-6; Huber W, 1996, AACHENER APHASIE TES; JOANETTE Y, 1990, DISCOURSE ABILITY BR; Johnson JE, 2012, BRAIN INJURY, V26, P1118, DOI 10.3109/02699052.2012.666370; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; Marshall R. C., 1999, INTRO GROUP TREATMEN; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCDONALD S, 1999, COMMUNICATION DISORD; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Raven JC, 1947, COLOURED PROGR MAT S; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Sacco K, 2008, J COGN SCI, V9, P111; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sohlberg M., 2001, COGNITIVE REHABILITA; Spinnler H., 1987, ITALIAN J NEUROLOGIC, V6, P20; Struchen M. A., 2005, REHABILITATION TRAUM, P88; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Tirassa M, 2008, EMERG COMMUN-STUD NE, V10, P81; Togher L, 2013, J REHABIL MED, V45, P637, DOI 10.2340/16501977-1173; Togher L, 2012, DISABIL REHABIL, V34, P1562, DOI 10.3109/09638288.2012.656788; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI [10.1375/brim.7.3.246, DOI 10.1375/BRIM.7.3.246]; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	78	38	38	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					E14	E28		10.1097/HTR.0000000000000087			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400003	25310292				2022-02-06	
J	Gardner, AJ; Iverson, GL; Quinn, TN; Makdissi, M; Levi, CR; Shultz, SR; Wright, DK; Stanwell, P				Gardner, Andrew J.; Iverson, Grant L.; Quinn, Tanya N.; Makdissi, Michael; Levi, Christopher R.; Shultz, Sandy R.; Wright, David K.; Stanwell, Peter			A preliminary video analysis of concussion in the National Rugby League	BRAIN INJURY			English	Article						Athletes; brain concussion; epidemiology; injury surveillance	INCIDENT ANALYSIS; PROFESSIONAL FOOTBALL; INJURY; MATCH; SITUATIONS; NHL	Primary objective: To conduct the first video analysis of concussion in the Australian National Rugby League (NRL) and describe player and injury characteristics, situational factors and time to return to play. Research design: Descriptive, observational case series. Methods and procedures: Video analysis of 20 medically diagnosed concussions for three consenting clubs during the 2013 NRL season. Main outcome and results: Most concussions (83%) occurred during a high tackle, and all injured ball carriers were hit high. Loss of consciousness was observed in 30% of cases. Common observable signs of injury included clutching of the head, balance problems or wobbly legs and a blank or vacant state. There were no post-concussive seizures. All players with loss of consciousness were removed from play. However, only half of the total sample was removed from play and one athlete who was removed returned to play in the same match. Of the players who were removed from play, the large majority returned the following week. Illegal play accounted for 25% of all concussions. Conclusions: Video analysis may be a useful method to study the incidence, mechanism and management of concussion in sports such as Rugby League. Future studies may include larger numbers to validate this preliminary data and may also investigate other levels of play and age ranges.	[Gardner, Andrew J.; Levi, Christopher R.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MGHfC Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Quinn, Tanya N.] Univ Newcastle, Dept Psychol, Callaghan, NSW 2308, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Makdissi, Michael] Federat Univ, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia; [Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Stanwell, Peter] Univ Newcastle, Fac Hlth, Sch Hlth Sci, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia		Gardner, AJ (corresponding author), Calvary Mater Hosp, Ctr Translat Neurosci & Mental Hlth, Level 5,McAuley Bldg, Waratah, NSW 2298, Australia.	andrew.gardner@neurogard.com.au	Gardner, Andrew/J-5162-2013; Stanwell, Peter/F-9136-2012	Stanwell, Peter/0000-0002-4780-0393; Wright, David/0000-0002-7535-8651; Iverson, Grant/0000-0001-7348-9570; Levi, Christopher/0000-0002-9474-796X; Gardner, Andrew/0000-0001-5031-5586; makdissi, michael/0000-0003-0334-7133	New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention Scheme Grant; Brain Foundation, Australia-Brain Injury Award; Hunter Medical Research Institute; Mooney-Reed Charitable Foundation	Andrew J. Gardner, Peter Stanwell and Christopher R. Levi have been funded to conduct research into concussion in rugby league through a New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention Scheme Grant, and a Brain Foundation, Australia-Brain Injury Award. Andrew J. Gardner acknowledges sport concussion research fellowship funding from Jennie Thomas, Life Governor of the Hunter Medical Research Institute. Grant L. Iverson acknowledges sport concussion research funding from the Mooney-Reed Charitable Foundation.	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Gabbett TJ, 2005, J STRENGTH COND RES, V19, P749; Gabbett TJ, 2004, BRIT J SPORT MED, V38, P743, DOI 10.1136/bjsm.2003.008391; Gabbett TJ, 2004, J SPORT SCI, V22, P409, DOI 10.1080/02640410310001641638; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; King DA, 2006, J SCI MED SPORT, V9, P110, DOI 10.1016/j.jsams.2005.09.001; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; Koh JO, 2004, BRAIN INJURY, V18, P1287, DOI 10.1080/02699050410001719907; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Miele VJ, 2007, NEUROSURGERY, V60, P307, DOI 10.1227/01.NEU.0000249247.48299.5B	15	38	39	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2015	29	10					1182	1185		10.3109/02699052.2015.1034179			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CR3UK	WOS:000361258400006	26083052				2022-02-06	
J	Johnstone, VPA; Wright, DK; Wong, K; O'Brien, TJ; Rajan, R; Shultz, SR				Johnstone, Victoria P. A.; Wright, David K.; Wong, Kendrew; O'Brien, Terence J.; Rajan, Ramesh; Shultz, Sandy R.			Experimental Traumatic Brain Injury Results in Long-Term Recovery of Functional Responsiveness in Sensory Cortex but Persisting Structural Changes and Sensorimotor, Cognitive, and Emotional Deficits	JOURNAL OF NEUROTRAUMA			English	Article						DTI; MRI; barrel cortex; tractography; electrophysiology	RAT BARREL CORTEX; FLUID PERCUSSION INJURY; WHISKER VIBRATION; WHITE-MATTER; ANIMAL-MODEL; MILD; NEUROINFLAMMATION; TRACTOGRAPHY; IMPAIRMENTS; BEHAVIOR	Traumatic brain injury (TBI) is a leading cause of death worldwide. In recent studies, we have shown that experimental TBI caused an immediate (24-h post) suppression of neuronal processing, especially in supragranular cortical layers. We now examine the long-term effects of experimental TBI on the sensory cortex and how these changes may contribute to a range of TBI morbidities. Adult male Sprague-Dawley rats received either a moderate lateral fluid percussion injury (n=14) or a sham surgery (n=12) and 12 weeks of recovery before behavioral assessment, magnetic resonance imaging, and electrophysiological recordings from the barrel cortex. TBI rats demonstrated sensorimotor deficits, cognitive impairments, and anxiety-like behavior, and this was associated with significant atrophy of the barrel cortex and other brain structures. Extracellular recordings from ipsilateral barrel cortex revealed normal neuronal responsiveness and diffusion tensor MRI showed increased fractional anisotropy, axial diffusivity, and tract density within this region. These findings suggest that long-term recovery of neuronal responsiveness is owing to structural reorganization within this region. Therefore, it is likely that long-term structural and functional changes within sensory cortex post-TBI may allow for recovery of neuronal responsiveness, but that this recovery does not remediate all behavioral deficits.	[Johnstone, Victoria P. A.; Rajan, Ramesh] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3052, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wong, Kendrew; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Melbourne Brain Ctr, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia		Johnstone, VPA (corresponding author), Univ Western Australia, Sch Anat Physiol & Human Biol, Mailbag M311, Crawley, WA 6009, Australia.	vicky.johnstone@uwa.edu.au; sshultz@unimelb.edu.au	rajan, ramesh/L-4842-2019; Johnstone, Victoria/B-5083-2015; O'Brien, Terence/AAU-5525-2021; O'Brien, Terence/L-8102-2013	Johnstone, Victoria/0000-0001-9885-3607; O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651; Rajan, Ramesh/0000-0001-9862-0520	NHMRCNational Health and Medical Research Council of Australia; Victorian Transport Accident Commission; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR)	The authors acknowledge the facilities as well as the scientific and technical assistance of the National Imaging Facility at the Florey Institute of Neuroscience and Mental Health (Parkville, VIC, Australia). This work was supported by grants to T.O. and S.S. from the NHMRC, the Victorian Transport Accident Commission, the Royal Melbourne Hospital Neuroscience Foundation, and the Canadian Institute of Health Research.	Alwis DS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00124; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Arabzadeh E, 2004, J NEUROSCI, V24, P6011, DOI 10.1523/JNEUROSCI.1389-04.2004; Arabzadeh E, 2003, J NEUROSCI, V23, P9146; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Davis AS, 2010, APPL NEUROPSYCHOL, V17, P104, DOI 10.1080/09084281003708951; Debert CT, 2012, J NEUROL PHYS THER, V36, P58, DOI 10.1097/NPT.0b013e318254bd4f; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Ding GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061241; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Galvin J, 2009, AM J OCCUP THER, V63, P701, DOI 10.5014/ajot.63.6.701; Gao PH, 2001, J NEUROSCI, V21, P5374, DOI 10.1523/JNEUROSCI.21-14-05374.2001; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harrison TC, 2013, STROKE, V44, P2300, DOI 10.1161/STROKEAHA.113.001272; Hartmann MJ, 2003, J NEUROSCI, V23, P6510; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paxinos G, 2007, RAT BRAIN STEREOTAXI, P456; Petersen C. C., 2009, ENCY NEUROSCIENCE, P41; Pinto DJ, 2000, J NEUROPHYSIOL, V83, P1158, DOI 10.1152/jn.2000.83.3.1158; Rajan R, 2007, EUR J NEUROSCI, V25, P2383, DOI 10.1111/j.1460-9568.2007.05481.x; Rajan R, 2006, J NEUROSCI METH, V157, P103, DOI 10.1016/j.jneumeth.2006.04.008; Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yan EB, 2013, NEUROSCIENCE, V248, P17, DOI 10.1016/j.neuroscience.2013.05.045	54	38	39	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1333	1346		10.1089/neu.2014.3785			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500007	25739059				2022-02-06	
J	Taylor, AM; Nigrovic, LE; Saillant, ML; Trudell, EK; Proctor, MR; Modest, JR; Vernacchio, L				Taylor, Alex M.; Nigrovic, Lise E.; Saillant, Meredith L.; Trudell, Emily K.; Proctor, Mark R.; Modest, Jonathan R.; Vernacchio, Louis			Trends in Ambulatory Care for Children with Concussion and Minor Head Injury from Eastern Massachusetts between 2007 and 2013	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; EMERGENCY-DEPARTMENTS; MANAGEMENT; SPORT; EPIDEMIOLOGY; VISITS; IMPACT; KNOWLEDGE; PATIENT	Objective To characterize trends in health care utilization and costs for children diagnosed with concussion or minor head injury within a large pediatric primary-care association. Study design We conducted a retrospective cohort analysis from 2007 through 2013 examining all outpatient medical claims related to concussion and minor head injury from 4 commercial insurance companies for children 6-21 years of age who were patients within a large pediatric independent practice association located throughout eastern Massachusetts. Results Health care visits for concussion and minor head injury increased more than 4-fold during the study period, with primary-care and specialty clinics experiencing the greatest increases in the rate of visits while emergency department visits increased comparatively less. These increases were accounted for by both the proportion of children diagnosed with concussion or minor head injury (1.3% of all children in 2007 vs 3.3% in 2013) and the number of encounters per diagnosed patient (1.0 encounters per patient in 2007 vs 1.7 in 2013). Although the overall population costs devoted to care for concussion or minor head injury increased 34%, the cost per individual diagnosed child decreased 31%. Conclusions Over the past 7 years, health care encounters for children diagnosed with concussion or minor head injury increased substantially in eastern Massachusetts. Care for these injuries increasingly shifted from the emergency department to primary-care and specialty providers.	[Taylor, Alex M.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Taylor, Alex M.] Boston Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Saillant, Meredith L.; Trudell, Emily K.; Modest, Jonathan R.; Vernacchio, Louis] Pediat Phys Org Childrens, Boston, MA USA; [Proctor, Mark R.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Vernacchio, Louis] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA		Taylor, AM (corresponding author), Boston Childrens Hosp, Dept Neurol, BCH 3124,300 Longwood Ave, Boston, MA 02115 USA.	alex.taylor@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997; Correa, Emily/0000-0003-1985-405X; Vernacchio, Louis/0000-0002-2012-5404	Provider-Payor Quality Initiative at Boston Children's Hospital [76315]	Supported in part by the Provider-Payor Quality Initiative at Boston Children's Hospital (76315). The authors declare no conflicts of interest.	[Anonymous], 2013, IRW BROH RES SPORTS; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Carl RL, 2014, CLIN PEDIATR, V53, P689, DOI 10.1177/0009922814526979; Centers for Disease Control and Prevention, HEADS UP; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Forrest CB, 2006, MED DECIS MAKING, V26, P76, DOI 10.1177/0272989X05284110; Gerberding JLBS, 2003, REP C MILD TRAUM BRA; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hotz RL, 2013, WALL ST J; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P1; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LeBlanc CMA, 2000, PEDIATRICS, V106, P1524, DOI 10.1542/peds.106.6.1524; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mackenzie B, 2015, PEDIATR EMERG CARE, V31, P25, DOI 10.1097/PEC.0000000000000325; Macur Juliet, 2014, NY TIMES; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Massachusetts Department of Public Health, 2010, HEAD INJ CONC EXTR A; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; National federation of state high school associations, 2013, NFHS HDB, V2013-14; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Ray KN, 2014, PEDIATRICS, V133, P1061, DOI 10.1542/peds.2013-3466; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; U.S. Department of Labor Bureau of Labor Statistics, CONS PRIC IND; Wilkins SA, 2014, J NEUROSURG-PEDIATR, V13, P82, DOI 10.3171/2013.10.PEDS13241; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	38	38	38	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	SEP	2015	167	3					738	744		10.1016/j.jpeds.2015.05.036			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CU4ZI	WOS:000363540200047	26116471				2022-02-06	
J	Allison, MA; Kang, YS; Maltese, MR; Bolte, JH; Arbogast, KB				Allison, Mari A.; Kang, Yun Seok; Maltese, Matthew R.; Bolte, John H.; Arbogast, Kristy B.			Measurement of Hybrid III Head Impact Kinematics Using an Accelerometer and Gyroscope System in Ice Hockey Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						mTBI; Concussion; Head injury; Head acceleration; Head impact biomechanics; Impact monitoring; Helmet sensors	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURIES; BIOMECHANICS; MILD; VALIDATION	Helmet-based instrumentation is used to study the biomechanics of concussion. The most extensively used systems estimate rotational acceleration from linear acceleration, but new instrumentation measures rotational velocity using gyroscopes, potentially reducing error. This study compared kinematics from an accelerometer and gyroscope-containing system to reference measures. A Hybrid III (HIII) adult male anthropometric test device head and neck was fit with two helmet brands, each instrumented with gForce Tracker (GFT) sensor systems in four locations. Helmets were impacted at various speeds and directions. Regression relationships between GFT-measured and reference peak kinematics were quantified, and influence of impact direction, sensor location, and helmet brand was evaluated. The relationship between the sensor output and the reference acceleration/velocity experienced by the head was strong. Coefficients of determination for data stratified by individual impact directions ranged from 0.77 to 0.99 for peak linear acceleration and from 0.78 to 1.0 for peak rotational velocity. For the data from all impact directions combined, coefficients of determination ranged from 0.60 to 0.80 for peak resultant linear acceleration and 0.83 to 0.91 for peak resultant rotational velocity. As expected, raw peak resultant linear acceleration measures exhibited large percent differences from reference measures. Adjustment using regressions resulted in average absolute errors of 10-15% if regression adjustments were done by impact direction or 25-40% if regressions incorporating data from all impact directions were used. Average absolute percent differences in raw peak resultant rotational velocity were much lower, around 10-15%. It is important to define system accuracy for a particular helmet brand, sensor location, and impact direction in order to interpret real-world data.	[Allison, Mari A.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Allison, Mari A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Kang, Yun Seok; Bolte, John H.] Ohio State Univ, Injury Biomech Res Ctr, Columbus, OH 43210 USA; [Maltese, Matthew R.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Maltese, Matthew R.; Arbogast, Kristy B.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA		Arbogast, KB (corresponding author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market St Suite 1150, Philadelphia, PA 19104 USA.	maall@seas.upenn.edu; arbogast@email.chop.edu	Bolte, John/AAK-9695-2021	Arbogast, Kristy/0000-0002-1694-4562; Bolte, John/0000-0001-9894-4998	National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); Fundamental Research Supplement, the Center for Child Injury Prevention Studies; National Highway Traffic Safety Administration; Toyota Collaborative Safety Research Center; SAFER Vehicle and Traffic Safety Centre	This study was supported by a National Science Foundation Graduate Research Fellowship and Fundamental Research Supplement, the Center for Child Injury Prevention Studies, particularly the National Highway Traffic Safety Administration and Toyota Collaborative Safety Research Center, and the SAFER Vehicle and Traffic Safety Centre. The sensors were provided free of charge by GForceTracker Inc and there is no financial relationship between the authors, Children's Hospital of Philadelphia, and GForceTracker Inc. Dr. Arbogast serves as a consultant for the National Football League Players Association (NFLPA) on head injury biomechanics topics unrelated to this manuscript.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; National Center for Injury Prevention and Control (U.S.), 2003, REP C MILD TRAUM BRA, P26; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L.E., 1972, SAE TECHNICAL PAPER, P720970, DOI [10.4271/720970, DOI 10.4271/720970]; USA Hockey, EQ SIZ GUID	28	38	38	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	AUG	2015	43	8					1896	1906		10.1007/s10439-014-1197-z			11	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	CN2KM	WOS:000358249800016	25476162				2022-02-06	
J	Elliott, TR; Hsiao, YY; Kimbrel, NA; Meyer, EC; DeBeer, BB; Gulliver, SB; Kwok, OM; Morissette, SB				Elliott, Timothy R.; Hsiao, Yu-Yu; Kimbrel, Nathan A.; Meyer, Eric C.; DeBeer, Bryann B.; Gulliver, Suzy Bird; Kwok, Oi-Man; Morissette, Sandra B.			Resilience, Traumatic Brain Injury, Depression, and Posttraumatic Stress Among Iraq/Afghanistan War Veterans	REHABILITATION PSYCHOLOGY			English	Article						resilience; PTSD; depression; combat exposure; traumatic brain injury	ACTION QUESTIONNAIRE-II; MENTAL-HEALTH PROBLEMS; POSITIVE EMOTIONS; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL RESILIENCE; EXPERIENTIAL AVOIDANCE; DEPLOYMENT RISK; SERVICE MEMBERS; PTSD CHECKLIST; SOCIAL SUPPORT	Objective: We examined the prospective influence of the resilient, undercontrolled, and overcontrolled personality prototypes on depression and posttraumatic stress disorder (PTSD) symptoms among Iraq/Afghanistan war veterans. After accounting for the possible influence of combat exposure, we expected that the resilient prototype would predict lower depression and PTSD over time and would be associated with adaptive coping strategies, higher social support, lower psychological inflexibility, and higher self-reported resilience relative to overcontrolled and undercontrolled prototypes, independent of traumatic brain injury (TBI) status. Method: One hundred twenty-seven veterans (107 men, 20 women; average age = 37) participated in the study. Personality was assessed at baseline, and PTSD and depression symptoms were assessed 8 months later. Path analysis was used to test the direct and indirect effects of personality on distress. Results: No direct effects were observed from personality to distress. The resilient prototype did have significant indirect effects on PTSD and depression through its beneficial effects on social support, coping and psychological inflexibility. TBI also had direct effects on PTSD. Conclusions: A resilient personality prototype appears to influence veteran adjustment through its positive associations with greater social support and psychological flexibility, and lower use of avoidant coping. Low social support, avoidant coping, and psychological inflexibility are related to overcontrolled and undercontrolled personality prototypes, and these behaviors seem to characterize veterans who experience problems with depression and PTSD over time. A positive TBI status is directly and prospectively associated with PTSD symptomology independent of personality prototype. Implications for clinical interventions and future research are discussed.	[Elliott, Timothy R.; Hsiao, Yu-Yu; Kwok, Oi-Man] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA; [Kimbrel, Nathan A.] Durham Vet Affairs Med Ctr, Durham, NC USA; [Kimbrel, Nathan A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA; [Meyer, Eric C.; DeBeer, Bryann B.; Morissette, Sandra B.] Cent Texas Vet HealthCare Syst, VA VISN Ctr Excellence Res Returning War Vet 17, Waco, TX USA; [Meyer, Eric C.; DeBeer, Bryann B.; Gulliver, Suzy Bird; Morissette, Sandra B.] Texas A&M Univ, Coll Med, Dept Psychiat, College Stn, TX 77843 USA; [Gulliver, Suzy Bird] Baylor Scott & White Hlth, Warriors Res Inst, Waco, TX USA		Elliott, TR (corresponding author), Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA.	telliott@tamu.edu	Gulliver, Suzy/X-9776-2019; Elliott, Timothy R./I-5301-2012; Kimbrel, Nathan/P-3109-2016	Elliott, Timothy R./0000-0002-6608-7714; Kimbrel, Nathan/0000-0001-7218-1005; Gulliver, Suzy Bird/0000-0002-6476-9447; Kwok, Oiman/0000-0002-4617-4562	Veterans Health AdministrationUS Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01RX000304, IK2CX000525] Funding Source: NIH RePORTER	This work was completed with support from the Veterans Health Administration. The views are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	Armed Forces Health Surveillance Center, 2011, DOD NUMB TRAUM BRAIN; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Berking M, 2009, BEHAV RES THER, V47, P663, DOI 10.1016/j.brat.2009.04.011; Berry JW, 2007, J PERS ASSESS, V89, P292, DOI 10.1080/00223890701629813; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Blashfield R.K., 1984, CLUSTER ANAL; Block J., 1993, STUDYING LIVES TIME, P9, DOI DOI 10.1037/10127-018; Block J. H., 1980, DEV COGNITION AFFECT, V13, P39; Bonanno GA, 2005, CURR DIR PSYCHOL SCI, V14, P135, DOI 10.1111/j.0963-7214.2005.00347.x; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brown M.W., 1993, SOCIOL METHOD RES, P136; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; CASPI A, 1995, CHILD DEV, V66, P486, DOI 10.2307/1131592; Chapman BP, 2011, J PERS SOC PSYCHOL, V101, P593, DOI 10.1037/a0024289; Clarke G N, 2000, Ment Health Serv Res, V2, P155, DOI 10.1023/A:1010141826867; Cohn MA, 2009, EMOTION, V9, P361, DOI 10.1037/a0015952; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Craig T, 2004, J MENT HEALTH, V13, P59, DOI DOI 10.1080/09638230410001654567; Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI 10.1016/j.psychres.2014.02.010; Denissen JJA, 2008, J PERS, V76, P67, DOI 10.1111/j.1467-6494.2007.00480.x; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Fletcher D, 2013, EUR PSYCHOL, V18, P12, DOI 10.1027/1016-9040/a000124; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Fredrickson BL, 2008, J PERS SOC PSYCHOL, V95, P1045, DOI 10.1037/a0013262; Fredrickson BL, 2013, ADV EXP SOC PSYCHOL, V47, P1, DOI 10.1016/B978-0-12-407236-7.00001-2; Fredrickson BL, 2003, J PERS SOC PSYCHOL, V84, P365, DOI 10.1037/0022-3514.84.2.365; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Grosso JA, 2014, J TRAUMA STRESS, V27, P478, DOI 10.1002/jts.21943; Hayes SA, 2010, BEHAV RES THER, V48, P238, DOI 10.1016/j.brat.2009.11.006; Hayes SC, 2004, PSYCHOL REC, V54, P553, DOI 10.1007/BF03395492; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holahan CJ, 2005, J CONSULT CLIN PSYCH, V73, P658, DOI 10.1037/0022-006X.73.4.658; Hoyt WT, 2008, REHABIL PSYCHOL, V53, P321, DOI 10.1037/a0013021; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kok BE, 2013, PSYCHOL SCI, V24, P1123, DOI 10.1177/0956797612470827; Kok BE, 2010, BIOL PSYCHOL, V85, P432, DOI 10.1016/j.biopsycho.2010.09.005; Kumpula MJ, 2011, J ABNORM PSYCHOL, V120, P617, DOI 10.1037/a0023927; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Letzring TD, 2005, J RES PERS, V39, P395, DOI 10.1016/j.jrp.2004.06.003; Liverant GI, 2012, J CONSULT CLIN PSYCH, V80, P957, DOI 10.1037/a0030485; Mancini AD., 2010, HDB ADULT RESILIENCE, P258; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Meyer EC, 2013, PSYCHOL TRAUMA-US, V5, P521, DOI 10.1037/a0030178; Miller M.W., 2011, RESILIENCE MENTAL HL, P56; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; Min SY, 2007, PSYCHIATR REHABIL J, V30, P207, DOI 10.2975/30.3.2007.207.213; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; Ong AD, 2010, PSYCHOL AGING, V25, P516, DOI 10.1037/a0019384; Ong AD, 2009, J PERS, V77, P1777, DOI 10.1111/j.1467-6494.2009.00600.x; Patrick CJ, 2002, PSYCHOL ASSESSMENT, V14, P150, DOI 10.1037//1040-3590.14.2.150; Pietrzak RH, 2011, J PSYCHIATR RES, V45, P720, DOI 10.1016/j.jpsychires.2010.11.015; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Saklofske D.H., 2008, SAGE HDB PERSONALITY, V2, P261, DOI DOI 10.4135/9781849200479.N13; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharma S., 1996, APPL MULTIVARIATE TE; Shiner RL, 2003, J PERS, V71, P1145, DOI 10.1111/1467-6494.7106010; Steca P, 2010, PERS INDIV DIFFER, V48, P442, DOI 10.1016/j.paid.2009.11.016; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tsai J, 2012, PSYCHIATRY, V75, P135, DOI 10.1521/psyc.2012.75.2.135; Vasterling J. J., 2012, PTSD MILD TRAUMATIC, P3; Vasterling JJ, 2012, J INT NEUROPSYCH SOC, V18, P390, DOI 10.1017/S1355617712000367; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Walser RD, 2013, BEHAV RES THER, V51, P555, DOI 10.1016/j.brat.2013.05.009; Weathers F.W., 1993, ANN CONV INT SOC TRA; Windle G, 2012, SOCIAL ECOLOGY OF RESILIENCE: A HANDBOOK OF THEORY AND PRACTICE, P219, DOI 10.1007/978-1-4614-0586-3_18; Windle G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-8; Wolf EJ, 2012, J ABNORM PSYCHOL, V121, P256, DOI 10.1037/a0023237; Yu C-Y, 2002, EVALUATING CUTOFF CR	83	38	40	1	40	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2015	60	3					263	276		10.1037/rep0000050			14	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	CR0UB	WOS:000361037600007	26214528	Green Accepted			2022-02-06	
J	Lukow, HR; Godwin, EE; Marwitz, JH; Mills, A; Hsu, NH; Kreutzer, JS				Lukow, Herman R.; Godwin, Emilie E.; Marwitz, Jennifer H.; Mills, Ana; Hsu, Nancy H.; Kreutzer, Jeffrey S.			Relationship Between Resilience, Adjustment, and Psychological Functioning After Traumatic Brain Injury: A Preliminary Report	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CONNOR-DAVIDSON RESILIENCE; EMOTIONAL ADJUSTMENT; POSITIVE EMOTIONS; SELF-AWARENESS; REHABILITATION; INTERVENTION; DEPRESSION; STRESS; SKILLS; SCALE	Objective: To examine the relationship between resilience, psychological distress, adjustment, and community participation after traumatic brain injury (TBI). Setting: Large university health system. Participants: Adult survivors of mild to severe TBI (N = 96). Design: Descriptive, preliminary. Main Measures: The Connor-Davidson Resilience Scale (10-item version) was used to assess resilience, the Brief Symptom Inventory (BSI-18) was used to characterize psychological distress, and the Mayo-Portland Adaptability Index (MPAI-4) was used to measure ability, adjustment, and participation. Results: Resilience scores were substantially lower than those of the general population. Significant relationships were found between resilience, psychological distress, and adjustment. Partial correlations (adjusting for the other MPAI-4 indices) showed significant correlation (P < .05) between MPAI-4 Adjustment and resilience. Partial correlations (adjusting for the other BSI-18 scales) also showed significance for Depression (P < .01) and resilience. Resilience scores differed significantly (P < .001) between individuals meeting BSI-18 caseness criteria for psychological distress (n = 55) and those not meeting criteria (n = 41). Conclusions: Individuals with TBI are at risk for low resilience, which was found to correlate with psychological distress and psychosocial maladjustment. Developing interventions to strengthen resilience skills has the potential to improve postinjury psychosocial adjustment, an important area for future research.	[Lukow, Herman R.; Godwin, Emilie E.; Marwitz, Jennifer H.; Mills, Ana; Hsu, Nancy H.; Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA		Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1200 E Broad St,Rm 3-109,Box 980542, Richmond, VA 23298 USA.	jhmarwit@vcu.edu			National Institute on Disability and Rehabilitation Research (NIDRR) of the US Department of Education [H133A120031, H133P090013]	Supported by grants H133A120031 and H133P090013 from the National Institute on Disability and Rehabilitation Research (NIDRR) of the US Department of Education.	[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Baum N. L., 2005, The trauma of terrorism: sharing knowledge and shared care, an international handbook, P487, DOI 10.1300/J146v10n01_08; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzies K, 2009, CHILD FAM SOC WORK, V14, P103, DOI 10.1111/j.1365-2206.2008.00586.x; Bertisch H, 2014, NEUROREHABILITATION, V34, P573, DOI 10.3233/NRE-141059; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bonanno GA, 2011, ANNU REV CLIN PSYCHO, V7, P511, DOI 10.1146/annurev-clinpsy-032210-104526; Brody D, 2007, CURRICULUM INQ, V37, P9, DOI 10.1111/j.1467-873X.2007.00379.x; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Campbell-Sills L, 2007, J TRAUMA STRESS, V20, P1019, DOI 10.1002/jts.20271; Campbell-Sills L, 2009, J PSYCHIATR RES, V43, P1007, DOI 10.1016/j.jpsychires.2009.01.013; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Cohen MS., 1999, FAM SYST HEALTH, V17, P149, DOI DOI 10.1037/H0089879; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Curtis WJ, 2003, DEV PSYCHOPATHOL, V15, P773, DOI 10.1017/S0954579403000373; Davidson JRT, 2005, INT CLIN PSYCHOPHARM, V20, P43, DOI 10.1097/00004850-200501000-00009; Davidson JRT, CD RISC CONNORDAVIDS; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Dodd Z, 2010, THESIS U N TEXAS DEN; Dowrick C, 2008, HEALTH-LONDON, V12, P439, DOI 10.1177/1363459308094419; Edward K, 2005, J AM PSYCHIAT NURSES, V11, P101; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Friborg O, 2005, PSYCHOL REP, V97, P77; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Godwin EE, 2013, BRAIN INJURY, V27, P637, DOI 10.3109/02699052.2012.750745; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hawley DR, 2000, AM J FAM THER, V28, P101, DOI 10.1080/019261800261699; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hoofien D, 2001, BRAIN INJURY, V15, P189; Iwaniec D., 2006, CHILD FAMILY SOCIAL, V11, P73, DOI [10.1111/j.1365-2206.2006.00398.x, DOI 10.1111/J.1365-2206.2006.00398.X]; Karoly P, 2006, PAIN, V123, P90, DOI 10.1016/j.pain.2006.02.014; Kralik D, 2006, EDUC ACTION RES, V14, P187, DOI 10.1080/09650790600718035; Kreutzer JS, 2010, J HEAD TRAUMA REHAB, V25, P113, DOI 10.1097/HTR.0b013e3181cf0712; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; 김원형, 2010, [JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION, 신경정신의학], V49, P611; Linley P.A, 2008, TRAUMA RECOVERY GROW; Luthar SS, 2000, DEV PSYCHOPATHOL, V12, P857, DOI 10.1017/S0954579400004156; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, 2008, MAYO PORTLAND ADAPTA; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGlone J, 2009, 63 ANN M AM EP SOC O; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; Ong AD, 2006, J PERS SOC PSYCHOL, V91, P730, DOI 10.1037/0022-3514.91.4.730; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rajkumar AP, 2008, SOC SCI MED, V67, P844, DOI 10.1016/j.socscimed.2008.05.014; Ramanathan DM, 2011, BRAIN INJURY, V25, P328, DOI 10.3109/02699052.2011.554336; Reeves RR, 2012, J PSYCHOSOC NURS MEN, V50, P32, DOI 10.3928/02793695-20120207-02; Richardson GE, 2002, J CLIN PSYCHOL, V58, P307, DOI 10.1002/jclp.10020; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Steinhardt MA, 2009, DIABETES EDUCATOR, V35, P274, DOI 10.1177/0145721708329698; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tedeschi RG, 2005, PROF PSYCHOL-RES PR, V36, P230, DOI 10.1037/0735-7028.36.3.230; Tegner I, 2009, J POETRY THER, V22, P121, DOI 10.1080/08893670903198383; Tugade MM, 2004, J PERS SOC PSYCHOL, V86, P320, DOI 10.1037/0022-3514.86.2.320; Vanderbilt-Adriance E, 2008, CLIN CHILD FAM PSYCH, V11, P30, DOI 10.1007/s10567-008-0031-2; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; White B, 2010, REHABIL PSYCHOL, V55, P23, DOI 10.1037/a0018451; Woodgate R L, 1999, J Pediatr Oncol Nurs, V16, P78, DOI 10.1177/104345429901600206; Yang CC, 2012, BRAIN INJURY, P1; Yi JP, 2008, BRIT J HEALTH PSYCH, V13, P311, DOI 10.1348/135910707X186994	75	38	40	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					241	248		10.1097/HTR.0000000000000137			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CM8JA	WOS:000357944700002	25931185				2022-02-06	
J	Lopez-Rodriguez, AB; Acaz-Fonseca, E; Viveros, MP; Garcia-Segura, LM				Lopez-Rodriguez, Ana Belen; Acaz-Fonseca, Estefania; Viveros, Maria-Paz; Garcia-Segura, Luis M.			Changes in Cannabinoid Receptors, Aquaporin 4 and Vimentin Expression after Traumatic Brain Injury in Adolescent Male Mice. Association with Edema and Neurological Deficit	PLOS ONE			English	Article							CLOSED-HEAD INJURY; MESSENGER-RNA EXPRESSION; CEREBRAL EDEMA; ENDOCANNABINOID SYSTEM; BARRIER PERMEABILITY; TEMPORAL PROFILE; D-AMPHETAMINE; UP-REGULATION; MURINE MODEL; ASTROCYTES	Traumatic brain injury (TBI) incidence rises during adolescence because during this critical neurodevelopmental period some risky behaviors increase. The purpose of this study was to assess the contribution of cannabinoid receptors (CB1 and CB2), blood brain barrier proteins (AQP4) and astrogliosis markers (vimentin) to neurological deficit and brain edema formation in a TBI weight drop model in adolescent male mice. These molecules were selected since they are known to change shortly after lesion. Here we extended their study in three different timepoints after TBI, including short (24h), early mid-term (72h) and late midterm (two weeks). Our results showed that TBI induced an increase in brain edema up to 72 h after lesion that was directly associated with neurological deficit. Neurological deficit appeared 24 h after TBI and was completely recovered two weeks after trauma. CB1 receptor expression decreased after TBI and was negatively correlated with edema formation and behavioral impairments. CB2 receptor increased after injury and was associated with high neurological deficit whereas no correlation with edema was found. AQP4 increased after TBI and was positively correlated with edema and neurological impairments as occurred with vimentin expression in the same manner. The results suggest that CB1 and CB2 differ in the mechanisms to resolve TBI and also that some of their neuroprotective effects related to the control of reactive astrogliosis may be due to the regulation of AQP4 expression on the end-feet of astrocytes.	[Lopez-Rodriguez, Ana Belen; Acaz-Fonseca, Estefania; Garcia-Segura, Luis M.] Univ Complutense Madrid, Fac Biol, Dept Anim Physiol 2, Madrid, Spain; [Lopez-Rodriguez, Ana Belen; Viveros, Maria-Paz] CSIC, Inst Cajal, E-28002 Madrid, Spain		Lopez-Rodriguez, AB (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Anim Physiol 2, Madrid, Spain.	lranabelen@gmail.com	Lopez-Rodriguez, Ana Belen/H-3631-2017; Acaz-Fonseca, Estefania/S-5884-2016; Garcia-Segura, Luis M/U-3711-2017; Viveros, Maria-Paz/S-6855-2016	Lopez-Rodriguez, Ana Belen/0000-0002-0747-7966; Acaz-Fonseca, Estefania/0000-0003-2549-6420; Garcia-Segura, Luis M/0000-0002-2450-2916; Viveros, Maria-Paz/0000-0002-4119-4636	Ministerio de Economia y Competitividad, Spain [BFU2011-30217-C03-01, BFU2012-38144]; Instituto de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en Salud, Red de Trastornos Adictivos [RD2012/0028/0021]; GRUPO UCM [951579]	Support was provided by the Ministerio de Economia y Competitividad, Spain (BFU2011-30217-C03-01 and BFU2012-38144), Instituto de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en Salud, Red de Trastornos Adictivos (RD2012/0028/0021) and GRUPO UCM (951579). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 1998, ACT NEUR S, V71, P104; Adriani W, 2004, NEUROPSYCHOPHARMACOL, V29, P869, DOI 10.1038/sj.npp.1300366; Adriani W, 2003, BEHAV NEUROSCI, V117, P695, DOI 10.1037/0735-7044.117.4.695; Adriani W, 1998, BEHAV NEUROSCI, V112, P1152, DOI 10.1037/0735-7044.112.5.1152; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bardutzky J, 2007, STROKE, V38, P3084, DOI 10.1161/STROKEAHA.107.490193; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Garcia-Gutierrez MS, 2013, NEUROPHARMACOLOGY, V73, P388, DOI 10.1016/j.neuropharm.2013.05.034; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Iring A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053390; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; KENT S, 1992, TRENDS PHARMACOL SCI, V13, P24, DOI 10.1016/0165-6147(92)90012-U; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; KOLB B, 1986, BRAIN RES, V397, P315, DOI 10.1016/0006-8993(86)90633-5; Kreiter KT, 2002, STROKE, V33, P200, DOI 10.1161/hs0102.101080; Larson SJ, 2001, BRAIN BEHAV IMMUN, V15, P371, DOI 10.1006/brbi.2001.0643; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Litvin Y, 2013, GENES BRAIN BEHAV, V12, P479, DOI 10.1111/gbb.12045; De Jesus ML, 2010, NEUROCHEM INT, V56, P829, DOI 10.1016/j.neuint.2010.03.007; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Marco EM, 2009, MINI-REV MED CHEM, V9, P1407, DOI 10.2174/138955709789957468; Marmarou A, 2003, ACT NEUR S, V86, P7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McCarron RM, 2006, J PHYSIOL PHARMACOL, V57, P133; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Onaivi ES, 2011, CURR NEUROPHARMACOL, V9, P205, DOI 10.2174/157015911795017416; Palazuelos J, 2006, FASEB J, V20, P2405, DOI 10.1096/fj.06-6164fje; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pekny M, 2007, INT REV NEUROBIOL, V82, P95, DOI 10.1016/S0074-7742(07)82005-8; Potokar M, 2013, GLIA, V61, P917, DOI 10.1002/glia.22485; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rodriguez JJ, 2001, J NEUROSCI, V21, P823, DOI 10.1523/JNEUROSCI.21-03-00823.2001; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Straiker A, 2006, AAPS J, V8, pE272; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Viveros MP, 2012, J PSYCHOPHARMACOL, V26, P164, DOI 10.1177/0269881111408956; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022	71	38	45	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2015	10	6							e0128782	10.1371/journal.pone.0128782			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7ST	WOS:000355700700120	26039099	Green Published, Green Submitted, gold			2022-02-06	
J	Tham, SW; Fales, J; Palermo, TM				Tham, See Wan; Fales, Jessica; Palermo, Tonya M.			Subjective and Objective Assessment of Sleep in Adolescents with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						actigraphy; adolescents; pain; sleep; traumatic brain injury	SCHOOL-AGE-CHILDREN; MINOR HEAD-INJURY; CHRONIC PAIN; LONGITUDINAL COURSE; WAKE DISTURBANCES; RISK-FACTORS; CES-D; INSOMNIA; IMPACT; DEPRESSION	There is increased recognition that sleep problems may develop in children and adolescents after mild traumatic brain injury (mTBI). However, few studies have utilized both subjective and objective measures to comprehensively assess sleep problems in the pediatric population following the acute post-TBI period. The aims of this study were to compare sleep in adolescents with mTBI to healthy adolescents using subjective and objective measures, and to identify the clinical correlates associated with sleep problems. One hundred adolescents (50 adolescents with mTBI recruited from three to twelve months post-injury and 50 healthy adolescents) completed questionnaires assessing sleep quality, depression, and pain symptoms, and underwent 10 day actigraphic assessment of sleep patterns. Adolescents with mTBI reported poorer sleep quality and demonstrated significantly shorter actigraphic-measured sleep duration, poorer sleep efficiency, and more wake time after onset of sleep, compared with healthy adolescents (all, p<0.05). For both groups of adolescents, poorer self-reported sleep quality was predicted by greater depressive symptoms. Poorer actigraphic sleep efficiency was predicted by membership in the mTBI group after controlling for age, sex, depressive symptoms, and presence of pain. Our findings suggest that adolescents may experience subjective and objective sleep disturbances up to one year following mTBI. These findings require further replication in larger samples. Additionally, research is needed to identify possible mechanisms for poor sleep in youth with mTBI.	[Tham, See Wan; Palermo, Tonya M.] Univ Washington, Sch Med, Seattle, WA USA; [Tham, See Wan; Fales, Jessica; Palermo, Tonya M.] Seattle Childrens Res Inst, Seattle, WA USA; [Fales, Jessica] Washington State Univ Vancouver, Vancouver, WA USA		Tham, SW (corresponding author), M-S CW8-6,POB 5371, Seattle, WA 98145 USA.	see.tham@seattlechildrens.org			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24 HD060068] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32GM086270-03] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30 NR 011400] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD060068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30NR011400] Funding Source: NIH RePORTER		Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carskadon MA, 1998, SLEEP, V21, P871, DOI 10.1093/sleep/21.8.871; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; Dierker LC, 2001, J AM ACAD CHILD PSY, V40, P929, DOI 10.1097/00004583-200108000-00015; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fallone G, 2002, SLEEP MED REV, V6, P287, DOI 10.1053/smrv.2001.0192; Faul M, 2010, TRAUMATIC BRAIN INJU; GARRISON CZ, 1991, J AM ACAD CHILD PSY, V30, P636, DOI 10.1097/00004583-199107000-00017; Gregory AM, 2008, SLEEP, V31, P1745, DOI 10.1093/sleep/31.12.1745; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Iglowstein I, 2003, PEDIATRICS, V111, P302, DOI 10.1542/peds.111.2.302; Johnson NL, 2007, SLEEP, V30, P899, DOI 10.1093/sleep/30.7.899; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LeBourgeois MK, 2005, PEDIATRICS, V115, P257, DOI 10.1542/peds.2004-0815H; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; MORRISON DN, 1992, J AM ACAD CHILD PSY, V31, P94, DOI 10.1097/00004583-199201000-00014; Murray CB, 2012, J CLIN CHILD ADOLESC, V41, P482, DOI 10.1080/15374416.2012.658613; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Owens JA, 2005, SLEEP MED, V6, P63, DOI 10.1016/j.sleep.2004.07.015; Palermo TM, 2005, J PAIN, V6, P201, DOI 10.1016/j.jpain.2004.12.005; Palermo TM, 2004, PAIN, V109, P461, DOI 10.1016/j.pain.2004.02.023; Palermo TM, 2012, J PAIN, V13, P1099, DOI 10.1016/j.jpain.2012.08.003; Palermo TM, 2011, PAIN, V152, P89, DOI 10.1016/j.pain.2010.09.035; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Roberts RE, 2002, J PSYCHOSOM RES, V53, P561, DOI 10.1016/S0022-3999(02)00446-4; ROBERTS RE, 1990, PSYCHIAT RES, V31, P69, DOI 10.1016/0165-1781(90)90110-Q; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Sadeh A, 2000, DEV PSYCHOL, V36, P291, DOI 10.1037/0012-1649.36.3.291; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; von Baeyer CL, 2009, EUR J PAIN, V13, P1005, DOI 10.1016/j.ejpain.2009.08.006; WEBSTER JB, 1982, SLEEP, V5, P389, DOI 10.1093/sleep/5.4.389; Wiggins KL, 2009, J THROMB HAEMOST, V7, P263, DOI 10.1111/j.1538-7836.2008.03243.x; Wolfson AR, 1998, CHILD DEV, V69, P875, DOI 10.2307/1132351	40	38	38	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					847	852		10.1089/neu.2014.3559			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700010	25707446	Green Published			2022-02-06	
J	Phelps, TI; Bondi, CO; Ahmed, RH; Olugbade, YT; Kline, AE				Phelps, Thomas I.; Bondi, Corina O.; Ahmed, Rashid H.; Olugbade, Yewande T.; Kline, Anthony E.			Divergent Long-Term Consequences of Chronic Treatment with Haloperidol, Risperidone, and Bromocriptine on Traumatic Brain Injury-Induced Cognitive Deficits	JOURNAL OF NEUROTRAUMA			English	Article						Morris water maze; beam-walking; learning and memory; bromocriptine; behavior; functional recovery; traumatic brain injury; controlled cortical impact; antipsychotics	CONTROLLED CORTICAL IMPACT; MEMBRANE-LIPID PEROXIDATION; ATYPICAL ANTIPSYCHOTICS; FUNCTIONAL RECOVERY; ANTIOXIDANT ENZYMES; TARDIVE-DYSKINESIA; TREATMENT REGIMEN; MOTOR RECOVERY; WORKING-MEMORY; CORTEX INJURY	Antipsychotic drugs (APDs) are provided in the clinic to manage traumatic brain injury (TBI)-induced agitation and aggression. Experimental TBI studies consistently show that daily administration of the APDs, haloperidol (HAL) and risperidone (RISP), hinder recovery. However, it is unknown how long the adverse effects remain after cessation of treatment. To elucidate this clinically relevant issue, anesthetized male rats were randomly assigned to four TBI (controlled cortical impact) and four sham groups administered HAL (0.5 mg/kg), RISP (0.45 mg/kg), bromocriptine (BRO; 5.0 mg/kg, included as a control for D-2 receptor action), or vehicle (VEH; 1 mL/kg) 24 h after surgery and once-daily for 19 days. Motor and cognitive recovery was assessed on days 1-5 and 14-19, respectively, and again at 1 and 3 months after drug withdrawal. No overall group differences were observed for motor function among the TBI groups, although the HAL group showed a greater beam-walk deficit on day 5 versus the VEH and BRO groups. Cognitive recovery was significantly impaired in the HAL and RISP groups during the treatment phase versus VEH and BRO. Further, BRO was superior to VEH (p=0.0042). At 1 month, both groups that received APDs continued to exhibit significant cognitive impairment versus VEH and BRO; at 3 months, only the HAL group was impaired. Moreover, the HAL, RISP, and VEH groups continued to be cognitively deficient versus BRO, which also reduced cortical damage. These data replicate previous reports that HAL and RISP impede cognitive recovery after TBI and expand the literature by revealing that the deleterious effects persist for 3 months after drug discontinuation. BRO conferred cognitive benefits when administered concomitantly with behavioral testing, thus replicating previous findings, and also after cessation demonstrating enduring efficacy.	[Phelps, Thomas I.; Bondi, Corina O.; Ahmed, Rashid H.; Olugbade, Yewande T.; Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Phelps, Thomas I.; Bondi, Corina O.; Ahmed, Rashid H.; Olugbade, Yewande T.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, 3471 Fifth Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Bondi, Corina/0000-0002-5733-4912	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS084967, NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084967, R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institutes of Health (grant nos.: NS084967, NS060005, and HD069620; to A.E.K.).	BENES FM, 1985, BRAIN RES, V329, P265, DOI 10.1016/0006-8993(85)90532-3; Besret L, 2000, EUR J PHARMACOL, V408, P35, DOI 10.1016/S0014-2999(00)00747-0; Bondi C. O., 2014, NEUROSCI BI IN PRESS; Bondi CO, 2014, J NEUROTRAUM, V31, P926, DOI 10.1089/neu.2013.3295; CADET JL, 1994, NEUROSCI BIOBEHAV R, V18, P457, DOI 10.1016/0149-7634(94)90001-9; CAMPBELL A, 1985, PSYCHOPHARMACOLOGY, V87, P161, DOI 10.1007/BF00431801; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Galili-Mosberg R, 2000, J NEURAL TRANSM, V107, P479, DOI 10.1007/s007020070089; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gold PE, 2003, NEUROBIOL LEARN MEM, V80, P194, DOI 10.1016/j.nlm.2003.07.003; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Huang GB, 2012, NEUROSCI LETT, V528, P131, DOI 10.1016/j.neulet.2012.09.024; Hutchings EJ, 2013, J PHARMACOL EXP THER, V347, P547, DOI 10.1124/jpet.113.209031; Karl T, 2006, BEHAV BRAIN RES, V171, P286, DOI 10.1016/j.bbr.2006.04.004; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kornhuber J, 1999, AM J PSYCHIAT, V156, P885, DOI 10.1176/ajp.156.6.885; LIU XH, 1995, J NEUROL SCI, V129, P9, DOI 10.1016/0022-510X(94)00239-K; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Naidu PS, 2002, BRIT J PHARMACOL, V136, P193, DOI 10.1038/sj.bjp.0704717; Nyberg S, 1997, ARCH GEN PSYCHIAT, V54, P953; OGAWA N, 1994, BRAIN RES, V657, P207, DOI 10.1016/0006-8993(94)90969-5; Parikh V, 2003, J PSYCHIATR RES, V37, P43, DOI 10.1016/S0022-3956(02)00048-1; Pillai A, 2007, J PSYCHIATR RES, V41, P372, DOI 10.1016/j.jpsychires.2006.01.011; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Stanislav SW, 1997, BRAIN INJURY, V11, P335, DOI 10.1080/026990597123494; Ukai W, 2004, J NEURAL TRANSM, V111, P667, DOI 10.1007/s00702-004-0109-z; Vogenthaler D R, 1987, Brain Inj, V1, P113; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Yael D., 2013, FRONT SYST NEUROSCI, V7, P1, DOI DOI 10.HTTPS://D0I.0RG/10.3389/FNSYS.2013.00110; YOSHIKAWA T, 1994, J NEUROCHEM, V62, P1034; Zhang L, 2013, TISSUE ENG PT A, V19, P1909, DOI [10.1089/ten.tea.2012.0622, 10.1089/ten.TEA.2012.0622]	52	38	39	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					590	597		10.1089/neu.2014.3711			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900009	25275833	Green Published			2022-02-06	
J	Wu, LM; Walas, S; Leung, W; Sykes, DB; Wu, J; Lo, EH; Lok, J				Wu, Limin; Walas, Samantha; Leung, Wendy; Sykes, David B.; Wu, Jiang; Lo, Eng H.; Lok, Josephine			Neuregulin1-beta Decreases IL-1 beta-Induced Neutrophil Adhesion to Human Brain Microvascular Endothelial Cells	TRANSLATIONAL STROKE RESEARCH			English	Article						Neuroinflammation; IL-1 beta; NRG1-beta; Neutrophil; VCAM-1; E-selectin	RECEPTOR SUBUNIT; ERBB RECEPTORS; INJURY; SCHIZOPHRENIA; INFLAMMATION; PROMOTES; LEADS; INTERLEUKIN-1-BETA; MICRODIALYSIS; ANGIOGENESIS	Neuroinflammation contributes to the pathophysiology of diverse diseases including stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and multiple sclerosis, resulting in neurodegeneration and loss of neurological function. The response of the microvascular endothelium often contributes to neuroinflammation. One such response is the upregulation of endothelial adhesion molecules which facilitate neutrophil adhesion to the endothelium and their migration from blood to tissue. Neuregulin-1 (NRG1) is an endogenous growth factor which has been reported to have anti-inflammatory effects in experimental stroke models. We hypothesized that NRG1 would decrease the endothelial response to inflammation and result in a decrease in neutrophil adhesion to endothelial cells. We tested this hypothesis in an in vitro model of cytokine-induced endothelial injury, in which human brain microvascular endothelial cells (BMECs) were treated with IL-1 beta, along with co-incubation with vehicle or NRG1-beta. Outcome measures included protein levels of endothelial ICAM-1, VCAM-1, and E-selectin, as well as the number of neutrophils that adhere to the endothelial monolayer. Our data show that NRG1-beta decreased the levels of VCAM-1, E-selectin, and neutrophil adhesion to brain microvascular endothelial cells activated by IL1-beta. These findings open new possibilities for investigating NRG1 in neuroprotective strategies in brain injury.	[Wu, Limin; Walas, Samantha; Leung, Wendy; Lo, Eng H.; Lok, Josephine] Harvard Univ, Sch Med, Neuroprotect Res Lab, Massachusetts Gen Hosp, Charlestown, MA 02129 USA; [Wu, Limin; Wu, Jiang] Jilin Univ, Hosp 1, Dept Neurol, Changchun 130021, Jilin, Peoples R China; [Lok, Josephine] Harvard Univ, Sch Med, Dept Pediat, Div Pediat Crit Care,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Sykes, David B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Hematol Oncol, Boston, MA 02115 USA; [Sykes, David B.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA		Lok, J (corresponding author), Harvard Univ, Sch Med, Neuroprotect Res Lab, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.	jlok1@mgh.harvard.edu			China Scholarship CouncilChina Scholarship Council [201206170107];  [R37NS037074-13];  [R01NS076694-02];  [P01NS055104-05];  [K08N5057339-04]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS037074, P01NS055104, R01NS076694, K08NS057339] Funding Source: NIH RePORTER	This work is supported by the following grants:; R37NS037074-13 (EHL); R01NS076694-02(EHL); P01NS055104-05 (EHL); K08N5057339-04 (JL); China Scholarship Council (#201206170107; LW)	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Asp L, 2009, BRAIN BEHAV IMMUN, V23, P733, DOI 10.1016/j.bbi.2009.04.004; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Boato F, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-6; Borlongan CV, 2011, PROG NEUROBIOL, V95, P213, DOI 10.1016/j.pneurobio.2011.08.005; Brooks TA, 2005, AM J PHYSIOL-HEART C, V289, pH738, DOI 10.1152/ajpheart.01288.2004; Brothers Holly M, 2013, J Alzheimers Dis Parkinsonism, V3, P110; Calvo M, 2010, J NEUROSCI, V30, P5437, DOI 10.1523/JNEUROSCI.5169-09.2010; Dimayuga FO, 2003, J NEUROIMMUNOL, V136, P67, DOI 10.1016/S0165-5728(03)00003-1; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Finigan JH, 2013, EUR RESPIR J, V41, P396, DOI 10.1183/09031936.00004912; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fisahn A, 2009, CEREB CORTEX, V19, P612, DOI 10.1093/cercor/bhn107; Ghosh S, 2013, J NEUROSCI, V33, P5053, DOI 10.1523/JNEUROSCI.4361-12.2013; Hedhli N, 2012, CARDIOVASC RES, V93, P516, DOI 10.1093/cvr/cvr352; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Iivanainen E, 2007, EXP CELL RES, V313, P2896, DOI 10.1016/j.yexcr.2007.03.042; Kalinowski A, 2010, FASEB J, V24, P2567, DOI 10.1096/fj.08-129072; Kanakry CG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001369; Kwon OB, 2005, J NEUROSCI, V25, P9378, DOI 10.1523/JNEUROSCI.2100-05.2005; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; Lok J, 2012, TRANSL STROKE RES, V3, pS119, DOI 10.1007/s12975-012-0157-x; Lyman M, 2014, NEUROSCI RES, V79, P1, DOI 10.1016/j.neures.2013.10.004; Maki T, 2013, CNS NEUROL DISORD-DR, V12, P302, DOI 10.2174/1871527311312030004; Makinodan M, 2012, SCIENCE, V337, P1357, DOI 10.1126/science.1220845; Mako V, 2010, CYTOM PART A, V77A, P962, DOI 10.1002/cyto.a.20952; Marballi K, 2010, J MOL MED, V88, P1133, DOI 10.1007/s00109-010-0653-y; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Mencel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070338; Norton N, 2006, AM J MED GENET B, V141B, P96, DOI 10.1002/ajmg.b.30236; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Ridder DA, 2011, J EXP MED, V208, P2615, DOI 10.1084/jem.20110398; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Rigor RR, 2012, AM J PHYSIOL-CELL PH, V302, pC1513, DOI 10.1152/ajpcell.00371.2011; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; Safa RN, 2011, AM J PHYSIOL-HEART C, V300, pH1311, DOI 10.1152/ajpheart.01104.2009; Schaff U, 2008, J LEUKOCYTE BIOL, V83, P99, DOI 10.1189/jlb.0507304; Tan GH, 2012, NAT NEUROSCI, V15, P258, DOI 10.1038/nn.3005; Ting AK, 2011, J NEUROSCI, V31, P15, DOI 10.1523/JNEUROSCI.2538-10.2011; Wen Y, 2008, J NEUROSCI, V28, P2624, DOI 10.1523/JNEUROSCI.5245-07.2008; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149	44	38	43	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	APR	2015	6	2					116	124		10.1007/s12975-014-0347-9			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CD8AH	WOS:000351317000004	24863743	Green Submitted, Green Accepted			2022-02-06	
J	King, S; Green, HJ				King, Summer; Green, Heather Joy			Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial	FRONTIERS IN ONCOLOGY			English	Article						cancer; cognitive function; cognitive rehabilitation; group; randomized controlled trial; survivorship	QUALITY-OF-LIFE; MEMORY SELF-EFFICACY; CHRONIC-FATIGUE-SYNDROME; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; REPEATABLE BATTERY; EXECUTIVE FUNCTION; CLINICAL-TRIALS; IMPAIRMENT; DYSFUNCTION	Although the impact of cancer and associated treatments on cognitive functioning is becoming an increasingly recognized problem, there are few published studies that have investigated psychological interventions to address this issue. A waitlist randomized controlled trial methodology was used to assess the efficacy of a group cognitive rehabilitation intervention ("ReCog") that successfully targeted cancer-related cognitive decline in previously published pilot research. Participants were 29 cancer survivors who were randomly allocated to either the intervention group or a waitlist group who received the intervention at a later date, and 16 demographically matched community volunteers with no history of cancer (trial registration ACTRN12615000009516, available at http://www.ANZCTR.org.au/ACTRN12615000009516.aspx). The study was the first to include an adapted version of the Traumatic Brain Injury Self-Efficacy Scale to assess cognitive self-efficacy (CSE) in people who have experienced cancer. Results revealed participating in the intervention was associated with significantly faster performance on one objective cognitive task that measures processing speed and visual scanning. Significantly larger improvements for the intervention group were also found on measures of perceived cognitive impairments and CSE. There was some evidence to support the roles of CSE and illness perceptions as potential mechanisms of change for the intervention. Overall, the study provided additional evidence of feasibility and efficacy of group psychological intervention for targeting cancer-related cognitive decline.	Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; Griffith Univ, Sch Appl Psychol, Gold Coast, Qld, Australia		Green, HJ (corresponding author), Griffith Univ, Sch Appl Psychol, Parklands Dr,Gold Coast Campus, Southport, Qld 4222, Australia.	h.green@griffith.edu.au	Green, Heather/C-1169-2008	Green, Heather/0000-0003-4254-4076	Griffith University School of Applied Psychology; Griffith University Research Grant [GURG36603]; Psycho-Oncology Cooperative Research Group (PoCoG) Protocol Development Workshop; Cancer Australia; Cancer Institute NSW	This research was funded through Griffith University School of Applied Psychology, Griffith University Research Grant GURG36603 and the Psycho-Oncology Cooperative Research Group (PoCoG) Protocol Development Workshop 2007. PoCoG is jointly funded by Cancer Australia and the Cancer Institute NSW. This paper is based on a Doctor of Psychology (Clinical) dissertation by SK. We would like to thank Dr. Alana Schuurs for assistance with implementation of the intervention; Haley Webb for assistance with random allocation; and Elizabeth Adams, Jessica Davis, Cindy Dimitrievska, Donna Griffiths, Joanne Hughes, Natasha Innes, Claudine Lombard, Collette Morris, Sarah Nash, Britta Walker, and Codi White for assistance with data collection.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Aben L, 2011, CEREBROVASC DIS, V31, P566, DOI 10.1159/000324627; Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073; Ahn SH, 2007, ANN ONCOL, V18, P173, DOI 10.1093/annonc/mdl333; Antoni MH, 2001, HEALTH PSYCHOL, V20, P20, DOI 10.1037/0278-6133.20.1.20; Bandura A., 1997, SELF EFFICACY EXERCI, Vix; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bender CM, 2001, J PAIN SYMPTOM MANAG, V21, P407, DOI 10.1016/S0885-3924(01)00268-8; Berger AM, 2012, CANCER-AM CANCER SOC, V118, P2261, DOI 10.1002/cncr.27475; BERRY JM, 1993, INT J BEHAV DEV, V16, P351, DOI 10.1177/016502549301600213; Biringer E, 2005, EUR ARCH PSY CLIN N, V255, P373, DOI 10.1007/s00406-005-0577-7; Bjordal K, 2000, EUR J CANCER, V36, P1796, DOI 10.1016/S0959-8049(00)00186-6; Bower JE, 2005, J CLIN ONCOL, V23, P8280, DOI 10.1200/JCO.2005.08.008; Bowling A., 1991, MEASURING HLTH REV Q; Boykoff N, 2009, J CANCER SURVIV, V3, P223, DOI 10.1007/s11764-009-0098-x; Brezden CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Campos MPO, 2011, ANN ONCOL, V22, P1273, DOI 10.1093/annonc/mdq458; Carlson MC, 2009, J GERONTOL A-BIOL, V64, P110, DOI 10.1093/gerona/gln008; Carver CS, 2004, HEALTH PSYCHOL, V23, P595, DOI 10.1037/0278-6133.23.6.595; CAVANAUGH JC, 1990, AGING COGNITION MENT, P189, DOI DOI 10.1016/S0166-4115(08)60788-8; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Cherrier MM, 2013, LIFE SCI, V93, P617, DOI 10.1016/j.lfs.2013.08.011; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Comijs HC, 2002, J AFFECT DISORDERS, V72, P157, DOI 10.1016/S0165-0327(01)00453-0; Cruess DG, 2000, PSYCHOSOM MED, V62, P304, DOI 10.1097/00006842-200005000-00002; Cruzado JA, 2014, SUPPORT CARE CANCER, V22, P1815, DOI 10.1007/s00520-014-2147-x; Cull A, 1996, BRIT J CANCER, V74, P1674, DOI 10.1038/bjc.1996.608; Curt GA, 2001, BMJ-BRIT MED J, V322, P1560, DOI 10.1136/bmj.322.7302.1560; Dietrich J, 2008, ONCOLOGIST, V13, P1285, DOI 10.1634/theoncologist.2008-0130; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2005, J CLIN EXP NEUROPSYC, V27, P565, DOI 10.1080/13803390490918363; Ercoli LM, 2013, BRAIN IMAGING BEHAV, V7, P543, DOI 10.1007/s11682-013-9237-0; Fan HGM, 2008, SUPPORT CARE CANCER, V16, P577, DOI 10.1007/s00520-007-0341-9; Fardell JE, 2011, CLIN PHARMACOL THER, V90, P366, DOI 10.1038/clpt.2011.112; Fayers PM, 2001, EORTC QLQ C30 SCORIN; Ferguson RJ, 2007, PSYCHO-ONCOL, V16, P772, DOI 10.1002/pon.1133; Ferguson RJ, 2012, PSYCHO-ONCOLOGY, V21, P176, DOI 10.1002/pon.1878; Fulton C, 1998, Eur J Cancer Care (Engl), V7, P232; Gehring K, 2012, EXPERT REV ANTICANC, V12, P255, DOI [10.1586/era.11.202, 10.1586/ERA.11.202]; Green H. J., 2005, PSYCHOL HEALTH MED, V10, P145, DOI [10.1080/13548500500093308, DOI 10.1080/13548500500093308]; Green HJ, 2003, CLIN PSYCHOL, V7, P81, DOI [10.1080/13284200410001707533, DOI 10.1080/13284200410001707533]; Greene D, 1994, Cancer Pract, V2, P57; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; Helgeson VS, 2004, HEALTH PSYCHOL, V23, P3, DOI 10.1037/0278-6133.23.1.3; Heritier SR, 2003, MED J AUSTRALIA, V179, P438, DOI 10.5694/j.1326-5377.2003.tb05627.x; Hess LM, 2007, ONCOL NURS FORUM, V34, P981, DOI 10.1188/07.ONF.981-994; Hodgson KD, 2013, CANCER TREAT REV, V39, P297, DOI 10.1016/j.ctrv.2012.11.001; Hofman M, 2007, ONCOLOGIST, V12, P4, DOI 10.1634/theoncologist.12-S1-4; Howell D.C., 2007, STAT METHODS PSYCHOL; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Hutchinson AD, 2012, CANCER TREAT REV, V38, P926, DOI 10.1016/j.ctrv.2012.05.002; Jacobs SR, 2007, J PAIN SYMPTOM MANAG, V33, P13, DOI 10.1016/j.jpainsymman.2006.06.011; Janelsins MC, 2011, SEMIN ONCOL, V38, P431, DOI 10.1053/j.seminoncol.2011.03.014; Jenkins V, 2004, PSYCHO-ONCOLOGY, V13, P61, DOI 10.1002/pon.709; Jim HSL, 2012, J CLIN ONCOL, V30, P3578, DOI 10.1200/JCO.2011.39.5640; Jocham HR, 2009, INT J PALLIAT NURS, V15, P336, DOI 10.12968/ijpn.2009.15.7.43424; Kesler S, 2013, CLIN BREAST CANCER, V13, P299, DOI 10.1016/j.clbc.2013.02.004; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kohler CL, 2002, HEALTH PSYCHOL, V21, P610, DOI 10.1037/0278-6133.21.6.610; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; Lemieux J, 2011, JNCI-J NATL CANCER I, V103, P178, DOI 10.1093/jnci/djq508; Leon AC, 2011, J PSYCHIATR RES, V45, P626, DOI 10.1016/j.jpsychires.2010.10.008; Leventhal H, 2004, SAGE HDB HLTH PSYCHO, P197; Man DWK, 2011, NEUROPSYCHOL REHABIL, V21, P884, DOI 10.1080/09602011.2011.627270; McDougall GJ, 2001, GERIATR NURS, V22, P185, DOI 10.1067/mgn.2001.117916; McDougall Graham J, 2001, Clin Gerontol, V23, P127, DOI 10.1300/J018v23n03_11; McDougall GJ, 2011, ARCH PSYCHIAT NURS, V25, P24, DOI 10.1016/j.apnu.2010.05.004; McDougall GJ, 2014, ARCH PSYCHIAT NURS, V28, P180, DOI 10.1016/j.apnu.2013.12.005; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Mehnert A, 2008, J PSYCHOSOM RES, V64, P383, DOI 10.1016/j.jpsychores.2007.12.005; Mehnert A, 2007, PATIENT EDUC COUNS, V66, P108, DOI 10.1016/j.pec.2006.11.005; Meyers CA, 2005, CANCER-AM CANCER SOC, V104, P788, DOI 10.1002/cncr.21234; Minton O, 2008, BREAST CANCER RES TR, V112, P5, DOI 10.1007/s10549-007-9831-1; Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017; Montazeri A, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-102; Montazeri A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-330; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Paunonen SV, 2010, J PERS, V78, P339, DOI 10.1111/j.1467-6494.2009.00618.x; Petrie KJ, 2007, CURR OPIN PSYCHIATR, V20, P163, DOI 10.1097/YCO.0b013e328014a871; Poppelreuter M, 2004, EUR J CANCER, V40, P43, DOI 10.1016/j.ejca.2003.08.001; Poppelreuter M, 2009, J PSYCHOSOC ONCOL, V27, P274, DOI 10.1080/07347330902776044; Prue G, 2006, EUR J CANCER, V42, P846, DOI 10.1016/j.ejca.2005.11.026; Pullens MJJ, 2010, PSYCHO-ONCOLOGY, V19, P1127, DOI 10.1002/pon.1673; Quinten C, 2009, LANCET ONCOL, V10, P865, DOI 10.1016/S1470-2045(09)70200-1; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; REBOK GW, 1989, DEV PSYCHOL, V25, P714, DOI 10.1037/0012-1649.25.5.714; Reich M, 2008, BREAST CANCER RES TR, V110, P9, DOI 10.1007/s10549-007-9706-5; Reid LM, 2006, DEMENT GERIATR COGN, V22, P471, DOI 10.1159/000096295; Schagen SB, 2009, PSYCHO-ONCOL, V18, P674, DOI 10.1002/pon.1454; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Schuurs A, 2009, PARTICIPANTS MANUAL; Schuurs A, 2009, CLINICIANS MANUAL FO; Schuurs A, 2013, PSYCHO-ONCOLOGY, V22, P1043, DOI 10.1002/pon.3102; Schwartz AL, 2000, CANCER INVEST, V18, P11, DOI 10.3109/07357900009023057; Servaes P, 2007, PSYCHO-ONCOL, V16, P787, DOI 10.1002/pon.1120; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Smith S, 2003, INT J BEHAV MED, V10, P162, DOI 10.1207/S15327558IJBM1002_05; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119; Valentijn SAM, 2006, PSYCHOL AGING, V21, P165, DOI 10.1037/0882-7974.21.2.165; Valentine AD, 2001, CANCER, V92, P1694, DOI 10.1002/1097-0142(20010915)92:6+<1694::AID-CNCR1499>3.0.CO;2-S; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; vantSpijker A, 1997, PSYCHOSOM MED, V59, P280, DOI 10.1097/00006842-199705000-00011; Vardy J, 2007, CRIT REV ONCOL HEMAT, V63, P183, DOI 10.1016/j.critrevonc.2007.06.001; Vearncombe KJ, 2009, AUST PSYCHOL, V44, P235, DOI 10.1080/00050060903096652; Von Ah D, 2012, BREAST CANCER RES TR, V135, P799, DOI 10.1007/s10549-012-2210-6; Wagner LI, 2004, ANN BEHAV MED, V27, pS10; Wearden A, 1997, PSYCHOL MED, V27, P81, DOI 10.1017/S0033291796004035; Wefel JS, 2012, CURR NEUROL NEUROSCI, V12, P267, DOI 10.1007/s11910-012-0264-9; Wefel JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/cncr.20272; Wefel JS, 2004, BRIT J CANCER, V90, P1691, DOI 10.1038/sj.bjc.6601772; WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/pon.2960040108; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020	116	38	38	2	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	2234-943X			FRONT ONCOL	Front. Oncol.	MAR 25	2015	5								72	10.3389/fonc.2015.00072			18	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	CO3TY	WOS:000359084000001	25859431	Green Published, gold			2022-02-06	
J	Ding, K; Wang, HD; Wu, Y; Zhang, L; Xu, JG; Li, T; Ding, Y; Zhu, L; He, J				Ding, Ke; Wang, Handong; Wu, Yong; Zhang, Li; Xu, Jianguo; Li, Tao; Ding, Yu; Zhu, Lin; He, Jin			Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis	JOURNAL OF SURGICAL RESEARCH			English	Article						Rapamycin; Traumatic brain injury; Apoptosis; Mammalian target of rapamycin; p53; Bax	CLOSED-HEAD INJURY; CELL-DEATH; KETOGENIC DIET; JUVENILE RATS; MODEL; P53; BCL-2; INHIBITION; DISRUPTION; AUTOPHAGY	Background: Rapamycin has proven to be a neuroprotective agent in traumatic brain injury (TBI). However, there is a lack of data regarding the effect of rapamycin on apoptotic neuronal death after TBI. Thus, the present study was designed to detect the modulatory role of rapamycin on apoptosis and explore the potential involvement of the mammalian target of rapamycin (mTOR)-p53-Bax axis after TBI. Material and methods: Neurologic severity score tests were performed to measure behavioral outcomes. The effect of rapamycin treatment on neuronal death was analyzed using immunofluorescence analysis of NeuN. Terminal deoxynucleotidyl transferase-mediated dUTP nick 3'-end labeling was performed to detect apoptotic cells. The expression of Bax and phosphorylated protein of p53 was detected using Western blotting analyses and immunofluorescence staining. Phosphorylated protein of the mTOR in the ipsilateral cortex was detected using Western blotting analyses. Results: Rapamycin administration after TBI was associated with an increased number of neurons, decreased apoptosis index, and improved neurobehavioral function, which was potentially mediated by inactivation of the mTOR-p53-Bax axis. Conclusions: Rapamycin can protect neurons from apoptotic neuronal death after TBI. This study presents a new insight into the antiapoptosis mechanisms, which are responsible for the neuroprotection of rapamycin, with the potential involvement of the mTOR-p53-Bax axis. (C) 2015 Elsevier Inc. All rights reserved.	[Ding, Ke; Wang, Handong; Wu, Yong; Zhang, Li; Xu, Jianguo; Li, Tao; Ding, Yu; Zhu, Lin; He, Jin] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81271377, 81371357]; Research Project of Jinling Hospital [2014040]	This work was supported by grants obtained from the Natural Science Fund of China (Nos. 81271377 and 81371357) and the Research Project of Jinling Hospital (No. 2014040).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P374, DOI 10.4161/oxim.3.6.14787; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Concha NO, 2002, CURR MED CHEM, V9, P713, DOI 10.2174/0929867023370761; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Hong LZ, 2010, NEUROSCI BULL, V26, P232, DOI 10.1007/s12264-010-1111-0; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Koehl GE, 2004, TRANSPLANTATION, V77, P1319, DOI 10.1097/00007890-200405150-00002; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lopez NE, 2012, BRAIN RES, V1489, P140, DOI 10.1016/j.brainres.2012.10.031; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wan CH, 2014, J NEUROSCI RES, V92, P1, DOI 10.1002/jnr.23305; Xia DY, 2013, BRAZ J MED BIOL RES, V46, P580, DOI 10.1590/1414-431X20133161; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yin LL, 2012, INT J NEUROSCI, V122, P748, DOI 10.3109/00207454.2012.721827; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	38	38	41	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAR	2015	194	1					239	247		10.1016/j.jss.2014.09.026			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CC5FH	WOS:000350384000031	25438952				2022-02-06	
J	Downar, J; You, JJ; Bagshaw, SM; Golan, E; Lamontagne, F; Burns, K; Sridhar, SK; Seely, A; Meade, MO; Fox-Robichaud, A; Cook, D; Turgeon, AF; Dodek, P; Xiong, W; Fowler, R				Downar, James; You, John J.; Bagshaw, Sean M.; Golan, Eyal; Lamontagne, Francois; Burns, Karen; Sridhar, S. Kavita; Seely, Andrew; Meade, Maureen O.; Fox-Robichaud, Alison; Cook, Deborah; Turgeon, Alexis F.; Dodek, Peter; Xiong, Wei; Fowler, Rob		Canadian Critical Care Trials Grp	Nonbeneficial Treatment Canada: Definitions, Causes, and Potential Solutions From the Perspective of Healthcare Practitioners	CRITICAL CARE MEDICINE			English	Article						attitude of health personnel; communication; decision making; ethics; medical; medical staff; hospital/ethics/legislation; and jurisprudence; medical futility; nursing staff; hospital/ethics/legislation; and jurisprudence	TRAUMATIC BRAIN-INJURY; EARLY PALLIATIVE CARE; OF-LIFE CARE; INTENSIVE-CARE; MEDICAL FUTILITY; COMMUNICATION-SKILLS; DECISION-MAKING; END; UNIT; PERCEPTIONS	Objective: Many healthcare workers are concerned about the provision of nonbeneficial treatment in the acute care setting. We sought to explore the perceptions of acute care practitioners to determine whether they perceived nonbeneficial treatment to be a problem, to generate an acceptable definition of nonbeneficial treatment, to learn about their perceptions of the impact and causes of nonbeneficial treatment, and the ways that they feel could reduce or resolve nonbeneficial treatment. Design: National, bilingual, cross-sectional survey of a convenience sample of nursing and medical staff who provide direct patient care in acute medical wards or ICUs in Canada. Main Results: We received 688 responses (response rate 61%) from 11 sites. Seventy-four percent of respondents were nurses. Eighty-two percent of respondents believe that our current means of resolving nonbeneficial treatment are inadequate. The most acceptable definitions of nonbeneficial treatment were "advanced curative/life-prolonging treatments that would almost certainly result in a quality of life that the patient has previously stated that he/she would not want" (88% agreement) and "advanced curative/life-prolonging treatments that are not consistent with the goals of care (as indicated by the patient)" (83% agreement). Respondents most commonly believed that nonbeneficial treatment was caused by substitute decision makers who do not understand the limitations of treatment, or who cannot accept a poor prognosis (90% agreement for each cause), and 52% believed that nonbeneficial treatment was "often" or "always" continued until the patient died or was discharged from hospital. Respondents believed that nonbeneficial treatment was a common problem with a negative impact on all stakeholders (>80%) and perceived that improved advance care planning and communication training would be the most effective (92% and 88%, respectively) and morally acceptable (95% and 92%, respectively) means to resolve the problem of nonbeneficial treatment. Conclusions: Canadian nurses and physicians perceive that our current means of resolving nonbeneficial treatment are inadequate, and that we need to adopt new techniques of resolving nonbeneficial treatment. The most promising strategies to reduce nonbeneficial treatment are felt to be improved advance care planning and communication training for healthcare professionals.	[Downar, James; Golan, Eyal] Univ Toronto, Dept Med, Div Crit Care, Toronto, ON, Canada; [Downar, James] Univ Toronto, Dept Med, Div Palliat Care, Toronto, ON, Canada; [You, John J.; Meade, Maureen O.; Fox-Robichaud, Alison; Cook, Deborah] McMaster Univ, Dept Med, Hamilton, ON, Canada; [You, John J.; Meade, Maureen O.; Cook, Deborah] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada; [Lamontagne, Francois] Univ Sherbrooke, Ctr Rech Etienne Le Bel, Sherbrooke, PQ J1K 2R1, Canada; [Burns, Karen] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Burns, Karen] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Burns, Karen] St Michaels Hosp, Li KaShing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Sridhar, S. Kavita] Lakeridge Hlth, Dept Emergency Med & Crit Care, Oshawa, ON, Canada; [Seely, Andrew] Univ Ottawa, Fac Med & Dent, Dept Surg, Ottawa, ON, Canada; [Seely, Andrew] Univ Ottawa, Dept Crit Care Med, Fac Med & Dent, Ottawa, ON, Canada; [Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol, Div Crit Care, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval, Ctr Hosp Univ CHU Quebec, CHU Quebec, Hop Enfant Jesus,Res Ctr, Quebec City, PQ, Canada; [Dodek, Peter] St Pauls Hosp, Div Crit Care Med, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Xiong, Wei] Sunnybrook Med Ctr, Toronto, ON, Canada; [Fowler, Rob] Univ Toronto, Dept Med, Interdept Div Crit Care, Toronto, ON, Canada		Downar, J (corresponding author), 200 Elizabeth St 9N-926, Toronto, ON M5G 2C4, Canada.	james.downar@utoronto.ca	Golan, Eyal/D-3086-2014	Golan, Eyal/0000-0002-2904-9321	Research Early Career Award from Hamilton Health Sciences; Clinical Investigator Award from Alberta Innovates-Health Solutions; Canada Research Chair in Critical Care Nephrology; Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Research Career Award from the Fonds de la Recherche du Quebec-Sante; CIHR (HALO translational study)Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation Career Scientist Award; Department of Medicine Integrating Challenge Fund, University of Toronto	Dr. John You is supported by a Research Early Career Award from Hamilton Health Sciences. Dr. Sean M. Baghsaw is support by a Clinical Investigator Award from Alberta Innovates-Health Solutions and a Canada Research Chair in Critical Care Nephrology. Dr. Karen Burns holds a Clinician Scientist-Phase 2 Award from the Canadian Institutes of Health Research (CIHR). Dr. Alexis Turgeon is supported by a Research Career Award from the Fonds de la Recherche du Quebec-Sante. Dr. Deborah Cook holds a Research Chair of the Canadian Institutes of Health Research. Dr. Bagshaw consulted and lectured for Gambro. Dr. Fox-Robichaud received support for travel from rCPSC (Examination Chair, Member Speciaty Committee, Member Assessment Committee). Her institution received grant support from CIHR (HALO translational study) and received support for development of educational presentations from SimOne/CPSI (Sepsis Education). Dr. Rob Fowler is supported by a Heart and Stroke Foundation Career Scientist Award. Dr. Fowler received grant support from the Department of Medicine Integrating Challenge Fund, University of Toronto. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; BRODY BA, 1995, J MED PHILOS, V20, P123, DOI 10.1093/jmp/20.2.123; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Canadian Institute for Health Information, 2007, HLTH CAR US END LIF; Chidwick Paula, 2011, Healthc Q, V14, P69; Choong K, 2010, CLIN INVEST MED, V33, pE240; Cribb R, 2010, TORONTO STAR    0904; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Downer J, 2012, CRIT CARE MED, V40, P1814, DOI 10.1097/CCM.0b013e31824e0fb7; Ferrand E, 2003, AM J RESP CRIT CARE, V167, P1310, DOI 10.1164/rccm.200207-752OC; Fine RL, 2003, ANN INTERN MED, V138, P743, DOI 10.7326/0003-4819-138-9-200305060-00011; Gabbay E, 2010, J GEN INTERN MED, V25, P1083, DOI 10.1007/s11606-010-1445-3; Gordon GH, 2000, PATIENT EDUC COUNS, V40, P59, DOI 10.1016/S0738-3991(99)00069-5; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Griffith L, 2004, INTENS CARE MED, V30, P1783, DOI 10.1007/s00134-004-2360-z; Hamric AB, 2007, CRIT CARE MED, V35, P422, DOI 10.1097/01.CCM.0000254722.50608.2D; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; Henry MS, 2006, J MED ETHICS, V32, P321, DOI 10.1136/jme.2005.013987; Heyland DK, 2006, CHEST, V130, P419, DOI 10.1378/chest.130.2.419; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Huynh TN, 2013, JAMA INTERN MED, V173, P1887, DOI 10.1001/jamainternmed.2013.10261; Johnson SK, 2011, AM J RESP CRIT CARE, V183, P915, DOI 10.1164/rccm.201008-1214OC; Knickle K, 2012, CRIT CARE, V16, DOI [10.1186/CC11141, 10.1186/cc11141]; Lienard A, 2010, BRIT J CANCER, V103, P171, DOI 10.1038/sj.bjc.6605749; Nappa U, 2011, ANN ONCOL, V22, P2375, DOI 10.1093/annonc/mdq778; Palda VA, 2005, J CRIT CARE, V20, P207, DOI 10.1016/j.jcrc.2005.05.006; Piers RD, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.12.014; Piers RD, 2011, JAMA-J AM MED ASSOC, V306, P2694, DOI 10.1001/jama.2011.1888; Poncet MC, 2007, AM J RESP CRIT CARE, V175, P698, DOI 10.1164/rccm.200606-806OC; Pope TM, 2007, TENESSEE LAW REV, V75, P80; Quill TE, 2011, JAMA-J AM MED ASSOC, V306, P1483, DOI 10.1001/jama.2011.1413; Rodriguez KL, 2006, J MED ETHICS, V32, P444, DOI 10.1136/jme.2005.014118; Schneiderman LJ, 1996, ANN INTERN MED, V125, P669, DOI 10.7326/0003-4819-125-8-199610150-00007; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Seely AJE, 2013, PERSPECT BIOL MED, V56, P65, DOI 10.1353/pbm.2013.0009; Sibbald R, 2007, CAN MED ASSOC J, V177, P1201, DOI 10.1503/cmaj.070144; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2002, J AM GERIATR SOC, V50, P496, DOI 10.1046/j.1532-5415.2002.50116.x; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Truog RD, 2009, CHEST, V136, P968, DOI 10.1378/chest.09-1269; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Tversky A, 1973, COGNITIVE PSYCHOL, V5, P27; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; White DB, 2004, CRIT CARE CLIN, V20, P329, DOI 10.1016/j.ccc.2004.03.003; White DB, 2012, JAMA-J AM MED ASSOC, V307, P151, DOI 10.1001/jama.2011.1990; White DB, 2009, AM J RESP CRIT CARE, V180, P320, DOI 10.1164/rccm.200811-1776OC; Wilkinson DJC, 2011, CURR OPIN ANESTHESIO, V24, P160, DOI 10.1097/ACO.0b013e328343c5af; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966; Zier LS, 2009, CHEST, V136, P110, DOI 10.1378/chest.08-2753	52	38	39	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					270	281		10.1097/CCM.0000000000000704			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AZ2YX	WOS:000348096200003	25377017				2022-02-06	
J	Raj, R; Skrifvars, MB; Kivisaari, R; Hernesniemi, J; Lappalainen, J; Siironen, J				Raj, Rahul; Skrifvars, Markus B.; Kivisaari, Riku; Hernesniemi, Juha; Lappalainen, Jaakko; Siironen, Jari			Acute Alcohol Intoxication and Long-Term Outcome in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; mortality; prognosis; outcome; alcohol	GLASGOW COMA SCALE; SERUM ETHANOL LEVELS; MORTALITY; LEVEL; ABUSE; CLASSIFICATION; EPIDEMIOLOGY; ASSOCIATION; SEVERITY; SURVIVAL	The effect of blood alcohol concentration (BAC) on outcome after traumatic brain injury (TBI) is controversial. We sought to assess the independent effect of positive BAC on long-term outcome in patients with TBI treated in the intensive care unit (ICU). We performed a retrospective analysis of 405 patients with TBI, admitted to the ICU of a large urban Level 1 trauma center between January 2009 and December 2012. Outcome was six-month mortality and unfavorable neurological outcome (defined as a Glasgow Outcome Scale score of 1 [death], 2, [vegetative state], or 3 [severe disability]). Patients were categorized by admission BAC into: no BAC (0.0 parts per thousand; n=99), low BAC (n=140) and high BAC (>= 2.3 parts per thousand; n=166). Logistic regression analysis, adjusting for baseline risk and severity of illness, was used to assess the independent effect of BAC on outcome (using the no BAC group as the reference). Overall six-month mortality was 25% and unfavorable outcome was 46%. Multivariate analysis showed low BAC to independently reduce risk of six-month mortality compared with no BAC (low BAC adjusted odds ratio [AOR] 0.41, 95% confidence interval [CI] 0.19-0.88, p=0.021) and high BAC (AOR 0.58, 95% CI 0.29-1.15, p=0.120). Furthermore, a trend towards reduced risk of six-month unfavorable neurological outcome for patients with positive BAC, compared to patients with negative BAC, was noted, although this did not reach statistical significance (low BAC AOR 0.65, 95% CI 0.34-1.22, p=0.178, and high BAC AOR 0.59, 95% CI 0.32-1.09, p=0.089). In conclusion, low admission BAC (<2.3 parts per thousand) was found to independently reduce risk of six-month mortality for patients with TBI, and a trend towards improved long-term neurological outcome was found for BAC-positive patients. The role of alcohol as a neuroprotective agent warrants further studies.	[Raj, Rahul; Kivisaari, Riku; Hernesniemi, Juha; Lappalainen, Jaakko; Siironen, Jari] Helsinki Univ Hosp, Dept Neurosurg, Helsinki 00029, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Dept Intens Care Med, Helsinki 00029, Finland		Raj, R (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Topeliuksenkatu 5, Helsinki 00029, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591	Helsinki University Hospital EVO [TYH2012142]; Medicinska Understodsforeningen Liv och Halsa; Maire Taponen foundation	The study was funded by a Helsinki University Hospital EVO grant (TYH2012142), Medicinska Understodsforeningen Liv och Halsa and the Maire Taponen foundation. No competing financial interests exist.	Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Berry C, 2011, AM SURGEON, V77, P1416; Berry C, 2010, AM SURGEON, V76, P1067; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Hadjibashi AA, 2012, J SURG RES, V173, P212, DOI 10.1016/j.jss.2011.05.029; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lange RT, 2010, BRAIN INJURY, V24, P919, DOI 10.3109/02699052.2010.489794; Lu J. J., 2004, ACTA NEUROCHIR S, V95, P281; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Macewen William, 1879, Glasgow Med J, V11, P1; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Molina PE, 2013, SHOCK, V39, P240, DOI 10.1097/SHK.0b013e318285b86d; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Pouw ME, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5913; Raj R., 2014, J NEUROTRAUMA; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185	35	38	38	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					95	100		10.1089/neu.2014.3488			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700003	25010885	Green Published			2022-02-06	
J	Chan, JL; Reeves, TM; Phillips, LL				Chan, Julie L.; Reeves, Thomas M.; Phillips, Linda L.			Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury	EXPERIMENTAL NEUROLOGY			English	Article							CLOSED-HEAD INJURY; EXTRACELLULAR-MATRIX MOLECULES; FOCAL CEREBRAL-ISCHEMIA; CELL-ADHESION MOLECULES; SPINAL-CORD-INJURY; UP-REGULATION; TNF-ALPHA; MICROGLIAL ACTIVATION; GENE-EXPRESSION; PROINFLAMMATORY CYTOKINE	Traumatic brain injury (TBI) produces axotomy, deafferentation and reactive synaptogenesis. Inflammation influences synaptic repair, and the novel brain cytokine osteopontin (OPN) has potential to support axon regeneration through exposure of its integrin receptor binding sites. This study explored whether OPN secretion and proteolysis by matrix metalloproteinases (MMPs) mediate the initial degenerative phase of synaptogenesis, targeting reactive neuroglia to affect successful repair. Adult rats received unilateral entorhinal cortex lesion (UEC) modeling adaptive synaptic plasticity. Over the first week postinjury, hippocampal OPN protein and mRNA were assayed and histology was performed. At 1 similar to 2 d, OPN protein increased up to 51 fold, and was localized within activated, mobilized glia. OPN transcript also increased over 50 fold, predominantly within reactive microglia. OPN fragments known to be derived from MMP proteolysis were elevated at 1 d, consistent with prior reports of UEC glial activation and enzyme production. Postinjury minocycline immunosuppression attenuated MMP-9 gelatinase activity, which was correlated with the reduction of neutrophil gelatinase-associated lipocalin (LCN2) expression, and reduced OPN fragment generation. The antibiotic also attenuated removal of synapsin-1 positive axons from the deafferented zone. OPN KO mice subjected to UEC had similar reduction of hippocampal MMP-9 activity, as well as lower synapsin-1 breakdown over the deafferented zone. MAP1B and N-cadherin, surrogates of cytoarchitecture and synaptic adhesion, were not affected. OPN KO mice with UEC exhibited time dependent cognitive deficits during the synaptogenic phase of recovery. This study demonstrates that OPN can mediate immune response during TBI synaptic repair, positively influencing synapse reorganization and functional recovery. (C) 2014 Elsevier Inc. All rights reserved.	[Chan, Julie L.; Reeves, Thomas M.; Phillips, Linda L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Phillips, LL (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	llphilli@vcu.edu		Chan, Julie/0000-0002-0782-6548	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 044372, NS 056247, NS 057758]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056247, R01NS044372, R56NS044372, R01NS057758] Funding Source: NIH RePORTER	This work was supported by the NIH awards NS 044372, NS 056247 and NS 057758. We thank Lesley Harris, Raiford Black, Nancy Lee and Terry Smith for excellent technical assistance and Dr. Adele Doperalski for helpful comments on the manuscript. The authors are grateful for the expert support and data analysis in the qtRT-PCR studies provided by Tana Blevins and Dr. Catherine Dumur, Molecular Diagnostic Services Laboratory, Department of Pathology, VCU.	Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Borges K, 2008, EPILEPSIA, V49, P1675, DOI 10.1111/j.1528-1167.2008.01613.x; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cayabyab FS, 2013, J NEUROSCI RES, V91, P920, DOI 10.1002/jnr.23223; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Choi JS, 2007, BRAIN RES, V1151, P195, DOI 10.1016/j.brainres.2007.03.016; Choi JS, 2004, EXP BRAIN RES, V154, P275, DOI 10.1007/s00221-003-1657-4; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Degos V, 2013, ANESTHESIOLOGY, V118, P1362, DOI 10.1097/ALN.0b013e31828c23f8; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Dityatev A, 2006, CELL TISSUE RES, V326, P647, DOI 10.1007/s00441-006-0217-1; Dumur CI, 2009, LARYNGOSCOPE, V119, P91, DOI 10.1002/lary.20005; Ellison JA, 1998, STROKE, V29, P1698, DOI 10.1161/01.STR.29.8.1698; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ethell IM, 2007, J NEUROSCI RES, V85, P2813, DOI 10.1002/jnr.21273; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Fifre A, 2006, J BIOL CHEM, V281, P229, DOI 10.1074/jbc.M507378200; Fuller BF, 2012, ENVIRON HEALTH PERSP, V120, P1684, DOI 10.1289/ehp.1104857; Goussev S, 2003, J NEUROSURG, V99, P188, DOI 10.3171/spi.2003.99.2.0188; GREIF KF, 1988, SYNAPSE, V2, P1, DOI 10.1002/syn.890020102; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Guest PC, 2012, PROTEOMICS, V12, P3580, DOI 10.1002/pmic.201200376; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Hashimoto M, 2003, J NEUROTRAUM, V20, P287, DOI 10.1089/089771503321532879; Hashimoto M, 2007, J NEUROSCI, V27, P3603, DOI 10.1523/JNEUROSCI.4805-06.2007; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Higo N, 2010, J COMP NEUROL, V518, P2633, DOI 10.1002/cne.22356; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; HWANG S, 1994, J BIOL CHEM, V269, P711; Iczkiewicz J, 2004, MOL BRAIN RES, V132, P64, DOI 10.1016/j.molbrainres.2004.09.013; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Ju WK, 2000, BRAIN RES, V852, P217, DOI 10.1016/S0006-8993(99)02140-X; Kang WS, 2008, BRAIN RES, V1228, P208, DOI 10.1016/j.brainres.2008.06.106; Keilhoff G, 2007, DEV NEUROBIOL, V67, P1382, DOI 10.1002/dneu.20384; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee MY, 1999, NEUROSCI LETT, V271, P81, DOI 10.1016/S0304-3940(99)00526-1; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lively S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-75; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; Long P, 2012, EUR J NEUROSCI, V36, P2733, DOI 10.1111/j.1460-9568.2012.08189.x; Lu L, 2008, HIPPOCAMPUS, V18, P1074, DOI 10.1002/hipo.20466; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; LUND RD, 1971, SCIENCE, V171, P804, DOI 10.1126/science.171.3973.804; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Maetzler W, 2007, NEUROBIOL DIS, V25, P473, DOI 10.1016/j.nbd.2006.10.020; Matsukawa N, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-126; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Meunier J., 2001, EUR J PHARMACOL, V698, P193; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Misawa H, 2012, J NEUROSCI RES, V90, P732, DOI 10.1002/jnr.22813; Moon C, 2004, J VET MED SCI, V66, P1307, DOI 10.1292/jvms.66.1307; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morita M, 2008, NEUROSCIENCE, V153, P1135, DOI 10.1016/j.neuroscience.2008.01.078; Nikonenko I, 2003, DEV BRAIN RES, V140, P185, DOI 10.1016/S0165-3806(02)00590-4; Park JM, 2012, J HISTOCHEM CYTOCHEM, V60, P550, DOI 10.1369/0022155412441707; Park KP, 2009, STROKE, V40, P2836, DOI 10.1161/STROKEAHA.109.554824; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; Pellerin L, 2004, NEUROSCIENTIST, V10, P53, DOI 10.1177/1073858403260159; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Plantman S, 2012, NEUROREPORT, V23, P647, DOI 10.1097/WNR.0b013e328355380e; Popa-Wagner A, 1999, J CEREBR BLOOD F MET, V19, P425, DOI 10.1097/00004647-199904000-00008; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; REEVES TM, 1986, EXP BRAIN RES, V65, P167; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sato K, 2000, BRAIN RES, V872, P219, DOI 10.1016/S0006-8993(00)02460-4; Scatena M, 2007, ARTERIOSCL THROM VAS, V27, P2302, DOI 10.1161/ATVBAHA.107.144824; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Shin YJ, 2011, GLIA, V59, P413, DOI 10.1002/glia.21110; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Sofroniew M.V., 2000, NEUROSCIENTIST, V5, P400; STEWARD O, 1977, BRAIN RES BULL, V2, P41, DOI 10.1016/0361-9230(77)90023-5; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Su JM, 2010, J COMP NEUROL, V518, P229, DOI 10.1002/cne.22228; Suzuki H, 2010, CRIT CARE MED, V38, P612, DOI 10.1097/CCM.0b013e3181c027ae; Takafuji V, 2007, ONCOGENE, V26, P6361, DOI 10.1038/sj.onc.1210463; Takeichi M, 2005, TRENDS CELL BIOL, V15, P216, DOI 10.1016/j.tcb.2005.02.002; Tambuyzer BR, 2012, CELL BIOL INT, V36, P1233, DOI 10.1042/CBI20120172; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Tschesche H, 2001, EUR J BIOCHEM, V268, P1918, DOI 10.1046/j.1432-1327.2001.02066.x; van Velthoven CTJ, 2011, STROKE, V42, P2294, DOI 10.1161/STROKEAHA.110.608315; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; Verslegers M, 2013, PROG NEUROBIOL, V105, P60, DOI 10.1016/j.pneurobio.2013.03.004; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang XK, 1998, J NEUROSCI, V18, P2075; Warren KM, 2012, J NEUROTRAUM, V29, P1922, DOI 10.1089/neu.2012.2383; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Wung JK, 2007, CURR ALZHEIMER RES, V4, P67, DOI 10.2174/156720507779939869; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yamamoto T., 2011, PLOS ONE, V8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhao C, 2008, NEUROBIOL DIS, V31, P209, DOI 10.1016/j.nbd.2008.04.007; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	121	38	39	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2014	261						757	771		10.1016/j.expneurol.2014.08.015			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR4AX	WOS:000343531500082	25151457	Green Accepted			2022-02-06	
J	Bennett, RE; Brody, DL				Bennett, Rachel E.; Brody, David L.			Acute Reduction of Microglia Does Not Alter Axonal Injury in a Mouse Model of Repetitive Concussive Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axon injury; concussion; microglia	COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; WHITE-MATTER; BETA; ACTIVATION; ENCEPHALOPATHY; VULNERABILITY; INFLAMMATION	The pathological processes that lead to long-term consequences of multiple concussions are unclear. Primary mechanical damage to axons during concussion is likely to contribute to dysfunction. Secondary damage has been hypothesized to be induced or exacerbated by inflammation. The main inflammatory cells in the brain are microglia, a type of macrophage. This research sought to determine the contribution of microglia to axon degeneration after repetitive closed-skull traumatic brain injury (rcTBI) using CD11b-TK (thymidine kinase) mice, a valganciclovir-inducible model of macrophage depletion. Low-dose (1 mg/mL) valganciclovir was found to reduce the microglial population in the corpus callosum and external capsule by 35% after rcTBI in CD11b-TK mice. At both acute (7 days) and subacute (21 days) time points after rcTBI, reduction of the microglial population did not alter the extent of axon injury as visualized by silver staining. Further reduction of the microglial population by 56%, using an intermediate dose (10mg/mL), also did not alter the extent of silver staining, amyloid precursor protein accumulation, neurofilament labeling, or axon injury evident by electron microscopy at 7 days postinjury. Longer treatment of CD11b-TK mice with intermediate dose and treatment for 14 days with high-dose (50mg/mL) valganciclovir were both found to be toxic in this injury model. Altogether, these data are most consistent with the idea that microglia do not contribute to acute axon degeneration after multiple concussive injuries. The possibility of longer-term effects on axon structure or function cannot be ruled out. Nonetheless, alternative strategies directly targeting injury to axons may be a more beneficial approach to concussion treatment than targeting secondary processes of microglial-driven inflammation.	[Bennett, Rachel E.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 South Euclid Ave Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020	Bennett, Rachel/0000-0001-9640-0575	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31-NS076047, R01-NS065069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS076047, R01NS065069] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ashki N, 2006, J NEUROTRAUM, V23, P1779, DOI 10.1089/neu.2006.23.1779; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davies AL, 2006, J NEUROTRAUM, V23, P1261, DOI 10.1089/neu.2006.23.1261; DeVos SL, 2013, JOVE-J VIS EXP, DOI 10.3791/50326; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gowing G, 2006, GLIA, V53, P331, DOI 10.1002/glia.20288; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hosmane S, 2012, J NEUROSCI, V32, P7745, DOI 10.1523/JNEUROSCI.0203-12.2012; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORTIMER JA, 1985, MINN MED, V68, P299; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Varvel NH, 2012, P NATL ACAD SCI USA, V109, P18150, DOI 10.1073/pnas.1210150109; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	53	38	39	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1647	1663		10.1089/neu.2013.3320			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400007	24797413	Green Published, Green Submitted			2022-02-06	
J	Mutschler, M; Paffrath, T; Wolfl, C; Probst, C; Nienaber, U; Schipper, IB; Bouillon, B; Maegele, M				Mutschler, M.; Paffrath, T.; Woelfl, C.; Probst, C.; Nienaber, U.; Schipper, I. B.; Bouillon, B.; Maegele, M.			The ATLS (R) classification of hypovolaemic shock: A well established teaching tool on the edge?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						ATLS; Shock; Blood loss; Trauma; Vital signs	TRAUMA LIFE-SUPPORT; BASE DEFICIT; HYPOTENSION	Uncontrolled bleeding is the leading cause of shock in trauma patients and delays in recognition and treatment have been linked to adverse outcomes. For prompt detection and management of hypovolaemic shock, ATLS (R) suggests four shock classes based upon vital signs and an estimated blood loss in percent. Although this classification has been widely implemented over the past decades, there is still no clear prospective evidence to fully support this classification. In contrast, it has recently been shown that this classification may be associated with substantial deficits. A retrospective analysis of data derived from the TraumaRegister DGU (R) indicated that only 9.3% of all trauma patients could be allocated into one of the ATLS (R) shock classes when a combination of the three vital signs heart rate, systolic blood pressure and Glasgow Coma Scale was assessed. Consequently, more than 90% of all trauma patients could not be classified according to the ATLS (R) classification of hypovolaemic shock. Further analyses including also data from the UK-based TARN registry suggested that ATLS (R) may overestimate the degree of tachycardia associated with hypotension and underestimate mental disability in the presence of hypovolaemic shock. This finding was independent from pre-hospital treatment as well as from the presence or absence of a severe traumatic brain injury. Interestingly, even the underlying trauma mechanism (blunt or penetrating) had no influence on the number of patients who could be allocated adequately. Considering these potential deficits associated with the ATLS (R) classification of hypovolaemic shock, an online survey among 383 European ATLS (R) course instructors and directors was performed to assess the actual appreciation and confidence in this tool during daily clinical trauma care. Interestingly, less than half (48%) of all respondents declared that they would assess a potential circulatory depletion within the primary survey according to the ATLS (R) classification of hypovolaemic shock. Based on these observations, a critical reappraisal of the current ATLS (R) classification of hypovolaemic seems warranted. (C) 2014 Elsevier Ltd. All rights reserved.	[Mutschler, M.; Paffrath, T.; Probst, C.; Bouillon, B.; Maegele, M.] Private Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Orthoped Trauma & Sportsmed, D-51109 Cologne, Germany; [Woelfl, C.] BG Hosp Ludwigshafen, Dept Trauma & Orthoped Surg, Ludwigshafen, Germany; [Nienaber, U.] Acad Trauma Surg AUC, Berlin, Germany; [Schipper, I. B.] Leiden Univ, Med Ctr, Dept Trauma Surg, Leiden, Netherlands		Mutschler, M (corresponding author), Private Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Orthoped Trauma & Sports Med, Campus Cologne Merheim,Ostmerheimer Str 200, D-51109 Cologne, Germany.	manuelmutschler@web.de	Schipper, Inger/ABE-7796-2021	Schipper, Inger/0000-0001-9952-3079			Brasel KJ, 2007, J TRAUMA, V62, P812, DOI 10.1097/TA.0b013e31803245a1; Committee on Trauma American College of Surgeons, 2008, ADV TRAUM LIF SUPP D; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Guly HR, 2011, RESUSCITATION, V82, P556, DOI 10.1016/j.resuscitation.2011.01.013; Guly HR, 2010, RESUSCITATION, V81, P1142, DOI 10.1016/j.resuscitation.2010.04.007; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Ley EJ, 2009, J TRAUMA, V67, P1051, DOI 10.1097/TA.0b013e3181bba222; Mutschler M, 2013, RESUSCITATION, V84, P309, DOI 10.1016/j.resuscitation.2012.07.012; Mutschler M, 2013, EMERG MED J; Mutschler M, 2014, EMERG MED J, V31, P35, DOI 10.1136/emermed-2012-202130; Mutschler M, 2013, CRIT CARE, V17, DOI 10.1186/cc12555; Parks JK, 2006, AM J SURG, V192, P727, DOI 10.1016/j.amjsurg.2006.08.034; Privette AR, 2013, CRIT CARE, V17, DOI 10.1186/cc12513; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5	16	38	38	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2014	45			3			S35	S38		10.1016/j.injury.2014.08.015			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AR0DP	WOS:000343237400008	25284231				2022-02-06	
J	Nguyen, BM; Kim, D; Bricker, S; Bongard, F; Neville, A; Putnam, B; Smith, J; Plurad, D				Nguyen, Brian M.; Kim, Dennis; Bricker, Scott; Bongard, Fred; Neville, Angela; Putnam, Brant; Smith, Jennifer; Plurad, David			Effect of Marijuana Use on Outcomes in Traumatic Brain Injury	AMERICAN SURGEON			English	Article							CLOSED-HEAD INJURY; DEXANABINOL HU-211; CANNABINOIDS	Traumatic brain injury (TBI) is associated with significant morbidity and mortality. Several studies have demonstrated neuroprotective effects of cannabinoids. The objective of this study was to establish a relationship between the presence of a positive toxicology screen for tetrahydrocannabinol (THC) and mortality after TBI. A 3-year retrospective review of registry data at a Level I center of patients sustaining TBI having a toxicology screen was performed. Pediatric patients (younger than 15 years) and patients with a suspected nonsurvivable injury were excluded. The THC(+) group was compared with the THC(-) group with respect to injury mechanism, severity, disposition, and mortality. Logistic regression was used to determine independent associations with mortality. There were 446 cases meeting all inclusion criteria. The incidence of a positive THC screen was 18.4 per cent (82). Overall mortality was 9.9 per cent (44); however, mortality in the THC(+) group (2.4% [two]) was significantly decreased compared with the THC(-) group (11.5% [42]; P = 0.012). After adjusting for differences between the study cohorts on logistic regression, a THC(+) screen was independently associated with survival after TBI (odds ratio, 0.224; 95% confidence interval, 0.051 to 0.991; P = 0.049). A positive THC screen is associated with decreased mortality in adult patients sustaining TBI.	[Nguyen, Brian M.; Kim, Dennis; Bricker, Scott; Bongard, Fred; Neville, Angela; Putnam, Brant; Smith, Jennifer; Plurad, David] Harbor UCLA Med Ctr, Torrance, CA 90509 USA		Plurad, D (corresponding author), Harbor UCLA Med Ctr, 1000 W Carson St,Box 42, Torrance, CA 90509 USA.	dsplurad@yahoo.com					Allegretti JR, 2013, INFLAMM BOWEL DIS, V19, P2809, DOI 10.1097/01.MIB.0000435851.94391.37; Asbridge M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e536; Borgelt LM, 2013, PHARMACOTHERAPY, V33, P195, DOI 10.1002/phar.1187; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Center for Behavioral Health Statistics and Quality, 2012, GUID DAWN TREND TABL; Durmaz R, 2008, NEUROSURG REV, V31, P215, DOI 10.1007/s10143-007-0119-z; Goodwin RS, 2008, J ANAL TOXICOL, V32, P562, DOI 10.1093/jat/32.8.562; Gowran A, 2011, CNS NEUROSCI THER, V17, P637, DOI 10.1111/j.1755-5949.2010.00195.x; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Lagbas C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/143092; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Sagredo O, 2011, J NEUROSCI RES, V89, P1509, DOI 10.1002/jnr.22682; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Tomida I, 2006, J GLAUCOMA, V15, P349, DOI 10.1097/01.ijg.0000212260.04488.60; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49	16	38	38	0	29	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	OCT	2014	80	10					979	983					5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AP7SV	WOS:000342277900015	25264643				2022-02-06	
J	Chen, S; Wu, HJ; Klebe, D; Hong, Y; Zhang, JM				Chen, Sheng; Wu, Haijian; Klebe, Damon; Hong, Yuan; Zhang, Jianmin			Valproic Acid: A New Candidate of Therapeutic Application for the Acute Central Nervous System Injuries	NEUROCHEMICAL RESEARCH			English	Article						Valproic acid; Brain injuries; Histone deacetylases inhibitor; Neuroprotection	HISTONE DEACETYLASE INHIBITORS; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; PROTECTS DOPAMINERGIC-NEURONS; PROMOTES FUNCTIONAL RECOVERY; MOOD STABILIZER; MEDIATED NEUROPROTECTION; BARRIER DISRUPTION; HEMORRHAGIC-SHOCK	Acute central nervous system (CNS) injuries, including stroke, traumatic brain injury (TBI), and spinal cord injury (SCI), are common causes of human disabilities and deaths, but the pathophysiology of these diseases is not fully elucidated and, thus, effective pharmacotherapies are still lacking. Valproic acid (VPA), an inhibitor of histone deacetylation, is mainly used to treat epilepsy and bipolar disorder with few complications. Recently, the neuroprotective effects of VPA have been demonstrated in several models of acute CNS injuries, such as stroke, TBI, and SCI. VPA protects the brain from injury progression via anti-inflammatory, anti-apoptotic, and neurotrophic effects. In this review, we focus on the emerging neuroprotective properties of VPA and explore the underlying mechanisms. In particular, we discuss several potential related factors in VPA research and present the opportunity to administer VPA as a novel neuropective agent.	[Chen, Sheng; Wu, Haijian; Hong, Yuan; Zhang, Jianmin] Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China; [Klebe, Damon] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA; [Klebe, Damon] Loma Linda Univ, Dept Pharmacol, Loma Linda, CA 92350 USA		Zhang, JM (corresponding author), Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.	zjm135vip@126.com		chen, sheng/0000-0002-8374-136X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171096, 81371433, 81371369]	This study was supported by National Natural Science Foundation of China (No. 81171096 and No. 81371433) to JM Zhang and by National Natural Science Foundation of China (No. 81371369) to Y Hong.	Abdanipour Alireza, 2012, Iranian Biomedical Journal, V16, P90, DOI 10.6091/ibj.1060.2012; Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Ahmad M, 2010, TRANSL STROKE RES, V1, P74, DOI 10.1007/s12975-010-0023-7; Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Ambrozaitis Kazys Vytautas, 2006, Medicina (Kaunas), V42, P255; Baltan S, 2011, TRANSL STROKE RES, V2, P411, DOI 10.1007/s12975-011-0087-z; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bredy TW, 2007, LEARN MEMORY, V14, P268, DOI 10.1101/lm.500907; Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002; Cannizzaro E, 2007, NEUROPEDIATRICS, V38, P42, DOI 10.1055/s-2007-981448; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Cavallucci V, 2011, CURR PHARM DESIGN, V17, P215, DOI 10.2174/138161211795049705; Chen PS, 2007, NEUROSCIENCE, V149, P203, DOI 10.1016/j.neuroscience.2007.06.053; Chen PS, 2006, MOL PSYCHIATR, V11, P1116, DOI 10.1038/sj.mp.4001893; Chiu CT, 2013, PHARMACOL REV, V65, P105, DOI 10.1124/pr.111.005512; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; D'Mello SR, 2009, DRUG NEWS PERSPECT, V22, P513, DOI [10.1358/dnp.2009.9.1428871, 10.1358/dnp.2009.22.9.1437959]; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DAVIS R, 1994, DRUGS, V47, P332, DOI 10.2165/00003495-199447020-00008; Dinarello CA, 2011, MOL MED, V17, P333, DOI 10.2119/molmed.2011.00116; Eyal S, 2004, EPILEPSIA, V45, P737, DOI 10.1111/j.0013-9580.2004.00104.x; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Filli L, 2012, ANN NEUROL, V72, P491, DOI 10.1002/ana.23630; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Gibbons HM, 2011, NEUROBIOL DIS, V41, P96, DOI 10.1016/j.nbd.2010.08.024; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Graff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427; Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x; Hamer HM, 2009, NERVENARZT, V80, P405, DOI 10.1007/s00115-009-2680-x; Hao HH, 2013, NEUROSCI BULL, V29, P484, DOI 10.1007/s12264-013-1355-6; Hao YL, 2004, J NEUROSCI, V24, P6590, DOI 10.1523/JNEUROSCI.5747-03.2004; Harder J, 2009, J IMMUNOL, V183, P5823, DOI 10.4049/jimmunol.0900444; Hasan MR, 2013, NEUROCHEM RES, V38, P1921, DOI 10.1007/s11064-013-1098-9; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hunsberger JG, 2012, AM J TRANSL RES, V4, P316; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jaffer H, 2011, DRUG DELIV TRANSL RE, V1, P409, DOI 10.1007/s13346-011-0046-y; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Kabakus N, 2005, J CHILD NEUROL, V20, P582, DOI 10.1177/08830738050200070801; Kao CY, 2013, J NEUROCHEM, V126, P4, DOI 10.1111/jnc.12292; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Koenig S, 2008, BLOOD COAGUL FIBRIN, V19, P375, DOI 10.1097/MBC.0b013e3282f3f9ec; KREUZ W, 1990, LANCET, V335, P1350, DOI 10.1016/0140-6736(90)91235-3; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Kwon KJ, 2013, NEUROCHEM INT, V62, P240, DOI 10.1016/j.neuint.2012.12.019; Lahue RS, 2012, EPIGENETICS-US, V7, P806, DOI 10.4161/epi.20922; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu XS, 2012, NEUROSCIENCE, V220, P313, DOI 10.1016/j.neuroscience.2012.06.012; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lv L, 2012, EXP NEUROL, V233, P783, DOI 10.1016/j.expneurol.2011.11.042; Lv L, 2011, BRAIN RES, V1396, P60, DOI 10.1016/j.brainres.2011.03.040; Marinova Z, 2009, J NEUROCHEM, V111, P976, DOI 10.1111/j.1471-4159.2009.06385.x; Marsh JD, 2010, J AM COLL CARDIOL, V56, P683, DOI 10.1016/j.jacc.2009.12.072; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Monti Barbara, 2009, Curr Mol Pharmacol, V2, P95; Mora A, 1999, EUR J BIOCHEM, V266, P886, DOI 10.1046/j.1432-1327.1999.00919.x; Mora A, 2002, BIPOLAR DISORD, V4, P195, DOI 10.1034/j.1399-5618.2002.40301.x; Mukherjee D, 2011, WORLD NEUROSURG, V76, pS85, DOI 10.1016/j.wneu.2011.07.023; Nalivaeva NN, 2009, TRENDS PHARMACOL SCI, V30, P509, DOI 10.1016/j.tips.2009.07.002; Osuka S, 2012, NEUROL MED-CHIR, V52, P186, DOI 10.2176/nmc.52.186; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev-bioeng-070909-105309; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Peng GS, 2005, MOL BRAIN RES, V134, P162, DOI 10.1016/j.molbrainres.2004.10.021; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piepers S, 2009, ANN NEUROL, V66, P227, DOI 10.1002/ana.21620; Pohlmann-Eden B, 2003, ACTA NEUROL SCAND, V108, P142, DOI 10.1034/j.1600-0404.2003.00149.x; Qian YR, 2010, KOREAN J PHYSIOL PHA, V14, P435, DOI 10.4196/kjpp.2010.14.6.435; Rao R, 2012, ADV CANCER RES, V116, P239, DOI 10.1016/B978-0-12-394387-3.00007-0; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4; Segovia J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029695; Shein NA, 2011, MOL MED, V17, P448, DOI 10.2119/molmed.2011.00038; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Suda S, 2013, EUR J PHARMACOL, V707, P26, DOI 10.1016/j.ejphar.2013.03.020; SYMINGTON GR, 1978, AM J PSYCHIAT, V135, P352; Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788; Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vajda FJE, 2002, J CLIN NEUROSCI, V9, P508, DOI 10.1054/jocn.2002.1133; Wang ZF, 2012, STROKE, V43, P2430, DOI 10.1161/STROKEAHA.112.652545; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Wu XF, 2008, INT J NEUROPSYCHOPH, V11, P1123, DOI 10.1017/S1461145708009024; Xuan AG, 2012, LIFE SCI, V90, P463, DOI 10.1016/j.lfs.2012.01.001; Yasuda S, 2009, MOL PSYCHIATR, V14, P51, DOI 10.1038/sj.mp.4002099; Yu FS, 2013, J NEUROSURG, V119, P766, DOI 10.3171/2013.6.JNS13135; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhang Z, 2012, NEUROSCIENCE, V221, P140, DOI 10.1016/j.neuroscience.2012.07.013; Zhang ZZ, 2012, EXP EYE RES, V94, P98, DOI 10.1016/j.exer.2011.11.013; Zhang ZZ, 2011, NEUROSCI LETT, V504, P88, DOI 10.1016/j.neulet.2011.09.003	106	38	41	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	SEP	2014	39	9					1621	1633		10.1007/s11064-014-1241-2			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AO9WV	WOS:000341711800001	24482021				2022-02-06	
J	Mannings, C; Kalynych, C; Joseph, MM; Smotherman, C; Kraemer, DF				Mannings, Carol; Kalynych, Colleen; Joseph, Madeline Matar; Smotherman, Carmen; Kraemer, Dale F.			Knowledge assessment of sports-related concussion among parents of children aged 5 years to 15 years enrolled in recreational tackle football	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Sports-related concussion; pediatric; parental knowledge; pre-high school-aged athletes	HIGH-SCHOOL; YOUTH; EPIDEMIOLOGY; RECOVERY; PLAYERS	BACKGROUND: Sports-related concussion among professional, collegiate, and, more recently, high school athletes has received much attention from the media and medical community. To our knowledge, there is a paucity of research regarding parental knowledge of sports-related concussion. The aim of this study was to evaluate parental knowledge of concussion in young children who participated in recreational tackle football. METHODS: Parents of children aged 5 years to 15 years attending recreational tackle football games were asked to complete an anonymous questionnaire based on the Centers for Disease Control and Prevention's Heads Up: Concussion in Youth Sports Quiz. The parents were asked about their level of agreement regarding statements that represent definition, symptoms, and treatment of concussion. RESULTS: A total of 310 of 369 parents (84% response rate) voluntarily completed the questionnaire, with 94% believing that their child had never had a concussion. However, only 13% (n = 41) could correctly identify all seven statements. Most did not identify that a concussion is considered a mild traumatic brain injury and can be achieved from something other than a direct blow to the head. Race, sex, and zip code had no significant association with correctly answering statements. Education (r = 0.24, p < 0.0001) and number of years the child played (r = 0.11, p = 0.049) had a small association. Fifty-three percent and 58% of the parents reported that someone had discussed the definition and the symptoms of concussion with them, respectively, with only about half reporting that information came from their health care provider. No parent was able to classify all symptoms listed as correctly related or not related to concussion. However, identification of correct concussion statements correlated with identification of correct symptoms (r = 0.25, p < 0.001). CONCLUSION: While most parents of young athletes demonstrated some knowledge regarding concussion, important misconceptions remain regarding the definition, symptoms, and treatment of concussion. This study highlights the need for health care providers to increase concussion educational efforts. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Mannings, Carol; Kalynych, Colleen; Joseph, Madeline Matar] Univ Florida, Coll Med, Dept Emergency Med, Jacksonville, FL 32209 USA; [Smotherman, Carmen; Kraemer, Dale F.] Univ Florida, Coll Med, Ctr Hlth Equ & Qual Res, Jacksonville, FL 32209 USA; [Kraemer, Dale F.] Univ Florida, Coll Med, Dept Neurol, Jacksonville, FL 32209 USA		Mannings, C (corresponding author), Univ Florida, Coll Med, Dept Emergency Med, 655 West 8th St, Jacksonville, FL 32209 USA.	carol.mannings@jax.ufl.edu	Meijer, Anna/K-5118-2016				[Anonymous], CONC; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gomez JE, 2013, J ADOLESCENT HEALTH, V53, P311, DOI 10.1016/j.jadohealth.2013.06.018; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Jinguji TM, 2011, PHYS MED REH CLIN N, V22, P565, DOI 10.1016/j.pmr.2011.08.001; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Theye Fred, 2004, Clin Med Res, V2, P165; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	24	38	38	0	40	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2014	77			1			S18	S22		10.1097/TA.0000000000000371			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AO2BK	WOS:000341120300005	25153049				2022-02-06	
J	Corbo, V; Salat, DH; Amick, MM; Leritz, EC; Milberg, WP; McGlinchey, RE				Corbo, Vincent; Salat, David H.; Amick, Melissa M.; Leritz, Elizabeth C.; Milberg, William P.; McGlinchey, Regina E.			Reduced cortical thickness in veterans exposed to early life trauma	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Posttraumatic stress disorder (PTSD); Trauma; Posterior cingulate; Amygdala; Cortical thickness	POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; CORTICOTROPIN-RELEASING-FACTOR; SMALLER HIPPOCAMPAL VOLUME; ANTERIOR CINGULATE CORTEX; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; PREFRONTAL CORTEX; LONG-TERM; BRAIN	Studies have shown that early life trauma may influence neural development and increase the risk of developing psychological disorders in adulthood. We used magnetic resonance imaging to examine the impact of early life trauma on the relationship between current posttraumatic stress disorder (PTSD) symptoms and cortical thickness/subcortical volumes in a sample of deployed personnel from Operation Enduring Freedom/Operation Iraqi Freedom. A group of 108 service members enrolled in the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) were divided into those with interpersonal early life trauma (EL-Trauma+) and Control (without interpersonal early life trauma) groups based on the Traumatic Life Events Questionnaire. PTSD symptoms were assessed using the Clinician-Administered PTSD Scale. Cortical thickness and subcortical volumes were analyzed using the FreeSurfer image analysis package. Thickness of the paracentral and posterior cingulate regions was positively associated with PTSD severity in the EL-Trauma+ group and negatively in the Control group. In the EL-Trauma+ group, both the right amygdala and the left hippocampus were positively associated with PTSD severity. This study illustrates a possible influence of early life trauma on the vulnerability of specific brain regions to stress. Changes in neural morphometry may provide information about the emergence and maintenance of symptoms in individuals with PTSD. Published by Elsevier Ireland Ltd.	[Corbo, Vincent; Salat, David H.; Amick, Melissa M.; Leritz, Elizabeth C.; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Geriatr Res Educ & Clin Ctr, Jamaica Plain, MA USA; [Corbo, Vincent; Amick, Melissa M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Corbo, Vincent; Salat, David H.] VA Boston Healthcare, Neuroimaging Res Vet NeRVe Ctr, Jamaica Plain, MA USA; [Salat, David H.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA; [Leritz, Elizabeth C.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA		Corbo, V (corresponding author), Boston Univ, VA Boston Healthcare, Boston, MA 02215 USA.	vincent.corbo@mail.mcgill.ca	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS062148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR010827] Funding Source: NIH RePORTER	This research was support by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C).	American Psychiatric Association, 2004, DIAGN STAT MAN MENT; Andersen SL, 2008, J NEUROPSYCH CLIN N, V20, P292, DOI 10.1176/appi.neuropsych.20.3.292; Beckmann M, 2009, J NEUROSCI, V29, P1175, DOI 10.1523/JNEUROSCI.3328-08.2009; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 2001, J CLIN PSYCHIAT, V62, P16; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Buss C, 2007, J NEUROSCI, V27, P2592, DOI 10.1523/JNEUROSCI.3252-06.2007; Carpenter LL, 2004, NEUROPSYCHOPHARMACOL, V29, P777, DOI 10.1038/sj.npp.1300375; Carrion VG, 2007, PEDIATRICS, V119, P509, DOI 10.1542/peds.2006-2028; Chen YC, 2004, P NATL ACAD SCI USA, V101, P15782, DOI 10.1073/pnas.0403975101; Cohen RA, 2006, BIOL PSYCHIAT, V59, P975, DOI 10.1016/j.biopsych.2005.12.016; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dannlowski U, 2012, BIOL PSYCHIAT, V71, P286, DOI 10.1016/j.biopsych.2011.10.021; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Dickie EW, 2013, PSYCHOL MED, V43, P645, DOI 10.1017/S0033291712001328; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fortier C.B., 2013, J HEAD TRAUMA REHAB, V66, P1373; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Geuze E, 2008, NEUROIMAGE, V41, P675, DOI 10.1016/j.neuroimage.2008.03.007; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hartley CA, 2011, CEREB CORTEX, V21, P1954, DOI 10.1093/cercor/bhq253; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Heim C, 2002, DEPRESS ANXIETY, V15, P117, DOI 10.1002/da.10015; Heim CM, 2013, AM J PSYCHIAT, V170, P616, DOI 10.1176/appi.ajp.2013.12070950; Hellstrom IC, 2012, PHILOS T R SOC B, V367, P2495, DOI 10.1098/rstb.2012.0223; Jarnum H, 2011, ACTA PSYCHIAT SCAND, V124, P435, DOI 10.1111/j.1600-0447.2011.01766.x; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kitayama N, 2006, J AFFECT DISORDERS, V90, P171, DOI 10.1016/j.jad.2005.11.006; Koenig LB, 2009, J STUD ALCOHOL DRUGS, V70, P296, DOI 10.15288/jsad.2009.70.296; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Kuo JR, 2012, ARCH GEN PSYCHIAT, V69, P1080, DOI 10.1001/archgenpsychiatry.2012.73; Landre L, 2010, PSYCHIAT RES-NEUROIM, V183, P181, DOI 10.1016/j.pscychresns.2010.01.015; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Leritz EC, 2011, NEUROIMAGE, V54, P2659, DOI 10.1016/j.neuroimage.2010.10.050; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039025; Lupien SJ, 2011, P NATL ACAD SCI USA, V108, P14324, DOI 10.1073/pnas.1105371108; Milad MR, 2005, P NATL ACAD SCI USA, V102, P10706, DOI 10.1073/pnas.0502441102; Nichols TE, 2012, NEUROIMAGE, V62, P811, DOI 10.1016/j.neuroimage.2012.04.014; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Pitman RK, 2001, J CLIN PSYCHIAT, V62, P47; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Rimol LM, 2010, BIOL PSYCHIAT, V68, P41, DOI 10.1016/j.biopsych.2010.03.036; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Tottenham N, 2010, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.068.2009; van der Kolk BA, 2003, CHILD ADOL PSYCH CL, V12, P293, DOI 10.1016/S1056-4993(03)00003-8; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Vogt BA, 2003, EUR J NEUROSCI, V18, P3134, DOI 10.1111/j.1460-9568.2003.03034.x; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Vyas A, 2002, J NEUROSCI, V22, P6810; Wignall EL, 2004, BIOL PSYCHIAT, V56, P832, DOI 10.1016/j.biopsych.2004.09.015; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Woon FL, 2008, HIPPOCAMPUS, V18, P729, DOI 10.1002/hipo.20437; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Zhang TY, 2006, BIOL PSYCHOL, V73, P72, DOI 10.1016/j.biopsycho.2006.01.009	68	38	38	1	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	AUG 30	2014	223	2					53	60		10.1016/j.pscychresns.2014.04.013			8	Clinical Neurology; Neuroimaging; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	AM6ZK	WOS:000340014300001	24862391	Green Accepted			2022-02-06	
J	Bere, T; Florenes, TW; Krosshaug, T; Haugen, P; Svandal, I; Nordsletten, L; Bahr, R				Bere, T.; Florenes, T. W.; Krosshaug, T.; Haugen, P.; Svandal, I.; Nordsletten, L.; Bahr, R.			A systematic video analysis of 69 injury cases in World Cup alpine skiing	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Alpine ski racing; injuries; mechanisms; World Cup skier; video recordings	CRUCIATE LIGAMENT INJURY; PREVENTION; MECHANISMS; SKIERS; SPORT; CONCUSSION; ETIOLOGY; SHOULDER; RISK	We have limited insight into how injuries occur in professional ski racing. The aim of this study was to describe the injury situations in World Cup alpine skiing. Injuries reported through the International Ski Federation Injury Surveillance System for three consecutive World Cup seasons (2006-2009) were obtained on video. In total, 69 injuries and 124 runs of matched controls were analysed by five experts to evaluate the skiing situation, skier behavior, as well as piste-related factors. A chi-square test (95% CI, P <= 0.05) was used to examine whether there was a difference between course sections regarding where the injury situation occurred. The skier was most frequently turning (n = 55) or landing from a jump (n = 13) at the time of injury. Most of the injuries to the head and upper body (96%) resulted from crashes, while the majority of knee injuries (83%) occurred while the skier was still skiing. Gate contact contributed to 30% of the injuries, while 9% occurred at contact with safety nets/material. Almost half of the injuries (46%) occurred in the final fourth of the course. A particular concern was the high contribution of inappropriate gate contact and the high-energy impacts to the body when crashing.	[Bere, T.; Florenes, T. W.; Krosshaug, T.; Nordsletten, L.; Bahr, R.] Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, Dept Sports Med, N-0806 Oslo, Norway; [Haugen, P.] Norwegian Sch Sport Sci, Dept Phys Performance, N-0806 Oslo, Norway; [Svandal, I.] Norwegian Ski Federat, Norwegian Alpine Ski Team, Oslo, Norway		Bere, T (corresponding author), Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, Dept Sports Med, PB 4014 Ulleval Stad, N-0806 Oslo, Norway.	tone.bere@nih.no	Krosshaug, Tron/AAT-2390-2021	Bahr, Roald/0000-0001-5725-4237	Royal Norwegian Ministry of Culture; South-Eastern Norway Regional Health Authority; International Olympic Committee; Norwegian Olympic Committee & Confederation of Sport; Norsk Tipping AS; International Ski Federation; DJO	The Oslo Sports Trauma Research Center has been established at the Norwegian School of Sport Sciences through generous grants from the Royal Norwegian Ministry of Culture, the South-Eastern Norway Regional Health Authority, the International Olympic Committee, the Norwegian Olympic Committee & Confederation of Sport, and Norsk Tipping AS. The FIS Injury Surveillance System is supported by the International Ski Federation and was established through a grant from DJO. We would like to thank the International Ski Federation staff and officials for all practical support in collecting the injury data, as well as Anna Banach and Infront Sports & Media for help with video capture and editing.	Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bere T, 2011, BRIT J SPORT MED, V45, P1294, DOI 10.1136/bjsports-2011-090517; Bere T, 2011, AM J SPORT MED, V39, P1421, DOI 10.1177/0363546511405147; Boden Barry P, 2005, Curr Sports Med Rep, V4, P45; Boutin RD, 2005, SEMIN MUSCULOSKEL R, V9, P360, DOI 10.1055/s-2005-923380; Chuter GSJ, 2009, INJURY, V40, P652, DOI 10.1016/j.injury.2009.01.107; Dainese, 2012, D AIR PROT; Ekeland A, 1985, ASTM STP, P293; ENGKVIST O, 1982, INT J SPORTS MED, V3, P50, DOI 10.1055/s-2008-1026063; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; Fischer J F, 1994, Acta Orthop Belg, V60, P194; Florenes TW, 2012, SCAND J MED SCI SPOR, V22, P58, DOI 10.1111/j.1600-0838.2010.01147.x; Florenes TW, 2011, SCAND J MED SCI SPOR, V21, P196, DOI 10.1111/j.1600-0838.2009.01048.x; Florenes TW, 2009, BRIT J SPORT MED, V43, P973, DOI 10.1136/bjsm.2009.068759; Hunter RE, 1999, AM J SPORT MED, V27, P381, DOI 10.1177/03635465990270032101; Johnson RJ, 1997, AM SOC TEST MATER, V1289, P37, DOI 10.1520/STP18287S; Kocher MS, 1998, SPORTS MED, V25, P201, DOI 10.2165/00007256-199825030-00006; Koehle MS, 2002, SPORTS MED, V32, P785, DOI 10.2165/00007256-200232120-00003; Krosshaug T, 2005, BRIT J SPORT MED, V39, P330, DOI 10.1136/bjsm.2005.018358; MARGREITER R, 1976, ORTHOP CLIN N AM, V7, P51; McCall D, 2009, BRIT J SPORT MED, V43, P987, DOI 10.1136/bjsm.2009.068767; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McIntosh AS, 2011, BRIT J SPORT MED, V45, P1258, DOI 10.1136/bjsports-2011-090509; Meeuwisse WH, 2009, CLIN J SPORT MED, V19, P1, DOI 10.1097/JSM.0b013e3181979c1d; Natri A, 1999, SPORTS MED, V28, P35, DOI 10.2165/00007256-199928010-00004; Raas E., 1982, SKI TRAUMA SKIING SA, P202; Ruedl G, 2009, KNEE SURG SPORT TR A, V17, P1393, DOI 10.1007/s00167-009-0860-7; The International Ski Federation (FIS), 2011, INT SKI COMP RUL ICR; The International Ski Federation (FIS), 2011, FIS SPEC FLEX POL; The International Ski Federation (FIS), 2011, FIS SPEC COMP EQ COM; The International Ski Federation (FIS), 2011, FIS SP REL PAN 2012; The International Ski Federation (FIS), 2011, FIS SAF MAT; The International Ski Federation (FIS), 2011, FIS SPEC WORLD CUP R; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	36	38	39	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	AUG	2014	24	4					667	677		10.1111/sms.12038			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AM2YF	WOS:000339716800020	23301907				2022-02-06	
J	Longhi, L; Orsini, F; De Blasio, D; Fumagalli, S; Ortolano, F; Locatelli, M; Stocchetti, N; De Simoni, MG				Longhi, Luca; Orsini, Franca; De Blasio, Daiana; Fumagalli, Stefano; Ortolano, Fabrizio; Locatelli, Marco; Stocchetti, Nino; De Simoni, Maria-Grazia			Mannose-Binding Lectin Is Expressed After Clinical and Experimental Traumatic Brain Injury and Its Deletion Is Protective	CRITICAL CARE MEDICINE			English	Article						complement system; inflammation; mannose-binding lectin; pathophysiology; traumatic brain injury	CONTROLLED CORTICAL IMPACT; LONG-LASTING PROTECTION; COMPLEMENT ACTIVATION; CONTUSION VOLUME; DEFICIENCY; SYSTEM; INHIBITION; PATHWAY; MICE	Objective: Mannose-binding lectin protein is the activator of the lectin complement pathway. Goals were 1) to investigate mannose-binding lectin expression after human and experimental traumatic brain injury induced by controlled cortical impact and 2) to evaluate whether mannose-binding lectin deletion is associated with reduced sequelae after controlled cortical impact. Design: Translational research, combining a human/experimental observational study and a prospective experimental study. Setting: University hospital/research laboratory. Patients and Subjects: Brain-injured patients, C57Bl/6 mice, and mannose-binding lectin-A and mannose-binding lectin-C double-knockout (-/-) mice. Interventions: Using anti-human mannose-binding lectin antibody, we evaluated mannose-binding lectin expression in tissue samples from six patients who underwent surgery for a cerebral contusion. Immunohistochemistry was also performed on tissues obtained from mice at 30 minutes; 6, 12, 24, 48, and 96 hours; and 1 week after controlled cortical impact using anti-mouse mannose-binding lectin-A and mannose-binding lectin-C antibodies. We evaluated the effects of mannose-binding lectin deletion in wild-type and mannose-binding lectin-A and mannose-binding lectin-C double-knockout mice. Functional outcome was evaluated using the neuroscore and beam walk tests for 4 weeks postinjury (n = 11). Histological injury was evaluated by comparing neuronal cell counts in the cortex adjacent to the contusion (n = 11). Measurements and Main Results: Following human traumatic brain injury, we observed mannose-binding lectin-positive immunostaining in the injured cortex as early as few hours and up to 5 days postinjury. Similarly in mice, we observed mannose-binding lectin-C-positive immunoreactivity in the injured cortex beginning 30 minutes and persisting up to 1 week postinjury. The extent of mannose-binding lectin-A expression was lower when compared with that of mannose-binding lectin-C. We observed attenuated sensorimotor deficits in mannose-binding lectin (-/-) mice compared with wild-type mice at 2-4 weeks postinjury. Furthermore, we observed reduced cortical cell loss at 5 weeks postinjury in mannose-binding lectin (-/-) mice compared with wild-type mice. Conclusions: Mannose-binding lectin expression was documented after traumatic brain injury. The reduced sequelae associated with mannose-binding lectin absence suggest that mannose-binding lectin modulation might be a potential target after traumatic brain injury.	[Longhi, Luca; Fumagalli, Stefano; Ortolano, Fabrizio; Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplantat, Neurosurg Intens Care Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Orsini, Franca; De Blasio, Daiana; Fumagalli, Stefano; De Simoni, Maria-Grazia] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [De Blasio, Daiana] Univ G dAnnunzio, Dept Biomed Sci, Pescara, Italy; [Locatelli, Marco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosurg, Milan, Italy; Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; Mario Negri Inst Pharmacol Res, Milan, Italy		De Simoni, MG (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy.	desimoni@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Longhi, Luca/AAF-9903-2021; Stocchetti, Nino/O-7444-2017; Fumagalli, Stefano/I-3097-2019; Locatelli, Marco/AAC-5745-2022	De Simoni, Maria Grazia/0000-0001-6695-5297; Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Locatelli, Marco/0000-0003-0778-3653; Orsini, Franca/0000-0001-7415-9936; Ortolano, Fabrizio/0000-0003-1996-948X; Fumagalli, Stefano/0000-0003-3598-6263	Fondazione CariploFondazione Cariplo [2012-0590]	Dr. Longhi received grant support from Fondazione Cariplo (grant number 2012-0590). His institution received grant support from Fondazione Cariplo (the study was done as part of a funded research project on brain trauma). Dr. Orsini was funded by fellowship in memory of Mrs. Amalia Ghezzi. Dr. Fumagalli's institution received grant support from - Fondazione Cariplo. Dr. De Simoni received support for article research from - Fondazione Cariplo (grant number 2012-0590). Her institution received grant support (the study was done as part of a funded research project on brain trauma). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433; Endo Y, 2011, INT J BIOCHEM CELL B, V43, P705, DOI 10.1016/j.biocel.2011.02.003; Farber K, 2009, J NEUROSCI RES, V87, P644, DOI 10.1002/jnr.21875; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Hansen S, 2000, J IMMUNOL, V164, P2610, DOI 10.4049/jimmunol.164.5.2610; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Orsini F, 2012, CIRCULATION, V126, P1484, DOI 10.1161/CIRCULATIONAHA.112.103051; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Osthoff M, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-99; Osthoff M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021338; Pedersen ED, 2009, SCAND J IMMUNOL, V69, P555, DOI 10.1111/j.1365-3083.2009.02253.x; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Trendelenburg M, 2010, EUR HEART J, V31, P1181, DOI 10.1093/eurheartj/ehp597; van der Pol P, 2012, AM J TRANSPLANT, V12, P877, DOI 10.1111/j.1600-6143.2011.03887.x; Wagner S, 2003, J IMMUNOL, V170, P1462, DOI 10.4049/jimmunol.170.3.1462; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	32	38	38	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2014	42	8					1910	1918		10.1097/CCM.0000000000000399			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL7QV	WOS:000339330700041	24810526				2022-02-06	
J	Oliveira, MD; Kairalla, AC; Fonoff, ET; Martinez, RCR; Teixeira, MJ; Bor-Seng-Shu, E				Oliveira, Marcelo de Lima; Kairalla, Ana Carolina; Fonoff, Erich Talamoni; Ruiz Martinez, Raquel Chacon; Teixeira, Manoel Jacobsen; Bor-Seng-Shu, Edson			Cerebral Microdialysis in Traumatic Brain Injury and Subarachnoid Hemorrhage: State of the Art	NEUROCRITICAL CARE			English	Article						Microdialysis; Metabolism; Brain injury; Monitoring; Subarachnoid hemorrhage; Critical care	PENTOSE-PHOSPHATE PATHWAY; PERFUSION-PRESSURE; METABOLIC CRISIS; INTRACRANIAL HYPERTENSION; GLUCOSE-METABOLISM; BLOOD-FLOW; LACTATE; RATIO; AUTOREGULATION; ASSOCIATION	Cerebral microdialysis (CMD) is a laboratory tool that provides on-line analysis of brain biochemistry via a thin, fenestrated, double-lumen dialysis catheter that is inserted into the interstitium of the brain. A solute is slowly infused into the catheter at a constant velocity. The fenestrated membranes at the tip of the catheter permit free diffusion of molecules between the brain interstitium and the perfusate, which is subsequently collected for laboratory analysis. The major molecules studied using this method are glucose, lactate, pyruvate, glutamate, and glycerol. The collected substances provide insight into the neurochemical features of secondary injury following traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) and valuable information about changes in brain metabolism within a short time frame. In this review, the authors detail the CMD technique and its associated markers and then describe pertinent findings from the literature about the clinical application of CMD in TBI and SAH.	[Oliveira, Marcelo de Lima; Kairalla, Ana Carolina; Fonoff, Erich Talamoni; Teixeira, Manoel Jacobsen; Bor-Seng-Shu, Edson] Univ Sao Paulo, Sch Med, Div Neurol Surg, Hosp Clin, BR-04040001 Sao Paulo, Brazil; [Ruiz Martinez, Raquel Chacon] Univ Sao Paulo, Dept Surg, Sch Med, Discipline Surg Tech, BR-04040001 Sao Paulo, Brazil		Bor-Seng-Shu, E (corresponding author), Univ Sao Paulo, Sch Med, Div Neurol Surg, Hosp Clin, Rua Loefgreen,1-272 Vila Clementino, BR-04040001 Sao Paulo, Brazil.	edsonshu@hotmail.com	Fonoff, Erich Talamoni/E-4327-2012; BOR-SENG-SHU, EDSON/AAC-9762-2019	Fonoff, Erich Talamoni/0000-0001-7831-9941; BOR-SENG-SHU, EDSON/0000-0002-6713-8974; de-Lima-Oliveira, Marcelo/0000-0002-7418-1516			Asgari S, 2013, NEUROCRIT CARE, V19, P56, DOI 10.1007/s12028-013-9821-6; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Bor-Seng-Shu E, 2013, NEUROSURG REV, V36, P361, DOI 10.1007/s10143-013-0453-2; Bor-Seng-Shu E, 2010, J NEUROSURG, V112, P1351, DOI 10.3171/2009.10.JNS091426; Bouras T, 2021, J NEUROTRAUM, V38, P1137, DOI 10.1089/neu.2011.1790; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; De Andrade AF, 2012, ARQ NEURO-PSIQUIAT, V70, P640, DOI 10.1590/S0004-282X2012000800017; De Fazio M, 2011, NEUROCRIT CARE, V14, P91, DOI 10.1007/s12028-010-9494-3; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Guiza F, 2013, NEUROL CRIT CARE, DOI [10.1097/CCM.0b013e3182742d0a, DOI 10.1097/CCM.0B013E3182]; Hanggi D, 2011, NEUROCRIT CARE, V15, P318, DOI 10.1007/s12028-011-9583-y; Helbok R, 2011, STROKE, V42, P1534, DOI 10.1161/STROKEAHA.110.604488; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Klaus S, 2004, CRIT CARE, V8, P363, DOI 10.1186/cc2882; Kristal BS, 1997, J NEUROCHEM, V69, P524; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mendelowitsch A, 2001, METHODS, V23, P73, DOI 10.1006/meth.2000.1107; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Nordstrom CH, 2010, CHILD NERV SYST, V26, P465, DOI 10.1007/s00381-009-1035-z; Nordstron CH, 2010, CHILD NERV SYST, V26, P456; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; RONQUIST G, 1992, ACTA NEUROCHIR, V114, P8, DOI 10.1007/BF01401106; Rooyackers O, 2004, CURR OPIN CLIN NUTR, V7, P515, DOI 10.1097/00075197-200409000-00003; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Schlenk F, 2008, CRIT CARE, V12, P1; Schlenk F, 2009, CRIT CARE, V13, DOI 10.1186/cc7689; Soehle M, 2007, ACTA NEUROCHIR, V149, P575, DOI 10.1007/s00701-007-1149-6; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stahl N, 2013, ACTA ANAESTHSIOL SCA, V45, P977; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wartenberg KE, 2011, CURR OPIN CRIT CARE, V17, P85, DOI 10.1097/MCC.0b013e328342f83d; Westermaier T, 2011, NEUROSURGERY, V68, P223, DOI 10.1227/NEU.0b013e3181fe23c1; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725; Zetterling M, 2011, J NEUROSURG, V115, P66, DOI 10.3171/2011.3.JNS10899	68	38	38	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2014	21	1					152	162		10.1007/s12028-013-9884-4			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AL7XP	WOS:000339350500023	24072457				2022-02-06	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.			Health-Related Quality of Life 3 Years After Moderate to Severe Traumatic Brain Injury: A Prospective Cohort Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries traumatic; Prospective studies; Quality of life; Rehabilitation	FUNCTIONAL ASSESSMENT MEASURE; HEAD-INJURY; INTERRATER RELIABILITY; 1ST YEAR; SF-36; REHABILITATION; CLASSIFICATION; SATISFACTION; INDIVIDUALS; DISABILITY	Objectives: To evaluate the time course of health-related quality of life (HRQoL) after moderate to severe traumatic brain injury (TBI) and to identify its predictors. Design: Prospective cohort study with follow-up measurements at 3, 6, 12, 18, 24, and 36 months after TBI. Setting: Patients. with moderate to severe TBI discharged from 3 level-1 trauma centers. Participants: Patients (N=97, 72% men) with a mean age +/- SD of 32.8+/-13.0 years (range, 18-65y), hospitalized with moderate (23%) or severe (77%) TBI. Interventions: Not applicable. Main Outcome Measures: HRQoL was measured with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), functional outcomes with the Glasgow Outcome Scale (GOS), Barthel Index, FIM, and Functional Assessment Measure, and mood with the Wimbledon Self-Report Scale. Results: The SF-36 domains showed significant improvement over time for Physical Functioning (P<.001), Role Physical (P<.001), Bodily Pain (P<.001), Social Functioning (P<.001), and Role Emotional (P=.024), but not for General Health (P=.263), Vitality (P=.530), and Mental Health (P=.138). Over time there was significant improvement in the Physical Component Summary (PCS) score, whereas the Mental Component Summary (MCS) score remained stable. At 3-year follow-up, HRQoL of patients with TBI was the same as that in the Dutch normative population. Time after TBI, hospital length of stay (LOS), FTM, and GOS were independent predictors of the PCS, whereas LOS and mood were predictors of the MCS. Conclusions: After TBI, the physical component of HRQoL showed significant improvement over time, whereas the mental component remained stable. Problems of disease awareness seem to Play a role in self-reported mental HRQoL. After TBI, mood status is a better predictor of the mental component of BRQoL than functional outcome, implying that mood should be closely monitored during and after rehabilitation. (C) 2014 by the American Congress of Rehabilitation Medicine	Erasmus Univ, Rijndam Rehabil Ctr, Med Ctr, Rotterdam, Netherlands; Erasmus Univ, Dept Rehabil Med, Med Ctr, Rotterdam, Netherlands		Grauwmeijer, E (corresponding author), Rotterdam Neurorehabil Res RoNeRes, Rijndam Rehabil Ctr, POB 23181, NL-3001 KD Rotterdam, Netherlands.	egrauwmeijer@rijndam.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	Supported by the Netherlands Organisation for Health Research and Development (project no. 1435.0020).	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cieza A, 2005, QUAL LIFE RES, V14, P1225, DOI 10.1007/s11136-004-4773-0; Collin C, 1988, Int Disabil Stud, V10, P61; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JENNETT B, 1975, LANCET, V1, P480; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van Baalen B, 2008, BRAIN INJURY, V22, P25, DOI 10.1080/02699050701810662; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHO, 2002, INT CLASS FUNCT DIS; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377	41	38	40	0	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2014	95	7					1268	1276		10.1016/j.apmr.2014.02.002			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	AK5QA	WOS:000338479700007	24561059				2022-02-06	
J	Kinnaman, KA; Mannix, RC; Comstock, RD; Meehan, WP				Kinnaman, Karen A.; Mannix, Rebekah C.; Comstock, R. Dawn; Meehan, William P., III			Management of Pediatric Patients With Concussion by Emergency Medicine Physicians	PEDIATRIC EMERGENCY CARE			English	Article						concussion; management; medication	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; CHILDREN; MILD; PROVIDERS; KNOWLEDGE	Objective: Despite an increase in concussion diagnoses among pediatric patients, little is known about the management of pediatric patients with concussion in emergency departments (EDs). The objective of this study was to assess strategies used by emergency medicine physicians when treating pediatric patients with concussions. Methods: A 17-item questionnaire was e-mailed to members of the American Academy of Pediatrics Section on Emergency Medicine. Two serial e-mails were distributed at 2-week intervals to nonresponders. The survey included multiple-choice and free-text questions that were created by the team of investigators on the basis of prior surveys of family practitioners and physical trainers. We collected demographic information and specific information regarding the use of medications, neuropsychological testing, neuroimaging, return-to-play decision making, and use of published guidelines. Simple descriptive statistics were used. Results: Two hundred sixty-five (29%) physicians completed the questionnaire, of which 52% had been an attending physician for more than 10 years. Ninety-nine percent of the respondents reported managing concussions, with the majority (76%) seeing more than 24 patients with concussion per year. Most clinicians (81%) reported using a published guideline in their management of concussions. The symptoms most likely to prompt head imaging in the ED included a focal neurological deficit (92%), altered mental status (82%), and intractable vomiting (80%). Most (91%) respondents reported using medications to manage the symptoms of patients with concussion, mainly acetaminophen (78%) and nonsteroidal anti-inflammatory medications (77%), whereas 54% of the respondents used ondansetron and 7% of the respondents used narcotics. More than half (56%) of the respondents referred patients with concussion for neuropsychological testing from the ED. Of those, nearly half (49%) of the respondents refer their patients to a sports concussion clinic, whereas 5% of the respondents refer their patients to a neuropsychologist. When discussing discharge instructions, 86% of the clinicians recommended follow-up with a primary care physician, 62% of the clinicians recommended follow-up with a sports concussion clinic, and 11% of the clinicians recommend follow-up with a neurologist. Most respondents (70%) have access to a designated sports concussion clinic. Conclusions: Nearly all emergency medicine physicians surveyed care for pediatric patients with concussion, most by using published guidelines. Emergency medicine physicians routinely use medications to treat the symptoms of concussion and often refer patients to primary care physicians as well as designated sports concussion clinics for follow-up.	[Kinnaman, Karen A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Kinnaman, Karen A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA; [Mannix, Rebekah C.; Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.] Harvard Univ, Sch Med, Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA		Kinnaman, KA (corresponding author), 77 Francis St,Neville House,First Floor, Boston, MA 02114 USA.	kkinnaman@partners.org	Mannix, Rebekah/AAD-8702-2020				Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sturm JJ, 2012, PEDIATR EMERG CARE, V28, P247, DOI 10.1097/PEC.0b013e3182494d87; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	27	38	38	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	JUL	2014	30	7					458	461		10.1097/PEC.0000000000000161			4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	AL2GP	WOS:000338944200003	24977993				2022-02-06	
J	Launey, Y; Nesseler, N; Le Maguet, P; Malledant, Y; Seguin, P				Launey, Yoann; Nesseler, Nicolas; Le Maguet, Pascale; Malledant, Yannick; Seguin, Philippe			Effect of Osmotherapy on Optic Nerve Sheath Diameter in Patients with Increased Intracranial Pressure	JOURNAL OF NEUROTRAUMA			English	Article						intracranial hypertension; adult brain injury; optic nerve sheath diameter; osmotherapy	TRANSORBITAL SONOGRAPHIC EVALUATION; OCULAR SONOGRAPHY; ULTRASOUND; HYPERTENSION; ULTRASONOGRAPHY; FUNDAMENTALS; MANAGEMENT; EXPANSION; ACCURACY	The measurement of ocular nerve sheath diameter (ONSD) via ocular ultrasound scanning is a recent non-invasive method for intracranial pressure (ICP) assessment. Few clinical studies have assessed ONSD variations during osmotherapy for the treatment of sustained increased ICP episodes. The aim of our study was to determine the rate of ONSD variation after mannitol administration for increased ICP episodes. We consecutively included in a prospective, observational study, the patients who had severe acute brain injury and monitored with an invasive ICP monitor. For each episode of sustained elevated ICP, the ONSD was measured in the right and left eye with a 7.5-MHz echography probe, and the mean value was reported. Simultaneously, ICP and cerebral perfusion pressure (CPP) were recorded. All measurements were performed just before and 20 minutes following a 20% mannitol infusion. Data were expressed as medians and interquartile ranges. Thirteen patients were included and analysed (traumatic brain injury, n=10; subarachnoid haemorrhage, n=3). The median value of the mannitol dose infused was 0.54 g/kg (0.49-0.80 g/kg). In all cases, the ONSD was greater than 5.8 mm before osmotherapy. The ONSD significantly decreased after mannitol infusion from 6.3 (6.1-6.7) to 5. mm (5.5-6.3) (p=0.0007). Concomitantly, the intracranial pressure decreased from 35 (32-41) to 25 (22-29) mmHg (p=0.001) and the CPP increased from 47 (50-60) to 66 (59-69) mmHg (p=0.003). The variations of ONSD appear to be an interesting parameter to evaluate the efficacy of osmotherapy for elevated ICP episodes in patients with acute brain injury.	[Launey, Yoann; Nesseler, Nicolas; Le Maguet, Pascale; Malledant, Yannick; Seguin, Philippe] Hop Pontchaillou, CHU Rennes, Dept Anesthesie Reanimat, F-35033 Rennes, France; [Launey, Yoann; Nesseler, Nicolas; Malledant, Yannick; Seguin, Philippe] INSERM, U991, Rennes, France; [Launey, Yoann; Nesseler, Nicolas; Malledant, Yannick; Seguin, Philippe] Univ Rennes 1, Rennes, France		Launey, Y (corresponding author), Hop Pontchaillou, CHU Rennes, Dept Anesthesie Reanimat, 2 Rue Henri Le Guilloux, F-35033 Rennes, France.	yoann.launey@chu-rennes.fr	Seguin, Philippe/P-9487-2019; Launey, Yoann/AAN-7176-2020	Seguin, Philippe/0000-0002-7774-4257; Launey, Yoann/0000-0001-9105-8862; Malledant, yannick/0000-0001-6680-5184			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Dubourg J, 2011, ACTA ANAESTH SCAND, V55, P899, DOI 10.1111/j.1399-6576.2011.02468.x; Dubourg J, 2012, J NEUROSURG-PEDIATR, V9, P570, DOI 10.3171/2011.10.PEDS11458; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI [10.1186/cc6893, 10.1186/cc7006]; Hansen HC, 2011, ACTA OPHTHALMOL, V89, pE528, DOI 10.1111/j.1755-3768.2011.02159.x; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Rajajee V, 2012, CRIT CARE, V16, DOI [10.1186/cc11336, 10.1186/CC11336]; Regillo C. D., 1999, OPHTHALMOLOGY; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Wakai A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub5; Young Jeanne, 2006, Intensive Crit Care Nurs, V22, P32, DOI 10.1016/j.iccn.2005.04.004	28	38	43	2	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					984	988		10.1089/neu.2012.2829			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200010	24372319				2022-02-06	
J	Su, SH; Xu, W; Li, M; Zhang, L; Wu, YF; Yu, F; Hai, J				Su, Shao-Hua; Xu, Wei; Li, Ming; Zhang, Lin; Wu, Yi-Fang; Yu, Fei; Hai, Jian			Elevated C-reactive protein levels may be a predictor of persistent unfavourable symptoms in patients with mild traumatic brain injury: A preliminary study	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Mild traumatic brain injury; High-sensitivity C-reactive protein; Postconcussion syndrome; Depression; Anxiety; Cognitive impairment	INFLAMMATORY RESPONSE SYNDROME; COGNITIVE IMPAIRMENT; SUBARACHNOID HEMORRHAGE; POSTCONCUSSION SYNDROME; CLINICAL-PRACTICE; HEAD-INJURY; DEPRESSION; DISEASE; ADULTS; QUESTIONNAIRE	The pathogenesis of persistent unfavourable outcomes following mild traumatic brain injury (mTBI) are not fully understood. Low-grade systemic inflammation might contribute to the development of persistent unfavourable outcomes in patients with mTBI. We used plasma high-sensitivity C-reactive protein (CRP) levels as the biomarker of systemic inflammation to investigate whether elevated CRP levels were associated with persistent adverse outcomes in these patients. A total of 213 consecutive patients with mTBI were identified in our study. Plasma high-sensitivity CRP levels were measured at baseline, 1 month, 2 months and 3 months after initial traumatic brain injury. The study endpoints included persistent postconcussion syndrome (PCS), persistent psychological problems (depression and anxiety), persistent physiological problems (frequent headache, nausea, insomnia, dizziness and fatigue) and persistent cognitive impairment, which were screened by International Classification of Diseases (ICD-10), diagnostic and statistical manual of mental disorders (DSM-IV), Beck anxiety inventory (BAI), Beck depression inventory (BDI) and montreal cognitive assessment (MoCA) 3 months post-injury. The associations between baseline CRP levels and persistent unfavourable outcomes were estimated from multiple regression models adjusting for various confounding covariates. Elevated baseline CRP levels were associated with a significant increase in the incidence of persistent PCS (odds ratio [OR], 2.719; 95% confidence interval [CI], 1.609-4.594; p = 0.000), persistent psychological problems (OR, 1.535; 95% CI, 1.063-2.216; p = 0.022), and persistent cognitive impairment (OR, 1.687; 95% CI, 1.135-2.507; p = 0.010). However, elevated CRP levels were not associated with persistent physiological problems (OR, 1.330; 95% CI, 0.905-1.956; p = 0.146). Furthermore, three adjusted models did not essentially affect the OR of elevated CRP levels for these persistent unfavourable outcomes. Among patients with mTBI, baseline elevated CRP levels may be an independent predictor of persistent persistent PCS, psychological problems and cognitive impairment. (C) 2014 Elsevier Inc. All rights reserved.	[Su, Shao-Hua; Wu, Yi-Fang; Yu, Fei; Hai, Jian] Tongji Univ, Sch Med, Tongji Hosp, Dept Neurosurg, Shanghai 200065, Peoples R China; [Xu, Wei] Shanghai Changning Cent Hosp, Dept Trauma Ctr, Shanghai 200036, Peoples R China; [Li, Ming] Shanghai Jiao Tong Univ, Sch Med, Dept Emergency, Xinhua Hosp, Shanghai 200092, Peoples R China; [Zhang, Lin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200003, Peoples R China		Su, SH (corresponding author), Tongji Univ, Sch Med, Tongji Hosp, Dept Neurosurg, 389 Xincun Rd, Shanghai 200065, Peoples R China.	sushdoc@sohu.com; haijiandoc@163.com		Su, Shao-Hua/0000-0001-7911-5406	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30772233, 81071063, 81271212]	This work was supported by the National Natural Science Foundation of China (Grant Nos: 30772233, 81071063 and 81271212 to J. Hai).	Allin KH, 2009, J CLIN ONCOL, V27, P2217, DOI 10.1200/JCO.2008.19.8440; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arfanakis K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073107; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Briones T. L., 2013, BRAIN BEHAV IMMUN, VS0889-1591, P00409; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dernellis J, 2004, EUR HEART J, V25, P1100, DOI 10.1016/j.ehj.2004.04.025; Dickerson F, 2012, SCHIZOPHR RES, V134, P83, DOI 10.1016/j.schres.2011.10.003; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Haroon E, 2012, NEUROPSYCHOPHARMACOL, V37, P137, DOI 10.1038/npp.2011.205; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lindqvist D, 2013, BRAIN BEHAV IMMUN, V33, P183, DOI 10.1016/j.bbi.2013.07.007; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Murray KN, 2013, MOL CELL NEUROSCI, V53, P14, DOI 10.1016/j.mcn.2012.09.004; Mustafa T, 2013, ADV PHARMACOL, V68, P445, DOI 10.1016/B978-0-12-411512-5.00021-X; Musunuru K, 2008, NAT CLIN PRACT CARD, V5, P621, DOI 10.1038/ncpcardio1322; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nazmi A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-212; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raison CL, 2011, CURR PSYCHIAT REP, V13, P467, DOI 10.1007/s11920-011-0232-0; Reuben A., 2013, EMERG MED J; Shaaban R, 2006, RESP MED, V100, P2112, DOI 10.1016/j.rmed.2006.03.027; Shacham Y, 2013, J CARDIOL, V2013; SHEK DTL, 1990, J CLIN PSYCHOL, V46, P35, DOI 10.1002/1097-4679(199001)46:1<35::AID-JCLP2270460106>3.0.CO;2-W; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Tam AKH, 2010, NEUROCRIT CARE, V13, P182, DOI 10.1007/s12028-010-9402-x; Tiainen M., 2013, INT J STROKE; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Wium-Andersen MK, 2013, JAMA PSYCHIAT, V70, P176, DOI 10.1001/2013.jamapsychiatry.102; Wood R. L., 2013, J HEAD TRAUMA REHABI; World Health Organization, 2004, ICD 10 INT STAT CLAS; Wortzel H., 2013, BEHAV SCI LAW; Wu SFV, 2011, INT J NURS STUD, V48, P1376, DOI 10.1016/j.ijnurstu.2011.04.008; Yamada A, 2009, J NEUROCHEM, V110, P791, DOI 10.1111/j.1471-4159.2009.06175.x; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; [张立秀 Zhang Lixiu], 2008, [中国心理卫生杂志, Chinese Mental Health Journal], V22, P123	53	38	41	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2014	38						111	117		10.1016/j.bbi.2014.01.009			7	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	AF8RU	WOS:000334984100012	24456846				2022-02-06	
J	Zonfrillo, MR; Durbin, DR; Koepsell, TD; Wang, J; Temkin, NR; Dorsch, AM; Vavilala, MS; Jaffe, KM; Rivara, FP				Zonfrillo, Mark R.; Durbin, Dennis R.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy R.; Dorsch, Andrea M.; Vavilala, Monica S.; Jaffe, Kenneth M.; Rivara, Frederick P.			Prevalence of and Risk Factors for Poor Functioning after Isolated Mild Traumatic Brain Injury in Children	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; epidemiology; pediatric brain injury; prospective study	QUALITY-OF-LIFE; OUTCOMES; RELIABILITY; VALIDITY; PEDSQL(TM)-4.0	This study aimed to determine the prevalence and predictors of poor 3 and 12 month quality of life outcomes in a cohort of pediatric patients with isolated mild TBI. We conducted a prospective cohort study of children and adolescents <18 years of age treated for an isolated mild TBI, defined as "no radiographically apparent intracranial injury" or "an isolated skull fracture, and no other clinically significant non-brain injuries." The main outcome measure was the change in quality of life from baseline at 3 and 12 months following injury, as measured by the Pediatric Quality of Life index (PedsQL). Poor functioning was defined as a decrease in total PedsQL score of >15 points between baseline and follow-up scores (at 3 and 12 months). Of the 329 patients who met inclusion criteria, 11.3% (95% CI 8.3-15.3%) at 3 months and 12.9% (95% CI 9.6-17.2%) at 12 months following injury had relatively poor functioning. Significant predictors of poor functioning included less parental education, Hispanic ethnicity (at 3 months following injury, but not at 12 months); low household income (at 3 and 12 months), and Medicaid insurance (at 12 months only). Children and adolescents sustaining a mild TBI who are socioeconomically disadvantaged may require additional intervention to mitigate the effects of mild TBI on their functioning.	[Zonfrillo, Mark R.; Durbin, Dennis R.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Koepsell, Thomas D.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Wang, Jin; Vavilala, Monica S.; Jaffe, Kenneth M.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dorsch, Andrea M.; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Koepsell, Thomas D.; Wang, Jin; Vavilala, Monica S.; Jaffe, Kenneth M.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA		Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Div Emergency Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zonfrillo@email.chop.edu	Durbin, Dennis/AAD-7829-2022; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563	National Center for Injury Prevention and Control, CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K08HD073241-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, CDC grant R49 CE 001021, and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH) grant 1K08HD073241-02. The CDC and the NIH had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.	Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Centers for Disease Control and Prevention National Centers for Injury Prevention and Control, CONC MILD TBI; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; Huang IC, 2009, VALUE HEALTH, V12, P773, DOI 10.1111/j.1524-4733.2008.00487.x; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Marr A., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Steinberg Alan M, 2004, Curr Psychiatry Rep, V6, P96, DOI 10.1007/s11920-004-0048-2; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zonfrillo M. R., 2012, PEDIATRICS, V52, P397	27	38	38	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					722	727		10.1089/neu.2013.3088			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200003	24294826	Green Published			2022-02-06	
J	Hetherington, HP; Hamid, H; Kulas, J; Ling, G; Bandak, F; de Lanerolle, NC; Pan, JW				Hetherington, Hoby P.; Hamid, Hamada; Kulas, Joseph; Ling, Geoffrey; Bandak, Faris; de Lanerolle, Nihal C.; Pan, Jullie W.			MRSI of the Medial Temporal Lobe at 7 T in Explosive Blast Mild Traumatic Brain Injury	MAGNETIC RESONANCE IN MEDICINE			English	Article						mild traumatic brain injury; MRSI; hippocampus; 7 T	WORD MEMORY TEST; SYMPTOM VALIDITY TEST; ENDURING FREEDOM; WAR VETERANS; IRAQ; TBI; SPECTROSCOPY; CONCUSSION; EXPOSURE; SOLDIERS	Purpose: Up to 19% of veterans returning from the wars in Iraq and Afghanistan have a history of mild traumatic brain injury with 70% associated with blast exposure. Tragically, 20-50% of this group reports persistent symptoms, including memory loss. Unfortunately, routine clinical imaging is typically normal, making diagnosis and clinical management difficult. The goal of this work was to develop methods to acquire hippocampal MRSI at 7 T and evaluate their sensitivity to detect injury in veterans with mild traumatic brain injury. Methods: At 7 T, hippocampal MRSI measurements are limited by: (1) poor B-0 homogeneity; (2) insufficient B-1(+) strength and homogeneity; and (3) chemical shift dispersion artifacts. To overcofme these limitations we: (1) used third degree B-0 shimming; (2) an inductively decoupled transceiver array with radiofrequency shimming; and (3) a volume localized single slice sequence using radiofrequency shimming-based outer volume suppression. Results: In 20 controls and 25 veterans with mild traumatic brain injury due to blast exposure with memory impairment, hippocampal N-acetyl aspartate to choline (P < 0.001) and N-acetyl aspartate to creatine (P < 0.001) were decreased in comparison to control subjects. Conclusion: With the appropriate methods robust spectroscopic imaging of the hippocampus can be carried out at 7 T. MRSI at 7 T can detect hippocampal injury in veterans with mild traumatic brain injury. (c) 2013 Wiley Periodicals, Inc.	[Hetherington, Hoby P.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA; [Hetherington, Hoby P.; de Lanerolle, Nihal C.; Pan, Jullie W.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA; [Hamid, Hamada] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Hamid, Hamada] West Haven Vet Adm Med Ctr, Dept Neurol, West Haven, CT USA; [Kulas, Joseph] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Kulas, Joseph] West Haven Vet Adm Med Ctr, Dept Psychol, West Haven, CT USA; [Ling, Geoffrey; Bandak, Faris] Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; [Bandak, Faris] Integrated Serv Grp Inc, Potomac, MD USA; [Pan, Jullie W.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA		Hetherington, HP (corresponding author), Univ Pittsburgh, Dept Radiol, B820 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.	hetheringtonh@upmc.edu	Altalib, Hamada/B-9656-2018	Altalib, Hamada/0000-0001-7154-1400	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EB009871, R01EB011639, R01NS081772]; DARPA/SPAWARUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-08-C-2005]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009871, R01EB011639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [F32ES027306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081772, R01NS090417] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant numbers: R01EB009871, R01EB011639, R01NS081772, and DARPA/SPAWAR N66001-08-C-2005.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Avdievich NI, 2009, MAGN RESON MED, V62, P17, DOI 10.1002/mrm.21970; Avdievich NI, 2011, APPL MAGN RESON, V41, P483, DOI 10.1007/s00723-011-0280-y; Avdievich NI, 2009, J MAGN RESON IMAGING, V29, P461, DOI 10.1002/jmri.21660; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cavus I, 2008, EPILEPSIA, V49, P1358, DOI 10.1111/j.1528-1167.2008.01603.x; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2009, J HEAD TRAUMA REHAB, V24, P105, DOI 10.1097/HTR.0b013e31819b1210; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hetherington HP, 2007, NEUROLOGY, V69, P2256, DOI 10.1212/01.wnl.0000286945.21270.6d; Hetherington HP, 2006, MAGN RESON MED, V56, P26, DOI 10.1002/mrm.20941; Hetherington HP, 2010, MAGN RESON MED, V63, P9, DOI 10.1002/mrm.22182; Hetherington HP, 1996, MAGNET RESON MED, V36, P21, DOI 10.1002/mrm.1910360106; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Jaycox L. H., 2008, INVISIBLE WOUNDS WAR; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Miyasaka N, 2006, J MAGN RESON IMAGING, V24, P908, DOI 10.1002/jmri.20709; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pan JW, 2012, MAGN RESON MED, V68, P1007, DOI 10.1002/mrm.24122; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Tanielian T, 2009, ASSESSING COMBAT EXP; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vaughan JT, 2001, MAGN RESON MED, V46, P24, DOI 10.1002/mrm.1156; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	43	38	38	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	APR	2014	71	4					1358	1367		10.1002/mrm.24814			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	AD2CL	WOS:000333040500002	23918077	Green Accepted			2022-02-06	
J	Lu, XY; Wang, HD; Xu, JG; Ding, K; Li, T				Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao			NADPH oxidase inhibition improves neurological outcome in experimental traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; NADPH oxidase; NOX2; Apocynin	OXYGEN SPECIES PRODUCTION; APOCYNIN; DAMAGE; NOX2; BARRIER	Purpose: Traumatic brain injury (TB!) is a worldwide health problem with oxidative stress recognized as a major pathogenetic factor. The present experimental study was designed to explore the neuroprotective effect of NADPH oxidase (NOX) inhibitor, apocynin, on mouse TBI. Methods: Moderately severe weight-drop impact head injury was induced in adult male mice, randomly divided into four groups: sham, TBI, TBI + vehicle and TBI + apocynin treatment. Apocynin (50 mg/kg) was injected intraperitoneally 30 min before TBI. The expression of NOX2 protein was investigated using immunoblotting techniques 1 and 24 h after TBI. Neurological score was evaluated 24 h after TBI. Blood-brain barrier disruption was detected by Evans blue extravasation and cortical apoptosis was analyzed by TUNEL assay. Additionally, we assessed tissue levels of malondialdehyde (MDA). Results: NOX2 expression increased rapidly following TBI in male mice, with an early peak at 1 h, followed by a second peak at 24 h. Pre-treatment with the NOX inhibitor, apocynin markedly inhibited NOX2 expression. Apocynin also attenuated MDA levels and TBI-induced blood-brain barrier dysfunction. In addition apocynin significantly attenuated TBI-induced neurological deficits and cortical apoptosis. Conclusion: Pre-treatment with apocynin effectively attenuates markers of cerebral oxidative stress after TBI, thus supporting the hypothesis that apocynin is a potential neuroprotectant and adjunct therapy for TBI patients. (C) 2014 Elsevier Ltd. All rights reserved.	[Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Lu, Xin-Yu] Jiangsu Univ, Dept Neurosurg, Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Science and Technology Development Fund of Zhenjiang [SH20130037]	This study was supported by the Science and Technology Development Fund of Zhenjiang (No. SH20130037).	Altintas R, 2013, J ENDOUROL, V27, P617, DOI 10.1089/end.2012.0556; Ano Y, 2010, NEUROSCI LETT, V469, P39, DOI 10.1016/j.neulet.2009.11.040; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; De Silva TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028393; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kandasamy R, 2013, INT J NEUROSCI, V123, P385, DOI 10.3109/00207454.2012.761983; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Ling HP, 2013, J SURG RES, V179, pE227, DOI 10.1016/j.jss.2012.03.030; Liu WL, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-22; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016; Pepping JK, 2013, AM J PHYSIOL-ENDOC M, V304, pE392, DOI 10.1152/ajpendo.00398.2012; Peters EA, 2001, FREE RADICAL BIO MED, V31, P1442, DOI 10.1016/S0891-5849(01)00725-0; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sahna E, 2003, UROL RES, V31, P188, DOI 10.1007/s00240-003-0314-5; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; Weston RM, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/648061; Ximenes VF, 2007, ARCH BIOCHEM BIOPHYS, V457, P134, DOI 10.1016/j.abb.2006.11.010; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	29	38	39	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	APR	2014	69						14	19		10.1016/j.neuint.2014.02.006			6	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AF8SG	WOS:000334985300003	24589771				2022-02-06	
J	Cifu, DX; Walker, WC; West, SL; Hart, BB; Franke, LM; Sima, A; Graham, CW; Carne, W				Cifu, David X.; Walker, William C.; West, Steven L.; Hart, Brett B.; Franke, Laura Manning; Sima, Adam; Graham, Carolyn W.; Carne, William			Hyperbaric oxygen for blast-related postconcussion syndrome: Three-month outcomes	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; OIF/OEF VETERANS; CHRONIC SEQUELAE; HEAD-INJURIES; WECHSLER TEST; MILD TBI; SYMPTOMS; VALIDITY	Objective Mild traumatic brain injury (mTBI) and postconcussion syndrome (PCS) are common among military combatants. Hyperbaric oxygen (HBO2) is a proposed treatment for these conditions, but it has not been rigorously studied. The objective of this study was to determine the effects of HBO2 by 3 months post compression at 2 commonly employed dosing levels to treat PCS; whether specific subgroups may have benefited; and if no overall effect was found, whether benefit is masked by other conditions. Methods This randomized, double-blind, sham-controlled study was conducted at the Naval Air Station in Pensacola, Florida on 61 male Marines with a history of mTBI and PCS. Intervention consisted of 40 once daily 60-minute hyperbaric chamber compressions at 2.0 atmospheres absolute (ATA) at 1 of 3 randomly preassigned oxygen fractions, resulting in respective blinded groups with an oxygen-breathing exposure equivalent to (1) surface air (sham), (2) 100% oxygen at 1.5ATA, or (3) 100% oxygen at 2.0ATA. The main outcome measure was the Rivermead Post-Concussion Questionnaire-16 (RPQ-16) collected before compressions and at 2 later points. Results The interaction of time by intervention group was not significant for improvement on the RPQ-16. Nor was there evidence of efficacy on the RPQ-16 for any subgroup. No significant time by intervention interaction was found for any functional, cognitive, or psychomotor secondary outcome measure at an unadjusted 0.05 significance level. Interpretation Using a randomized control trial design and analysis including a sham, results showed no evidence of efficacy by 3 months post-compression to treat the symptomatic, cognitive, or behavioral sequelae of PCS after combat-related mTBI. ANN NEUROL 2014;75:277-286	[Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Cifu, David X.; Walker, William C.; West, Steven L.; Franke, Laura Manning; Graham, Carolyn W.; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.; Walker, William C.; Franke, Laura Manning; Carne, William] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Cifu, David X.; Walker, William C.; West, Steven L.; Sima, Adam; Graham, Carolyn W.] Ctr Rehabil Sci & Engn, Richmond, VA USA; [Walker, William C.; Franke, Laura Manning; Carne, William] Richmond Def & Vet Brain Injury Ctr, Richmond, VA USA; [Hart, Brett B.] Navy Med Operat Training Ctr, Pensacola, FL USA; [Sima, Adam] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA		Carne, W (corresponding author), Richmond VAMC, 1201 Broad Rock Blvd 127, Richmond, VA 23249 USA.	William.Carne@va.gov	Walker, William C/N-3162-2014	Sima, Adam/0000-0001-8426-9987; Cifu, David/0000-0003-1600-9387	Defense Advanced Research Projects Agency grant [N66001-09-2-206]; US Navy Bureau of Medicine and Surgery; US Army Medical Materiel Development Activity; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Funding was provided for the primary study by a Defense Advanced Research Projects Agency grant (N66001-09-2-206). The US Navy Bureau of Medicine and Surgery provided contract funding for temporary duty requirements, and the US Army Medical Materiel Development Activity provided end of study contract funding. W.C.W. and W.C. were additionally supported through contracts from the Defense and Veterans Brain Injury Center. The funding sources had no role in the study design, analysis and interpretation of the data, writing of the paper, or decision to submit the paper for publication.	Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; BENTON A L, 1981, Journal of Clinical Neuropsychology, V3, P33, DOI 10.1080/01688638108403111; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Centers for Disease Control and Prevention, DOD VA COD PROP DOD; Churchill S, 2013, UNDERSEA HYPERBAR M, V40, P165; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cifu D, 2011, OVERCOMING POSTDEPLO; Cifu DX, 2013, J HEAD TRAUMA REHABI; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Conners C. K., 2000, CONNERS CONTINUOUS P; Cripps A, 2013, J SPORT REHABIL, V22, P67, DOI 10.1123/jsr.22.1.67; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Delis D.C., 1991, PSYCHOL ASSESS, V3, P19, DOI [10.1037/1040-3590.3.1.19, DOI 10.1037/1040-3590.3.1.19]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donders J, 2007, J INT NEUROPSYCH SOC, V13, P354, DOI 10.1017/S1355617707070439; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Flaherty S A, 1996, AANA J, V64, P133; Gesell LB, 2008, HYPERBARIC OXYGEN TH; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; National Institute of Neurologic Disorders, TBI COMPR EV COMM DA; NEUBAUER RA, 1990, LANCET, V335, P542, DOI 10.1016/0140-6736(90)90777-3; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Walker WC, 2013, NEUROREHABIL NEURAL; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Wechsler D., 2008, WECHSLER ADULT INTEL; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549	67	38	40	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2014	75	2					277	286		10.1002/ana.24067			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AD1PD	WOS:000333005000014	24255008				2022-02-06	
J	Dunham, CM; Cutrona, AF; Gruber, BS; Calderon, JE; Ransom, KJ; Flowers, LL				Dunham, C. Michael; Cutrona, Anthony F.; Gruber, Brian S.; Calderon, Javier E.; Ransom, Kenneth J.; Flowers, Laurie L.			Early tracheostomy in severe traumatic brain injury: evidence for decreased mechanical ventilation and increased hospital mortality	INTERNATIONAL JOURNAL OF BURNS AND TRAUMA			English	Article						Head injuries; tracheostomy; hospital mortality		Objective: In the past, the authors performed a comprehensive literature review to identify all randomized controlled trials assessing the impact of early tracheostomy on severe brain injury outcomes. The search produced only two trials, one by Sugerman and another by Bouderka. Subjects and methods: The current authors initiated an Institutional Review Board-approved severe brain injury randomized trial to evaluate the impact of early tracheostomy on ventilator-associated pneumonia rates, intensive care unit (ICU)/ventilator days, and hospital mortality. Current study results were compared with the other randomized trials and a meta-analysis was performed. Results: Early tracheostomy pneumonia rates were Sugerman-48.6%, Bouderka-58.1%, and current study-46.7%. No early tracheostomy pneumonia rates were Sugerman-53.1%, Bouderka-61.3%, and current study-44.4%. Pneumonia rate meta-analysis showed no difference for early tracheostomy and no early tracheostomy (OR 0.89; p = 0.71). Early tracheostomy ICU/ventilator days were Sugerman-16 +/- 5.9, Bouderka-14.5 +/- 7.3, and current study-14.1 +/- 5.7. No early tracheostomy ICU/ventilator days were Sugerman-19 +/- 11.3, Bouderka-17.5 +/- 10.6, and current study-17 +/- 5.4. ICU/ventilator day meta-analysis showed 2.9 fewer days with early tracheostomy (p = 0.02). Early tracheostomy mortality rates were Sugerman-14.3%, Bouderka-38.7%, and current study-0%. No early tracheostomy mortality rates were Sugerman-3.2%, Bouderka-22.6%, and current study-0%. Randomized trial mortality rate meta-analysis showed a higher rate for early tracheostomy (OR 2.68; p = 0.05). Because the randomized trials were small, a literature assessment was undertaken to find all retrospective studies describing the association of early tracheostomy on severe brain injury hospital mortality. The review produced five retrospective studies, with a total of 3,356 patients. Retrospective study mortality rate meta-analysis demonstrated a larger mortality for early tracheostomy (OR 1.97; p < 0.0001). Conclusion: For severe brain injury, analyses indicate that ventilator-associated pneumonia rates are not decreased with early tracheostomy. Further, this study implies that mechanical ventilation is reduced with early tracheostomy. Both the randomized trial and retrospective meta-analysis indicate that risk for hospital death increases with early tracheostomy. Findings imply that early tracheostomy for severe brain injury is not a prudent routine policy.	[Dunham, C. Michael; Gruber, Brian S.; Ransom, Kenneth J.; Flowers, Laurie L.] St Elizabeth Hlth Ctr, Trauma Crit Care Serv, 1044 Belmont Ave, Youngstown, OH 44501 USA; [Cutrona, Anthony F.; Calderon, Javier E.] St Elizabeth Hlth Ctr, Infect Control Serv, Youngstown, OH 44501 USA		Dunham, CM (corresponding author), St Elizabeth Hlth Ctr, Trauma Crit Care Serv, 1044 Belmont Ave, Youngstown, OH 44501 USA.	dunham.michael@sbcglobal.net		Dunham, C. Michael/0000-0002-7842-9750			Ahmed Nasim, 2007, Surg Infect (Larchmt), V8, P343, DOI 10.1089/sur.2006.065; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Chintamani, 2005, BMC EMERG MED, V5, DOI 10.1186/1471-227X-5-8; DAMELIO LF, 1994, AM SURGEON, V60, P180; Dunham CM, 2011, J NEUROTRAUM, V28, P1009, DOI 10.1089/neu.2010.1301; Dunham CM, 2006, AM SURGEON, V72, P276; Higgins JPT, 2008, COCHRANE HDB SYSTEMA, P391, DOI DOI 10.1002/9780470712184.CH13; Kallel H, 2005, J TRAUMA, V59, P705, DOI 10.1097/01.ta.0000177749.09844.c6; Kocaeli H, 2008, ACTA NEUROCHIR, V150, P1263, DOI 10.1007/s00701-008-0153-9; Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14; Muscedere J, 2008, J CRIT CARE, V23, P138, DOI 10.1016/j.jcrc.2007.12.008; Rea-Neto A, 2008, CRIT CARE, V12, DOI 10.1186/cc6877; Reilly PM, 1997, INTENS CARE MED, V23, P859, DOI 10.1007/s001340050422; Rizk EB, 2011, NEUROCRIT CARE, V15, P481, DOI 10.1007/s12028-011-9615-7; Schauer JM, 2009, J TRAUMA, V66, P220, DOI 10.1097/TA.0b013e31816073e3; Stocchetti N, 2000, INTENS CARE MED, V26, P1101, DOI 10.1007/s001340051324; Stocchetti N, 2000, J NEUROSURG ANESTH, V12, P307, DOI 10.1097/00008506-200010000-00002; Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002; Walker E, 2008, CLEV CLIN J MED, V75, P431, DOI 10.3949/ccjm.75.6.431; Wang HK, 2012, INJURY, V43, P1432, DOI 10.1016/j.injury.2011.03.059; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	21	38	39	1	1	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	2160-2026			INT J BURNS TRAUMA	Int. J. Burns Trauma		2014	4	1					14	24					11	Emergency Medicine	Emerging Sources Citation Index (ESCI)	Emergency Medicine	V4G4J	WOS:000218908800003	24624310				2022-02-06	
J	van Delft-Schreurs, CCHM; van Bergen, JJM; de Jongh, MAC; de Sande, PV; Verhofstad, MHJ; de Vries, J				van Delft-Schreurs, C. C. H. M.; van Bergen, J. J. M.; de Jongh, M. A. C.; de Sande, P. van; Verhofstad, M. H. J.; de Vries, J.			Quality of life in severely injured patients depends on psychosocial factors rather than on severity or type of injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Quality of life; Injury; Trauma	TRAUMATIC BRAIN-INJURY; HEALTH-STATUS; MULTIPLE INJURIES; FUNCTIONAL STATUS; WHOQOL-BREF; DETERMINANTS; POPULATION; VALIDITY; IMPACT; WORSE	Background: Former studies have demonstrated that health-related quality of life is decreased in severely injured patients. However, in those studies patients were asked about their functioning and not about their (dis)contentment concerning their functioning. Little is known about how severely injured patients experience their quality of life (QOL). The objective of this cross-sectional study was to measure this subjective QOL of severely injured patients after their rehabilitation phase and to examine which accident- and patient-related factors affect the QOL of these patients. Methods: Patients of 18 years or older with an injury severity score (ISS) above 15 were included 15-53 months after their accident. Comorbidity before the accident, accident and sociodemographic characteristics, and QOL were obtained from the trauma registry and questionnaires. The WHOQOL-BREF was used to measure QOL. A reference group of the Dutch general population was used for comparison. Results: The participation rate was 61% (n = 173). Compared with the reference data, severely injured patients experienced a significantly worse QOL in all domains except social relations. The QOL scores were significantly decreased in all domains for patients with intracranial injury in combination with other injuries. Patients with a severe intracranial injury (AIS > 3) only reported significantly impaired QOL in the general and physical domains. Patients who resumed working or lived with others had significantly higher scores in all domains of QOL than patients who did not work anymore or were living alone. Significantly lower QOL scores were obtained from patients with comorbidity before the accident and from patients with longer durations of intensive care unit (ICU) treatment or hospitalisation. Gender, accident characteristics and time since the accident did not appear to be important for experienced QOL. Conclusions: The experience of impaired QOL appears to depend on living alone, inability to return to work and pre-accidental comorbidity rather than on the injured body area or the severity of the injury. Duration of hospital or ICU stay is important to subsequent QOL, even if ISS or body region is not. (C) 2013 Elsevier Ltd. All rights reserved.	[van Delft-Schreurs, C. C. H. M.; de Jongh, M. A. C.; Verhofstad, M. H. J.] St Elizabeth Hosp, Trauma Ctr Brabant, NL-5000 LC Tilburg, Netherlands; [van Bergen, J. J. M.; de Sande, P. van; de Vries, J.] St Elizabeth Hosp, Dept Med Psychol, NL-5000 LC Tilburg, Netherlands; [Verhofstad, M. H. J.] St Elizabeth Hosp, Dept Surg, NL-5000 LC Tilburg, Netherlands; [Verhofstad, M. H. J.] Erasmus MC, Dept Trauma Surg, Rotterdam, Netherlands; [de Vries, J.] Tilburg Univ, Dept Med Psychol, CoRPS, NL-5000 LE Tilburg, Netherlands		van Delft-Schreurs, CCHM (corresponding author), St Elizabeth Hosp, Trauma Ctr Brabant, POB 90151, NL-5000 LC Tilburg, Netherlands.	k.v.delft@elisabeth.nl					AAAM, 1998, ABBR INJ SCAL 1990 R; Alves ALA, 2009, REV SAUDE PUBL, V43, P154, DOI 10.1590/S0034-89102009000100020; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Anderson JP, 2007, J CLIN EPIDEMIOL, V60, P300, DOI 10.1016/j.jclinepi.2006.06.003; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brasel KJ, 2010, J TRAUMA, V68, P263, DOI 10.1097/TA.0b013e3181caa58f; Breek JC, 2005, J VASC SURG, V41, P443, DOI 10.1016/j.jvs.2004.12.042; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Centraal Bureau Statistiek, 2011, WAT IS KWAL LEV MENS; Christensen MC, 2011, J TRAUMA, V70, P1524, DOI 10.1097/TA.0b013e3181f053c2; de Vries J., 1996, NEDERLANDSE VERSIE W; De Vries J., 2001, ASSESSMENT BEHAV MED, P353; De Vries J, 2003, NEDERLANDSE HANDLEID; Hamming JF, 2007, BRIT J SURG, V94, P923, DOI 10.1002/bjs.5948; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Hladki Waldemar, 2009, Przegl Lek, V66, P134; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; O'Carroll RE, 2000, QUAL LIFE RES, V9, P121, DOI 10.1023/A:1008901320492; Orwelius L, 2011, J TRAUMA; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-783; Ringburg AN, 2010, J TRAUMA; Saban KL, 2011, J WOMENS HEALTH, V20, P179, DOI 10.1089/jwh.2010.2334; Sampalis JS, 2006, J TRAUMA, V60, P806, DOI 10.1097/01.ta.0000215103.62783.4d; Sanderman R., 2012, METEN ALGEMENE GEZON; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Toien K, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-22; Trompenaars F, 2005, QUAL LIFE RES, V14, P151, DOI 10.1007/s11136-004-0787-x; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; van der Steeg AFW, 2004, EJSO-EUR J SURG ONC, V30, P1051, DOI 10.1016/j.ejso.2004.07.003; WHOQOL Group, 1996, WHOQOL BREF; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	43	38	38	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2014	45	1					320	326		10.1016/j.injury.2013.02.025			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	264OJ	WOS:000327887800057	23510753	Green Submitted			2022-02-06	
J	Chen, CC; Wei, ST; Tsaia, SC; Chen, XX; Cho, DY				Chen, Chun-Chung; Wei, Sung-Tai; Tsaia, Shiu-Chiu; Chen, Xian-Xiu; Cho, Der-Yang			Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brain contusion; cerebrolysin; cognitive abilities screening instrument score; head injury; traumatic brain injury	HEAD-INJURY	In adults, mild traumatic brain injury (MTBI) frequently results in impairments of cognitive functions which would lead to psychological consequences in the future. Cerebrolysin is a nootropic drug, and can significantly improve cognitive function in patients with Alzheimer's disease and stroke. The purpose of this study was to investigate how Cerebrolysin therapy enhances cognitive recovery for mild traumatic brain injury patients using a double-blinded, placebo-controlled, randomized phase II pilot study. Patients having head injury within 24 h sent to our hospital were screened and recruited if patients were alert and conscious, and had intracranial contusion haemorrhage. From July 2009 to June 2010, totally, thirty-two patients were recruited in the double-blinded, placebo-controlled, and randomized study. Patients were randomized to receive Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60-min period for 5 days) or placebo (Group B, same dosage and administration of normal saline as Group A). The primary outcome measures were differences of cognitive function including Mini-Mental Status Examination (MMSE), and Cognitive Abilities Screening Instrument (CASI) scores between baseline and week 1, between baseline and week 4, and between baseline and week 12. Thirty-two patients completed the trial. For Group A, the CASI score difference between baseline and week 12 was 21.0 +/- 20.4, a significantly greater change than that of Group B (7.6 +/- 12.1) (p = 0.0461). Besides, drawing function (one of the domains of CASI; p = 0.0066) on week 4 and both drawing function (p = 0.0472) and long-term memory (one of the domains of CASI; p = 0.0256) on week 12were also found to be significantly improved in the patients receiving Cerebrolysin treatment. Our results suggest that Cerebrolysin improves the cognitive function of the MTBI in patients at 3rd month after injury, especially for long-term memory and drawing function.	[Chen, Chun-Chung; Wei, Sung-Tai; Tsaia, Shiu-Chiu; Cho, Der-Yang] China Med Univ Hosp, Dept Neurosurg, Taichung 40402, Taiwan; [Chen, Chun-Chung; Cho, Der-Yang] China Med Univ, Coll Med, Taichung, Taiwan; [Chen, Xian-Xiu] China Med Univ, Inst Publ Hlth, Taichung, Taiwan		Chen, CC (corresponding author), China Med Univ Hosp, Dept Neurosurg, 2 Yu Der Rd, Taichung 40402, Taiwan.	cck36701@gmail.com		Chen, XianXiu/0000-0002-7955-9506			Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; [Anonymous], 2005, MED SCI, V26, P104; Bae CY, 2000, J AM GERIATR SOC, V48, P1566, DOI 10.1111/j.1532-5415.2000.tb03865.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; GRAVES AB, 1993, ALZHEIMERS DIS ADV C, P113; Gromova OA, 2003, ZH NEVROPATOL PSIKH, V103, P59; Gromova OA, 1998, ZH NEVROPATOL PSIKH, V98, P27; Heiss WD, 2012, STROKE, V43, P630, DOI 10.1161/STROKEAHA.111.628537; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kraus F, 2005, TXB TRAUMATIC BRAIN; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Prigatano GP, 1998, BNI Q, V4, P30; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; TEASDALE G, 1974, LANCET, V2, P81; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59	20	38	42	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	DEC	2013	27	6					803	807		10.3109/02688697.2013.793287			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	268KF	WOS:000328168100018	23656173				2022-02-06	
J	Pascual, JL; Murcy, MA; Li, SH; Gong, WF; Eisenstadt, R; Kumasaka, K; Sims, C; Smith, DH; Browne, K; Allen, S; Baren, J				Pascual, Jose L.; Murcy, Mohammad A.; Li, Shenghui; Gong, Wanfeng; Eisenstadt, Rachel; Kumasaka, Kenichiro; Sims, Carrie; Smith, Douglas H.; Browne, Kevin; Allen, Steve; Baren, Jill			Neuroprotective effects of progesterone in traumatic brain injury: blunted in vivo neutrophil activation at the blood-brain barrier	AMERICAN JOURNAL OF SURGERY			English	Article						Intravital microscopy; Neutrophil; Endothelium; Blood-brain barrier; Traumatic brain injury; Progesterone	HYPERTONIC SALINE; INFLAMMATION; HORMONES; SODIUM; EDEMA	BACKGROUND: Progesterone (PRO) may confer a survival advantage in traumatic brain injury (TBI) by reducing cerebral edema. We hypothesized that PRO reduces edema by blocking polymorphonuclear (PMN) interactions with endothelium (EC) in the blood-brain barrier (BBB). METHODS: CD1 mice received repeated PRO (16 mg/kg intraperitoneally) or vehicle (cyclodextrin) for 36 hours after TBI. Sham animals underwent craniotomy without TBI. The modified Neurological Severity Score graded neurologic recovery. A second craniotomy allowed in vivo observation of pial EC/PMN interactions and vascular macromolecule leakage. Wet/dry ratios assessed cerebral edema. RESULTS: Compared with the vehicle, PRO reduced subjective cerebral swelling (2.9 +/- .1 vs 1.2 +/- .1, P < .001), PMN rolling (95 +/- 1.8 vs 57 +/- 2.0 cells/100 mu m/min P < .001), total EC/PMN adhesion (2.0 +/- .4 vs .8 +/- .1 PMN/100 mu m, P < .01), and vascular permeability (51.8% +/- 4.9% vs 27.1% +/- 4.6%, P < .01). TBI groups had similar a Neurological Severity Score and cerebral wet/dry ratios (P > .05). CONCLUSIONS: PRO reduces live pericontusional EC/PMN and BBB macromolecular leakage after TBI. Direct PRO effects on the microcirculation warrant further investigation. (C) 2013 Elsevier Inc. All rights reserved.	[Pascual, Jose L.; Murcy, Mohammad A.; Gong, Wanfeng; Eisenstadt, Rachel; Kumasaka, Kenichiro; Sims, Carrie; Allen, Steve] Univ Penn, Div Traumatol Surg Crit Care & Emergency Surg, Dept Surg, Perelman Sch Med,Trauma Ctr Penn, Philadelphia, PA 19104 USA; [Li, Shenghui] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Tianjin, Peoples R China; [Smith, Douglas H.; Browne, Kevin] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA; [Baren, Jill] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA		Pascual, JL (corresponding author), Univ Penn, Div Traumatol Surg Crit Care & Emergency Surg, Dept Surg, Perelman Sch Med,Trauma Ctr Penn, 3400 Spruce St,Maloney Bldg,5th Floor, Philadelphia, PA 19104 USA.	jose.pascual@uphs.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL109009] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12 HL109009] Funding Source: Medline		BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Chaveiro A, 2010, REPROD DOMEST ANIM, V45, pE40, DOI 10.1111/j.1439-0531.2009.01519.x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hermenegildo C, 2005, J PHARMACOL EXP THER, V315, P722, DOI 10.1124/jpet.105.090456; Kim JV, 2006, J IMMUNOL, V177, P5269, DOI 10.4049/jimmunol.177.8.5269; Li S, 2011, CRIT CARE MED, V39, P1493, DOI 10.1097/CCM.0b013e31821201d3; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; MIYAGI M, 1992, J PERIODONTOL, V63, P28, DOI 10.1902/jop.1992.63.1.28; Orvieto R, 1999, AM J REPROD IMMUNOL, V42, P288; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Pascual JL, 2003, J TRAUMA, V54, pS133, DOI 10.1097/01.TA.0000064526.33647.63; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; ROTH JA, 1983, AM J VET RES, V44, P247; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	26	38	40	0	9	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2013	206	6					840	845		10.1016/j.amjsurg.2013.07.016			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	267CT	WOS:000328075000004	24112683	Green Accepted			2022-02-06	
J	Ryan, NP; Anderson, V; Godfrey, C; Eren, S; Rosema, S; Taylor, K; Catroppa, C				Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy			Social communication mediates the relationship between emotion perception and externalizing behaviors in young adult survivors of pediatric traumatic brain injury (TBI)	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Emotion perception; Social communication; Externalizing behaviors; Childhood; Traumatic brain injury	CLOSED-HEAD-INJURY; FACIAL EXPRESSION; CHILDREN; ADOLESCENTS; RECOGNITION; CHILDHOOD; ABILITY; COMPETENCE; ADJUSTMENT; AGGRESSION	Traumatic brain injury (TBI) is a common cause of childhood disability, and is associated with elevated risk for long-term social impairment. Though social (pragmatic) communication deficits may be among the most debilitating consequences of childhood TBI, few studies have examined very long-term communication outcomes as children with TBI make the transition to young adulthood. In addition, the extent to which reduced social function contributes to externalizing behaviors in survivors of childhood TBI remains poorly understood. The present study aimed to evaluate the extent of social communication difficulty among young adult survivors of childhood TB! (n=34, injury age: 1.0-7.0 years; M time since injury: 16.55 years) and examine relations among aspects of social function including emotion perception, social communication and externalizing behaviors rated by close-other proxies. Compared to controls the TBI group had significantly greater social communication difficulty, which was associated with more frequent externalizing behaviors and poorer emotion perception. Analyses demonstrated that reduced social communication mediated the association between poorer emotion perception and more frequent externalizing behaviors. Our findings indicate that socio-cognitive impairments may indirectly increase the risk for externalizing behaviors among young adult survivors of childhood TBI, and underscore the need for targeted social skills interventions delivered soon after injury, and into the very long-term. (C) 2013 ISDN. Published by Elsevier Ltd. All rights reserved.	[Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Anderson, Vicki; Taylor, Kaitlyn; Catroppa, Cathy] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Godfrey, Celia; Rosema, Stefanie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia		Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au; vicki.anderson@rch.org.au; celia.godfrey@mcri.edu.au; senem.eren@mcri.edu.au; stefanie.rosema@mcri.edu.au; kaitlyn.taylor@mcri.edu.au; cathy.catroppa@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021; Ryan, Nicholas/K-5445-2019	Catroppa, Cathy/0000-0002-9750-0436; Ryan, Nicholas/0000-0002-0878-8889	Victorian Neurotrauma Initiative, National Health and Medical Research Council (NHMRC) Fellowship (VA)National Health and Medical Research Council of Australia; NHMRCNational Health and Medical Research Council of Australia; Victorian Government Operational Infrastructure Scheme	Victorian Neurotrauma Initiative, National Health and Medical Research Council (NHMRC) Fellowship (VA), NHMRC Career Development Award (CC), Victorian Government Operational Infrastructure Scheme.	Achenbach TM., 2003, MANUAL ASEBA ADULT F; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Anderson V., 2012, DEV SOCIAL NEUROSCIE, P231; Anderson VA, 2003, STUD NEUROPSYCHOL DE, P217; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Cohen J., 2013, STAT POWER ANAL BEHA; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Denham SA, 2003, CHILD DEV, V74, P238, DOI 10.1111/1467-8624.00533; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2010, BRAIN IMPAIR, V11, P171, DOI 10.1375/brim.11.2.171; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Guercio John M, 2002, Case Manager, V13, P55, DOI 10.1067/tcmg.2002.122043; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hanten G., 2012, DEV SOCIAL NEUROSCIE, P254; Hawkins JD, 2005, ARCH PEDIAT ADOL MED, V159, P25, DOI 10.1001/archpedi.159.1.25; Holdnack J, 2011, ASSESSMENT, V18, P192, DOI 10.1177/1073191110394771; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Karow Colleen M., 2003, Seminars in Speech and Language, V24, P69, DOI 10.1055/s-2003-38900; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KUPERSMIDT JB, 1990, CHILD DEV, V61, P1350, DOI 10.2307/1130747; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S., 2000, ADV UNDERSTANDING CO; McDonald S., 2012, DEV SOCIAL NEUROSCIE, P325; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; MORRISON RL, 1981, BEHAV THER, V12, P69, DOI 10.1016/S0005-7894(81)80107-4; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Parker J., 2006, DEV PSYCHOPATHOL RIS, V2, P419, DOI DOI 10.1002/9780470939383.CH12; Pearson, 2009, ADV CLIN SOLUTIONS W; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; Poggi G, 2005, BRAIN INJURY, V19, P777, DOI 10.1080/0269905500110132; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Ryan N.P., 2013, J NEUROTRAU IN PRESS; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Sengpiel F, 2007, CURR BIOL, V17, pR742, DOI 10.1016/j.cub.2007.06.017; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Sobel ME., 1982, SOCIOLOGICAL METHODO, V13, P290, DOI DOI 10.2307/270723; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tenneij NH, 2007, J APPL RES INTELLECT, V20, P391, DOI 10.1111/j.1468-3148.2007.00383.x; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J., 2007, BRAIN IMPAIR, V18, P458; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	76	38	38	1	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	DEC	2013	31	8					811	819		10.1016/j.ijdevneu.2013.10.002			9	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Developmental Biology; Neurosciences & Neurology	283TP	WOS:000329270200013	24140241				2022-02-06	
J	Neselius, S; Zetterberg, H; Blennow, K; Marcusson, J; Brisby, H				Neselius, Sanna; Zetterberg, Henrik; Blennow, Kaj; Marcusson, Jan; Brisby, Helena			Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; FLUID APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; AXONAL INJURY; CONCUSSION; RISK; BIOMARKER; SPORTS	Introduction: Diagnosis of mild TBI is hampered by the lack of imaging or biochemical measurements for identifying or quantifying mild TBI in a clinical setting. We have previously shown increased biomarker levels of protein reflecting axonal (neurofilament light protein and tau) and glial (GFAP and S-100B) damage in cerebrospinal fluid (CSF) after a boxing bout. The aims of this study were to find other biomarkers of mild TBI, which may help clinicians diagnose and monitor mild TBI, and to calculate the role of APOE epsilon 4 allele genotype which has been associated with poor outcome after TBI. Materials and Methods: Thirty amateur boxers with a minimum of 45 bouts and 25 non-boxing matched controls were included in a prospective cohort study. CSF and blood were collected at one occasion between 1 and 6 days after a bout, and after a rest period for at least 14 days (follow up). The controls were tested once. CSF levels of neurofilament heavy (pNFH), amyloid precursor proteins (sAPP alpha and sAPP beta), ApoE and ApoA1 were analyzed. In blood, plasma levels of A beta 42 and ApoE genotype were analyzed. Results: CSF levels of pNFH were significantly increased between 1 and 6 days after boxing as compared with controls (p<0.001). The concentrations decreased at follow up but were still significantly increased compared to controls (p = 0.018). CSF pNFH concentrations correlated with NFL (r = 0.57 after bout and 0.64 at follow up, p<0.001). No significant change was found in the other biomarkers, as compared to controls. Boxers carrying the APOE epsilon 4 allele had similar biomarker concentrations as non-carriers. Conclusions: pNFH, even without unconsciousness or concussion symptoms. Possession of the APOE epsilon 4 allele was not found to influence biomarker levels after acute TBI.	[Neselius, Sanna; Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden; [Neselius, Sanna; Brisby, Helena] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Dept Psychiat & Neurochem, Clin Neurochem Lab, S-41345 Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden; [Marcusson, Jan] Linkoping Univ Hosp, Geriatr Sect, S-58185 Linkoping, Sweden; [Marcusson, Jan] Linkoping Univ, Inst Clin & Expt Med, Linkoping, Sweden		Neselius, S (corresponding author), Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden.	sanna.neselius@vgregion.se			Marianne and Marcus Wallenberg Foundation, SWEDEN; ALF Grants, County Council of Vastra Gotaland, SWEDEN; Sahlgrenska University Hospital, Gothenburg, SWEDEN; Gothenburg Medical Society, SWEDEN; ALF Grants, County Council of Ostergotland, SWEDEN; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study has been funded by the Marianne and Marcus Wallenberg Foundation, SWEDEN; ALF Grants, County Council of Vastra Gotaland, SWEDEN; Sahlgrenska University Hospital, Gothenburg, SWEDEN; Gothenburg Medical Society, SWEDEN; ALF Grants, County Council of Ostergotland, SWEDEN and The Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Bramley H, 2012, CLIN PEDIATR, V51, P283, DOI 10.1177/0009922811422434; Constantinescu R, 2009, PARKINSONISM RELAT D, V15, P205, DOI 10.1016/j.parkreldis.2008.05.001; De Strooper B, 2000, J CELL SCI, V113, P1857; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; Ganesalingam J, 2013, AMYOTROPH LAT SCL FR, V14, P146, DOI 10.3109/21678421.2012.729596; Graham DI, 1996, ACT NEUR S, V66, P96; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kuhle J, 2011, NEUROLOGY, V76, P1206, DOI 10.1212/WNL.0b013e31821432ff; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Olivecrona Z, 2012, ACTA NEUROCHIR, V154, P675, DOI 10.1007/s00701-012-1292-6; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Piccini A, 2005, J BIOL CHEM, V280, P34186, DOI 10.1074/jbc.M501694200; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Puchades M, 2003, MOL BRAIN RES, V118, P140, DOI 10.1016/j.molbrainres.2003.08.005; Roses AD, 1996, CURR OPIN NEUROL, V9, P265, DOI 10.1097/00019052-199608000-00004; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Tegner Y, 1991, Br J Sports Med, V25, P87; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Xie YY, 2003, J NEUROSCI RES, V73, P557, DOI 10.1002/jnr.10667; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zetterberg H, 2008, ARCH NEUROL-CHICAGO, V65, P1102, DOI 10.1001/archneur.65.8.1102; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	35	38	38	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e81249	10.1371/journal.pone.0081249			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255RX	WOS:000327258600111	24260563	Green Published, Green Submitted, gold			2022-02-06	
J	Scholl, EA; Dudek, FE; Ekstrand, JJ				Scholl, E. A.; Dudek, F. E.; Ekstrand, J. J.			NEURONAL DEGENERATION IS OBSERVED IN MULTIPLE REGIONS OUTSIDE THE HIPPOCAMPUS AFTER LITHIUM PILOCARPINE-INDUCED STATUS EPILEPTICUS IN THE IMMATURE RAT	NEUROSCIENCE			English	Article						Fluoro-jade B; lithium pilocarpine; status epilepticus; immature brain	TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; TRAUMATIC BRAIN-INJURY; FLUORO-JADE-B; LIMBIC EPILEPSY; ACQUIRED EPILEPTOGENESIS; MEDIODORSAL NUCLEUS; FUNCTIONAL-ANATOMY; AMYGDALOID COMPLEX; ENTORHINAL CORTEX	Although hippocampal sclerosis is frequently identified as a possible epileptic focus in patients with temporal lobe epilepsy, neuronal loss has also been observed in additional structures, including areas outside the temporal lobe. The claim from several researchers using animal models of acquired epilepsy that the immature brain can develop epilepsy without evidence of hippocampal neuronal death raises the possibility that neuronal death in some of these other regions may also be important for epileptogenesis. The present study used the lithium pilocarpine model of acquired epilepsy in immature animals to assess which structures outside the hippocampus are injured acutely after status epilepticus. Sprague Dawley rat pups were implanted with surface EEG electrodes, and status epilepticus was induced at 20 days of age with lithium pilocarpine. After 72 h, brain tissue from 12 animals was examined with Fluoro-Jade B, a histochemical marker for degenerating neurons. All animals that had confirmed status epilepticus demonstrated Fluoro-Jade B staining in areas outside the hippocampus. The most prominent staining was seen in the thalamus (mediodorsal, paratenial, reuniens, and ventral lateral geniculate nuclei), amygdala (ventral lateral, posteromedial, and basomedial nuclei), ventral premammillary nuclei of hypothalamus, and paralimbic cortices (perirhinal, entorhinal, and piriform) as well as parasubiculum and dorsal endopiriform nuclei. These results demonstrate that lithium pilocarpine-induced status epilepticus in the immature rat brain consistently results in neuronal injury in several distinct areas outside of the hippocampus. Many of these regions are similar to areas damaged in patients with temporal lobe epilepsy, thus suggesting a possible role in epileptogenesis. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Scholl, E. A.; Ekstrand, J. J.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84108 USA; [Dudek, F. E.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84108 USA		Ekstrand, JJ (corresponding author), Univ Utah, Sch Med, Dept Pediat, 420 Chipeta Way,Suite 1700, Salt Lake City, UT 84108 USA.	jeffrey.ekstrand@hsc.utah.edu			National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS-070957]; CounterACT Program, National Institutes of Health Office of the Director (NIH OD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [HHS N271201100029C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045144, K08NS070957] Funding Source: NIH RePORTER	The project was supported directly by the National Institute of Neurological Disorders and Stroke (NINDS) Grant K08-NS-070957 with additional support from the CounterACT Program, National Institutes of Health Office of the Director (NIH OD), and NINDS, Grant HHS N271201100029C which was subcontracted to the University of Utah (W81XWH-12-2-0122).	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060; Andre V, 2003, EPILEPSIA, V44, P893, DOI 10.1046/j.1528-1157.2003.61802.x; Baram TZ, 2011, EPILEPSY CURR, V11, P21, DOI 10.5698/1535-7511-11.1.21; Bertram EH, 2009, EPILEPSY BEHAV, V14, P32, DOI 10.1016/j.yebeh.2008.09.017; Bertram EH, 2001, EPILEPSIA, V42, P967, DOI 10.1046/j.1528-1157.2001.042008967.x; Bertram EH, 1998, EPILEPSY RES, V32, P194, DOI 10.1016/S0920-1211(98)00051-5; Bertram EH, 2000, EPILEPSIA, V41, pS3, DOI 10.1111/j.1528-1157.2000.tb01548.x; BOAST CA, 1976, BRAIN RES, V103, P527, DOI 10.1016/0006-8993(76)90450-9; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO, V31; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; CAVALHEIRO EA, 1987, DEV BRAIN RES, V37, P43, DOI 10.1016/0165-3806(87)90227-6; CAVANAGH JB, 1956, BRIT MED J, V2, P1403, DOI 10.1136/bmj.2.5006.1403; CLIFFORD DB, 1987, NEUROSCIENCE, V23, P953, DOI 10.1016/0306-4522(87)90171-0; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Drexel M, 2011, NEUROSCIENCE, V189, P316, DOI 10.1016/j.neuroscience.2011.05.021; Druga R, 2005, EPILEPSY RES, V63, P43, DOI 10.1016/j.eplepsyres.2004.11.001; DU F, 1993, EPILEPSY RES, V16, P223, DOI 10.1016/0920-1211(93)90083-J; Dube C, 2001, EXP NEUROL, V167, P227, DOI 10.1006/exnr.2000.7561; Dudek FE, 2006, MODELS OF SEIZURES AND EPILEPSY, P415, DOI 10.1016/B978-012088554-1/50036-0; Dudek FE, 2010, EPILEPSY CURR, V10, P95, DOI 10.1111/j.1535-7511.2010.01369.x; Ekstrand JJ, 2011, NEUROSCIENCE, V192, P699, DOI 10.1016/j.neuroscience.2011.05.022; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FEINDEL W, 1991, CAN J NEUROL SCI, V18, P603; Fernandes MJD, 1999, J CEREBR BLOOD F MET, V19, P195; Francois J, 2011, NEUROPHARMACOLOGY, V61, P313, DOI 10.1016/j.neuropharm.2011.04.018; Frank TC, 2003, NEUROSCIENCE, V118, P667, DOI 10.1016/S0306-4522(03)00019-8; Fritsch B, 2009, NEUROSCIENCE, V163, P415, DOI 10.1016/j.neuroscience.2009.06.034; Fujikawa DG, 1996, BRAIN RES, V725, P11, DOI 10.1016/0006-8993(96)00203-X; GLOOR P, 1992, P505; GOLDRING S, 1992, J NEUROSURG, V77, P185, DOI 10.3171/jns.1992.77.2.0185; Hasson H, 2008, EPILEPSY BEHAV, V13, P62, DOI 10.1016/j.yebeh.2008.02.008; HIRSCH E, 1992, BRAIN RES, V583, P120, DOI 10.1016/S0006-8993(10)80015-0; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; HUDSON LP, 1993, ANN NEUROL, V33, P622, DOI 10.1002/ana.410330611; Knopp A, 2005, J COMP NEUROL, V483, P476, DOI 10.1002/cne.20460; Kobayashi M, 2003, J NEUROSCI, V23, P8471; Kubova H, 2005, EPILEPSIA, V46, P38, DOI 10.1111/j.1528-1167.2005.01005.x; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Kubova H, 2004, EUR J NEUROSCI, V19, P3255, DOI 10.1111/j.0953-816X.2004.03410.x; Kubova H, 2002, EPILEPSIA, V43, P54, DOI 10.1046/j.1528-1157.43.s.5.36.x; Kullmann DM, 2011, BRAIN, V134, P2800, DOI 10.1093/brain/awr246; Lado FA, 2002, EPILEPTIC DISORD, V4, P83; Larsson E, 2001, BRAIN RES, V913, P117, DOI 10.1016/S0006-8993(01)02762-7; Laufs H, 2012, CURR OPIN NEUROL, V25, P194, DOI 10.1097/WCO.0b013e3283515db9; LOSCHER W, 1995, BRAIN RES, V697, P197, DOI 10.1016/0006-8993(95)00843-F; Mares P, 2005, EPILEPSIA, V46, P31, DOI 10.1111/j.1528-1167.2005.01004.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; MILLER LA, 1994, J NEUROL NEUROSUR PS, V57, P1099, DOI 10.1136/jnnp.57.9.1099; Morin F, 1998, J NEUROPHYSIOL, V80, P2836, DOI 10.1152/jn.1998.80.6.2836; Nairismagi J, 2006, EPILEPSIA, V47, P479, DOI 10.1111/j.1528-1167.2006.00455.x; Noebels JL, JASPERS BASIC MECH E; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Pitkanen A, 1998, EPILEPSY RES, V32, P233, DOI 10.1016/S0920-1211(98)00055-2; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Priel MR, 1996, EPILEPSY RES, V26, P115, DOI 10.1016/S0920-1211(96)00047-2; QUESNEY LF, 1988, ACTA NEUROL SCAND, V78, P52, DOI 10.1111/j.1600-0404.1988.tb08004.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raol YSH, 2003, ANN NEUROL, V53, P503, DOI 10.1002/ana.10490; Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x; Sankar R, 1998, J NEUROSCI, V18, P8382; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scallet AC, 2004, TOXICOL SCI, V81, P364, DOI 10.1093/toxsci/kfh224; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Simerly R., 1994, RAT NERVOUS SYSTEM; SO N, 1989, ANN NEUROL, V25, P423, DOI 10.1002/ana.410250502; SPENCER DD, 1984, NEUROSURGERY, V15, P667, DOI 10.1227/00006123-198411000-00005; SPENCER SS, 1994, EPILEPSIA, V35, P721, DOI 10.1111/j.1528-1157.1994.tb02502.x; Spencer SS, 2002, EPILEPSIA, V43, P219, DOI 10.1046/j.1528-1157.2002.26901.x; SPERBER EF, 1991, DEV BRAIN RES, V60, P88, DOI 10.1016/0165-3806(91)90158-F; Stafstrom CE, 2005, EPILEPSY BEHAV, V7, pS18, DOI 10.1016/j.yebeh.2005.08.005; STAFSTROM CE, 1992, DEV BRAIN RES, V65, P227, DOI 10.1016/0165-3806(92)90184-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Tuunanen J, 1999, NEUROSCIENCE, V94, P473, DOI 10.1016/S0306-4522(99)00251-1; Tuunanen J, 1996, EUR J NEUROSCI, V8, P2711, DOI 10.1111/j.1460-9568.1996.tb01566.x; van Vliet EA, 2004, EXP NEUROL, V187, P367, DOI 10.1016/j.expneurol.2004.01.016; Wieser HG, 2004, EPILEPSIA, V45, P32; WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019; Xu B, 2004, EUR J NEUROSCI, V20, P403, DOI 10.1111/j.1460-9568.2004.03489.x	88	38	40	1	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 12	2013	252						45	59		10.1016/j.neuroscience.2013.07.045			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	236YS	WOS:000325836000005	23896573	Green Accepted			2022-02-06	
J	Zhang, YQ; Li, Y; Wang, SB; Han, ZY; Huang, XT; Li, SH; Chen, FL; Niu, RD; Dong, JF; Jiang, RC; Zhang, JN				Zhang, Yongqiang; Li, Ying; Wang, Shaobo; Han, Zhenying; Huang, Xintao; Li, Shenghui; Chen, Fanglian; Niu, Rongdong; Dong, Jing-fei; Jiang, Rongcai; Zhang, Jianning			Transplantation of expanded endothelial colony-forming cells improved outcomes of traumatic brain injury in a mouse model	JOURNAL OF SURGICAL RESEARCH			English	Article						Endothelial colony-forming cells; Traumatic brain injury; Cell transplantation; Angiogenesis; Functional recovery	NEURAL STEM-CELLS; CORD BLOOD-CELLS; PROGENITOR CELLS; GROWTH-FACTOR; AUTOLOGOUS TRANSPLANTATION; THERAPEUTIC ANGIOGENESIS; CROSS-TALK; IN-VITRO; NEOVASCULARIZATION; OUTGROWTH	Background: Endothelial progenitor cells (EPCs) are critical for repairing injured tissue. Endothelial colony-forming cells (ECFCs) are a homogeneous subtype of EPCs. We investigated whether intravenously infused human ECFCs homed to injured brain promoted angiogenesis and ameliorate neurologic disabilities in a mouse model of traumatic brain injury. Materials and methods: ECFCs were generated by in vitro propagation of EPCs from human umbilical cord blood. Young female nude mice received intravenously ECFCs from human newborns (1 x 10(6)) 1 h after they were exposed to lateral fluid percussion injury. Neurologic function was evaluated by a modified neurologic severity score and Morris water maze. ECFC homing and neovascularization at the site of injury were examined by fluorescence in situ hybridization and histochemistry on days 2 and 14 after injury, respectively. Results: Donor ECFCs were detected in injured brain 24 h after infusion. The modified neurologic severity score and Morris water maze tests were used to evaluate neurologic disability, and found the rate of neurologic disability was improved in mice that received ECFCs. Microvessel density and expression of the proangiogenic growth factors stromal cell -derived factor-1 and vascular endothelial growth factor were also increased in the region of injured brain from mice that received ECFCs compared with those received vehicle control. Conclusions: These data suggest that ECFCs are effective in promoting neovascularization and improving neurologic functions after traumatic brain injury. (C) 2013 Published by Elsevier Inc.	[Zhang, Yongqiang; Wang, Shaobo; Han, Zhenying; Huang, Xintao; Li, Shenghui; Chen, Fanglian; Niu, Rongdong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Li, Ying] Tianjin Med Univ, Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin 300052, Peoples R China; [Dong, Jing-fei] Univ Washington, Sch Med, Puget Sound Blood Ctr Res Inst, Seattle, WA USA		Zhang, JN (corresponding author), Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com		Huang, Xintao/0000-0002-9683-9518	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81100920, 81200907]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCQNJC07200, 12JCQNJC6800]	We acknowledge Li Liu, Yanjun Zhang, Weiyun Cui, and Lei Zhou for their assistance with the technical aspects of experiments and data interpretation. This work is supported by the National Natural Science Foundation of China (grants 81271361; 81100920; 81200907) and Tianjin Research Program of Application Foundation and Advanced Technology (grants 12JCQNJC07200; 12JCQNJC6800).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Barresi V, 2007, ACTA NEUROPATHOL, V114, P147, DOI 10.1007/s00401-007-0251-4; Bogoslovsky T, 2010, NEUROLOGY, V75, P2059, DOI 10.1212/WNL.0b013e318200d741; Bompais H, 2004, BLOOD, V103, P2577, DOI 10.1182/blood-2003-08-2770; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chu K, 2008, STROKE, V39, P1441, DOI 10.1161/STROKEAHA.107.499236; Di Stefano R, 2009, THROMB RES, V123, P925, DOI 10.1016/j.thromres.2008.10.013; Erbs S, 2005, CIRC RES, V97, P756, DOI 10.1161/01.RES.0000185811.71306.8b; Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Huang PP, 2004, THROMB HAEMOSTASIS, V91, P606, DOI 10.1160/TH03-06-0343; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jujo K, 2008, J MOL CELL CARDIOL, V45, P530, DOI 10.1016/j.yjmcc.2008.08.003; Kogler G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Lavergne M, 2011, CELL PROLIFERAT, V44, P44, DOI 10.1111/j.1365-2184.2010.00722.x; Lee CW, 2011, HYPERTENS RES, V34, P999, DOI 10.1038/hr.2011.68; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Moise KJ, 2005, OBSTET GYNECOL, V106, P1393, DOI 10.1097/01.AOG.0000188388.84901.e4; Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Renault MA, 2007, MICROVASC RES, V74, P159, DOI 10.1016/j.mvr.2007.08.005; Rocha V, 2006, BIOL BLOOD MARROW TR, V12, P34, DOI 10.1016/j.bbmt.2005.09.006; Rosenkranz K, 2010, J NEUROSCI RES, V88, P1223, DOI 10.1002/jnr.22292; Senegaglia AC, 2008, REV BRAS CIR CARDIOV, V23, P467, DOI 10.1590/S0102-76382008000400003; Sharma M, 2011, STEM CELLS DEV, V20, P933, DOI 10.1089/scd.2010.0263; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Ward NL, 2004, NEUROL RES, V26, P870, DOI 10.1179/016164104X3798; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	42	38	41	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	NOV	2013	185	1					441	449		10.1016/j.jss.2013.05.073			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	238MP	WOS:000325951100084	23953790				2022-02-06	
J	Zimmerman, RM; Kalish, LA; Hresko, MT; Waters, PM; Bae, DS				Zimmerman, Ryan M.; Kalish, Leslie A.; Hresko, M. Timothy; Waters, Peter M.; Bae, Donald S.			Surgical Management of Pediatric Radial Neck Fractures	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							DISPLACED FRACTURES; CHILDREN; HEAD; REDUCTION; FIXATION	Background: Management of pediatric radial neck fractures is controversial regarding acceptable alignment, variable reduction techniques, and suboptimal outcomes. The purpose of this study was to assess the characteristics, management, and results in a surgical cohort, in efforts to identify prognostic factors and offer treatment suggestions. It was hypothesized that less invasive reduction maneuvers would precede open reduction and that worse results would correlate with fracture severity, open reduction, and the presence of associated injuries. Methods: Retrospective analysis of 151 children in whom a radial neck fracture had been surgically treated from 2001 to 2011 was performed. The mean age (and standard deviation) and duration of follow-up were 8.4 +/- 2.9 years and 13.3 +/- 20.0 months, respectively; 40% of the patients were male. A successful clinical result was defined as elbow flexion of >= 120 degrees, flexion contracture of <20 degrees, forearm rotation of >= 90 degrees with >= 45 degrees of supination and pronation, and no complications. Results: An isolated radial neck fracture occurred in 54% of the children. The mean angulation and displacement improved from 43 degrees +/- 19 degrees and 37% +/- 35%, respectively, before treatment to 13 degrees +/- 7 degrees and 0.9% +/- 4% after treatment (p < 0.001). Twenty-two procedural combinations were used to treat these patients, and 67% of the open reductions were not preceded by percutaneous or closed reduction attempts. Among 131 patients with adequate follow-up, 31% had an unsuccessful outcome. An age of ten years or more (odds ratio [OR] = 5.85, p = 0.001), a time to surgery of two days or less (OR = 4.73, p = 0.02), and greater fracture displacement (OR = 1.25 per 10%, p = 0.001) were independent predictors of unsuccessful outcomes. Increased fracture severity and open reduction were associated with poor results, although the presence of concomitant injuries was not. It is predicted that closed manipulation will fail for half of fractures angulated >= 36 degrees, and that half of fractures displaced >= 65% will require open reduction. The predicted frequency of unsuccessful outcomes is 50% with 76% displacement. Conclusions: There continues to be great variation in the approach to treatment of displaced radial neck fractures in children. Suboptimal results occurred in 31% of the patients in this series, with worse results in patients older than ten years, who had increased fracture severity, and who underwent open reduction. Less invasive reduction methods should precede open reduction whenever possible.	[Zimmerman, Ryan M.; Kalish, Leslie A.; Hresko, M. Timothy; Waters, Peter M.; Bae, Donald S.] Boston Childrens Hosp, Dept Orthoped Surg, Boston, MA USA		Zimmerman, RM (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,WHT 535, Boston, MA 02114 USA.	Donald.Bae@childrens.harvard.edu					BLOUNT W P, 1950, J Iowa State Med Soc, V40, P203; Brandao GF, 2010, J PEDIATR ORTHOPED, V30, P110, DOI 10.1097/BPO.0b013e3181cf118a; CHAO EY, 1980, J BIOMECH ENG-T ASME, V102, P301, DOI 10.1115/1.3138227; COOPER JE, 1993, ARCH PHYS MED REHAB, V74, P805, DOI 10.1016/0003-9993(93)90005-U; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; Eberl R, 2010, EUR J PEDIATR SURG, V20, P250, DOI 10.1055/s-0030-1249104; Endele SM, 2010, J PEDIATR ORTHOP B, V19, P246, DOI 10.1097/BPB.0b013e32833918c0; Evans MC, 1999, J PEDIATR ORTHOP B, V8, P93; FOWLES JV, 1986, J PEDIATR ORTHOPED, V6, P51; Futami T, 1995, J Shoulder Elbow Surg, V4, P162; Garcia-Alvarez F, 2001, Chir Organi Mov, V86, P211; HENRIKSON B, 1969, ACTA ORTHOP SCAND, V40, P246, DOI 10.3109/17453676908989505; JONES E R L, 1971, Journal of Bone and Joint Surgery British Volume, V53, P429; Klitscher D, 2009, J PEDIATR ORTHOPED, V29, P698, DOI 10.1097/BPO.0b013e3181b76895; LANDIN LA, 1983, ACTA ORTHOP SCAND, V54, P1; Magermans DJ, 2005, CLIN BIOMECH, V20, P591, DOI 10.1016/j.clinbiomech.2005.02.006; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; Navali AM, 2006, J HAND SURG-BRIT EUR, V31B, P689, DOI 10.1016/j.jhsb.2006.04.020; Neher CG, 2003, J PEDIATR ORTHOPED, V23, P626, DOI 10.1097/01241398-200309000-00009; NEWMAN JH, 1977, INJURY, V9, P114, DOI 10.1016/0020-1383(77)90004-3; O'Brien P I, 1965, Clin Orthop Relat Res, V41, P51; Petuskey K, 2007, GAIT POSTURE, V25, P573, DOI 10.1016/j.gaitpost.2006.06.006; Prathapkumar KR, 2006, J BONE JOINT SURG BR, V88B, P358, DOI 10.1302/0301-620X.88B3.17099; Schmittenbecher PP, 2005, J PEDIATR ORTHOPED, V25, P45; Shukla DR, 2012, J SHOULDER ELB SURG, V21, P789, DOI 10.1016/j.jse.2011.12.001; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tan Bryan Hsi Ming, 2011, J Orthop Surg (Hong Kong), V19, P209; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; Ugutmen E, 2010, J PEDIATR ORTHOP B, V19, P289, DOI 10.1097/BPB.0b013e32833918a0; VAHVANEN V, 1978, ACTA ORTHOP SCAND, V49, P32, DOI 10.3109/17453677809005720; Vocke AK, 1998, J PEDIATR ORTHOP B, V7, P217, DOI 10.1097/01202412-199807000-00007	32	38	44	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	OCT 16	2013	95A	20					1825	1832		10.2106/JBJS.L.01130			8	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	244DQ	WOS:000326367700002	24132355				2022-02-06	
J	Roberts, DJ; Jenne, CN; Leger, C; Kramer, AH; Gallagher, CN; Todd, S; Parney, IF; Doig, CJ; Yong, VW; Kubes, P; Zygun, DA				Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Gallagher, Clare N.; Todd, Stephanie; Parney, Ian F.; Doig, Christopher J.; Yong, V. Wee; Kubes, Paul; Zygun, David A.			Association between the Cerebral Inflammatory and Matrix Metalloproteinase Responses after Severe Traumatic Brain Injury in Humans	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; cerebrospinal fluid; craniocerebral trauma; cytokines; matrix metalloproteinases; neuroinflammation; microdialysis	ACTIVATED PROTEIN-KINASE; MATRIX-METALLOPROTEINASE-9 EXPRESSION; FUNCTIONAL RECOVERY; CEREBROSPINAL-FLUID; BARRIER DISRUPTION; TISSUE INHIBITORS; EDEMA FORMATION; CARE PATIENTS; HEAD-INJURY; BLOOD	An increasing number of preclinical investigations have suggested that the degree of expression of the matrix metalloproteinase (MMP) family of endopeptidases may explain some of the variability in neurological damage after traumatic brain injury (TBI). As cytokines are a prominent stimulus for MMP expression in animals, we conducted a prospective multimodal monitoring study and determined their association with temporal MMP expression after severe TBI in eight critically ill adults. High cutoff, cerebral microdialysis (n=8); external ventricular drainage (n=3); and arterial and jugular venous bulb catheters were used to measure the concentration of nine cytokines and eight MMPs in microdialysate, cerebrospinal fluid (CSF), and plasma over 6 days. Severe TBI was associated with a robust central inflammatory response, which was largely similar between microdialysate and CSF. At all time points after injury, this response was predominated by the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-8. Use of univariate generalized estimating equations suggested that the concentration of several MMPs varied with cytokine levels in microdialysate. The largest of these changes included increases in microdialysate concentrations of MMP-8 and MMP-9 with increases in the levels of IL-1 and -2 and IL-1 and -2 and TNF-, respectively. In contrast, the microdialysate level of MMP-7 decreased with increases in microdialysate concentrations of IL-1, -2, and -6. These findings support the observations of animal studies that cross-talk exists between the neuroinflammatory and MMP responses after acute brain injury. Further study is needed to determine whether this link between cerebral inflammation and MMP expression may have clinical relevance to the care of patients with TBI.	[Roberts, Derek J.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Roberts, Derek J.; Doig, Christopher J.; Zygun, David A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Todd, Stephanie; Doig, Christopher J.; Kubes, Paul] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Kubes, Paul] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee; Kubes, Paul] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Jenne, Craig N.; Leger, Caroline; Kubes, Paul] Univ Calgary, Calvin Phoebe & Joan Snyder Inst Chron Dis, Calgary, AB, Canada; Foothills Med Ctr, Calgary, AB, Canada; [Parney, Ian F.] Mayo Clin, Coll Med, Dept Neurol Surg, Rochester, MN USA; [Zygun, David A.] Univ Alberta, Div Crit Care Med, Edmonton, AB T6G 2B7, Canada		Zygun, DA (corresponding author), Univ Alberta, Div Crit Care Med, 8440-112 St, Edmonton, AB T6G 2B7, Canada.	zygun@ualberta.ca	Roberts, Derek J./L-6229-2019; Doig, Christopher/AAC-7949-2020	Roberts, Derek J./0000-0001-6111-6291; Doig, Christopher/0000-0002-8576-9139; Parney, Ian/0000-0002-9702-8047; Yong, V. Wee/0000-0002-2600-3563	Alberta Innovates-Health Solutions; Canadian Intensive Care Foundation; Snyder Chair for Translational Research in Critical Care Medicine; Alberta Innovates-Health Solutions Clinician Fellowship Award; Clinician Investigator and Surgeon Scientist Programs at the University of Calgary; Alberta Innovates-Health Solutions Postdoctoral Fellowship Award	This work was supported by grants from Alberta Innovates-Health Solutions (formally the Alberta Heritage Foundation for Medical Research [awarded to Dr. Zygun]), the Canadian Intensive Care Foundation (awarded to Dr. Zygun), and the Snyder Chair for Translational Research in Critical Care Medicine (awarded to Dr. Kubes). Dr. Roberts is supported by an Alberta Innovates-Health Solutions Clinician Fellowship Award and funding from the Clinician Investigator and Surgeon Scientist Programs at the University of Calgary. Dr. Jenne is funded by an Alberta Innovates-Health Solutions Postdoctoral Fellowship Award.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Crocker SJ, 2006, J NEUROCHEM, V98, P812, DOI 10.1111/j.1471-4159.2006.03927.x; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Genersch E, 2000, J CELL SCI, V113, P4319; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; JENNETT B, 1975, LANCET, V1, P480; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim KS, 2008, BIOCHEM J, V410, P605, DOI 10.1042/BJ20071207; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Lei J, 2013, J NEUROTRAUM, V30, P529, DOI 10.1089/neu.2012.2548; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Noble LJ, 2002, J NEUROSCI, V22, P7526; Perez-Barcena J, 2011, CRIT CARE MED, V39, P533, DOI 10.1097/CCM.0b013e318205c7a4; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Roberts DJ, 2009, CRIT CARE MED, V37, P2767, DOI 10.1097/CCM.0b013e3181b755d5; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Schumann G, 1999, J NEUROCHEM, V73, P2009; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; SNOW WG, 1988, CAN J SURG, V31, P191; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; TEASDALE G, 1974, LANCET, V2, P81; Thornton P, 2008, MOL CELL NEUROSCI, V37, P135, DOI 10.1016/j.mcn.2007.09.002; Van Hove I, 2012, J NEUROCHEM, V123, P203, DOI 10.1111/j.1471-4159.2012.07900.x; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vittinghoff E, 2012, REGRESSION METHODS B, P261; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Woo MS, 2008, J NEUROCHEM, V106, P770, DOI 10.1111/j.1471-4159.2008.05430.x; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807	55	38	40	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1727	1736		10.1089/neu.2012.2842			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000005	23799281				2022-02-06	
J	Waters, RJ; Murray, GD; Teasdale, GM; Stewart, J; Day, I; Lee, RJ; Nicoll, JAR				Waters, Ryan J.; Murray, Gordon D.; Teasdale, Graham M.; Stewart, Janice; Day, Ian; Lee, Robert J.; Nicoll, James A. R.			Cytokine Gene Polymorphisms and Outcome after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; genetics; head injury; inflammation; traumatic brain injury	TUMOR-NECROSIS-FACTOR; ALPHA PROMOTER POLYMORPHISM; IN-SITU DETECTION; HEAD-INJURY; TNF-ALPHA; ASSOCIATION; INTERLEUKIN-1-BETA; DAMAGE; INFLAMMATION; INHIBITION	Clinical outcome after traumatic brain injury (TBI) is variable and cannot easily be predicted. There is increasing evidence to suggest that there may be genetic influences on outcome. Cytokines play an important role in mediating the inflammatory response provoked within the central nervous system after TBI. This study was designed to identify associations between cytokine gene polymorphisms and clinical outcome 6 months after head injury. A prospectively identified cohort of patients (n=1096, age range 0-93 years, mean age 37) was used. Clinical outcome at 6 months was assessed using the Glasgow Outcome Scale. In an initial screen of 11 cytokine gene single nucleotide polymorphisms (SNPs) previously associated with disease susceptibility or outcome (TNFA -238 and -308, IL6 -174, -572 and -597, IL1A -889, IL1B -31, -511 and +3953, and TGFB -509 and -800), TNFA -308 was identified as having a likely association. The TNFA -308 SNP was further evaluated, and a significant association was identified, with 39% of allele 2 carriers having an unfavorable outcome compared with 31% of non-carriers (adjusted odds ratio 1.67, confidence interval 1.19-2.35, p=0.003). These findings are consistent with experimental and clinical data suggesting that neuroinflammation has an impact on clinical outcome after TBI and that tumor necrosis factor alpha plays an important role in this process.	[Waters, Ryan J.] Univ Hosp Southampton NHS Fdn Trust, Wessex Neurol Ctr, Southampton, Hants, England; [Murray, Gordon D.; Lee, Robert J.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Teasdale, Graham M.; Stewart, Janice] Univ Glasgow, Inst Neurol Sci, So Gen Hosp, Glasgow, Lanark, Scotland; [Day, Ian] Sch Social & Community Med, Bristol Genet Epidemiol Labs, Bristol, Avon, England; [Nicoll, James A. R.] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England		Nicoll, JAR (corresponding author), Southampton Gen Hosp, Mailpoint 813, Southampton SO16 6YD, Hants, England.	J.Nicoll@soton.ac.uk	; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9601296N]; APOE genotyping; Fausto Iannotti Scholarship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish	This work was supported by the Medical Research Council (grant number G9601296N) which funded establishment of the Head Injury Prospective Cohort (1996-1999) and APOE genotyping; and a Fausto Iannotti Scholarship (Mr Bob Barber) that funded Ryan Waters.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Culpan D, 2003, NEUROSCI LETT, V350, P61, DOI 10.1016/S0304-3940(03)00854-1; Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Harcos P, 2006, CYTOKINE, V33, P100, DOI 10.1016/j.cyto.2005.12.006; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; JENNETT B, 1975, LANCET, V1, P480; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; Lio D, 2006, MECH AGEING DEV, V127, P567, DOI 10.1016/j.mad.2006.01.015; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Ruuls SR, 1999, AM J HUM GENET, V65, P294, DOI 10.1086/302517; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Tanriverdi T, 2006, SURG NEUROL, V65, P7, DOI 10.1016/j.surneu.2005.05.024; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Um JY, 2003, MOL BRAIN RES, V115, P50, DOI 10.1016/S0169-328X(03)00179-7; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229	59	38	38	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1710	1716		10.1089/neu.2012.2792			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000003	23768161	Green Published			2022-02-06	
J	Arnett, AB; Peterson, RL; Kirkwood, MW; Taylor, HG; Stancin, T; Brown, TM; Wade, SL				Arnett, Anne B.; Peterson, Robin L.; Kirkwood, Michael W.; Taylor, H. Gerry; Stancin, Terry; Brown, Tanya M.; Wade, Shari L.			Behavioral and Cognitive Predictors of Educational Outcomes in Pediatric Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Executive function; Neuropsychology; Adolescent; Language; Special education; Brain concussion	EXECUTIVE FUNCTION DEFICITS; ACADEMIC-ACHIEVEMENT; YOUNG-CHILDREN; HEAD-INJURY; TERM; RECOVERY; ADOLESCENTS; CHILDHOOD; PLACEMENT; RATINGS	Research reveals mixed results regarding the utility of standardized cognitive and academic tests to predict educational outcomes in youth following a traumatic brain injury (TBI). Yet, deficits in everyday school-based outcomes are prevalent after pediatric TBI. The current study used path modeling to test the hypothesis that parent ratings of adolescents' daily behaviors associated with executive functioning (EF) would predict long-term functional educational outcomes following pediatric TBI, even when injury severity and patient demographics were included in the model. Furthermore, we contrasted the predictive strength of the EF behavioral ratings with that of a common measure of verbal memory. A total of 132 adolescents who were hospitalized for moderate to severe TBI were recruited to participate in a randomized clinical intervention trial. EF ratings and verbal memory were measured within 6 months of the injury; functional educational outcomes were measured 12 months later. EF ratings and verbal memory added to injury severity in predicting educational competence post injury but did not predict post-injury initiation of special education. The results demonstrated that measurement of EF behaviors is an important research and clinical tool for prediction of functional outcomes in pediatric TBI.	[Arnett, Anne B.; Peterson, Robin L.; Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Arnett, Anne B.; Peterson, Robin L.; Kirkwood, Michael W.] Univ Colorado Denver, Sch Med, Aurora, CO USA; [Arnett, Anne B.; Peterson, Robin L.] Univ Denver, Dept Child Clin Psychol, Denver, CO USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Cleveland, Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Stancin, Terry] MetroHealth Med Ctr, Dept Psychiat, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Brown, Tanya M.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Arnett, AB (corresponding author), Childrens Hosp Colorado Rehabil Med, 13123 E 16th Ave,B285, Aurora, CO 80045 USA.	arnett.anne@gmail.com	Stancin, Terry/L-7993-2019	Arnett, Anne/0000-0003-1342-0488	NIH from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	The authors thank Robert Blaha, Elizabeth Hagesfeld, Michelle Jacobs, Daniel Maier, and Nina Fox in data collection and entry, Amy Cassedy in data management, and John Stullenberger in Website support. We also thank the therapists JoAnne Carey, PsyD, Britt Nielsen, PsyD, and Brad Jackson, PhD. Conflicts of Interest and Sources of Funding: This work was supported in part by (1) NIH grant R01-MH073764 from the National Institute of Mental Health; and (2) a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program. We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated AND, if applicable, we certify that all financial and material support for this research (e.g., NIH or NHS grants) and work are clearly identified in the title page of the manuscript. This clinical trial was registered with clinicaltrials.gov, assigned identifier: NCT00409448. The authors acknowledge that the information in this manuscript and the manuscript itself has never been published either electronically or in print.	Achenbach T. M., 2001, CHILD BEHAV CHECKLIS; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barrett P, 2007, PERS INDIV DIFFER, V42, P815, DOI 10.1016/j.paid.2006.09.018; Biederman J, 2004, J CONSULT CLIN PSYCH, V72, P757, DOI 10.1037/0022-006X.72.5.757; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; Delis D.C., 1994, CVLT C CALIFORNIA VE; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia G.A., 2000, BRIEF BEHAV RATING I; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; METHUEN LK, 1998, MPLUS USERS GUIDE; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Moos RH, 1994, LIFE STRESSORS SOCIA; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Reynolds C. R., 1998, BEHAV ASSESSMENT SYS; Ryu WHA, 2010, INT J REHABIL RES, V33, P84, DOI 10.1097/MRR.0b013e32832e6b4b; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2013, J HEAD TRAUMA REHABI; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	38	38	38	0	47	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					881	889		10.1017/S1355617713000635			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800005	23790158	Green Accepted			2022-02-06	
J	Chang, JC; Brennan, KC; He, DD; Huang, HX; Miura, RM; Wilson, PL; Wylie, JJ				Chang, Joshua C.; Brennan, Kevin C.; He, Dongdong; Huang, Huaxiong; Miura, Robert M.; Wilson, Phillip L.; Wylie, Jonathan J.			A Mathematical Model of the Metabolic and Perfusion Effects on Cortical Spreading Depression	PLOS ONE			English	Article							CEREBRAL-ARTERIES; BLOOD-FLOW; MECHANISMS; POTASSIUM; ASTROCYTES; DIFFUSION; ISCHEMIA; NEURONS; VOLUME; OXYGEN	Cortical spreading depression (CSD) is a slow-moving ionic and metabolic disturbance that propagates in cortical brain tissue. In addition to massive cellular depolarizations, CSD also involves significant changes in perfusion and metabolism-aspects of CSD that had not been modeled and are important to traumatic brain injury, subarachnoid hemorrhage, stroke, and migraine. In this study, we develop a mathematical model for CSD where we focus on modeling the features essential to understanding the implications of neurovascular coupling during CSD. In our model, the sodium-potassium-ATPase, mainly responsible for ionic homeostasis and active during CSD, operates at a rate that is dependent on the supply of oxygen. The supply of oxygen is determined by modeling blood flow through a lumped vascular tree with an effective local vessel radius that is controlled by the extracellular potassium concentration. We show that during CSD, the metabolic demands of the cortex exceed the physiological limits placed on oxygen delivery, regardless of vascular constriction or dilation. However, vasoconstriction and vasodilation play important roles in the propagation of CSD and its recovery. Our model replicates the qualitative and quantitative behavior of CSD-vasoconstriction, oxygen depletion, extracellular potassium elevation, prolonged depolarization-found in experimental studies. We predict faster, longer duration CSD in vivo than in vitro due to the contribution of the vasculature. Our results also help explain some of the variability of CSD between species and even within the same animal. These results have clinical and translational implications, as they allow for more precise in vitro, in vivo, and in silico exploration of a phenomenon broadly relevant to neurological disease.	[Chang, Joshua C.] Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA; [Brennan, Kevin C.] Univ Utah, Dept Neurol, Salt Lake City, UT USA; [He, Dongdong] City Univ Hong Kong, Dept Math, Kowloon Tong, Hong Kong, Peoples R China; [Huang, Huaxiong] York Univ, Dept Math & Stat, Toronto, ON M3J 2R7, Canada; [Miura, Robert M.] New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA; [Miura, Robert M.] New Jersey Inst Technol, Ctr Appl Math & Stat, Newark, NJ 07102 USA; [Wilson, Phillip L.] Univ Canterbury, Dept Math & Stat, Christchurch 1, New Zealand; [Wylie, Jonathan J.] City Univ Hong Kong, Dept Math, Kowloon Tong, Hong Kong, Peoples R China		Chang, JC (corresponding author), Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA.	chang.1166@mbi.osu.edu		Chang, Joshua/0000-0001-9690-9179; Brennan, K.C./0000-0003-4193-5841; WYLIE, Jonathan James/0000-0001-8314-9764	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008185]; Army Research Office [58386MA]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS NS059072, NS070084]; Department of DefenseUnited States Department of Defense [CDMRP PR100060]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Mathematics in Technology and Complex Systems; National Science FoundationNational Science Foundation (NSF) [DMS-1022848, 0635561]; Research Grants Council of the Hong Kong Special Administrative Region, ChinaHong Kong Research Grants Council [CityU 104211]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS059072, R21NS070084] Funding Source: NIH RePORTER; Direct For Mathematical & Physical ScienNational Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS) [1022848] Funding Source: National Science Foundation	The authors thank grant number T32GM008185 from the National Institute of General Medical Sciences and grant number 58386MA from the Army Research Office (JCC); the National Institutes of Health (NINDS NS059072 and NS070084) and the Department of Defense (CDMRP PR100060) (KCB); the Natural Sciences and Engineering Research Council of Canada and the Mathematics in Technology and Complex Systems (HH), the National Science Foundation through grant DMS-1022848 (RMM, HH, JJW), and agreement No. 0635561 (JCC), and the Research Grants Council of the Hong Kong Special Administrative Region, China, CityU 104211 (JJW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Aperia A, 2001, Curr Hypertens Rep, V3, P165, DOI 10.1007/s11906-001-0032-8; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Bennett MR, 2008, BIOPHYS J, V95, P5648, DOI 10.1529/biophysj.108.137190; Brennan KC, 2010, CURR OPIN NEUROL, V23, P266, DOI 10.1097/WCO.0b013e32833821c1; Bures J, 1974, MECH APPL LEAOS SPRE; Busija DW, 2008, PROG NEUROBIOL, V86, P379, DOI 10.1016/j.pneurobio.2008.09.008; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Dirnagl U, 2010, J CEREBR BLOOD F MET, V30, P1, DOI [10.1038/jcbfm.2009.252, 10.1038/jcbfm.2010.191]; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Farr H, 2011, J THEOR BIOL, V286, P13, DOI 10.1016/j.jtbi.2011.07.006; Filosa JA, 2004, CIRC RES, V95, pE73, DOI 10.1161/01.RES.0000148636.60732.2e; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hansen A, 2008, ACTA PHYSL SCANDINAV, V113, P437; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; Kager H, 2000, J NEUROPHYSIOL, V84, P495, DOI 10.1152/jn.2000.84.1.495; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Keener J., 2009, MATH PHYSL; Klein J, 2003, PRINCIPLES CEREBRAL, P291; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KRAIG RP, 2002, CEREBROVASC DIS, P142; Lashley KS, 1941, ARCH NEURO PSYCHIATR, V46, P331, DOI 10.1001/archneurpsyc.1941.02280200137007; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Mazel T, 2002, PHYSIOL RES, V51, pS85; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902, DOI 10.1152/ajpheart.1990.259.3.H902; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; Nicholson C, 2001, REP PROG PHYS, V64, P815, DOI 10.1088/0034-4885/64/7/202; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Sakadzic S, 2009, APPL OPTICS, V48, pD169, DOI 10.1364/AO.48.00D169; Shapiro BE, 2001, J COMPUT NEUROSCI, V10, P99, DOI 10.1023/A:1008924227961; Somjen GG, 2008, J COMPUT NEUROSCI, V25, P349, DOI 10.1007/s10827-008-0083-9; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; SOMJEN GG, 1975, ANNU REV PHYSIOL, V37, P163, DOI 10.1146/annurev.ph.37.030175.001115; Sukhotinsky I, 2008, J CEREBR BLOOD F MET, V28, P1369, DOI 10.1038/jcbfm.2008.35; Sukhotinsky I, 2011, CEPHALALGIA, V31, P1601, DOI 10.1177/0333102411425865; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Tfelt-Hansen PC, 2010, CEPHALALGIA, V30, P780, DOI 10.1111/j.1468-2982.2009.02015.x; TUCKWELL HC, 1978, BIOPHYS J, V23, P257, DOI 10.1016/S0006-3495(78)85447-2; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Yao W, 2011, B MATH BIOL, V73, P2773, DOI 10.1007/s11538-011-9647-3; Zamir M., 2000, PHYS PULSATILE FLOW	47	38	38	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e70469	10.1371/journal.pone.0070469			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	WOS:000323221500016	23967075	gold, Green Submitted, Green Published			2022-02-06	
J	Levi, Y; Rassovsky, Y; Agranov, E; Sela-Kaufman, M; Vakil, E				Levi, Yifat; Rassovsky, Yuri; Agranov, Eugenia; Sela-Kaufman, Michal; Vakil, Eli			Cognitive Reserve Components as Expressed in Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Reserve; CR; TBI; Structural equation modeling; Head injury; Rehabilitation	CONSTRUCT-VALIDITY; EDUCATION; RISK; MEMORY; INTELLIGENCE; PREDICTION; SEVERITY; DEMENTIA; LIFETIME; MODERATE	Traumatic brain injury (TBI) is the most common cause of brain damage, resulting in long-term disability. The "reserve" construct has been proposed to account for the reported mismatch between brain damage and its clinical expression. Although numerous studies have used various measures thought to reflect this construct, few studies have examined its underlying structure in clinical populations, and no studies have systematically studied this construct in TBI. In the present study, structural equation modeling technique was used to evaluate several models hypothesized to represent cognitive reserve (CR) in TBI. A broad range of data typically reported in the literature as representing CR was collected from 89 individuals who sustained moderate-to-severe TBI. Analyses revealed a best fitting model that consisted of three separate factors representing premorbid intelligence, socioeconomic status and leisure activity, with distinct pattern of associations among the three factors. Findings provide empirical support for the notion of a multi-factorial CR and suggest a coherent framework for further investigation.	[Levi, Yifat; Rassovsky, Yuri; Vakil, Eli] Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel; [Rassovsky, Yuri; Vakil, Eli] Bar Ilan Univ, Leslie & Susan Gonda Goldschmied Multidisciplinar, IL-52900 Ramat Gan, Israel; [Rassovsky, Yuri] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Agranov, Eugenia] Sheba Med Ctr, Ramat Gan, Israel; [Agranov, Eugenia] Tel Aviv Univ, Fac Med, IL-69978 Tel Aviv, Israel; [Sela-Kaufman, Michal] Acad Coll Tel Aviv Yaffo, Dept Behav Sci, Tel Aviv, Israel		Vakil, E (corresponding author), Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.	vakile@mail.biu.ac.il		Rassovsky, Yuri/0000-0002-6362-9944			BENTLER PM, 1996, EQS STRUCTURAL EQUAT; BICKEL H, 1994, PSYCHOL MED, V24, P179, DOI 10.1017/S0033291700026945; Bigler E. D, 2006, COGNITIVE RESERVE TH; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Brosch I., 2000, MEGAMOT, V40, P185; CAPRON C, 1989, NATURE, V340, P552, DOI 10.1038/340552a0; Central Bureau of Statistics, 2012, OCC INC ACC NAT INS; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.2307/1131385; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; HAUSER RM, 1986, J LABOR ECON, V4, pS83, DOI 10.1086/298122; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HOLMAN TB, 1984, J LEISURE RES, V16, P277, DOI 10.1080/00222216.1984.11969600; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jamshidian M, 1999, J EDUC BEHAV STAT, V24, P21, DOI 10.2307/1165260; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kraus JF, 1993, HEAD INJURY, P1; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KURTZKE JF, 1984, ANN NEUROL, V16, P265, DOI 10.1002/ana.410160302; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Legendre SA, 2003, J NEUROPSYCH CLIN N, V15, P333, DOI 10.1176/jnp.15.3.333; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Manly JJ, 2005, J GERIATR PSYCH NEUR, V18, P213, DOI 10.1177/0891988705281868; Mortimer JA, 2003, J CLIN EXP NEUROPSYC, V25, P671, DOI 10.1076/jcen.25.5.671.14584; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Murrey GJ, 2004, REHABIL PSYCHOL, V49, P259, DOI 10.1037/0090-5550.49.3.259; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Nixon S.J., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [DOI 10.1037/10198-001, https://doi.org/10.1037/10198-001]; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Roe A., 1956, PSYCHOL OCCUPATIONS; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; Ropacki SA, 2007, ARCH CLIN NEUROPSYCH, V22, P73, DOI 10.1016/j.acn.2006.11.001; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Satz P, 2011, J CLIN EXP NEUROPSYC, V33, P121, DOI 10.1080/13803395.2010.493151; Scarmeas N, 2003, ARCH NEUROL-CHICAGO, V60, P359, DOI 10.1001/archneur.60.3.359; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Schmand B, 1997, PSYCHOL MED, V27, P1337, DOI 10.1017/S0033291797005461; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Siedlecki KL, 2009, J INT NEUROPSYCH SOC, V15, P558, DOI 10.1017/S1355617709090857; SNOWDON DA, 1989, AM J EPIDEMIOL, V130, P999, DOI 10.1093/oxfordjournals.aje.a115433; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, P112, DOI 10.1097/01.wad.0000213815.20177.19; Sumowski JF, 2009, J INT NEUROPSYCH SOC, V15, P606, DOI 10.1017/S1355617709090912; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Valenzuela MJ, 2007, PSYCHOL MED, V37, P1015, DOI 10.1017/S003329170600938X; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742	59	38	38	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2013	19	6					664	671		10.1017/S1355617713000192			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	170QY	WOS:000320869700005	23575273				2022-02-06	
J	Post, A; Oeur, A; Hoshizaki, B; Gilchrist, MD				Post, Andrew; Oeur, Anna; Hoshizaki, Blaine; Gilchrist, Michael D.			Examination of the relationship between peak linear and angular accelerations to brain deformation metrics in hockey helmet impacts	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						neurotrauma; impact biomechanics; concussion; ice hockey	HEAD; INJURY; BIOMECHANICS; MODEL	Ice hockey is a contact sport which has a high incidence of brain injury. The current methods of evaluating protective devices use peak resultant linear acceleration as their pass/fail criteria, which are not fully representative of brain injuries as a whole. The purpose of this study was to examine how the linear and angular acceleration loading curves from a helmeted impact influence currently used brain deformation injury metrics. A helmeted Hybrid III headform was impacted in five centric and non-centric impact sites to elicit linear and angular acceleration responses. These responses were examined through the use of a brain model. The results indicated that when the helmet is examined using peak resultant linear acceleration alone, they are similar and protective, but when a 3D brain deformation response is used to examine the helmets, there are risks of brain injury with lower linear accelerations which would pass standard certifications for safety.	[Post, Andrew; Oeur, Anna; Hoshizaki, Blaine] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada; [Gilchrist, Michael D.] Univ Coll Dublin Belfield, Sch Mech & Mat Engn, Dublin 4, Ireland		Post, A (corresponding author), Univ Ottawa, Sch Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca; aoeur016@uottawa.ca; thoshiza@uottawa.ca; Michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Post, Andrew/0000-0002-5960-5552			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F.A., 1994, 38 STAPP CAR CRASH C, P145; Canadian Standard Association, 2009, Z262109200938 CANCSA, P38; CHALUPNIK JD, 1971, 7111 ME U WASH; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Foreman S, 2010, INFLUENCE HEADFORM G; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gimbel G, 2008, INT J SPORT SCI ENG, V2, P154; Gimbel GM, 2008, EUR J SPORT SCI, V8, P341, DOI 10.1080/17461390802438763; GURDJIAN ES, 1975, SURG GYNECOL OBSTET, V140, P845; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hardy WN, 2001, STAPP CAR CRASH J; Holbourn AHS, 1943, LANCET, V2, P438; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Nahum AM, 1977, P 21 STAPP CRASH C; Ommaya A. K., 1967, P 11 STAPP CAR CRASH; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Prange MT, 2002, P 44 STAPP CAR CRASH; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P159, DOI 10.1243/17543371JSET36; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P89, DOI 10.1243/17543371JSET34; Rousseau P, 2009, AM SOC TEST MATER, V1516, P152, DOI 10.1520/JAI101877; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Schreiber DI, 1997, P 41 STAPP CAR CRASH; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; UENO K, 1995, J BIOMECH ENG-T ASME, V117, P319, DOI 10.1115/1.2794187; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	41	38	38	1	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.	MAY 1	2013	16	5					511	519		10.1080/10255842.2011.627559			9	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering	146RH	WOS:000319107700006	22185521	Green Submitted			2022-02-06	
J	Steinmetz, S; Tipold, A; Loscher, W				Steinmetz, Sonja; Tipold, Andrea; Loescher, Wolfgang			Epilepsy after head injury in dogs: A natural model of posttraumatic epilepsy	EPILEPSIA			English	Article						Traumatic brain injury; Seizures; Risk factors; Biomarkers; Antiepileptogenesis	TRAUMATIC BRAIN-INJURY; CANINE EPILEPSY; SEIZURE CLASSIFICATION; STATUS EPILEPTICUS; ANIMAL-MODELS; LEVETIRACETAM; EFFICACY; GENDER; EPILEPTOGENESIS; EPIDEMIOLOGY	Purpose In humans, traumatic brain injury (TBI) is one of the most common causes of acquired (symptomatic) epilepsy, but as yet there is no treatment to prevent the development of epilepsy after TBI. Animal models of posttraumatic epilepsy (PTE) are important to characterize epileptogenic mechanisms of TBI and to identify clinically effective antiepileptogenic treatments. The prevalence and phenomenology of naturally occurring canine epilepsy are similar to those in human epilepsy. However, the risk of epilepsy after TBI has not been systemically studied in dogs. We therefore performed a large retrospective study in 1,000 dogs referred to our clinical department over a period of 11.5years with the aim to determine the incidence of early and late seizures after head trauma in this species. Methods Two strategies were used: in group I (n=392), we evaluated whether dogs referred for the treatment of a head trauma (group Ia) or other trauma (group Ib) developed seizures after the trauma, whereas in group II (n=608) we evaluated whether dogs referred for the treatment of recurrent epileptic seizures had a history of head trauma. Data for this study were obtained from our clinical database, questionnaires sent to the dogs' owners, and owner interviews. Key Findings In group Ia, 6.6% of the dogs developed PTE, which was significantly different from group Ib (1.9%), indicating that head trauma increased the risk of developing epilepsy by a factor of 3.4. The risk of PTE increased with severity of TBI; 14.3% of the dogs with skull fracture developed PTE. In group II, 15.5% of the dogs with epilepsy had a history of head injury, which was significantly higher than the incidence of PTE determined for group Ia. Significance Our study indicates that head trauma in dogs is associated with a significant risk of developing epilepsy. Therefore, dogs with severe TBI are an interesting natural model of PTE that provides a novel translational platform for studies on human PTE.	[Steinmetz, Sonja; Tipold, Andrea] Univ Vet Med, Dept Small Anim Med & Surg, D-30559 Hannover, Germany; [Tipold, Andrea; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany; [Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany		Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973	Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany) within the DFG Research Unit (FOR) 1103German Research Foundation (DFG) [Lo 274/11-1, TI 309/4-1]	We thank Asla Pitkanen for constructive discussion during preparation of the manuscript and Christina Brauer and Karl Rohn for help during performing the study. The study was supported by grants (Lo 274/11-1; TI 309/4-1) from the Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany) within the DFG Research Unit (FOR) 1103.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Berendt M, 1999, J VET INTERN MED, V13, P14, DOI 10.1892/0891-6640(1999)013&lt;0014:EASCID&gt;2.3.CO;2; Berendt M, 1999, ACTA NEUROL SCAND, V99, P276, DOI 10.1111/j.1600-0404.1999.tb00676.x; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Brauer C, 2011, VET J, V187, P272, DOI 10.1016/j.tvjl.2009.10.023; Chandler K, 2006, VET J, V172, P207, DOI 10.1016/j.tvjl.2005.07.001; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CROFT PG, 1965, VET REC, V77, P438; CUNNINGHAM JG, 1971, J AM VET MED ASSOC, V158, P589; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Davis KA, 2011, EPILEPSY RES, V96, P116, DOI 10.1016/j.eplepsyres.2011.05.011; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Ekenstedt KJ, 2012, MAMM GENOME, V23, P28, DOI 10.1007/s00335-011-9362-2; Engel Jerome Jr., 1994, Emergency Medicine Clinics of North America, V12, P895; Engel J, 2011, BIOMARK MED, V5, P537, DOI [10.2217/BMM.11.62, 10.2217/bmm.11.62]; Engel JJ, 2008, EPILEPSY COMPREHENSI, P767; FENNER WR, 1981, VET CLIN N AM-SMALL, V11, P31, DOI 10.1016/S0195-5616(81)50004-0; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Geary JG, 2008, J SMALL ANIM PRACT, V8, P577; Govendir M, 2005, AUST VET J, V83, P602, DOI 10.1111/j.1751-0813.2005.tb13269.x; Guha A, 2004, POSTGRAD MED J, V80, P650, DOI 10.1136/pgmj.2004.019570; Hardy BT, 2012, J VET INTERN MED, V26, P334, DOI 10.1111/j.1939-1676.2011.00868.x; Hawthorne JC, 1999, J AM ANIM HOSP ASSOC, V35, P135, DOI 10.5326/15473317-35-2-135; Hayes GM, 2009, J VET EMERG CRIT CAR, V19, P629, DOI 10.1111/j.1476-4431.2009.00478.x; HOLLIDAY TA, 1970, EPILEPSIA, V11, P281, DOI 10.1111/j.1528-1157.1970.tb03892.x; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Koestner A, 1989, Probl Vet Med, V1, P516; Leitgeb J, 2011, J TRAUMA, V71, P1620, DOI 10.1097/TA.0b013e318226ea0e; Leppik IE, 2011, EPILEPSIA, V52, P31, DOI 10.1111/j.1528-1167.2011.03231.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2004, EPILEPSIA, V45, P1228, DOI 10.1111/j.0013-9580.2004.21204.x; LOSCHER W, 1985, ARZNEIMITTEL-FORSCH, V35, P82; LOSCHER W, 1984, FED PROC, V43, P276; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Mani R, 2011, NEUROSCI LETT, V497, P251, DOI 10.1016/j.neulet.2011.03.010; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Munana KR, 2012, J VET INTERN MED, V26, P341, DOI 10.1111/j.1939-1676.2011.00866.x; Nowend KL, 2011, MAMM GENOME, V22, P476, DOI 10.1007/s00335-011-9348-0; Pakozdy A, 2008, ACTA VET HUNG, V56, P471, DOI 10.1556/AVet.56.2008.4.5; PALMER AC, 1972, VET REC, V90, P167, DOI 10.1136/vr.90.7.167; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Podell M, 1996, VET CLIN N AM-SMALL, V26, P779, DOI 10.1016/S0195-5616(96)50105-1; PODELL M, 1995, J AM VET MED ASSOC, V206, P1721; Scantlebury MH, 2010, EPILEPSY RES, V89, P27, DOI 10.1016/j.eplepsyres.2009.11.002; Schwartz-Porsche D., 1994, CLIN SYNDROMES VET N, P234; SCHWARTZPORSCHE D, 1982, J AM VET MED ASSOC, V181, P592; SCHWARTZPORSCHE D, 1985, J VET PHARMACOL THER, V8, P113, DOI 10.1111/j.1365-2885.1985.tb00934.x; Stein VM, 2012, VET IMMUNOL IMMUNOP, V146, P101, DOI 10.1016/j.vetimm.2012.02.003; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Volk HA, 2008, VET J, V176, P310, DOI 10.1016/j.tvjl.2007.03.002; von Klopmann T, 2007, J SMALL ANIM PRACT, V48, P134, DOI 10.1111/j.1748-5827.2006.00290.x; Wessmann A, 2009, VET J, V180, P290, DOI 10.1016/j.tvjl.2007.12.023; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7	61	38	38	1	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	APR	2013	54	4					580	588		10.1111/epi.12071			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	117PL	WOS:000316965500006	23294259	Bronze			2022-02-06	
J	Umschweif, G; Alexandrovich, AG; Trembovler, V; Horowitz, M; Shohami, E				Umschweif, Gali; Alexandrovich, Alexander G.; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther			Hypoxia-inducible factor 1 is essential for spontaneous recovery from traumatic brain injury and is a key mediator of heat acclimation induced neuroprotection	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						acriflavine; edema; HIF-1 alpha; hypothermia; preconditioning; traumatic brain injury	FACTOR-I HIF-1; CEREBRAL-ISCHEMIA; FACTOR 1-ALPHA; UP-REGULATION; RAT-BRAIN; EXPRESSION; MICE; PROTEIN; HYPOTHERMIA; BARRIER	Heat acclimation (HA), a well-established preconditioning model, confers neuroprotection in rodent models of traumatic brain injury (TBI). It increases neuroprotective factors, among them is hypoxia-inducible factor 1 alpha (HIF-1 alpha), which is important in the response to postinjury ischemia. However, little is known about the role of HIF-1a in TBI and its contribution to the establishment of the HA protecting phenotype. Therefore, we aimed to explore HIF-1 alpha role in TBI defense mechanisms as well as in HA-induced neuroprotection. Acriflavine was used to inhibit HIF-1 in injured normothermic (NT) or HA mice. After TBI, we evaluated motor function recovery, lesion volume, edema formation, and body temperature as well as HIF-1 downstream transcription targets, such as glucose transporter 1 (GLUT1), vascular endothelial growth factor, and aquaporin 4. We found that HIF-1 inhibition resulted in deterioration of motor function, increased lesion volume, hypothermia, and reduced edema formation. All these parameters were significantly different in the HA mice. Western blot analysis and enzyme-linked immunosorbent assay showed reduced levels of all HIF-1 downstream targets in HA mice, however, only GLUT1 was downregulated in NT mice. We conclude that HIF-1 is a key mediator in both spontaneous recovery and HA-induced neuroprotection after TBI. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 524-531; doi:10.1038/jcbfm.2012.193; published online 2 January 2013	[Umschweif, Gali; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Umschweif, Gali; Horowitz, Michal] Hebrew Univ Jerusalem, Environm Physiol Lab, Dept Physiol, IL-91120 Jerusalem, Israel		Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Environm Physiol Lab, POB 12272, IL-91120 Jerusalem, Israel.	m.horowitz@mail.huji.ac.il; esty@cc.huji.ac.il			Professor Jashovam Shani Fund	The authors thank the Hoffman Leadership and Responsibility Program of the Hebrew University and the Professor Jashovam Shani Fund for generous support to GU.	Althaus J, 2006, NEUROCHEM INT, V48, P687, DOI 10.1016/j.neuint.2005.12.008; Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Du F, 2011, EUR J PHARMACOL, V666, P19, DOI 10.1016/j.ejphar.2011.05.018; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Higashida T, 2011, CURR NEUROVASC RES, V8, P44, DOI 10.2174/156720211794520251; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; Huang RQ, 2010, NEUROSCI LETT, V473, P22, DOI 10.1016/j.neulet.2010.02.011; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MacAulay N, 2010, NEUROSCIENCE, V168, P941, DOI 10.1016/j.neuroscience.2009.09.016; MAHER F, 1993, J CEREBR BLOOD F MET, V13, P342, DOI 10.1038/jcbfm.1993.43; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Rite I, 2008, NEUROCHEM INT, V52, P897, DOI 10.1016/j.neuint.2007.10.004; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Singh N, 2012, CELL MOL NEUROBIOL, V32, P491, DOI 10.1007/s10571-012-9803-9; Tanaka T, 2010, AM J PHYSIOL-REG I, V298, pR661, DOI 10.1152/ajpregu.00732.2009; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109-011-0855-y; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027798; Zhang XM, 2010, J BIOL CHEM, V285, P32869, DOI 10.1074/jbc.M110.135509	42	38	41	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2013	33	4					524	531		10.1038/jcbfm.2012.193			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	117CR	WOS:000316930200008	23281425	Green Published, Bronze			2022-02-06	
J	Wu, HM; Huang, SC; Vespa, P; Hovda, DA; Bergsneider, M				Wu, Hsiao-Ming; Huang, Sung-Cheng; Vespa, Paul; Hovda, David A.; Bergsneider, Marvin			Redefining the Pericontusional Penumbra following Traumatic Brain Injury: Evidence of Deteriorating Metabolic Derangements Based on Positron Emission Tomography	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; ischemia; metabolism; PET scanning; traumatic brain injury	CEREBRAL-BLOOD-FLOW; CLOSED-HEAD INJURY; INTRACEREBRAL HEMORRHAGE; COMBINED MICRODIALYSIS; ISCHEMIC PENUMBRA; FDG-PET; THRESHOLDS; DAMAGE; CONTUSIONS; ASTROCYTES	The pathophysiological changes in the pericontusional region after traumatic brain injury (TBI) have classically been considered to be ischemic. Using [F-18] fluorodeoxyglucose (FDG) and triple-oxygen PET studies, we examined the pericontusional "penumbra'' to assess for increased oxygen extraction fraction (OEF), anaerobic metabolism, and tissue viability. Acute (<= 4 days) CT, MRI, and PET studies were performed in eight patients with TBI who had contusions. Four regions-of-interest (ROI) containing the contusion core, pericontusional hypodense gray matter (GM), pericontusional normal-appearing GM, and remote normal-appearing GM, were defined using a semi-automatic method. The correlations of cerebral blood flow (CBF) with OEF, cerebral metabolic rate of oxygen (CMRO2), and cerebral metabolic rate of glucose (CMRglc) were examined. The oxygen-glucose ratio (OGR) in each brain region was evaluated for anaerobic metabolism. The results show that pericontusional tissue had progressively diminishing OEF, CBF, CMRO2, or CMRglc approaching the contusion core. In general, there was a preserved ratio of CBF to CMRO2 in pericontusional hypodense GM. The OGR of the pericontusional hypodense GM was low (<4.0) and was inversely correlated (r=-0.68) with time after injury. A large proportion (% area: 22-76%) of pericontusional hypodense GM tissue had CMRO2 values less than 35 mu mol/100 g/min, with this percentage increased with time after injury.	[Wu, Hsiao-Ming; Huang, Sung-Cheng; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Huang, Sung-Cheng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; [Vespa, Paul; Hovda, David A.; Bergsneider, Marvin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Vespa, Paul; Hovda, David A.; Bergsneider, Marvin] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Wu, Hsiao-Ming] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan		Bergsneider, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039,Semel 18-246, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu	Tanne, David/F-2560-2010	Tanne, David/0000-0002-6699-2220	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS058489, R21-NS059610]; DOEUnited States Department of Energy (DOE) [DE-FC02-02ER63420, DE-FG02-06ER64249]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS059610, P01NS058489] Funding Source: NIH RePORTER	We wish to acknowledge the contributions of Maria Etchepare, R.N., Jill Hutchinson, R.N., and Larry Pang for technical assistance. This work was supported by NIH grants P01-NS058489 and R21-NS059610, DOE grants DE-FC02-02ER63420 and DE-FG02-06ER64249, and the UCLA Brain Injury Research Center.	ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Heiss WD, 2001, BRAIN, V124, P20, DOI 10.1093/brain/124.1.20; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Keep RF, 2005, STROKE, V36, P1594, DOI 10.1161/01.STR.0000170701.41507.e1; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; Rousseeuw, 2009, FINDING GROUPS DATA; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Soares HD, 1995, J NEUROSCI, V15, P8223; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wu HM, 2005, IEEE T NUCL SCI, V52, P1311, DOI 10.1109/TNS.2005.858239; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	34	38	42	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					352	360		10.1089/neu.2012.2610			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600005	23461651	Green Published			2022-02-06	
J	Larrabee, GJ; Binder, LM; Rohling, ML; Ploetz, DM				Larrabee, Glenn J.; Binder, Laurence M.; Rohling, Martin L.; Ploetz, Danielle M.			Meta-Analytic Methods and the Importance of Non-TBI Factors Related to Outcome in Mild Traumatic Brain Injury: Response to Bigler et al. (2013)	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Meta-analysis; Non brain injury factors	POST-CONCUSSIVE SYNDROME; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; COMPLICATED MILD; RISK; PREDICTORS; DISORDER; BLAST	Bigler et al. (2013, The Clinical Neuropsychologist) contend that weak methodology and poor quality of the studies comprising our recent meta-analysis led us to miss detecting a subgroup of mild traumatic brain injury (mTBI) characterized by persisting symptomatic complaint and positive biomarkers for neurological damage. Our computation of non-significant Q, tau(2) , and I-2 statistics contradicts the existence of a subgroup of mTBI with poor outcome, or variation in effect size as a function of quality of research design. Consistent with this conclusion, the largest single contributor to our meta-analysis, Dikmen, Machamer, Winn, and Temkin (1995, Neuropsychology, 9, 80) yielded an effect size, 0.02, that was smaller than our overall effect size of 0.07 despite using the most liberal definition of mTBI: loss of consciousness less than 1 hour, with no exclusion of subjects who had positive CT scans. The evidence is weak for biomarkers of mTBI, such as diffusion tensor imaging and for demonstrable neuropathology in uncomplicated mTBI. Postconcussive symptoms, and reduced neuropsychological test scores are not specific to mTBI but can result from pre-existing psychosocial and psychiatric problems, expectancy effects and diagnosis threat. Moreover, neuropsychological impairment is seen in a variety of primary psychiatric disorders, which themselves are predictive of persistent complaints following mTBI. We urge use of prospective studies with orthopedic trauma controls in future investigations of mTBI to control for these confounding factors.	[Rohling, Martin L.; Ploetz, Danielle M.] Univ S Alabama, Mobile, AL 36688 USA		Larrabee, GJ (corresponding author), 2650 Bahia Vista St Suite 308, Sarasota, FL 34239 USA.	glarrabee@aol.com					Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Batty GD, 2007, ANN EPIDEMIOL, V17, P278, DOI 10.1016/j.annepidem.2006.07.010; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler E. D., 2012, PTSD MILD TRAUMATIC, P15; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Camilli G, 2010, TEACH COLL REC, V112, P579; Cappa KA, 2011, HEALTH PSYCHOL, V30, P542, DOI 10.1037/a0025220; Cheng ASK, 2011, ACCIDENT ANAL PREV, V43, P1464, DOI 10.1016/j.aap.2011.02.024; Choi J, 2009, BIOL PSYCHIAT, V65, P227, DOI 10.1016/j.biopsych.2008.06.022; COHADON F, 1991, J NEUROL SCI, V103, pS27; Cohen J., 2013, STAT POWER ANAL BEHA; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; DICKER BG, 1992, J HEAD TRAUMA REHAB, V7, P83; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; ELANDER J, 1993, PSYCHOL BULL, V113, P279, DOI 10.1037/0033-2909.113.2.279; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Franklin G., 2004, CLIN PRACTICE GUIDEL; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geary EK, 2011, J INT NEUROPSYCH SOC, V17, P709, DOI 10.1017/S1355617711000646; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Heaton R. K., 2004, REVISED COMPREHENSIV; Heaton RK, 1991, COMPREHENSIVE NORMS; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rohling Martin L, 2002, CNS Spectr, V7, P387; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Rosenthal R., 1984, METAANALYTIC PROCEDU; Ruff R. M., 1989, MILD HEAD INJURY, P176; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Saito Y, 2008, RADIOLOGY, V246, P536, DOI 10.1148/radiol.2462061469; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Symonds CP, 1943, LANCET, V1, P7; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WechslerD, 2001, WECHSLER TEST ADULT; Weiser M, 2004, ACTA PSYCHIAT SCAND, V110, P471, DOI 10.1111/j.1600-0447.2004.00385.x; Weiss A, 2009, PSYCHOSOM MED, V71, P385, DOI 10.1097/PSY.0b013e318198de78; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	97	38	38	0	27	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB 1	2013	27	2					215	237		10.1080/13854046.2013.769634			23	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	146MH	WOS:000319094700003	23414416				2022-02-06	
